<SEC-DOCUMENT>0001213900-24-028731.txt : 20240401
<SEC-HEADER>0001213900-24-028731.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401160616
ACCESSION NUMBER:		0001213900-24-028731
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		24809157

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0202772-10k_china.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:38 UTC 2024 -->
<html xmlns:cphi="http://www.chinapharmaholdings.com/20231231" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-11379">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-11380">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-11381"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-11382">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-11383">2023</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-11384">&#9744;</ix:nonNumeric> TRANSITION REPORT UNDER SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the transition period from _________ to
_____________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-11385">001-34471</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-62"><b>China Pharma Holdings, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>(Exact name of registrant as specified in
its charter)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; "> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-74"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center; font-size: 10pt">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-79"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>73-1564807</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(State or other jurisdiction of<br/>
incorporation or organization)</i></p></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(IRS Employer<br/> Identification No.)</i></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-96"><b>Second Floor, No. 17, Jinpan Road</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-11386">Haikou</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-11387">Hainan Province</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-11388">China</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-11389">570216</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of Principal Executive Offices) (Zip
Code)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
the area code: <b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-11390">(011)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-11391">86 898-6681-1730</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-131"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-135"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CPHI</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-11392">NYSE</ix:nonNumeric> American</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities registered pursuant
to Section 12(g) of the Act: <b>None.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-11393">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-11394">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to
such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-11395">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-11396">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 30%"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-11397">Non-accelerated filer</ix:nonNumeric></p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9746;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Smaller reporting company</p></td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-11398">&#9746;</ix:nonNumeric></p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>Emerging growth company</td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-11399">&#9744;</ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-11400">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-11401">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-11402">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market value
of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last
sold, or the average bid and ask price of such common equity, as of the last business day of the registrant&#8217;s most recently completed
second fiscal quarter: $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-11403">3,896,941</ix:nonFraction> as of June 30, 2023, based on the closing price of $1.7055 of the Company&#8217;s common stock on such
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of outstanding
shares of the registrant&#8217;s common stock on March 24, 2024, was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11404">14,816,865</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Documents Incorporated by
Reference: None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K ANNUAL REPORT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FISCAL YEAR ENDED DECEMBER 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 8%">&#160;</td>
    <td style="vertical-align: top; width: 84%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#s_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">1</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">17</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">45</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="vertical-align: bottom; text-align: center">45</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">46</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">46</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">46</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">47</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: justify"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">47</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center; vertical-align: bottom">47</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">48</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">55</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">55</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">55</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">55</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">56</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</span></span></a></td>
    <td style="vertical-align: bottom; text-align: center">56</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">57</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">57</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">60</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">62</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">63</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">64</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules.</span></a></td>
    <td style="text-align: center; vertical-align: bottom">65</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="text-align: center; vertical-align: bottom">66</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT INDEX</span></a></td>
    <td style="text-align: center; vertical-align: bottom">67</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: justify"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">F-1</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The statements contained in
this report with respect to our financial condition, results of operations and business that are not historical facts are &#8220;forward-looking
statements&#8221;. Forward-looking statements can be identified by the use of forward-looking terminology, such as &#8220;anticipate&#8221;,
&#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;seek&#8221;, &#8220;estimate&#8221;, &#8220;project&#8221;,
&#8220;could&#8221;, &#8220;may&#8221; or the negative thereof or other variations thereon, or by discussions of strategy that involve
risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained
in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other
factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors
affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report
including in &#8220;Risk Factors&#8221; in Item 1A and some of which are discussed in our other filings with the SEC. These forward-looking
statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results
may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements
that have been made regarding anticipated events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risk factors should
be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may
issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons
acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors
not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations
or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date
of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;) expressly state that the safe harbor for forward-looking statements does not apply
to companies that issue penny stock. If we are ever considered to be an issuer of penny stock, the safe harbor for forward-looking statements
may not apply to us at certain times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="s_001"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>PART I</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1.</b>&#160;<b>BUSINESS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China Pharma Holdings Inc.
(the &#8220;Company&#8221;, &#8220;China Pharma&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) is a Nevada holding
company. China Pharma is not a Chinese operating company and all the operations are all conducted by our wholly owned subsidiary, Hainan
Helpson Medical and Biotechnology Co., Ltd. (&#8220;Helpson&#8221;) and its subsidiaries in China. We, through Helpson, are principally
engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence
and high-mortality diseases and medical conditions prevalent in the People&#8217;s Republic of China (the &#8220;PRC&#8221;). All of the
operations are conducted in the PRC, where the manufacturing facilities are located. Helpson manufactures pharmaceutical products in the
form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of Helpson&#8217;s
pharmaceutical products are sold on a prescription basis and all of them have been approved for at least one or more therapeutic indications
by the National Medical Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug Administration, CFDA) based upon
demonstrated safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, China
Pharma, through Helpson, manufactured 19 pharmaceutical products for a wide variety of diseases and medical indications, each of which
may be classified into one of three general categories:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Basic generic drugs, which are
common drugs in the PRC for which there is a very large market demand;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">First-to-market generic drugs,
which are generic drugs that are new to the PRC marketplace; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Modern Traditional Chinese Medicines
(&#8220;TCMs&#8221;), which are generally comprised of non-synthetic, plant-based medicinal compounds that have been widely used in the
PRC for thousands of years. We apply modern production techniques to produce pharmaceutical products in different formulations, such
as tablets, capsules or powders.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In selecting generic drugs
to develop and manufacture, we consider several factors, including the number of other manufacturers currently producing the particular
drug, the size of the market for that drug, the proposed or required method of distribution, the existing and expected pricing for that
particular drug in the marketplace, the costs of manufacturing the drug, and the costs of acquiring or developing the formula for the
drug. We believe that generic drugs we have always been selecting to manufacture have large addressable markets and higher profit margins
relative to other generic drugs manufactured and distributed in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, China Pharma,
through Helpson, manufactured comprehensive healthcare products and protective products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China Pharma, through Helpson,
currently own and operate two production facilities in Haikou, Hainan Province, PRC. One has a construction area of 663.94 square meters,
the other factory has two buildings with production area of 20,282.42 square meters and 6,593.20 square meters. We implement quality control
procedures in this facility in compliance with the PRC&#8217;s Good Manufacturing Practices, or GMP standards, and applicable NMPA regulations
to ensure consistent quality in our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA promulgated <i>Good
Manufacturing Practices for Pharmaceutical Products</i> (2010 revised version) on February 12, 2011 (effective as of March 1, 2011) (the
&#8220;Year 2011 GMP Standards&#8221;). The Year 2011 GMP Standards outlines the basic principles and standards for the manufacturing
of pharmaceutical products and the management of quality controls in the pharmaceutical products manufacturing industry in the PRC. All
of Helpson&#8217;s production lines: tablets, capsules, dry powder, liquid injectables, solid oral solution Cephalosporins (specifically
designated), are in full compliance with the Year 2011 GMP Standards. A newly revised Drug Administration Law (the &#8220;New Law&#8221;)
came into effect on December 1, 2019. The New Law cancelled the GMP certification but impose the pilot inspection mechanism in the event
that if any production line(s) does not satisfy any pilot inspection under the New Law, the production on such production line(s) could
be suspended. As of the date of this annual report, Helpson&#8217;s production lines are in full compliance with the New Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson markets and sells its
products through 16 sales offices covering all major cities and provinces in the PRC. To comply with applicable Chinese laws relating
to sales of prescription drugs to certain hospitals and clinics, Helpson also uses a distribution system comprised of over 1,000 independent
provincial-level, city-level, and county-level distributors. Helpson&#8217;s sales system has further developed and expanded with the
expansion of Chinese healthcare reform, and its 16 provincial offices deliver the products to basic health care institutions as well as
tier two and tier three hospitals through the above mentioned distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry Background and Market Opportunities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the relevant data
of the pharmaceutical manufacturing industry released by the National Bureau of Statistics of the People&#8217;s Republic of China (&#8220;NBS&#8221;),
as of the first half of 2023, the cumulative value of the operating revenue of the pharmaceutical manufacturing industry in China was
RMB1,250 billion, down 2.9% from the same period last year; the accumulated value of profit was RMB179 billion, down 17.1% from the same
period last year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While fully enjoying the expansion
of the industry out of rigid demand, the development of the pharmaceutical industry is also under the pressure of medical insurance fee
control. According to the data of NBS, the proportion of China&#8217;s population over the age of 65 has reached 15.4% by the end of 2023.
With the gradual deepening of population aging, the demand continues to be strong, but the ensuing medical insurance pressure has also
become the main theme of industrial policy changes in recent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On one hand, more and more
people use medical insurance funds; on the other hand, fewer and fewer people pay premiums. Under this circumstance, population aging
has become one of the main factors aggravating the imbalance of medical insurance fund. According to the latest <i>Statistical Bulletin
on the Development of National Medical Insurance in 2022</i> issued by NBS, the number of people participating in national basic medical
insurance reached 1.35 billion in 2022, and the participation rate remained stable at more than 95%. According to the <i>national medical
security plan for the 14<sup>th</sup> five-year-plan</i> issued by the General Office of the State Council of China on September 29, 2021,
personal health expenditure only occupied 27.7% of the total health expenditure in 2020, and it is expected to remain to be at around
27% by 2025. This means that the vast majority of medical and health expenditure is being borne by the government and society. Under the
background of medical insurance adjustment, domestic drug sales have also experienced great changes. The use of adjuvant drugs has gradually
fallen out of favor, giving up the share of medical insurance funds for specialized drugs and tumor drugs with more clinical efficacy.
Under such policies, pharmaceutical enterprises have to carry out innovation and transform, and the overall environment of deepening medical
reform has greatly reduced the profits of generic pharmaceutical enterprises in China.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China National Healthcare
Security Administration (&#8220;NHSA&#8221;) has gradually promoted volume-based procurement for the entire national market, therefore,
pharmaceutical manufacturers have greatly reduced the price in order to win the bid. Since 2018, the National Medical Insurance Bureau
of China (&#8220;NMIB&#8221;) has organized nine batches of national organized drug procurement, including a total of 374 drugs, with
an average price reduction of over 50%. The ninth batch of China&#8217;s state-organized centralized drug procurement was announced in Shanghai
on November 6, 2023, of which 41 drugs were successfully purchased, and the average price of selected drugs was reduced by 58%. The collection
covers infections, tumors, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, mental diseases and other common diseases,
chronic drugs, as well as emergency drugs, drugs in short supply and other key drugs to improve the sense of gain of the masses. The
National Medical Insurance Bureau is working with relevant departments to guide selected enterprises in the implementation of the marketing
of the selected products, and in March 2024, patients across the country have been able to purchase products selected in the ninth batch
with reduced price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have observed the continuous
improvement in medical demand and consumption level in recent years, and the value of high-quality medicine with innovation and consumption
attributes has become prominent. In addition, in February 2023, the Implementation Plan of the Major Project for the Revitalization and
Development of Traditional Chinese Medicine issued by The General Office of the State Council of China made it clear that traditional
Chinese medicine will become an important supporting force for the construction of a healthy China. In the future, with the advancement
of medical insurance and centralized procurement policies, TCM treatment and conditioning will be favored by more patients. The market
size of TCM has been rising year by year, reaching RMB 697 billion in 2022, an increase of 2.63% year-on-year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact from the New Coronavirus Global Pandemic
(&#8220;COVID-19&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the epidemic has entered
the era of JN1 mutant, its infectivity has been further enhanced, but its pathogenicity has been significantly weakened. In addition,
vaccination has been popularized and prevention and control experience has been accumulated. Some countries around the world have significantly
loosed the epidemic prevention and control, and moved to a new stage of coexistence with the virus. Recently, China&#8217;s epidemic prevention
and control guidance has also been continuously optimized, which includes the end of zero-case policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From December 25, 2022, the
China&#8217;s National Health Commission of China will no longer release daily epidemic information. On December 26, 2022, the National Health
Commission issued the Plan for &#8220;Class B disease and Class B Control&#8221; of COVID-19 Infection (the &#8220;Plan&#8221;). The Plan
clearly points out that the &#8220;COVID-19 infection&#8221; will be adjusted from &#8220;Class B disease and Class A Control&#8221; to
&#8220;Class B disease and Class B Control&#8221; from January 8, 2023, which is a major adjustment of China&#8217;s COVID-19 epidemic prevention
and control policy. At the same time, the Plan points out that quarantine infectious disease management measures will no longer be taken
for people and goods entering the country. This means that China&#8217;s prevention and control will focus on &#8220;protecting health and preventing
severe diseases&#8221; to minimize the impact of the epidemic on economic and social development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2023, the World Health
Organization announced that the COVID-19 epidemic would no longer constitute a &#8220;public health emergency of international concern&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intercompany activities between the holding company and our subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
none of our subsidiaries has distributed any dividends to China Pharma, nor has China Pharma distributed any dividends to the investors.
The Company currently has no intention to distribute earnings to the shareholders and investors. The tables below present cash flow transfer
between China Pharma and Helpson, through China Pharma&#8217;s wholly owned subsidiary Onny Investment Limited (&#8220;Onny&#8221;) for
the year ended December 31, 2023 and 2022. The Company&#8217;s management understands that there is no tax consequences for cash flow
transfers between China Pharma and Helpson through Onny.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">For the year ended December 31, 2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">No.</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Transfer from</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Transfer to</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Approximate value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Note</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-style: italic; text-align: center">1</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 30%; font-style: italic; text-align: left">Helpson (via Onny)</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 11%; font-style: italic; text-align: left">China Pharma</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 13%; font-style: italic; text-align: right">30,000</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 39%; font-style: italic; text-align: left">For the payment of the agent service fees of China Pharma</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="11" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">For the year ended December 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">No.</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Transfer from</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Transfer to</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Approximate value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">Note</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; font-style: italic; text-align: center">1</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 30%; font-style: italic; text-align: left">China Pharma (via Onny)</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 11%; font-style: italic">Helpson</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 13%; font-style: italic; text-align: right">1,300,000</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 1%; font-style: italic">&#160;</td>
    <td style="width: 39%; font-style: italic; text-align: left">For Helpson&#8217;s operations</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash management policy
basically is to allocate the cash resources based on the needs and projection of each subsidiary within the Company. Although the purpose
of all transfers needs to be business operation-related, there is no strict limitation on how much cash can be transferred, because the
Company treats all subsidiaries as a whole group under the Company&#8217;s policy of the fund transfer. The cash transfer is requested
when needed and approved by authorized persons based on the amount of cash transfer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Consistency Evaluation for Generic Drugs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the disclosure
of the State Drug Administration of China in May 2022: China&#8217;s modern pharmaceutical industry started relatively late, and drug production
is dominated by imitation. More than 95% of the drugs approved for marketing are generic drugs, covering nearly 30 treatment fields such
as cardio-cerebrovascular system, respiratory system, anti-tumor, anti-infection, etc., which basically satisfy public drug demand. A
total of 916 supplementary application acceptance numbers passed the consistency evaluation, and 1,803 new registration classification
generic drug market application acceptance numbers were deemed to have passed the consistency evaluation in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the requirements
of the relevant documents of the State Council of China, in the reform of the review and approval system of drugs and medical devices,
the state has listed the improvement of the quality of generic drugs as one of the important reform objectives. For the generic drugs
that have been approved for marketing, the consistency evaluation shall be carried out in stages and batches according to the principle
of consistency with the quality and efficacy of the original drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 17, 2019, the State
Council released the &#8220;<i>Pilot Program for the Centralized Procurement and Use of Drugs by the State Organization</i>&#8221; (&#8220;the
Program&#8221;). According to the Program, the trial drugs are selected from the generic drugs that have passed the consistency evaluation,
and the state organizes the centralized purchase of drugs to reduce the drug price and reduce the burden of drug expenses on patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Drug Evaluation Center
of the National Medical Products Administration issued the &#8220;<i>Guidelines for Acceptance and Review of Quality and Efficacy Consistency
Evaluation of Generic Drugs (Draft for Soliciting Opinions)</i>&#8221; (the &#8220;Guideline&#8221;) in September 2023, which reiterated
that within three years after the first product passed the consistency evaluation, they will not accept applications from other pharmaceutical
manufacturers for consistency evaluation of the same product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson has actively promoted
the consistency evaluation process of several important products in 2023; and its flagship product, Candesartan, has passed the evaluation
of consistency in August 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The PRC Legal System</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Legal and Operational Risks Associated
with Having the Majority of the Company&#8217;s Operations in China</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
PRC legal system is based on written statutes. The laws, regulations and legal requirements of China are relatively new and are often
changing, and their interpretation and enforcement depend to a large extent on relevant government policy and involve significant uncertainties
that could limit the reliability of the legal protections available to us. New laws and regulations that affect existing and proposed
future businesses may also be applied retroactively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
PRC government has broad discretion in dealing with violations of laws and regulations, including levying fines, revoking business and
other licenses and requiring actions necessary for compliance. We cannot predict the effect of the interpretation of existing or new PRC
laws or regulations on our businesses. We cannot assure you that our current ownership and operating structure would not be found in violation
of any current or future PRC laws or regulations. As a result, we may be subject to sanctions, including fines, and could be required
to restructure our operations or cease to provide certain services. In addition, any litigation in China may be protracted and result
in substantial costs and diversion of resources and management attention. Any of these or similar actions could significantly disrupt
our business operations or restrict us from conducting a substantial portion of our business operations, which could materially and adversely
affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, the enforcement of laws and regulations in China can change quickly with little advance notice. In 2021, the PRC government
initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including
cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas, adopting
new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. Since these statements
and regulatory actions are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and
what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and
the potential impact such modified or new laws and regulations will have on our daily business operation, the ability to accept foreign
investments and list on an U.S. or other foreign exchange. Any action by the Chinese government to exert more oversight and control over
foreign investment in China-based companies could result in a material change in our operation, cause the value of our ordinary shares
to significantly decline or become worthless, and significantly limit, or completely hinder our ability to offer or continue to offer
our ordinary shares to investors and cause the value of such securities to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
cannot predict the effects of future developments in government policy or the PRC legal system in general. We may be required in the future
to procure additional permits, authorizations and approvals for our existing and future operations, which may not be obtainable in a timely
fashion or at all, or may involve substantial costs and unforeseen risks. An inability to obtain, or the incurrence of substantial costs
in obtaining, such permits, authorizations and approvals may have a material adverse effect on our business, financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>CSRC Filing Requirements and Cybersecurity Review</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As China Pharma is already
publicly listed in the U.S., the Trial Measures (as defined below) do not impose additional regulatory burden on us beyond the obligation
to report to the CSRC any future offerings of our securities, or material events such as a change of control or delisting. In addition,
we believe that we are not subject to cybersecurity review, since we (i) are not network platform operators engaging in data processing
activities that affect or may affect national security; (ii) are not critical information infrastructure operators purchasing cyber products
or services that affect or may affect national security; (iii) are not network platform operators with personal information data of more
than one million users and do not need to obtain any permission or approval from the CAC in accordance with the New Measures for Cyber
Security Review. See <i>&#8220;Risk Factor - We are not required to submit an application to CSRC pursuant to the M&amp;A Rules, nor are
we subject to the cybersecurity review. However, based on the recent promulgation of the Trial Measures, which became effective on March
31, 2023, we may be required to complete the filing requirements when we have re-financing or any additional offerings in future&#8221;
for more details.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Permissions and Approvals for business operation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
the Company and Helpson have obtained all the required permissions and approvals from PRC authorities and have never been denied any applications.
Helpson has never failed to receive or maintain any permissions or approvals, nor were they rejected any such applications. However, the
PRC regulatory authorities may in the future promulgate laws, regulations, or implementing rules that require us, or Helpson, to obtain
additional permissions or approvals to operate business. Upon that time, we cannot assure we are able to receive such additional permissions
and approvals on time. If we do not receive or maintain the approval, or inadvertently conclude that such approval is not required, or
applicable laws, regulations, or interpretations change such that we are required to obtain approval in the future, we may be subject
to an investigation by competent regulators, fines or penalties, and these risks could result in a material adverse change in our operations
and the value of our common stock, significantly limit or completely hinder our ability to offer or continue to offer securities to investors,
or cause such securities to significantly decline in value or become worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The PRC&#8217;s Medical Insurance System</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">National Healthcare Security
Administration (&#8220;NHSA&#8221;) issued the Statistical Bulletin on the Development of National Medical Security in 2022 (the &#8220;Bulletin&#8221;)
on July 11, 2023. The Bulletin showed the total income of the national basic medical insurance (including maternity insurance) fund was
RMB3.09 trillion in 2022, which represented an increase of 7.6% over the previous year. According to the Bulletin, 1.35 billion people
had participated in the national basic medical insurance (hereinafter referred to as the basic medical insurance) by the end of 2022,
and the participation rate was stable at more than 95%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&#8217;s medical insurance system
reform has gone through a long process. At present, it has gradually realized a comprehensive and multi-level medical insurance system.
After 2018, the establishment of the NHSA opened the prelude to a new stage of reform, and the rules and procedures of the adjustment
of the medical insurance catalogue and the national medical insurance negotiation have been gradually improved. After six rounds of adjustment,
the NHSA has added a total of 744 drugs to the medical insurance catalog, including 446 newly negotiated ones, covering all 31 treatment
areas in the catalog. The monitoring of some sample hospitals by the Chinese Pharmaceutical Association shows that from 2018 to 2022,
The proportion of medical insurance drug consumption amount to the total drug consumption amount of sample hospitals increased to 86.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical insurance is the largest
medical service purchaser in China. Entering the Medical Insurance Catalogue (the &#8220;MIC&#8221; or the &#8220;Catalogue&#8221;) will
greatly help speed up the large-scale sales of drugs. The list of the MIC drugs was born in the first edition of the list in 2000, revised
for the first time in 2004, adjusted for the second time in 2009, and then remained unchanged for 8 years, significantly affecting the
availability of drugs and the efficiency of fund use. The Ministry of Human Resources and Social Security issued the <i>Notice on Publicly
Soliciting Opinions and Suggestions on Establishing and Perfecting the Dynamic Adjustment Mechanism of the Drug Catalog of Basic Medical
Insurance, Industrial Injury Insurance and Maternity Insurance</i> in April 2017, which gradually established the dynamic adjustment mechanism.
Starting from 2020, it is planned to update the MIC every year. The average time interval between obtaining approval and completing the
formalities for entering the medical insurance list through negotiation was 6.5 years in 2017, while it was reduced to 1.3 years in 2021.The
frequency of products entering the MIC has greatly accelerated. In the face of increasing medical and health demand and increasing medical
insurance pressure, how to efficiently use medical insurance funds has become the focus of the adjustment of the Catalogue in recent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 29, 2023, the NHSA
published the &#8220;<i>2023 National Basic medical insurance, work-related injury insurance and maternity insurance drug catalogue adjustment
work plan&#8221;</i>. In this annual catalogue adjustment, a total of 126 drugs have been added to the national medical insurance drug
catalogue, and 1 drug has been deleted from the catalogue. 143 off-list drugs were negotiated or bid, of which 121 drugs were successfully
negotiated or bid, the negotiation success rate was 84.6%, and the average price reduction was 61.7%, and the condition were basically
similar to 2022. After this round of adjustment, the total number of drugs in the national medical insurance drug list reached 3,088,
including 1,698 Western medicines and 1,390 Chinese patent medicine, and 892 kinds of TCM prepared in ready-to-use forms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">National medical insurance
negotiation: In 2015, China first proposed the general idea of centralized and classified drug procurement, and the drug price negotiation
was also started. The negotiation for the pilot procurement led by the National Health and Family Planning Commission was launched at
the end of the same year, which also provided practical experience for the subsequent national health insurance negotiation. After the
establishment of the NHSA in 2018, the NHSA will formulate and implement the rules of the medical insurance catalog access negotiation.
Up to now, seven rounds of national medical insurance negotiations have been completed</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2023 Version of The
Medical Insurance Catalogue has officially been implemented from January 1, 2024, superimposing negotiated price cuts and medical insurance
reimbursement factors, and the adjustment is expected to reduce the burden on patients by more than RMB40 billion in the coming two years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that under the background
of national medical insurance cost control, centralized procurement of drugs and medical insurance negotiation should be the new norm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">We believe that the pursuit
of innovation is imperative for providing the basic medical solutions needed by the majority of patients. We are passionate about protecting
human health, and we always adhere to the highest standards of ethics and integrity to fulfill our firm commitment to our customers and
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we are well-positioned
in a comparatively steadily growing industry in one of the fastest-growing economies in the world. With China&#8217;s per capita GDP exceeding
US$12,700 in 2023, consumption structure upgrade, and the establishment of a high-quality health care system has become one of the most
important tasks. We currently manufacture a number of off-patent branded generic drugs. Our diverse portfolio of products and new product
pipelines include products for high-incidence and high-mortality conditions in the PRC, such as cardiovascular, central nervous system
(&#8220;CNS&#8221;), infectious, and digestive diseases. We launched several epidemic prevention products such as medical masks, surgical
masks, KN95 masks, and N95 masks, and wash-free sanitizers since the outbreak of COVID-19 at year end 2019. In addition, we continue to
explore comprehensive healthcare market after the launch of Noni enzymes in 2018. China has entered a post epidemic era with the end of
the dynamic zero-COVID policy since December 2022, and the burden of being protected from the COVID and other epidemics has fallen on
each individuals, which we believe will boost the sales of Helpson&#8217;s products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistency evaluation of
our current existing major products will be the focus of our strategy in the near future. The consistency evaluation of generic drugs
will improve Chinese generic drugs quality and eliminate unqualified enterprises, so that high-quality generic drug companies are expected
to benefit from it. Consistency evaluation, together with the centralized drug procurement, are optimizing the competitive landscape of
the Chinese pharmaceutical industry. We believe that the market space and growth potential for Chinese generic drugs are huge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A series of medical reform
policies introduced in recent years has profound and far-reaching impact on pharmaceutical companies. Therefore, early considerations
of the transformation and upgrading, as well as product positioning become very important. Based on more than twenty-year experience in
R&amp;D, production and marketing experiences, and our market insights, we have decided to gradually adjust our strategy to produce generic
and innovative drugs with high value in pharma-economics, good clinical efficacy and market differentiation. These include drugs that
treat chronic diseases prevalent in China, such as geriatric diseases, cancers, and nutritional products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as another direction
of strategic development, we will actively explore digital interactive healthcare solutions on the Internet. After the advent of the Internet
era, marketing is no longer a vertical down logical relationship, but a decentralized form of interconnection. We will proactively adjust
our business focus and allocate resources to meet market development preferences, provide a more convenient user experience, better standard
treatment plans, and bring higher patient satisfaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our objective is to leverage
our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical products. We intend to achieve this
objective by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Promoting Our Existing Brands to Increase
Our National Recognition</i>. We intend to support and grow the existing recognition and reputation of our brands and to maintain our
branded pricing strategy through continued sales and marketing efforts through our production lines. To achieve this goal, we plan to
promote the efficacy and safety profile of our established prescription pharmaceutical products to physicians at hospitals and clinics
in all provinces of PRC through the efforts of our sales force, independent distributors and educational physician conferences and seminars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Promoting the progress of consistency
evaluation of our current existing main products. </i>We intend to cope with the latest policies and the GPO requirements. We aim to make
efficient use of our existing human and material resources, and strive to create favorable conditions for product sales and international
development through gaining a favorable result in the consistency evaluation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Exploring on the consumption healthcare
market. </i>Consumption healthcare generally refers to products or services that have certain medical features and can bring health improvement
to consumers, but are mainly paid by individuals (less dependent on medical insurance) and have brand effect. We have observed that it
has become a high growth field in recent years. It is not limited by medical insurance, and has low penetration rate and high growth.
It covers the fields of consumption of traditional Chinese medicine, physical examination, health care, rehabilitation and so on. We
will continue to actively explore this niche market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Expanding Our Distribution Network
to Increase Market Penetration</i>. We intend to expand Helpson&#8217;s reach beyond its current 16 offices in the PRC to drive additional
growth of the existing and future products. We currently contract with over 1,000 distributors in the PRC and plan to expand on these
relationships to target new markets. We will continue our conservative sales strategy of increased cooperation with customers with reliable
accounts receivable collection performance. In addition, we plan to continue to broaden our marketing efforts outside of major cities
in the PRC and to increase our market penetration in cities and rural areas where we already have a presence. Over the long term, we also
intend to expand our presence beyond the PRC to international markets by working with international pharmaceutical companies to cross-sell
our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Explore CDMO services. </i>Since the
State Council of China issued <i>The Pilot Scheme of Drug Marketing License Holder System</i> in 2016, Helpson has been actively exploring
the CDMO market, especially in the field of high-end manufacturing. Helpson will focus on developing CDMO of pharmaceutical preparations
required in the whole life cycle from preclinical, clinical trials, scale-up manufacturing to drug marketing and make full use of its
more than two decades of whole process experience in China&#8217;s pharmaceutical industry to engage in pharmaceutical formula research,
development, NMPA production application, industrialization and commercialization. Helpson strives to achieve internal and external coordination
and complement each other&#8217;s resources and advantages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i>Acquiring Complementary Products Lines,
Technologies, Distribution Networks and Companies</i>. We intend to selectively pursue strategic acquisition opportunities that we believe
will grow our customer base, expand our product lines and distribution network, enhance our manufacturing and technical expertise or otherwise
complement our business or further our strategic goals. Pursuing strategic acquisitions is a significant component of our growth strategy.
The Company has not identified any strategic acquisition opportunities as of the date of this report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson currently has a product
portfolio of 22 products, including 19 pharmaceutical products that address a wide variety of diseases and medical indications, and the
remaining are comprehensive healthcare and protective products. All of its pharmaceutical products have demonstrated safety and efficacy
in clinical trials sufficient to obtain approval by the NMPA and are sold on a prescription basis. The following table summarizes the
approved indications for our marketed products and the year in which each of such products was first marketed to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 35%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt; width: 53%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Year of</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Commercial</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-size: 10pt"><b>Product</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Indication</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Launch</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Cerebroprotein Hydroloysate Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1996</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Gastrodin Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain, including vertigo, neuralgia and headaches.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Propylgallate for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cerebral thrombosis, coronary heart disease and complications after surgery such as thrombus deep phlebitis.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Ozagrel Sodium for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute thrombotic cerebral infarction and dyskinesia associated with cerebral infarction</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Alginic Sodium Diester Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Bumetanide for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue from acute drug poisoning.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2007</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Candesartan</span></td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Hypertension</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2013</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 35%"><span style="font-size: 10pt"><b>Anti-infection and Respiratory Diseases</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt; width: 53%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 10%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Roxithromycin Dispersible Tablets</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pharyngitis and tonsillitis caused by Streptococcus pyogenes; sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacterial infection, Mycoplasma pneumonia and Chlamydia pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive bacteria.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1995</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Cefaclor Dispersible Tablets</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tympanitis, lower respiratory tract infection, urinary tract infections and skin/skin tissue infection.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2002</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Cefalexin Capsules</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute tonsillitis caused by sensitive fungi, airway infections, such as pharyngitis, otitis media, nasal sinusitis and bronchitis; pneumonia, respiratory tract infection, urinary tract infections and skin soft tissue infections.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2002</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Andrographolide</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Detoxification, antibacterial and anti-inflammatory. For sore throat caused by upper respiratory tract infection</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2003</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Clarithromycin Granules and Capsules</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2004</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release Tablet</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Relieves cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 35%"><span style="font-size: 10pt"><b>Digestive Diseases</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt; width: 53%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 10%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Hepatocyte Growth-promoting Factor for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis).</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Tiopronin</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Compound Ammonium Glycyrrhetate S for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Omeparzole</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2009</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Others</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Vitamin B6 for Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Vitamin supplement.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2005</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Granisetron Hydrochloride Injection</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors.</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2006</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Comprehensive Healthcare and Protective Products</b></span></td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Noni Enzyme</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">natural, healthy and nutritionrich<br/>
a natural, healthy and nutrition-rich food supplement</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2018</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Sanitizer</span></td>
    <td>&#160;</td>
    <td style="padding-left: 9.25pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">75% alcohol wash-free sanitizer</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Masks</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">KN95 Particulate Respirator, Disposable Medical Mask, Particle Filtering Mask, N95 Medical Protective Mask</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2020 to 2023</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are our revenues
by product category in millions (USD) for the years ended December 31, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td/><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Twelve Months Ended&#160;<br/>
    December 31,</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b>Net</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"/><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><b>Product Category</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>% Change</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-0.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Anti-Viral/ Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-28</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Digestive Diseases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-31</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of the pharmaceutical
industry, Helpson continually strives to change our product portfolio to respond to changes in market demand. Based on a foundation established
by a number of our widely-recognized prescription products, such as Cefaclor and Roxithromycin, Helpson has launched and will continue
to launch a variety of pharmaceuticals. The core criteria for Helpson&#8217;s selection of potential pipeline products is strong market
demand, proven efficacy, and safety. In an effort to gain an advantage in the marketplace, Helpson often seeks to improve the production
process of the new generic products Helpson elects to manufacture or to improve the quality of a proposed product to increase its efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson also adjusts the delivery
systems and marketing for each of our products based on the product&#8217;s target patient group. We believe that maintaining a variety
of delivery systems (e.g. tablets, capsules, injectables and dry powders) for certain of its products targeted at different groups enhances
its competitive position in the marketplace. As a result, its sales and marketing personnel work closely with management and the research
and development personnel to determine which of the products can successfully be marketed for more than one delivery system and which
generic drugs in the marketplace may be good candidates to manufacture and distribute using different delivery systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Product Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research &amp; development
and innovation represent the core competitive advantage for a company&#8217;s sustainable growth. For pharmaceutical companies, products
with proprietary intellectual property are not only strategic resources for comprehensive strength, but also important tools to engage
in social responsibility. Helpson has been focusing on the research and development of both first generic drugs and innovative drugs.
Additionally, Helpson also has actively worked to meet unfulfilled medical needs by sticking to a market-oriented approach and continuously
improving the effectiveness and ease of use of our drugs, which are supported by our well-designed system for intellectual property management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC State Council issued
&#8220;<i>Opinions on Carrying out Consistency Evaluation on Quality and Efficacy of Generic Drugs</i>&#8221; on March 5, 2016, requiring
all manufacturers of generic chemical pipeline products to carry out Consistency Evaluations before they may obtain final registration
approval. Drugs failing to meet these requirements may not be re-registered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, due to this newly
issued NMPA production approved standards and experimental requirements, as with all other Chinese generic pharmaceutical companies, almost
all of Helpson&#8217;s pipeline products have undergone major adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson&#8217;s recent research
and development work is mainly aimed at promoting the consistency evaluation of several major products already on the market, as well
as the continued exploration of comprehensive health product categories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson has recently acquired
formulas for dry eye syndrome, chronic obstructive pulmonary disease, and a pharmaceutical composition for treatment of psoriasis, etc.
It is expected to launch those products as soon as the registration process is completed.. In addition, Helpson has launched N95 Medical
Protective masks in early 2023. Since China ended its zero-case policy and no longer requires shutdown or quarantine in December 2022,
the market demand for prevention materials, such as masks has surged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Distribution and Customers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson has a well-established
sales network. As its current pharmaceutical product portfolio is comprised mainly of prescription drugs, its major sales targets are
hospitals. As of December 31, 2023, we have 16 sales offices covering all major provinces of China, and over 1,000 sales representatives
who assist in managing the delivery of pharmaceutical products, and our promotion and service with hospitals, doctors and local drug distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the nature of Helpson&#8217;s
products and current governmental regulations, all of its customers are located in the PRC. Helpson has established long-standing relationships
with key customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Production Facilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China Pharma, through Helpson,
manufacture and package our products at our manufacturing facility in the Haikou Free Trade Zone in Haikou, Hainan Province. The old manufacturing
facility, which was built in 2002, is approximately 8,000 square meters (approximately 12.4 million square feet); and the new building,
approximately 20,000 square meters (approximately 31 million square feet), was completed in 2013. Helpson has production lines conforming
with the 2011 version of GMP certificates for different forms of its products including: tablets, capsules, dry power, liquid injectables,
solid oral solution Cephalosporins (specifically designated); other than that, it also has production lines for health care products and
various types of masks that meet national standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019, the newly revised Drug Administration
Law (the &#8220;New Law&#8221;) came into effect, which cancelled the GMP certification but impose the pilot inspection mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Raw Materials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson requires a supply of
a wide variety of raw materials to manufacture its products. Helpson employs purchasing staff with extensive knowledge of its products
who work with the product development, and formulations and quality control personnel to source raw materials for the products. Currently,
Helpson relies on numerous suppliers in the PRC and overseas to deliver the required raw materials and believe it has at least three principal
suppliers for each of our most critical raw materials. Historically, Helpson has not had difficulty obtaining raw materials from suppliers.
For the year ended December 31, 2023, the purchases of raw material purchases from its three top suppliers accounted for 17.7%, 13.8%,
and 8.9%, respectively. For the year ended December 31, 2022 suppliers accounted for 21.7%, 9.1%, and 8.9%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Competition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe we have established
a commercially competitive position in the highly-fragmented pharmaceutical industry in China through our core competitive advantages,
as described below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Helpson has a highly-efficient commercialization
process for new products, including significant experience with the NMPA registration process.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson has over 20 years of
product-development experience during which time it has implemented processes to efficiently introduce and market new and existing products
to the Chinese market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Helpson has a market-oriented product portfolio
and product lines.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson&#8217;s product focuses
on developing and manufacturing medicines that help large patient groups, such as the infectious disease and cardio vascular disease patient
groups. Its diversified GMP-certified manufacturing facility includes various production lines targeting a variety of delivery mechanisms,
such as tablets, capsules, cephalosprine tablets, cephalosprine capsules, liquid-injectables and dry powder injectables, which enables
it to effectively manufacture a broad range of new drugs; other than that, it also has production lines for health care products and various
types of masks that meet national standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>We have product diversification to target specific
sub-markets.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We attempt to differentiate
our products from those of our competitors by changing, and, in many cases, improving certain physical aspects of our products to market
under different market segments. For example, to make our Cefaclor product more patient friendly to children and patients with swallowing
problems, we added an enteric coating to make our tablets easier to swallow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Helpson has a national sales network and a
highly-trained marketing team.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson&#8217;s experienced
sales team has industry knowledge and know-how to synergistically combine its strong market insight with successful commercialization
platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Helpson has developed high-quality relationships
with leading hospital and clinic administrators and physicians.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While sales of the pharmaceutical
products to hospitals are made through the distributors, Helpson believes it has established long-term cooperation relationships with
leading hospitals and healthcare clinics throughout China resulting from its long-term promotional efforts and periodic physician seminars,
so that to improve the perception of the products in the marketplace and help identify and select high-volume drugs to develop into new
generic products relatively early in the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding such favorable
positioning, Helpson is subject to intense competition. There are both local and overseas pharmaceutical enterprises that are engaged
in the manufacture and sale of potential substitute or similar pharmaceutical products in the PRC. These competitors may have more capital,
better research and development resources, better manufacturing and marketing capability, and more experience than we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our profitability may be adversely affected if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">the number of our competitors increases;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competitors engage in increased price competition; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competitors develop new products or product substitutes having comparable medicinal applications or therapeutic effects that are more effective, less costly and/or have more perceived benefits than those produced by us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, imported products
and China&#8217;s admission as a member of the World Trade Organization (&#8220;WTO&#8221;) creates increased competition. The PRC became
a member of the WTO in December 2001. As a result, competition in the pharmaceutical industry in the PRC intensified generally in two
respects. First, with lower import tariffs, imported pharmaceutical products manufactured overseas may become increasingly competitive
in terms of pricing. Second, we believe that well-established foreign pharmaceutical manufacturers may set up production facilities in
the PRC and compete with domestic manufacturers directly. With the expected increased supply of competitively-priced pharmaceutical products
in the PRC, we may face increased competition from foreign pharmaceutical products, especially in terms of high-end pharmaceutical products,
including certain types of products manufactured by U.S. manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We regard our packaging designs,
trademarks, trade secrets, patent and similar intellectual property as parts of our core competence that are critical to our success.
We rely on patent, trademark and trade secret law, as well as confidentiality agreements with certain of our employees, distributors and
others to protect our intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2008, Helpson purchased
the patented medical formula and the manufacturing processes for a cerebral/cardio-vascular indication from a third party laboratory.
In connection with that acquisition, we obtained the title of the patent. This patent expires in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2012, Helpson acquired another
patent related to a medical formula for the treatment of cerebral/cardio-vascular diseases. This patent expires in 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Helpson, our wholly
owned subsidiary, acquired a utility model patent and an invention patent application regarding the creation of an ophthalmic oxygen enriched
atomization therapeutic apparatus from Chengdu Bonier Medical Technology Development Co., Ltd. (&#8220;Bonier&#8221;). Based on the technology
transfer agreement, Helpson will receive the utility model patent right of the technical invention and the patent application right of
the invention, and Bonier will provide relevant technical services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
Helpson owns 15 registered trademarks, including marks for eight of the 19 pharmaceutical products Helpson manufactures, including the
tradenamesFukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang, Shenkaineng, XERONINE, and Aronino, as well as marks for
the HPS logo, two HELPSON logos and two other logos.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Environmental Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson complies with the Environmental
Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance, Helpson actively
ensures the environmental sustainability of the operations. Penalties may be levied upon it if we fail to adhere to and maintain certain
standards. Such failure has not occurred in the past, and Helpson does not anticipate that it will occur in the future, but no assurance
can be given in this regard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><i>Regulations Relating to Pharmaceutical Manufacture
Industry</i>. The pharmaceutical manufacture industry in China is highly regulated. The primary regulatory authority is the NMPA, including
its provincial and local branches. As a developer and producer of medicinal products, Helpson is subject to regulation and oversight by
the NMPA and its provincial and local branches. The Medicinal Product Administration Law of the People&#8217;s Republic of China provides
the basic legal framework for the administration of the production and sale of pharmaceuticals in China and covers the manufacturing,
distribution, packaging, pricing and advertising of pharmaceutical products. These regulations set forth detailed rules with respect to
the administration of pharmaceuticals in China. We are also subject to other PRC laws and regulations that are applicable to business
operators, manufacturers and distributors in general.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Registration and Approval
of Medicine</i>. Pursuant to the PRC Provisions for Drug Registration, a medicine must be registered and approved by the NMPA before it
can be manufactured and sold. The registration and approval process requires the manufacturer to submit to the NMPA a registration application
containing detailed information concerning the efficacy and quality of the medicine and the manufacturing process and the production facilities
the manufacturer expects to use. A series of policies on consistency evaluation and drug review process have been issued in recent years,
and potentially more reforms and adjustments are underway in order to promote the pharmaceutical industry in China in line with the international
standards. In this context, we believe that the uncertainties in the timetables for obtaining NMPA production approvals for products under
research are increasing. If a manufacturer chooses to manufacture a pre-clinical medicine, it is also required to conduct pre-clinical
trials, apply to the NMPA for permission to conduct clinical trials and go through the clinical trials. If a manufacturer chooses to manufacture
a post-clinical medicine, it only needs to go through the clinical trials. In both cases, a manufacturer needs to file clinical data with
the NMPA for approval to manufacture after clinical trials are completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>New Medicine</i>. If a new
medicine is approved by the NMPA, the NMPA will issue a new medicine certificate to the manufacturer and impose a monitoring period from
one to five years. During the monitoring period, the NMPA will monitor the safety of the new medicine, and will neither accept new medicine
certificate applications for an identical medicine by another pharmaceutical company, nor approve the production or import of an identical
medicine by other pharmaceutical companies. As a result of these regulations, the holder of a new medicine certificate has the exclusive
right to manufacture it during the monitoring period. We currently have the new medicine certificates for our Pusenouke, Cefaclor dispersible
tablets and Roxithromycin dispersible tablets and Bumetanide for injection products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>National Production Standard
and Provisional Standard</i>. In connection with the NMPA&#8217;s approval of a new medicine, the NMPA will normally direct the manufacturer
to produce the medicine according to a provisional national production standard, or a provisional standard. A provisional standard is
valid for two years, during which time the NMPA closely monitors the production process and quality consistency of the medicine to develop
a national final production standard for the medicine, or a final standard. Three months before the expiration of the two-year period,
the manufacturer is required to apply to the NMPA to convert the provisional standard to a final standard. Upon approval, the NMPA will
publish the final standard for production. The NMPA has no statutory timeline to complete its review and grant approval for the conversion.
In practice, the approval for conversion to a final standard is time-consuming and could take a number of years. However, during the NMPA&#8217;s
review period, the manufacturer may continue to produce the medicine according to the provisional standard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Transitional Period</i>.
Prior to the latter of (1) the expiration of a new medicine&#8217;s monitoring period or (2) the date when the NMPA grants a final standard
for a new medicine after the expiration of the provisional standard, the NMPA will not accept applications for an identical medicine nor
will it approve the production of an identical medicine by other pharmaceutical companies. Accordingly, the manufacturer will continue
to have an exclusive production right for the new medicine during this transitional period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Continuing NMPA Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical manufacturers
in China are subject to continuing regulation by the NMPA. If the labeling or its manufacturing process of an approved medicine is significantly
modified, a new pre-market approval or pre-market approval supplement will be required by the NMPA. A pharmaceutical manufacturer is subject
to periodic inspection and safety monitoring by the NMPA to determine compliance with regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NMPA has a variety of enforcement
actions available to enforce its regulations and rules, including fines and injunctions, recall or seizure of products, imposition of
operating restrictions, partial suspension or complete shutdown of production and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pharmaceutical Product Manufacturing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Permits and Licenses for
Pharmaceutical Manufacturers.</i> A pharmaceutical manufacturer must obtain a pharmaceutical manufacturing permit from the NMPA&#8217;s
relevant provincial branch. This permit is valid for five years and is renewable for an additional five-year period upon its expiration.
Our current pharmaceutical manufacturing permit, issued by the NMPA, will expire on November 8, 2025. We are confident the permit could
be renewed before its expiration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Good Manufacturing Practice.</i>
A pharmaceutical manufacturer must meet the Good Manufacturing Practice standards, or GMP standards, for each of its production facilities
in China in respect of each form of pharmaceutical product it produces. GMP standards include staff qualifications, production premises
and facilities, equipment, raw materials, environmental hygiene, production management, quality control and customer complaint administration.
Prior to December 1, 2019, if a manufacturer meets the GMP standards, the NMPA will issue to the manufacturer a Good Manufacturing Practice
certificate, or a GMP certificate, with a five-year validity period. However, for a newly-established pharmaceutical manufacturer that
meets the GMP standards, the NMPA will issue a GMP certificate with only a one-year validity period. The Year 2011 GMP Standards became
effective on March 1, 2011, and pharmaceutical manufacturers (except for manufacturers of injectables, blood products or vaccines, which
had a three-year grace period) had a five-year grace period to upgrade existing facilities to comply with the revisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of Helpson&#8217;s existing
production lines have met the Year 2011 GMP Standards. On December 1, 2019, the newly revised Drug Administration Law (the &#8220;New
Law&#8221;) came into effect. One of the major amendments is the cancellation of GMP certification. The New Law eliminated the requirement
that drug administration authorities shall assess drug manufacture enterprises and drug trading enterprises, and issue assessment certificates.
Instead, it requires that drug manufacturing enterprises and drug trading enterprises establish and improve the quality management systems
of manufacture and trade of drugs, and ensure that the process of manufacturing and trading of drugs always meets all legal requirements.
This means a stricter form of supervision is implemented comparing to the prior GMP certificates system. Helpson&#8217;s production lines
are subject pilot inspection under the New Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that GMP inspection
only switches to another form, which includes flight inspection, drug production license inspection (for on-site management and quality
system), as well as product inspection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Liability and Consumers Protection</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product liability claims may
arise if any of our pharmaceutical products have a harmful effect on a consumer, who may make a claim for damages or compensation as an
injured party. The General Principles of the Civil Law of the PRC, which became effective in January 1987, stated that manufacturers and
sellers of defective products causing property damage or injury shall incur civil liabilities for such damage or injuries. The Civil Code
of the PRC, which came into force on January 1, 2021, stipulates that if damage is caused to others due to defects in products, the infringed
can claim compensation from the manufacturer of the products or the seller of the products. If the defect is caused by the producer, the
seller shall have the right to recover compensation from the producer. If the product is defective due to the fault of the seller, the
producer shall have the right to recover from the seller after making compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Product Quality Law of
the PRC was enacted in 1993 and amended in 2000 to strengthen the quality control of products and protect consumers&#8217; rights and
interests. Under this law, manufacturers and distributors who produce or sell defective products may be subject to confiscation of earnings
from such sales, revocation of business licenses and imposition of fines, and in severe circumstances, may be subject to criminal liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law of the PRC on the Protection
of the Rights and Interests of Consumers was promulgated on October 31, 1993 and became effective on January 1, 1994 to protect consumers
when they purchase or use goods or services. All business operators must comply with this law when they manufacture or sell goods and/or
provide services to customers. In extreme situations, pharmaceutical product manufacturers and distributors may be subject to criminal
liability if their goods or services lead to the death or injuries of customers or other third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the regulations
relating to pharmaceutical industry in China, Helpson is subject to the regulations applicable to a foreign invested enterprise in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Foreign Currency Exchange.
</i>Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 1997 and various regulations issued by the
State Administration of Foreign Exchange, or the SAFE, and other relevant PRC government authorities, Renminbi is freely convertible only
to the extent of current account items, such as trade-related receipts and payments, interests and dividends. Capital account items, such
as direct equity investments, loans and repatriation of investment, require the prior approval from the SAFE or its local counterpart
for conversion of Renminbi into a foreign currency, such as U.S. dollars, and remittance of the foreign currency outside the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments for transactions that
take place within the PRC must be made in Renminbi. Unless otherwise approved, PRC companies other than foreign investment enterprises
(FIEs) must convert foreign currency payments they receive from abroad into Renminbi. On the other hand, FIEs may retain foreign currency
in accounts with designated foreign exchange banks, subject to a cap set by the SAFE or its local counterpart.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dividend Distribution. </i>Under
the PRC regulations governing dividend distributions by wholly foreign-owned enterprises and Sino-foreign equity joint ventures, wholly
foreign-owned enterprises and Sino-foreign equity joint ventures in the PRC may pay dividends only out of their accumulated profits, if
any, determined in accordance with PRC accounting standards and regulations. Additionally, these foreign-invested enterprises are required
to set aside certain amounts of their accumulated profits each year, if any, to fund certain reserve funds. These reserves are not distributable
as cash dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PCAOB Regulations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As auditors of companies
that are traded publicly in the United States and a firm registered with the PCAOB, our auditor is required by the laws of the United
States to undergo regular inspections by the PCAOB. We are required by the Holding Foreign Companies Accountable Act (&#8220;HFCAA&#8221;)
to have an auditor that is subject to the inspection by the PCAOB. <span>On June 22, 2021, the U.S. Senate
passed the Accelerating Holding Foreign Companies Accountable Act, or AHFCAA, which proposes to reduce the period of time for foreign
companies to comply with PCAOB audits from three to two consecutive years, thus reducing the time period before the securities of such
foreign companies may be prohibited from trading or delisted. On December&#160;29, 2022, the Consolidated Appropriations Act, 2023 (the
&#8220;CAA&#8221;), which the AHFCAA forms a part, was signed into law, and it officially reduced the number of consecutive non-inspection&#160;years
required for triggering the prohibitions under the HFCAA from three years to two, thus, would reduce the time before an applicable issuer&#8217;s
securities may be prohibited from trading or delisted.</span> On December 16, 2021, the PCAOB issued a report to notify the SEC its determinations
that it is unable to inspect or investigate completely registered public accounting firms headquartered in China and Hong Kong, respectively,
and identifies the registered public accounting firms in China and Hong Kong that are subject to such determinations. Our auditor, B F
Borgers CPA PC, is headquartered in Denver, Colorado and has been inspected by the PCAOB on a regular basis, with the last inspection
year being 2023, and is therefore not subject to the determinations announced by the PCAOB on December 16, 2021. On August 26, 2022, the
PCAOB announced and signed a Statement of Protocol (the &#8220;Protocol&#8221;) with the China Securities Regulatory Commission and the
Ministry of Finance of the People&#8217;s Republic of China. On December 15, 2022, the PCAOB announced in the 2022 Determination its determination
that the PCAOB was able to secure complete access to inspect and investigate accounting firms headquartered in mainland China and Hong
Kong, and the PCAOB Board voted to vacate previous determinations to the contrary. Should the PCAOB again encounter impediments to inspections
and investigations in mainland China or Hong Kong as a result of positions taken by any authority in either jurisdiction, including by
the CSRC or the MOF, the PCAOB will make determinations under the HFCAA as and when appropriate. We cannot assure you whether NYSE American
or other regulatory authorities would apply additional and more stringent criteria to us after considering the effectiveness of our auditor&#8217;s
audit procedures and quality control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach, or
experience as it relates to the audit of our financial statements. There is a risk that the PCAOB is unable to inspect or investigate
completely the Company&#8217;s auditor because of a position taken by an authority in a foreign jurisdiction or any other reasons, and
that the PCAOB may re-evaluate its determinations as a result of any obstruction with the implementation of the Protocol. Such lack of
inspection or re-evaluation could cause trading in the Company&#8217;s securities to be prohibited under the HFCAA ultimately result in
a determination by a securities exchange to delist the Company&#8217;s securities. In addition, under the HFCAA, as amended by the AHFCAA,
our securities may be prohibited from trading on the NYSE American or other U.S. stock exchanges if our auditor is not inspected by the
PCAOB for two consecutive years, and this ultimately could result in our Common Stock being delisted by the NYSE American.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had 239 employees, among which 231 employees were full-time employees and 8 employees were temporary employees. None of our employees
is represented by a labor union and, in general, we consider our relationship with our employees to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by applicable Chinese
law, we have entered into employment contracts with substantially all of our officers, managers and employees. We are working towards
entering into employment contracts with those employees who do not currently have employment contracts with us. The PRC enacted a new
Labor Contract Law, which became effective on January 1, 2008. We have updated our employment contracts and employee handbook and are
in compliance with such law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1A. RISK FACTORS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factor Summary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The following are some material risks, any
of which could have an adverse effect on our business financial condition, operating results, or prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Risks Related to our Business
and our Industry</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If our products do not attain
market acceptance among the medical community, our operations and profitability would be adversely affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we fail to meet standards
pursuant to the newly revised Drug Administration Law, certain production lines will be suspended and our profitability would be adversely
affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may be subject from time
to time to product cessations or recalls initiated by us or by the NMPA. Product recalls could impose significant costs on us and adversely
affect our ability to generate revenue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we fail to develop new products
with high profit margins and our high-profit-margin products are replaced by competitors&#8217; products, then our gross will be adversely
affected;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Most of our products are off-patent
branded generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition
we face;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are not able to maintain
and enhance our brand recognition to maintain our competitive advantage, our reputation, business and operating results may be harmed;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Reimbursement may not be available
for our products, which could diminish our sales;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">The growth and success of our
business depend on our ability to successfully market our principal products to hospitals and their selection for medicine purchases;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our future research and development
projects may not be successful;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We cooperate with research
institutions and universities in the PRC for the research and development of certain new products and any failure of such research institutions
to meet our timing and quality standards may pose impairment loss on our financial results and our failure to continue such collaborative
arrangement could adversely affect our ability to develop new pharmaceuticals and our overall business prospects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to obtain
regulatory approval for any of the new products and failure to obtain these approvals could materially harm our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">New product development in
the pharmaceutical industry is time-consuming and costly and has a low rate of successful commercialization;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to successfully
identify and acquire new products or businesses;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on distributors for
all of our revenues and failure to maintain relationships or to otherwise expand our distribution network would materially and adversely
affect our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on a limited number
of distributors for the majority of sales of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our operations may be affected
if we could not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We face risks related to health
pandemics that could impact our sales and operating results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our operations may be affected
if we could not obtain raw materials from our current key suppliers on acceptable terms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to effectively
manage our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected
by actions taken by our distributors and third party marketing firms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have limited insurance coverage
and may incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our future liquidity needs
are uncertain and we may need to raise additional funds in the future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Risks Related to Doing Business
in China</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Adverse changes in political
and economic policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could
reduce the demand for our services and materially and adversely affect our competitive position;</span> &#160; &#160; &#160; &#160; <span style="font-size: 10pt">o
The Chinese government may intervene with or influence our business at any time. That may negatively influence our operation, our ability
to continue listing on U.S. exchange and the value of our shares may significantly decline or be worthless, which would materially affect
the interest of our stockholders;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">The PRC legal system has inherent
uncertainties that could limit our legal protections available to us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">You may experience difficulties
in bringing original actions in the PRC against our company or our management based on U.S. or other foreign laws;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Because we receive substantially
all of our revenue in Renminbi, which currently is not a freely convertible currency, we are subject to changes in the PRC&#8217;s political
and economic decisions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We cannot be certain that the
Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially for foreign
exchange transactions;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are subject to the environmental
protection laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Compliance with China&#8217;s
new Data Security Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for consultation), regulations
and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses
and could materially affect our business;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are not required to submit
an application to CSRC pursuant to the M&amp;A Rules, nor are we subject to the cybersecurity review. However, based on the recent promulgation
of the Trial Measures, which became effective on March 31, 2023, we may be required to complete the filing requirements when we have
re-financing or any additional offerings in future;</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Although the audit report included
in this annual report was issued by U.S. auditors who are currently inspected by the PCAOB, if it is later determined that the PCAOB
is unable to inspect or investigate our auditor completely, investors would be deprived of the benefits of such inspection and our Common
Stock may be delisted or prohibited from trading;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Risks Related to our Common
Stock</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may be held in default on
our convertible note, which could trigger penalties that worsen our financial condition and potentially disqualify us from listing on
the stock exchange where we are currently listed;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">The market price for our common
stock may be volatile;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we issue additional shares
of our capital stock, our stockholders will experience dilution in their respective percentage ownership in the company;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are likely to remain subject
to &#8220;penny stock&#8221; regulations and as a consequence there are additional sales practice requirements and additional warnings
issued by the SEC;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">There is substantial doubt
about our ability to continue as a going concern;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">We do not anticipate paying
cash dividends on our common stock;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">o</span></td><td style="text-align: justify"><span style="font-size: 10pt">Restrictions on the Use of
Rule 144 by Shell Companies or Former Shell Companies.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Business and our Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The commercial success of our products depends
upon the degree of their market acceptance among the medical community. If our products do not attain market acceptance among the medical
community, our operations and profitability would be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The commercial success of our
products depends upon the degree of market acceptance they achieve within the medical community, particularly among physicians and hospital
administrators. Physicians may not prescribe or recommend our products to patients and procurement departments of hospitals may not purchase
our products if physicians or hospital pharmacists do not find our products attractive. The acceptance and use of our products among the
medical community will depend upon a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">perception of physicians, patients
and others in the medical community as to the safety and effectiveness of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the prevalence and severity
of any side effects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the pharmacological benefit
of our products relative to competing products and products under development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the efficacy and potential advantages
of our products relative to competing products and products under development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the relative convenience and
ease of administration of our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the methods by which our pharmaceutical
products may be delivered to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the effectiveness of our education,
marketing and distribution efforts and those of our distributors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">publicity concerning our products
or competing products and treatments; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the price of our products and
competing products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to meet standards pursuant to
the newly revised Drug Administration Law, the production at certain of our production lines will be suspended and our operations and
profitability would be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">All of our existing production
lines have met the GMP Standards which became effective as of March 1, 2011. On December 1, 2019 the newly revised Drug Administration
Law (the &#8220;New Law&#8221;) came into effect. One of the major amendments of the New Law is the cancellation of GMP certification.
The New Law eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading
enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading enterprises
establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of manufacturing and
trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented comparing to the prior
GMP certificates system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">While all of our existing product
lines are in full compliance with the GMP standards issued in 2011, in the event we fail to continually meet the requirements of the GMP
and receive the deficiency feedback from any pilot inspection under the New Law, the production on such production line(s) could be suspended
and our operations and profitability could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject from time to time to product
cessations or recalls initiated by us or by the NMPA. Product cessations or recalls could impose significant costs on us and adversely
affect our ability to generate revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In our business, we must comply
with a variety of product safety and product testing regulations. In particular, our products are subject to, among other statutes and
regulations, those issued by the NMPA. If the NMPA issues any notices to cease the production, sale and use of any of our products, or
request Helpson to recall any of our products we sold, we must comply with such requirements. As a result, we may incur significant costs
in complying with cessation or recall requirements, and our financial results could be materially and adversely affected. Furthermore,
concerns about potential liability or potential future changes in product safety regulations may lead us to voluntarily recall or otherwise
discontinue selling selected products, which could materially and adversely affect our results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Recalls may also harm our reputation,
increase our costs and reduce our net sales. Governments and regulatory agencies in the markets where we manufacture and sell products
may enact additional regulations relating to product safety and consumer protection in the future or take other actions that may adversely
impact our business. The NMPA has the authority to revoke drug approvals previously granted and remove previously approved products from
the market for various reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to develop new products with
profit margins and our high-profit-margin products are replaced by competitors&#8217; products, then our gross and net profits margins
will be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had gross loss margins
of -4.0% for the year ended December 31, 2023, compared to gross loss margins of -6.1% for the year ended December 31, 2022. The pharmaceutical
market in the PRC remains very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease
in the cost of sold products. To the extent that we fail to develop new products with high profit margins and our high-profit-margin products
are replaced by our competitors&#8217; products, our gross profit margins and net profit margins will be adversely affected. In addition,
three of our products are included in the National Essential Drug List (the &#8220;EDL&#8221;), which are subject to strict governmental
price controls. Therefore, our gross profit margin and net profit margins could be adversely affected notwithstanding any increase in
our revenues.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products face substantial competition.
Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We operate in a highly competitive
environment. Our products compete with other products or treatments for diseases that treat similar medical conditions. Many of our products
may compete against products that have lower prices, superior performance, greater ease of administration or other advantages. We would
face enhanced competition if competitive products are added to the National Medical Insurance Program. Our inability to compete effectively
could reduce sales or margins, which could have a material adverse effect on our results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Some of our competitors are
actively engaging in research and development in areas in which we have products or in which we are developing new product or new indications
for existing products. In the future, we expect that our products will compete with new drugs currently in development, drugs approved
for other indications that may be approved for the same indications as those of our products and drugs approved for other indications
that are used off-label. If alternatives to our products are dispensed or prescribed to patients, the volume of our products sold may
decline or we may be required to lower the prices of our products to remain competitive, either of which could negatively impact our sales.
In addition, an increasing number of foreign pharmaceutical companies have introduced their pharmaceutical products into the Chinese market.
Competitive products introduced by these companies can also negatively impact our sales and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Large Chinese state-owned and
privately owned pharmaceutical companies and foreign-invested or foreign pharmaceutical companies may have greater clinical, research,
regulatory, manufacturing, marketing, financial and human resources than we do. In addition, some of our competitors may have technical
or competitive advantages over us with respect to the development of technologies and processes. These resources may make it difficult
for us to compete with them to successfully discover, develop and market new products and for our current products to compete with new
products or new product indications that these competitors may bring to market. There may also be significant consolidation in the pharmaceutical
industry among our competitors. Alliances may develop among competitors, and these alliances may rapidly acquire significant market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Furthermore, in order to gain
market share in China, competitors may significantly increase their advertising expenditures and promotional activities or even engage
in irrational or predatory pricing behavior. In addition, our competitors may engage in inappropriate competition or illegal acts, such
as bribery. Third parties may actively engage in activities designed to undermine our brand name and product quality or to influence customer
confidence in our products. Increased competition may result in price reductions, reduced margins and loss of market share, any of which
could materially adversely affect our profit margins. We may not be able to compete effectively against current and future competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Most of our products are off-patent branded
generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC which may increase the competition we face
and reduce our business profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Most of our products are off-patent
branded generic pharmaceuticals and are not protected by intellectual property rights. As a result, other pharmaceutical companies may
sell equivalent products at a lower cost, and this might result in a commensurate loss in sales of our branded generic products or require
us to lower our prices to compete. If other pharmaceutical companies sell pharmaceutical products that are similar to our unprotected
products, we may face additional competition and our business and profitability may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business depends in part on our well-known
Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage, our reputation,
business and operating results may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe that market awareness
of our Helpson brand has contributed significantly to the success of our business. We also believe that maintaining and enhancing the
Helpson brand is critical to maintaining our competitive advantage. Although our sales and marketing staff will continue to further promote
our brand to remain competitive, we may not be successful. If we are unable to further enhance our brand recognition and increase awareness
of our products, or if we are compelled to incur excessive marketing and promotion expenses in order to maintain our brand awareness,
our business and results of operations may be materially and adversely affected. Furthermore, our sales and results of operations could
be adversely affected if the Helpson brand or our reputation is impaired by recalls or negative publicity for one of our branded products,
or certain actions taken by our distributors, competitors, third-party marketing firms or relevant regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reimbursement may not be available for our
products, which could diminish our sales or affect our ability to sell our products profitably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Market acceptance and sales
of our products also depend on a large extent on the reimbursement policies of the PRC government. The Ministry of Labor and Social Security
of the PRC or provincial or local labor and social security authorities, together with other government authorities, review the inclusion
or removal of drugs from the national medical insurance catalog or provincial or local medical insurance catalogs for the National Medical
Insurance Program every other year, and catalogs under which a drug will be classified affect the amounts reimbursable to program participants
for their purchases of those medicines. These determinations are made based on a number of factors, including price and efficacy. Generally,
there are two catalogs, the National Insurance Catalogue (&#8220;NIC&#8221;) and the EDL on which a product can be included. The products
selected for the EDL generally are selected from the NIC. A consumer can be reimbursed for the full cost of a medicine on the EDL and
can be reimbursed from 80% to 90% of the cost of a medicine listed on the NIC. Our Cefalexin, Clarithromycin and Omeprazole products are
currently included in the EDL. If government authorities decide to remove these products from the medicine catalogs, such removal may
reduce the affordability of our products and change the public perception regarding our products, which, in turn, would adversely affect
the sales of these products and reduce our net revenue. Furthermore, if we are unable to obtain approval from the relevant government
authorities to include our new products in the national, provincial or local medicine EDLs or NICs, sales of our new products maybe materially
and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The growth and success of our business depend
on our ability to successfully market our principal products to hospitals and their selection in tender processes used by hospitals for
medicine purchases.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our future growth and success
significantly depend on our ability to successfully market our principal products to hospitals as prescription medicines. Approximately
80% of the end-customers of our products are hospitals. Hospitals may make bulk purchases of a medicine included in the national and provincial
medicine catalogs only if that medicine is selected under a government-administered tender process. A hospital&#8217;s interest in a particular
medicine is evidenced by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the inclusion of this medicine
on the hospital&#8217;s formulary, which establishes the scope of medicines physicians at this hospital may prescribe to their patients,
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the willingness of physicians
at a hospital to prescribe this medicine to their patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe effective marketing
efforts are critical in ensuring that hospitals and physicians are interested in purchasing our products. If our marketing efforts are
not effective, hospital administrators may not want to include our products in their formularies or may remove them from their formularies,
or physicians may not be interested in prescribing our products to their patients. As a result, we may find it difficult to maintain the
existing level of sales of our products, and our revenues and profitability may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future research and development projects
may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The successful development
of pharmaceutical products can be influenced by many factors. Products that appear to be promising in their early phases of research and
development may fail to be commercially viable for various reasons, such as failing to obtain the necessary regulatory approvals. Additionally,
the research and development process for new products for which we may obtain an approval certificate is long. The process of conducting
basic research and various stages of tests and trials of a new product before obtaining an approval certificate and commercializing the
product may require ten years or longer. A few of our product candidates are in the early stages of pre-clinical study and clinical trials
and we must conduct a significant number of additional clinical trials before we can seek the regulatory approvals necessary to begin
commercial production and sales of these products. We cannot guarantee that our future research and development projects will be successful
or completed within their anticipated time frames or budgets, or that we will receive the necessary approvals from the relevant authorities
for the production of these products, or that these newly-developed products will achieve commercial success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our competitors may obtain
approval for a competitive product before our product we are developing is approved. If this occurs, we may be precluded from getting
approval until the competitor&#8217;s monitoring period expires and realize little to no benefit from our research and development investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even if such products can be
successfully commercialized, they may not achieve the level of market acceptance that we expect. Additionally, the pharmaceutical industry
is characterized by rapid changes in technology, constant enhancements of industry know-how and the frequent emergence of new products.
Future technological improvements and continual product developments in the pharmaceutical market may render our existing products obsolete
or affect their viability and competitiveness. Therefore, our future success will largely depend on our development capability, including
our ability to improve our existing products, diversify our product range and develop new and competitively-priced products that meet
the requirements of the changing market. Should we fail to respond to these frequent technological advances by failing to improve our
existing products, develop new products in a timely manner, or have these products reach a desirable level of market acceptance, our business
and profitability will be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cooperate with research institutions
and universities in the PRC for the research and development of certain new products and any failure of such research institutions to
meet our timing and quality standards may pose impairment loss on our financial results and our failure to continue such collaborative
arrangement or enter into such new arrangements could adversely affect our ability to develop new pharmaceuticals and our overall business
prospects</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our business strategy includes
collaborating with third parties for the research and development of new products. We have maintained long-term cooperative relationships
with a number of research institutions and universities in the PRC. These research institutions and universities used to collaborate with
us in a number of research projects and certain of our products with approval certificates were developed by such research institutions.
Any failure of such research institutions to meet the required quality standards and timetables set forth in their research agreements
with us, or our inability to enter into additional research agreements with these research institutions on terms acceptable to us in the
future, may have an adverse effect on our ability to develop new medicines and on our business prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">While the Company may resume
the development of these formulas in the future if sufficient funding and other favorable conditions arise, we cannot guarantee that we
will be able to enter into agreements with new parties on terms acceptable to us. Our inability to enter into such agreements or our failure
to maintain such arrangements could limit the number of new products that we develop and ultimately decrease our sources of future revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to obtain regulatory
approval for any of the new products and failure to obtain these approvals could materially harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">All new medicines must be approved
by the NMPA before they can be marketed and sold in the PRC. The NMPA requires successful completion of clinical trials and demonstrated
manufacturing capability before it grants approval. It often takes a number of years before a medicine can be ultimately approved by the
NMPA. In addition, the NMPA and other regulatory authorities may apply new standards for safety, manufacturing, packaging, and distribution
of future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Complying with such standards
may be time-consuming and expensive and could result in delays in obtaining NMPA approval for our future product candidates, or possibly
preclude us from obtaining NMPA approval altogether. For example, due to the enhanced criteria introduced during the implementation process
of the trial of one of our products in the dried powder injectable and granule production lines in our old plant, the clinical trials
lasted longer than originally expected. Furthermore, our future products may not be effective or may prove to have undesirable or unintended
side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval and prevent or limit their commercial
use. The NMPA and other regulatory authorities may not approve the products that we develop and even if we do obtain regulatory approvals,
such regulatory approvals may be subject to limitations on the indicated uses for which we may market a product, which may limit the size
of the market for such product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New product development in the pharmaceutical
industry is time-consuming and costly and has a low rate of successful commercialization</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our success depends in part
on our ability to improve our existing products and to develop new products. The development process for pharmaceutical products is complex
and uncertain, as well as time-consuming and costly. Relatively few research and development programs can finally develop a commercial
product. A product candidate that appears promising in the early phases of development may fail to reach the market for a number of reasons,
such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the failure to demonstrate safety
and efficacy in preclinical and clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the failure to obtain approvals
for intended use from relevant regulatory bodies, such as the NMPA;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to manufacture
and commercialize sufficient quantities of the product economically; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">proprietary rights, such as
patent rights, held by others to our product candidates and their refusal to sell or license such rights to us on reasonable terms, or
at all.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Delays in any part of the development
process or our inability to obtain regulatory approval of our products could adversely affect our operating results by restricting or
delaying our introduction of new products. Even if we successfully commercialize new products, these products may compete with our mature
products and may result in a reduction in the sales volume of our mature product or vice versa. Failure to develop, obtain necessary regulatory
clearances or approvals for or successfully commercialize or market potential new products or technologies could have a material adverse
effect on our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to successfully identify
and acquire new products or businesses</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition to our own product
development efforts, our growth strategy also relies on our acquisitions of new product candidates, products or businesses from third
parties. Any future growth through acquisitions will be dependent upon the continued availability of suitable acquisition candidates at
favorable prices and favorable terms and conditions. Even if such opportunities present themselves, we may not be able to successfully
identify them. Moreover, other companies, many of which may have substantially greater financial, marketing and sales resources, are competing
with us for the right to acquire such product candidates, products or businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on distributors for all of our revenues
and failure to maintain relationships with and collect payment from, our distributors or to otherwise expand our distribution network
would materially and adversely affect our business</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We sell our products exclusively
to pharmaceutical distributors in the PRC and rely on distributors for all of our revenues. We have business relationships with over 1,000
distributors in the PRC. For the year ended December 31, 2023, no customer accounted for more than 10.0% of sales, and three customers
accounted for 62.5%, 13.5% and 6.2% of accounts receivable. In line with industry practices in the PRC, we enter into written sales agreements
with our distributors. However, such sales agreements are not in substance equivalent to a typical distribution agreement in the United
States. Each sales agreement is more in the form of a sales order and specifies one or several purchases of one or more products without
any continuing obligation to purchase any additional amount of products. There are no written contracts between the Company and any of
its distributors requesting the distributors to pay the Company&#8217;s account receivable upon their receipt of funds from its customers,
or state-owned hospitals. Pharmaceutical distributors typically process the payment of the account receivable to the Company upon their
receipt of payment from their customers, i.e., the state-owned hospitals, as a matter of implied consensus. In the event the length of
collection term is deviated from any of the past pattern of any particular customer, the Company will adjust its credit term. Any potential
default in repaying the accounts receivable without recourse by the Company may materially and negatively affect the Company&#8217;s profitability
and business. In the event certain distributors choose not to continue their relationship with us after completing their existing sales
agreements, they can do so without breaching any contract or agreement, our financial results could be adversely affected if we cannot
find the substantially similar distributors in time under such circumstances. In addition, some of our distributors may sell products
that compete with our products. We compete for desired distributors with other pharmaceutical manufacturers, many of which may have higher
visibility, greater name recognition, financial resources, and broader product selection than we do. Consequently, maintaining relationships
with existing distributors and replacing distributors may be difficult and time-consuming. Any disruption of our distribution network,
including our failure to renew our existing distribution agreements with our desired distributors, could negatively affect our ability
to effectively sell our products and would materially and adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on a limited number of distributors
for the majority of sales of our products</i></b>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We rely on a limited number
of distributors for most of our net revenue. Our top five distributors in aggregate accounted for 22% and 20% of our net revenues in 2023
and 2022, respectively. We expect that a relatively small number of distributors will continue to account for a major portion of our net
revenue in the near future. Our dependence on a few distributors may expose us to the risk of substantial losses if a single large distributor
stops purchasing our products, purchases lower quantities of our products or goes out of business and we cannot find substitute distributors
on equivalent terms. If any of our large distributors reduces the quantity of the products they purchase from us or stops purchasing from
us, our net revenue would be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations may be affected if we could
not pass the Consistency Evaluation requirement issued by the State Council for any of our current existing products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Generic drugs refer to drugs
with the same active ingredient, dosage form, delivery channel and therapeutic effects compared to the original drugs. The &#8220;Consistency
Evaluation&#8221; requires currently marketed generic products to prove their consistency in term of quality and therapeutic effect, and
substitutability during clinical trials with original drug. The Consistency Evaluation could enhance the development of pharmaceutical
industry, ensure drug safety and effectiveness, promote the upgrading and restructuring the pharmaceutical industry, and improve international
competitiveness. Both <i>Relevant Matters Related to the Implementation of the Opinions of the General Office of the State Council on
the Consistent Evaluation of the Quality and Efficacy of Generic Drugs</i> (No. 106 of 2016) issued on May 26, 2016, and <i>Announcement
of the General Administration on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs</i> (No. 100 of 2017) issued
on August 28, 2017 require that if a drug has more than 3 manufacturers passed the consistency evaluation, then the drug manufacturers
without consistency evaluation valid status will have no access to participate in the drug Centralized Procurement. NMPA issued an official
document on The Implementation of the Evaluation of the Quality and Efficacy of Chemical Injection Generics on May 14, 2020, requiring
consistent evaluation for generics of pharmaceutical injections that are already on the market. If we fail to complete the consistency
evaluations for our generic drugs per the government&#8217;s requirements, our business and operation will be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations may be affected if we could
not obtain raw materials from our current key suppliers on acceptable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We need a supply of a wide
variety of raw materials to manufacture our products. Currently, we rely on numerous suppliers in the PRC and overseas to deliver our
required raw materials. We have at least three principal suppliers for each of our most critical raw materials. For the year ended December
31, 2023, three suppliers accounted for 17.7%, 13.8% and 9.1% of raw material purchases and for the year ended December 31, 2022, three
suppliers accounted for 21.7%, 11.1% and 8.9% of raw material purchases.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Historically, we have not had
difficulty obtaining raw materials from suppliers. However, we cannot assure in the future we will not encounter any difficulty in obtaining
the supplies, nor can we predict the impact on our suppliers of the current economic environment and other developments in their respective
businesses, either. Insolvency, financial difficulties or other factors may result in our suppliers not being able to fulfill the terms
of their agreements with us. Furthermore, such factors may render suppliers unwilling to extend contracts that provide favorable terms
to us or may force them to seek to renegotiate existing contracts. Although we believe we have alternative sources of supply for the raw
materials used in our business, termination of our relationships with any of our key suppliers could have a material adverse effect on
our business, financial condition or results of operations in the unlikely event that we are unable to obtain adequate raw materials from
other sources in a timely manner or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to effectively manage
our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected by
actions taken by our distributors and third party marketing firms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have limited ability to
manage and control the activities of our independent distributors and third-party marketing firms that we contract to promote our products
and brand name, therefore, our reputation, business, prospects and brand may be materially and adversely affected by actions taken by
them. Our distributors and third-party marketing firms could take one or more of the following actions, any of which could have a material
adverse effect on our business, prospects and brand:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">sell our products outside their
designated territory, possibly in violation of the exclusive distribution rights of other distributors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fail to adequately promote our
products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">promote competing products in
lieu of our products; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">violate the anti-corruption
laws of China, the United States or other countries.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Additionally, although our
company policies prohibit our employees from making improper payments to hospitals or otherwise engaging in improper activities to influence
the procurement decisions of hospitals, we may not be able to effectively manage our employees, as the compensation of our sales and marketing
personnel is partially linked to their sales performance. As a result, we cannot assure you that our employees will not violate the anticorruption
laws of the PRC, the United States and other countries. Such violations could have a material adverse effect on our reputation, business,
prospects and brand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Failure to adequately manage
our employees, distribution network or third-party marketing firms, or their non-compliance with employment, distribution or marketing
agreements could harm our corporate image among hospitals and end users of our products and disrupt our sales, resulting in a failure
to meet our sales goals. Furthermore, we could be liable for actions taken by our employees, distributors or third-party marketing firms,
including any violations of applicable law in connection with the marketing or sale of our products, including China&#8217;s anticorruption
laws and the Foreign Corrupt Practices Act of the United States, or the FCPA. In particular, if our employees, distributors or third-party
marketing firms make any payments that are forbidden under the FCPA, we could be subject to civil and criminal penalties imposed by the
U.S. government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Recently, the PRC government
has increased its anti-corruption measures. In the pharmaceutical industry, corrupt practices include, among others, acceptance of rebates,
bribes or other illegal gains or benefits by hospitals and medical practitioners from pharmaceutical manufacturers and distributors in
connection with the prescription of certain pharmaceuticals. Our employees, affiliates, distributors or third-party marketing firms may
violate these laws or otherwise engage in illegal practices with respect to their sales or marking of our products or other activities
involving our products. If our employees, affiliates, distributors or third-party marketing firms violate these laws, we could be required
to pay damages or fines, which could materially and adversely affect our financial condition and results of operations. In addition, PRC
laws regarding the types of payments to promote or sell our products that are impermissible are not always clear. As a result, we, our
employees, affiliates, our distributors or third-party marketing firms could make certain payments in connection with the promotion or
sale of our products or other activities involving our products which at the time could be reasonably determined to be legal but are later
deemed impermissible by the PRC government. Furthermore, our brand and reputation, our sales activities or the price of our common stock
could be adversely affected if we become the target of any negative publicity as a result of actions taken by our employees, affiliates,
distributors or third-party marketing firms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited insurance coverage and may
incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The nature of our business
exposes us to the risk of product liability claims that is inherent in the research and development, manufacturing and marketing of pharmaceutical
products. Using product candidates in clinical trials also exposes us to product liability claims. These risks are greater for our products
that receive regulatory approval for commercial sale. Even if a product is approved for commercial use by an appropriate governmental
agency, there can be no assurance that users will not claim effects other than those intended resulted from the use of our products. While
no material claim for personal injury resulting from allegedly defective products has been brought against us to date, a substantial claim
or a substantial number of claims, if successful, could have a material adverse impact on our business, financial condition and results
of operations. Such lawsuits may divert the attention of our management from our business strategies, may be costly to defend and may
negatively impact our reputation and our Helpson brand&#8217;s reputation, and may harm the sales of our other branded products. In addition,
product liability insurance for pharmaceutical products is not available in the PRC. In the event of allegations that any of our products
are harmful, we may experience reduced consumer demand for our products or our products may be recalled from the market. We may also be
forced to defend lawsuits and, if unsuccessful, to pay a substantial amount in damages, legal fees, and other related expenses. In addition,
business interruption insurance available in the PRC offers limited coverage compared to that offered in many other countries. We do not
have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and diversion
of resources. Lastly, we currently do not have directors and officers insurance. In the event we or any of our directors or officers are
sued under any proceedings or actions that could be covered by a standard D&amp;O insurance, we may incur substantial costs and expenses
to defend such case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future liquidity needs are uncertain
and we may need to raise additional funds in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Based on our current operating
plans, we expect our existing resources to be sufficient to fund our existing operations for at least 12 months. However, we may need
to raise additional funds to expand our operations. In addition, we may need to raise additional funds if our expenditures exceed our
current expectations. This could occur for a number of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide to devote significant
amount of financial resources to the development of products that we believe to have significant commercialization potential;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide to acquire or license
rights to additional product candidates or new technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">some of our product candidates
fail in clinical trials or pre-clinical studies or prove not to be as commercially promising as we expected, and we are forced to develop
or acquire additional product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Some of our product candidates
require more extensive clinical or pre-clinical testing or clinical trials for these product candidates take longer to complete than
we currently expect; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we decide or are required to
conduct more high-throughput screening than expected against current or additional disease targets to develop additional product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">Our ability to raise additional funds in the future is subject to a variety of uncertainties, including:</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our future financial condition,
results of operations and cash flows;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">general market conditions for
capital-raising activities by pharmaceutical companies; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">economic, political and other
conditions in China and elsewhere.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We cannot assure you that our
revenues will be sufficient to meet our operational needs and capital requirements. If we need to obtain external financing, we cannot
assure you that financing will be available in amounts or on terms acceptable to us, if at all. Our future liquidity needs and other business
reasons could require us to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity or equity-linked
securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased
debt service obligations and could result in operating and financing covenants that would restrict our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure to manage growth effectively
could have an adverse effect on our business, financial condition and results of our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The rapid market growth of
our pharmaceutical products may pose more requirements or more costs on the employment management for managerial, operational, financial
and other purposes. As of December 31, 2023, we had 239 employees. To keep up with the rapid development of the Chinese pharmaceutical
industry, it will impose significant responsibilities upon the members of management to identify, recruit, maintain, integrate and motivate
new and old employees In addition, we may need to increase the salary, or the equity incentive plan for the employees to keep them in
the Company. Aside from the increased difficulties and increased costs in the management of human resources, we may also encounter working
capital issues, as we need increased liquidity to finance the purchases of raw materials and supplies, drug formulas for new products,
investment in research and development, acquisition of new businesses and technologies. Our failure to manage any of the above business
administration may lead to operational and financial inefficiencies that will have a negative effect on our profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon key employees and consultants
in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability
to develop and market our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent upon
the principal members of our management team, especially Ms. Zhilin Li, our Chairperson, President and Chief Executive Officer. We cannot
not guarantee that Ms. Li will stay in the Company in the long run, and the loss of Ms. Li&#8217;s services would adversely affect our
ability to develop and market our products. We also depend in part on the continued services of our key scientific personnel and our ability
to identify, hire and retain additional personnel, including marketing and sales staff. We face intense competition for qualified personnel,
and the existence of noncompetition agreements between prospective employees and their former employers may prevent us from hiring those
individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract
and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult
for us to compete successfully for key personnel.</p><div>
</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Certain of our employees and
consultants were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors,
or at universities or other research institutions. Although there is currently no claim against us, we may be subject to claims that these
employees or consultants have, inadvertently or otherwise, used or disclosed trade secrets or other proprietary information of their former
employers. It may be necessary to for us to litigate and defend against these claims. Even if we successfully defend against these claims,
litigation could result in substantial costs and be a distraction to our management. If we fail to defend such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights or personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Power shortages, natural disasters, terrorist
acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and results
of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">All of our products are produced
at our manufacturing facility in Hainan, China, which is exposed to certain natural disasters such as typhoons. A significant disruption
at that facility, even on a short-term basis, could impair our ability to timely produce and ship products, which could have a material
adverse effect on our business, financial position and results of operations. Our manufacturing operations are vulnerable to interruption
and damage from natural and other types of disasters, including earthquake, fire, floods, environmental accidents, power loss, communications
failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, we do not maintain
any insurance other than property insurance for some of our buildings, vehicles and equipment. Accordingly, unexpected business interruptions
resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. Our production
process requires a continuous supply of electricity. We have encountered power shortages historically due to restricted power supply to
industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity
supply network. Because the duration of those power shortages was brief, they had no material impact on our operations. Longer interruptions
of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss
of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a
material adverse impact on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot guarantee the protection of our
intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation and
business may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">To protect the brand names
of our products, we have registered and applied for registration of certain of our trademarks in the PRC. Currently eight of the 19 pharmaceutical
products we manufacture are marketed under a brand registered as a trademark in China. We also purchased six pharmaceutical compounds
from certain third parties that we are seeking to develop into a further product. &#160;&#160;To date, we have not experienced any infringements
of our trademarks for sales of pharmaceutical products or our exclusive patent license, and we are not aware of any infringement of our
intellectual property rights. However, there is no guarantee that there will not be any infringements of our brand name or other registered
trademarks or counterfeiting of our products in the future. There is no guarantee that there will not be any third-party infringement
of our patents. Should any such infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also
incur significant expenses and substantial amounts of time and effort to protect our intellectual property rights in the future. Such
diversion of our resources may adversely affect our existing business and future expansion plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Litigation may be necessary
in the future to enforce our intellectual property rights or to determine the validity and scope of the intellectual property rights of
others. However, because the validity, enforceability and scope of protection of intellectual property rights in the PRC are uncertain
and still evolving, we may not be successful in prosecuting these cases. In addition, any litigation or proceeding or other efforts to
protect our intellectual property rights could result in substantial costs and diversion of our resources and could seriously harm our
business and operating results. Furthermore, the degree of future protection of our proprietary rights is uncertain and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. If we are unable to protect our trade names, trade secrets
and other propriety information from infringement, our business, financial condition and results of operations may be materially and adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in China</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse changes in political and economic
policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce the
demand for our services and materially and adversely affect our competitive position.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We conduct substantially all
of our business and have historically derived all of our revenues in China. Accordingly, our business, financial condition, results of
operations and prospects are affected significantly by economic, political and legal developments in China. The Chinese economy differs
from the economies of most developed countries in many respects, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the degree of government involvement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the level of development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the growth rate;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the control of foreign exchange;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">access to financing; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the allocation of resources.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">While the Chinese economy has
experienced significant growth in the past 30 years, growth has been uneven, both geographically and among various sectors of the economy.
The Chinese economy has also experienced certain adverse effects due to the recent global financial crisis. The Chinese government has
implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures benefit the overall
Chinese economy, but may also have a negative effect on us. For example, our operating results and financial condition may be adversely
affected by government control over capital investments or changes in tax regulations that are applicable to us, and by government policies
or guidance aimed at curtailing the perceived over-capacity of certain industry sectors, such as pharmaceutical companies. The Chinese
government has implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures
may cause decreased economic activity in China, which could in turn reduce the demand for our products and materially and adversely affect
our operating results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">China&#8217;s economy has been
transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented
measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the
establishment of sound corporate governance in business enterprises, Chinese government still has substantive power to certain areas that
may be related to the business operations of our operating entities, such as the right to use land, price of certain of our products,
and it could materially and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any adverse change in the economic
conditions or government policies in China could have a material and adverse effect on overall economic growth and the level of investments
in health industries in China, which in turn could lead to a reduction in demand for our products and consequently have a material and
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Chinese government may intervene with
or influence our business at any time. That may negatively influence our operation, our ability to continue listing on U.S. exchange and
the value of our shares may significantly decline or be worthless, which would materially affect the interest of our stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Chinese central or
local governments may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures
and efforts on our part to ensure our compliance with such regulations or interpretations. Accordingly, government actions in the future,
including any decision not to continue to support recent economic reforms and to return to a more centrally planned economy or regional
or local variations in the implementation of economic policies, could have a significant effect on economic conditions in China or particular
regions thereof, and could require us to divest ourselves of any interest we then hold in Chinese properties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As such, our business segments
may be subject to various government and regulatory interference in the provinces in which they operate. The Company could be subject
to regulation by various political and regulatory entities, including various local and municipal agencies and government sub-divisions.
The Company may incur increased costs necessary to comply with existing and newly adopted laws and regulations or penalties for any failure
to comply. The Chinese government may intervene with or influence our operations at any time with little advance notice, which could result
in a material change in our operations and in the value of our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The PRC legal system has inherent uncertainties
that could limit the legal protections available to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The PRC legal system is a civil
law system based on written statutes. Unlike common law systems, it is a system in which legal cases have little precedential value. In
the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing commercial matters. The
overall effect of legislation enacted over the past 20 years has significantly enhanced the protections afforded to foreign-invested enterprises
in China. However, these laws, regulations and legal requirements are relatively recent and are evolving rapidly, and their interpretation
and enforcement involve uncertainties. These uncertainties could limit the legal protections available to foreign investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The practical effect of the
PRC legal system on our business operations in China can be viewed as two separate but intertwined considerations. First, as a matter
of substantive law, the Foreign Invested Enterprise laws provide significant protection to keep the Company from government interference.
In addition, these laws guarantee the full benefit of corporate articles and contracts to foreign invested enterprise participants. These
laws, however, do impose standards concerning corporate formation and governance that are not qualitatively different from the corporation
laws found in the United States. Similarly, PRC accounting laws mandate accounting practices that may not be consistent with the U.S.
generally accepted accounting principles. PRC accounting laws require that an annual &#8220;statutory audit&#8221; be performed in accordance
with PRC accounting standards and that the account books of a foreign invested enterprise be maintained in accordance with PRC accounting
laws. Article 14 of the PRC Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned enterprise to submit certain periodic
fiscal reports and statements to designated financial and tax authorities. If a foreign-invested enterprise refuses to keep account books
in China, the financial and tax authorities may impose a fine on it, and the industry and commerce administration authority may order
it to suspend operations or may revoke its business license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Second, while the enforcement
of substantive rights may be less clear than United States procedures, foreign-invested enterprises and foreign wholly-owned enterprises
are PRC registered companies that enjoy the same status as other PRC registered companies in business-to-business dispute resolutions.
The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present a significant
impediment to the operation of a foreign invested enterprise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management based
on U.S. or other foreign laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our operating subsidiary, Helpson,
is incorporated under the laws of the PRC and substantially all of our assets are located in the PRC. Additionally, substantially all
of our directors, executive officers and managers reside within the PRC, and substantially all assets of these persons are located within
the PRC. As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC upon certain
of our directors, executive officers or managers, including with respect to matters arising under U.S. federal securities laws or applicable
state securities laws. Moreover, the PRC does not have treaties providing for the reciprocal recognition and enforcement of judgments
of courts with the United States, and many other countries. As a result, recognition and enforcement in the PRC of judgments of a court
in the United States and any of the other jurisdictions in relation to any matter may be difficult or impossible. Furthermore, an original
action may be brought in the PRC against us, our directors, executive officers or managers only if the actions are not required to be
arbitrated by PRC law under Helpson&#8217;s articles of association, and only if the facts alleged in the complaint give rise to a cause
of action under PRC law. In connection with any such original action, a PRC court may impose civil liability, including monetary damages.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a Foreign Invested Company in China,
Helpson&#8217;s ownership structure may be impacted by the foreign investment regulation and its measures in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In accordance with Decree No.
723 of the State Council of the People&#8217;s Republic of China issued on December 26, 2019, the Regulations on the Implementation of
the Foreign Investment Law of the People&#8217;s Republic of China came into force on January 1, 2020. On December 28, 2020, the National
Development and Reform Commission and the Ministry of Commerce publicly released the Directory of Industries to Encourage Foreign Investment
(Encouraged Catalogue) (2020 Edition). On December 27, 2021, the National Development and Reform Commission of China (&#8220;NDRC&#8221;)
and the Ministry of Commerce (&#8220;MOFCOM&#8221;) jointly issued the Special Administrative Measures for Foreign Investment Access (Negative
List) (2021 Edition), and the Special Administrative Measures for Foreign Investment Access in Pilot Free Trade Zones (Negative List)
(2021 Edition), effective January 1, 2022. As per these policies, the national negative list of foreign investment access was reduced
from 33 to 31, and the negative list of foreign investment access in the FTZ was reduced from 30 to 27. Industries listed in the 2020
Encouraged Catalogue are the encouraged industries. On the other hand, industries listed in the 2021 Negative List are subject to special
management measures. For example, establishment of wholly foreign-owned enterprises is generally allowed in industries outside of the
2021 Negative List. Also, foreign investors are not allowed to invest in industries that are expressly prohibited in the 2021 Negative
List. The industries that are not expressly prohibited in the Negative List are still subject to government approvals and certain special
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The majority of pharmaceutical
manufacturing industry including the segments under which the Company conducts its business is not included in the 2021 Negative List.
Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and
private retailers located throughout the PRC. The Company believes Helpson&#8217;s business is not subject to any ownership restrictions
prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement
with Helpson&#8217;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005
and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day.
Helpson received its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005. However, in the event
the 2021 Negative List is amended in the future to include any of the business Helpson is operating, our ownership structure could be
subject to change to the extent our structure is not given any &#8220;grandfather&#8221; protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we receive substantially all of
our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency conversion
and the fluctuation of the Renminbi, we are subject to changes in the PRC&#8217;s political and economic decisions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We receive substantially all
of our revenues in Renminbi, which currently is not a freely-convertible currency. The PRC government may, at its discretion, restrict
access in the future to foreign currencies for current account transactions. Any future restrictions on currency exchanges may limit our
ability to use revenue generated in Renminbi to fund any future business activities outside China or to make dividend or other payments
in U.S. dollars. Although the Chinese government introduced regulations in 1996 to allow greater convertibility of the Renminbi for current
account transactions, significant restrictions still remain, including primarily the restriction that foreign-invested enterprises may
only buy, sell or remit foreign currencies, after providing valid commercial documents, at those banks authorized to conduct foreign exchange
business. In addition, conversion of Renminbi for capital account items, including direct investment and loans, is subject to governmental
approval in China, and companies are required to open and maintain separate foreign exchange accounts for capital account items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We cannot be certain that the Chinese regulatory
authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect to foreign exchange
transactions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Fluctuation in the value of
the Renminbi may have a material and adverse effect on your investment. The change in value of the Renminbi against the U.S. dollar is
affected by, among other things, changes in PRC&#8217;s political and economic conditions. From 1995 until July 2005, the People&#8217;s
Bank of China intervened in the foreign exchange market to maintain an exchange rate of approximately Renminbi 8.3 per U.S. dollar. On
July 21, 2005, the PRC government changed this policy and began allowing modest appreciation of the Renminbi versus the U.S. dollar. Under
the new policy, the Renminbi was permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies.
This change in policy caused the Renminbi to appreciate approximately 21.5% against the U.S. dollar over the following three years. As
a consequence, the Renminbi has fluctuated sharply since July 2008 against other freely traded currencies, in tandem with the U.S. dollar.
It is difficult to predict how long the current situation may last and when and how it may change again. There is significant international
pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more
significant appreciation in the value of the Renminbi against the U.S. dollar. Significant revaluation of the Renminbi may have a material
adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from securities offering
into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount
we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments
for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative
effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%, represented
the largest yuan depreciation for 20 years. Concerns remain that China&#8217;s slowing economy, and in particular its exports, will need
a stimulus that can only come from further cuts in the exchange rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, appreciation or
depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms
without giving effect to any underlying change in our business or results of operations. The income statements of our operations are translated
into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies,
the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for
our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign
currency denominated transactions results in increased revenue, operating expenses and net income for our international operations. We
are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars
in consolidation. If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries&#8217; financial
statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income.
Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered
into any hedging transactions. While we may enter into hedging transactions in the future, the availability and effectiveness of these
transactions may be limited, and we may not be able to successfully hedge our exposure at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to the environmental protection
laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our manufacturing process may
produce by-products, such as effluent, gases and noise, which are harmful to the environment. We are subject to multiple laws governing
environmental protection, such as &#8220;The Law on Environmental Protection in the PRC&#8221; and &#8220;The Law on Prevention of Effluent
Pollution in the PRC,&#8221; as well as standards set by the relevant governmental bodies determining the classification of different
wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing facility, which details the types
and concentration of effluents and gases allowed for disposal. We are responsible for periodically renewing this waste disposal permit.
There is no assurance that we will obtain a renewal of the waste disposal permit when the current permit expires in February 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">China is experiencing substantial
environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies will adopt stricter pollution
controls. There is no guarantee that future changes in environmental laws and regulations will not impose costly compliance requirements
on us or otherwise subject us to future liabilities. Our business&#8217;s profitability may be adversely affected if additional or modified
environmental control regulations are imposed upon us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with PRC regulations regarding
the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines and other legal
or administrative sanctions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On March 28, 2007, the SAFE
promulgated the Application Procedure of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Holding
Plan or Share Option Plan of Overseas-Listed Company, which were superseded by Notice from SAFE regarding Issues related to Domestic Individual
Participating Offshore Public Company Equity Incentive Plan promulgated on February 15, 2012 (&#8220;SAFE #7&#8221;), or the Share Option
Rule. Under the Share Option Rule, PRC citizens who are granted stock options or other employee equity incentive awards by an overseas
publicly-listed company are required, through a PRC agent who may be a PRC subsidiary of such overseas publicly-listed company, to register
with the SAFE and complete certain other procedures related to the share options or other employee equity incentive plans. We and our
PRC citizen employees who are granted share options or other equity incentive awards under our 2010 Long-Term Incentive Plan, or PRC optionees,
are subject to the Share Option Rule. If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be
subject to fines and legal sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. regulatory bodies may be limited in
their ability to conduct investigations or inspections of our operations in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any disclosure of documents
or information located in China by foreign agencies may be subject to jurisdiction constraints and must comply with China&#8217;s state
secrecy laws, which broadly define the scope of &#8220;state secrets&#8221; to include matters involving economic interests and technologies.
There is no guarantee that requests from U.S. federal or state regulators or agencies to investigate or inspect our operations will be
honored by us, by entities who provide services to us or with whom we associate, without violating PRC legal requirements, especially
as those entities are located in China. Furthermore, under the current PRC laws, an on-site inspection of our facilities by any of these
regulators may be limited or prohibited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulation of loans to and direct investment
in PRC entities by offshore holding companies and governmental control of currency conversion may delay us from using the proceeds of
this offering to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our
liquidity and our ability to fund and expand our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any funds the Company transfer
to our PRC subsidiaries, either as a shareholder loan or as an increase in registered capital, are subject to approval by or registration
with relevant governmental authorities in China. According to the relevant PRC regulations on foreign-invested enterprises, or FIEs, in
China, capital contributions to our PRC subsidiaries are subject to the approval of or filing with the Ministry of Commerce, or MOFCOM
or its local branches and registration with a local bank authorized by the State Administration of Foreign Exchange, or SAFE. In addition,
(i) a foreign loan of less one year duration procured by our PRC subsidiaries is required to be registered with SAFE or its local branches
and (ii) a foreign loan of one year duration or more procured by our PRC subsidiaries is required to be applied to the NDRC in advance
for undergoing recordation registration formalities. Any medium or long-term loan to be provided by us to our PRC operating subsidiaries,
must be registered with the NDRC and the SAFE or its local branches. The Company may not be able to complete such registrations on a timely
basis, with respect to future capital contributions or foreign loans by us to our PRC Subsidiary. If the Company fail to complete such
registrations, our ability to use the proceeds of this offering and to capitalize our PRC operations may be negatively affected, which
could adversely affect our liquidity and our ability to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On March 30, 2015, the SAFE
promulgated the Circular on Reforming the Management Approach Regarding the Foreign Exchange Capital Settlement of Foreign-Invested Enterprises,
or SAFE Circular 19, which took effect as of June 1, 2015. SAFE Circular 19 launched a nationwide reform of the administration of the
settlement of the foreign exchange capitals of FIEs and allows FIEs to settle their foreign exchange capital at their discretion, but
continues to prohibit FIEs from using the Renminbi fund converted from their foreign exchange capital for expenditure beyond their business
scopes, providing entrusted loans or repaying loans between nonfinancial enterprises. The SAFE issued the Circular on Reforming and Regulating
Policies on the Control over Foreign Exchange Settlement of Capital Accounts, or SAFE Circular 16, effective in June 2016. Pursuant to
SAFE Circular 16, enterprises registered in China may also convert their foreign debts from foreign currency to Renminbi on a self-discretionary
basis. SAFE Circular 16 provides an integrated standard for conversion of foreign exchange under capital account items (including but
not limited to foreign currency capital and foreign debts) on a self-discretionary basis which applies to all enterprises registered in
China. SAFE Circular 16 reiterates the principle that Renminbi converted from foreign currency-denominated capital of a company may not
be directly or indirectly used for purposes beyond its business scope or prohibited by PRC laws or regulations, while such converted Renminbi
shall not be provided as loans to its non-affiliated entities. As this circular is relatively new, there remains uncertainty as to its
interpretation and application and any other future foreign exchange related rules. Violations of these Circulars could result in severe
monetary or other penalties. SAFE Circular 19 and SAFE Circular 16 may significantly limit our ability to transfer any foreign currency
we hold, including the net proceeds from this offering, to our WFOE, which may adversely affect our liquidity and our ability to fund
and expand our business in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On October 23, 2019, the SAFE
issued the Circular on Further Promoting Cross-border Trade and Investment Facilitation (the &#8220;SAFE Circular 28&#8221;), which took
effect on the same day. The SAFE Circular 28, subject to certain conditions, allows foreign-invested enterprises whose business scope
does not include investment, or non-investment foreign-invested enterprises, to use their capital funds to make equity investments in
China. It is also implemented in practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In light of the various requirements
imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that
we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if
at all, with respect to future loans to our PRC Subsidiaries or future capital contributions by us to our WFOE in China. As a result,
uncertainties exist as to our ability to provide prompt financial support to our PRC Subsidiaries when needed. If we fail to complete
such registrations or obtain such approvals, our ability to use the proceeds we expect to receive from this offering and to capitalize
or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability
to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with China&#8217;s new Data Security
Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for consultation), regulations and guidelines
relating to the multi-level protection scheme and any other future laws and regulations may entail significant expenses and could materially
affect our business.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">China has implemented or will
implement rules and is considering a number of additional proposals relating to data protection. China&#8217;s new Data Security Law took
effect in September 2021. The Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification
and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in China from transferring data stored
in China to foreign law enforcement agencies or judicial authorities without prior approval by the Chinese government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Additionally, China&#8217;s
Cyber Security Law requires companies to take certain organizational, technical and administrative measures and other necessary measures
to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that China adopt
a multi-level protection scheme (MLPS), under which network operators are required to perform obligations of security protection to ensure
that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed, stolen or
tampered. Under the MLPS, entities operating information systems must have a thorough assessment of the risks and the conditions of their
information and network systems to determine the level to which the entity&#8217;s information and network systems belong-from the lowest
Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection
of cyber security. The grading result will determine the set of security protection obligations that entities must comply with. Entities
classified as Level 2 or above should report the grade to the relevant government authority for examination and approval. The Company&#8217;s
management believes that they are currently classified as Level 1.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Recently, the Cyberspace Administration
of China has taken action against several Chinese internet companies in connection with their initial public offerings on U.S. securities
exchanges, for alleged national security risks and improper collection and use of the personal information of Chinese data subjects. According
to the official announcement, the action was initiated based on the National Security Law, the Cyber Security Law and the Measures on
Cybersecurity Review, which are aimed at &#8220;preventing national data security risks, maintaining national security and safeguarding
public interests.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">It is unclear at the present
time how widespread the cybersecurity review requirement and the enforcement action will be and what effect they will have on our business.
China&#8217;s regulators may impose penalties for non-compliance ranging from fines or suspension of operations, and this could lead to
us delisting from the U.S. stock market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Also, recently, the National
People&#8217;s Congress released the Personal Information Protection Law (the &#8220;PIPL&#8221;), which became effective on November
1, 2021. The PIPL creates a comprehensive set of data privacy and protection requirements that apply to the processing of personal information
and expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals
in China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing
products and services to, or analyzing and evaluating the behavior of, persons in China. The PIPL also provides that critical information
infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to-be-set
by Chinese cyberspace regulators are also required to store in China personal information generated or collected in China, and to pass
a security assessment administered by Chinese cyberspace regulators for any export of such personal information. Lastly, the PIPL provides
significant fines for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year and may also be ordered
to suspend any related activity by competent authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On December 28, 2021, the CAC,
and other twelve PRC regulatory authorities jointly revised and promulgated <i>the Measures for Cyber Security Review</i>, or the New
Measures for Cyber Security Review, which came into effect on February 15, 2022 and replace the prior Measures for Cyber Security Review
promulgated on April 13, 2020. The New Measures for Cyber Security Review provides that, among others, (i) the purchase of cyber products
and services by critical information infrastructure operators and the network platform operators engaging in data processing activities
that affects or may affect national security should be subject to the cybersecurity review by the Cybersecurity Review Office, the department
which is responsible for the implementation of cybersecurity review under the CAC; (ii) network platform operators with personal information
data of more than one million users are obliged to apply for a cybersecurity review by the Cybersecurity Review Office before listing
abroad; and (iii) relevant governmental authorities in the PRC may initiate cybersecurity review if they determine the relevant network
products or services or data processing activities affect or may affect national security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe that we are not
subject to cybersecurity review, since we (i) are not network platform operators engaging in data processing activities that affect or
may affect national security; (ii) are not critical information infrastructure operators purchasing cyber products or services that affect
or may affect national security; (iii) are not network platform operators with personal information data of more than one million users
and do not need to obtain any permission or approval from the CAC in accordance with the New Measures for Cyber Security Review. However,
as PRC governmental authorities have significant discretion in interpreting and implementing statutory provisions and there remains significant
uncertainty in the interpretation and enforcement of relevant PRC cybersecurity laws and regulations, we cannot guarantee the PRC government
will have the same analysis and application of law as we expect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">	In November 2021, the CAC
released the Measures of Regulations on the Network Data Security Administration (Draft for Comments), or the Draft Regulations on Network
Data Security. The Draft Regulations on Network Data Security define &#8220;data processors&#8221; as individuals or organizations that
can make autonomous decisions regarding the purpose and the manner of their data processing activities such as data collection, storage,
utilization, transmission, publication and deletion. In accordance with the Draft Regulations on Network Data Security, data processors
shall apply for a cybersecurity review for certain activities, including, among other things, (i) the listing abroad of data processors
that process the personal information of more than one million users; (ii) merger, reorganization or division of internet platform operators
that have acquired a large number of data resources related to national security, economic development or public interests affects or
may affect national security; (iii) listing in Hong Kong which affects or may affect national security; or (iv) any data processing activity
that affects or may affect national security. However, there have been no clarifications from the relevant authorities as of the date
of this annual report as to the standards for determining whether an activity is one that &#8220;affects or may affect national security.&#8221;
In addition, the Draft Regulations on Network Data Security requires that data processors that process &#8220;important data&#8221; or
are listed overseas must conduct an annual data security assessment by itself or authorize a data security service provider to do so,
and submit the assessment report of the preceding year to the municipal cybersecurity department by the end of January each year. As of
the date of this annual report, the Draft Regulations on Network Data Security has not been formally adopted, and their respective provisions
and anticipated adoption or effective date may be subject to change with substantial uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Many of the data- and data
privacy-related laws and regulations are relatively new and certain concepts thereunder remain subject to interpretation by the regulators.
If any data that we possess belongs to data categories that are or may become subject to heightened scrutiny, we may be required to adopt
stricter measures for protection and management of such data. The Cybersecurity Review Measures and the Draft Regulations on Network Data
Security remain unclear on whether the relevant requirements will be applicable to companies that, like us, are already listed in the
United States. We cannot predict the impact of the Cybersecurity Review Measures and the Draft Regulations on Network Data Security, if
any, at this stage, and we will closely monitor and assess any developments in the rule-making process. If the Cybersecurity Review Measures
and the enacted version of the Draft Regulations on Network Data Security mandate clearance of cybersecurity review and other specific
actions to be taken by issuers like us, we may face uncertainties as to whether these additional procedures can be completed by us timely,
or at all, which may subject us to government enforcement actions and investigations, fines, penalties, suspension of our non-compliant
operations, or removal of our app from the relevant application stores, and materially and adversely affect our business and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In general, compliance with
the existing PRC laws and regulations, as well as additional laws and regulations that PRC legislative and regulatory bodies may enact
in the future, related to cybersecurity, data security and personal information protection, may be costly and result in additional expenses
to us, and subject us to negative publicity, which could harm our reputation and business operations. There are also uncertainties with
respect to how such laws and regulations will be implemented and interpreted in practice. In light of the fact that laws and regulations
on cybersecurity, data privacy and personal information protection are evolving and uncertainty remains with respect to their interpretation
and implementation, we cannot guarantee that we will be able to maintain full compliance at all times, or that our existing user information
protection system and technical measures will be considered sufficient. Any non-compliance or perceived non-compliance with these laws,
regulations or policies may lead to warnings, fines, investigations, lawsuits, confiscation of illegal gains, revocation of licenses,
cancelation of filings or listings, closedown of websites, removal of apps and suspension of downloads, price drops in our securities
or even criminal liabilities against us by government agencies or other individuals.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Certain PRC regulations may make it more difficult for us to
pursue growth through acquisitions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Anti-Monopoly Law of the People&#8217;s Republic
of China promulgated by the Standing Committee of the National People&#8217;s Congress, which became effective in 2008 and amended in
2022 (&#8220;Anti-Monopoly Law&#8221;), established additional procedures and requirements that could make merger and acquisition activities
by foreign investors more time-consuming and complex. Such regulation requires, among other things, that State Administration for Market
Regulation (&#8220;SAMR&#8221;) be notified in advance of any change-of-control transaction in which a foreign investor acquires control
of a PRC domestic enterprise or a foreign company with substantial PRC operations, if certain thresholds under the Provisions of the State
Council on the Standard for Declaration of Concentration of Business Operators, issued by the State Council in 2008 and amended in 2018,
are triggered. Moreover, the Anti-Monopoly Law requires that transactions which involve the national security, the examination on the
national security shall also be conducted according to the relevant provisions of the State. In addition, PRC Measures for the Security
Review of Foreign Investment which became effective in January 2021 require acquisitions by foreign investors of PRC companies engaged
in military-related or certain other industries that are crucial to national security be subject to security review before consummation
of any such acquisition. We may pursue potential strategic acquisitions that are complementary to our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Complying with the requirements of these regulations
to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval or clearance
from the MOFCOM, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business
or maintain our market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are not required to submit an application
to CSRC pursuant to the M&amp;A Rules, nor are we subject to the cybersecurity review. However, based on the recent promulgation of the
Trial Measures, which became effective on March 31, 2023, we may be required to complete the filing requirements when we have re-financing
or any additional offerings in future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Regulations on Mergers
and Acquisitions of Domestic Companies by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and
amended in 2009, require an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies
and controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading of such special purpose
vehicle&#8217;s securities on an overseas stock exchange. In September 2006, the CSRC published a notice on its official website specifying
documents and materials required to be submitted to it by a special purpose vehicle seeking CSRC approval of its overseas listings. However,
substantial uncertainty remains regarding the scope and applicability of the M&amp;A Rules to offshore special purpose vehicles. Currently,
there is no consensus among leading PRC law firms regarding the scope and applicability of the CSRC approval requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Based on our understanding
of the Chinese laws and regulations in effect at the time of this annual report, we will not be required to submit an application to the
CSRC for its approval of an offering in a foreseeable future and the listing and trading of our common stock on NYSE American. However,
there remains some uncertainty as to how the M&amp;A Rules will be interpreted or implemented in the context of an overseas offering and
our belief is subject to any new laws, rules and regulations or detailed implementations and interpretations in any form relating to the
M&amp;A Rules or overseas offering approval. We cannot assure you that relevant PRC governmental agencies, including the CSRC, would reach
the same conclusion as we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Recently, the General Office
of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the &#8220;Opinions
on Severely Cracking Down on Illegal Securities Activities According to Law,&#8221; or the Opinions, which was made available to the public
on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to
strengthen the supervision over overseas listings by Chinese companies. Effective measures, such as promoting the construction of relevant
regulatory systems will be taken to deal with the risks and incidents of China-concept overseas listed companies, and cybersecurity and
data privacy protection requirements and similar matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On December 24, 2021, the China
Securities Regulatory Commission, or the &#8220;CSRC&#8221;, published draft regulations (the &#8220;Draft Rules&#8221;) on domestic enterprises
issuing securities and being listed overseas. The Draft Rules lay out specific filing requirements for overseas listing and offering by
PRC domestic companies and include unified regulation management and strengthening regulatory coordination. On February 17, 2023, the
CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial
Measures&#8221;), which became effective on March 31, 2023. The Trial Measures supersede the Draft Rules and clarified and emphasized
several aspects, which include but are not limited to: (1) criteria to determine whether an issuer will be required to go through the
filing procedures under the Trial Measures; (2) exemptions from immediate filing requirements for issuers including those that have already
been listed or registered but not yet listed in foreign securities markets, including U.S. markets, prior to the effective date of the
Trial Measures; (3) a negative list of types of issuers banned from listing or offering overseas, such as issuers whose affiliates have
been recently convicted of bribery and corruption; (4) issuers&#8217; compliance with web security, data security, and other national
security laws and regulations; (5) issuers&#8217; filing and reporting obligations, such as obligation to file with the CSRC after it
submits an application for initial public offering to overseas regulators, and obligation after offering or listing overseas to report
to the CSRC material events including change of control or voluntary or forced delisting of the issuer; and (6) the CSRC&#8217;s authority
to fine both issuers and their shareholders for failure to comply with the Trial Measures, including failure to comply with filing obligations
or committing fraud and misrepresentation. Because we are already publicly listed in the U.S., the Trial Measures do not impose additional
regulatory burden on us beyond the obligation to report to the CSRC any future offerings of our securities, or material events such as
a change of control or delisting. Despite of the foregoing, we cannot assure you if we will be able to complete the filing procedure in
a timely fashion when we are required to do so for any offerings in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Restrictions contained
in Chinese law on the ability of overseas securities regulators to collect information in China may deny investors in our Company the
benefits of U.S. securities regulation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">China
has often restricted U.S. regulators&#8217; access to information and limited regulators&#8217; ability to investigate or pursue remedies
with respect to China-based issuers, generally citing to state secrecy and national security laws, blocking statutes, or other laws or
regulations. Any disclosure of documents or information located in China by foreign agencies may be subject to jurisdiction constraints
and must comply with China&#8217;s state secrecy laws, which broadly define the scope of &#8220;state secrets&#8221; to include matters
involving economic interests and technologies. In addition, according to Article&#160;177&#160;of the PRC Securities Law (&#8220;Article
177&#8221;), which became effective in March 2020, no overseas securities regulator can directly conduct investigations or evidence collection
activities within the PRC and no entity or individual in China may provide documents and information relating to securities business activities
to overseas regulators without Chinese government approval. There is no guarantee that requests from U.S. federal or state regulators
or agencies to investigate or inspect our operations will be honored, by entities who provide services to us or with whom we associate,
without violating PRC legal requirements, especially as those entities are located in China. The SEC, U.S. Department of Justice, and
other U.S. authorities face substantial challenges in bringing and enforcing actions against China-based issuers and their officers and
directors. As a result, investors in the Company may not benefit from a regulatory environment that fosters effective enforcement of U.S.
federal securities laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; ">As
Article 177 and the PRC Securities Law are newly promulgated, there are uncertainties as to the procedures and requisite timing for the
U.S. securities regulatory agencies to conduct investigations and collect evidence within the territory of the PRC. If the U.S. securities
regulatory agencies are unable to conduct such investigations, there exists a risk that they may determine to suspend or de-register our
registration with the SEC and may also delist our securities from NYSE American exchange or other applicable trading market within the
US.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Holding Foreign Companies Accountable
Act, or the HFCAA, and the related regulations continue to evolve. Further implementations and interpretations of or amendments to the
HFCAA or the related regulations, or a PCAOB determination of its lack of sufficient access to inspect our auditor, might pose regulatory
risks to and impose restrictions on us because of our operations in mainland China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On May 20, 2020, the U.S. Senate
passed the Holding Foreign Companies Accountable Act (the &#8220;HFCAA&#8221;) requiring a foreign company to certify it is not owned
or controlled by a foreign government if the PCAOB is unable to audit specified reports because the Company uses a foreign auditor not
subject to PCAOB inspection. If the PCAOB is unable to inspect the Company&#8217;s auditors for three consecutive years, the issuer&#8217;s
securities are prohibited to trade on a national securities exchange or in the over the counter trading market in the U.S. On December
18, 2020, the HFCAA was signed into law. The HFCAA has since then been subject to amendments by the U.S. Congress and interpretations
and rulemaking by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On June 22, 2021, the U.S.
Senate passed the Accelerating Holding Foreign Companies Accountable Act (&#8220;AHFCAA&#8221;), which proposes to reduce the period of
time for foreign companies to comply with PCAOB audits from three to two consecutive years, thus reducing the time period before the securities
of such foreign companies may be prohibited from trading or delisted. On December 29, 2022, the Consolidated Appropriations Act, 2023
(the &#8220;CAA&#8221;), which AHFCAA constituted a part, was signed into law, which officially reduced the number of consecutive non-inspection
years required for triggering the prohibitions under the HFCAA from three years to two, thus, reducing the time before an applicable issuer&#8217;s
securities may be prohibited from trading or delisted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On December 16, 2021, PCAOB
announced the PCAOB HFCAA determinations relating to the PCAOB&#8217;s inability to inspect or investigate completely registered public
accounting firms headquartered in mainland China of the PRC or Hong Kong, a Special Administrative Region and dependency of the PRC, because
of a position taken by one or more authorities in the PRC or Hong Kong. The inability of the PCAOB to conduct inspections of auditors
in China made it more difficult to evaluate the effectiveness of these accounting firms&#8217; audit procedures or quality control procedures
as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause existing and potential investors
in issuers operating in China to lose confidence in such issuers&#8217; procedures and reported financial information and the quality
of financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditor, BF Borgers CPA
PC, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor
of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States
pursuant to which the PCAOB conducts regular inspections to assess our auditor&#8217;s compliance with the applicable professional standards.
Our auditor is headquartered in Colorado, and is subject to inspection by the PCAOB on a regular basis with the last inspection in 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On August 26, 2022, the PCAOB
announced and signed a Statement of Protocol (the &#8220;Protocol&#8221;) with the China Securities Regulatory Commission and the Ministry
of Finance of the People&#8217;s Republic of China (together, the &#8220;PRC Authorities&#8221;). The Protocol provides the PCAOB with:
(1) sole discretion to select the firms, audit engagements and potential violations it inspects and investigates, without any involvement
of Chinese authorities; (2) procedures for PCAOB inspectors and investigators to view complete audit work papers with all information
included and for the PCAOB to retain information as needed; (3) direct access to interview and take testimony from all personnel associated
with the audits the PCAOB inspects or investigates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On December 15, 2022, the PCAOB
announced in its 2022 HFCAA Determination Report (the &#8220;2022 Report&#8221;) its determination that the PCAOB was able to secure complete
access to inspect and investigate audit firms in the People&#8217;s Republic of China (PRC), and the PCAOB Board voted to vacate previous
determinations to the contrary. According to the 2022 Report, this determination was reached after the PCAOB had thoroughly tested compliance
with every aspect of the Protocol necessary to determine complete access, including on-site inspections and investigations in a manner
fully consistent with the PCAOB&#8217;s methodology and approach in the U.S. and globally. According to the 2022 Report, the PRC Authorities
had fully assisted and cooperated with the PCAOB in carrying out the inspections and investigations according to the Protocol, and have
agreed to continue to assist the PCAOB&#8217;s investigations and inspections in the future. The PCAOB may reassess its determinations
and issue new determinations consistent with the HFCAA at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">While the HFCAA and AHFCAA
are not currently applicable to the Company because the Company&#8217;s current auditors are subject to PCAOB review, if this changes
in the future for any reason, the Company may be subject to the HFCAA and AHFCAA. The implications of this regulation if the Company were
to become subject to it are uncertain. Such uncertainty could cause the market price of our common stock to be materially and adversely
affected, and our securities could be delisted or prohibited from being traded on NYSE American earlier than would be required by the
HFCAA and AHFCAA. If our common stock is unable to be listed on another securities exchange by then, such a delisting would substantially
impair your ability to sell or purchase the common stock when you wish to do so, and the risk and uncertainty associated with a potential
delisting would have a negative impact on the price of the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulations relating to the establishment
of offshore special purpose companies by PRC residents may subject our PRC resident beneficial owners or our PRC subsidiary to liability
or penalties, limit our ability to inject capital into our PRC subsidiary, limit our PRC subsidiary&#8217; ability to increase their registered
capital or distribute profits to us, or may otherwise adversely affect us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In July 2014, SAFE promulgated
the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and
Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37, to replace the Notice on Relevant Issues Concerning Foreign
Exchange Administration for Domestic Residents&#8217; Financing and Roundtrip Investment Through Offshore Special Purpose Vehicles, or
SAFE Circular 75, which ceased to be effective upon the promulgation of SAFE Circular 37. SAFE Circular 37 requires PRC residents (including
PRC individuals and PRC corporate entities) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 is applicable to our stockholders who are PRC residents and may be applicable to any offshore
acquisitions that we make in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Under SAFE Circular 37, PRC
residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose
vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is
a direct or indirect shareholder of an SPV is required to update its filed registration with the local branch of SAFE with respect to
that SPV, to reflect any material change. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders
to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration
or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or
the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional
capital contributions into its subsidiary in China. On February 13, 2015, the SAFE promulgated a Notice on Further Simplifying and Improving
Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice
13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including
those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the
applications and accept registrations under the supervision of SAFE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Some of our shareholders that
we are aware of are subject to SAFE regulations, and we expect all of these shareholders will have completed all necessary registrations
with the local SAFE branch or qualified banks as required by SAFE Circular 37. We cannot assure you, however, that all of these shareholders
may continue to make required filings or updates in a timely manner, or at all. We can provide no assurance that we are or will in the
future continue to be informed of identities of all PRC residents holding direct or indirect interest in our company. Any failure or inability
by such shareholders to comply with SAFE regulations may subject us to fines or legal sanctions, such as restrictions on our cross-border
investment activities or our PRC subsidiaries&#8217; ability to distribute dividends to, or obtain foreign exchange-denominated loans
from, our company or prevent us from making distributions or paying dividends. As a result, our business operations and our ability to
make distributions to you could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Furthermore, as these foreign
exchange regulations are still relatively new and their interpretation and implementation have been constantly evolving, it is unclear
how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented
by the relevant government authorities. For example, we may be subject to a more stringent review and approval process with respect to
our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect
our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that
we or the owners of such company, as the case may be, will be able to obtain the necessary approvals or complete the necessary filings
and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and
could adversely affect our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our China-sourced income is subject to PRC
withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the rate of
25% when more detailed rules or precedents are promulgated.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The PRC <i>enterprise income
tax</i> is calculated based on the taxable income determined under the PRC laws and accounting standards. On March 16, 2007, the National
People&#8217;s Congress of China enacted a new <i>Enterprise Income Tax</i> Law of the PRC, which became effective on January 1, 2008
and amended the <i>Enterprise Income Tax</i> Law of the PRC on December 29, 2018. On December 6, 2007, the State Council promulgated the
Implementation Rules to the <i>Enterprise Income Tax</i> Law of the PRC, or the Implementation Rules, which also became effective on January
1, 2008 and amended the Implementation Rules to the <i>Enterprise Income Tax</i> Law of the PRC on April 23, 2019. On December 26, 2007,
the State Council issued the Notice on Implementation of <i>Enterprise Income Tax</i> Transition Preferential Policy under the <i>Enterprise
Income Tax</i> Law of the PRC, or the Transition Preferential Policy Circular, which became effective simultaneously with the <i>Enterprise
Income Tax</i> Law of the PRC. On October 17, 2017, the State Administration of Taxation promulgated the Announcement of the State Administration
of Taxation on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises, which became effective on December
1, 2017 and amended Withholding at Source of Income Tax of Non-resident Enterprises on June 15, 2018. The <i>Enterprise Income Tax</i>
Law of the PRC imposes a uniform <i>enterprise income tax</i> rate of 25% on all domestic enterprises, including foreign-invested enterprises
unless they qualify for certain exceptions, and terminates most of the tax exemptions, reductions and preferential treatments available
under previous tax laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Moreover, under the <i>Enterprise
Income Tax</i> Law of the PRC, enterprises organized under the laws of jurisdictions outside China with their &#8220;de facto management
bodies&#8221; located within China may be considered PRC resident enterprises and therefore subject to PRC <i>enterprise income tax</i>
at the rate of 25% on their worldwide income. The Implementation Rules define the term &#8220;de facto management body&#8221; as the management
body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties
of an enterprise. In addition, the Circular Related to Relevant Issues on the Identification of a Chinese holding Company Incorporated
Overseas as a Residential Enterprise under the Criterion of De Facto Management Bodies Recognizing issued by the State Administration
of Taxation on April 22, 2009 provides that a foreign enterprise controlled by a PRC company or a PRC company group will be classified
as a &#8220;resident enterprise&#8221; with its &#8220;de facto management bodies&#8221; located within China if the following requirements
are satisfied: (i) the senior management and core management departments in charge of its daily operations function mainly in China; (ii)
its financial and human resources decisions are subject to determination or approval by persons or bodies in China; (iii) its major assets,
accounting books, company seals and minutes and files of its board and shareholders&#8217; meetings are located or kept in China; and
(iv) more than half of the enterprise&#8217;s directors or senior management with voting rights reside in China. Although the circular
only applies to offshore enterprises controlled by PRC enterprises and not those controlled by PRC individuals or foreigners, the determining
criteria set forth in the circular may reflect the State Administration of Taxation&#8217;s general position on how the &#8220;de facto
management body&#8221; test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they
are controlled by PRC enterprises, individuals or foreigners. It is uncertain to us as to how it will be implemented and the respective
tax base and the tax exposure cannot be determined reliably at this stage. In case we are required to pay the income tax on capital gains
by the relevant PRC tax authorities, our financial conditions and results of operations could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to distribute dividends are
to large extent based on the dividends paid to us by our operating entity in China, and its ability to distribute dividends may be limited
by the PRC laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As we are a holding company
with all of business operations conducted in PRC by Helpson, which is our wholly-owned subsidiary, we depend on its dividend issuance
to us to pay the dividends to our investors. According to the PRC Company Law and Foreign Investment Law, our PRC subsidiary, as a foreign-invested
enterprise, or FIE, we may only pay dividends out of their accumulated profit, if any, as determined in accordance with PRC accounting
standards and regulations. In addition we are required to draw 10% of its after-tax profits each year, if any, to fund a common reserve,
which may stop drawing its after-tax profits if the aggregate balance of the common reserve has already accounted for over 50% of its
registered capital. The reserve funds are not distributable as cash dividends. A PRC company is not permitted to distribute any profits
until any losses from prior fiscal years have been offset. Our ability to distribute dividends may be restricted because of the above-mentioned
regulations. We may even cannot distribute dividends if we are suffering loss in certain fiscal year in the future. As of the date of
this annual report, Helpson plans to retain all the revenues and re-invest them into Helpson&#8217;s daily operation. Therefore, the Company
does not intend to have any dividend distribution in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends payable by us to our foreign investors
and gain on the sale of our shares may become subject to taxes under PRC tax laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Under the new EIT law and its
implementation rules, to the extent that we are considered a &#8220;resident enterprise&#8221; which is &#8220;domiciled&#8221; in China,
PRC income tax at the rate of 10% is applicable to dividends payable by us to investors that are &#8220;non-resident enterprises&#8221;
so long as such &#8220;non-resident enterprise&#8221; investors do not have an establishment or place of business in China or, despite
the existence of such establishment or place of business in China, the relevant income is not effectively connected with such establishment
or place of business in China. Similarly, any gain realized on the transfer of our shares by such investors is also subject to a 10% PRC
income tax if such gain is regarded as income derived from sources within China and we are considered a &#8220;resident enterprise&#8221;
which is domiciled in China for tax purposes. Additionally, there is a possibility that the relevant PRC tax authorities may take the
view that our purpose is that of a holding company, and the capital gain derived by our overseas stockholders would be deemed China-sourced
income, in which case such capital gain may be subject to PRC withholding tax at the rate of up to 10%. If we are required under the new
EIT law to withhold PRC income tax on our dividends payable to our foreign stockholders who are &#8220;non-resident enterprises&#8221;,
or if you are required to pay PRC income tax on the transfer of our shares under the circumstances mentioned above, the value of your
investment in our shares may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face uncertainty with respect to indirect
transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On February 3, 2015, the SAT
issued the Public Notice Regarding Certain Corporate Income Tax Matters on Indirect Transfer of Properties by Non-Tax Resident Enterprises,
or SAT Bulletin 7. SAT Bulletin 7 extends its tax jurisdiction to transactions involving the transfer of taxable assets through offshore
transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 has introduced safe harbors for internal group restructurings
and the purchase and sale of equity through a public securities market. SAT Bulletin 7 also brings challenges to both foreign transferor
and transferee (or other person who is obligated to pay for the transfer) of taxable assets, as such persons need to determine whether
their transactions are subject to these rules and whether any withholding obligation applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On October 17, 2017, the SAT
issued the Announcement of the State Administration of Taxation on Issues Concerning the Withholding of Non-resident Enterprise Income
Tax at Source, or SAT Bulletin 37, which came into effect on December 1, 2017. The SAT Bulletin 37 further clarifies the practice and
procedure of the withholding of non-resident enterprise income tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Where a non-resident enterprise
transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an &#8220;Indirect Transfer&#8221;,
the non-resident enterprise as either transferor or transferee, or the PRC entity that directly owns the taxable assets, may report such
Indirect Transfer to the relevant tax authority. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard
the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing,
avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC enterprise income tax, and
the transferee or other person who pays for the transfer is obligated to withhold the applicable taxes currently at a rate of 10% for
the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under
PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We face uncertainties as to
the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring,
sale of the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company
is transferor in such transactions, and may be subject to withholding obligations if our company is transferee in such transactions, under
SAT Bulletin 7 and/or SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident enterprises, our PRC
subsidiaries may be requested to assist in the filing under SAT Bulletin 7 and/or SAT Bulletin 37. As a result, we may be required to
expend valuable resources to comply with SAT Bulletin 7 and/or SAT Bulletin 37 or to request the relevant transferors from whom we purchase
taxable assets to comply with these circulars, or to establish that our company should not be taxed under these circulars, which may have
a material adverse effect on our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be held in default on our convertible
note, which could trigger penalties that worsen our financial condition and potentially disqualify us from listing on the stock exchange
where we are currently listed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 17, 2021, we entered
into a Securities Purchase Agreement pursuant to which we issued an unsecured convertible promissory note (the &#8220;Convertible Note&#8221;)
to an institutional accredited investor Streeterville Capital, LLC (&#8220;Streeterville&#8221;). The Convertible Note, as amended, is
due on May 19, 2024. The parties may negotiate in extending the Convertible Note. There can be no assurances that these negotiations will
proceed or be successful. The Convertible Note has a principal balance of $1,423,474.27 as of December 31, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although no event of default
has occurred as of the date herein, pursuant to the terms of the Convertible Note and its amendment dated April 13, 2023, upon our failure
to pay back the Convertible Note upon due, Streeterville can, at its sole discretion, send us a notice which turns this into an Event
of Default (&#8220;Event of Default&#8221;), which would give us 10 days to cure. As of the date herein, Streeterville has not sent such
a notice and therefore no Event of Default has occurred. If an Event of Default occurs and is not cured within the 10-day notice period,
pursuant to the terms of the Convertible Note Streeterville can impose additional interest payments and other penalties upon us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Such penalties, as well as
other similar penalties that could be imposed upon us as a result of our ongoing negotiations to extend the Convertible Note, if and when
imposed by Streeterville, could worsen our financial conditions by consuming or tying up our cash reserve, cash flow, and assets, as well
as dilute our existing shareholders if Streeterville initiates conversion of some or part of the Convertible Note into our equity securities.
Thus, such penalties could generally and negatively impact the operation of our business and the public trading price of our common stock.
Particularly, it could cause the values of our shareholder&#8217;s equity and market capitalization to decline further. As a result of
such decline, we may become unable to satisfy the continuous listing standards of the stock exchange where we are currently listed, which
would further negatively impact the operation of our business and the public trading price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price for our common stock may
be volatile which could result in a complete loss of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The market price for our common
stock is highly volatile and subject to wide fluctuations in response to factors including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated fluctuations
in our quarterly operating results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements of new products
by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in financial estimates
by securities analysts;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">conditions in the pharmaceutical
market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in the economic performance
or market valuations of other companies involved in pharmaceutical production;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements by our competitors
of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">economic, regulatory and political
developments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">addition or departure of key
personnel, or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">potential litigation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, the securities
markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may issue additional shares of our capital
stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders will experience
dilution in their respective percentage ownership in the company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may issue additional shares
of our capital stock to raise additional cash for working capital. There is no anti-dilution protection or preemptive rights in connection
with our common stock. Thus, the percentage ownership of existing holders of common stock may be diluted in their respective percentage
ownership in us if we issue additional shares of our capital stock.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are likely to remain subject to &#8220;penny
stock&#8221; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If at any time we have net
tangible assets of $5,000,000 or less and the trading price of our common stock is below $5.00 per share, the open-market trading of our
common stock will be subject to the &#8220;penny stock&#8221; rules of the SEC. The &#8220;penny stock&#8221; rules impose additional
sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors
(generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For
transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and
have received the purchaser&#8217;s written consent to the transaction before the purchase. Additionally, for any transaction involving
a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the SEC relating
to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative
and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited
market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common
stock and may affect a stockholder&#8217;s ability to resell the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">There can be no assurance that
our common stock will qualify for exemption from the &#8220;penny stock&#8221; rules. In any event, even if our common stock is exempt
from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person
from participating in a distribution of a &#8220;penny stock&#8221; if the SEC finds that such a restriction would be in the public interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Stockholders should be aware
that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse.
Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter
or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii)
boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive
and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters
and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices
and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are responsible for the indemnification
of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable to recoup.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our bylaws provide for the
indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney&#8217;s fees and other
expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of
us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have identified material
weaknesses in our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports,
affect the ability of our auditors to attest to the effectiveness of our internal controls should we become an accelerated filer in the
future, and weaken investors&#8217; confidence in our financial reporting.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As directed by Section 404
of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies in their annual reports to include a report of management
on the reporting company&#8217;s disclosure controls and procedures and internal controls over financial reporting. We became subject
to this requirement commencing with our fiscal year ended December 31, 2007 and a report of our management is included under Item 9A.
&#8220;Controls and Procedures&#8221; of this Annual Report on Form 10-K. As set forth in such report, our management has concluded that
our internal controls over financial reporting were not effective as of December 31, 2023, and there existed a material weakness in our
internal control over financial reporting as of December 31, 2023.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are taking appropriate actions
to internally training related personnel, such as Chief Financial Officer, to remediate such material weakness; however, such measures
may not be sufficient to address the material weaknesses identified or ensure that our controls and procedures are effective. We may also
discover other material weaknesses in the future. Any failure to maintain or implement required new or improved controls, or any difficulties
we encounter in the implementation of such controls, could cause us to fail to meet our periodic reporting obligations or result in material
misstatements in our financial statements and affect the ability of our auditors to attest to the effectiveness of our internal control
over financing reporting to the extent we become an accelerated filer in the future. In addition, substantial costs and resources may
be required to rectify any internal control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence
in our reported financial information, the market price of our common stock could decline significantly, and our business and financial
condition could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is substantial doubt about our ability to continue as a
going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our auditors have indicated
in their report on our financial statements for the years ended December 31, 2023 and 2022 &#160;that conditions exist that raise substantial
doubt about our ability to continue as a going concern as discussed in Note 1 to the financial statements. The Company incurred recurring
losses from operations, has net current liabilities and an accumulated deficit that raise substantial doubt about its ability to continue
as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">To alleviate the conditions
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of comprehensive healthcare products. In addition, management believes that the Company&#8217;s
existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund
its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives
raising substantial doubt about its ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If we are unable to generate
enough cash or obtain additional sufficient funding, we would need to scale back or eliminate our business plan, reduce our operating
costs and headcount, or discontinue or curtail our operations. Accordingly, our business, prospects, financial condition and results of
operations could be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to continue
as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited
consolidated financial statements, and it is likely that investors will lose all or a part of their investment. Our financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not anticipate paying cash dividends
on our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">You should not rely on an investment
in our common stock to provide dividend income, as we have not paid any cash dividends on our common stock and do not plan to pay any
in the foreseeable future. Accordingly, investors must rely on sales of our common stock after price appreciation, which may never occur,
as the only way to realize any return on their investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restrictions on the Use of Rule 144 by Shell
Companies or Former Shell Companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Historically, the SEC has taken
the position that Rule 144 under the Securities Act, as amended, is not available for the resale of securities initially issued by companies
that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance with the requirements
of Rule 144. The SEC has codified and expanded this position in its amendments effective on February 15, 2008 and applies it to securities
acquired both before and after that date by prohibiting the use of Rule 144 for resale of securities issued by shell companies (other
than business transaction related shell companies) or issuers that have been at any time previously a shell company. The SEC has provided
an important exception to this prohibition, however, if the following conditions are met: the issuer of the securities that was formerly
a shell company has ceased to be a shell company; the issuer of the securities is subject to the reporting requirements of Section 13
or 15(d) of the Exchange Act; the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable,
during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form
8-K reports; and at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting
its status as an entity that is not a shell company. As such, due to the fact that we had been a shell company prior to October 2005,
holders of &#8220;restricted securities&#8221; within the meaning of Rule 144, when reselling their shares pursuant to Rule 144, shall
be subject to the conditions set forth herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1B. UNRESOLVED STAFF COMMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1C. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have implemented cybersecurity
risk assessment procedures to ensure effectiveness in cybersecurity management, strategy and governance and reporting cybersecurity risks.
We have also integrated cybersecurity risk management into our overall enterprise risk management system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have used a cybersecurity
threat defense system to address both internal and external threats. This system encompasses various levels, including network, host and
application security and incorporates systematic security capabilities for threat defense, monitoring, analysis, response, deception and
countermeasures. We strive to manage cybersecurity risks and protect sensitive information through various methods, including technical
safeguards, procedural requirements, an intensive monitoring program on our corporate network, a robust incident response program, a review
of the effectiveness of our security system with reference to applicable security standards by qualified third parties and regular cybersecurity
awareness training for employees. We continuously monitor the performance of our apps, platforms and infrastructure to enable us to respond
quickly to potential problems, including potential cybersecurity threats.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
we have not experienced any material cybersecurity incidents or identified any material cybersecurity threats that have affected or are
reasonably likely to materially affect us, our business strategy, results of operations or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors is
responsible for overseeing the Company&#8217;s cybersecurity risk management and be informed on risks from cybersecurity threats. The
Board shall review, approve and maintain oversight of the disclosure (i) on Form 8-K for material cybersecurity incidents (if any) and
(ii) related to cybersecurity matters in the periodic reports (including annual report on Form 10-K) of the Company. In addition, our
management team, including those with experience in dealing with confidentiality-related cybersecurity issues, oversee and manage cybersecurity
related matters and formulate policies as necessary. Our Board review on an annual basis regarding assessment, identification and management
on material risks from cybersecurity threats happened in the ordinary course of our business operations. If a cybersecurity incident occurs,
our Board will promptly organize relevant personnel for internal assessment and, depending on the situation, seek the opinions of external
experts and legal advisors. If it is determined that the incident could potentially be a material cybersecurity event, our Board will
decide on the relevant response measures and whether any disclosure is necessary. If such disclosure is determined to be necessary, such
disclosure material will be prepared and reviewed by our Board before it is disseminated to the public.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. PROPERTIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no private land ownership
in the PRC. All land is either owned by the government of the PRC on behalf of all Chinese citizens or collectively owned by farmers.
However, land use rights may be allocated by the PRC State Land Administration Bureau or its authorized branches. Helpson was granted
land use rights by the PRC government for approximately 22,936 square meters (approximately 246,881 square feet) of land located on Plot
C09-2 in the Haikou Bonded Zone, Hainan Province, PRC in 2003. These land use rights will expire on September 10, 2063.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Helpson owns two production
facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters and is located on the 6th floor
of Standard Plant Building B, Jinpan Industrial Development Zone. The other factory, located on Plot C09-2 in the Haikou Bonded Zone,
has two buildings with production area of 20,282.42 square meters, certificate number HK477872, and 6,593.20 square meters, certificate
number HK122889.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Helpson rents
offices located on the second floor and third floor of the Jiahai Building owned by Hainan Zhongfu Foreign Export Personnel Service Center
(the &#8220;Center&#8221;) as its principal executive offices. For office spaces on the second floor and third floor at a monthly rent
of RMB 17,600 (approximately $2,485) and RMB 30,000 (approximately $4,236), respectively, based on the current lease dated June 5, 2023
that is for a two-year term ending June 30, 2025. The aggregate area of the office space rented by Helpson is 1,686 square meters (16,812
square feet).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that all our properties
have been adequately maintained, are generally in good condition, and are suitable and adequate for our business. However, we anticipate
a potential need for expansion and additional space as our production increases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mortgaged Property</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 25, 2023 the
Company received a line of credit for RMB 10 million (approximately $1.41 million) from Bank of China. The loan bears interest at the
rate of 3.35% and is due September 26, 2024. The loan is collateralized by the Company&#8217;s new production facility and the production
line equipment and machinery contained therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company&#8217;s
Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was $11,225
for the years ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The loans referred to above
are set forth in the table below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Total Amount of the Line of Credit</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Lending Institution</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Contract &#160;Period</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Interest Rate</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Properties under<br/>
 Mortgage</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 30%; text-align: left">RMB 10 million <br/>
(Approximately $1.41 million)</td><td style="text-align: left; width: 1%; vertical-align: top">&#160;</td>
    <td style="text-align: center; width: 13%; vertical-align: top">Bank of China</td><td style="text-align: left; width: 1%; vertical-align: top">&#160;</td>
    <td style="text-align: center; width: 12%; vertical-align: top">September 25, 2023 to September 26, 2024</td><td style="text-align: left; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">3.35</td><td style="vertical-align: top; width: 1%; text-align: left">%</td><td style="text-align: left; width: 1%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 30%; text-align: left">Helpson&#8217;s new factory: 20,282.42 square meters (Certificate #: HK477872) Production line equipment and machinery included in the facility</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. LEGAL PROCEEDINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. However, we are
currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse
effect on our business, financial condition or operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares began trading on
the NYSE American (Formerly known as NYSE Amex, NYSE MKT) on September 30, 2009 under the symbol &#8220;CPHI&#8221;. Prior to September
30, 2009, our shares traded on the OTC Bulletin Board under the symbol &#8220;CPHI.OB.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2024, there
were approximately 133 stockholders of record of our common stock and an indeterminate number of beneficial holders who held our common
stock in street name.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent and registrar for our common
stock is Equinity Trust Company, with offices located at 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120. Their telephone
number is (651)306-2920.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6pt 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6pt 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid
or declared any dividend on our common stock and we do not anticipate paying cash dividends in the foreseeable future. As a result of
our holding company structure, we would rely entirely on dividend payments from our subsidiaries, Onny Investment Ltd. and Hainan Helpson
Medial &amp; Biotechnology Co., Ltd., for our cash flow to pay dividends on our common stock. The PRC government imposes controls on the
conversion of Renminbi into foreign currencies and the remittance of currencies out of the PRC, which may also affect our ability to pay
cash dividends in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="font-weight: bold; text-align: center">Equity Compensation Plan Information</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="13" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>securities<br/>
 to be</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>issued upon </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>options, warrants </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and rights</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-<br/>
average </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise<br/>
 price of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>options, warrants </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and rights</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of securities </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>remaining available for </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>future issuance under </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>equity compensation </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>plans (excluding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>securities reflected </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>in column (a))<sup>*</sup></b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(a)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(b)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">(c)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Equity compensation plans not approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">482,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">482,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares have been retroactively restated to reflect the effect of the 1-for-5 reverse stock split effective March 6, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The statements contained in this report with respect
to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking
statements can be identified by the use of forward-looking terminology, such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; or the
negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to
caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to future
events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory,
technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and
other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and
Exchange Commission (the &#8220;SEC&#8221;). These forward-looking statements are only estimates or predictions. No assurances can be
given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and
actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">These risk factors should be considered in connection
with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral
forward-looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are
expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely
on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations or estimates or
to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or
to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Overview &amp; Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">China Pharma Holding Inc. (&#8220;China Pharma&#8221;)
is not a Chinese operating company but a Nevada holding company. All of our operations are conducted in the PRC through Hainan Helpson
Medical &amp; Biotechnology Co., Ltd (&#8220;Helpson&#8221;), our wholly owned subsidiary incorporated under the laws of the People&#8217;s
Republic of China (the &#8220;PRC&#8221;), where the manufacturing facilities are located. Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables,
tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and
all of them have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the &#8220;NMPA&#8221;,
formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">China&#8217;s consistency evaluation of generic
drugs continues to proceed in 2023. Helpson has always taken the task of promoting the consistency evaluation as a top priority, and worked
on them actively. However, for each drug&#8217;s consistency evaluation, due to the continuous dynamic changes of the detailed consistency
evaluation policies, market trends, expected investments, and expected returns of investment (&#8220;ROI&#8221;), the whole industry,
including Helpson, has been making slow progresses in terms of the consistency evaluation. One of the flagship products, Candesartan tablets,
a hypertension product, has passed generic-drug-consistency-evaluation in early August 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Helpson has taken a more cautious and flexible
attitude towards initiating and progressing any project for existing products&#8217; consistency evaluation to cope with the changing
macro environment of drug sales in China. In 2018, relevant Chinese authorities decided to implement trial Centralized Procurement (&#8220;CP&#8221;)
activities in 11 selected pilot cities (including 4 municipalities and 7 other cities), since then, nine rounds of CP activities have
been carried out as of November 6, 2023, which significantly reduced the price of the drugs that won the bids. In addition, the consistency
evaluation has been adopted as one of the qualification standards for participating in the CP activities. As a result, Helpson needs to
balance between the market access brought by CP, the investment of financial resources and time to obtain the qualification of CP, and
the sharp decline in the price of drugs included in CP before making decisions regarding CP for any products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition, Helpson continues to explore the
field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed by the Chinese government according to the development
of the times, social needs and changes in disease spectrum. According to the Outline of &#8220;Healthy China 2030&#8221; issued by Chinese
government in October 2016, the total size of China&#8217;s health service industry is expected to reach RMB 16 trillion (approximately
$2.5 trillion) by 2030. This industry focuses on people&#8217;s daily life, aging and diseases, pays attention to all kinds of risk factors
and misunderstandings affecting health, calls for self-health management, and advocates the comprehensive care throughout the entire process
of life. It covers all kinds of health-related information, products, and services, as well as actions taken by various organizations
to meet the health needs. In response to this trend, Helpson launched Noni enzyme, a natural, Xeronine-rich antioxidant food supplement
at the end of 2018. It also launched wash-free sanitizers and masks, in 2020, to address the market needs caused by COVID-19 in China.
As Chinese government officially terminated its zero-case policy, now the responsibility to protect people from the impact of COVID-19
falls more to the citizens themselves, and masks and sanitizers have been more and more popular due to increasing demand. Helpson has
sufficient production capacity for medical masks, surgical masks, KN95 masks, and N95 masks, which meets the personal needs for protection
against the epidemic outbreak. Helpson&#8217;s N95 medical protective mask has received registration certificate by the end of 2022 and
right now has been selling in the mainland China nationwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Helpson will continue to optimize its product
structure and actively respond to the current health needs of human beings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Trends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As a generic drug company, Helpson is presented
with a huge domestic market. Helpson believes that through further upgrades and better conformity with Chinese consistency evaluations,
which are based on European and American production standards, it will be able to export the products to overseas markets. In China&#8217;s
market, Helpson believes that in the future, cost management and control ability will gradually become important factors in determining
the competitiveness of generic pharmaceutical enterprises. Although price control leads to a decline in the profitability, enterprises
who win the CP have a good chance of achieving bulk pricing to increase their market share and support their continuous innovation and
transformation. On a separate note, growing and advancing consumer demand in China drives the increase of discretionary consumption. With
the improvement of residents&#8217; quality of life, the healthcare demand is also changing. Helpson believes that there is a large number of
unmet demands in comprehensive healthcare and internet healthcare sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In addition, the Office of the State Council issued
&#8220;<i>Pilot Plan for Marketing Authorization Holders</i>&#8221; on May 24, 2016, allowing eligible drug research and development institutions
and scientific researchers to become Marketing Authorization Holders (&#8220;MAH&#8221;) by obtaining drug marketing authorization and
drug approval numbers from the State Council. This policy uses a management model of separating drug marketing authorization and drug
production licenses, thereby allowing MAHs to produce pharmaceuticals themselves or to consign production to other pharmaceutical manufacturers.
This policy not only transitions the production practices to meet the European and United States standards by separating drug approval
and production qualifications, thereby changing the existing model of bundling drug approval codes to pharmaceutical manufacturers in
China, but also serves as a supplement to the ongoing consistency evaluations policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In general, demand for pharmaceutical products
continues its steady growth in China. Helpson believes the ongoing generic drug consistency evaluations and reform of China&#8217;s drug
production registration and review policies will have major effects on the future development of our industry and may change its business
patterns. Helpson will continue to actively adapt to the national policy guidance and further evaluate market conditions for the existing
products then adjust accordingly, and compete in the market in order to optimize the development strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations for the Fiscal Year ended
December 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Revenue was $7.0 million for the year ended December
31, 2023, which represented a decrease of $1.1 million, as compared to $8.1 million for the year ended December 31, 2022. This decline
was mainly due to an increasing number of drugs from other medicine providers being included in national CP, while Helpson&#8217;s related
products have not passed consistency evaluation. As Helpson&#8217;s related products are not qualified to participate in CP, the resulting
sales has decreased.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Set forth below are our revenues by product category
in millions (USD) for the years ended December 31, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Twelve Months Ended<br/>
 December 31,</b></p>

</td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Product Category</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2023</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2022</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Net&#160;Change</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>%
                                            Change</b></p></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-0.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Anti-Viral/ Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-28</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Digestive Diseases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-31</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The most significant revenue decrease in terms
of dollar amount was in the &#8220;Anti-Viral/ Infection &amp; Respiratory&#8221; product category, it generated $3.57 million in 2023,
compared to $4.94 million in 2022, which represented a decrease of $1.37 million. This decrease was mainly due to a decrease in sales
of Helpson&#8217;s Roxithromycin Dispersible Tablet due to the inclusion of this product in the seventh round of CP, and the Roxithromycin
produced by Helpson not passing the consistency evaluation, therefore not eligible to participate in CP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Sales revenues in the &#8220;Digestive Diseases&#8221;
category was $1.09 million of sales revenue in 2023, which represented an increase of $0.68 million compared to $0.41 million in 2022.
This increase was mainly due to an increase in sales of the Omeprazole due to market fluctuation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Sales revenue in the &#8220;CNS Cerebral &amp;
Cardio Vascular&#8221; category was $1.62 million in 2023, which represented a decrease of $0.08 million compared to $1.70 million in
2022. The sales revenue of this category in 2023 is similar to that in 2022, because the increase and decrease in sales of various products
due to market fluctuations offset each other.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Sales revenue in the &#8220;Other&#8221; product
category was $0.73 million in 2023, compared to $1.06 million in 2022, which represented a decrease of $0.33 million. This decrease was
mainly due to a decrease in sales of the Vitamin B6 for Injection due to market fluctuation, and change in foreign exchange rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"/><td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Twelve Months Ended December 31,</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Product Category</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">CNS Cerebral &amp; Cardio Vascular</td><td style="width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Anti-Viral/ Infection &amp; Respiratory</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">61</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Digestive Diseases</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">For the year ended December 31, 2023, revenue
breakdown by product category experienced certain variances compared with that of the prior year. Sales in the &#8220;Anti-Viral/Infection
&amp; Respiratory&#8221; product category represented 51% and 61% of total sales in the years ended December 31, 2023 and 2022, respectively.
The &#8220;CNS Cerebral &amp; Cardio Vascular&#8221; category represented 23% of total revenue in 2023, compared to 21% in 2022. The &#8220;Digestive
Diseases&#8221; category represented 16% and 5% of total revenue in 2023 and 2022, respectively. The &#8220;Other&#8221; category represented
10% and 13% of revenues in 2023 and 2022, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2023, our cost of revenue was $7.3 million, or 104.0% of total revenue, which represented a decrease of $1.3 million from $8.6 million,
or 106.1% of total revenue, in 2022. The decrease in cost is mainly due to the difference in the proportion of different products to total
revenue this year and last year.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross Loss and Gross Loss Margin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Gross loss for the year ended December 31, 2023
was $0.3 million, compared to $0.5 million in 2022. Our gross loss margin in 2023 was 4.0%, compared to 6.1% in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our selling expenses for the year ended December
31, 2023 were $0.8 million, a decrease of $0.3 million compared to $1.1 million for the year ended December 31, 2022.&#160;Selling expenses
accounted for 11.1% of the total revenue in 2023 compared to 13.2% in 2022. &#160;Because of the adjustments in the sales practices and
Chinese national CP, we reduced selling expenses to efficiently support the sales and the collection of accounts receivable, especially
in the context of the increasing impact of CP, like other players in the industry, we have reduced the promotion expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and
administrative expenses for the year ended December 31, 2023 were $1.2 million, a decrease of $0.7 million compared to $1.9 million
for the year ended December 31, 2022.&#160;General and administrative expenses accounted for 17.0% and 23.4% of our total revenues
in 2023 and 2022, respectively. The decrease in administrative expenses was mainly due to the higher exchange rate of the RMB
against the US dollar in 2023 and the higher government subsidies obtained in 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our research and development expenses for the year ended December 31,
2023 was $0.24 million, compared to $0.19 million in 2022. Research and development expenses accounted for 3.4% and 2.3% of our total
revenues in 2023 and 2022, respectively. These increased research and development expenditures in 2023 was mainly due to the fact that
as the contract progressed, the expenditure for Candesartan consistency evaluation was higher in 2023 as compared to 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Bad Debt Benefit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our bad debt benefit for the year ended December
31, 2023 was $15,757, as compared to $93,851 in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In general, our normal customer credit or payment
terms are 90 days. This has not changed in recent years. Such relatively long credit term is due to the peculiar environment affecting
the Chinese pharmaceutical market, as deferred payments by state-owned hospitals to local drug distributors are common, and their deferred
payments will indirectly delay the payments from our customers to us. Due to the timeliness requirements of the NMPA for logistics of
drug sales, Helpson, like most other pharmaceutical companies in China, sells substantially all the drugs to local drug distributors,
certified by GSP (Good Supply Practice), the standard of products supply, which is a standard protocol to control the quality of the products
during circulation. These GSP certified distributors then sell the drugs to state-owned hospitals. The GSP certified distributors&#8217;
payments to us are usually delayed as they will pay us after they receive payment from the state-owned hospitals. Therefore, as most of
our customers are GSP certified distributors, we adopt a unified policy for bad debt allowance reserves for GMP&#8217;s customers who
are typically GSP certified distributors. As is typical in the Chinese pharmaceutical market, there are no written contracts between the
Company and any of its GSP certified distributors requesting the distributors to pay the Company&#8217;s account receivable upon their
receipt of funds from the distributors&#8217; customers, or state-owned hospitals. Nevertheless, the Company&#8217;s customers typically
process the payment of the account receivable to the Company upon their receipt of payment from their customers, i.e., the state-owned
hospitals, as a matter of implied consensus or industry standard. In the event the length of collection term is deviated from any of the
past pattern of any particular customer, the Company will adjust its credit term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The amount of net accounts receivable that was
past due (or the amount of accounts receivable that was more than 180 days old) was $0.01 million and $0.03 million as of December 31,
2023 and 2022, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The following table illustrates our accounts receivable
aging distribution in terms of the percentage of the total accounts receivable, respective gross accounts receivables as well as the allocated
allowance for doubtful accounts as of December 31, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">1 - 180 Days</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.45</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.28</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>180 - 365 Days</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.06</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>365 - 720 Days</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.09</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">&gt; 720 Days</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96.40</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97.44</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.00</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.01</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross Accounts<br/>
 Receivable Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Allocated Allowance for<br/>
 Doubtful Accounts</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/>
&#160;2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">1-180 Days</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">495,366.30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,046.24</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">180-365 Days</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,341.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,662.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">834.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,666.20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">365-720 Days</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,825.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,628.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,678.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,139.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify">Over 720 Days</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,845,897.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,721,720.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,845,897.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,721,720.98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: justify">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,363,431.33</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,161,057.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,856,409.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,739,527.01</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our bad debt allowance estimate practice is that
we consider accounts receivable balances aged within 180 days current, except for any individual uncollectible account assessed by management.
We account for the following respective percentage as bad debt allowance based on age of the accounts receivables: 10% of accounts receivable
that are between 180 days and 365 days old, 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts
receivable that are greater than 720 days old.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our allowance for doubtful accounts as a percentage
of accounts receivable was 96.5% and 97.5% as of December 31, 2023 and 2022, respectively. The 1% decrease is due to the write-off of
accounts receivable in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We conduct analysis and review on accounts receivables
for customers on a specific, per-customer basis in the fourth fiscal quarter of each fiscal year. For customers (i) whose business license
has been cancelled or expired; (ii) whose key business certificates such as GSP (Good Supply Practice) license have been invalid or revoked;
(iii) who have no ability to continue operations, or (iv) who are encountering other issues that lead to accounts receivable unrecoverable,
the receivable will be written-off as per the resolution of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We recognize bad debt expenses per actual write-offs
as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that
of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is
lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances
were $13.8 million and $16.7 million as of December 31, 2023 and December 31, 2022, respectively. The changes in the allowances for doubtful
accounts during the years ended December 31, 2023 and 2022 were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the Fiscal Years Ended</b></td><td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td><td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Balance, Beginning of Period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,739,527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,312,707</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Bad debt benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,851</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debt write-offs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,671,896</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(265,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,479,329</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance, End of Period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,786,074</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,739,527</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our bad debt benefit for the year ended December
31, 2023 was $15,757, as compared to $93,851 in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating loss for the
year ended December 31, 2023 was $2.8 million, compared to $3.5 million in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Interest Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Net interest expense was $0.33 million for the
year ended December 31, 2023 and $0.42 million for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss for the year ended
December 31, 2023 was $3.1 million, compared to net loss of $3.9 million for the year ended December 31, 2022. The decrease in net loss
was mainly a result of the decline in expenses more than the decline in revenue.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Loss per basic and diluted
common share was $0.91 for the year ended December 31, 2023 and $3.78 for the year ended December 31, 2022, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The number of basic and diluted weighted-average
outstanding shares used to calculate loss per share was 3,383,573 for 2023, as compared to 1,051,371 for 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our principal source of liquidity is cash generated
from operations, bank lines of credit and the convertible note payable. Currently the Company has not witnessed or expected to encounter
any difficulties to refinance those lines of credit this year.&#160;As of December 31, 2023, the aggregated advance from our CEO was $1,133,809
for use in operations. Our cash and cash equivalents were $1.42 million, representing 8.6% of our total assets, as of December 31, 2023,
as compared to $2.03 million, representing 11.4% of our total assets as of December 31, 2022. All of the $1.42 million of cash and cash
equivalents as of December 31, 2023 are considered to be reinvested indefinitely in the Company&#8217;s Chinese subsidiary, Helpson, and
are not expected to be available for payment of dividends or for other payments to its parent company or to its shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company obtained various lines of credit in
details described under Note 7 to its audited condensed consolidated financial statements contained in this annual report which is incorporated
by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">China Pharma issued a convertible note to an institutional
accredited investor as disclosed in Note 8 to the audited condensed consolidated financial statements contained in this report which is
incorporated by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Although the Company obtained additional lines
of credit in 2023, there can be no assurance that the Company will be able to achieve its future strategic goals, including the launch
of new products. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Although our Chairperson
and Chief Executive Officer had advanced funds for working capital in 2023, there can be no assurances that this will continue in the
future. We may seek additional debt or equity financing as necessary when we believe the market conditions are the most advantageous to
us and/or require us to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our
business objectives.&#160;&#160;There can be no assurance that any additional financing will be available on acceptable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Net cash used in operating activities was $0.70
million in the year ended December 31, 2023, compared to $0.41 million in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of December 31, 2023, our net accounts receivable
was $0.50 million, an increase of $0.08 million from $0.42 million as of December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of December 31, 2023, total inventory was $3.7
million, compared to $2.9 million as of December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">During the year ended December 31, 2023, net cash
used in investing activities was $0.01 million, compared to $0.40 million for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Cash flow provided by financing activities was
$0.07 million in the year ended December 31, 2023; compared to cash flow used in financing activities of $1.77 million in the year ended
December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">According to relevant PRC laws, companies registered
in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income,
as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account
balances reach fifty percent (50%) of the companies&#8217; registered capital prior to their remittance of funds out of the PRC.&#160;&#160;Allocations
to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans,
advances or cash dividends.&#160;As of December 31, 2023 and December 31, 2022, Helpson&#8217;s net assets totaled $(2,289,000) and $(190,000),
respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson&#8217;s net assets that
was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends,
was 50% of Helpson&#8217;s registered capital, which was both $8,145,000 as of December 31, 2023 and December 31, 2022, respectively.&#160;The
amount that Helpson must set aside for the statutory surplus fund accounts exceeds its total net assets at December 31, 2023 and 2022.&#160;&#160;There
were no allocations to the statutory surplus reserve accounts during the twelve months ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Chinese government also imposes controls on
the conversion of RMB into foreign currencies and the remittance of currencies out of China.&#160;&#160;Our businesses and assets are
primarily denominated in RMB.&#160;&#160;All foreign exchange transactions take place either through the People&#8217;s Bank of China
or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People&#8217;s Bank of China.&#160;Approval
of foreign currency payments by the People&#8217;s Bank of China or other regulatory institutions requires the submission of a payment
application form together with certain invoices and executed contracts.&#160;The currency exchange control procedures imposed by Chinese
government authorities may restrict the ability of Helpson, our Chinese subsidiary, to transfer its net assets to our parent company through
loans, advances or cash dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As of December 31, 2023, we did not have any off-balance
sheet arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Management&#8217;s discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with
United States generally accepted accounting principles (&#8220;GAAP&#8221;). Our financial statements reflect the selection and application
of accounting policies which require management to make significant estimates and judgments. Please refer to Note 1 to our consolidated
financial statements, &#8220;Organization and Significant Accounting Policies&#8221; for the discussion of our critical accounting policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
are not required to provide the information required by this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated balance sheets,
as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity
and cash flows for each of the two years in the period ended December 31, 2023 and 2022, together with the related notes and the report
of our independent registered public accounting firms, are set forth on the &#8220;F&#8221; pages of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain disclosure controls
and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information that would be required
to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC&#8217;s
rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer
and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Rule 13a-15
under the Exchange Act, our management, including our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness
of the design and operation of our disclosure controls and procedures as of December 31, 2023. Based on that evaluation, our Chief Executive
Officer and interim Chief Financial Officer concluded that as of December 31, 2023, our disclosure controls and procedures were not effective
to satisfy the objectives for which they are intended due to the material weakness in our internal control over financial reporting discussed
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Report on Internal Control
over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is
defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s
principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board
of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes
those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of a company; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures
of a company are being made only in accordance with authorizations of management and directors of a company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company&#8217;s assets that could
have a material effect on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any system of internal control,
no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and
misstatements due to error or fraud may occur and not be detected in a timely manner. Also, because of changes in conditions, internal
control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance
with respect to financial statement preparation. In addition, the design of any system of controls is based in part on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree
of compliance with policies or procedures. Therefore, any current evaluation of controls cannot and should not be projected to future
periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed our internal
control over financial reporting as of the year ended December 31, 2023. In making this assessment, management used the criteria set forth
in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the report entitled &#8220;Internal Control-Integrated
Framework.&#8221; The 2013 COSO framework summarizes each of the components of a company&#8217;s internal control system, including (i)
the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication, and (v) monitoring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on management&#8217;s
assessment using the COSO criteria, management has concluded that our internal control over financial reporting was not effective as of
December 31, 2023, to allow our management, employees and consultants, in the normal course of performing their assigned functions, to
prevent or detect misstatements on a timely and reasonable basis and to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting
principles (&#8220;U.S. GAAP&#8221;).</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness is a control
deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the
annual or interim financial statements will not be prevented or detected. Our Chief Executive Officer and interim Chief Financial Officer
has determined there existed a material weakness in our internal control over financial reporting as of December 31, 2023, with respect
to our lack of accounting financial reporting personnel knowledgeable in US GAAP. As of the date of this report, we are undertaking steps
to address the aforementioned material weaknesses by obtaining education and training for our personnel regarding the proper accounting
under U.S. GAAP and reviewing the processes to correct the identified weaknesses. Notwithstanding these material weaknesses, management
has concluded that our consolidated financial statements included in this annual report are fairly stated in all material respects in
accordance with U.S. GAAP for each period presented herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we are a smaller reporting
company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding
internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Controls over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules
13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9B. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Trading Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">During
the fiscal quarter ended December 31, 2023, none of our directors or officers&#160;<ix:nonNumeric contextRef="c29" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-11405"><ix:nonNumeric contextRef="c29" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-11406">adopted</ix:nonNumeric></ix:nonNumeric>&#160;or&#160;<ix:nonNumeric contextRef="c29" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-11407"><ix:nonNumeric contextRef="c29" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-11408">terminated</ix:nonNumeric></ix:nonNumeric>&#160;a &#8220;Rule&#160;10b5-1&#160;trading
arrangement&#8221; or a &#8220;non-Rule&#160;10b5-1&#160;trading arrangement&#8221;, as those terms are defined in&#160;Regulation S-K,
Item&#160;408.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>Item
9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Listed below are the names
and ages of all our directors and executive officers as of March 24, 2024, along with their positions, offices and term:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="width: 20%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 70%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson, President, Chief Executive Officer and interim Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our independent directors
hold offices until our next annual meeting of the stockholders, at which a successor will be duly elected and qualified or until his or
her earlier resignation, removal from office, death or incapacity. Non-independent directors will hold office for a term of three (3)
years or when their respective successors shall have been elected and shall qualify, or upon their prior death, resignation or removal.
Directors may be re-elected for successive terms. Officers serve at the discretion of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth biographical
information regarding the above directors and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Zhilin Li</i></b> is
the Chairperson, President, Chief Executive Officer and interim Chief Financial Officer of our company. She has served as a director since
2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as Chairperson and Chief Executive
Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou Bio-Engineering Institute as well as the vice president
of Sichuan Institute of Biology. She graduated from Sichuan University with a degree in biology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Heung Mei Tsui</i>&#160;</b>has
served as a director of the Company since April 28, 2009. Previously, Ms. Tsui served as a member of our board from October 2005 to February
2008. Ms. Tsui has been a self-employed businesswoman engaged in strategic investments and was previously engaged in the pharmaceutical
chemical raw material import/export business. Ms. Tsui graduated from Hunan Financial&amp; Economic College in 1982.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Gene Michael Bennett</i></b>
has served as our independent director since February 2008. Presently, Mr. Bennett is Chairperson of the board of directors for Bonita
Healthcare Ltd, Houston, Texas, USA, and Chairperson of the Board of Redwood Senior Living Inc. located in Alameda County, California,
USA. From 2013 through 2015 Mr. Bennett served as part-time CFO for Kang Jia Fu, Royal Traditional Health Investment Management Co. Ltd,
located in Wuxi, Jiangsu Province, China and advisor to Swiss Capital Asia, located in Hong Kong. From 2009 through 2013, Mr. Bennett
served as the CEO of American General Business Association, located in Beijing, China. Mr. Bennett was a partner of Nexis Investment Consulting
Corporation based in Beijing from 2004-2009. He was a partner of ProCFO Company based in California which provided contract chief financial
officer service for firms during 2000-2004. During 1998-2000, he was a basic law, accounting and tax professor at University of Hawaii,
and an accounting, tax and audit professor at Chaminade University of Honolulu, Hawaii, USA. In addition, he previously served as the
chief financial officer and member of the board of directors of Argonaut Computers in Southern California. Mr. Bennett worked as an accounting
and audit professor at Chapman University and an accounting, tax, and audit professor at California State University at Fullerton. He
also acted as chief financial officer and a board member of the National Automobile Club. Mr. Bennett graduated from Michigan State University
with an MBA in Finance and BA in Accounting. He obtained his CPA license from the State of Colorado, which is currently inactive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yingwen Zhang</i></b>
has served as our independent director since February 2008. He also currently serves as a consultant of Shanghai Reseat Medical Tech Co.
Ltd., a medical device producer. He acted as Senior Consultant and Chairperson of HSE (Health Safe and Environment) Committee of SINOFERT
Holdings Limited (HKG: 0297) of SINOCHEM Group from October 2005 to June 2009. He served as an independent director of a public company,
Chongqing New Energy Co., Ltd. (SH.600847), from 2007 to 2018. Additionally, Mr. Zhang was appointed as the Commercial Counselor of the
China Embassy in Malaysia from March 2000 through October 2005. Prior to that, from 1988 to 2000, Mr. Zhang was appointed as the Director-General
to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (the Commercial Bureau of Sichuan Province, China). In his early career
he was a chemical engineer and senior economist, and then became a senior manager for several chemical corporations in China. From 1983
to 1988, Mr. Zhang served as vice CEO and then CEO of a large nature gas-chemical state owned enterprise (SOE) in the PRC affiliated with
the SINOPEC Group. Mr. Zhang graduated from the Chemical Engineering Department of Tianjin University in 1967.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Baowen Dong</i></b>
has served as our independent director since February 2008. Mr. Dong participated on the expert team of the Sichuan University from 2003
to 2008, doing teaching evaluation and assessment work in Engineering and Medical Science faculty. In the past few years, Mr. Dong has
focused on the research of China&#8217;s Health Care Reform. Previously, he concentrated on biomedical and medical information researches.
Mr. Dong has had different roles in areas of teaching and research, including serving as a department head and a professor, at Sichuan
University from 1974 to 2001. Additionally, Mr. Dong was engaged in the field of communication technology from 1966 to 1974. Mr. Dong
graduated from Xidian University in 1966.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director or Officer Involvement in Certain
Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, our directors
and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 16(a) Beneficial Ownership Reporting
Compliance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Securities
Exchange Act of 1934, as amended, requires our directors, executive officers and persons who own more than 10% a registered class of our
equity securities (&#8220;Reporting Persons&#8221;), to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the
SEC. The Reporting Persons are also required by SEC rules to furnish us with copies of Section 16(a) forms they file. Based upon a review
of the filings made on their behalf during the fiscal year ended December 31, 2023 as well as an examination of the SEC&#8217;s EDGAR
system Form 3, 4, and 5 filings (including amendments to such forms) and our records, we believe that, during the year ended December
31, 2023, the Reporting Persons met all applicable Section 16(a) filing requirements except for the following: (i) Zhilin Li did not timely
file Form 4 after being granted 2,751,413 (pre-reverse stock split, 13,757,063 shares) shares on September 29, 2023. However, the Form
4 corresponding to the transaction was subsequently filed on October 19, 2023; and (ii) Tao Liu did not timely file Form 3 after being
granted 3,000,000 (pre-reverse stock split, 15,000,000 shares) shares on December 28, 2023. However, the Form 3 corresponding to the transaction
was subsequently filed on January 26, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2008, we adopted
a code of business conduct and ethics for all directors and employees (including officers) within the meaning of the regulations adopted
by the SEC under Section 406 of the Sarbanes-Oxley Act of 2002. The code has been designed to deter wrongdoing and promote (i) honest
and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships,
(ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and
in other public communications made by us, (iii) compliance with applicable governmental laws, rules and regulations, (iv) the prompt
internal reporting of violations of the code to an appropriate person or persons, and (v) accountability for adherence to the code. The
application of the code to the persons it applies to may only be waived by our Board of Directors in accordance with SEC regulations and
the Sarbanes-Oxley Act of 2002. A copy of the code is available on our website at <span style="text-decoration:underline;text-decoration: none">www.chinapharmaholdings.com</span> or may be obtained
by sending a written request to our corporate secretary at China Pharma Holdings, Inc., Second Floor, No. 17, Jinpan Road, Haikou, Hainan
Province, China 570216.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2008, we established
an audit committee, which currently consists of our three independent directors: Gene Michael Bennett, Yingwen Zhang and Baowen Dong.
Mr. Bennett, the Chairperson of the Audit Committee, is an &#8220;audit committee financial expert&#8221; as defined in Item 401(d)(5)
of Regulation S-K promulgated under the Securities Act. The audit committee carries out its responsibilities in accordance with the terms
of its Audit Committee Charter, a copy of which attached as Exhibit 99.1 to our Annual Report on Form 10-K filed on March 17, 2009, and
available on our website at <span style="text-decoration:underline;text-decoration: none">www.chinapharmaholdings.com</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11. EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Executive Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal
financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other executive officer received
compensation in excess of $100,000 during the fiscal year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SUMMARY COMPENSATION TABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Non-Equity</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Nonqualified</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"/><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Option</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Incentive Plan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Deferred</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">All Other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name and principal</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Salary</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Bonus</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"> position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Earnings ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23.5%; text-align: left">Zhilin Li</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2023</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">225,600</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">16,000</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">241,600</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Chairperson, Chief</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">President and interim Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Zhilin Li</i></b>. Hainan
Helpson Medical &amp; Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (&#8220;Helpson&#8221;), entered
into an employment agreement with Ms. Zhilin Li, our Chairperson of the Board and Chief Executive Officer. Upon the expiration of the
original agreement, Helpson renewed the agreement with Ms. Li on the same terms as the original agreement. The new employment agreement
will expire on June 30, 2025. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson&#8217;s
Chief Executive Officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li&#8217;s compensation based
upon her production and operating achievement and her technical ability and working performance. Ms. Li&#8217;s total annual cash compensation
for the fiscal year ended December 31, 2023, when aggregated with her compensation from our U.S. holding company level, was $241,600.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Payments upon Termination or Change-in-Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>PRC Law. </i>Under the
applicable laws of the PRC, we must pay severance to all employees who are Chinese nationals and who are terminated with or without cause,
or whose employment agreement with us expires and we choose not to continue their employment. The severance benefit required to be paid
under the laws of the PRC equals the average monthly compensation paid to the terminated employee (including any bonuses or other payments
made in the 12 months prior to the employee&#8217;s termination) multiplied by the number of years the employee has been employed with
us, plus an additional month&#8217;s salary if 30 days&#8217; prior notice of such termination has not been given. However, if the average
monthly compensation to be received by the terminated employee exceeds three times the average monthly salary of the employee&#8217;s
local area, as determined and published by the local government, such average monthly compensation shall be capped at three times the
average monthly salary of the employee&#8217;s local area. Except as described above, our executive officer does not have any other agreement
or arrangement under which she may be entitled to severance payments upon termination of employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discussion of Summary Compensation and Grants
of Plan-based Awards Tables</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of certain material
terms of our existing compensation plans and arrangements is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 12, 2010, our
Board of Directors adopted, and on December 22, 2010 our stockholders approved the 2010 Long-Term Incentive Plan (the &#8220;2010 Incentive
Plan&#8221;). On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment
No. 1&#8221;), pursuant to which the term of the 2010 Incentive Plan shall be extended to December 31, 2029. The Amendment No. 1 was adopted
by the stockholders on December 19, 2019. The 2010 Incentive Plan, as amended, gave us the ability to grant stock options, restricted
stock, stock appreciation rights and performance units to employees, directors and consultants, or those who will become employees, directors
and consultants of our company and/or our subsidiaries. On October 25, 2021, our Board of Directors approved, and on December 27, 2021
our stockholders adopted the Amendment No.2 to our Long-Term 2010 Incentive Plan (the &#8220;Plan&#8221;) to increase the number of shares
of the Common Stock, that are reserved thereunder by 100,000 (500,000 pre reverse stock split) shares from 80,000 (400,000 pre reverse
stock split) shares to 180,000 (900,000 pre reverse stock split) shares (the &#8220;Amendment&#8221;).&#160; On October 27, 2022, the
Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan
to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 (500,000 pre reverse stock split)
shares from 180,000 (900,000 pre reverse stock split) to 280,000 (1,400,000 pre reverse stock split). On October 18, 2023, the Board of
Directors approved and on December 17, 2023, the stockholders adopted the Amendment No.1 to the Amended and Restated Long Term 2010 Incentive
Plan to increase the number of shares of common stock that are reserved thereunder by an additional 300,000 (1,500,000 pre reverse stock
split) shares from 280,000 (1,400,000 pre reverse stock split) to 580,000 (2,900,000 pre reverse stock split). As of March 24, 2024, 482,000
shares of restricted stock were outstanding, and no options were outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning cash and non-cash compensation earned by or paid to our directors during the year ended December 31, 2023.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="29" style="font-weight: bold; text-align: center">DIRECTOR COMPENSATION</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="29" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees <br/> Earned <br/> or <br/> Paid in <br/> Cash <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> Incentive <br/> Plan <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Qualified <br/> Deferred <br/> Compensation <br/> Earnings <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All <br/> Other <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left">Heung Mei Tsui</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">16,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">16,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Zilin Li</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gene Michael Bennett</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Yingwen Zhang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Baowen Dong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,202</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors will also be
reimbursed for all of their out-of-pocket expenses in traveling to and attending meetings of our Board of Directors and committees on
which they serve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Zhilin Li, our Chairperson,
President and Chief Executive Officer, was also compensated for serving on our board of directors as set forth in the Summary Compensation
Table appearing earlier in this Item 11.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Engagement Letters</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2023, we renewed
the engagement letters with each of our three independent directors. Pursuant to the renewed engagement letters entered into on the same
terms and conditions as the previous engagement letters and for a term of one year, each of Mr. Zhang and Mr. Dong is entitled to receive
annual compensation of RMB40,000 (approximately $6,202), payable quarterly and Mr. Bennett is entitled to receive annual compensation
of $16,000, payable quarterly, and a warrant to purchase 5,000 shares of common stock at an exercise price of $0.55 per share (pre-reverse
stock split, $0.11 per share). As of the date of this report, no warrants have been issued to Mr. Bennett.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information as of March 24, 2024, with respect to the beneficial ownership of our common stock, the sole outstanding class of
our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each
executive officer and (iv) all executive officers and directors as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2024, an aggregate
of 14,816,865 shares of our common stock were outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owners(1)(2)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount and Nature of Beneficial Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percent of Class(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify">Directors and Executive Officers</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Zhilin Li <br/>President, Chief Executive Officer, <br/>Interim Chief Financial Officer <br/>and Chairperson of the Board</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,027,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20.43</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Heung Mei Tsui <br/>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Yingwen Zhang <br/>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gene Michael Bennett (4) <br/>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Baowen Dong <br/>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">All directors and executive officers as a group (5 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,213,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.69</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: justify">Beneficial stockholders with 5% or more ownership</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Tao Liu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lihua Li</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Kui Lai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Jianying Cai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 1%.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People&#8217;s Republic of China 570216.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the percentage of common stock owned by the beneficial owners, (a) the numerator is the number of shares of common stock beneficially owned by such owner, including shares the owner may acquire, within 60 days of March 24, 2024, upon the exercise of the options or warrants, if any, held by the owner; and (b) the denominator is the sum of (i) the total 14,816,865 shares of common stock outstanding as of March 24, 2024, and (ii) the number of shares underlying any options or warrants, which such owner has the right to acquire upon the exercise of such options or warrants within 60 days of March 24, 2024 (for those who have options or warrants).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of his engagement letters, Mr. Bennett is entitled to receive warrants to purchase an aggregate of 75,000 shares of our common stock (5,000 shares in each of year between 2008 to 2023 fiscal years). As of the date of this report no such warrants were issued.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Tsui, one of our directors,
has made various loans to the Company. The balance of such loans from Ms. Tsui remained $1,354,567 as of December 31, 2022 and 2021. The
loans bear interest at a rate of 1% per annum and principal and interest were payable by December 31, 2022, pursuant to a loans extension
confirmation letter executed by the Company and Ms. Tsui in 2021. We recognized interest expense of $13,546 and $13,546 for the years
ended December 31, 2022 and 2021, respectively. On August 23, 2023, Ms. Tsui entered into certain loan transfer agreement. Pursuant to
the agreement, Ms. Tsui agreed to transfer the Company&#8217;s debt of $1,854,452.1 to Ms. Li. On September 28, 2023, Ms. Li and the Company
entered into certain loan settlement agreement on the above debt, of which Ms. Li agreed to settle the above-mentioned loan in the form
of 2,751,412 shares (pre-reverse stock split, 13,757,063 shares) from the Company. Such issuance was completed on September 29, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company received net advances
totaling $0 and $1,183,414 and repaid $223,013 and $562,659 of the advances during the years ended December 31, 2022 and 2021, respectively
from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer as of December 31, 2022 and 2021, respectively. On July
8, 2019 the Company entered into a loan agreement to borrow cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer
and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement.
The due date of the loan agreement was extended to July 9, 2024, on identical terms. Total interest expense related to the loan for the
year ended December 31, 2023 and 2022 was $27,644 and $28,962.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Independence of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
determined that Gene Michael Bennett, Baowen Dong and Yingwen Zhang are &#8220;independent directors&#8221; as defined in the listing
standards of NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.25in; "><b>Pay
Versus Performance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In
August 2022, the SEC adopted final rules to require companies to disclose information about the relationship between executive compensation
actually paid and certain financial performance of the company. The information below is provided pursuant to Item 402(v) of SEC Regulation
S-K with respect to &#8220;smaller reporting companies&#8221; as that term is defined in Item 10(f)(1) of SEC Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">(a)<br/>
 Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(b)<br/>
 Summary Comp <br/>
Table Total for PEO<br/>
 ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(c)<br/>
 Comp. Actually Paid to PEO<br/>
 ($)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(d)<br/>
 Average Summary<br/>
 Comp. Table for Non-PEO<br/>
 NEOs ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(e)<br/>
 Average Comp.<br/>
 Actually Paid to Non-PEO<br/>
 NEOs ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(f)<br/>
 Value of<br/>
 Initial Fixed $100 Investment Based on<br/>
 Total Shareholder Return<br/>
($)(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(g)<br/>
 Net Income<br/>
 ($)(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%; text-align: left">2021</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">241,600</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,179,200</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">108.25</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,399,476</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">241,600</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21.51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,972,841</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">236,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,022,018</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
dollar amounts reported in column (b) are the amounts of total compensation reported for Chairperson Li for each corresponding year in
the &#8220;Total&#8221; column of the Summary Compensation Table. See &#8220;Executive Compensation - Summary Compensation Table.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">The dollar amounts reported in column (c) represent the amount
of &#8220;compensation actually paid&#8221; to Chairperson Li as computed in accordance with Item 402(v)(2)(iii) of SEC Regulation S-K,
which prescribes certain specified additions and subtractions from the amount in column (b). In accordance with the requirements of Item
401(v)(2)(iii) of Regulation S-K, we adjusted the amount in 2023 and 2022 to show the compensation as unpaid. In 2021, we adjusted for
$1,179,000 paid via the issuance of 35,200 shares of fully vested common stock at the price of $33.50 per share from the Amended and
Restated Long Term 2010 Incentive Plan to Chairperson Li in lieu of salary from years prior to 2021.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Total Shareholder Return is determined based on the value
of an initial fixed investment in the Company&#8217;s common stock of $100 on December 31, 2020 and calculated in accordance with Item
201(e) of SEC Regulation S-K.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">The dollar amounts reported in column (g) represent the amount
of net income reflected in our consolidated audited financial statements for the applicable year.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><i>Analysis
of the Information Presented in the Pay Versus Performance Table</i></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Nomination and Compensation Committee of the Board of Directors of the Company does not have a policy or practice regarding evaluating
Total Shareholder Return as part of its determination of compensation decisions for the named executive officers. The Nomination and Compensation
Committee takes various factors into account in determining the competitiveness of its executive compensation. Over the past three fiscal
years the Nomination and Compensation Committee has recognized the significant time and effort required by the executive officer to manage
the Company&#8217;s liquidity by raising capital while reducing operating expenses and cash used in operations, secure and maintain the
Company&#8217;s listing on the NYSE American Market, and to source and evaluate patent technology acquisition opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All
information provided above under the &#8220;Pay Versus Performance Information&#8221; heading will not be deemed to be incorporated by
reference in any filing of our company under the Securities Act of 1933, as amended, whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate fees billed
by <span>B F Borgers CPA PC, </span>our principal accountant, for professional services rendered for the
audit of our annual financial statements included in our Annual Reports on Form 10-K, for the reviews of the financial statements included
in our Quarterly Reports on Form 10-Q, and for services in connection with statutory and regulatory filings or engagements were approximately
$132,000 and $132,000 for the fiscal year ended December 31, 2023, and 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit-Related Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur any audit-related
fees during the fiscal years ended December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not incur any tax fees
during the fiscal year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>All Other Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not engage our principal
accountant to render services to us during the last two fiscal years, other than as reported above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Approval Policies and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Sarbanes-Oxley Act
of 2002, all audit and non-audit services performed by our auditors must be approved in advance by our Audit Committee to assure that
such services do not impair the auditors&#8217; independence from us. In accordance with its policies and procedures, the Audit Committee
pre-approved the audit service performed by <span>B F Borgers CPA PC</span>, for our consolidated financial
statements as of and for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The following documents
are filed as part of this report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following financial statements
of China Pharma Holdings, Inc. and Reports of Independent Registered Public Accounting Firms are presented in the &#8220;F&#8221; pages
of this report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 90%; padding-left: 10pt; text-indent: -10pt"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of B F Borgers CPA PC, Independent Registered Public Accounting Firm</span></a></td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets - as of December 31, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Loss - for the years ended December 31, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Stockholders&#8217; Equity - for the years ended December 31, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows - for the years ended December 31, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Exhibits</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index following
the signature page of this report, which Index is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 1, 2024</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHINA PHARMA HOLDINGS, INC.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="width: 35%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson of the Board, President, Chief Executive Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer) and interim Chief Financial Officer<br/>
(principal financial officer and principal accounting officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heung Mei Tsui</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gene Michael Bennett</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen Zhang</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2024</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baowen Dong</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit Index to Annual Report on Form 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Fiscal Year Ended December 31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/cphi8kex31010413.htm">Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on December 31, 2012).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex3-2_china.htm">The First Amended and Restated Articles of Incorporation of the Company</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex3-3_china.htm">The Second Amended and Restated Articles of Incorporation of the Company.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/cphi8kex32010413.htm">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on December 31, 2012).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262ex4-1_chinapharma.htm">Convertible Promissory Note dated November 17, 2021 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1106644/000121390022016151/f10k2021ex4-2_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Registered Pursuant to Section 12 of the Exchange Act (incorporated by reference to our Annual Report on Form 10-K filed on March 30, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-1_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter dated December 12, 2018 from the Company and accepted by Ms. Heung Mei Tsui for Ms. Tsui serving as a director of the Company (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 28, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/f10k2018ex10-2_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter dated December 12, 2018 from the Company and accepted by Ms. Zhilin Li for Ms. Li serving as a director of the Company (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 28, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054915000090/cphi10kex102123114.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Independent Director Engagement Letter (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 30, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054916000541/ex101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated July 1, 2015 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Zhilin Li (incorporated by reference to Exhibit 10.1 to our Annual Report on Form 10-K filed on March 30, 2016).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex101060111.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054911000554/cphi8kex102060111.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Non-Qualified Stock Option Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390022072361/ea168496-def14a_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restate 2010 Long-Term Incentive Plan of China Pharma Holdings, Inc. (incorporated by reference to the Appendix A of our Proxy Statement on Schedule 14A filed on November 14, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390023084279/ea187801-def14a_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.1 to the Amended and Restate 2010 Long-Term Incentive Plan of China Pharma Holdings, Inc. (incorporated by reference to the Appendix A of our Proxy Statement on Schedule 14A filed on November 7, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262ex10-1_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement between China Pharma Holdings, Inc. and Streeterville Capital, LLC dated November 17, 2021 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262ex4-1_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note dated November 17, 2021 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390023031309/ea177239ex10-1_chinapharm.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Convertible Note. (incorporated by reference to our Current Report on Form 8-K filed on April 20, 2023)</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 90%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/ea169540ex10-1_chinapharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology Transfer Contract between Hainan Helpson Medical &amp; Biotechnology Co., Ltd and Chengdu Bonier Medical Technology Development Co., Ltd. dated November 28, 2022 (incorporated by reference to our Current Report on Form 8-K filed on December 2, 2022)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex10-13_china.htm">Loan Settlement Agreement between China Pharma Holdings, Inc. and Ms. Zhilin Li.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14*#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex10-14_china.htm">Technology Transfer Agreement between Hainan Helpson Medical &amp; Biotechnology Co., Ltd and Tao Liu.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex10-15_china.htm">Technology Transfer Agreement between Hainan Helpson Medical &amp; Biotechnology Co., Ltd and Lihua Li.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex10-16_china.htm">Office Lease for Second Floor of the Company&#8217;s Principal Executive Office Dated June 5, 2023.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17*#</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex10-17_china.htm">Office Lease for Third Floor of the Company&#8217;s Principal Executive Office Dated June 5, 2023.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054908000562/cphs1ex141071108.txt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (incorporated by reference to the Registration Statement on Form S-1 filed on July 11, 2008).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1106644/000101054911000201/ex211.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Company (incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex23-1_china.htm">Consent of the Independent Accounting Firm.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex31-1_china.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex31-2_china.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex32-1_china.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020277201ex97-1_china.htm">Compensation Recovery Policy of the Company</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive data files pursuant to Rule 405 of Regulation S-T</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions of the exhibit, including certain private and confidential information has been omitted pursuant to Item 601(a)(6) and Item 601(b)(10)(iv) of Regulation S-K. The Registrant hereby agrees to furnish a copy of any omitted portion to the SEC upon request.</span></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 90%"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center">F-3</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in"><a href="#f_003"><span style="font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">F-4</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#f_004"><span style="font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></td>
    <td style="text-align: center; vertical-align: bottom">F-5</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in"><a href="#f_005"><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center">F-6</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.5in"><a href="#f_006"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="padding-right: 0.8pt; text-align: center">F-7</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the shareholders and the board of directors
of China Pharma Holdings, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of China Pharma Holdings, Inc. as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity
(deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&#8217;s
significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Audit Matter</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Critical audit matters
are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">We determined that there
are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>/S/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-11409">BF Borgers CPA PC</ix:nonNumeric> (PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-11410">5041</ix:nonNumeric>)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company's auditor since
2016</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-11411">Lakewood, CO</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 1, 2024</p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED BALANCE
SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-11412">1,423,838</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-11413">2,029,971</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Banker&#8217;s acceptances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:BankersAcceptances" scale="0" unitRef="usd" id="ixv-11414">65,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:BankersAcceptances" scale="0" unitRef="usd" id="ixv-11415">13,784</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Trade accounts receivable, less allowance for doubtful accounts of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-11416">13,786,074</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd" id="ixv-11417">16,739,527</ix:nonFraction>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-11418">504,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-11419">421,531</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Other receivables, less allowance for doubtful accounts of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-11420">27,017</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-11421">27,149</ix:nonFraction>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-11422">157,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-11423">29,139</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvanceToSupplies" scale="0" unitRef="usd" id="ixv-11424">2,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdvanceToSupplies" scale="0" unitRef="usd" id="ixv-11425">444,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-11426">3,732,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-11427">2,947,787</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-11428">110,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-11429">77,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-11430">5,996,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-11431">5,964,546</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-11432">7,100,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-11433">9,973,065</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-11434">116,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-11435">39,046</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-11436">3,255,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-11437">1,807,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-11438">16,469,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-11439">17,784,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Trade accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-11440">966,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-11441">667,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11442">298,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11443">404,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-11444">2,282,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-11445">2,390,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Advances from customers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11446">90,507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11447">520,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Borrowings from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11448">1,133,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11449">2,475,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11450">77,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11451">40,445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Current portion of lines of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="0" unitRef="usd" id="ixv-11452">1,030,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="0" unitRef="usd" id="ixv-11453">2,440,915</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Convertible, redeemable note payable, net of issue discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-11454">940,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-11455">3,800,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11456">6,820,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11457">12,739,447</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-11458">39,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Lines of credit, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="0" unitRef="usd" id="ixv-11459">1,411,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" unitRef="usd" id="ixv-11460">742,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" unitRef="usd" id="ixv-11461">754,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-11462">9,014,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-11463">13,494,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Commitments and Contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11464"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11465">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11466"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11467">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <span style="-sec-ix-hidden: hidden-fact-6"><span style="-sec-ix-hidden: hidden-fact-7"><span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9">no</span></span></span></span> shares issued or outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11468"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11469">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11470"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-11471">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-11472"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11473">10,625,788</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-11474"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11475">1,498,180</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-11476">10,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-11477">1,498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-11478">35,282,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-11479">28,926,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Retained deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-11480">39,290,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-11481">36,211,496</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-11482">11,452,054</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-11483">11,573,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11484">7,454,621</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11485">4,289,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-11486">16,469,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-11487">17,784,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-11488">7,011,299</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-11489">8,104,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-11490">7,292,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd" id="ixv-11491">8,598,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross (loss) profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-11492">281,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd" id="ixv-11493">493,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-11494">780,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-11495">1,069,785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-11496">1,466,084</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-11497">1,893,269</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-11498">240,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-11499">185,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Bad debt benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-11500">15,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-11501">93,851</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-11502">2,470,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-11503">3,055,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11504">2,751,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11505">3,548,977</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-11506">6,602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-11507">10,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-11508">333,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd" id="ixv-11509">434,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-11510">326,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-11511">423,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-11512">3,078,818</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-11513">3,972,841</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax&#160;&#160;expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11514">3,078,818</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11515">3,972,841</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income (loss) - foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-11516">121,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-11517">990,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-11518">3,199,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-11519">4,963,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12">Basic and diluted</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11520">0.91</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-11521">3.78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Weighted average shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-11522">3,383,573</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-11523">1,051,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Retained</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: right">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-weight: bold">Balance, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11524">946,791</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11525">947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11526">25,691,760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-11527">32,238,655</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11528">12,563,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11529">6,017,881</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares" id="ixv-11530">310,446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11531">310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11532">1,707,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11533">1,707,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock option compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-11534">36,270</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-11535">36,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-11536">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-11537">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-11538">41,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-11539">42,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversions of note payable to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-11540">234,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11541">235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11542">1,449,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11543">1,450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11544">3,972,841</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11545">3,972,841</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-11546">990,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-11547">990,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11548">1,498,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11549">1,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11550">28,926,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-11551">36,211,496</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11552">11,573,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11553">4,289,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock for intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares" id="ixv-11554">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11555">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11556">1,647,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd" id="ixv-11557">1,650,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversions of note payable to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-11558">3,362,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11559">3,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11560">2,856,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-11561">2,860,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversion of related party note and interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-11562">2,751,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-11563">2,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-11564">1,851,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-11565">1,854,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11566">3,078,818</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11567">3,078,818</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-11568">121,011</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" sign="-" unitRef="usd" id="ixv-11569">121,011</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Share rounding due to reverse split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-11570">14,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="cphi:StockIssuedDuringPeriodValueStockSplits" scale="0" unitRef="usd" id="ixv-11571">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="cphi:StockIssuedDuringPeriodValueStockSplits" scale="0" sign="-" unitRef="usd" id="ixv-11572">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">Balance, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-11573">10,625,788</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11574">10,625</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11575">35,282,256</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-11576">39,290,314</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11577">11,452,054</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-11578">7,454,621</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated<span style="font-family: Times New Roman, Times, Serif">&#160;</span> financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11579">3,078,818</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-11580">3,972,841</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-11581">2,753,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-11582">2,700,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Bad debt (benefit) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-11583">15,757</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-11584">93,851</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Stock and stock option compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd" id="ixv-11585">78,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Loss on disposal of property, plant &amp; equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-11586">45,385</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Trade accounts and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" unitRef="usd" id="ixv-11587">938,021</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" unitRef="usd" id="ixv-11588">170,194</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" sign="-" unitRef="usd" id="ixv-11589">437,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd" id="ixv-11590">459,959</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-11591">25,032</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-11592">689,104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Trade accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" unitRef="usd" id="ixv-11593">312,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" sign="-" unitRef="usd" id="ixv-11594">187,734</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Other payables and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-11595">257,778</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-11596">692,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left">Advances from customers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" sign="-" unitRef="usd" id="ixv-11597">423,261</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" unitRef="usd" id="ixv-11598">339,659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd" id="ixv-11599">25,089</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd" id="ixv-11600">24,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-11601">699,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-11602">409,545</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromProductiveAssets" scale="0" unitRef="usd" id="ixv-11603">11,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromProductiveAssets" scale="0" unitRef="usd" id="ixv-11604">401,964</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash Used in Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-11605">11,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-11606">401,964</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Payments of line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-11607">1,490,049</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-11608">2,140,921</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Proceeds from lines of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd" id="ixv-11609">1,532,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd" id="ixv-11610">564,965</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Borrowings and interest from related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-11611">30,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-11612">28,962</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Repayments to related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-11613">223,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Cash (Used In) Provided By Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-11614">73,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd" id="ixv-11615">1,770,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Effect of Exchange Rate Changes on Cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" unitRef="usd" id="ixv-11616">31,925</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" sign="-" unitRef="usd" id="ixv-11617">247,573</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Net Increase in Cash, Cash Equivalents and Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-11618">606,133</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-11619">2,829,089</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-11620">2,029,971</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-11621">4,859,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, Cash Equivalents and Restricted Cash at End of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-11622">1,423,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-11623">2,029,971</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash paid for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash paid for interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-11624">92,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-11625">141,797</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Noncash Investing and Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable collected with banker&#8217;s acceptances</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:AccountsReceivableCollectedWithBankersAcceptances" scale="0" unitRef="usd" id="ixv-11626">865,733</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cphi:AccountsReceivableCollectedWithBankersAcceptances" scale="0" unitRef="usd" id="ixv-11627">503,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory purchased with banker&#8217;s acceptances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:InventoryPurchasedWithBankersAcceptanceNote" scale="0" unitRef="usd" id="ixv-11628">813,105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cphi:InventoryPurchasedWithBankersAcceptanceNote" scale="0" unitRef="usd" id="ixv-11629">575,713</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-11630">156,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued for intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-11631">1,650,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-11632">1,707,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Conversion of related party note and interest to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:ConversionOfRelatedPartyNoteAndInterestToCommonStock" scale="0" unitRef="usd" id="ixv-11633">1,854,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-9612"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations" id="ixv-9616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization and Nature of Operations &#8211;&#160;</i></b>China
Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns <ix:nonFraction contextRef="c30" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-11634">100</ix:nonFraction>% of Onny Investment Limited (&#8220;Onny&#8221;), a
British Virgin Islands corporation, which owns <ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-11635">100</ix:nonFraction>% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a
company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;). China Pharma Holdings, Inc. and its
subsidiaries are referred to herein as the Company.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Onny acquired <ix:nonFraction contextRef="c32" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-11636">100</ix:nonFraction>% of the ownership in Helpson
on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former shareholders. The transaction was approved
by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises
with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise
(&#8220;WFOE&#8221;) status on June 21, 2005.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located.
Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin
oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one
or more therapeutic indications by the National Medical Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug
Administration, or CFDA) based upon demonstrated safety and efficacy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="cphi:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-9627"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity and Going Concern</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had cash
and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherCashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-11637">1.4</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAppropriated" scale="6" sign="-" unitRef="usd" id="ixv-11638">39.3</ix:nonFraction> million. The Company&#8217;s Chairperson, Chief Executive Officer
and Interim Chief Financial Officer (&#8220;Chairperson Li&#8221;) has advanced an aggregate of $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="cphi:WorkingCapital" scale="0" unitRef="usd" id="ixv-11639">1,133,809</ix:nonFraction> as of December 31, 2023 to
provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company
anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its
existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its
ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Accounting Standards
Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i> management
must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially
does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of
the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating
effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating
effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern
within one year after the date that the financial statements are issued.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 205-40, the strategic alternatives being
pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s current plans have been finalized
at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively
implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial doubt is deemed to exist about
the Company&#8217;s ability to continue as a going concern within one year after the date these financial statements are issued.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cphi_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cphi:ReverseStockSplitsPolicyTextBlock" id="ixv-9671"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reverse Stock Split&#160;</i></b>&#8211;
Effective March 6, 2024, the Company implemented a 1-for-5 reverse stock split as more fully discussed in Note 14. All share and per
share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-9678"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Consolidation and Basis of Presentation&#160;</i></b>&#8211;
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States dollars. The accompanying consolidated financial
statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in the consolidation.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson&#8217;s functional currency is the Chinese
Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average exchange rate for the period.
Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#8217;s
financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Gains
and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction
are included in the results of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates" id="ixv-9686"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Accounting Estimates&#160;</i>-&#160;</b>The methodology used
to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. &#160;Significant
estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance,
valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used
to calculate derivative liabilities. Therefore, actual results could differ from those estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-9691"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents&#160;</i></b>&#8211;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#8217;s
acceptances notes purchased with maturities of three months or less.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="ixv-9696"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Accounts Receivable and Allowance
for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for
doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts
and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company reviews a customer&#8217;s
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in
an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable
to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense totaled ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-11640">15,757</ix:nonFraction>) and ($<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-11641">93,851</ix:nonFraction>) for
the years ended December 31, 2023 and 2022, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable that have been fully
allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company
charged off uncollectible trade accounts receivable balances in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-11642">0</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-11643">0</ix:nonFraction> against the allowance for the years ended December
31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current
balances when calculating the allowance for doubtful accounts.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" id="ixv-9704"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advances to Suppliers and Advances from
Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from
customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances
received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&#8217;s
credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate,
resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the
period they are considered unlikely to be collected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-9735"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory&#160;&#8211; </i></b>Inventory
consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated
portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable
value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable
value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs
to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value.
Net realizable value for raw materials is based on replacement cost. Provisions for inventory write-downs are included in the cost of
revenues in the consolidated statements of operations. Inventories are carried at this lower cost basis until sold or scrapped.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-9740"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Leases</i></b></span><b><i>
&#8211; </i></b><span>At lease commencement, the Company records a lease liability based on the present
value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain
to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases
do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would
have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date,
the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received
and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial
term of 12 months or less (&#8220;Short-Term Leases&#8221;). For any Short-Term Leases, the Company records the rent expense on a straight-line
basis and does not record the leases on the balance sheet. </span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>After lease
commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments
using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability,
adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent
expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line
basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-9753"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Long-Lived Assets</i></b>&#160;&#8211;
The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate
that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated
from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying
value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash
flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the Company will use the projected discounted
cash flows to be generated by the asset. For the years ended December 31, 2023 and 2022, the Company evaluated its long-lived assets and
determined that no impairment adjustments were necessary.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-9758"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property, Plant and Equipment</i></b>&#160;&#8211;
Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are
capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-9763"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;&#8211;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration
that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company does not disaggregate its
revenue streams as the economic factors underlying the contracts are similar and provide no significant distinction. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following
five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether
the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement
of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
(or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed price and reflect standalone pricing for each
item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s performance obligations are transferred
to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer picks up the goods at the Company&#8217;s
warehouse.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2">For all reporting periods, the Company has not disclosed the value
of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is
an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year.
These advances total $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11645">90,507</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11646">520,295</ix:nonFraction> and are recorded as a liability on the accompanying balance sheet as &#8220;Advances from customers&#8221;
as of December 31, 2023 and 2022, respectively.</ix:continuation> The subsequently recognized revenue was $81,456as of March 29, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-9799"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues</i></b>&#160;&#8211; Cost
of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery
of products.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-9804"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;&#8211;
Research and development expenditures are recorded as expenses in the period in which they occur.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-9809"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b>&#160;&#8211; The carrying
amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure to credit risk in relation to its
financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations
of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate
have not exceeded management&#8217;s estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has its cash in bank deposits primarily
at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#8217;
interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation
of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow
the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="cphi:InterestRateRiskPolicyTextBlock" id="ixv-9817"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest Rate Risk</i></b>&#160;&#8211;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and
viability of securing future debt instruments within the PRC.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-9824"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic
loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31, 2023,
the Company has potentially dilutive common shares related to the option to purchase <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OptionIndexedToIssuersEquityIndexedShares" scale="0" unitRef="shares" id="ixv-11647">13,300</ix:nonFraction> shares of common stock and the <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-11648">6,267</ix:nonFraction> shares
issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods
presented because the effect is anti-dilutive due to net losses of the Company.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-9832"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;<i>Financial Instruments &#8211; Credit
Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance
introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies
the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial
assets with credit deterioration since their origination.&#160;The pronouncement will was effective for public business entities that
are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including interim periods within those
fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December 15,
2019, including interim periods within those fiscal years. The adoption of the standard had no material impact on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the FASB or other standards
setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise
discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to
have a material impact on its consolidated financial statements upon adoption.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-9873"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8211; INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-11649">Inventory consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfInventoryCurrentTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-11650">1,849,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-11651">1,839,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-11652">413,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-11653">557,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-11654">1,469,707</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-11655">551,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Inventory</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-11656">3,732,517</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-11657">2,947,787</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-9940"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; PROPERTY, PLANT AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-11658">Property, plant and equipment consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Permit of land use</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11659">397,684</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11660">404,427</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11661">9,234,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11662">9,391,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11663">27,170,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11664">27,780,585</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11665">303,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11666">438,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11667">388,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11668">308,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11669">37,495,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-11670">38,323,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-11671">30,394,655</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-11672">28,350,365</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd" id="ixv-11673">7,100,425</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd" id="ixv-11674">9,973,065</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="cphi_UsefulLiveOfAssetsTableTextBlock-c0_cont_1" escape="true" name="cphi:UsefulLiveOfAssetsTableTextBlock" id="ixv-11675">Depreciation is computed on a straight-line basis over the estimated
useful lives of the assets as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="cphi_UsefulLiveOfAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: left"><b>Asset</b></td><td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><b>Life - years</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permit of land use</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c44" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11676">40</ix:nonNumeric> - <ix:nonNumeric contextRef="c45" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11677">70</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c46" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11678">20</ix:nonNumeric> - <ix:nonNumeric contextRef="c47" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11679">49</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c48" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11680">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c49" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11681">10</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c50" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11682">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c51" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11683">10</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11684">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11685">5</ix:nonNumeric></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation relating to office equipment was
included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-11686">2,529,858</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-11687">2,663,975</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-10081"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 - INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets represent the cost of medical
formulas approved for production by the NMPA, the intellectual property acquired from Chengdu Bonier Medical Technology Development Co.,
Ltd. (&#8220;Bonier Agreement&#8221;) and the Technology Transfer Agreement (the &#8220;<b>Agreement</b>&#8221;) with Tao Liu discussed
below. The Company did not obtain NMPA production approval for any new medical formulas during the years ended December 31, 2023 and 2022
and no costs were reclassified from advances to intangible assets during the years ended December 31, 2023 and 2022, respectively. On
August 9, 2023, the Company obtained the &#8220;Drug Supplementary Application Approval Notice&#8221; from the NMPA for the indicating
that the Company&#8217;s existing formular Candesartan tablets have passed the quality and efficacy consistency evaluation of generic
drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod" id="ixv-11688">Approved medical formulas are amortized from the
date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.</ix:nonNumeric>&#160;&#160;It
is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to
changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets
was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-11689">223,796</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-11690">36,558</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively which was included in the general and administrative
expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2023, the Company entered into
a Technology Transfer Agreement (the &#8220;Agreement&#8221;) with Tao Liu (the &#8220;Transferor&#8221;). The Transferor owns an invention
patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the &#8220;Invention Patent&#8221;). Pursuant
to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third
party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing
of registration materials, registration application and other technical services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective December 15, 2023 China Pharma issued
<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-11691">3,000,000</ix:nonFraction> shares of its common stock valued at $<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsStock" scale="0" unitRef="usd" id="ixv-11692">1,650,000</ix:nonFraction> based on the closing market price of its common stock of $<ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-11693">0.55</ix:nonFraction> per share at
that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2023. The value of the
intangible asset will be amortized over its remaining useful life of approximately <ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-11694">14.8</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the ten years after the product launches
to the market, if and only if the product generates profit, Helpson shall pay <ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="cphi:PercentageOfNetProfit" scale="-2" unitRef="pure" id="ixv-11695">15</ix:nonFraction>% of the net profit of the sales in cash on an annual
basis to the Transferor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, the Company entered into
a Technology Transfer Contract (the &#8220;Bonier Agreement&#8221;) with Chengdu Bonier Medical Technology Development Co., Ltd (&#8220;Bonier&#8221;).
Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which
has obtained a utility model patent (the &#8220;Utility Model Patent&#8221;) and applied for an invention patent (the &#8220;Invention
Patent&#8221;) at the same time. Pursuant to the Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical
invention and the Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant
technical services in Haikou, which include but are not limited to product research and development, writing of registration materials,
registration application and other technical services, with a term of ten years. Effective November 28, 2022 the Company issued <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-11696">310,446</ix:nonFraction>
share of its common stock valued at $<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsStock" scale="0" unitRef="usd" id="ixv-11697">1,707,452</ix:nonFraction> based on the closing market price of its common stock of $<ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-11698">5.50</ix:nonFraction> per share at that date.
The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2022. The value of the intangible
asset will be amortized over its remaining useful life of approximately <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-11699">9.7</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will pay a service fee of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:PercentageOfNetProfit" scale="-2" unitRef="pure" id="ixv-11700">15</ix:nonFraction>% of the
net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent
on the successful authorization of the above mentioned Invention Patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates each approved medical formula
for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement.
The Company&#8217;s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data
for the related drug and the Company&#8217;s estimated market share. If the carrying value of the medical formula exceeds the estimated
future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula,
which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the years ended December
31, 2023 and 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="ixv-11701">Intangible assets consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">NMPA approved medical formulas</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-11702">4,766,353</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-11703">4,847,176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Technology from Bonier</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-11704">1,726,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-11705">1,707,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Invention Patent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-11706">1,653,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-11707">4,890,646</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-11708">4,747,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-11709">3,255,232</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-11710">1,807,486</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-11711">The estimated aggregate annual amortization expense for each of the
next five years and thereafter is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:continuation id="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd" id="ixv-11712">327,050</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-11713">321,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-11714">292,156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-11715">292,156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-11716">292,156</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd" id="ixv-11717">1,730,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-11718">3,255,232</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-10283"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-11719">Other Payables consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation payable to officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="0" unitRef="usd" id="ixv-11720">1,243,506</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="0" unitRef="usd" id="ixv-11721">951,506</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation and interest to related parties</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11722">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11723">372,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Business taxes and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-11724">1,027,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-11725">1,065,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11726">2,282,692</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-11727">2,390,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-10374"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A member of the Company&#8217;s board of directors
(&#8220;Board&#8221;) had previously advanced to the Company an aggregate amount of $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvancesToAffiliate" scale="0" unitRef="usd" id="ixv-11728">1,354,567</ix:nonFraction> as of December 31, 2022 which is recorded
as &#8220;Other payables &#8211; related parties&#8221; on the accompanying condensed consolidated balance sheets. The advances bore interest
at a rate of <ix:nonFraction contextRef="c67" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11729">1.0</ix:nonFraction>% per year.&#160;&#160;Total interest expense years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-11730">6,773</ix:nonFraction> and $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-11731">13,546</ix:nonFraction>, respectively.
Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance
sheet totaling $<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-11732">12,000</ix:nonFraction> and $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-11733">372,578</ix:nonFraction> as of December 31, 2023 and 2022, respectively. On August 23, 2023, the director entered into a certain
debt transfer agreement with Chairperson Li, pursuant to which the rights to collect a total amount of $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLoans" scale="0" unitRef="usd" id="ixv-11734">1,854,452</ix:nonFraction> were assigned to Chairperson
Li. On September 28, 2023, Chairperson Li entered into a certain loan settlement agreement, pursuant to which both parties agreed to convert
the aggregate amount of $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="cphi:AggregateAmounts" scale="0" unitRef="usd" id="ixv-11735">1,854,452</ix:nonFraction>&#160;owed by the Company into&#160;<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="cphi:RestrictedCommonStock" scale="0" unitRef="shares" id="ixv-11736">2,751,412</ix:nonFraction>&#160;shares of restricted common stock of the Company.
Such issuance was completed on September 29, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received advances totaling $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-11737">2,928</ix:nonFraction>
and $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-11738">0</ix:nonFraction> and repaid $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-11739">0</ix:nonFraction> and $<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd" id="ixv-11740">223,013</ix:nonFraction> of the advances during the years ended December 31, 2023 and 2022, respectively from its Chairperson,
Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvancesToAffiliate" scale="0" unitRef="usd" id="ixv-11741">1,121,273</ix:nonFraction> and $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvancesToAffiliate" scale="0" unitRef="usd" id="ixv-11742">1,425,123</ix:nonFraction> and are recorded as Other
payables &#8211; related parties on the accompanying condensed consolidated balance sheets as of December 31, 2021 and 2020, respectively.
On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLoans" scale="0" unitRef="cny" id="ixv-11743">4,770,000</ix:nonFraction> ($<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLoans" scale="0" unitRef="usd" id="ixv-11744">738,379</ix:nonFraction>) with its Chairperson, Chief
Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of <ix:nonFraction contextRef="c80" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-11745">4.35</ix:nonFraction>% and is payable within <ix:nonNumeric contextRef="c3" format="ixt-sec:durwordsen" name="us-gaap:LoansHeldForSaleTerm" id="ixv-11746">one year</ix:nonNumeric> of the
loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2023. Total interest
expense related to the loan for the years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-11747">27,644</ix:nonFraction> and $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-11748">28,962</ix:nonFraction>, respectively. Compensation payable
to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying consolidated
balance sheet totaling $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-11749">1,243,506</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-11750">951,506</ix:nonFraction> as of December 31, 2023 and 2022, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LongTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-10384"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; LINES OF CREDIT AND CONSTRUCTION
LOAN FACILITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lines of Credit</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021 the Company entered into a loan
with Bank of Communications bearing an interest rate of <ix:nonFraction contextRef="c85" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11751">4.17</ix:nonFraction>%. <span>The Company paid all principal and
interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing interest at&#160;<ix:nonFraction contextRef="c86" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11752"><ix:nonFraction contextRef="c87" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11753">4.17</ix:nonFraction></ix:nonFraction>% and
due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line of credit for an aggregate
amount of RMB <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11754">7,300,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11755">1.0</ix:nonFraction> million) with interest payable monthly at a rate of <ix:nonFraction contextRef="c89" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11756">3.9</ix:nonFraction>%. The Company received an advance
on the line of credit in the amount of RMB <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11757">3,800,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c90" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11758">0.56</ix:nonFraction> million) on December 30, 2022. On February 24, 2023 the Company
received an advance on the line in the amount of RMB&#160;<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11759">3,500,000</ix:nonFraction>&#160;(approximately $<ix:nonFraction contextRef="c91" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11760">0.51</ix:nonFraction>&#160;million). The Company has no further
availability on this line of credit.&#160;The line of credit was payable on December 20, 2023. The line of credit was paid in full on
December 15, 2023.&#160;On December 20, 2023, the Company received a new line of credit in the amount of RMB <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11761">3,800,000</ix:nonFraction> and an interest
rate of <ix:nonFraction contextRef="c92" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11762">3.9</ix:nonFraction>% and is due December 15, 2024. </span>In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for
the years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11763">31,750</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11764">53,283</ix:nonFraction>, respectively. On February 2, 2024 the Company repaid RMB <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="0" unitRef="cny" id="ixv-11765">3,500,000</ix:nonFraction>
under this line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company obtained a line of credit of RMB <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11766">3,200,000</ix:nonFraction>
(approximately $<ix:nonFraction contextRef="c94" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11767">0.5</ix:nonFraction> million) from China CITIC Bank in September 2020 and obtained an advance of RMB <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny" id="ixv-11768">2,343,340</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd" id="ixv-11769">0.3</ix:nonFraction> million),
and the remaining of RMB <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny" id="ixv-11770">856,660</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c96" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd" id="ixv-11771">0.1</ix:nonFraction> million) in October 2020 under this line. The loan bears interest at the rate of
<ix:nonFraction contextRef="c97" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11772">4.50</ix:nonFraction>% per annum. In September, 2021 the Company repaid the line of credit in full. Also in September, 2021 the Company entered into a
new line a credit in the amount of RMB <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11773">3,200,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c98" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11774">0.8</ix:nonFraction> million). The loan bears interest at the rate of <ix:nonFraction contextRef="c99" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11775">4.50</ix:nonFraction>% per annum.
The line of credit was due on September 2, 2022. <span>The line of credit was paid in full on September
6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears interest at a rate of&#160;<ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-11776">4.5</ix:nonFraction>%
and is due on September 7, 2023</span> and was repaid in full as of that date. In addition, the Company&#8217;s Chief Executive Officer
and Chair of the Board had personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total
interest expense under this facility for the years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11777">19,579</ix:nonFraction> and $<ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11778">20,548</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_LongTermDebtTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 18, 2021 the Company obtained a
line of credit for RMB <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-11779">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c103" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11780">1.54</ix:nonFraction> million) with Bank of China. The loan bears interest at the rate of <ix:nonFraction contextRef="c104" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11781">3.85</ix:nonFraction>% per
annum. <span>The line of credit was paid in full on the due date of September 18, 2022. On September
30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at the rate of <ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11782">3.45</ix:nonFraction>% and was due
September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a
three-year revolving loan and received proceeds of RMB&#160;<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="cphi:LoanAndReceivedProceeds" scale="0" unitRef="cny" id="ixv-11783">10,000,000</ix:nonFraction>&#160;(approximately $<ix:nonFraction contextRef="c106" decimals="-5" format="ixt:num-dot-decimal" name="cphi:LoanAndReceivedProceeds" scale="6" unitRef="usd" id="ixv-11784">1.4</ix:nonFraction>&#160;million). The interest rate for
the loan is&#160;<ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11785">3.35</ix:nonFraction>% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate
less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month
anniversary of the loan.&#160;The loan is due on September 24, 2026. </span>The loan is collateralized by the Company&#8217;s new
production facility and the included production line equipment and machinery. In addition, the Company&#8217;s Chief Executive
Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11786">48,624</ix:nonFraction> and
$<ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11787">54,923</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="ixv-11788">Principal payments required for the remaining
terms of the lines of credit as of December 31, 2023 are as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lines of<br/>
 Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-11789">2,442,571</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-11790">2,442,571</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2020, the Company obtained a line of
credit from Postal Savings Bank of China for an aggregate amount of RMB <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="cphi:AggregateAmounts" scale="0" unitRef="cny" id="ixv-11791">10,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c111" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-11792">1.4</ix:nonFraction> million), of which RMB <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny" id="ixv-11793">5,000,000</ix:nonFraction>
(approximately $<ix:nonFraction contextRef="c112" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd" id="ixv-11794">0.7</ix:nonFraction> million) was advanced in April 2020, and RMB <ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="0" unitRef="cny" id="ixv-11795">3,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMortgageDeposits" scale="6" unitRef="usd" id="ixv-11796">0.4</ix:nonFraction> million) was advanced in July 2020. The
loan bore interest at a rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRateFloor" scale="-2" unitRef="pure" id="ixv-11797">4.25</ix:nonFraction>% per annum. Advances on the line of credit were due two years from the date of the advance. A third
party company had guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next
to the creditor of the construction loan facility as discussed above. In addition, the Company&#8217;s Chief Executive Officer and Chair
of the Board personally guaranteed the line of credit. Total interest expense under this facility for the years ended December 31, 2022
was $<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-11798">12,063</ix:nonFraction>. The Company repaid the remaining RMB <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cphi:RepaidAmount" scale="0" unitRef="cny" id="ixv-11799">5,900,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="cphi:RepaidAmount" scale="0" unitRef="usd" id="ixv-11800">0.85</ix:nonFraction>) during the year ended December 31, 2022 as per the repayment
schedule in full satisfaction of the line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Lines of Credit</i></b> &#8211;
Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts
of the construction loan facility outstanding as of December 31, 2023 and December 31, 2022 approximated its fair value because the underlying
instrument bears an interest rate that approximated current market rates.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShortTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:ShortTermDebtTextBlock" id="ixv-10457"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; CONVERTIBLE NOTE PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 17, 2021,
China Pharma entered into a Securities Purchase Agreement (the &#8220;Agreement&#8221;) pursuant to which the Company issued an unsecured
convertible promissory note (the &#8220;Note&#8221;) to an institutional accredited investor Streeterville Capital, LLC (the &#8220;Investor&#8221;).
The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13,
2023 China Pharma entered into an Amendment (the &#8220;Amendment&#8221;) with the Investor which extended the maturity date of the Convertible
Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-11801">65,639</ix:nonFraction>, representing&#160;<ix:nonFraction contextRef="c116" decimals="3" format="ixt:num-dot-decimal" name="cphi:PercentageOfBalanceNoteAndAccruedInterest" scale="-2" unitRef="pure" id="ixv-11802">2.0</ix:nonFraction>%
of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance
by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition,
China Pharma decreased the price at which the Investor can convert the balance from&#160;<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-11803">85</ix:nonFraction>% to&#160;<ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-11804">82</ix:nonFraction>% of the lowest daily volume weighted
average price during the ten trading days immediately preceding the applicable redemption conversion,&#160;and assumed an additional obligation
to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Note was originally
convertible into&#160;<ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" unitRef="pure" id="ixv-11805">70,000</ix:nonFraction>&#160;shares of China Pharma&#8217;s common stock at a price of $<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11806">75.00</ix:nonFraction>&#160;per share through April 19, 2022.
Thereafter, the Note was convertible into&#160;<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" unitRef="pure" id="ixv-11807">35,000</ix:nonFraction>&#160;shares at a price of $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11808">150.00</ix:nonFraction>&#160;per share. As of December 31, 2023 the Note
is convertible into&#160;<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" unitRef="pure" id="ixv-11809">6,267</ix:nonFraction>&#160;shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><ix:nonNumeric contextRef="c0" name="cphi:InterestAccruesOnNoteDescription" id="ixv-11810">Interest accrues on the
outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest
accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor
may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%,
depending on the nature of the Event of Default.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Pursuant to the terms
of the Agreement and the Note, the Company must obtain Investor&#8217;s consent for certain fundamental transactions such as consolidation,
merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization
or recapitalization. Any occurrence of a fundamental transaction without Investor&#8217;s prior written consent will be deemed an Event
of Default.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><ix:continuation continuedAt="_ShortTermDebtTextBlock-c0_cont_2" id="_ShortTermDebtTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Investor may redeem all
or any part the outstanding balance of the Note, subject to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedeemOfOutstandingNote" scale="0" unitRef="usd" id="ixv-11811">500,000</ix:nonFraction>&#160;per calendar month, at any time after one hundred twenty-one
(121) days from the Purchase Price Date, as defined in the Note, upon three trading days&#8217; notice, in cash or converting into shares
of China Pharma&#8217;s common stock, at a price equal to&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11812">82</ix:nonFraction>% multiplied by the lowest daily volume weighted average price during
the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations
specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note.
The Company may prepay the outstanding balance of the Note with the Investor&#8217;s consent. At inception, the Note was redeemable into&#160;<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" unitRef="pure" id="ixv-11813">176,229</ix:nonFraction>&#160;shares
based on the lowest volume weighted average price of $<ix:nonFraction contextRef="c125" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11814">29.79085</ix:nonFraction>&#160;on the inception date of November 19, 2021. As of December 31, 2023,
the Note was redeemable into&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:NoteRedeemableIntoShares" scale="0" unitRef="shares" id="ixv-11815">2,159,964</ix:nonFraction>&#160;shares of common stock based on&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-11816">82</ix:nonFraction>% of the lowest volume weighted average price
of $<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrice" scale="0" unitRef="usdPershares" id="ixv-11817">0.436</ix:nonFraction>&#160;on that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Total interest expense
for the years ended December 31, 2023 and 2022 was $<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-11818">206,744</ix:nonFraction> and $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-11819">250,314</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>2023
Redemptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
5, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11820">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c128" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11821">3.815</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11822">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11823">39,319</ix:nonFraction>&#160;shares of common stock to the Investor on
January 6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
18, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11824">250,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11825">3.815</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11826">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11827">65,531</ix:nonFraction>&#160;shares of common stock to the Investor on
January 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
2, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11828">250,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c136" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11829">2.875</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11830">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11831">86,957</ix:nonFraction>&#160;shares of common stock to the Investor on
March 8, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April
7, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11832">200,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11833">1.404</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11834">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11835">142,450</ix:nonFraction>&#160;shares of common stock to the Investor
on April 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 1,
2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11836">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of
$<ix:nonFraction contextRef="c144" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11837">1.322</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11838">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11839">113,465</ix:nonFraction>&#160;shares of common stock to the Investor
on May 3, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 24,
2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11840">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of
$<ix:nonFraction contextRef="c148" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11841">1.2435</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11842">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11843">120,628</ix:nonFraction>&#160;shares of common stock to the Investor
on May 25, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
6, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11844">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11845">1.328</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11846">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11847">112,952</ix:nonFraction>&#160;shares of common stock to the Investor
on June 13, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ShortTermDebtTextBlock-c0_cont_3" id="_ShortTermDebtTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
23, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11848">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c156" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11849">1.4225</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11850">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11851">105,448</ix:nonFraction>&#160;shares of common stock to the
Investor on June 27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
9, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11852">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c160" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11853">1.0715</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11854">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11855">139,991</ix:nonFraction>&#160;shares of common stock to the Investor
on August 11, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
21, 2023&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11856">245,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c164" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11857">1.0715</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11858">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11859">228,652</ix:nonFraction>&#160;shares of common stock to the Investor
on August 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September
1, 2023,&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11860">140,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c168" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11861">0.666</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11862">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11863">210,211</ix:nonFraction>&#160;shares of common stock to the Investor on September
6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September
12, 2023,&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11864">75,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c172" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11865">0.579</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11866">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11867">129,534</ix:nonFraction>&#160;shares of common stock to the Investor on September
13, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2023&#160;the Investor delivered
its notice of redemption for $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11868">100,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11869">0.546</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11870">82</ix:nonFraction>% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11871">183,150</ix:nonFraction>&#160;shares of common stock to the Investor on October 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2023&#160;the Investor delivered
its notice of redemption for $<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11872">115,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c180" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11873">0.513</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11874">82</ix:nonFraction>% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11875">224,172</ix:nonFraction>&#160;shares of common stock to the Investor on October 13, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 17, 2023&#160;the Investor delivered
its notice of redemption for $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11876">115,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c184" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11877">0.513</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11878">82</ix:nonFraction>% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11879">224,172</ix:nonFraction>&#160;shares of common stock to the Investor on October 17, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 6, 2023&#160;the Investor delivered
its notice of redemption for $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11880">80,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c188" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11881">0.3765</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11882">82</ix:nonFraction>% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11883">212,444</ix:nonFraction>&#160;shares of common stock to the Investor on November 7, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><ix:continuation id="_ShortTermDebtTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 29, 2023&#160;the
Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11884">125,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c192" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11885">0.368</ix:nonFraction>, which
was&#160;<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11886">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11887">339,674</ix:nonFraction>&#160;shares of common stock to the Investor on November 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 30, 2023&#160;the
Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11888">115,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c196" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11889">0.368</ix:nonFraction>, which
was&#160;<ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11890">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11891">312,500</ix:nonFraction>&#160;shares of common stock to the Investor on December 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On December 13, 2023&#160;the
Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11892">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price of $<ix:nonFraction contextRef="c200" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11893">0.4045</ix:nonFraction>, which
was&#160;<ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11894">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11895">370,828</ix:nonFraction>&#160;shares of common stock to the Investor on December 18, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Subsequent
to December 31, 2023 the Investor delivered additional notices of redemption as discussed in Note 14.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>2022
Redemptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On March 21, 2022 the
Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11896">100,000</ix:nonFraction> of the Note at the lowest volume weighted average price of $<ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="cphi:WeightedAveragePrice" scale="0" unitRef="usdPershares" id="ixv-11897">15.565</ix:nonFraction> during the
ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-11898">6,425</ix:nonFraction> shares of
common stock to the Investor on March 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
30, 2022 the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11899">200,000</ix:nonFraction>&#160;of the Note and related interest at the price of $<ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11900">15.645</ix:nonFraction>, which
was&#160;<ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11901">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11902">12,874</ix:nonFraction> shares of common stock to the Investor on March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
13, 2022 the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11903">200,000</ix:nonFraction>&#160;of the Note and related interest at the price of $<ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11904">9.90</ix:nonFraction>, which
was&#160;<ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11905">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11906">20,202</ix:nonFraction> shares of common stock to the Investor on June 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
3, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11907">200,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c215" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11908">8.775</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11909">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11910">22,792</ix:nonFraction> shares of common stock to the Investor on August 4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On October
17, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11911">100,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11912">5.60</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11913">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11914">17,857</ix:nonFraction> shares of common stock to the Investor on October 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
1, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11915">100,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c223" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11916">4.145</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11917">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11918">24,126</ix:nonFraction> shares of common stock to the Investor on December 2, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
5, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11919">310,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c227" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11920">4.145</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11921">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11922">74,789</ix:nonFraction> shares of common stock to the Investor on December 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
13, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11923">90,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c231" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11924">4.55</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c232" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11925">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11926">19,781</ix:nonFraction>&#160;shares of common stock to the Investor on December
14, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
14, 2022&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="0" unitRef="usd" id="ixv-11927">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c235" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-11928">4.145</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c236" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure" id="ixv-11929">85</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-11930">36,181</ix:nonFraction> shares of common stock to the Investor on December 15, 2022.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-10677"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has leases for certain office and
production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options
to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the
lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount
rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company&#8217;s incremental borrowing
rate at the initial measurement date. For the years ended December 31, 2023 and 2022, operating lease cost was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-11931">77,265</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-11932">78,092</ix:nonFraction>, respectively
and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-11933">80,647</ix:nonFraction>
and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-11934">82,015</ix:nonFraction>, respectively. As of December 31, 2023 and 2022, the Company reported operating lease right of use assets of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-11935">116,610</ix:nonFraction> and
$<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-11936">39,046</ix:nonFraction>, respectively and operating use liabilities of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePaymentsUse" scale="0" unitRef="usd" id="ixv-11937">117,637</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePaymentsUse" scale="0" unitRef="usd" id="ixv-11938">40,445</ix:nonFraction>, respectively. As of December 31, 2023, its operating leases
had a weighted average remaining lease term of <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-11939">1.50</ix:nonNumeric> years and a weighted average discount rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-11940">4.75</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-11941">Minimum lease payments for the Company&#8217;s
operating lease liabilities were as follows for the twelve month periods ended December 31:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-11942">80,647</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-11943">40,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-11944">120,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-11945">3,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-11946">117,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-11947">77,727</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-11948">39,910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has leases with terms less than one year for certain provincial
sales offices that are not material.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-10735"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered
or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that
includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liabilities are established for uncertain tax
positions expected to be taken in income tax returns when such positions are judged to meet the &#8220;more-likely-than-not&#8221; threshold
based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a
component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2020 through December 31, 2023 and the Chinese income tax return for the year
ended December 31, 2023 are open for possible examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the current tax law in the PRC, the Company is and will be subject
to the enterprise income tax rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-11949">25</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no provision for income taxes for the
years ended December 31, 2023 and 2022, respectively due to continued net losses of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-11950">Following is a reconciliation of income taxes calculated at the federal
statutory rates to the provision for income taxes:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(Benefit) tax at statutory rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-11951"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-11952">25</ix:nonFraction></ix:nonFraction>%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-11953">769,704</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-11954">973,717</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prior year refund received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other, primarily the difference in U.S. tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd" id="ixv-11955">3,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" unitRef="usd" id="ixv-11956">8,416</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-11957">766,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-11958">965,301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-11959">The temporary differences which give rise to the deferred income tax
assets and liability are as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Allowance for doubtful trade receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-11960">3,446,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-11961">4,184,882</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Allowance for doubtful other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" scale="0" unitRef="usd" id="ixv-11962">6,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" scale="0" unitRef="usd" id="ixv-11963">6,787</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory obsolescence reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd" id="ixv-11964">32,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" unitRef="usd" id="ixv-11965">34,921</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-11966">3,201</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-11967">3,201</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible in current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="0" unitRef="usd" id="ixv-11968">1,069,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="0" unitRef="usd" id="ixv-11969">1,087,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Advances for intangible assets impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" unitRef="usd" id="ixv-11970">9,619,060</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" scale="0" unitRef="usd" id="ixv-11971">9,782,172</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-11972">257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-11973">349</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">PRC net operating loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-11974">5,275,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-11975">5,036,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-11976">2,078,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-11977">1,849,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-11978">21,531,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-11979">21,985,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-11980">21,531,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-11981">21,985,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net deferred income tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred income tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" unitRef="usd" id="ixv-11982">742,114</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" unitRef="usd" id="ixv-11983">754,698</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had net operating
loss carryforwards for PRC tax purposes of approximately $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11984">21.1</ix:nonFraction> million which are available to offset any future taxable income through
2028. Approximately $<ix:nonFraction contextRef="c238" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11985">3.4</ix:nonFraction> million of these carryforwards expired in December 2023. The Company also has net operating losses for United
States federal income tax purposes of approximately $<ix:nonFraction contextRef="c239" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11986">9.9</ix:nonFraction> million of which $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd" id="ixv-11987">5.1</ix:nonFraction> million is available to offset future taxable income, if
any, <ix:nonNumeric contextRef="c0" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="ixv-11988">through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each
tax year</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. federal tax legislation, commonly referred
to as the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;), was signed into law on December&#160;22, 2017. The U.S. Tax Reform
significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax
rate from <ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-11989">35</ix:nonFraction>% to <ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-11990">21</ix:nonFraction>% for taxable years beginning after December&#160;31, 2017; limiting and/or eliminating many business deductions; migrating
the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory deemed repatriation of previously deferred
foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends
from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realizability of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&#160;&#160;The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those
differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management considers projected future taxable income
and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment of the level of historical taxable income and
projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management
believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2023 and 2022.&#160;&#160;Therefore,
the Company provided for a valuation allowance against its deferred tax assets of $<ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="cphi:DeferredTaxAssetValuationAllowance" scale="0" unitRef="usd" id="ixv-11991">21,531,017</ix:nonFraction> and $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="cphi:DeferredTaxAssetValuationAllowance" scale="0" unitRef="usd" id="ixv-11992">21,467,355</ix:nonFraction> as of December 31, 2023
and 2022, respectively.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also incurred various other taxes,
comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts
are reflected on the balance sheets as accrued taxes payable.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="ixv-11046"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 11 &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Fair value is defined
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,
a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#8211; Quoted
prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level 1 including quoted prices
for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable
market data; and Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial instruments whose value is
determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination
of fair value requires significant management judgment or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-11993">The Company uses fair
value to measure the value of the banker&#8217;s acceptance notes it holds as of December 31, 2023 and 2022.&#160;The banker&#8217;s acceptance
notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at
fair value:</ix:nonNumeric></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Reporting Date Using</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11994">65,915</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11995">65,915</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11996">65,915</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11997">65,915</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reporting Date Using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11998">13,784</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-11999">13,784</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-12000">13,784</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="0" unitRef="usd" id="ixv-12001">13,784</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-11210"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-12002">500,000,000</ix:nonFraction>
shares of common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-12003">0.001</ix:nonFraction> par value, and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-12004">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-12005">0.001</ix:nonFraction> par value. The preferred stock may be issued
in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#8217;s
Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to relevant PRC laws, companies registered
in the PRC, including the Company&#8217;s PRC subsidiary, Helpson, are required to allocate at least <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:AftertaxNetIncomePercentage" scale="-2" unitRef="pure" id="ixv-12006">10</ix:nonFraction>% of their after tax income, as
determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account
balances reach <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:ReserveAccountBalancesPercentage" scale="-2" unitRef="pure" id="ixv-12007">50</ix:nonFraction>% of the company&#8217;s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves
and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash
dividends. The amount designated for general and statutory capital reserves is $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" scale="0" unitRef="usd" id="ixv-12008"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" scale="0" unitRef="usd" id="ixv-12009">8,145,000</ix:nonFraction></ix:nonFraction> at December 31, 2023 and 2022.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2024, the Company implemented
a <ix:nonNumeric contextRef="c258" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-12010">1-for -5</ix:nonNumeric> reverse stock split as more fully discussed in Note 14. All share and per share disclosures have been retroactively restated
to reflect the impact of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2023&#160;China Pharma&#160;implemented
a&#160;<ix:nonNumeric contextRef="c259" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-12011">1-for-10</ix:nonNumeric>&#160;reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s Board of Directors
through unanimous written consent and&#160;China Pharma&#8217;s stockholders at its Annual Meeting for the fiscal year ended on December
31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of&#160;China Pharma&#8217;s
issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional
shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up
to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s percentage
interest in&#160;China Pharma&#8217;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying consolidated financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2010 Incentive Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2010, the Company&#8217;s Board
adopted the Company&#8217;s 2010 Incentive Plan (the &#8220;Plan&#8221;), which was then approved by stockholders on December 22, 2010.
On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment&#8221;), pursuant
to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December
19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to
the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by <ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12012">100,000</ix:nonFraction> shares from <ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12013">80,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12014">180,000</ix:nonFraction>
shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated
Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional <ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12015">100,000</ix:nonFraction> shares
from <ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12016">180,000</ix:nonFraction> to <ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12017">280,000</ix:nonFraction>. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive
Plan to increase the number of shares from <ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12018">280,000</ix:nonFraction> to <ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-12019">580,000</ix:nonFraction>. The Plan gives the Company the ability to grant stock options, restricted
stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees,
directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to <ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" scale="0" unitRef="shares" id="ixv-12020">580,000</ix:nonFraction> shares
of common stock. Through December 31, 2023, there were <ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-12021">84,700</ix:nonFraction> shares of stock and stock options granted and outstanding under the Plan.&#160;
A total of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cphi:TotalOptionOutstanding" scale="0" unitRef="shares" id="ixv-12022">13,300</ix:nonFraction> options were outstanding as of December 31, 2023 under the Plan. As such, there are <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cphi:AdditionalSharesAvailableForIssuance" scale="0" unitRef="shares" id="ixv-12023">482,000</ix:nonFraction> additional units available
for issuance under the Plan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">There were no issuances of securities from the Plan for the year ended
December 31, 2023 and as such, no compensation expense was recognized for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On October 3, 2022 the
Company issued <ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="cphi:IssuanceOfCommonStock" scale="0" unitRef="shares" id="ixv-12024">6,000</ix:nonFraction> shares of common stock pursuant to a contract with a consultant to the Company for services. The Company recorded
compensation expense totaling $<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="0" unitRef="usd" id="ixv-12025">42,000</ix:nonFraction> based on the closing market price of its common stock of $<ix:nonFraction contextRef="c270" decimals="2" format="ixt:num-dot-decimal" name="cphi:ClosingMarketPrice" scale="0" unitRef="usdPershares" id="ixv-12026">7.00</ix:nonFraction> per share on the issuance date. The
contract also calls for the issuance of up to <ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares" id="ixv-12027">18,000</ix:nonFraction> additional shares of common stock contingent upon the achievement of certain milestones
as described in the contract. At December 31, 2023 these milestones had not been met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On October 4, 2022 the
Company issued an option to purchase <span><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="cphi:PurchaseOfCommonStock" scale="0" unitRef="shares" id="ixv-12028">12,000</ix:nonFraction> shares of common stock at an exercise price at $<ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-12029">28.00</ix:nonFraction>
per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires on October 3, 2027.
</span>The fair value of the options granted of $<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="0" unitRef="usd" id="ixv-12030">36,270</ix:nonFraction> was calculated using the Black-Scholes option valuation model using the closing
market price of $<ix:nonFraction contextRef="c272" decimals="2" format="ixt:num-dot-decimal" name="cphi:ClosingMarketPrice" scale="0" unitRef="usdPershares" id="ixv-12031">7.50</ix:nonFraction> per share, volatility of <ix:nonFraction contextRef="c272" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-12032">115.5</ix:nonFraction>%, risk free interest rate of <ix:nonFraction contextRef="c272" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-12033">3.84</ix:nonFraction>% and an expected life of <ix:nonNumeric contextRef="c272" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" id="ixv-12034">2.5</ix:nonNumeric> years. The value was
charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On September 9, 2021
the Company issued an aggregate of <ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-12035">35,200</ix:nonFraction> fully vested shares of common stock at the price of $<ix:nonFraction contextRef="c273" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-12036">33.50</ix:nonFraction> per share, representing the closing
market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan, as amended,
to partially offset certain unpaid cash compensation totaling $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-12037">1,179,200</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Also on September 9,
2021 the Company issued an option to purchase <span><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="cphi:PurchaseOfCommonStock" scale="0" unitRef="shares" id="ixv-12038">1,300</ix:nonFraction> shares of common stock at an exercise price
at $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-12039">73.70</ix:nonFraction> per share, under the Plan. The Option vests immediately and expires on September 9, 2024. </span>The fair value of the options
granted of $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited" scale="0" unitRef="usd" id="ixv-12040">15,243</ix:nonFraction> was calculated using the Black-Scholes option valuation model using the closing market price of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="cphi:ClosingMarketPrice" scale="0" unitRef="usdPershares" id="ixv-12041">33.50</ix:nonFraction> per share, volatility
of <ix:nonFraction contextRef="c274" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-12042">118.4</ix:nonFraction>%, risk free interest rate of <ix:nonFraction contextRef="c274" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-12043">0.75</ix:nonFraction>% and an expected life of <ix:nonNumeric contextRef="c274" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" id="ixv-12044">1.5</ix:nonNumeric> years. The value was charged to general and administrative expenses
on the accompanying Statement of Operations for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2020 the Board approved the issuance
of <ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="cphi:IssuanceOfCommonStock" scale="0" unitRef="shares" id="ixv-12045">40,000</ix:nonFraction> shares of common stock from the Company&#8217;s 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid
compensation totaling $<ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-12046">864,480</ix:nonFraction> to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there was no remaining
unrecognized compensation expense related to stock options or restricted stock grants.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-11296"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; RISKS &amp; UNCERTAINTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current vulnerability due to certain concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, no customer
accounted for more than <ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12047">10</ix:nonFraction>% of sales and two customers accounted for <ix:nonFraction contextRef="c278" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12048">62.59</ix:nonFraction>% and <ix:nonFraction contextRef="c279" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12049">13.5</ix:nonFraction>% of accounts receivable. One suppliers accounted
for <ix:nonFraction contextRef="c280" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12050">13.8</ix:nonFraction>% of raw material purchases, and three different products accounted for <ix:nonFraction contextRef="c281" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12051">29.2</ix:nonFraction>%, <ix:nonFraction contextRef="c282" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12052">27.3</ix:nonFraction>% and <ix:nonFraction contextRef="c283" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12053">12.5</ix:nonFraction>% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, no customer
accounted for more than <ix:nonFraction contextRef="c284" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12054">10</ix:nonFraction>% of sales and three customers accounted for <ix:nonFraction contextRef="c285" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12055">52.9</ix:nonFraction>%, <ix:nonFraction contextRef="c286" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12056">11.4</ix:nonFraction>% and <ix:nonFraction contextRef="c287" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12057">10.4</ix:nonFraction>% of accounts receivable. Two suppliers accounted
for <ix:nonFraction contextRef="c288" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12058">21.7</ix:nonFraction>% and <ix:nonFraction contextRef="c289" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12059">11.1</ix:nonFraction>% of raw material purchases, and three different products accounted for <ix:nonFraction contextRef="c290" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12060">25.0</ix:nonFraction>%, <ix:nonFraction contextRef="c291" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12061">22.8</ix:nonFraction>% and <ix:nonFraction contextRef="c292" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-12062">13.9</ix:nonFraction>% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nature of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Impact
from the New Coronavirus Global Pandemic (&#8220;COVID-19&#8221;)&#160;</b>- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Economic
environment -&#160;</b>Substantially all of the Company&#8217;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#8217;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In addition,
all of the Company&#8217;s revenue is denominated in the PRC&#8217;s currency of Renminbi (RMB), which must be converted into other currencies
before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require
approval of the PRC government.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHINA PHARMA HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2023 AND 2022</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-11346"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE
14 &#8211; SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On February 2, 2024,
the Company entered into a Technology Transfer Agreement with Lihua Li (the &#8220;Transferor&#8221;). The Transferor owns an invention
patent of a pharmaceutical composition for treatment of psoriasis (the &#8220;Invention Patent&#8221;). Pursuant to the Agreement, the
Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide
relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration
materials, registration application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The aggregate transfer
price as contemplated by the Agreement is $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="cphi:AggregateAmount" scale="0" unitRef="usd" id="ixv-12063">1.365</ix:nonFraction> million which was paid to the Transferor and his two designees upon the issuance of <ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-12064">3,000,000</ix:nonFraction>
shares of common stock of the Company at $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-12065">0.455</ix:nonFraction> per share based on the closing market price of the Company&#8217;s common stock as of
that date. During ten years since the product launches to the market, if and only if the product generates profit, Helpson shall pay <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cphi:RedemptionPercentage" scale="-2" unitRef="pure" id="ixv-12066">10</ix:nonFraction>%
of the net profit of the sales in cash on an annual basis to the Transferor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2024 the Company implemented
a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s Board of Directors through unanimous
written consent and the Company&#8217;s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held
on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company&#8217;s issued and outstanding
common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a
result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number.
The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s percentage interest in the Company&#8217;s
outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts
have been retroactively restated for the years ended December 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
11, 2024&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c294" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedemptionAmount" scale="0" unitRef="usd" id="ixv-12067">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c295" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-12068">0.3945</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c294" decimals="2" format="ixt:num-dot-decimal" name="cphi:RedemptionOfWeightedAveragePercentage" scale="-2" unitRef="pure" id="ixv-12069">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c296" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-12070">380,228</ix:nonFraction> shares of common stock to the Investor on January
16, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February
1, 2024&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c297" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedemptionAmount" scale="0" unitRef="usd" id="ixv-12071">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c298" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-12072">0.3725</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c297" decimals="2" format="ixt:num-dot-decimal" name="cphi:RedemptionOfWeightedAveragePercentage" scale="-2" unitRef="pure" id="ixv-12073">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-12074">402,685</ix:nonFraction> shares of common stock to the Investor on February
5, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February
16, 2024&#160;the Investor delivered its notice of redemption for $<ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="cphi:RedemptionAmount" scale="0" unitRef="usd" id="ixv-12075">150,000</ix:nonFraction>&#160;of the Note and related interest at the conversion price
of $<ix:nonFraction contextRef="c301" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-12076">0.3675</ix:nonFraction>, which was&#160;<ix:nonFraction contextRef="c300" decimals="2" format="ixt:num-dot-decimal" name="cphi:RedemptionOfWeightedAveragePercentage" scale="-2" unitRef="pure" id="ixv-12077">82</ix:nonFraction>% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;<ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-12078">408,164</ix:nonFraction> shares of common stock to the Investor on February
21, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:LongTermLineOfCredit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-11" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.91</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">3.78</ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-23" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-24" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-26" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-27" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-28" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-36" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-37" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-38" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:StockOptionPlanExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-40" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-43" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-44" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-45" name="cphi:ConversionOfRelatedPartyNoteAndInterestToCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c65" id="hidden-fact-46" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-47" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-48" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-50" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-51" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-52" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c245" id="hidden-fact-53" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c247" id="hidden-fact-54" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c248" id="hidden-fact-55" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c250" id="hidden-fact-56" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c252" id="hidden-fact-57" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c254" id="hidden-fact-58" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c255" id="hidden-fact-59" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c257" id="hidden-fact-60" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-12142">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-12143">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-12144">0001106644</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="cphi-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:OnnyInvestmentLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2005-05-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-15</xbrli:startDate>
    <xbrli:endDate>2023-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:HelpsonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-28</xbrli:startDate>
    <xbrli:endDate>2023-11-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:NMPAApprovedMedicalFormulasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:NMPAApprovedMedicalFormulasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:TechnologyFromBonierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:TechnologyFromBonierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:InventionPatentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:InventionPatentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-23</xbrli:startDate>
    <xbrli:endDate>2023-08-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-01</xbrli:startDate>
    <xbrli:endDate>2023-09-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:InterimChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:InterimChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-08</xbrli:startDate>
    <xbrli:endDate>2019-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-30</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-31</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:CITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:PostalSavingsBankOfChinaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-13</xbrli:startDate>
    <xbrli:endDate>2023-04-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-13</xbrli:startDate>
    <xbrli:endDate>2023-04-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-19</xbrli:startDate>
    <xbrli:endDate>2022-04-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-05</xbrli:startDate>
    <xbrli:endDate>2023-01-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-06</xbrli:startDate>
    <xbrli:endDate>2023-01-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-18</xbrli:startDate>
    <xbrli:endDate>2023-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-19</xbrli:startDate>
    <xbrli:endDate>2023-01-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-02</xbrli:startDate>
    <xbrli:endDate>2023-03-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-08</xbrli:startDate>
    <xbrli:endDate>2023-03-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-07</xbrli:startDate>
    <xbrli:endDate>2023-04-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-13</xbrli:startDate>
    <xbrli:endDate>2023-04-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-03</xbrli:startDate>
    <xbrli:endDate>2023-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KH4G5D/Mr+8XNRTGkKnKeVc8=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-24</xbrli:startDate>
    <xbrli:endDate>2023-05-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-25</xbrli:startDate>
    <xbrli:endDate>2023-05-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-06</xbrli:startDate>
    <xbrli:endDate>2023-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-13</xbrli:startDate>
    <xbrli:endDate>2023-06-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-23</xbrli:startDate>
    <xbrli:endDate>2023-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-27</xbrli:startDate>
    <xbrli:endDate>2023-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-09</xbrli:startDate>
    <xbrli:endDate>2023-08-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-11</xbrli:startDate>
    <xbrli:endDate>2023-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-21</xbrli:startDate>
    <xbrli:endDate>2023-08-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-22</xbrli:startDate>
    <xbrli:endDate>2023-08-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-01</xbrli:startDate>
    <xbrli:endDate>2023-09-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-06</xbrli:startDate>
    <xbrli:endDate>2023-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-12</xbrli:startDate>
    <xbrli:endDate>2023-09-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-13</xbrli:startDate>
    <xbrli:endDate>2023-09-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-06</xbrli:startDate>
    <xbrli:endDate>2023-10-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-12</xbrli:startDate>
    <xbrli:endDate>2023-10-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-13</xbrli:startDate>
    <xbrli:endDate>2023-10-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-17</xbrli:startDate>
    <xbrli:endDate>2023-10-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-17</xbrli:startDate>
    <xbrli:endDate>2023-10-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-06</xbrli:startDate>
    <xbrli:endDate>2023-11-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-07</xbrli:startDate>
    <xbrli:endDate>2023-11-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-29</xbrli:startDate>
    <xbrli:endDate>2023-11-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-01</xbrli:startDate>
    <xbrli:endDate>2023-12-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-13</xbrli:startDate>
    <xbrli:endDate>2023-12-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-18</xbrli:startDate>
    <xbrli:endDate>2023-12-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-21</xbrli:startDate>
    <xbrli:endDate>2022-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-30</xbrli:startDate>
    <xbrli:endDate>2022-03-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-13</xbrli:startDate>
    <xbrli:endDate>2022-06-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-13</xbrli:startDate>
    <xbrli:endDate>2022-06-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-03</xbrli:startDate>
    <xbrli:endDate>2022-08-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-04</xbrli:startDate>
    <xbrli:endDate>2022-08-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-17</xbrli:startDate>
    <xbrli:endDate>2022-10-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-18</xbrli:startDate>
    <xbrli:endDate>2022-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-02</xbrli:startDate>
    <xbrli:endDate>2022-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-05</xbrli:startDate>
    <xbrli:endDate>2022-12-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-06</xbrli:startDate>
    <xbrli:endDate>2022-12-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-13</xbrli:startDate>
    <xbrli:endDate>2022-12-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-14</xbrli:startDate>
    <xbrli:endDate>2022-12-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-14</xbrli:startDate>
    <xbrli:endDate>2022-12-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-15</xbrli:startDate>
    <xbrli:endDate>2022-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2023Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cphi:EffectiveMarchSixTwoZeroTwoFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cphi:EffectiveMarchSixTwoZeroTwoThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cphi:TwoThousandTenIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-03</xbrli:startDate>
    <xbrli:endDate>2022-10-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-04</xbrli:startDate>
    <xbrli:endDate>2022-10-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-09</xbrli:startDate>
    <xbrli:endDate>2021-09-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesBenchmarkMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesBenchmarkMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-11</xbrli:startDate>
    <xbrli:endDate>2024-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-11</xbrli:startDate>
    <xbrli:endDate>2024-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-01</xbrli:startDate>
    <xbrli:endDate>2024-02-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-01</xbrli:startDate>
    <xbrli:endDate>2024-02-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-16</xbrli:startDate>
    <xbrli:endDate>2024-02-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-16</xbrli:startDate>
    <xbrli:endDate>2024-02-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>ea020277201ex3-2_china.htm
<DESCRIPTION>THE FIRST AMENDED AND RESTATED ARTICLES OF INCORPORATION OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.2</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-2_002.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_003.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex3-2_004.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_005.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_006.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_007.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex3-2_008.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>ea020277201ex3-3_china.htm
<DESCRIPTION>THE SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.3</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex3-3_001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="ex3-3_002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="ex3-3_003.jpg" ALT=""></B>&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="ex3-3_004.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex3-3_005.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B><IMG SRC="ex3-3_006.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="text-align: center; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex3-3_007.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>ea020277201ex10-13_china.htm
<DESCRIPTION>LOAN SETTLEMENT AGREEMENT BETWEEN CHINA PHARMA HOLDINGS, INC. AND MS. ZHILIN LI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certain information marked as &ldquo;xxx&rdquo;
has been excluded from the Agreement because it is both not material and is the type that the registrant treats as private or confidential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white">LOANSETTLEMENT
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; background-color: white">&#36151;&#27454;&#22788;&#32622;&#21327;&#35758;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">Party A: Zhilin
Li (or &ldquo;Ms. Li&rdquo;) ID Number: xxx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">Party B: China
Pharma Holdings Inc. (NYSE American: CPHI) (or the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">&#30002;&#26041;&#65306;&#26446;&#24535;&#26519;&#65288;&#25110;
&ldquo;&#26446;&#22899;&#22763;&rdquo;&#65289;&#36523;&#20221;&#35777;&#21495;&#30721;&#65306;xxx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="background-color: white">&#20057;&#26041;&#65306;&#20013;&#22269;&#21307;&#33647;&#25511;&#32929;&#32929;&#20221;&#26377;&#38480;&#20844;&#21496;&#65288;&#32445;&#32422;&#35777;&#21048;&#20132;&#26131;&#25152;&#32654;&#22269;&#20195;&#30721;&#65306;CPHI&#65289;&#65288;&#25110;
&ldquo;&#20844;&#21496;&rdquo;&#65289;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Whereas</B>,
Ms. Zhilin Li is the creditor of $1,854,452.10 to the Company (&ldquo;Loan&rdquo;) and the Company is the debtor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Whereas</B>,
the Company is not able to pay Ms. Li the Loan in U.S. Dollar in cash in the foreseeable future; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Whereas</B>,
the two parties agreed to settle the Loan in the form of securities of the Company subject to proper corporate governance procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&#37492;&#20110;&#65292;&#26446;&#24535;&#26519;&#22899;&#22763;&#26159;&#26412;&#20844;&#21496;
1854452.10
&#32654;&#20803;&#65288;&ldquo;&#36151;&#27454;&rdquo;&#65289;&#30340;&#20538;&#26435;&#20154;&#65292;&#26412;&#20844;&#21496;&#26159;&#20538;&#21153;&#20154;&#65307;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&#37492;&#20110;&#65292;&#20844;&#21496;&#22312;&#21487;&#39044;&#35265;&#30340;&#26410;&#26469;&#26080;&#27861;&#20197;&#32654;&#20803;&#29616;&#37329;&#24418;&#24335;&#21521;&#26446;&#22899;&#22763;&#25903;&#20184;&#36151;&#27454;&#65307;&#21644;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&#37492;&#20110;&#65292;&#21452;&#26041;&#21516;&#24847;&#25353;&#29031;&#36866;&#24403;&#30340;&#20844;&#21496;&#27835;&#29702;&#31243;&#24207;&#65292;&#20197;&#20844;&#21496;&#35777;&#21048;&#30340;&#24418;&#24335;&#32467;&#28165;&#36151;&#27454;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Therefore</B>,
the two parties above have reached the following agreements with regards to the settlement of the Loan, for good consideration as of September
28, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">The Company agrees to issue an aggregate of 13,757,063 shares of
its restrictive common stock, par value $0.001 per share (the &ldquo;Shares&rdquo;), based on the resolutions from its audit committee
dated September 27, 2023, including the per share price of 0.1348 per share, the closing price immediately prior to the date of the AC
authorization.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Ms. Li agrees to receive the Shares to settle the Loan.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">The Company shall issue the Shares to Ms. Li by September 29, 2023.
Upon the issuance of the Shares to Ms. Li, the Loan will be offset in its entirety by the Shares and therefore extinguished.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&#22240;&#27492;&#65292;&#25130;&#33267;
2023 &#24180; 9 &#26376; 28
&#26085;&#65292;&#19978;&#36848;&#21452;&#26041;&#23601;&#36151;&#27454;&#30340;&#32467;&#31639;&#36798;&#25104;&#20102;&#20197;&#19979;&#21327;&#35758;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">1.
&#20844;&#21496;&#21516;&#24847;&#26681;&#25454;&#20854;&#23457;&#35745;&#22996;&#21592;&#20250; 2023 &#24180; 9 &#26376; 27
&#26085;&#30340;&#20915;&#35758;&#65292;&#21457;&#34892;&#24635;&#35745; 13757063
&#32929;&#38480;&#21046;&#24615;&#26222;&#36890;&#32929;&#65292;&#27599;&#32929;&#38754;&#20540; 0.001
&#32654;&#20803;(&ldquo;&#32929;&#20221;&rdquo;<FONT STYLE="background-color: white">)</FONT>&#65292;&#21253;&#25324;&#27599;&#32929;0.1348&#32929;&#30340;&#27599;&#32929;&#20215;&#26684;&#65292;&#21363;AC&#25480;&#26435;&#26085;&#26399;&#21069;&#30340;&#25910;&#30424;&#20215;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">2.
&#26446;&#22899;&#22763;&#21516;&#24847;&#25509;&#25910;&#32929;&#20221;&#20197;&#32467;&#28165;&#36151;&#27454;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">3.
&#20844;&#21496;&#24212;&#20110; 2023 &#24180; 9 &#26376; 29
&#26085;&#21069;&#21521;&#26446;&#22899;&#22763;&#21457;&#34892;&#32929;&#20221;&#12290;&#22312;&#21521;&#26446;&#22899;&#22763;&#21457;&#34892;&#32929;&#20221;&#21518;&#65292;&#35813;&#31508;&#36151;&#27454;
1854452.1 &#20803;&#23558;&#20840;&#37096;&#34987;&#32929;&#20221;&#25269;&#28040;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The parties
signed this agreement below as of the date referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&#21452;&#26041;&#20110;&#19978;&#36848;&#26085;&#26399;&#31614;&#32626;&#26412;&#21327;&#35758;&#12290;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Party A:</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#30002;&#26041;</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 35%; text-align: left">/s/
    Zhilin Li</TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin
        Li</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#26446;&#24535;&#26519;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Party
        B:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">China
    Pharma Holdings Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#20057;&#26041;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yingwen Zhang</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Name:</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yingwen
        Zhang</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#22995;&#21517;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#24352;&#24212;&#25991;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Title:</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#32844;&#20301;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Independent
        Director, Member of the Audit Committee </FONT></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#23457;&#35745;&#22996;&#21592;&#20250;&#22996;&#21592;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>5
<FILENAME>ea020277201ex10-14_china.htm
<DESCRIPTION>TECHNOLOGY TRANSFER AGREEMENT BETWEEN HAINAN HELPSON MEDICAL & BIOTECHNOLOGY CO., LTD AND TAO LIU
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.14</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Certain information marked as &ldquo;xxx&rdquo;
has been excluded from the Agreement because it is both not material and is the type that the registrant treats as private or confidential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Technology
Transfer Contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Party A: Hainan Helpson Medical
&amp; Biotechnology Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Party B: Liu Tao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Date of Contract: December
15, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>1<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A (Transferee): Hainan Helpson Medical
&amp; Biotechnology Co., Ltd.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal representative: Li Zhilin&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: C09-2, Haikou Free Trade Zone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B (Transferor): <U>Liu Tao</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ID No.: <U>XXX</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No. 9, Unit 3, Building 3, Labor People&rsquo;s
New Village, No.16, Shierqiao Road, Qingyang District, Chengdu City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In this contract, Party B owns
a drug combination for the treatment of chronic obstructive pulmonary disease, has obtained a patent (the patent number is <U>ZL201510062968.1</U>).
Party A shall acquire this invention patent, and Party B shall provide relevant technical services. Both parties have reached the following
agreement on the transfer of the patent right of this technology through equal consultation, based on the true and full expression of
their own wishes, and in accordance with relevant laws and regulations, which shall be strictly observed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.2pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Project related information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1 Details of The Patent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent No.:_ <U>ZL201510062968.1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patentee:_ Liu Tao</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventor/Designer: Do not disclose name</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent authorization date: September 18, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Main classification number: A61K 36/8966 (2006.01)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Term of Validity of Patent: September 18, 2038</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Patent Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 2.1 Status of Party B&rsquo;s implementation of the invention (time, place, method and scale): The invention has obtained an invention patent. Party B has solved the implementation of the core technology and completed the prototype development that meets the patent requirements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 2.2 The condition (time, place, method and scale) that Party B permits others to use the invention creation: None.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Main Obligations of Party B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3.1 Party B guarantees that it will sign any necessary documents and take any necessary actions according to Party A&rsquo;s requirements to ensure the realization of the transfer of invention patents.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3.2 Party B shall provide all technical data to the transferee within 30 days after the contract comes into effect.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3.3 Party B shall ensure that its patent application right does not infringe the legitimate rights and interests of any third party. If a third person accuses Party A of infringement, Party B shall be liable for breach of contract.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3.4 Party B or the third party designated by Party B shall provide Party A with technical services in Haikou, including but not limited to product research and development, writing of registration materials, registration application and other technical services.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>2<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Transfer fee, service fee and payment
method</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.1 The transfer fee of the patent right is USD 1.65 million. Within 10 days from the date of signing this contract, Party A, through its parent company China Pharma Holdings, Inc., issues shares worth USD1.65 million to Party B at US$0.11 per share;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.2 The service fee for the patent right is: within 10 years after the product is listed, Party A shall pay 15% of the net profit of the product sales to Party B in cash annually. If there is no profit, Party A shall not be required to pay Party B 15% of the net profit from the sale of the product.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Confirmation by both parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.1 Party B shall be responsible for transferring all rights and obligations of its patent right and proprietary technology to Party A.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.2 Party B has solved the implementation of core technology and completed the prototype manufacturing that meets the patent requirements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.3 Party B shall be responsible for completing all the declared technical documents and third party testing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.4 During the validity period of this contract, the new technical achievements made by Party A and Party B using the technical services provided by the other party shall be jointly owned by both parties.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.5 During the validity period of this contract, Party A and Party B have the right to use the invention and creation involved in the patent application right delivered by the other party for subsequent improvement. The resulting new technical achievements with the characteristics of substantive or creative technological progress shall belong to each party and each party shall obtain benefits.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 6.1 Party A and Party B shall abide by the following confidentiality obligations:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (1) Confidential content: all relevant information and data files of both parties during the transfer period and cooperation process;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (2) Scope of confidential personnel: relevant personnel directly or indirectly involved in the technology and information in this contract;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (3) Confidentiality period: 20 years;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>3<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.2 Party A&rsquo;s Responsibility for Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party A divulges secrets, it has no right to
recover the technology transfer fee paid to Party B and bear the actual loss of Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.3 Party B&rsquo;s Responsibility for Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party B divulges secrets, Party A has the right
to require Party B to bear the actual losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Liability for breach of contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.1 If Party B fails to submit relevant materials according to the above time, place and requirements, it shall pay Party A penalty of 3/10000 every day.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.2 If Party B violates Article 3 hereof, it shall pay Party A penalty of RMB1 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.3 If Party A fails to perform its obligations in accordance with Article 4.2 of this Contract, it shall pay Party B penalty of 3/10000 per day.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 The change of this contract must
be agreed by both parties through consultation and confirmed in writing. However, under any of the following circumstances, one party
may request the other party to change its contractual rights and obligations, and the other party shall reply within 30 days; If no reply
is given within the time limit, it shall be deemed that:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Major changes in national policies lead to
major adjustments in project contents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The research plan of this project is adjusted
or changed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Party B&rsquo;s organization adjustment or project
leader change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Other force majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 During the performance of this contract,
Party A shall designate as the project contact person and contact information. Party B shall designate as the project contact person and
contact information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Disputes arising from the performance
of this Contract by both parties shall be settled through consultation and mediation. If negotiation or mediation fails, the case shall
be submitted to Hainan International Arbitration Court for arbitration.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 For matters not covered in this
contract, a supplementary agreement can be signed by both parties through consultation. The supplementary agreement has the same effect
as this contract. In case of merger and acquisition, spin off, share transfer or restructuring of enterprises in the process of cooperation,
the formed new company still has the obligation to perform this contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 This contract is made in quadruplicate,
with each party holding two copies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 This Contract shall come into force
from the date of signing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>4<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party A (seal): Hainan Helpson Medical &amp;
Biotechnology Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 37%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal representative/authorized person (signature):&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Zhilin Li</B></FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Date: December 15, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party B: Liu Tao</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 37%; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal representative/authorized person (signature):</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/ Liu Tao</B></FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date: December 15, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#31532;<I>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>6
<FILENAME>ea020277201ex10-15_china.htm
<DESCRIPTION>TECHNOLOGY TRANSFER AGREEMENT BETWEEN HAINAN HELPSON MEDICAL & BIOTECHNOLOGY CO., LTD AND LIHUA LI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain information marked as &ldquo;xxx&rdquo;
has been excluded from the Agreement because it is both not material and is the type that the registrant treats as private or confidential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Technology
Transfer Contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">Party A: Hainan Helpson Medical
&amp; Biotechnology Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">Party B: Lihua Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">Date of Contract: February
2, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>1<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A (Transferee): Hainan Helpson Medical &amp;
Biotechnology Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal representative: Li Zhilin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: C09-2, Haikou Free Trade Zone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B (Transferor): <U>Lihua Li</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ID No.: <U>xxx</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: Room 402, Gate 3, Building 15, Xiaohong
Temple, Xuanwu District, Beijing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this contract, Party B owns
a pharmaceutical composition for treatment of psoriasis , has obtained a patent (the patent number is <U>ZL201601006377</U>). Party A
shall acquire this invention patent, and Party B shall provide relevant technical services. Both parties have reached the following agreement
on the transfer of the patent right of this technology through equal consultation, based on the true and full expression of their own
wishes, and in accordance with relevant laws and regulations, which shall be strictly observed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.2pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Project related information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1 Details of The Patent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent No.:_ <U>ZL201601006377</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patentee:_Lihua Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventor/Designer: Do not disclose name</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent authorization date: May 1, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Main classification number: A61K31/593(2006.01)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Term of Validity of Patent: May 1, 2038</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Patent Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.1 Status of Party B&rsquo;s implementation of the
invention (time, place, method and scale): The invention has obtained an invention patent. Party B has solved the implementation of the
core technology and completed the prototype development that meets the patent requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.2 The condition (time, place, method and scale)
that Party B permits others to use the invention creation: None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Main Obligations of Party B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.1 Party B guarantees that it will sign any necessary
documents and take any necessary actions according to Party A&rsquo;s requirements to ensure the realization of the transfer of invention patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2 Party B shall provide all technical data to
the transferee within 30 days after the contract comes into effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3 Party B shall ensure that its patent application
right does not infringe the legitimate rights and interests of any third party. If a third person accuses Party A of infringement, Party
B shall be liable for breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.4 Party B or the third party designated by Party
B shall provide Party A with technical services in Haikou, including but not limited to product research and development, writing of registration
materials, registration application and other technical services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>2<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Transfer fee, service fee and payment
method</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.1 The transfer fee of the patent right is USD
1.5 million. Within 10 days from the date of signing this contract, Party A, through its parent company China Pharma Holdings, Inc., issues
shares worth USD1.5 million to Party B at US$0.10 per share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2 The service fee for the patent right is: within
10 years after the product is listed, Party A shall pay 10% of the net profit of the product sales to Party B in cash annually. If there
is no profit, Party A shall not be required to pay Party B 10% of the net profit from the sale of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Confirmation by both parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1 Party B shall be responsible for transferring
all rights and obligations of its patent right and proprietary technology to Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.2 Party B has solved the implementation of core
technology and completed the prototype manufacturing that meets the patent requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3 Party B shall be responsible for completing
all the declared technical documents and third party testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.4 During the validity period of this contract,
the new technical achievements made by Party A and Party B using the technical services provided by the other party shall be jointly owned
by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.5 During the validity period of this contract,
Party A and Party B have the right to use the invention and creation involved in the patent application right delivered by the other party
for subsequent improvement. The resulting new technical achievements with the characteristics of substantive or creative technological
progress shall belong to each party and each party shall obtain benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1 Party A and Party B shall abide by the following
confidentiality obligations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Confidential content: all relevant information
and data files of both parties during the transfer period and cooperation process;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Scope of confidential personnel: relevant
personnel directly or indirectly involved in the technology and information in this contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Confidentiality period: 20 years;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>3<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.2 Party A&rsquo;s Responsibility for Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party A divulges secrets, it has no right to
recover the technology transfer fee paid to Party B and bear the actual loss of Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.3 Party B&rsquo;s Responsibility for Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party B divulges secrets, Party A has the right
to require Party B to bear the actual losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Liability for breach of contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.1 If Party B fails to submit relevant materials
according to the above time, place and requirements, it shall pay Party A penalty of 3/10000 every day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2 If Party B violates Article 3 hereof, it shall
pay Party A penalty of RMB1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3 If Party A fails to perform its obligations
in accordance with Article 4.2 of this Contract, it shall pay Party B penalty of 3/10000 per day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 The change of this contract must
be agreed by both parties through consultation and confirmed in writing. However, under any of the following circumstances, one party
may request the other party to change its contractual rights and obligations, and the other party shall reply within 30 days; If no reply
is given within the time limit, it shall be deemed that:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Major changes in national policies lead to
major adjustments in project contents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The research plan of this project is adjusted
or changed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Party B&rsquo;s organization adjustment or project
leader change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Other force majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 During the performance of this contract,
Party A shall designate as the project contact person and contact information. Party B shall designate as the project contact person and
contact information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Disputes arising from the performance
of this Contract by both parties shall be settled through consultation and mediation. If negotiation or mediation fails, the case shall
be submitted to Hainan International Arbitration Court for arbitration.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 For matters not covered in this
contract, a supplementary agreement can be signed by both parties through consultation. The supplementary agreement has the same effect
as this contract. In case of merger and acquisition, spin off, share transfer or restructuring of enterprises in the process of cooperation,
the formed new company still has the obligation to perform this contract.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 This contract is made in quadruplicate,
with each party holding two copies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 This Contract shall come into force
from the date of signing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>4<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party A (seal): Hainan Helpson Medical &amp;
Biotechnology Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: left; width: 37%; padding-bottom: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Legal representative/authorized person (signature):&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; padding-bottom: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>/s/ Zhilin Li</B></FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14pt 0pt 0; text-align: left"><B>Date: February 2, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party B: Lihua Li</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: left; width: 37%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Legal representative/authorized person (signature):&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>/s/ Lihua Li</B></FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14pt 0pt 0; text-align: left"><B>Date: February 2, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#31532;</I></FONT><I>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;&#65292;&#20849;</FONT>5<FONT STYLE="font-family: Times New Roman, Times, Serif">&#39029;</FONT></I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>7
<FILENAME>ea020277201ex10-16_china.htm
<DESCRIPTION>OFFICE LEASE FOR SECOND FLOOR OF THE COMPANY'S PRINCIPAL EXECUTIVE OFFICE DATED JUNE 5, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.16</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Certain information
marked as &ldquo;xxx&rdquo; has been excluded from the Agreement because it is both not material and is the type that the registrant
treats as private or confidential</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Office Lease
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 32pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Lessor:
Hainan Ruiran Jiahai Industrial Co., LTD. (hereinafter referred to as Party A)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Add:
Jiahai Building, No. 17, Jinpan Road, Jinpan Industrial Zone, Haikou City, China. Postcode: 570216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact
number: 66827489</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Lessee:
Hainan Helpson Pharmaceutical Biotechnology Co., LTD. (hereinafter referred to as Party B)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Business
License: xxx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact
number: 66819020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact:
Zhong Zaming</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">In
accordance with the Contract Law of the People&rsquo;s Republic of China and other relevant laws and regulations, Party A and Party B, on the
basis of equality and voluntariness, agree as follows on matters related to Party B&rsquo;s lease of Party A&rsquo;s premises:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 6.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
1 Basic Information of the Premises</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party A owns the property right
of Jiahai Building, located at No. 17 Jinpan Road, Haikou City, Hainan Province. The land use right of the building is obtained by means
<U>of</U> transfer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">(See Annex
1 &ldquo;House Ownership Certificate&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The premises leased by Party
B (hereinafter referred to as the Premises) is located on the second floor of Jiahai Building with a gross floor area of about <U>712
</U>square meters.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
ownership status of the house</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">Party
A has full and unblemished ownership of Jiahai Building, and the building is not mortgaged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
2 Purpose of lease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Party
B leases the building for <U>office</U> use. Party B warrants that it shall not change the use of the leased building without the written
consent of Party A and the examination and approval of the relevant authorities as required. Party B must accept Party A&rsquo;s property management
and safety supervision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
3 The lease term of the lease is two years</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The lease term is from July
01, 2023 to June 30, 2025.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration of the
lease term, if Party A&rsquo;s ownership and business direction of Jiahai Building do not change, if Party B intends to continue to lease the
building, it shall submit a written request to Party A for lease renewal 30 days in advance. After reaching an agreement through consultation,
Party A and Party B shall re-sign the lease contract or supplementary agreement. The upward rent shall be 10% of the total rental and
property charges.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration of the
lease, Party B shall have the priority to lease the property under the same conditions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
5 Rent Fee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rent standard: From July 1,
2023 to June 30, 2025, the monthly rent fee is RMB 15,065.00 and the property management fee is RMB 2,535.00 per month. The total rental
and property fee is RMB 17,600.00 per month(tax included).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Time of rent payment: Rent
payment shall be made in one natural month. The first payment of rent shall be made within 5 days after the signing of this contract.
The rent (security deposit) shall not be allowed to move in until it reaches the account.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rent payment method and time:
Party B shall make payment to the account designated by Party A by means of transfer (or cash). The last payment time of rent and utilities
for this month shall be from the 10th to the 20th of each month.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After Party A receives the
rent in full, Party A shall issue an invoice of the corresponding amount to Party B.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
6 Lease deposit (Deposit)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Within 5 days after this Contract
is signed, Party B shall pay the lease deposit to Party A for withholding Party B&rsquo;s breach or violation of the contract. The specific
amount is <U>RMB 10,000.00</U> (in words: RMB Ten thousand<U>). </U>Party A shall issue a corresponding receipt to Party B upon receipt
of the deposit.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After deducting the rent, liquidated
damages, compensation or compensation, Party B shall make up the deposit within 15 days upon Party A&rsquo;s notice. If Party B fails to make
up the deposit within the time limit, Party A shall have the right to terminate this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon termination or early termination
of this Contract, Party A shall refund the lease deposit to Party B in full after deducting Party B&rsquo;s rental fee, penalty, compensation
or compensation, property management and other expenses in accordance with this Contract. If Party B does not incur any relevant expenses,
Party A shall return the lease deposit to Party B in full.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
7 Other Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">During
the lease term, expenses related to the premises shall be borne as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall set up water
meters and electricity meters separately and pay water and electricity charges to the property management party of Jiahai Building according
to the actual consumption. The water charge is RMB<U>5.00</U> /cubic meter, and the electricity charge is RMB<U>1.3</U>/KWH. (The water
and power department will be notified of any adjustment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall bear all telephone
charges, TV viewing fees and other expenses incurred by Party B in leasing Jiahai Building.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
8 Delivery and return of the premises</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Delivery: Party A shall deliver
the Premises to Party B in accordance with the agreed terms after this Contract takes effect and Party B pays the rent and lease deposit
to Party A as agreed. The List of Facilities and Equipment belonging to the Premises shall be deemed to have been delivered after it
is submitted, signed and sealed by both parties and the key of the door is handed over.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Return: Upon expiration of
the lease term or termination of the Contract, Party B shall return the Premises and its ancillary facilities to Party A on the same
day. Party B shall dispose of the items belonging to Party B in the premises by itself; Party B shall not dispose of the floor, walls,
doors, Windows, ancillary facilities and other articles belonging to Party A on its own and shall ensure that they are in good condition
and tidy. Party A and Party B shall sign and seal the List of Facilities and Equipment Attached to the Premises after acceptance. If
Party B fails to return the premises to Party A within 15 days after the expiration of the lease term or the termination of the Contract,
Party A shall have the right to unilaterally take back the premises and return Party B&rsquo;s belongings left in the rear room. Party A shall
have the right to dispose of the premises by itself and claim the rent of Party B according to the actual return date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
9 Internal Decoration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B may decorate the premises
with the permission of Party A and does not require the restoration of the original condition after the expiration of the term. Otherwise,
Party A has the right to ask Party B to stop work immediately. Party A shall have the right to ask Party B to restore the building to
its original state if Party B destroys the structure of the building while decorating, decorating or adding new things. Party A shall
have the right to rescind this Contract and compensate Party A for the corresponding losses if Party B renovates or damages the building
structure without permission and disobeys the management.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expenses for house decoration
and improvement shall be borne by Party B. Party B shall bear the personal injury and economic loss caused by Party B&rsquo;s personnel during
the decoration and relocation and shall compensate for the personal injury and economic loss caused to others.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
10 Maintenance of the premises and ancillary facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
A shall ensure that the Premises and ancillary facilities are in suitable and safe condition. When Party B finds that the Premises and
its ancillary facilities are damaged or malfunctioning, it shall promptly notify Party A to repair the premises and its ancillary facilities
at Party A&rsquo;s expense.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall repair and repair
the decoration, improvement or addition of the premises by itself, and Party A shall not undertake the obligation of repair.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall use and accept
the premises and its ancillary facilities in a reasonable manner. In the event of damage or failure of the premises and its ancillary
facilities due to improper use or storage by Party B, Party B shall be responsible for maintenance or bear relevant expenses and liabilities.
If the premises and ancillary facilities are damaged due to natural aging, Party A shall be responsible for maintenance and bear relevant
expenses.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B causes personal
and property losses to Party A or a third party due to its improper use or maintenance of the premises and facilities, Party B shall
be liable for compensation at Party B&rsquo;s expense.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
11 Liability for insurance and safety</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">During
the lease term, Party B shall insure and pay insurance premiums for its own property, personnel and other liabilities it may bear in
the leased premises. During the lease term, Party B shall bear the responsibility and compensation for personal injury and property loss
caused by itself, and for personal injury and property loss caused to others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
12 Sublease, lend and transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall not sublease,
lend, transfer, or exchange the premises with others, in part or in whole; otherwise, Party B shall be deemed to have violated the rules
and Party A shall have the right to recover the proceeds from the sublease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B violates the provisions
of the preceding paragraph, it shall be deemed as breach of contract by Party B. Party B shall rectify the breach within 5 days upon
receipt of the written notice from Party A. If Party B fails to make such rectification within the said time limit, Party A shall have
the right to terminate this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
13 Change of ownership and operation of Jiahai Building</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party A transfers the ownership
of Jiahai Building during the lease term, Party A shall notify Party B in writing 90 days in advance. Party B shall vacate the leased
premises of Jiahai Building within <U>90 days</U> after receiving the written notice from Party A without the consent of the new owner.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, if there
is any change in the business direction of Jiahai Building, which involves the part leased by Party B and requires Party B to relocate,
Party A shall notify Party B in writing 90 days in advance, and Party B shall vacate its leased premises of Party A&rsquo;s Jiahai Building
within 90 days after receiving the written notice from Party A.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
14 Termination of the Contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Contract may be terminated
upon mutual agreement of both parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under any of the following
circumstances, this Contract shall be terminated and neither party shall be liable for breach of contract:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The building where the house
is located is included in the scope of house demolition according to law due to urban construction needs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The house is damaged, lost
or cannot be used normally due to force majeure such as earthquake or fire.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall have the right
to unilaterally terminate the contract under any of the following circumstances:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The house has not been delivered
as agreed for 15 days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other termination of the
contract as agreed herein occurs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under any of the following
circumstances, Party A shall have the right to unilaterally terminate the contract and take back the premises leased by Party B:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B does not pay the rent
or does not pay the rent as agreed for 15 days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Changing the purpose of the
building without authorization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Demolishing, altering or damaging
the main structure of the building without authorization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Using the building to engage
in illegal activities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B causes serious damage
to the premises or poses a serious threat to the premises, property or personal safety. Affecting the life and office of other parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B fails to move out of
Party A&rsquo;s Jiahai Building without Party A&rsquo;s consent within 90 days after receiving Party A&rsquo;s written notice of any
change in ownership or change in business direction of Party A.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 6.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other rescission of the
Contract as agreed herein occurs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Either
party may terminate this Contract by giving a 90-day notice to the other party in any case other than the circumstances set forth in
paragraphs (1) to (6) above. If Party A proposes to terminate this contract, Party A shall pay one month&rsquo;s rent to Party B as compensation.
If Party B proposes rescission, Party B shall pay one month&rsquo;s rent to Party A as compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
15 Liability for breach of contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party A delays in delivering
the leased premises of Jiahai Building to Party B, it shall pay Party B a penalty equal to 1&permil; of the first rent and the total
amount of the lease deposit for each day overdue.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B delays in paying
the rent, it shall pay a penalty equal to 1&permil; of the amount owed to Party A for each day overdue.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If either party breaches other
obligations agreed herein, it shall be held liable for breach of contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Where the liability for breach
of contract is otherwise stipulated in other provisions of this Contract, such provision shall prevail.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
16 Settlement of contract disputes.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.6pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any dispute
arising under this contract shall be settled by the parties through consultation. If no agreement can be reached through consultation,
either party may bring a suit to the people&rsquo;s court in the place where the property right is located according to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
17 Other agreed matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.6pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
A may inspect or repair the premises and ancillary facilities at any time after notifying Party B in advance, and Party B shall cooperate,
and Party A shall bear the maintenance expenses if necessary.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
B shall abide by the regulations and management of the property management of Jiahai Building and shall undertake the security and sanitation
of the leased area by itself.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All taxes and fees incurred
by Party A and Party B due to business operations shall be borne by Party A and Party B respectively according to law.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B must strengthen its
awareness of fire prevention during the lease term. In case of fire caused by Party B, Party B shall be responsible for all personal
losses, economic losses of property and legal criminal liabilities. Party B shall be responsible for compensation for injuries and property
losses caused to others. All losses caused to Party A and fines imposed by relevant departments shall be borne by and compensated by
Party B.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B commits any violation
during the lease term, Party A shall have the right to stop providing property services and water and electricity to Party B after management
and rectification by Party A. Party B shall be solely responsible for any losses caused to Party B&rsquo;s production.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party A shall, under any possible
conditions, give priority to Party B&rsquo;s (paid) parking space.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
18 The Contract takes effect</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This <U>Contract is </U>signed
and sealed by both parties on July <U>1, </U>2023 <U>and shall come into force on the same day.</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Contract is made in triplicate,
with Party A holding two copies and Party B holding one copy.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After this Contract comes into
force, the parties shall make any modification or supplement to the contract in written form.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The appendix is an integral
part of this contract and has the same legal effect as this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lessor (Party
    A) :</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lessee (Party
    B) :</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature/seal:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature/seal:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2023,</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 1, 2023</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">6</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>8
<FILENAME>ea020277201ex10-17_china.htm
<DESCRIPTION>OFFICE LEASE FOR THIRD FLOOR OF THE COMPANY'S PRINCIPAL EXECUTIVE OFFICE DATED JUNE 5, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.17</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Certain information
marked as &ldquo;xxx&rdquo; has been excluded from the Agreement because it is both not material and is the type that the registrant
treats as private or confidential</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Office Lease
Agreement</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Lessor:
Hainan Ruiran Jiahai Industrial Co., LTD. (hereinafter referred to as Party A)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Add:
Jiahai Building, No. 17, Jinpan Road, Jinpan Industrial Zone, Haikou City, China. Postcode: 570216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact
number: 66827489</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Lessee:
Hainan Helpson Pharmaceutical Biotechnology Co., LTD. (hereinafter referred to as Party B)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Business
License: xxx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact
number: 66819020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Contact:
Zhong Zaming</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">In
accordance with the Contract Law of the People&rsquo;s Republic of China and other relevant laws and regulations, Party A and Party B, on the
basis of equality and voluntariness, agree as follows on matters related to Party B&rsquo;s lease of Party A&rsquo;s premises:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 6.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
1 Basic Information of the Premises</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party A owns the property right
of Jiahai Building, located at No. 17 Jinpan Road, Haikou City, Hainan Province. The land use right of the building is obtained by means
<U>of</U> transfer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">(See Annex
1 &ldquo;House Ownership Certificate&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The premises leased by Party B (hereinafter referred to as the
                                                                                                                        Premises) is located on the third floor of Jiahai Building with a gross floor area of about <U>1188</U> square meters.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
ownership status of the house</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Party
A has full and unblemished ownership of Jiahai Building, and the building is not mortgaged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
2 Purpose of lease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Party
B leases the building for <U>office</U> use. Party B warrants that it shall not change the use of the leased building without the written
consent of Party A and the examination and approval of the relevant authorities as required. Party B must accept Party A&rsquo;s property management
and safety supervision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
3 The lease term is two years</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The lease term is from July
01, 2023 to June 30, 2025.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration of the
lease term, if Party A&rsquo;s ownership and business direction of Jiahai Building do not change, if Party B intends to continue to lease the
building, it shall submit a written request to Party A for lease renewal 30 days in advance. After reaching an agreement through consultation,
Party A and Party B shall re-sign the lease contract or supplementary agreement. The upward rent shall be 5% of the total rental and
property charges.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the expiration of the
lease, Party B shall have the priority to lease the property under the same conditions.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
5 Rent Fee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rent standard: From July 1,
2023 to June 30, 2025, the monthly rent is RMB 25,771.00, the property management fee is RMB 4,229.00, The total rental and property
fee is RMB30000.00 (tax included).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Time of rent payment: The rent
payment shall be made in one natural month. The first rent shall be paid within 5 days after the signing of this contract. The rent (security
deposit) can only be transferred to the account.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rent payment method and time:
Party B shall make payment to the account designated by Party A by means of transfer (or cash). The last payment time of rent and utilities
for this month shall be from the 10th to the 20th of each month.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After Party A receives the
rent in full, Party A shall issue an invoice of the corresponding amount to Party B.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
6 Lease deposit (Deposit)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Within 5 days after this Contract
is signed, Party B shall pay the lease deposit to Party A for withholding Party B&rsquo;s breach or violation of the contract. The specific
amount is RMB<U>27,600.00</U>. Party A shall issue a corresponding receipt to Party B upon receipt of the deposit.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After deducting the rent, liquidated
damages, compensation or compensation, Party B shall make up the deposit within 15 days upon Party A&rsquo;s notice. If Party B fails to make
up the deposit within the time limit, Party A shall have the right to terminate this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon termination or early termination
of this Contract, Party A shall refund the lease deposit to Party B in full after deducting Party B&rsquo;s rental fee, penalty, compensation
or compensation, property management and other expenses in accordance with this Contract. If Party B does not incur any relevant expenses,
Party A shall return the lease deposit to Party B in full.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
7 Other Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">During
the lease term, expenses related to the premises shall be borne as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall set up water
meters and electricity meters separately and pay water and electricity charges to the property management party of Jiahai Building according
to the actual consumption. The water charge is RMB<U>5.00</U> /cubic meter, and the electricity charge is RMB<U>1.3</U>/KWH. (The water
and power department will be notified of any adjustment.)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall bear all telephone
charges, TV viewing fees and other expenses incurred by Party B in leasing Jiahai Building.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
8 Delivery and return of the premises</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Delivery: Party A shall deliver
the Premises to Party B in accordance with the agreed terms after this Contract takes effect and Party B pays the rent and lease deposit
to Party A as agreed. The List of Facilities and Equipment belonging to the Premises shall be deemed to have been delivered after it
is submitted, signed and sealed by both parties and the key of the door is handed over.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Return: Upon expiration of
the lease term or termination of the Contract, Party B shall return the Premises and its ancillary facilities to Party A on the same
day. Party B shall dispose of the items belonging to Party B in the premises by itself; Party B shall not dispose of the floor, walls,
doors, Windows, ancillary facilities and other articles belonging to Party A on its own and shall ensure that they are in good condition
and tidy. Party A and Party B shall sign and seal the List of Facilities and Equipment Attached to the Premises after acceptance. If
Party B fails to return the premises to Party A within 15 days after the expiration of the lease term or the termination of the Contract,
Party A shall have the right to unilaterally take back the premises and return Party B&rsquo;s belongings left in the rear room. Party A shall
have the right to dispose of the premises by itself and claim the rent of Party B according to the actual return date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
9 House Decoration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B may decorate the premises
with the permission of Party A and does not require the restoration of the original condition after the expiration of the term. Otherwise,
Party A has the right to ask Party B to stop work immediately. Party A shall have the right to ask Party B to restore the building to
its original state if Party B destroys the structure of the building while decorating, decorating or adding new things. Party A shall
have the right to rescind this Contract and compensate Party A for the corresponding losses if Party B renovates or damages the building
structure without permission and disobeys the management.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expenses for house decoration
and improvement shall be borne by Party B. Party B shall bear the personal injury and economic loss caused by Party B&rsquo;s personnel during
the decoration and relocation and shall compensate for the personal injury and economic loss caused to others.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Article
10 Maintenance of the premises and ancillary facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
A shall ensure that the Premises and ancillary facilities are in suitable and safe condition. When Party B finds that the Premises and
its ancillary facilities are damaged or malfunctioning, it shall promptly notify Party A to repair the premises and its ancillary facilities
at Party A&rsquo;s expense.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall repair and repair
the decoration, improvement or addition of the premises by itself, and Party A shall not undertake the obligation of repair.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall use and accept
the premises and its ancillary facilities in a reasonable manner. In the event of damage or failure of the premises and its ancillary
facilities due to improper use or storage by Party B, Party B shall be responsible for maintenance or bear relevant expenses and liabilities.
If the premises and ancillary facilities are damaged due to natural aging, Party A shall be responsible for maintenance and bear relevant
expenses.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B causes personal
and property losses to Party A or a third party due to its improper use or maintenance of the premises and facilities, Party B shall
be liable for compensation at Party B&rsquo;s expense.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
11 Liability for insurance and safety</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">During
the lease term, Party B shall insure and pay insurance premiums for its own property, personnel and other liabilities it may bear in
the leased premises. During the lease term, Party B shall bear the responsibility and compensation for personal injury and property loss
caused by itself, and for personal injury and property loss caused to others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
12: Sublease, lend and transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall not sublease,
lend, transfer, or exchange the premises with others, in part or in whole; otherwise, Party B shall be deemed to have violated the rules
and Party A shall have the right to recover the proceeds from the sublease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B violates the provisions
of the preceding paragraph, it shall be deemed as breach of contract by Party B. Party B shall rectify the breach within 5 days upon
receipt of the written notice from Party A. If Party B fails to make such rectification within the said time limit, Party A shall have
the right to terminate this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
13 Change of ownership and operation of Jiahai Building</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party A transfers the ownership
of Jiahai Building during the lease term, Party A shall notify Party B in writing 90 days in advance. Party B shall vacate the leased
premises of Jiahai Building within <U>90 days</U> after receiving the written notice from Party A without the consent of the new owner.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, if there
is any change in the business direction of Jiahai Building, which involves the part leased by Party B and requires Party B to relocate,
Party A shall notify Party B in writing 90 days in advance, and Party B shall vacate its leased premises of Party A&rsquo;s Jiahai Building
within 90 days after receiving the written notice from Party A.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
14 Termination of the Contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Contract may be terminated
upon mutual agreement of both parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under any of the following
circumstances, this Contract shall be terminated and neither party shall be liable for breach of contract:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The building where the house
is located is included in the scope of house demolition according to law due to urban construction needs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The house is damaged, lost
or cannot be used normally due to force majeure such as earthquake or fire.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B shall have the right
to unilaterally terminate the contract under any of the following circumstances:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The house has not been delivered
as agreed for 15 days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other termination of the
contract as agreed herein occurs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Under any of the following
circumstances, Party A shall have the right to unilaterally terminate the contract and take back the premises leased by Party B:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B does not pay the rent
or does not pay the rent as agreed for 15 days.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Changing the purpose of the
building without authorization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Demolishing, altering or damaging
the main structure of the building without authorization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Using the building to engage
in illegal activities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B causes serious damage
to the premises or poses a serious threat to the premises, property or personal safety. Affecting the life and office of other parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 6.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B fails to move out of
Party A&rsquo;s Jiahai Building without Party A&rsquo;s consent within 90 days after receiving Party A&rsquo;s written notice of any
change in ownership or change in business direction of Party A.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.55pt; text-align: justify; text-indent: 6.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any other rescission of the
Contract as agreed herein occurs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Either
party may terminate this Contract by giving a 90-day notice to the other party in any case other than the circumstances set forth in
paragraphs (1) to (6) above. If Party A proposes to terminate this contract, Party A shall pay one month&rsquo;s rent to Party B as compensation.
If Party B proposes rescission, Party B shall pay one month&rsquo;s rent to Party A as compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.5pt; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
15 Liability for breach of contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party A delays in delivering
the leased premises of Jiahai Building to Party B, it shall pay Party B a penalty equal to 1&permil; of the first rent and the total
amount of the lease deposit for each day overdue.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B delays in paying
the rent, it shall pay a penalty equal to 1&permil; of the amount owed to Party A for each day overdue.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If either party breaches other
obligations agreed herein, it shall be held liable for breach of contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Where the liability for breach
of contract is otherwise stipulated in other provisions of this Contract, such provision shall prevail.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
16 Settlement of contract disputes.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any dispute
arising under this contract shall be settled by the parties through consultation. If no agreement can be reached through consultation,
either party may bring a suit to the people&rsquo;s court in the place where the property right is located according to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Article
17 Other agreed matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
A may inspect or repair the premises and ancillary facilities at any time after notifying Party B in advance, and Party B shall cooperate,
and Party A shall bear the maintenance expenses if necessary.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the lease term, Party
B shall abide by the regulations and management of the property management of Jiahai Building and shall undertake the security and sanitation
of the leased area by itself.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All taxes and fees incurred
by Party A and Party B due to business operations shall be borne by Party A and Party B respectively according to law.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party B must strengthen its
awareness of fire prevention during the lease term. In case of fire caused by Party B, Party B shall be responsible for all personal
losses, economic losses of property and legal criminal liabilities. Party B shall be responsible for compensation for injuries and property
losses caused to others. All losses caused to Party A and fines imposed by relevant departments shall be borne by and compensated by
Party B.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Party B commits any violation
during the lease term, Party A shall have the right to stop providing property services and water and electricity to Party B after management
and rectification by Party A. Party B shall be solely responsible for any losses caused to Party B&rsquo;s production.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Party A shall, under any possible
conditions, give priority to Party B&rsquo;s (paid) parking space.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Article
18 The Contract takes effect</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This <U>Contract is </U>signed
and sealed by both parties on July <U>1, </U>2023 <U>and shall come into force on the same day.</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Contract is made in triplicate,
with Party A holding two copies and Party B holding one copy.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">After this Contract comes into
force, the parties shall make any modification or supplement to the contract in written form.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The appendix is an integral
part of this contract and has the same legal effect as this Contract.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Lessor (Party A) :</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Lessee (Party B) :</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Signature/seal:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature/seal:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">July 1, 2023,</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">July 1, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>ea020277201ex23-1_china.htm
<DESCRIPTION>CONSENT OF THE INDEPENDENT ACCOUNTING FIRM.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consent to the incorporation
by reference in Registration Statement on Form S-3 (File No.: 333-276481) and Registration Statement on Form S-8 (File No.: 333-267989)
of our report dated April 1, 2024 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as
of and for the years ended December 31, 2023 and 2022 appearing in this Annual Report on Form 10-K of China Pharma Holdings, Inc. for
the year ended December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>/s/ </B><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">B F Borgers CPA PC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lakewood, CO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">April 1, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>ea020277201ex31-1_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing
the equivalent function):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>ea020277201ex31-2_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing
the equivalent function):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>ea020277201ex32-1_china.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby certifies, in her capacity
as principal executive officer, principal financial officer and principal accounting officer of China Pharma Holdings, Inc. (the &ldquo;Company&rdquo;), for the purposes of 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: April 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhilin Li </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhilin Li</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification accompanies each Report pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed
filed by the Company for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement required
by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>ea020277201ex97-1_china.htm
<DESCRIPTION>COMPENSATION RECOVERY POLICY OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 97.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>China
Pharma HOldings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMPENSATION RECOVERY POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Effective December 1, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with Section
10D of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), Exchange Act Rule 10D-1, and section 811
of the NYSE American Company Guide (&ldquo;<B>NYSEA Guide</B>&rdquo;), the listing rule of the NYSE American (the &ldquo;<B>Exchange</B>&rdquo;)
where the securities of China Pharma Holdings, Inc. (the &ldquo;<B>Company</B>&rdquo;) are listed, the Company&rsquo;s Board of Directors
(the &ldquo;<B>Board</B>&rdquo;) has adopted this Compensation Recovery Policy (the &ldquo;<B>Policy</B>&rdquo;). The purpose of this
Policy is to recover the erroneously awarded Inventive-Based Compensation (defined below), if any, in the event that the Company is required
to prepare an Accounting Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Capitalized terms used in the
Policy are defined in <U>Section A</U> below. The application of the Policy to Executive Officers is not discretionary, except to the
limited extent provided in <U>Section G</U> below, and applies without regard to whether an Executive Officer was at fault.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify"><B>Definitions</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Accounting Restatement</B>&rdquo; means
an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities
laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to
the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current
period or left uncorrected in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Accounting Restatement Determination
Date</B>&rdquo; means the date that a Company is required to prepare an Accounting Restatement, which is the earlier of: (a) the date
the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not
required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the
date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Excess Compensation</B>&rdquo; means
the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive-Based Compensation that otherwise would have
been Received had such Incentive-Based Compensation been determined based on the restated amounts (this is referred to in the listings
standards as &ldquo;erroneously awarded incentive-based compensation&rdquo;) and must be computed without regard to any taxes paid.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Executive Officer</B>&rdquo; means each
individual who is or was ever designated as an &ldquo;officer&rdquo; by the Board in accordance with Exchange Act Rule 16a-1(f).</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Financial Reporting Measures</B>&rdquo;
means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial
statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also
Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Incentive-Based Compensation</B>&rdquo;
means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure
(for the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&rsquo;s
duty to recover under the Policy has lapsed) and excludes the following: salaries, bonuses paid solely at the discretion of the Committee
or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon
satisfying one or more subjective standards and/or completion of a specified employment period, non-equity incentive plan awards earned
solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent
upon achieving any Financial Reporting Measure performance goal and vesting upfront, upon the signing of certain agreements, or is contingent
solely upon completion of time requirement (e.g., time-based vesting equity awards) and/or attaining one or more non-Financial Reporting
Measures.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&ldquo;<B>Received</B>&rdquo; means, with respect
to any Incentive-based Compensation, actual or deemed receipt, and Incentive-Based Compensation is &ldquo;Received&rdquo; under the Policy
in the Company&rsquo;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award
is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of
doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to October
2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify"><B>Persons Covered by the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Policy is binding and enforceable
against all Executive Officers who received Incentive-Based Compensation covered by this Policy from the Company (See <U>Section E</U>
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Administration of the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Compensation Committee
of the Board (the &ldquo;<B>Committee</B>&rdquo;) has full-delegated authority to administer the Policy. The Committee is authorized to
interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy.
In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another
committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer
to such independent members of the Board or such other Board committee. All determinations of the Committee will be final and binding
and will be given the maximum deference permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Accounting Restatements Requiring Application of the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">If the Company is required
to prepare an Accounting Restatement, then the Committee must determine the Excess Compensation, if any, that must be recovered. The Company&rsquo;s
obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>E.</B></TD><TD STYLE="text-align: justify"><B>Compensation Covered by the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Policy applies to all Incentive-Based Compensation
Received by an Executive Officer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">after beginning service as an Executive Officer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">who served as an Executive Officer at any time during the
performance period for that Incentive-Based Compensation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">while the Company has a class of securities listed on the
Exchange;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">during the three completed fiscal years immediately preceding
the Accounting Restatement Determination Date. In addition to these last three completed fiscal years, the Policy must apply to any transition
period (that results from a change in the Company&rsquo;s fiscal year) within or immediately following those three completed fiscal years.
However, a transition period between the last day of the Company&rsquo;s previous fiscal year end and the first day of the Company&rsquo;s
new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">on or after October 2, 2023.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>F.</B></TD><TD STYLE="text-align: justify"><B>Excess Compensation Subject to Recovery of the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">To determine the amount of
Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is&nbsp;not&nbsp;subject
to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate
of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation
was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide the documentation
to the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>G.</B></TD><TD STYLE="text-align: justify"><B>Repayment of Excess Compensation</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Company must recover Excess
Compensation reasonably promptly and Executive Officers are required to repay Excess Compensation to the Company. Subject to applicable
law, the Company may recover Excess Compensation by requiring the Executive Officer to repay such amount to the Company by direct payment
to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not
need to be identical as to each Executive Officer). These means may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">requiring reimbursement of cash Incentive-Based Compensation
previously paid;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">seeking recovery of any gain realized on the vesting, exercise,
settlement, sale, transfer, or other disposition of any equity-based awards;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">offsetting the amount to be recovered from any unpaid or
future compensation to be paid by the Company or any affiliate of the Company to the Executive Officer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">cancelling outstanding vested or unvested equity awards;
and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">taking any other remedial and recovery action permitted by
law, as determined by the Committee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The repayment of Excess Compensation
must be made by an Executive Officer notwithstanding any Executive Officer&rsquo;s belief (whether or not legitimate) that the Excess
Compensation had been previously earned under applicable law and therefore is not subject to recovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Company is prohibited from
indemnifying any Executive Officer or former Executive Officer against the loss of Excess Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition to its rights to
recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce
an Executive Officer&rsquo;s obligations to the Company or its affiliate or to discipline an Executive Officer, including (without limitation)
termination of employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction
of future compensation opportunities, or change in role. The decision to take any actions described in the preceding sentence will not
be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of
the Company or of any applicable affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>H.</B></TD><TD STYLE="text-align: justify"><B>Limited Exceptions to the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Company must recover Excess
Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below are met, and the Committee
determines that recovery of the Excess Compensation would be impracticable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The direct expense paid to a third party to assist in enforcing
the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover
the Excess Compensation, document the reasonable attempt(s) taken to so recover, and provide that documentation to the Exchange;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Recovery would violate home country law where that law was
adopted prior to November 28, 2022. Before reaching this conclusion, the Company must obtain an opinion of home country counsel, acceptable
to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Recovery would likely cause an otherwise tax-qualified retirement
plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13)
(Assignment and alienation) or 26 U.S.C. 411(a) (Minimum vesting standards) and regulations thereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>I.</B></TD><TD STYLE="text-align: justify"><B>Other Important Information in the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Notwithstanding the terms of
any of the Company&rsquo;s organizational documents (including, but not limited to, the Company&rsquo;s bylaws), any corporate policy
or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will
indemnify or provide advancement for any Executive Officer against any loss of Excess Compensation, or any claims relating to the Company&rsquo;s
enforcement of its rights under the Policy. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums
for an insurance policy that covers potential recovery obligations. In the event that pursuant to the Policy the Company is required to
recover Excess Compensation from an Executive Officer who is no longer an employee, the Company will be entitled to seek recovery in order
to comply with applicable law, regardless of the terms of any release of claims or separation agreement such individual may have signed.
Neither the Company nor any affiliate of the Company will enter into any agreement that exempts any Incentive-Based Compensation that
is granted, paid, or awarded to an Executive Officer from the application of the Policy or that waives the Company&rsquo;s right to recovery
of any Excess Compensation, and the Policy shall supersede any such agreement (whether entered into before, on, or after the adoption
of the Policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Committee or Board may
review and modify the Policy from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">If any provision of the Policy
or the application of any such provision to any Executive Officer is adjudicated to be invalid, illegal, or unenforceable in any respect,
such invalidity, illegality, or unenforceability will not affect any other provisions of the Policy or the application of such provision
to another Executive Officer, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary
to render any such provision or application enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Policy will terminate and
no longer be enforceable when the Company ceases to be a listed issuer within the meaning of Section 10D of the Exchange Act or when the
Exchange Act Rule 10D-1, and the section 811 of the NYSEA Guide are no longer effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 2P# 2(  A$! Q$!_\0
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MG_?D5YR0 V#P5]OO4%"6*COT]JKZO .=GHW_  N3Q)_TZ?\ ?D4?\+D\2?\
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M'_"GO"?_ #PN/^_QH_X4]X3_ .>%Q_W^-=_11SR#DB<!_P *>\)_\\+C_O\
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MC1_PI[PG_P \+C_O\:[^BCGD+DB<!_PI[PG_ ,\+C_O\:/\ A3WA/_GA<?\
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MX*.60<R+M!JC_:UA_P _MO\ ]_!2/JUCMPE[;[NW[P4<LA<R.'^*O^K\,_\
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M+?\ :=W_ ,]/YT?VE=_\]/YU3) ')I>@ST'\Z.6(^8M_VE=_\]/YT?VE=_\
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MYDW<.K?TJY?>%-*2+4[5(/*2RTR.]M[K/^LD[[O6J]JB>0\NSCC();E0K?\
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M6MJ?P%J%O#<1+-#)?6=FMW-!ZJW2K+^ 'MH[MKC48XYK:R6_GC$1;"'M3]I
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M %U7^=?5L7^K7Z#^5<&,Z'72V*'B3_D7-0_Z]V_E7RA??\?;_0?RKZO\2?\
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M7C@5=P8X)QNY'Z49S@E02#D<=*7L1\QZF]_IUSJ^D3#6[-2NF&*9CEBS*/\
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&-G?1V/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex3-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M*H:0%F9QA03STK\ZV_X+5_'_ .T[?[:_9?$N_BWV:HQ_W=_VC;[9S7?>$?\
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M'QHT:UM?B!K,HT>T:UU<9\N]BMXFMEF2(A"[+"K 75T0)7 #_JW110 4444
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M/+Y(=;E+$S2."RLH$:LI9F8_=5% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5YS^UU\3_%?P5_9A\=^+?
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M5O$%GXG\2^)]?CUKPI'J&A:U-K[Q/?"/3S.HMRC6\/DLTLV )?-%PTKL?8?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M([5+TAG<-->3NKR(ZNWT70 4444 %%%% !1110 4444 %%%% !1110 4444
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MUH^AR2Z78QM:P3JD9#QM.K2ET+,P*DN6+@U[MILVI?M.:-HV@C3[:TUCXO\
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MS9Z3J'B*.UD;3;;5+R2SLI[C:?+6::.*5XXRV,LL3D#.%/2@#PCX.?&[X/\
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M1XPTFY8&2'3[")GCBE56(!EA34DZG!4'D4 ?IA\!_'FO?%#X1:#XB\2>%9_
M^L:S:K=S:'/?1WD^FA^4CEDC 0R!2NX(656R S ;CX-_P4__ ."F8_X)H:#X
M!U2[^'^J>/+7XA>(X/"6GP:5J<,%[_:5PKM @AD'S1L(W!<-\K% 5^8&O:_A
M1^TQX'^.OC3Q9H7@[Q!8>)+GP/-#::U<:=(+BTLKJ4.WV4S*2AG15#21@EHQ
M)'NP6 K\Y/V]O$^G_ME?\'%/[-GPC^W64WAG]G71+WXJ^*#]I41V5Z"IM%FR
M1M>%XK&7GHEWGID@ ^R?V>_^"D7AWXN_M:^+O@)XF\.ZW\/?B_X/T^+66T?4
MI(KBTUW3I,8O=/NHF*SQ*60,'6.16)&SY'V\?^RK_P %3M0_:J_;I^)WP1TO
MX6WUFWP<N1:^*O$P\06UQIEM)(K&".$*OF2RN48%"J^7Y<@9@5"M\@?"'Q38
M_M3_ /!:WXH_MN)?PZ?^S;^SSX%N?"NE^+=Q6S\83P13F\EM7(VSV\,DMVOF
MH2CM'!L+;CM](_X-9/ &H:W^P_XZ^.?B&*V;Q5^T9\0M8\87<Z'=(8!.T*Q,
MV>=MPMXXZ<3=* /L']L;_@H3X"_8PU7PGX?UE=9\3?$#XA7@T_PGX,\/6ZW>
MM^()L@,8T9TCBA3.YYYY(XD )+Y&*K^'?VN?&DGQ]T/X<>(?@_K.@ZQXF\.:
MAXDT_4(];M;W24CLVMXY+:XFC_>17 EO+92!$\>)25DDVL!\+_#/PG);_P#!
MW/\ $C6/B4TENLGPQMA\)O[5*K#=1_9[".]%@S=9$D;5-R*=^);AL;3FOL;_
M (*6?MX^&_V5_P#@G[\9OBAI&M6,VJ>"='N],TV[B.Z-=8F @M[=),%7<7+Q
M!U0DH4(8 J< 'F?[(O\ P6BO/VQ?@E\9OB%H?P@O])\)_!<:A:W^HZCXILUM
M]6OK%%FN+>VD164QK 3)Y[E8SNC )#,T?*Q?\%^UB_X)C7W[6-_\%M>TGX9Q
MW\%G86UYXBM$U;6(WNVLGG@@"E2J7&U=K.K,BRR ;4!?X+^,WPOUK_@F-_P;
M ^"])T[XI^++'Q)\?K"UL8O"MO#HB:;?2ZX/M%RCR&Q-XRKIY:-G^U8#;!N5
M"J5[)_P4_P#@%I,(_P"">_\ P3YT>XL;ZUN-5L=3\7VT<BI)-IVE6P$\LJ9
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M5=I Z':JG! X(.,$5^FM !1110 4444 %%%% !1110 4444 %<W\7?A1X?\
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MW#5:-ZN*::E[T+OW3\MS_AC$8>NL=@)./*[JSM9VLK[[;7LTUI*VY[!^RO\
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MS$DDYKFOV4?V/? _[&GPV7P[X+TQH/.83:EJ=TXFU+6Y^<W%U-@&1R2Q X1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML?&7@^ZU"\T'4+B[M(WOM*N]+N8YK6ZEM+B*2VNXHIXGCG@E0K)&IRA/0@D
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M31AFVE,%<G&,UZ#=:;:WUQ:S36\$TUG(9;=WC#- Y5D+(3]TE79<CG#$=":
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M?'^O>&[JU\>:';-96GB70=:O_#^L"V;.;=[NPG@FE@Y)\J1V0$DA<F@#SO\
MX*S>&M#M/^"=?[5&L6UO8KXFO_@_K%IJ$R$?:)+2&PU)K97&<[%>>[*DCDM)
MUQQ^+N@>*KOXK_L^_P#!.?X%?'RWL?"O[-?BK[/KNE^+-%9_M=_J\+SP0Z=>
M22'9:1[KA0[HK96YC<.FR39^\'C[]@;X6_$[X)^(/A[K.BZW/X9\72&37U@\
M3ZK:W^OYC\EEO;Z*Y6[ND:+]VR32NK( I!  '"Z[_P $;_V<_%7[(]E\"=7\
M WFL?"G2]034]/T34?%&KWG]ESIN"FUN)+IKBW4!W&R*14(D<;<.V0#XM_X+
M*KX@;_@OK^PN/"K:,OB+[)KW]GG5EE:Q$ODMCS1$0^W_ '3GI7Z!?LB17E[\
M&?A_IWQ2M](N/C0WAJRU#Q(DD DN!<P.P:568%A$ES--Y)8Y =BO\5<;XQ_X
M(Y? /X@_$;P;XPUK0_'VH>*OA[:I9^&]6E^)OB<WFBQ(, 0R#4-REAPS9W/_
M !%J]+^!W[%OP_\ V=_''BSQ-X:M?$TGB/QQ;6EGK.J:WXMU?7KRY@M//-O$
MLM_<SO"D9N9B%B*#+Y.<+@ _/?\ X(]:-:^(/^"U_P#P4AT_4+6WOK&^UC1;
M>YMKB(20W$;K?JR.K AE92000002*[W_ (+\>$8?VS?@3XT^!5E;>/+JZTCP
MI)XJM5\,^%M7UA+K7E?.DV$\EC;RQ1QNL-TSQSE2#+:2CA>?IS]GO_@EO\%O
MV6/CSK_Q-\#Z'XKTOQMXL=I==U&Y\<Z]J(UQR' :[AN;V2&X9?,<H948H6RN
MT\UV7PN_8W\#?!KQ-X\UCP^OC&WU#XEW,E[XADN?&FM7RW-P\:1&:))[IUMI
M!%'%&KVXC9(X8D4JL:!0#XD_9J_;K;_@H3_P;3?$+QMJ%Y]L\6Z7\*O$OAOQ
M3O/[T:G9Z5/'(\G^U-'Y5Q@=!<#IT'Y>^'O&6H>.O^"7G[!OP4^-T-KX3_9/
M^(7B"\N]1\<Z,I?4[>_AU+5(X["X:4^3:Q%IA(TVUB8]S*/W$BO^XGPY_P""
M*7[.?PB\">/O#/AGPGXNT;0OBDC)XLM+?XB>)%770Y/F&8_;]Q:0,RNP(,B.
MR,65BINI_P $;?V<S^R#<? 6X\ WNH?".:]CU"+P]?\ BG6+V/3YTE,JM:2S
M7;36F79V9;=XU;S)-P(D<, ?,_\ P<T?L_W6@?LX^#_VJO!5W;Z+\5/V7M=M
M->TZ[8$+J5A-=P136<NW!=#(8GVL=NS[0F/WS5]B?L!ZP/C-\"-'^-5Y#Y6M
M?'#2]/\ %;1-)YITK3I[99=/TY7P/EMX)<M@!6N)KJ0!?-(J#XI_\$T_A#\;
M/V8=*^#7BK2O%VM?#?1XA;Q:1-XYUT?:8E<2)%<SK>">ZC1E4HD\DBQA$"!0
MJ@>@_LZ?LY^%?V4_A1IG@?P3;ZS9>%]%B2WT^SU'7;_6#80QQI%'!%)>3321
MPHD:*D2L$0#Y5&3D _,K_@L!%JT7_!P;^P5-XLVGX6-=W4>D_:/^/5?$&]]O
M7CSBYTSR\\[A\O0U+_P<*6VMW_\ P4R_X)WP^!OMC>/O^$]OW@%D3YRZ>)M*
M-X9-O/DB$2%\\>6)NVZOTP_:#_9M\"_M5?#UO"OQ!\-:?XFT3[3'>PQ7&Y);
M*YCSY=S;S(5EMYTR=LT3)(NXX89-<[\+/V&OAC\'_BW-X^TO0M0U+QU-IXTE
M?$/B'7M0\0ZI;688M]FAN=0GGDAB+,69(F56)RP)H _).&'XP2_\'"/[?B_!
M&3PU'XX/@#2A =86X+>7]AT??]E,)&+O;N\DOE/,V;OES7[<66F6/AO1YEM+
M.&SM2TUU)'!$(]\DC-+*Y"XR[NSLQZLS$G))->#_  F_X)8_!/X'_M0ZM\:/
M#>A>*[7XF^(%,>JZY<^.M>OI-5C*JHBN(I[UXIHU"1A(Y$9$\N/:%V+CZ$FB
M6XA:-ONR*5(!QP?>@#\)/$<?QT_X(;?!>/QKX7U+0_VEO^">_C"]M]972-0_
MY#7A73M3N8YHGA8[<$R3Q;65GB>1V8PV[R;Q[G_P=Y:'9>'O^";OPQM]/L[6
MQ@D^,^F7+1V\2Q(TLUIJTLLA"@#<\CN[-U9G9CDDFON3P)_P2K^!/PUT+0]%
MT;P;?6OAGPW>Q:EIWAN3Q+JT_A^WNHG$L<_]F27+6;2+*!*':$MYH\S._P":
MM3]M+_@G!\'_ /@H9I>CZ?\ %[P]K/BK3-!N!>6-A'XIU;3+**X4,%G,%G<Q
M1O,JNZK(ZEU5V (!((!VO[0WQ0TO]G+X2^+/B%-H\FIW^EZ:H2UL;<OJ&MS*
MS+9V$>Q6DDDEN)_*B0!CYEQA5)8@_DM_P3[^+4O[ ?\ P7Q\3>!=4O/%\W@G
M]K30;?6[?4/$'AK5="\_Q;;1[KORTU&*%]DLGVP@(K ?:[2/=\N*_4CXM_L-
M?#_XY^!/"/AOQ/\ \)U?:;X'NXM0TAX?'NO6=XES$5:*>:ZAO$GN98V4,KW$
MDC*W(())KG_VLO\ @F+\%_VXOB!X3\5?$SP[X@UW7O D@G\.W-KXPUK21HLX
M=9!<6Z6=W"D<^](SYRJ)/W:?-\BX /A7_@\.T>TT3_@D=IL5E:V]G'+\2-/N
M'2"(1J\LD%^\CD #+.[,S'J2Q)R37O?_  <AZ)9P?\$7?V@=1CM+6/4+K1=+
MMI[I8E$TT46K6S1QL^-Q5&EE*J3@&1R,;CGWG]L;_@FW\'_V_P#P9HWAWXN>
M']<\7:!H+K+::<?%>KV-J954JLTL=M=1K/*JE@))0[@.V&&YLWOCM^P%\,?V
MF_V=;;X3^/+'Q9XE\!V^P26%SXTUI9M0"-N5;NZ6[%S=J&PP6XDD&Y4.,JI
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M#/XC:_#I.B^)'O-4N WE6?\ 9EW'<2E+LV4ZK&T08O;W"F.X4#=;'F81@@T
M?'/CC]F;]HS6W\0S>';[XM:+X?NM*\0)X=L+KQ]--J^G2W\&BZ;9O<R_;BDD
MD,L.KZJ%WN($>&&)D:26%?=O@C\//C!XA_;3\2>(O'=UXITOPSX=U&]M?#UK
M9ZB%T74],,$,5J9HUNV6:1B9IV+V<<R3%@)_)2.*3V3XA?'+_A'OB#'X-\/:
M7_PDWC*329=;?3A=K:Q6EHK^5')/*0PC\V;*1@J2_E3E01"^/&/%/_!3%? ?
MPO;6M6\"W,NK"UU[7%T_3-7BN;=]!T4+]MU<7,B1#R"[)'!E 9WFA*D1.TR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:MX@M].L;B2VTV/3+4PV$!M[=S!&6#7+1D"6<MF39&H$<<442>N444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP/+'#XCN)/,27P^\FTQB\@*^=;[E=&!E1058-]TYH ]?HKY]C_X*J_L]R_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO7O#FI>"?$EGXLT/4M+>%GM-0M=XB:2&>.2">/$C@I)&P!(9=KJK  ^&/\
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MEC<2,91<3DGY0B 'V/1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@
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M3_$GB;PGI.L:UIL<4,=Q/&?W\<,WVB".=00MQ'#/^^B28.L4O[Q K_-7?44
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MR/I^EM=> M2O-7T'2&=3]G@F_M5;?SFV+*\C6Q$DJIO5HXHHHP#Y<\=_M/\
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ML6BOC[PC_P %NO@W\2/B1\/] \+V?C;Q)9?%;7+_ ,/>$/$%KIL,.BZ_=6!
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M/<V9LW#13V=OY;+"TRA@T@83GA2 3X/^TY_P1-_:(^.GA7]N#1;&3X,V=O\
MM5>(/#^J:-<S^*=2WZ)#I-\LX%RBZ60SS1HO",0C,1N< ,?UXHH _.7X4?\
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M$)QNWK]/44 %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M231V\%U;/),9X[:)1YNT><21@9'X=_\ !-?XH?L]:1\;OV;OAGXB^-P\-R?
M3XC>)YO#>G:OX7UBR\3>(]0U*[>"WL]3G^S_ &"R9'!+E;J;SP\<;+;L'6OZ
M!]8U2/0M(NKZ9+B2&SA>>1;>W>XF95!8A(XPSR,0.%0%F.  20* /S6_8>_X
M*/\ [3W[8?B3]H"&WNO@3#!^S_\ $P^$;NV;PIJ5HVO:7;WC1WERMP^KNEK.
M+:.61%9)4WJJL<$L/M70O^"@/P'\4>#F\1:7\:_A+J7A^/4X=%;4[3Q=I\]F
MM_,I:&T,RRE//D525BSO8#@&OB?_ (("_"SQO\&_V@/VMYO&OP_\>>#+?XI?
M$N_\9^&I]:T.>UAO].FN)RI,F"D<H$L9,4A5\,< [6VZ_P"R-^P9XI_9]_X+
M!_&[2=&GLD_9R\5C2_B_;Z3&H*VOB6=KFU\I%W;5C::WN+ML(,-;V"J0(F#
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M16UWY89Q!+L:-G56*%E<*^S8WB?[17[#OQ,_:#7X^?$*30?#.D?$#XH?!_\
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M"GQ7\$]W-;QS0O/;A3+&K@O&&SMW#J,X.,]<4 34444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445\X_M9_MH^//V8_'>@S6_P@D\3?#>\\
M1:-X9U/7T\1I;:I;W&IW4=K'+9Z;Y#F\ACDG@5R9XI,L^V-UC+T ?1U%<!XG
M^*FK1_'*V\'Z#8Z?J3VWARZUW5#/,T7V5VE2'3H6<!M@N72^._:^!92?+G&>
M._8]_;,C_:0_91NOBAXFT2T\!PZ3J&NV.JV@U0ZE!8KI6H75G--Y_DQ%E/V5
MI/\ 5C ;'.,D ]PHKXU^.W_!1_XK?LW?!0_$;7?@'=:AX'\*Z=I^I>.+Y=?&
MGZEI27*1S7']GV#PR"_6SAF03,UQ &E25(PQ1MO:?M"?\%![KX9>._'VB^#/
M!*^/#\(_!T'C?QFW]LC3YK.TN/M+V]K:1^3)]HO9(;*YE\J0P(%$(,H,HV@'
MTM17R'^TO_P4Z\0_!'X<M\5?#OPEF\<? 32[32]3U?Q?%XA%C?OI]['%,U]I
MVG-;M]L@@AGB9R\]NQ;S$56\MB.J_;9_;<\;?LCV\/B/3_A%-XR^'6G7FEV>
MO:O'X@6SU.)K^\AM4&GZ?Y$AOFC:>,NK2P$EU2/S&#A #Z2HJ.\>6.TE:"-)
MIE0F-'?8KMC@%L' )[X./0U\Y_!W_@HGI_B+]C[XF_%[Q_H,?@?3?A-K'B;2
M]=M;/4_[6&W1+JXMYI(9#% 9#+]G8HFP$EE7))H ^D**^>_@/^V]J7C3XS:?
MX!^(/@VW^'_B3Q!X*3Q]HR1:S_:=O<:>LR0W4$\I@A$-W:O/;>9&OF1E;A62
M5PK[3X]_MO:IX'^,VL> ? '@NW^('B/PKX,;QWKT4FM?V;';V+2R16MM XAF
M$MY<M!<F.-_*C @R\J!UR ?0E%?+[?\ !2*/XM:]X)T;X+>%K?XB:UXT^'B?
M%&.'4M8.APVVC3,D=FK2>1.1=7,K.B1,JJOV><O(FP!O2_AQ^VA\/?B;^R9I
MOQJLM:2U\":CX4/C-KBZVI-9Z<L!GE>6-2=K1*&5P"0K*1DT >JT5\M_!?\
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MA[S4[\V4K1RS75N;:);1C^[Q$LDQ!+@L-H+ 'TI1110 4444 %%%% !1110
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MAGQ=X(UBRU>^\/WVM37+VL8A:[T2[AB5=-MXE*[D62XGN&GWJ((XI57]^Z*
M/R=_:P^'7B?_ (?X^&?B)H'@?7Y(?&_[/T^B^$]?D\(7-Q:P>*/MD\UJ;LF
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M5I]">0Z9%J7F^=8-JJ1M#Y4=]=1YMUGR_D^:J%5WC]&** /R]\7_ +.6O_\
M!2:]^ FBV.F:YX,D^&/P6\6>'O%\FIZ7/:1Z#KFLZ-::-%IH9U7SI(F6^E?R
M@Z!((7W;9H2_4?LW^!/$7QV^(_[#FG-X<UO0;S]FWPI?3^/X[[3YK:/1M471
M(]%CTU964),[S2W,JF)F1H;829VRPE_T:HH ^:?VSOB!/\1/C7\.?@MH.K6^
MBZWK%]'XLO[W4/#]WJ6FK;Z;(MS;VKM&\,?FS7<<+A#.A,5K/P<J#X)^R?\
M%7_A@O\ ;!_:*^$OCK6&U#P[XJN6^*6C:SI7AG5(M*LK^_CD.KZ6,FX2.02P
M)>)"DSE_MTA W94?HC10!^77[+'P?\16.J^!K?0=-UF\^$?[27PMT+_A8$\T
M4\$?AC4_#UM:66HQW$4BJT/]HZ=ML&4*)/,L]W &Y?9_^"(?BFUUKPA^T+#'
M#J5K->?'#Q=X@MTO=.N+)KG3[_4'FL[J,3(F^&:,%E=<C@C@@@?;U% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
MGC/7KKPOX6OM0L=%U/Q'=VD1DBTS3GMX[J];^Y&UQ+%"&/\ TTD1?>M.B@#X
MI^!?_!<;P/\ M-?LV^(/B_\ #_X4_&SQ9\.?"LUQ;ZKJUCINE^9:R6\:2S 6
M;:@+N39'(C$Q0N""<9P<=MXV_P""MGPO\'>'/CIJ4>G^.-8C_9WCL)_&,=GH
MI1H8+N#[0LUNT[QI<(D6YWV,6"KE0P9"WYG_ /!J1\"/&/Q(_8\\&^*]'\?7
MUOX.\&_%S6[GQ!X0:UM#9ZHLF@K;Q3^<(_M&^.2YC;RFD,3 ;MH95-;/Q"^*
MOB36/"/_  5^\%ZKXV\5>(/"O@71;2/P[IFLZ]<:E!H2W5CJ,DT5L)Y'\E&D
M"KL3  C10 %  !^F7P@_X*;_  Q^-WQ;^&/@G1?^$I77?BW\/T^).@B?1)EM
MAI3E OG3J&CBF^;E"V%PH+ R1"3Z%K\5?^"<WQ4\4:9_P4?_ &,_AY;^-_&5
MOX#\7?LF:1J^H>&X_$=XNESWPMYX!<QVPE\N*7RK=/FB"D&,L,,68_/7[)W[
M8'QL\._!CX!^/I/C]\6]<O-0_:O_ .%:W&GZOXE;4-/NM"F2V\V&=90TEP2#
M\K2R,(MY:,(S%B ?T7UPO[2OQWM?V8O@9XF^(&I:'K^OZ/X1L)M5U.WT9;=[
MN*SA1I)YU2::)7$<:LY16,C!<(KL0I_)7]KV/]JWX^_&?]H_PGX=\1?%C_A9
MFG_$C0M+^&3>"]:U2Q\&Z/X?;]_/%J=S82);07/V26*6YCO'6Z_>VYA'ER1[
MOTL_X*)Z9#X9_P""8_QTLXY+AK;3_A?K\*R75U)<2E$TJX4&265FDD; R7=F
M9CDDDDF@#R_X&_\ !<OX*?&F[^%/VBW\:^"=-^.<D]O\/]5\1Z7''8>*+B&?
M[/);QRV\TP@F$ORA+D0EB5V[MZ;OLBOQK_X(F_\ !,:P_;A_X)[_ +'7Q"^(
MWC)]0\*?!>?4M<\+>$])TP6:-J(U>9A-J%TTTK7.R2!2J1);J. P8;MWG?A'
M_@J5XHO_ -N+]G74O#?Q]O/'&A^,/B_K?@[Q)JDVHG3M*\0Z<\EOY$46AM/-
M#;0VZS+%#>%;>:9]QV. LTH!^[%&:_%G]I.#]JC]HCXT_'+PMX?\2?%QOB=I
MOQHT[3/!,GA+7-4T_P $Z3X1"&9XM1N;"2.TAG%M)&]S'.XOMSP>6NV1=UY_
MVNOCI\8_^"A7QX\&Z'\3/"?P[\5?!3QWH>G^$_#_ (P\?WVEVM[X=BP)$_LM
M+.X;6'U*-P6GED:XC>XMO*9,J' /UBG_ &A/#(^/$/PUM;BZU+Q<NG#5[^UL
M[9YH]%LV+K%->2@>7!YSQND2,WF2E)"B,D4KHWXV_M#^%_V=;70[[QA=7&CZ
M+KFIP:,NKO;L]A8W4[K';I=2KD6ZRR,L:RR;8O,9$+JTD:O^;/[%GBOQAK/P
MZ_X*9>)X?&6C_#OXFR_%?7M%TWQ9KY\NUT*WM;.*VTF2XE*N4MX8F3$A5EC4
ME]I (/*?#/XZ>+/CC_P2\_;D^'/QHT7QMX?^(GPE^&\FG>(M'US6G\0Z3%/_
M &/>W4&HZ?>S/),PN2$N#'+)*8]L)25D*I$ ?L317YS_ +('Q8D\>VO[!>J>
M/?VB?$G@WX@>(/APUV_PZ9U\GXD.^FPDW5UN!/F(!YH,F2[;O*V,)"WZ,4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BGQO\
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M"_[47BGXD:'<6]G:_$JRM[;QUX>NK%;RQ\13VB%+*]3<P^SW,:'RW8!TFC5
MR!XTD7/^/?[ '@_XT?!Q_AEI]KI?@7X9^(-4_M#QCH?AO2HM.?Q7%E&>U>:$
MIY,<S1QK.ZJ998E,8>,,6KWBB@#GY_A/X5NO$GA_6)?#/A^36/"<$MMHE\VG
M0M<Z-%*BQRQVTFW="KHJJRH0&50#D 5T%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ[6\E)X2YSA?-3."PKI/A-^UU\+_ ([-K7_"&^/O"?B1?#L*W.HO8:E',EK
MQD5;@L#@P,89@)03&QBD 8E6P >C45\#W'_!5O4/&O\ P5Q^"'PI^'?BOX=>
M-O@_\6/#FKZK<7=E:23:A:36-O.ZM#=+<>4\,KHA#& @JK[6;(*N_P""_'_!
M0SXK?\$SO@-\/O'?PUF\%W"^)_&EGX.O;#Q!HL]Z!]IM[J<7,<D5U"5*?9=N
MPA@WF9W+C! /O:BOG/X(?%CXB:C\7?$&H:KXZ\!^-OA'X<L-6L-5O]+\.RZ=
M?Z/KEC/:AH2XO9UGB,3W@8)$K1R6VTL20*V?A/\ \%-/V>_CKXQ\.^'?!_QF
M^'/B/7_%D<TFCZ;8ZY!+=ZB(2XD\N(-N)'ER'&,D(Q&0": /<Z*^"9?^"V?A
MGXT? O\ :/USX<ZMX5\*ZA\']6D\-Z+J_CZ"^L=&N[U([=6GO,1J]O%]JG:!
M48AR8PS; ^!V'AS_ (*Z>%;']I;X/_!C6[C3=2\:^-?A_%XXUW5]"M[R;0XH
MY(81";!S&6N(;B9Y623.$C@PYWL  #[&HKPOP3_P4P^ OQ)^'\GBOP]\4O"V
MN>&X=:M?#CZE83-<6ZZE<X$%H752/.D+* O4ET'5E!\]_P""W/[87Q"_X)_?
M\$[_ !E\9OAS-X7;6/ \U@TNGZ[I<M];:C'=:A;66W,4\+1,GVCS-V6SLVX&
M<@ ^MJ*^6O@W_P %'_ _P\^ 7PKN_CM\5OAUX9\>?$3PA!XO$<X_L.TE@DMO
MM,ODI/-)\L*[E),I)V@D#<!7"_\ !1;_ (+&^%_V<_V5OAGX\^%NM^%?&T/Q
M?\9V'A31=<A\S5-*LH9+@QWEXRV[*9F@5'00"2-C(1UV.I /M^BOF_X1?MJ1
M_![X=^&=#_:4\=_"'PM\7-0B>ZN[31=1D@L'LY+U[:RN]ER?,MXYLPIF5MIF
M9D5B?E'5?%7_ (*)? SX%^/?$'A?QI\5?!/A3Q!X4TZ/5M6L=6U)+.6SM)&B
M2.8B3&59YX5!7.6<*.<B@#V:BOGSQ!_P5?\ V:?"5_K%KJWQR^&>DW'A^]@T
M[4([[78+9K:><.T*G>PR'6-W##*E%W9VX-=_\.OVM_A?\7OBCXH\$^%?B!X/
M\0^+O!8#:[I&GZK#<7>E G!,J*Q*X8A6_NL=IP>* /1**\K\$_MO?"7XE^(=
M5TCPYX_\.:_J^CZ2=>GL-.N/M5U+IP)'VR") 7N("P*B2$.K' !)(!^/M%_X
M+@6O[3GP)\ ^-/A/KWPP\(Q>*_BJGA<1_$62]LUU;0DN)H)&LWC15.I3[(Y(
MH26"([!@66@#]%:*\V^(O[8GPK^$?Q&M_"/B?X@>%-!\27*V[#3[W48XI8A<
M2F&V,N3B(32@QQ&0KYC@JFYN*XSQO_P5-_9Q^&7BG7]#\2_&OX<^'=8\+:E'
MI&K66J:U#9SV%U)OV1NDA4@D1N<]-J[LXP: /?**X_Q-^T'X&\%_%7POX%U;
MQ=X?T_QEXVBN)M T:XO8X[W6$MT\R9H(B=SA$RQP.@)[''84 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !67XW\32>#?"6H:I'I>J:Y)8PF5;#38TDN[LC^"-795+'MN91ZD5J4
M4 ?@)\)_^";7[17AO_@VP^*'[-MY\%?&4'Q6UWQM::E86'VG3FMKJU-W97+2
MB<76P*BV4BL&PV]XP%(;</H'0_\ @G]\7OBA^U=^V8FE_#_7/AQX9^./P7TK
MPAX/U:_:TMK*WO;;1K>T:UE2WFDDA4,6CRL94+')@\*&_7JC% 'XQ_ ?]C;]
MHG7/CU^PMJFI_ /Q-X'A^ /@/5/A]XIUQ]=T22>"673ET^"_A6.[+R6T;/YX
M&1+_ ,? 2,E4,W??\$>?V!/B)^S/X7^&5E\8/AA\1X?&/[,,7B:WT+5[#Q+I
MDWAK6+34FE,BZ?;0,MU<37&8B8[U41&A$OF(Y$(_5ZB@#\:O@Y^Q/\;OA]\>
M/VGO"OA'X1^(O!OPI_:\\(:K<Z9=SM:Q'X5>)+Z.Y@,5P([IF%O*/+EF>S61
M48VT<89("]:?[/'_  2W^*7Q8_8!\6>&O$G@+QY\._CIIWP.N?@S;:MKWBC3
M)M!U"U657@M;&*P9F-O)Y1\R:Z1'B%SL0W(W,G[!44 ?C]^R5^RA\?%_;C_8
M=\::]^SYXF\)Z'\!OA<_PX\6:C=ZWHDDOVA-/-DEQ$D5XSR6@=PZ\^;AI\1?
M*IF]7_X.;/V7/B9^VK^RW\,_ OPO^'/B#Q[JFD_$"Q\5ZB+1K2.UALK:TO8)
M$9KB:,-(S7,>U "" V2,<_I510!\H_LZ:S=?!3X@/X/^&_P \;^"?AK,-5\7
MZU=WEIIUE:K>R*A33M.M8K@OYLLQ>1BR)$NT@.=_R?EO^Q/_ ,$TOCY\$/A=
M^P[I.J_ SQ9I^J?"#XM:SXD\:S0RZ85MK.YDLQ%=%ENLS?N@ 0H9PMJXQ\L8
M;]]J* /QUO?V'?CQX$_8L_X*%_"__A4OB+5M4^,WQ USQ+X.OM/U+3I+77+?
M5+BW$ C#7"NC(BR23&98PBJH7S&8J.V_9K_9&^-/PP_X*._LK_%:X^%>O3>&
M=&_9VTWX5>(0=1T^&?PSJMM<NTSW2-/EH AW*UOYS/P M?JI01D4 ?G;^R;^
MPSK7PD_X+%?&C6/#6L:=-^S[XZM-*^*8TJTE\R$>*)GO+,E?F*E&>&[NW*C_
M %JV>"/)P>X_X.%O@CXZ_:E_X)7?$'X6_#;P;K?C3QCXXFTN*QMK!K>.. 6V
MJ6=Y(\TDTL:HOEV[@8))8J,<Y'TI^RW^R7\/?V+?A1:^!_AGX>7PSX7L9)9+
M>R^VW%YY/F2O*RK)<222!-\CD)NVKN(4 <5Z-0!^3GC_ /9D^*7CS]HS_@F[
MXDE^"_C:XT3X :#=VOC5+J/3F;1KN2QL[. A#<D2,EQ:&;?%NVIY;J2WRCYX
M^'O[ 7[0O@__ ()6?!?X;W'P.\?-XP\$_M!Q_$'4M/AGTL^5H\$C3F57^V!&
M=O/V)'NW%XY,[5"LW[U44 ?D7^W9_P $[/C7XN^-O[:5QX=\%ZEXVT_]K+PC
MX8TWPG>1WEK%!X<N+,);W-MJ GF1X!&,W :-)$900#YOR'J/A?\ \$\_&FE?
M\%A? =Y\0?AYJ'Q$^&'AW]G:S^$NK>*M3M[.\TS5M450US(\,TQF:&:%IHF=
MHCEYF0@J6>OU,HH _$+]L/\ X)X_&+X@?$'_ (**'P[\#O$EW:_&K2_"NB_#
MR>)=,CBNX]+EMH;A$S<@V\/[I)4#!0T<"G 940^C_L^?LB?%KPO_ ,%![?QE
M-\!]<;PE'^RG;?#$6>J3V%I87NNQPV]RVG3&*X=HX'\MK9I@A429 RF'/Z[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO!^@:G8:9<:3I>H?;Y3#%/=6WGS2*D)1Y65)BSC$>\'][0!^N5%?#.D_'/\
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MRTRPT7Q?X?T:>&UTOQC96);[-!>H8FDVK&[0L8)(FE@Q#(9(E5![]10!X/\
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MCMR[G&2QY))-7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]BO0?#^O76B^ /C1X1TZ=/#WB/0+R74+?2+F2V>TFB\V2"&2:RO+9C'<0/$
M5DQ\S11R5I>,_P!B;Q=\.?VM+?XY?"/5O#=OXEUKPU:^%O&WA?7?.ATKQ9!:
MG=9W27<*/+:WEOOEC$AAG22)]AC0@/7U'10!YKJ-K\5W^'>LZG9GP/'XYN+9
M$TK1I[JZDT&Q<,"WG72Q+/.S#/[P0Q@811&/F=_24W;%W8W8YQTS2T4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%'[8W[;W_")^(KOQ]H_PL^&'AW6/"UIJ5E:77V6:]ETV)KMYX84EGB@%[<7
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M,.@L/V</ NG6_P 0(8_"^DM;_%2Z>\\6V\L7G0:[(]E#8OYT;Y4J]M;Q1L@
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M'3X[,K;6=[(D2/=1Q@[5F*P1#S  V$'-?1U% 'GOQ<_9+^&/Q^\1^%=8\<>
M?"GB_5/ \YN=!NM8TV*]ETJ0[,M$T@)4DHA^J*>H!'(2_P#!,[]GJ?X-+\.W
M^"WPU;P*NKG7QH1T"W^PC4"-IN?+V[?,V_)NZ[/D^[Q7N-% 'D.A?L"_!CPS
M\7M>\?6/PU\)P>,/%%C+I>L:H+(--JEG(B1O:S9R)("D<:^4P*!8U  "C%GX
M>_L/?"+X3>$_$6A^&?A[X9T/3?%VFC1]7CL[01-?V*Q-"EJSCY_(2-V1(P0L
M88A0N:]5HH ^?]#_ ."5?[.OAD>$QI_PA\&V2^ [Y]3\-K#:%%T*Z>2.5YK4
M XA=I(HV8I@L44G.*[7]I']CKX7_ +86C:?IOQ0\$Z'XYTW2Y3<6MEJT1N+:
M*4C'F>43L+@9 8@D L 1DY]+HH \W^#W['_PP^ /B>ZUSP?X'\/Z)KU]:1Z?
M/JL5L)-0EM8\>7;FX?=+Y*8&V/=L&!@#%<CJ7_!+[]G/6;K4I[SX'_"ZZFUC
M75\37TDWARU=KO4E+D7+DIEG!EEZ\?O'X^8Y]VHH \YUC]D'X5^(OC=-\2M0
M^'?@R^\?7.F/H\VOW&D02:A-9NAC>%I64LRM&3&0>J$I]TD5D_"?]@7X)? G
MP%XJ\+^#?A1X!\,^'?'$;P^(-.T_1((+?68V1D,=PBKB2/:[J$;*@.P &XY]
M<HH P?A?\+O#GP4^'VD^$_".AZ7X;\-:#;K:Z?IFG6ZV]K9Q#HJ(H  R2?<D
MD\DUS_QI_9=\ _M$ZIX>O?&GANS\077A.Z-]H\L\DBMIMP1CSXMC#;*!D!Q\
MP#, 0&(/?44 8_B7X?:)XQUK0=2U32[&_P!0\+WC:AI%Q-$&ETZX:"6W:6)N
MJL89YHR1U61AT-<EHW[(_P ,?#OQ5O/&]AX&\-V?BK4+U]3N-1ALU222\>+R
M7N\#Y1<M$3&9@/,*DJ6()%>BT4 > W/_  2T_9\O/"=WH,OPK\,R:-?:V?$M
MS9LDAAN-4*[3?LN_#7./^6Q^?@'.0*ZZW_8G^$-K^T.?BW'\-?!:_$YH_*;Q
M3_9,)U5AY8BW&?;O+^4!'O)W;/ESCBO4** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2?&R[^*=]X8^T7S:3XBT^ZM#;_V3?GRE+_9Y4MKI'*2132P*'@55!J3X>_\
M!-/XN?"B/X.6%CKGPRU73OAA\6O$/Q&NI&BO=/:_@U-M246\42K,L+)%JUP<
M%W :WA&6#,5 .V_X+RWNJ^%_^"4OQ?\ %'A_Q)XP\)>)/"&D?VMI6J>'/$%[
MHMW;7"2(H)DM98S(A5F!C?<ASG&0"//_ -C[XNW?C3_@IY<Z3\%?&/CCQ]\!
M]+\%3VWCN[UC7-0\0Z)I'B=+B)K:WL;^^DEF^V_9Y&,]O'*8DC:)F59#D^^?
M\%2?V7O%W[:_[#WCCX2^#;OPWI=_X]M!I=QJ.M33+#I\!=7>1(XHV,LGR!0I
M* ;MQ8[=K<A<_LA_%;P+^TGHOQF^']_X!T/Q1XLTV#2OBOX5N[F[ET3Q4;90
MMIJ%M=+")8;Z% 8O,DA</"ZHP/E(Q $\%?\ !:7X)>.OC7X9\'VFK2?9_&G]
MIKH6O+?Z=<:??O81R33*T<-T]Y;[HHI9(VN+>-)!'A6W,BOM?"?_ (*A^&_C
M!XX\!:%I_P /_B5:R?%3PS-XR\&W5U!IJVWB'28TBD-S&RWK&(E;BU/E3K'*
M!=1[D7$GE\#\#/V;OBC_ ,$Y_@=K6B:S\1O#>N?L^_!_1M0U+0;:P\)7$WB^
MXTV"*>>'3;IQ<&&>.V7"+Y,2RW(AC#%-T@?Q'_@F'\%/B)\"?%/PJURTD_9S
M^*%AJGAQ]"M[WPWXEUJXU#1;22U-VTEJDUQ=6%E9/=0VZS0V,$$*AXA&I$<4
M) /H#]E__@HQ\+/^&?\ X61_#KP/\1%3XCIXDU'0?"EU-:?VVJ:7J3Q:FS&Z
MOBLCBXFW+!%/+*4?*H$C<1Z3_P#!2:Z\+?M2?$;2O%WA+4_"_P *? /PVT;Q
MY=>(KN6T633X;L:I)++=P>?YZ@?8/(2***23S4<L CQL?*?AM_P2=\?6?[!_
MACX->/8?@QX\M-!GU^>6&\MKQ(UO=1U"2]M=5LKM5%S8W-F;FYC"1'=*K*1/
M W([;Q?_ ,$J]>^(-CXL\-^)/B WB3P[\1?@MHWPK\2:W=PR+X@EO-,&H[-5
M0[VC>2>343*XD)VM!CY_,)0 O77_  6W^%=GIWQ/_P")+XJO=:^%7@\^/]1T
M72[[1-5O-0T)'>.XO+9[74)+<_9WC(EBEFCE7*$(RNC-TGQ/_P""K/@WX/6U
MK'XA\*>*]'UK5-/FUO2M&U'4] TZ\U;3(H[9C>Q&YU*.)%:2Y6%8II([AI(I
ML1;(V>N9\=_LF_M*?&K]C#XI_#[X@?$;X7^(/$GC3PC?^"-.N=+T.ZT;3VAO
M8?L\^K7R^9.TEYY9)6&%8H4;>,D2#R[GQ&_8T^,P^(/PU^*7P]\5?#GPS\3O
M#_A#_A"/%6EZWI]WK/AW7K#S8YHWB:-[:>*6"99)$P!N$Y1CA0Q .6_:=_X*
M.^ _VH_V)_'</PUTWXB>.H=6^%;^-;J]\)W":=/X9L[J"Y-FUQ,;NWE2X:2U
MG)M[=I)@MO(&3:Z"3Z!_X)TZA<:O_P $^?@3=7EQ->7=U\//#\L\\LADDG=M
M-MRSLQY8DDDD\DFO%_$O_!.[XD>'_B-\5M<\,^.O#.N?\+Z\"V_AKQHVOV$U
MO)!J]M:W-M#JUF(69?):*YV-8ML"B)&6?JI]H_9R^#OCS]F_]A;P?X!BU+PC
MXD\>>!_"MMH-E>O;7&G:1=2VT @MWD0--*JA$CW[3EV5BHC#!4 /!_CY^UYX
MU^%__!0_X;^(AJ0A_9_N==F^#VM0.CX/B&^ABNK74P5RK0I=0PZ:&;'ERSW(
M[BOH#X\_M?Z;\$_B3H_@NS\+>+?'?C+6=%U#Q)'HWAY+/[1#IMD]O%/<NUW<
M6\>/-NK>-45S([2<*55V7YK^+_\ P1WTSXR?\$[=8\%:CX+^$,?Q_P#$&G9O
M_'\-HT-P^N-<"XEUQ;Q+=;M9FN-UT(00H8^3O\L;J\]_;-\)_$WXR?'CX-^!
M]>\7_!/1?B]X2\":G?ZU<ZC?ZWH-EK2WMS;VOFZ=>Z?<V=Z<BSF-Q9"1X8_/
MMVD#L+9U /H*X_X+&?"F3X0>"?%UC#JUY_PL31+GQ)H.DW&H:1I-]>Z; \4;
M7.;Z^@@7<\T:I&THE8EOD CD*9_A'_@M!\/OBA::E=>"O!7Q*\:65C\.;7XI
M176F6^FI#?Z/-)<0MY1GO8RMS%-:W,3PRB-M\+;=P^:N"^%_[(OQDU'1?A=\
M2?AK=?!SX:^.O .@WWPWO=$73+W5/!/B7P_'>(UI/9J)8KFW\LPB6/YFW>8R
MEW3;(W1^,_V$/C1??M#_ !"\9P^(O 7B+_A,O@]'\-!<ZI-=V=P]Z+F\NSJ+
MQ10ND<'FZA<(MJKL5CBA FSNP =7\//^"C&H?&7]NOP+X$\*^#]2U+X;^,OA
M5#\1K7Q$LUJDEQ%>7-LEM*T,DR2Q0QQLX8!7D=YUPBK&6;ZOKXW_ &0O^"?7
MC_\ 9V^)GP3\3:EKW@^ZF\ _""#X2Z_;VR7+K/%9W,$MM?6K,%):5(2LD<@4
M1M("K2A<-]D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:?Q/IVD^%?#OB^[U*&*UO)[N%(TU03R-Y;JD EO?O'>L+!=Q(! /HZBOC_\
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M\B=YENKVX^R6JR2J(HML)"01^8^[Z9HH ^7?#7_!+WX??!O]LK4OC9X)\/\
M@/PG=P^!?^$9TS2]+\%6T?\ 9EZMQ<S-J4;PE&:1XY_(:-%5G1,>9AMH]C_9
MM'CC5/@)H:?%%=*N?&$L,T>IFTLA:0W2>;(L+O;^;,L,CP>4TD2RRHDC.BNZ
M@,>_HH ^9_V:OV%/%W[&WAMO ?PW^)]I8_!^UNII=$\/ZSX:.IZKX6@FD:5[
M2RU'[5&&@221S$+NWN7C!"%W154>>_M4_P#!('4/VB=0^,WV'XJ/I%E\8-!\
M/Z.[:KX>.LZAH3:/,LL0M[EKJ,FUF=1)-;LFYI7ED656<X^VJ* /G'X8_L9>
M./ W[8WQD^*5[\2-!O+#XL:%INC1Z39>$Y;.ZT1M/2X6VG2[:_D$I_TN<NIA
M7<?*VE A#^:>.O\ @C-IGQRO/B'J'C[QO]IU[Q]X7T_PY<ZOX5T)/#=U=7%C
M?0ZA::S?!)I([S4H;JWA9) D4:H)(_*V/@?;-% 'QW\=O^"8_B[]I'P)\0)_
M%GQ2T"X^)7C;X<7/PKA\0VW@V6#3M)T>\D\R_D73_P"T"TEW<,(R9#<"-#;P
M[(E D$O2?"C]AOXA^#?VWO#_ ,8=>^)_A/6[?2_AU#\/;W1;+P1/I[7J),+D
MW:7#:E-Y3FY&=AB=1$=G+?O:^H** /"?VD?V*?\ A;/QP\(_%KP9XH?P!\6/
M!=E/H]MK1TY=2LM5TJ=UDFTZ^M3)&9K<R(LBE)8I(Y%#*X!96S_VG?V0_'W[
M47[)'Q"^'NJ_$S1-/\1?$+P_<>&9M5MO"DO]E:;9W*^7<M#IYOO,:=XR0));
MIPC!2J@;T?Z&HH ^9;7X(7'[*/Q6OOCQXV^)6BKI.F_#?3?#'C,1^&98(+E=
M+FOKB*^MR+F5[9<W\V^$K.2%3#K@[N8_X)]?L]6?PY\$_&;Q]X*N-:T[2/B-
MK6H:CX#35=(F;^Q-+D,MV/)L&\N7R)=6N]4O$C_=M)#<P+\H5"/L&B@#A_@.
M_CN[^!.A_P#"=R:3'X\:R*W\UM9>5;F;+".1K=9Y!&Q78SQ)/(JN71974!SY
MG\*_V';B^_9>\=?"CXT:OX3^*7ASQWJNM7]Y#I_AJ?08A%JE_<7\\)5KZZ?=
M'/<OY4J.CQA(SDR+YA^A** /(_V?_P!D72_A%^QQIGP9\1:G=?$'1;?1KC0]
M3O=8CW3Z];S^8)C<C)WO(LK"1L_.2QXS@6?V*OV6[+]B_P#9C\(_#:QUK4O$
MB^%["*SEU?4<?:M29%""1\$XPJJBC)VHB+DXR?4Z* /'/VE_V6]2^,?Q,^'7
MCSPMXIM_"?CCX9SW_P#9MQ?Z4=6TR\MKZ!8;JWN+59H';/EPNDD<T;HT0Y9&
M=&Y;PA^Q5XN^$GP;OO"W@/XF6GA'4O%WB+5O$_BS7X?"\=S>7%YJ-PUQ.^FQ
M23FWLBK.RIYT5V,!2XDDWR/]&44 >.Z3^QSHOPJ_8NU3X-?#&\F\!V<VA7^D
MZ;JVUM0NK"YNTEWZA(7=6N+@S2O.S.X+R$DGFJOQU_8BT'XG_";X=^'_  [<
M+X.U'X/:IIVL^![^*V-U'HL]E$;>.)X=Z>=;R6KRV\D>]2T<K%7214D7VRB@
M#YY\$?L?>-?@_H'B;5/!_P 0O#EK\2OB%XO7Q7XO\0:OX0:^L=546J6BV,%G
M'>P26\$4$%LD1-S(Z^4[,9'E=BWQQ\#_ !Y\#OA9XTUKX8ZMINI?%SQ]XFM_
M$&JWNHZ(9]/U>X6"VLUMC"MQ']CM5L[.V@\T22/&D32%;B9B)/HBB@#'^(G@
M#2/BO\/]=\+>(+-=1T'Q+I]QI6I6C.R+=6T\;12QEE(8;D9AE2",\$&OG?X;
M_L&>./#'P&\/?![7_BS9^)/A/X=LK?1?LH\*BT\0:OI-N D5A>WXNF@>-X52
M&9X;.&22,-AHV8O7U!10!\_>.?V6/B=<^)?B9-X3^+VF:-HGQ-N5GET[6/!R
MZP?#_P#Q+[>QD-BXNH5#.(/-(N4N(_,;_5[2ZO1^&7["FL?!SXG?""'0?&FD
M_P#"H?@SX1/AC1O"-_X>DNM0>;[/';+J+:B+M4^T+#&8A_HI CN;I>LH9/H^
MB@#YI\*?L.^,/ /_  4I\8?'30?B#X8TWPI\0-#TW1/$/@Y/!SF?4S8)*+:\
M?4?MP_TI/.DC#"WV>05C,;,JRCZ6HHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*AB\?Z++X"7Q0=3M(?#K:>-5.H3/Y,"6OE^;YS,V-J"/YB6Q@=<4 ;%%<O\
M!GXT^%/VA_AII?C+P/KVG^)O"NM+(]AJEC)YEO=JDC1,R-_$ Z,,C@XKJ* "
MBN-^#'[0_@?]HO3]<O/ GBK1?%EGX;U:;0M2N-,N1<0VE]$J/+;EU^4NJR(3
M@G&ZNRH **XWXB_M$_#_ .#_ (L\.Z#XM\=>#?"^N^+[E;/0M.U?6K:QN]:G
M9U18K6*5U>=R[HH6,,2748R147Q:_:8^&_P!U'1[/QW\0/!'@F[\0RF'2H->
MUVUTV34Y 0"D"S.IE8%E&$R?F'K0!V]%%% !117'>+?V@_!/@/XM>$_ >L>*
M-'T_QIXY^T'0=%EN!]MU06\+S3-''U*I'&[%C@?*1G/% '8T45S/Q1^-/@[X
M':)#J?C7Q9X9\'Z;<SBVAN];U2#3X)92"1&KS,JEB 3M!S@'TH Z:BLOP=XX
MT7XB:#%JGA_6-+US2YR1'>:?=1W5O(0<'#H2IP?0UJ4 %%%% !1110 4444
M%%%>>_#O]JWX<_%GXG:IX,\.^+M(U3Q1H]F-1GTZ.0K-):>:T!N8=P G@696
MB:6$NBR#8S!N* /0J*Q?'_Q&\/?"?PI=:]XJU[1O#6AV.W[1J.JWL=G:6^Y@
MJ[Y9&5%RQ &3R2!4/PZ^+7A7XP:.VH>$O$WA_P 4:>I"M<Z1J,-]""1D O$S
M#D<]: .@HHHH **** "BO.]+_:]^$VM^+KCP_9?%#X=WFO6MP+6;38/$EG)>
M0S%Q&(VB$F]7WD+M(SN('6O1* "BBB@ HHHH ***KZMJEOH>EW-]=2+#:V<3
M3S2$$B-%!9CQSP 30!8HK)\ >.])^*/@31?$V@7L>I:%XBL(-4TV[C5E6ZMI
MXUEBD 8 @,C*<$ \\@5B+^T%X)D^.O\ PK%?%&CR?$!=';7WT!+@-?1V"RQQ
M&Y=!RJ>9*B@MC);C/- '8T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U_\%9/#.GV/_!-/]J'
M6H;.&/5M0^$FOV5S=JO[V:"'3+YHHV;KM1KB<@= 97]37@__  4^\+6:_P#!
M%O1]>M[&Q;Q ]M\.;$7<@*O+$/$FB2)$[@%B@=B1UV[V(ZG/V5^U+^SGIG[6
MGP*\0_#O7=8\0Z/X>\66DFG:O_8T\4%Q?6<J-'-;&1XW*QR(Q5B@5\<!@"<\
M+\7O^">GAOXY?L?:/\$_$/B[X@7'A71WL"MY#?V\.J7*6$T<]FDDZP#/E2PP
M.&55=C A=GR^X \9^(O_  4I\>_ [XJ_&SP/K6C^'?%6M>#]<\#:/X2N-'T^
M2Q^U/XINWLH4N89[ME=K:6-Y"PGA692J$PG,M>T?L8_%GXU>//%/Q!T?XO>!
M+/PS:Z%=V<OA?68#9VK>(+*XA)D$MA#J-^]M+;SQR1EWFV3*49%7#JN!XK_X
M)2_#?XG>+OBKJWC;4O&/C>/XS:58:3XGL-5OX8[.9;!@]A- MO#$UO/;MO:.
M2)E(:5F.YMK+Z;^S+^RMH/[+7A>ZL-)U?QEXFO\ 4&1KW6_%GB"YUS5KU8]P
MBC>XN&9A'&K,$C7:@W.V-SNS 'S#\1O^"E/Q"^'G[7_ASPOY/@'6O"6M?%R'
MX;7=II-A?74^DV\^FR7$,]QJQE6T34//C#/IZ02/'!(A=U+*S>'^+_BU\=KS
MX(?M#:M_PMC3XY-+_:9T/PG R^&I!-'9/JOAVR%JC+>JJ6ODW"AHU4/)MF+2
M[IV=?LC5/^"6'PQU'Q*VH1W7C2QAC^(G_"U+.PMM>ECL]/\ $#[C<W,2<G;<
M&21GB<M&K2R-&L3.Q.EXH_X)M?#OQ1HWQ*TYI_%5G8?%#Q+9^,M0M[35WCCT
M[6K:6SGCO[08/ERF;3[24A]Z;HB @6217 /$?VC_ /@HQ\3OV=_C;;Z(TWPX
M\3:?I/C7PGX2UFRTK1-0FN1;ZL]K;S7UQ>?:?LVF3?:+DM#8.+F9HD1RQ242
MIWWA#]K3XK?M!^+_ !OK'PWA^'<7@OX9?$QO FM:;KT-Q'J-Y9V;6Z:K?I>)
M.L5N\1EE>*)H)1)' "74S!8][QI_P2R^''CBX\1M<:IX\M8?%/B32?&=];VV
MO.D+:[IWV40:F 0<S,ME;*ZL6A?RE;RQ( XO7O\ P3)^&,_[2&I?$ZU;QII6
MJZ[=6NI:UI%AXGO8-!U[4+58UMKZ\L!)Y,]Q&(8B&=2KM&K.KM\U 'RC^S-^
MTKXX_9@\._;=-7PK?^$_'/[6GBWP-J>GW-C.=1$>H>)-2C2ZANEG6.-HIE4F
M-H) Z C>C$%?6/@]^WS\;OC_ .,?"7BWP?\ "^#5O@]KGC?4/"^I//\ V?97
M.F:=;ZA=Z;_:J7DFK;I76YM49[/^SUD*SE$=FB!FZ:3_ ((^>"9/!>GZ%_PL
M'XN?8]-^(,GQ2@<:O:><OB%YC<-=EOLO*^>\DOD_ZDO*Y*$$ =G\/_\ @F=\
M,?A=^T#JOQ T,>+[%M8U:7Q'<>&4\2WO_"+_ -L2MNDU0:9YGV?[4Q^;<5*A
M\.%#A7 !\<?&;]I[QG^V_P##7]D?XOK)X3T_X9^,OV@-(DT+14TRX_MFVLXI
MM1@M;B>\-P8GDE6$R/"MNGE^<$#N8R\GVY^VM^TGK7P#L?AOHOA>STNX\6?%
MCQI:>#-)N=31I;#2FDMKJ\GNYXD>-YECMK*?;$DB&20Q+O0%G7B=0_X)$_"B
M[TBQT6WO/'VD^$='\9KX_P!'\.:9XFN;'3]!U?S)II);,Q%9X(I)KB60P)*(
M4=V,:1Y.?6_VGOV5O"/[7/@*PT'Q=;WW_$DU:V\0:-J.G7;V>HZ%J=L2;>]M
M9DYCFCW, >59796#*S*0#X.\"_M2>*_V2?VJ?VC+'5IO#.N?$+XH?'/P5\/]
M,OX=.GM-'@GO?"VFNMU+;FX>7;%9P2.8A/F695021K)N3U+Q_P#\%*/B)\ /
MBKXV^%/C#2_!^J^.H/$G@W1_"&OV%E<V6CW]OXENKBTAFO+5IY9(Y+62QO2R
M).1<!8@IAWL4]3U;_@E5\+?%5[\0[[7IO&VO:Q\3;[2=7U?4;GQ%<0SV^IZ9
M%;QV6HV@@,<=I=Q_9H6$L*(1MV#$?[NM?QE_P3<^&/Q4^%7C;POXUM=8\:2?
M$5[*;Q!K>I7[1ZO>RV14V,B3VXB%O]F90T2VZQHKF1]I:61G /,?BM^U'\?/
MV=OC/\+?#_BMOA/J6D>.OBM;>"A=:=I=Y#=:CI-UH]W?1W:PM>O]CGBN+"Y@
M(<SI,N' BV[6\YO/^"DOQQTJ/5+?_BU-[=:'^TM:?!>>5O#]_;QW.E74&GR1
MW*K]O<I=(UW(&8EHW 4A$P=WT5%_P31^'X^%VB^'Y]6\?:EK/A_Q+:>,;'Q=
MJGB.?4O$<6KVJ&*"Y:ZN?,#A8&>#R71H#%)(IC.]L\MXH_X([_#+7KO4+BS\
M1?%#0Y]4\?6WQ-NGLO$TD@EU^V14@NPEPLJ+LV E54+)A!()%CB5 #RKXT_\
M%%_C9\%/AG^TSKDS_"_5IOV;/%>FV<BIX?OK=?$VFW=EIEZT(7[>WV6XCCOG
M03;ID=D5O)0 JW5^-/V^/C9XU^)/CR7X1_#*W\6>%?A;XZ3PEJ]M=#3[:35(
M8([.34ITOKC5[?[')$MS(T:O9S)(+=<N//\ W/8_$K_@DEX'^+.@_&32]:\;
M?%&73OCQJ%IJ7BZ"+5K:(74ELD<<*PLMMN@010V\1$94LD$88GYBVW+_ ,$N
MOAK<_'=OB)+?>/#K>J+9/XEM(/$UU::3XUN;.)(K>[U2Q@9+>YF58TS^[5'Q
MAT9>* /#OBY_P48^,_P>\ ?'CQ==K\,=0TOX(_%S1O!GV&'1+Z*XUS2K\Z&6
MS*UZ5@NHTU@D2A)(V:''E*#D^._%']HCXQ:'^P]^V7J6I?$*&\O+SXS_ /"M
M]-O;739-/N] MKR[T;26DMY5N&6-8K2Y/EA$5UE4RF1G<FOK3XC_ /!(OP/\
M5?!WQ0\/ZQXZ^*TFD?&#Q-:>+O$D$6KVT?FW]J83 T+BVWP*OV6R&V,CBR@'
M0/OVO''_  2^\!^-?@K\9O!+ZIXH6R^-DDFI:M))>*ZV6KO# IU6WB551+@S
M6MM<%<&(2Q?*B*[JP!Q/[9'[8&K_ +!'C#PYX4TVQ\)_#7X3VOANSM-#\3:W
MX>N[KPPFH"=[6/2+J[M9T31XTA6U,<UQ&T,OG,H=#"0^QXPUQO@__P %E_ M
MGIHFCL/C5\-]9&N6L("PRWNB7>GM9WK@#F46^H7,!<_,R"!22(D Z;5_V,/^
M&G/!%T?BY)K&GZYXDT*/PEXUT[P]KLL>A^+M/@DN"%\HC=#%/]HE8F/RKA5E
M,)F=%RV[\/OV>]6US]L;7/C)XL6&QN-/T%_!/A#2+>X\Y;'3&NDN;N\G( 7[
M1=S0VO[M=PBBLX?F+R2*H!RG[7W[1OQ&_9__ &I_@[IMKJ7@73/A3\3)=3\-
MW^I:IHL]Q>Z'KB:==7FG.TRWL41M9C;R*R&(.'A1 X^T;X?)_P!C[_@HO\3O
MCK\'-'UCQ/+X+TOQ)X,U3Q-+\3]/M?"EY#]@T_2BC0PVJ2:@SPW5Q#<V,\;3
M&1'BGD(52BA_KC]H3]G7P?\ M3_#=O"/CK1X==\/MJ-AJC6LK%5:>RNXKN D
MC!P)84W+T92RG*L06^"?V;O!OP]^*OC_ ,::7HT,'B+XGR6<GB2Y9BXU$VEL
M+6#*$[1MA 4X'S=\X& #XBU__@I!^TX/V9IOBYIOPS\+V_@G6OA=J7CS3[_5
M;:U6WT"[@TP:I9VTGDZV]QJ<%S"LT)>*WM9(71)60HS1Q^@:K^W)\7M"T3X)
MZ1]A\+>(O''QZTI_$&EV^AZ 5A\/V5KI5K<WJ.MYJT O9#<W,8C(FM\1,Q*.
MT9W]-H'_  1G^$7@_P"&'B_P7H^H_$C3O"?BK2[O0[72#XLNKRP\*V%YN%Y;
MZ5;W!DBLQ.CO&SJAD5)'6-XPQKK_ (B_\$VO /Q7_9Y\ _#W7-3\;2GX6M!)
MX3\3V6M/IGB30I(86MXWAO+41'=]G8Q-N4B1<%P[_/0!U'[''Q$^)WQ.^ <-
MU\6/">G^!?B-9W5U8W]E:SP7%K($D/V>Z1(;JX\I9H##*8'G9XRY4NP =OSW
M^'_[1?Q<_9 _X)M?M<_&+2=4^''B;Q'\/?C!XRU"UM]8\,WGD230ZQ):W#;D
MU#>J-"=L2 @Q*-C/*#D?IM\(?@SH_P #OAO;>&- DU3[+;B1WO+^_EU'4+N>
M1B\ES/<7!>2:9W8L7D+9/'0 #YYN?^"/O@/4_P!FOXF?":_\;?%+4/!OQ<UR
M;Q%XDAFU2T%Q<WMQ<&YO'CE6U5XEN9MCR1H0GR814#RAP#RG]J7]IY/V-_\
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MC>-%UGQ5X8\9>'=.N=*T[6-$U(P/!:W$D,D\3P2*]M<*[00G$\,FTQ@KM/-
M'R=\&?V]]-\/? O0=%^$_P +M;\+_$'QA\6-:\&:_P"#[^WLYG\'^(8[.]UO
M55"K=6UM=QLD#R1/'=1K*+N.7<3NB/4?![]L?]H'QW\3-!^$/C#PEX-^&?Q,
MU4^)-8CUG4[=-0L-1T+3)M.AM;F+3;/4I&AN;EM4AW027Q,2VEPV6#Q@>F>+
M/^"6WP?\:?L^7'P[OM*UK[+<^)#XU?78-9N8/$(\0E_,.LK?HPF2\W' =2%5
M,1*JQ 1C.\=_\$G?A;\0? _A'3[S4/B-;^)? ^H3ZKI7C>V\87\?BZ.ZN(EA
MN9'U/S#-()H42)T8F/RXXU556- H!P&M_M6_M':9\?/V?_AEJ4/P8\,^*/BM
MX2\477B!X["_URUT75M'^RA)+=EN[<S6\OVN,M ^R2/:P\YB!FO\#?V]OCI^
MT'K?@OQ=X7^&MEJOPG\0>+;[PWJ=Q)%8V,FFV4%Y=Z>-62ZDU@O*1=6T;/9?
M81(4N"B2,T0:;V:7_@GCX,@^-7PM\<:;K/C+2+[X/V-[IWA^S@U%)[5HKXJ;
M\W)N(Y)KF2Z\N,RRRRM(6C#AED+.T'PY_P""9_PQ^$_Q^U7Q]H/_  E]BVKZ
MM-XBF\,CQ+>GPNFKS-NEU-=,\S[.+EB2V[:5#'>JJX#  ^;/V9_VG/B]\-?V
M6H=6USXA>!];O_$WQC\4^%UU#5_#E]<:C'';:WK4.RTT^UNFEU&:0VMND5M#
MY(MH!(S-*D):M?X8_P#!2'XR?%GX.?LXZ]:V'P[T74OBE\2-;^&WB>WOM'O)
M/LLU@FM;;RU1+S]UDZ02T$CR\S;!,,>97NL?_!,GX>V&KZ7J&FZCXTTF^\.^
M,]0\=:%/:ZP=VA7^H_:CJ"6X=67R+DWMV9(Y _\ KR%*A8PF3IO_  2B\!>&
MM-\#V.A^*/B5H>G_  [\8W_CK0K:'6TN4MM3O)+EY7<W$4K2KB\O$ D9B5NI
M-Q8[64 \SG_;7^.?PG^*'QJ^%WCC5/A5J/Q'T?0-"U;X73Z7X3OM/T_Q,VIW
M)TY3<PR:I.X2'5&BMY0DJ>7%+'-N.\I'[Q^VU^U+J7[#?[$VM?$+5+;3?%/B
M+0X=-TX+"C:;87VIWMY;:?%(RL\KP6WVFY1V&^5TB# ,[ $\OJ_PH;]J;]O#
MP;XSU[X:>)?#%G^S^VLP:1KFM2VB)XCNKY+>%6LX[>XE:2S$<;RLURD+"5;4
MHI*OL]O^.7P/\)_M*_"+Q#X#\=:):^(O"/BJS>PU33K@LJ7,+=1N0AT8$!E=
M&5D9592& ( /FWQ5^TG\7O"/[17C'X*>(-0\$SZIJGPQO?'OA7Q?I.@7-I#:
M?9+J&SO+2YL7OY'>0&ZMY(I8[A!AV#+F/+Z?_!%31=3@_P""6W[/][K5YI&I
MW,W@#1C836NF-:36MH]C;L()&::4RN&&6D7RU<X/EJ17=:1^PAX>TS1/$'G>
M*O'FJ>*/$/AY?";^+=0U..ZUVRTE69A:P2M$8TRSNS2F,S2,5>21W2-DZK]E
M#]FG2OV0/@1H/PY\/ZQXBU?PYX6MTL=(&LSQ7%Q86B(J16RR)&A:.,+A3)N<
M XW$!0 #@?\ @H'^SQKWQZTCX=WW@?Q/X9\/?$OX<^*/^$L\)6_B2U:\T76+
MR.QN[9[:ZA5A)L,%U,1-%F6!@LB E2I^-?VF?VK=<C_8/_;0N-#\,WO[/O[1
MGA.ST^]\?V40AU2UN!=6RP6NHZ=>Q>6LR75I R"=@L\+P.K1H\:-7Z(?'3]G
M#0/V@9?#-SJUUKVFZIX,U)M8T+4='U.6QNM.O&MYK8R@H=L@\F>9#%,KQ.'(
M=&&*X'4O^";WPU\4?"SXI^&?$46N>)[GXU6Z6WC/7M1OS_:VLK%$8K<>9$$2
M!8$_U4<$<<2$LVPL\C. ?/\ ^WS_ ,%'?BM^P_#XH:&Z^&7BN3X>Z-H6K7^F
M66@ZA)>:K%=ZB]O=RW#)=&'18EA""V,[W+7$B3%5(1D%'_AK;XF?L]_M ?M6
MZE?:O;>.K73_ (D^$O OA/01I9A>QN=:LM"2T*R-=I%Y$+:E(TD3",SN"WGP
M!\)[9\5O^"3'PQ^--EX^AU[4_'TR_%32-.TSQ>8=?> Z_-I__'I?R[%&VYC&
M!^[V0LJHK1,J(%Z'QU_P35^%OQ1D^*D7B:SUK7M+^-%O9)XKTN[U24VE[<VE
MO!;P7T87#PW2Q6MJ!)$R[6@1U"OEB /_ &,?BQ\:_'7BWXA:/\7O EGX9L]#
MNK.;PKK,)L[5_$%G/"3*LMC#J-^UO);SQO&7:8+,K(R*N'4>7?\ !?+XI^(O
MA+_P3'\8WGA[5KWP\-8U31M!U;6+.0Q3Z5IE[J=M:W<J2#F,F&5DWCE?,R""
M 1V^K?\ !/N3P+^S!XC\%_#WQ]\2K/Q?X@:V*^-=;\8WE_KMJT$FZW)N9A*T
MD$/)^R )%,&E1BOG22'WOXA_#W0_BUX#UCPOXFTJQUSP[XALY=/U+3[R(2V]
M[;RJ4DC=3P5920?K0!QWB_\ 94^&^M?!G0?!,WAG0]*\(^"[K3]0T2SM+6*V
M@T.6PGCN+62W&W;"8WB7!4#C<.A-?*WQ9_X*=_$73?@7\=OC1X0TKP;>> ?V
M??'&H^&-6\-7UG.VLZ]::3+##JES%>K<K#:RAFN&AB>WE#);H68&?$7TI\'/
MV,]#^"VFZ=I%IXG\?:YX5T$QG1= US7&U"STGRR#$%DD7[3<+'A=BW4TP0HA
M4!E5AB^(O^"<?PV\2>.?%FJ21:];Z)\0M3M]<\6>%H-19= \2ZC (@EW<6Q!
M(D800"58FCCN!"@G249! /G+]H7_ (*1?&KX2Z+^V!JVFK\+[JS_ &9M2TF?
M3;>YT&_677K"[TNTU&6WF<7O[F=4N3&LZHR[EW&''RF_^UY_P4/^,7[,^I?'
M_2+3_A6NJ:I\.?@_:?%OP_/-H=ZENJFZU""YTZZ1;W=.2MFC1SQM#@NP:,\&
MO4_B;_P2;\#_ !:C^-D.K>,/B7]E_:"FM)?&5O!J=M%'=K:QI#!'#BVW0*+>
M.*$^60SI&H<L<L:_Q>_X)'>#/CIK_B34_$OC_P"+%]>>,/ T'PYUMEU6TB&I
M:+$YD\APMJ KO(TSO*FV0FXE4,$;: #$U[]JKXVP?MB>(OA/:ZC\+8%D^%2?
M$;2-5D\.7\QT^=;M[26SGA%^GVF-F\MUE1X&4!E*-N#+P'A3_@IS\</VFO@Y
MX8F^$'PYTO4/'5Y\(O#_ ,1[^WEM8+S3YK[6%OA;Z>OGZI8/;P^9ILX,X:X*
MB:,E!L(D]XE_X)KZ'-\83X^;XC?%9O%;>!3\.C>G4[/G2B=YRGV79]H\[]]Y
M^/,W]]GR5R^E_P#!&#X2Z'X:^'-G8:U\4M)U+X7Z.WAC2-=TCQA=:1J\^AF7
MS1I%S<69B:>T1L;%?YTQE7!)) .:^$7[;GQL\<?'+XK:?XIM/AWX)\._";P]
MX7\9ZII::1<:QJZ6>H6-[<W^E_:8M06V>YA:UV1W<:M$VTGR6#@KK_#7]I[X
M_?$_]GKPK\5K%/A#'X3^(WPZN/%^FV\UG>+<^&;Z2TAOM/M)6^U?\3)'@>99
M6B2U*- 77<IV#UCX,?L'^$_@3\?/&GQ T75O$TEQX[TNQT74=%NI[>31X[.Q
MC,5C## (08E@B>5% ?YA,YD\QL,.-^%7_!)3X7_ WPIXCT/PCJ?Q%T?1]9TZ
M\TG2[$^*;J\L_!MK=Y-S'I%O<&2&S\S)RZH74$A64$B@#S?7O^"A_P 3-7_9
M*_9_\8Z/+\.M+\4?%KX9KXRO+%]%U#6[J[U(Z99W:VUCIL%Q%(MF'N)3+=SW
M/EVZK$KMNE5ZH_LU_'JX_:H_;L_9=^)=YI\&DWGC[]F_6]?N+*&0R16LESJ/
MAB9HT8\E59R 3S@"O9?!_P#P2\^'O@G0_AW96>K>.5;X:>%+GP'IMVNL^3=7
M?AZ?R=VEW$D2(6A7[-;[)$V3H85(E!R2OP4_X)C^"_@!\1_AMXD\.^*/B$DW
MPK\(MX&T2QN=5BGL_P"R6:-FMY4,.7W-!;$L&#9M8L$8;< ?1U%%% !1110
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M>(OY,<-Q*SO(7=T $9\Y^%/[%7Q,^(/_  3S^+'@_7O",WP_^)<GQ&UWXE>
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MB^\0Z[K7C?2=+\3P7GAKQU9RP7:6,T&GW#9M/$$DPL'GFC^S6Y47&^XG,FP
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MU2XU/2[JS@U2,6EH+V\BNY(4M;@1SSH)?(D;RS*FX*&&?,?V#?V??BQ\"O\
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M28.$;;<^)'P ^)OPY_;D^*'C[PSX;MO'7A7XT> M.\,R*NK0V5YX7U+3C?B
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MX?\ B#XLL-;\/7MQJ5C<_;8+?1=/TIP\<$TCQ,SZ>95##_5S("5<,H /,O\
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MT_Q?\*?"VC:5J/B74["ZLH==T;7I=>6TOH+2XEF:SE:9+622(.?DF*JR%'8
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ME94DE92 ?JQX.^)&A?$&]UVWT35+74Y?#.I-H^IB!MRVEXL44KPL>A94FCW
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M5FU*W8_8=0A@O+>XLY75QB[,@3[DT??:%\7?"?Q7\>ZMI?QWU#Q1\/?!NM?
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M$]5^+7[-/A;QA\5-.N)=+^._Q(\(?V:GBRXL;&YT=(-:6RMOL3W39M3.]C#
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M$5UH?@/5M:^!7Q"T;PM=)$+NWM=;L-0M='F\Q 7=H9T.KIU,B'R&'\89;/Q
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MP_IVG_$R7XL:/;:<VEM_8VM33W-S-Y;3V4ID@>YNIYO*F\P N5!V!57ZNHH
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M1L)8F8I.<,&5669_^"2WA<V'C!1\0/B,]YXL^)FG_%N.[EDTYWT?7K/[.!+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)3!+!)#)<"2?:CM$L !^F(/%%?G/X>^*>K?M,?MV?!"\\:V.@MK'AGQU\2_
M3RZ3%<6UM?V-G9M$C-%)-(5=U52WS'#;MI -<;^P#^UA\1OV>OV3OA7X,M?^
M$)_L/Q1\)[F_^&QO=/NIKS4/$5M?QVLFG7<OVM0\9:\M)$V(CNDL_P P^S,T
M@!^I5%5=$BO8-%LTU*:UNM06%%NIK:!H(99=HWLD;.[(I;)"EV(! +-C)M4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_C3=>.;7PW<6=]J%O%!>Z1;:K=P^'=0:*U%G%-/I*R"QFF2V"PK))"S*B(
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M0 30O'+&RR;5!RP&Y0'8 ^B**** "BBB@ HHHH **** "BBB@ HHHH ****
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M,8R6V*P/[/\ _!/3]L32?V_OV*_AU\8-%B^S6WC;25N;BV 8"RO(W:"[MP6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX\_;#_;M^()
M\7>,OA3\*?V5OBE\;-6L=/\ (U.]O[BV\(>%;F*X15>.#4[XA;E@CN&$$;@,
MNW<.67[#HH _#S_@@JO[<]U^P-#\.OAK>?LY^"= ^"_BG7/"%W!XLM-2U#6V
MU%;U[NYBG%M)Y"K'+=.JLC98 <8 9OM&Z_89_;K\5W%I>WG[=FA>%9-H%SIN
MA?!/2;JV'SL3LFNIVD)VD#)4 ;1\I.2W(?\ !#/7-'\-_MH?M]?#[2[62UDT
M'XPMXADC+.5"ZE%)@@,,<R6DQX8\$<  9_2&@#X3N?\ @DS\;_%#+>>(/VZO
MV@)]7DW>?)HVGZ3H]DWSL5V6T4!6/"D X)R1G@845_VO/^"4/B+XH_\ !)OX
MS?!K7?BG\0OC=XB\06,FK^'KWQ4;)KVSU&UVW%K!!)%#&0CS0HC;V8XDD *J
MQ%?>E% 'XY_\%)OVLM"_X*0?\&L%K\2KC2]/\3>*?$-MH=BD=Q:)-<V'B1-2
M@L;EX%1?W4Q<W(0J$+17&,!)"I^Q?@9_P05_9'^$/A'PW#'\ _ 6IZAHUE#$
MUUKNGKJEQ<2*HW23F;<DDA;))*XR> !@#X1\?_\ !/KXC:!_P5/L_P!ERR\)
M^(IOV7_&OQ6L_P!H:WUG#26%A%:VLQU/1)2D2Q^1+J+6JI"SAH4\AL.\WF5^
MVM 'Y3_L1?L]^$/@U_P= _'Z#P7X=\/^#=%T?X/Z;;0:1H>EP:?9 W-QITLD
M@CA55#;H!D@<[R3TKZ+_ ."['[$.I?ME_L)ZE?>#GNK/XL?".\C\?^!+VS#?
M:DU.PS*((RN&W31AXT ( E,+G[E<!^R/I6G:]_P<7_M;:Q'<3/?:#X$\):4T
M:G$2^?$9GW KDL/)BP5; #,""<;?T,H \2_X)R_MI:/_ ,%"OV*?A]\7='CA
MM5\7:6DM_91R&0:9?QDQ7=MN(!(CG2158@%E"M@!A7YW_MR?$/X2:-_P6^U>
M;]LW2_$5U\-M#\.Z3:_ _2[KPQJ.O>&];OIMC:C/]GLXIA-?K<.L CDB8&/8
M3@^3GT__ ()D:?9_\$Y/^"LW[0?[*:"2S\&_$94^-7P[A:.'9%'='[-J=J&1
MMRK'-"B0Q,N1%:2,3DAI/TNH _$_]H_7_$5]_P %(_@?^V3KOPZUSX9? /X7
M>(]%^%^@:%XO\/0Z1<?8]2CU&WNM?E@+^9I\%M/-9"$2QJ7&PXAVD-]R?\%+
MO^"O]O\ \$\_C=\.? ^F?"OQA\9-9\7V5]K>MZ9X.)N]:\-:/;&-#J!LUC;S
M8FD9T!>2%,PR?.2"!U'_  6Q^!%K^TC_ ,$G?CYX5NEA8-X1NM6@\V62-%N-
M/VW\#$I\W$MM&<8(.,$$$BO%?^#>[P7XB^-_[.\W[5'Q0U72_$WQ4^.%M;VL
M5[9S321:+H.GJ+2VTZ,22/L8SPW-S,5(+S7!WY9,T =5HO\ P<D_L5ZQ\.F\
M2-\;]+LX(V6*73[C1]1758I"44I]C%N9W(9P"T:,G#$,0I(^.]<_X+1_M$:O
M^UM<?M0^ /@S\8O%G[$>GZ);>'-5TZ[TU+.]D^9IY]>L+3S"\ODD[3,<PM&K
M1N\1Q)#^P4?P5\&Q>*O[>7PEX977//-R=1&EP"Z\T\F3S=N_<?[V<UTU 'YF
M_&K_ (.3/!/Q \.Z+I_[)W@WQ7^TA\1)KE=1UGPY:>'M6TV31]$MT,]]<%YK
M55DG*(+>%$9LS3H1YI"PS=9X?_X.B/V+KO2[<Z]\2]<\%:TR,;S0]<\&:S'J
M&F2*6#PS>3:RQ>8I4J0DCC<, D\5^@U8?B/X8>&O&&M6NI:MX=T/5-1L0%MK
MJ\L(IYK< [@$=E++R2>".: /S7_:=_X*):I_P66\)'X"_LEZ3XFUOP/\0F?0
M?B1\5]1\-W6GZ)X6T69 E];6HO8XFGU"2WD91'M&U9 5Y;S8?2KW_@@)X/\
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M_ +P9XG\6>%;GP/XG\0:-:W^J^'KB4RRZ+=21*TMLS%5+&-B5R5!XZ"NTHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO%'Q&DU+4Y? 5Y=ZK;^.-8@U347U"^TV.]\^\CN5GF26.ZN 4=V0!\J%*(5
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M?"AB51 ODUK_ ,$H/A3):>-K;4_^$JURV\<>+E\?2I=:N\;Z)XA5RZZKILL
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M\U;3_&WBU?'LMY<:Z\>I:-X@%P+C^T]/NHE26TG,JHW[I@H"E0H5Y%?Z>HH
MS?"'A]_"GA;3],DU'4=7?3[=+<WNH2+)=7>T >9*RJJLYQDD*,GM6E110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/T!110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *VKZ-9^(+![6_M+:^M9,;X;B
M)9(WQR,JP(-36UO'9V\<,,:10Q*$1$7:J*.  !T ]*?10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex3-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_002.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\$V7;&S,#\HSQ7Z1>"_\
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M_*Q_Q"(_M@\_Z#\-?_"H_P#M-(O_  :)?MA<_P"A?#/KT_X2?_[37]5&.:*
M/Y5W_P"#1']L)5_X\?AIR1Q_PD_3_P @TC?\&B7[84:_\>/PT_\ "H_^U5_5
M310!_*B?^#1W]L8#_D#_  [^@\4I_P#&Z:__  :0_MCJ?^0)\/6P.H\4Q_\
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MSG?'_"'^#..__"66GY=:_J_HH _D]D_X-/\ ]M!3@>"_"#'IQXML^?UIK_\
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M?^#5W]MS/_),="_\+#2__CU-3_@U=_;;C<'_ (5?HO'_ %.&E?\ Q^OZU**
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M&>'P,^C)<*1D,O\ :TMF<$<@D#-> ?M3_&O5/"VL?&3Q1J'P_P#$7@5/B_\
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ML/#=Q/#;S:_<61MC'I]NL!=H;1LL%91'=(8WD=3)0!\P_&'_ ()_?%CQ;/\
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M]=O!I^EZC,3?I([-+B51&^GN&$<4I GA/WO,2, [+P%KNAQ_M/>(O&>N>,/
MZ6%EX>L/#7A^.WU>W53\\EUJ-VL?F'R5GE>UB\LLS?\ $O5B2&6O5O\ A>W@
M?_H<O"O_ (-K?_XNND6PA(Y@AS_N"C[!!_SQA_[X% '-_P#"]O __0Y>%?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK5U8WVL>!?"6EZ!>W%D6-M/-:VD4#O&7"ML+(2-P!P1D \5Z70!\Y_M%6/\
M;'_!17]FV':Q_LZP\6ZKQVV6EG;<^W^E_GBL_4K*Q^$/_!4Y;21+=M*_:&\
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MLEO<H)H%>4Q19D\IT+@)A7+*&< .WIE !1110 4444 %%%% !7RK_P $7?\
MDP:Q_P"QY\<_^IAK-?55?*O_  1=_P"3!K#_ +'GQS_ZF&LT ?55%%% !111
M0 CG"FOY3/\ @XJNU3_@LO\ &H?N^+C2NO\ V![&OZLV^Z?I7\F7_!QQJ+1_
M\%HOC<O[GY;G2Q\P.?\ D#V/M0!^<\XS;R?[IK^\KX8(L?PU\.JO*KIEL!GT
M\I:_@UF/^C2_[I_E7]YGPV79\.M 7TTVW''_ %R6@#:HHHH **** "BBB@ H
MHHH "<5^#O\ P</_ /!7R^^,OQ6U#]F_X::I;Q>$]'N3I_C343)Y<.KWZ2%)
M+!G[6=LXQ.>DDNZ,_)$XD_3/_@M-^W%)^P/^P!XP\6:5>):^,M8C&@^%_D,C
MB_N 5\]5!R?L\(FN#GC]Q@]0#_.7\&/AY);_  UU[5/$&GZTW]N:3_:&H:L+
M8WTVCVZ0A[?[;#(B;8)V*3&2*4RL0@.1N5@"?X@>#8_V=?@IJ.E>(=*@\/7M
MG)'>KK0FCU-/%EQ&%CDMX9[<D0A%.X;&,84L) Q$3#!\(^"_$_QL\?Z#X5OO
M"NMWE_8:IIUO-\.]&TN72O$FJ:3<6[RB_%P;=K:.,PO$IN+GD^:A *YQCVVK
M1_M"?%R:/2[?PYJU]]ODT.U\,:IIESJ4AL6LIXTOP\('GR6H6-$!+22S[3M8
M"OU(_P"")FL^$K;]B^ZNM!M)]/U:T\1W^BZ_>WI;^UKPVLL/DM?2/AE80"';
M"&"QD!1\V\D \3_94_X(=^.X;[PSXB\1>+O#/P_\3>'KB^>"VTK1$\2:M<17
M64$=[<7,@M'>..;:K1P';O9R>!M^FOAW_P &]FBZKH?A^;2_BI\9+6XT'0KG
MPU9W#7-D@@TZZP)[>-6M^%D$T@8EMP[-P,?3OPJ\:>';#5]_B76M+L)(RTTZ
M&Z"/91QF/EU3[L>&),C8 4+\W'/UWX#T:/1M'LMJJT855$2 KM^1-H5<\ <@
MYSD#/4<@'XS_ +1/_!L;XYBT.2Z^'_CSPCXQN[/P</"ND:7XLT/[!-I>V598
MKN"\LFC5KI/F3S9XVRKD/N&-GYZ_%OX2_$O]B7XO7VAWFB^)/!^MV-G:>'M-
M\->(W75M7\2S:E%+!=RZ1+:QF%T60NRO"1*ADAQND//]8EKJ5O.C+;O#<*NU
MRB,K;00H&-HQS@_X@=/G/_@HE^SEX5_:,^'5OX?\76L<VE-=B2*:V_<ZEI-T
MJKY5[:3CYX9T+,5<?-D+Q@D4 ?SI_$+XF^$_B;\)]2UC4M%EO-8DOEM_L\%P
MMM)X-BB@NH[73+>%FWLJ%$EEN</YA(5]D@9Y?K3_ ((#?\%?-0_8D^,VF_!G
MXB7UPWPB\;7@CTB_O&D6/PO>S2D1SQ[@0MC<.ZK)R(XW*RY4&<GY%_;#_9OU
M+_@GK\<XK?6E\)M8Z,D-S8W5XUW<7?Q-BGO)F>ZN8I/,A$\0*1W(!1=AC*JY
M)SD_&6XT7XE>!X]>OO$WA^SO[C1+5O#FF"]%]>7EG;P16#QW[B% LLL=D!L+
M@EBI6)4D,E ']>H;-+7Y]_\ !N-^W[/^VC^PK;^']?O6O/&WPC:#P_J,SLSR
M7MB8RVG7+N22[M IB=F.YI;:1C]X9_02@#&^(GA-?'O@'6]#:XDM5UJPGL&G
MC4,\(EC:/> >"1NS@^E?/7CC_@FSIOBW_@E>G[,,/B233[7_ (02Q\"MXDCT
MU&N)([:WB@^T-!O +.(BQ7?P7/)ZGW/XZZU#X<^"GC#4+C4-4TFWT_1+VYEO
MM-MWN;VS5+=V,L$2 M)*@&Y44$LP  )-?AQ^P?\ M-Q?L*ZOXL\0^&[[PK\7
MO%&G_ ;6O&.GZYX$\>:CJ>E>*8K%X)4N_$VCWC//9:D9&+-+'*@!EN(E0?\
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MZ^%'C;PX?$'@SP9XSNM*T/4TDM]1UJW61Y8KV:\6WBRKI-#;JEX[1',DJ,<
M U?CE_P1?^)7Q$_9ZT'X4Z7\8/!M]X!_X5YI7@75M-\8> UUV/1[FRLS:-K>
MB*URGV.[EC/W&9PK@.'+!<=I\1/^"7/Q0\ ^.O$6H?L__&X?#6Q^(WA[2?#O
MB\ZWH;:Y?!].LUL(-6T^?SXO)OOL<<<3;U9&,:/PZ@UYSX._X*R_&CPQ\,-'
M^-GQ$TWX1V/P%NOB?=> ]5GTR"_&JZ!I\6HW^FC6+F>2X,*QBZ@M%9%C;"2N
M^X<*OL$__!2GQ7\-_P#@CE>?M/>-O!=E;ZU)H4GB2Q\-VD[PQK:W5V5TI)Y9
M"Q1C;S6CSN.%)E*C  H B^)7["WQN^%'QXU;QY^S_P#$OPCI]]X\\.Z7X?\
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M,'[.GPJ^#TOP[\7>$M8\:?LUZ[XDL_!$/B1[AK+Q)X2U9AC3=1FB0/!=Q(D
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R3_P %S?\ E&%\0/\
ML(^'O_3_ *=7UM7SG_P5D^!?C#]I+]@+QUX/\ Z3;Z]XNU"32[K3M.FOH[%+
MQK75+2Z:,S2?)'E('^9N,XX/2N3/[9/[4^>/V,[K';_BZVB__$T ?7%%?(W_
M  V3^U1_T9G<_P#AU]%_^)H_X;)_:H_Z,SN?_#KZ+_\ $T ?7-%?(W_#9/[5
M'_1F=S_X=?1?_B:/^&R?VJ/^C,[G_P .OHO_ ,30!]<T5\C?\-D_M4?]&9W/
M_AU]%_\ B:/^&R?VJ/\ HS.Y_P##KZ+_ /$T ?7-%?(W_#9/[5'_ $9G<_\
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M_#9/[5'_ $9G<_\ AU]%_P#B: /KFBOD;_ALG]JC_HS.Y_\ #KZ+_P#$T?\
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M:/X7OM;\0^%_#WC6>:"2PUW5=!A,VJ0"!"98HT5)_+E;(E-O* %(Q7F>L_\
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M5RN'7!Z@>X4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_C] '745S]O\6O"MVS"+Q-X?D*]0FHPMC_QZKD7C?1;@?N]6TQ_]VZC/]:
M-2BJ*^)M-8?\A"Q_[_I_C4D6M6<_W+JW?_=E4_UH M44U)5E'RLK?0YIQ.*
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MP^*OQ4\=^&;Z'7/&'BFX$EY+;);LWD1CDJC,D98N[L?*09"J%'PQ_P $,_V
M?"6@_P#!"#Q9^T%X-\'PW7[15[X?\7MX=\1VYFDU2QEC@O+&**U4':CE%<#8
MNYFDZDXP ??S>'/^"<,OQK/P[;PY^QTWCP77V Z(=#\/_;/M6_;]GV>7_KM_
M'E_?SQC-?*O_  7#\1?L]_L$>,OA'\._A?\ L\_L73?$SXH:ZFGW<OC7P;IB
MZ?X8L&*1+>W:1+&\,322 B5SM"P2X5R./E;PG\-?V/V_X-1[K7KZW^'8^*)M
M+@F_WVQ\3_\ "3B\80P;L^>/W7EGRA\OV8ERN"6KT3]M7X(K\2?%/_!).3XO
M>$]+U3QYXXN++2_&DFL:<LE]K=M$-)*6U^7&^7:LS[DESAY9,C+-D ^E/@#^
MS9\.K_\ :;\*>$_B/\!O^"==YX'F^'"^+-?U_P *:3I23FZ9I)$GM+>=S/\
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M?A3Q!I_BC2_B]?>,M3MK+3- \":K9ZKJMS#*6W7*1++C:NW: Q7?(RH""3@
MJ>)O^"&W["?A'PPVN:U\&/AIHVBLJN;Z^O9K2V4.!M^=YE5<Y&.1R?6C0/\
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M_2OE'PA^RWX]\>?\$1]6_;FO_P!I;XQ0?'UK>[\:P7T7B=H]$@6"^>(:;]C
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M@1J* /RMC_X+M?M800;KC_@G'\8LMC CU68]L]/L!->L?\$Z/^"T_C#]LO\
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M[#I/A ^'_#<"1;KC2+NYN))-0NQN!0M)'%IZ+U($$@/#D$ I_LL?MO\ @_\
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MT5\4OCOH/P?\$VOB+5H_$5YIEY-'#%_8GA[4-<N&,BED)M[*":8*0.7*!1D
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MK2.Z,LRQO&]VS;<I*5_46V#"W0.VYP,,1W/<T 24444 %%%% !1110 4444
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M;FUU3X>_Z/"LIBM+5S+%(9HIY X@DB;S"Q(?..$_:HU+X.?M+?\ !KAK^N>
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M?\'%7@K1?^"4/A7]H[0_!NIZSXB\;:NOA/2O _VK;=?V]YC)+:/,J'Y$6-Y
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M"7 7B.7P1#D=,_V,W^%?H>PRM?GO_P $QD,O_!9W_@H9-QM_MCP7'T[C1I:
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M+>*O$UYK4G@3PY+H&@^$[C3XFTVQ:03![K>22TA\^4\KG_5\_NUK,_X*6?\
M!([P[^WU9_#*^T+Q!'\*?&OPG\5V_BK0O$>E:+#=30R1D.8C'NC!#2QP2;BQ
MPT(X.37U_10!\L_#'_@FA#\/O^"K7Q _:D?QE->WOCSPC;>%)/#O]E+'%9>3
M]DS.MQYK,V[[(/D*#'F'YC@9\\^)_P#P2?\ 'L'_  5WM?VIOAC\8K?P8NO:
M=IVA>-?#U[X=CU(:YIEO-;M-;PS,X\@S1VT*[PN^-E+!B&*U]TT4 ? 7P]_X
M(,>&++X-_M8> _&7C*\\4>'_ -J3Q7<>*KC[+IPL+CP[*]RUU"J,99!,T,WE
MN&(4,8P"N"17&?L[?\$8OCY8?%WX,_\ "Y/VF)O&GPS_ &?0G_"*Z%X=TA]#
MNM7,(B6W&I3))^]C188E*,9-ZH03\[EOTPHH ^"?AY_P18A@_;%_:V\>>-?$
MECKW@W]J#15T*71K2V>WO-+MS%Y4A,S$J7QRI5>& /:O,?@1_P $E/VQOA#X
M;\ _")?VK-)T?X#?#O40]E=^'=%>R\87^FIN\K3Y96!A5 K;<[FVY!(?8BC]
M1** /@?]MC]A;]J3QY^T)XDU_P"&?Q*^$OC;X8^,[&*WO?AM\8-#FU/1-&G1
M54S6GD(6;)#/M?&"[#YAMV=K_P $5/\ @EL__!*?]EW5O".HZ]8^(O%'B[7I
M_$NN7&G6[6VFVT\D<<2VUI&QW"&-(E 9@&8DG"C"C[#HH ^"_P#@I[_P3%^)
MGQF_:U^&/[3'[/OBSPUX;^-OPOM'T<V'B>.5M$\1Z6[3,UM*T2L\;?OYURHR
MRS<-&R*U9/[!G_!,#XO6G[7GQ#_:<_:1\4>$=6^,GC#0&\*Z#HOA4SC0O"6F
MD ^6KRJ)'<LJ^NW=*2TAD^3]"J* /CS_ ((8_P#!//Q7_P $POV ]*^%?C;4
MO#.K>(K76+_4KFZT*:::SE6>0,F&FBB<L$"@Y0=.":Q?^"V__!/?XE?\%-?A
MO\-/ACX5UCPWHOPY;Q=:ZO\ $.2^OI[>_NM.MW3;!:)'"ZR,0\SXD:,!XH>>
M25^W:* /R[_;K_X-:_V<?B7^R=XST?X+?#70_ OQ2N+-7\.ZQ-K>IR0P7"2(
M_ERB2:1=DJ*\18HQ42;@,J*U-:_X)R?M!?%;]L_]AOXK>-I/!MU?? W0+S3?
M'L]OK$DKW-V\#0K<0!H5,OF[5=L[2&=AT&X_IA1C- 'PW^S!^P+\0/A/_P %
MN?VBOCYK,>BKX"^)7AW2]*T1H+WS+QI;>&S23S8MHV#,#@'<<X'KQ\<_#[_@
MWU^*_C;_ ((I?%WX&^+#X<\/_$K5?BM=_$7PJ?[06ZL9B+>UBB2>1%.SS%2Y
MCZ';N0D8R*_:KK1B@#\C?V!OV#/BMKG[87P\USQ/^Q7^S/\ L[>%? -O]JUW
M6;:ULM7UC7=2C'[J73&MR#9XD56R^[:KL=TC; /:O^"7/["GQ,_9A_:Q_;>\
M7^,M!MM/TSXS>-9-9\(W$6H03MJ-H9=092P1RT)Q/%\L@4C=[&OT( Q1B@#\
M-?"__!#KXYZS_P &]6B_"NZT"U\/_'#X=_$2?Q_HVC3ZC;2QZFT<DBB#SXW:
M-6DAD9DRPR\<88H&)'<_&OX6_M@?\%(OV[OV-?BEXN_9[7X6^#?A!XJ^UZW8
MR^);2\OK:4S6CW=\Z_(5MF$"K"BF20^5(6 #(6_9 +@4NV@#\(/VO_\ @E5X
M@^ /_!1;X^^--<_9)U#]J[P?\9K@^(/".H:1KD]A/X9U.3S'EM;N.*:,B%IG
M^9^<1QQE6RSHO>_M!?\ !(#XJ:;_ ,$DO@W>> ?A+X(\&?&+X2?$*#XH3?#O
MPUJEW>65V^X*]ND]Y<3,UQY<=N[J)=G[N1(RQVE_VB(S1B@#\=?B-I'[17_!
M0/\ X*X?L>_&36/V=?&?PO\ ACX N=0CN%UF:"74K&62$M-<7<:<P0LRPQQ!
M_F8QR,0NY0?T:_X*1:-\4/$?[!_Q2L?@K=2V/Q2NO#\Z>'IH9%BG$^!N6%VX
M29H]ZQMD;7*G(QD>X8I"H- '\S'A_P#8P^(7C?6_V7_&WA_]D7]HC2_&GPZ\
M9Z1=_%[QIXOCO;W5_$U\DT,CR6L$\C2FQ18II#(L2JK21H<L"[_I]\"_@+XV
ML/\ @Z(^-7Q&U#P7XGM? =Y\*+/2M,\33:7,NDWESNTHO#%=%?*:0>7*"BMN
M'EMD<&OTJ*Y-&* /P[^'_P#P3<^+'Q^_9:_X*B>!?^$+\3>&M9^*7Q1O-;\'
MG6=-FT^'Q)';ZK-?1&UDF55ECF\I$6124_>J<XKR/]OG]I#XH?\ !0'_ ()1
M? GX*^&_V7?V@M/\4_"OQ#X?L_&$]WX)N5L].GL;">U6.W55,SF0.)&)C41*
M55L&5,_T08XI-O/>@"*PC\FRA3^ZBCIZ"IJ** "BBB@ K\]_V$2+W_@OU^W9
M-N7,&C^ X1@?]0R7_P")K]"#7Y[_ /!.TK/_ ,%S_P#@H!)\NY(O *<#_J&7
MF?Y"@#]"**** "BBB@ HHHH **** "OXD?\ @IM=+<?\%)_VAI%;Y9/B=XE8
M8/4'5KHBO[;C7\0?_!1@FZ_X*$_'B3&-_P 1?$)QGI_Q,[B@"3_@FA9?VC_P
M4;_9]M_F_?\ Q,\-1$#J<ZK;#CWYK^W@5_$E_P $M"Q_X*:_LX[>'_X6GX7P
M??\ M>UQ7]MM !1110 4444 #'Y:_/7_ ()4MY__  5L_P""A4Q[^*?"L><?
MW=*E%?H4WW37YW_\$BIVOO\ @J'_ ,%"+A@>?'6A0#/_ $ST^5?\* /T0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F_\
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MF%?(M[M-DB*F"SY(7E_E7]GGPQI/CO\ X,[_ (YW.J6.FZQ-X,^(QN_#\TL
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSQ_X)K2>=_P %P_\
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MTNT75O$/A71'OHM=T>Q #RL2;AU5D7)8JUQL 8E2%)'HO_!2O_@X+T?X _\
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MFAI=?$:)K'X^>.O'P_MSQ7*\UX3:KID+>7MWV[$SJ 1]GVL6,AP ?TH_%/\
M;U^'_P (_P!L'X8? O4KC4IOB)\68KV[T:SMK0O##:VEM<7$MQ/*2%1"+:1%
M"[G+$?*%RP]GW_7\J_$7_@I;^POX$_:"_P"#G;]G_P /^()O%4%G\5/!5_JN
MN_8=>N;27SK2PU%81;2(^^V7%K'N2(JK?.3DNY/F?QE\4:E_P4-_X*@_M5:?
M\0O"/[4OQ"T/X0:@GA#P)IOPIG6.T\'2(+B(7TZM<PEIY'@,J,WF!]T@;Y5C
M4 '] Y;'_P"JD\P8[_E7\]O[:GQ?_:ETS_@B-^S1HGQ U+XC?#KXT1_&.#PC
M'J=]<RV&J:I9_9[K['-<%7'FKAXE)D+"0P;F+$DGT#X[_L:^+?A+_P ' 'PX
M^ '@OX]?'C3_  ;\:OA_)K/CJ\NO%\MUJ6H+')?M<>3+("+=IOL$(WQ*K1B2
M41E4;90!^Z8;)HW\]_RK\-OV.?VI/B!_P3C\)?\ !3;P[H_C+Q;XXT/]G.6Q
MG\"1^*+U]5FTF>Z&H1AB[Y9T!CMV93A#Y!;:I=R?$/@O\:?CS\.?AQ\"_C3\
M+=4_;N^)_P 7O$.JZ?JWCZRU[PAJM]X'U_2+I&DN([0+$\7E)E4BE3.Y7,B>
M60@4 _HYK*\=>.=&^&/@O5O$7B+5+'1-!T.TEO\ 4=0O9EAMK*WC4O)+([$!
M45022> !7Y*>/HOBM^V%_P ''?QF^!MG\=/BI\//A7IOP[L-3U#3_#&K"WE(
M,6G$QVK2*ZVDDDDP9YHD\PH'0,!(2/"?A)KOQ,^+G_!([_@HE\)_''Q@^(GB
M*']G?Q-K.GZ1KEQJ/FZCJ=K9+<A[*YE<,\EM.;;YT+=)6"D#B@#]POV>?C_X
M5_:F^#>A?$#P/J7]M>$O$T+7.F7_ -GEM_M<0=DWA)%5U!9#C<H)&#CFNTKX
M)_X-O_@)J'P>_P""6GPTU>\\>>+_ !9!XVT.TU:VTS5ITDLO#2,'/V6R55!2
M([LD,6)(SP.*^@?CW^W/IWP:\4ZKH.F^&-<\8:UH]UH5A/;V,L%O&+O6+W[+
M9V_FS.J;\!YI 3\D?EGDRJ* /=:*\%^$'[>.G_$SXF6_@G4?"/B'POXN_MN_
MT"^L;J>TNH["YM-.L]2;,UO,Z.KV]];XVG<K%E95*\U;G]OZ'5/&UGX=\+_#
MCQSXSU:ZE\2(\.G3:9;"W70]2ATVY=FN[N%2))YT,84DE=Q8)B@#Z$HKY=G_
M ."J_A+5='\/W?A7P3\1/&\NN>#(O'SV&CV5I_:-EI3R21$_9IKF.6ZG5X9@
MT%HL[_N^,F2(2>E:_P#MB>%?#?@3XC>(KB'6C8?"_4HM+U<+9_O999;.QO$\
ME&8%E\K4( =VTA@XQ\N2 >L8S17F%A^UOX1U+]J?4?@_%-J#>+-+T4:W-)]D
M86!7='OMEN/NM=)'/;3/#]Y8KF)^C<<9\*_^"D_P[^.?P>^'_C3P8NO>)[+X
MF6-_>:)8V-DIOGDLH&FN+26-Y%6.X7:R!&;!?C=@AB ?05%>3?LZ?M;Z;^TQ
MH>M:EI'A3QYH]GH=S=63R:WI L_M-S:W,]K<P0CS&+O'/;RH1P,@$$@@URGA
MS_@I-X&U>U\876IZ+\0O">G^ <QZ]>:[X8N;2"QN/)MYTM0P#&6YD2[MO+AB
M#O(TRHH9CMH ^A"N:*\P^"7[6?AGXX^+-2\.V]GXH\-^*-+LXM2FT3Q)HMQI
M-\UG*[QQW,:2J!+$7C92T;-Y;;5<(S &KX3_ &X?A?XWT;6[[2_%5O?0^&_'
M)^&^J"*VF,ECK_VR.S^Q.FS<"9I8@'QL*NK[MIW4 >LXXHKQ7X:_\%!/A?\
M%76]%L]-U37[-/$D5S-H]]JWAG4M+T[5UMD>6;[/=7,$<$I6**27"N28XW<
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M!!J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^>/\
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M/^"/_"/_ /"1Q^$W<> "+R+5W@>XCLWM%M/M*2M#$[@-$ 0IQD\5J>!_!_\
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M4(]O^7D^W_UZL3?\$.OV^K61UM?^"@WBF2-<%#-]O#,??]\V/S- 'UE\0O\
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M1[_@H%-W/Q'TR+_OBQ<5[-9?\%P/V0]04>7^T7\*%W?\]->BB_\ 0B*^?_\
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M/\5N.PS4B_\ !;+]E:5OF^-7A6,9P#(MS&#_ -]1 ?Y- 'Y[_P#!3#X,>)_
M7QZ^($?A?X??$*X\9^*O#_A;2T\-7WP_A\=^ _C1]BAC2*&281;M'EM9-Z2.
M]Q'Q$DRCYLMVMY'J'PM_X*E?M":IXFOOB9X+M_%'C+0;[3H=/^!L_C+3]>MH
M='L(I#'J2V4WE 2)+%\KJ$VE@,DX^V(?^"UG[)\\JJWQ[^',#-P!/J?D?^A@
M?G[BI8?^"T?[)<^[;^T9\'UV]0_BBV0C\"PH \Q_X*R7FD^$/VNOV2_%_B_P
MKK_B3X?>$]?\23^(#IWA2\\21V7G:#/!;/+;6L$SD&>1 IV'!YX"DCY)\0>
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MYX9)B#MS^JB_\%7?V6&7(_:4^ .W_LH>D_\ R15FW_X*D_LPW9/E?M&_ B3
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MGGD.Z:Z:\PZS2'YP\9X' ^N+;]L7X/WH9H?BK\-YMO79XGLFQ_Y%J[:_M/\
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M8\MD4^6,J<D5]T5QOPN^!'A7X,Z_XOU+PYID>FWGCS66\0:[(LTDGV^^:&*
MS$.Q"_NX8EVIA?ESC))/99H ,449HH ***,T %%&:,T %%&:* "BBB@ HHHS
M0 449XHH * N#FC-% !111F@ HHHH 0+CU_.E*Y]:** $V^Y_.@KGU_.EHH
M;Y?NWYT-$&Z\X.>:=10!#+80S_?CC;'3*@XJ'_A'K %O]"M/FZ_N5Y_2KE%
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MM9VM[/SP>8X9/,(M]Q4%AFM^VU_P1XN==O/VU&\%_ NWEC_L7X?:;\'VL;.
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MWBSQG>PZ3:37+6MM)<2V]Z4A$LL<X4$Y*V\S$!49JYW_ ()X?L37'[.OB_\
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M!/PIJ?@ZXOM>\1:9<:[X@GLW-_<)9Z7!)'JM^MSY(DL[E9#L< 0[)9&/V_\
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M4 &*,<T44 95UX'T>]\66NO3:5ILNN6,#VMMJ#VL;7=O"Y!>-)2-ZHQ4$J"
M2!D<5JE<]J** $V+G[H_*EVCTHHH 3:/04;%_NC\J6B@!-H]!^5&Q1_"/RI:
M* $"@'H/RI=H]*** #;7RO\ M(/Y_P#P5@_9BA_YX^&/'$_URFD+_6OJ@U\J
M_'YO,_X*Z_LZQ_W? _C63Z?O-%']: /:?%^K>*]8^*W]A^']6T?1[6TTN._G
M:]TA[YIWDN&0!2L\04!(G&,$DNIZ+AB+PS\3ECPWC+P6S! ,_P#"(W ^;:H)
M_P"0CT+!CCL& R<9-O3(?-_:)UJ3^*'PYIZ@Y_O75\3_ .@"OBO]F#X1_$[_
M (*;?!"X^.6I?M ?%CX:WOC2^U*?P/H/A&[M;71_"FG0W<T%E]JMW@?^T9W6
M$23F=MC&0K&L6 U 'V8F@?$Q(<-XL\#R2>O_  BETH/_ )4:CO=&^*1;_1_$
M7P_*X?\ UOAR[ST;9TONWR9]<'&,C'RCXV_;6\3?LA?MG?!;0?CEXHF9=6^#
M^K7'B*V\'^']3U?3;_Q!#J6C1K=16]M;RW"1B.2["LZ*JB7:<%E!\Q^*/_!3
M+6/B99?MY>(OAKXT\10Z'\*OA-HNI^&1?:)<Z3)H>JR6^MR3S)!>P1R[F\BU
M.60J=@QGF@#[\CL/BE'YF[5OA_)\S;<:5>1_+EMN?])/(!3/KANF1AT,/Q11
MOWDWP_D'.2L%VG<8XWGMGC/)]*^&_CG^W_\ $S]E;_@I%#J&LZD=7_9U\.?#
M_P +IX\@:./SO#-SJUWJ44?B$$*&:&*2TBBN &(6*X\P(1&2/;O#G[9]Q\)?
M&W[9GB;QMK$U]X&^"FK:?/IELJQC[+:_\(KI>H2P1$ &1Y;BXD*[BQ+S!1Q@
M  ]V9OB@&7$?@&1>-P\V[7^YG^$_]-/_ !WWJ.*Z^*BRMYFG_#UDR,;;Z\5@
M.,_\L3[_ )#UX^<_^"5?Q_\ B]>^*?&7PM_:&U*WO/BK9:=I?CZP$=I':>5H
MVK0<V(1!AS8:A!>VID/+*L+'ELG._P""G_[1OB7X7?MA_L[^!['XXVOP%\(^
M/K#Q5=Z]KD]OI3">2PBTUK2(2:C&\2$M<2=.6!(]" #ZACU'XH+&V[1/A^[<
M8 UN[4=%S_RZGOO^N%Z9.,'XE^!_%OQG\%:AX9\7?#_X4>*/#>I1H+K3=4U>
MXNK6[9&611)$]B5*AU!&0>5!Q7P)X]_X*3_$WX2_ ;]JK^P?C9X2^,FE_"#2
M?#FJ:'\2M.T:RCCL+J^O6AN],NOL^ZRN9888DEW1("JW0# -M ]A_:E_X+(_
M#77_ !;\$?#7P+^-7PY\5>)?&7Q7\/>'=8TW2;^UU2ZFT:YED6\Q'EC&-H4>
M: "N1@@L* /K2'6/BA;Q^6GA/P"L:!EC5/$UTH &_9_RX\9Q&"!TW-C.T;I5
MU_XE'[W@_P %=#D+XGN"<Y;_ *<?3;SVR?09^4OVQO\ @H9XW^#?[:%NOA^;
M1X_@E\&9=#LOB[-<VP:X\[Q!.;:S\J8_ZL6"M:WD^WK#>)GCD7OV[OVH?''A
M#]O7P1\+]$^-W@;X&^&]8\ ZGXGN=7\1:/:7RWM[;ZC8VL5LAN9X54LES(^%
M8D^2>.I !]0'Q)\20XQX-\(;2&S_ ,51-D$=!_QX]_T]Z2'Q1\2&;$G@GPJJ
M[AROBJ5N-P!.#9#HN3^ '?(_/S6/^"GWQ@\,_LU?M6C0_'7PM^+&N?!,>'8?
M"GC[0=&>WT?5;O5)0DMC<Q+<30M<6W[HN8)2N+J/*JP*UZA\<?\ @J-XR\$_
M\$?=%^+F@:)I-U\;-<M1X?CT&YA;[';^)+7SUU>)T#A_*M/L&IS$;@2EKUYS
M0!]8)XO^)"O\W@/PWMX/R>*G;^YGK9C^\_\ WP.F[AW_  F_Q 4Q[O .FMNP
M6V>(T.SY5)SF =]PX] >_'S%^U#^WS\5/"W['/P/F^%NB^%O$GQV^,FAQZW8
MZ7J,,J:<T%KHYU349-BR!E5BL5M'F3"RWT&20#GZI_9Q^.FB_M.? +P9\1/#
MCL^A^-M&M=:L@Q!DCCGB601OCI(FXHRGE65@<$4 9B?$/XA!FW?#:W !P"OB
M2 Y''/\ JQ]?PIW_  LGQU&K;OAO+M5=R[=?M"2W/'./;G/>O+OV;?\ @H!H
M'CCQK\8M$\=>,/A[X?O? ?Q"OO"^F6LFI16-Q+8PVUI)&\R33%FD,DTHW*%4
MA1A1@UX5\'?^"JGQ4^/G[,7P-M_!WA?P1JWQN^.UWXEDL'N_M%OX7T#2='U*
M6WFU*Z"/)/(OE&S18DD!EEN,AT4' !]CCXI^,$@=F^&>K%U)PL>LZ>=Y^;H3
M*.N!U_O#T.$N/BSXNMIMJ_##Q%,NY@6BU;3,8&_!PURIYVJ?^!CT./$/A/\
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M;?+QG,QSGRQG/7<^<[FRR/\ 9OTZ$_)XF^(:\ '/BJ^?.-O]Z0_W>?7)SUH
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MJ^\/^-)[.P\:_P#""_\ $PDT^*VC,NGZQH]Q]F%EJ$4\K;BH3,4<+^6GFD
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M_P $U/#\EPRV_P 8/VD(?)^1XT^*VK2;6.""=\K'/?!X]J /IHG%&ZOEX?\
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M.+4$NM(TNY759HKB]$MI&_VR2+8(WDROSLGEQ[2V2NQ<8P*^>E_X*@Z6?O\
MP3_:<C[D'X8:BV!S_=4YZ=N?YU,?^"G_ (=C7][\)?VEHB #C_A4FN2=?]R!
MA0!]#:MX4TW7M0T^[OK"RO+K2)C<V$T\"2264I1HS)$S E',;NA9<$J[#H36
M#XL^ 7@?QY;>)H=;\'^%M7A\:6L5CXA2\TF"==>MX@RQ0W>Y#YZ('<*LFX+O
M;&,FO&?^'HO@J-R)OA[^TC"%!.X_!/Q4Z_\ CE@U2#_@J1\/<?-X._:)7Z_
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MTC'D'G?IY'8C_@1]L*WP4\2%HV7XL>/@$()7[%H7SXV\'_B7=]IZ8^^>GRX
M/1MU*6P*\UMO@GXJMGW'XN>.;CYMVV73M$QCY?E^6P4XX/?/SGVPJ_!WQ?''
MM'Q8\5,W'S-I6D'IM]+0=<'_ +[/H, 'I-%>;#X3^-$N W_"UM>9/[C:-IG/
MRXZB 'K@_7VXHN/A;X\,&V+XHWZL-V';0;%B<EB.-HZ J/?;[F@#TFBO-IOA
MI\0"6\OXF;?3=X=M6QUZ_,/4?E[TB_#_ .(R=/B1I[<\;_#$9[MZ3#L5'_ ?
M>@#TJBO.4\$?$I)MQ^(&@L@ZH?"O4<]_M7T_(^O#(_"'Q10_-X^\'L..O@^7
M/5?2_P#9OS'IR >DUQ/QO+?V9X=55C8R>(]-'SC@ 7"L?QP#CWJC!X8^*".N
M_P :^!Y%7.1_PA]P"W"]_P"T?4-V[CTR6S_#SQQXAUG1VUSQ1X3O--TR^BOY
M+>R\-7%K/.T8.T+*U_(JC><\QMP,=?FH ]&KY1_X+F1B?_@D5\?XVZ3>$KB(
MX[;BJY_6OJ[-?*'_  7&D"_\$I?C(&5F632[>)E7JP:]MU(_'- 'U<O3\:6D
M7I^-+0 4444 %%%% !1110!F^,-W_"):IM^]]CEQ]=AK^#*U&;6+_<7^5?WE
M^.95A\%:P['"K8S,2!G $;5_!I:?\>D7)^X._M0!]Z_\&QJ[O^"VWP;YQM&K
MGZ_\2J[K^NJOY(?^#7.V:Y_X+<?";">9Y=KK3G_9 TJYY_#-?UO4 %%%% !1
M110 R==\94,RLPP&7&5/KSQ^=?D?_P $C/!7P;T/]O?Q9XX^"_Q GD^%O@GP
MGJ.A^)O$WBCQJM[K'Q7UG[;%<7&LW$+N,VUDH>/[:T42R-,1'F-=Q_6W4M/@
MU:PFM;J&.XMKB-HI8I%W)(C##*0>H()!%?/?P\_8I_97TCQCXQ\*>$OAK\$[
M'Q$NAMH7BC2M&TK3X=0ATR_C!-M=Q0@2I!/&H(5P%<*",X% 'D?_  <3W9U[
M_@C+\3Y-)V:C_:ESX:CM?(N_*2\$WB+2U4+,IX5PP&\'HV:^+?V6=7U/]@7]
MM#]HSQ5:_"^R^ <_P7^"FI>)KWX4Q>/;_P 26WQ""N9[;6;>2:,0QVT1MVMV
MDB'FQO*595WL#^Q/BGX!^"?''PDM_ 6L>%M!U3P7:Q6D$6B7-HDEC&EI)%);
M*(B-N(GAB9./E,:D=*B\9_L\>!?B+\1='\7:]X3T'6/$WA^SN].T[4KRS2:X
MM+:[39<PJS#_ %<J_*RG@@D=S0!^;/A+_@J3^US;_!'QKY_P]\,>)/&S^%_#
MGB7PK/-H T&.2;4;U(+O3TL9M59[]DB<O:,LT!N6B=-N_"'D_'?_  4)^.W[
M2/P2^'.GZ1\3?#OA3Q]I/[0_A[P7KUM)X$U?PWJ-O;W$7GP6NK:=+?;@K2(Y
MEB@N7BN8BB"1"LF_[_\ "O\ P2>_9M\$?"SQCX)TGX+_  _L?"OQ :!O$&G1
M:8HCU,P,7@WG[P\EF+1[2/+8DIM/-1WW_!+?]G/1_P!FG5/AG<?#+PO9_#J\
MU4>)=0LC)+$LE\A5OMLEQY@F\U0@'F&3(1=N=O% 'S5XN_X*Q_%+2_\ @I!H
M?PWT:/X?^)/AGXA^($_PY?4;#PKK.="OX]-DN"D^JS316EQ=I/$YDL[:)U2(
M;3<+(#CQG]E/_@I[\??AA^QC\#]-UC6=%\??$OX^>./%T&EZY=>%=9UY=$T[
M2[F[EN?.LK.=KF\<NGEP16YACAA*ALB%F;[^TW_@EW^SQ<?'./XL6?PS\,MX
MTGU6'Q'!K,,DQVWRJH6\B02>4DCJJ%W11YNU2^[ -4?$_P#P2C_9TN?AIJGA
MN_\  .GV7A_5/$S^+62+6;^S:RU:;*M<VD\=PLEFS^8RE;9XU/F,-IW'(!\[
M^'/^"I?Q\^.S_#?PCX5^&O@OP7\1M6^'>M_$/QA9>-3J-K;QVVG:D-,6WL0J
MI+$UW*RS)+.&$,,BEDD8;3TG[ W[8$W[-O\ P;V^"?C9XRDU[QA<>%?A_+X@
MOO/OFN+_ %5T:5E1IY2QRQ*KO;.!S@XQ7LOCW_@D)^SG\2?AYX#\*ZE\,=+A
MT'X:V<^FZ!::=?WFFK;6=QS<6LK6\R/<03'YI8YS(LK%F<,68GU'P?\ LJ_#
M_P "?LVP_"'3?#&G+\-;?2'T!- G+W5J;!T9'MV\UF=U968'<Q)SUH ^(_&G
M_!6/XX?LS^$_']G\6/ WPR;Q?I_P;O?C#X8;PSJ%W+I_E6LL,,NF7RR_O/-1
M[F'$\3".0!\!2,5]F?L;>/\ XF?%'X%Z?X@^*_A7PYX)\4:N[7<6C:-JCZE'
M96;@/ DTS(@-P%;$FP%-P^4X->:^"/\ @C]\ ?AY\+?&7A"S\(ZE=Z/X]T&/
MPKJ[ZIXDU/4KTZ/'D1Z=!=3W#S6]JFXE8H7103G!/-?3&G6T-E8PPV^!#"@C
M0!MV% P!GJ>!WH FHHHH **** "OE$'S/^"XDGR_-#\#$R?3?K[8_P#0#^5?
M5U?*.DE9?^"X?B+^]!\#-*SR.C^(-1Q[_P#+,T >_P#CMG;XC>"45V4"[NI&
M QA\6DHP>_5L\>@KJ[E]EK(W7:I)K)\9^ K'QS'9B[DU&"2QE,T,ME?36<BD
MHR$%XF4E2&/RDD9 .,@$8,OP*LW5@OB#QL@==I \0W1P/^!.>>>M #O@C=M9
M_LZ^#[A8VE:'PY92"-.KXMD.T?7I^-?&_P"RS\+/&'QI_9Y^'?[2VM?M$^./
M"_C3Q@]CXIO+.^UD/X&LM/O)T)T,Z2S1V^U;>3[,EP6%T+C9(97QY1^\- T&
MW\,^'K'3+-#':Z=!';0*6+%410J@D\G  Y/)KYJTK_@D3\*-&^(4.J0W7C[_
M (1>W\0_\)7#X#?Q1=/X0AU3SC<BY73BVP;;D^>L6?)65581@@4 ><:'_P %
MF8?$G[6T/@RQ\)V=UX/G\<R_#P745U?OKT=]'<O:-?-;"R^R"Q%TAC)^V>:J
M'S64 %!F_#+]OCX[_M#?'[]GV^L_ /A'P5\,?B!K^OVT\4_BI[S4]6L;*TN%
M$[Q+8A(?WD1FC1927!C5S'\Q'O=A_P $YO"&D_'QO'5CXF^)6GVLFO/XJE\(
MVOB>XA\,S:L^\O>-9K@[GD=IGB#B%YCYC1E^:U=&_8-\&>&]!^$]CI=WXCTT
M_!G49M0\/W%OJ&)G\^*:*>"XRI6:&1)W#*0#PI!!&: /ARQ_;$^)GC/5Y/%$
MTWC33?ACX3^"&@>+;&WL_',*ZMJ-]K%]=VZRW3'3B)Y@+5HU)Q'&(B^QWG"P
M_6/PT_;C^('Q3^(UY<:/\#]2U#X1KJ.MZ38^+K3Q/9M?75QIAGB>1]-D$?E6
MT]S:SP0R_:&8MY3/''')O79M/^":WP[TSX;7/A6&7Q$FEW7@[0_ S_Z<&F_L
M_2+FYN;4[MG^M,EU+O?'S#: %QD\]KG_  2?\%>)M;\2PWWC/XH/X%\1?VY,
MO@:+7%@T#3+O68;B'4;F!8XEN"TGVN[=8Y9I(8I+F1XXT.W: ?-?Q'_X+C>,
M/B!\(/C#I7@/P=X'M?B1X/\ !T'BC23I'Q&T[Q-;V\;ZA#930WCVT+16]Y#Y
MP81 S1N0P$O&3Z1\8_\ @NYX'^!O[2%U\/\ 7M.\-6W_  BVIZ5H/BR9O&UA
M#J&GZA>K;LWV'3I=ESJ-M;?:8O-F18VXD\N*4QLH[2U_X(\^%;[1]7AU_P")
MGQ8\57>I>!7^'EK=7][I]N-%TSSK::$VL%K9PP)-#):Q,LC1L7Y$GF# '5W_
M /P3KD/Q6F\0Z7\9/BQX;TS7K_3M9\6:#I%SI]I9^+M1LT@C^US2+:BXMFN(
M[:!+A+*2WCE"?<4LQ8 L_M>_M'>.O@U^U!^SSX9\-Z-I]]X5\?ZYJ]MXLO;B
M^CMWL+6UTF>Y0HK(S-\R-*2A4_Z,$Z2Y&;^SG_P4?;XZ?$'P;I^I?##QEX)\
M,_%:PN-4^'_B'5;BSEA\2P0Q"XVR00RM/9RRVI-S'',HW1(VXI(ICKU+XX_L
MU:?\<O&_P]\07&L:QH^H?#O6)=5M?L(@:/4$FM)K.XM+A98W!AEAG<$ILD4@
M%74UY;^S;_P36A_9]^)'A;5+KXG>.O&GAKX::9<:-X \-:PMF+7PE;3(D1Q/
M%"EQ=R1VZ"WCDN)'*0EA\SLSD \B_P""KW_!1[Q)^R[\<_"OAOP3XR\&^'?^
M$(\/W'Q-\>66M26JS:_HEO=00+I-H9F!6YN8_P"T)$:/+*UDB_\ +49]H^-?
M_!1:W^&_Q%7P[X/^%_Q*^,']GZ#9>*==N_!UO9W$>BZ;>R31VLGES7$4MU-+
M]GG=8+9)9=D9;;RH;I?#'[!G@2Q^+/Q3\:>(M.L_'&L?%6^M;B]_MVQM[F/3
M[6ULH[2"Q@!3Y8$"RR<Y)>XE8DDUY+H/_!*#5OAGH/A[2O /QT^(/@FQM/"M
MAX%UY[6RLIKS6M%L);EK%(IVCWV=W!!=2VZW4>7,>PD&1$D4 [.P_P""DFEZ
MA\5-4T]/AO\ $@_#O1]6U+0;SXDBSM6\-VU[IT4SWOF!;@WD=O$]O- ;I[<0
M>=&R!SP3R4?_  6.\'Z+X"UKQ-XK^'/Q4\#Z):^#+WX@:!<:UI]FK>,-%M/+
M,\UHD5T[1S*L\#_9[L03;)T;9][;N6__  3=OHO'NN6+?%3Q,?@KX@U/5M;O
M?AU'9PPQ7-UJ:S&\ADOUQ<-8R37-S<&VQGS91F0HHCKD+S_@DKK_ (\\':IH
M'CSXX>(/&FFV/@^[\#>#VFT"TM;GP_873VQFFN9$/^GWC16=M$96$2;4<B,-
M([$ OO\ \%D?#>E>(M:TW7/A#\;?#<WA.^TR+Q-)J.C6:Q^&;'4G1+#4;DI=
MMNAF9\&*$27,7E2F6&/8:ZCP?_P5-\%^,?C1'X37PG\1-/TV3QG?_#Q?%=[I
M<,6@MK]I)/&UB)1,96,AMWV2B(PEF6,R+*3&-GXQ_L#V?Q?NOC#--XFNK(_%
MV+0H9PMFL@TQ=+?<NS+#?YF3DG&W/&<5X]^S-_P3X^(&K^+6U3QUX\U*S\!:
M=\7/%/Q"L? CZ+!'.+N36]0ET^4Z@DA9K3;+'?+"8P_FR+ND*+Y0 /0(_P#@
MJ_X)T_QE-I>O^"/BOX/L[C1=9U[1-5U_PY]AMO$UMI47G7GV6-I?M",(?WB"
MYBA\Q.5)R,Q> _\ @KM\-?&L%]/=:#\1O"]K;V^@ZE:3Z_X=:Q75--UF_33[
M34H0SEA;+<2*)3*$>-3O*;>:\!^'W_! *Z\.A9-0^(G@Y[VQ\+^(O"L>KZ=\
M/X[;7/$":KI\UD=0UC4&NGGO;Q#(LA(*1L1)\@:0.GN?[8/[+MCI7@7XB>+-
M3T_Q/XZL-4^%"?#@>%_#FC_:=6O&,\Q$]O\ /@.6N(\9 $7E>87 4X /H#X8
M?'30/C#XH\;Z3H4EU<3?#[6QX>U:<P[(/MOV6WNGBC;_ ):;([F(,0,!RRY)
M5L?F_P#L^?\ !:#XD?$OX>?#/Q(WQ&_9C\<>)/&^O:;IE]\*O#&FWT/BZR@N
M=06UF*2?VG<#S;>-C,_G6T<02.0LZ  G[G_X)Z?L\:O^S#^R%X1\-^*+K^T_
M'5W%)KOC+4,JQU'7[^5KS4I\J%4JUU-*%P  @4    >8:+_P3"N/!'[(_P %
M_"?ASQ98Z9\3_@.]I-X=\8KI959MCXO+6:%9 [6=Y TD4L7F8RR2#YXT( /0
MX/\ @HQ\-[GXY'P+'_PEK2+K9\+GQ$?#5Z/#7]L*2IT[^TO+^S_:-X\K&[:9
MOW.[S?DKS#XK?\%G?AWI'[-_Q%\=>"])\:>*KCP7X?;Q'ID$WA?4K.S\3V?G
MI;)>65P\(2XM?.D7=)$20GS[=A#'B_#'_!&Z3PC^V%)XQM[7X+WGA2X\>7/Q
M"?4[_P %-<>-8;F>[DOWLTO6E\@Q+=29CG,7FQQ (OS!9!S?@7_@C#X^T'2?
MC%;S>,?A_H,WQ \':CX>C'A?2K_3M-\0ZE/<03P:WJ>F&X-E!=)Y#(XL8H_,
M%Y<DD#8B@'TKXO\ ^"H_PA\ >-[?PWK6H>+K#5 =+357/@_59;3PM+J:Q-90
M:I<QV[06,TGG1#RYW4IO4OL4ACSGPV_X*V?#_7?!_BG5O$UCXM\-2:'\0=4^
M'VFZ:OAC5+_4O$-S9NXW6EK#;-/<$I$\CB)&$(!#E<$UXK^V'_P2G^-7[7?C
MCQ#>:SXT\ 7EGX@?1M2M9M0N]=E7PO/9Q69N;"PT]+A;(6\US;2RK=2(UP@N
MG5ED*HRWOCC_ ,$E/&WC[6)-8AO/ /B:X\._$/Q%XJ\/:7JU_JND6VH:;KNR
M6[M;NYLR9H+J&X4&*>(2(8UVM%ELJ >_?$;_ (*K_ [X<_#CPUXFO/&VZP\:
M6-]J&C_9]$U*ZE,-DPCNYKJ&&W>6RAMY2(YY+I(EA?*N58$#L/@?^U-8^-OV
M&?!_QK\5?8_#>EZUX%L?&VKA93+;Z5#+IZ7D^&QEDC5FP<9(7I7S#X-_X)R?
M%[]G7P=H%Q\,V^#,/B;4_"VK>%?%&GWYU1-&L1?:G<ZE'>V4DGVBYN'ADNYE
MDBN&3[5D,9("-M>A?$[_ ()_>)OB!_P3+^%_[.+:WI":;I^E^&?"_CN\CEN+
M?^T]%L([==1@LVC7>KW2V_D@MLQ'-(<JP% &A^QK_P %)?\ A<W[.WCKQE\6
M/#4/P=U3X:^7?>)-,N[XWBZ5IEQIT&IVMY)(J X:UN ' 4[)89TY,9K)T7_@
ML5\-?B;X_P#'GA_P7J$-T?!OA/2_%4>KZW::EI6D7D5W>W%JZF9K,E%C\J%E
MD 99C= (#Y4I7D_C[_P28U&74_BI'\,=:DAT3XQ?#2Z\(>)++Q=XHU;6))M2
MAG5M+NDFNFN9!$D-QJ44BAP!YD+*C'?77?MA?L4>/OC?\4/BA/X<F\)+X?\
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MX377CZU^(7@.^\"V$K17/B./7;232;:16",KW6_RE8,P7!8') [BOBOXF?\
M!.3Q9^TKX'^,FN>/OAAX3N/&GQ8USX<WMU:RSVMUBUTT:,^J6_G$D>5"\>I
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M!,\D<"2D3$_, ?:S?\$CO ,"L+/XD?M,:;RN3:_&SQ.O3K]Z]/7O]>,4V_\
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MC6EU_P )_P"#_$'@V6]T;PE;:+K.IV^K<>?K-S#)Y>IS6B#; [0Q'JS;F.:
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MG^TU^TAXHU3QC'INI?#KQ5\,CX$O-/$DBWXN#J+7?VA#LVIL C:.0-O65%8
M;0:^?_V>/^">7[1G[)Y\,^-;77/AE\6/B5HNO>+5U5-=U"ZT:SU[3-:ET^5;
MT3PV<QM]21]*M=Z"!XF6XN5#YVL0#[FT'X[^#?%'P;M_B)I_BC0KKP)<Z8=9
MCU]+U/[/-D$\PW!FSL6,("2Q( P<XP:\T\)_\%.?@!XX^'VN^*].^+'@Z3PW
MX8N+2VU74)KS[/#8-=OLM6D,@7$<S9$<OW'(.&.#CD/!_P"R#\2/A]_P3'\1
M?#'1]:\%VGQ4U^UU_4%NUM#)X?L-4U;4+O49((HYHI";2*2\>&-I(7.Q$9HF
MYC/@G@/_ ()H_&7Q9\0M6\0>,K/08;+6KWP&T]GK7Q&U+QCJ,D>@^(Y]3NGD
MGN+*&)%EAN"(X($2(/&<A2[-0!]7_#C_ (*6? 3XN^)_#>A^&_BQX+U;6O%S
MRQ:380WX%S=2QF0/$8VPT<O[J7$;A7;RVV@X-;GA#]N/X._$#XG^)?!6A_$K
MP7JWBSP<EQ)K6DVNJQ276FK;MMN#(@.1Y3$+)C.PD!L'BO&?%'["/B34]=\<
MWUO9^%XY?$WQU\/?$BVE24K*NG6-OHT,S.?*XN<V-T549!#CYQO;'SU^SE_P
M2E^*?PM7P[X9U30X[VU^&.AZ_I^B^);[XG:C>V6I37FG7=E!-::.81'9R3"Y
MW7 D=DB);R_-.UD /NOX8?MT_!GXUZ3XDU#PC\5/A_XCT_P?:?VAKEU8:[;3
M0:1:[&D^T3NK[8XMBN3(Q"C8W/!QQ_PI_P""G'PA^,'BOQDND^./!LG@_P (
MVVE2GQ6-?M3I5[-??;"+99-VU)8A9L65CGYQP,5X+\8/^"9GC/Q)\./!.DZ#
MHO@M9/!_PDT;PR]A>7!73=8U#2]9TG4H]+G"H6^PSK8W$#2;3A+ESM.2#FZ?
M^Q+\4/V@/C?XC\=>-OA3X3\&:?XM^)7@SQ/<Z$=;M]2E^R:-;7$<UQ=,B>5)
M.91!M5,YC$7.Y&P ?8W@#]LWX1_%;Q%H.C^&?B=X!\0:MXHL9-3TBQT[7K:Y
MN=3M8V97FAC1RSHK(X+*" 48?PG&EX=_:<^''B_7/$^EZ3X^\%ZIJ7@E6?Q#
M:VFMVTTVA*N=[72*Y, 7:V3)M VG/0U\IZ+_ ,$\-<\-ZC:WVG>%] TO4IOV
MB-2^)-S>VLD*3)I\]M>VZ7F>"TQ2:-3'][#$=,U\T_!/_@EA\5M&^%TGA74O
M _C:TUSP)\+?%?A.VU.]\6Z"= UN_P!0L&M(UT^*TM4O)H+J3_27_M"2#R76
M,GSG!8 'Z*?&+_@H1\'O@K\'O$GCC4OB!X4OM!\(ZC;:3JTNG:O:W1L+NXFC
MAB@EQ)B-]T@)#D$*&8\*:]!TCXT^#]?\:'PU8^*_#5]XD6T2_;2K?4X9+X6[
M@,LWDAM_EL&!#XVD$$'!KX0_:-_X)TZYH_A[Q<GP]^&&BW&G'X9^"='AT>P>
MRM5U>\T;Q!+?3VBJ[+%YJVV CR[49I%4N "5H^%/V4OB)I'_  55A\<:'\(]
M2TG1]7\9MXFUO5/$*:!JFB0VDNBK:M>6%ZA76;/5.$MGL\36>1*5D\LJU 'Z
M+:+XET_Q)HT&HZ=?6>H:?=+OAN;:99H9E_O*ZD@C@\@]JR_#GQ:\*^,--NKS
M2/$OA_5;.QG^RW,]GJ,,\5M-G'ENRL0KY(&TX.3BO#?BOJ=Q^T/_ ,$N?$-U
M\*_AWI]Y)XR\$SMX?\':Y;0VEM=QSPG9;2Q0S+$%=&.%2=4?</WBJVX?#/PR
M_P"">WC?X@WOQ%M;SX-^*='\#_$#3_A_IUWIVOZ'X7\/B]CT[Q8+G4HOL&C.
M8D@2P=B//DEF95=0Q&Q: /TA\-?MH>!?B)XC\4:3X/U)/&FI>#=4TO2]8@T:
M:&8VK:AY+13!FD5'B2.=9'9"<!'50[J4KH_CE^T!X;_9^^#OCGQOKETTND_#
MO1;K7M:BL@L]U!;6\#W#XCR#N,:,5!(SZU\9ZI^Q??> /CO\6=(\'?".UT'0
M]>^)/PW\6:5J>CZ?8VFFSZ;I]WI0O(@(V5U>V>RNIVC* ;90REF=A7B,G[)F
MI6_[)_Q:\$Z;^RSXJTWXX_\ "J/%VA>*OB-^XAC\=:C>P/@V\T4K2:L]_<A9
MU6=%^RKE<QMMC8 _6:VUFWN'AC\Z-9IXA.D+,!(4X^;;UP,@9J9+A)79596:
M,@.H/*9&>?2ORB\6?L@^.KO_ (*.:EJ6M>$_B)>>);WXJ:9XF\/>,M&\%:3<
MV-KH44ENRP'79IA=6<$%K'-;3VA4"0-*D4<WG;SU?_!-;X"^)?@S_P %&_$U
MW9_"WQ!I^FZTWB6;Q+XB\1^&)-+U2QEFU)+B!!K,,PM/$5O.^YH"\!GMH57,
MB?.D@!^FAX/3]*0."<X;\J_)K_@L#\'_ !I\8/V@_B8^D?"7Q%JGB'1_"UC_
M ,()X@T[P7JWB.^O+A(I)VDL-1%Y%I^AO%-N1PL;74VT,!+NCC/3?M,_L@>+
MI_AC^T-X^T/PWXJ_X2WQ-\4K6*^E73+W4=3OO!2-I;W5I86<<\$LUO(\4DLD
M%O+$\X6X0%F(0@'Z?LR_Q?P\T@8 ]#SSTKXZ_P""-W@F^\#?#7XB11+XFM?"
M-UXH$V@6&H^ KSP3862_8[9;@:;I]]=W%W%:-,&;$@A7SC.8X]A#'X_\=?LF
M>+/A_P#LX?!W4[S2_%UAX>\;>)-=OOBP^I:'XB\23RW*3W)T/[=8:?=07PL(
ME:6-5B;RD9K0R1NOSJ ?L*54M]W].E8_ASQ]HOBSQ#KVEZ;?V]YJ'A>[CL-5
M@C)+6$\EO%<I&_'#&">&3']V13WK\</VB=!\8>&_@#\$=0N+CXV>*M4T/PUK
M,WAS1-5\.^)]'BUDG5'>QM[*?3;VYOM.UF.V6".V?5%G1[62/S0D@G ]+_:,
MTO3_ ((^*/VFIHO _C_1-0^(7Q,\*ZCKE\M]K^G:;'I5QX=MG\^YO--BGFEM
M1J,-_;RQ6.UC+)$DDD4!#  _4;7?'.B>&?$>BZ1J&H6EKJGB2:6WTNUE?;+?
MR10M-(L8_B*QH[GT -;&U?SK\<_V5/ NMZKXU^$/B#Q-IGCK4(_ _P 8_%&E
M^";O4[#Q':V=K!>^'[:?2L)>227BZ?)=$A)+MB@RRDHK;!R?[*_Q+^. ^'?B
M2Z\+^.O&6J?&"U^%.N7/C/0/[+\4W&K1ZW]G@*RS1ZF[6%MJ4$YE%M':(J3Y
M*JAA"E0#]GK;Q_HMS\0+OPK'J$#>(;#3X-5N+$$^;#:SR3113'C&UW@F4<YS
M&U;6T=?US7P-_P $K+[P'XB_;'^+VJ?#'Q9\2/''@J3P%X/BCU7Q=>:E?2I?
M?:]?:ZABGOQYI;YH9)HQ\L<TLBX0Y1/.O%OQYU"W_:]U6TOOB;\3M/\ VAX?
MC+8:-H7P_M[J[_L6[\'/?VZ&4:<JFWELGTEI[J:_8%XKE67S4*)%0!^G%[=P
M:98S7$\BPV]NC22.QPJ*!DDGT YJGX*\9Z3\1_!^D^(=!U*TU?0]<LX=0TZ^
MM91+;WMO*@DBEC<<,CHRL".""#7YP_#8^.O#MS\/?'5[\2OBAK<GQ$\6?$C0
M==T;5M6EN=%CTRV37YK!([5@4@: Z?;*DJX=A(ZLS*45,7]DCXG_ !"\&> O
MV</@;I.MZ]';_&+P3X$\5Z/JD9<#P[I&FZ1;CQ!:0RX(C1A96"*IY\S7I".%
M) !^I055/Z4FQ<^_UKXH_P""O7[0+_#3Q-\+?"*?$;5/AJOB_P#M6[DOF\8Z
M=X*TBY6T6U41W6L75O<S1.&N@T=O:0/+-MD9BJ0MN^;_ (0_&WXN?M7_  &T
MG59?COXY\-W/A/X$WGBNYGT 6B/J^M6VJZA;07=PTUH#(BK8,LB"*$3;@61.
M4 !^J_BKQ!I/A/0;B_UJ]L-.TNW4?:+B]E2*WC4D*-S,0H!) Y[D"KL5E"CK
M(L4:NJ>6I"@$+_='MQTZ5^0O[:'[4MU\8?!'C1?&GQVF\#^(HI? EMX?^&R&
MQMK'Q=I^IPZ/=75RL,T37-TTMW/?PB:"0" 6&,#$N_[,_P""K7[2%Y\$O#'P
MZT#2_&'BKP;J?C[Q#+817&A-HUG/=1P64]S)$VH:NWV.Q3]VK%_+FF<(4CCW
M,70 ^HW\):3+HLNFMINGMITX(DM3;IY$@/7<F-IS[BKMK;1V<"1PHD<4:A41
M %50!@  < "OS&_8H_:M^,7[5&K?"G3G^+5Y=6>FZ;X]UC6)-!72=0NO&:Z%
MXDTZST^W-TMIY!66&X:.6>VAB\U6!01EPZZ/_!+K]N?XO?'[XX_#FZ\5>+]+
MUS1?B?X9O]7U/1Y?$/AZX31[J(02"/3;2Q1;^!;=Y7MIX[YYF4F/<Z2*RN ?
MI66P*BL;^'4H3);S131AVC+1N& 92589'<,"".Q!%?GU^UM^VC\2/@O_ ,%%
M8[67Q])IOPDT6Z\,:9=:=H%AI&K&QN-2NO)D36K2>2+5$%QYD*VUSI[21QX)
M>)RK@<MI?[6/CA+FX\.Z3\2_ OP+TG2E^)'C"74[G0;'[/XAN-.\7ZA9);LD
M@6,0Q1HLUY)%BYE-PC"1"S,0#]-,T9K\O=2_;E_:&\7_ +*>L?$[1/'GA?2&
M^'_P%\&?%&[L)/#D5Q%XCU6_M+^YOH)78JT-I(EJH41;9%9U(=55E?IO%W_!
M0CX]:G^V9XMM?#/AJ\;P#X#^).F^ I]/EL=#BTR]@G:Q6:>YU"YU:&^AO7^V
M-);1Q6;1N! FV4RLZ 'Z-%QNQ2[N:_-;X=?'7XE?M"_M;?LJ^./$WC#P7<>$
M_&WQ!\7G2?!]IIIM]2\,+8:)KMFD;7'G$W+A<BZ#QKY<[1JFU00W4_MB_$#X
MG>"/^"C/Q,U+X;^-OA]X1?P?\"-.\5WT'BK3)M0BU1;75-<80@)<PBWMS\PG
MN '=/W&!@G(!^@.:*^$_#?\ P4L\=>+/BWI7P[CT/1=*\:>/M:\*:OX5L[V!
M_,M_"FHZ:;_4Y[A/,!DN+0Z?J]MO7""1['>O[P@^F?M^_M/^/O@YXZ\"^%_A
MUJ'AR+6/$<%_?7EK)X-U?QAJYM[?[.B206-A)!''!YLZI+<W5S$B%XU4.SY4
M ^H,U\F_\%MXS/\ \$\->CZBX\6>#(?^^O%FD+_7I7ANG_\ !4?X[_%?]FJ3
MXB^#M#^%>EV_AOX':?\ %S7+75[2^N9+ZY>75/.TZV,=RBPQR1Z8VR9S(8F/
M*S!LI[A_P5>U+_A+/^">UE>&+R?[3\9_#Z?RR=WE^9XOT1MN>,XSC/?% 'UH
M.E%"]** "BBB@ HHHH **** .!_:IG%M^S#\1G;HOA?4V_*TE-?PNVQ;[-'P
M/N+_ "K^YC]L>58/V1OBE(_W4\(:NS?064U?PT6W_'K%_N+_ "H _1/_ (-3
M58_\%J_AZ5!*_P!C:YGC.!_9\O\ ]:OZS*_DY_X-1X_-_P""TW@,]H]"UMOK
M_H,@_K7]8U !1110 4444 <?^T(6'P%\;>7'),_]@7^V-$+M(?LTF% '))Z8
M')K\;_V>_P!G[XI?#;X??\$]]:^-7CC6/%_[/\<_AVZTS1])\)VFD7W@+Q.+
M/_B3C4)8XI+BXL 7D@DE+PC>4:;@\_M^QP/Y5X[X]_X* ?!KX8:/I&H:Y\0O
M#UC9Z]ITNLV4JRM,LVGQ,%DOCY:MLM4) -PV(AD'?@@T ?EE^R+^T-\>/B#^
MU'?V&O\ Q3\4>%OB59W?CJ/Q_H43:]XF?2+**&\72I(]#336TZS6V9;.>U>"
MYW:@"8]TCR;%\U^"7Q=\;?'7]D#]J;X<ZI\2O'7Q>AC^ &JZ_<^)_#WC'5M3
MTB74H6)CMKNTU*R2[TW4KA0XELXYQ"]NDR^0IRP_>S0]<L?%&A6>J:;=P:AI
MNH0)=6MS;2"6&YB=0R.C+D,K*0002""#5'P7XUT3XC:/=7VBW]GJEE#?76FS
MRVY#HMS:SO;7$3?[4<T4D;#L4([4 ?A7^W1^W7JGPG_9Z\%Z9\&_C!\2+=O"
M'P>TCQ%X?U>7QU-%:^(I#>E+EK6RAT^635IH1!+%.+FYB@MHA]P;2:]&_:$^
M+7BK]FK]H;_@H1XX^&?CCQ1)\4+CPQX-\0:-I<UX)H_['GBLQJ&K6]N\4FY+
M**2=8Y LBP!F!1S@']GFMK73H5FVPPI:1,BOA56"/@D _P *_*N1T^4>E1:5
M+IVOQ0ZM9M9W4=[;H8;R';(+B!OG3;(,[HSNW#!(.<CK0!^,EI^VS\5-(^#=
MU;2_'Z'_ (4K<_&GPWX5U'XBZ-XD;Q)?^$](N;":34(9-=FTRTMGB:]6S5;I
M%D^S"[>.1_E 'U5_P0$\16NL_#W]J+5(/%USXTTN;X]Z^]IXDO4BCDU:U33M
M*6*X=HT2-\Q*O[U559 /,  >OO ^%=*_L!M);3K#^RV4HUG]G3[.P)R08\;<
M$DG&.M3P:7:6L,BPV]NL<Q)=40!7) !R.AR !SV H _"KPO^TOXLA_;/TS]N
MRX^&?Q L_ _BGXFIX:?QS)J%I'X<7X;SH-&M@]KYYNU<7Z17Y9K<*Q8?,!L+
M>H?\%$M3^-'[0OPS_P""AE[<?'+Q=HGPY^#D3Z1HGA#2=,TY(;M7T2SN[E;F
MY:!KEH6,N JNI4-(0V#@?KGI5CX=\:>#HK>SAT;5-!8&!(HDBGLV$;[2@493
MY'0C&/E9,<$5=;PMIKVU]"UA8M#JF?MJ&!-MYE0A\P8^?*@*=V<@8Z4 ?D;\
M8OVN?%'[-FC_ !3U[X;>-]$\47'A7X > YK#QY)H>EZE>*EWKU]:76I2SV\"
M_:8K6W+S+"Q,"F!F*9:1FT/VI_B3;^,/A;X)\-C]I2Q_:0M=&_:0^'-M#JG]
MBV5O-H/GW<4S6TE]8A+.]+8:4&*-7A5]CEN#7ZG:3\'O"?A_3Y+33_#/AZQM
M9=/727AM]-ABC>S7>5MBJJ 81YDF(S\H\QN.3FMX=^ ?@;PAX6L]"TGP;X3T
MO0]/O5U*TTZSTBW@M;6Z5MRW$<2H$64-R' # \YH _+G]FW_ (*>_'[XJ_M;
MPQ7GBKP]8V>J>-/&GAO4?!.MW_ANWM?#-II<-W]FEBACE76Y+BW>VAEN3*K)
M)%-(42-?*8VO^"7O_!0+XU?%CXG>(O!7Q@^,UK;ZUJWPNO\ Q5IFJ)9>%]<\
M-69AN!"=<M=1TN2'RK2,2*?L6HPECM)-R-I4_I_IOP,\%Z-\3;[QM9^$?"]I
MXTU.!;6\U^'2H(]4NX5^[')<A?-=!@85F(K'\&?LE_"WX<Q>)4\._#7P#H*>
M-$:+Q"NG>'K2U&O(RLK+=B.,>>I5F!$FX$,WJ: -;X$7-U>?!'P?+?>+-/\
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M,<H3Z<\>?M7:A\$_V4C\1O'?@/7-&US?;VB^$-/O+;5-2GOKJ]2SLK*.6-Q
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MU9JFBWWC[PK;Z]>>'UFBL9_M5Q:R1PS;#- [02(9()/+3?#)NC;:,J:]2HH
M\I\.?L0_"GPA\/-6\)Z7X)T?3_#>M^&1X,O-/@\Q(9='#7;"R #96(&^N\!2
M"/.(! "X\Q_X*R:=!I'[$EAI]O&([>/X@_#ZVA0=$5?&&BA1D\X &*^I*^7?
M^"NQ:3]ESPS OWKKXI^ 8P1VQXKTM_\ V6@#ZA4Y'XTM X%% !1110 4444
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MZ3>:1K.LO::5J6I^(/MM]-?WEWY]U:2-9WD]S<W#M-:>4<2* ,11;.P\+?\
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M\.] \9VNJWVAO#J-W=ZI>W=K'IWV(O\ :?M,LL4<$,'DAVFBN 2%,)?<NO\
M@K3\/M#\'ZA>:UX7^*&@>)M-UNP\/S^#;WPVS>(OM>H132:?LMXG=)([GR)5
MCECD9 Z.KLACDV8OC7_@F3XI\9+>O<_&75+[5-0\&^'])FUC4-!AFU%O$&AZ
MQ/J^GZSN21(_*$]S,LEF(\-&(U65-I+2>#O^">GC?Q/\4+/XC?$[XA:#KWQ
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M!<+%K.OZQ?:;.XBGN[=9K>)H(?+C,T;,Q^9U5F9/JS]I+X*6?[2'[/\ XT\
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M5H/_ ,%0OAE/XUTW2M.'BK7-.U)]"#>(=.T.:?0[)-;2,Z7+-=<!4N&EB0$
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MQ8N?BHOB<7ER?$<@?5YM:CT_[%Y(B$WVR8PO=_:3NM@<Q[V(/N7[)/[--_\
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M_P!H9EZCX;^(._\ U#IZ_BAC+!%PO&* /U6_X,Y(?._X*PZ\W_//X;ZHX_\
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MU/>7UY.[7*RV@CA#3R.%B6-5VJJ@ 'A5Y_P4H^+WC_P;)9Z'\._#^B>,-/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,48HHH
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M&S#>6>#;7#!"H=T8!@&!7< VW(&,GXW_ +)GP]_:3U"WNO&7A^/6KFUT?4-
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MHOA_Q=:>!M3O#XGCBUY]0G>&)YK32O)9KBS@EG1))#.DGR7#+&ZPG=E>,?\
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M3_'GA6S\)^,_LXT;[9XK@M+<V]O)-=M8&> B/:'CM7ABD*DM&3)*7[CXG_\
M!-#3?'_B#Q%K5C\1?'GAW7=3\5V'CO1[ZSCTZ5O#&NVVE_V3+>6Z36KK*MS9
M#RIH+D2Q<LT:Q,=U '#_  J_X+,Z)^T#X2\,1_#GX?ZY\0?'6O:CK.GW/A[0
M==TNZM=.&C_8S?W']J"?['-#MU"P\EHY"96O(E*QD2^7Z'^P_P#M;3>/O^"<
M>B?&3XA7]Q9QMI>J:_JL][:QVL]C:07-RVV6./Y5>*"-48 GYD/)/-8^J?\
M!-75)M.\)ZMI_P =/BEIOQ0\*W6J2+XW,.EW-U=VVIFV^V636,EJUA';'[%9
MF-([=?+>V1_F+2^9L'_@FSX;E_8 TG]G6;Q-XKNO!]G';6>H7TTD#:AKEHEX
MMU/;W#B,(5N<-%*4524D< @G- '@?_!._P#X*G>(/&?PW^+&M?%3Q%X9\67&
MA^#+?XQ:19^&9;22XT[0;NWN97T=Q%)M:ZLI+4Q,\A4O]IB)/.:M^-_^"L'C
MI_$OB&[O?A3X^^&_P\L_@OK/Q*34KW^QKO78! 4:WN$M5O9(]QB.!;R[2)9
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MEK?O@?$6ZDSS_P!-%;Z?YS0!],45\RC_ ()I%'#)^T!^TTFT 8_X3G>#[_-
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MBGY=W!FB![>F>>WMUK^.-CST_6@#]F_^#*2US^VM\89=O^K\#P)G/]Z_C/\
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MR2W=EY\LENQW*KJDK%D2-P1OVK]=?#;_ ()C_L_?"#PEXRT'PW\(_!&DZ/\
M$"W:S\06D>G(\>I6QS_HK!L[;=<DK"FV-"2552<UE^%/^"6O[.OPV^'_ (J\
M&Z5\,_#^GZ/\1M*AT+Q#;B>;[1XAM;?S&C2>9I/.E9!(_P"\+E\8!;"J  ?0
M6DB<:9;_ &IH6N?+7SFBSY9? W%<\[<YQGM5BH=/L8M+L8;:!!'#;HL<:#HB
MJ, ?@ *FH &^Z:^3_P#@E?\ /K'[3TGS?O/CKX@Y(Z[;;3T_]EKZP;[IKY-_
MX)02>?;_ +1\G.)/CMXJ'/\ LO;I_P"RT ?65%%% !1110 5D^.O$TO@SP=J
M>K0:5JFNS:;:R7*:=IJ(]Y?%%+>5"LCHAD;&%#.HR1DCK6M2/]V@#Y/\'?\
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MX%\4_P#"8^'D\*^)EDDUS[!,;1;B[U"_?2%,-^(!9R6,"!XR$C40/(5^D/\
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M1>+M9^-OQ%T.VM3K%[INBOIMBFL0Q)?;4D>2&VDMSY,2H3A+;)5PT@ZS5_\
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M?P/\._% _%;X4Z%X%BU:YU73K2+P#=VEE+:RQ7"SL)'L4DF^V(UDLDAF\T;
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MF?A&TUUO&^F:=H^LM+<3QM<VVGW%Q=600HZF&2">ZGD26+9(K.#N^5<>J44
M?.[?\$IO@0O@/3?#T/@[4+.VTG5[C7H;^T\3ZM:ZS+?3PB">>;4H[I;V=I(5
M2-A-,X9(HE(*QH%J:U_P2)_9[U?P9HGAZ'P%-H>C^'H-1L[.#0/$.IZ+_HFH
M3>?>6<CVES$\UK+-^\:WD+1;B2$&3GZ3HH X3X??LT^"?A1\2_$7B[PWHO\
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MH<6D6]O=^*/&&O6?AO0H+A6,+7-PQ9Y9 N"8X+:.XN&4%2RVY4$%A7SQ:?\
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MECW#:A;@C\<X_&NSH KZQK%GX>TJYOM0NK>QL;.)IKBXN)1%%!&HRSNS$!5
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M5.YPI^E>7?#GX6^%_'$?B*^UCPWX?U:[D\07Z-/>:=#/*P2=D4%F4D[0H ]
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MJ-U=P0W6RP1V^R.N9L0Q"8OL?8L3=Y^R-X[\:?'7]B_5HYO%VJ_\+&LY]<T
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M72"5$?:TLARRD_-Z8 ^=/B)_P6#^'?@?P'H6O0V=W>6_B+0=#U:R^TZA9Z;
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M?_X)@^ /#/Q^TWQY:ZY\0A#H7B2Z\7Z-X6;Q#(?#>BZK=Q74=W=6]GC"M/\
M;;EF5F9$:60QK'YDF_Z+EG6"!I'(55&YB3@*.Y-87AWXJ^&?%\&I3:3XAT/5
M(=&;;J$EI?PSK8G8),2E6(C.PAOFQ\I!Z<T >4?#[_@G-\-?A[\/M>\)QVNK
M:GX;\3> M+^&^HV%_>F1)]'L([Z.%-RA7$C+J-P'<-D_(1M*Y/,0?\$MM!U+
MX9>(O#?B;XK_ !T\<3:S'IZ:;K.N>*5?4O"K6$Z7%G-I[0PQ11W$<\<<AN98
MY9YBBB:25?EKZ0\.^)M.\7:);ZEI-]9ZGIUXN^WNK2=9X9U_O*ZDJP]P:YCQ
M/^T5X)\(P^'Y+WQ-I*Q>*-;7P[I<D5PLR7>H,LC_ &<,A(#A89"02,;"#S@$
M \H\-_\ !-CP[I=_X>U35O'WQ/\ %WB71=?OM=NM;UO4[6>ZUU;RS2RN;"YB
M2V2V6Q>WA@7R;>&':8$=2'+LW'Z5_P $=/!H\)ZIX?UKXB_%GQ1H*^$-2\">
M&+'5-1L7C\#Z1?PK!/%8%+16DE\E$A6:\-Q(L2*F2"Y?ZRM-<L]0O;JVM[JW
MN+BQ95N(HY59[<L,@. <J2.1G&17.WOQN\-V/Q'\-^%#J*RZSXLL[^_TU(4:
M6*>&Q:W2Y)E4%%*-<PC#$$ECC.TX /&_VS/^";NC_MK7[6^O^/\ X@:5X5U+
M3H=*UKPQ9/876DZK##*\L<BQWEK.;.ZS(4-S:-#,4"C<&2-T^CT78BJ.BC I
M(I5GB62-E=' 964Y# ]"#3J "BBB@ HHHH **** "BBB@ KY8\?%I_\ @LY\
M+X_X;?X1>)Y/Q;5M$7^E?4]?+/B5EG_X+5^"4(;=;_!37Y!QQ\VNZ,/Z&@#Z
MFHHHH **** "BBB@ HHHH _/;_@Z8G,/_!$'XMJ/^6MYH*'G_J-V)_I7\E3\
M-7]9G_!U1*$_X(F_$Q>\FIZ$H&.I_M>T/]*_DU:,N<T ?OO_ ,&0"_\ %/\
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MA\#WW@'0IO#%O<6UY%:JCQR17%O:1V4,ZSJPF69;2)+?S ^XQ#RR2I(/KE%
M' G]EKX=+X4U+08_!GA^WT35M%M/#EW86]FD%O+IMIYOV:TV( JPQ>?-L10
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M8'OYK11)??8TO01=2+,I\Z*. ,OQ0UOXP6WP@\5^//'/Q!^+G@GQ%#K7P_\
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M(Z+B3WC]OWXVZU\%O'FCWF@2>!=/U:Q^'WC#6K#4O%,HMK"PNK;^R4A::X+
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MBBB@ HHHH **** /S=_X.P)S#_P1=\;KVDUW0U/T_M"$_P!*_E#<X:OZMO\
M@[*?;_P1E\7+_?\ $.B _P#@:A_I7\I+<M0!_0-_P9"VQ3X<?M&3;L^9JN@I
MCC/$%Z?K_%WX].]?NQ7X9_\ !D9:[/@W^T'-_P ]-<T=/^^;:Y/_ +-7[F4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YP_\
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MQEJ.K:_HNJ^,#!X8\)WMXMIH%IJT]G]NG3DVZQ0I%)*)2K EMJEL1T =D/\
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MJJ/^"J_[$\W@V/P^_P 5/@^OA^W(\O2YA''9Q$,2,0M&$4AL_P /!K;\+_\
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M?[)/ASX0:1XVU/5/AI#X9\27MQIUI))H:M<2W-MG[3$]J(3/&UOMS,)(U\D
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M9.@RA=OQ<_:5BV\#'Q5UCGIUS*<]/U-<%H/[,'PU\0_M >)/A7IO[1G[1?\
MPL'PWIEOK6HZ*WQ*U$W$%E<,RQ7">:"KIN&TE"VPE V"ZY /M/-&:_.S7;SX
M)^$;+PW)_P -3?M57W_"60ZC<Z3'I>JZMK$]U%878LKR3RX+"5U2*X98RT@
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MP6G\6-VA^"FBK]=VNZJ?_9: /J2BBB@ HHHH **** "BBB@#\M/^#P"?RO\
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M,O$GAKQ%_P )!IW@Y;/1K :%.);.V&FFZ=YE97N%DE>Z\UO.7#(L4:+-;_\
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M\>O _A^RT>YO_&7A2QM_$,2SZ5+<:O;QQZG&T9E5X&9P)5,:LX*9!52>@)H
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M1O%VHV*:A923RW:V>I107"_:82]Q.RQW 8;+B51\DC _*/[$WQ3U[XJ?M$_
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MX$\)>%(;@&9HDFTB[O;F1G)B#>7NN@T> 26#$A>*]B_;;_9X\7?&OQ%X/O\
MPG'HDS:99:]I%_\ VC?/:FVBU'3)+=+B+;%)YC1S"(&,[,J[$-E0K?/>A?\
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M3<^#-6AU;56U&*26Q:SLVM_/N$G2"X*E4^46\IDV!&( /'8O^">-[;?&6_\
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MX9\6Z9H^K:_XGAO%L;PV4\-EJ/Q4M;]9$:*17C8Z0)K@.I#+'G!#<5E_$O\
M9YTCX#_%W_A$/%'@WQ1JWP2'C+Q'J'ASP/H_B5;.>7?HV@/!?6T$EW \EE;W
M3:R"%D"VL]Y#+M1562/ZDA_X*@^ ?%7Q1;PWX<N&U"WFTCPMK5EK=Q8ZC%I&
MH0ZYJQTV*-+E+22-9P_EA$=AOEE,;&(07#Q0^./VOOV7?VG(-:T'QI-X5\4:
M1X/M]2UVY;Q;X3N&T>%=+D\B_G@N+VV%K,]L[[)/)=W3?R #0!XM:_!YOCG_
M ,$&O@;:^*/#_BKQM)I^F>!?$>IV%L]S?ZS>6]M?Z=<WC)Y#+-<3_9!<'Y/G
M<\J-Q6L*Z_8^^)/P\5_&GPQLO'FD_$SQ5XU^)*F2ZU2Y_L^UL;BV\02:,9;6
M60VT5NUZNES(3&#YLVXG,CY^T/V:_P!L'X:_M0SZ]I7@+6+B\OO!J6J:MIEW
MHM[H]WI N%D-NLMM=PQ21[TB9E!490*WW64GG_AQ_P %*?@3\6+S6H=#^(NB
M3CP[IUWJ][/<Q3V=NMI:-LNYXYIHTCE2W;"S&)F\IB ^TD"@#X=_9Z^ GQ'\
M3Z/%H=M>_'#3/"NJ:]X2_MZVE\/>(/#$T,R74[ZG+]IU#5+N[=I+=8XKF:U9
M+8JT;)(TF6'N7[(/[./BKX,?'CX?ZIYWQ8FANM2\=:+J::[K6I:C8V>C6^J.
MNAPM'/(\<:K;Q0F"5AYLJNY,C[V)^@OA;^WQ\'/C-;PR>'?'&E737#W,:Q7$
M4UE.&M[:.ZF#1SHCKMMY4F&X#=&V]=R@D6=7_;G^#WAWX?0^*[GXA>&8_#]S
MI6GZY!>I=>8EQ9ZA))'8RQA06?[0\,JQJH+.8G !VG !\B?M3?##4_AY^U)\
M9]>M;+XRV>C^,-0\%WOBJ_\ "_\ ;=T]UX<C\VWO4L?LQ8)*LT<0G2S"W4=M
M)*Z@*VX^A?"/6/BKI_\ P3*^,5[X'_X3N]UB >(Y?A,WBF"XD\1R:>(V.GF6
M.[!N'<3>;]G%R#*\(M?,R6(KWRW_ &X_@_>W?@>&'XB>%)[GXE 'PM#'?*\N
MN OY9\E1RVV3Y&X&Q_E;!XK2\??M<?"_X5_%72? OB/Q]X3T7QAKQA^P:->Z
MG%#>7)GD,4.V,G/[R0%$SC>PVKD\4 ?G[\*/%_QJM_@]XRD^'.N_$+Q!KS:U
MH)\!Z;JVE^)OL?\ ;6+MM2BU*YUL)<G3I+55-RC$16\F/L["Y=(QS/QL^-?Q
MHT27PE]A\5_%+1P?!=G?>&;C7;;7;?4M5\5O?7G]I075C86,\%W,DZVT*Z?<
M.MN+=AY'[LF9/TO^'W[3_P -_BW\1?$'A'PSXX\*>(?%/A5GCU?2;#4XKB\T
MXI*8G$L:DLNR4&-LCY7&TX;BLKQG^V[\&?AOXKU/0O$'Q6^'6AZWHT,D^H:?
M?>([2WN;*.,*7,L;.&3 =3R <,#0!\C_ !,U3QAX1C\1>+O&?Q(^+'A?P+KW
MQ:O]!\2ZC9W,\,7A/PY:V]Y]C%HJQ,;:WGU%;9);Y%,@CG">:D:J\? ?%3XZ
M>/&^$RWGAOXH>/K'PG;V/A%8/$/C*VG\.W'B.R-WXG#F[U.VL97TU;F.'3F%
MZ\!W*ML)!&;MC7Z!^(?VN/A1X1_X18ZK\2? .F?\)Q%'/X=^UZ]:P_V[')L$
M;VNYQYRMO0!DR"74#DBNMM_B%H-U]G\K6M)D^V7\VE0;;R,^?>1>:);9>?FF
M3R9MT8RR^4^0-IP ?EA\0OVUOC9JB^"9H?&FK>!)CX'T?4_",/BO4?L=YXWU
M5KNX@O=]K9Z+.NL,WEVB_9[<VKB&[CE6.)IEDC_6> L8QO&UNX]/I2B)<[L<
M^O>G4 %?-_PS0'_@K9\9V_N_"GP,H_'5O%G^%?2%?-OPJF\W_@K1\<%[Q_"[
MP(O_ )4_%A_K0!])4444 %%%% !1110 4444 ?DC_P 'E]WY7_!+KPE#N \[
MXBZ>?KBROZ_F*=F+?+TK^FS_ (/.#_QK-\#^O_"Q+(C_ , ;^OYE#&,GYF7G
MH%H _I>_X,M%(_X)N?$IO[WQ-NL?^"K2Z_82OR'_ .#,&V\G_@F5X\?_ )[?
M$N^/Y:;IH_I7Z\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '+_ !LN#9_!OQ9,&VF+1KQ\YQC$#FO+_P#@EE;"S_X)C_LYQ !?
M+^&'AI<#M_Q*K:O1/VDI_LO[.WCV3_GGX<U%ORM9#7!?\$QHO(_X)L_L]Q]T
M^&GAM>/;2[:@#W&BBB@ HHHH *X+]H']HOPS^S3H&BZMXLNO[.TG6=8AT8W\
MDL4-KI[RI(XFN))718X5$3;FR2,C@]N]KP7_ (*$_ 3Q-\?/AEX0C\)Z+X3\
M2:IX/\::3XK.D>([MK2QU..RD:1H?-6&;9(25*,8V57"D\"@#T#5OVG?AKH'
M@70_%%_\0O ]EX9\4,D>C:O<:]:QV.KLX)1;>=G$<Q8 D!&.0#6Y\0/B-X;^
M%_AB;5_%>N:+X=T:/*S7FKWL5G;)P6(9Y651\JL>3T!/:OSM^(/_  3%^+%\
M+7Q=8Z'H,U]XH3Q-_;/@;2O&"Z3I_AUM8N8+AHX+N;3KE+B-_(VW.+>(O),\
MB!AE#]2?&3]C>;XF?"W]G_PG>6VC:_IGPQ\3:1JNM1ZH[W,=U%8Z;=0JZ^:'
M:607+V[CS.3M+$[AR >T:-\5/"?B?QE<:#I_B+P_J'B+3[6.^GTZWOX9KZVM
MY0#',T2L76-P1M<@*V1@FJ_ACXL>"O& FOM%\1>%]5VS+92W-EJ,$^)/-,*Q
M,Z,?F\W*!2<[\KC/%?G?;?\ !*7XKW_Q-\7:2UQ<:+:WFJ^.=7T_QM#XGM/(
M8Z]:ZC#;'[##IZ7QFC^W0K)')=^4@LHWC=RL21'A_P#9_P#'.J_'_P"(JZ/\
M _"/PSU[P]X;^&>M6/A?0M;M6LM?31_$E_=RI'=)!##'(8[9H81(H)2. R&$
M-MC /T+UGQ5X<M;ZW\-W%G8S:;<0W N!M@:QLA (F:.=68;"1,A VD<9.WY<
MZ>G>/_#7B$6*6FM:)??VXLK6:PWD4O\ :"Q\2&, GS N,-MSC&#BOS]^(?[
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MW+<"S_8I^,$S?=B\$ZTY^@L)S3/V$HC;_L1?!N,@_N_ VB+S[6$% 'JU%%%
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MQ*2Z)\S* ,T ?88\;:*T)D75M+:,'!874>T?CFK46N6,[[8[NU=L9VK*I/\
M.OB[X_\ [(W_  3Z_9;O-'@^)?PU_9A\#W&N,YT^/6M"TJS>Y5,>9* Z ^3'
MN7?*<1IN7<PR*S/'W[*7_!.7P#\2;'P3XB\"_LJZ+XNU"XM[>VT:YT_2;>_E
MDN K6X\K ?$N] A(PY=0,E@" ?=JNLB!E^96&01T-'X?I7P#\ /V'OV*?C[X
MG\:>'YOV=O@3H6O>$_$6KZ/%ICZ98->ZE::?+%!-J"1!%D6$23(A."J,R@ME
MA5KX9_\ !-/]AWXN?$:\\+Z1\ ?A#?02:!8^*-$U>PL;>[L/$6EW+R*MS;3Q
ML0VR6,J^"1LDMV#%9 % /O0,#_"?RHSD]/TKY17_ ((9_LBQME/@#\.XVQ@N
MEBR-CCC<&SV%23?\$1/V69(U6/X.^'[;:<@VUY>V[#G/6.93V''8<=* /JL_
MYXI,X[?I7RK%_P $2OV9;>!HXOAO-"K<?NO$^L1LH'3!%WE>O08ID?\ P1(_
M9MBF\R/P7XEA< #,7C[Q%'^BWPH ^K>/3]*7CT_2OEFW_P"",7[/UH"(=#\?
MP@G.(_B?XI0?@!J/%2P_\$=?@7;NK1V?Q4CVKM 3XN^+E7'/8:GB@#Z@!SV/
MY4$X['\J^8H?^"/OP3@'[M?B[$V3RGQB\7J?_3G48_X)"?"B&4-!KWQUMPN.
M$^,?BK!/KSJ!- 'U%Q_D4;0:^89_^"3/P[(D^S^-/V@;-I,X:+XP>)3Y?TW7
MK#VYS43_ /!)_P )I*K6_P 5/VE+/:V[$7Q;ULCW'S3G@_TH ^H]@I&0/UKY
M>E_X)7Z.RQB/XV?M00^6<DI\5-3^?V.7-,_X=96*JOE_'G]J1&7&#_PLV\;I
M[,".?IF@#ZD,8/6LG5HV7Q9I<WERM###.&=4+*A/EXSCN><?0U\W+_P2V:(Y
MC_:-_:HCZ8SX]$F.O]^W.>O?TJW'_P $U-1@DW1_M*_M/K['Q59.!_WU8G_/
M3% % _\ !*/P/<>-[KS/&WQ.F^'ESXJ'C9_AI)J<!\)G5/M/VUG,?V?[2UNU
M[_I9M3<&W,Y+&,@[:B\<?\$G_!OQ"\2>)89_'GQ.MOAIXV\0GQ3XB^'$5_;_
M /"-ZQ?/.+BXW^9;M=QV]Q<#SIK>*X2*5V<E<2.&T)?^"</BH!A!^U9^TU &
M.>=2T.4]N[:6?2FR?\$[?'2QJL/[6W[24.T@DL_AN3<.X^;2#U_2@#?_ &K?
MV%-._; ^%_Q(\&:]\2_B9I?A_P")<UC)<VVE7UM&FEP6J1)):6PDMW M[DIN
MN(Y _F>8XR%8K6/9_P#!.*Q\2_"'QA\//'?Q8^)GQ,\#^+-'318]'UA-(LH]
M#$;*\5Q9MI]A;-'-$R1-&266,Q*0N13$_8"^)4#_ +G]K[]H58\YVO8>$Y&Z
M?WFT8^U3-^PY\6K:#;:_MA?'1&4<&?P_X.G].N=%!/YT ;7[.?[%C_"'XTW?
MQ"\7?$[QI\6?&_\ 88\+:=J.OQ65JND:698YY(8H;."&,RSS11/-,P+R>3$/
ME" '+^)/[ MAX^T;QU?#QA=6?CWQAXPTKQC:^)'L$F_LJ32;B"72[(6Y8+):
M0K!L:/<ID:YNI R22EA3?]B;XV-;_)^V1\8EFQ]YO"'@TKW_ (?['!]._P#.
MH/\ ABKX_(Q*_MD?$9O0/X$\*'\\:>/Z4 >K_LI_ RS_ &8OA!_PCK:]/XCU
M&\U74_$6KZM/ EN=0U#4;V:^NYEB3Y8HS/<2;(P3L0*,L06/I8O(]VW<-P[5
M\LR_L=?M&(#Y/[8/BAF_A\_X<^'74?4+ I/'H1S[<4Q/V2_VGK=AM_:X\Q0O
M_+?X5Z2S;O7*2J,>V/QH ^J&O88SAI(U(&3EAP*&U"%%RTL:Y]6 KY;;]EO]
MJ*)5\G]JS278#G[1\)[!PQ_X!=)BIK7]FW]JBV;#?M0>#9E_Z:?"&+=C_@.I
M >G;UH ^H$NHY1\K*V3@8/6FF^A R9$ QG)8=*^9H_V>?VJ8YF/_  TM\/G7
ML'^#_P#AJPJ-O@3^UI$?E_:$^$<_KYGPAG7/7TUGUQ^% 'T^+N-C_K%Z9QFD
MBO(YQ\LBM]#TKYA'PD_:^A+%?C5\"YL?=5_A??IGCN1JYQS_ "I8_AS^V+"[
M;?BE^SQ(O\.[X=:JN>O7&K?3]: /H#P%<QW=[X@:.1I%7573G^$K%$"![9%?
M//[))\W_ (*:?M<,"3Y;>#X#D="-(D?_ -J#\ZF7PG^V<BMM\=?LQR>A;P-K
MB_B<:K6#^P$NL+^WI^UFOB&;3;K7H;[P=%J,VGPO#:2W(\-6IE:&-W=TB,C,
M55G9@" 68@D@'V!1110 4444 %%%% !1110!^+W_  >K7&W]B[X/0_\ /3QU
M(^?3&G7 _P#9J_G .<_=_6OZ,O\ @]?N-O[)_P $XQNW-XQNF]N+%Q_7^=?S
MFL03_%0!_4I_P9_0M%_P2(5F Q)XVU=EQW&+<<_B#UK]3*_+O_@T+39_P1_L
MCC&[QCK!^OS1#^E?J)0 44 Y)HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \+_X*@3K;_\ !-;]H1F8JO\ PK;Q$,CWTRX%>@? BQ5_
MV>O!UKN;:?#MC$2.N/LT8KS7_@JR=O\ P3'_ &A#P/\ BW.O#G_L'SUZS\&H
M?L_PB\*Q[=NS1[1<#H,0)0!F^%? ?B7POX?L=-B\2V4L&G6T5K$SZ.-Q6- H
M)(FY) ]JU_"_@N;1?$VJ:M=7QO;S5(;>!PL(BCC6'S-N%R3DF1B23Z5T%%
M>17S)XV_X).?"WQ[XUUB\O+SQY#X1\2ZFVMZYX"M?$US!X1UN^>4323SV"G:
M?-E'F2Q*RPSN6:6.0LQ/TW10!Y/XR_8T\&^.?%FO:U>KJRWWB36O#NO7IBO-
MJM<Z'<Q7-CM&,*@DA3>H^^,CC-<7\2?^":7@WQTUO>:3XH^(O@'Q):ZQK6L0
M^(/"VN"SU)/[8ECFU&UW/')&;>:2&!MA0LC6\3(RL@:N?_X+&OXPN_V2-'T?
MP'XVUKX<^*O%7Q \*>'['Q#I<C+<:8;S6[2W9]H8>:FV0[HF.UURK<$UX=X6
M_P""D?BO7/C5I][K[:;H/C;X5_"GQDOQ#\%WFO\ ]EZ-9^(K"^T%8+F:63*1
MV<\4KSVUTZL?LUV2,L72@#W_ %K_ ()4>"7U73W\-^-/BU\/](CTG3M$UC1_
M"_BJ2QM?$]M81I#;F]D*M<F?R$6%[B":*:6-55Y&"KCV?X8? /0_A/:^,(=-
M:^DB\;ZY=^(-16>?.+BZ5%E$94*53"# R2.?FZ8^(?AK_P %C_B%XGM_$FBO
MX'\!^(?&&GZIX0M-(DTN_P!9TW1M2BU_4KG3P6DU#3X9QY#VDCF6*&6*1&&T
MAP\:]C\+/^"CGQJO_'&FP^-OA;\/='\,Z=\1)/ACXBU'2_%EU=W+ZB4+Q7EC
M!)9QA[,!H5?SI$EW&7"$("X![)^S)_P3R\/_ +,_Q;N/&H\:?$3QUKBZ$/"V
MES^*]3AOI-&TD3B?[)'*D,<L^9$CS+=/-,5B0;_O%N=^/'_!,#2OC%X_\<ZM
MI/Q.^*'P]TGXK1QQ>.] \-WUJFG^)MENEJ9?W]O+):3R6L<<$DMJ\3.D:9.Y
M0]>;_L1_\%C[C]KOX[^%= ;P7:6/AGXC6]W>>'+O3YM2N=0TV**%KF(ZJDUC
M#:PB>W1B&MKFX592D>7#"2NV_:>_;3U;]GCX^>*[#0/">H>,M:CM_ VE66FS
M>(39Z?/-KNL:I8HX3R7$#1FW#R2@.7C"#:/+&X N?&'_ ()0>#?B2_B!=*\3
M>*O!]CK47AZ2VTS38[&XTW2;W0W0Z?>16]U;RH[+%'' \4V^%T1#Y8D1)%C\
M%?\ !+'2?!6H1ZLGQ.^)6H>*/^%@V7Q)EUFY?3_-FU"#2SI,L/DI:K MK/9/
M)$8DC7RPRF,IL%>C?L7?M(>)?VAO#7C.W\:>%-.\'^,/A]XJNO"FKV>FZLVJ
M:?/+%!;7,=Q;7#PPR/%)!=PMB2)'5MP(XR?E7]D7_@JGXT^'_P"SMX1UKXU^
M"[V/PS??#S6_%UEXMMM9CO\ 5=?.CF-KE9K%88D@>XAE$D 69]P7#^6QP #T
M[PM_P2+T_P *:#KGA>'XK?$,_#J31-6T+P_X56'3H;?P]!J-O/!(/M"6XN;Q
M8$N'%NES(ZQ +D.54KZ/\0_V#-%^(VG>.K>XU[6K6/QU\,(_A=<>4D)-K:(+
MT"ZCRO\ KC]N?(/R?NUXZUY5XS_X*B^.O@AI.L6_Q(^!MYH/BP:/I_B#P]HF
MD^*(-4&NVUSJMEIDML9S%$L-];S7]KOBP\+><NR=AN97:?\ \%0_'VE^-=6T
MOQ-\!;[1K+P7XXT?P1XNU2U\6VU[:Z?-JS62V,]F/)22\0?VA:F=76!HA*NT
M2G<% -SQ'_P2ZBU']HZ_\9:-\1=:\.^&_$VKV/B#Q%X:AT'2[G^T+^T@MH \
M%]- UQ9QSQV< F2(Y8AV1HF=F/>>&OV'--\+W/@N2+7M0E_X0OXD>(?B1%O@
MC_TJXU<ZP9+5L?=CC_MB3:P^8^0F>IKQ?X!?\%OO ?Q^_:=T?P/86>C0Z+XM
MUV^\.>'=1A\8:;>:O>75HD[-+=:1$YN;2UE-K.(IF+,3Y/F1PB5<=U^V1_P4
MUL?V2_VB?"OPZ_X0ZX\0:GXDTS^UT>7Q!IVBF_B^TBW:VTU;R2,:A>Q\RO;(
MZ,L9C.XF15H WM$_8-BTG_@G#K7[.MQXLU#6-)O/"FH>#K#5[JTAANK*RG@E
M@M@RQ!5=[>)XUWX#.8@S?,2:Y?5?V)-4_:T^'3:Y\1;S6/ _C7Q-\/M/\*:K
M9:;)!,VAZG97QOH]0MIPSK(4NPLD8(P55=P!+*.=M?\ @H5X_P#A?IOQPU;Q
M;\/X;[2_!_Q.;PGX>EC\2Z=I]C#8?V=;W'VF^N[DQ16L()SO<NYDO(XE4E03
MS'@3_@KU??&+XE?"76M(\,V^E_"W7-%\;W_C74)=9LKX:0_A^>U@DF@GMWDC
MNK93([*\#$RK,A&W8RD [_1_^";'BCQ7X@NO%7Q,^+'_  F_CR\UOPI=C4['
MPO%H]A:Z;X?U3^T[>QBM!/*0\]Q)<--.TK$F5=J(L:I7/_$?_@CII/B_]K;6
MOB#8:A\-[?0?%GB2R\5:U9:O\,=,US7X[RW2!)$L-6N&)M8+C[/$SK)!,\;&
M4PO$7&SJ/V'O^"M_@C]MWXH0^$]-TFX\/ZKJ^@2>*M&BFU_1]4>]TY)8(W\]
M+&[G:TND-S S6\P!"R<,Q258_9OVH_BROP9\%:#JCW&L6_\ :/BW0=#7^S;:
MWN)96OM3MK01,L[*BQ.9@CN#O1&9D!8 4 ?$?[7'[-OQ._97UV34/A2OQ(U+
M6O''_"507^M>%?"MEK2M'J^N76JP:?);3WL!M)[=[V40ZDS/;KF8S0@-&H]<
M^&?_  3,U:V_9"\5^!]6\26>FZO\0/@?X?\ A5=B&Q-S#H<^GZ=?VLERK>:O
MVA"]^2$_=\0_>._Y=?\ X)X_M0^/?BM^RY\2/BS\3K/Q)IZP>)?$+Z;H-U9:
M9"=*TS3KJ>%((&M9I/.8+"R/)<2!FGCEV@1>6[]%\7O^"G_P_P#@K\+[7Q=K
M&G>+/[+O/A[_ ,+'C2&UM_,^PF:SA6!BTZHEP9+Z 9=A"@#L\R*I:@#JOVK_
M -FK7?C+H/@;5/!OB+3?#/Q ^%^MIX@\-ZAJ>FMJ&FO,;.YL+BWNK=9(W:&:
MTN[F/,<B/&[(X)*;6^7/V</V(?CA8:%:^*K;Q9X7T?XL>#_B?XQO[B]\0>$Y
M_P"Q/$=CJTP$TT-K%=)-$HV0O PG;<(MKD[RP]NT3_@H#9>-[#X=ZS-X?\=^
M!;?Q)XBU/2'TO5]+L+I]56TT.\U/S(KNVO);9K9HX-Z7-M+.KO'Y3;#YACP_
MA[_P63^&_B[PO?:YJWA7XH>"-%C\"K\1=*N_$.AQPKXETAI(H=UBD,\LDDWG
M7%M&('6.1VN82BNLBL0#Q7XA?\$4/B!XR^$O@OP/=?$?P'XJT?2?!USX:OW\
M3^'+^>WTZ^FN;J>36;&PM[^*W>YG%RBNMUY@C-I"T;8,B/Z9\#O^"7/B/X5^
M/?"FM7_C/1]2_P"$?UCPKJ=PD6G21FY71_"MSHDBKESM,L\XG7J%1=IR3FO9
M/V5/V[M$_:G^(_CCP;%X-^(G@7Q;\.K32[W6]*\6:7%9S0IJ/VHVWEM%-+'-
ME;20EHW91N5=V\.J9UY_P4<\)Z7^T/I'P_OO"/Q,TV+Q!XAG\)Z9XHO/#[6^
M@:AJL,<LCVT4SN)6'[B95E$/DLT9"R'C(!X9XI_X(\:OXP_9[T/P;?>+-!EN
MO#WPT\.^$[:62QG:TN-4T;58M3BFF19$D-I))"D;HKK)L9]KJVUA3^'7_!+C
MXC_"[0K#QKX?3X+^'_BQX=\6VOB72],L(M6FT*[@ATW4-,:SO+VYEENW+0:I
M=.DL<2+ XC41. Q?Z(_:M_X*(^"?V0/%<6B>(-%\>:YJ;:#=>*98?#?AZ;5#
M::7:RQQ7-W*8^$CB,J%L_,0WRACQ7.>%?^"N7P?\4>'/%&L22>,M'TGPYHMA
MXCM;G4_#5Y;?\)-IM].;:RNM,C*>;=+<7&V*-502.\L0"XD0D O_ ++'['GB
MCP+^S;\2O!_Q(U[1-4USXI:_KVL:I>>&;:6QMK5=4R&2!9"SJT:L0&8L20&)
M))KY7\#?\$9?B-I_P7\3>#]5D^&<5S8_#'5OAUX<UN+Q!XCU*XU%KR"&W6Z>
MWO)GM]+B,5O'YL%NEQO8*%=$B0-]2Q?\%3?AD/ 5YJEY9>/M,\166MVWAR3P
M9=>%[M?%3:A<P/<V\":>%,CB6WBFF65<Q&."9MX\I]ODEC_P6#4_"#Q=X^ET
M_P _2] D\;2Z=H$7AO4H]:U6WT%[6+#HW-K+'+,ZW"RQ9 Y 0129 .\_:M_8
ME\:?%#XL^*_&'@V\\)VMY)I7@;^P;+4WFB@EO?#OB&_U=HKEHD8QP3)<11*Z
M!V0[CL( #<]!^P3\1/#_ ,6;'Q)I]UX1NH9M?\>OJ-K<7D\;)I_B%H);>:)Q
M"P,\+VD2-$RA665R'!4!M+]G3_@I#);?!EM?^,FJZ+;:^NFZ#.=#\.^$=9MM
M2^VZJD\D-C%93^;<W$SB+"1Q+OQ%([*JD;?0]0_X*8_"'3/ &D:]/K'B!9-:
MU*ZTB#1(_#&I3>(8KNT3S+R*73$@:\B-O%B64O$%2-D<G:Z%@#XU\7?\$>OB
M=!:7'A>WM=%\6^'?'_@KP[X=\0SW'Q.\2>';'0KC3])ATN[632]/9(M6MIHH
M$D0.]O)N9T=@A4CU_P )_L._%KPC_P %(1XTT6WT/PI\/YO%-[XFUF]TWQ=?
M3V7B6&XL98!"WAVXBDM[34O,>+S=0M;B+S5C=FC+3,B^V?LR_MSZ%\8/V%E^
M._B*ZTW1O",=OJ^K3WUKYLUM'I=E>74:78^4R$-;VZRD!<Y8@#M3/#O_  5!
M^!OB;PAXPUZ'QM]GTOP(MA)JTE[I%]9R>7?R-'82V\<L*R7<=U(K) ]NL@F8
M80L2 0#C?VKO@C\6M-_:4UCQY\,?!OPZ^("^// D/@'4+3Q9JK:;%X=,%U>S
MI=G;;SFZM91?,L]LH1F^RP88@DIYSIO_  2T\3>"OV;?BKX%L9M$UZ[US2O!
M&AZ)JU\_EW&H0:%96$+2W/RL8V\ZWGD1=S89\Y!)->\6O_!3_P""-QX(?7V\
M77EK;1Z^?"KV5UX?U*WU9=5%J;P61L'MQ=^<UNID1/*RZCY=W2G?!G_@J!\!
M?VA/&EAX?\&_$G1=:U35+"?4K54BN(89HX%5[A/.DC6(3PHZM+;EQ-$,ET4
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M^.WQ*\5>,/$%]X,G\2>.?";>!]:OH/$BVDFH:;YJW"*?+E4>=')&K)./WJ!
M P"@#U?]HEE'B?X7JVT^9XR@"[NQ%C?'(Y'/'O\ 3O7I8C#J,]: /C_X>_LF
M?LW^ O$\NO7'Q(NO%'B::?1[R^UCQ+\2YM5O;R31[J>[L6<RSE56*268[(U1
M""P*]37<'P+\ E59&\9>&MLGCK_A8:D^*H@#K !'F#]YS'\K?NON\'CCCZ':
MSC<_,BDGN13'TJWD7:T$++C&&0&@#Y<^ /[-_P $?V>OB5::[X?^*VL7>GZ/
M'<P^'_#-_P#$$W6@>&8Y2_G+9V9D"A54.B"4R"%%*1>6H(KJ?B%\%?@_\6OB
MC/XSU#Q=9OJLUYX=NG^SZ_ L'F:'>7EW8C;SQYUW/O&?G"J.-IS[LWAZQ?.Z
MSM&W=<PKS^GU_.JY\%:.P;.DZ;\QR?\ 14Y/7TH X'X2:7\/?A'K'C*^T?Q1
MIDMQX]\0OXCU+S]7AE7[6]M:VI$0R-J>7;0X7GDDYYQ7F\'[&GP3U/X6^"_!
MM]K=OK7AGP3X5U/P;;V=QK<3+?Z=J-O#;W*W#)M9F:-$ 9"A&\D=1CZ E^&_
MAZ<CS-"T:3:<C=8Q'!X_V?\ 9'Y#TJM)\'O"4J;6\+^'67C@Z;"1QC_9]A^0
MH ^9O"?_  3H^'\$]Y=>)OBYXZ^(NMS+HUE8:KXBU^SGN](L--U.WU2"R@\J
M&-"LMQ;0&:617FF")ND)52/2O$W[+'@7QG;>/%E\170C\?\ C+1?&^H&*]@_
M<7NE?V5]G2/Y3MB;^R+;>&R3ODPRY&WTI_@CX,DC56\(^%V5<8!TJ# QC&/E
M]A^0J-_@)X&D1E;P7X399/O Z1;X;@CGY/0D?B: /%?@Y^PKHOP2^+&GZIHO
MQ6\<)X%T._OM6T?P%_:%FFC:9<WAF:;$J0K>36ZM-.\=M-.\,;-\JXCC"5OV
MZ/\ @GMX?_;QN?L>N?$;Q)HWA?4M._LCQ!X<M1I][I^LVPE>161;N"8V5T-\
MB_:K4Q3%2HW9CC*>X_\ "@/ A1E/@KPB58$%?['M\$'>"/N=_,?_ +[;U-$O
M[/\ X#GD9G\$^$6:0EF)T>WRQ)8DD[.Y9B?7<?4T ?/'Q[_X)D:;\9M>UK5=
M/^*7B3PYJ5]XSA\<Z8C6&EZO8Z+J TLZ9<!+6[MY(YHYH-KXG#M%*N^)H]S!
MJOP__P""2_A7P3:Z'!<?$/QCXCBL]0\53ZN-4-BW_"1V7B(1MJ5A.(H$6*)I
MH8I5:W$;(4*@A25KZ/?]GSP%+(SMX)\(L[J59CH]ON(/49V=#Z4/^SWX"?KX
M)\)'G/.D0>Q_N^H'Y4 ?.7P8_P"">7C+]F;PKXBN/#OQBU;Q5XDL_#$_A[P5
M_:F@:186^B@^68Y;IK6V1KV8>3"IEFS\BM\FYV9O?_C]\#[?]H#PSX?TVXU*
MXTU=#\4:/XG5X4#&=].OX;U(6!_A=H0I/4 Y'2K2?LX?#Z)PR^!_"*,IR"ND
M0*0<H>R^J)_WPOH*1/V</A_%!Y2^"_"ZQX4;!ID(4!=@ QM[>6G_ 'POI0!A
M?"?]E[3_ (:?LZZG\.)]2OM6TW6)M9>ZNF58)W74[VZNY0-O"E3=N@/^R"><
MU\__  ]_X)4^,?#VA7BZ]\?->\0:U;_#[_A76AWJ>%=/M8-)LTN89X97MF\R
M.Z=A!''<)+^[N$RNV('%?3,_[,WP]N<^9X+\,L6&"?[/CZ8QZ>G%)+^S+\/Y
MB^[P?X?S(-K$6B@L/F]/]YO^^C0!\Q_ /_@CY;_!7PUIL)\9:3'?6_B[5?%U
MS!X>\)1Z%H237OA^YT0PV>G)/(EHBK.+AMKN99%;. P*G[3O_!..:7]FS3;?
M3[S7O%6H?#WX0R^ --T_1K>"TU+4+F.XTFZ@U&V>>7R4N(I=)CD2"7,;NRJT
MB@$GZ?;]G#P.8RB^&].C1FW%8PT8)^;^Z1_>;\Z?>?L]^$;ULMI;+\Q?]U>7
M$?)W9/RR#^^WY^PH ^5_^"5/@#XO:I\;OC3\5OBQ)XDDF\<V?A[0](;7?#-O
MX9N7ATQ=0:1DT^*YNF@A,E^<&:9I'D$S@)&8U&-IW_!&S6H?VQ--^*%Y\0/!
M-XVB_$*7QW!?S^ O.\67\4INA_9=SJTEZ=MK#%=-%$L$$2JL46Y&"8/UVW[.
M/A-I5?['J2E, ;=8O5  P>@FQV%,A_9K\*VQ7RU\0(5Z;?$FI#^Y_P!/'^PO
MZ_WFR <=\8_V2YOBK\9/$'BM?$45BFL_#G4/ 26C6'F_9WNIUF^U[_,&X+M"
MF+ SC.\=*\O^*7_!,O4O'6AZ.NF^/[;1M6\-^!O#WAO2+W^Q?/2#4]%U6#5+
M:]DB,P#P--;1J]OD$H6Q(#@CZ&B_9X\.P2(T<WBE6C(*X\4ZH.FW'_+QS]T=
M??U.7/\  '0WQ_IWC0;5"C'C#5QP !VN?]D<_7U.0#Y>U/\ 8"^,&O\ BF3X
MO:A\0_ /_"^K?7=-U;3X[?0+A/"=K96.GZE8+I;1M.UTXE35]0D:ZWAUDECV
MQ[(MC9<7_!*CQMJ7P_U>UUSXB>&]4\2:]IGQ&AO;^VT&6QM?M7BIH'C:.'SY
M&6*V,)4@NS.NWG.2?K.[_9^T.[15_M'QLFTYRGC'5U/3':YILOP!TJ1 HU;Q
MM&JA@-OBS4\_,7)))G))^<XSTPN,;5P ?*O[4/\ P2AU/XZ76K:K;ZUX7NM4
MLM2\-:WH6GZK#=KI]Q<:5IE]I\L%XUO(DRQ317\I5XCNC948K( 4:A\+_P#@
MFW\3OV>E\#^-/ =Q\&]+^(F@ZCKKZGHHM=37P]<V6KQ:=%(%N9))KN2Z@_LJ
MR<3,%$RK)%LA5E9/KM/@380H0FN>-ESGD^);USR2?XI#Z_H!T II^!EN#\OB
M/QP/^X_<'^9]J /!_#'[!?BGP_\ \$CO$W[/MUX@\.ZEXPU[PMK^BMJZ6SV^
MFRW6I27CB4Q?,T<8:Y&4&[: 0,X&7?M@?L>?$;XE^)OB)XB^'OB+2=%U+Q)X
M;\)Z-9V_V^YTJ>[CTK5]0O;VU:]@1I;(7-O>+#'<P*TL+;G4 A37NUI\#8[,
M_+XJ\</AP_[S6Y'Z;>.1T^7I[MZFG#X+S+%M_P"$P\;=N?[10GC;_P!,_P#9
M_P#'F]: /D7]C;_@FMX]^#/QTB\:>)Y?"<,,_CQ/&C6%KXDU?Q!<:<@\+WNB
M_9S?:D&GNI ]Q&WFL45E:3;'& J'7U7_ ()D:_XO^ O@SP/J&K:-I::?JGCZ
M75K^P\QI8(/$,6M1Q26X*J6E3^THF<$J,HV"< U]0P_!FXBB*_\ ":>.#P%!
M:^B)&,#.?*ZG'.>N33O^%-7892OCCQLN&W8^UVYR,8QS!T[_ (4 ?,/_  3[
M_89\<?!?XVV?B;QUX:T+1YO"/A(^%--O[;XG>)?&,VJ^9);M/-%#J3K!IMLW
MV2)OLZI,Y8J/-41?O.J;]BSQ-=?M5Q^,KK^P9]#A^,DGQ"1&F9IDM/\ A!TT
M&/"E,>>+P,V 0!'AMV?EKW:7X1Z@[?+X[\:1_>Z2V9SG=ZVQZ;AC_=7.><NE
M^%FJ/$RKX[\91DDX*_821][IFU/3<#S_ '%]\@'E7PO_ &8_$?@;]A;Q_P##
MQETF'Q!XCO?&UU8+%*?LJC5]7U2\M-S;05_=WD6_"G:VX<XR?GSQG_P2J\<:
M+X]_9O\ $G@O4=%L%\/R^$;?XLZ/+(?L^LC0HD-IJ5M)C)NH"CVYR/WT$L8)
M'DI7VF_PEUJ1N/B-XXCY!P(]+XY)QS9^X'T4=\DB?"C78C_R4KQPW*\&WTDY
MQMS_ ,N/?:<_]=&QCY=H!\(_LC?\$N/''P^^)7@WPGX^\/ZEKW@?X=W6LSKX
MBO/B1<W6G:[%>V]Y;_N-$$0\J6>.^D%PLTOEJ?,VF<NK+2T#_@GQ^T!X$_9H
M\<M>+HGBSQ_IEWX;\%^%DBFLI;ZZ\%^'[Q9;:>WFU".6TM]7N&DFN-]PCJDL
M<1+!E1D^^F^%7B K_P E,\;#E?\ ETT<]-N?^7'O@Y_WVQCY<-/PG\2'=M^)
M_C)=Q[V.D':..G^A>W?/4^V #\]?@Y^Q7\=/A;XJF^)6K?"_4/&]Y9_%;_A-
MAX1USQEI>H:MJEK-X6@T;[7]K*0V8U"UFB=UC.R+R[F14F)17:.#]BCX[>"?
MA1\*]/T_X5QZ6MC?^/[G4-,\$ZKX<34/##:SXB:_LK6*^U2WDCBTQK4J)C9Q
M"XW11#R]J[*_0Y?AAXIAN"R?$CQ%(N,!9],TU@.#SE;=3_\ JIUSX!\92%O)
M\?31!E8<Z+;,5R' /;D%D//!\O&.30!YC_P33^$OB;]GS]DCX4_#OQ9X3?2=
M<\#> =&TB_U-;VUNH9[J!)89;1&C<R,(O+60,RB,K=*%.X2*OT17!R>!O'*M
M(T?CRW^8G8)- B8*/GQG$@)ZJ.H^Y[FHD\$_$2.''_"?:2[\?,_AD'^+)X%P
M.W'MUYH ]!HK@XO"WQ&B" ^,_"\FT_,6\+2Y<<>EZ/?I[>G(GA[XE+)#N\6>
M"612OG#_ (1.ZW2#Y<[3_:7RYPV,@XRO7!W '>9HK@9O#WQ,*_N_%G@8-L ^
M;PG=GYL#)_Y"70G=@=@1R<$EHT'XH+"O_%4> Y) /F/_  C%X@)VGH/[0/\
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M!\1=2\,ZYX?@T74+#3;;5%:WU(7L<L4TDT6"?+0JRM W8@@@YZBN[H ****
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M<9M^?N-C'7Y<9W+D [BBN)B_:&\+RQEO,UR-0VT^9H%_&<\]FA![']/49/\
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M4:72R#*Y/T&:7SO]EORH ?13?.']U_\ ODT"7/\ "W_?)H =130^3T;\J=0
M48HHH ,4444 >;Z)&&_:V\3297<OA+1UQ@9 -[JO?KV^E>D5YWX>M]O[5?BR
M;^]X4T1 ,^EYK!Z9]_2O1* "BBB@ KYE_P""?:M+\</VLIR1M;XO^4!Z;/#.
M@?XU]-5\N_\ !.*99OBQ^UFR_P#1:[E3]1X<\/C^E 'U%1110 4444 %%%%
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M@/8Z"^[[W W7??/M][ZU&OA/P[,HW_ F1-PVG=I>AG:,YYQ<GN :]FQ1MYH
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MXUN]1M]&\0:'JUQH[^7?QV5]%</9-R-LH1B4/RMPV/NGTKP__@K;JOB30_\
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ME?\ A,M=;YL[C;6.<>G_ ![X[_I4,G@#779B/'7B!>N +/3\#_R6[?UKKJ*
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MX*+_ !N_:'^+/PYUSQ3X;FL_AW\9#?-8V=QH]AIT/AU([::X@%O?#4I;C4)
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M FM^,OB-=^(YO#"^$?#^NZ1J*F>+3UU%[@:G'=?8?LHM7C/F&4,)9%B*!\@
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M-YSF@#^P?_@W*M%LO^"*/P"1>0VC74G3NVH73'^=?;-?&?\ P;TP^1_P1?\
MV?EQC/AUF_.ZG/\ 6OLR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^8_\ @KH0_P"Q]81'I/\ $GP!&?\ PL=&/]*^FU.:^7?^
M"N]QY?[,'A2'YO\ 2OBOX B.._\ Q5FE-_[+7U&O3\: "BBB@ HHHH ****
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M^(M!U#1+FSAOIEAL[HV]W!',;6>1@J7"H8FPWS?*V ##^'?_  2.^#_P_P#
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M-NJD$%I H&#FDC_;#^$LTL<:?%#X=M)-K9\,HH\2V19]5&,Z>!YO-T,C,/\
MK.?NT >CT5S,_P 9_"-K\2X?!<GBCP['XRN;<W<.@MJ< U.6$#)E6VW^:4 !
M.X+CBG>'_C)X1\6>*I-"TOQ1X=U+6X;<WDFGVNIP374< <QF4Q*Q<)YBLF[&
M-P(SD8H Z2BO-;7]JWP?J_QZT/X>Z7J$>M:MKFE:SJOVG3IX+FST\:7/IT-S
M!<.LFZ.<MJ<!5-IX27<5(4-V&A_$CP_XG\/7&KZ;KFCZAI-HSI/>VU[%-;PL
MG+AI%8JI7OD\=Z -JBN(^$7Q^T'XV>(?&VGZ&;J5O >M1:'?7#JGV>YFDTZS
MU%'@=6;S(C!?0_,<?,'&, $]O0 4444 %>6I\5/#OPX^*_BY?$6L:?HINFLG
MMC>RK")T%O@E2<;@&##V((KU*N1\5_'OP3X$UB73M;\7>&M'U"&-99+6]U2"
MWFC1@2&*.X(!"D@GJ : .2\9_'+PAX[U_P (:9H?B;P_K%]-K]NQM[6^CFFV
M+%+(6"J2< *#G&,&OEC3O"_[07P_^$GQT^%_AOX'ZC<:I\2O&7BN[T3QC?>)
M]&B\/6-KJ]U,T%[-$MR]\WDI,':!;;<YC*[EW!A]I>'?VA? ?B[6K?3=*\:>
M$]2U*\)6WM+75[>:><A2Q"(KEF(56;@=%)Z"K?@_XS>$?B%_;W]@>*/#NN?\
M(O>2:=K/]GZG!=?V3=1@-)!<;&/DRJ""R/A@#D@4 ?GQ\:O^"<?BCPOX-\1:
M/I?@OQ9XHTKP[X@\*2^&KOP]J.B_VRD.E^%_[,-]%9ZIFPNRLQ,4EM>&,&.2
M22)O,CB)\C^,O_!.WXRZS\"OA2W_  H_3[KX@Z3X)O?#R6FC:;X5N?"ML[ZI
M/=06.JZ3=S+'8HT?V:62\T6Y9TE^T*JLJ6^?UQ\"^/\ 0_BAX2L=?\-ZQI7B
M#0M3C\ZSU'3;N.[M+M,D;HY8V9'7((RI(R#6ON% 'YK?$[]C'Q;KOQQ\86+_
M  0_M;XB>+?B?HOC'2?C3#-IGD^']+MI-/=XQ<O.-1B:U@M[FSCM(XC'*DPY
MV33D+X.^$/Q<_9D\5:?XBB^#OBKQE-KNC_$G05L=%OM.,VGW>J>+)=4TZ2X:
M:YC2.TGM1N,JLYC.U60,P%?I1N%&Z@#\K?"'[#'B_P #VK6DOP?N(]?UKP!\
M'=/GU^SL[$R"31M8M5UFSFG63S?-CMT@<CYD>*S7#'RD%=!\!OV7-6T7]J[P
M"UO\$O$'AOXN>&_B3KOB+Q]\6Y[.UALO%&B7 U+8J7Z2&6\BNA<V*QV)7_1/
M*Y2,6Z%OTRS10!^>O_!,#]@]OV3O$?[-6J6/P_G\(:Q=? ^]T[XCWP@$<][K
M?FZ!+!%J+@YFN$;^T1$7+&-%E12J?+7Z%444 %%%% !1110 4444 %%%% !1
M110 $XKYF_X)5%7^!7Q D4G;-\8_B(XR,<?\);JM?3)KYB_X)+2_:/V9/%$R
M[=LWQ6^(,@QTY\7ZM0!].T444 %%%% !1110 4444 ?SS_\ ![9<Y^-G[/L.
M[E=#UIL>F;BSY_\ '?TK\-W*AN217[=?\'LL^_\ :.^!$))^7PUJC8^MU /_
M &6OQ%V?W2,>] ']D/\ P0(M_LW_  1N_9[7YN?"D3\C'WI9#_6OK^OE'_@A
M?"MO_P $?_V=E7H?!-BWXE23^IKZNH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /EO_ (*VMGX!?#V/ /G?&'P"O(Z?\5-IQ_IV
MKZD'2OEO_@K"X/PC^%<3 LLWQF\"J1]-?M&_]EKZD% !1110 4444 %%%%
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MFO-_V,/^"3T?['GQ2T+4[7Q=X=U3PUX+TJ;1_#EA;> -+TO5TMW5(HOM^JQ
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MXJ!<^GY5^TG_  >MM_QF1\&5]/!=R?\ R>:OQ;WJ/7KZ4 ?V??\ !$>!+?\
MX)%?LYK&-JGP%I;'G/)@4G]2:^I*^8_^"+2;/^"2?[.('_1/='/YVL9KZ<H
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MQ]XFUKQ9;+9OJ5GIFJ0>)HK&Y>8-NEC9;K2@(02R8CW(IC8KPG_!)_\ 8?\
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MM?%.F^%$\.^&/%6D:U#=SZC;SS6<L>HQ3_9?+8VTR2!W1XC$[,FW8S]UI?\
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MV[S-8\1ON'\6?$&HG/XYS7U(:^4_^")*!?\ @F1\-2IW"1]7DR>Y;5[UOZT
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M1110 4444 %%%% !1110!\O_ /!2%EF^(/[+MN?O3?&?3W'_  #2-6?^E?4
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M'CE1AE65AP5((((X(-8_A#XK>&/B#=WMOH'B+0M<FTU_*O(]/OXKIK1\D;9
MC$H<@C#8Z&OGG]H_]ERX_9Z_X)2>,/A7\&[3Q!(NA>&+BQTFSM;MY-6GMBYD
MN(89OOM<O"TZ1MG>793NW<UX+:^(_@I\6?CE\-E_9=M]/T6Z\)^&->C\6ZKX
M,TD:4_A_0GTF>*VL+PM"%2\&I"QDBMIU::-K2=BB@/N /O[3?B_X3UFYM8;/
MQ/X>NYKYI%MHX=1AD>X:-_+D" ,2Q60A"!G#'!YXKH%D#+FOR/\ V0/V=O\
MAFWQ1\-]4TO6M6U2:U\*?";0+:VU30M)EBTVVO\ 4;RXNXH2MDDD1#(6WJ_F
M;I6=V>18W39U+_@H7XZTG]GNZ\4:3\=K[Q!\1[NTLX_'/A"[T"QM+3X2S2Z_
M965W(URMFW]GBSAENX5&H)<B80_:L&."7< ?JQO'K20SK/&K(RLK#(8'((]1
M7YX_LP_M%_%K]HKQ/X \-Q_&"%-'N_%_B!)=>\/2:5KUQKFE:?I^GRK:O>_V
M=%9NZWMU-$TUK ,Q1;-_FAV6C<?M'ZY^R9_P4*^'_P $=!^(44_PS\/MX?\
M!EEX2LI],NM5LHGTP1I]NL[B*+4IU=C#,-1LKF6&)8Y%EM\1RN #]&I[R.V
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M&+IO%'B[Q%J6KS+>ZI<3Z?IFM: -,E$-S>/<7%U>6\P+JUPX65.,Q8"K[?\
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MPV6O6-]J?AW4K36([^2ZM[21$;[=;JBM822I(LL2,T@9 X9HY%,= ' >#/\
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MK8_L>?"B%&W+#X.T= Q[@6,(S7IE><_L>QK%^R5\+D7A4\(Z2H'M]BAKT:@
MHHHH ***\]_:3\=_$3X>^!8+[X9^ =+^(^O->)%-I5_XD7042W*2%IEG:&8,
MP<1J$*C(<G<-N" >A45\C_\ #6W[64*Q[OV0='E9OO"'XO:>=G'?=:K].,\^
MW-2M^U_^U)%)M;]CUI%X.Z'XK:0P^GS1J<C^E 'UG17R7+^V=^TS;L/,_8UU
MQUR!F'XF:"^,G&>7''].?:FVW[;_ .T;*JF3]C/QG'N4,=OQ!\/,1GMS..:
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M^)/!N@:OX0T?[-_9^E3VJ_9]/-NH2 P@8,1C4;5*$$*2O0D'O<T9H X7X?\
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M8_Q"N?$%GX)U.7PK9Z1J'B)(&.G6VJW<EI933?PK++''*Z)ZE8V/M6Q03@4
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M)H-XCT3XM?V3X"\*376L?LY6GPP\-_+;H5OXQJV^U7/^KCS+I^'.%^1>?DX
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M@*AH _3)_A;X8=][>'=!+9R6-A#G.,?W?3BJ;_ _P4Y);PCX7;=U)TJWY_\
M'/I7YQ^'?B-=:3^U)I^EQ_$CXRC]HRT^,)T<^";B]U&?1)?!*:DT".]FP-JU
ME_8 ^UB_/[U[[[TQ<F.O-_V8/VGM6\0>$O#NM>#?C'\7O''Q*;PMXTO?B5HV
MJ:I=7=EH&GV]I?-I]PL#CR[65;Y+".UDBQ)<PRSN3( Q4 _4*^^$?PC@\8VO
MANX\(^ 1K6IVD^IP6+Z+:^;<00O"DLP7R^51YH03ZNM1Z_\ LX_!GPS;*^I>
M ?AG8PZC<PV2M<:'8QK<SRNL<47S1_,[L555Y). *^$?BQ\0?%7['OP+T-K[
MXD?&?68]2^">H>(-=U5]=$U^FK76I>';;[:)KI)8+**$7%PQ=8F6U@>XD2,E
M<'P7PW\6O^%KMK&F^+OBKJFJ?#7P%\5OA[K=KK>B?$_5?$UAIJW<NHVMQ(FN
MSVMI+-:F:.W!*AH(I>5D#;@@!^M4_P"Q9\&[R?S9OA+\,I967:7?PO8LQ'IG
MRNE<7\2?V>/V6_A[XE\-Z+XL^'OP*TO5_&U[_9VAV6H^'=+CN-;N57<8H$:/
M=*ZK@X4' (]17Q5\ ?VIOB]XO_;ZL[+5/BAX1T_QA/\ $[5=#U;X>7WCBZFU
M"'P]!/=)"J>&H=)86P^PQ6UW'J#7H20R!WF*3"!?5_\ @HK8>*O _P"W+)\2
MO UYXDU/QSX!^ /B_5O#OA^*3S]/NKU;FQ1 ;4(6D+F569%8&1[6W'\&& /I
M6Y_X)M_LZ:A'^^^ ?P5F4DL1)X'TQN3U/,'>J5U_P2X_9EO"S3?LZ_ B1F&"
M7\ Z4Q/_ ) K\\/#G[:WQ@\*_ SXC7G@WXX_#_XB:*UEX<^W:_9_$8>++CP0
MU[JD=K>ZI-J":#;VFFP_8WEF,4L-P;8P^=]G$0=:T=1_:W^*6E_LO^(+6Q_:
M"\":CI=G\0],TBQU>U^)MO=W=S ^F37%WH__  E$NBQ:;!<M-'#+&9(F8@R6
MQE222(4 ??%U_P $IOV7[U-LG[./P'89SQX!TH'UZB#UJE+_ ,$AOV59XA&W
M[-_P-VJ^\8\$:<ISDGJ(L]^G3\JG_P"";G[3^G_M"?LE_#?4;SQ1>ZQXFUS1
MKB\8:W+IT>L:E%:W;6DMX8[%S;S0^8$ N;?]S*)(G7:) M?0E 'S3+_P1K_9
M.E"Y_9O^"GR^GA"R7^4=13_\$8/V39YUD_X9T^#JLN<!/"]K&O(QT50*^FZ*
M /ER3_@B=^R7))N_X9[^%B,!@>7H<<?_ *#C\ZI2?\$-/V29/^:#^!8_4QP2
MQGIC^%Q_GGK7UA10!\EG_@A5^R6%POP1\*Q<8S%-=1G\UE'I1_PXO_91\TO_
M ,*<T4,?34;\;>O3]_QU/2OK2B@#Y,'_  0U_994_+\*X4YR FOZJ@'3L+GV
M_GZFH/\ AQ7^S"&D(\ :POFL6(3QIKJA?8 7F /85]=44 ?)#_\ !#K]F_?N
MA\,>-+7^]]G^(OB.+>,YP=M]R/:F+_P1"^ <"*MK;_%:QVOO'V;XK^*(\<<C
MB_Z=_K7UU10!\G1?\$8?@[:#%OK'QRM<'</*^,?BI<'&,_\ '_UZ?D*?_P .
M=/ABJC9XT_:(CP<Y7XS^*.?;_C^KZNHH ^3Q_P $?? <>?*^)W[3D(/0)\:O
M$HVCT'^EU O_  1]\+Q3[X_C9^UE&N00@^-.O%1@8[SD^G4]J^MZ* /DI/\
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M>'+76/#^J:;KFCWR>9:W^GW275K<J"5)21"589!&03R#6MTH **** "BBB@
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M7D6,4?\ <0+^0%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#();;1I;5I;>2RCEG%S*H9'!823JLC[]V]P&;)KUZB@#@?@K^R]X%_9V:_\
M^$+T%-!CU*226XBBNIY(6>29YY&$;NR*6EED<E0"2Y)KOJ** "BBB@ HHHH
M**** "BBB@#^1_\ X.B,?\/P/C(W_3OH/_IDL:_/\X)^[^M??_\ P= MN_X+
MB?&@?W8]!'_E"L*^ <*/_P!5 '][EN-L=/HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***#TH
M _D7_P"#G>X^T_\ !<3XW8_A_L-,_30M/%? K!@?6OO+_@YDE$W_  6]^.6W
M'$VC+GZ:)85\&R_ZP]: /[XJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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ML^-'_@/IG_R97\T9XIQ/ _SWH _I<3_@]3_9Z+?-\+OC2OTMM+/_ +>U,/\
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M_%E/KX:CX_*XJY#_ ,'?'[($I^:X^)T?&<MX8/\ 24U_*V.GY?UIL1RH^O\
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MG"B@#^O&#_@YZ_8?F'/QLCC_ -[POK/_ ,B5:7_@YF_8=8?\EVL/Q\,ZU_\
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MX(_CXSL!_P"U:F7_ (+ ?LHM_P W)? S_P +?3O_ ([7\4)D;)^9NOK3B>*
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MLL#_ .U:L#]M+X.,X4?%GX9EFZ#_ (2BQR?_ "+7\+Z0H5'R+U]*FAMXR_\
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MU+_X]0!_5GNI=W-?RW6'_!07X]/MW?&[XO-P.OC'4?7_ *[5K)^WY\=C.O\
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MTB[R,-<.W9?>@#^5G_@XJN_M?_!:GX_-M48UBSCX_P!G3+-?Z5\4[\5]B?\
:!P.[/_P68^/Q9B3_ &_#R3_TY6U?'(H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex3-2_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_003.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MR_BA\:U]=UUI;9_\DAWIB?\ !E?^SZNW_BZ?QHW#O]HTO_Y#K]CZ* /QR?\
MX,L?V?7)S\4OC3TX_P!(TOK_ . =,D_X,K?V?R?W?Q4^,R\G[T^EMQV_Y<Q_
M]?VK]D** /QO3_@RP^ (9O\ BZOQFV[LH/.TO*KCH3]CY.<\\?3O1-_P97?L
M_N/E^*GQF5L_Q3:6>/\ P#%?LA10!^,=Y_P93? V2RD6W^+GQ<CN"/W;R+IT
MB*?4J+<$CVW#ZU@W7_!DO\-WL2L/QV\>1W'F0$/)HEF\?E@CSUVA@=SKD(V[
M$9()63&#^W5% 'XLR?\ !E!\&V;Y?C+\45&.,VNGG!_[]?I6;-_P9+?#$W-N
MT7QR^("1KGS@VD6;-)QQM/&WGGD-D<<=:_;BB@#\3U_X,H?A:%Y^.'Q%W9(!
M_LNQ^[SQT^G/^15B_P"#)GX;^6/,^.WCQI/XF71;-5/X9/\ .OVZHH _$FW_
M .#)KX9A/WWQS^($DG=DT>R0'\.?YTG_ !!*_"\D_P#%\?B#[?\ $HLJ_;>B
M@#\1[C_@R7^&;D>7\=/'R\<[M&LV_J*AG_X,E?AVZ-Y?QY\<*V."VA6C#//^
MT/;]:_;ZB@#\*XO^#(OPVB?-^T5X@+>4%R/!\ ^?')Q]JZ9Q@=1ZGK3=7_X,
MA?#,\4?V#]HKQ#;R*H$AN/"$$ZL<<D!;I,#/8DX'<]:_=:B@#\*$_P"#(GP\
ML; _M&:YNV@)CP;" #[C[7R/8$5!/_P9#:/)(VS]I'5%4] W@>-C^?VX5^[U
M% 'X.Q?\&0^GP@A?VE;[YCDY\!I_\GTZ;_@R,L)HRI_:4O1G'3P$G;_M_K]X
M** /P:/_  8_Z=_T<MJ'_A!I_P#)]1R_\&/UF?N?M+77T;P"O_RPK]Z:* /P
M1E_X,@(Q&"G[2LAD[AO 0Q^?]H56N?\ @R!FP/*_:2C/'._P+CG_ ,#J_?>B
M@#^?V7_@R%U?HO[1VG[>, ^"6_'_ )?:A;_@R"UK/R_M':;C_L2G_P#DVOZ"
M** /X7_V0GAA_:N^%[SQ^;#'XPTAI4QGS%%]"2O7N./Q_&O[H*_A=_9&O/[.
M_:M^&%PL8F:#QAH\@C)P'Q?0G&<'&<8Z&O[HJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^M'_  1W\3^"_%W[%MEXV\,V(34-9U/4(_$.HWE\;S6-0FANO*B:_NVP[MY
M@?;PJ^;A10!\Y_LF?\$)?B)>:-X9U;QEXG^'/P_U:QT_4M)U&*PT(>*-0U9+
MXRH[W+7$HM(YTCD:**2W&(]JL/F.1])^$O\ @W1A\5^$5AL?C-\3(X;;PE+X
M*BD:QTM8X]-8[S %,/1F;<7W>9D$;QFOL#X<ZEX7T[Q=);ZQJ^FV<DBAIA)=
M")PO[L%9>Z EB"Q*C+,!@U]9^ ='&CZ/96Z[I%MX0I(4X0+A0H'IP .YQ]:
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M2\3WTD4:/;WD@R3OGMWB=VX!E\W 4#:/M2@#E/CO\,_^%U?!#QEX-^W'3?\
MA+=#O=&-V(O.-K]IMWA\S9N7=MW[MNX9QC(ZU\]?'#_@EYIOQ<_X):V?[-=M
MXAL]'DMO"^A^&'\3#04E:>/3I+-V=K82K\LWV3!3S2%\SJVWGW;]ISQ!%X5_
M9R\>:E<>(+[PC!9>'K^9]=LK*2]N-$ MW_TQ(8U=Y&A_U@558G9T-?B[^QI^
MU[K/_!.'2?B)?-=V/Q8\7+\&]4\<Z5XB\+_$G4/$GA?QPMG);.-3U;3;QWN]
M/U$^:&DD22.)UDE18U(!4 ^\/CA_P1C^U:O\6+7X(^--!^"'@OXZ^%X_#OC/
MP]I_A3[1:M*I,;:A8K'<P1VL\EF\EO(JH5?<)"/,&X\W\2O^#?OPOI\VJQ_"
MGQQXD\&:;XB^%&L_";5;37]0U'Q0LFG74*+I_D&ZO/\ 1XK*1798(P$996 V
M=3YIX;_X+%?'ZU\(+H>M:9\*[76/$'Q"\->#M$\>7-LD?A^S@U6PN+N::\L+
M;5KB19(6@$4.ZZB6X^T0M\I#+7I7PT_X*"_';XG?M4?"_P"&^D>(/V>O$UI>
M>!M5\:>+=;\+6.HZU:ZLFG:X-/DM]*87<0BFDC8*5E\U8I@XW2JH! &?$+_@
MWV\(_$7]L#0_B/>^)IAX>O/AU>>!?&F@1VSH/$,\^D?V3_:4#^:5MIS;",,0
MK'_1HN<Y:NJLOV#/VIO%?P[U+P/XT_:+\(W_ (*L/!^L>$]-M=+\$BWO/%#7
M>G2V5I>:Q/),^UK8LDVRS6,2/NW';A3\-_''_@M+^U%^T3^P?X@\2:-I'A?X
M:Z?XFT#2?$^D^)M+M;V&;1[>XU^WTU]-\Y[DF:9Q/&_VN)(EV1W,?E*Y20?6
M7BO_ (*U?$WX:_MP_#OX:7-G\/\ QGX?U+QOI_PV\7:AX?T35+>'2-7GTQ;A
MV6^N)O)68S%W6Q2*Y*0*-]UYC84 A_:._P""./Q4^*W[/O@_X:VOC+X/^+O!
M^G_#W3/!%YI/CWP6VH)X:O;:T2VDUK1+F%X[B&>0*&\J1MH9%;>/NCI/"/\
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MW3?%&CW'@Z]M==M-7N[C3[K3-;U)K(K:R75A&)Y!,(H1<1(]NR2S2QN6B5&
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M^^'>M>9XO^&&K>+(Y]'\.2S/<B+6]*/GQ6PN++S=WDOYRR+,YC"2HKG]:J*
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MG'_,3MZ_N&H **** "BBB@ HHHH *,T4,<+0!_.__P '+OQ;F^/'_!57P_\
M#F_U);/PI\/=(LK*;SI2L,4][MO;EB54L@>/["K, S*$#!6"L#\L?';2KSQ$
M/!7@>Y/B+QK>7+DWVDZ9J%EXHU6RMHA*TO\ 9]Y;J^(A9_:7\F23 :V$CJ"=
MH]/_ ."HFJ:/XM_X+8_'<>+M:M?#=C#?E(-0NI9_(@:.PT^!7*V\;NQ$:,50
MA59@%9U7)'S'\3_!$:^*KVU\,_VAXYL=)\'WNNKJ.D:M_9\EJRHX-^))8XGD
M@17^:W"AF$CJ&; :@#]6O^#<?PE'9^(/%WQ O_%6MZ]KVO:;8QV,NLI$U]#H
M=O<?9=.CD,>02MM!'P&( 50 1@G[@\8_L]?#CX/?M(67B#3=&TNT7X@6UQ?Q
M1VC^79SZL$-O?72VB,L7VF2":(L\:B0^3*20P);\[?\ @A7\6[MOB=9^&=1L
M46&32'TA8XH'C5GBACFBC#;<!2D2OW&9WY#?*OZ3?M*?#F\_:/\ @S%::/)J
M6G^(O TLNIV5GIEP]B^OVXBVW%B7C99%>5/G1T91YJ1[R5#A@!VFWV@?!'5;
M71O#?A32Y;B.(V[Z!:VMNT]Y%* 7^T;]K01%)&!:0[!M Q,Y56R?!E[XF\.>
M(Y$^*NL^--,M='B>ZT+0/#UM<G3M-CD:180UX<-J#QIM_=7$916V#RQT;QO6
M?^"D?P#^,'PPTWP;\.]>\*:1'/-;O9:G)>7GATZC<W,)$;Q7<5L[*[.Z>9(S
MHRD@Y(SBM\8?^"@MCX#U_P /6'C_ ,5:-JR_;B_V"7QA9?/% & E,4;1QW0$
M\<NR94C4F--R*P1F /K?PK\>=%^*'A72=+U+Q1#;R236WV22&"73;VZ./EM[
M@Q!DM7DP XC;.URNV/.!X_X^\+W7@:?69-6\2:A=^%)CJ+:AILVJ7*M$[28B
MBM+WFXAC! C6.-6<ED\LHY /@/Q]^/GP[^&O[/%U\5O#<>M75G;^+K.&0W6O
M>9:ZK&\43W L\2'S"D.058GFT\L':/EP?#__  4.^$OAOXG76O>(K7XB:3_P
MCJ&[TK1&U1]4@^T2)(&OVACF>-# (Y/)C0-L<M,S A!& >(_\%F?A_I/CSPY
M-XNT;P[XB\ ZGX&NKFYO(=20:Q<'0;Z()?/#;3.R)NCDDDA1VBF0Q$-%"VTU
M\#_!/75L/!7BCPSI]O'=R:3J#1V.IZ_!::6;+2Y1*'N1:S ,;J13&R;GD$.%
M*@G8Z?HE^TY\5?!_Q$^(OCS7-6\:6^I^%O$5I=V$<,D,JPO:20,X#!T!? .[
M&>-I _O'\S_AAXSA\/\ Q0O-4\7>'_%GB+4-2\&:?+!_PGL+7US>7*VUH8IE
M.Z,FQ=+=H86)?9"RGYR-M 'Z%?\ !L]X_'[-/_!3_P"('PGBO9VT+QQI-S%;
M1LI03W%@RW5G.5Q\K26<]R<$@X4YP1BOZ!J_F)_X)$>+5N_^"Y_P3ET. Z7:
MW5[.)K98XDC9FT+4EDPL0 7]WV;)8Y8GFOZ=J .;^,/Q9\._ ?X5^(?&OBW5
M(=%\,^%=/FU75+Z4,RVMO"A=VVJ"S' .%4%F.  20*^/_A+_ ,%"OV3_ (:^
M%/''B#P[X-D\ ZU)J.E:=K/A^/X<S:5XE\1W&K;GTT)8I )[S[7NE*'#9VRE
MMN&-?6G[0.I>*-'^"7BJZ\%>'=.\6^+H=,G;1M&U"Y6VM-1N]A\J*:1N%C+X
MW'^[GOBOS-\.?L)?M#^)OAUH_C[Q5\+X;KXZ^%/BKH'Q5UJ:]\::?<#QZ]M:
M7-C-IEFT<:II]M:V\_\ HL4K,H).Z1F9W8 ]NO/VS_V)_AI^RQ86FG^#M#_X
M5_\ $JUU36;WPEH?PSN+AG@TN81:E=:EID%J6@2UFCV227,:A6CP"=M>L?$7
MX_?LQ_L1_!#P%\:M1;P;X1\#7NE:?X6\+>)=+T;,%OI5]LN+6WA:WC)BLWV)
M+T$:[0QQ7QOXD_8R_:2\$?LO6OP]T_X4RZY8_&CQ1XH\6_%I_#/BO2K35=*L
M]5O9+A?#UA=WCQ@K+&8X[BX53\H<1G+!T^A_^"AG[$>H_M;_ +'/[/\ \/M+
M^&-C;^&]#\=>$K_Q-X+N+VV$&BZ#:J5O+-G63RY5@C(BQ S%MOR;A@T =[X.
M^ O[*NO?&GXO?#31_AS\-_\ A+-:T:SU3X@6,7AB.)-5L;YYF@>>;RA',KO%
M*^%<E64,0#M-=AH__!.OX Z)XZT;Q59?"?X?6WB+01I_]EZI%I,*W5B-/A6"
MS\J0#*^3"BQKM/"(HZ 5^6]K_P $;OVG/ ?B+XM:#>>9\2OA_HVK>"K/189=
M>MK"[^*7@K27U&2;P]-*)%>*95O+>,O<>7'*;,)N*-NKO/AG_P $E/'OC;X]
M_"6#QK\,[O1?@!)\2/%?B$?#N;Q)'>Q?#_1KG06BMK:=H9]H6ZU)?/\ L=J\
MUO#YI3<59\@'T%^T[\%OV=OVK/ G@S]GG1/B)I_@_P"'K?$2]\/:OX(\.:/!
M);>*=7L676;O2I)VA9[1D96EE>%XRWF2(6W' ^T/BSX%\(>._A+K6@^-M*T'
M4O!=U8M%JUCJT$3Z<;51N;S5D&P1J%W9. NW.1C-?C_\'?\ @C%K'A[]M'3=
M OO@/K&C_#NQ^.GB;Q3>>(++7+:WTV[\,76D7$6EP1M#>"[^24A)(C&N!-M)
M<,X'TM\$OV#OBI\0/^" /B7X Z]-JOAWXAZI8>(]%T\>(-2>[DBMCJ]X^GP3
M3J\C>0]I]GCX+!8G VD#;0!UG[)O_#"'Q4TO2?@]\(Y/AS?0Z;KT/CG2]%LI
M)X9-2U*RD#1ZE!+(5>^:(Q+^\1Y5"(H/R8KZ7_:?_8P^&'[9OAS3])^)GA*Q
M\30Z/<&[TV<RS6E[IDI #/;74#QSP%@ &\N1=P&#D<5\@^-OCA\3_C3\([K2
M/#G[$_C+PYX@\ ^!=5M+:]U?6M/\/3Z#??9! FF^'[NQ=YW6<1E//M7ME5$C
M(8$JH^4O W[)_P"T9XKT'4O"]QH?QET'P3X@^.O@+58K?37O_#/]E^'9K&0:
MV;:)=0N)[.WCE.V0?:6<'9(VUSA0#].G_P""67[/Y\/?#W28_AIH]KI_PKDN
M9/#45K<7-M]D-R%%T)3'(INDN-H,R7)E68C,@<\US6F_\$6?V:M+\&:MX?B^
M'MZVDZYI%AH-U%-XJUF9Q96%S]JL8HI'NR\/V>7!B:)E:, *I"#;7QI\4OV;
M?C#\ /\ @IGIJ_#31OV@OB%X?BOM(MM"MM;\0:S:>'/#.G1VAA:6/58]4DM;
MBUA=1)+9W]F;F<JP#/Y@+\[^SG\-OVH/#UW;O'IG[2VF^.+#P!XK3XS77C#Q
M!+?:)K^L364CZ8?#JQRO!YXO"K1-IZQK# #$Y+G! /T<\+?\$V?@_P""/CQ9
M?$G2-"US3_%5G(EQOB\4:J+.]NDM/L8O+FT^T_9[F[^S_NVN)HWE<'+,S ,.
MSN_VMOA7I7QFA^&UQ\2? 4'Q"F"^5X8DU^U76)-P+*!:F3S22H+ ;<D GI7P
MM_P2<^%?QB^#G[4/PVA\5:O\<M6\,^+OV==&UWQ5_P )KK6HZM9V?BXW,0GB
M0W;,+6X6)G5H(RIVC+*2,UX;\<?A)XV^&7[?NO:I\,?A?\1)/%OB?XL6/B/5
M?AYXQ\$VOBCP/XB03)'_ ,)-IVMK%LTF=84:8>9,)HI%92@&U: /V.\/>,=*
M\6-?KI>I:?J3:5=O87HM;E)C9W*!6:&3:3LD4,I*-A@&&1R*T ^:_$'X(?LR
M_$/X?>.[SX8>&]9_:A\%KXE_:@U1?&%_;ZIK433>&YK74Y;.\BOI T3"Y"JT
M]S&S2,_D-(PD$)'8?!?Q=^UYX9_;*\<Z+IWBSX@:AXHT.X\86EKX<\56>KW^
MA:II-M:2#P[+!.;!=.CD9Q:,;DWQEG:619AO8  '[#ZIJ]KHED]S>7$%K;1\
MO--((XT&<<L2 .2/SJPIRM?S\>-(OCO^T]_P3;^)T?C#QQ\9_$FGZ-_PA>LZ
M]H\^E:[)K&D:S'JT1U<*\^D6J-;10,\S6=J;E();6&1)&3.?WA^"=[8:G\'/
M"=SI6J:QKFEW&C6<MGJ6K+(NH:A"T"%)[@2(CB9U(9PZ(VYFRJG( !T]%%%
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M'7A?6?!MWXNMXYKB:"<VVGV_B<Q&WBN)FNY;DPV<T<2><S*R//\ 9XHW+%N
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M_P!GM/'&J6MK\6-9\6>+-8\5>%O$]\+GQ7I]Q?3ZEX8P+(&**)=JA(526-4
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M%[<N6(@"0P($23?DH-WJWQ(_X)5VVO\ Q"\87W@GXT?%CX2^&?B;J;ZUXO\
M#/A*]M;6WU>_?8)[J"XD@>ZL9IQ&GG-;2IO(+85F8EOQA_X)):+\2OB3XH\9
M:7\0O&'A7Q9KWCGP]X^L[^WAM+S^RK[1])&DQ($N(G$T<ML9"XDR?,<,#Q@@
M'8?"W_@IQ\.OB]#\+$TFU\6C4_BUK.KZ%I^E7.E&&_T>ZTH3?VB-0B+?Z,('
MA\MB2QWRQC'S9KE/^"QG_!1/Q)_P3/\ V=?!_CKPOX)7XA7VN>-].\-3Z(AE
M^U75O<17,D@MA&"3<'R J AAEN0>E>5?LK?\$[/B?X:^,_[2?Q@URRTSX?\
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MRVM-1M)DL'AL_#]I<V=S=1&[G9?+\]OLTJ"W1B_[N1CM55W>O_M]_MR^$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_%W[./COQ-\(O&4EYH>J:'K;V=[I<UP6MQ=0%$60#A7S'\\<A7+PRQLN P
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MCT_'IS4L7[4'_!7R"VW-^SE\"YFZ?\ABV##WQ_:E 'W%_P %!/\ @E=\(?\
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M(VB:V>*3SCYQ(*[#07_@YU^(4-RL5U^PA^TA"[;OE%A<EN.. ;,=QSZ4U?\
M@Z8URV$C7?[%O[1UO'&0&/\ 9TA"D\\Y@&."#^- 'J'P[_X)0_'B]T;X=GQY
M\1?"FJ-X-^->C_$I-+>_U#6ETO3;/3;RSFM(M2O(_ME[+*T\;I]I $2J4$A
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M4Q^);/*^XW61%>._M+?L@^#?^"<W[!"ZA\0_VBOVCM6^(W[4VOZ#<:M%X/\
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M3^CW[(_PU\7?!W]FSP;X7\>^+Y/'WC+1--2VUCQ#(C(VKW R6F(8DC.<<^E
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MGL,>C>(OCQX(\(>!K'Q1JWC'PKI?AG5'BCLM7O-6MX+&\:7_ %0CG9Q&Y?\
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MPK/?J/T44 ?K#1110 4444 %%%!.!0 44F[_ #BESF@ HHHH **:7%+O'K0
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MV3_C;=?M!^!-#'A+1;G3="^V>'-1>"#R;.\:>-F+X559UA5TD*$JZA\)RO\
MP4]_92_:V^/7[ _[)_Q@^*^E>+-=^*7PC\57.L^,-*^'<,-GXATK3+F6W>*Y
M@\LR)]NA2S0[HHRL;W&2FV)V(!^A'[!?_!93P_\ MA?M :M\'?%7PV^(GP1^
M+^EZ9_;:>%_&-D()-1L,JIGMY1@28+<J5!P&*[@K[?#_  C_ ,'4/P8^*WC3
M2=!\#_"WX\>.-4NKB\AU&ST;P];W-UI?V<2$$HEP1(TGEL456R0#_%A3XO\
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MC\+_ !*NDVTML+?6H1!#;WDL<B)DW,T-N=W+;I)CU(R ?T%-(J]ZX.X_:?\
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M_P""FO[%WA?XO:7HO_",2:W+=VE_HC7HO7TBZM[AX7B:4)'OR%613L4E)5R
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M !.K^OOJOA+_ (-G(_*_X(>? <#_ )\]5/YZS?FONV@ HHHH **** "BBB@
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M#/YGD7*[6>*:WE,4RK-#)(A:&1"0Z,H\SU7]C+QEX>^ ?P]L_"OB30(_B/\
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M.#7X8_\ !6G]D;6OCI_P6E\4>+OAKI/P8_:D\1:?X.M=.UWX.^*=6:'4O#4
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MSX\?&R7X;ZS)X9\%67A/Q)'IUK\.D1KJ.&Y\B6>#=)(+:*13M=&(E+J[,IH
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M\2WWBY;[1?B)X4L? ,<K^)=3\0^&+G3]/T-H[.&]:.>=AL$AM[B"157<6$J
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MZ3X_TEK[1M0M=2M8[F>SDDMY-XBG@E:&:)NZR1RHZ,IP592" 0:U: "BBB@
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M3_M?\(\6_P#15?MQGBC- 'XAQ3?\%LH3M:'X?38(^9CX:P1QZ$?R[4P>)?\
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M0TCL(F8H&8L "2:_I'*\?_7KG/%&O:C:^,](TVQ-LL=];W,TKRQM(4\HQ8P
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MC]H#X$^,/ ?BCX'^"KGP_P",]'N='U$6D.GQW(@GC:-_+87Y ?:QP2#@XXH
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M_C;4O$DGAG09/$&M:4FA7^HO8QM<WNGHSLMI*Y&7@#22$1ME?G;CDUP'@O\
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M*V_M3^,K[P%X9\.^"X(?&'C;P)=_%N."S\$_V_-'I%SJLUMI&FO;_P!IV7E
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MOXP_^"_%Y]N_X+)?M"2==OBJ6/[V[[L4:^I].G;IQTH ]"_X-IK=KG_@M?\
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M'GW?V8WRQ;5#3*C8#L":\8\,_M&?%B#Q_P#">/Q5\3/'6HW/CKPQX/L!X?\
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MB-X?E;:-<T?=R<"]B)XSG^+V/Y&KK^'+&0?-9VI^L2_X5$OA#2E&/[-T_ &
M/LZ<#CCI[#\AZ4 -7QMHK, -7TLDYP!=)SCKWKG[+5K75?C<S6L\-TJZ( SQ
M,'5#]HZ$CC)]/:N@'@K1U((TG305& 1:IQT'I_LC\AZ5+I7AC3M"D9K&QL[-
MFX/D0+'GIUP!Z#\J +]%%% !1110 55UV7R-&NI.FR%VSZ84U:K'^(,S6_@3
M6I%R&CL)V!';$;4 ?-?_  0UA^S_ /!(+]G5?7P18-P/6//]:^K*^7?^")<7
MD_\ !(S]G-<8_P"*!TIOSMU/]:^HJ "BBB@ HHHH **** "OXN?^"\4OG?\
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MGQ1ODU[Q0-*;238ZK-IU[8LRP2^8RRV\D:.@P[LA(1-S#T3]N_\ ;WU[5?\
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MX1O?BE)X;;0_'$%G#XG;P7+XAET5ET6/60^Q+/SMQ=M[%0LJQF$,X1I%DR@
M./D^.O[8%H?F_9R^#=T,XQ#\9KI>/7YM"_\ KU5N/VF?VO+60C_AE/X=S+D
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M=CUK0K&/QM97+>(;>RNK:YMK.YN+*&*]8I9M<W,<;06GGN"L8N'C+M\JY/%
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MIX0NM<\)ZU;ZOI]A,]K>%8Y(IK&9%5VAFA=5EBD",C;'56VNIQA@3X3\"_\
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MO*RJID<GE],_X)P_"[1;K0O[+M_%6D6FAVUC:MI^G>+-3M;'5TLMHM/MT*7
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M_&/Q"%7V^:Z)_7-7;?\ X(]^"[5VV_%K]J;RV4 1CXU>(PJD?Q#%UG)]R1Z
M4 >K_LO?LF:?^S)IGB!8?$&K>)-2\27*SWE]>V.GZ>0B)LCC2WL+:VMU"[G8
ML(M[M(2S, H7R'6O^"0'@OQ'H_PST>]\4>)+O0/A?IFB:;I]I<6&ES71.DB
M6\L-\]J;RR9S;Q&5;2:)&(<A4:21FJS?\$:_#\F[;^T!^V%'N4@%?C5K7RGU
M&93S]>/:BU_X(XZ3:)A?VB_VQ"<]7^+^HN1_WUGT_P \T >N_M!?L7:-^T/)
MXX;4=8U:P;QUX6M/"ET;41_Z-!;W5Q<B1-RGYV:Y93G(PJX&<FO(/B__ ,$<
MO"'Q+OY-4MM9M;?7KC4=<NYKS6O">D^)(_)U74IM1DB2"^@DCC>&:9_*D4?=
M8B191C;-_P .B#%!&MO^T_\ M@6[(Q8R?\+'\YGZ\$2V[C R.@'09SSET?\
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MTWX >.)[_P >?LPW%E#H-^]RL'@77;:0PBV<ML8ZM(%?&[!*D#@X/2@#O_\
M@C)%Y'_!)C]G!>G_ !;K1&_.SB/]:^F*^<_^"0$?D_\ !*?]G!0&4?\ "MM
MP&ZX_L^'&:^C* "BBB@ HHHH **** &R'"-]*_BM_P""X$\EQ_P5X_:*:;[P
M\=:DHP<_*)2%_P#'0/I7]J;_ '#7\57_  6YE:?_ (*Z_M&,R[3_ ,)YJ:X/
MH)V _E0![C_P:]R7,?\ P6U^$/V:/S/W.LK+U^6,Z5=;CQZ5_7+7\E7_  :N
M%?\ A]K\,>O.F:X.G_4+N:_K5% !1110 4444 9_BKPQIWC3PY?:/K%A9ZII
M.J0/:7ME=PK-;WD,BE'BDC8%71E)!4@@@D5\P?"[_@DW^RKX \">./A[X6^'
M_A^+3?%3V1\2:?%K=Y<7CK9S1SVL32-<-/!#%+&CK"C)&#GY>3GT/_@I)?>-
MM._8 ^-$WPV_M8>/H?!FJ/H)TK=]O6\%K)Y9M]OS><#RFWYMP7'.*^0_V2M*
M_8#\,^(_V:+KX9W'@V/XFZU$#X8OO"<TC>)-6;^SV>Y.M/9_OI8RH8S?VAE%
MDZX^:@#[N^*WP3\%_M,^'M A\2V</B#3=!UVQ\3Z8T5Y)&D6H6,XFMIPT+KN
MV2*#M)*-C#*1Q7$1_P#!.?X/Q:'HVFQ^%&CL_#_Q#?XJV,:ZI=_NO$CRS2M>
MDF7+ O<2GR23$ V @ &/S!_X),?M#?$#]DKX1_L5_P!J?%);SX0_%JR\<G5?
M#5QH-JMOH%II5MJ&I1W4-Q&INGE#Q.9-SLK+(%5$VC-OX'?\%8_C5<>+M7NO
M^%PIX_\ #?B#X"^*OB3IG]IZ#X?L+S2+RQ426=PEKITL[VT3*P @O9IG.Q]X
M#AE0 _23Q_\ \$QO@S\2OA3X@\&ZEX9NETKQ%XON/'TL]KK%Y;ZA9Z]-)YC:
MA:W22B:VE#<#RF50I*[=I(-CX8_\$VO@_P#!S2_ -KX=\,RV'_"N/$%YXKTN
M<ZE<37-SJUW:SVMS>WDTCM)=S2Q7$@9YF<D[>FU0/SOG_P""C_[3'[,?PZEU
MOQ'X^T?XM7WBS]F6?XQ:?9R>$K;38_#FIPO9(-OV7#W%N$O&DD$AY,)*^4IV
MJ[XB_P#!5/XX_L9WOQ(:X^*W@?\ :1A\)_ FU^(UK_9WA^TT];35+W5K2U1K
M@V<C;[:&"=KA5!C+0%=S9_?D _0*_P#^"8OPCU#5?MDFDZH)C\4XOC(<:K/M
M/B..(1+/C=_JMO\ RQ^X3VKF_&O_  1U^#/C.]M;\1>--!UVR\8Z[XWMM:T'
MQ3>Z5J=M>ZVZMJD<=Q Z.MO<A45HP1A5 4KUKXQO_P#@HG^U]\+=-\.^$/%!
M\.Z:WQ-\8^%O#.A_$?Q#I^@,="_M5+MIG?3=(UB[BEC9;>-K1Y98PYD=&9R$
M8^K?L!:I\3-3\9_M11GXP> ;GQAI/QJTC2;_ ,1/IO\ Q*M3MK?3-+CN;2*U
M:Y<6UU*GF1LJ2,$N-^%'10#Z"\*_\$E/A+\/_#?P?TOP[_PF'A^'X%^(K[Q#
MX2EL?$$Z7%J+ZXDGO+":0DM<6<S2%724L[( I?!8-S[_ /!%'X1:7\*/A_X9
M\-ZQ\3/ ]Y\-=,O-#T?Q)X9\4S:9KC:==W#7-Q9SSQ@+/"TS;PKH=A&5*DL3
MZU^U9XIUBW\7_"'PKHNJ76BR>-O&T5KJ%U;D"0V-G8WFISP@D$J)_L*0,5P0
MDSX(-?,47@WQ1I7[$OB[X[V/Q@^*%CXX\/WOB'Q#:P7WB*2]T.]6TU2^\C2W
MT^3,'V>6*..V C595RI1A( 2 >X^$/\ @E=\(_AUXJM]4\,Z9J?AU;'X7R_"
M*SLK*]/V6TT22X-RQ4.&9KDRDL9G9BQ)+;B23=\<_P#!-[P/X[_X)TI^S'/J
M'B:U\ P^&[3PQ%>P7<?]JQV]KY1BD\TQE/,S$A)\O!YXKS37/^"C_P 0O!_P
MQA^).I?#_P *P_#CQ98ZQ)X52+7;A]<BFL=-U'48?[0A:V6*-+B'3I=RQR,U
MN[(A\WYF6/2/^"@WQHT/QK)9^+OA7\/=/T?3M4\*V^I76F^-+BZN4@\17B65
MJL$+6"+)-;S.&F+R1HR >668D* =9\+?^"5/A_PE\:]#\=^-/B7\6?C/JGA6
MSO+/0;3QWJEI?6.C_;(#;7<D<,-M"'DE@)B)DW@(S@ ;CGE-%_X(I^%_#_P:
M\7?#.'XO?'"7X6^(O"U]X1TWP?=:];W&E^&+*Z!!%MOMS+(T0.V%KF2;RU^7
MD8KGOA[_ ,%EM<^)7B;6$T/X1ZYXDTZZT[5KWPQ:Z3::U_:5\UE!<3PK=-/I
M<5E&+M8-J&VNKDI))&@$N_(C^$G_  4M^(?[27Q@^#^C^&;3X:1M>>,+S1_'
M>DPZOJT%Y868TB6\@+V^HZ-:W<,K!9941HHUE,")YNUY&B /0OB=_P $@_ G
MQ0\(_M!Z1<>)/&%K'^T9I6AZ1KTL,UL7TZ+2K-;2 VNZ$@,\:Y?S-^23MV]*
M^6_V\_\ @F3\8_C1^T)\1O"O@/1_%FB_#GXN:YX>UC4=4L?&6FQ>&1-9FR%S
MJ&H:;) +\W@CL]GDVTAM[@K;R2$,K!?I+]G7]O7XB?%;X>^#;WPG\)=0\:Z)
M#H&@:AXGU"Y\7VL6LVTFIPK.4MH/LT<-[)!;R0SS,[V:LLF(EED4QU]B1C(S
MW]: %4_+Z5\B:XRR?\%ZO#"Y4M%\ M8R.X#>(M+Q^>P_E7UY7Q[?.K_\%^-+
M4#YH_P!G^\)Y[-XCM??_ &3VH ]8_:)_9<\0?$/XA:?XZ^'?Q NOAKX\L]/.
MBW-\^DQ:SIVL:>9#*L%U9R/'N:*1G>*2.2-T,LHRR2,AH_!3]BF;X4?$3PKX
MMU3QUXD\9>)-'L=<BU:_U2.,/KEUJLVFR23!(\1VT4*Z;'%%!$H14(R2P+/[
MQ10!\!^,O^"(1\1>&[+2;7XC:3%;P^#8/"4E[J7@*PU35K80I<IYEA=S.6L8
MIA<$311J6;:S1RPNV\?2!_9(8>$+?2_[<WM#\0Y/'S2-: "4MJ$EZ+3&_P"4
M#>(_,Y.%W;<G%>V44 ?E[\&_V1OB=^U@_A[X8^.+#QQX7^%/@/P#KW@IK?7/
M"]KIUW8+>V,>F6\:7RW=PFK310^=B>*""!DC#2*7D5*].T3_ ((R1Z=\#/&G
MAR:U_9^CU3Q-<Z<_DZ7\([2QT'6(+(R,L>J6IFDFF,KRM)NMYX# Z1F+: ZO
M]W3W$5K_ *QDCW' +,%R<?X9IR7,;])$XX/S"@#YS\"?L*WW@_\ X)W>)O@C
M)XH2:\\2:+J^F1W\<$[6&C&_6;;#:PSSRS+:6_FA(XGG=@B ;@, <A\0OV$?
MBI\3M=\4:5J7Q \&P^ ?BQ=Z3K'CRQA\/3?VA'>6=KI]K<PZ7*;C;%;746G0
MJ?M"S20[Y"K,2NSZ_!S10!X;^T[^S;XP^+WQ;\%>(O"OBNS\*C1=&\0Z!J$[
M6[R7L$6IVT"QW=DP8*MS;W%K"P$@*,K/P&"D?,/@'_@CAXGC\*_$*QUZ3X1Z
M-)\1_#EMX<U1?"NG:G#->"&^AN'N[J^N;B6ZN)I8_M"@LX:#]WM9R7>OT0ZT
M4 ?GOXU_X(\^(] T/P[H_@W4/">I>%_A?K6JOX%\/ZWJ6JZ='::+JJ6\MQI\
MUY8NMPKVUY!O@E)F#0OY<B[@LJR>(O\ @DGXR\.>(O!5Q\/=0\%^"[S3=#M-
M/O/$.AZOKFC:GH5REY-=7,D$*3S1:Q;R-<W)6WU5GV/([&202,B_H)1G% 'B
MO[1/P0\6?$#XX?#GQ1X:D\/_ &3P[::UI6K1:E<S6\J6^H6\*K/;&.-P\L<E
MN@,;[%99&.\%0&\&^.W_  3'\8?%7]G_ ."_A>QUCP[8ZM\)? $.AK)]OOK2
M"YU6VO/#MU"JS6OEW,=JYT:9&EB>.:,2QLJD@@?<>ZC&: /!?V$?V;-6_9^\
M+^*+SQ%H^FZ+XA\6:J+V[@L_&NM^,/W<,,=O!YFH:LPFD?RXQ\J10H@*J%8J
M7;SG0?V7?C!\ M;\%^*_!.F?#GQ=XCTOP_K7AS4M/UO7;K2[:W6\U1=0@N;>
MZCL[AV52NR6$Q+O_ '9#CR_F^P** /A7X?\ _!+/Q5X,^%?@?P&_B+2Y-)\,
MZC EQJ]L[PW1M$^'MQX9,T,(3:D@O)@ZQ;\+$ =^X;:S]3_83^,_Q>\+:%#K
M>F_#/P'K_P '_ )\-^!KW1=4FOX-6UF&ZTN]L[Z96MHC:V,5QHUJ?LV)F(GE
M!)"#S/OJB@#\^_!G_!*/Q=\-? GQ4TR#4]*U>/5?AOJ>D>%[=KR3Y_$6LZ?!
M%K5U.TB_()KJQ@E1P3@7MR-J#[WJWB/]C_79_ GQ,ACTC2(M4\6?$;PEXGBN
M8)%DGEL]+B\.I),QV@F6+^S+KRTY)V)C!? ^KLT=10!^8?\ P3\^+&F_%S]H
MG]G'P/X=TGX>ZU8_ OPCJ]E=>(M U^WO+Y4^R6MHDEU8*GVG2VN6.^2VO"DR
MW"R(4D,+R#N/VNOV$_B1\3OVMO'TEMIGBK6_A_\ %J306GNM$\2:/I=OH_V!
M8XW6^6\LYKS$91KB"2Q9F\R1AB!AYS??EKI%K8SS2P6\$,EPV^5XXPK2MZL0
M.3[FIRN: /B_3_V+O'%SXO\ #<L=M;>'[BSU7XI7*ZS!<Q/-HQUW4YIM.ND"
MD.SM%(KD(=R'Y6(-?//P<_X)G?%&Y^"&L:7K'A/Q-;Z]X9^&UKX%CT?7=4\,
M0:!XHABO]/N;C3K0Z38Q3R6<\.G/ D^I,K1K?NIA;?,P_5<#%(5!- 'P=X5^
M!&I7?QY^'/Q$L?V:V\ Z/9_$.YN9]'A&E-JUFDNB2:=_;%U%%<M:Q)YHA4BU
MD>4Q0Q2,'8A4^VO -TE[X,TN6/1[CP_%):1,NESQQ1RZ<"@Q ZQ,T:LGW2$9
ME!7@D8-:WEKZ>]*J[1Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5YQ^V+*(/V1_BE(>!'X0U9L_2RFKT>O+_P!MM_+_ &,_BXW]WP7K
M)Z?].,U '&_\$FH3;_\ !+K]G5&ZK\-O#X/_ (+H*^@J\+_X)@6GV#_@FU^S
M_#U\OX<^'Q_Y3H*]TH **** "BBB@ HHHH ;)]P_2OXHO^"SN)/^"M'[1Q;>
MI_X6)K0PQYXO)!^7I[8K^UV3[AK^)W_@L$3J'_!5K]I"1@P/_"RM?3ICA=0G
M4?RH ^DO^#5B%9?^"V7PS+;MT6EZZR^Q_LR<?R)K^M*OY+_^#5.)G_X+6_#=
MMI;R](UUB0/N_P#$MF&?UQ^-?UH4 %%%% !1110 UBO?^=<GX8^ W@;P/XWU
M+Q)HO@[PIH_B+64V7^IV.DV]O>WJDYQ+,B!W!//S$\US?[:FG>+M6_9<\:6_
M@5-6D\3S6&VVCTJX2VU&:/>OGQVLKLJQW+P>:L3EEVR,AR,9'R+%X>T^/QC:
MW$>D_M:0_L^K>W_FVDMQXC.I2ZQ]GL1;S1Q*_P#;RZ:0+U-DO[G[5^\V+&5D
M8 ^X]*^"G@S1%\._8?"GAFS_ .$/,QT$P:9!'_8AF1HY?LNU1Y/F([*VS&X,
M0<@FL#2OV0/A+H$-S%8?#+X>V,=\EY'<);>'K2$7"7B".[5PL8W"=%59 <AU
M4!L@5\,_$GPK\5O"G[+/Q5\<^,=<^+ND^)/!_P *M.7PZT.NW5O)!/)-JWF,
MT,4@MKG5A:-81RR2"0B9$92I.X]!>OXBMM?N'TFZ_:$M_P!F^37=._MV:\D\
M0?\ "5I<+I^J"^%NSYU>/3_M2Z,LGD8Q-]H\O$1F- 'V-\0OV7O"/C'P=?:?
MIVFZ?X5U5O"]QX0TS7=)L+:/4= T^5%40VKO&RI&C)&XB96B)C7<C#BO ?V'
MO^"4>@?L6?$W6_&&O>+M*\7ZUX@\/0>"K6&V\):5X7TNWTX3R7+P_8K&-(II
MYYY&9Y&!+ !0 !SY;X>TWXI+X,^)'BJX;X_ZU8^ _!5W<_#_ $D:Q?:7J6L"
M?5M=CA>Y5T9KB\CL8K(H+F&:98WA=XGN&%<%X#TKQ9X\UK38_%FL_%C4/ NA
M>-O!OB"TN;=_%B16<TC:M;7D<=U?8O[JW$B6 D)6.*-I01''\\C@'V[X'_X)
M]?LXP_"WQ!X?\.?!WX0P^#_&NU=9LM-\.6*V6L>5)E/-$:;9/+D7*YSL9<C!
M%;/A[]@CX)>$/ D?AC1_A;X#TGP[#J]EKZZ=9:1#;VXU"S6);6ZV(H'FQK#$
M%?KA!UYKXV\5_%/XF'P=<7GB;Q5\9/#GB:'PE'<?#BRT+2KEH]>\0-=:B)(K
MU([=XYG$B6$?D7)6)8'W@#<\B^F0:/\ %B/XNV/BB/X@?$"WN/$'Q+U[PV-'
MDM%NM#TO2X]"U,V[+:&)6D1;VU@G60R!G9A&)/+?:0#Z>^/7P17XUVGA9H=8
MN=!U3P?XDL?$FGWL$22LLD#,LL+*W6.>VEN;=\$,%G8J00*XOP]_P3A^"/AC
MQQ;^(K7P#I:ZE:ZDVLP)-<W%Q9VU\9S<?:H[621K=)EF)D5UC#(Y+*5))KPG
M_@DA\>O&WC7Q1XC\*^,-4\1>-GM=%M-0;Q.VK7-[IIN1(\4UO-!=:98SZ9?/
M\DC69,ZH%;'E%</Y5%^U1\3H_A)JFJ^'_BEXZUWXE-X$\2WOQ!\.:CH=NMO\
M.M4@TV9[1K>+[(C0/%J B@ACD>07<):7$H0RJ ?;.H?L.?!J+7_$&I7/@S08
M[SQK#?:=?EY75)QJ ;[<L,>_9#)=9<RM J/*22Q8\UT^O_L[^!-9O;B2_P!%
MLVGUBZTFXE)GDC:YFTJ875AC##)@DCW@#@[3N##(KXZ^(GAWQOX:_:K\+?#O
MQ!\0/%WQ#TS2O&GA/7K'5M6L;&*]TZXN]/\ $L=R$:UMXH?*#6,$B(T9\MI6
M'*E5&3X_^,WC+XY_LW?$?5?&&I/;ZE\!9=$T>%(K 6RZGX]T_4DG\^&38',=
MQNTR%4C;RV6_G0@]@#ZTA_8#^$L7B77=4;PFMQ)XD@O[>\L[G4KRXTU%OBS7
MK6]D\IMK62<LYDD@CC=][Y8[FS'X>_8 ^&/ACQ#H^M6^F^([CQ!H6JP:Q:ZU
M?>+-6O\ 5C+!%<0Q127D]R\\MJL=U<K]ED=H")Y,QG<<^T44 >#S?\$U?@[(
M?#<:^%[J"R\+V6F:=!I\.M7\=AJ%OIC%]/COK99A%??9I#OC-RLA5@"#7O &
MT444 %?'2LTG_!?^1=ORP_L^H0V/NE_$C9&??8/RK[%)P*^/M&62;_@OCX@;
M/[N#X :7Q[OXCU'_ .-T ?8-%%% !1110!Y7^T/X!T7XE>./AKIOB#1M-UW3
M5URZN&M;^V2Y@+KI=ZJLR."IQO;!(R"1BFZ]^QK\(_[.NIV^%_P\:98F*R-X
M>M-P(&1SLSQ@5T7Q6\ ZQXLU/P_J&A:YIVB:CH-S/.C7NFO?PSB2VDAVE%GA
M(PSJ^0W.S'&<C/O?"_Q*O]+NK=O&7@GS)XVC5QX1N?DRK <?VCSC*=Q]T_WA
MM ,?X$_#VR^(7[$O@7P[K$FH?8[[PAI5O</IVHW.G7&!:0D^7<6\B31G(^\C
MJ<<9Y-?GM\6?"&H?!'_@G%^U?\0/"_C;XK+XR\$^--<\/^'+FY^(>NW*Z5:1
MZC:P10)'+=O'\JE@)61I ')R37ZC?"[P4?AO\,_#_ATW37QT'3+;3?M)C\LW
M'DQ+'OVY.W=MSC)QG&37%>)?V*OAGXN^$7C+P'J/AB.Z\)_$'5KC7?$%@;VY
M4:C>3SK<2REQ)O3=*B-M1E4;<  <4 ?-OQ,_X*K>,/V<_$WCCP3XY\#Z#>?$
M#1;[PK9:)%X;N[^^TV_?Q!)>QPB4+:M=_P"CMI]T7\BWD:51&416<HGLG['_
M .V9J?QW^$?C36O&7A'6O!NI> -0N+/4&ETJ_L['5(4@2Z2[L1?06]R\9AD1
M6$L*%)DE0;U"R/TGQ,_86^%_QA\4>+=:\1>&5OM6\;6^D6^J7BW]U#,?[*FG
MGTZ6!HY%-M-!+<2NLT!23+#+':,;GP(_9?\ !W[.GA'5]'\-V-])#XBU"75=
M9NM7U*YU>^UFZE1(WEN;FZDDEE)CCCC 9BJHBHH"J  #Y'^#7_!:/5OBEX'U
M3Q9)\+]4C\+W_@#4_B!X=O+6#4REO!9VHNX[359[BQAMH)KF"2,QM:S7499+
MA=Y"1O+Q_P"UA_P5*^.&E_!(V.D^!/"_@/QCXL\':/X^\/7B^)VU'[!83:UI
M=C<VMVK6.U+K&HQ >4)H\&4A]T:;_J#P_P#\$M_A#X8L-:L;;2_$4NCZKX<O
M_"-II5UXEU"XT_P[I=\NV[M=-MWE,=DLBA%S"%*K'&B%44+5SXS_ /!-3X6_
M';2K2TUO3]9C73_",?@JSEL]6GMY;/3XKVSOHMC!O]<EQI]JXD.6_=X.0Q!
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M]\%Z9M\4V-UKZ75M#/+]LNM*C+-;V$JVTABF:8R$/"7AC\P >G^-OV"/ OQ
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M^A6?C#5O$>K7YL=:T&6ZTV;2]1T[1[62SD\NX24313Z-!<),C*&5FB9,-O4
M7]F3_@L#X"^)O[-7AWQQXMO19W6O-K.I21:!I-_J=OI6B6>L7MA#JMXT<;FS
MM'CM-[37!1,K,1\L3[-K]N?_ (*N> ?V1_A=\0KK3+O_ (2GQAX%T"+69;"V
ML;VXTRV>Y0FPBO=0@ADM[/[4<>5YKJ7RNT'<N?GG2?\ @@?JWA'P6T4/C+X?
M^+_$VN:!=>&]<O?$OA&X>PB$NKZGJ27]I:Q7@PZ?VG-&]I+(\4NV-M\85ED[
MO]H7_@EE\1-9\(_&KP=\-?&'@;2?!_QVT;2K35EUS1I6GT&YL--MM,)M([<I
M&T-Q:6=LNUBOV=T=U$H81J ?=VGS/<6,,D@"O(BLP!SM)&<5-7.^!D\2Q:AK
MR^(&T-K-=1(T,:>LHD%AY$.W[3YA(-QYWVC)CPFSROXMU=%0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>2_M\R>5^PM\:'W;=G@37&W>G_$OGYKUJO&?^"CETUE_P
M3V^.TR_>C^'NOL/_  77% #O^"=-J++_ ()]? N$=(_A[H"C_P %UO7LE>2_
ML#1^5^PI\%5'1? >ACC_ +!\%>M4 %%%% !1110 4444 -E_U;?2OXG_ /@K
MDS'_ (*H_M(?-YG_ !<WQ%R?^PE<<?AT_"O[86&5K^)K_@JZ?._X*C_M),1_
MS5+Q,/RU:Y% 'U#_ ,&HT9;_ (+0^!=J[O+T'6R2&QC_ $%QGW]/QSVK^L6O
MY/?^#4(J/^"T7@G=")"WA_6\$KGRC]C;G/;C(S_M8[XK^L*@ HHHH ****
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MBBB@ HHHH \[^+NFW?B7XB>#](CU/6-,L;P7TMTVG7;VTC[(D" LIZ N3SW
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MJ$G9<(KA3]Y<@'!'8C/([592=) "K!@PR".<BOS2_:._85U3X(W7Q+L?A/\
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M\:_JFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%-:VUNJR10R6TUX;Z2TG1'"W%HUT?.^S3!X1( P0$#'NE% 'C]U^P=\*;_\
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M8Z[:N2^ 4'V;X%^"X\$>7H-BN#U&+>,5UM !1110 4444 %%%%  3BOXBO\
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M/"3DQ'(Y3/.T\>U?)7A/_@J1JGQ&\">'?$EG\.9-'\,_%9-7M?AIJM_K2/\
MVO?V5I>74,.I01PLUA'<PV-Q-$\;77[N)O-$4A2)O./ G[5WQN^'W_!OG??'
M/4-6MO$7Q<U#P0?&%O>ZE>P/;P?:(TD615CLH8T$4;&1+8Q.-RB-IW!,M 'V
M9\%?V<O#_P $?$GC+6M-\ZXUKQUJBZCJ=Y.5WF.*)8+2TC50%CM[:W1(HXU
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MLF];FZB=KF+^S[C,*!B^T["V": /LNBO@GPI_P %/_%GQ N?B9>SZ#XC\/\
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M<^)M&L]5EL6D\QK)YX$E:$M@;MA<KG SCH*ZB@ HHHH **** "BBB@ HHHH
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MFTS_ (*:?%CP)^RE\/?B_P".M-^'<VA^/O'ND^$/[/T*PU-[K38+C69=/GN
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MR[4-G]X8V=/D7')!)&1P:\/^%?\ P5<^'_Q5T+P7JT?ASXEZ%HGQ$UJQ\/\
MAK4M9\-26EMK%U>+</$(CN)VA;64LQ "C;G[PH \U^+O_!(B^^('Q,\0>.(]
M?T/4M;D^)U]X_P!+TK4[:XCTR>VO/#]CHLUC=/!(LZR+]C$\<\)^5@%9'5F%
M>F_#[]A?Q%\,?^"<OBKX1>'?%&@>$_''B;3M9(\1>']$^QV6G:AJ#S2":*W>
M221A&957S))&F?R]Y8.>/IL44 ?GK_PZ#\;>*] ^-C:YXH\/6.J_%3PGX?T6
MP\O4=7U\Z9=Z1J%W>QO<7>I327%S%,\\88*8O+12BJ2HD;>\4?\ !/SXT_$;
MX_7WQ4US4OAC#KUQXO\ !VOP:%8W-[]CAL]%BU.*6W:[:#>\KG4#(D@@4938
M5 &\_4/C_P#:U\$_#;XB:IX3U*ZU:3Q!HNEZ;K-W9V.CW=](EKJ%^^GVT@$,
M;[@;B-PP7/EJC.^U 6'I= 'QKX4_X)L>(M*^$7P=\)WFN:*5\ _$+Q3XOU:Y
MMA*K7%MJX\0"-(,K_KD.L1%M^%S$^,\ ^9^._P#@E)\5_BK^S)IGPYU;6/A]
MI\7PQ^#OB#X3^#KRRGNI'\0MJ&GVVGPZA?JT*BQ58+2%FMX?M)\R1R)=J*K?
MHM6%H?Q,\/\ B7QKKGAO3]7L;S7O#*VSZM80RAI].%PK/!YJC[N]49E!Y(&>
MA% 'RE^U[^R5\==7^+?B[QM\$=<\%Z!X@\0?#O2/ EA>:K>2V\FB>3J=Y<W=
MU$%MIT+^1.BQ;E($GS,,(%?A_%/_  3+\7?V9\&M3\-^%='\.O\ !6^UP)X8
ML/B?J]K)XL75K>)9]4GURWMH;I-1%PLCL7CE$RSW 9P9!C] J* /SA^'_P#P
M3 ^*7[.GAN]C\(^&OA-KC^/?A9>^ ]?TN]U[4UL_#UY-J>IZB);>ZNH[JYO+
M21]7N%F20QL[P1NH17*1^N?$#]A/Q)K?_!*+X8_!^70_"_BKQA\.=!\*Q&SN
M=>U#2+>:]TE+7>]IJ=F4N;2=6@=H+@(P#A=\3(S ?85% 'PK^R!^PG\6O!O[
M4O@WQY\1I/#=]I?AD>+FL$EFMKO6=.&I+H<=L;BY@M+=+RZ9;&_\RZ9!+Y<L
M:.\S%GKY^O\ _@EC^T;H'[*D?PUTC3_"D*ZS\'KSP'=3:5J6FV4L5Y+=ZC+Y
M%]>SZ?/=RZ>([J QQ6;0X=95? 82+^M=% 'YZ?$#_@F'\0/B!\"OVFM%M8]!
MT?Q%\5_^$072;E[M?^)A:Z1I>DQW%E<2+&_EQS2VMY;_ #)(NV<N8W4E&Y+Q
M/_P3R^)?B^+7O'-UX \6R>*)?'WAWQ!IX?Q_I2^)K,:?97=H=6@1+,:,;J-;
ML1K!<K*+B"'][*KK"J?IQ1B@#X]^&7[-WQ.L?^"17Q ^'.M>'_#MC\0->\.^
M*K'2M*TJWL=-C8WIO?L2W"VNVRCNY%FB:=H-L'FO(5.WD^*_M%?\$V_'7A[2
M)K?X9_#'P?=:2OP-TSP5<:.\L$-GJ.H6VM6=PT+VZSPK/)':K>-%YLBP22.8
MY'\N1PWZ68XHQ0!^6_A;]@[XQ^&-+^,GQ$TWP#=0?$+1?&_AGXA_#FPO)]&T
M^35Y++3DLM1LGBT^3[+;-<VK7UJ0S-@7,;F61E#+D_$7_@F%\2O#/A?PAJ&O
M:'XA^(4?B'PCK%]XPT3P]8^';^X_X3?5[V.]O[EUUA'MUMY5)M$G@(>!+2,!
M=DC8_5W:*7;0!\<_M;_LQ^//%7_!&BX^%5K8:YXY\>MX9TC2;FTN-<CN+_5)
M8[BT^TJ]^ZVZN^Q)<SE8\XW8!KYK^,G[$_Q*\<?%?4O%GP\^%NK?"[X*37_A
MZ+Q-\/$M-,DU+Q.]E#JXN-273O,ELID62^TP-%))NNAIK,0VV(2?JT1FD" =
MA0!^5VJ?L;_%+2O@+\+X6T#QQ)\+M-\3>)=3UCP-?:'I&L7UA;7<872R-&0B
MU^RQN+HK9K)*;<WT3 ?NL0;_ ,(O^">>M^.-?T-?B;X%\4>)-%T7X)ZAI.F6
MOBF[BN9;*]GUFYGM+&06\AB%S;V?V=(R&D> *H69G4R-^F6P>@_*C:".GZ4
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M?'LW\,?PLOU(QU+:MI!_]EK^FROYF?\ @RW<#_@I;\15[GX8W1''8:KIO?\
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MQ#X:TOP[+X6TG2?$&NWVK6>@V$RHMPMDD\K?9I)?+0M-$5D&P!64#%=);?\
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M!NOZ2O@#Q%H.B>*KR#Q)8W<&G1:W+;Q:?- %P]U)NN%\Z(*OE@?*\V16]/\
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MXQN?'-CXOM?'&F>)H8K2T&CZA;6SVD4=O8PQ+:I:M;2SQ2Q%"TPN9B[EF!4
MUOV!OVG?$7[2_C7X\-KVGZIH=KX*\>IX=TK2=4L8K6_TJ%-%TN>6&;RF=9#]
MJN+EUE5W5XW1D9D*&OHRO!_@+^QAJWP"\:ZYK5G\3O$VL3>,O%TWB[Q0NHZ?
M8L=<D?2K?3TM=R1+Y$,1M89$\K:P"*C,RY)]XH **** "BBB@ HHHH ****
M"BBB@ HHHH *^+?^#A>/[1_P2(^*4/\ S\7?AZ$C^]O\0::N/QSC\:^TJ^-?
M^"_R&7_@E1X^C SYVM^%8R/9O$VE*?YT ?92]**!THH **** "BBB@ HHHH
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M#7O"\GB2W\*7MEJNIV;_ -JR6E[J&GH%F6.2,QS.)T,FTX.)$QA\CZ!\4_L
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MNJ>%?!'A_P /ZCX3TFYT'2KFQM_)EMK&YN!<SVY8'+I)<#SF#[LR$O\ >))
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M=5\A_P#!;>Y6+]C+0XR,M<?$[P-&N3QG_A)M.;\>%- 'UXO2B@'-% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;$&AM)%1_P!P&?<O1:%_P2,FM=&+3>(/ .B:I<?$/PEXUFA\)> ;?0M+BMM
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M]/M=/N/&7B+X5^+9/%NJOJ"P6^H^*=:UC1=2N[!F5BZP7"6MW:B15,:0A>
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MQZQ]?N#^5?W7?M%WS:9^SYX[N%^];^'M0D''=;:0_P!*_A0M'_T6/I]P?RH
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M03Y$IA$3D D)(QP>A^7_ !_\'/CU^V?K?Q$\?>*O@S:_"?5M+^"_BCX>>'-
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MXX?MS_!G]F;Q%'I'Q&^*GP\\!ZK)!#=)9Z_X@M=/N'AE>5(I%25U9E9H)@&
MQF)_0U\-Z1_P2%^(?[8WP1^*?CGQU\5/C!\*/B!\=M1N_$-WX-L[C2SI6C/#
MB'0X;H?9Y9)'M[>TL"_EW"'<C!2K L?;/V-/AYXW^)O[6=O\4?BI\.9-#\0W
M7P3\*Z'>W.HVD$C6>MQ:EK3ZK:PN"V$W-;294@.CP,>0  #L/V+/^"F7A7]N
MK0_ NM^"]2\#/IOBI-96_P!/E\602ZYID]C)"$A2TB1A,3%-'++ET,*30'#B
M4-76>*_^"A7PMD^%GQ.UOP+X\\ _$G6_A9X?U#7M4T+P_P")[.\O(?LD,CF*
M987=H-SQF/<Z\-V)&*^$_@=^RA\4?&WP?^&/@*R\ ^+/ACXD\$_#/XE^![K5
M[^T6UM+/6;Y=-6SO89X'(DAE9Y'CE4@L8),<KFM36/"-U\7?V3AX1\+?L>^*
M/ GBKX6_";Q)H<VHZOIL5G)HE]+H,MBFF:/)"6_MC[7,,&1,PE(HY&(E>):
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MP:9/>WVFR:G<16VFV$J0QM(!9V?V*WD<J$B$,KML4,0 ?5]%(IR*6@ HHHH
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MA0\8?>0S(9K7X&_MWJ7\SX_? 'I\N/AE>'GC/_,1'3GU_P 'Q_"+]O2V=O\
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MD[EM)-BD#)*@D9R.'B\5?MWPGYO!O[*-Q@$_)XJUV'GTYL6IO_"P/V[8>?\
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MR?\ \$)XC%_P2/\ @6QY\[P]Y^<]?,N)G_\ 9J^K-4?9IMPQ_AB8_H:^*O\
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MSRT8^7QU\1!@@\ZR&R <XYC/T]<4 >BAU)ZTM>>Q? :ZA$87Q]\0,1C!W:A
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M:.6R/MCXA2>3X"UM^FRPG;_R&U> _P#!&F'R/^"3?[-Z^OPYT-OSLHC_ %H
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M=+(K!2&T'4EP>O4V_N.?<>HS#<_\%*O@G9%?M'CRSM=S% 9K"\C&1C)):$
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M[M:^4M8&_P#X+\>'^?N? '43C/3/B&R_P_2@#["HHHH **** "BBB@ HHHH
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M1[D6FBVL5NA_TD1":21II4B4-'$L:;OG7XR_\$U?'/Q+^"&N>#+'X*^'=/\
M&VGZ?XLDUGQ]<7NE3_\ "T&OK'4HK:VSO^U;I[RZL;QQ>K'%:R6,>QI#'&]
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M>9J*-_%M_A/^SGZGT ,;WGQ^6:15T[X/R1Y.QCJ&I(QP&QD>0>I"#KP'8\[
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M !%U$AFZMBRL%S^G:OUIK\G_ /@S@;=_P2?UCESM^(.J#EL@?Z-9=!VK]8*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y]_P""
MLURUI_P2Y_:,=?O?\*T\0C\]-G']:Y[XE_%7XS?!W]G+X(_\*;^&>C_$B74(
MM+LM=M[[5SIQTNP%HCR7"MM(/RHRY^9@[1XCDR0-/_@L1<"U_P""4W[1;%MN
M?AWK:Y]S92C^M>R? J VWP0\&QL/FCT*R4_46Z"@#YK\-?ML_%'QU^TU\+_
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MUB]?4]4D\0V^KK:+-!]E"6PMWU1DE*RS&0(KKMP4;<U7]C7XJ:?\3=)TC3=
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M"/C0>+O$MCXDTSXC7VL0VUWX1AMM.@M_L@3 O/,62WE$20MY#C4)/-*+YJ2
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M+X?-I'YEK%IVEROJ-A=AIS:#[:]N0MQ)+?SI&YCM0B_0WQW^//C;P/\ LN_
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MM<?K7\?(9L5_8#_P<A3_ &?_ ((F?'ML;LZ39)C&?O:G:#^O_P"JOX_'&6H
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M\.S?$S3_  ?J,G@W1I?%MD-:T^&^FTN'3XX/M-_ KHSH8?-AW21C<ID0=2*
M/E'PI_P43^,WQ+\$1_$+3KSX:Z3X5T3PGX"\2:KH4NAW5W>ZE)KH#7<,5X+Q
M5MT1'0Q,89CNSN! ^;V_X,?M=>*/B/\ M6WWPEN8M$CUSP+?:S=^+WCM94\O
M2R\1T)X@7(22ZAND8L2RLVGW@ 4X"^\V_P +_"]G8W%K#X<T2&WO5A6>%-.B
M5)Q#@PAE"X;RR!MS]W'&*R/AC\#K/X<>./&'B635-6U[7O&EXDMW>:B(?,M;
M6'>+6PA$4<86VMQ)*4#!G+32N[NSEJ /G+6OVK/B5XH\0>+M5BU[X7Z)\/[7
MQ3K7@*#0KW[19>*4N;.TN"+J&[^T&*6XD>!KB.S%LC&U=)1-D8;S'P'_ ,%#
M_B9X8L/A]:Z?<:'XH\,Z++X)\+^)I+C0;Z:\-UJUOI*2M/K,]Y# +Q6U&.;R
M(+>\=E:/>R&20P_5OQUT/X&_ 7Q5-\7/'FA^"='\1:E GAEO$ESH\<FJ:A'/
MA%L5D6-IYMX0#RUW95#QM4XYKP-X&_9C_:%^.6J:AH?A7X:^)?'OA56T"[U"
M/0(GO+$:=-$AMA<&,?\ 'M+Y285B49-HP4( !\^WO_!3_P",_AO3?$5GJ_A7
MP]:^.M6\[_A"O##^&;V(:A''>6Z2S6NI?;FLM<,5I<"86]M):SW#QE(T&?E]
MT^%?[=,US^QG\1/'VO-:^(/%7PI@U!_$.E66@ZAX8E@G@M5O([:2SU$M/;LT
M$L)+EI(V5Q(C%2 /0/\ A@[X+G5?&5]_PJOX?_;/B'%)!XEG_L*W\S7(Y'62
M1;AMN7#R(CMGJZ*Q^8 UU'PD_9\\#_ GX<_\(CX.\)^'_#?AEC([Z78620VL
MK2_ZPN@&'+#@ELDC Z#% 'S#\0?VQ/CS\,OB%HGPVO-)^#VI?$#QE<:?+I%]
M9W.H+H]C:W#7@F%Q&W[YWB%KNC=&47&779"4R>[_ &X_VFOB9^SGIO@F+PCX
M9M=<FUL71UO51H.JZY;:288XMH^Q::LEYY<KR/\ OPKI$(L."TB ]3\+_P!E
MWX$?L^7D.G^$O"/@'PM=G7XI8HK&"*&8:HMI,\48 .X2):S3LD71(Y7*J%8Y
MZSX_?LN^ ?VHM$T_3_'?AJP\0V^ESFYLVF:2*:U<C:QCEC99%#+PP# ,, @T
M ?)_A+_@KGKWQ4^)>GR>#/!MOXI\ Q:OH^@WUYINFZ]<SW\M_!83O>6ETNG_
M &%+>!=0C;R[J6*5TB<L(245HE_X*<^,/!7PJT_XH>/O#&CQ:-=:)XLUW2]+
M\.ZG<R23VNF2VT$0N0\1#2RO(&RJD0JQ^^0<_3,O["/P?E^)?AWQ<OP_\-P:
M]X2AMH-)F@@\F&S6VC\JVQ I$+-!'A8F9"T050A7:N-BW_93^'=KX=TO1U\(
MZ+)I.BZ5?Z':6<\7G6\=C?%#>6Y1R59)O+0.&!R!CH2" ?*'_#T/XK6W@3Q'
M_P 6IM]2UW0=1TF.;5-/TKQ,VB6-G?&^#R2PR:4FHS/ ]B(V^S6TJ9O;9W:)
M!+Y?M=O^W ^M?LF^$?'7A^Q\-^+?$GC35+;P[IUEIFKS)I+ZI)<-;R(]U+;+
M-#%$T<QD#VXE7RV3RR^ =#2_^">GP5TWP;K'A"U\,LL&HW=OJ]TXU[4#JT$J
M"2.WDBO?M!N[=$4SQQK%*B*KSHH >0'K)OV0?AS/^S_)\+W\-P?\(3(WFM8B
MZG$QG\_[3]I^T[_M'VG[1^^^T>9YWF_/OW?-0!\Q^(/VGOC-\4OVT/A%\-S%
MHW@>;0?$.II\0;71]>-Q!JD=MIVGW]I]FFFL"\EN\5Z?,B*P2;U*^8JXD;U'
M]H/]NKQ'\+_&OQ!B\,?#ZT\5>&?@WI4&L>-[^X\0?V;>012V[W1CL+<P2)<R
MQVR"5A++ IW*BLS9QW_PS_8T^&?P0N_#]]H.@&SO/#,M[-9WUSJ=W>7;RWJ0
MQW,L\\\KR7,LB00IYD[.P$:@$  51^+?[%OPH_:9\>CQ-XATF35M1LUCTZ_2
MTUR[M;/5$MY&DCMM0MK>9(;Q8I'=ECN4D"EV& &((!Q_C;]NK4[?X3-J6B^%
M[>36-5\8^)_!&DI<:GMMQ<:5:ZS+'=2N(F*QRR:3M90I*";.7V;6\G^!O_!6
M;Q-_PG/PK\!_$WPAX2\)Z]XK\/Z)?:AK&I>*I-/M]5GOX4(;2A)8)!>$221Q
MO")XI%E:2-%E"*\GT%%_P3W^%,?QEF\>?V!?2:]-J=SK*I)KE^^G6]Y=6LUI
M=3PV1F^RQ23PSRB5HXE,C-O;+_-7/VO_  2V^$MK#X?M6A\<76D^'H[.-=(N
MO&^KW&F:F+.02V?VVV>Y,=T8&6/RS,K$+#$ARD:J #P&T_X*[_$#X0?LY:+X
M@\?_  _\$77BRZ37]3NM-M?'<<4\UCI]_/ !9VRVC7%Q,$B<']RD6$1FF4NZ
MQ>O67_!2;5-7^*^J6MG\+=0D^'&@^)- \,ZAXK?7;9)XY]:L=,N;1TL-I=T2
M35;:*;]XI4-O3S0&5=?6?^"7'P<\6:MJ3;?&$"WHO;/6;*Q\::I;6^IVEY/+
M=2Z?=1QW \RT\VYN)$MV^1!=3!0%E8'O](_8R\ Z)X:U#2;?3;I;75-=T3Q'
M<[KV5GDO=(CTZ.Q?<6)PBZ59!EZ/L8MDNV0#YP\4?\%)/&WB;5]%\1V/@W5?
M"OPMU_X=>)O'&BZM]LL;J]\0VUI;V,MG,(F#&SE9+AI5BD60%742;65HU[2U
M_P""HJ:-XEN[KQ1\-/$7AGX=QZCXGTFT\6/J5G=K>W&@B_DNR+2)S.D30Z9=
MLCL Q>/:4 9';I=,_P""7WPNTO5]4N%;QC/9WVA:GX9M-*G\2W<VF:%INHB#
M[5:V-LSF.VC8VZ%=@R@^52$"HO0^-/V(?".L_#2WT.QM8VFTB]\0ZOI8U1I+
MNS%]K,>H+=M<Q*Z-/ QU.YS$'3Y6 #*0" !?V=?VK=>^,GQ1\0>$?%'PN\3?
M#;5M%T>QUZ :IJ%C>I?6EY-=118:UED"3(UJXDC8_*67#."&KPWXC?\ !7FW
MU71?VAM*\&^&_)\1?!OPWXCOK>2_UG2Y+N:]TNWD8>9HXNAJ"0R.A:-WB598
M]C;E616KNOV!OV,O&_[/OC[Q?XL\?>)4UK5->TK3= T^SCUR^UM-.LK*2[E7
M_2KQ4D.YKQE";"P6)2\LSL7%[XM?\$P/ ?QX\9:IJ/B[Q%X^UZQN8]2_L[1K
MK5DDLO#L^H6LUK<W%FQB^T*S0W%PJQR320Q^;\D:A(P@!5U/_@I')X8\*^+I
M-<^%'C30/$GA"ZT]+C0]3UC1+5C:WZS-:W;WLE\+*&-C;S1E7G#B1%0*QD0M
ME>#O^"M_A7QWX?\  VK:7X+\77>D>*M'USQ!J^I0W6ER6/A'3M%OX[#4;JZG
M6[,<\<<TF5^Q&X:5%9HPP!KMOV@O^">OA/\ :#\;WGBJ?7/%'AOQ7-<Z9?6>
MJZ6]I))I=Q8PW]O%)%#=6\\#%H-2NXV$L<@^=64(ZJP7X>_\$[O G@&5EGNO
M$GB:VN-%\0:#=PZW>B[74+;7+^/4-1\]@BL[27",0<@*LKJ!C:% /*=;_P""
MX'PW\)^'TN-:\,^)M%U35'MFT'3+S6- 5]=@F?9YXN!J1M;-8_D,BWTUNZF6
M)0K.X6OJ[X3^/Y/BE\.=+U^;1=2\.RZG"9'T[4);::XM""5*L]M+- _3(:*5
MT8$$,<U\^^%O^"6&A>#O!^O:7I_Q$\>6\VJQ06MG>1VFB1MI=K$>+<P+IXM[
MY74*LC:A%<NVQ3N# L>T_95_9%D_9#-GX9\,ZR9/A[;V%Y<3V<]M;0SW>LW=
M\US/>".W@BAMXR'<"& 1Q#?\L2XW, >5^+/^"DOC/PO\<=8\,_\ "G_&%W8Z
M/\3T\!V_V&.SN[S7X7\,2ZNLMLJW@6)Q,D3,]QY<2VTZ$D2"01]=-_P5(\#S
M>%;'5--\+?$C7&73)]8UVST_1%DNO"-K;W5U9W#7R-*HW1W-C>Q&.W,\CFUD
M,:NH#'MK+]CO3;+]H>_^(+>)?$=P]YXE@\60Z,XMA865^FA2:'(Z,(A,5EM6
MC+*\C 20J5VAG#>,_%#_ ((M_#_XCZE97ZZY?VNI1OJ$5]<WN@:+K;WMI>:O
M?:J\"_;[*86[1SZC=*DL&QPCC=O*J0 >B67_  4B\"ZE\6!X9M=+\87>E_VW
MI_AS_A+(-+$GATW^H65M>6,*W(?<_G1W=NH=(V17D579-RD\?^V+_P %(]4_
M9D^)?C#P_#\/M>O['PCH/AS7Y-<%JUQ8S1ZEK@TV:!4A9IGG6,,\4:1LTDB.
MN,*"WI5_^Q#X?N;22VAU/5;6U;QUI7CI(H_+*PS:?!900VH)7)A*6,6227R6
M^;I57]H#]B6'X]_$F;7)O%VK:/8ZA8Z-9ZCIMO:P21W;Z3K2:M9RB1U+QD.;
MB)U4X9)\\,BF@#)'_!07P#JOA]K^7POX^D\5:7K<V@KX3/A::?Q)!=QVD%Y*
M5MU#8B%I=6TIG#^5BXB0OYCJA]$3]J+PI>_ -?B/IYUK6/#\F8XH-/T:ZN-3
MEG$YMFM19K'YXN%N T3Q,@:-U8/M"L1XW^U#_P $K?"_[2/B'4/$,NH:?'XF
MF\42>)K.;6O#]KKVG6QFTBQTJ>V>SG 22-X]/MY0^Y94E4;7V%D;?\8?\$]M
M+U3]@V#X':-K<>A6=O)!=?;;?1K>&SN9TU!=0F6:PM_(A:VGF\Q98%*!XY64
ML22Q &O_ ,%1?A?%X8M+Y[?Q]_:EYKUWX8'AZ/P;J4VNQZE;60OY;9K*.%I5
M86C).&QM*.IW=JL> O\ @IE\$?C+X&\1:Q8^([J3P]I&E6^K2SZCX>U"SCU;
M3[IV@AGLXYX%>]BDF#0+Y"N6DP@!+)NY7]E[_@E]9_LU^+]'UR'Q5;W5QI_B
M;4/%4]EIGANUT;3GN;S1;327CAMX3B&)%M1*NXR2%I&WNY)<UO$/_!*;3/%W
MPNL?"^H^,M2FM]+^'.A>!+><6*!_/TB^2^M]092Y5MTT46^#H54C?SD '7/_
M ,%)/@[X)T'1[-7\7Z?>7=S)I%AX8@\!ZTNMQ2P6BW)A_LQ;3[3&HMB)%)B"
M,BDJ3M.,/]H;_@J3\*?V=/@<VN>'9F\42-X<M/$&D6&E:7>_87MKL[;(7%S#
M;O#8"<Y$8N/++%2 .#57]F;_ ()H+\ ?BSH7CBZU[0+C7-.N+Z6]AT+PX=+L
M[U)K9+>! );FXG'E*)&R\T@9I6VK&.#S/B7_ ()4^*+/X+7_ (!\'_%6QT#P
M_P"+]$TS2O%[7GA?[?<ZE)8016ZS6K?:D%KY]O#'%(K"4 *&38Y9F /3/$O_
M  56^!/A'Q?J/A^\\97O]L:9>W^EO:V_AO5;I[F\L96CN[2W\JV87-Q#M,CP
MPEY!%^^V^5\]='KG_!0+X0^'M;\/6,WC*TD;Q1866J65U;V5U<V,=K>X%G-<
M74<306B3D@1FXDC#DX7-87@[]B.?PKXS\$:I_P )+]H3P?XY\6>,S&;+;]J_
MMM]286X._P"7R/[0QOP=_E9PN[CP^]_X(SSQ7.DV=IXMTN;0=4T31='\8V]U
M'J\4E^=.L8;!I;1+748;91/;01J8[J&X567<=ZGRP >X>)O^"H/P7\/ZUXPT
M:'Q9_:7B#P3;:O-?Z=;:9>,SS:7'))>VD4OD^5+<QK&S&%&:38-X4I\U=/X4
M_;:\ :W^R1X=^-FK:S%X5\!^(+"ROOMNLQO9K9?:Y(X8DEWJ"N9I4C#$;26!
M!VD&N+\1_L*ZAXA\!>']#/BB&V72?%_C#Q/-*ED6,B:XFNK'$H+\-!_;*DL3
MA_(/"[AC:L/V9/$VL?L?_#OX>^(-8\/RZ]X1OO#5S>WUA:2QV-U'I&IV=UB.
M*1W=6DBM OS,<.V>0,4 2^ O^"D_P)^)NK-8:)\3O"]]?Q:9=:Q-;"=HY;>W
MM06N?,5U!CEA7YGA<"5%^8H%YKK/B'^UG\,_A/X?N-5\1^--!T?3[/3[/59)
M;FY"@6MY*\-K*!U832(Z( "692 *\;\0_P#!//4/%&BZEIMQXDL[>VU?QEXJ
M\2W$L-H6D2'6-,O["-%!.&DA%XK$D@,$(&,BO/\ 7_\ @G9\6/BEX(UAO'-]
M\+=8URW\.^'=#T"RTZ?6=+M[>32;N]E^UG4+>5+RVN)DNAMDM^8&!4B=2V\
M]]^'G_!07X3_ !;^.^C_  ]\->+=-UK7?$'AS_A*---I()(;VT\^:!@I!_UB
M/!)N4@%=I!YXJSX8_;J^&>L?M'>)OA+=^*M T7X@>'=6CTN+0[[4[>.^U;S-
M-LM06:WAW^8R&.\"#(!+02X!"YKSK]D;]E/XO? _XQZ?X@\7>+=$\8:?J&C7
MNFZBMSJ5[=W^A*;UKJSM;:YFC,E_"GFS(TUTT<H 3 ( 5:'CK]CKXG>-/CA\
M0+3[1\/[?X8_$+QWH?CB?4DENE\3:<VEVFCQBVCB\KR':6;2EVS&5?*C=ODD
M9AL />/AM^U%\-/C-XVU[PWX2\>>$O$WB'PNQ35]-TS5H;JZTXABA\V-&++A
MP5.1@,"#SQ7.^+OBG\#_ (B?M(>'_!&L>+O >J?%+PC.VJ:7X;FUJ%]4L9C
M6\\6>_<7$)+JS(61277;UKP?]AK_ ()P>-_V<_BKX-NO%VN0:]H7PI\-W'AO
MPU>_\)9J6HW6HI*L$)EDLI88K>Q!BMD+1))<J7QM*!!F/7?V&?B]XC_:MM/$
M^J:MH%]X-\.?$3_A-=+5/$-W;YM&AD0VJZ/!9I;K<IYS$W,UQ<M*T18"%IVV
M 'TMX,_:]^$_Q(FUI?#_ ,3/ >MOX9A@N=6%CKUK/_9<4X!A>?:Y\M9/X2V
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MUFTK3_$M]J2WVH6TEU#9Z7H]YJUTEK!L$UW)#:12O%;1&2,/,X$:EU!;) H
M^-/VF/V.?%_PGN?%^D?#+P_XJ_X5K)>>%=0U;38KB^UPZW%%#J\6H%;8ZA;S
MW+^8=(DN(TN$:=8B2)R6C?T/X1^#_BAX#_X)@>/H[;2_&'BCQ)J*ZI<^&?#U
MTMSX9U*QLI2%AM( ;^XN[=5422Q1O>+.JND0,!"A/3?V??VV9_VD/VL_B!X-
M\/:-I]QX"\":=ITR^)Q)>DZU<WMK!>0FU/V46<EM]GG4^8ETTA."(]C!ZZ&?
M]OSX0V6IZM:W/C*UL8]'CO))+V[L[JWTZ\^QL4NTM+MXA;WDD#@K)';22.C
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MOVF_AU\0-0\9"Q\3:%--\-=7.@^());E(QH]X4B8QN[D!<^:BYS@L&7[RL
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M-[>6$ER+"6::[EMKM[)EMX(U:6X:2XC,<*QJS3,R!%;>N?#/C5_P4VN8->\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2/\
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M&&""=%D2"+9$I483'%?5G[4G[.OP'_9\\1_!W3K/X%_ >&/XF>/[;PC<K=>
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M7&HRM&L]Q&UV#Y43)B15RRE@" 3B@#])D_X*9?LWR)N7]H+X(LOJ/'6EX_\
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MC%ERH#CU% 'Z80_M2?#*X_U?Q%\"R?[NOVA_]J5>A^/_ ($N%#1^-?"4BL2
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M;4\A7$@9]R-\H,@.^OT(HH _%;X^_L*^+_@E^S;^QK^S/I7B*WA^.5]9ZMX
M\4R^'8+B\LQX)U5G;6[LRM$@5(O(M2C.%82G QN)/Z%_\%/OV*=4_:J_X)M^
M)O@I\/;?P_IUSJ"Z+9:;!J4S6]A;6MEJ5E.R$JDA %O;L% 4Y.T< YI?C'^V
MGJ'PK\=_&36#'IDWA7X0Z=H^FO97^I6FCP7>K7Y6=Y9[ZY8+%!#;S60 4,S&
M68*DT@C2O&_$_P#P5@^)'C?PEI6K?#?X7Z'K-Q::GK^D:];R^*56U+V6C0:G
M;7%G<R6Z>?#)'<QON,:9*,HRI$A .=_X*%?\$H?'WQD_:X\=?$;P?I^G^.M
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M;\)_VA#\3!\0CK\7]L:YI5Q?W5Z6-N8@ZW$:SK#-N<!_L]N(Q(H+)]4>&?\
M@HWXKC^*WC+P]KWPA\9Z?X@M+S2=&\,^#EGTQ]4U:[N+*_OYY!=K>&R%NMM:
M,^]YDVM#(F"[(K<'I/\ P51^(4WPLM=7M/AKJ6M>*IO&=IH=UX:V65G/IEC=
M>,=:T./?*]Z(GNA%IBH0C&(2LLFXQLWE@'8_M\?LW^/IOVROA/\ '3P;X TK
MXRV_@/0]8\.7G@R^U.WT^>W-^8'34[*2Z'D>:OD&&0.58Q2_*205KQS]AO\
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M$V4S:?J:6YN1):P M!"CRI;L8@P_9;RQFFQVR1%MJJNYMS8&-Q]3[T ?"/\
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MU_:L12VWGX<RDCWP)2<4L?\ P5>TMWPWP%_:KC7^\?A7J! XSV!-?56VEVT
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M="/'M0!]245\QCXW?M;+'\W[//P99O1?C1>#/Y^'_P#.*J7?[0'[75NBF/\
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MCUZ^O//-?=5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !BC:/2BB@ Z48XHHH 3:*4# HHH ,4 8HHH
M,<TFT>E+10  8H(S110 !<4FWFEHH -O%!7-%%  1FOC[_@G].;K_@H-^VQ)
MV7QKH$0^7'W?#=A7V#7Q[_P3N"R_MT_MK3*V6/Q"TB-AZ;?#FF_XF@#["HHH
MH **** "BBB@ HHHH _*?_@\5;'_  2:TH?WOB%I0Z?].][7\O.W/>OZ@?\
M@\;./^"4.A?]E%TKGT_T6_K^8!?NT ?V!_\ !N7'Y7_!%'X C9''_P 26Y.$
M4J#G4+HY^IZD]R2:^V:^+O\ @W>1H_\ @BU^S^&9I#_8$IR3G -Y<$#\.GX5
M]HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7Q__P $M0LOQM_;%F[M\<+N,\?W="T85]@5
M\??\$H/WOQ'_ &OYMN/,^/>K(#CKLTC1U_I0!]@T444 %%%% !1110 4444
M?D-_P></M_X)K^ _^RB6?'_;A?5_,SL)K^EO_@]!D8?\$\/ANH!V-\0H-Q[#
M_B7WN,U_-*I"K0!_9I_P0YT]=,_X)"?LZQKCYO VGR\+M^_&'/\ Z%U[]:^J
MJ^6_^"(T;1?\$BOV<PS.Q_X0/3#EEVG!@4@?0#@'N,5]24 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\A?\ !)I%_P"$D_:P
MD4Y6;X_:^<^ZV.EH?U4U]>U\>_\ !(63S;K]J9N>?V@?%(Y[X2R7^E 'V%11
M10 4444 %%%% !1110!^./\ P>ER$?\ !/\ ^%Z?/\_Q CZ'Y>-.O.M?S7;\
M_P -?TC_ /!ZG/M_87^$L6Y@9/'V<8X.-.N_\:_FUQN]J /[1?\ @BQ"MO\
M\$DOV<57H?A]H[=<\FU0G^?X5].U\T?\$9K:2T_X)-?LXQR*R.OP[T4D-U&;
M.,U]+T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\;?\ !&\^9IO[3DOS'S/VA?&?)_V;B%/_ &7'X5]DU\=_\$;867P7^T-,
MRG_2/V@O'C9)SG;JSQC_ - Q^% 'V)1110 4444 %%%% !1110!^,7_!ZOS^
MQ+\'Q_U/C'_RG75?S=%=U?T??\'K=R(_V-_@S'_$_C>9@/II\X_]F%?S@*S,
M.,8H _M7_P""02R)_P $K?V=5FR9/^%=:'N)[_Z#%[FOHROGK_@DJ[2?\$N_
MV>6888_#O0LCG_GPA]>:^A: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A]H  ';_B6V]>Q4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?&HG!]CS0/\ @LK?+$))/V0OVU(T;@?\6^M'/;^%;XMW[C'Y&@#[4HKXJ/\
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MN?:Q\5L5!^4D?V*!D>O/'U-?@DKB,;37[V_\'P!Q=?LP?[GBS_W"5^"B#"T
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MQKUG)IFJ7D_V; M+?3[6&?\ LS_1G8O?,9T-RP2$DRR2 'W?X _;?\$_%?\
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M_9]U YN/@3\&YSZR>"]-;^<-4KC_ ()B_LUW>WS?V>O@=)MQC?X$TML8Z?\
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M\*LV55]5T>7:/3)T[GZU&/\ @EM\24'R_MG_ +2V[/!:30V&,<#']G^O?_\
M77V110!\<I_P3*^+4(C\O]M+]H3C[_F6>@.6^G^@<?K5:Z_X)J_'3[1NMOVW
MOC7"O.%D\.^'Y>_'_+F/?M7V?10!\9#_ ()V_M%02,T/[<7Q1Q_")?!/AV3'
M'?\ T49YY[?UJ9_V#/VG(2_V?]N#QHJMT\[X;>')6''KY [^U?8]% 'QN?V&
M_P!JR(_NOVX-<Y[3?"CP\X_1%ILO[%'[72$>3^VYG_KO\'=%?//^S*O;'^>G
MV510!\<I^QQ^U]&K_P#&9VDNV"$W_!K3.N.IQ=#//IBHYOV3_P!M"UE9K?\
M; \"SIDX2Y^"UOT[<IJ(Y_K7V5FN)\0?M+?#GPE\3;/P3JWC[P3I?C+4#$+7
M0;O7+6#5+GS21%LMF<2MO((7"G<0<9H ^;;?]F7]MB,J6_:J^%<F,\-\&^#Z
M=-4%6T^ G[;$;_\ )QGP3D5<XW?"2Y&_TSC5N/PKZ[,@!YZGI0)5(ZT ?(H^
M#/[;T$R[?CM^S_-&.ID^%M^I/X#5OZU'+\-/VZK8GR?B]^S1<\<";X<ZM'SC
M_9U4]^__ .JOJ.U^)_AN]\=3^%X?$&AR>)K6 74VD)?Q-?PPG&)&@W>8$.Y?
MF(Q\P]:T]6UNST#2[B^O[JVL;.U0RSSW$HBBA0=69F(  ]3Q0!\@W'@C]O@0
M3+'\1/V49F(/EE_!.NQYZXSC43C/XX]Z]I_8'_9@'[&/['G@'X9?:+2[N/"N
MF"&\GM?-^SS74CO-</%YK-((S-)(5#L2%(&>*])_X3O11J>GV1UC2UO-6C\Z
MQ@-W'YMY'C.^)<Y=<<Y4$8K6!R* "BBB@ HHHH **** "BBB@#\#?^#WP?Z9
M^S!_N^+/YZ)7X*J-HQ7[S?\ ![W<[M7_ &8X=I_=Q>*GSV.6T88_\=_6OP9!
MR* /[K/V>D\OX">"5R&"Z!8 $#&?]&C[5V%<G\!%V? [P:O VZ%8C .0/]'C
MKK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK
MHLB[64,OH:=10 V.)85"JJJHX  P!3L444 %%%% !1110!GZ!X4TOPI:RP:7
MIMAIL,\\EU)':6Z0K)-(VZ20A0 79B26/)/)S6@1D444 4="\+Z;X7BN(],T
M^QTV.\N9;V=;6!85GGE8O+*P4#=([$LS'EB222:3PSX5TOP5HT>FZ-IMAI.G
MPL[QVME;I;PQL[L[D(@"@L[,Q('+,2>2:OT4  XK+A\#Z+;^,+CQ%'I&F1^(
M+RRBTV?4UM4%Y/:Q/))% TV-[1))-,ZH3M5I7( +$G4HH **** $*AJ4C(HH
MH :(U!SCI2[%#9QS2T4 -\E<_=%. P*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BAN17Y_\ P!_X+)7VO>)/%UYX^L-#T_PCX/\ #^N>)-:N+'2=
M6LIM MK'4FLK7,EY&MOJ NS'<!'M7PKV[ Y!RH!^@%%?,'P:_P""M?PH^-F@
MZY>:6WB"&;09K2RDM)+:&>2]O+F[%G':6LEO-+!<S>=);AO*D9%%W 2PW';E
M:9_P6)^$^EZ,S>(-0OK:XTGP?8^+M<N[;3Y&L=.BNK&*]B0[CYP\R.5 C&/R
MR[K$9!*?+H ^M#TKY7\>_P#!/N\^./[2WCKQ#XH\4:UI_@;6K_P]?0^'].2P
M\G6GTL),IN)I+9[N';<QQ\6\\>5C/]YB:-G_ ,%@?AS\0O#FAW7@&UUSQA=:
MIKVF:%?);63M;>''O-6ATT&_N(O,CAR7F>(Y9)?)(# ,#7MWQA^/-]\-OV<?
M%'CS2_!OB+Q)>^'[&[NX?#ZB*QO[TP%P1FX=$13L+[BW,>"H8D*0#\WX_@K\
M>/V;/!WCOQ;\6D\?3>"]=UOP[<WWAK0_'>L7%Q<&!-:^V_9+V*ZN+FSA:>;2
M)S(\T/VD6AA9(O,6%O2/V%?V<_VG+?\ :#^%/CGQEXH\=KX1;PSI1O+"^U?S
M(;>S_P"$<@BFL+Z":?S)+_\ M7S9VF%IYAX+7*C=!7T9JG[</B?PM\1/A^VM
M> =)L/A]X\CB2#6?^$E5]2@8Z3+J=Q=_8O)VBPMUB:&29YTD#D$1%2A?%U+_
M (*:W'AGPG_:6K_"_P 2::K?"UOB3 3>1-#?2EK94TB' \TW&Z[A5V:)%#N%
M02G=M (;+X*ZYXI_X*/VOB2^^# \+^$O!]Y=ZEI/BK3AHYD\1:E<Z;]EGO[Z
M5;D7JIY+-:QVXMVW,J32282-(_$?V@?V(_C5^TAI'Q&\)>)--\?7^C^(]0N7
MU*>;QPBZ/X@@_P"$GT^XTW^SK5;O?9"VTB*Z25&2 2/P1.[+(/;O"7_!2S6/
MB+H7@.R\(^ ='\<^./&UWK$$VE:'XH>*R\/Q:;+;0W$][/?V=K<Q"-[VS\R/
M['YJB=2B2Y0.WPI_P5"N/$<NFW,GPZNH=#M3IUOXEU&WUR&ZCTN>_P!<O-#M
M6LPJ#[?;-=64DAF!B/V>2-U1F+1* 0?M,? 27XB?MI^ S:_ Z:30=)O-%U2_
M^(FGVNC27GF6-VTUI81M-=QW5K:P.HDF>*&0R1R-$B?.S5]>K]T5\K6G_!0'
MX@W7B#7/#\GP#UJS\3Z)IUGK]U97'C#2E@TK3+D7ACDO[@2%+:X#64JF%!,I
M+*1*R"1T^A?@_P#$:'XP_"GPSXMM;.^T^T\4:3::O!:WBJMS;1W$*3+'*%)
MD4. P!(R#@GK0!TE%%% !1110 4444 %%%% '\^__![G,?\ A87[.*Y;:NG>
M(BHQP"9=-[^O _2OPI' K]S/^#W"XS\6?V>(MV=ND:\VW/3,]A_A^E?AHARM
M ']VOP2M?L/P<\)PB;[0L.C6<8E*[?-Q @W8[9ZXKJ*R? MDNF^"])MUCCC6
M"RAC")]U0(U&!R>!CU/UK6H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB?J3U^M2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '\W?_!ZHV?VW_@^N[IX'F./3_B8
M2_X5^,+<GFOV9_X/4I ?VZ_A&O&5\!NWYZA/_A7XS-P?ND^] ']S,?[9'PCD
M"D?%3X;E6&5(\361R/\ OY4O_#7OPGQG_A:'P[QZ_P#"26?_ ,<K^%L6\?\
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*K\KD^X/I0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex3-2_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_004.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MQZT\?=_:8U  =/\ B@DX_P#)^OWHHH _!<_\&/=B6'_&3%\<?]2"G_RPJO\
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M'TK^F.B@#^9-O^#+K]I_"X^('P%SW_XG&K<?^4[_  J$_P#!E[^U, /^*\^
M!]?^)YJX_P#<97].5% '\QA_X,P/VID_YGK]G_\ \'VK_P#RLJI-_P &:/[5
M4,K*OC#X#N!_$-?U/!_/3@:_I^JK<2()FRO- '\0_P#P3NC5_P#@H!\"59O+
M5OB+X>!;<5V?\3.VYRN2/J!FO[@J_B#_ .";P7_AX;\ RRR,O_"R?#FY$&6(
M_M2VX'O7]OE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\Q?^"AK6X_;"\7^9>>2W^A93[?%%C_0K?^%I5(_$#^M?IU7Y/_\ !2T:M_PV
MSXU^RQ:&T'^@[3<+#YG_ !X6V<[CGKGKVQ0!_/K_ ,$J6_XV?_LV_P#95?"O
M_IWM:_MJK^)+_@ED[)_P4Y_9Q*KN9?BGX6(&3_T%[7'0$_D#7]MM !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7DO[:G[9_@C]@GX&7'Q$^(5\VG^'+7
M4;#3'="N\R7=U';J0&(!5!(97YR(XI&P<8KUK-?+_P"W%^Q9J7[>B>,O!7BB
M:]TKX>W7@ZXTG3GL9K.X;4-0O&/G2S07$#F)K<0VWD2QNC RW'(RIH V/^"@
M/_!1GPW_ ,$Y]"\*ZYXR\.^)M4\+Z]J*6.HZMI"0R1>&HVGMX/MMXLDB,MJ'
MN8PSIN(9E&TEA4WC_P#X**>%/ O[=WP__9^71?$FJ>*OB'IU[J5KJMJD']CV
M*6D'VB6.:5I1)YOE&)@J1OQ/$20&R/#?AC^P]\5OC'^PQX)^#?Q\TG0=2OF^
M&>O_  ]\2ZWINJB\BC:4V"Z=>HLB*\DNRT#LV 4FC##(;*X/P2_X)K?%3X1?
MM6_L=^(M4NK'Q?8_!GP1K.D^-_$=SJ(^W:AJE]8P6X>.-EWS)']FBA#L0WE+
M&.=F" >W?L\_\%2M$_:6U.]@T'X;_$P6^C^/+[X=ZK=O'IKQZ;J%E)''<7#Q
MQWC3-9+)+$AG2-L&5-RJ#D5_A-_P5Y^'GQDN_C!H^E^'O'4/CCX)71M]?\(7
M=I:0ZS=Q>;Y0N[)6N/*N+5FSB42J,;20-\8;PK_@G?\ L0?%O]COXA>./%=]
M\.UN/&'C_P"*&O7[7G_"8QSZ3IGAS5]1LKN:X>VW#-W&MHRA(4!D)3>Y4 1[
M?[1/_!,#Q)\=;7X4_%?PQ:W'PY^-WP]\4SQW\8O8&_X23PO=:U))>Z9=RQ,T
M;HUI(TT08ML<E,(SED /8OB5_P %8_ _PI^*'Q:\+ZIX1^)4LWP/TZPUGQC>
MV.EVUW;:9I]Y$TL5VJQW!FFC5$=G$43.@1B5P":V_$?_  4Q\ Z;\9_"/@?1
M=/\ $WC+4O'OA"7QSX?O=!AMI].U32HP"\J3R3QKD!D(#8SYB8)S7S)\7_V6
M/CI%^UQ^VMXB\,_#%=9T_P"/G@O1/"'A'4+K7M.M[*.6&PN+2XN;Q&F,Z0H;
MDN L3NXCV[!NR.(U3_@D]X^^&'[07[/.BVWA_P =^,/A[\(/@P_@Z]\1^&M>
MT_2Y[O5Q>6]PL9MI[V!YK63[-MDADS$\<H1BPW$ 'V;XD_X*;>"/#/C;X5^&
M9O#OQ$D\3?&30KS7O#FDIH6V\>.S@\^[@GC=U,%Q"A :)\$LP1=S<5ZC^S9^
MTQX+_:W^$]CXV\ ZU'KGA^]DEM_,\F2WGM9XF*2V\\$BK+!-&X*M'(JLIZCD
M$_''QT^'/QN^)?\ P43_ &4_C=-\$_$3:1\.]!\7_P#"2Z98:[HDEWI$NHP>
M596O[V^C2:<K%'YC1,T2L_$A4$CN_P#@D]^R[XZ_8E_9/^)6L>-M"D_X3CXE
M>.-?^)MUX2TJZ@NI-*>]V&+2HIMZP23;((P6#B+S)6 <J-Y /I7PE^T!X2\;
M?&?Q;\/=+UJUO/%W@6TL+[7-.CR9-/BOA,UJ7.,9=8)&VYR!M)P&7/EO@3_@
MJ+\'?B9:?%8:'KVI:AJOP2O7L/&6BIH]TNK:5(CE"1:E!)-&65P)(@R-L;!.
M*^5_"_[)OQH^ '_!3KX-_'S1_"\GB*U^+7AV\\/_ !G@TVTBL9=%,LJ75E=3
M"6[?[2]M+-]FS$"RV]D% (**'_M'?\$[/&GQ+U7PW\=_A)9:AX3^+.F^+-9T
M3Q9I=[;"T/CCP=>^(+J26">.4A6DCMY4NH'8[L+M^^(U0 ^J?'O_  4]^$'P
MO^)/CKPIKVL:[8:K\,;6SO\ Q8X\.W\UKH%I=IYD%U//'"T:P%<EI Q6,*Y<
MJ%8CTCXK?M(^#?@Q\!K_ .)VO:U O@+2].76+G6+%'O[=;(A6%ROD!S)%L8/
MN0,-OS=.:_/GXV?"KXD:)^VM^W;K6E_"/QIXNA^,/P]T3P=X)\BR1;'7[Y=-
MN+:='GE=(K>WCDN4WRSLBE8Y"I<A0WI/QO\ V1/&WP=_X-V]4^!UO9ZEXV\?
MZ;\)T\*)9Z7$]Y)>7YMEA,4( RT:.2JL0 $0$[1T /I7X;_MX_"_XM>(]2T7
M0_$DDVO:9X=A\7/I-QIEW9ZA<:/*,QW\$$T2R7%NQPN^(. Y"'#$+5?X+_\
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M^*4!D\,2^%;F>Z\83_V;#:63V<NTK*L=ZH&T+M5@LS2HL8)\]_:(6R\86_\
MP4T\)MX:UKQ%XH^)WB/1M(\$:5;://-<:QJBZ7%!;36W[O!6"ZCWM,"%B$18
MLHP2 ?M,#D45Q'[-/AKQ)X+_ &=? 6C^,KYM3\7:3X<TZSUN\,GF?:[Z.UB2
MXDW?Q;I0[9[YS7;T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MY<_\%%KN]B_;)\8K#_JQ]BQ^Z1O^7&W[E@:_4:OR _X*C^-+[2?V[/'5O#J5
MQ;QQ_8,1K:RN%SI]L>JH1WSP: /P1_X)81B?_@IW^S?&P^63XJ>%U.1ZZO:=
MC_6O[;:_B4_X)6#/_!4#]FWU_P"%J^%L9[?\3BUK^VN@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OG/_ (*C?MV-_P $\?V4=3^(UKX;OO%UUI5U:M+IMI&9
M&CL?M,0OKIPI!6.&W:1MWW=YB#8#9KZ,KQ/XZ?L::;^TGXN\42>-+JWUOPOK
MGA.3PK9Z*]K+$M@MP9#>2M(DX$PG'V<&,HH46L>&R2: /,?^"@7[?^M?LV:E
M^SM=>"[WP+=^&?C=XSM/#4VL:PDLUM:6ES;/<1WT3QSQ(R[(S\K'#^8I#+CG
MF?V?O^"@?Q@_:5_9F\=>//#_ (=^'MGI_P .?$WBC1Y==F-Y<:5XTL-*A;[-
MJ.DJC@M#<S@QES+(B"&4JTIP*H^&/^",VJ6'P$_9B\!:Y\6/^$HM/V:?$@UN
MVNK_ ,+(S^(;5%DB@L9D^U%8UC@E:(. Q*K'E<JQ?M_V5O\ @F3JG[)/[//Q
M@^$OA_XD277P[\;3ZG)X)TJ\T0R-\/(;]9?,M(Y/M.;NV1Y \:$1,N'RS%R0
M >*>,/\ @K/\;? O_!)"W_:HNO!_PQO+'5/#FD:Y9Z1'<7L31S7>H+:R6TC$
MME1%-#*DJ]661"@&US[Q-^W-XM^)?[:M]\!_AWHWAVZ\0>!?#5EXB\>^(]8:
M==-TAKQ<VEC:V\1,DT\P#2$R21I'$ <RL2HXGXD?\$B=8\?_ /!'/0?V3E^)
MFGV4FBZ?INER>*_^$5:1;F"RNTN(\6/VU=CL(HU9C.PX<A1N 7T"]_80U_X?
M?MPWWQX^'GB;1=/U[QEX9MO#GCC1-4TR633_ !$UH!]CO89(YA):SQ#=&0PF
M5XF"_(R[V .>^)'[?'Q2^#7[1'[/_P .?$_PY\)6>I_&;Q3K6@W-S;^()IH+
M&VT^#[4EY!^X!E\^ ,?+D$9C?"DL/GKI?^"A?[>>J_L3^,O@KIUGH?AW5++X
MM>,%\(W%_JVKOI\6AEX'F6Z;$3AXU6*3<I9.=O.,XR_C_P#L*_$;XW_'S]G?
MXC3>/O"8UOX&:GJVJW5M_P ([-#::^]_;FU,48%RS6R10L0K,9F9L$XP0>2_
M:J_X)N?$O]K_ %SX:ZEXS\7_  ]UI/ ?Q&?QI+HEQH,[:5=:>+%+*/255Y7.
M&4SR232!@TDY(C"@)0!H_&O_ (*GW'[-WA3X8S?$'3/!7@]OBMXAO-*TCQ+?
M:_+_ ,(C'9QVWVJTNYKWR \+W<90)%*B!6$V9"(P9/9-;_:[A^#G[&FO_&'X
MJ:3!X/L?"NFW^JZI::=J2ZO&UO;2RK$]K/MB$XN8TCDA!5"?M"*0#FO.?%7[
M'?Q"\=?#^#PMXJL?@SXY^'\;7=A)\/M6TRX_LG^S!#8PZ;%'>.LTB7%M]GN)
M#.T#[VNBJK%M1TK_  P_X)4Z#X9_X)0ZI^RSK&KW%SH&L:1JVFBZ@,DG]C+?
M75Q=0QVYF8NZ6;31I$96RXMU+ ;BH ,_3_\ @J-K/@C0O@3XF^)GP[@\&^"?
MVA-2M-(T&^M-<:_O-!N[Z$SZ;#J<#6\2QF>,;6:*2189<(2RGS!+\"O^"F7B
MKX_>)/'=IH_POTEH?AW\5;GX7:@A\7D:A?R6IA:[O[.W-F%ECA@G$YB:5'*1
MR@98('YS4?\ @G5\3OCYX=_9T\#_ !4U?P;_ ,(3^SWJ]AX@NK_1;BYEU#QW
M?:9 8-.9H9(D33X\D3SJ);@LX\M"%_>5L?\ !/W_ ()BM^S5\>/B]\1/&FF>
M#[[Q?XT^)VO>-?#^M:1)(][8Z;JD,,;Z9<.\,;,JM LA4%D+D, "O(!Z5^TM
M^W,W[//[7OP)^$:^$Y-<O/CM<:K;V.I+J0MXM*.FVZ75P98S&S,#"Q*;3RRE
M6V AJ\Q^%W_!8O2/B5XJ^,G@G_A =<T/XI_!V1Y9?#.J7B01^)M/2\-DVI:=
M=;,36WG*R[C&I!,8(!? ZO\ :W_8^\:?&W_@H?\ LN?%30Y/#Z^%O@C<^(I]
M;@O+N6*]O/[4T];*/[.JQ,A\K!=M[KN! '<UP7[0W_!*_4/VFM$^%?C*:;3?
M _QB^&'C2XUF*_TZ\DN(=4T2YU>6YO-(N)0D;20SVTN<,A"2@@?*[E@#U;3_
M -OI?B3^TMXY^&/PU\$ZEX\U+X5QP#QEJJZC!I^EZ7=SQ&6+3H)9"6N;TH"6
M4(D,>562:-CM&?9?\%)+?QO\:='^&?A/X;^--6^)%QX33QGKFA:A)9Z:?!UE
M(VR&'49FF=%O)9/E2"'S> 79UCQ(W+_ +]DSXD?L/_M3?'S7O!^CZ'X\\ _&
M_7D\:6MO/K']F:CH&L/"(KN&4M$ZS6LK*DB2(0\0!3RG^^7:=^RK\2/@1_P4
M2\7?'GP]H^C>++'XL^"M-T?Q5H$6JBUN-+U?30WV>>UFF0)-:R([1,&\MU(#
MX;)10!MQ_P %H/AL?@3\//'NF^%_'VL6_P 0OB)#\*5T2WMK&+6= \22S20K
M97T4UU'#'MDB8,Z3.!NC8;E;<'>.O^"S_P .?AO^S=\9OB/K7A'XD6:_ /7X
MO#WC/PZ;*P?6-.FEEACBE0+>&UFA87$;AH[@G;GY<C;7SEKG_!&SXGZ9^S+\
M+]'1M"UKQM??M)6GQW^(9L=8DL;6RB\Z5Y[/3Y]J2LZ1F&-'Q&2RN^4^4#GO
MBU_P2K_:"TS_ ()Q?M6_LWZ+I.@^,[?X@>*HM?\  WC*]UN*/5M;@N-3M;RY
MCUJ24>9)<P1Q,BW+,[2A0N(U5* /KS4/^"R/PE\)^%?B=>^*K7QAX.UOX2:E
MINCZSX;U/3HI=8N;O4X1-IL-I';3317+W2']V$DR-K%]@!([KX:?M[Z#XY^.
MEQ\,=:\(^-_A_P#$9?#X\3:?X?\ $D-DL^N6&2LCV<UK=3VTCQ2 ))&95="R
MDKM.ZO!_V[/^"4=K\3OV<O#]_P#"CPW8:7\2?"?Q&T'XMR6NK:D]Q-XMU/34
M:,V=[J$S2N<V\DD<;L6C1E0 *A)'17_[./CO]HW_ (*;>"/CMXB\&ZAX%\,?
M!GP9J6FZ%I=YJ%C<:MXBU34UVS[A;3RP16\,*!5,DN7DDSA57<0#>_9Y_P""
MQ7PG_:+?X9-86/C?P_9?&+4-1TKPG?ZSHXAM=5O;$R"XMB\4DGDR#RI-HEV"
M38=I:O>-8_:%\(:/^T'I/PLN-:M4\<ZYH=UXDL]*)/F26%O-#!++Z#]Y.H4'
ME@DA&0C8_*K]@O\ X)G_ +0G[)%[^ROXVU;P'?\ BH^ KWQ%H_BSP%?^)--N
M(_"PU&^N9XO$>E.UR;<3B&5(I(U?>4!"JI=W'K?[77[(WQS\7?'+X._M1^#O
M!MQ>?%3P;\09Q?\ @Y7L;74?^$1N!]BFLWO7O?LS_P"C6Z7"ID[9KZ8@ [A0
M!]4>+_\ @IIX"\$?&+P[X#OM$^(H\3>,=4UK2/#MLGAJXQKTVD!FOS;LV T<
M:HQ5VVK(!E"X(-:/P]_X*.?#'XB_%S4_!,-YK6D:QH?@VV\?:D^M:5-IMIIV
MC3HKQW$\TP5(B S!D<AT,4NX#8:\T_;!^!OC7XF_\%2_V.?'>B>%=4U#P?\
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MRP#]+;.Z%[:QS!702*&"NNUER,X(['VJ2C&** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFU#5/$NKW.OZYJ4ZA9=4OYRN^4@<*JQI%#&@SLB@B3)VY/<4 %%%% !1110
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M'7OA;+8QZJTT.R"X6[24QR0-G]XBR07$+-@ 2V\J=4->=_!C_@IKX8^+NJ>
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M+"6(5S&22H;&0#@X(.!F@#N**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K^67_@X>6%O^"QGQE)DO%/G:3D*!C_ ) ]
MCTK^IJOY8O\ @XA\036__!8[XS1CR<++I(&4&?\ D#V- 'S=_P $'M/;5/\
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MLC??VE#]E$[LJ)#YF[;YC,Z*%SDEU &2*Z0'- !1110 4444 %%%% !1110
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MI\10R;]T?V110!X;^W#\+_%WQ-TOX>_\(CH>D:U)H?BZ#4=0-U<Q6]WI]O\
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M<].>N:]9DTNWF(WP0MM&!E <#(./S /U ]*?<V<-[;M#-''-$XPR.H96^H-
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M;@[F7((_L^[ROU(XSV)K^Q2@ HHHH **** "BBB@ HHHH **** #&:,<444
M&*-M%% &3X[\#:3\3?!.L>&]>L8=2T/Q!93:=J%G+GR[JWF0QR1M@@X968<$
M'FN7^#O[-7A;X&SR3:*/$%Y=R0+:"[USQ#J&N74, .1#'->S2R1Q9 )1&"L0
M"02 1WU% &?;^%]/M?$5SJT=K"NI7D,=M-<X_>211EF1,_W5+N<#C+$]35\K
MFEHH 3;]?SH"[:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'5;=M.#N"OF!NE_X)V>&M-UGXO?M(ZM=:T/%6I:;\8=16WDNX[66;1W&D:7
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MOQI\ ?A[I.N>%[SPW>2^'/!6H61CC1K!9_!TNK)^_>82RW;216VWRHFM_)E
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M\%_C9XZ^#G@+X=_!OXQ>+->U;4O%FI>&]3^'?CTWT]C<^+[&34+)[O1KZ5)
M6U*W@>57#-B\MCY@!>.<+TDWCCQ1\)OCW\:OV?+[Q;XHFUCXIW=CKWPPU*ZU
MVXGU&RTJ_1;75([25FW(=*DM[FZ5<\1SP [N:^OG_9Z\&S^!_"GANXT&SO='
M\#W-E>:#!=L]RVESV>/LTL<DC,X>,# 8L3@D$D$@Z&N?"+PWXD^)F@>,K[1K
M&Z\4>%[.\L-*U*1,SV$%V83<I&>PD^SPY[_(,8R<@'@__!3?Q?XG^$_[-/A>
M/P/?:M<:Y<>+M$T^+1+34GM=7\:6XG#7&EV][N#P7$UO%*_G%U^6*3<Z!F<?
M)VO_ +2OQ!TS]B;P;\0-6^)7CO4O %G\'O$&NQ^-_#ME<":#Q7;SAK2#4XP@
MF;[/$CP*MRBPSS0SB=?,:-:_1[XS_ OPS\?O#%GI/B:QFNH--OX-5L)[:\FL
M[O3KR$DQ7$$\+))%(N6&5895F4Y5F!YRS_8R^'-AX&\'^%X_#J_\(QX%NX]0
MTG27O)Y+,7<<WGQW,Z,Y^U3+/F8/<>8?./F_ZP!P > ^)?!WQ&\5?%[X#ZI=
M?$_XD>&?%_Q GL-7\0^#["YLUT'1K"PTZ.?4X_(-N9G62Z,%LS^=N5]05@=J
M!#XOX0_X*,_$#X-?!3PS\6M<U"X\8S_$CX,^)OB3+X7D8+:V&IVNHZ6FF6D#
M ?Z/ %U9;.7KN,*2G+AV?]%O^%7Z.WQ1_P"$R>W>37UTO^QHIWE=E@M3-YSH
MB$[5+R!"[  MY40)(1<>7Z/_ ,$[/A5I4'B^WD\/R:AI_C+2M0T"XL+R\DDM
M=/TR_F:XO;&T3(%O#-.[2L$P=PC (2*)$ ,_]A3XJW7B6?QUX-\5:KXKU#XH
M> [VSC\6C6%@2W\V[M([F&2P2W+0)9,C,J("9%\IA*6<%VYW_@H=<^,OAY%X
M/\0>'?B%XHT"/Q%XZ\(^$WT^P2U%O#:W>L)!>2?O(79I9H;C9N)Q&(D*@'<6
M],\#_L>^&?A]")+'4/%CZI<Z[;>(-2U:76YVU#6Y[> 6\,=Y*"#-;I"J)Y+#
M80@)!8LS;GQ[_9YT/]HW0-"T[7IM6MX/#NO6'B6T.GWAMG%Y93">W+$ [D65
M58H>&*C((XH ^6?BU^T]XP_8?_:A\00ZM>>-OBGX-T#P)IVL:EON+"W?2TNO
M$-]!]I*!8_-DCMS%& BYDCLR21(<O[5\./VY[/XH_M S>#=)\'^+KK1H]3U?
M0_\ A)X["1M-BO\ 3&$=S%,VP+$AD6:*.3<P>2!UPNZ,OJ?';]A_P=^T/K?B
MJ^\07'B".;QCX>M/#&H"RU VZ_8[6\DO(@@"G8_FR/ENI5MO3&&_"[]AWPG\
M'OC]XD\?:%JGC*U;Q1>3:M=^'3KDK>'H]2G 6XU".S^ZMQ, =YR4+.[A [%B
M <M\2?\ @HK8_#;]H74O DW@/QE>6NB^(O#?AS4/$$#6?V"UEUUA%92!&F$[
MH+ADBDV1DIO#8V\US6L?\%<?"GAM?'\>H>#?&4>H> ;*RU.?3;=K*XOKFVNM
M7DTM<QK/^XG62,2M!,4D$<J8!?<B^B^/_P!@WPE\1OB%X@\27VI^*([WQ)XB
M\,^)KJ*"]C6!+G0)TGLE13&2L321H95R2^, KDUYQIG_  1Y\ :1HEYIMOXP
M^*"Z==:3%H<5N^K6TBV=G%K(UB%$+6Q8M'<;T\R0N[Q2,'9VVNH!N>#/^"FF
MBZY\0[?P]KG@'Q]X.;_A++[P3?WVJC3WL]+U2VTN35UBD:WNI2R2Z?&9UEC5
MHU+"-V63*#LOV5OVX/#G[6VJ:I;Z#HGBK3([/3+#6[6YU.R$=MJ=C>B5K>6*
M1690^(B7A?;+&'C+(-PJCJ'[ /A?6/&4FM76M>)KB2;Q_-\1)K62:W:WFO9=
M%?17MF7R,_9/L;L-@._?\WF'I6I^R'^Q[;_L?>#_ /A']/\ 'GQ#\9:)8P16
M&B6GBC4(+I?#MC%N\JSMVB@B9T4,%WW!EF*QQJ9"% H SO!7[>_A;QWXPT#2
M['1?%#6OC8:HOA'5'@@6R\52Z=N^T16S>;NC9E222(W"Q+-'$[HQ49KQ_P"%
MW[9_Q \"?\$V-9_:6\866N>*_P"U?"EIXHLO!BVNFV4FDLZLTB17,<F'M662
M%OWQ:=%AD/SLZQKZI\(O^"?VB_!W7]'ET_Q5XHN]#\'WFJ:AX0T2[%JUKX5G
MU#S1*8'6$2R+&EQ<1PK.\@CCG9?F 3;=N_V&-(N?V )/V?)/$WB*XT/_ (18
M^%(=;G6V.IQ0B+RXIB$B6!I$ 3_EF%;9R#DY //_ (=_M^W.A?M@^// ?CBS
M\10Z?-XOT?PYX=E71X_LNA37N@6VH)9WEQ$[*\LDYN$#1F15(C#,JO&S^A_L
MW?\ !0CX:_M6_$+4/#7@[4KF^OK728]?MI6C4V^IZ=)/);K=1.C-M'FQD&.8
M1S ,C^7L=6.->_\ !/:QUCQG/K^H>.O%=[J5YXWT+QY<L\%BBSWNEZ=!8+&5
M2  13I KR!<,KD[&1?EK5_8Z_8VU#]D+0SX?M_B5XO\ %O@W1H!IWA70=6BM
M5A\,V ;<ELLL42RW/EJ%BC>9F9(D51R69@#+7_@IU\,3=Z["P\56_P#8>O3^
M%1/>Z++I]GJ.KPW-S;R6%M<W'EP23 VLLA_>!%BQ(6"Y(K+_ ,%7?@M<^ =)
M\4V>NZOJ?A_4M'LM?FO+#1;NZ_LRSO+Y].MI+B*.,RJTE['+ $5&<-#(6541
MG%+Q/_P3KN[SX73:7H/Q)USPWXJT_P"(VI?$OPYXD@TRWEDT2]OIKIYK9K=A
MY=S;-%?7<#*Y#,DWW@RAJ\0_:_\ V:?BU??M(:'J&BZ7KWCR]TKPI8V5OJVH
M^'].U#1?$6H1:A->XU!%U"QDMHX[D6TJH8YHHTC5HL2!E8 ^A]*_;H\-^%M8
M\9)KOB&ZUV2U\:77AG2=(TGPAJ$>IV\EMI,&H7%KY1WR7CQP^=<>?$B(Z.B(
MK.!OET3_ (**^";OQ-\0K'4[/Q-HL?@3Q5;>#XI+G1[EG\07\^GP7Z)9QK&6
MD/DSYP,D(AD8+&0QX?XU_P#!,2Z^-_P\\?:%?^+=!,?Q"\83>,)VO/#+74FB
M7+:=;65O)83)=0S6]W;-:QRQ72.IR7!0AN(?B7_P3"U[Q1J&O:EHOQ6DT_6)
M/&.E>/= NM4\-PZK]AU2UT*/0KK[:K2H+R"[LHR"@\EXY)7=7)"[0#NM*_X*
MH? ?7+C15LO'$EW%KWA^/Q5:W4.A:D]I'I;BZ_TR><6_E6T2FSN4D,[)Y3Q[
M'VNRJV]I/[?GPK\2:/=W%AK^I7%U9ZRGAZ72U\.ZF=8%^]H+Y8!IWV?[6Q-H
M3/E8BOE*[YVJQ'"^*O\ @G&_Q)B\?V?B7QHMUI_Q$^%D?PUU#^SM#BT^XMF$
MM_*]] 5=HD&[4)-D!B8*(H\N_P V[%T?]@+XE:1I?P\\1?\ "Q/A_P#\+.^'
MNNS7\=[9^ AI^@ZO:3V+V$Z7-E!=+*UPT;^<)EG55EC55C6(LC '<?LI_MJV
MWQ!_X)Z>!_C=\1+S1]$M_$6AVVKWLVGVTXM0;B0)"L$)\R=C(7B5(_FD9I%4
M L=M;>I_\%!/A#H?@>'Q%>>,([72IFU8.9M.O$GM%TJ;R-3>X@,7G6\=I+A)
MGF1$C++N(W+GD-"_8K\:>"?^":VD?!30_B!96?B[0=)M-.M_$L>F36UO<"WN
M4E*/!'/YT:30H8':*=9 )&=&1MNWY(_:#_8@\8? :[\*^$[:.SUC1=1?QS<W
M5QHOPVU^\TV>RU^\L[BXT1QI-X\]LK;)@7FVQ.H@*MYL3. #[]NOVROAC8^*
M])T67Q98+?ZZL1L0(Y3#,\MJ]W##YP3RUGDMHWF2%F$KH-RJ01GA-<_X*K_
MNQ^$FM^,M,\;6_B71] MM*N[C^QK.>\E>+4YO(L)$14RT<LV8_,'R(R.'92C
M <#\&OV+/B#:_',?$*ZM_A9I&B^-XM*\4ZYX=U/PS_:6L^%O$%MI=K8F'3=0
M$BI':[+2!26C9TVR^64,FY>2_P"'4OCS1_@MI'AW3O%O@]]3\._"SPMX)LII
M["Y6"YU'0]674%GE"L66WFV!&5277).6X% 'V=\0?C+X9^%7ABSUCQ#JL.F6
M.H3);6AE1VENYG5G6**)09))"BNVQ5+!48D84D>+_&7]OJUM?'/PX\(_"W_A
M%_&GB3XH:'J'B;09;K4I8=)U*RL_LP*I=012@/.UU&J.040!V8':J/TO[1OP
M-\8>/O%?PK\:>%[S0#XL^&NJSWTNG:F\T&EZQ#=6,UG<Q^;&DDD#KYHDCDV2
M8V%&4B0LOGW[/7["7BCX!_%CX2ZI;ZMX?N]#\&Z-XR@UJ%%E@DDO?$.KVNK/
M]D385%O!+;M$BNP8HZGJN" ;/[3O_!1[PS\"4\;:3I<-OKWC3X=_\(S/KVE7
M4\EC;V5KK6J1V,<QN3$R-Y:M),0!@A%!*;B5])3]L#X52?#2/QFOQ$\&-X1D
MO)M.361J\!L6N(?,\Z+S=VW='Y4I89^58V8X521X-^V%^P[\0OCC\2?B=>>'
MY_ \V@^/M)\$6R0ZQ=7,,T5QH7B";4+B.14MY4:":UN'53R?,4*R[&+CB/B/
M_P $X?BB_P 2-4\7:'8_"'Q*]_XW\47DWAKQ%J.H6NFZCH&MVFG1.[SP6SO%
MJ"2Z<N4\J6)X[F=3("P( /I#]K3XF^ ?@>G@WQYKWAF'Q1XS_M1/"_@9+2UA
MEU6YO]4VQFUM)Y"JPI,L(>5V=8Q%;EW.$%7O#'[1&M:'KVM6_P 2?"-O\/=*
MT?2K?5/^$@DUV&[T2;S96B:W^T,D31SQL$W*Z!6$R;&<[@O'?M)?L<:QXW^!
MGPIL? \_AK1_%WP1UO2?$'ANVGCFM=#N7L[9[.2RD""66&WEM9YXT91(T),;
M8DV%6I?M ?#'XQ?'?P[X+UK^P? ^CZY\.O&6G^*;7PZ^OSWEKX@2&*Y@N(9K
MK[(@A8+<^=;GR7 FMH6=DR0@!['=?M(_#VQ\-Z7K%QXY\'V^DZY#]ITZ]EUJ
MVCM[^+>D?F1.7"R+OEC7*DC=(HZL!5_PG\9/!_CRXO(=#\5>&]9FT^W2[NDL
M-4@N6MH9-Q21PC$JC;6PQP#M.#P:^3?AY_P3FU:Q^/\ \/\ Q;XH\/> M2\/
MZ?K/C?Q)J^E7-R;J+P[<:W/9SVZ6226VR;!MI'F<F+$MQ(Z!P:^;_P!F3_@G
MAX@_:5_8N\+^(/!_AOP!X)OF^'>K:+!>+<?+XWEO-=L[];;41%!N2T,>GO#*
M&\QP;^4*I$9,@!^H6E?&7P?X@\*QZ]8^*/#E[H<KR1IJ-OJD$EH[1AC(HE#%
M"5",2 <@*<XP:C\4_'+P;X&T?7K_ %?Q1X>TZU\*V)U/6))]0B7^R[79O\^8
M;LHFWY@S8!'3-?&_Q+_X)Z^(/CW\;;#QMXB^'_A?^P_$GQ+T/Q/K_A#5+N"]
MAM+6QT&_TV:\D4*T$UU-)<VZF--P>WM8BS;\QCA_BG_P3M^+'C[XE^.!:^!?
M!>E:'K'AWXF^&-/:QU2WM[!DUQ;.32[DVP@\XM(;6-;DRR.4G#M&JPB,4 ??
M'A/XNQ^,?$[+96$C^%9=!M-=M/$?VRW%K>>>\X,(BW_:$:..*.0O)&L9$P56
M+(ZKU46K6<EBETMU;M:R(94F$H,;)C)8-G!&.<]*^!OB#^QU\3O%_B*[\26/
MPZTO2[=O!WPYBO?#3:G9,NO-H>L:E>ZCHS,C"(LUM=P(C28MWEBV,XBRYJ:I
M_P $Z-1\=_&/P_J^K?"33KCX?S^*/%WB"'PI?R:=/'X5MK_P_:V0MFA\TP,;
MW4(;F[:.%I(XWNE9RK L #[M^)_C6Z^'W@FZUBQT#6O%5Q;-$$TS2!$UY<AY
M$0E!+)&GR*Q=LL#M1L9. =W>H#?-G;U&:^._&W[./CS7?^"-_P ._AK/X7N]
M2^(6B^'O!UEJ6DO>VSRI<Z?<:<]V3,TPB<H+>5MPD.[ P235_P#94^!/B[X>
M?M[_ !+\13>&;RW\&^($U&=-5UVSL5U6WNY;^)U@M;RVF:2\TZ:-7F1+N,2V
M>V.)'V.8T /9_"/[5VA^./$GQ0TG3]'\3->_"2Z%CK2M:1JL\[6B7BQV[>9B
M4M;RPOG( \U5)#;E';?#CQQ;_$WX?Z+XCL[>^L[/7;&'4+>*\C$=PD4J!TWJ
M"=K;6&1G(Z'G(KYGL?#7CKX!_'+]HB.S\!Z_XIA^,&J6FN>&=3TN2W%G'*=&
ML],DM[QI)4:W,4MGYI?:RM%*"A>0&(>3_$?]B?Q?;?M#ZMX@T_PGX@U.XT7Q
M=\+CH>LP7B1QFSTZ>./6;F*/SQY:BS\V.92H:5"%"R#% 'W=X$\:?\)U::E-
M_9.NZ/\ V;J5SINS5+7[.]UY$AC^T1#)W028W1OQN4@X%;@14/8;C^9K\W/'
MWP!^*6G>'-&_LOP3XKU36].^)OC?5X-!U2%;G0=9TZ\\1QW-JTMU#=+<:?<F
MV=9;.[3<L CNHY8\.J-#!\*?B?ING?&[4M3\!?'35OB-8V/B2PFEM]7LK3PY
MXTLKS5A/82V;V[B\FGBLUB6.(F)X8TN8 Z^9'Y@!^DSV4,MS',T4;31 JDA4
M;D!ZX/49KD_C3\8/"_[-WPOUKQKXHFETWP[HT:SZA=6UC+=.BLZH&,<*-(WS
M.N2%.T98X4$CX"^$'[,_C[Q]\4? WA?QEH?Q<T_P+9_$7QE<S_9[NYT.SCTN
MYTZ&XLE(M+HO%9FZ=_)B\PE'38<8<&CX_P#!/CSXE?LE?&K2=8^'?QRA^+L6
MCWNA>(+Y/.FT3Q3/+J\3P7>EQ!V%P1#EX7BB46T&Z)]I"I0!^F5MI%K9M<-#
M;PPO=OYDYCC53,W3<V!\QP,9-<+K'Q-^'VF_M#>'?!5XUB/B%<:5<ZEHUNVF
M2/.EC&5CGDCG\LI'&I:-&&\<R1J1EU!\7_9H^(LG[._QD\>>"=>L?B8VB^+O
MBC/IG@F[U>VU'4K>.(Z!8WLW^F7!=A;/=QZB$=G*>8'52!BLC]KC3_$1_;BD
MU32-!\;20V/P)\76-OJ^CZ3>R)!J,]YILMO!%<PQD+=,MK*T:*WF$H,#)4$
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M1BBB@ *Y&.W2FI"L2X554>@%.HH ",T@4"EHH -M%%% !BC'-%% !BC;110
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MP7^,&@_M ?"7PWXX\+W,U[X<\6:=#JNFW$D#P/-;S('1C&X#H2I'RL 1W H
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MM<\8:'I7A^^M;F2W-DEOISWDENT:I"KJY>^NF8ER"9.     >C4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9.4-?Q1
M_P#!8.[;Q'_P5:_:/N9/W;+\2=>M\#TBOYH@>?4(#^-?VN2'$;?2OXG_ /@L
M./M'_!5W]I!HSY:_\+)UY<<KR+^8$X]R"<]^M 'T5_P:PRJG_!;3X6[E9O\
MB7ZX!A"VTG2[CDXZ#KSTK^M@&OY+?^#59&?_ (+8_#9E5F5=)UPN>?E']F3C
M/YD#\:_K2H **** "BBB@ HHHH **** "BBB@ HKR3XM?ML> _@KXRN-'UNZ
MU(+I<FGQZYJ%M8O/8>&_M\IALC>RKQ$LL@QD!A$I627RHF60XME_P47^&>K:
MQK.GV<OBNYNM%\1'P@2?#-_!;W^LB]ELOL%M<2Q)#-,)879MCE$BQ,[+%\X
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MK'BC5]4U#PUJ6H-KLFOO>V-SXAU&7395UP+_ &M']D,_D+'<L@D= @7S/W@
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MIR>.M!OIYM+@NAJW@G5["/1CJ<\MM8-?R2VZI9+//$T:-<&,%F4=Q7+^*/\
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MXK6=QI9\<?#N-M-OI[%],T30-8M='$\\1"J\5M)+?W(2=W*EHN6<AB<33_\
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M3R:W--\.:?HU]?W5G8V=I<ZK.+F]EAA6-[R41I$))"!EV$<<:;FR=J*.@ H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 &OXB/^"EBLW_!1S]H+=))(W_"RO$F7E(+L?[5N>6(X)]2.*_MW-?Q
M?\%$YTNO^"@WQXDB.Z.3XC>(60X(R#J=S@X/- 'V;_P:2:.FI?\ !8W0YVA:
M5M/\*:S<1L"/W+&*./<<]L2%>.?F';-?U95_*M_P:,6\TO\ P6#TTQW A6'P
M=K#RKY8;[0I$("YS\N&*MD9^YCH21_530 4444 %%%% !1110 4444 %%%%
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MUT/AC_@HA\0/'OB36/ .A^!/"\GQ9\+KXCEO["_UR2UTC5$T>6QB'V.X\EG
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MGP[X?OH?AA':6_B'6-<U.6UMVU*ZMQ=1:?;I##(S%+>2"265B @N(PJ2'=M
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M$)CE4-.8D,"M$%*R?2$W[,?Q*TW]K+XD6/A^&ZL?AWXNBA^).CWUW?$C2/%
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M+:^-G9_$-O)X0\%RQ:WN8LPN5;0\2@L2Q#YRQ9CEF)-K4/\ @FG]LU>34?\
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MB32_".GWD#:GJ7Q*N]-UY[ZYE@:2ZN;B6RO4NE*P1 86-HMC*H9&")WOA?\
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M_$S2[5M"\4>&]1N+.]LDN-9L?$%Z+Z\BG8VI4;+D!HVA6-@NY'+HS ]I=?\
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M\9?CIX;^ >CZ1J/BB\FT^QUS6[#P[;3K:RSQB]OIUMK5)#&K>6LDTD<?F/A
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MA!CM1PS("LRL"1U](7]IOX;R0>&Y%^('@HIXR@BN=!8:W;8UJ*5E2*2V._\
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M67Q#PU^S#XA^/W[7'QFFNX[/0_".C_&71?&5C>W.DW":CJ%SI_A31K>-K9Y
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M!\7/$$>B^(KG4M&T72]*LKW1HY)="DTV>^G6XBN&9B6=[W=C8NQH(V!) (^
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M,UKP/>V]G=6\$;6>KW\M_?S(BP;(II)YI<>6JQQH^U(U 7'A?Q5^*WQE\?\
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MWP'HNN^&/@OIO@6&6#4KR[L[C5].U.SNX5EQ##(;&XCL8TE96$B">10K[0S
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MHTBD0+@(H8@'UC?^)-/TK5;&QNKZSM[[5&=+.WEF5);LHI=Q&I.7VJ"QV@X
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MZ@A3-&"1N&?G[]O3]K63X9?L8:3\3O!GB"UM_"FM:CH4UYXKAB-U!I6@WMU
M)M150CDIY$B_O-C"-9?,(PAKY;^-/[1'CZY^#<UC:_&*U\7:IJ7[/OQ-\0:7
MXD\/Z/;6=SJ5S87NE?V;<VLK0F7=]GFEC9H-L5P8S,B K&Z@'Z3:9XYT76O$
MVIZ+9ZMIMUK.BK"^HV$-U')=:>LP9H3-&#NC$@1RI8#<%8C.#6INK\OK+X]7
M'P\_:6\5>,O _P 5M,O].CM_@MHVHW$D=C>?\)39ZKJUY8R-<3!!L)M;MIHW
MA$;;HPQ+)E:ED_X*9?$S6?@'\:?'%C\3OAOINM>!_#.KRWO@^[@%SJ?@?6K/
M5E@CBNHS!!Y,)A8PLMQ)*\SA98'V;A0!^F6MZ[9>&M*FOM1O+6PLK5=\UQ<2
MK%%$OJS,0 /<FK2MN&:^7_VY]<\2? O_ ()H^/=2\1>(/#/C37]+L6EGO]8\
M/6XTN_62]79')9,[1%5B=(AN9LE0YRQ(/#^%?VN_B1/^VC9Z)=>+O"EUX,NO
MC)JOPW&C1Z2L5TEK%X3;68G-SYI)GCN(MA 0!HY3D [< 'VQFC.:^(_V^OVO
MOBQ\%?C+\0+7P/XG\!:?I/PY^&UAX_31=7T5[J]\33MJ%];OIT4JW$9C^T"W
MAAC=8W99IHP%;=M/,?$#_@I)\2$U+XR:EX=UCX5V,/POC\76-UX7UBZ9];LI
MM+TZ2[L+KR%*O(DYA,CABL?D7"%'#H0X!^@>:,U\3ZG^V%\7O@_X_P#AA;^.
MKWPM?^&?&<6F-=:QX<\./-''?ZE<S)::5-!]N>YM1*B+%;WYC>WEG#K((/E!
MX?QO_P %1OBEX4_9ET?X@V</P_UC_A8'PBO_ (F:'%'9W"6_ANYL[C2T?3KQ
MQ<$W",FJI'YJ^2RS6<I*$2*D8!^B&<T9KPO]F#X]^+/&,WQLL?&BZ/J-_P#"
MGQC-H<$OAZQE@&H6ITC3=4C'DR2RMYZB_,)P^',2L NXJ/G;Q3_P5%^)'A']
MG/2?'\>B^ ==3QY\*+CXG^'(;62XBATAK>XTQ'TZ[D\QC.'CU6$+<(L6)+>4
M&,AE"@'WV7 ;'>G9R*^3_P#@H0/',/[ BS:\OAV3QU'XS\+>4ND7EU:::[OX
MJTY(4\Q@9E1HG5)/E;.Z0!2"!7,C_@I+XT^$\\-Q\3="\)Z=X=\+_$:\^'?C
M;7=)EN)+6T=]-BOM+O[=7.4BF>XM[.6.0LT=Q*H#$= #[6HKGOA/JNO:[\,]
M!OO%%C:Z9XBO;"&XU*RMBQBLYW0,\*EB2=A)7)ZE2>,XKH: "BBB@ HHHH *
M*** "BBB@ HHHH **** "OX2?C(/^+Q^,,LK'^W;_+ <-_I,G(K^[:OX2_C(
ML?\ PN3QAY;9C_MZ_P!I!&"/M,F* /U._P"#+F)F_P""F7Q$D ?RU^&%V"0W
MRY.JZ7C([G@X/;GUK^F:OYHO^#+*T:3_ (*,?$RX\S"1_#>9&38/F+:G8$'/
M48V$8'!W<]!G^EV@ HHHH **** "BBB@ HHHH *#THH;D4 ? \G[:'Q2L_VH
M-6TU?'7@W4-#T_XF:SX)G\,)H\:ZAI^EQ^'O[4BU2283%LVTRQJVY%C>*?#$
M.4-4_@U^U]\6O'/PV^%D7B;XI^!_#FJ?$_X4O\3['Q'+X>CMM+%PECIA.F 2
M3,LL,3W%Q=3NK),T4L83REC9C]??!;]FK0/@AK'C:_LIKO5+SQUX@N_$-]+?
MQP-) ]RL2O;QLD:'R (4PKEFXY8\8=H_B#X=?%WQAKO@V*QT?5M4^&5S:K?6
M%SI.8]&EN+82P&(R1B,EH)/O1$@!BI(.10!\KVG_  4(\>M\3O@Y!KTV@^#_
M  U\8-$\/3:DUQ;%KKX<ZY=1K<'2+PM\I;48]\%JTNQHIH\,LAEA1O0/V;?V
MJ_&VO?%7QCX-^(5]H.E7OP;O]4E\9ZJUG]ATZYTR=A-H-S#)(^Q!)9,[SD,P
MCELYE.T,F?I#7/!WAV>TU&>_TO1FCNW2[OI;BUB*RM$HV2R%AABBJ,,V=H4=
M,5Y7^S7X!\'P>'/'W@6[\6:G\6->T[4!IOCF]\4VL4MS=S3VD,T=M/&L,5N8
M19S0!8XD\O:Y)R[R,P!Z[XEU"\3PE?76CPPWVH+9R2V,;-^[N)=A,:DY'#-M
M&<]#7QE_P3G^"?PX^/'[#OPA^(GB>YBU;XE:I/I^O:]XLN9UBUX^)H[A&NK*
M6?[Z^7=(]HUF<*L<?D[%"@#[=BC6&%44*JH-H & !Z8KC],^ /@'PY\0;GQ=
M8^"_"5CXIO96EN-9@TBWBOYY' 1F:=4#LS#"EB<D<=* /B[Q7_P5.\?:'\#-
M5UVTC^'=QXDTOX;?$;Q<]G);W&P7GAK6(K"U#1K<[U@F1I?,7.X21G:Z@%:Z
MS5?VU?C1X&^-^LZ%K=M\+[S0_#?Q,\,^#;S[#9W\=W=6FMVUJRF-GN"J36LU
MRI,C*RSQ@XCMV'/M_@#X%? 7XT:;XBUW0? WPTUVUU^_UC3-=ND\/6K_ -I7
M3W'D:I%<[H\R,\]MLG#YWM#\V<5V-W^S=\/=0U>6_G\#^#YK^?4;'6)+E]&M
MVFDO;%%2RNBQ3)FMT55BD)W1JH"D "@#Y*\3_MR>(_BMX)N/"&M6'AEH/%GA
M_P"+%CJ+67GQR+_PC6J_V5!)$#*Q59HW9I <E7QM8#BJ7P:_;D\6_#N'X"^!
M]-L_"^L:!J=AX2\+:C*K7-QJ&EW%_H,]TL]S*62)'#00$6RB622*0R,\(:/=
M])?$#]GWX#_"%-=\<>)/!_PU\/\ ]JRW,>KZW>Z9:V[7,FJ/%;7"RS,H):[<
MPQN"<RLP!R6.=)OV'?@\_C#2_$/_  K7P7_;FBKIR:?>_P!E1>=9#3LBQ\ML
M?*8 2L9'*J .@ H ^7?V9OVA?B1\7-)_9[UC6++P;XF^)WC+X;^-->T_5I1=
MZ=:6US%=:0L-J8$E9?(E\^-7D8.Z"%=G5]^]X*_X*KZI\4_A;X!\0>'_  [I
M;/XZO-&\(2133 -H7BRXAN[C4M-G5Y8E/V-+98]GF*SSSI&&!SCZ8\ ?LI?#
M?X5ZOI%]X;\%>'=#O-!_M'^SI;*S6%K(:A*DUZ(]OW1/)'&S@=3$G]Q<5_'_
M .R#\+_BG\)=:\">(/ WAK5/"/B+49M8U'2Y;)1!<WTUP;F2Z.,$3M.QE\Q2
M'WG((- &G^SQX[\3?$CX-Z/J_C+PW!X1\53++#JFDP:C%J$=G/%-)"VR:(LC
M*WE[P,[E#;6PRL*^=M=_X*AW'PYB^*]OXJ\*V]OK7P5O=<U#Q-IMA?>=.WAN
MRTS[?9ZI &"Y:[\ZTA5'PBR&Y7>PMV8_4_@'P%HOPL\&:=X=\.Z;9Z/H>CP+
M;6=E:Q".&VC7HJJ/S)ZDDDY)JA=?!SPK>^+->UZ?P_H]QJ_BC2H-#U>YEM$D
M?4K&%IVBMIMP(>-3=7'RL"#YK Y% 'RG^T7^W5\6OACXBC\&0^'O ]CXP;5_
M ]W#?P:A<WVDW6DZUXBBTBY@#-"CK<QOO ?:4:*59  ZF(7-)_;$\0^"_BEX
MB\/^%_ L.L:YXH^-5[X&_P")KXPNOLD<D7A5-66\0O;R&W@V6P1K:)=JGS'7
M>SD'U9/V,O@GHWA@_#J31-/$&N0V5Q#IUSK5S)J$D&DSQRV9MY'F-PD-G,T;
MQB%E2%Y<@*7.>EM?V/\ X=67C"+Q!'X>5=7A\52^-H[C[;<Y36)+$Z?)=@>9
MMR;0F'9C9M)^7)S0!\W7W_!7K4O^%5^#=<L?AG)=:QXF\'1>*#I$FL^6;VX.
MJ0Z;+IVGRK WVJ:.67S#E$)1H,+F0^7]B>-+VYL?A]JEPL.ZZAT^:3RHKIH<
MN(V.U9@N5YX#[<CKM[5\A_&+_@EG?7?CC18_AOJ5CX1\):-X;3P[I26_B/Q'
MI6I>&6^U7$\MTDEC?1KJ(8W 98+K:$:+B3;(RU]@3^%8]4\$MHFH75Y?17%D
M;&YG,IAN+@&/8[[X]I5VR3N3!!.1CB@#XJTC_@I]J'PC^!O@J73?AUKWB;0=
M/^$/ACXB:EJ6K>+A/JD5C?2_9I(G=X2UY>QJ@E+N8UG(ER\;!1)]@?''XN:7
M^S_\&/%GCK7/M3:+X+T:\US4!;())V@MH7FD$:D@,Y5"%!(R2!FO,-4_X)I?
M![5O!3>'9O#^K?V.?!6G?#S[.GB/4H\:)83&:UMMZW ;<CDYFSYS@E6=EXKU
M_P"(?@W1?B%X"UKP]XDL[74O#^O6$^G:G:70S!=VLT;1S1R#^XT;,I]B: /D
MKXE?M:^.OB+>?#>&Y\*^,_A7=6GQ:T'2+HNTRV7B>PNK*>=XXY)H8))(U;]W
M,AB4+)!\K2(0QWO!W_!4ZU\8>&H=>C^&OC:#PWXDM=*G\&ZO) \-CXBEU+4H
M].LK5YI42.">22:";"-,@MY=^\LC1#NOAY_P3K^&/PZ\%>&='L4\87UGX1UV
MR\1Z3-JOBS4]2NK:XLXWBM8O/GG>1K6*.1U2V9C"-['9DDUB^'?^"6/P=TGX
M7^*O"5G:^*CX5\53_:K?3SXIU![?PS)]J6]5M(7SL:<4O$2X0V^TK(B$$!54
M &3XK_;(^(4/QCT7PAJGPUF\,Z?J7@WQ=KVISIKD,NJ12:1<VEK&]C\GDO%.
M+R*6*28HQ$J^9'$8V5LWP%_P4JT'PU\"-$US^Q_''B3PMX7T+PU-XN\2WTMF
MUYI']JVEO-#+<HA3SY(X;B"XNFAC5$2<-&LA#QIZ-'^P!X)M;CPS>-JWCJ;5
M/#&BZSH9U.Y\27,][J]OJJPB\-[+(Q-P^ZV@="W$30IL"JJJ,_2_^":?P[T4
M6=M9W/B>#0_[&T?0]7T7[>K6'B:#20JV#7RLA=Y(U1$9XVC,T:+'-YD:A* .
M;'_!5/0;;X@:AH]]\._B19:?8ZKXFT1-6^S65Q#?WNA6[W-S%!%%<O._FP13
M-$?+ 9H]C;6.![%^RY^T=IO[5?PBL_&FBVJP:/J3M]BFCU*SU&"^B 4B:*>T
MEEB9#DJ06#*R.K*"*XF7_@GEX/&J07UKX@\<:??VFO>(?$MK<VNJ+'+:7VMV
M\L%U)&WE_+Y:SR-"/^6;-GYL #MOV<OV9M _9HT3Q%;:+<7U]=>+]=N/$FLW
MUW';0S:A?S1Q123M';10P(66"/(CB7<P9VW.S,P!R/C3]O3PWX*^)-UHMQH/
MBJXT?2_%FF^!M2\2V\-LVE:;K&H+;&UMI!YPN"&>\LXFD2%D22ZC4GB0Q\O^
MQG\5/B!^T=\9/B5XCUR^U[P_X;\'^+M7\(V?AJ:UTU[&\BMS;I%<K-"\ERLZ
M.D[/O<(PN54+\@([#4OV%/"^I_%K7/$K:OXECTSQ-X@TWQ;J_AI)X?[(O]8T
M];=;6^(,1G1U^QV;,D<JQN]K&S(29-_5?L^_LZZ9^SG9>+(=,UC7M77Q?XGU
M#Q5='5'@<VUS>R>9+%#Y44>(0WW0^YAG!8T >1^*/%_Q,\=?M_\ CKX=^'_B
M OAC0=!^'VB>)M-C.@6U\$O[V_U2U<3%]KR6X73T;RU>-R99,2*-N//?A+_P
M4RO-:T+PSK7CZ;4-%UOPSI'Q"'B_0O#.EI>Z/JUUX7O[:SO)[>XG87$8!S)!
M",^8+IUD8M""?=/''[&TGB;X]^*/B+I'Q)\=^$=?\5>'K'PQ<KI<6F216UG:
M37,\1A%Q:2LLOF7ER=Y9A^\'R_(N.4US_@ESX#D\&^'O#N@ZAX@\+Z'X<\'^
M)O!T-O:S)=/<Q:^8'OKR:6X6266[,T F\QF(:221G#[N #.OO^"NWPST+0].
MOM6TGQWHG]HV\&IBUU#2$AO(-,N+A+:VU(VYE\U[>61F*B)7FVPS,T2B-B+W
MQO\ ^"G/ASX4?"_Q_P")M-\'^._%=GX*T/6-9MKJPTY5TW7?[+F2WO8X+IGV
M)Y4SX)E"&18YGA$P0UH>)/\ @G_Y_P 4_!'BWPU\3/'W@O4O#?ABU\&:V-+-
MHT?B_2+9S+##<K+"XAE21YF6XMO*E07$RJRAAC"C_P""8EO'\,OBSX!_X6;X
M\?X<_$BRUBUTOPV5LQ;>$7U5YIKR6"41">X_?SR/&ES(Z1!RJKC& #M[G]O3
MP=HWB>PTG5+7Q!I[2ZMIWAS4KZ2PW:?H.L7T44MMIMW,C,$N'\^W3Y=R*]S"
MK.K2**YWPE_P5-^&OCK2DN]+T_XA3K=7UUIMA&_A*]@DUBYM!?&[BLQ(B_:G
M@_LZY$BQ%F#>6H!:15+M-_X)[K%XCU1]0\<:QJWA[Q1K^C>,?$>DSZ?;*-7U
MW35M-MXLJJ#!'-)I]A+);HNS=;G:461P>7\;_P#!+>/QK^R#I/P=NO&D=]H]
MK?ZQJ%U?ZCX=M[F[-Q?W5S=1WEHZO&UE>VDURS07$394CYE?- 'U-K'B:S\/
M^%+K6+Z86NGV-J]Y<3.I BB12[,1C/"@G&,\5X?#_P %-/A.-%6\N-1\164W
M]OZ?X9^P3^'+_P#M 7VH60O;&,VRQ&0>? RE"5Y=A&<2?)7KOC#P//XF^$NJ
M>&;77-9TJZU#2)=,AUBWF!U"R9X3$MTCD8\Y"0X8C[P!KY0^#?\ P27U+X7:
M_I>I7/Q(L+R:U\3^&_%5W%9>$(M/BO;G2M.GLIN!<NP-UYJRL[L[JZ,27W<
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MX \=>.M ^(E_ITVF/)J=IJ6DG366&"X\T)Y$[:59L2R%XOWX7=YB&' \,_\
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M+Y'638,$Q?M#?MP6GPY^-/PW\%>&9;/5=3\2>.K3PKKPDTZ\FM]/CGTVYO\
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MWP6\#6%QIRZQIXF\<ZM!=6EX-4W_ &KRMUO;APL]P\<TBRJ@4")%/L'Q2_9
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MVE/AQX2T73=2U3Q[X)TS3=8MX[O3[N[URUAAOH)'1$EB=G"R(SR1J&4D%I%
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M 8_<OB?XYZ/X1^/'A'X>7-OJ3:SXTTO5-6T^6.)6M8XM/:S6=9'W95S]MA*
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M27'BKP;XX\"Z7:Z9XHO;J_U..TN(8)_#ER;?5K3%M/*[/&RL4=5\N8*=C,<
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M&M':2:-;Z</(C2*3;71$=NLLQ6UF(C.%#</X%^.WCOX[_MY>,_"NC:A?>'/
MWPRM]$O7D^P6%]8^*XK^WNI)%,OG&YB8XMVA>,*JB&7S%?S$"]A\??V'M'^.
MOQ$U?Q%_PDWBCPU+XL\*'P1XGM]*:W\KQ!I(DGDCAD,T4C121FZO DL11PMW
M*,D[&3H?A'^S!I?P;^-GCSQGINK:Q(OCJWTFU.C2K;KIVC1Z=;O;Q+:B.)9
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M(!PRL",C/-:55-"TS^QM'M;4W%U>-:PI"9[E@TT^T ;W( !9L9) &23Q5N@
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M'_V&+29]!2V_X1VT\E-.GD\V:R"^7C[/))\[Q8V,W)!/- 'AWB#]M3Q=X?\
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MWQ.O;&[UJ)-'?3]/S96T$%MY,+3S/'(K0>;Y@EW"1LKM"K6]JW[ 'P;US6_
M>I77P]T"6^^&,)MO#<VQU;3XBZ2&,X8><GF(LFV;>/,'F??^:O8J* .0^&GP
M'\)_!Z;Q0_AO1X=,_P"$RU>?7M9599)$O+V?'G2[79E3>1N94"J69FQN9B>
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MAD1BI7,8#(R$H:,W["_ANZN]!OI]<\53:YH_C&/QY=:NUS +O7-4CLFL%:Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9ZYI/AFZ\1W>K)X6TDZ!?Z5=6UGJ,EJMQ,L4E\9;:"=2$C@$?G1JX$6/<_\
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M2\->$]?F\36WP_\ '3^"+WQ#JNIW<6I0#1TOH;4Q,SFV\XP"\40WD89I1O\
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MD7VZ6.W,GR^3"?,A"E2I;:WW3YS9_M>_$;0/VI/'7@V\UGPK=QZ]\5;3X?\
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M)0RA5WD \Q^''_!/?XH?#[P]X5A&K> [JZL?!OCWPQJJF:[2/S-<U2+4;*6
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M]AH^H:4MO?ZXVL1-)IQME,FS$HCFW&5X_)^SRM+Y:*6K:_X)_P#QS\1?M#_
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M(R 1L_"[X5Z1\'_!T.AZ,MY]ECDDGDFO;R6]N[R:1B\DTT\K-)+(S$DL[$]
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M0:QE_9W\ +>V]R/ _@\7%I-?7$$HT:VWP27PQ?.IV95KD$B8C!ES\^ZNQHH
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M/Q%^)5F_B*^UF^DM()--DAMO[4TD:7<1QM+9O*46,*\0>1O+8;5Q&2A^J**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M(_\ !3&7R?\ @G!^T"_ V_#;Q&<D9 _XE=S7\1\7RQ+R?NCO7]LO_!4YY(_^
M"9?[0QC+J_\ PK;Q#@JNX_\ (-N,_I7\32!F1?O=* /Z$O\ @R,TNUB^#?[0
M5\H_TRXUS1X)3YF<QQVURR?+VYDDY[YQ_#7[F5^(/_!DKH[P_L]?'K4/*41W
M7B;3;=9 OS.8[1V()[X\T'';<?6OV^H **** "BBB@ HHHH **** "BB@G%
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M,/B*O[)EIX5\5?$"XD^(TFERV=SXOLK&V^T1SL7"7*P^4MN940IG]T(RZD[
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MAS1M.M8#+]LM3I9U)G:;<NPB1M0.-I^41\YSP 4=!_X*#_#;PS\--+UGQ_\
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MWPS:>/OBMHFL1ZGX?M_@WI5GK>O:K?Q1K8O9W$%Q<>?"R.SE(X[:7?N56!'
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M+M)UWX5/:7.BW5HMEI%OI:Q?VU_9^^?S8;:*-[F H</,A"@2K@@ _219%=F
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M)-U>Z39QZK<606WE$T4=P9W=H!,]N(I7C02D!@#]'Y[E+>/<S*O7'/7 SQ^
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M\%FWD:'455DP$\GRKL7H)S<%[4L1B):?_!+3XZ_$;QYXZ\"P^-OB!XB\9?\
M";?![3_%M_;ZKI]K:K8:D+U[=S"(8(C&6C.)(W+$M&& 7D5]<?!GXY:3\;!X
MBAL+/7-*U#PEJG]C:MI^K6+VMS9W/V>"Y P<K(C17$3++&SQMN(#$J0.U5ES
M_%^M 'Y^_P#!5Z2U^'GQDUCQYX;\:>#[/QIH_P -Y;/7_A_XVLQ+H7Q0\//<
MW#?V=;RY$D-\)5F53")"S7$"O&RLI&1??M+^(OAG^T3\3I+[QAXI\)6?B3QS
MX-LM:M]3-M-_PKO0KW0(I!/&KQ%(8Y-25K%IF+QH\LCGYT+U^C#;&//4'/3O
M2/'&Z,K*&C8$,K+D,#U&* /SIU7]NWQAI$FE^%/%GQFC^&^CZY-XPL_!7Q*E
MT2ROX_&,]A>VL>FI)"T(AD;R9KC]W;B)KXVV^!XQE6T?@'^U4O@;_@H[\6/"
MFJ:M'X,\&^)/B-<WMMK*R6LD'B35[?PIH8FT2Y\Q&:S>.!3=+M(><V\J!X_(
M=)OT"EM+>8Q[HHV\E@\8*9V$# (]",D9'K5?5[2SBTRXDN/)MX55I9)F(C\K
M"G,F[C:0,_-G(QUH PK7XFZ5\2/@FWBSP?KNGZMI.K:0^HZ3JVGR)=6]Q&T1
M>*:,C*NO0CL>E?G9\(_^"BOQ0L/@_P"'_$7B?XO:#X@TGQM\//!7B*YUBR\/
M64*^$=8U34;:TDL ^];=?M4<DY22[8K;R022,K1XA'V9\$/C?\)OB'\,X_!O
M@74[G0]%/AI]2T]VTJZTQ6TI\I_:-M)>0K'/$3('\\>8K&17;<'!/9? S]F[
MPO\  CX!^'?AWI]M_:V@^'=)L](234[>"2?4([6&.&*2Y\N-(Y)=L298(,D#
M@4 ?'7[*W[9/Q8_:G\;_  ;T&S^*7@W39-2A\;7?B8VVE6VK3:G'X?\ %=C8
M0Q(R/&L37%C,X>5$"@OYB1CY0OT/_P %!/VA/$'[(_@3PK\3(;U8OA_X7\1V
MJ?$"!;$W4RZ)<YMFNX]JM(#:W$MO.XC5F:%)AC."/1/BQXR\"_L\^&#XR\1P
M6.DV=M=0V/V^'2WGFCEOKN.%%_<QLX$MQ,@9L;<ON<@985?CO^T9\.?@F]GI
M?Q U_1](_MS3]1U"VM;]&D6^MM/@%S>LJA2'\J']X5^\5!(!P< 'R3\8OV_/
MB/\ !SXK>!]#U+Q)X9M]6FU7P8GB7P]=V<%JVFVWB'7KBT:.29Y0\TT-MY:1
M_95(#V<\DQVR1I67\&/VHKG]G:\_L?3]8\+:#X<\6>.OC'?7]S?0C;#>:=K%
MS/#M?S$4$8N))$/+JK'*[2:^RO#5S\,?VB=2;6K&T\(>++RWM;,B^:SBN9A:
MR>7?6C*[KN,+'RYXV4E"R[E.Y3C>U3X)>#=<M[>&]\)>&+R.SU%]7MTGTJ"1
M8+U]P:Z4%3MF;>^9!\QW-SR: /C#]GO_ (*/_$3X\>-O MG#J7PMTNX,'A";
MQ!HVHZ@UI>:Q9ZSHT%Y/?Z>F&D;;=7/E0(-Z,;*X5W4D/'VW_!87X+ZE\:?@
MWX5_L._\/:CKGA76EU^'P1X@9?[+\?Q(OV>6QFW'$;I]I26*=DE2*5$9HV'*
M_1>K_"+X?>$-0L/%]QX3\)V>H>"]+DM+#5AI$ NM%L%0EX8)0F^*$+NS&A"X
MSQ7E_P </BS^SA\>_AI=?\+"O?A_XF\,Z'H>F^,IO[<M5FBT_3[\NEE>XD7,
M:SF.1%QAFPRD8)! /A/XY?$S2_B3\"/%WBSPG_PDGA72?!'[.NG>*OA3I%W<
M22WN@:_+JVI*Q@?<WF3136>E6JLA<-%,$5C'<,'^Q_VV);?XH?M)_ #P'KTU
MM=?#_7=8UP^)[ 2YMKR]M=$EN+2TN"I&%4/-=!&XW6L;XRJD>_ZK\"O!.O3^
M&YK[P?X7O)O!VT:"\VE02-HFW9M%L2O[D+Y<> F,>6G]T8J^(_V;/A[XPTK5
MK'5O O@_4[/7M3&M:E!=:/;S1ZA?")8?M4JLA$D_E(D?F-EMBA<X&* /RIU;
MXO\ CKQ3^QEK'B37?$FN2>+OA[^S?X:\6_#R]>Z<75WK-SJNJ+#?=<S7-PFG
MZ+$Y;+,MW)&?EN9%;[_TP2Q?\%9-85;[4OLK_">SD>S:ZE:T63^V+I1(L1;R
MUD*J5+*H8@*"2 ,>O^)O@/X'\;Z]X?U+6/"/AG5=2\*$'1;F[TR&:72L,C#R
M&928P&CC8!< -&A'*J1<3X1>%X_BDWC@>']&_P"$R?3!HK:V+-/[0:Q$AE%J
M9L;S")"7"9VAB3C)- 'D_P"U_P#';XB?#;XI_"OP?\.;/P7<:I\2KO5;!KCQ
M&]R(-/>UTV:\BE"P8:1=T.QDRI(<$,NTY\;^ 7_!37XB?M,7W@]_"_PZT;R5
MTKPOJOC*UN=:@C:QAU=IUGGM9I)HRT-LL0DC/D2?:\M&#"RAF]V_::_9 L/V
MF_BY\+=<UR32KKP_\/;S5+N[T>\TXW)U4WFG362[)?,40[!,[$['W E1MR35
M[QU^RE\%=/\ %V@?$?Q!X$^']EJWPQTH6^DZ_=:9;P-X<T^V#2*B2D 100?,
MZKD+$<LNTY- '/\ [!_Q_P#B)^TO\/=1\6>,M#\(Z#I,U_>Z=HT.CWUS=7,Q
MLM1OK*>6X\V-%17%O \:H6(#ON/ %?-?[=W[9'BGQU\*?CY\/[K3V\)>(/"D
M4-YHNGF6^TW4]4M(M:LH;?4+>] ^SW-I<;QYA@;=;,XAF1B^3]P?!#P!X-^&
M_P ,=-TWX?V&C:;X1E$FH:?%I(7['(+J1KEYHRN582R2O+N'#&0MWKSKXC?L
M>? _3-%\2:AXNT#0+73O%%T?[3N=5U&6.)Y;G4(KPI&\DH$'G7R0RF.+8))5
M0D,0* /$OBS_ ,%/?'GPH\ ?$*>[\$^#Y/$OPXU;Q%;7=E:ZS=W@U:'3=(M=
M6A%M$EL)\RQWL,,L[H(;9E+L6$D<;7O%G_!3GQMX?O/B%JD?PUT&3P?X%U#P
M]H4=W)XJ=-0U/4M=BT<V$7D?9/+CB275E69S*2%C#(KDE1ZSKG[$?P%^.VJ^
M(I[OPGX6\37DVL:B^NLMV]PPOKRSAM;V&XVR?*9+:.V1X&^7;% 2F4C(UX?V
M!?A"OPP\9>"Y/ ^F77A7X@6UM:>(-,NI9[B#4H[>VBM8-PD=BKQPPPJKH58>
M4ASN52 #H/V;_B/XN^)?@2ZN_&_@Z3P1KMCJMWIYLC>QW4=Y!%*5@O(RARB3
MQ;)!%)\\98J2V [><_M7?&F;X7?M+_#FWLO"OB3Q5JS>$_%^N6%KI7B"XM!=
MRV,%B19M8J/(NY)S.%CDF(\AERH)E8KT'PY_89\%_!WQSX%U3PK%J.BVG@+3
MM3L+2T34KRX:^^W/ TSW<DTSFY.8$(,P>0,J$. NT]!\=?V?O /Q.U&W\3>-
M(#'+H.BZIHT>H'6+G3DL['48XH[U2T4L:C>L,6)&^:,QJR,C#- 'SK#_ ,%;
MXI?AOX+\2+H7A632_%^MW>@MJ;^(KVUTK2;V%[54L+V:735DT_4)3/,JV]]%
M;H'M60RAI8MVQK7_  5/@\%Z1#JFO>";JTT>WN?B#'J=Q::I]JDLX?"DTZ/*
MD9A3S?M26[,%)0Q,0N9.6'I5]_P3T^%^L:/+97FFZ]>6M_/<7.JI-XCU&3_A
M(6G%N)/[0)G_ --!6TMD GWX2)4&$+*8C_P3D^#Y\?:EXEN_"\M]>:A/K-S+
M!>ZO>W&G0G5XO+U18[1YC;QQW7+S(L85Y&+D;@" #CO#'[?OBS7=>T?PO??"
MB\T/QIXLUDZ=X>MM0U6XM=*U6U33#?W%W]JELDG40!'@=%M6S*8]C,C-(FY_
MP2T\?Z_XZ_X)O_"OQ'XHN]9U?Q#?>'UNK^;4+L7=]-+ODRLDI.))!C;NR 2.
MPJOX=_X)G_!KPU\*/#.C6 \51Z?X3U&'6]!UL^--4EU;22EN]M&EMJ+7!GBM
M?LLLD @200^7*XVY8D^J_!K]G'PG\"O@%IOPS\.V-S'X-TC3VTNUL[N]FO'6
MV;=NC:65FD88=ARQP, 8 % 'SCX7_P""N2Z_H&K2#X;ZC<:OINH^#[,6.GZY
M;W4<R^)+Q[*WVW+*D3R6\\<B3")I(@5.R:0!BN3\<O\ @IEK'C']E#Q];^%?
M!^MZ1\3--\)>-KV^M8-5@!\--H5Q-ILMQ%<E2DTC785H%V*'6-RY3;M;TOP-
M_P $I?A5\/;738-/E\=M#I,7AVWMDN_%=]=+''H-W)=Z4FV21AM@DD. !@JH
M!SEBT?CO_@DY\+?'^G7,,MUXWTNXU >)(+V\TWQ#/:W5]:>()S<ZI9RN/O6\
MMQME5"/W;HI0KR" >A#X\V'P-_8NL_B)XSO+RYL] \*6VK:K.B>9<W3"U1FV
MJ<;I)'. #M!9ADCJ.(O?^"B%MX3^*MIX%\4>!]>T'Q=/KFA:7)9?:[>YCCM=
M86]%G?+*K;7C$^GW<$B+\Z/"2 R%7;UCQ7^S[X9\>_L_WGPRUZSDUKPCJ&B?
M\(_=6UW,TDMS:>2(?FDSN\S:,^8"&#?,"#7FFL?\$ZO"OB7P]MU7Q1X^U3Q0
MEYHU[#XNN=3B;7;=M)>1[)%D$(B\M&GNBRM$?,-Y<%MS/D 'GMC_ ,%71J/B
M>2^3X?ZTO@?2_!7B[Q5JMXEW#-J44WA[6&TN>VBMD)$@=XG=7W_,)(^%VO6]
MIG_!1;4?$WQ#^'-KI'@&?5O"_C;PSXA\4OJND:W9ZPTUMI;VJ)]A6U=Q=BX^
MUQ,A1@W(0H&W;-3P?_P3$\&?#FVT5?#/BKXE^';K0=.U_3+:]L]>W731ZQJ7
M]ISM)))&[2/%=_/$6S@95Q(N0:LO_!*/X=MI-M9PZQXTL(?)\4P:E_9][;V/
M]M)XB,;:B)A# BQYEAAE3[,(=KQ@G<&=6 *6A_\ !5[PKKVGK'9^#O%^JZY_
MPFMKX";2](FT_4"NI7.D?VM"/M"7/V<Q^21&[^9B*7<'*HIDKS_]K?\ X*L-
MJO[ GCCQ;\)]-\::?XXL? 4_BHO_ &9933>##]IN;.%KR.>0Q2,;JRO$V1";
M*VD[ $!-_J?@[_@F'X8\&^+=*US_ (3KXDZI?Z7XFTKQ9_IMW8&.YO=/TB32
M(PZ1VB!8I+5P)$CV#?&C)L^8-R/BC_@C+X)U_P"&U]X8LOB-\7O#MGKGAJY\
M):_/IM]I@F\16$NH7>H1+<^;8R()+>>^O/*>%(F"7,BN9 : .NU/]N+3/A5\
M1/'\.J?\)_XI%O\ $K3/A[8:3:Z+9#^S;ZZT6RO8D@=9%:6VD^T([33D-'),
MZD+#'O5NJ?\ !5'X?:7\)-)\8/HOC9K>^T/Q!XDO=.&G1?VAH=AH-U'9ZO+<
MQF7:6MKB9(S'"\KODF-9%!(WM<_8"\/Z]\1+[Q')XJ\:QW.I?$73OB9/;I)8
M_9SJ%EID&F1VP#6I86KP6\+.N[S/,3<DJ D'YY_:+_X)RZ]I/B#P!H?AFQ\?
M>+/#'AFW\2WD6JP#PIJ%R=1UO5DU"ZBO[35;:.'[*",1/: RA3(KJ<*S@'UM
M^T%\8X_ G[(_C+Q_#?:GH%OI'A.\UU+U-)^WW>FJEH\PF^QEE\YXP-WDEAN*
M[<C.:\Y\0_\ !2[P'\+_ !9_PBNN0>.M0U;2KGP_I>IZC9>%[B>T2YUE,6#$
MQ!A^_FVQ;4W%9)54_+EAZ'X\^"NK?'K]D+5OA[XVUE;76O&/A.7P_P"(-4T2
M$(J3W-H8+J:U28,%7<\C('#8&W(.,5YQX@_X)SVNO^)-7U23QOKOG:UKG@W7
M9XS96QC63PW-%- B@*"%N)(4,N22!D)LH 9K'_!5CX8:-X*TG6)+#X@37&LG
MQ!'%I-OX7NY]2@GT*3R]3@FB52(Y(F!QN;:X!*EA6EX?_P""G_PE\1:-KE^F
MIZS8VNCKH<L#:GI%QIW]LQ:UN72Y;3SU021W#QRH&.T(8G+[%&ZN<_X=DP_V
MY]N7QYJ2L+[QM>A1I<'!\3R>;,N<]+9_]6>K+P^X_-67XB_X)21:KHJ+I_Q*
M\0Z'K6DZ#X0TSP_JUIIUNT^C7GAM[M[.\*/NCF$WVV=)X64(\;E04SNH C_:
M@_X*N^$?#O[$WB_X@?#/4YM:\16?A+6M?TN!="NM02P?3II;25K^*+:88EO8
MW@)9QN,<SH62*1U]&3]K[2O!'Q/\>:;KWB*?6CH^O:7X=LM!TGPC?MJ%C>W&
MEK?- 95,BW@DCW3B6-(XXD#(S%E)KS[X_?\ !,7Q!\;/#^KPQ_&+6M-U?QQX
M!N? 'C34)M!MKD:Y:R2SSPSP0JT<=K+!)=W2H )%,-PR,"X68;GQ%_X)]ZWX
MX\>^*]>A^(<-JOBSQ?I'BB\TVX\/?:M/O8K+2?[->QNX?M"BYA?$=TF=HCN(
M(6*RJFP@&KH/_!3GX8>)?%EQ#:W>K-X9M_ VG>/U\3/IERFF7%A?S2Q6J1L8
M]S3.87 B*AR^(U5I-RKG:I_P4)TGQ3\6_AO:^"K^UU;PSK&N^(-!\5Q3:3=C
M5M)N=,TN2],*0$+(LH*IE#$YD2:,ID,I;SO1?^".]UIOP3L_!,WQ2N&M[?X=
M:3X&^W0>&X(YEN-'U*?4-)U!$:5XQY4D^)8&1DG\M,&(;E;T.V_94\3_  YG
M^'_CSQ%XEL_%VL?"MM;UR_T_PUX.BTUO$$ESIWV58+*W6X(B<*F?WCRM+(^-
MT:[54 ]<^$/[3_@CX]6'A^Z\(ZTNM6OBG0(O%&F31VL\<=QILKA(IR710F]C
M\J/M<[6(7"MCG/BI^WE\(_@_\4F\#^*O&%GI/B-9-/BFM9K2Y:.V_M"5X;)Y
MIEB,4,<TR-&LDCJGF;4W!F4'E?\ @FW^SE'\#?A;KVI?V/X@\-P^--:NM8TK
MP]K1A^V>$]+EN);BVTLK$S)&D<EQ<S"(,WE&[:/<=E>>_%[]E[Q)^TQ^V9\;
M/#MTK:-\._%OA'P7INI7]UHT[MJ:VE_K%S<06-PS+#Y@2:)&.',1G5Q\PVT
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M7:/X+TS5)M/\'1^,GU74/$:Z=;"!KN6U,3+Y$A5E:/=N/R[3U!&*XS_@G?\
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MF^WZ5JD<[Z>DZ,_[U)I6@/DD$1R1*[!2H>@#]#VO;<31QF:,22@E%W_,X'7
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M2R:@FH2S2/-Y4X,/F2V9F:YB4PL#A: /T\7IQ12+TI: "BBB@ HHHH ****
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M7$_ OX\:9\?+'Q-<:78ZI8KX5\2:AX8NEOHDC:2YLI?*DD3:[ Q,>5)()!Y
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M\ _ME?%#QO\ '75/@[-X@\":9XJM/$'B>R@\5OHDOV"YBTVTT:[@M5LC=?\
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MYJUO8LNL>'6GBGF2TE'EL)K<DGRR&",&&/F /7%>,_$+]B']E/X2?#2\\/\
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M=2\(PZSXVN=(N/"=WX%TG[5JB2S>%M$N<>98V#F/*)M2% TGF2!+:!=^(U
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M)*\D5QIEO'N@,;%]T4<KJ;:10X,HRA /O93D44B<+2T %%%% !1110 4444
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MN8A.5WC?Y)'MGP-^-FF_'+PI>WUE%-9WVBZG=:)J^GSD>=IE_;2%)H'(X/\
M"Z./EDCDC=?E<5R=I^V[\/WUR.WOM>L='L]4\53>"="NKV98AXAU>W,JW<%J
MA^9A!)#-$SG +PR 9 5G /B?P]H/[0<>N:3K7C&\^-,GC;1;_P"#Z:A%IHO_
M .Q;B:6=(?$[K;VX-K+%]G>?[4%#0PLH<;&VL?8?^">UQ\0M>_:#\1WGCS4?
MC%8^)-._MC3_ !%HVL:!=6_A2Z?^TV>PN]/O)F:WF5;;Y(A8XS"_^D*)%0U]
M#?LN?M1Z/^TS\/7UJ"'^P[^&_P!5LI]'N[N&2\M4L-4O--:=A&Q'ER26<C*W
M3!QG(->A>'/%&F^,-$@U+1]0L=5TZZSY-U9SK/#+@E3M=25."".#U!H \ _:
MDBO&_;K_ &96O%F;PJE]XC/_ $R76_[)/V'=_M?9/[6V^^<<U)\"M.NHO^"C
MG[0-]-I^JV]G>:!X1@M[NXL)H;6\:)-4:589F41S&/SXPXC9BA=0V"0*YSXH
M_P#!37X(ZK\'M:\27$C>+-/\)^%)/B3+9:?+;2:@FG6=_+:M=0(9D;SH9[>4
M,%8-$RA'VR.J'U'P%^T1X;_:&\?>//A?JFA^(O#_ (F\*6%E<ZUH^JK'&TUA
M?B=;>XBGMI9(I(I#;W$9"R;U:)@RJ"I8 X[_ ()4M=O^Q+H:R?:#H\6LZ]%X
M9,V<MH"ZS>KI.W_IG]@%MY9'!CV8XQ7R3^T[\0?'7CFT^.WA.^OO%WBC3[C4
M+&ZT?5],AN9;?2%7Q791)8W6F2V^+6\MHP3%+"TD5Y:P/<.,@LWZ:^'+?3K#
M0;.WTE;*'3;>%(K6*T"K!%$HVJL87Y0H   '  Q5SSDW*NY=SYVC/WOI0!^7
M_P ?OVE_B=\,?A_\0?"^G^-OBE-KFD^+O&FG^%M3;2R_VG[+HMO>V<$L\5G)
M).Z7%Q-]FA2,+<"WD1Y"L!5]C4/VG?BUK'@7XV?$[1_B%XVO+'P:_A<67A^P
M\.07-O9:7J6EZ'/JFIQVXM/M<\ELLFI311B0['CE#*X 1?TI;CJ<=NM)\K'[
MWOUH \1_8"\<:A\1O@1-K%S\0!\3M-OM9OI-&UX:-)IOFV!DW10?.%-QY.6B
M^T!5WB,9!96=O#O%O[4'Q"G_ &I=7T.Q\47&F^)M!^*ND>'['P#)96WDZ_X1
MN;6T:YU50T9N75!+?S_:HY!$CZ>T)!VR!_I/XR?M8>%?@AXSM?#NH0Z_JVN7
M&D77B&6RT;2Y=0GL],MGC2>\D2,$[%>6-51 TLA+".-]C[>N\*>/M!\<S6\F
MEWUK=7%SIEMJJ(#MN%L[G?Y$K(?G5)#%)C<!DQN.JG !\[?\$D++3]0_9GU'
M4HM>G\4W*^/?&\<=Y="W>:VCD\4ZE(55HHT(691#.0<AMZ,N$* 8?A7Q3X=^
M&'_!5'XS:C\4M2TW1;[6/#6AQ?#^_P!<ECM[6318X9CJ-M9S2X3S%OM\EQ&K
M;RCVK,"FS'V&JJI^7&?:N'\+?%?PM\8?B%XT\(PV\UYJGP[OK2VU6.]L2L44
MT]M'=0M$SC$@\J53N7(!)&<@@ 'QS\4_VB+W]GB+QEX.^$^J:7X(L_AMH&@:
MG\,_!":?#]G^(-O=S2>;:P+,AN'624"SC2T9# S1L=PD10VV_:6^+'C']IK3
M_#EE\6=-TK1_$GQ>\4_#R.U7P_8S26%E9:%-J4,L;,"6NH9K8QYDW1M',=\;
M,%:OLCXR?&#P?\&Y_#LWB9IWOM:OVT_1(+/2;C5;^ZN?(DF=8(;>.28XAAE=
MV5=JHC%B!5SX4^._"OQS\"Z?XJ\-M'J&D:B\LEO<2V,EM*)$D>&4-',B2QR*
MZ.C*ZJP*D$4 ?G)?_P#!2KXO:_\  32_'&G_ !"\&:;<:;\$?!/Q$O;9]%@F
MM=1U+4-5N[2\#DR!TM95AV;(V5T<+MD7YE;U_0?VS/'6F_&*Z^%OB#QYI$,:
M_%/4O![>-O[,M86M88_#UEK%K9-&2;=+F26ZEA5W4[H[1UVF5MP^C[KXZ_#*
MU\4>*/#JVLUUJ?A+4-(\/ZS:6OAFZN/LLNHM&UFG[N AX3YR.TB;HH06:1DV
MN59\=?C9\'_A'-'HWCJX\/VW_"21ZCJ'V2?33>)J!TVT^VW;.J1N&EBME\W:
MWSLJG8&Q@ 'Q/XR_X*5?&;3_ (?ZCK__  D7@'1&\%_#+_A-M0@FT8R1^(GM
M_$-YIRW4+M.K0V5_:VR2QG#%?.0HS\U^D'CB2"+P3K#W5]-I=JEE.9KR%MLE
MH@1MTJGG#*/F!]17(^!_$/PU_: L)I-)C\.^(K>?2K-I ]DC^=IUP@N+0[70
M%[:1?F0@&,LC@?,C!=;XQ_&7P?\  +P9'J_C;7--\-^'YKF+3S>Z@WEVB23-
MLC220C8@9B%!<A<L!G) (!^5<-YK_P"Q;^SSXZ\*Z>?!>C^.-)^$/]J^$_C+
MX&EC-KXQT"&_L(6N]5MI#^YU0K*DANB\J2>?<2)("A4?7%Q^W1XT?XA:A<Z9
M>>&]2T;P[\6-(^&%[X=:U/\ :=Y;7T5E_P 35)5D^5_]+^UJ@C,;6<+G[Q+I
M[\/ 7PH\$^)&\(+X7\&:7J'Q"L[E9]-CT6",:_;0*//695CVRQH)QN#Y'[WI
M\W/06WP5\$Z;XWA\40^$_"L'B2WMX[&'5TTRW6^CA4%$A6<+O"!6*JH. &(
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M%8_$K2_%5QX83PS'<_;Q=+'I2:LE\D]K'*3 ]K+&H B++.^Q@%!DKTK]O[X
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MNI7,)DMY3"D4<WV=D69(D4@8H ^I0<BBD48%+0 4444 %%%% !1110 4444
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MB36M,:XOKF^6(7+2>?*,2>4JQ[U "G8 N5XXKS'X<?M]W7PH^.?Q-T/XB?\
M"27WA8?$W5=!TGQ)+'9)I_A^"U\+6^N&T=8RMPT:Q6]^WF^4^&*HSLQX /6/
MV1_V'- _8]\7_$*\\.WEPVC>+M46\TK27R8?#EN4\R>VA+,2PEOI;VZ=C@EK
MK!SL!JC_ ,,U>-/A)^U#XZ^('P[U;PS-IOQ4CL9_$FBZ]%./L^HV=N+2.^M9
MH2>)+9((Y873!-M&RNA9PW.^+_\ @J#H_P .? OBC6O$7P_\<Z3)X;\&I\1(
MM/9;66ZU/P^'"W-U'LF*+):AD>>!V5U5TV^86Q5_Q%_P5"^'?A+Q5\0-+U*/
M5(&^&EY%%K=PBQS11V<FCSZPNH)L<L]O]FMIDSM#F9#$%+8R <[\7_V _%GQ
M/\2_$;39O$N@W7@SXSPZ+-XK,]G+'J&GWM@L,,LM@%R@6>WMX0@D;-O*AD!E
MW; SPA^P;XR\-_%OPWXCDUSPM-#H/Q%\8>-C&MO<++)#J]I=6]K"&Z"2+[3^
M\?H53"CGCJ-/_P""E7AO[3I\&K>"OB)H,MWXVT[P),U[ID:V]C>:A DMG,\P
ME\M[>1Y$MR\1D9+AA&RC*L7>,_\ @IOX!\%ZW;6,NF^++Z1GB>\-E9Q3MIUI
M/J<VF6MZ\8E\V6">:WN)$^SI*X@A:5T1=N0#PRX_X)2>/H/V>)/!L.O^![B\
M/P;\(_#$2S0W2P/<:1J$\]S.?E8B&6&;")@L'7YOE/'>V_[$WQ,^'W[4^K_%
MKPU>^!]4U"^\2Z]<IH>IW%U9VDNEZGINAVV]YD@E9;R*?0H7P(V1X[F9-RG:
MU>U?L\?M=Z1^TMXK\6:;HGAGQMI]OX.U.]T6[U35=-6WT^ZO;2^N+*X@MY1(
MWFLDEN6) VE)$PQ;>J>KDX6@#\^_%?\ P2:\:Z1\&=<\'>&=1\$W\<_P@T'X
M=Z9=:J]S;M%>6>J7-Y<R%4@D\FT=+A1$BEV0P1J00 P^Q?VC_"/B+QW\+KC2
M_#NF>#];FOIXHM1TCQ2K'2]7T]G NK24K%,5\R$LH8Q. V,JPR#Y@O\ P5+^
M%]KXXU31]47Q7H-IHM]X@TR\US4]%E@TB*YT2)I[^,7'(;;;I),C*"KI$X#;
MU*#T7X/?M2:#\8O'FM>%4T_Q#X;\5:#86>L7&CZ[9?8[Q]/O/-%M>(H9@T;O
M!,A7(DCDB=)$C8 $ ^7?@Q_P3,\9_ VX\"_\(XWAC0O#GA/XK:AXOL?"4/B&
M_O+'PMHUYX>N](DMM.N9;7S#()[J2\6W,<4"&9HD9%4.V'<_\$P_BQXD^ _A
M'0;R^^'6C^*OA3\-6\!:!J5I<W5U:^+'CU#2;N"34HFMXS!;2#1HEFA3SR&O
MKC#,$!D^S?VH/C&W[._[./CSQ\FEW&MOX+T"]UL6$!P]V;>!Y=F>P.WD\X&3
M@XQ7@'P*_P""AUEX3L-4TGXF:YXDUSQ19:-:>+;Y-+^&^IV\?AS3;G3Y+A8[
MAX1<1R,TME>^6RL&;?##M>569@#SW]I#]@3XU?M,Z=X,UZWL/A/\,?%NG7.O
M:_JEGHFJW4]C<:E<6MFME#>,;!1JEO<26FR^WQP'R) B"8H';[?\ RZS+X T
MF;Q-8Z3I.O\ V*-M2M-,O7N[&UN-@\Q(9I(XFDB5LA6:-"0!E5Z5Y4G_  4-
M^'$OA>\U%)/$DUYIVK7^B76BV^@7=SK%O=V,*SW:&UCC9RL4+QN77*$2Q@,6
M=5/'^*/^"C?A_P 6:/\ $*+P_J%]X3C\#WGAFU'B36O"E_J.FWK:P]F\21V\
M7ER-OBNX(PS,IC>?>Z;(FW &_P#L'^$;\:M\:/'US:W%AIGQ6\?2Z_HMM/$8
MY#86^FZ?I45P5/(%R=.>Y3N8IXF."2!X=\"/V9O&6D?!OX'^&+?1]-UCQ+^S
M[\7=5U#Q!:ZI=_8I+VPN5UR"'4H7,<F\O'J=M> 8&\QRIE9%('U!'^V;\/6\
M<'P\NKWGVZ2YU"RMYCI%Z+&_NK!7>\MK>Z\GR)[B$13;HHG9\V\X )AD"\GX
M#_X*:_!?XE^&9M:T7Q-J-U9QZ=H>K1[_  YJD$]_:ZU*T&ER6T4ELLER+B97
MB A5RKHRN%(( !\DW_\ P2M^)^I_#N:WTO0_"_AGQ-JGA#XBZ3J-XNH #4;C
M6O%EAK-A:W,T*B9K>6TM)K>9URT/VHA X!-?8W["7PBOOAA\.->O-5^']O\
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M/E%KN1BI+_H_:?![PCI_CZ3Q7;^%_#L/BB:R73)-8CTV%=0DM%.5MS.%\PQ
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M0_"/B3P[HOBB3Q'IUUIVG>()I8-)\7R6[M<-H]T\1\Q8KA(GSL#<H 5==R,
M:O[.W[&]O^S'XF\/VOACQ1XL_P"$%\,>$SX;M/#^H:I)>P2RF\:Y%Z^__ENJ
ML\?F DNC@' C7-;5O^"?/@37_$EUJ&H77B*^6^\:WGCJZL[BYCEM+J[N]&?1
MI[=T,9W6K64LB^5G.YRV[.,?-_P2_;!\;#2/!?@#X:^#M#^&_BC7/$7BW1O$
M.B>.]0N=:MO"NK:?;17WE6=Q!*@N;)C,"@1E"Q2C:(Q"8JX7QQ^TO+\9OAG\
M2/BWJ_A/3;B7Q1^S;X+U_4_#EY>7/V!_/U36GEB1X720H07\N5"K.HC)..
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MUET^PUG[#%;P/-$?WS;PH:3"#RU:1P9..O\ B7_P5;M?@U\9/%FD^(O":_\
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MZT70_$FC:=9:A!<2:K8:GJMKIA'F-LCCNK::\MS-$6*;95\N63DJ 6_V2?\
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ML$[,6 6*5D=4<_*Y1@"2#0!\):#!\;-3_:/\<^7'\;+/Q_HL%[J/@IY[=O\
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M=XX=0MHY%::PDDC65(Y5!.QS&Z/M/.UE/0@D _/+PW^V)XHU:R72=<^*EQX
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M;:U-X9^'_BZQ\(WG]ML[:%H&J6L$R736<?F$V\#J1F!,-E1\@QC%?GSXK_:
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M_P"*,E\1>'OM\OA^6;5H_%FJ75S-::1<O<V%O'-+=-B%!-)&JY,?ERE2C*%
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M7?M'P;^RY^WUXZ_8I_8C^&%CJFG_  ]U?PI??"W2M:\.W%K/-:RZ$\NM:7I
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M\7^%_ACXH\6:+X'TGQ+=V^KK<6L&F7EYH9:.[MY6,AEA4S1W$<;F,^8UI/@
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M!ND+XF^)>L>*KK4=/O[A]1M-.O/!<OAV$Q$VBAKJ*642!&94"1KB0G@>C?\
M!.S]FGQA\!?#VH77Q \*_#;0_&%QI6E:!<ZCX2U74-2&NP:='+'#-*;N.,VZ
M_OI/+MD$@B#MF5\@* 5/"?\ P4VT_4O&'A>PUKP'XHT/3?&'Q%U;X76&J?:;
M6[B&LV#7BL'CCD\U8)?L%ULE"';L!D$8;->[:A\=?!.E:GK=C=>,?"MO>>&4
MBDUB"75K=)=*64@1-<*7S$') 4OC<2,9KXT^&/\ P3?^)/P:^*VC_%SP_;?#
M^'XH6GCKQ1=ZO83ZO=3Z3K_AG7-4DO7B,S6>^VU*W)@,<L<1#"*2)W:.;]WK
M_!?_ ()QZMJ?B3QYX8^*W@_PEKO@^_3Q;I^F>)H_$^I7FI:EI?B+4&O;BT.G
M2J+>S=<H)9$=Q(\$3(JY.T ^P?$7Q1\->#].OKS5O$.AZ79Z7#%<7L]Y?Q01
MVD4K%8I)&9@$5V5@I; 8J0,X-23?$;P_;:C'9R:[HT=U-&)8X6O8ED=#&\H8
M+NR5,<4CY'&V-CT4D?#NO?L*_&W1/V<?A=J5\V@_$OXL>#O%,&J^*;5/$EYX
M=B\46$&DW>C0+#?0KOAG2":*[*,/*,[W> /,!INA?\$O(- N_BM]K^#_ (0F
MT_4?ACX?\&^%H-+US=?61MK?58+VVM-0NHS/;E8+^.&*XDQYHCPZH@"  ^UM
M7\5^$/B!X"VSZUHM_P"'O$ZOI:31:D@AO_-#1F*.5'&7;Y@ C;L].17G.O>.
MO _[!/@SX:_#?PGX5O'_ .$DU"3P_P"%/#VES1*T\J6\][.[SW4J+D1PS2.\
MDADD=OXW<U\A_$#_ ()]?%[QEI7AJ+Q?X$T'XP:'JVG>(_"^K:5?^*!X2O[2
M#4=3AN[;5K]M,06UQ=/'"%OC:@,9$CDAWMN!^J/V[O@+:_M%^ ="\)^)/A@_
MQ2\'RW;75^MAJ<6FZWH-Y"F;/4-/FEGAV3)(9%++,DBJ^0S#<C@'??##]I#P
M_P#$RZT;3674/#OBK6K&\U)/#6LA(=7MH+.Z6TN'DB1W7:D[HH=79'W@JS#)
M'<Q:E:RVK3)<0M#'NW2+*"JXZY.<<=_2OS@\6_\ !/KX\:_\/_#:W6WQ)X^?
MX2>+/!2^+M9U>WDU;29;C4(;G28-0NHPDD\K64?V.>YM@W[UYY,E7WOTWCG]
ME+QY'<:]XY\#_!B'0/#%UK/A:]U7X03WNF6Z^*$T^'4(K^55AF?3UD9;O3O+
M6211*VAQ[]JM&: /L:U^/VEW7[1]Y\,OL6J+JUGX:A\4F^(3[#);2W4ML$5@
M^_S \3$@J%VD$$\@0_'7]HG1_@-+X5L[K3]8UW7/'&K'1/#^CZ4(C=ZI=+;3
MW<BJT\D4$:I;VT\K-+*BXCV@EV16^*?''[$GQ*T#XN^%/$?A'X3Z;!X'\+>$
M]$LKOX;G5+"[TK7(EUJ^N)]-:6XD!2>QBN[>[@/%J9[8Q9*"-E^EO^"@'P&T
MO]I3X:^&O#?B+X<^(/&NAMJZ7LMWH.IQZ=KW@ZZBAE:VU2RF,\3+-'(?+)A<
MOME/RNF]2 >N_"7XFV/QE\ 6?B'3[/5[&WO'FA:VU2S>SO+66&9X)8Y(WY5E
MDC=>,J< J64@GDM6_:ETNR^(7C;PM9^&_&&M:UX#31)KVVTZSCF:ZAU2:2*&
M6#,HW)%Y4SR[MI1(G(#<9_/?XL_LW>+OB7J_PV\ ?&#PEXA^,'C[4/A'X[LK
M43WUE#J4'_$]TP:'=ZA)'-' MU!;20>9<P>9Y5QYDB%CASZU\1OV3_BL=-\=
M6USHNK>*M8F7X3VZ:Q!=0*==ET;58[C5[F,O*KJ%C,K'S A?<54-G! /NO0O
M$>D^*[J_CT^\L[Y](NVL+OR)1)]EN%1&:)B/NN%=,CJ,@&M.&VCMA^[55'7
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M5K?[):W*'#P22[]B2*>"C$,#U%=3:W4=[;QS12))'(H='1MRL",@@C@@^M?
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M ITYXDOE-V3LM?)B,D8ABM[EQO;?OXW]HKXS:A^TU\)_B3X\U#29/#NJ:O\
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M3HMSI<FF:SHNK:+KVF3>&M)L1H$%G=Z)=S2%M0F2*]-TPA7='/))#<95E9U
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M2Z#%)/*CFF5=WER21N"*]DM_^">_PGL&N/LOANZL8;BZ\.WGV>TUB^@MX9-
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MC\0(O%\UXWB^RU'51J";M-Z02+A!(9<['AQ$2DK[0#[*HHHH **** "BBB@
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MR\#L L\.)U7S8RR%TD4'*,!T5%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 8YS1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Y:_\'?TDB?\$BU$;[5;QSI D&[&
M]<7!QCO\P!Q[9[5_+:#D5_47_P 'A./^'2-K^Z,C?\)[I.UO^>1\JZ^;\LK_
M ,"K^704 ?UP?\&O<*Q?\$-?@DRM(WF'76.YMVT_V]J(P/0<=![]\U]^5\$?
M\&PL1A_X(:_ X%M^Y=<;/UU[43C]:^]Z "BBB@ HHHH **** "BBB@ HHHH
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M=!U*>YT&YBL1JCO8I'817;*();ASJ%N517Y3S).$C=@ ?05%?'/Q?_X*._\
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M@YH **,T9H **,TR>XCMHFDD=8T7JS' 'XT /HH!R** "BBB@ HHHH ****
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M>H7^EW1D:&.>81@R-<",%A)Y+*L@+ABP!^DJSJRL0V=O7VI4F60G!Z5\Y_\
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MNM(M(V1@1';W TZYEG6+:X-Q$(WC"D'K_"?_  4+\:>/O'FE^,;5H[#P3/\
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M0?06^&6A+XL_MB7Q19Z=X*CUR6VTS]P][XD,5O9R1!6_U;73,CX'[OJ1MYH
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M)^&]#OM.TJ/0;6?3]-AMI+?3XW,B6:%%!6!7)81CY0Q) R: .LHHHH ****
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MQ:;XCM;[5+FVUJU&L^(K:2Y@6WWS0WMFLEO:--'$B/M9HW);J/VBIOB]X/\
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M,5N7N6:>273YB4N[V0RSJ[K*\980CW'5_P!G?Q]8_'GQ)K6I_#>^\2?"^_\
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M &RO OB#Q?\ '+]FZ^T?0=4U;3?"OQ%EUC6[FT"%-,M#H&K6:S2!F4E?M%W
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M]JW1_AGK7BSX6^$?$FDP>&K_ %'1/$$[VU[XHM]3DG%Z-/B6-FF:#:MO"8F
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M!_[)>A_!#XC>(O&$>K>(O$GBKQ/8V>EWNJ:Q+ ]S)9V;W#VT+-##%YGEFZE
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MTGQUH%]XHM9M2MI;%)2'2;3I!%?1%B GF0,PWINW*"&QM.:Y_P#9X_;1TO\
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M\3>/H_"MOK'B2TM]5M[;05G^SV=O/;PRK"[3,3)(C-("Z[58!2%7D4 >?_\
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ME<Z+::E9R-<P&Y!N(+N#5;Q&C5XVB#*5D++NK8US_@GWXHU?]H[1?B!-X_\
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MY^)R^-#XEL?%L?B=M6MY-2@U"VTP:6[*&MS;^5<60,4T#0F)MVY41E4K _\
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MLZ_L9^.O'?A^>RL]8\-Z>E]#)?6;74* 31APT2L&8E"P&"2&(.&QM/$^+_\
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M?'EQ\,_'#OH/A_4-?NM&74O"$-OJ5IIFFR:A$KR)<6D6I/(KLK*QCVL"6+T
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M2\$?![PS\-M?\2:KH.BV.E:AXPU :KK4]NFUM3NA&D7G2\_,_EQQIGKM11T
MKIJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\2_\ @]EDQ^R_\#D\
MQ0&\67K;-W+8LCSCVSU[9'K7\Z+_ "MBOZ(/^#VC4 GP$^ =KN^:;Q)JD@&1
MR$M(@??^/MQSSVK^=\G/_P"N@#^W+_@F3I[:7_P3B^ =O(JJT?P\T$$+T_Y!
MT!KW"O&_^"=<,UO_ ,$_O@;'<2^=,GP_T$.^ NX_V=;]AQ7LE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!^&?_  >VR!?@Y^SZN%W-KVL'.!D8MK;O^/Z5_/2QV-CK[]*_
MH-_X/<&4?#;]G49^;^V-=('J/(L\_P!*_GR)V\8!H _N"_X)\$G]@KX([EVM
M_P (!H.1Z?\ $NM^*]@KR?\ 8-=7_8=^#3+'%"I\"Z(1''G8@_L^#@>P[>U>
ML4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM(X_)2U\*Z7"L><^6%LX@!G Z8QT%>@T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X&?\
M![\^VX_9A'MXL/\ Z9!_6OP1)P?NY]\U^]?_  >^RJVI_LQQB13(L7BMRF>5
M!.B@''O@_P#?/UK\%P@Q]T4 ?W1_LN6K6/[-'P[@D4*\/AG38V .0"+2('FN
M[KC/V<[+^S?V?? MO^\_T?P]I\?[PY?BVC')[GCFNSH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^>/_@]GGD?X[?
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MW:=OX?:FM!&"OR+^5 ']Y:?%'PS)]WQ%H3=CB_BX_P#'J7_A9OAO_H8-#_\
M Z+_ .*K^#18(P/N+^5*8(_^>:_E0!_>=_PL/0,_\AS1_P#P-C_QIP\>:&<?
M\3G2?F.T?Z7'R?3K7\%_D1^6OR+^5"P1[O\ 5K_WS[4 ?WK1>+M*G+!-3T]R
MHR0MRAP/S]C^5.'BC36E9!J-CO7)*^>F1C&>,]LC/UK^"4PI_<7KZ>]#P(%/
MR+^5 '][@\0V#3&,7UF9%&2OG+N XYQGW'YU8CNXI<[9(VQSPP-?P-F!"1\B
M]?2FM&HD^ZO3T]Z /[Z%D5QE2&^E+NY[_E7\#&T+C  X[4UC@M]!_.@#^^C?
M]?RI=WU_*OX%O/DB+;79>,<''!ZT+K-X6S]JN<COYK?XT ?WT;_][\C2[^._
MY5_ PNK72D,+FXW+T/F'C/7^5.&MWOS-]LNMV>OFMWZ]Z /[Y=_U_*D\SG^+
M\C7\#I\7ZLT8MSJFHFWC^98C<OL4^H&<5)%\2/$4?W=>UI=WS'%]+R?7[U '
M][V__>_(T;\?WOR-?P2Q_%/Q/:;A#XCUZ,.,,$U"5=P]_FJY8_'KQUICEK;Q
MIXLMV9=I,6KW"$C&,</TQQ]* /[S]WU_*C=SW_*OX,%^/?CI9-X\:>+ ^,;A
MJ]QG'UWTX?'_ ,> ?\CMXNZ8_P"0Q<=/^^Z /[S=WU_*DW_7\J_@U@_:'^(%
MLVZ/QSXPC;IE=9N1_P"SU(W[2/Q$?[WC[QHWUUNY_P#BZ /[Q]_U_*C?]?RK
M^#Q?VG/B4H;'Q"\<#=C=C7;KG'3/ST+^TU\2$^[\0?'"\$<:[==#P1]^@#^\
M+?\ [WY&@2?[WY&OX08?VJ/B?;,IC^(_CR,JVX%?$%V,'&,_ZSKBKS?MF?&!
MI&<_%;XE%F3RBQ\37N2G]W_6=.!Q[4 ?W8;^._Y4N_\ WORK^%B7]NKXW3QL
MLGQC^*CJ_+!O%E^0W&.?WOIQ4@_;T^.8MUA_X7/\6/*4Y5/^$NU#:ISG@>;Z
MT ?W1[L^OY4;OK^5?PO1?M]?':%U9/C5\6E9>A7Q?J (_P#(U3+_ ,%#/C\L
M84?'+XP!1T \9ZC@?^1J /[F]WU_*ES7\,R?\%$OV@HUPOQT^,:CT'C34A_[
M6I5_X*+?M!JFT?';XR!3U \::E@_^1J /[F**_AI7_@HY^T,IX^/'QF';CQM
MJ7_QZI7_ ."D?[1.-O\ POOXT[=H&/\ A-]3]O\ IM0!_<C17\.5Q_P4E_:*
M C'_  OSXU8\L#'_  F^I_\ QZMK2/\ @I+^T4?._P"+^?&KJW_,[ZG_ /'J
M /[<Z*_B>MO^"D?[1.VW_P"+]_&C_5I_S.^I^@_Z;5OZ9_P4@_:(-K#_ ,7Z
M^-'WF_YG;4_]G_IM0!_:%17\9EC_ ,%(/VB/LL/_ !?KXT??/_,[:GZG_IM5
MN]_X*/\ [1 FC_XOU\:.A_YG;4_[W_7:@#^RBBOXW9_^"CO[0WGO_P 7Y^,_
M#''_ !6VI>O_ %VK2TO_ (*.?M#>3+_Q?CXS?<'_ #.VI>O_ %VH _L0HK^0
M32_^"CG[0WD+_P 7X^,W0?\ ,[:E_='_ $VKI]'_ ."C7[0C:3)_Q??XS?ZC
M/_(ZZE_=/_3:@#^M2BOY.;3_ (*,?M"'3P?^%[?&7.\<_P#":ZEZ_P#7:NRL
M_P#@H-\?&1<_&_XO']YCGQCJ/_QZ@#^I2BOYB=/_ &^OCL\\.[XU?%ILR*#G
MQ?J'/S#_ *;4[_AOGX[;IO\ B]7Q:XGP/^*OU#@9/_36@#^G2BOYH[G]N_XX
MKIEPP^,WQ6W*6P?^$MO\CC_KK61:_M\_'5G?/QI^+1_[F_4/[I_Z:T ?TYT5
M_-/HG[=WQPE:+=\9/BLV9L'/BV_.1D?]-:[:[_;8^,RI8X^+GQ.&^SW-CQ3?
M?,<-R?WO6@#^B*BOYS]6_;>^-$?B6:-?B]\4%C &%'BJ^P/O=O-KO?"O[8WQ
M>N%T_P SXJ?$B3S+U4;=XEO3N&YN#^\Z4 ?OG17X:Z+^UM\5I89MWQ-^(3;1
M'C/B*\.,OC_GI79?#;]J+XF7T;^?\1/'4W[N,_/KUTW4/GK)["@#]F**_(N7
M]I3XC!9/^*^\;<"3'_$\NN,22 ?Q^@ _"NL'[07CW^T;-?\ A-_%^UF7(_MB
MXY^7_?H _4BBOR^'Q_\ 'GFK_P 5MXN^Z?\ F,7']^3_ &_8?E4%O^T%X]:1
M\^-_%_\ K,?\ABX_N_[] 'ZD45^:/AWX\>.)WU+?XR\5OY<D07=JUP=N6?./
MG[X%>A?#3XN^++_6;=9_%'B*96FC!$FI3,""1GJU 'W917R/X4^)/B*YMXS)
MKVM2<R?>OI3T*X_BKIK[QUKB>(-01=8U4(D)*J+N3"GRW/ SZ@?E0!])45\H
M:/\ $;Q!+ID+-KVLLQ5LDWLA)X_WJZ/0/'&M37=F'UC5&#&;<#=2'.' &>>U
M 'T917@>I>,=8CUB15U74E43D "Y?&/FXZUCZMX[UR/5K-5UG5E5H4+ 7<F"
M>.O- 'TI17B-[XLU1/!5O,-2U 2L1EQ</N/ [YK/T?QEK$NJWBMJNI,JF3 -
MRY PPQWH ]^HKRG6/$6H11Q[;Z\7]RAXF8<\^]:ECK=XYAW7=T<J,YE;G[WO
M0!Z%17->&;Z>XGF$DTLF'P-SDXZ5IRSN$?YF^]Z_[1H TJ*R8[B0J_[Q_NCO
M]*NP.2R\G[M %FBJ]J[-)U/W1WJQ0 4444 %%%% !1110 4444 %%%% !111
M0!_.3_P>MRJW[7/P43YMR^$+QB.V#>\?R-?BPO(Y%?L[_P 'JIS^VE\'/^Q*
..N/\ TO>OQ=E/SF@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex3-2_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_005.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#\K?\ @BE^PCX4_P""DO\
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M9@-O7Y"7#8!)&&P1O:E_P9U_LBWGB/3;R&7XHVEG9B;[181^(4:&_+KA-[-
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M?^#-?]DU](U:W75OB\D]\ZM:W0UZV,NF@*H(C'V78V2&)\Q6/SD#&!C]9**
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M5_T4GXY?^#'2_P#Y J:Z_P"#*K]F6>"V6/X@_&Z%H8RDCKJ>F$W#;V;><V)
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M[1EC9S;$*KIW@UKE=^7W F2\C. OED'&22PP, G;_P"(&K3O^CF+W_P@5_\
MEA7[XT4 ?@=_Q U:=_T<Q>_^$"O_ ,L*/^(&K3O^CF+W_P (%?\ Y85^^-%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYVO^"ZO_*5
M+XI?]PG_ --%E7]$M?SM?\%U?^4J7Q2_[A/_ *:+*@#Y*_X-.M,DO_\ @MC\
M/98VM56QT?6YI!+<Q0LRG3IX\1J[!I6W.IV1AF"AW(V([+_6U7\F_P#P:/\
MA%_$G_!9[PK>*+HKX?\ #FLW[^5$KH UJ;;]X2P*)FX'S*&.[8NT!BR_UD4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^
M=K_@NK_RE2^*7_<)_P#3195_1+7\[7_!=7_E*E\4O^X3_P"FBRH ^5/^#2SP
M[+K?_!:?P5=1K<E='T'6KN0Q6LDRA3920_O&4$1+NF7YWPI;:F=SJ#_6A7\C
MG_!J3M_X?=_##=MW?V=KFW/K_95UT_#/ZU_7'0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?SM?\%U?^4J7Q2_[A/_ *:+*OZ):_G:_P""ZO\ RE2^*7_<)_\ 3194 ?.G
M_!GSXQM_#'_!82WL9I+I)/$7@S5M/@$44KI(ZF"Y(D*2HJ+LMW.Z195W!%$8
M=DEB_JPK^4'_ (-#M;L]*_X+)Z)!=74%O/J7A76+:S22WGE:YE$22E$:.5$C
M81QR/NF66,JC*(Q(\<L7]7U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_.U_P75_Y2I?%
M+_N$_P#IHLJ_HEK^=K_@NK_RE2^*7_<)_P#3194 ?+7_  :1^,KCPQ_P6@\)
MV,-IIEQ'XC\.ZSITTEU;":6U1;5KD20,?]5*6MU0N.3')*G1S7]95?R=_P#!
MHO!X;F_X+,^'&URXU2'5(?#.L/X>2U"F&>^\@!UN,J2(OL9O&&"I\Q(N<94_
MUB4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^"8_"<FI>'_ !UH/B6['B&8I;&SL+Z.ZF2,?9K@&=UB$<;%%,3R"975X4!
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MOP=UZXT^V30I-?:YU*.TU/1DU=K@Q2FSD0-MMH85EN5F:%T\TI&LTD;(>O\
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M&FC:+X/N?%VDC37:>'7(4M&N8#&\2N3'*NPB158!6W<@5YIJ/_!/'7[O6_\
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MB&8W*""VD0-</]1?LD_!G5OV=/V:/!'@+7->T_Q1J'@[28='.J6.E-I<-Y%
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MRF8V,^FVPW@%6B /I:Q\5:7J>OWVDVVI6%QJFEI%)>V<=PCW%FLH8QM(@.Y
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MB#P+H\VEW'Q8M=;^$=Y\3%\$M\=+*+3YI?#=O<Z'%?6S7)CL_P"RY&_M69+
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M^!-?TO5_'/\ \')O_*;GX]?]A*P_]-=G0![9_P &>7PP'C[_ (+ +JQ^P_\
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MEP7^C2:BMK/#]M<B]FG2&TBE>2.,'4+:0PN2(9/,?BK_ ,%-OC)HUYXD\/\
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M;K4-'OK3P=?^.VO;BQE336TNPECCO7%UCRO,@,]NSQE@RK/&V,-FL_2/VV_
M^L>-]&T='U:.WU[5&\/6FKO9'^S?[:2*66727E!)CNHUAE1PZB,3(UOYGVD&
M 6OVC_V2M"_:5\8_"W7M2U+6M'U3X3^*X_%6F76DW/V6>Y86T]O)9RRK\_V6
M99OWL:L!*(U1]T9=&YNT_8!\,0^+;6:XU"\OO"^G^/KGXE67AV>TMC:VFM3!
MI#*L@C$C*MY+<7JAV9A/-D.(XXXU .1^"W_!3KPS\7/ACX'^(FI+J'@?POXI
M^&VM?$B31=3T66^U5M,L'TTM?1S6DLB"...] -N(7FF:>,IM\IUD[#P5_P %
M+/@SX^\-QZI8^*-2MX)]7TC0K:#4O#6JZ9>7MYJJH^GQP6US;1SS":-Q('C1
MD6-)9&94BD9?+V_X)!Z5'^R=I_PSC\>:LUSH?P;\3?!?2]6GTZ%DBT_6/L82
MYE@1D\R:W2PME 61!)^\)VE@5YO_ (*)?L=^.M:\'7=QH.I7.L6^O:[X-5;S
M3O#CWVJ>!$T:6XG_ +1BAANH;B]26X,$;);2V]S;QW%Q*LLZJ(* /J+X._M;
M> ?CW\!;CXG>%]8N[SP3:B^,NH76D7NGNGV*26*ZS!<11S?NY(94/R?>C8#)
M%<O\-?\ @H]\&/B[X+UKQ!H'C+[7IN@VNCWMR9M(OK6>:'5U4Z4UO!+"LMU]
ML9Q' ($D,TV8DW2@H.%^#_PH\4?#/_@F3XT\+S^'=+^UKHNOOH>G:!H%QH\^
MIQ7*7$\;/837-U+#=3S32,5DN))7,BO+Y<SR0Q^8?![_ ((]WLW@7X9>(->\
M>6%]X]^%OAGP?HO@'4SX1N]+BT"VT5WE;[=IYU)_M5Q=QSRP3;Y(Q$NTQ+'(
MID8 ^EO"?[?GPG\;WNA6>F>*)I]2\27NJZ79:>^CW\-_]NTR'S[VQEMGA$T%
MY'#^]%M,B321@O&CKS5?PE_P43^#OCKPKI>M:3XP^W6.N^';+Q3IFS2;X3:G
M97OVH6:V\)A$DUU/]BN_+LXU:YD\A]L1Q7+3_P#!.J*[L-4U#_A-=1L/&VK_
M !4L_BK)KFG6$<2V5W!;VNG26MK#(TACBGTFV>TD+R2$F[N'^XP@'!ZQ_P $
MKM:^$GP2TC0_@[XXL]+U/X=_$+_A.OA_8^*-/.J:-H=L;:YMVT-T+&06@6_O
MQ'-"8YX5EA4%A -P!]"^#?VR_A/\0M>\)Z3HGQ'\%ZEJWCS38=8\.Z?#J\+7
MFM6<L5S+'<00[O,DC,=G=-N"X'V:7.-AQM_';QGK'@+X:7.H>'V\)KKDEY96
M-@OB74Y--TV::YNX;=(GFCBE<2.TH2-5C8O*T:<;LCQ7P/\ LG^-?@-XQ^('
MC7PO-X%;Q!JOPST?PYI&G:?H/V/35U>PO->OI&6S6>)4M99-6B5$-R'^1S)+
MG,C=Y\=OA3XX^-W[,6CZ3]H\*Z3\0K6^\.Z]<,?/N-&2_P!.U.RU&6-3A9F@
M9[5T4D*VUE)P<T <_P""OVQ-2^+?[:WC#X:^#]+T'5M#^%MS9Z9XXNY]1>WU
M#2[B]TZ2_MI;>(1LD\7RPPNI9&#3NP/[AD?M?^&Q_A,-:\8:;_PLKP+]O^']
MI<W_ (EM_P"V[?S-"M[;'VF6Y7?F)(=RB1FP(RRAL$@5S7[-O[,^M?!_]IG]
MH#QYJE]IDUG\7O$.F:IIUG:M(\EC#9:/9Z;^]9E4;W-J9,*"%# ;FQFOF_XQ
M?\$I?B%\6=6^*^I2:]X$M]6^(?A/XB^!H[HMJ!":7K\EO<:61 &%M:R6TL 2
MX$,)^T$R7#.\\\I(!]A67[4WPTU)[1;?X@>#9VO]:A\-VPCUB!C<:G-:B[AL
MDPWS3R6I$Z1CYGB(< J0:Z?PAXYT;X@:=<7FAZI8ZO:V=]=:9/-:3+,D5U:S
MO;W,!*D@2131R1NO571E.""*^./^"@?PLGTOPGXVM]NH#X@_$35=*/P?N-!T
M&YU:?3/$VE6)N;"XN7^SM;VB_:8I!(9V%N;59A+((WF5/H#X2^&/$GP-\<^%
M? %CHMGJ?@1O#-]J6H^*/.:.]?7EO;=YC/#@JS7QO+JY,@?<)()MP.]2 #T?
M4_'6B:+KMMI=YK&E6NIWDD<5O:37<<<\[R+,T:HA.YBRV]P5 &2()2,[&QXG
M\(/V[(_V@OVL/&/@+P3H6E^(O"OPYU.X\.>*_$4'B*$7>B:Q%;P7 @;3RF][
M=_/>%;A9,BXL[J-HE$:R/S_BK]C;Q5KWQK^(LTTGA_4O"OCWQ_X0\?6U[=SN
MUWH3:,NF^;9I;&-E8,^CPO',LJ8;4IR8U-N#<=#^PS^SMXL^ ?C?]H#4/$\.
MBPVOQ,^)]YXPT7^S[Y[EA8R:?I]D@G#11^7,38F0JN]0)0-[$$D Z3XQ_MN_
M#[X.:=;SR:Q;^(I/^$PT;P/?6VAW=M=W&C:AJE]'8P?:T,JF%%EE!?/SA5<A
M&(Q7H&F_$WPWK.A:3JEGX@T.ZTO7A&=,O(;^*2#4?,*A/)<-MDW%E VDY+#'
M6O@Z?_@F1\5/$AU+1;R?P['X!_X3CP3XATSP]K.MC7I--M-*\17&HZC:PWQL
M(;B2R:V>,6]G=&81R/.JR11MAMWXF_L(?&&[&E6OAO3?AW#H^GZQXK\1?9$U
MJ:QN9[N\\6)KEG;278LY)%LKA8+=YXX0A6X1 _VJW5HG /MS6?'.B>'--U*\
MU#6-+L+/1K>2[U">XNXXH[&&-=TDLK,0(T102S-@ <DBKFEZK;:YIEO?6-Q;
MWEE>1+/;W$$@DBGC8!E=6'#*0001P0:^(/B5_P $^M5\,V_C[X@>$_A+\.[K
MXA3_ !9M?':6MA?_ &&_\9Z5:SV%S]FEO52W\JY>XM%N4MYI&M6NK>!IV=7E
M-4_A]^P5J'PJ^.'P/U3X>_#+4? VD^']%LH=:TW6K_3O%&BZ3;F\U"]ELQ<W
M-RVHV^HVLE[/Y%S:">W87)@(6(+-" ?>=>1?%#]L;1?AS\?]'^&EGX=\8>+O
M%5];6.I:C!H5E%,OA[3;V_-A!J%T998RT'GK+O\ ($TD<<$LCHJ+N/G'[;G[
M/>K?%SXOV+ZW\,8OC5\+/$'A"_\ "FJ>&_[4BM9-)O)YX94OC'<W,-NT+QQM
M&\Z"2]MVCA-NNV2XS2_9!_9!U+X'?M>7WB;Q!X-T_4M<_P"%1>$_"=]\2B+1
MKSQ'J=C)>KJ 9B[7K>:G]G,SS* _V6)2S>4N #T+XT?M]^"?V>?$OBVU\86?
MB71=%\"P:1=ZWXBFL5_L>Q@U.Y-K;3-,'W%%F5Q*0I\E4,DFV/#GV^OFKQ[^
MQSI?[3O[0?QBL?B1X9\37WPX\4:#X6TV*"77?LNE:\]C-JEQ,%AL[D7!4&\A
MCG2Y5(YQ'$NR1$)/C'QN_8MU&V7XI?$.R^%_BR_OIOB;'JVKZ%;:C97E]\0?
M"L<%A]KL[:":YFM?L]Q/!YIM)?L[S+;LA6)I58@'UA^T/^U7X>_9P?2[74-.
M\3>)-=UFWNKVQT+PWICZGJUW:VIA%U<1VR'?(D1N+<,$#-F= %.:],K\Y];_
M &;OB)K%]\(=#^&7@_XA>!?^$9^ _CO1-&U3Q)>6MM+X;U'5&TI=)M)I[(R)
M;3Q?8B_EV\9CMT6-(PP3:N7\&?V6_'?Q,\ ?"FTUGP_^TKX9T?7/']O!XXTC
MQ9XYCCOK"QM/"&L:>_D3Z-) 5T\W*Z=&)BR2W<JB:2(%A)* ?I96#\2_B5H_
MPB\&W/B#7I[FUTFSDACGF@LYKMHO-F2%6*0H[A TBEGV[8UW.Y5%9A\&>+?V
M>/B)X$\&:SXRTOPY\9O$M]!\8-43QCX;_P"$QGW:_P""WU.^N($T:UFEDMUC
M4W&GSLD8MKB9+:ZMQ,L;K&_.?&/X7^*_A_\ !^Q\-7O@7]ICXM:'8_#GP_J'
M@J>:6.XU6UU=-8N;B\LM02*X@(O([6330WVIWMY(;&2(,TA=+D _0;XS^)_!
MN@>'+&U\;?V7<6&N:G;:=96-Y:?;#J-ZS[X8XH KM+(IC,ORJ2BPO(=JQLRN
M^%WCKPC\:]'M_&7AF:QU19%FTW[;]E,-Y:M%,4N+.9)%6:"6*>-DEMY55XY8
MV5T5U('E?_!1CX<^$_B7\'O#]KXJL/B0KV'B:UOM#\0^!M,N-1UCP5JB13BW
MU58K=))#&A9H7_<S1[;DB5/),C+\JZCJ?[15QXN^!?BN\TOQ!XP^(&F^#/B7
MX<M-;3PI=:7I^LZHCV8\-WVIV38CTUKR"VE=C-Y,2232H#&KHE 'Z)>(_A]H
M/C&_M;K5M#TC5+JQ1X[>:\LXYY+=7*,X1F!*AC'&2!U**3T%<CXOL_!M_P"+
M'\!:?J$/A7QUK'A[5[_3+O2+.!=4TFVGGA2\O;=Y(9(4<W4\$A$BLLLJAF20
M(V/BOQO\1?BQ=_#_ %7Q)\-]-_:#N?A_!X3\$V'B'0->TO4X?$T21:J4UX:>
MT[+J$^K/H[%))+98U\Q$E@GENG)BTOVA_''C23QI\)_%W@S0_C%XT\#VNB>)
MSXQ>^\/:YH?C"ST?4/$VAA(;$1VL4ZSVT4,\B0-']KGLK!MA,LJ3D ^X_A%\
M,;7X/?#[3]!MK_4]7:U#R76IZDZ/?:K<R,9)[J<QHD?FRRL\C"-$C4MA$1 J
M#.NOV:OAS?/XP:?P#X+G;XA1^5XJ\S1+9O\ A)4\L1;;W*?Z2/+ 3$N[Y0!T
MXKC?VR/&VJ:%\/\ PI);_P!N6?@S6M>@LO&>J:6;FWU+1=&EMKC-PC0IY]NO
MVG[)%-.OEO;033S^9"8?-3YT_9YT3X\^.?C3\)-&UKQA\3=#^&FFW'CC54NE
ML"M]K^EV.NZ.OAZSUN>]M&EAEEM7O<8:.YN+>'=)(9'N* /KKP#^S!\-?A5!
MX:B\+_#SP-X;C\&1WD/A]-+T&ULUT*.\=7NTM!&B^0L[JK2B/:)&4%LD"L[6
M?V,_@_XCM_#<.H?"GX:W\7@V_N-5\/I<^&;*5="O+BX^TSW-J&C/D327 $KO
M'M9I!O)+<U\V?\%6OVY=1_9>^(/A;2-+U+QAX;E7P_?>*+G5X+-I-&6TM-0T
MU;HOLL+QI[B.V>X!B?R84ANI96ECF6VEBQ_#/[0?BB7]KV*Q'[1'B36-"U[X
MT:Y\.X/#ITG0D@T^"/PO<:AY2%=.%WYMGJ"QQK++*RLAB$@E\Q6< ^R? 7P%
M\#_"OQ%J^L>&/!WA?P[JOB">6ZU.\TS2X+6?4)996FEDF>-09&>5WD9F)+.Q
M8Y))KK*^=?\ @GQ\0_B-\4_ LC?$+7IK[7/ !G\#:Z4T1+"V\0:U8W,D=SK$
M<@7;)#/$ML\:V^R.)Y;J.1?-3RK;Z*H **** "BBB@ HHHH **** "BBB@ H
MHHH *_CG_P"#DW_E-S\>O^PE8?\ IKLZ_L8K^.?_ (.3?^4W/QZ_["5A_P"F
MNSH ^FO^#*G_ )2F^/O^R5:C_P"G?1Z_I^K^7C_@RXTF+4O^"J_C&:1KI7T_
MX8:E/$(KF2)68ZGI4>)%5@)5VR,=CAE#!6QN167^H>@ HHHH **** "BBB@
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M/_*4WQ]_V2K4?_3OH]?T_5_,#_P94_\ *4WQ]_V2K4?_ $[Z/7]/U !1110
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MJVY5P]4_X*!_MP6CVOV;_@GNUVLL"23G_A>OA^/R)#]Z,9B^;;_>X!K[SHH
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M ,')O_*;GX]?]A*P_P#379U_8Q7\<_\ P<F_\IN?CU_V$K#_ --=G0!]-?\
M!E3_ ,I3?'W_ &2K4?\ T[Z/7]/U?S _\&5/_*4WQ]_V2K4?_3OH]?T_4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7\<__!R;_P IN?CU_P!A*P_]-=G7]C%?QS_\')PQ
M_P %NOCU_P!A+3__ $U6= 'TU_P94_\ *4WQ]_V2K4?_ $[Z/7]/U?S _P#!
ME3_RE-\??]DJU'_T[Z/7]/U !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_&7_P<%Z+-H'_
M  6;_:"@GL4T^23Q+]I$2ZI/J099;>&59/-F =3(KB0PC]W 7,,9,<:$_P!F
ME?QS_P#!R;_RFY^/7_82L/\ TUV= 'TU_P &5/\ RE-\??\ 9*M1_P#3OH]?
MT_5_,#_P94_\I3?'W_9*M1_].^CU_3]0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?QS_\
M')ZLG_!;KX];@5_XF6GGD>NE65?V,5_%]_P7NU#PMJ7_  6._:&D\'M&VDKX
MMGBN#''+&/[01$34.)0&S]N6YR1\A.2A*%20#[#_ .#*G_E*;X^_[)5J/_IW
MT>OZ?J_F!_X,J?\ E*;X^_[)5J/_ *=]'K^GZ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_B<_P""SNH6>I?\%:?VCY+'4]:U:%?B)K433ZI$L<Z2I>2)+"H620>3%(KQ
M1-N!:&.,E(R3&G]L=?Q"_P#!6:)H/^"I_P"TLKJR,?BIXG;##'!U:Z(/X@@_
MC0!^@?\ P93);G_@I[\0V:69;M?A=?".,1 QNAU;2=[%]V58$( H4A@S$E=H
M#?T[U_,?_P &4.B2W'_!2GXDZDL-\T-K\,[JV>9+8M;(TNJ:8RJ\N<+(PB8H
MF#O"2'(V<_TX4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7\1/_!7'4KC5?^"JG[2DMU<3
M7,B_%'Q)"KRN78)'JERB*"?X5154#H H X K^W:OX@_^"L7_ "E-_:6_[*KX
MH_\ 3O=4 ?J-_P &07_)R7QV_P"Q:T[_ -*I*_HVK^<G_@R"_P"3DOCM_P!B
MUIW_ *525_1M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?Q!_\%8O^4IO[2W_ &57Q1_Z
M=[JO[?*_B#_X*Q?\I3?VEO\ LJOBC_T[W5 'ZC?\&07_ "<E\=O^Q:T[_P!*
MI*_HVK^<G_@R"_Y.2^.W_8M:=_Z525_1M0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q!
M_P#!6+_E*;^TM_V57Q1_Z=[JO[?*_B#_ ."L7_*4W]I;_LJOBC_T[W5 'ZC?
M\&07_)R7QV_[%K3O_2J2OZ-J_G)_X,@O^3DOCM_V+6G?^E4E?T;4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM._]*I*_HVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1HD4_*1F5>1P#_0Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?P=_M._\G*?$+_L9M2_]
M*I*_O$K^#O\ :=_Y.4^(7_8S:E_Z524 ?M=_P8[^';*?X@?M#:LT.K?VC:Z?
MHMG'*L8^P^5))>.ZLV,B;=$A49&5W\'&1_0M7X!_\&-UK>&+]I.9;R-=/4^'
M4DM3!EWE/]IE9!)NX 4."NTYW Y&,']_* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^#O
M]IW_ ).4^(7_ &,VI?\ I5)7]XE?P=_M._\ )RGQ"_[&;4O_ $JDH _=/_@Q
MJ_Y%W]IC_KY\-?\ H.JU^^-?@1_P8V6$;Z;^TK=;IO,CE\.1!1,_ED,-4))C
MSL+?*,,1N R 0"0?WWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OX._VG?^3E/B%_V,VI
M?^E4E?WB5_!W^T[_ ,G*?$+_ +&;4O\ TJDH _=/_@QJ_P"1=_:8_P"OGPU_
MZ#JM?OC7X'?\&-7_ "+O[3'_ %\^&O\ T'5:_?&@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_@[_:=_Y.4^(7_8S:E_Z525_>)7\'?[3O_)RGQ"_[&;4O_2J2@#]T_P#@
MQJ_Y%W]IC_KY\-?^@ZK7[XU^!W_!C5_R+O[3'_7SX:_]!U6OWQH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"6,#VLHAN0[2FW8S,DZ%8XDE7[*#(\BM L7[D4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%+Q)_P B[J'_ %[2?^@FOX$*_OO\2?\ (NZA_P!>TG_H)K^!"@#^DS_@R.\2
MW=U^QE\9-'?PU<VMC8^-(+R'Q W^IU.2:QB22S7Y1\ULL$<C?.>+]/E7J_[8
M5^.?_!E%_P HU/B1_P!E,NO_ $U:97[&4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+Q)_
MR+NH?]>TG_H)K^!"O[[_ !)_R+NH?]>TG_H)K^!"@#^G#_@RB_Y1J?$C_LIE
MU_Z:M,K]C*_'/_@RB_Y1J?$C_LIEU_Z:M,K]C* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"EXD_P"1=U#_ *]I/_037\"%?WW^(^?#U_\ ]>\G_H)K^!"@#^G#_@RB_P"4
M:GQ(_P"RF77_ *:M,K]C*_'/_@RB_P"4:GQ(_P"RF77_ *:M,K]C* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^:_5.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \-_X*??\HU/VAO\ LF?B3_TU7-?PZU_<
M5_P4^_Y1J?M#?]DS\2?^FJYK^'6@#^K;_@T"_P"4.NG_ /8WZO\ ^A15^HU?
MES_P:!?\H==/_P"QOU?_ -"BK]1J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PW_@I]_RC
M4_:&_P"R9^)/_35<U_#K7]Q7_!3[_E&I^T-_V3/Q)_Z:KFOX=: /ZMO^#0+_
M )0ZZ?\ ]C?J_P#Z%%7ZC5^7/_!H%_RAUT__ +&_5_\ T**OU&H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /#?^"GW_*-3]H;_ +)GXD_]-5S7\.M?W%?\%/?^4:G[0W_9
M,_$G_IJN:_AUH _JV_X- O\ E#KI_P#V-^K_ /H45?J-7Y<_\&@7_*'73_\
ML;]7_P#0HJ_4:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'RS_ ,%NK5[W_@D9^T1''?:;I[?\(-J+&:_QY) B)*#*M^\<
M HG&=[)@J?F'\5-?VM_\%K_$EOX3_P""2G[0UY=:59ZU#_P@VI0"VN@#'OEA
M,22X(/S1LZR+QG=&N"#R/XI* /ZP/^#1'2I-._X(UZ%,\EI(M]XIUB=%AN$E
M>,"98\2*I)C?*$[' 8JR-C:ZD_IY7Y_?\&M\2Q_\$*O@>RJJM(=>9B!]X_\
M"0:D,G\ !^ K] : "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?(__  7E_P"4.O[0W_8GW/\
M-*_B[K^T3_@O+_RAU_:&_P"Q/N?YI7\7= ']?O\ P:X_\H*/@9_W'_\ U(-3
MK[_KX _X-<?^4%'P,_[C_P#ZD&IU]_T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R1_P %
MY1G_ ((Z_M#?]B?<_P UK^+JO[+/^#B"\T>Q_P""+7[0$FN7#6UDV@11QNLT
ML.;IKRW6V7,1#'=<&)=I^1MVUP4+ _QIT ?U^_\ !KC_ ,H*/@9_W'__ %(-
M3K[_ *^ /^#7'_E!1\#/^X__ .I!J=??] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQM)-8OI+1U#\^4ULT+1D?*8FC*_*17W50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? G_!
MT*T2_P#!"SXZ><DDB[-" ".$(;^W]-VG)!X#8)&.0",C.1_']7]?O_!T=_R@
MH^.?_< _]2#3*_D"H _LX_X-_(+RW_X(T?L^+?:Y:^(9CX85ENK>\^U)%$9Y
M3%;%\##V\92!H_\ EFT+)D[,G[$KYE_X(OL7_P""2O[..23_ ,6\T8<_]>D=
M?35 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\ ?\'1W_*"CXY_]P#_ -2#3*_D"K^OW_@Z
M._Y04?'/_N ?^I!IE?R!4 ?VP_\ !%W_ )1*?LX_]D\T;_TDCKZ;KYD_X(N_
M\HE/V<?^R>:-_P"DD=?3= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\'1W_ "@H^.?_
M ' /_4@TROY J_K]_P"#H[_E!1\<_P#N ?\ J0:97\@5 ']L/_!%W_E$I^SC
M_P!D\T;_ -)(Z^FZ^9/^"+O_ "B4_9Q_[)YHW_I)'7TW0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ? '_!T=_R@H^.?_< _P#4@TROY J_K]_X.CO^4%'QS_[@'_J0:97\
M@5 ']L/_  1=_P"42G[./_9/-&_])(Z^FZ^9/^"+O_*)3]G'_LGFC?\ I)'7
MTW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ? '_!T=_P H*/CG_P!P#_U(-,K^0*OZ_?\
M@Z._Y04?'/\ [@'_ *D&F5_(%0!_;9_P1XT2Y\.?\$J/V=K.\6-+B'X>Z+N"
M2I*O-G$00R$J<@@\$U](5\Q_\$6_^42?[../^B>Z-_Z21U].4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'Y0_\'D=]/:?\$C].CAFFACNO'^EQ3JCE5F06UZX5@/O+N56P
M<C*J>H%?RPU_4S_P>5_\HE-'_P"RAZ7_ .DE_7\LU ']RO\ P3CTG^P?^"?'
MP,L_M5S>"W\ :$BS7&SS&']GP8SL55X&!PHZ>O->SUXK_P $V[?4K3_@GG\"
MX]6NK:\U)? &AB>:WB,4<C?V?!R%)XXQ]>N!T'M5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!^3G_!Y7_RB4T?_LH>E_\ I)?U_+-7]3/_  >5_P#*)31_^RAZ7_Z27]?R
MS4 ?W0?L _\ )B'P3_[$+0O_ $WP5ZY7D?[ /_)B'P3_ .Q"T+_TWP5ZY0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?DY_P>5_\HE-'_[*'I?_ *27]?RS5_4S_P 'E?\
MRB4T?_LH>E_^DE_7\LU ']T'[ /_ "8A\$_^Q"T+_P!-\%>N5Y'^P#_R8A\$
M_P#L0M"_]-\%>N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Y.?\'E?_*)31_^RAZ7_P"D
ME_7\LU?U,_\ !Y5_RB4T?_LH>E_^DE_7\LU ']T'[ /_ "8A\$_^Q"T+_P!-
M\%>N5Y'^P#_R8A\$_P#L0M"_]-\%>N4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@_['E_\ T@N*_FKK^E3_ (/;?^3(/A!_V/+_ /I!<5_-70!_?Y1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?BO_ ,'MO_)D'P@_['E__2"XK^:NOZ5/^#VW_DR#X0?]
MCR__ *07%?S5T ?W^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK_\'MO_ "9!\(/^
MQY?_ -(+BOYJZ_I4_P"#VW_DR#X0?]CR_P#Z07%?S5T ?W^4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'XK_P#![;_R9!\(/^QY?_T@N*_FKK^CS_@]Z\:V=A^RY\#O
M#KK)]OU3Q5?:E"PDB""*VM!'("I<2DEKJ+!2-D&#O9"8Q)_.'0!_?Y1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?A'_ ,'Q4>I'X3_L[M%K%C!I"ZOK8N=)>[5;F]G,
M-EY-PD/WGCA43H[CA#=1@_ZP5_._7[_?\'SG_-KO_<U_^X6OP!H _O\ ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\ ?\ @^<_YM=_[FO_ -PM?@#7[_?\'SG_ #:[
M_P!S7_[A:_ &@#^_RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ '_@^<_YM=_[FO\
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M ,>H_P"'BG[07_1=?C)_X6FI?_'J /[F**_AG_X>*?M!?]%U^,G_ (6FI?\
MQZC_ (>*?M!?]%U^,G_A::E_\>H _N8HK^&?_AXI^T%_T77XR?\ A::E_P#'
MJ/\ AXI^T%_T77XR?^%IJ7_QZ@#^YBBOX9_^'BG[07_1=?C)_P"%IJ7_ ,>H
M_P"'BG[07_1=?C)_X6FI?_'J /[F**_AG_X>*?M!?]%U^,G_ (6FI?\ QZ@_
M\%%/V@C_ ,UT^,G_ (6FI?\ QZ@#^YBBOY!_AQ_P4,^/S_$[P:K?'+XP%;B5
MGE!\9ZCB5O\ A';,Y;]]R<\Y/>N]\??\%"?CX-)^) _X7A\8,6_AT/$/^$RU
M']V?L]V<K^^X.0#QZ"@#^KNBOY9_A]_P4#^/4WP_T&1_C=\76>33+9F9O&.H
MDL3"A))\[J:V/^&_OCQ_T6SXN?\ A8:A_P#'J /Z@**_E_\ ^&_OCQ_T6SXN
M?^%AJ'_QZC_AO[X\?]%L^+G_ (6&H?\ QZ@#^H"BOY?_ /AO[X\?]%L^+G_A
M8:A_\>H_X;^^/'_1;/BY_P"%AJ'_ ,>H _J HK^7_P#X;^^/'_1;/BY_X6&H
M?_'J/^&_OCQ_T6SXN?\ A8:A_P#'J /Z@**_E_\ ^&_OCQ_T6SXN?^%AJ'_Q
MZC_AO[X\?]%L^+G_ (6&H?\ QZ@#^H"BOY?_ /AO[X\?]%L^+G_A8:A_\>H_
MX;^^/'_1;/BY_P"%AJ'_ ,>H _J HK^7_P#X;^^/'_1;/BY_X6&H?_'J/^&_
MOCQ_T6SXN?\ A8:A_P#'J /Z@**_E_\ ^&_OCQ_T6SXN?^%AJ'_QZC_AO[X\
M?]%L^+G_ (6&H?\ QZ@#^H"BOY?_ /AO[X\?]%L^+G_A8:A_\>H_X;^^/'_1
M;/BY_P"%AJ'_ ,>H _J HK^7V;]O_P"/ C;_ (O9\7/_  L-0_\ CU?8G_!0
M+]K'XI^#/^"L/QD\.:/\2OB!I/A[2] U6:RTNS\0W<%G:.G@R2Y1XX5D"(RS
M@2@J 1(-P^;F@#]OJ*_E_P#^&_OCQ_T6SXN?^%AJ'_QZO5OV#_VV_C1XP_;=
M^$.DZM\7?B?JFEZEXQTNUO+.[\4WT]O=Q/=1J\<D;2E71@2"K @@X- ']%5%
M?B+^SI^U?\4M<_:V_:^TV]^)7C^\T[PSX"\?WFCVL_B&[DATJ>VNT6WEMT,A
M6)XE.$9 "@X4BO"?VROVWOC1X7\2^#H],^+WQ0TZ.Z^&?A*_F6U\57T(FN)M
M"LY9IF"RC,DDC,[.>69B22230!_1A17\]/[2/[:GQDT*[^+@L?BU\3+,:;\5
MKK3K00>*+Z/[+:@ZEB"/$HV1#8F$&%&Q>.!7KWCW]J_XI6>J?L++#\2O'\2^
M+K'37UT)XANU&M,^MI$QNL2?OBT9*$R;LJ<=.* /VXHK\_?^"V_QF\8?"CX&
M_%*[\+>*_$OAJZT_2_!\EK-I6ISV<ELT^JZK',R-&RE3(D<:N1C<L:@Y"C'U
MY^Q]KE[XF_9)^%NI:E>76H:CJ'A'2;FZNKF5IIKF5[.)GD=V)9F9B26)))))
MH ]&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\ ?^#YS_
A )M=_P"YK_\ <+7X U^_W_!\Y_S:[_W-?_N%K\ : /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex3-2_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_006.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M2NRZ;\1D#'*J/%$F$'H/DS^9/2D'_!H;^QV,_P#$N^(^?7_A*'X_\<K]0:*
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MOCD!QP-0TK_Y ]:=)_P99?LVLWR_$CXYJ, ?\A+2CSC&?^/"OV&HH _'./\
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M_!D[\(A<LR_&CXF>468J/L-AN"_P@G9R1W.!GT%?M;10!^)Z?\&3WPG4-O\
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MPG,&[9_Y>?7./PZ4T_\ !D=XQ\],?M!>&1'GYS_PBD^X<\8'VGT]^M?T+44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 1ONGZ5_-Q_P7OO--A_X*R_%=9VG\U?[(W;;H(/^0-8]L'%?
MTD-TK^:S_@OOK5Q9_P#!6OXL1I);*J_V. &SG_D#6/\ LT >'_\ !I_!'<?\
M%G_!<DF[='X?UMXP(]W/V-AR<C;P3SSV&.<C^L.OY-_^#4NW63_@M)X!9P&\
MO0M<9249MO\ H$@ZCA>">3D<XZD5_610 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 #?=-?S
M1_\ !?Z?5E_X*X?%H06]K)#G2-C,.2/[&L>M?TN-TK^9G_@X#OWC_P""NOQ<
M475E& =(^5KHJ5_XDUCU&[B@#R'_ (-1-26Q_P""T7@>%D9FO/#^MPIB0J$(
MLG?) ^]PA&#QSGJ!7]8E?R<_\&I<<;_\%IO K21M(\>A:VT3#_EDWV&0;CR/
MX2P[_>''<?UC4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%%  WW:_ES_X.%[I5_X+#?&(>78G
M$ND_>;!_Y ]CUXZU_46_W:_E^_X.$9K-/^"P/QA$C?/YFDYP%Z_V/8^] 'GO
M_!J+<^1_P6C\#H5MV\[0=;3+KEE/V)V^3T;Y<9./E+#OBOZQ*_DQ_P"#5:1E
M_P""UWPWQ]V32-<!]?\ D&S'^E?UG4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBFA\T;N>A_*@!U%-,@%!DP>AH =13?,'/M3MV!0 44!MU-9PM #J*0N :6@
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MQX\,_&+5-=L-"O+M]1\,7$=KJME>Z=<Z?=6,DD8EC#Q7$:/AT(96 *D'()H
M["BDWCUI=W% !2,<+2;U(ZTV:>.&-F=E55&YB3@ #UH _.__ (*>Z.W@'XW>
M-/B]-I'A'XM>!O!_@O3[/Q]X,O)_L?BCPI9Q7-W<PZQH5PV$$T@EEWPL8S.U
MC&J2[U"#;T?X66GCG]K7]K S^%OAOJGAZW\;>'5UV^UZ^DL[K1[(^'=*FOKB
M!TC/DR)$YE1O,B_>;G+ @$_5MWX.^%/QH^+NJ?;?#?@OQ)XT\#R6D-Y<7FC0
MW%]I+,HNK8"62,LN 5D7:WRD@\&KOB/]E?X7>+]:U#4M6^''@'5-2U:9;F^N
M[OP_:3S7LJ@!9)7:,L[ *H#,20%'I0!\S?LR>!/#?[67BO\ :6N_BW';ZQXB
MT;QWJ?AH17T[1/X5\/Q00/IOV0[@;5)K<K>?:(]C/),S%CY:[6_&W]G/P98_
MME?LZZ"MO)K6F^+K?Q,VM3WMX\\NO+'H]O'&\[9 DV@(RX 5#\R!2<U]1>,O
MV:_A[\0?',?B?7/!/A35_$4<"6HU*\TN&:Z:%&+I&TC*2R(Q+*K9"L20 >:C
MUW3/AWXJ^/6B1ZE;^%=0^)/AC3IM4TD3QPR:OI5E.WV>6>'.9(XI&'ELRX#$
M8.<8 !\$?''Q!J7[//BO]J/_ (1G7-:T&QA\4?#+PEJ&M+J$CW'A_1[L:?:Z
MA=Q2.Q\F06US*[3C:RLWG,24#5Z'^VAX%LO@S^T%X+\'^"?MEGH/CSP/XM'B
M[0+:^N%A:ST^QBFM-6RL@>"YAO6MX!<H0[_:\,Q9(ROUUK'PE\ ^&D\;:Y?^
M'_"MC%XMM=WBZ]NK.%(]8MXH6CS?,PQ+&D&Y,RY"QY'"\5Q/PS^#?P+O(=4T
M7PI8^";Z3Q1X7M?MD-G=I<W5WX?G61+5=V]I1I[A9A$%(A)$FP9W4 ?/?PY\
M:>*OA-\0?AW^SY\6]>U+Q%X@M-=LM9^'GC*YE:&X\>:/;AGFM[MH]JOJ5FF!
M<(1MGA,5P 3YPC^Z+ZS74+%X':54F0HQCD:-\'@X92&4^A!!'45R=IIO@?Q1
MXDL?#\<GA_4];^'36VH6]B9TN+[P\98)H+><J29(3)#]H17;&]?- )&ZNON;
M?[5;M'N90P*DJQ5N1V(P0?<<T >$_P#!+SQ!J7B3_@G3\%M2UO5-4UO5K[PC
MI\]WJ&I73W5Y>2-"I,DTLA+NY/)9B23R:L_\%"? 7B+XA?LZM9^#_&VO?#KQ
M?_;NBQZ-X@TJ5RUA<2ZI:P9F@W".ZMV65ED@E#(RL> P5EZ[PA^ROX#\ >$/
M /A_1=!CTW1OA?-Y_A>TBNY_+TEOL\UL H+_ #J(;B5 LFY0&& "JD9G[7?P
MWUKXD_#JRCTGQAX;\&PZ+J5OK5W?:WIES?6H^R.)X6/D7UF4V31Q2$O(R$)A
MD(.0 ?,4/_!0;6+6Q\6>*/%>D7&C_%?X ?#_ ,1W?CGP#%K=Q;:7>7=N=.FM
M[Z!2&$MG=1"X:TN7C8A994;$D4BIZI\0?^"@FM>%OBWJW@W2? =MK&I6?CW2
M/ UM)-KILX9FO]#_ +5^TR'R'*+$<QLH#$K\XR?W=9GC;]CCX@?&C7_$4OB#
MQ[\"-?U/6O"\_@W7';X87ZW5SH]T2[6<K1Z^&$39=E!Y!=RI&YL\YX=_X)F^
M*OAM?1ZQ;^-_A6NH6NNV/B9M0U#POXDGDEU"RL/[/MKF:27Q,QE9;4^41(2K
MC!8,0" #D_B?_P %*/&/Q<_9-\>9\%W?P_O]5^$'BWQ9HVL:1XF%U>65_HMP
MEA=1KMBBV#SYXI+>8/ET4F1(6^2O3G_X*5:YH?CO5_A_K7PNO--^)UIKMKI6
MFZ5%J[ZA8:C:W.F7>I0WAN;>V>5,0V-U%)&MNY6>-0"\3":N5/\ P3)\8Z?X
M9AT./6O@U<Z6OA[6?"@MI_#GB55?3M7N5N=1@.?$+DF:6-7WG,B%0$9 *A\;
M_P#!-?QYXU\)R6.K>(/AG=W']N6_B:/Q"D/B6SU^WO[>W-O#<)J*:N;E3';L
M\0 D"F-W4@[F+ 'K'P/_ &YO$?QO^-VG>#HOA!XL\/JOAO2/$GB&[UB_MK6;
MPPFHPZB8[:>V)\U[A+C3VA98]PQ*DFX+P?HEU\V$KEEW#&0>17QMHO[&WQD\
M(OXPDT6Z^&-A=>-O#EIX7OM0M=:\10WL5I:I<K;R0R//*8[E3=W$AN ?->23
M>[NW->J6#_M(:;8QVW]F_!6=(8EC60ZSJPDX7')>W<L?]IB2>XYH \<_X)Y_
M%_QU\:?#O@J^\0>+OBQJ5_+XB\4PW5S>:'IQ\/ZG9:?JE]8P02RQ0H\;F,6[
MQNA5G>W8D%2ZFM^S7_P4HN_"/[.OP]L_$FD?$#XH^,[CP_;Z_P"(+K1M*%Y=
MV]E=:K/86\[10(HD<M%*Q1%7$=I,PRP1'O?"7]CGXS_ _P *^'= T.+PO/X=
M\+ZK-K=KI$_Q&U%+:]NI9YKES<N-(:>1/M$[S",R%-ZIE2H"5R?AS_@G5\4/
M VH>!K[0?#.@:+?>!](_X1UY=.^-NJ6C>)]*%U)=)8:CCPZ1)&DTLK(\7ES*
M)9%$F';(!ZW\>/\ @I%>?#[X+_$#QAX7^%_C#Q1I?A/2-=OM-U<26L.DZG<:
M1<+;7,+OYWFP9F,OE;T!F6TN"N,1F32N?VS;+P#\<_%FDZO;_$2[UQAX:TO3
M?")M-+\N2^OX;V8+92I,-SF.VG:X-S.(HUL\QD@DMXM<?L#_ !6GT3XE>'_^
M$-\.1^#/B;#JBR^'(?C=?_V7X;FU-WDOKG3XCX;!266:22;$KRQI)+)Y:(KN
MK7O%7[''QB\5>,M0\27OA/2;CQ3<W&@7UIK@^*:_:=,O='BGAANXHQX<6(O/
M'<W*SI(KQNMQ(JI&,8 /3O$O_!57PIH.E69MO ?Q0UK7)E\1K=Z#IVGV4FH:
M3/H7DF^MKC==K"LA6:-XF25HY59=KDO&'^AOASX^T_XI_#K0_%&CO)-I/B33
M[?5+%Y$,;/!/&LL993RI*N"0>E?&%S^R)\5&UJVU;_A7NBC6!:^(X+V[C^)<
M9?59M<%NMU=3!M#"B6);6%85C"HJH%*N!QZG\(]:^.7P4^%_A7P78_!GP[J6
ME^$]'M-'M[RX^(\9N)TMH4A1Y NFHNYE0$E549)PJCB@!C?\%5?A_!+K<%YH
M/Q T^^T*Z\/V\VGS:,K7[IK>I/IMA+]GCE:6/=<(=T4JQSJC(WE?.H+?&'_!
M27PSJ7P(U#6?#^E^-E\4S0>)88-#&AK<:MIDVANT%_--;^9L:."<PCY9&\TS
MPJFXR 5\W?#G_@G+\5/AU;Z=YF@^)=:&DQ^'(8TN/&6B^9>+H.O2:W9/,ZZ9
M&\DSS2.DTC.7E#L[-O.5W=:_8Z^+S:LFKZ+X7\6>&]:DU3Q9+<7-OXCT2\2;
M3_$EQ'=7MDT<D2KB*X@MY(9@2Z&+#!U=U(!]E_LK?$#6OBS^R7\-?%6L-:W'
MB+Q-X2TO5KYHE\F"2ZGLXI9-H .U#(QP #@'O7C7PV^-7QQ\1?M2^-/AQJ&N
M?"B4_#W0?"&O:E<Q^&[^V6_74[G4DU"*)S?OY7EPZ<QA9D?YI!Y@(!-:?P)\
M6_%/X$_!#P?X*C^"/B;5X?!^AV6B1WC^*=&66\6V@2 2,HE559@@8@  $D"N
M/\%Z9\2_#/[3WQ,^)%Y\$_'VH#XE:-HWAZXTE=8\/)'86^G?;BDB3C40SESJ
M$^X,H(PF, <@'<6__!5[X'S^']3U1?%LC6.EQ:3=F2/3YYVNK/5;PV6G7D*1
MHS26\]R/+5P."4R '0M-#_P5+^#HU6"QNM4\6:;?3:AI^DO;7W@W5[>6UO+^
MT2[LK696M@8YYXY$6.-L/)*PB4%_EKYE\&?LU_'#P=^S_8_#:\\,_%+Q!H/A
MG5_#L_AF2;3/",-UIVF:+J=M?VMG<R1ZVAO9R+2"W:[;R\HA;R?,9W;I/'?P
MB^)GC#XO^(/% ^%?Q8M8O$'Q&\->/7L_LWA2;[-'I%K;V[6 D_X2--QF^SJ_
MG%!Y99AY<@Q@ ^GO"7[>/PS\=VOAB72=8U*^_P"$J>2.VB31+[S[)H[XZ=(+
MR+R=]GMO0UNWVA4VR(X. CE?2?'_ ,0=%^%O@O4O$7B+4K72=%TB!KF[N[AM
ML<*#N>Y). % )8D  D@5^<C_ +,OQ,LO$/A'5)OAO\4+/4?"7C#4_%5AK.E:
M#H-OK5FNH>(9]6O;".XA\4,IM;B"<V<L4\4T;JHE"*X 'O'[7'Q,\2?M(? K
M5O"$/P?^.?A/5+B:SU/2M6&D:1J,>GW]E>0WMI))#'J?[Z,3V\9>/<N]-R[E
M)! !V'QY_P""B?A7P#\(QK7AMM0U?5I_&&E>!VL9=!U(7.C7]]<V\:F]L_)6
MYB"07"W"HZ(9U,01OWJ-7H&O?$;Q=\-/V5]9\6>(M/\ #MSXO\.Z!=ZK=6FG
MW$Z:;<RP0R2A4>6/SHU<(,AD9D+$?/MR?C'Q/X=\7>,O$6L^)KSP+\3K'Q7X
MC\>^%_&&KF/P+NT\VFAF#R[&%5OF<RR-"2;A]V!(!Y9$:U[O\=?VJIOBW\$/
M&GA33_AA\:=-U#Q%HM[I5O<WO@JY:"W:>!XEE81L2RKOW;5P3C&5SD $'@O_
M (*"^)M+T7X'Z_\ $#P+I6C>$?CS_9UCI>JZ+K;W[Z#JE_:FYM+2]AE@A(BE
M :);B)G_ 'Q16C57#CMOA7^W;X!U+P[X/M_%?Q&^%5MXJ\;M(VCV6C>(A=6^
ML1G4&LH&M&E6.2;=(8HR0F/-+*I8 ,?EW0(=8\4Z9\!_#?C[0_B3;^$/@2-+
MU)--T;X::W/)XHU73[3R+2ZFN#'_ */;Q.3,+98Y&:01EI0(]KXO[//A"#X<
M7_AV'Q1IOQ*FT_3_ (<:[X)O[G3/A;XJ6^\_4]52^,T'_$N(55C4 DL&\P9
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M\*>'_$FH?#NWAELYCK2:@!X5C730R7-AJ33O#?6=Q,RPO83J9HKAI;A2$7%
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M.V6^L[W1M2:PVM&+AI+C[3Y5Q*5\B$VPC16,PDWK])4 %%%% !1110 4444
M%%%% !1110 4444 #?=K^5O_ (.(9[@?\%C_ (S;5N"OGZ5@K;DC_D#V/>OZ
MI&/%?R5_\''%[;I_P6C^-RLWS"[TO/#?] BQ]J -;_@T\TV.^_X+.^#YGW;K
M/P[K<T>!W-H4Y_X"YK^KZOY3?^#2CR/^'Q^@>=,T<@\*ZSY"@-^]?RDRIQQ]
MW>W.1\OKBOZLJ "BBB@ HHHH **** "BBB@ HHHH ^8_VX/"^M>'OVF?V?\
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MTJ>^\/OJ]AX@^'W]FA;_ ,)W<&J/%:2&18(WAA>U7 \^28761+"RJDBG[,H
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M4:M\8M5NM)\+W%QJIATF22WLKNZD:6:*.5E :T,!54+++( 0-K"H/VCOV_\
M1_V=O!/B^RNH-+O/BIX/^&U]\2+CPD=3,:26]I$S20BZ\HYR\<JJPC)(C+%5
M&* /$?BE^SOXV\9_$WQI]F\#>,M-\-:]\3?A]JEA!9W\5HEOI5I:6:Z@0(+D
M>7%"(I898TX8CY5D4[JXGPM^R)\6/ .C*_P_T'QQX7\576A?%70--N+O7'-K
MI4,VH-+X7B)>>1(H401M;[5/DY<$)N8'[HT3]K/X8ZI\/KSQ-_PL7P"=#TB[
M&FZIJ">(;1[/3+W8KM:S3>9L28!U.QB&PP..14?[17[4OA/]G#]FG7OBIJVH
MV-UX8T;2_P"U(9H;R%8]25E!@2&5F$;&8LBH=V#O!Y% 'E?_  30\#S:%X*\
M5:Q)X:^+W@N'Q)=VLDOA_P >2Z>IL+F&U2"X:T@LE")%(R!GE))N)?,EQ\Y9
M_F'X(?L[^(_AK\*]%\'^(OA]\5M+\!Z?IWC6RCL?#ANH;RV\1OJ[365ZGV:3
M?MELR5M+MB(HG1RS(948_9'P3_:\NO$>H>,$^(=E\/\ P+8^';JSM[#4+3QY
M::M;ZPETCR0S8V1/;K(@1HUE :3<Q4;5!;IO'_[97PG^&O@?6/$6L_$;P7:Z
M3H6B_P#"17LPUFWD,>GE8V2Y"JY9HW$T(1@"',T07)=<@'A_[9?PC\9>.O\
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M,=HR JL<<L:^GAX&T+_A*8M<_L?2_P"VK>U^Q1:A]DC^U16^=WDB7&\1YYV
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M7]CX&\,V_@G6O"WB:]UC1M(U2%;AULKVTT:#4(3<3&11,6>219(88=L2F/\
M?F3=&/</'W[%/PC^*6MZ_J?B+X<^#=:U+Q9;K::U=7>EQ23:M"J;%CG<C,J*
MA*A6) !('!-3+^QY\*D^+/\ PGB_#WP>OC0:B=7&MC2XA?"\-N+5I_-QN\PP
M 1ELY(49S@4 ?*'P>_X*X^)OBEXW\!>%Y/#OA^PUWQUH":>L;+.T>G>-+/4(
MK;7=$?#Y;[' \EUC ;R878DX->[?L=_M>ZO\?OB?\0_"OB;3K'PSXB\%SQ>;
MX>EM;FWU.R@EN+N.&=GD!@O+6:*"*2*ZM6,;,TR%4:+YO7+/X+>$=/U/3[VW
M\-Z)#>:5J=WK5G-'9HKVM]=K*MS<H0,B659Y@[CEA*^2<FLSX0_LT>!O@+=7
MTWA'P[9Z+-J$4=O,\;R2-Y,;RR1PH79O+A1YYF6),(K2N0H+&@#Q+P=^WKXB
M\9>,?!=Y;^'='_X0?XC>-_$7P^TJ=;B5M2TW4-*.I(EQ<IMVM!.^DW@*)AX0
MT)8MF3R^#_8]\2^,O"?_  39\4?'R^OX]9^*6M^$]3UN;^T-4OYM&NI+5[VX
MMG>U:3;$<-Y;&!4)BCACSMC0+],^'/V1/AYX0^)VJ>,-+\.16>O:Q<W-]<2Q
MW4XA6ZN46.YNHH-_DPW$R*!)-&BR/SN8[FSI?#_]G#P3\+?@=%\-=#T&WL_
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M+8-X2\!6'P_^)UE"\LT7B2PL8X+FTBMW*KN6/4(9%S*B[[:_NU*@O@ 'T_\
M#?6/ OAB4_#_ ,)WGA>SF\&6<%N?#NESPK)H=L$ @0VR',,>S:$!4#&,<8JS
M\2O&^I>"[?3/[)\+ZKXHNM2O1:&*RDAB6T3RI)#/-)*RJL8\L)P2Q:1  <DC
MY5_9]_9$^)'P&^)7BS7+KPAX(\5:EX5D\6:AX'\13^+]1COM<_MO46U/^SY[
M5H6M[!?.\N.:=?/W^1$ZQC+ ?8$][>6OAUIX[-;C4$MS(+5)@JR2A<^6'(
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M^/?V@_%OQ F\*W'A$:;X^^#NL_#F7^U[JX@DL[RY=C!,!'#('A(F??G#+Y0
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MRC+D??\ >I* -HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ QD4@0 TM% !1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HQ110
M8HQ110 8HQ110 8YHHHH **** "BBB@ HHHH **** "BBB@ HHHH &Z5_'=_
MP<HW,R_\%N_CR/.DXU#3L?/T']DV5?V(MTK^./\ X.1M_P#P^V^/>\$-_:EC
MU.>/[,L\?IB@#WS_ (-";6.?_@KY$[2.K0^"=7=0 ?F.ZV7!X/&&)YQR!SV/
M]4%?RP_\&@B;_P#@KPK+N^7P-JYZ9S^\M.OIUZU_4]0 4444 %%%% !1110
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M **0N!1NH 6B@'-% !12;Z3?D?RH =11GB@'(H **** "BBB@ HHHH ****
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MB"*2V?38]%D=KLX593=?;XVN-XD"_9QY>W^.@#Z0^)/[,E]\0?VP_AO\4/\
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M?_$K]D[PM\5?B1X \1:HLRP_#EKXZ=H\4-O_ &7="[MOLT@GB>)BP5,E C(
MQ.=PXH ^"(OVXO%7@BVU#XV:Y9>&]*\=7GP3\!OK4DT<D-GI\5]XGOK2XU1T
MPTB6L4,TEYAP0D:_,<;C7U;\"O"</[3/ACPCX\\>:]X!\9:U\*_$^J7OASQ)
MX6OA/:26[P2VZ>;.J*@D\B?;.L/[HR1#I@H/H2]\%:/J4ETUSI>GW#WUJ;*X
M:6V1S<6YSF%\CYH^3\ARO/2G>&O!ND^#/#=MH^CZ9I^DZ19Q^3;V-G;)!;0)
M_=2-0%5>3P!CF@#YY_X)W?M.>*_VB=)\5Z?\0!!9^,?#<E@=1TJ'3XTM+1;F
MU\U);2\AGFAO[&?#203*5D"?)*BNI)^*?V)I%\+_ +4OP=MVL[+X?^%=0^)7
MQ%.F^,M/OY)E\:W46KZO:P^$[N,!(H%^S[;R RF;?_9HCA$;!C7ZF> ?A%X5
M^%.F7%EX7\->'_#=G=R>;/!I6G0V<<[[0FYEC50QVJ%R1G  Z"LH_LT?#G_A
M"F\-_P#" ^"O^$=?4/[6;2O[#M?L+7F\/]I,.S9YV\!O,QNSSG- 'QIJ?_!3
M[XIW'[._Q$^*&D:3\-)-%T71=<O=+TR]OG74M.OM,UA;+[)=0QRF20-"2TS[
M83;S!$VRJX(] \"?MO?$ZP_:<TWX9^,M+\$?:6^)<_@VZU/2H;J.VN+*3PC<
M^(;9X1+(2MS$T*02JQ975A(HCWA1Z9^T=_P3]\!?&_X4_$S0M)\/^%/!FN?%
MJWCM?$OB*P\.VK7^K(LBL?M+ (UP2JL@\UF WDX/0]I>_LG_  QU?P=9>'KS
MX=^![C0]-U4:Y:Z<^AVS6=O?C=_I21%-JS?,WS@;L,1G% 'Y^6'[<_Q,U&_/
M[1'A_P /^"[ZX7]G;1/'?B;1KG4[N.VNK9+_ %*XF@L H<+<2Q)((Y),C<L:
ML'!RGJ)\7+X:^/?C)9]*N-8M]9_:2T.QM8[O5KRU.D-)X4TRX,L:QOB3;)YC
M&"0^23(S%20 ?J:S_8N^$FF-X;^R?#7P19+X/M%L-%CMM&@@CTVV683K!&B*
M%$2S*LJIC:LBAP PS6A??LL_#G4==.J3>"_#K:BWB*+Q:UR+-5D?6(X1!'J#
M$<M<+"!&)#E@@"YP,4 <%^QY^TYXI_:7T_1/%%UIWA&V\"^./#L?B+P])9:J
M\FJV^9BCVEU RX9DC:%GE0J(Y7>$H=@D?G(/V^=5N?'.D3Q>%;";P+K7Q%O_
M (7QWBZD_P#:MMJ5LUQ"+F6V$6P6[W5I+'@2;UC:*;D,R)ZU\'/V3/AK^SYX
MJ\1ZYX(\$^'?"^K>+KEKO5[G3K-87O9&=G8G' !D=W*KA2[LY&YB2[3OV5?
M&D?%.Z\:6OAVWM_$5Y>MJ<LR3S+ UZUO]F:]%OO\A;MK?]T;@()3&2I?:2*
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M"^DZ/K;E-2CU&WFM]3^VK%&)HU$;3Q/83I*L32Q*VT+*YW;?H"O&OV:/V%/
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MDVEIJ9N+B!Q:;3=PW#7-K'\K//YXB*%I5XB?3OB_\-OAY>:Y9ZY\>-+U+6_
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M?QBO_#-UXAL9KZ?P=J\>O:.R7L]O]CO8TDC2;$3J'(261=K[E(=@0037644
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M!UJ'X[?LSS?&KXE^ _$B^(I]'E\"C5C'!%9I,MX]]I\EF&8L05\KS"X SN(
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M6E,;!02,53\&?\% ?@S\0;O5H='^(WAB\;0]*OM<U!_M/EQ6EC8W!MKVX=W
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M&NFK\A_AQ^V7J7@[Q9\#?'&HZY8V-IX@^#^FVWC#QMIEKIT+>%;.ZUXQK?\
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M?V_PWN/&6@?![XL:O%JL-A'=R6ESH&NZ=90[)DFP+:X18Y)XD8*[Q(5=0H
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M?CI9:M-X=O+B>30;T:=J5M=V,]C=6$[017"I+#.B2*6@GAD4E<,DJD$@UV%
M!1110 4444 %%%% !1110 4444 %%%%  WW37\4O_!:L+%_P5N_:,$;+M_X6
M!JQ^4YY-RY/IWS]/?K7]K+?=K^*3_@LK*VH_\%8_VCI+A?*D'Q%UN,*&W_*E
M[*JG( ZJ <=1G!R1F@#[N_X,P$9O^"H7CPY^5?A7J (]2=6TC_"OZ;J_F/\
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M7=M);+=W2FY=)'C23>4A$"/(-V%7$8^@:* /EO7O^"=^K:SK6O7G_"<VL?\
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M#/"'@&RTRWT7PWHNEQZ+%=0:?]FM51K&.ZE66Y2)L9199$1G"D!BJD]!7/\
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M1Y-'\%Z'JFF>%=*@TN2.YMIM2BL4N'NIS*5F16LBR!$C;%RP).Q20#'\#_\
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M7= EU^YT'^VM#_X2RQLOMMUH@U*!KVU3:K;GCW;E3YU^<@+\P.<$5\6^.O\
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M^ 7B'PEI?B%M;-]XXO9]-T:'3=&NM2>[N8;:2Z>+;;QNRGR(9I 6 !$3 '.
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MR/'WCK3_ (:^"-8\1:HTZ:7H-G+?WKPP//)'#$A>1EC0%W(52=J@L<8 )P*
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M@!:*3=2>8* '=:*16W=*6@ HHI"X6@!:* VX<44 !YI N*4G% .: #%&***
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MYW)MK6)!+$P:1I<+&GZ+8HVB@#\]?V?_ -B3Q1\2_#FD^&_%7AWQ1X#U"_\
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MGK-@9KM[8Q7[3^7)&P:.;[.R^4Q&0P4@C:#6;\#OCG=^&?C?XT\">'_%6B>
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M/!/</ DEO:0/*4CC55758-H550"U^UEJ4MI^WWX'DLYKBZM[?X/^/;Z[T_\
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M5_P[XI^%?@63XF:/KW@GQUX@\)0^,-9LH]!U&33=$TUY;R)=2N+EH0MI:/\
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M/B%XB\-Z[H5MJNJWSF$"^-TEJ;JZCME>XDA@GB66X%NCW$D3.44R$CR+2/\
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MHHH **** "BBB@ HHHH ***IZ^;I=%NC8M#'>"%_(:8'RQ)@[2^.=N[&<=J
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M48<J2""0#L**:9% ZCCK[4><N[&Y<T .HIOFK_>%(;B-752ZAFSM!/+8ZXH
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MXP\5>--$\%R^++7P7K,VJZ787SZCH5U/;P7*M&)$97:"3R_F0/N0.R;RR[B
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M%+/ WBKXH7'A*QT#X@2:HFH>(=&M7.@LMOJ>H:(S?;+.WDWXDE*JSQ=%D56
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M;[8*I&]L_47Q&_:PU+X3_#_X9ZEKOP[UB'Q!\1M9M?#HT6WU*RF;2+^XBDD
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M%>)DC4!6=V9^W^.7[:7B[7/$_P 0K?PQXN^(=KH^J>-9;3P?>0Z--:V/D?\
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M_I7]"5?SU_\ !D5 Q^+'[0DN/D72-$0G:>OG7G?IV/'6OZ%* "BBB@ HHHH
M**** "BBB@ H9MHHI&Z4 ?/7B/\ X*/>%_!L'Q(U#5O"/Q"L_"_PCUE]&\6Z
M^FGV]U9Z0R6L%V]PT4,[W3VZV]S!*TL<#!%<EMNQ]OL'A'XD+XU\3W5M8Z;J
M$FBKIEEJ=CKX>&33=82Y\X[+=DD+LT:QHSED52MQ$5+9;;\IGX<_&#0= _:;
M\/Z'\-)Y-6^,GBZ]N?#NKZKJFGC0[.UGT73]-6[O52=[G8C6LLAA2!G<>6N4
MWLR>=^*/^"<7B/P+X2UCP)HWA/5/%'AK2M'^$'A^QU$75I:RZU!X=U9VU*8_
MOT9'6Q"A@VTOOV)N% 'W.?@IX=;XZ?\ "QC!=?\ "5_V#_PCGG_;9?(^Q?:/
MM&WR-WE;O-Y\S;OQQG'%;WB+Q9IOA*VMYM3OK6PANKJ&QA>>0(LD\TBQ11#/
M5GD95 '))KX.N_V(O%GAK]J+Q1I'AOP/KV@Z;IY6]^%_C31M8L;30O"%HOAU
M=+73;B#_ (_@L5UYTJVL226TIF25BCQ\89_9<U;QY\ O">L7'[,^L>&?$WA?
MQIX+U#7]$GU+3[Z;6Y],G:*]O[.,W36[1A)F/VF5X;BYCWF5/DC# 'Z.[AB@
M\5^<6H_LM_%35O!\L;>$?$5G\2-+M?'5KXQ\00W<(MOB!8WMK?KIT,+B7=*[
MW,NFS0K(L8M%M)X\Q H)-*#]ECQ-\)_%O[/[>#O!OBJ]FL;71;KQ5IVNK->:
M>T]Q>69U"^2_%SYUEJEJMMYT@<207<?[G:Q8D 'W)\3OB5H'PH\+ZKJ^N7"Q
MV^G:7=ZI<11Q^=<SVMK&9)RD2@O+M4_=4$Y=1U8 V/AYXKTGXH> -!\3:2K/
MI?B"QM]6L6EB\N0Q30J\;%3RK;& ]1TKY:_;Y^!6I>)_VG?#?B[2? .I>*+A
MOA3XW\+)J.GVZ2R6-[<II\UG%*6==JR+%>(A&[YWVG&X&O /^%#_ !3^ 7A2
M[AT/PA\7+[P/:Z=\.[_Q+H]A<_;M1UA(;/48-8CM(KAY%DF1QI37%N-HEC@9
M%#G((!^FT_A_3[H6_F6=K-]CD\V#="K>0X_B7CY6]QS6+XT\2Z%X-U/08]0L
MKJ6X\0ZLEA9/:Z5->!+HPRR+)*T4;"! D3CSY2B E5W!G56_.?X^?L[_ !&C
M^&NKMX7_ .&DKR3PW\'K>Y\(F]U2Y&I-K2ZY//:QW"6CI%)>0PF%?+=21 =L
MN\H2/M;]JU_$'_"?_ F30H?%$EG_ ,+#0ZS_ &4EP88[$Z/JHW7HBX%L)S;Y
M\[Y!)Y1^\%H ],\#_#;0_ASX+@\.Z/8QVNCPB0"W)+JYD=I)2V[)8N[NS$YR
M6/K4E]X T#4M/T^UN-&TFXM='ECGL(9+.-H[*5/N/$I7$;+V*X([5\3_ /!/
MOPO\0/"'QA^&-UKQ^,TD?B3PSXW_ .$E_P"$G?5;BT@EA\16K:*DJW.8K>46
M<EYY1&QY8LEM_P IJ_XLN_B=J/[3>L6P_P"%E6?CC3?BMI$NA/:17Q\*WO@E
MX[,7BR,!]AP(3J.\2_Z0MVL14[3!0![?X@_:J^"GA3QWJ.EWEU;#6K"^>5WM
M_#=W<K=:@LUM:21V\\=NR75ZLMU;PM% [SJS[2HVL%TO@-JOP;_:J^%N@^)/
M!^@Z#K'AG0[VXCT9[OPNUA_9EQ')ME,$-U!&\)\Q?O*@#%<@GK7QCI?P+:#X
M._#VW;PW\7H7;]J'5M4GB9/$"2VEA)K.KRP7S@G=':O;R6[_ &@XC)F#%]Y8
MUJ>)_BIXX\,PQZ?\0+K]H;3O >L>./B/I#:SX8TW5)]8TR[.J@>'F40Q/<-8
M_97NQ;,$>U9UM0^Y-H(!^ATFAZ?/K*:@UK:MJ$<#VJ7)B4S)$S*S1A\;@K,B
M$KG!*J3T%<39_LB_"C3=)N+&W^&?P]M[&[C@BGMH_#EFD,R07+74*LHCPRQW
M+-,@(PLK%QACFOE7PU\5_'S?MZZUI/BGQ!\5- _X135+?5K#2HO"-W>Z7X@\
M,'0(O.$UU!(=-61-0-P\C1Q_:1<1)%"7BD5&]>_;$_:/U35_^">5Q\3OA//K
M5];ZI#HVK0W>FZ1-=:A'HL]_:'4+B*S^28S1Z<]TXC&V563  < 4 >Z>/_AU
MX=^*WA2XT'Q1HND^(M%O-IGL-2M4NK>8JP="R."I*LJL#C(*@C! -9NA? GP
M/X8U70;_ $[PAX7L;[PK:3:?HMS!I4$<^DVTQ4S0V[A=T4<A1"ZH0'*@G)%?
M$\'Q0^*W@/P?\-/B!X'\8^./C!X5\6:[JWA$6UUX>N-+6*/4]SZ-J+17#&Y:
MWL;Q%M7NIF#-;7!D8.8E<ZVD?&3QIIO[>FI_#C6OBEXJT*Y\&W5@=)TNZ\+R
MW,/CCP]_8,7VF^-V%%NL@U%KEY)^#"]K''M(D". ?8GQ5^"'@WXZZ?8VGC#P
MWH_B2WTNY^V627]LLWV2?8\9DC)&48QNZ$J1E793D,0>*^+OP-^"&H>)=#B\
M:^%?A_-JGB2T3P;I$>IV-OYFHVT;&]33859?GC0V[3"(#"^46 &#7SK_ ,$M
M_C5\1O&/CKP=8^-_'GB+QE_PEWP/\-^-;V'5K"WMOL6K2W%S#=&(101%-P$:
MO&^2&C!P"QSYCKMGJ'BK]HZ\\-S?$'Q5;ZY%^U*762;R9[S0+.3P9=M ;=9H
M6CCC97"1LRN@7R\ L?F /N/XE_L/?!_XS^&-8T;Q5\.?".O:9X@UM/$NHP7F
MGI(+O4TC2%;UCC/GB*-(O,!W&-0A)7BNL\#?!+PC\,_%.MZUX?\ #^FZ/JGB
M1+2+4I[2(1F[2TA\BV5@. L40V*  %7@5^<OAO\ ;V^+.O\ [,DVIS_$&:P\
M=Z-\++'Q%X*MFTRT5?B=KB7VI6]S;2QM#F:1FM+""2WM/*>,WY<;?,B\OUS4
MOVX/$WAW]M"/X;R>-[1KA?CS%X6?2)K6V%TOAVZ\$MJT*, @81G4%813\,VQ
MH]S[6  /H[XS?L\_!VZ^*6B_%WQUH'A.'Q1X1CBLK'Q)JDB6YM5><>1$[LP1
M\7$BF(2;MDL@,>';)P;;_@F?\![/3-7MX_AKH=O;ZYI5QHEZJ23)FQFN_MCP
M*0_[M%N<RQ[-ODL6,>S<<_ 'B#]LKQ)^U9^Q1XRN]:^+'@77;3^P/"<]]IZZ
MAI%TVF^(9_$L"7$B06KBYBL(T^Q>6EUY<H,H#'S-X3[]_89^+/B+XBGXO:+X
ME\21^+)?AU\1;[PS9ZF;:"WGDM5M+*\CCG6!5B,L1O&B+*B;A$I*[LD@!X7_
M &&/@;XQ^'\BZ#H-I=>&_$%U?:G<2Z5KUW]FUM[V*."\:>2*?%TEPD,:RK(7
M239E@3DUU'@7]BOX8_#/X[Z[\2M!\*VVE^,/$A+ZA=07,XMYIF1(WN!:[_LZ
M7#QHB-.D:RNB[68@D'\\_P!E[]LKQ3\._@/\#/A_X-\>?#+P!!<>!+'7M ?Q
M/<>79^-;EM:N8;[3K?;!(UQ)#;Q1*(+5XYP^H1-\ZC:/:-1_;K^)0\:_%CPY
M9:II>H^)M)U**?PW9VM]I":7JVDG7Y;,QZ??R.$CU?[,C6S6>HJH%]&2K-"2
M% /K/XA_LN^"_BE\1]-\5:]8ZA?:EI<EC-#"=5NDL'ELKAKJSEDM%D$$DL$[
MF1'="RMCGY5QY]J?_!-;X(^+_!G_  B\F@7LVFZ7IFH:$L$7B._$MG#?WT.I
MW #K/O25KN&WN%D)\Q&CC*,H %>9_M#?M,:YXY_X(^VOQ.\*^/-6T'5-2L=)
MG;Q%/I<&FW<<<NH6]O<F6!C)%;ML>57*.53!9'QAJX;P-\8?$7P;_;>\=77A
MK7?"-QX3\;_'/1_"VM6;6 :\U-[GP1I\WVM+B.0(CAH8751$0X\T$X*E #ZD
M\%?L$?#3X?\ B33=7TS3]?74M'U^_P#%%M/<>)-1NF74KZT-G=7!\V=MS20E
MQALJ&D=P S%CU_PE_9Z\*_!+X%Z5\-]!L;B+P?HNG'2;6SN;R:Z=;4AAY;2R
M,TC?*Q&68G'?BO@GX??\%5OB7XQTU8]-\2?#35[C6;[X;W.E7[Z81;W5IXEU
MNXTZ[\FVCO//6!$CB>W-QLG&_P#>H"Z[?IOX,_M2>)KG]AKXB>._%^K>#4\1
M?#F_\8Z=<:J;6XL]%<:)J6H6D5U/$C3S11M':))*L9D89?8#\HH MM_P2^^$
MLOP8NO!$UCXCO+&33]+TNSU&?Q!>-K&C6^ER^=IJV=[YGG6YM929(V1@V\DL
M6R:]=^$_PETWX.?#RQ\.:7=:U>6]B';[9JNI3:C?W4KNSO--<3,SR2,[$Y8D
M#@ !0 /&/^"?7[5OBC]HM?BAIWBY=+.I> ?$5II=O+9VJ6<MW;7&BZ;J DEM
MUN;D1MYMY,J@R!O+6,.BR!Z\ _X>L?$;4/@?=_$+33\,M0TG6O@CJ_Q>T>PB
MM+F2;2)+2XMECL+N5;H"4&*=T=U2(B>"7 VKLH ^F_AQ_P $_O!/PL7P'_9=
M]XM+_#D:V-'DN=8>9U.KL7NS*6'[T[R60MG83QQQ6 O_  2R^&+?#V/PM,_B
MFYT6'X=V?PS@ADU8[[?3;28S6LZ2*H=;R&3:R3@[E*(<9 -<Q=?MV^+M=_:G
MU;X2Z0?!EGJ5QXT/AO2=8NK2>[MK6&+PQ:ZW.)H4N(S/=,\[HB++"/*CDD.3
M$5?F_@W_ ,% OB]\?_&>CZ=HWAKX?:+;6?A.[U[Q'+J$UW<.)[+6-0TJ=;(1
ME0\,KV0FA:0J?+<!LEL@ ]*UW_@F;X>\1Z%X=6Z^(7Q<D\2^';/4],/BF3Q!
M'-K.J6.HQ1175I<O) T3PLL%LRA8E:-[=)%97+LW?>(?V0/"?BO]D"'X*ZDV
MK77A.UT"U\/0W!N@FH11VT<:V]PLRJ MQ&T4<BN% $B*=O:OF>Y_X*I^-V^$
MVEZ]9>%?"-UJ&K?#SX;^,8[22]N(XXKGQ/K)TZ>!W4.PBB4;XW"DL00P(&:[
M#X/?MT_$SQ'\?/#_ (7\4>%O!4&C:AX_UWX<W5[I=_=-=&[L=.N-3M[Q(I(P
MJPO;VYC>,NS+(P(8KQ0!Z /^"?\ HNJ>(=)\0:YXK\5:]XPT_P 3Z;XHNM<F
M^QP3ZI)I]O/;VMK+'' L2VRI<3$K$B,7E=]P+&N?T3]C>;]D;0[?QC\/T\3?
M$CQ7X-T;Q!9:3X=U'5K'3H=;?6=8BU6Z$ER;<".03QJ(V.$" JP).\1_M._M
MZZY\&O$WQ67P_P"&M-UK2_@7X;TWQ3XJCNKQH;[4+6[:Z=H[%0"N^.VLYG#2
MG;+(1$-FUW%/X*:%J_QE_P""AOQAU+Q-?326/PMU'2+/PK'9:G=VRVT5QH_F
MS13P*5AF60WCNXD5R72$_P#+&(J >H_L2?LSV'[)O[.^D^$+.TM;*6.6XO[N
M"WF:>&VEGE:06T4C@,T%M&8[6'(7;!;0J%55"CF+[]A?3M.^*6N>+CJ^MZY8
MW?BQ?B+%X6D-O';R:]#IT5C"PGVA_)58(I%C8X68!RQ4!!\YVO[1/Q@^)_B7
MX'^(I_\ A'[KQ-_PM/XD:#;Z=:ZO>:7HE]9:7!KUC;K>!8Y&?:]BC F.0[L.
M-A)"^H?"/_@IOK_QYM/ MUX/^%^I:Y!K'A?PCXI\201:@HN-$@\01M(HB+(L
M<PM8T:65G:,.@81Y<%* /1/V$_@+=?#2R\=>-M8\,W7@CQ%\6-=/B*^\,S:M
M'J2^&P8D4VJRPDPYDN/M5Y((24\^_GPS_?.;^T#_ ,$_O^%Y_$/QEKT/CC4M
M"B\;6OAB*[LDT^"XBBFT+5CJ5M,C-A_WFYHG0G;M.X8-<S^W=XJ\1:/^V%^S
MSH>CWGCR72?%1\2PZQI'AG5TL)=36#3/.@8F2:% T<N&!#J22 =RY%<A^PU^
MW7XW\<_!+PCX3DLV\=?%ZYOO%T%]:>(+Y-'GTBVT34X[?[)J,L-NZ-J*17VF
M1N8(C#([R2K(8PK2 '8^*_\ @F9JS?$BX\;>$?BKJ7A'QA=>*-8UE[QM M-2
MM9=.U2.Q6YTQ[>;Y6"OIMG+'/D.KQ'*LK,I]D_:3^ 6H?'#]G&^\"Z5XLOO"
M]Y=?80FKM!]K:1+:Y@F>&XB5XO.AN$A:":,.F^*>1<KFO$X?^"KVF:K>_">^
MT_P9J4GA3XI1^'/)N;B_C35=/DUJ>:WA\RRC60+'!-&D<TDTL2DR$0F<H5,W
MPF_X*/ZY\;-*T&&U^%>I:3JGCJYU&T\,6]YXBM5345TXW2:A.\D2N;>.)X(D
MC)1FE>\@^5$$CQ@%_P"#/_!.C4/A!J_@.6W\=6%SI_@;X@^(_'4-E#X:2TCF
M36(KV,V*[)L1+ ;^<JZJ=P$:E!M):QX)_8"UWP?%\/\ S/'NFWDG@/Q_XJ\=
M(Q\.M&+PZY_:Y:U(^U$J(&U>8B3)WB) 57DU6_9,_:DNO O_  2M^"WQ"\:S
M:]XH\1^)/#?ARWD#R12:EK.K:D;:VAC9V*1^9)<W"*SL5102QP!7._M!?MO>
M*O$>AV_A'P_HMUX9\::?\5-$^'WBR&/48RUI;WL,-\)[&Z,>V1)[26,"0HDD
M9>0;%= 0 =#X8_X)XZUX9^%GP%\.Q>/-->7X)>";[P>UV?#[XUKSM*BTZ&Y"
M?:OW!C\I9'3=)YA)4-']X<Y_P[,\9^'O"%O9Z!\5-/TO4+/P%X)\#).N@31I
M=P^'[^>ZN/-V78D$5]'<2P,D3H\:G(E8]>D^.NH>.OA;\6OV7O .F?$GQ2;'
MQ7JVIZ'XDU*>TT^34=;BMM!OKV*:1S;>7'-Y]K$6:*- P9P5^88X&#]L?Q5X
M ^-GCKX3^./$?B+6IO OC_P-9Z3XH\.66G07VHV&OW&(;75(I<0JJS030SR6
ML:2-;SPO&B2;F !J?#[_ ()C>,/ABEO#IOCKP>UK'X?\>Z \*>&);:**+Q#J
MHU2V\E%NB(_LTPV..1)& JB,_/76Z=_P3E:'Q[\"?$4GB2*&X^&/A2#PEXGM
MK:SVP>,K6V%M/9*VYB8A;ZA:I<)]XA99DW;9'W/T+_@J7X9U;3);A_ ?Q&TY
M9_$6I>%M&^WIID/_  D5_ITVIPWZ6Q%Z5"0?V5,S23&-6$T(0NS,J=)X"_X*
M":#\4AX?D\-^!OBAK5KK TM=0FAT-8V\+S:A;BX@@U"&259X72-HFE*QO'")
MHV=U4E@ <W^R5^PEKG[./QJ\0:CJ%Q\-=:\-IJFLZGX<U.+PL(?%T*ZK>->W
M%K=7Y=@\4<CLH:-5:54AWX,9W]3^T/\ L8#XU_M*_#SX@6>KQZ.GA^"XTCQ3
M9B /_P )3I#/'>06;-_#Y=_;6TF3G,4EU'TF-<+\'/\ @J=8^/\ X$Z3XNU#
MX=>.(M5OM&U+Q1>Z%IBV5[=:/H]I=R0"[E/VD*^_80L41>:1XIMD;!,UJ:S_
M ,%9/AEI6J>*#'8^,-0\.^$;"PU&_P#$]MI\?]@B*_M;:ZL2+IY54>>EU$%9
MPJJ<EV11NH QM$_8#\6)?Z'H&I:YH,WA'P7X_P#$/C[1-7C>=M:N'U6/5#]C
MN(B@C58IM7N,S+*QEB@B4QH79AYU\,O^":GQ.\)3?#6UURU^#?BW0[7P!X7\
M#^*K'5?M\R:=+X?N9YK/4+!0H2Y,GG;S!.(Q%-%"ZR,%(;[=^&OCH?$CP59:
MU_96KZ']LWYLM4A2*Z@V.R'<$9T(.W<K([*ZE65B"#7GVJ?MN>"=(^)T/AN9
M]6$,WB)/"']MBTSI$>M/$)$T]I\\3-E4!V^7YK+%O\T[* *O[4GP9\6>,_B1
M\)?&WA'^RM0U#X:Z[=7USHNJ7CVMMJ=M=6%Q92,DJQR>7<Q><'C8H05\Z,E1
M+N'EWP?_ &&/%GP>\?\ P'N+<^&YM&\!WOC/5=<BBNY8_P"S9-<N)+J&TL(S
M%B2"W>9H 7,6(HT(09V+Z]^S;^U_X<_;"^&NH^)/ ]KXJM]+CA5K/4-:\/76
MGV]XS(WS0><J>>L;JR/L. RD9Y!KPC]E_P#X+">!]>_93\/^)?B3J&KZ7XJL
M? ^C>+?$A'AB]L[6:"]:*"2]LU=#Y]G%<R!))8F=(0RL[!"'(!9_X*K_ +(7
MQ0_:LT^\TWP)I_@V\T_5/A_X@\-SRW^I2:3J$-[=M:26W^D1P2O)9L;=A);@
MQJ\@@=RPC 'K7[<OP*US]IC]FNT\,6VDZ#J&H2>)O#6KWMC?7&ZR,%CK-C?7
M48=HSOS%;RJFY!N)7(4$X[G6?CWH^D>$?'6M+;ZM?6WP]-PFIQVMFTDTTD%J
METZ6Z\><VR15&W@OE<Y4X^;O"W_!5G1XOB=H%]XJ6;PQ\//%7PT\/^-+(3Z)
M>3:EIEQJ>H3VI^VR0[XXK5,6X\UT1%,A8N5(P </H_\ P3E\9>#OB?#KVA^#
M?A_:W"_$_P ;^*%EDN (VTW5=$O+2SCF6*-)&26[GB::%&&T*6#,P%>/Z3\#
M/$WP9U_2_"_C32_"VD^+O'7CGX4Z_I/AZVUZSO-0VZ/J%C!J4L-G!#$D5O;1
MV^0\0*B+:"00U?H=H_[9WPWU_P".:?#>U\26\GBZ:6\MX+8PR+#=W%FJ/=V\
M,Y7RI9H%D1I(T8LHW9'R/MN>)OVE_ /A/XA7VAZIK$=GJ6B0M+J%U+:3"RTM
M1:O>,L]YL\B%OLT+S%'D4^6H;&"N0#X[O_V"_B/J_AO^RKKPKI_]O^$;_P >
M7DOB==1MA_PL.TUJTU**TLY1N\U6:2]M))EN!Y4;Z:FPNNPK'XG_ .":.J67
MPF\(^%_"_P ,_"^CK-\!/%O@W7VB>S2/_A(]3MM#2%I\'=<%WTZ;?/\ -R%9
MCSFO??V@/V_=+\/_  '\0^)?AW<6.L>(/#.L>';&]TK6[*\T^2&WU34[2U29
MH9%CFV20S2O#(!Y<CQ$9.U\>IZ+^TSX&\1?%MO MGXBLY_%"K=.EGLD477V5
MHTNEAE*B*9X&FB65(V9HC(H<*30!\;^ ?@Y8>)OVN_!OAOP[:>%/#MQK'@C2
M;7XU>!XKVUN[[P\=%>"]T3S!:EH4>5KJ>W<,<3V[ Q[A#E?H;]N7X;>(O'>M
M_"J]L?"DGQ"\'^'_ !2]UXM\*(UKG5+233KNWAG\NZDCAN!;74L$IA=AD#S%
M!DAC4]!?_M;?!GP3\9O$?A6?QCX/TWQUI\0N==L3,D=]$D=M#*K7'&>()X2F
MXY*N N>E.UW]O?X-^%?#-KK&K?$KP?I%C>R:A#";_44M93+88^W1&*3$BRVY
M($L;*'0D!@"10!\V_!+]B[Q7X+^+7[,MWXB\"-JEKX!?QM)<:E=7-E?2^#;.
M]O6GT/3WD:4RR&WM6CMU-N)4C:#[P7:Y]*_:]^"^J:S^V7\,?'VE?#N3Q<NC
M^"?&&@W&IVD=D;C2KJY739K$,9Y$DV/]FO(E,>[:\^&VK(6KUC2?VT?A+X@L
MM:NM/^)7@6^M?#C6*:G-;:Y;S1V;7QQ9!BKD?Z0WRQ8SYC JN6!%9\W[6WA>
M?Q3H]Y9^,?AG-X!OO"E_XKN=9D\50QW$5K;2V\8NHX=I1[("63S;DRJL3K&I
M!W\ 'PAX8_9'^*_P!^"FFV7A?X>_$!=-L_ WPTD\7Z+8:G9SW7B.ZTZ2^CUV
MU@6YGDAEN5MGL \;@174=MY 9N,?<'[+GP\F^&7[&UOH;6?Q MXX;34)+6Q\
M2ZA%>:]:P2RSRPV[O:?(A1'5(XHF)B01QAB4K2U_]K7POJND6=UX(\5?#OQ6
MR^*M-\,ZBK>++:WCLI+J6(/$'42;[P0RB2*U(5IB54%=P:NG\&_M&?#_ .(7
MB2XT70?'7@W7-9LX9;FXL=/UJVNKF"**8P2R/&CEE5)5:-F(PK@J<$8H _.>
MU_9C^(G@3]G7X%:5?:3^TE-I?B[P ;3Q@_AO7#>^)M!\:/:Z5%#?3_;IG^SJ
MD=I=(DT1$,$OS,,3,Y[[7_@3XU\1?M//J%]_PO5-+OOC=):7+V^O:S#8GPS)
MX/CBE8)#*L26CZJ@_>1JNV090H.:^Z_ OQ?\)_%)9O\ A&?$_A[Q%]FQYW]F
M:C#=^5G!&[RV.,@CKZBOGM_^"G]IH7PW\:>.-;^&/CRQ\"_#OQ-J/AGQ%K5K
M+87RZ6;"Y^SW6H- DXG:Q1@S%XT:541F:%54F@#Y$U#4?C;H/PN^%"?V-^T%
M'XF\*Z'X=N'NS#K5\][##XM:&^MY(8V51=+IB1M/)>>?)<V\\8C3Y)I#Z?J/
MA7XF>.OC3I^E:MJ'QSL?"\WQ5\=F_DL;[5[%?[&_L60V*^=$59;7[28_LQ1@
MH<;8SG(/VOX?^.5E?^*?$5OJ#Z/IFB:.]FEAJKZW:R1ZL+BV$^?+5M\.T$@"
M3!D4;URO-=/IGCG1=9U5;&SU?2[N^DM5OEMX;N.25K=L;9@H.?+.Y<-T.X<\
MT ?FAK_CCXZ7O['M]>3ZA\:;/QI<?LS>$;HO;6.HK>0>*C<W"WTB1K$0-1W&
M+SD"[RF-RE,UU/QF^+'C/X!ZCXHT^[U[XJW7@ZQ^.9T^WC9-:N=2U#1)?!RW
M3Q6UY;V\]U]EBU=I7#HKQAHO(W*GRU]UZY^T#X)\.:AX?M;SQ7X?BN/%.J/H
MFDQ_;HV;4+U(I)7MXP"=TBQQ2,P_A"G.*R?C#\"? /[15_I\GB 7$^J>#9Y)
M+6]TG7KO2=0TEI8P)$^T6<T4R+(@4M&7VML4D':I !D?L&:[<^(OV0? -QJ'
MC)OB%K"Z3%#JWB%HI(6U*_CS'=,8Y4CDC*SK(FQXT9=F"BD$#UVL?P)X1T?P
M'X7M=(T&VAM-+L08XHHG+@'<2Y9B26<N69F8EF8L6)))K8H **** "BBB@ H
MHHH **** "BBB@ HHHH *_A/_:$ECN?V@?'LD94QR>)-293R,@W<N*_NPK^$
MSX]W*W/QX\<R0JT<4GB+46177#*#=2D @<9^E '[4_\ !D1Y(\?_ +1'[Q?.
M_L_0MJ_Q%?,OLGZ X_.OZ"J_GO\ ^#(A%/Q-_:&;"[_[+T, ^6,X\V]_BZ^G
M'X]J_H0H **** "BBB@ HHHH **** "D<96EI&Z4 ?+7@O\ X*!ZMJ'C;XK?
M#_Q)X9TWPW\0O!-IJ.K>%P]^\FD^/-.M5P]S;R[%>-XIR(;B AW@+QN#*DBD
M^I:/^UIX/LM9\/\ AW7O$&EV/BW5Q9VTMK$)FM8+^YM_/BLS<%/+2:1<M'%(
MRR2*4*J=Z@^?_&[]@"/]HOX):UX?\0:XND>+(_$>I>(_"7BK0K8P7WA:>X>3
MRROF,WF PR/!/&2([B)Y$*J&XHZ[^P-JVJ^*?%&E#Q#I+?#GQEXUT3Q_J%I)
M82?VO97^F_8'$%O/YGE>1+-I5DV73?&K7*@G?&T0!Z[^TM^TAX=_9L^'=]JV
MM:C8VU[]AO+G3K2=I-U\]O;O._$2.ZQHJ9DD"%8UY/;/.?!/]M7PGX^^&WPO
MO/$&K:/X?\5?$?0M)U*/2?M#.D%S?VGVF.U$I4*'?9,(E<J\HB;:I((&+^US
M^R]XV^+'Q.\/>,/ /B3P[H^K6'AO6_!NHVGB#3Y[RQN-.U0V<KS1B&6-UN8I
M["V(R2CQM*I"L4=?*?@M_P $Q_%'P?\ BUX9NI=0^%?BGPB='\.IKRZUX3:Y
MUC3M5T73X;&*YTB9I2D$<JP1.%E#O X=T9F?@ ^A9OVV_A':QZU)<?$3PC:Q
M^'?LYU&2YU&.&.V2XN6M()"SD!HI+E'@6124,L;INW*P&AX2_:Q^&OCR_P!"
MMM%\<^&-4E\36XNM)^S7Z2+J"&%IU\M@=K,84>4*#N,:.X&U21\T:9_P3Z^+
M5W^RQ'\+]>\2?#'5K/PC<>'-,\+ZFFC7$-[J&CZ/JUG?1_VF[,^;AH;01;(
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M&^&=7\WQGJMF/">I>'9IIH[FVMX8D34(6>59(DD\EUF3YF"'@ ^^O%/CW0?
M]MYFM:UI.CQF)Y0U]>1VZ[%VAFRY'RKN7)Z#</45/_PE.EB>2,ZE8"2%HT=/
MM*[D,G^K!&>"_P#"#U[9KYZ_;0_9'N_VC/C=X%UJ3PGX9\5:)X=\)^+-*N8M
M7,3,MUJ-O9QVP5)$8,C^1,CDXVAU.&&<?/VO?L"_&2W\$:+HMIX7\*ZK->?#
M_P"%&B:M>7'B 0_9=0\+Z]+>WZ\PLTV^&<-%+QDPMD!M@8 _0#5?$FASVEW;
MWFI::L:V\CW"/=JFR(?([-SE5&<$\8)]:Y'P+\9_#Y^-?B#X5Z?I<ND2>!]
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ML\.7WA>__L'2I[75-2L;K2YK,6][-]K-M>1PW$PNX6EM?,B:,1JX1G#/U?\
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MUN85D0,%DCD575AG'(&>HX(-=%0 4444 %%%% !1110 4444 %%%% !1110
M5_"/\;IFG^-GC.1MTC/K]^Q8?+N)N9.<=J_NX)Q7\(?Q;?SOBUXL==^UM;OB
M-Z[&_P"/B3J!T/MVH _;3_@R'A_XKC]HI]QR+'05VY_V[\U_017\_O\ P9"6
M^?%/[1DWEQG;:^'TWD'>/FU X!Z8XR>.H%?T!4 %%%% !1110 4444 %%%%
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M@ 1FRR>^_'SX 6OQ^TWPK:WFK:AI<?A7Q/IOBF/[(D3&[EL9A-'#)YBMB-G
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MX:T/7]2T_6-9T?2[:QO+VQLFLK:ZDBC5"\<+22-&IQPID8CUKJZ** "BBB@
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M@ HHHH **** "BBC- !11FC- !11FB@ HHHS0 449HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!ER<6\G^Z>OTK^
M#CQFP?QGK3!@0VH7!!7H?WK=*_O&NFVVTA/0*2?RK^#GQ9.L_BW5W7[KW]PR
MY&.#*Q% '[Q?\&0 ?^Q?VECN7R_M'AKC;\Q.S4^<^GM7[T5^$/\ P9"1,/!G
M[23[OD;4/#RA<="(M0R?U'Y5^[U !1110 4444 %%%% !1110 4444 %%%%
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M:VD*-/.42-2[?*K-M0$L1T)J33O!'A3Q9X/NO*T/1;C1_%0%]>0OI\?DZD9
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MWQ'<:0S6;-/O@ADM[;[2S SM&;RVP'0'?]&?M3:7\./C]\+OA1XY\3>(8(O
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MS$95)$8$&) ?HOPW^TCX#\7?$>X\(Z;XLT.]\2VOV@/I\5TK3%K=E2Y1.SO
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MU3PWKEDNH6-Q]CFAEEB()Y@D19D<8(,;HKJP*E00174RPK-&RMG:PP<'%5-
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M+3K'3].ABM_$NJP@P:?J3ZG9!]MR/,:"\DDDCD?<Z>:ZA@C%3ZE\'_@5X;^
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M#\8K;Q8OC2P81?%>3XF26AT1OF1_#K:']A#_ &C@B-O-\['WN/+QS0!TK_\
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M<3R>,CF@#UJB@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#K2@Y%?$FC?\%!V^/G@+PW?7N@7&AZE9_$[P[X;U;0M.\3WFEZUX7N+J5?\
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MG@+S+E_A_I][;RK<^$;:=68:9)/O8W%I!*S>0<+)'$5B)8(I')M^P9XML?V
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MZ?=265U>R:@BQ6T\< N9(WR<JRVY$QR!B,AS\IS0!Z917*I\;?"3_$Y?!?\
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MOBY^U1X'^#7P+\3_ !%U+7M/O/#/A.&:2]GL+F*X+21<&W3#;3.6P@0L/F8
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MO8:%:K'!)<,;N^E\FU1Q&K&-9),J)'VID<L*ZQ9,C^?M0 ZB@'<** "BBB@
MHHHH **** "BBB@ HHHH **** ."_:FF6W_9H^(<C1QR+'X8U-BC@[6 M)>#
MCG!]J_A<M%7[+'_N#O[5_=#^U; ES^S!\1XY#MC?PMJBL3C@&TE!Z\?GQ7\+
MMJ@^S1\?P#M[4 ?TG_\ !E9-<G]@3XK1L6^QK\0W:(;.!(=,L=_S=^!'QV_&
MOV2K\=?^#+ ?\:Z_B=][=_PLF?/''_(*TW_/Y5^Q5 !1110 4444 %%%% !1
M110 56U?4ET?3+BZ:.>9;:)I62&,R2.%&2%4<LWH!R35FJ/BB_.E^'+^Y6"X
MN6M[>200P1F264A2=J*.68] !U- 'EOP3_;K^&?[0&H^%K3P[KEYY_CK1&\2
M>&EU'2KO3?\ A(-.7R]]Q:&XC03!!-"SJF7198V90KJ3Z]YJYK\O_P!D[]EW
MXK>%=,_97D\.:#XVT_Q3\.?A%J7ACQ(_C2!?[)\)WLVE0I ;,2G<UVU];VR,
MT EA^RK*K%&*AM=- ^)&G_">XUC1?"?QPMU'@?1=/\?:)=7FJ"_NO$8UFP%S
M=6I#>;>^3:_VD]V^GL%OH##%%+N*&, _2GS5!KE[CXR:%9_&:Q\ R7$R^)M4
MT:YU^VM_LTOER6=O/!!*_F[?+W+)<PC9NW8D!QCFOA;]FSX5?$;QY\3_ (9Z
M!XV_X7EI>B^&[KX@F>6;4=7TFRO'3Q%I]WH"W3PW+[K?[()Q$LDK#RXV@W,A
M*/?_ ."?>@^,+_\ :V\">(/&/ACXO6/C"S^%^LZ+X]U#Q/!J#Z4/$+:OILD@
MLI9<VGE2^3<21&S_ '1@6! <QA$ /T",@P<5YUH_[0_@CXG>-]:\&VLUSK%Q
M8V]V;I?[(N9M.O!;3"WO(8KCRS;W$D$S"&6&-V=),HRAE8#YBOI?B=KG[4-Q
M;B;XE:;X\TOXKP26P4ZA_P (E?>!VA029 _XEY_T8S#YO]*6^12/E,>[T;_@
MEQX83X;?LKZY]JL_%6EL/'OC/4'@UQ+_ .T?9Y?$FIW%M*D=U^\V2VLL,JE1
M^\\S<=SLQH Z[X9_M6_ GXJV7@G3]!\1>$)K+6)2?!L4]K]CM]2EMPZ%=-\Y
M$2:2(+*"MON9 KY  :NGLK#P?\<]$U8^&98=/U?PP]_X5MM;L]+B2_\ #-TB
M&&46AN(60&,D$85XF*@$.N17Y_>%?#.M_''_ ()(_"'X%:!X1\:0_%"^U/1[
MD7%_X;U#38?!#6>M)?3ZG<75Q%&D+0Q0OY:(_FS/(B1JRLQ'H]G;?$?XO?'#
MP=X=U+QA\9O#OA[4OB;X]AO+G3FN[+?IL(+Z=&\YB(CM@P7R&R%<#:I8,<@'
MUK\-OV4O"W@GX6WGA;6+>/QM;ZQJLVO:O<>(+2WN3JNH33><]R\2QK"I\P J
MJ1JJ;5P!C-=?>_#KPW>^.[/Q1<:'HLWBBQMGL;35Y;*)K^W@8[GACG(\Q8R<
MDJ" 3U%?G-X3^._QBM_A;\3?$D^O?&:Z\>>%U>R\;>$4\&WB0:9&OB.(7-]I
M%U-O@N)$TC[8;9+#>)8UB=U,RJ&O?$OQQXAC\8>#_''PGU[XT^,+B^^'WQ&?
MX?1>)-/U&!;_ %?&EW6FV<EM/%&[*@6^6&3455Y1!@R.HC9@#]%/#/@;1/!?
MAQ=&T?2-+TG2(_,"6-E:I;VR^8[.^(T 4;F=F/')8D\DUSMM^S-\.;/4/#5W
M#X!\%PW7@V 6V@2QZ+;))HD0.1':D)F%0<$*F #SUKXA^(GQA\<2^$O$=Y\.
M/B-\2IO FI7?PW73]:NK"6XU/3=0O-?6WUR!!<0,Y7^S##+-%(A2VD=L!<O&
MGHGP5^('C#P3_P %$(?AS>>+O%/Q$\,V5A+8Q7\E\4O-(>UTRP+)K%DUM'%*
MLTCM<1:E:N TMRUNT>%4H ?4'QU\-> M9^'-Y??$G3_"MYX3\+C_ (2"ZG\1
M6\$MAI?V0&;[:YF!2/R0K/YAQL )R.:P_#?[+?PAO/!S0Z7\._AZV@ZW96<;
MQV^A6OV:_M8)C=6JL FUXXYI&FC!R%=RXPQ)KXU_;:^.WBV+X[_'CP;-JU]X
MH\)W7@37[>VLM$NV5O"DB>&(KDVVJ6#0[IHIWE\Z"_MI6/FW M63*@C+\/?M
M+^+/@C;:EX2U3XC^)M0T:&Y^'\-E=36UM9QV3:I87'GV<EY%;DV5E(]K!B41
M2RH\XC0AIE90#ZV^',GAG]F;QCXWO?B+\8M%U[QM?:<_B'4[W7)M/T>71?#5
MM<3_ &8-#'L6.RMFN)U-S+G?))*6?HJ])\<OA7\&_B#XE\!>)OB-HOP_U35=
M%U:%?!NIZ_#:O-;:A.5,264DO/G2-&A58SN8QJ0"5!'YIZG^T)J'Q^_9!\0>
M+O&FOV^J^);_ /8_\6KK-ZUO]D:>Z6Z-M*S1;$V.9864H$4[\@*.!7V1_P %
M#;B/4_@1\"[>QURWT>35/B9X0BL-258IC&3<*P>(291GV!MNX,N2"58 @@'J
MOQ<_8H\#_$'X77^AZ3H/AWP[K$>E:[I^@ZPNEK/)X>FUB.5;VXB7<A)EDE:2
M10Z^8W5LG-5OA5^P1\,_AQ\)- \+7'A'PSJ1TG^Q[F>X&G^4MW?:7'&EG=!&
M9RGDM&'B3>PB/W3GD_!?QB_X*@^./A=^SII]U#\9+'_A+/#MIXMNC<ZC8:;;
M6_B:#1_%0TZ.6:7R6628V:C?:VL,.1,\[30*(\_1VG_M'_%K1/VA?BI\/8[C
M4/%UUX3W_$?P_>1Z=;10ZUX8N=.E%EI*O'%L$W]K0S0[R?.>"'?D%L@ ]^\0
M?L2_"7Q7\;-0^(^I?#[PO>>.M6TI]$O=;ELE-U=6;Q-"T3M_%F%VBW$;O+9D
MSM)%8&J_L8? VSO=(T6_\,Z%'>WAN3:VMSJ$OVG5U,5JMPD@:7S+R/R;.S5X
MY?,01V\2D;54#S+_ ()4?M6:Y^UGX5U;7;[XH^"_B/I5YI6DW\4.BKON_#E]
M-%)]LL[EDM;=(0&5"EK*C74.)/-D<-'M^8? ?COQ%X\;X-21?&%KSX@:5XE^
M+T)U_5X-/U#4-(%I=7D:P"%4CC4I&MLY1T*JA "K'Y80 ^^OVNOV8IOVG/\
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MI>,-'\&_#CX<^"_A%/X7\>YU>35D\4P11V\B>?"T*Q0VUFD5XWF F27[2RE
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M+L6B3*@?87[&\%O9?M*?M626ZKS\1K$O'&O(;_A%-"9OQ9F8_4D]Z ,+P_\
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M#VJT1H[:-69I&50I=ARQ'<_6I*16W#-+0 4444 %%%% !1110 4444 %%%%
M!1110!Y#_P % GCB_80^-330RW$2^ M=+Q1-MDE7^SI\JI[$] :_A\M6Q:Q_
M[H_E7]O/_!1V[_L__@GM\=KC)'D?#OQ!)PVWIIEP>O;ZU_$' N((_E_A'\J
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M[K/Q3U"34K[P;%X>U&^71(5N'U.UU-=5L-3@VR!(5M[P$_9F21718T+C:S.
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M<^%_^$<\2ZSXBU>>*X@CTR32+BQ@?RIV5;>6)7N;A)61G\MX-I(.172^*?\
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MZ) R3&9#$+N8;'$:;V?&;_@E+X@\9?$GQ5KGAGQQ'X=AD\<V_C/PG;11R*-
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MGCP+X-U"ZT/4O&$FOV:6MMJ=N;<-;20,XD5',[K'*"VY[6<%4'EM)\S>&/\
M@E9XS^'\$44>F^$?$FK:&?A/::?XCNKLQZA>0^&)H'U*=F:%GBDD6-UC4.QD
M\P[F45/\0/V'OBY;PSZM;^"=!\76:_%?Q5K][X/7QE-HL>O:-K%O);Q7?VN*
M,".\A5V!@<,ICGG D+%30!]\7WCG0]-OI+6ZUC2[>XC7>\,MW&CJNPR9*DY
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M\/VNCZUX;\1N^M:>+K2Q";B2*78USY$R*ZR+)@%V0,"1TR*^6_'OB+X@6O\
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MU+3?$<VF:I;)9"*1FA6026TPCF:!-COO:%4RNT ^WO@M^R1\/_V?#CPGH/\
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M_P!.DEOI-/UV77+>X?S+)@D@NI75DB"0F)8D\O\ <Q%/F;X%_P#!0_QQX?\
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MH YG4_@QX0UCXBV?C"\\*^&[OQ=I\*VUKK<VF02:C;1 OB-+@J9%4>9)A0P
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M#OB"TDL=1L+M-\-U"XPRD=1Z@@@@@$$$ UT%% 'CMO\ L+_#Y+?1VGM=>O\
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M?VR?\%5(6N/^"97[0JJP1O\ A6_B Y/8#3IR?Y8K^)M6W*I;)) R: /Z>?\
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MG=2D\E8_M'C[57$@;)FQ!9KDCMC&/H*_5RORK_X,\B#_ ,$DKK!7Y?'FK @
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'KCPSJ=M>Z3,ERZ:S<:2VUIKDR&1&E.F9B6TB!A\N0KC]./*7;C%!C4G_/%
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M>&KX^!XO#GB33]%LX(XI]4MM2>ZT:*Y>5K--D>GVMPL]QYCI#?A=L\CV^_\
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MQI??\$R?&'C:^\:+XV\<:,_B^YBOKBUB8P7%I?7P@MY(8<#">5&/+&TA650
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M;RP\'^%K&ZTN2\ELIK?2;>.2S>[(:[:-E0%#.P!E*X\PCYLUR]A^PW\%=+\
MV_A2V^$'PMM_"]IJ$FK0:/%X4L$T^"]DB:&2Z6 1>6LS1.\;2!=Q1V4D@D4
M>8?![]LCQ)XW_;+7P7J\FDV/A/7M'.J>$+NWTJ::V\7VZ6EG++<6^H+,R1S0
MS33K)9W$,<GEF"2-I )#7A_[5_C?Q]X]^)?Q$TO4-=T;5M/\%?'GX:Z9X3T]
MK%K5=)#RZ/>NTTB2,TP9[QPQ*@MM(!"X5/N+P_\ L^> _"?Q"NO%VE>"O"6F
M>*[Y62YUFUT>WAU"=66-&#SJ@D;<L,*G)Y$,8/"+BKK_ .R_\-_%7C6[\2:I
M\/\ P3J7B&_N=/O;G4KO0[:>[N+BP9FL9FE9"S26Q9C$Y.Z,GY2* /D?2O\
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M"*ZE:^(O&&M>%/$&H)K-O-;:8VGZ:M[YUJZ$BZCE6:!E<;<*) 5#%:K?"_\
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MR-(KM-E2& /4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%+;3;N$76NZ;#J"Q[K6$36\]GJ"1*_E!D>.4I(3C: ?7P8&C.*^7=._;PL_
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M^B^(?^$U\,^(M%\+7VBW^DM]MT>;5;NVM[>[>$,!-"8[GS(V1RDCH8MZN'"
M'U#17COQ!^-.H_L@_L9^*OB!\2M6C\47'@/1M0UR^N-.TO\ LU]0AB,LL$*P
M&20).8O*B8[]C2[F"QJP1<?PGXX^,7AKP_X8\9>/+_X<V'AFZMI=2\8:=#9S
MVS>#[7[%+<!H[Z2X*W(@D6.*5V@C\Q6:55B"^60#WJBOG>__ ."J'P4TK3I)
MKCQ%K2W,>J0:-_9T?AG4[C4FNKBPEU&VC6UBMVF;S[6&62(A#YAC9%S(I01^
M$O\ @I_\,]=\*^(-<U!/&7A^PT3Q%J?AU(]0\+:DMW>OIT#3W<\=NL!E$2)'
M,22HVA &VLRI0!]&45X#JW[>G@7P3XX\37>N>/-$_P"$1TZQ\+M;1VVB7\EQ
M;2ZW<7$-G-)<*KQ30W3K"L?EJ/**.9& 9<>H?!/XY>&?VA_ B^)/"6H2:CI)
MO+O3F>:SGLYH;FUN)+:XAE@G1)8I(YHI$9'12"O3&#0!UU%>-_ C]H#Q!\4/
MVDOC5X-U*QTBUTKX7ZKING6%U;&3[1J N]-@OF:56.U-@N%C&W.XJ6^7.T4X
M?VT?"W@W4/&C>+/%7A_[+HOBFXT"P@TJRO9[V$V^EP7\\-S$$9GFCC,\[-"I
MB6#RV)!W4 :7QY\"^(/B]\5_!N@QKK&D^#=*,VOZEK%HUE(MQ>P[([.P>&<2
M%D/FS7);RB%>U@PP)./D'P]^QC\5]'_8T^%?P4O/"?B6\TOX1_&"P73=7@\0
M6=M=W7@VQOIIK*]$L5Q&\<T5L8(6C7;(3%E5.>/?[+_@I9X+T']JO6/ ?BCQ
M1X0TK1=2T_PU>>"]02Y=VUU]7%X$5WP8D5GMD6)B55S,J@EB%J[;?MEZQ+\3
MO ^D0?\ "$ZYI?BSXCZ]X*NKO2[RY:32HM/TZ_O%#K)&H-VKV1BF0'8A8[2V
M. #+_P""?'PF\9?LC?#GQY\/O$?ANZU9- UF]U71_&5M/;S7?Q$AN?WR7%[N
MD64ZN,B&>295CE:)'5]K%4\UTS]GWXA>'_\ @CW^S]\.6\#ZY<>-O"$_@*/7
M-&BN+,SV"Z3JFG7-\Y?SQ"X6.TE*[)"7+( ,DX]<^'O_  4J^'S:=HMGXN\4
M>&K?5[KP7/X\U#4]':YG\-VNE1W7V?[2M]+$BF,MN.6 V^6Y;:-A;W;PW\1=
M$\6ZM-8Z;J-K>7EM9VVH2Q1-N9+>Y\SR)3_LR>5)M/?8?2@#YG_9MTCQE^R#
M\1_C)X=U#X?^*/%6F^-/'.H>./#VO:)]EDM[Z+4!$[V=SYLT;6]Q;RJ\>7'E
MM"L+*Y.Y%S_ M_X\^!O[5?[2?BR/X2^,M=M_%/\ 8'_".#339_9]7DM-,^SR
M(CR3H8XUFXWR(GRY8 ]*^DO&7[07@CX>>.=+\,ZWXHT/2M>UEHDL[*YNTCEE
M:5S'".3\IED#)&&P9'5E3<P(KS?X8?MA7GQL_:D\:>!_">DZ%J7A_P"&NKGP
M_P"*=2EUIH=2L[TZ?!>HT-F(&66WS<) SF='$@D(0JF6 /&-!\'^+? W[0O[
M0'BRZ\%_&::;7/B3I>O^&[+0+N&"P\1P6NA:/IX\XF7:L#7%G-YAE"GRT1L'
MA3ZW^V+X6USQ'\??V9;K3?#^K:QI_ACXB7.K:U=6=OYD6EVK>'=9L4FD.1A3
M<WMNO ) +'&%-7?''[5WB[3/VJ-?^%WAKX=VOB6[T'PC9^+C>2>)$L1=17-S
M<VRVZHT# 2[[24@LX0C;EER0*WP>_;YT'XX:3X2UG3;>PT'1]477HO$5OXEU
MB#2M9\*7>CR""\MY+-@PG\F<2)-(DHCB"H^YUD4T >%_'+PEXVB_:;\/?M0>
M%OAKXEN_['U6#P9KG@M]/*:OX@T-7EC&N" .4-Y:33RO;!\-]CEN5+*\ZI']
MXV,WVFTCD"NOF*&PZE6&1T(/(/L>E<19?M/_  UU*RL+FW^(7@:>VU2__LJS
MFCU^U:.[O,QC[-&0^'FS+$/+7+9E3CYAF/XE_M5?#;X.Z1XKO/$GCKPKI*>!
M].;5M>BFU.'[1I5J I\V6(,9%!WH%RN6+H!DL 0#T"BN7TKXU^#]:N]"M;?Q
M1X?DO/$UJ+W2;4:C#]HU*$J6\R%-VZ1< G*@C@^E27/QE\'V5M=S3>*_#<,.
MGE%NI'U.%5MB[R1H');"[GBE49QEHW Y4X .DHIL<JS1JRLK*PR"#D$5Y]^T
M[^U#X/\ V0_A?_PF'C>^DT_0_P"TK+2VECC\QDDNKA(%<K_SSCWF61OX(HI'
MZ+0!Z'133)A2<=*^>-7_ ."D?AOPYI_Q)U74/!/Q&M_#'PAUR;0O%FNQ6%K=
MVNE-#;0W<MSY,-P]W););W$,C/' Q56.5&Q]H!]$T5RO@[XJ1>.?$MU;V&G7
M<V@KIEAJFG>(4F@DTS6EN_/(2W9)"[-&L4;L614*W,6QG^8+TRWL+NJK+&S,
MN]0&&2OJ/;WH DHK)\3^.='\&65O<:IJ5C8PW=[#IT#3S*@FN9I!'%"N>KN[
M!0HY)-:@D4G&X4 .HHW8_G32^!Z^GO0 ZBO.?@A^T[X?_:"N;YO#UGX@;3+>
M&*ZL]6N=-DATW6K>1Y8UGM)S\DB[X9 5)5P-C[?+DC=[GBS]HSPKX+^)/@_P
MG>7TCZQXYU>ZT/2TMH7N(_MEM83:A+%-(@*PL+:"1P)""< #)- '=44F\ =:
MR/B!\0-%^%7@O4_$?B35+'1-!T6W:ZOK^]F6&WM(E&6=V;@ 4 ;%%>=_#G]J
MCP3\4_',?AK2[_5(=?GTIM<AL-3T2^TN>XL5DCB-PBW,,>^,/+&I*YP7&>M>
MA&10?O"@!U%-\Y<_>7\Z/,7'WA0 ZBF^:O\ >7\ZY]OBMX?3XFV?@TZI:_\
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MAOXB>$_%WQ%\+6>LZS8+J%O:V]K:)M,]O:W:HUP8EA$JQ7(C!1Y &"A":/\
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M\:?XN:\AN)-3U+3M,%I?2/:1_9=EQJ=K)YJ"53"SX&]-C==J_P#P4+^)%O\
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MI(X->^6X:.^>22;+*71 L4:@AN7^)_[./Q8\=Z1XET.W\#_%BU\*>)/%NO\
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MG3=%^#?AFPU)[JSMY=:MO#>L22ZG.RF9&C*V)"G(4R>840,*V)?V$/%WA_\
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MXK6UWXF:'I.L_P!C_P!JZ3)X@FM)+VVTEKZ..\NXU5CN2,G<5^4C< 0,'T-
M'S[^U3\:-4^)_P !KC5OAWX7^)1NM/NM*DU:[@\-7^D:Y%HLNIV9U6VL4N(X
MKHW36<<K;($+#RL*1-Y0/B^I?#[QU\0/&GACPWI_B+X^:7\)_$7Q8NX]*U"Q
MO-9L]5M?#K^$Y3*ES<NOVF&T_MLD6[W!5E&SRV$8B-?7_P"RC^TSH/[6?P+\
M)^,])\FSN/$V@:=KUQH[WD5Q>:.E[;I<113A"=K;7[X#8)&17<:QXLTGP]>6
M=MJ&IZ?I]SJ,WD6<=Q<)&]U)Q\D88@NW(X7)Y% 'YD> -8^-%\OB+5OA/XQ^
M+7B[QMH&N_%31[O3?$-Y=7>A"VL[S5H-"2,W*_9VN$O(K".)T9F9/M".2D>V
M/I/'WC3QA?6<C?#GQE\<8?AOK>K?#R(ZCJ*ZC-KFFZA<:WY>M0J]U&TL<8TP
M1/<QE?(@?. A,B#ZD^%/Q+\(_";XWZE\(/ASX/U34K?3]7DU7Q7=VFII-%X?
MO-6:[U%IY5N)C,XEF#M)Y8(1[N'"D,^SI/VAOVL['X'>+]+\+Z;X=UKQUXVU
M;2;[7[7P[HUQ:Q7]Q863VT=S)']IEBC9P]W J1[PTC.<8".R@'Q_J'B[QSX;
M_;ET/X?V'B3XX77A>QU^?P7J\^J-J-U)?63^#9);6[2Y@A6VB1M0B5Q=EVNG
MN#-EXXT"5Q/PI^-_Q0^&7[+/PFL_ VI?$6\;2OV=+*ZUBQNM.N+F\T^^AU32
MK74+E(IXMSZA;VIU/RH6#;VMP%C< AOOSXH?M4:;\%?V?M'\>^(O#^O6*ZH^
MDP-H<;6TFI6<NHW=K:*C@3>4WDRW2>:8Y' 56*[^ WJ"SPN^WSD9LG@')R#@
M_ET]J /S\USXF_$+4OB]H/AOPO\ $[QE-\*/$7Q1TO3-(\26OE7=]<6$_AS4
M;C4++[5+#)YEM'>Q696X(W1RW#P^8#&J+]*_\$U/B7KWQ;_8A\!ZWXFU:\U[
M7)+>XM+G4;N%8;J_%O=S6Z33*JHOFO'$C,550S,2  0*]4\>^//^$+LM.FAT
M37?$']HZI:Z6Z:5"DSV8FE$9N9@SKM@BSND8995!(5CQ6\)%+-Z]#@=.] 'Y
M?Z]\:_%OQET6[\-^(/%E]KUS#\6_ EQI7B31[F"^TB2WE\4S,GD0/;))8W\,
M=N([BTN1*D?V>*0%P[[LKX]_\%$/B#\)?@5(UK\5+V/Q-X.N/&4D%YJUI:6\
M.NVND^+180/.R6S"ZN%L!'O@@C@0Q3/</(F(Z_57Y1MZ_D>:"JF/VQ^= 'YS
M?$;Q%HMY\5O'4BWVFR+>?M9^#XXV\U&$CKX?\/E=I[G=&X&.Z,.Q%?4__!1W
MXQ:]\!_V4=0\2>&?$ECX3UJ/7O#VGP:E>V\5Q;P+>:W8VDHDCD^5E:*>12 5
M;!RK*P##T#X4?&KP]\:[OQ=;Z+]M:3P3X@G\,ZH+JRDM]MY#'#*X3>!OC*3Q
MD2+\K;C@D<UU']JZ?=ZG-IOVBUFO;>&.XEM=P:6.-V=4=DZA6:.0!B,$QL!]
MTX /@/P1^VEXPU?XHZQ\-?$WQJL_"NDZ5XG\::+;?$"XM-)CN)KO3%TR6STV
MX\R(62RI!?WDTBB&-Y4T[@IME+=5_P $Z/VA?&GQQ_:M\27WQ \37VCZ]KWP
MD\#>(_\ A G>**STBXN1J?VV:VMW07*IYJQY+NS S*DA;9$J?:=UHMEJ4*QW
M%K;7$:OYH62(,NX?Q<CKSUZT\Z39KJ37OV6 7C1B$W'ECS3&&W!-W7;N).,X
MR<T ?#?_  4>\;:]\,OVP])\2>$_&GA/P#XBT'X*^+]3M]1UO3%ODO/L^I:)
M.+789$.QF0!RNYPKML"NP87O@;^W=\1?C)^UXOAB^U;X;>"Y-#UC3]*UWP%K
M&IO'XA>UNO#MOJ1N+:V%N9'G%Y.R++YXM_L]M.K1B9"X^S=<\&Z/XIN+*;4M
M+T[4I=-G%S9O=6R3-:2CI)&6!*,/[RX-,?P%H<GC6/Q(VBZ2WB*&S;3TU4VD
M9ODMF<.8!-C>(RX#%,[21G&: -96W"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#XP_X.'+G[+_P1>_: ;?'&6\/(F7&0=UW;KCZG. >Q(K^/!_O?_6K^
MP?\ X.+HS+_P16^/JB3RO^)';G=C.<7]J=O0]>GX]NM?Q\,Q)Z_K0!_65_P:
MJ;?^')GPSVQ[/^)GKN3_ 'S_ &M=<_T_"OT4K\]O^#6:V>#_ ((??"%FC\L3
M76NNK9_UH_MN^7=^A'_ :_0F@ HHHH **** "BBB@ HHHH *X7XY? /2?C[9
M^&;?6+S5K6/POXCL/$]J+&98_.N;.3S8DEW*VZ(M@LHP3@<BNZKY_P#^"@]S
MXBL/!_@*XTW0_%7B3PA;^,;1_'.F^&X99]4N='-O=*ICBA_?31I?-8R31Q9=
MX(Y1M=2R, =A\*OVCO!?QN_X1_\ L"UU:]M-2EUA+&XDT"YAMK2;2+W^S[I)
M'>,+;R"?<L:N5:14D9 RJV/0+_PEI>JV5Q;76FV%S;W3^9/%+;H\<S?WF4C#
M'CJ:_,/P-\+?B9X"_9:M]'\.>%?C%H;?\*W^,T-K8(E^EW!?W7B".XT-9,.2
M+V2%I7MY&8R$,Q#_ #'/=?$7X5^+O!7Q/\"^%XI_VE(?#/B3PQI^HZ)KWAQK
MK6+K2_$YOVN-2&IRW)D%F)HC:*HN5%JD8NX@L>[8P!]_:CX>T>&]@U:ZL=-6
MZTN)EAO)8$\RSCP=P5R,HN,YP0,9IO\ PAFB7823^R=+DYE=&-K&<&88E(X_
MC7AO[PZYK\Y?CMX3\5?'C]GK]I3P_P"(/!?QXG^*%IX;\9Z==00)J2>%_$EK
M+<F?1FTTY\F[F%M':QPQ6G[Q=UVDZL\A\SNO$]W\0M?^*>N0Z':_%O1_$5CX
MO\'W7P\=[354T-_";IIO]IP7@=?LRRJG]LBY6\Q<*WV?;\ZVPH ^V-.^%WAK
M2(H8[7P[H=JEO)#-$L-A%&(GA3RX67"\-&GRJ1RJ\# KD/%G[,&F^*/B7X7U
MI-;US2M!\,R2W9\)Z?\ 9[?0]5O3*LT5Y<QB+S7EAE!D3$BKYFUV5F4&O#OV
M(O&#?!SP%:>(/B)K/Q@F\0?$SQ]K'A;3[+Q1#J4T6FQIK&L2:8!!+&/LL,EH
ML2K<2 ++FW4N?D%8?[?WB_X@)^UAX>\-6>O_ !6\'^&-9\.0S>&-8\&^%KW6
MX3XABU$O/!>&W<0Q[K9;58Q?J;1HY+LL5*$T ?:US:1WEJ\,T:2Q2*4='4,K
MJ1@@@\$$<8KDYOV>_ -QX>;2)/!/A%]*DTEM!:S;1K8V[:<QW-9&/9M^SD\F
M+&PGG%?%/C7XF_%SP7^T=\1(O"=S\1O$WAOQ%:>)=4^&:W=I>-;6GBVRLF@G
MTN]=E"KI+R*);$3;8I)OM 5BHM-V+XP_:,OM.^!OAWQ5X/\ %7[17_"N?$'B
MW3;3QG>^)O"FKW&I>%X3I-VLHCB1+?4%B.H1V7VF2!S##)*5AQ&9$4 ^W=1_
M9'^%>KZ-_9MU\,_A]<Z?_:!U?[-+X<LWA^VF$0&ZV&/;YQA C\S&[8-N<<5I
M^*?@/X$\<2ZTVM>"_"FL-XBTI=#U8WVCV]P=3TY2Q6SGWH?-MP7<B)\H"[<<
MFOSJ\?\ Q,^+6C>+-2\-:3\<OB1JGQ"\->"O 6I>%=,FT&#3O^$QU&YU+5+>
MZDO+!H7E19[:")KB(NAA0/,XC\O]W]1_\$X(H[&__: L;K5/%%QJMO\ %36V
MNXM8FN7:Q@=E-J(7F&/*-MY3)L) 0Q]L4 >L?!7QW\*O#VK3?"OX?W7A'2YO
M!UH2/#6AP16D.F6ZS-$WE01JJ*B3!XVV#"2 JV&R*DU?]D/X4Z_I]Y:7WPS^
M'M[:ZAKDWB:ZAG\.6<D=QJTT;12Z@ZM'AKIXW9&F.9&5B"Q!(/P'^S'\2+CP
M5\(O!?A^Z^)'C;P/X!\2?\+$U.W\3QE7N9-=7Q&[V5H\D\+;7:VEFNHK=E'V
MQMQQ(J;&]Q_81\=?%SXV?M$7US\1O&WB+1;GPKX+\(7^J^";?3K*WTU=7O\
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ML?'35[C2)?"&AZ5J.MS7'AS4TUFWNK.T:7Y[>4+'N=UB_P!6ZH\;L8W"LK8
M/*?#/_!*JZ\'>&-9TBQ^)-T]KXW\-ZMX1\7+/HB.NI:?>ZKJ.HH]LHF MKFW
M.K:A$DC^<C+*A>)C&,]1;_\ !.B/3/'$.I6?BA8M-MOB-:^/(=.;2052*#P\
MN@C3O,$P.W[.HD$N,AQC:17G?A7]LGQY\+_VL_BDWCCP_?+9W6K?#GPW8Z!;
M^(4O[/1)-9GN;66ZA8PQCY9)83,FW+>0Q5V&S/7:+_P4!\8?$+X]>'_#OAGX
M>V-YI=Q:^/1>+/K0COKB[\-:M;Z7Y4 \OR]EQ+.C*SL" ^&V["7 ,/P#_P $
MN/%G@']G:Q^'\?Q5TN^A\%ZOH%[X+OIO!4$4UC:Z/J$%Y;0ZD89T;4)2L"0F
M56M\J-VS>6=L?XC_ /!)#Q5\0_&/C76+GXJ:/<7WC+PWXU\+2ZA?>$FN-4-C
MX@DMI((YK@7H\Q=/^SB*&-42,0X4(K;G;W_]E']L73_VN= T76- TBYM]'U7
MPKIOB*>XEN%9M.NKPRYTR5 ,K<P"%O-4X*%D!'S UA>!_P#@H#IGCKX@^$]-
MM_"^LP^'?B)J6L:+X2U]IH6M]8O=,6X>:)XPV^!94M+MX';(D2W8L(RR*X!R
MOQV^"$GQV_:I^$/A^70?&5C<_#>T75->\6VEDEKH&N:5-$Z2Z%YC.SR^=>VE
MA/);A3MCMU+.-P#^Q?MA?L]G]JC]F;QA\/X]8F\/W/B:Q,%KJ<<*S?8+E666
M"5HR0)(UECC+QY&]-RY7.1X1^R1\3/B+\6OV,_%WQ@\2^*->TS5/$&C:Q-8Z
M.!I\UCH,EO<7WDW%H5AWY$8BB*3-(C?95<KN=R\_PB_X*26/A?\ 9T\(ZIXI
ML?$?B(Z#H/A:/Q]XHM8K46NBZAJUI9R+)-'YD;L +J&>8P1$11W", 1N" &5
M??\ !/WXN^*O%7B#6M<^(/P[FNO&?C'3O$/B'3;;PQ=KI.I6=OX=;2);*2)K
MPR.AF$-R%,H5Q%Y<@='9:PM._P""4'C2U^!D?A.;QSX3N+N#X=^!O <=RNB3
MQQ9\.ZI-?-<,OGL6%PDQCV9&UE#$D$H/<-%_X*!Z%X@M/$BVOA'Q[)K'A'Q!
MK7AW5-$ATV*ZU2*72['[<\T=O%,S30W$3VGV?9EY#J%H"B>9\OG>O_\ !0:3
MXO>)_A[!X(FO]#DL?C%;^ _%ME(=/U!+U)/#ESJI@CN(9)XBI$MFQ>*1762-
MXR0 P(!R?[1/_!+?XD_%B+XE6&C^//"MIH7Q.U;Q1?ZC8W=C>1B--3T>PL+/
M<\$RO,;=[%F>)B()?M09D+6\8;SF_P#"?C+PK^VZMC)X5M/$EUI6I^%;RYT7
M^RM<TVUUJ^L-.CMAJ]M=+;S64B1B:;:9IX@/L<"S*#$DC?1GP"_X*AZ3\2=$
M^'LWB[P;XD\!S?$N3Q*=(EO9+.;3XTT:68R1RSQW#;9WMHGF5-O(@N2/DB+G
MN/VA/VQI_@?^S[X1\=6_@+Q7KDWC+6] T:'0U%M;:A8-JMW!;J9UDE"*T9F
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M%7AGP3JNE^&O!D]AILH87<GAO4)O$%WJD=G9K+$"+:TAN8X(9@48+  (U!X
M/K;QAJ7AG3]9T'^W;C1(;YKP_P!C+?2Q+*UT4:/_ $<.<^;LD9?D^;:[#H35
M?QM\8_"GPVT77=1U[Q#HVD6?AFP;4]6DN;R./^SK55+--*"<H@ )R1@]LU\E
M_P#!4K]DKXI?M*^(9E\#^%O"FL6!\(/:17=QJB:=J!U"+5[&_2UDD>&0_9G6
MT5T\HI^_B7S6VA2O.^+/V'OB-X_\%_'3P=K'PS^&]UJ.NZ=XY7PQ\0KC5Q+?
M:HOB(2RPV,D/D"2+R&-K;RRRLR>3IUMY:MG$(!]S>'O'NB^*[73YM/U2RNDU
M>T6_LPLHWW$##*R*A^;;@]<<=*T+W4K73C#]HN(;<W$@AB\R0+YCGHBYZL>P
M'-?&?PG_ &9/'6G?MC^ _'2>!5\*:5;:5:V_B.SU&XTK5-/M$CT66")]-EBQ
M>6FH1W$IM98D#6,MOYDBGS2";_[>W[+GBCXT_%3Q1(O@.W^(GAWQC\-9_"&C
M,U[;P/X*UIKB=_[0/GR(8HIEGMF:XM?,N(CID96-B5H ^E_#OP7\.^%OC)XF
M\=6<=TOB;Q=86&F:G*]]+)#+!9&=K=4A9C'&5-U,244%O,^8G QUGF*&"[EW
M-T&>N*^6?V+/V,O^%4_M)_%CQQXN\*V=SXLU/4M/31O&$_V>2\U6T70-)LKR
M1=CL\'FWEC-(Z,%+[HV.[^'C_BM^RQXU\9_M1^*KN3PK)>:CJ'C_ ,+^*_"G
MQ!BN+8#PUHMBM@M_I+;W^T1EOLNI 111M%,-7^9AF;8 ?;'6L'2_&S:EX^U?
M06T76[6/2;6VNEU2>!%T^^,QF!BAD#%FDB\K,@95"B6/!.[C\U;C_@EUKM[X
M"M;>\^#\$E]J'@;XH66KP_:[)OM6H:AK45[X>BE(GVR.D?VAX6)9;5Y.&C;D
M>A>/?V7_ (B>(CX\DOM!\=6,WB#PY\/H(M2TZ/3M7:75--^W27<ES97%P([R
MW1Y+6.>)F4RIN,;$HK  _025_*C9MK-M&< <GZ5A_#7Q<OQ%\#:1X@_L?6M
M;5K5+K^S]8M1:ZA8[P"8YX\G9(.-RY."*^'/A]\ /BEI/[0'P5\17WP^^RW&
MF^%M,TCQ?I12.YT+P\D6EZBIDT6\^U&ZAGCFF^S2VTJS0SK/$P?,1F'!:/\
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M]F$5;^G_ /!2+2QXOT+0=4\(Z]HNIZAXKU7P-J37-U;+::)K-EIK:G%#),6
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MQD2PR/#*"T>[R_+8OL )KU+PCX^TOQQ=:S%ILTD[:#J#:7>DPNB)<(B.R*S
M"0*)%!9"5#;E)W*P !M4444 %%%% !1110 4444 %%%% !1110 4444 ?"O_
M  <MZ@--_P""(/QVD90V^STN'!./]9K%BF?PW9K^0UG8'BOZZO\ @YN3?_P0
MZ^.7^LXBT5OD&3QKFGG\O7VS7\B>S/3^= ']='_!L1&T7_!#7X&!I%D)CUML
MKVSKNHG;T'(SCZCO7WM7P;_P;(PM!_P0X^!:L&!\C6&Y8-UUO4#V^O3J.AYS
M7WE0 4444 %%%% !1110 4444 %>8_M&_':;X4ZCX$\.Z5#'<>*?B9XA7P]H
MXE4M!:E+6XO;JZE ()6&TM+APH(WR"-,KOW#TZO(/VHO@MJ7CSQC\*_&FA0K
M>:U\*_%#:V+(N(VU&TN-/O-.NX$9B%$@BO#,@8A6>!%+*&+  YC_ (:I6Z^)
ML>BP^/-#3S/BDW@K['+X,U)908]$^W/I?G>9L^T'!N5OB!;M$1&J,^'-/X>?
MMH23Z5\*=4OM7TGQ1X9^*'B75?"<.LV6C76C?8M0AEOWM4>VN6:0*RV,EJY;
M!,ZHR_)* LK?L&7DGQ87Q0_C.%E7XKGXGFU&BXR?["_L5;'?Y_018D\W;DN/
MN <5A:'^Q%KGAO1O@OX$FU!=<\/_  ]\9W_Q UG6_LZV/VV=I=0GM;.*#S)&
M#"ZOTD9L[?+M",AI   =3^V=^U%K_P '_B#\-_ ?A);.R\3?$RZU""VUC5=&
MO-0TG25M+":Y#SBW*<-*D2-F5 D;2R'A*GMO^"COPETCX?ZEKFN^+H=*M_#^
MCV.MZE<7.E7]K#)97<PMX;ZV$T*O<V;S$*)X@Z*"I9E!!.E^TO\ LDM^TA\2
M/!.J7FO1V6@^&K76;+4M,^PF2758=2L&LG"3^:OD,B,S ['R3CBO'?%G_!+[
MQ+\0OA#9Z%KWQ&TJ_P#$'AGPE:>"/#^L#PVZ :?%J.GWDTM[%]I/VBXF&F6B
M$QO%&C"5U3$FQ0#VCXH_MP>"OAA^R;J7QFD7Q!JG@_3[?SE%IHMV+Z=C<?9E
M06TD:S(3,0I,B*%&6)"C-<C\+O\ @H-X?UK]J/X@_#'Q1?Z;I&IZ1XMLO#GA
M>/[)=1R:H+CP]8ZPJ7#,ICAN#Y]TJ1N8VD6U;:I*L!Z%^V)\ KK]I[]F7Q?X
M%L=6AT'4/$%F$M+^:V-S%:SI(DL321JZ,\>^-0RJZDJ2 RG!KR34?V _$VM_
M%"^\4:AXPT&:XU3XI:/\1KN*#1)H4*67A^WT:2T3-RQ5I/LXF60EM@8H5?&^
M@#V?X3_M4_#_ ../B[5-!\*^)K'5]6TFUBOY[>-9$,EI+))'%=PEU43VSR0R
MJL\)>,LA 8UD-^W-\(XOCBOPUD\?>'(_'4FI-HXT62X*7/VU;9+K[.00 )6@
M=9%4G+KDKNVMCS[_ ()\?L0>(/V.-(_L;7-5^'VO:;X<TN'PUX9U'1_""Z3K
MD^E0$"!=5N_.<74R(J+F)(4+>8[*S.-GGOA']F3Q-\>_VJ_BZVKVL6A>!]'^
M-6B^-K2:[T6ZAU'6)--\.Z,D+6DLH$3VYO+<HTR!OE@FC',@= #WZS_;T^$.
MH:1?:A#X]T%K#3IK"">Y+NL(^WW#VME(KE</#<7$;Q13(3'(ZE58GBK/Q1_;
M=^$WP3NKR'Q?X^\,^&YM/>YCGCU"\$+JUM!#<7  /+>7#<P2-MSA9 3WQ\?:
M]^PIKGP+^'7Q NOBY)=?%K3_ (F>"=,^'FH0>"_#>H77B"]O8+V_DM=07=,\
M=LH^VJWRK%!:-#&$\N*,$>L7/[!'C?5_"/PO^W^(O#^J^)O#WA#Q)8>*M3O;
M=UDUG7-9LX4EO(Q$H58A<))E< B)D5<!<$ ]V\.?M??"_P 9:=XDN])\?>$]
M4MO"+6RZQ)::E'.MB;D?Z,&*DY\XG;'MSYC95<L"*SM?_;N^"_A33M.NM6^*
MG@'2H-6MOM=JU[KEO;F:$7/V5GP[ @+<9B;(&QU96P58#YH\5_\ !+3QU=?#
M*^L]*U_P&VN:?X/^'>DZ+%J6G3W&DW.H>%;N[NF6^A&&:SN6NO+ C(DB"A_F
M8 4SXF_\$S/'7Q#\">)K6UTOX+^%;[Q5\'O$_@:;3]"M;FSTJSU?6[R"XEF4
M"$M);CR=TDK*LL\I+&- 0% /K7X<?M+>#?BQ\6/'7@G0=62]\1?#>ZM[+Q!;
M"-E^Q33V\=S&H) #?NY8R2N0"V,Y! O#]H+P))\0[KPBOC+PN?%-G%)-/I/]
MJ0_;(4C57D+1;MPV(\;,,959$)P&4G@_V?\ X'>+OA?^T=\8O$6J2>'9?#/Q
M$OM*UC3X[6:=KVTN8-)M-/N(959%C\H?8U='4[F\TAD38"_F?@#]AGQGHGQ3
M\/Q:M-X1F\)>"/BIXA^*&C:O:7,Z:W=MJRZJYT^: P^7$L4FK2H9EG?S8;>-
M3$I<E0#T3]C']L&X_;(TV^\3:/H.DI\.YFF30]<M?$,=]<7[PW<]O(ES:K$O
MV5B(DE3;+,&289*,-M<]XH_X*,:))X^^*&A^$/\ A#?%B_#?PKIOB!M1'C6S
MM-/N+F\O+VU^P3SE6CM'1K/.^1CGS5&T8YO_ ++_ .R_XL\ ?\$_E^%?BC4M
M+TGQ7<:7J^GSZEX>N9;FWLGO)[IXY8))8H9"R+.IY1?F4\GJ?F^\_P""=7QV
M\?\ P/\ B%H.N:+\%='UCQ)\(_#7PVL1IFOWQLYKG2+V^=KF3.G!K>"2&[W1
MQ*)FC90A9@2X /L[XM?M=?#'X#Z/XDN_%WC[PGH?_"'Z<VKZS;W.IPK=6%J-
M@\UX-WF@$RQ*ORY9I8U&2Z@I\2/VG_#7A+P-K%]HNK^%_$FO6.ES:G9:*GB.
MRLY-1$<22X$LL@CC4K+$3(Y"*LJ,2 P)^5_VCO\ @GW\4/BEXT^/DGADZ#H^
M@_%#PEKFFC3=1U@WUEJFJW%O8Q65[$K6OGZ:SK;-%=K'-)#((;>01&3+)-\8
M_P#@GQXN^+/@[]K34KKP/\.T\;?'#2K.T\.SMJ'VE[0_V%::?/%+<M:J\<<<
M\#,K(I\Q-A*HWR@ ^F?A1^U1HOQ(^*OCSP;=+;Z#KG@G7QH45M=ZA"TVLC^R
MM/U)KB",'<8UCU!%/!(,9)P"*WO'O[1G@/X8?#S4O%FN^,/#FF^'=)TTZQ=7
M\NH1^3': [?.R"=REOE!7.YB%&6(%?+?B?\ 8 \0>.OVJ]>\27OA7PK;+J?Q
M0\/_ !(L?& N5DU32[33M*L+272T7RQ*))9;.:,[7,)M[^8E@^8W\=?_ ()G
M_&C5/@7J_@N[\)> XX-'^$'C'X?:1,FO>:=6O+S5;2\L)#&;<+#"Z6X/+$Q/
MG(. 2 ?7OC'X,?"W]H'XTZUXB\7> ]'N4T'1M/6+Q1<:K ;37K*7SYA;S0Q3
M;I((26(6[C\IOM#&/<-]>U_\)7I-OIL-U_:6GK9W$7G0S&X01R1\?.K9P5^9
M>1QR/6OB;XB?L>_$KQ!\<]?\?6?@/P^FGR:WX)UZX\*#5('A\20Z=I][;7ED
M6(2/S+62[@FMS*%CDET^#)C7!7DO$G_!+S6O$>HZ6VI?#GP_KGAK[%\2;FU\
M/7LUI-#X7;7&M'T_3XU<F/#&&=W$1\F&6Y8*651)0!^A[:I:?;UM?M5O]J=/
M,6'S!YC+_>"YSCWZ5E'XE:"OQ%7PB-6T]O$S:>=6_LSSA]J6S\P1>>4ZA#)\
MH)ZD'&=IQ\5_LT_L?_%'X=_M/?"/Q-?^&VMX='\-:;I/C2YU>ZTW5+9I+?PW
M]F6ZTR="+ZVO%O6-M+$WF6DT&^8;93DZG[=O[''Q!^*7[1?C;Q3X&\+Z3>3^
M)OA?:>'8=4DO8+-Y)[/6'O)]+G?_ %ZQ7]I*]N)$#(H9]^T8R ?;%I>07\"R
MPS1S1L/E='W*?Q'%9/C+X@Z%\/M!FU/6M5T_3-/M98H99[FX$:1R2NL<:$D_
M>>1T51U9G &217BO[%_P4U7X=?$SXI^)1X7N?AWX1\;7FFW&D>$)9+7_ (EL
M\%F(;N[\JUDDMX3<,(U*QN=WV82-AI"*^5?&?["WQ%UKP1\7K5_A:WBC1=8\
M2^'O%>G6.NC1V\27=Q;>*O[2U#3TNUG%O>6BVYG>UENQ#.JW9AD=QD( ?I89
MH]Q4NNX#<5W<@=,UQ?QL^/FA_ 6Q\-W&LPZE/#XH\2:?X5M390B7RKN]F$,)
MERPVQ[R S<D9'!KY ;]D?XI:Q\08AIN@7'@_X@:7XZ\0ZTWQ)CO+9K;5= O;
M.^6PL'V2&X;[/]HTRV^S/$(HSI0E1B$B+\A)^RA\3_B!^S%X?TWPW\*O$GP2
M^)2^)/!R:[K#ZGI>L0-=Z8\ANM<AM3=20SQ(S!S+*([N[ROF1?NT- 'WA??'
M/1=*_:$T?X:2PZD/$.N>'K[Q-:R"'-F;6SN;.VG!DSQ()+ZWPN.5+'/%=DY5
MUW?>YQP:_,_XQ?LC?$;X_?"72_MWP/U+PKX@T3X$^.-!33;#7;:2V@\6W-UI
MDEE);SF[,DC33V<UU#<3G?&QC>5DF&1Z"WP(^*7B'XS7EYJ'A7Q+#XZ7XB^&
MO$'A_P ;B[@^QZ?X7CAL5U'2YF$_F(/)BU6"2U5"DL]Y%.-Q9I(P#ZA\,_M;
M^#_%_P"SMXB^*-K_ &T/"WA4ZR+_ ,S3I5O$_LJXN;>\VV^/,8B2UF"J!N;
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MOA[\,_&UOX;\0>,?#^CZY<_9@EE=7B1R*;F1HK8-GA#-(CI$&(\QE95W$$4
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M "23P *J^$/&.D^/_#EIK&A:IIVM:1J">9:WUA<I<VURN2-R2(2K#((R">E
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ME=!\4?&._P#!>FZ?XBU&?2KF;3[_ %6VTYY=)L;V*W@N7M)IUSY<OD7,+@N
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MJO@+X7>(/B-X7TF\TWP7=^+OA_:_VCX>L76!M0\/6[+]F\^VB_UD$;*#%O0
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MM\1OC-JNFCPQ\.?"=I8VGP__ .$U\2-K?B&XMY=/DBOM1L+JUM1%:R"X7SK
MM%*WEAXR68(2JF#X<?\ !5#QUJ5SX8TKQ?\ #GPOH^O?$S1?"FL^#3IGB.:]
ML&76FEC>*_EDM8FAEMS;R2!8UD6965%8,":^@/B3^S3\/O"'A+6M2TNS\+>!
M=9N?!G_"O[#5Y$$-KINGL76UM?*WHGE)/*"L8*DEMH8;JP/@E_P3B^'?PY_9
MKTGX?ZSHECK\L>B:'I6K:EONH9;Z72$3['- S3/-:B"96F@2*4>0[DH0Q+$
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M0E]\&_CM\)]%9M&M_#?C&XUA-:NKP.);.*STR:\26-]P1%!B(?>K?*1C&":
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M_P"%_AGJ_P 1;*&YT^Y72)8K-'$<4UTB[%WRK@@'<%![LH.Y\-_V\?AC\0?
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MK:Z=5O=,MEN]&B_L^SL3:Q3A1)Y'E62,=S9S))G@XH ^=/V;?VW/C9\9=/\
M@_8:QK'PCTO6OC5I^N:KI-[:^&]0>QTX:3Y4;6;(VHYN;BX:<3KM>+RX;2Z7
M$AQ*I\/O^"D_Q(\4WWPSL=6T+PKI&I?';P3;WW@6%;.YGC;Q!!<K%J<<S_:%
M\ZQ2VFAOX2@CD>VBN2261=WK5I\7OV7_ (B>$M+\!1M\.;[P_8RV%Y8:&^B(
MNGV37TDBV,Z1-$(XOM,C2K%( !*6D"ELL*]>^%NO>!_C?X%\(^,/"RZ/K.@I
M#]I\.W\-H%6WC:-H-T&Y0T0,99. ORDCI0!\C> _VG-7;QYXD^'/AW2?AGX4
MUGQMX\\>;]0N=.N6L=1CTE;97\R!;E&FU"X6YC9V$J+Y=K<.(_E"UR_[!G[7
M_CJP_9W_ &?_ (>>#])\+7D?A7X0?#;6-<;6KY+62^LM3A%K/-!*UPC(($MF
M*GR)_.F81'R\AS]I>*OV2OA?XXT&33-9^'O@K5-.DUH^)9+6ZT6WDBDU1A\U
M\RE<&X8$@R'YF!()(.*\W^)FA_LL?";X@>$[CQ=;_!7PSXD^$NF+)H$NI1V%
MK/X-L3\J,A;'V. D81FV+N!V\T >2?LO?M ZQ^U1^W%\%OB/<R:!!X;\:?"?
MQI>:-I]DDZWE@D>N^'(Q#>,TK1RSHO#;8X_*D::/Y@-S='^W%_P4-\8?LA?$
M/QEH4/AG1]>N_P#A%;7Q;X%LH_.^U^)HK6Y9?$%KC> 9[2U,-RFS@I+\P^4D
M^]^ _P!D/X6_#+XF7GC;P[\/_".A^+M0DNI;G6+/2HH+R5KIXWN29%&[]Z\2
M,^/O,N3DDD]GK7@71O$.NV.J7VEZ?=ZEI<,]O:74UNLDUK'.$$R(Q&5601H&
M ^\$&>E 'QA\7OVQ-6UK5AX]\*Z=X9NGD^$GC[Q;X%\0M<WL\$EG8SZ0+:26
MV21(9XKOS$G#YWK&L00KYD@/*Z1^TO\ $/X'_M"^*_&%U;Z/XD6\\(?">+Q1
M'/J%S;1K)JFJZMI\TUC!M=$ES/%(V2H<0*I&2&3[2G_9B^']PVC%O".@[?#N
M@3^%=,3[*H2QTF=8DFL8U^Z('6"$,F,$1)_=&.;TK]@3X.Z%X9FT>U\!Z+#I
MEQ::/82VX,FV6'2;AKG34;+Y/V:9FD0GD,Q.3F@#PWP7^U9XN\/^+6\,^!/!
M/AV;6/&WQ7\7^'7EUKQ/?O:V\MC:SW4=V2T4KJDOV<*UO$%CC+X3C)KM_'OQ
M:N/VM_\ @DM>_$2SNO$G@/4O%GPWD\56<VB:M-;7^A73:<;J,Q3Q-&7,4N.&
M^20+AU*L5KO==_9M^$/PEANO&FIZ;HOAFW\.ZIJWC*YUFYU"2SM],N[Z!X]1
MOWE:14CWPM)O9B%4%B-O)KHM/_9M\$V7[/$7PKL]&6S^'\>D?V%'I-M=3PQI
M8;/+\A9%<2A-AV\/]WC.* /F7X4?&WQ1XL^-'@?X%_%[7-0TWXL^"]2N9KJ[
MTG4+G1[7XEZ$VEZA%!K$"02+UD6(W%N&)M;I 1\CPN_DO_!(']H?QQ\8/B/\
M%]-U/Q-XZMV;X%:?XI\6VOC'66U'_A/+F^-J;?5=*5GE*);R"YCN7WQ;3=VR
M&!BPD3]!O%_P1\+^/]?T'5M7TN.\UGPM'=1Z1J/F21WFG+=0&"X$4RL)%\R,
M@,0V255OO*K#C]"_8;^%WA/3/AC:Z;X8^PQ_!E6B\&/;ZC=QSZ'"T8C>W642
M^9) Z*JM#*SQL$0%2%7 !\X?L&?%;QEX2_:0TOX<_&?4_B#IOQ0FTK5;N"ZF
MU ZIX+^*-LMS%(-3TR7E;2:WCDC#686'RX[D964*LB]U^WE\*/%>J?$SP1?>
M&_C)\5O"FL>,_$>E^&],T'0;FQATB.WC:6]U"XECDM9)9)/L,%X2QD"Y6!0%
M.6;U'X%_LJ?"WX?WVA>(O!D%Q>KX?T^?1=#FD\27VL6>DVK.BS06D<]Q+% -
MT"(WE!2!$$R%7:.U\1>#O#,WQ5\.^)=2,/\ PDFFV=YI6CF:\95"7!AEN!'"
M6V/(5M8_GVEU17 (5W# 'Q1\&/VEO'NK_P#!6[5?!FK^/+@^%)M9\0QZ0N!+
MHWB6"VL-.QH]JH3$.H:=.;B6X<OF16<*9,2):^L?M[?#WQY?>-?"EYX0^-'Q
M'\'ZQXLUW3/#&C>'M#@TK^RRHDDNK^[N?M-I-/(ZV,-XYV2QKB&)0H8EV]"\
M(?L5?"J'XIR_$;1].FEU:^O;_58)H-:NI+"VO+Z%+>]O+: 2F"&>:./:\L:A
MLM*00TLA?I_"?P,\*V-[X*O;6XU+5)_AOID^@:1/=ZM-?R0JR00RO.\CLT]U
MMMPAFF+2C?-DYD?(!\I?'K]J#XH?LQ_M*_%[Q%XRA\:1>']&\$:[XG^'.DZ=
M?:=>>$_$4>EZ='/+!>*+1-1MM1+EI IG,#HS!23%\VU\$O&/Q+\<^-/$WPQU
MCXLZG9>9\.?"7CVY\6V]E8_VAI4NH2ZK#J$5KYD36T4+-IT3Q&:*7REEN ,X
MC,?T1I7[-/A3PSXBUK6-4NM<U]];-W#Y?B#6)]1M=/AO67[1;6Z3,5BBD8*-
M@Z !%P@"CB8O^";'P_MOAGJ_AFQU+QSIL&MPZ78SZA:>()X]273],W"PT]9_
MO"UA#.-G63S)#*TC22,P!I_L$^)/&VL_LPVM]XZU:^\47ZZEJ:Z3K%W8QVFH
M:YHZ7LZZ;=W$,:1QK/-:+#(0B1AMZG8A8J/-M$_X*W>']6CU* ^ ?&,NL:;J
M?A?3I-,L;O3KJ:-O$%S-:V:R.+D1)-%<6\L5S%O)A8<,ZY8?0'PR^ FF_#3X
M<:AX9;5_%?B2UU9YWO+O7]:GU"^G$JA&7SW;<JA %54VA<9'))/BO@7_ ()/
M?#SX<KHOV7Q'\1;J/08O"]O:QWFM)-&(?#EU<7&E1%3%@+&;@HVW!D6-2Q+E
MW< Y'X[_ /!3&7Q%^QUXSU+P7X9\::3\1(?!/BS6C8*=/:]\*2:-/<:=<2RM
M)*UO*4OHF$:H9!*L3MC P?1_VF?$7Q3C_8U\.Z_\,_$FG6/Q(+:&UFNK6T<V
MDZ[-/-;1/:WGR&2.&;S6!D@*21DJP) *-B>-?^"4/P_\4:']BA\3_$30[F\M
M/$>E:A?Z;JD$=UJ^GZ]=RWVHV,Q>!D,374K3(R*LL1&$D52P;VSQ'\#[?7_A
MIX?\+QZUK=C:^';K2[J*YA:%[FY^P3131I*9(V4J[0H'*JK$%L%2<T ?+_B+
M]O+6/C)\$O$/C#P?JVM>!/$'@OP%XMN?$OA*]M;.XN/#GB72DL6%K=&2)F81
MFY9@8V$<\3PR*=K G/\ V,_VS?BO\?=8\=6OAN\L_B-8^&?AUI^HR3ZUI7]@
MW-CXTN;072Z05VPL]E)!);S"0P_()0//EW83WKXR?L ^ ?C'\0_&GBZ2/4M"
M\5?$#P/<_#[7-3TN5(Y+W3)F5LLCJ\9GC =4E*E@LA4[@J!<F+_@G/X8TOQ/
MI^MZ/XH\::#K"^!?^%>:Q=Z=<V\+>)=.2(I;278\DK]JMBTCPSQ"-T,KJ=T;
M;* .1_X)J_M::E^TQ)K5IK7C:34/$_AO3K&'Q3X-UO0%T3Q)X.UIO-^TI)"F
M%:P?"_9W'FY$;_Z1/G*Z7QG\4_'7P?\ M9>!--TGQQ\.SX4\<>*!;1^&6\(W
M%QJ5MHEK9M<7]T]_]M4+(718E86Q1'O+=3N)W'T/X4?LI1> /C7>?$+7/%6N
M>-/%DF@0^%K:_P!1MK2W>WT^.9IV0BVBB$DDDQ#LS# *@(L8+ANG/P8M9_VA
M$^(=Q>7D^H6OA]O#MC:-M^SV,4MT+BYD3 W%YVBM%;)( M(\ $MD ^8O^"<'
M[<WQ$_:F_:/^)GA/Q5_PB\*_#T7-GKNFVD)M[K0M2&KWUO:0P-YK_;+2:PMH
MY6N2 //WJI!\R"V[GXR?$'X]>!OVI? ND:5XB^#_ /PA/C?Q2EA!H=QX9U&X
MUZ/28+)KJ^NFOEU&.%9 871,6C(C7%N&+DG-/X+?\$P]/_9YFOKSPCXY\1:;
MK%GX4N?!GA346L;.XG\+Z?/J$E^5_>1E;UTE:,*UR'PL70M)*\GN,GP<@NOV
MA(OB!<7UU<7%CX=?P]I]BP @L$FN5N+J53U+3F"S5@> +1<8W-D \3_9"_:R
M\:?'S]H+XI^%_$ATWPC=^%&=M+\(:IX1O=-UN"S>XFAM=3:]>]DMM1M)Q QW
M6L4?EN?+8@J"_HO["7QOUK]I;]COX>>/O$MKI=KKWBK1XM0OH=.BDBM$E;.?
M*61W<+QQN=C[U)\%OV>]<\%:_P#\))XR\9MX\\:6^ER:+9ZO)HT&F);6CS"9
ME\B [6D=DA,C;@I\A-B19;=H?LF? 5OV6_V<O"/P]&L2>((_!^GIIT5_):K:
MR72(3M+1J2H(! .#@XSQF@#B=3_X*7?"70_#6J:Y?:UJEEH-AX<O?%]MJ4NC
M71M=9TBS=4N[RS94/GQPF2,L5&?+ECE ,3K(>[A_::\*#X'W7Q$N)-9T_P ,
M6AE#O?:)>VMXVR<P?+:21+<,7D $8$>9 Z%<A@3\\ZO_ ,$FGUK]GO\ X5Q-
M\0KB31_#O@C6?A_X+N9=$5[KP]INI+%"QG;S\7DT-K#';QN1$-H+.LCL6KZ%
M_:2^#FM?'3]G?7_!^D^+;OP=KFM6:6\>N6=L7:W=71FS$)$8QR!61T656*2,
M ZG#  X?6/\ @I9\(?#NAV=Y>Z[K$3WL^L6BV47AK4[J^CN-)&=1@>WA@>19
M(%RQ7&64%UW("PZ7PO\ MN?#'QM=:Q#I/B;^T)-!@T.YO/(TZ[8>3K1 TN6(
M^5B:.X)P&B+JI#!RI5L>)^ /^"6NH> /$$5W;^.]'CM+?5O%>JVUA9^$5L[:
MU.NVD4)A14NL"."5'D'&75]A((\PU_@!^R2^G?M)?#NUFT[QA9V_P \$6?@W
M5-?N[""PT?XDS0V]LVFS0PB::21;)C?29?8(IKDA3)C* 'T?\9/VC?!O[/\
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M<O'?@_P_X5M?&NL7?C30;/Q-:W$'ARY-G8V-RUY&DEW-MV6^V:QFB99""'V
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M:#\,;'7--\)^%_!EQH]KJ$KZ/XB@TW7K/4;F67-J/+A$-K)';PF.0I]KG5B
M<M]B?%/X9R7W[/OBCPKX1TWPO:W-YH5[IVDV.HV0;15ED@=(XYX(P-UN68!T
M4<J6'>O,&_X*>_">/2]8O)+SQ9#%HNJ:+I4B-X6U'[1<MK#^7IDT$(A,LL%S
M)F..1%(+@KUXKFA_P4@T'QO\1/A=J/AK6M-LOAWK@\61^+I=?T^;3=0\/SZ+
M"IFCN%G,;6;02+*)EFCSC:<J.6 / (_^"=/Q@;X?>-$N-!LK#Q%KVN:)XDT2
M_P!(\:Q37.AWUKX:;2I&>&>P2RG@W(L#VIB$#VUU(%4&)0?NA?!>NR?LM_\
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M4+:NL=UL _UA@D=$E$>XQ,Z*X5F (!\(_M.?L0^)OC=+\:M>U#X(C7]7\2>
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M]MWQ'I?AJQ\;>/(?%VIZU\0- \7:[#H]MJ=K-HMA#H%^_P D",B20S20W,,
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M\*P2R^=);6*;%<1>9C:)GE,:@)&43*D ]JHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _+7_@[_O/LW_!(I4W,/M'CC2(\ GYL+<-@X_W>^!QZX%?RU@X
M'I7]1G_!X6RC_@DG9A@"S>/M)"?,1@^5=_GQGK]>PK^7-_O4 ?VI?\$@;:.S
M_P""5G[.L<*LD:_#K0\*QR1FQB-?1E?.?_!(33'T?_@E?^SK;R- SQ_#K0\F
M'.PYL8CQG'K7T90 4444 %%%% !1110 4444 %>8_&#]EO2/C)\6/!OC6ZUK
MQ1H^O> X;^#29-+OD@C07J)'.9$9&60E8T W9VXR,$FO3J^5?^"A/[;_ (I_
M93U1?^$6M_">L?V5HHU_5-+NH[B74)+;^T+:UW[EDBBMH<2R 2LTTCR *ENX
M5V !VVF?\$^/ >C:1H]O:R>(EO--\:V_C^\U2;4VNM1\0:M"AC22^GF#O,@C
M*1A 5")#$B;$0+6+XE_X)G^$=8^$'@WPMIGBSXB>%]0^'^O7WB+0?$VCZK##
MKEC<7LMS)=IYC0-%)#,+N9&CDB8%2O\ $BL.+T#]M3XI^(OVD9O":Z7\/X?#
M]YX]\0> -,N";MKP3V>B'5;2ZF&X(4S'+#+&@R<JZLF"I[S]@W]KW6OVNO#8
MO+[3=-TF\\-V"Z3XQLHED+:/XIBGEAO]-1BQ!2W,(;+?,R7,#\!L4 7/#G[
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M[ OBSPO^T]8^./\ A$=%O=4M?C-:>)I?$IN;9=2O-%7P:-%FG8XWJ\EWND>
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MA\>%C'>?!V\FUR.VU&YD>1-L<=M:R2QJDZ2AQ;I=[GC68R?2'_!*/5['Q/X
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M1-S$N> #V3_@HE\*O$/QW_80^+W@CPIIZZIXE\7^$=2T;3;5KI+19I[BW>)
M97^5!E\[CTQ7(?$+_@FOHOQ,,VO2^//B+H_Q(?Q%9>)[3QK97-G!J^G3VEG-
M900+&MO]C>V%M=74;P/ T<ANIF8$L".%TS_@J%KG@[3O NH^//">DZ;I/BB?
MQ;X8N;G2[^2XSXGT*[NX5L+82*F^.^CL;MX"Q5RT0C(+.IKL_ 7[:'Q"\<?%
MR^T2S^&=OJVB^%=:?PGXFO[#684.GZHFD0Z@TD:S,C/;F>>.U52HD;S4FQL)
M  -+QW_P3FT3Q\/$SW?C?QTUWXJTCPSI-Y=RSVMQ<'^PM3N-3MKC<\!S++/=
M3"7(*%&"HD85<4_ /_!-G3?AQ\9M+\4:7\0O'"Z1X>U;7]:T3PU,MC)IVD3Z
MTKM>"-S;_:&C$\LLR(\I"&0J/D 6O-?A)_P4>\<?'OXC?!6QT>P\&Z;#XF\9
M:EX>\::3<_;H=8T!K?P]+J/V*:">&-X+F*X1E8LI65(X9(VV3$+FZ%_P4HNO
M@I^S%X3U#2? NI:M<:AX9\4^+8[/5?%=S?SZB^EZHD#:3:7<T3S7-[<-=;H(
MV4 )&$ V@; #T*#_ ()/>'[3X22>#XO'7BU;!O .@?#X3&"S,R6FC7DMU;3C
M]SCSF,TB/D;"I!"@C-><_"S]EWXS:'^U1XR\2VNG:SX7_MS7_$%T]_>6OAJ]
ML8;:ZC>.&?3;F/-\MQ)Y.FDK=VVS_1BLOFJB;O3/B/\ \% ?$W@G]H2W^'\?
M@O19;K49+K2K>[76YYXK748O#DFMI]I:.V*0POY4L 1W2Y(03"$Q.IKD?A=^
MV'X\\2^&OAIXHF\%W'B?XB>(/@'<>/DT32O%,UKI&KW?F:6[VBVK0,HN9&G7
MRIV!,>^2+E7+T ?2-U\$;KXL?LI7'P[^)FIMXANO$WA9_#OBB_LP+-M1:>T-
MO=2Q^6%$1?>Y!15"D@A5X \KTO\ 8*\7VV@^!;[5OC5XF\5?$/X;ZLU]H?B3
M5=%LQ"+5[26SELKBSMQ"DR20S,SR;EE,JQN&"H(ZSIO^"H6F^*?"/A75O!/A
MF3QA#X^_LZW\./;W<WEW=S<:3<:O<1RB&WFEC6WM(H22D<C-)<JA1 CL/H+X
M(_$6]^*_P@\-^)M4\-:UX-U'7-.AO;K0M70+?:1*Z O;S!21O1LJ2#@XSQG%
M 'SEXE_X)1Z?K/@KQ1HUGXZU>Q7Q?\/-=\"ZA,VG0RNTVM:C+J&H:D!D 2/-
M/-MB'R(''7:!61^T9^QGXPT;XZ>%_%?A'4KO5;[Q/\6-%\4:I*=(BFM?#5O9
M>&[G2VD>/SXWEAD*P!@KAT,[%>%&/1]7_;WCTOX@6L*^%9KCP3>>.F^&ZZ_%
MJ :>+60"H+VOE_+:&Z4VGG>:9!,5_<^4?-&S^QY^UQ??M3_L^P_$K5O ]_\
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MOA_XU\$WW@VT\.:CJEE?W.F321V6LW<EFMTCP7;QR1VLT,HN"K'8L;,GF#J
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M\3?VI;:KJFEVFBV$5W=:QI6G>6+C5+9!,!-:L9H!#M/FS_:(3%&X=2:.I_\
M!23X;:?\5YO"*MKEWJ$,M[9F6WL/,C-[9Z;_ &G/9LF[SHYEM0S9DC6,NC1;
M_-^2@#V+P#\/[/X;?#_3?#^FM<?9=*M%M8IIF#32X',KD ;I&;+L<#+,3QFO
MA.3_ ()8?$_4OV;%\$WVI_#M]0LO@5=_"&UNH[F\,4D[W,7E7;[H"RQF""-W
M4;F$A*C*J'/IEW_P6,\#:IX2MK[P_P"#_B/JFH7TWA5['3KO1_[,GU'3_$-]
M%966I0?:'426XFD,;8.X2*%("N)*^A_C'\==+^"/A[3K_4K'6K^35KEK2UM-
M.LS<3R.D$US)N.1'&J0P3.7D=5^3:"69%8 ^;/BQ^P+X[\;^#_C;<Z3<^"=-
M\6^,OB7HWQ$\-M-+<O:W TVUT:-+#4'C2*5$EDTI\O$7*"=6 9DPWGOQQ_X)
MM?%3XE_#9=)T7PS\'?#::IIDMY?:98:YJ$$=IK!UV'5"9+S[*9]1BE"ON,HA
M19WDF,,A9 GOEW_P56^$, T&:'4/$E[I_B+1/#_B6#4;;P]>265OIFN7$EMI
M]W--LVQ1O-&4;<0R'E@ &(]4^.W[1GAS]G;1;*\\0_VI)_:+SK;6^GV$MY/*
M(+>6ZG;;&#M6."&1RS$ [0HR[*K 'R3X]_81^,%OXHU#7M'TGX?^(UTKXG:Q
MXNLM!OO%%]I=OXDT_5M.-M,DUQ#:NUG<V[NP1@DZRQB0$1[QB&7_ ()G^*-$
M\4ZE-HOA3X<:;9Q^(OAA>:2;*\DC^Q6'ANXAFO(8_,@:10B1O% I=C()#N:,
M$BOI?_AN[X9W.J>&[:RUJ]U2+Q5%ITME>:?I5U=6D?\ :,9EL$FE2,K"]P@W
M(DA5L-'N"^9'NX+X2_\ !1;PY\;="^&/C"'4H_!'A7QMX=U[Q-<:=XGT6[@U
M!K'3C;AKE;D,+:VCA$P>42ARZRKL(V.2 >!Z1_P3>^*ND?"WQ5HLOA#X=ZIX
ML\+WZ3>&O%EYXLU":7QY8+XIM=>DL;VV>!DT_P"T1V@BG93<*TTI<+LW(WM/
M[,VB?%#]F_QGK$>L?#?P_P"3\9/BIJ&M7JZ-XA:X'AJPETFW87<F;1$E=KBU
M9)%W1\S!U>0G:?2;S_@H#\*])L+R:^\07^FR:?>Z58SVE[H6H6]ZDFJ2&/3F
M^SO )3%<R*Z1R!-A>.1,AT91O>&_VCM%^,?[.&I?$+P#>+JEDMEJ#V+WUE<6
MI2ZM&FAEAG@E6.:-H[B"2.2-E5U*,.#0!Y'_ ,%-_P!G+QY^TAHGAO2O!OA_
MP[K%G+I_B#3=4N+R\CL[[3_MNE36L+0RR0RA89&=HY_+43;'78P7S WAOA?_
M ()V?$+_ (2S3_%&I> ?#,?BB/QW\/-;-^FJP37=I8:3I5K::CMF*!MRM'<H
M%&/-2;K@D#W3]G+_ (*J_#'XC?LS:3XP\5>+-+TO6M/\.>'-5\60P:=?1VVF
M3:O'&L#Q!XV:2TDN&>))E:2,%"K295J^B_#WCW2_%6IZU9V%P;BX\.WHT[45
M\IT$$Y@BGV!F #?NYHFRI(&[&<@@ 'Q9^Q)^RE\4OA5^T;\,[[QAX!T6S7X>
M^%/%WAK6?&-MK%O/+XMN+_5=+O+:^\H#[1^_%M<2NLN#'++*.1M>3US]M_\
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MK*MTCJJR 997#*S?5^E?M?VOC?\ :EU3X:^%='MO$G_"(S6]OXMOHM8MXI=
M>XM9IXC]F;YYE!CBCD*E61KF+"N!(4I^.?V^O /AKQ?HNDZ3J.G^)6NO'1\
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M% !1110 4444 ?DS_P 'D#W"?\$LO#8C"_9Y/B+IHF)ZC%G?E?UK^8?>!_\
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M\0^-KSQU+XD\8?"GP'K#QZQ:WMO9&7['<B]:**1%@MW^ULY:%=K!G=M@#DD
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M@O'::+X\OO!R>&KB;Q3;I#>V_B"^AM-K%$D?SK47%O*Y">5(LV%<,FUJ=O\
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MIIT5UJ&EV8U&33O.:.&5_.W3P71582[/':RN!R@?1U#_ (*C^'[;Q9K6BQ>
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M_A)OA_H_B?X?/HWCFW_LD->-J.M6JWFDS21VXLY_*C6"Y#1Q+F*^B20NH?<
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MHF^&/AW5/AOH,?A^#PYJ-QIWB>]:UO?$MEJ-W<P74MG@[F:,0+'$(T?,^4D
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M^.;;Q9X3TS5+.YUI)K6/2=<FN4BO8)D0"20/87EN8G$922/?F2/89.+^ /\
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M['/:O6J\M_8<M)+#]BSX0P3,6FA\$Z+&['J6%A #W/?W->I4 %%%% !1110
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M())AO.58\9-1_&/_ ()P_P#"P_'>L>,M!^)GB[P3XXO/%=KXNT_6-.L[*?\
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MAJGC#Q]KFM:SXJ^#?P]\3)HUU'!;VHDN;6\-[=00)"AC!N?OA2 'D*L,+&J
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MND'A/2@USC_CX/V.'+_\"Z_C7H= !1110 4444 %%%% !1110 4444 %%%%
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M&ZL[J-HIX)4$D<R,,,K*<@J02"".0:LT4 1V]K':6\<,4:1QQ*%1$7:J <
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _"?\ X/=K:1_AU^SG
M-^Y\F/5=>1LK^\W-#9$8.?NX5LC')V\C'/\ /FT6X]Z_H"_X/>;LCPS^S9!Y
MBA9+WQ')LWD%ML>FC.W&"!NQDG(W# .3C^?\OGO0!_? C[USC%.ID!S&#3Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\$O^#WUOW'[,8VQX\WQ0=V/G'RZ1P#Z'O[A:_
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M.?P4/)[_ )U^]O\ P>_<W?[, Z?+XL.?QT2OP3. ?O8_"@#^^"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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?GI_AI!:P23,T=L'8,^Q2<+N/)QC)K\GT^Z/I0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex3-2_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_007.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y=_X-PO\ @A)\,_\ @K-X
M)^)/BKXF^(_%UAI_A&]MM)L=/T":&UD>61#*TTDLD<N5"@*$"CDDEN@K])-?
M_P"#+[]E^]M(5T[QA\8K"9;F*21Y=5LIQ)"'!DC ^RK@LN5#9.TG.&Q@^=?\
M&0W_ ":U\<?^QJL?_20U^W] 'X[Z=_P99?LWP>)&N+GQ[\7+C2VFG=;-;VRC
MD5&$?DIYOV8_ZLK(2=OS^8O"[?FW/^(,K]E#_H8OC1_X/K+_ .0Z_6RB@#\D
M_P#B#*_90_Z&+XT?^#ZR_P#D.C_B#*_90_Z&+XT?^#ZR_P#D.OULHH _(74?
M^#+W]E^?6--FMO&'QBM[*W:0WMNVJV4C7:E"$"O]D'E[7PQ.&W 8XZU>_P"(
M,K]E#_H8OC1_X/K+_P"0Z_6RB@#\A4_X,OOV7QXEDN&\8?&)M+:U6-+/^U;(
M2),'):4R_9.05*KLVC!!.3G L:G_ ,&8G[*]SIMQ':^*?C+:W4D;+#,VM64B
MQ.1\K%?L8W 'G&1GUK]<J* /R37_ (,ROV4>G_"1?&C..?\ B>V7_P AT'_@
MS*_90'_,Q?&C_P 'UE_\AU^M8^^?I0W5?K0!^2?_ !!F?LH?]#%\:.W_ #';
M+_Y#I?\ B#*_90_Z&+XT?^#ZR_\ D.OUI'3\!3Z /R2_X@S/V4/^AB^-';_F
M.V7_ ,ATH_X,ROV4#_S,7QH_\'UE_P#(=?K2.GX"G+T_$T ?DH?^#,O]E '_
M )&+XT?^#VR_^0Z!_P &97[*!_YF+XT?^#ZR_P#D.OUJ;[WY?SI5Z?B: /R4
M/_!F7^R@#_R,7QH_\'ME_P#(= _X,R_V4"?^1B^-'_@]LO\ Y#K]:F^]^7\Z
M%^]^?\Z /R5_X@ROV4/^AB^-'_@^LO\ Y#H_X@ROV4/^AB^-'_@^LO\ Y#K]
M;** /R3_ .(,K]E#_H8OC1_X/K+_ .0Z/^(,K]E#_H8OC1_X/K+_ .0Z_6RB
M@#\D_P#B#*_90_Z&+XT?^#ZR_P#D.@_\&9?[* /_ ",7QH_\'ME_\AU^ME-;
M[WY?SH _)4?\&9?[*!/_ ",7QH_\'ME_\AT'_@S*_90'_,Q?&C_P?67_ ,AU
M^M2_>_/^=*W3\10!^2@_X,R_V4"?^1B^-'_@]LO_ )#H/_!F5^R@/^9B^-'_
M (/K+_Y#K]:E^]^?\Z5NGXB@#\D_^(,S]E#_ *&+XT=_^8[9?_(=+_Q!E?LH
M?]#%\:/_  ?67_R'7ZTGI^!I] 'Y)?\ $&9^RA_T,7QH[_\ ,=LO_D.E_P"(
M,K]E#_H8OC1_X/K+_P"0Z_6D]/P-/H _)+_B#,_90_Z&+XT=_P#F.V7_ ,AT
MH_X,ROV4#_S,7QH_\'UE_P#(=?K2>GX&G+U;ZT ?DH?^#,O]E ?\S%\:.F?^
M0[9?_(= _P"#,K]E _\ ,Q?&C_P?67_R'7ZU/_0TJ]6^M 'Y*'_@S*_90 _Y
M&+XT?^#ZR_\ D.C_ (@R_P!E#/\ R,7QHZX_Y#ME_P#(=?K6_P!P_2D_B_'^
ME 'Y*_\ $&5^RA_T,7QH_P#!]9?_ "'1_P 097[*'_0Q?&C_ ,'UE_\ (=?K
M910!^2?_ !!E?LH?]#%\:/\ P?67_P AUB7_ /P99_LWS>/;"]M_'GQ;@\.P
MV[)=Z8][923W,I#[76X^SCRP,IE?+;.SJ,\?L/10!^2?_$&5^RA_T,7QH_\
M!]9?_(='_$&5^RA_T,7QH_\ !]9?_(=?K910!^2?_$&5^RA_T,7QH_\ !]9?
M_(='_$&5^RA_T,7QH_\ !]9?_(=?K910!^2?_$&5^RA_T,7QH_\ !]9?_(=9
M?A?_ (,NOV9]/.I?VMXT^+FI?:+^6:Q\C4;.U^QVK;?+@?\ T9_,=<-F3Y=V
MX?*,<_L!10!^2?\ Q!E?LH?]#%\:/_!]9?\ R'1_Q!E?LH?]#%\:/_!]9?\
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M*B@#^>W_ (@<-:_Z.0TO_P (F3_Y-H_X@<-:_P"CD-+_ /")D_\ DVOZ$J*
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M*?3!T_ 4^@!@Z?@*<O3\331T_ 4Y>GXF@!&^]^7\Z5>GXFD;[WY?SI5Z?B:
M$;[WY?SH7[WY_P Z&^]^7\Z%^]^?\Z '4444 %%%% !36^]^7\Z=36^]^7\Z
M !?O?G_.E;I^(I%^]^?\Z5NGXB@!%^]^?\Z5NGXBD7[WY_SI6Z?B* &GI^!I
M],/3\#3Z &'I^!I],/3\#3Z &'I^!IR]6^M-/3\#3EZM]: $?^AI5ZM]:1_Z
M&E7JWUH '^X?I2?Q?C_2E?[A^E)_%^/]* '4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?E_.E7I^)I&^]^7\Z5>GXF@!&^]^7\Z%^]^?\Z&^]^7\Z%^]^?\Z '4444
M%%%% !36^]^7\Z=36^]^7\Z !?O?G_.E;I^(I%^]^?\ .E;I^(H 1?O?G_.E
M;I^(I%^]^?\ .E;I^(H :>GX&GTP]/P-/H 8>GX&GTP]/P-/H 8>GX&G+U;Z
MTT]/P-.7JWUH 1_Z&E7JWUI'_H:5>K?6@ ?[A^E)_%^/]*5_N'Z4G\7X_P!*
M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^E "?Q?C_2E?[A^E)_%^/\ 2E?[A^E "?Q?C_2E3[@^E)_%^/\ 2E3[@^E
M"?Q?C_2A/Z"C^+\?Z4)_04 *W5?K2TC=5^M+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7\H/_!QW_RFA^-7_7;2/_3-85_5]7\H/_!QW_RFA^-7_7;2
M/_3-84 ??_\ P9#?\FM?''_L:K'_ -)#7[?U^('_  9#?\FM?''_ +&JQ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRM<Y&^.5FN877+REE9MY1P5KZ\H **** "BBB@ HHHH **** "BBB@ HHHH
M*_E!_P"#CO\ Y30_&K_KMI'_ *9K"OZOJ_E!_P"#CO\ Y30_&K_KMI'_ *9K
M"@#[_P#^#(;_ )-:^./_ &-5C_Z2&OV_K\0/^#(;_DUKXX_]C58_^DAK]OZ
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MC<U[<S)'*9$BDE)154*J][X-^"8\ ?LXZ5\.M,\1:Y:)HOAR/P]9ZW%Y"ZE
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M('S'.7XE_9G^'/C37M>U76/ /@O5-4\5::NC:U>7>B6TUQJ]BI!6UN)&0M-
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M0#[I\,?L:?"_P9X8L]&TOP7H]CINGO;-:Q1A_P#1DMKL7EO C;MRV\5PJRI
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M;Q!:^(IO$ANX/%-['/;7DUE':,IV2C]S]GCA @8&,>5&VW(!K'_:Y^*/Q#^
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M$\<B;')&WTSXO_MJ^/=*^$NCW'A/7O U[K7QMU75+CX9ZCJ972=.L-+M]/\
MM5J]P\C2I=^=Y+2[D:)VM[D,J PL:^GO _[/O@7X93>)Y/#G@WPQH,GC:[>_
M\0/I^F0VS:W<."KRW)10978$@L^2<GU-<Y=_#_X._M-?#;PSHEUX=\#>-O"6
MGN+[0K"XTN"\T^S>PD%N'AC9"D;0.?+  !3E>.10!\L?$S]IG7/VH/"T=GK#
M>!=#G^%WQ8^&^EZI;"Z^V6VLWMW<:#J33V%P&4[<Z@BVQP?,$,A;<' 3TO\
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M<?VU_;UQXH\^34KJ51J,UC_9\DXC:0H";3]T%"[%7[J@\T >5Z5_P4"^P_\
M!/O2?C1K7AW&I7ES:Z+/I6F7B7ML-3FU9-''EW"$J]I]K</YRY/D?-M)^4\C
MJW[=?Q4\-^-]4^'D?A'P#XF^(/A7Q?I.A:S<+JEYHVE/I>KQR2V&HPJT%RWF
M+Y4L4ML9&(:'>)-LB >\>%?V1?ASX*_9UNOA)IWA>UA^'-Y;W5G+HDEQ-- 8
M;EWDF0,[LZAGD=AM8;2?EVX&*\/[&WP[M(=)5-&OS)HNMQ>)(IWUN_>XNM1B
M5%BN+J4S%[MD2-$47#2!414 "@"@!GQE^,'C'X:1?#>QTWPWH&M>(/'&L_V)
M=PR:O):VMA*-,O+UY4D\AFDC5K1A@HK%3D#=A3Y)X<_X* ^.O%G@?5]4M_AC
MIMG>> M-;5/&=A=>(QYD$<.K:MIMTE@R0LD[I_8UU,GFF$.)(5)4ERGTIXF^
M'FC^,?$?AW5=2M6N+[PG?R:CI4GGR(MK<26L]HTFU6"N3!<3IAPP'F$@ @$>
M867[ 'PUTC6]-U"UT_6H9K*UN;&\7^V[MX]?M[B]EOY8M05I"+M#=SSS 2YP
M9YD&(Y9$8 R/V"?VH?$_[4%U\9Y?$5GH-K9^!OB9J?A/0SIAE/GZ=;V]H\4D
M_F ?OF\YF8KA1N"@?+D^:ZC_ ,%5[\_#[3_B!IO@O1]2^&_B^'Q/:>$KLZ\\
M&J:KJ>C0:E<K!-;M;;((+J#2;UTE$KLF(E:/+G;])?"#]G7PK\"/$GCC4O#%
MI=V,WQ"UY_$NLQ/>2S027[PQ1231QNQ6+>L*%@@ +#.,UX;\7?\ @GA\.OAO
M\,?B=J?AN671M4\56^M2Z7;Z_P"+;V+PWHVKZS#+;330P.[PVWVB:Y(.R,X:
M9Q&JF1@P!BW?_!1WXI>%O%-_X;\0_ /^S_%EQ/X?NM"L(?%\4UOJ.FZK=FR>
M66Z^SB**YL[@()H%+Y29'B>4 UL?!G_@H7XN^*VJ:O\ #VY^&%OX>^.WAI]3
M_M+PQ>Z^K:3-#8-I;&XMM02%F>&Y@U>T:$O!&VXR+(L?EDG2^)_['BS_  W\
M+:+87QC\2:QXD\/S:G?:IXKNOM\=KILS7OV:QNC&99C;@3M%&RH'W2O(?FDW
M=9K/_!/GX>ZW?>%M1\SQA9:[X5N]0O8-9LO$M[;ZA?/J"1I?K<RI(#,DXBA)
M5AB,PQ>5Y?EI@ \O\.?\%H/A7J?@#0_%^K1ZCX5\+ZQHEKXD6\UI3:RS:=<:
M;#=I<6D)4O?A9YELW2V\R1)P<KLRP[SP1^W/?^)-8U#P]J/PS\6>'O&"^+M0
M\(:1I]_^[L]<:TTS^T3?PW94+]C=,Q"0*3YPV%>I%[6_^"=7PR\16-II-Y9Z
MY<>$]/M#86OA>76+B30[2(Z2VD!8K5F*Q@63O&%3"[G>0@R,7+#_ ,$]?!K^
M M%T?^W/'\FJ^&M5M=:T7Q-<^(9KO7](G@M19J(KN;>WEO:^;#(CAEE6YN"X
M9Y7<@'B7['/[6/Q*L_\ @B]??%JYCC\<?$#09O%-Z\&MZD8UFCL_$&HQ>4TZ
M(=PAM8=J  !O)1<J#N'N'BO]M63PGXF:%O!>J:AH.AZ[IWA?Q5JUA>PS#PYJ
M5[%;/&AA.)+B%&O;-9)8Q\GGEMI$<A30TO\ 83\!^'?V3=>^"VEC7M+\$^(/
M[3+);ZI*+RS:_N9KN<PSDEQ^_GD<*VY<':0R?+5'2/V!?#.B>.;S58?$7C1M
M,UF\T_6-;T2;4A+8:[JMCY8AU&?<AD\YA# )4C=(9?L\1:,E26 /.?\ @IY^
MV+XM^!.K^'_AWX5TW[/-\2/!_C#4'\2PZBMO>>'3I>EB99;>-HW5Y0\\;@MD
M#RB-ISD8O[&?_!2DW?[*?AYO'V@^+M/\1:3X"\':M#J>J(+D>,GUBU$$%POV
M7SI86DU""YB99HU< "7;L8[?<_VJ_P!C;2?VJY-+GN_$WBKPI?:;IFJZ*;K0
MY;=6N[#488X[FVE6XAE0HSP6TF557#6ZKNV/(C\A)_P3-\(2>!H_#P\1^,(]
M/T_PKX7\,Z4T5Q;I/H\GARXENM*U&*00Y:ZBN)3(PDWPR%0K1%-RD L_$7]I
M[5/B/_P31\??$_P]9^(OA_XBL?!NMW]M#J-FJ7VC7]G!<#.R5&21!-#N1RA2
M6,JP&&%5O&O_  5%^'?PL\0ZMH/C&SU_P7XIL!ILMEHFNO865UK<&H23QVLU
MM(]SY&UFM;H,LTL3Q_9W\Q4^7/J:? *SUGX$:YX!\4ZSKWC+3_%%G?V.L7NI
M7"I>7T5YY@E0-"L:Q*$E*(L2H$55 Y&:\H\5_P#!,[P_\1?&*^,O$_C3QEKG
MQ*T^^TF^T3Q<Z:?;WWA\Z;]L\B*WBAMDMVB8:CJ"RK-%)YBW; _<B,8!H_"7
M_@I'X)^.^@^';WP?HOC'7)O$VAZ=KUK8QV<$%Y'%>SSP1I)'-,A5D:UN6D<9
MA58&/F'<@?N?V5OC]?\ [1/[-7AGQ]JOA#5O!EYKNG+?3:+<W$%[-;DKDJCP
M,RR*3D*?E9N,JN<5S?C7]BZ'XF?$3P'K7B;Q;K'B.W\!WEMK%I!?6MNERFIV
MYF(NX;F!(I(1-YY6>$9BD2**-4C02++TGPD^!.K?!?\ 9P7P+I7C&\NM2T^P
MGL])UN^TZW<Z<65A ?(C")(D)*X5R6<+\SDDM0!X?\/O^"LOP^A@\'>'9++X
ML>(M2OM'\(WMYK,GA-EAAMO$"K%8:A>RQ!;>$23YCD6/[D@DVH4BD9(=&_X+
M#>#?#OP3\7>,/'VBWGA&7P[X]\3^#+#1DU*SN-1U^/1+F:*XN[:-I8_,VQPL
MSPH6<.I2,2EHC))\./\ @E]K'P[^#VI^'X?B?'-KEUI7@O0K765\*VZ>38^&
MKA9H8Y(O-+2M<*9D<^8JQ^<S1)&VXMGM_P $C[KP[XTF\4>$_C!XF\,^*;'X
M@>(/&GA[4/[$L+Q="MM?=9M7TT12)LG6:<-(D\H,D0$:KE5?S #T?P+_ ,%+
M/ /Q ^('C#2K73_%5AX=\$6<=[J/C/5+2'3_  R4FL].O+8)=S2KEIX=1C,>
MY5!,$VXJ!&9'^%O^"F?PQ\8>,F\-6#^)[KQ1!KNL^'[O1K;1)[N]LIM)NK6V
MO)9$A#CR%-[9R"12P,=PK<;9 F7I/_!..UCT+XT:3J/C+5+W3_BO=Z3?VDRV
MH.HZ!<Z986=G:W#7$[S?;I@=/M)F:Y5A)(CAU>-_+&-^T;_P3H\8?M0^$(])
M\3_&)YA<:=+;7%U'X2M5NM+O7:,)J6D3B03:;=1Q(Z*RO*I,K.RL0H ![-^S
M)^TE;?M->$/$&L6_AOQ-X7C\/>)]7\,/%K5ND+7DFG7DMI)<0E&97A9XGPV<
M@JP(XR?'/VD_^"K?@KX5_LY_$_Q9X9AU;6-:\%^ KOQUHMOJ&CW=C8^);2-0
MJ3VL\J(EQ LTMN)3$Q9%GB. )(RWJGP7_9BG^&OA3Q]X=UOQ1<>*O#/C/6]8
MU2UTY[&.S_LF#4[NYO+FV$L9\R4F6[FQ(S A0@ !!9OGWXS_ /!)O7_VB/V5
M[SP1XW^)-OXB\8:1X$USX>^&?%4FC?9Y(K'5#9&2XO($EV2W*I86\9:/RU8"
M1L R80 ]E\0?M ZU^RU^S)_PG'Q%N=4\<27>O6%M#'H7A*>POH+;4]2M[2VB
M:P\R:5I8/M*[\'>^P@(&(4X7P>_X*">'=7_:&\=_#WQ;K5OI>M6?BVUT?P];
M2:-=6>R&Y\/:;JL5M=3/NA2[9KBZ 1G1G\K:J9&#WGQV^#GB[XV_LT0^'_[>
M\/Z3X^MI=(UF'4TTV6?25U;3KVVOXR;8S"4VKW%JJLGG!Q&Q ?<-U<#XO_8X
M\:>*O#WBJQE\5Z 9?''C[1O%FKW<5A/;2PVUA:Z/ R6P64^7/(VE%U=BRQ^>
M!A]F6 /1/V>/VR?AW^U/KOBK3/!'B"'6+_P;+:KJ< C:-DBNH!/:7*;@-\$\
M1+1RKE6"M@Y4@<+X@^/OQ@^)47CS6/A3X9\%WFB^!=6NM&L+;Q!/=PW'CBYM
M%"7BV\T:[;%([M9[19'BN/,DMY&VI&$:34_8C_9(U;]E3PA;Z-J6M:#JT.C:
M7;>'["73-#ATV74+6V+"&[OF4%I+QHRBR%"L6Y&=47S"JN_X57\6/A#XRUZW
M^'=U\/[WP=XFUF?6DM=>6Z@G\-37+0R78A$(87<<MQ]MNMLCQ,);PJ'\M54
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M?: ?8_C+QOHOPZ\.SZQX@U;3=#TFU:-)KW4+I+:WB,CK&@:1R%!9W51D\LP
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M^.7[0FF6?B#5?B#X?N;:/5;BW6QMK!O-MC!NMPT+1-$)8IU(:1)60/)"RQ@
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MF2Y_5JB@#\L_CA^VC\3_ (0_ML^-/A7=?%7Q'=^$?#>L:?/)>11:/8:TQO\
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M^)=>\1:IJ'PZ\$WVI>+?+76KN?1;>2;51&8G3SG*9DVM!"PW$X:&,]44C/\
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MBNFQ7;C/9>!O^"??A'X?_%KPGXPTZ\U*UO\ PE=:Y+'!;/Y-O?P:E,LJVLZ
MXDAMC'$8E/"O&),>82QQ]8_8%U35/!/ARUC^(4EKXB\$_$O4?B3X?U9-#C:.
MSEOI+]KBSEMVD*S1,FJ7T6_<KA9$((= Y *OP@_;7U#XU?\ !0"'P9H[1_\
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M]U!#<V\PVO%*@=''H0>#^-176A6-_?PW4UE:S75OCRII(5:2/'(VL1D=3TH
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M?3_&GCQ;:#P%X=^',KM+9"2YTS1+R2YM-Q%L,2,DTMO*RX#QR$X$@$@VIO\
M@FAX8N?C_=?$&Z\6>,+B\NOB';_$QM.)LULQJ5OH[:/$@*VXE\A;4J-I?)=
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MG-=#I7C6T\9^ (?$'A>XT[Q)9ZE8B^TJ:UO%:UU)'3?$4F7<NQ\KAQD8.>:
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M;/2+&]O4M/&.J6]C]HMKZQ>>&&.RM+5'8A%DCF R&#LW:0_M(:UX!^&_PO\
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MQ^_X+ Q^+O#WQ'L?B'I_BGX V>H6EQ;);Q0VH;6W9H(HXU61 I8,T<[/-&7
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MK^-;_@OQX6OK/_@L?^T"LVGB-I/$[3*$MKE R/#$Z-AQDEE8,6'RL22ORE:
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MO3]#L=>\":#I7B#Q_I&D:OX3:UUI[JP9;]3OBO&,22QO;,,L41EE5TV%6WA
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MBCWY+.CQLWS$D^\UF^$O!VC^ - M])T'2M-T72[0;8+.PMDMK>$=<+&@"K^
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MC]IKP='HO@7QE)I>@?&/_A-;O6[/4K=+-M&G\-S03H@:X#LS7^ T)3:'VO\
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MKP;X(T?X<>&;71?#NDZ;H6CV*LMM8Z?;);6\ +%B%C0!5RQ8G Y))ZFOB_\
M;B\=_$"#]K6QU+P???$S2[/X>ZYX M[]+*&\DTK4K+5-=F@U2-+2*%X[P&R
M$LSY-L8HO+\MF=CP.JZGXN\/_"#XG:UX=^+'Q0UC6++PMXYB\10W>M&XAT 6
M5SJ!TFY@8H!;7 9/+!C(:2,G<&$*-& ?<6I_LE?"S6_!=OX;O/AOX$NO#MG>
MSZC!IDN@VKV<-U/O\Z=8BFQ9)/-DWL!EO,?).XY[B#2K:VTQ;*.V@CLXXO(6
MW6,")8P-H0+T"@<8QC%?GW^T%\>?$?[/E_XL_L/Q1\2O%?P5UCQ=9V7BSQ U
MI?ZM=^$(-0M-<BU#^SKBW5;D0V]]'HW$!<VHN'";!C8W5?VE/%_PU^,7PV\*
MZCXR\;>(=6T&+P7!J&NWNF76F-KMOJ=_):7#G2H()(F,@2)YYKAXS:EHU4(S
MMN /ICP;^S+\ ?C7\(]>\,>'_#GA?5O!<5G+\.]3T_3G>.SA@T^[F$VF%48!
M1'<M,'48+'(8L.*Z;PQ^Q9\*?!7QTN/B=IO@+P[!\0KJQ@L)?$)MO,U"2*"
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M %%%% !1110 4444 %%%% !7\6?_  75_P"4P7[1'_8Z7O\ Z$*_M,K^+/\
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MZ6W@X:4=1W><"8!=9&W:)B!GR^: /?\ X]?&;1OV5_V>/%_C_P 0+JEUX?\
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M.Y\%3/LC\JZLKU7G6929;F*UN+<ND\$Y4 ]H'_!,3X0KX:TK1QI7B+^S=%\
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M0AC.+6*WB=HFB65;:$.K[>?-)_\ @BO\-)/A5/X/77_&<6EW'@+Q#\.6=;F
MSC3-8U2/4IF!,1'GQ.GEHY!&UCN5B :[7]@K]K;QQ^U!#%=>,/#/A7P[;:OX
M!\*^.-,CT?4Y[YT35TOO,@F:6&(91K(,I4'B4J<E-S5/VY_&?B;P[\?O@98?
M#^W\.ZM\0]4O==.G:9KOB&XTK3WM8](F,US,L,<S31Q3M9(0L3.IN%PR!F)
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M?[1G[._B*XUR+PZ8?&'C3QA\5O%EMK2>,;'1;&/1_AK#IXAC5@DKDJQM&G1
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M7* "BBB@ HHHH **** "BBB@ HHHH **** "OXL_^"ZO_*8+]HC_ +'2]_\
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MX7\/^%;+P)';2P:O#+J&E6E[;O'<>:DN^UO3;P!UDC+&"X",C-M#5Z#^R_\
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MGX#MO'VEZKX6M=3O8O%.HW)\3:?HLCVR7$L]Q$[6X%K(TL5JBNL>YH_,.05
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M&S7]XBO/*S:G?-IKY6\)_P!*VD(WS!% /UBTZ>#Q'JNM0W&BW%O_ &?.-/\
MM%W!'LU*(PQ3%XB"2T(:4QG<%/F12#;@!FTKC3[>[MY(9H898IO]8CH&63Z@
M]>@ZU\(^._"WC#7_ (@^,M4OO _Q!NO FG_%ZQU[Q=X8-A+=MXHTBY\'6>GN
MMJ"^+RWL]5*S30P[D=;.3RUE8)')XW\5OV ]4UGQC<^#[OP?\5U^'_@CX3_$
M,^%+6VO;\R::SZOI3Z-IXN;24K<S*;6ZGM;9GE=(4L]R^9$-H!^IUQH=E=_:
M/-L[63[45,V^)6\[;]W=QSC QGI7+_$/XQ:/\)]-N+R^T_5Y)KC4X].M[:RT
M]IKG5[EX%D @1>9,1JV6Z 0.,_)2? WXJVOQ5\%0W$=KXAL;RSCBAO(-:T>Z
MTNZ$GEJ2WEW$:.RDYPX!4D, >#7REK5I-;?M%S7%YX6^*6I6.@_'X:]HLTNA
M:S>P6-M)X173[FZ@9D95LS>W-\@VGR097=%VX>@#[)\-:II_Q!\,:/KD=C.L
M.H6D5[;)J%DUO=0+($E57BD4/%("$+(P#*RX(!7B72_!VD:'KVJ:K9:7IMGJ
MFN-$^HWD%LD=QJ#1H(XS,X :0H@"J6)VJ,# XKPW_@HSI_BG6OACX7T_PS9^
M(KQ;S7)QJ:Z4UZ%2W31]3FC:X^Q8NC']JCM0JPO&S3FW4N$9E:]^Q%XVUC4_
M^":GPIU[XC-XH7Q%_P *XTNY\5/J%G=Q:Q]L738C>M)$%%QYYE$I^1=[-RN2
M1D WO#/Q!\!_M:W.FK)X1NO$FEZ/>IKNBZKK/ALMIOVB!8)+:_LIYDV,S+=!
MH9XN2%EVL-IKKM6^#GAVZ\--IUGH>@Z?Y>H3ZU9NFE02)8ZI+)),VH)&R[?M
M!GEDE,F-S.[L22Q)_+;^UO$7A;_@GI\/]"^'H^)WAF+1?V/?&!&FVRZG:W>G
M^) V@PV49!^=;T74=_'"H)=5$HCPAY](\8>,+CX>_%G5OAT+GXX>)+=I]&UB
MZFUJ;Q(^EQ:C<Z/>ET?4;>%Y&C.RT*6=O(L;W("$Q2,<@'U'^RA^S7\*_P!E
MCX4:7^S78V.GZ]_9?A*(ZDE]X>@C7Q!IP)LEDO3'"MO<RLL8CD!R[!0SC#@G
MU0_LX?#QK"&U/@/P6;6UTV3188?[$MO+BL9'$DEHJ[,"!W56:,?(S*"02*\/
M_95\<:IXT^+OPIN_$*ZX/$VI_!.RU'5/[2TR:TG6XDGM3*)PT:K%/YF_=$=K
M@@_* *P?VG_CWXB\$?M5MH.CZAXXC9M9\$R-!%I]W/8M:7&J36MTL'DV[1>4
MR2YNII9?W6V#*+F.2@#VX^"_A!\+/$W_  B\'A'PCI&I:KI-SKOV&R\.1K]M
ML[&"#3Y9,1Q;9#%;W<%MLY?RIPBJ4.*>W[%/PAN/@SI?P^'PW\'Q^"-%ADM]
M/T:/2XH[6SBESYR1J -JRAF60#'F*[J^X,P/PI)^T!XC^('PLT/6M:N_BEX;
M^+&A?!CQ];^*+EM*OK./P_XHAET2\DBBG,1@C@,MC=-;?.4DMT"KNSBO</VC
M_P!I?7/@OXS\<65U-\4;EIO$G@C6M/CT/P_>:FMOH[7UA#JKPF"%U^S+'!<F
MX0%F03$X!FC# 'U)JOQ0\+^!/'OA?P3<ZA:Z=KGBBWNGT/35B9?M45FD1G";
M5V*(UECX)'!X!P<<9X!_8U^#.B>%?#(\.?#7PCH^DZ+'>SZ-;6FC)8QV<6HX
MDO(Q"%7;'.0ADA9=K%$W+E%V_%GPB^..M?$[XO>!/^%I>-/B!H/Q,\/W_C*V
M\?Z=:0B#0_ ""SOS83G,316[_8466SG9G2YB^T2%ICM-;G[&_P"TIXP^,7Q"
M\'1^*_B1XST_Q9J&@>%]2\(:5:V<=UI/C/2IO#ML^HZE<(J 2JNJW=REQ)'*
MCP?9+,#RQ,// /T2 P*\9L/V2?@KXHT[QQX7M?!?A^2SU&\,'B33XH'AAEEF
MVWK1LHPNV0W"RNJ?(S2$L"V:_/K5_C+J7[1WPQ\36?BCXH>*(M&LI/ACXK,L
M6I&35-"OQXLEM=:DNX+=/)L6VI 6TYI)EM3&KE492!]%>+/VL;[QS^T?XU\!
MZU\5(?#?@6W^),WA,:SX=OK.&[T.0^%],NK/2[F=T)MS/>R:M()N6\ZT@M=W
M[TQT ?;\:")%5?NJ,#FN)F_9G^']QK^O:H_@_P /M?>*#,^KR?9%_P")B\MN
MMK+)*,8:1[=%A9R-QC4(3MXKXM\4_M2?&&'X7_%/5;KXEP^"=>^%_P .1XPT
M[3+[3-.G_MM8-6UZ*"[NUDB25([ZQT^P:1(O+,<EVOEM'C:_OG_!2C]JG6OV
M8_V=_#_BCPW)9V^EZWXITC2-6\3S7T%MI_A;3;N8*^I3SR0SQI#N,4/FF&5$
M-RKL BLP /5O _[.7@WX:>,[/7?#^BIH]YIWAJT\(6L5I/)%9P:7:N[VUNMN
M&\D"(R.%;9N56*@[213?C+^S?X/^/E[X?O/$NF33:EX5N9+K2=1L[V>POK R
MQF*9([B!TE$<L9*21[MD@QN!VKCXY^&?[6OQB\,:O\$;'Q5\2O ?Q"AOM*L8
M/%-[X-CMA<:I>W.O#3([];.XCC:?3)5.T3V<D91XI9A%/$R1CC_!W[;_ (D^
M&GPNOU_X6U=R:I\/;CQ!J.N:/KMWI$U]#_Q6$UDD6K7CCRUCM[<I$L5F1(6D
M&YT5K82 'V7X6_9+^#UW\3O#/BCPSI.GV.L?"RS'A6PBT#4YK.RTZ"%&,=C<
M6EO(MO+Y"W#M&D\;&$SN4"ER3ROA?]BCX"ZMX6\%^&_#LCII.@:-JVF^'K+2
M/%MY&ALFO(7OR@BN/WOEW@M29#N:*5(<%2%KQ[QCXZ\=?!7]I7Q5KO@WQOI:
M:/>_&W0_#.I> 5T*"9M875+'0XKJZ:X4_:(Y+>U:ZO5*!5(MY#('3)5^B?'#
MQ%\'/A_]G\%ZW\/=)C;P]\3=3TK_ (2)X[32+?4;3Q7:P6LD]TOS16P-XRNJ
MX7[I/W5V@'O7@+]A#X8_"_QG;W.EW'BX:W_;E[XP"WGC75;R6XO[BS73Y[QD
MFN6WXMV$8R-D?F$J%+9/;_LU_LU^$?V2/A%IW@7P+9ZAIOA;1RPL;*ZU*YO_
M +&IY,:/.[NJ9R0H. 22!R:^1=<^,/CCXB?&+PMKEOXGTCP#XH\'Z#XYM]2F
M\4>'8;R6PMK?^P97MF-I=&*;;(T$KW,!"O&C 0HQ^72^ O\ P5"UW]HX^"UL
M=4^%/A#4)%\+7^KZ;K^IS6TWB.SUC0(K\MI*E=[A;NZBAC=@5)M;I7PR< 'T
MEXM_9 \'^,_B3JGB:Z_MJ&;Q!)IT^M:?;:E+!INM2V#$V\ES I"R,!Y:.>/-
MC@ACDWQQJ@M_ KX#:'^S;<^*+?3_ !!K^H-X^\37WB=[?6=02<6]U<XDGBM%
M"KY<.5+^6N0"SMU9B?,O^">O[6.O?M%W_P 0M#\775L/%G@>]L8[[3X=)%M%
M9QW=HMQ#);W4=Q-#?VDRDR0SH8W*'$D:,.?&I(_'OCK4? \B_$+PQXF^(FG_
M !P\6VOAJ^\0:##*WA*Q&G^)[2&!HK62*2:,):DJ6:-GV[68A,@ ]U_:F_X)
MH?#O]KOQIJFN^)KKQ;8WFN:;I&DZDNCZL;);Z#2M3;5+#<0I96BNI)&!C9<[
M_FR4C*6C^QG:?#3P;X+F\/:IXT\2:U\-=?U7Q7IL&H^($A_M[4-1^V"X^VRF
M%E9<7]R$P@V!@!TKYYU'_@I!\2O#NI:/9ZEK'P_&M>%#X?T_Q9IEKI%S);ZI
M)>^++SPQ=:A'=RSPQ6EN9K83V\):65L2(^5&\?2?[!FJ^+]6^$WB'_A-/&J^
M.M6L?&GB+3H[PZ;%8R6]O;ZM=010,D3%3M2-=IPI"%0=V-S &S^QU^S)I/[)
M_P ')/#NEZ?I.FS:KK>J>)-2BTV+R[87FH7LUY*J<#*1^:(D.%&R) %0 *.B
M^('P7MOB)\1?!7B*ZUK7K-_ M]-J5G8VDL26=W/):S6I:=6C9VVPW$P 5U +
MYY(&/C?06^)U_=_"'7+'Q+X-\;?%"U\2^.-'77/$>GFQ!TZV:^1+:1;,Y/[V
M"VS@*JJQ.TLBA^N^ W_!27QI^T?X7^%.K>'O!>@P7&M#PO=?$#1=0U);6[\+
M:?K>ERW<6H0O*Z>;%]H$5LB&/S)764*#M!H ]0\2?L#:9?\ @O6+72_&WC73
M?%.N^*-.\67_ (HFFM[[4;RXL;B.:VMW66(PBTC$21K#'&@"Y(.]G=LB'_@G
M%9_\*=^'NA2?$+Q='XP^%5U-+X6\;VEO8P:QI5O-\DUH$\AK:2![?$++)$V5
M2-SF1%<=S^T5\7?&G@OXA> ?"O@C2?#5]J'C::_BGN];O)8(-*CMK4S"81QJ
M6G)?8GE H2'+;U"G/R_\(/\ @L'XP_:=T[0X?AW\+9K[6O#FI:3!\1AJ-W;V
MNDZ1:7-Y<VMQ<6EY+<1LXC%G/*FZ ^8K1K\K[E ![MIO_!.OP[H'Q3@\2:7X
MQ^(6FV][!9_\)/I<6J(]OXVN[.*.&WO=1D>-IGG$,8CD,<D8F41B0,(U H_#
MW_@G'9_!S1O 6E^#_B1\0-"TWP+X?NO""0K-;2-J&BNP-I9R/Y0*O8J-MO<)
MB90S;WD+'/#ZY^WK\5/A]X(T_P 8>+/"_@K2_ NK:[?6BZW8_P!HZC'H-C;7
M,T23:I&D8DM4F545[I%EM[0HSRDI(H7L]'_;<\0>-/$</B30=!T^Z^%MGX\?
MX>ZJ\XDCUJ*X^U&PCU&%0QBDM'O7ME4#YFMYA<!L?NZ -3X>_L3WG[.J?%*\
M^'/BJ?2]0^(VK:;J-O!/IMM)9Z MI8VFFI##'M4O$+.S@4JS;B48AE+9'MGC
M_P "Z7\4/ >M^&=;M_MFB^(K"?3+^ 2-'YUO/&T<B;E(9<HS#(((SP17QM^Q
M)^V#\6/^"A?PA\$77B?0_"OPUM_B+X7T[QUHMSX>UJYU"[CAM=4MC<P7"O%$
MJ+<0M&%5)'*K)(KENE>X_LI_M?7W[2/C7Q5HFI>#I_ ^H>$8;<WVEZG?YU>"
M:6XO$4O;B,*;9X((98KJ*66*4RS1J=UNY(!Q7B'_ ()J-K?PHOM);XBZU>>+
M+?X?7?PWT#Q'J>FVUY)I&G37'F>:\>%-Q</%%913.742_8U<+&SMFQ\0OV)?
MB!X\G^-<_P#PLCPE:W7Q@\(:?X768>"2TFBF"WEAN)0_VT-/')]ING2%R/):
M1?F?#[U^-O\ P47C^ _QQN=#UCP_I<G@_2XM0DU;6;?71+>:0+32IM3WSVZP
MF&%98X)%19;F.7Y=YC"$-6/\9_VW?BQ\)/#_ ,-3K/PU\->'=6\=_$KPYX1V
M_P#"2?VM9OI^HQM+<2QRQQ1LMQ#Y<D6UHS&6 97=6R #M4_8KU:Z^(/BJ:\^
M(>J+X#\;1?:=7\+6=D(5GU&2R^Q7,J7+.[I;2QK')]F ^696?>VXJ,OP-^QM
M\1O#?PB\*^$]:^+.G>+/^$5\3Z9JD.I7WA00WEQIFGM"8+25HKI1)=,(1YET
MP(8L2(5Z5TG[)7[7-Y^TUXO\>:;=>&;;PRO@Z[AMD@EU0R:H&<S!DO+)X8Y+
M21?*5E(,L,RRJT4LB@FIOBA^UE?> _$5TVG^$9M:\->'?%-CX6\37XOU@NM-
MDO(K-XKF"W*D7$*-?6XES)&ZJ79%DV[2 >B> ;WQ1>ZIXE/B*UTVTL8]5:/0
MEML^;+8B*+$DYWL"[3><1@+A-@*@Y)Z2O,_V:/C=XA^.FD^(M0UKP7_PB-GI
M6NW^C:>QU>+4&U-;.[FM)9B(U'D_O8'PA+<$'/4#TR@ HHHH **** "BBB@
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M%U!&G98A)));;1;QN7R84C5MVP&@#SS3/^"A&K?#/]NKX\>#?&=GX@U7X?\
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MOM)TU[5?#&J3S>?JMNMQIRA8K=]WVF-LQD9!967AE91VG@K]G:Z\#_L=:?\
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M/& ?;]U\$_!E]'$DWA'PQ,L$%W;1*^EP,(XKHDW4:Y7A9B29%'#Y.[-1:?\
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MMG=)K=UJ5FVGQF26!;;S99$CB+7$C_NL!C)DYXKBO^"=/[17C#]HOP;\4O\
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M_91M2_\ 2+3Z_6ROR3_X,R?^44'B+_LHVI?^D6GU^ME !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_%G_ ,%U?^4P7[1'_8Z7O_H0K^TROXL_^"ZO_*8+]HC_ +'2]_\ 0A0!^\'_
M  9D_P#**#Q%_P!E&U+_ -(M/K];*_)/_@S)_P"44'B+_LHVI?\ I%I]?K90
M 4444 %%%% !1110 4444 (W3\133T_ TYNGXBFGI^!H ?3#T_ T^F'I^!H
M<O5OK2/_ $-*O5OK2/\ T- "KU;ZTC_T-*O5OK6)\1]9UO0/"%U=>'=#A\1Z
MRAC2WT^6_6QCFW2(KLTS*X140LYPK$A, $D"@#:_B_'^E*_W#]*^4_ W_!1;
MQ%XT_9ZUSXC3?#?3]&T;P_KVH>'[R6X\4QM%#/8:\NCW)9O(4A,+<SHV,%8
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M (*<^,&^$'@S1$\7^'/V;-2U7PAIZVJM&VLKJ,T-KA691N8%8,[EQ$?+W*G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?BS'X-AU#Q!>ZD^J:5I#7MMX>OI='ADU2V%QI[MJ B^RB.<,B(WFG,DBIU-
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MPT>2:VFAD6XM9M2OI[*T9Y,E&6XG188T5=P=&R2&7 !\!_#3_@FK\<+'X:^
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M%/\ 8LNM6#W^B:3_ &E)X<-U9(3-(1B2.%Q T9:-69F:-=IW<?&^H? +XK?
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MDL6 &<BH;SXA^'].U<:?<:YH\&H,746TE[&LQ*>5O&PG/R_:(,\<>='G[ZY
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M=CT 4 G+*#H^&=<N-8T6.YU#39M%N))I8A;3SQ2/M61E1]T;,I$B*K@ Y <
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M_B-XSF31M!N_$>E:]!8V%M.41H5DN+2*\FD@0(90DIA,7EG'U!_P4T\6>+_
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M^SN?#NM?V%;^-OBYH?AW7(UC1S?6,\-W(]L'<90-)#%DJ S %> Q%<_^SO\
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M<>.?"]AX .A)J5II5OIL$<UP8]4-XR>?$\#7+R%XO,D4HC1Q%U!H ]U^'?Q
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MMZ;K%O+JOPQ\56NIRZ=KPNTE>4Z+*865KB>VAV20R$EKF))1)&YA=W[K4/\
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M  G\/ZEI^C)I.GV<-EJMWX9-Y=WKK);M*TGVY6"QES&A1DVMT'Z2!LG'<44
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MP_>W,=O>*^D_;=+N+J"YN+P*UK&6N8HH!;$><5G20#:R[N!T3_@JA\1OA/\
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M !%^#OQ'^&MO+\1M"U[X;_"M]5M-&L;W0YFU^;3KFV6.TBGO_M.QGM3NB!6
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M<KG@^/W'[>EQHG[#O@SQ]J5GX=A^(WBCP?9>(V\.?:Y?LXD>".6Z5)%1V\M
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M,VT"^&)4U+04O2[6^T>1/9:C>R2F4 QBU\R-HE5P/8O#O[:NL?M8_M8MX/\
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M.TM;6#2GT?8UC)#&D#_,\IB<MN, !:,TOVD?VR?BQX&^,4D>@^-O \?@N_\
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M!G0.FFO(I?<A?S7X8?L:_'3P-\&/A-:^'_#/Q#T7QUKOA/XC0^*)9->$-O\
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MZ?O^#43_ )0C_#7_ +">M_\ ITN:_1ROSC_X-1/^4(_PU_[">M_^G2YK]'*
M"BBB@ HHHH **** "BBB@!&Z?B*:>GX&G-T_$5SWQ8\5:7X%^%GB;6]<OIM-
MT71]*N[W4+N(XDM;>.)GDD4X/S*@8C@\B@#H#*H+?,OR]>>E1BXC<A1(C,RE
M@ W)'J*_)7]GKP1XR_;9^%&M6_Q(^#]UJ7B[QIX5\&6VIM8^*])-KXK\/Z=K
M5K._VKR-1EECO)+>:<M(_E+*D;QJ 4 /TIXZ_9=\0>%?VPM-U3P7\&[/3=)T
M_5-EKX@TF73H4@L&\.WEB#YDEPMS L5Q+"@LH(1" OG L[O@ ^R/%OC71_A_
MH-QJNNZKI^CZ9;NB2W5[<)!#&SLJ(I9B "S,J@=26 &216D\@W[=PW;2<9YK
M\T_ _P#P3P\8>%OV0]&\"ZI\)8O$6N:A\(/#=KXD;4-0LKZSO?$MA-ON YFG
M8O>*CR^5-M\K)5?-1 "OIWQ3_9#^)GB?XZ>.M2\.Z/-X?\2:?]JE^&OC.#7;
M>#3-*LY]"2Q73;NV2+[2(H+Q&G2V59(&>03%PR>70!]=6_Q+T_4/BS?>#?)N
M&O[/2(-9DD*J8#%+/-"J@YSN#0.2,8P1S7122+G[R_+QR>A_R?UKYO\ V0?A
MIK'A;XLMK%Q\+;[X;V-]X.LK&_BFNM/G\W58;F9[AWDMIY&G:43JPG<;I/+8
MOM; /S/^T!^RI\9/COX#^,GAK1_ NIV]MXBE'B2TB\17]K%J%GJD/B&TO$@M
M[JWD-M?17%I!(T,DQ2:R6.&V>38^(@#[P^(G[17AOX6_%_X>^"=6:^36/B=>
MWUAHCPVQDMWN+2REO98Y9!Q&3!#*R[N&\LC.<"NP:X4:J+;[+-\L)E6?8/*7
MG&S.<[N^,=*_/'XR?LP:U\<_CMH?B3Q9\&?$B_#>P^+.KZQXBT:]@M+JXO=.
MOO!*:6LZV]G/*9E:_<!]A+#YW(PK$=E:_!'XB^#Y_$&AZ#K'B2W^(;?"?6H-
M$CDUT7%S;[]:N)M-A-U/YH-Q;0RQP+,Q9,D[_,4*5 /N8!9%;HRM^((K@_'O
MPYT;XX>+=#9O$VN0K\/=;CO+W2M)U/[-;W=VL,<\$-\J?.RQ^9!.L6Y5;*;P
MZ':?A74O@_XT\.0^$;NQ^'G[3&K?![Q=/K;ZOX0GURQA\3:+K%XFGII]S$MO
M=1+8V$ AO\(MP4@DG!$2)MV_5W[('A&]\ _%/XRZ;=^#_$&BPZWKNF^(1JM_
MY$EOK4LV@Z;:SXEC<F6=);)UE;RU3)4J6R0 #VCPKXOTGQSI']H:+J5CJUC]
MHGM?M%G.LT7FP3/!-'N4D;DECD1AU5D8'D&I=7U+3O#MA]HO[BRL;598X_-N
M'6*,2.X2-<M@;F=E4#J68 <FOS8_9,^ /C;]F3X'^"OA_P"(OACXXA^$^DZU
M\0K/Q!HGA\2R7;W,^O"_T&Z@%O.)?L9LO.C5XR-LSH'"@EZ]L^*W[/GB/XF_
M\$P_AQX6^*VCZ_XZUS2=5\*ZAKUI;K,^JRP6NKV<SF80S.\MS';)F8QR.'D2
M5E+94T ?2_P?^-7A;X\Z7KEWX:NOMT7AOQ!J'AS4@]NT36VH6,[07$9# 9PZ
M9##(8$$'FM[4O#L;>$IM)T^0:/&;-K.V>UACQ9#9L0QHP*?)QA2I7@#&.*_.
M[X$_ _XG:(]UKVC:5\4O".M^*OC'\0M9AB;S+>"31[^QO7L_M<$A,4$<MY'I
MSH[*LB2*2&0-(3]"?\$Q_"GB+0/ OB;5/%=U\5/[=\536.LZIIWB^R6TM]&O
MY+&%;NWL55FR@E1FE9"8FE=VC.UJ /0OV;?V<O#7[%G[-G@OX6Z7;ZGX@T?2
M;.V\."[FTZ*6YO8HX!!')>^1&D;!8(HXFE90"%4'K4WQDOOA#^R)X.O_ (J^
M*]'\+^%=/\+V\,-SK\.@B2XT^ [+2(;H(FE6-5=(^!M1.N$!Q\M_L^^ 9_"/
M[)WP9\06?BKXX#Q)XU\4V=MJ^H^(]0U>]OX&2#4K=3+;72E8;:-G#+YL2Q/Y
M=O)(7(5S\\Z=XPU+X]_LZ?$:P\07'QXTV^U'P+X9T?7K*Z\'>()O[6U6+4K9
M-0URVANK,6WVIT:(&&%&!\IV(9 7(!^JS?"CP/HZ:A WAKPG:KXG46%[&=.M
MXQJR[#B&0;?WPV!OD;/R@\8J/4?@!X#U-V:Z\$^$;AC"T!,NCV[DQF*.$IRG
MW3%%$A'0K&B]% 'QO\69[G2_VK/!=O-%\4O$6D^ /C]#J$1&DZCK7]G6=_X*
MN;2)A,X.VQ&HW<R&1&=(6;#;5)9?4/'[^/-8_P""HE[8VEYXQ3PGI?PECU;0
M[2*>YM]!N]=&I7<;B<H5AED\DV^8Y&^X0P'&X 'T-)\(_"=Q]H\SPOX=D^U7
MD5_-NTV$^=<Q*%BF;Y?FD0*H5S\R@  C%:'AGPGI7@;0;?2M$TW3]'TNT5A!
M9V-NEO;PY8L=J( JY8DG Y))K\X?AGXK^+WC/]GC6/$%QX^^,=GXXU"6"3Q+
MX?\ $GA34])T.PU6UL;NYU'3;.ZM@][9VQF9%6[MGGMB;>WCB\_S)%?N?@=\
M7OB+\2OCYH=GXTU+XR?#4Z<-'U/PSI3Z!/J%KJ^B3>&8VU"/5;V.-K5KM-2-
MT"TOERQ26<&V/;<%7 /LF;X"^!KG4=0NI?!OA6:YU;4#JE[+)I4#O=79@%N;
MAR5RTIA41ES\Q0;<XXKJ+6SATVRCM[>*.W@MT$<44:A4C51@* .     *^%=
M-7XN?#W]D3]GOXD>%;KXE>/_ !C?QZ=:^+=+UN^N]\L^IZ:+'[7=6A,02*SU
M![>66-8ALB%PX4,-XO"_^*G@K]M'P[X'_P"%A>/%\.^"=1T&/3X]0\*7&J?\
M)UITNE/;7IGU&.6.!6%PLMS+),A>*2"'R\K+Y3@'O$7[,/P"\$:OJ'@.'P/\
M-='O/B?I=\+S0X=-MK>3Q'813^;>!H54>;"LVH!I!@KNNAG[PK:G_9Y^$?B'
MX@:]#-X!\'W?B*7PY::1JDLV@Q-)<:0WVB."T:5H\20_).OE!B /O* RY^0?
M@7\7K[XG_P#!0[]GN;Q$OC/_ (3;2O"WC[3?&-MJ^E31P^']9GE\/3C3XI4B
M%N+<0VTIMV1V\V"..1GD>4N_:?M"_':^U7_@H)!\,-#^+FO>&[[4M4\-P_V7
M8-;O-")-.\1SWL444L#CRV@ALIVD8,$D\G+?=B(!]&>(?V,OA+XO\(Z/X?UC
MX;^"]8T7P_JHUK3K._TF&ZBL[T<BY02*<2#.-W7&!T %=-=7'A/XE0^(/!,L
MFEZF-/MHK;5](5AFWAGC)C61!RJN@;;V(4XZ&OE6U\=S?M!?\$;?BY_9_CK7
MO&EYINC>-?#]CXCTVX\O6+Y-/N=1M;*4O;JI:Z:W@MV+H@\XOO"XD K@?'7Q
MW\/_  NN?%WQ \!_&"]TOPEX+\&_#O3]-GN$ANK7Q#YT]]+!!=RW,+32FXL[
MNV8M$\;*+@R,V0=H!]F^*/V>_AO\6?!VE^%=8\+:!KNB^"K^*73K*ZMA*FCW
M4=NRQO%GE)%AN&4,ISME89Y-1:1^R9\+_"W@CPSH-CX'\,Z;X?\  UTVI:%9
M6]FD-OHLY9W:6!5P(R2[DXP#N.>M?"^K?MN?$_7-1\4PW'Q&N].7PW\5O%OA
M]M(T:#3[?Q'<:=::A9)8"S2[MY(+PI#*Z&T_=W-R+E7AE9HO+?[#_;2^)S:5
MHOASX=Z9H^D^)O$7Q6O)-(CT74+]+.&]TR*,S:H2S*V<68DC50IS)/'G";F4
M T?AK^R;\%[+POX*OO"/@?P7#I&@;]4\,7.F6<:Q6:W4B73RVSIT2:18YFVG
M:[!7.2 :L?&#]D'X3?%GP[-8^+O".@W5G?>((O$#NY:UEFU0B.%9O-C97,DB
M(D#+NQ+$3"P:-BA^/O#'Q5USX,_#:R_9ETSXCV/PI\9>"_BA8>$M#FMDL[R_
ME\%SS&YTW[/'<HT;R-8;; R&-C%-"25<A6DT?V;?BKXS^$UC\;5\5_$/Q1K&
MJ+^T;I7A33(?%1M6>+39KC1U1;=!!'M6:UFD9=@V 1^9&%;>S 'U?XK_ &>_
MA1\/M=A^)&K:3H_A\^!XSJQU&6\>RT[3A;V#VGVR:+>MN6ALFDB6:1"T<195
M95KI/B]\!O"7Q]T[28O%&E_V@=#O5U/3+J"[FL[O3[@*R>9#<0.DL9:-W1MK
M@.CNC!E8@_G7^T=^TOXB_:&_X)Q?M/3>*/&%S8^+%^&GCV+7OAD^G0,?" M;
MJ:#3Y7G1%FA9[/!_?LZWFYIH=B0NI]XG_:G\;ZQ_P4?UKPA!\0OA_P"&_#_@
MC5[6QNO">JS,NI>(=&GT2UO6U&W@\CS"\=Y--']J2?[,L=I,DD8<&0 'T7X6
M_98\!^!_B7HGBW1=!_LG6/#GAF/P=IHL[VX@LK328W#QVBVBR"WVJP7:QC+
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MZ4 "]6^M+2+U;ZTM !1110 4U_Z&G4U_Z&@!U,/3\#3Z8>GX&@!R]6^M(_\
M0TJ]6^M(_P#0T *O5OK2/_0TJ]6^M(_]#0 ?Q?C_ $I7^X?I2?Q?C_2E?[A^
ME "?Q?C_ $I7^X?I2?Q?C_2E?[A^E "?Q?C_ $I4^X/I2?Q?C_2E3[@^E "?
MQ?C_ $H3^@H_B_'^E"?T% "MU7ZTM(W5?K2T %%%%  :\L^$7[45I\<+;XDP
MZ#H=^VM?#G6)M&:QGN(%75V^R0W=K<03*[1F"YAN(61R?E)97"LC*-#]J_5/
M'6D?L]^)I/AKH\VN>-YK=+73+>*[MK66)I94BDN$>Y(AWP1/).J2?*[1!#]Z
MO'=0^ 'B#]D+X\>#?$GPJ\$ZUXT\+GP#'X"UW2;?6;2VGA32\2:+=YNI8DE=
M1->V\C9+E9XFSB(JX!M_#;]ORZ\<_#S2_$5U\+_&&G0^+/![>,/"EK#<V=]<
M>)$6T^UFQC2*4M'=^4T>%D C8R8$A(Q6E\&_VQ]>^*GQAUKPG=?"OQ-HJ^&?
M$7_"+ZOJ0U&SO+;3[LZ/#JZ.XBD+B!X+B",2$#$TJH5YS7@_[!_[)WQ2_8GU
M7X9ZC'X3U+Q#HWB;P#I/AWQCH]_XECU#4OA_J]HB"233II[@Q-I<[O.TMO"V
M5>*%XTP3$GLW[,OAKQU\,/BU^TQJVM>!]8^Q^*O&H\3>&7CU&PD.N6T6@:3I
MRPQCS\PR--ITI G\M0LT99@=P4 Z+PW^V_X?\1Z3\/HX?#_BY_$OQ#CU*2U\
M/0V237VG#3<IJ#W+K)Y$<<$YBMS(9=CRW,"H6\Q:=X0_;8T;Q9\2HO"LGA+Q
MWI&IOXONO!3MJ%A!'##>0:0FL"0NLS;K>6T?,<B;LNK*0I%>?_ ?X->/O!7B
M#X3>+M0\-3V$FFMXQT37M#DN;6:ZTRTU?5HM0M[_ ,Z.<Q/Y?]GP(T,>]R+[
M<"#"R-T?Q"U;QIXO\;?"/Q)>?#W6K'3M'\7WFI7,,$]O=7NG6;:+>V,+W4:2
M'][)/=YVPF54B0%V5LJ #O\ XR_M%0_"#QIX;\/Q^$_%_BS5O$]M>W=M#H<%
MM((8[0VXE,C3SQ!<_:8]H!.<-TQSMS_$NXM?A'=>*I/"OBE;BTL9KYM!6WAD
MU>3RPQ\E(TE,;2MM^51)R649R:^:OC;JOB[XA_&/X8:QXH^$WQ4M-)TJ3Q19
MWTOA/6O*FTZ)KP1:7-,]I=Q3NMW:V8F:*+S!"UQ$LH! (] ^#OQ!\2? W]@_
M0]0;X:_$_P 0:AX1TZVTC3_#,UW9WGB_5+6!X[.*>Z>6>.V-T\:_:)?WY&-W
MS,_RT 7O!7[?'A3XF>!_A-KWAG0_&7B&V^+TA6P@L-/CDN=#C0A+F;48_-!M
MH[:1A%.?F,4I6,C>RJ>M_94_:8\/?MB? /0/B1X3@U:#P[XE6:2Q&I6XM[AT
MBGDAWE S;0S1EER<E2"0"<5X?\.?A7K7[(_[75KJWA'P3K7B#PK^T!-?:SX[
MNK*!+.W\):I$/-M[W[,\GR_:HYFAG2/<[RV\<V-[S&39_P""./PN\3_!3_@F
MK\+/"GC+P_J7A?Q/H=C<V]_I=^$\^U?[;<,-WELR$,K*P*L>&'?( !]-4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?MF>%;G7OV?O$FH6?B+Q1X;O/#>EW^KV\NB:BUE)-+'9S^6LC*-S1JS*^T$
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M/^P3K'C6ZCMFLDL;V\UR2ZO])MK.[AO(+2">0,ZPB:"$L&+-((T#LP5<<?\
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M "2K;E(W(X7F/#__  4-^"?BSPM?:UI/Q*\,ZII>GS6<#SV<YG$[7D\MO:&
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M $G[=?:3;W3*TJ)- EXB;8_D0YV*BD+\R?!3]J_QW\&?CSX/\&Z<_C_7-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9
M3MC;'H:_@M^-_C'4OB'\:?%_B#6+C[9JVN:W>ZA?3E GGSRSO)(^%  RS$X
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M[02!@4 =%16?%XDCE\5S:1]FU 30VD=X;AK206C*[N@19L;&D!0DH#N564D
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MY0N_L_\ _8O/_P"E=Q7V=7QC_P &\O\ RA=_9_\ ^Q>?_P!*[BOLZ@ HHHH
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M]0N;FUT<W.IWU_%/:2M;K]IB87IAFMY(H2XCB82?N]K=)\+_ !U\>/BI\+?
M_P 2--F\&1V_C"^TV^N/"-U8M_Q+O#]U>1LTJW:S!FU".P<2,"#"9%=%4C:Q
MVOC!_P %)?A3\#?!=YXC\2:IK5GH-KX=N/%,=^FBW4T-]IL%U';3SVY1#YPC
M::&0B,$^3-'*,QL&H ^?-4_X)1>,-(\-W\.E77@N^U.W^,G@?QO87TZFTN;W
M1= LM#MW@N)8X&87#OIUTRJ=Z_OERXR<>O?\$\/V3/%'[+MYXDCUK3?#^CZ/
M=Z-I&G:98Z?K4VM-:/:O?-/''<W%O'=)9 W,?V>VFFN/(S*$95;:>F\>_P#!
M1KX>?# 1KKUC\0M/N/["C\37%N?!>J23:?IKW$EN;FX1("8A')'F16^>-'1V
M4*V:UM9_;J^'.A_%+3_"<VI:D;C5-5M]!MM3CTNX;1Y=2N;4W<%D+W9Y!FDA
MVLJA^3)&N=SJI $_:_\ @CKWQ8_X5QKGAU;6^U'X:>,K?Q5_8UY<_9[77(UM
M;JT>%WVL!)&MV;B$L-HGMH<E!\Z^?_ /]C[Q=\"_C'H>J275GK&BW/B/QGKU
MQ#Y_DQ^%X-7N(+F"TMDVGS5$D3E\>6-\\K<\!NFT3_@I/\,]7^%G_":2?\)C
MIOA]M-NM<26_\+W]K-)IMJ8A=7ZPO$)&MH3-%OD"X D4\@@U>OOVRM%O=#\7
M37;ZEX#/A/X@:=X!%UK6FFX35;JZFTX0&W2)SNCNOM\<<<A(VF0.R@*5H ]L
MD#;)/+V^9@[2W3..,U\)>(_V(_B;<>)?'&N^"O!_A'X9^(_$7A.QF\3C3]>G
M70OB+XBBN+"X*K;1%6M;=8;6\LWNF6.>5-1.Y'6($_2OQ2_;D^&?P6#R^(O$
M$EE9?8]7O4O4L;B:UG.E*[7]O'(B,KW,20S/Y"YD98)BJL(WVZ?[/?[67@3]
MJ>TUB7P7J\]^V@RI%>076GW&GW$:2IO@G$5PB2-;S("T4P4QR!6VL=IP ?'G
MB7]D[XK6GB?1?'FG_ GPAX@M?&EEKVE^)/A3KGCD76D^'KO5[M+JYUIKJ:&6
M.5I66:*:"VA \NX_=DX=7Z#]K#]CWXA>./B'<6_AGX>Z3=>'[7XU> ?B'::G
M%JUK'/)::8EDFH'R9 I62*+3]BL9"TOVE5 "HQ/W5_%^/]*5_N'Z4 ?GM\1?
MV"?B1\3?V9OB/X3M?!&A^$?%]K/X]AT_6;36T:/Q]::W8:U':),4VNC&YOK.
M65;H%8WM59"W!3(O?^"=?C;P'XIU/2?"?@35O#GA&3P3X0-M+X2UK3;-8_%F
MG7&H276I-9SR+#=DK<VB2K<@+=):E7)"QY_1_P#B_'^E*_W#]* /-OV/OAWK
M'PC_ &7/ 'ACQ!IOA?1]<T'1;:SOK+PY9+8Z5;RI& RV\"DI$F?X$)522%)
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M"1G&58J<<$CFKM0Z?I]OI-A!:VL$-K:VL:Q0PQ($CB11A551P%    X %34
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M_@Q=*21K.?33%-;Q1WQD\T6YO;>WNG1E9V99$\P1R%!]+4P]/P- 'R5\;/\
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M"@!6ZK]:6D;JOUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTB?T% "G@CZTWJ/P%.;JOUIHZ?@* 'XIN<K^ IU,'3\!0 _%,SD?@*?3!T_
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MX>>'X]:.I+H>CKJ+7_\ :ANA91^<;O[-]D^T[\;O.^S$P^9G=Y7R9V\5G_\
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M'EM\9H?%.K>,/#-S;0_$74?&OV.UT6:)I+:70'T:SM#(UPV)(E99))0N)""
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M?PGXC\(WNE_#_P"$U]\.GU+7))[>6^N+O5-!NGG\B*&15B6+2)<#>2S3(IP
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M?W4?_"!:1=[[R7S9=T]JD[+G ^56D*J,?*BJ.<9KZ2H **** "BBB@ HHHH
M**** $7I^)I&^]^7\Z5>GXFD;[WY?SH 5>GXFANGXBA>GXFANGXB@!%^]^?\
MZ5NGXBD7[WY_SI6Z?B* &GI^!I],/3\#3Z &'I^!I]-(X_ TXG% "+T_$TM(
MO%+0 4444 %%%% #?XOQ_I0G]!1_%^/]*$_H* %;JOUI$_H*4]5^M(@Q^0H
M5NJ_6FCI^ IQY(^M(!Q^ H =3!T_ 4^F#M]!0 ^F#I^ I],'3\!0 Y>GXFF3
MP1SLN^-'\M@R[ESM/J/>GKT_$TC?>_+^=  OWOS_ )TK=/Q%(OWOS_G2MT_$
M4 (OWOS_ )TZFK][\_YTZ@ HHHH **** "BBB@ IL<:Q(JJJJJC  & !3J*
M"BBB@ Q1110  8H/-%% !1110 4444 02:7:S:E#>-;P->6\;PQ3F,&2-'*%
MT5NH5C&A('!*+GH*GHHH *YSXH_"G1?C)X;@TG7X;R>QMM1L]5C6VOI[-UN;
M2XCN;=]\+HQV311OM)VDH,@CBNCHH **** "BBB@#'^(G@FU^)?@#7/#E]-=
MV]GX@T^?3;B6UD$<\<<T;1LT;$':X#$@X.#@UE_ ;X-:3^SK\$_"?@'09M0F
MT+P7I-MHFFM?3^?<"VMXEBB5WP-Q6-57)&3CG)YKK** &R1+,,,JL 00",X(
MY!_"FRV<,PDWQ1MY@ ?<H.\#IGUJ2B@!HC4,&VKN4;0<=!Z4-$KNK,JLR'*D
MC[IZ<?G3J* (X[2*&:218XUDEQO<* SXZ9/>D:RA>[6X:&(SJNU9"@W@>@/7
M%2T4 5VTJU<<V]N</YO,8^__ 'OK[]:#I-JR,IMK<JRA&'EC#*.@/L.PJQ10
M!0A\*Z7;ZNVH1Z;81W[.\C7*VZ"8LRHC,7QG++%&I.>1&@Z*,5+3X;>'=/\
M'%UXGM] T6'Q)?PK;7.K1V,2WUQ$N-L;S!=[*,#"DD# K:HH 0*%)( RW4XZ
MURUU\"? ]]X+_P"$;F\&^%9O#OV@W?\ 9;Z3;M9><6+F7R2FS?N);=C.23G-
M=510!S=G\&O!^G^'M+TBW\*>&X-)T2\74-.LH],@6WL+E69EGAC"[8Y SL0Z
M@,"Q.>35S4OAWX?UKQ=8^(+S0M'N]>TM&BLM2FLHY+RT1L[ECE*[T!R<A2 <
MGUK8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_ /:S_P"3
M5OB9_P!BIJG_ *1RU_"'7]WG[6?_ ":M\3/^Q4U3_P!(Y:_A#H _MR_X)#^&
M[/PG_P $M/V>K/3XFAMO^%?:+<;6E>0[Y;.*5SEB3R[L<9P <    ?15>!_\
M$J?^48_[//\ V3C0/_3=!7OE !1110 4444 %%%% !1110 B]/Q-(WWOR_G2
MKT_$TC=?RH 5>GXFANGXBN>^'/Q6\._%FRU2X\-ZO::Q#HFJW6B7[0$G[)>V
MTACG@<$ AT88(^A&00:WS,C2M'N7S%"L5S\P!)P<>^#^1H 5?O?G_.E;I^(J
M#4=1BTC3KB[G+K!:QO+(4C:1@JC)PJ@EC@= "3V%8WPN^*&B_&CX>Z7XH\.W
M4EYHFM1>?:3O!) TB;BN3'(JNIR#PP!'<"@#>/3\#7A'[2'P]\/_ !6_:E^&
M6B^)]/M=8TH>'O$5Z+*Y<^2TT<FE*DA4$ LJO( 3G =L=:]W/3\#7.^(O@QX
M/\7^,K/Q'JWA/PUJGB'3X'M;35+O2X)[RUA<,'C29E+JC!F!4$ [CZF@#X6\
M"I=Z9^R_\.?A7KEQY/P]^-&C^']0\!:IJEU-.-*U1S%J%SH%S=AC)(72*22T
ME=4#@R0$YCC#_H1J>G0:QIUQ9W4:S6UU&T,L;='1@0P/U!(KR?PU\7/@S9Z)
MJGAG1[KP?#H_PMM;/4;BRL[)%T_0("\OV:>/:GE*B-!-AHN(S"^2I4X]0\-^
M)-.\9>'K'5M(O[/5-+U.!+JSO+299K>ZB<!DDC=25964@A@2"#F@#\X[KQYI
MO[//ACX>ZYY=]<VO[(_Q+U7PYXKFO-7N-/;2?#6H-+8VT\R3.XNT2VU#3[H/
M,X#1V,SJ=X"GZ.U']GGPW\(_C)\'ET9M2N_[>\<>(]?N;VZO99IIIM0TS4+B
M3DG 1?W:QIC"+#'@ KFO>-:^$'A7Q)I'B:QOO#FB7%KXS4IKR&SC']LCRE@_
MT@@9E(B18P6)(55 X Q5\;? GPI\1O'GASQ/K6DK>Z[X1E:?1[HW$J&Q=@0S
M*JL%)*DJ<@Y4D="10!\V_#7]@/X6Z+^UQXNT.#0+G[#H/@_PG=V_F:G<R,\H
MN-=@E=]TA#&>*&-9N!YVP%]QYKR7XL:-XB^ 7P&\1?#'XC?;=8^&>O7;R?#S
M5]8N-MWH-VFJS)'H$LI82R)]C6*2SF?+NAFA9F*1&3[<\-?LO^ _!_Q7\2>.
MM,\/PV?BWQA MKK.II<3>=J,2EBB/E\83>^P #9O?;C<<Z&E? CP?I7@"U\+
M'0+'4/#]C<QWD%EJ8.HI'/'*)HY<W!<[TE575B<JR@C! H ^ /"GP'T]/CK^
MT9INE_"C3?%F@Z=\7=%T">[/B<Z++X&T:?PYH,]W?6I8?=MVGGN/+C=&9Y"1
MWKWWPY_PD?PN_:5DU#Q)X@U+QKX UCQM??V)X@TSQ#-#_P (C?7D:6(T/4=/
M\TQW5N+CY8)%#>3,Z;HH@&F;U(?L$_"%M0UNZD\#Z;<2>)M6@UW5UN)IIH]5
MOH"/*GN(W<I*R[4 #@C$:#&$4#H=#_9?\ ^&OB)<>+-/\+Z;::]=W,U[-<1[
M@LMS-GS;@QY\LS,"5,NW>5^7=CB@#Y__ &4?$FO?!SXO?#CP#X]\3:QXQDU#
MPYJUOX/\;VFOR:AIGQ B$UM=O+?VYW"#4HX5#(Z,\+QM=>6T:E8$]A_;K^'/
MB+XK?L=_$31?!VL:]H/C";0Y[C0KW1M1?3[R._@7S[95F4@JKRQHCCHR.RG@
MFMGX._LI_#K]GVXC;P3X1TCPS';VXLK:WL4,=M90<$QP0Y\N!20"PB50Q )R
M>:]!3^@H ^'X?VO&UK]HFU\4:;<>(]0^%7QM^&RQZ-?6.LB='\26Q$HL=,@\
MPK'>2V=W,S ["SZ9A0SI(:B^&-]KGP__ &F/VN/A[9^(O'&O>'O ?PO\*3:#
M:7_B2ZNKV&XN+?Q T\L=U-+O2XF:&(M+O4@HG*A%Q]5>'_V>_AU\*OA]H>BZ
M?X7\.:+X9\%W\NMZ7;BW2.UTBZ9IY)+I,\(Y:XG8OUS*YSS7*>#/@E\*?'VN
M?$+XJ>'=575/^%MZ/#HFOZWIOB*66RNK2P6XMT6%DD,4#0&6Z!>+:RN\A)W9
MP ?)?PDU+Q!K'P6_9-U.ZL?B]\6-2\3? >36M;A\/^/KO3Y-5O88="G6]D:6
M_MA+([WUTJMDNWVA0P"(NS1^/GQ2M?A#J_P_\27WAWXY:KX=;X;R:EKEK8>/
M[V)O"4L-[I\!GU)FO8BYM?M,PGD$<KJEO.\B-L-?0G@+]C#X2V?@_P %Z1X1
M\2>)[73OAKHK>&-#.D>.KX/IVGRO!BU,B3EF7-K;*N\D@0HH.!BND^'_ .Q1
M\._A=K&@'3(M;\O0_#LGAFSTR]UZ[O+.?3VV^<DUO-(R3L[;6DDD#.[89F)/
M(!X-\8;'QUH/Q(^$,/BK2?'_ ,4?%EW\,-8O/$UEX \7SZ#I][J%C-HVV>.(
MWUK&Q9KNYC0H S^:"R*H4)UWP*\+ZUX\^)=OX%USQ=X^M?#'A_X=:5K4GA^_
MU:2/7);G5[[46Q>:A'Y=VQLH[&.VCVLC-ND,K2N05[#PA_P3=^'OP_M]"AT/
M5/B9I<'A?39-&T>.#QSJP73+%VA9K:$&<[8LV\ "C@"% ,!0*Z"7]COP#X=\
M$:39V;:]X=C\-P3A=8LO$-W::D\4TKW%P+B]$HFF629FF?S78&0ENM 'S5IG
M[0?C3P+\=[?2;^_^('CBU^%7Q6O?!L%WIFQIO&.F7GA"?6OLL]NC)!<7%E<"
M"'SL+)_HN20TDP?[9\!WC:IX/T^^>/5+=M2B6^-OJ0"W5IYQ,ODR ?=,>_9M
MYP$ R<9/%3? GX?:[J?A#Q!:3?98_!NM7.M::VFZO)!9S:C>H\4L\ZQN$N)9
M%NI5S+N)^TOCEZZ'4_A[J6H?&G1_%">)M6L]+TK2+K3IM!A8?8M2EGE@=;B8
M-GYX1"RQE K?OY0Q8$* #B_VU?VB-:_9G^''A76=$TK3M5DU[Q[X9\*77VR=
MHUL[;5-8M;"6=%4$R2(+CY4)49.XDA=C>/\ @_\ ;4\0?!3Q9X^G\::#KM_X
M M_'WB"P3Q#<7\+2:;!9Z5+J6RVM$4R36JK9W$>6<2+,VU8VB 9?H[X\? +P
MW^TGX 7PWXJ@OIM.AU.QUB!K*_FL;BVO+*[BN[6:.:%E=6CGAC<8/5<'(R*Y
MWQ%^QEX!\6>&(=%U.QU._P!-CUV\\130SZK<NM]<WD5S!<K/E_WT+PW4\9A?
M,>Q@NW & "7]F+]H/4OV@K3Q9-J'@GQ#X.3PWKKZ59RZE:75O%KUO]G@G2\M
MQ<P03>6?.,3!HAMEAE4,X 8TOBU^U,WPR_:6\'_#./P^VHZEXZ\+Z]X@TB[^
MV^3#Y^E-8B2VF&PF-9!?Q%95WX*N"G0G>_9Q_9TT7]F+X?P^&]!U+Q5JEC"L
M:1R:]K=QJD\:11)#'&CS,=B+'&H"H ,Y8@LS$XO[3?[&/A']JO5?#&I:]=^*
M-'U;PF;J&TU'P]K,VDWCV=VB)>6+S1$/]GG$4)<*5;,$95U*YH \3\)?\%9Y
M?'?Q,M=%TCX4>(+G2+5_!']N:R^LV4<6E)XI3%JZ1%O-G\J>2WB<!5)#RN.(
MU$L?CK_@H'%X:^-WPS\6ZA_;F@_#GQ/X%\6>+%B-W#<1ZKINFOI L[H6R(6$
M]U_:0:%%EW[#&CH)9#'%V/A;_@EEX#\!VOBJ/0/$GQ TF3Q5<^&;AIQJ<-Y-
MIJ^'I4ETR*!KF&7]VCHI82^86 VY"_+6!I'_  1A^#2.\-U?>/M<\/VVGZOH
M.EZ!>>)II-)\/Z;J(A6YT^SA7;Y4"R6T$D8)9XI((RK#RT"@&_I7_!0?7I]-
M\/V]Y\#_ (E6WB3Q!XUU'P1%II6"WB,UK93Z@EZD]VUN);*6U@DVSJNT3*T7
M+ %L[X\_\%(O"?ACX%_%;Q-]A\62:#\,W@M]9N-$N;>WUFPF:^%H\#VMRT<T
M$RLKS#>GES6SPR0R2>:%7OO!?[$ECX,TWX?1M\0OBAK=]\/]9GUU=2UG5X=0
MO==N);>2U87CRP$%!;RO$JP"$*&R/G^:N%\>?\$E? ?Q3\+>.M+\3>+OB9K_
M /PGEFNE7-Y>ZM!)>6.GKJKZI]BAE^SAFA\YQ$OG>:\<$4<4;QJ#D Z?Q'^W
MQ8:5^T#X.\$:?X3UC6K7Q9XOU#P,=7M[VS2/3=5L]..I.DT#RB7RC:PWC[PN
M[,$8",LZ-7&?"'_@KEX5^+'PIT'Q=)X#^(7AFP\;Z9I&H^#XM5@M/,\4'4KJ
MWLH(H?(GE$+"ZNK>-FN#&H642Y,89EC^'/[,OQ:\/_M#^(-8;4I-"L]9\;3^
M(+B^M;_3KRQO=.%P@BMS;R:>+P326$<=LY-UMB<N\;&-8X3J3_\ !)KX?O\
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MF:/_ %:@'W@OBG3&@M91J-B8[V!KJW<7";9X0 QD0Y^9 &4EAP P/>LCP?\
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M)OB%K.GZMJVF^&;9;F:STN$37EUND6-4B1BH9RS@ 9&?K7R+XI_9]^+'A?\
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M%*J^0#D DD ^A)JQ5/3-&72II/*FF^SLD<<5M\HAME08 0  C/&<D]!C%7*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** //\ ]K/_ )-6^)G_ &*FJ?\
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M?\Z5NGXB@!IZ?@:?3#T_ T^@!AZ?@:?3#T_ T^@!%Z?B:6D7I^)I: "BBB@
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M?@K3M-DOK#Q%\0;Y[6YUEF\U+5;31K8-=.UQ(;,11W,MI(WV@J51U (!RO\
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M "C'_9Y_[)QH'_IN@KWRO _^"5/_ "C'_9Y_[)QH'_IN@KWR@ HHHH ****
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MA+X/\1>-O"OQ$\5?#W2;VS\ W0TG3KSQYIWA_7]7EU%+J*>VMGGGBDLF,=M
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MQLOQE\>:?*MYI7A:SC>T\!^#I@V]?L5@>;J6,Y N;O?(P"G:I4$?:"J$& ,
M< #M0!\O>+_%/P/_ ."0OPA.N>)]4UJ\UG7#(T^K7R3^(/%WC.Y@MVEE9F16
MEF9(8W<JBI!"@8A8D''3_#+]O.U^/'[#FA?'#P'\./B/XFL_%D"3Z'X9^R6M
MKK5\LER;>*1EDN!!%"W$WFM+M6!O,/\ =K@O^"W7Q6^'_P (OV -<U#XF:M%
MIO@VZUO1+36+=&_TW6--?5;4:A96RAT>1Y;+[2KHF=T)E!&TL1[%^RS\3/&G
MQ5T&[U/7_AO%\,_"ICA7PQI]U?B36)K;Y\27=JD8CLCY?D[8!)(Z'>K[2H%
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M.@ 7[WY_SI6Z?B*1?O?G_.E;I^(H 1?O?G_.G4U?O?G_ #IU !1110 4444
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M/PSX?^,&N>)-4N%TCPSXKU2:6>X9YEL;."V@D8*HR0BKO.U1ZX&30!YOI/\
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M17PV\=V7Q2^'>@>)M-6==.\1Z=;ZI:K,NV013Q+*@89.&VL,C)YH ^*?AO\
M\$WOB1\#_A;X9G\'P_"O2OB'\,M>T^2SO+:*2WM/B9I5C8W5C"FJDPO)83>5
MJ%VZ+;>=%#*2R@J^U-S]H?\ 85^+'Q3^$^H>$]/E^$CKX_\  VL>$?%$AM;S
M2]/THWES+<(;2UM\M/&?/>)RTL,C;/-W;I&5?M2B@#XQ^+?[%GQ0\9Z[X#M+
M:U\%2Z+X$^/:?$F"Z.J3Q7%WI$J7LDRO$8&5;J.:_>-4#E'2!6+H7VKNQ?\
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MG_.E;I^(H :>GX&GTP]/P-/H 8>GX&GTP]/P-/H 1>GXFEI%Z?B:6@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U_P#!9#_E$_\
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ME_.E7I^)I&^]^7\Z !?O?G_.E;I^(I%^]^?\Z5NGXB@!%^]^?\Z=35^]^?\
M.G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\U_\ !9#_ )1/_M'?]DZU
MO_TBEK^)>O[:/^"R'_*)_P#:._[)UK?_ *12U_$O0!_>=^S_ /\ )!_!/_8
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MI6ZK]: $0\?K0PY_*A/Z"E;JOUH 13S_ )[TYAD4P=/P%/H :O6G4U/Z"G4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110!\-_\')W_*$7X]?]@W3_ /TZV5?QSU_8Q_P<G?\ *$7X]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'PW_ ,')W_*$7X]?]@W3_P#T
MZV5?QSU_8Q_P<G?\H1?CU_V#=/\ _3K95_'/0!_?Y1110 4444 %%%% !111
M0 4444 -_B_'^E*GW!]*3^+\?Z4J?<'TH 3^+\?Z4)_04?Q?C_2A/Z"@!6ZK
M]:1/Z"E;JOUI$_H* %;JOUIHZ?@*<W5?K31T_ 4 /I@Z?@*?3!T_ 4 /HHHH
M **** "F_P 7X_TIU-_B_'^E "O]P_2D_B_'^E*_W#]*3^+\?Z4 *_W#]*3^
M+\?Z4K_</TI/XOQ_I0 J?<'TI/XOQ_I2I]P?2D_B_'^E "I]P?2D_B_'^E*G
MW!]*3^+\?Z4 "?T%*W5?K2)_04K=5^M ")_04K=5^M(G]!2MU7ZT -'3\!3Z
M8.GX"GT -3^@IU-3^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?#?_
M  <G?\H1?CU_V#=/_P#3K95_'/7]C'_!R=_RA%^/7_8-T_\ ].ME7\<] ']_
ME%%% !1110 4444 %%%% !1110 W^+\?Z4J?<'TI/XOQ_I2I]P?2@!/XOQ_I
M0G]!1_%^/]*$_H* %;JOUI$_H*5NJ_6D3^@H 5NJ_6FCI^ IS=5^M-'3\!0
M^F#I^ I],'3\!0 ^BBB@ HHHH *;_%^/]*=3?XOQ_I0 K_</TI/XOQ_I2O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PW_P<G?\H1?CU_V#=/\
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M :.GX"GTP<+^ I] #4_H*=34./R%.S0 4449H ** <T9H **,T4 %% .:,T
M%%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCA==0UG1[63S 254WT;Y7!&&R@ZY&">.X_DGK^LO_@[<_P"4+WB[_L8=&_\
M2M:_DTH _O\ **** "BBB@ HHHH **** "BBB@!!]\_2EI!]\_2EH ;_ ,LU
M_"G4W_EFOX4Z@!!]\_2A>GXF@??/TH7I^)H &Z?B*6D;I^(I: $'WS]*%Z?B
M:!]\_2A>GXF@!:*** "BBB@ I!]\_2EI!]\_2@ 7I^)H;I^(H7I^)H;I^(H
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M2EH(R*0-EF'I0 C?ZQ?QIU(5RP/I2T -C_B^M*W3\12 [7QZ\TXC(H ****
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M09- #Z*;'P*=0 4444 %%%% ";<-FD8MNXIU% !GY:;YB^M.HH ;O7UIU%%
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-%M?_ $W7]?S$T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex3-2_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-2_008.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
M!1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP8(7^(7Q(U!=&T6:8;H]/!*+)<E?XB-ZA>P9@2"%*GJ/A'_P3H^'?@OPNO\
MPEFCVOQ'\6WT6=8\0>)D&I7FH3L!O*F0$1QYSM1  HP*^4_^"Y<UQ\/?VB?V
M?/',R?\ $FT?49$F<D[8VCN+>8D_]LPQ_ U^DEEJ5OJME#=6\BRV]Q&LT3J>
M'5AD$>Q'-88J'L,OH3I.SGS-M=TTDOE^I497J-/I8^<_@)^PAIO[)G[5VN>)
MOA[:PZ3X%\<:/Y.L:.DNV+3[^"16@EA0\['628%<G:>1PV!\Z_#3Q#I?[./_
M  75^)L.K7UGH.B^+- .H/<WMPMO SM'!,6+L0OWEEZ]"I%?HS<7,<:9=E1<
M8RQP*_.7]OWPMI?A[_@LM\!-<UK2;'5-%\4:?'I%Q;7MLD]O-/YEU"&97R"5
M^T0G!'!52.:Z,EK/$5:M.KJY4Y*_7W5=?E8FLK*Z[C_VY+>#_@I?^U!\*_#W
MPCW:]9_#W5#>>(O%EH/^)9IJ&2%Q"L_220",L F[EAUYQ]B_MI^$U\:?L@?$
MW2R-YN/#%^5W+N+.D#.N0.^5%?&'[1O[/_C;_@E#\6KKXP?!6WN-2^%>I3*_
MBSP@K,T-@O\ %(H^8B/NK@9B)P<H<#ZZ^#O[9WPO_:?^ DGBBP\4:38:/=V;
M)J<.H7D4%QI+.I5XYU9OE()(!^ZW!!((IXY2]EAZN&]ZC#9[M2O=J2Z.^W2V
MP4])24MW_2/E7_@D7XJ^-WBK]A_0[7P/_P *MAT71[V[LTN/$#WT]T6\TN08
M8-BJHWC'SY(]*^BOV&_!/Q*\ ^-_BU8_$Z[L=7U;5-<M=;MM3TZV>&PNHI[5
M(@D089'E?9@A4Y(P"2=P)^1_^")G[6/ASX!?LX^+/#OB2'Q4UPOB&74+%-/\
M.WU_]I@>"%,IY,3?QQMP?[P]:^C/BK^TIX\_:'\:^"?"_P ._AW\1M+\+WWB
M&QN?$OB;4]/?2%MK&*42O%&DA67Y]@#-@?+E<'=QIG%&K]<K*,4H2=[Z+S"F
M_=3>Z/<_VNO#:^*_V5_B1IK(SB[\-Z@@56"EC]G<CGZBOGK_ ((1ZW_;'_!.
M[08V*[K'5=0M\9Z#SBP_1N*^E/CW'X@G^%>LVOAO08_$6J:M;RV45M)>QVD2
M"2)UWR.^?D!P"%!8[N!U(^=_^"6'[*/Q9_8O^&-YX/\ %=IX/O=&O=2?4([B
MSU:7[39;T 9/*\@I)EE!!\Q<9/6N&C6A_9M6BY*_/&275V33_,N47SIKLSZ(
M_:&^+=O\!O@GXI\87'EM'X>T^6Z1&./.E"XCC'N\A11[L*^;/@=^SW^T!X0_
M9HL_ ]Q%\#FTW5+*=M3CU&'5;BXNY+PO+<F8*R+O:29\@<#H#QFO4OVW_P!E
MCQE^U=X6TGP[HGC;2_!^AV>H6^J7R3:,VHR:G);R>9%"X\^-1"&5&*X))45[
M/X?LM2AT>V75I[*[U%8Q]IEM(&MX)'[E(V=V4'T+L?>N&-94J"4&FV[O?2VW
MYO8NUY:['Y\_\$C/&6N?LI_'[Q]^S+XREC^T:3</K'AZ9 RQW2'F41[N?+:,
M)*HZC]X"<BC_ (+@:?;ZA\<?V:#>0P7%H_B@P30S /'-&]S9!U92,,I4$'/8
MXQS7O'Q=_P""86F_&3]IVQ^+5[X_\8Z7XKT<QKIKZ7%9P1V<<;.40@Q,9,!V
M4ER<@XK2_:2_X)OZ'^UEXIT35/&WC#QK>-X;82Z9!9W$%G%9R_)NE41Q@[RR
M!LDG!X&!7N4\RPRS"GCFWM[R2^U9IM>NYC*,N1Q7R/FO]M+X(:I_P3(_:+L/
MVA_A-HD:^"[YA9>-/#]I$$MXHV('FHB@!$?C!& D@4XVN0/N_P""'QI\._M"
M_#/2?&'A74%U+1-9A$T,G1XCCYHY%_AD4\,IZ$&K=I\-(9?A[-X:UJZO/$UC
M=6TEI>2:FR22WD3@AEDVJH/RG' 'YUYU^RS^P?X+_8W:YA\"W?BRQTN\E>>;
M3+G69+JQ:1@!YGEOG#  #(QG SG KS,1CJ>)PRC6O[6&B?\ -'S\UT-(QL[G
MH/QM6-O@SXN\Q4:-M$O0P;&&'V=\YR"/SKXX_P"#?.!;?]BO6F"INF\571)
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MJLR[MH.ZLYY?B8+FE!I>A=/'8><N6$TWZGW)134;>BD'((R".].KC.L****
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M7/BCQ]\38?#>MMK%A'I?A^[T:\<P^&[1#NDMQ!,H<&9P&:1"Q) !PH!'1?\
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M,FI?LH_LIZ7H?B/[+_PEVN7EWXC\1?9VW10WUY,TSP(W\20(4@4]UA%>:?\
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MF:ZDUZ^\(Z9-?/< B9Y3;H2SC^\>I]R:]DJO:6D=E;0PPQ1PPPJJ)'&H5(U
MP%4#@ #C JQ7Q!^@!1110 4;<FBC- $<D(W;MHW=/PIJH"XZ5-14N-]0$VCT
MI0-HHHJ@"BBB@ HHHH ***"<4 %&:*;C&<?C0 XG HW5#*RR1[>]?%/[9O\
MP5-C\&>(_P#A!/A) OBCQE=O);M?P1"YM[5UR&2!<A9I$/WW8B*+^(NV4'1A
M<+5Q$_9T5=G+B\92PU/VE9V7Y^GF?1?[27[6G@7]EG1!>>+=86WN;A"UIIML
MAGO;SKRD:\JN009'VQK@EF4 FOACQG^WA\</VVKVZL_AK8GP+X-V,DNJ+<&%
MD'0L;P[7? ))^S!5!_Y;Y&3X-\2_^$;^!?CO3[CXO2:]\7OC7XP<7&D_#K0
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M(';KIPI!_P $&_VA%#?Z%XLQT 'QLEXP1C_EQI_V[4_Y^K\/\B?]65_)^?\
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M%  O"T444 %%%% !1110 &BBB@ HHHH **** "BCO10 4444 &:AENUB+;N
MHY)/&.Y^E++,RM\O/]:^!/\ @I-^V5K/Q'\=K\#?A?-]JU#47:VU^\A)*-@
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MXE7GG>#]0E!T;5&7$-B9&(61#T$#L562,<12/Y@Q'(=OZ66[$ALXZ]J^7S#
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M2O"'A*PD$NF_#C36X:")A@37DPP9[@C)/R*=H)?[42-4/RBFA-H_SQ3@#O\
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MIE6,.2I\NWX(D7&<8'OWPE\'^"/BW\*[7PE>)XPTO4-/F;4]/M/$=[Y?B#3
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M7'X?Y^E?%W_!+/\ Y2CWR\97XQ>+3GV_L&&OM#_@F&V_X*>,2N[;_P )+KG
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MW:WO<]!_95\;7'A']GKXAW_F ?\ "M/BY\._'%DN1F,3R75E=.H[;A'$I/\
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ME_$?Q_TF/Z9'K7P^,DHU\:UM&*7X)'T3C=8&GW;?XGZ36XZU+4<76I*^!/O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? _\
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MK]4\%?"W4/V1/^$H_P"$D>?XL7&I2VSZ0L5Q%:E-\<NU5V,2\4,BPHQ81$#
MW.H)YS3;!M)T^"T:3=]G0 [3D9YZ=0/F:1\J2I$X(Y!K]0R'+'6Q&&R]7W4I
M=-(ZMKYZ7[H^#SK&QI4*N)\K+YGOVK_"GX7_ !*\*7?C&.3QY\,='N-0^Q6M
MUJ6E#6-(N)F$C!(I80DJA5C);Y7V[@.37D?Q/\'VOP^\=:II%CJ,&N6^DR"T
M^WQ*8X;EA&/."HV&""9X%4L,MG) Y G^&/C+3?!OB17UK19?$6C,Z27&EC49
M;.*ZV-N4.4^^H(!VD'\*YKQOXK:SBUC7[K_7,)=1F &"RMF4#T.\O"4(_AC.
M<;A7Z5Q-2J4_98.4FXSFET^&+N[Z7V6M]-4?$Y3.G5YJR2YHQ?2SN]-MMVK=
M=#Z@_8<\#Q:[\+_A#I1B+W'Q@^/QUF3NLVE^%K+#'_=6XE<'ZBOT8_X)D68^
M)7_!0'XL>*F'F1Z:+JWAD ^4Y>WMCSZ%K:4@>Q/>OD7]CCX?/\%OBWX5L=6
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M">3X&?L_^$?"]QL^W:3IT:7S*00]TPWS'(ZYD9^>]?F3^P7I,'[>_P#P4/\
M^$NTNV7_ (5A\-U6Q\-P1@_9X=/TZ18XG ^Z/M-[$C+T)CL>.,BOUYV GH/R
MKXG.JL8PI86&T5=^;9]#D>'E*I6QM3XIO3T0R/[U24 8HKP5HK'T@4444 %%
M%% !1110 4444 %%%% !1110 4444 %% -% !1110 44#BB@ HHHH ****
M4444 %%%% 'Y,_MJIN_X*L:]U.?$WA =,X_XE-_V_+_.:Z+_ (.#5V_\$^K5
M>?FU72/I_P ?D/3M^=<[^VH<_P#!57Q /3Q3X1;![XTB^_&M_P#X.$&Q_P $
M^[->N[5]'/7G_C[B)_G7W6'_ -QH>D_U/SO&7_M:IZP_0]3_ .""+B3P3^TW
MA=O_ !?O7QU!_P"7#2O2OO2O@G_@@62? ?[3!*[<_'K7^",'_CPTOJ*^]J^+
MQ'\1GZ#3^%!1116)84444 %%%% !1110 5\I_P#!93G]C*$;=V?&_A4?^5RS
MKZLKY3_X+)G_ (PZLUX^;QUX5'/_ &&[.M\+_&CZK\S#%?P9^C_(\]_X)C$R
M? /Q3SN_XG^MD_7^T;G\NG2OC7_@D@V__@I_=?Q'_A:OCDY)Y_Y!%G7V5_P3
M!;;^S_XFVL2O]NZUQC_J(W/8=:^-?^"1/S?\%.KK)Y_X6GXZ/'0_\2FS'^?K
M[U];GFCJK^MD?#<+_P 2/I_F?MI">34E1PGDU)7Q9^@!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 444"@ HHHH **** "BBB@!G
M);[M>;?M9_ .']I3X$ZYX3=[>WO;I%GTVXF0O';7D9WPNP')3<,,.ZLP[UZ9
M4=PNX549.$E*/0F4%*+C+9G\ZZZIXB^$_@+7/AS##/I/Q&_9]OY/BA\*&NS^
M\>RMI#_:V@/G(?:HF4H=V^/&!C&?"?C?X5T'PWXGT7Q=X';_ (M;\7K:;7_"
MJ(WS:-<!PVI:)(3TEL[HEHP<AHFA;D @?JE_P7O_ ."?M_XJT^W^+'@6:;1_
M$%M<)(;RU&PV.HE?*24D=(KM-MM+GY=WDL>"^?QI_8N^)MG;:'XD^"_Q.>YT
M/P#XOU:+[#K\\+,/AWXIB#"VOEX^5) #!<QKR\+D_P#+,8^DHX^$)QKSC>$U
MRS7EU7JMTSYZ&7N=.6&O[T7>+_7Y[,VF0!CM;*2'<-H(49YX)YVD'*YP<9!Y
M1B>Z^'G[-_BOXI?#CQ-XLTNT7^P_":K-?7,[&-%CV2,SH<'>4,:AE7+9D3C&
M2./\0>&-<^''C?7?!WBZQ_L?Q5X7NS8:M9B4%%D^\)89,E7MY5*R13+E2&!Y
M5G%7=$\>:YX*TN^T_3M6O]/M=2,3W*VTKP_:%B+[<X/ !=P5/?@YQ7ZEP_G%
M=T5ELIKG5G"3U4X?YK9KN?"9EE].-1XB47R_:2M[LO\ )[IE3PG::;?^+_#K
M:I%'+9V>KV5W('9AF-)XS)]WJ?*4C!($@55YD"EOJ#PCJOBJ'QOXET-O$EQX
M9L=!TV/58]42WNKR&X=5MXS.DV!;)!.%N9Y&D,@GW^3)$[@*/E$QJX964;,8
M(9>"#Q_B.G3ZU[M^P1^U-X1_9Q^-.GZM\0?!.F^//#Z3"1);E?.N='E^4"ZA
M61C"S(54DNIR0"6#;G/Q/'W!=7"N68Y9#GAO*"W7=Q7;NON/IN$^)X.*PF*=
MI=)-[^3[?J?H_P##+]BSQ-HG[$'@.ZL;&;6-2U;PC;ZG?>"I)UM-8TQPBM'-
M8[W!4IOC\R!GVJP*Q,N1&W.>!_AEH?C_ ,.6]K;33:?)X=D%I>-*CK)"'0*]
MM<V[A0N[:$VCYE$8*-#]\=,8X]6U/7OBYX/\>>,/%7AGXC:9HF@7WCC2'DOO
M$/A*TMKBXN[P-:PQ&>&XN6DAMDB@A,4;?,\<:J=WT-H?@_PO^V_>^,_&$UK)
MX>T[P[J+Z9X;\7:%=M:ZSK%O:J%NI92%,<UL+M9XT1UDC<P%MNX+C\+QF!AC
MH\^$DK]5U7_![GZ)&JU\6Q\M^'O%_C_0M)_M#Q+-HMG:Z'-Y1TFW>2YNO$C%
MW_>R7B*CV\(9_-7F5V,8WAF;8^'K&N^-M3\376O:9I_BS4-3@B-DULVE6=I"
MB12>9;S74K3 JP WI#&LDI64JQ0?<])?X$>./B=ID.N> _$OAOXO>&1 )(7T
M*ZCT?5HDF031M);W#& R9$;+N>,$(QP,X'G7@_QT/@!>7C?$;PCXNMY[-'E>
MUUFWN[=TGE!%S';ROMBO>(UD=X6E$LCG:Q(C6N>G1^JQYYTU==E^IOSINT6=
MW\-OCUK'PKAA70X/$MK/"(1,988HUG 08$D1)&6^;/ (R<'C->D>/_VOO#?C
M_2?-\=>$]<TF]2W:&"\TK4@S2$,2$,+LL94G).22,@#%?)'[0WQMTVSO(Y-#
MU#X>VVI0VDNJ_P!JQ:I';F.P"["CF>3Y7:0+B$^8K$$&$MBLC]D*?PY_P4*_
M:.T.Z\?3>!;'PGX+M[HQ1RW%M;?VR&<!7=0P\MV7R]P4XPC8^^0/2P%2=;=:
M:Z-_\ 6(DDM=_(U=(\7V_B)HXM;M_LT=_=2ZIJL5S#(7)SMA@=5'[OY78D("
M%#2@$AN/JCP9XS^%"Z T>I> ?&$FK1IY;26.O3EY\ 8(VS0JK9'W0FT =2*H
M_M,W_@1/&W@^#X=Z?H>K0:);7UNVF>"=%>_N;,R?9]LC16D3,%;9C<<!=N2>
MIJ"?X(_$"/0GU#Q =+^%N@D@O?\ BC5(YI@OHEI;R,&9@"0&F#$\% 0:ZY1C
M3J6AV[&,9*4/>.W^(W[6^H?#[P_#<:!XM\11V:R_Z0GB'3+4R6P925"RJPW'
M=M4)AF/;)Z^9Z7\ -6^/,=[JGCIK[PW;^+!,NF:=*)H]>\2SRQRE"Z1MNL+-
MF7&Y@LC A<P<;II/$/A_X=PV?B;P/#:>/ET^]TV"Z^)_B&ZM[[2="@O7B07>
MFVD#%$C\R54:7Y7C*/YAD$1K/TSX,>);/Q=XL\8?%G7+70=2\!7\4>F_%'4-
M3G$NG&UD697M(I08[BTU"!T\ZTBD2".:%E$6_#@K48*U7$OE\B?:6T@?!?B/
MPE\0/$V@> )+V/4-0UK4-VG&;4-+M8;72%M;.&":&*X1UE@M[9_/66$IY2#R
M^9+ASM\1_:IU#1=?_:=\;:QH?V>XM[^XM4%Y$S;;N2&T@C>8#C:#)&2!_$R>
M8<XC->\?\%2?V[? O[5_Q?O;CX<^#-.T6WF1+?5/$LD#6VI>(MCEP)8U8)Y>
MXAMLB,V[[Q!W1CY'0D@@,67')W$@G_Z_K7Z?P)P35S"4<QQ\'&BM5%Z.?;3M
MIL_R/AN)^)X4J?U7#.\WNUM'_@G::G\ O%6A_!ZQ\=S::S>%M2N%M+6[A;SE
M=L/N+;<E%0IL/F8.YE SG(X]8_/+*%;'\80X9O8'U/0$\#[QPH8CH-6^+7B;
MQ#X%L_"^H:]J%UH=G,)K6SGN6\FV(CV$#<=J1A1N(^Z" W7)KF;^XF3[/:65
MC?ZMJ&ISQ6-EIMM"S76I7,I"1VZ1$;O-D9@H5AE59E."TN?TS/LXK4*7]GTI
M+VLTW=;0AMS/LUT7X'Q>6Y?3K36):;BK;[REV7ZG2_!OX/-^TK\7+'P<VI1Z
M%X=CLY]<\7Z[SY/A_0K9=]W<D_PO(BBW@7(!9HP.C,?H'Q7^T++X@^&VJ>,?
M#]J/#GB_]HB#_A!_A_IR8'_"O_ASII\HSCT:7R7RQY9R<'%?.?[;OCN#]D?X
M-:A^SYH.H17WCOQ'<0:E\9-;LI-\)NHB'L_#L$H^];61!:3DAYV;^[BONS_@
M@E^P1XB^/_CS3_B5\2$>XLO#>G6%E#;21[8K6TMTC>PTM$.0@)"W4P'K&",R
M-C\FQ6,I5:O[K^%25H^O5OSD]?\ AC]!C@Y4Z"@W^\J/WOET]([?\.?I9_P2
MJ_9&A_90_94T>T;33IFK:[!#<W-O(F);.V1-MK;/WWI$07!_Y:22]R37U #4
M*DX]\5,#DU\Y4J2J3<Y;L]ZC35."A'9!1114F@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y,_MHG=
M_P %5_$1*_*GBCPER1_U![X]?QKHO^#@U/\ C "Q&[KK&C9SGG_3(O\ /XUS
M_P"V/M;_ (*O>(E;I_PE7A,GCGC1;[_&MW_@X.1G_8*TX+C<-;T4<C[O^EQ?
MYXK[G#_[C0])?J?G>,TS:IZP_0]/_P""!'_(A?M,8Z?\+ZU_^';_ ,N&EU]\
M5\"?\$ )/-\!?M.-_P!5\\0=L?\ +AI5??=?&8C2HS]!I_"@HHHK$L**** "
MBBB@ HHHH *^4?\ @LH-_P"Q]IZ^OCOPKWQC_B=6AKZNKY/_ ."RK$?LAZ7C
MJWCWPJ.N/^8S:UT87^-#U7YF.)_@R]'^1P/_  2_5E_9[\2'YLMKNLGJ03G4
M;GG_ .OUKXV_X)#9?_@IK,W.W_A:/CQL[<9_XE5D/\^M?9/_  2^.?V<_$79
MO[;UGH/^HC<U\:_\$@./^"EL@_O?$WQ\<XQ_S#+"OK,\WJ_UT1\+PO\ ''^N
MY^VD P34E1PG.:DKXL_0 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH #S1110 4444 %%%% !11WHH *:Z;Q3J* ,?Q9X4T_QGX;U
M#1]6LX=0TO5+:2TN[:89CN(9%*NC#T()%?A3_P %-/\ @GXG[(GQ8\3_ -L:
M3>:]\*/B+;B/6Q:(9+J2W@(-OJ=N/^?^Q9@)5SF:#<Y)W.%_>UEW5P'[0?P&
MT#]H_P"&]]X9\0V^^VN#O@N(P/M%A.OW)HF[,OY,I96RK$5V8/%>RERRUB]U
M_74XL9A?:QO!VDMG^C]3^<<^![[QY_PBOP?\<:UHZ_$C2]-1?@S\19+L1Z%\
M0]#9MT.AW=R<*,ELV\S;F@DS"V%((\LW76GW^H:3JVFZAH>M:+<-9ZGIFI1&
MUO=*N8QAX9D?'ER* .3A6&,D *X^T?VM/V.(_P!CK7-:^&OQ8\/R^(/@CKL\
MFI1OIL3?:_",I/.MZ0>66$9_?V8),;'(5D(->>_M#_L^WW]E^&K;XF>+-'::
MXMX[/X??'N-&FTGQ7;;?W&C^(U3+QOC:D-ZPW1\ LR @?1X:HJ5-0DW[*]X2
M7Q4WW7==U]YX%7EQ$K.RJI6<7M)=FNOE^!X#X0UB/PCXKT[4KNRFOH=/N5G^
MS+,;4SF-L[ Y5BC!@ R[200P(S79_M3?%7P[\8/B[=:QX6\-Q^%M)2-;>"S@
M8+"53&&6)5419.XLH)RQ)SR17#>*/#6O?#+QO=>%?&&AW7AGQ3IR))/IMT5D
M\R(C$<\$J$I<6[C:4FB8X7@'&Y#3,'EA64M)&<[3]YL#G/  88'.!N7^-4P1
M7Z/D_$--UH+,G:5N6,T_<FGKKTC+^ZSX_'95.%*4,(M-W%_%'_->9W7[.?[3
M?CS]E#QO'XB^'_B"\T&_'$L:X>VNU_N21L"C*?=2 <'&54C] /A!_P %6_ &
MM^#?'/@?XB>%9O@/XU^(&G?V3JWB?0M+WQ2J\9C23R&(:,F.1V4)DYD)4$Y:
MOS;\">$%\;^*+.QFD>WT]B9;^YC4M]EM44O-(?3"*V,]6P*]V^)^O6?CK0_
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M4D=7)']!WP%^!^A_ 'X6:7X3T&.:.PTN,J99&S-=RL=TL\C=Y'<EB>@S@8
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M%X#U2;XO>#].?.I/IVG-:^*O#/EYV_VQHK9FB9,'_2(!)%U.Y<D5^S7[1?\
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M^T*>72]S#_6"ZMMUNWKD/@]ZXK2OB!H>M,L=IKFCR2,.9DNK>:8^PBV*R_\
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M/V7/V@FTM&EDN/#NJ0W>E7C9B6_A619;>96? ^9-F2<;2&!P0<>@>-?&NA_
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M$/PL/_*K!7UI7R7_ ,%EW _94\.J<_-\0_"PR.W_ !-8*Z,)_'AZK\SGQ?\
M GZ/\CAO^"8/R?LNZO@ALZKJIQCK_I]Q_GGFOC;_ ((V,'_X**1\_P#-1?B$
MV/7_ $+3?SZ]3_4U]D_\$PUS^R[JW^SJFJXW#&?]/N.??Z]Z^./^"-V3_P %
M%8LKC/Q&^(9YQS_H6F?G]:^KSW_E[Z_Y'P_"OQ1]/U9^V$7WFJ2F14^OC#]
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M^ /C#/X4\0_\%(?AGJWBS19)-*\2?#275=2L%LYKA9+KS $D>*,$EU4;0Q'
M4#/ KZ,_8_T[P#JU]XP\2?#_ $_4=(TVXO5T6XM95EAADFM-^Z>.&3YHRWG;
M3PNX1*<9R3.(PGLH*3>ZOMINU:]_+L3&=V>Y&= =NY=V!Q_GZ&O/_$?[4G@;
M0=?UG1FUQ;S7/#]JU]?Z78P275[!"N<N8D4MCY6Z==IQG%?,'Q[^ 7BWP#^V
M1XJ^(/P9;['XQTW0;'5KGPX[;--\96_F7"74##HEP2D&R08^8G)&XFN[_9D_
M:>\,_M)_M":;XDT6&33[_6_"UQI.NZ3>H(K_ $>\T^Z1FMIX_O97[8P!(P0.
M.X&GU*/L_:Q?,K:]&GV>^G9]0YW>WF=?X<_:UU[XU?"VW\8_#'X?W'B3P_?6
M[W=C>:KJT6EC441F4B&(++)N)5@!*L0SU(KA/CK^TC\0?V2_VB-+\5^/98;_
M .!.OPK8"YTVR,,GA&[D90CWREF:5&Z>8NT(2<KTSYK^Q9\&/$?BWPA\9_@E
M'X^U+PCH_@7Q9?:;%9Z?80O>-8W8%S"?.DW%8V64KA%!^4_,*^M_!WBGPY\=
M_#'B7PO=2:?XFM]#D_X1SQ!E$DL[VX-M&TZ!03P/-VLIP0P([9K2M3I8>JXV
M4H_.]G:SOM?T"+;6ISWPWDT_4/VOO'&H:=]DFAU'PEH5PMS %*W2M-J!5PP^
M\"N"#D\8KE_BOX ?XD?M4ZOX3FUZ'2=#\7>#K=]6MFMHYKC4XX[FXB,,)DS'
M&"L@WG8[<KC;UIW[&'[$5S^QW\1O'$>GZW-JW@G6(K2/P[:W4K276APQM.QL
M]S#YH4,I*'<3\S C/)]HG^%6AW'Q#A\62:38S>);:T_L^#49%+S06Y8LT<9/
MW Q))V@;N,YP*YZU6$*EZ4KJR2?W?BFBMUJ>$_LP?L=>,_V4OC!JFD^%?%S-
M\#Y(EGLM U4/>WNGW+ [X[2;</)MQP<,&R2>!]YO=/AI\*-!^$'AJ/1_#NE6
MNE6"RM-(L*!6N97)9Y9&ZO(S$LS-DDFNFA!5,&G5C6Q%2J^:;UZ]+VZOS\PC
M&VP8Q1116)0449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BCO10
M 4444 %%%% !1110 444=Z  T9YHHH **** "BBB@#\D?VJ6S_P5A\38*9_X
M3KPZ.1_U+\U=1_P<&C=^Q9X94#./%&A$# _Y^X_7_/X9KF/VHEW?\%8_$W)S
M_P )UX>P/7_BGIC73?\ !P5'N_8V\+_*S;?%.A<;0V?]+C_SFONJ7^XT'_=F
M?G>*_P"1Q4]8?H>E_P#!OVZR?#;]I5A_%\>O$)//0_8M,K[\KX!_X-]V!^&G
M[2JCGR_CWXA7[V[_ )<],K[^KXO$:U&?H%/X$%%%%8F@4444 %%%% !1110
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M ^)*C'3_ (]M,_IZ\U]9GV];U_R/BN%OBCZ?JS]OHQS3J;'3J^+/O%L%%%%
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!6_P""G7["DFK>,[RWG^)W@G6+C1O$RQQK#YNYC-:SB(?<1H7$7/)>VE-
M'WM17XS_ /!47]H;XI_ W_@OY^SQ\(/"_P 6/B1I/PW^+W]G7GB#1(M9;R]T
M^HW4$JV\F/-@1DB3Y4<!>=NWI79?MF_\%&_B7_P14_X*=_"SPGXQ\9ZI\2OV
M<?C8@AC/B)89-8\&72W"P3O%=QQH\]O'YUM(5G\QRC2*"&4.P!^LU%>>_M5_
M'B/]F?\ 9Z\5>-?[/N-:OM'LC_9>DVZLT^MZC*1%96,04$^9<7+PPJ<8!D!)
M !(^6O\ @WL_X*7WW_!3?_@GQI?B+Q1?17?Q&\(7TWA_Q45C6(S3IB2"X"*
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M1%VJB@8  '  ':H=#T*Q\,:/;Z?IMG:Z?I]G&(K>VMH5AA@0=%5% "@>@&*
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M?RW4L.Q)&3C-=A5;1M&L_#FCVNGZ?:VUCI]C"EO;6UO$L4-O$BA41$4 *JJ
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH[T4  HHHH
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M%&: "BBB@ HHHH **** "BBB@ HHHH **"<49H **** "BBB@ HHHH ****
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M2[MK:\CFFM65BC"1%)*D,I4@@8((ZBM:OQ_^$G_!9OPSX8_X)_?%[]J+P?\
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MT?X__P#!-/QE:>+K'3_$]CK_ (+>:[$^CS::L[26N3,EK<%I[-\L65'8S0'
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M^%_CCXJ7>K^&M!L9IX;"[TW1HIM%L99<,'D260:A>JI8+F]0X.T5?_X)J?\
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M )=[*OOBOB:WQOU/T2.P4445F4%%%% !1110 4444 %?&?\ P6F./AG\$_\
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M8=8\5:Q::+IUQ?VFEP2SD_O[JZG2WMX$506>2261$55!)+?6NDS0!\U^$_\
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M']IK]IKQG\)? ?B;_A)O%GP^LDO=?-K:R?8K'=((UB$[ )*^3G]UN4#JP/%
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M3>VGQX\,:Y<6MYJ,,$L-A"]P);QT9@5@C)PTI&Q<\D5^G%-,:EL[5SC&<=J
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M?^$4L>W;UKM/^"\C;O!?P57JI^)OASO_ -/-<1XD?=_P5=\8#GCXLW9QGO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOPZU3Q;&MFOC/QQ\/-0U2VT>U7^VAING07MAJD6Y"L=S%YY@F0!H'EMY"(T
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M^31=+^)?AOQ1XOM(?%6K6S:7H$4NO7=KIUI'=6<5S S"Q181<0?;9V:U#K)
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M_CW4V'T\JUK[CKX?_P""!.#^QQXF(</N\<:D>!T_=6O'O]:^X*^&J?$_4_1
MHHHJ "BBB@ HHHH **** "OC?_@LRVWP)\#\<'_A;&G8^;;G&FZF:^R*^-O^
M"S)QX%^!O7=_PMC3L8Q_T#=4]:Z<'_O$/5?F<^,_@3]'^1S_ /P2]RO_  3[
M\)?*W&B69Z'_ )Y+WKXZ_P"#>@^9^TMX9/\ U#?'1SCUUNQ[U]B?\$OD\S_@
MGQX2QRK:+9X/.1^Z7O7QW_P;SC=^TQX;*Y _L[QWQST_MNQ_SQ7U?$'Q5?\
M%_\ (GQ/"?V?1?J?M9'R?PIU-CIU?%GWRV"BBB@ KRSXH?L5?#'XS_%&'QKX
ME\,KJ7BJWTR;18=2^WW4,T-E,K+-;IY<JA8Y QWJ  _!.2!CU,\U\Q?M'_\
M!0;7O@=\7?B)X5TOX5W_ (F'PW\"V_Q"N[O^W8+3^U-.::XCGBM8]DC-<H+6
M4HDOE)(RD;T!5F /1?A#^PU\*?@+XTTCQ%X1\(6NBZSH.@+X5TZYBNKAS9Z2
MLIF6Q0/(5%NLA++'C:IZ 8%=A\5O@QX6^..AV.G>+-%L]:M=,U"#5K(3 B2R
MNX6W17$3J0\<BY(#*0<,R]&(/@%Y_P %/]+?X\> _"UCX;230_B9?VNE^&]3
MN]76UOM7DNM#DUF"^AL?+9VTORXWMGNRX=+I'C$#!"]9OPR_X*2^,/B/X%L[
MF/X4:7'XNL]9\4Z3XD\+P^,1)>:$-#)2202/:1Q2F>1K78&:-/+O[63>0Y"@
M'IOB?_@F]\!/&G@+P[X5U?X1> =3\-^$]4GUK1M-N=(BEM=,NIY&EF>)",*L
MCL2R#Y&P 5(4 =)K_P"Q[\+/%/[06D_%?4OA_P"$[WXDZ':_8[#Q)-IT;:A:
MQ8("K+C/RAF"GJH9@" 3GYJM_P#@L!JUY\-'\2Q_"&X$,WP>MOC;91/XFB4S
MZ+Y?F7=NY$)\N]C!3RHP&BF$B[YH"&5>P\6_\%6?#6C_ +0VE^"=)T&;7K63
MQ!HWAC59H+]5U33[O5K2VNK2:.PV$S6:1WEH;B<RIY(FR$D$<A4 ].'[ OP;
M3PEXIT&/X?Z#!HWC2WFLM8LX4>*&YMIIC//;*JL/*@EE9GDBCVQNSL64ECG5
M\2?L@?#7QCX5\(Z+JOA.PU"Q\ KL\/FXDEDN-*0Q>0T<<Y;S?+>$^6Z%BLB?
M*P9>*\0^$W_!3K6OBIXA\,::_P +6\/S^-K[Q?X?T?\ M'Q)$^S6?#US<0SV
M]U]GAE$5O*+:8K<1&9@T;#RF78\G5_LQ_MK:AK?_  2_\/\ [0GQ8LM(T.-O
M 2>/-930IY;Z)+,6 O79%>*-UD\O=^Y&_:0%$LOWR ;_ (7_ .":_P !/ QL
M?[%^$_@K1X],N;"]M8K+3UMXH+FQS]EN B87SXU)02XWE"4+%?EJ3P?_ ,$Z
M_@SX \0^'M6TCP1:V>H>$]9O/$6D3"_NV:PU"\"K=W*;I2/,G"XD)^_N?=G>
MV?%/VD?^"D?C;P3\$_C-I-OX)T_P9\6O#'PJN_B;X7BO-;%[87>F(KI),TR6
MS!;RTD"&2U,;Q.\D"K<,CO+'Z+\&+3Q%^R;^R-KWC34X_'GC[7M4ABUP^&CX
MLF\3BTF:"&#R;*]O(8)DMY"@N9!*-D#S7'E@1JJT =CX$_X)]? WX8^ _&GA
M?P]\)O &C^'/B,[/XFTVUT6".UUO=N^69 N&1=[[4^ZF]MH7)KLO@7\ O!?[
M,GPTT_P;\/\ PQH_A#POI>XVVFZ9;K!!&6)9FP.K,Q)+'))ZDU\Q^ ?^"M,W
MQ.C\(V>@?#RWUK5?$GQ%U7X97%UI_BJWN-!L]2L].DU&.>.\\L2W%I/;Q[A(
MEL&3;("FX(LDG@#_ (*F^(_C!XOT7PGX5^#MU=>,M0T[Q2+RTU#Q1;6EC8:O
MX=U*'3]0TW[0L<CN&>>)XK@0A'2>$D)F7R0#Z>M?@EX0LM3M;R'PSHL-W9:U
M/XC@F2T17CU*>"6WFO 0/]<\,\L;/U*R,,X-<AK7[#GPI\2:_P".-4U#P;I]
MYJ'Q(EL;CQ+---,[:K+8R))92/E\*]N\<;1.FUHRB[2N!7@7@_\ X++:7\0M
M)N?$VE?#W6(?A_I/PXTSXK:KKNHZI!;RV>AW*WIN2MK&)'>YM9+&:-H25WM&
MY1B AD=\9_\ @KM>?L\>'?$'_"7?"75H?$UCX6L?'.E:/I^NV]Q_:FBW%_!8
MS.\[K&D-W:2W,'GP+YB?OXO*FG!8H >R'_@G)\%?[>_M)? EDEY_PE$/C4,E
MY=*J:U"A2+4%02[5N$C.Q7 !"80?* !Z)\:O@IX7_:)^&FJ>#?&FDQ:]X8UI
M!%J&G32R)#>1A@WER;&4LA(&5)VL."".*^:_B%_P5+U'X7_$S4O NJ_"V]E\
M9:3XW\-^%)X;/7H9-/%GKYD33=3%Q)'&[(989HI8A"7C>"0C>FR1])OVO];\
M&_%OXI/JOPU\71^+_"O@CP7J-SHT'BI+[2F.J7FJ0%HUXAM8K6>&Y-U>E%=[
M>W$AC*P1JP![#JO['_PYUS0_ .FWGAW[39?"Z\BU#PK')?7+?V-<1*4CEC/F
M9+(A9%+%MJ.ZC"LP-*']AKX3VOBGP[K5OX*TVSU+PGKE]XDT>6UDEMQI^HWS
ME[NXC5'"AIF9]XQ@B648Q(X;P/P[_P %._%7QID^"\G@3PKX+F@\:?%'7/AU
MXC:Z\3RRVT<FEV.J7#S:=<PV;BX@E_L\R),Z1LR[(S&GFM+!VG[(_P#P4\T'
M]KKXQ6OAW1=";^P_$7A^;Q-X>UJSU!;Y9;6&>.%HM0B5%^P7$BSPS0Q%I?,B
M,F6CDC:( 'J_P+_8[^%?[,?B+Q/JWP]^'_A3P;J7C.Z^VZW<Z3I\=M)J,N6.
M7*@<!F<A1A078@9))[:Z\&Z7>^,;'Q!-8V\FM:;9W&GVMXR_O8+>=X9)HU/9
M7:W@)]3$OI7R]X\_X*?WGPW\5?$)M7^&=_9^#_A7X_TKP/XDUEM<@>XACU..
MP-KJ4-K&C>9 &U&V,J-(DD<;%@KLKQ+'H?\ P5(N/^%6^)_&GB3X=2>$?#N@
M^*KKP+#+?^([9I9];CUI=)CAE"*4BMV=Q*TX=]B1R_(Y5/, /HKXO? ?PA\>
MM+TZT\7:%9ZPNCW@U#3I7+1W&FW(1X_.@F0K)#(8Y)$+1LI*2.IRK,#@ZE^Q
MQ\,]3^(W@OQ8?"-A:Z]\.;(:;X8GLY);--#M>,P011.L:1, JL@7:ZHBL"JJ
M!\YO_P %F-+3P#IEXW@H6OB&^\1ZUX72UO=<6STC6;[38HIDM]*U.6%8KV6_
MCGB:R5U@$^)U9HGA9*]?\-?M@^)/B1XVUD>#?AC?^*/!6B:SJ_AB?6H=;M;6
MZ_M334D$P^RS[!]E:ZB>S6;SC)YXR81!^_H ]'\2? #PCXN^,7A_Q_J&EM<>
M+O"MM/9Z5J'VR=#90SX\Y%C5Q'MDPF\%3N\N/.=B8K^-?V9?A[\1_"OC70]?
M\%^'-8T?XC2I/XGL[NQ26'7)4AA@22=2,/(L5O;JKGYE$$>""BX^8? ?[=>J
M?M37?[->J:E\/?%_@OP_\;KJZ;P_J>F>-U3[*S^&=2O&6^MHE7SB%AF$:,'C
M61(9]R2(B5P_[$G_  4TN_@%^Q/\(;CXR6>OWVG:Q\--4\46GC"?6?[6U'7)
M-'@-Q>PW2.JF.XDM\S0L9760(X<PN A /M3PE^R[\.? GP3TSX;Z/X)\-:?X
M!T=HI+/0(;",6$#Q7 ND<18VEA<*)MQR3)\Q)8DU1^+W['?PP^/GB*XU?QCX
M*T3Q!J5U86^F37%U$2\UO;7)N[9&P1N\FX+2Q,?FB=W9"I9L^$^$/^"LUGXF
MN-<T%O!?G>-H?$FC^&= MM-UD7VA^([C5()[B!H]2\E HMXK2]:[7RF: 6C[
M!/OA\S8_X).>,_%GC#X:_%I?&.HZW?:KHOQ9\2Z7''J>KOJK:?#%<*$MH9V5
M2UNF3Y7R)^[*Y1&RH /2[C]@?X+WGCW_ (2:;X:>$;C6%U=O$$<DMBLD4.I-
M%Y3WL<)S$EPZ8#RJH=R 6)(!&O\ !O\ 9%^&O[/FKK?^"_!VC^';Q-)M]"$U
MHC!Q86S2-;6V23^[A\V18UZ1HVQ=J@*/'_\ @I-XU\?6?BWX&>"O",=FNB_$
MOQM+H>O2IXMOO#>H2PIHVIWBP0W-G:RS0J6M1(9HY$?= D6"DTDD7F_P-_X*
M[^"? WP[2SOV\4>*?!?A?P'=Z_IOC*;5(=6U?6[?3&BMF_M5$BACM+^\$D4T
M 9MLRNY<P2*T8 /J"U_8U^&=I\6/%7CC_A$[.;Q1XYT]M*\07EQ/-<#6+,KM
M^S3QNYC>(+D*A7:H9@H 9L\SIG_!,SX!:5+X#D7X4^$+B7X7N7\)R7=I]KDT
M %_,"6[2EBD:N Z(#LC894*>:\FE_P""PNBZ)H&O-KF@Z+H]YH/B[3O"TNLR
M^(7/@QEOK26Z@O#K1M0J1?N)+5MT V7ABB8A)4F/UC\,_%MQX^^&_A_7KS2;
MO0;O6M-MK^?3+J1))].>6)7:"1HR49XRQ4E25)4X)&#0!)_P@&A_\)TWBC^R
M=/\ ^$C:P_LHZF(%^U_9/,,OD>9C=Y?F$MMSC=SUKR_2?^">/P6T7PS9:/#\
M/]'?3=/N;VZ@@G>:X :]DCEO4)D=BT5S)#&\\3$QS,@:16.37RK^T5^UC\5O
MB1\$OC%J%TL?A ?"?X[^&?"VA3>#_$DZWNL6K:IHD4]K=B2"%=DT.H/N EVL
MTI0@+$'E]>UO_@J;8^&--U32-6\/:+HOQ"T[QIJ/@H:;J7B46^BR3V=A%J1N
M?[1-N76%[2XM@/\ 1C()YUC*; TP /:O#_[&_P *?"G[0>L?%C3?A[X3L?B1
MK]M]DU'Q'#IT::A>1X"D/(!DDJJJ6^\P4 D@ 52^$O[#'P?^!7C#3?$'A'X=
M^&-"UK1;"72=,O+>T'FZ592R&5[2V+9^SVY<DB*+:@W'"@$@Y'A;]M.+Q[^P
M]I/QHT/P1XNO#K&F07D7AJX@%IJ5M-)*L#QSF3"QQPR%FEFY18HGE7>H&[YI
MUC]NG7_VF_'_ .SUXH\"BZM=2L_BIXG\ ZSH&G>+\^&?$4MKH>J2B5[N.'_2
M;/S+:WGCE-OO4,V(2^!0!]<?$?\ 8U^%OQ=\47NM>)/ ^@ZMJ6J^2NIRRPX_
MMF.$ 0Q7BJ0MW#'CY8IP\:DL0H+$E_CW]C[X8_$_Q'K&L:[X+T74-6UYK"2^
MO6C*7$TMA*);.;>I#+-!(J%)5(==B -A5 \8\(_\%.;SXMZ99Z3X'^&]WKGQ
M,M=-UW4?$'A.ZUR&T.CG1M4?2;RVCNE26.>>6^BFCM>$CE6)GDDMP0#D^'O^
M"KUQ\0-:U(^&? >GWVB:M\++'XH^ KJ^\126=UXUBNGBA6P$ LW%O<1W$L4,
M@$DQ5[NS 5O//E@'O/A3]C+X5^!=7T>^T?P+X?TVZ\/W&I76G-;V_EK9OJ,B
MS7VQ0=H6>5$D=,;2Z(^-R@C$TC_@G3\#-#TZZM;?X6^#O)O/#,G@R7S+%96.
MBNS,VG!FRRVPW$")2%50JJ JJ!YYIG_!4C2;W]I;0_A[_P (]#>1ZAXEE\$Z
MA>:7JC7USI.L16AGE:2T$"O_ &:)5>U^V.R-YZC,*QLLIZ_]I7]LC7_@E\=M
M \ :#\.Y/%&H>)O">M>)[#4+C78=-L"^F&V\VT<[)9E9A=18<1%<NHZ;VC .
MHN?V'_A#>_&KP[\2+CX<^$[GQ]X3LET[2?$$U@DFHV<"@JJB9LLQ4,V&8EAN
M;!&XYR/&'_!/7X2^*?A-XO\ !D/@_2=)T?QQ81Z9J0LXRC+;)(94C@YQ"J2,
M\J+& BRNTFTL6)\RUK_@K%I=BOPAU:'P7?0^$_BU!X3EL;[5-4AL;R=_$-S'
M;6\5C;;7%Z]F\UNUZ!+'Y$=S"R><6*AFE?\ !4/5]6\9QZ;_ ,*HOK6UD^*E
M_P#"3S9_$-OYZ:E%8O>6UT8T1E^R2JA$C"0RQ;EQ%-\P4 Z__@HG^RSXJ_:M
M\+_#31_#MIX1O-/\*^.=,\5:O'K^I75J;BWLF9A# T,$K"9B^5E)4QM&K#<<
M%?1)_P!D+X9W/A+PSH;^"]$_LOP;?2ZGHT0B*M8W,JRK/,'!WL\ZW$XF+$^>
M)Y?,W[VS\\^+?^"P>G>&/@_IFJ?\(?:_\)Q<1>*);OPU<^(H[9"?#NI'3;Z&
MTNC"?M-Q-<;1:1F*(3!OWC6^"!Y__P % /V_]6^-7[+WB"Z^$]OXPT"S\)WO
M@F_UO7UU270=4TR35[O3KJ&P%J(S)*?L5W";M))(0B72*IF<2(@!]4?#K_@G
MK\%?A%XBL=4\+_#GP[X?NM/T*;PO MA&T%NFES.TDMF8581-"\C&1E92&?#G
M+ $:$'[#OPEMO#$>CQ^!=$CL8=3MM8@"JXEMKJV3R[:2*7=YD?DQDQ1JC!4B
M9HU 1BIQ_P!K+XOV_P -?BS\!=)N]-\27$?C;QXVD6]YIFMMI]O:7*Z/J5RB
MWD2$&[@>.";]RP,?F)&YPT:9K_LS_MN6O[2_Q@\9>%]-T2WMX?!M_J.FWTJ:
MLDU_I<]I=BU6+4+(HDMF]UB6XMN9$FMHQ('!;8 "Q<?\$VO@)<>'VTD?"7P/
M#I<EMJ-G-:6^FI!#<PZ@Z27D<JI@2)+)'$Y5\@/%&PPR*0>*?^"</P5\:ZKX
MBOM4\"V=U=>+;K3[W69#?7:_VE/IXQ8R2A90&:WX\HG[A *X(!KP?PA^U5XD
M_9S_ &O_ ([6>JKXB\9^#;CXL^$_#$,E_KQ9O#']MZ9ID<265NRE6@6]NU:2
M,-%L28NIE8%*W+G_ (+#Z'>>-]4T_0?!UWXKT[^SO$MQH\^DZI'+=376AM(M
MQ!?Q,BQZ>ESY,[6LKS.)4B.]879(V /J3P+\&O"_PR\0>(M5\/Z'8Z3J'BZ]
M74=9FMTVMJ-R(TB\Z3G!D*(H+=6QDY/-<KK?[%OPK\1:9J5I=>!]#:/5O$'_
M  E<SQQM#-'JQW$W\,B$/!<$R2DR1,C$S3$G,KEOG/Q5_P %D/\ A#OA%H_B
M2^^'<-OJNO>#XOB'I^@OXGC^VZAH3VUI*JP 0'S-3DEGGABLP CFS<FXC#QA
MN9\(?MSZQ^S[\9?VBO&>H0^*O&/PET[Q9X6N;F?5-9D2Y\'Z?JNCZ<Q:TL)(
MR?)BFN1--"6B9$=BHE=6C !]*?MD?LQWOQ3_ &!?'WP?^&]AX7T.;Q-X6N/"
MNE07C/9Z7ID-Q$;=GQ#%(V(HG=UC5,.R*A9 Q=:>@_\ !/CX8Z_\#+/PMXI^
M'OAV'[=/8:QK-EI]_=2V[:E:Q*L+)<GRII([<J!!N5!&(XRJ1E5"\Q\+OV^?
M%WQ!\6ZIX5NOAOH>D^,M#^)S> -0TD^+7F\FS73O[3_M</\ 85)CDLRDL4;*
MH?S%0R(^4'5_M@?MK?\ #+WB/0-#L?#/_"2:UKFC:UXCVW6J1Z39QV&DPPRW
MBK<2*ZO=LLZ&&#"JX29GEA2,O0!W'B']EWX>^+/BG9^-M2\)Z/>>*K&.WC74
MI8BTLPMG:2U,W.)F@D9I(6E#&%V9D*L2:\6_8@_8/O/@S\3_ (C>-OB!X?\
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M;Q'-\/O#'_"63:5'H>HV]YJ5A(DIMKNVC>W$EQ9S-$ZK=PI)  CL7PC$<YX
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M\/>"G\#LGC#Q9J$G@?Q'XFUV)[R.Q;^TXO$%S<7.HV5PJVZKY32W#%6C5'4
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MC4X"UL77_!.Z&Z^*]WXZ_P"%E>.$\9+ITFCZ9K*0:<MY:6$FHPZ@]E.XMO\
M3;??;I"B7(<QP-*J%7EDE;Z.HH \]_9:_9MT']DKX*:?X'\-M,VEV-U>W^7C
MCA7S[R[FO)_+BB58H8O.GDV0Q*J1IM10 HKT*BB@ HHHH **** "BBB@ HHH
MH _(.^4C_@JGXR9@.?BQJ6W..WAK3J['_@NPIS\ QV_X6CX>R /^F]<8X_XV
MG^-/O-N^+FJ9..!_Q36G=Z[+_@NL?,G^ *_]52\/\;?^F_I_2ONX_P"YT?\
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M5KR34EU)K>TDM6@2. 0RZFQ>19Y?-2V4!4\UO+Y'P;_P33^+%QHJZ;XQ\/\
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MOKE+>/3K^2]CDM!,PMY'>2&(K*\6QGC"LL;EE620 .VON&[;D;L9Q2[N<=Z
M"BF^:H7=N7:#@G/X5X?\<OVY;#X&?&?5_!-QX)\8:U?:7\/-2^(L5SI[V'D:
ME;6%Q;P3V</G7,;"Y!N8F_>K'$5;B0D%0 >Y45S/P7^*5E\;O@]X2\9Z?!<V
M=CXPT:SUNU@N=HGBBN8$F57"DC<%< X)&0<$U@_%O]HFS^$'Q=^%OA&\T76+
MUOBIK-WH5GJ5LUO]DTVYM],N]2"W :59OWL-E<!#%&ZADPY3*[@#T2BLFYU^
M_A\=66EIH=]-I=S87%U-K*S0"VM)HY(%CMFC,@F:259975DC:,"W<,RLT:OK
M!LGZ=?:@ HI-XW;<C=C.*%<-G!!P<'!Z4 +13?-41[MR[3T.>*<3B@ HKS6;
M]I6SM?VNK3X03:#KD6H7WA*Y\7VVLL;<Z;/#;WEO:RVZXE,XF5KJ)CNB5"K?
M*[$,!Z3O79NW#;C.<\8H 6BD+!,9.,G SWI=P+8[]<4 &:*:74'&X9^M8WC/
MQ1J'AV#36TSP_J'B1KS4;>SN$LKBVB.GP2-A[N3SY8PT<2_,RQ[I&'W$<\4
M;=%>-^)/VVO"NE_$SX>^']*MM0\36GQ \4:GX.36M+DMI-.TG4["TNKJ:WN"
MTJREMME<IF*.15>%E=D. ?7M0U&WTG3Y[NZGAM;6UC:6::5PD<2*,LS,> H
M))/  H FHKQWX>_MK>&OBC^T-I?@/1=/U:\M=?\  \7C[1_$BM;G2=6L)+B*
M "+$IG#YFC;]Y$BD,-I;G'L6X!L=^N* "BBB@ HHHH ***,<T %%%% !1110
M 4449H _'\X_X>J>-&Q\S?%G51GV'AS3<?RKM/\ @NH%>\^ 4>WK\4?#^?\
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MT#X8PJC=X;\9MG;U_P"*AM/<]/PK[$_X)H?)_P $]?"  Y;0+'D#&?W">O\
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M2-@R2*1D,"."".014E 'Y._ O1O%R>&?V:=#\->"/BCX7U#0?$OQ2M-.FO\
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MFH:;XA@TB>/4PK1/8QV]UI,'E^;NMS 59%91O_3+K39IEMXFDD98XXP69F.
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M\$]/!Y[?V!8'.#Q^X3U__57Q]_P;DQL_QZ\-LW7_ (1/Q@WY^([45]B?\$V
M$_X)Y^#MF[Y= L.3SC]Q&:^0/^#;@ _'#0U^7 \%>+2OS9_YF>T[=N]?5<0;
MU?\ $_\ VT^)X3^SZ+]3]GXOO-3Z;%U-.KXL^^6P4444 %?FW_P4L^)TG@']
MI[XX:;-\7?'OA'4F^"5AXC\"Z/IOBBXL5D\1Q7VJQ0"RM8V N9I9(;2-K8B0
M3A]K1N,;?TD(KR*P_9R30OVT=<^+TGC346FUCPI;>&Y/#LEO:K90VMK/-<1S
MB39Y^\2W-P22^PB4 K\JD 'P5XZ^.OC;3[C]KC7[#XA>+M4^('PJD\.7<_AW
M1O%,U];^$K:]TNR377M]/CD9'%LKWTT2RI*(Y[964%@X?H/B-IOC#XF^!?C[
M>?"+XB>/O&?P[^%UWX8\>^!+S2?'>J7+:W=0))<Z]X=74HKDSWMK/:0P!8Y)
M91#-J1VD"-(X_P!+X&CFC62,HRR#<KKR&!YR#[TY5"#"@*/0"@#\X/&/QM_X
M0C]IKX(^)H?BSXP\+6WQRL/&OBZ+1-0\0W=_%#9-I,,NF21Z5<RM\\44:3"U
MC4(D\LZJO0CC=$_:KU#PQ^R8TGB+XEW^D:MX,^,/P[TZZ\3Z=\19]4\,^)8+
MK5=,^W+:7MRXN1!)9R7DEUI]PS&WVO\ ,T 4U^J)0$YP,^N*3RE*XVKC).,>
MO7^= 'YC^)_VAO$.N_$*\N+CXG>)/#WQ&TSXN>)/#'C7P])XCEL+/1O L<6I
M-!J0LI&$-K'%IL=A>Q:DL:EYV"F5A*8:\Y_9O_:XU37?A9HNDZ?^T(X\1>.O
MV;/#'B2]O?$/BNXU6&VUXZ@+*>>0QRF:Q1S+]GNIK;RWA \XXEBWU^OQC4DG
M:N2,$XZB@1JIX51WZ4 ?-O[!GQ:A^+7[$VI:IKE_K?A^VT^]UO3K_4[SQ7_;
M$-K'!<3(]Q9:RX5KFR103#=2@2!$'F?.CFOS<'[:]UKW[)VBZS-^T!XD;Q/;
M_L8W'B\0P>/Y89#XIL_)$%XZQS!Y+PW*RQNLA;S2CQR(XW+7[;;%V;=HVXQC
M'&*3RES]U>N>G>@#YT_;;^,G@J]_X)N^)/%'B/Q)X3_X0WQ)X>@\W4;Z^@72
M=1ANA&NWS&;RI(YE<J "0X? SFOG2?\ X3G]C_Q9X)^#_A#3[WQAX8TK^V?%
MGP3UKS3?6CV4?AO5DB\.W$N[)>TFGMQ;.6Q-92HH8O:RL?T2DGMTN([=GA66
M12\<1(W,%QD@=P-PR1TR/6I/+7Y?E7Y/N\?=[<4 ?E3\#-+\8?MR_LF?%BX^
M&O[1'BCQ5XAN?">E:QIVEZ1X@URQU#PYXJLQ.\EK>7;7*R6GV\@07&G($CA$
M?FQQQ%D+>H^-?C'8^.OA=\-?'4GB;XD>&=._:<\96TVBZ;J/C34?#]C;V"^'
MKIK:VGO!+YNF1R?9WO56Q"RW5R;>)_W<DC)^@]!&X<\]Z /P[^)W[7UW^TE_
MP3A\0W'Q6^)NK:?K-C\#_!/B'PO$GB!]/@\7S3KG6[N2&-UCU&072"UGC=)!
M;A4*K%)*7;Z>TG]K*\UW_@K'X+AT+XC:Y=:!K'Q)UGP;K&E:AXD;R9;=/"4M
M_;10:2G^C0V@GMX)H;UO]*N7N)0/W)0O^DI4$C@<=/:EV\YQSZT ?G?_ ,%.
M/BCXLT[_ (*1_"[0OA#XV^'>B_&,_";QLFAZ;XB,=PU]<S76A/;VL<9N(O)N
M)_LTQAEE6:,?9Y2T,JH^WQ75?VC_ (9^ _V1?V>_AG\+?C%??";X/V_A/7O#
MVI:WK^K7FG:QX2\56RV#66GZO/8O";345#ZM+]EF*07$EL5".HC5OUTM9X-0
M@CN(6AFBF421R(0RN#R"".H]#4H4!B<#+=3CK0!^>_B_P!\0M$_:+\*Z'K'C
M3XF:_:?M,?#W3=$FU>QUO6M#M?#7B#3?+N-2OK6T2X"Z5)>Z>\LT<:!"LVFF
M-B?/DW<I\3OVB-5T[X@?M':#H/Q>TN9_!OQFT:WM=&\2>/;S2;6YL6\)6EW/
MI']JV\AETE'NH;]XY2/+:YM&@D#B24']-*A\^W-TUONA\XIO:+(W%22,D=<9
MSSZT ?EG\+/VG_$WQC_:/^&VD7WQ@\1?#/6%L_!&M>#-#\3&_EU;QOHEQIML
M^H++:6\B6>HW$T[:A#<3%':T^SI./*10[1_!CX[V/Q+_ &S_ -F?Q)XV\=7\
M7Q6F^)7CK0O%'A.]\02-!X>F2RU2"PM4TUG*6I6V6V6*1$1KE+@2.96E5J_5
M:@* V<<GJ?6@#X9_X*'>*]#^$_QP\3>.?"/Q8\,_#/XMZ%X(MH]3T/QL(Y/"
M7Q&T@2:@]K8W$999C/%,;L)+:.)8OM9#QSI*J'Q7XD_%S1?AK\3?BQX]U*?Q
M_P#"/6-:^!/PYOH- MO$LUO>Z#'=ZEJEI<0>3<2BUMTMM\$,UWY0^Q;YIUV2
M.YD_4YD5\;E5MIR,CH:4J&Z@'C% 'Y&_L_ZS#\;?VI/A'I?CCQQKU];^&_B1
M\1_!FGW-C\1M6+01O;6]S8V*ZBL\-Q=2>6\HADE/G211C'RJ .1L?CA=?&#]
MGC1_#E]\3/&7B3Q%KG['WB^TU[2'\87\\MUXBTV2P \Z!9O^0HA:]24X$[IY
MB2;D&VOVAQ0%"]!C/)H _*C5OCO>2_&[P-X)\/\ QP_X0.RAT3P?K7PRENM:
MUC6T\<PO<,VIV\(6[\O5WE?-K)%</*UM$T4D?E %Z]B_9R_:SM_AW^VK\4K7
MQ]\1+&_\*Z8/$FIKXB3Q?(=&T>"+7+>T6PU;3KI@NDWEHQ%M;20GR+Z$33<2
M!@?O4# I H!)P,GJ<=: %ZU\"_L4?MQ?!OX8_&K]KZ^U_P"*OP^TV#_A;+31
M)+X@M?.N0F@Z/ PBC#EY6\Z*2(*@+-)&R %@5K[ZJ/[-&65O+CW+]T[1Q]*
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MDO\ 4;;6K+^S[>)H+F.+4K*:6"Y2"9HS]NMK6)I Y@ CX>]_:NO+W]AKQ_\
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M.HZG!%J@6!)A%);S6$C/*LH= K^=\I"N/UDVC;C P.@QTI/)3^XOY4 ?+/\
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M<5^@;4'VR)*=K0DLKIP)$/S5[EX6_P""8/P6\$^%/!&BZ3X=\0:?8_#O7_\
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M:;K[)$WC/2](DE6],"^<3!,(XC,D=P(RT; Y#!D7O/V./^"KWA/]L#XS^'_
M=OX2\7>$]>\6_#&P^+FBKJAM)8K[0[N<6RN7MYI/+E65E!C?!PP/8@>-^'O^
M" &B^'/ =OH"_$F^U"W\%^ /$'PY^'LE]H:._AJPUIIQ=7%WLF3[==I!,8(W
M7[/&J#+12.2U=K^QG_P2/U;]DW]J#X=_$BX^)NG^)!\/_@W:_!:+3H_"KV/V
MW3;:[%U#=-*;V7;<>8B!L(490P"J2& !V?[7O_!6#P/^R+\5=>\(W?A_Q3XJ
MU+P3X-;X@>+6T=+<)X=T07*VXG<SRQ^=(S%V$,6Y]D+DX)C#T/!'_!6KP]\5
MOV@O&7P]\&^ /''C&^\(VOAK5EO=)%I);:II6N>6T&HP[YD810QRK)*KA9 @
M9E5@I(I?MK?\$C-'_:W^,'BSQA8>,]0\&77Q,\"'X;>-(H=.CO?[3T?[4EP'
MMBSK]FO% DB$SB:/9)S"656&M^R7_P $RE_9%_;+\=?$O0_%EC)X7\7^&-$\
M)VGA9=#>-M'M-'MDMK+9>&Y8R$1A]^Z(;BRXV[3N .5_X*0?M3?$K]G?]NS]
MDSP_X+U>_F\/?$[7M8TGQ#X;BM=/9-82WL//A*SW$8DA97/)2905'W6/!KC_
M (+R?!V?X+>"O$:PZE9^)/'&OZMX7M_"VKW^GZ3=:=J.DHTFHQ75W<7"642P
MJ(\/YY$C7-NJY+D+ZQ^V3^PG)^U1\8O@_P"/].\7R>%?$_P3U*]U?0_,TQ=0
ML;NXN8HX&%U%YD;O$(ED&V.2-B9 0Z[<'Q_PW_P1 \._"OPS\']1\#>.M6T7
MXI?!_P 5ZMXR@\77^FQ7R:]>ZS\NL1WEFC0J8+F,+$JQ21O$D<8$C,&9@#RW
MQQ_P5&\>_MB_ME?"7PC\$?&EK\.?A?XR^%;_ !6?Q5>Z'::G.T4-^D4UO=VL
M[@K"B1S0.L#QRB63S%D9(RK>I>&O^"\/PW\4^")/$$/A'QI:V.L>"=:^(/@[
M[7]DB?QGI6DO*+PP+YQ,$PCB,R17'EEHV4Y#!U7NO&7_  3>U/Q__P %"M*^
M..L>/-.U+3;7P%<_#R^\-7'AMLZCI]S*T\[&Z2Z79(92 I$)58AL(9CYE>.^
M'?\ @@%HOASP'!H/_"RM0U&'P;\/M?\ AM\/I;[0XW?PUI^LM,+JYN]DR?;K
MM()C!&Z_9XP@RT3N2U 'H&J_\%JO GA;]G;PC\3M>\'^,O#OA7XC6_AH>$;[
M4VLK>UUZ^UI9V2R$S3A+=K5;>5[B2X,<21J'5G#IO]0^$/[=F@_M1?L.ZW\7
M_ $-Y<16-EJR_8O-M)[BWO;!IHIH0ZS&VDQ)"2CK-Y4BE&#[6#5YGXJ_X))?
M\)K^P!\%?@W>?$6ZL_$W[/\ J>BZYX-\8:=HRP_9K_2$>*RFGLI)I%F7R799
M$\U0Y)8;.%'TEXT^'/B#QK\"-?\ #-QXCL1XBU[2KFQ?5CI1-I;2S1,A=+03
M!O+7=E8VG+8 !D8Y8@'P-\!?^"M7Q$\4Z7^P;H6GZ?=?$*;]HRVUV\UOQ'J5
MM9:#>7\>EV%R[H+*)Y8;=VD:WF+)*5V0,BJ6E^3ZM_8"_P""BGA/_@HQ\/7\
M7>!=+U1?"[-*L%_<7-G)\\<S1F">&*9YK6XVA93%.B'RYHV!;+!?'?@+_P $
M86^!OA_]E%8_B9)?ZY^RG/K<.E7@\/K%;ZYI^JP/;W$,T!N&,<ZQL-DRR%0P
M),39P/3/V0O^";6E_LL?M+?$#XK-KUOJGBKXBZ3IVEZPVG:+%HMMJDMJ97?4
MKN"%S%+J$\DK%Y8DACV@ 1!C([@',_$C_@M3\(?AO^U^/@Y<3W%QK,7B:P\%
MW5ZMY:)';:S?0--;6_V=I1=21']U')<1PM#%)<1JS?+*8W_LG?\ !5BX_:\^
M(/C;PIHOP9\>:+XB^&FI:AH_BVQU;4=,BDT"[MH8Y+=)"EPZR)>.\B02Q%XV
M^SS.65 K-U_PK_8,O/@)^UU\5/B5X+\=3Z;H?QDFM-4\0^&;W2EO(X=5MH1"
M+JTG$J&))D5!-$Z2%\'8\1VE/+/A-_P30\;?LZ_MJ^)/VC=2^,D6N:IXH\./
MIWC[1M,\#7"Q>+D@::2UGCA2^G>.YMX?(MH1#'(3%!MV/)*[L 9'P>_X+R>$
M/CWX ^&>K6'P_P#'WAJ/XY:5XEG\!W6I-ISQZE?:)YHN;1]ERPAD8Q-Y1F*)
M(5(W+P31_9"_X+")=_L__LFV_BFS\:?$;Q-^T=8ZM#IGB%=)T[1GNKW3_-9E
MN;..Y>.W:5555,;M&"<N8QG'S]_P1O\ ^"6GBGXN_L'_ +/>I?$*^\5^ /%'
MP(B\9PZ%X4\0^![K39=-U36+NZ5;N[%RT3WEO';RQS1)"(L22N&G;;Y:?0WP
M5_X(DZU\%='_ &4+&U^+FGWL7[*MYJ\^GM+X.96U^/425D2;%]B)DA=U5E!^
M8JQ4@;" =G\5?^"TOA'X%WFBKXS^'/Q/\*PW%WX:T[6Y-4T^"U.@W6NH[VT(
M#2C[:T C/VD69F,!(!#,'5/&_B__ ,%:OB9/X-_;FNK;1;GP;I7[/$\>A:+K
M6E16.L7E@XCW2:@UK=20QW$C+*LHA9E14B"99\[_ $+]MC_@B2?VT_CGXZ\:
MZG\9O%>GQ^*&\.3:3H\VDVM_9^&WTB=9C' TF)EM[APTDD,4D(:9A([2;$1=
M#XN?\$;6\=^%/VI=#T7XE-HNF_M236UWJJW7A\7TFBW"QQQ7#0L+B+>LB(=B
ML!Y98DF0   #=8_X+??#GX6Z9>KKUAXLU;3?A[I'A"Y^(GB>&RMK>U\,2>(D
MC-BTMN9O-DR'665;59A"D@P7(*B3X^_\%Q?!G[-WCWXY:7XC\ >.6T;]GF]\
M-P^+]<LY;":U@MM=95LKJ&/[0)I5^="Z*FY1G@X&>9\4_P#!!#0/'NE^)-)U
MKQ]<W'A_XI:=X/L_B38V^C>2?$C^&D2.R>SD-PQL%FCBC2=")]P7Y&B8EC3_
M &N/^"%&J?M4ZK^U!N^+FG^'])_:@/A=-3M8_!S7$VAQ>'VC-FL$GV]0S/Y8
M$C.F#D[53I0!]7?MH_MH>&OV(_A[X=UC7K'5M:U+QIXGT[P7X:T;3%C^U:WJ
M]_(4M[9&E=(H\[9'9Y'556-N2<*?DO\ 83_X*1>/+"T_:1D^*3>-/&\G@3XR
MQ_#_ ,,:;;Z/82:A9QW MHX(KB2PBCMQ$DDQ:2YD.%0')+;4/TQ^W-^PS#^W
M'\)? ^EZGXED\/>+OAOXMTGQYX>URQL?,M[36]/+&*5[1Y/WENWF2@PF4'#C
M]YE0U>$>(O\ @B/>:U\/_C'I-O\ '+Q=IEU\:OB'9_$'66M]$LC8K)%)NFL#
M;,"9[2=!&C132.I$$6Y7!E64 YW]H;_@N8=2_86@^)/PC\)W%UKLOQ8M_A)J
M=KJUW;8T*_\ M2QSR(\3R07:M&5\IXY#&?/1V.$9#ZFW_!:WX36/[5NG?".^
M^T6NN77BJV\!7,Z:C8S+9>()[3[4MF;=9OM;1*<0-=+#Y G81[\[BO#Q_P#!
M"32K/]F/QQ\.(?B9JTC>(_C#_P +ETG5;C18#)IFH>=!+]FGAB>..XA)A.?+
M^SGY^-H %>V_LY_L#WG[,'[2OQ.\9>&O'UV/"OQ=U.#Q+K_AB?2D<0ZTL2Q7
M%Y:7/F#R8[H(AFB>.4Y4>7)$.* .<_:U_:Z\2?"+_@I9^S/\,--U#5K32?B9
M9^*KB?3(-(LKJV\3S6&F&X2"2[EG2>P,#!'5HXI%F,P1B@4L//\ _@A1^TU\
M:_V^OV;/^%Y?$KQ?8KH?C9[^RT[PG9Z':PPZ+-:ZE<P_:+:[1O-:%HE2(PW*
MR/YD#2"39($'JW[5G[ ^O_M!_MN_ _XU:+X\TGPW?? NWUI-,TJ]\-2:E#J,
MNJVGV2X>:1+R!@JQ!"BJ 0X8EF!"K>_X)7_L%W7_  33_8\T?X/R>,8?'%CX
M>OKVYL-2&C'3)O*N9WN725//F5V$TLN'78-A1=N5+L ?+'_!/W_@K]KWAW03
MI?QRN_$GB>+Q-\?->^$/A_QB+'3+>WM)H64:;;74-J(GS+MD3SD@VAR-Y52&
M'J>D?\%R?"%_JVE6EQ\//'%HU]\=YOV?;EC-8N+'7HQ"?/;$^7M2)'.],L/)
M.5RR@U_AK_P0_P!!\'^,]&_MCQYJ'B3P7H/Q8O?C5:Z%+I4=O.WB.?=Y>^Y6
M0AK* MYB0^4',@R\SIB,8OB[_@A9]M^(ZZMX?^*]QI.D0_M #]H:+3;SPVE\
MS:NZ(L]I),MQ$6MV9,Q[51HU=PQE.QD *'QV_P""U6F?%?\ X)@?%/XT?"9?
M%7A^P\,P.EOXB@LM)U>\TAUU!+1S-IDUVACN I$OV>Z\HM#*CKO.Y%[7X^_\
M%H]"_9@\>ZYX3UKX>^.O$FH>%/A-!\7K[4-.?3H8;K13/':S2*DERI699C)^
MZYR$^4G(SR/QO_X(*V?QET'XW;?B1:Z'XB^.OA[2_#GB'5+'PG';QWZVEU]J
MFU&ZM8;B.&;4IY/E-PBQ(L8P(2[/(UO]HO\ X(H^(OVB_B)XB\27WQ@TC3KS
MQ/\ !"+X(7<<'@IVC2R^TQW4]\F=0R)GF$NQ22J(ZJ?,*%V .P\4_P#!=?X'
M^'?CWI'@6&^O+V2];PU'>WS3VMFNFOXA19-,'V>XFCN+@&.2"29K>.06Z7$;
M/CY]D%E_P70^%M_^RU\0OC)'H?BB3P)\.[R;3[ZZC>R>X6Y74XM-C@GMA/YU
MG+)+-'*%N4C'D,),\,J[/[(7_!+2^_8X^.]QXX\._$N:9O%GA/P_X:\;:=)H
M2^1KLVB6:65C?6K&=FLI/LZ>7(A\Y7#L1L;:RU?!_P#P2,L?"?QX^(7Q*'C"
MQ;Q9\1_#MCX:UIH/"5G%I_B"&*\6ZO)]5LB6M[VYNU#VSRJD)6"1@ 9#YM '
MTG\&_C-;_&#X7P^*H=/N+'3[A6F@*7-OJ,=] !N2YMY;226.>&52&C9&+,"
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MV=]J%@B27ME;WCQ"UN+BW5P9(8I6=,/D#8^UOQ]_X*'_  G_ &8OC)H_P_\
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MX1>#-0^&_B_PUX@EN+W1M9TJ9A)!?6C2V+;;M)5!>*6 HR,8Q*I'F$ ^Q_\
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MOQ%O=#\2V-UXDL3<^(O!6M:9 ML'L@\#HRR)&CK,)X9(9,$*X7Y@#T?X-_\
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M)?#/A;XF?!_XH?\ ";:+XF\)ZI<W2QVD^I23WD:RS6L$D<CVEW=Q"/8R-)#
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M% !1110 4444 %%%% "! #T'?MZTM%% !FBBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %?#O_!:>39/\ ^W_ !6E\<@[<?\ $@U/O7W%7PU_P6J'^F?
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MW_D_R/SB,O\ A4J?XU^%S[(_X(_)L_X)?_ OW\'V)_\ (8KZ0KYO_P""0/\
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MIX[^ >#C_B8>)LG./^9=O:^^J^ ?^"W4IC\?? ,*Q4_;/%)R#_U+MY7=E?\
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MUO>7,*G/V:Y* 3PGW24.A]U->I"OS-Q<6XRW1]1&5U=!1110,**** "BBB@
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MW^R#^PYJ7[,O@SX1^"VGLI/"OPSAUG6$AMYW:.VU2^N)3;VMOO&XV=I:WE]
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MM7Y!_P#!K[K<B^+?C9I\A;9=6VB7B+GA=IO%/YAU_*OU\KX?,HVQ,O.S_P#
ME<^@PKO204445PG0%%&:* "C-%&* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *,T44 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%!HH **** "@T44 ?CO\
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M*_(XB^@U+P-XENM.N=6U;PO97[#3/$!MMQD6W$@9@T:G#[",[3R<GMFOI/\
M89^,?A^TN;[P/%?WDT>FWD\FD:B9# FKVH8#!B9?FD'&6)/;BOG[^PM4\?R:
ME-';WFJ2Q1-=WDJH9"B<;I'/8#/)-;_P;U1YI=%_X2&XO+K0/!=VJ:59V+):
MSP/<-N,AEVX8!@%'F' W<C'-<_&>3_5W*I'X):IQZ2>\7Y/=>3*R3%^TM&6Z
MW]#]%O\ AG2T^(GA/3M1N/M%UH=Q<2Q0@:GA+*9$R-RD@#:65A\F, C'->27
MG@KQ/;VLNDQ^(M'U"&VE,4MQ;-(3\N,-N[G<,]"2.]=_\.O#_B[5_@%I_BZX
MLK[3M%O-0FMA([!X(Q'<&)]YCRH+;1EB"K8P.3@;.BZ-_P (PEK8ZI9WUPTK
M?:[>XM80UMY/4R,W"KA<'#?,0, &OR/&9A6IR]G!7?1?F?5JGIZF9X._91^(
MOC_2M/U3PWX;\,W$$,CMYME>P^=<L,[<P,ZG>%P.I&2?E)Y%_P &_LW_ !,M
M?'/A^\UCX>ZKI,EB91=RR7D:Q/B$J#L"!@6D&2%;;D_GM^"/BQ:^%/'T,^ES
MK;Z?#<A[5AM;*#;OWDY*OE3M)ZAOK7TC\1?VM]'\6?#.ZN[7Q3!9WD",[V6K
M0HD<A'.$?RL/GD#Y@:]*CBYU*7OZ/L3[-1=T?.?B3P/)HGQ(\&:Y>6]XVI>'
MM.DL;.2"Y3R6CX\PR1XW\%1SP!7 _P#"A+CX@Z7X@EUJ8Z.LGB6+Q,CVEU&\
M]V/-E9 (V.[:JR*& ]!^/=? K6=%^+_BZXN-=N/#UNKRM<M<&::QD8R*N(=\
M2_+&J@?+@9;).:]E\3:U\/OA;X)^RV<:WEU=$M:+936^I0F3/"LSCSURS9V[
M><G'I5.ZCYFO.[V:/B'XPWUS_;NM7EUH%U<QR^8Z70CSY W$ESZ?+GCCIS7R
M!\2OC#!X\UR^U+_A(=6\/WWAV-#X32TMG47\QDQ(Q<'*]#\PSSP17WG^W%X]
M\0:3X-NO"?B+PW=Z?9^)+2)Y4L)U@D:(SB(QRJ/F#;CC9&=PV_-UP/@3QOX>
MUW7?B)#X9DN)M=3PGNTK1XXH%,L<).\QDH/WCAB5+=BIKUN'<'+$XF*@FY:V
M\O-^2W9Y^98KV=+WOAZ_UZF3X;\-:OJVEWVI&&^U-K?_ $G4+LJ9"K.W+R-Z
MDG.?>J\>GWFNZK8Z7IL3W>J:E=0Z=80*?FGN9Y%BBC![%I'4?CGM6E!XGU+P
MWI>H:;#=7-I:ZB5AO;='*K-M.0''7((/'.,=\U]Q_P#! /\ 8FG^.'[0\OQ8
MUNU9_"?PWD:+3?,CS'J6K.I 93T(MT+9QQOD'=17ZWG&(AEV!C@HM6C9OS>Z
M7_;TM?1'QN#IRQ5?VT_3TM_P/Q9^N/['OP"MOV7?V8O ?P^M=LG_  BNC6UE
M<3!<?:KE4!GF(_O22EW)]6->I553/GCAASZ5:Z5^52DVW)GUT8I*R"@]**3M
M04*#D44#BB@ HI,9I>U !11BB@ HH(R*.] !111VH **.]% !BB@FB@ HHZT
M8H ,<T4AI1TH ,444G2@!:CNKF.RMI)II(X885+O([!510,DDG@ #O4G2F20
MK-"T;JKJP(96&00>H(H ^;=9_P""QO[+.D:'=W\7QZ^&>M+9J"UMH6M1ZU?3
M$D )#;6AEGF<D\)&C,>PKA=/_P""]/P!\;^*;W0/ ,?Q<^*/B+1U+ZMI'A/X
M9:_>7^BIP%:ZA>UC:(,3A<C)-?8^DZ3:Z!I=O8V-K;V=E9QK#!;P1B.*%%&%
M557 50   . *^"_V*_@]8_L/_P#!9GX\?#_3[[Q#JVG_ !\\,0?&""ZU3;.T
M-]%J=Q9ZA:I.-I\N/[59-'&58JDF-_R@$ ]ELO\ @H)XN\475Y'X?_97_:.U
M2&W81Q7=Y;>']%M[AB@8$+?:M#.%!.TL8N"#@'C/-:3^UQ^UQJ5C;S3?L>Z#
M823*"\,_QCL2\)/9MEDR\?[)-?7@XH% 'R9^R9^WU\0/C?\ MY_$[X+>-OA[
MX6\#W'PW\/:9K$CV7B"]U26^DO<LODO)I]O#)$B!0[(YVNRJ-Y\P1=3_ ,%;
MOCGXJ_9H_P"":/QJ\=^!Y)K?Q9X;\+75UIEU#&)'L92 OVD*RLI\H,9<,I7]
MWSQFN#_X*C6\G[.GQ'^#?[3=C]I@M_A3K9\/>-FMHC(USX4UEXK:Z>1$&^5;
M6[6QNP!G8L,S ?>SUW_!9J\BL_\ @DW^T=YTT</F?#K7(U+N%W,;&4!1GJ3T
M ZF@#TC]C"^\3:M^RSX"O?%GBBU\;:QJ&@V-W)KL-@;%M5$EM$_G/%A0KLS,
M3M1 >#LCR4'R+X _X+,^))O^"POQ"^!OBKPCH^E_!C2=8L?!N@>.QYMJJ>)9
M]-^VC3;J69_)D>?9.D*QJC!TA3]XTZ&OJ;]C;QWH>E_L9?"AKK6M)MUM_!6D
M-*9;R-!&!80DDY/  YYK\Q_ /[0'[*OQ?N/VZ?#?Q%^//@+1])^*WQ.@70+O
M3-;62_MI;?3+.2SU>Q>%B9/*NXBR21Y026NUS\P4@'[.4"OS0_88_P"#A#P_
M\6O@,='\0>#/BU\2/C1X'<:7KUC\/_ U]J\/B2*.0P)K]K(L,-O#9W?EM*J3
MM"ZL)(U1PJ,_M^I?\%+OBEXIL(?^$!_8W_:!UJ^F@:4)XEFT3PO C%,Q!I)[
MUV 8Y#?(6C Y4G"T ?8% /%?-WPW_P""@MGX#^'EC=?M.2?"?]FGQEJ]Q)]@
M\,ZM\3]/U"6:V6.(^89W2V0R!Y&5DB$BJ%1O,._"^^^"_&^B_$GPGI^O^'=7
MTO7]"U:!;JPU+3KI+JTO8F&5DBEC)1T(Y#*2#0!J8HHI#R.E "T49HH ^%?A
MM\!_$O\ P4?\<?$[QSXE^.'Q=\&Z3X9\<ZYX/\'^'?A_XI;0H- ATR9;![F]
M2.(&[NY;JUFN52[,\"PSP@1[7=3]$?\ !/;XM:Y\>?V%?A!XT\3W$-WXB\4>
M$-,U+4[B*+RDGN9;:-I'"9.W<Q)P#@9KY(_:.^,FG_\ !#O]H#XM?$;7--U>
M?X'?M ROXA;4;&.:>W\%^,(K+RGAN8HTDD$&K>7"4N%#>5<1,KKY<B,GUS_P
M3Y^&,GP5_8/^"_A&X6[6Y\-^"-&T^X%TA2?S8[*%9-ZGE6W!L@]#Q0![!17S
M3_P4)_X*A^"?^"?,_@W0;_1O$_CSXE?$B[-EX2\%>&;3[3JFMNK(LC@L1'%&
MGF*2TC#/.T-M?;V_P_\ VLHK?X6>%M>^+>@?\*-U?QAK']AZ;H?B;6K&:>:Z
M<2/!$)K>5X?,FCB=ECW[LC:1N^6@#U^C-(SA%+,0JJ,DGM7S-XL_X+&_LS^#
M_&4F@R?%KP_JE_:ZM;:'>MHL5QJ]KI=U<2K#$MU<6L<D-NIE=(R\KJJR,$8A
MN* /IK'-'2CM1WH ,44=Z,4 %%&:* "B@]*!TH ,444&@ HIN*=0 8YH-&:*
M /QU_9.DW?\ !0/7.%;'CGQ\<#.1_P 3NW'K75_\%JF\K]JS]F7G!'C1VZ],
M63US'[)3_P#&?.M;OO?\)MX^]>/^)[!^ KH?^"V1/_#5O[-!YW#QC*WI_P N
M3]#_ %K[J>N&I?X/_D3\YIK_ (4YO_IY_P#)'V[_ ,$D?^48GP%_[$?2S_Y+
M)7T17SS_ ,$E7W_\$QO@*?\ J1]*[Y_Y=DKZ&KX>?Q,_1([(****DH**** "
MBBB@ HHHH *_/3_@N*<?$[X%_>^6S\:'';_D R?X]:_0NOSS_P""XTHC^*/P
M-Z_\@_QJ>/\ L!-7=E?^]T_\2_,X<T_W.K_A?Y'9_ <!/^"<=GP% \-1'@\#
M_1%]:^1_^#8>,#7M+;'(^$-CV]=?U3_ 5]=_!2/9_P $X[=5#-_Q3<:X R>+
M1?\ /-?(_P#P;#*#K6GMW_X5'IW?IG7=5_*O>SOX9_XO\CY7A?=>G^9^QBME
MC[4ZFH<NU.KY,^X"BBB@ HHSB@4 %&,BBD)P* %HI!WI30!'(.0?PKXL_P""
MQ/\ P3-7]N3X1P^(O"UO;P_%#P9%+)ICE53^VK?&Y["1O]H@&-B<(_/1FS]J
MLI_AILB?+Q54JTZ<U.!%2FIKE9_*SIGB'6O USK.F^;J6CW"M)I>K6;NT,D+
MHV'MYUSU5Q@@_P CSN>!_#>M0V%YXGTT0_9O#CQ37(DF\M9,M\JL@(+J3P5'
M'XU^S'_!5G_@C7I_[9AG\?> WLO#_P 5;6(+,)B4L?$D2](I\9\N4#(68#)X
M5\K@K^*/COP-XC^#?C>_\*^*]$U3PSX@T]L7>F7\1AG0 \,.TB'J'7*D$'/>
MOT;*\[P^)PTL'BES0DDFFK\OW:M=$]X]>Y\QBL#4I5/:TV[]]OFO/NNI^DG[
M)W_!2'PQ\1+FWCF>Q\*^(H[&*T;P[?3>5HNIF)9MBVS?ZN-6:4%XW #F),L>
M37O?QO\ AWX9LYM/AAA\4:%'-I]O-?ZE!;QMIKW3PRSF$0,WR QQ.Y,;E$ "
MCGK^-WPRMK.\\30WE_;QW6EZ>R274;]'#,%53[$GJ.W/:O<OA;\>?B)\"/B'
M/X-\)^+=273[$W$\]E?(FJV!";FC @E&%+*%&0>KC!%?)YYX>RYO:97.-2&Z
M4WJO)37Y-?,]+ Y\VE'$1M+:ZUOZK_(^\/#_ ,$/$%KX+U6'0]<\$^+-/:]>
MP:ZFNI;5H[A,KY6R8?>WJ^XCC'.:Y;X!_LE^.-=^.6CP^.#X1UCPS8&2]M-+
MLO$5L9KN0QLRDA1EHU4,P7OM)Z9QX5X,_P""GWB32[:\TR]\%^!=66S277;C
M^SI[G3)2XB$,P90S#=Y2A7"_*1V.36GH7_!4^[L_%NGW6B_"/3%U;P?82SVY
MB\1/,EM;^2492JQ+N"QN1M).!R<D9KYJEPGF]";<L--/R<&OS_,]26;8.4=9
MI?)GU3XQ^'VBS>,+[5SK>BZ'I&I7MN(K?3K'SGM6N%40*7VI$J/]X-T*DG)P
M:CU.'3_ASX8U+6+JX7X?Z38C[-_PDFNW$<]Q<[XYMLEO*,!0&6(M'$N\K-C<
M2./BU_\ @IE\1?$_A>SE\.Q>!O EG'=QZ!;/;:8U]=V2&,",-+<%PL04!5*K
ME .!7B.MSZQ\:=<\1K\0O$NIWGB6SO([.VO[^\:2"WE_>9C9>@1MH4%0-IP<
M8S7L8+@G-J\V\2E277F?-*W^&.GWLYJ^=X:"Y:=Y/TLOO9[1^U?^W/9_&CPK
MIWPO^'=C)J%O->H9/$%YOAFFN'^1OL8+;X(G8[CO8_,2P"YX^59_[8^$/C66
M-9IM,UK19VB9X7_>0RC@[6_3(ZYK+U&";1=0FMI@%NK64QN%?.UAQU';Z'OF
MO7/V*?V"OB-_P4#\?_8?"-J]MH=O*!JOBF_B;^S]-'=5;_EM-UQ&IZ_>*C)K
M]!P=++<AH.G@FISEO.6NOF]-/[B6I\]4>)Q\^:HK);)=OZZF1^R1^RAXR_;U
M_:!M_!OADR?:+@_;-:U>0%XM$M&8[IY6[NQW!$ZLQZ8#$?T5_LY?L\^&_P!E
MOX,Z!X$\'V'V'0= MQ#"#CS)F))>60_Q2.Q+,>Y-<M^QC^Q%X*_85^#T/A'P
M59OLD<7.I:E=$/>ZS=;0&GF<=20  HPJ* J@ 5[+"&&WZ=Z^ S+,98JHVKV\
M]V^_EY+HM#Z3"8548VZ_UHOZU'&/D4ZFGG%.KSCJ$S2YYHHH *3.:6B@ HQ1
MFB@ I,9I>U /%  >E%%&:  \T49HH *!110 =Z*** #I1BBC- !BC%%!/- !
M1CFBB@!#1T%+1UH P_B1K>M^'/ NJ7WAS0X_$NO6UNSV.ER7RV*7TO\ "C3L
MK"-3W;:V!G"DX!_+7_@H3H7[56G?MF_LH_$/Q-XP^!_P=N-4\3WGPUT^]T'3
MK[Q1+I=QK-H90LINE@2X\YM.CBC"PQ"*23+.R$E?UF%?&?\ P7+@N-&_9/\
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M<KGXJ_ U?[VF>-__ $Q'MWK]$*_.[_@N1\WQ9^!RY/\ R"?')]O^0'7?E?\
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M:.U)CB@!:",T44 %&:** "BBB@ HH-% !1BBB@ Z"C&:** "BB@CF@ HHHH
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M3:^*M3M[?PUJ&E7&N0Z;<*'$WVN\M3Y$B+</'I_F; VPT ?H?J_[5?PO\/\
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M\SC\0OE)S_S,Z<XK>_X+8JO_  UU^S?\RY_X2*^YZ8_XETF*^ZJ:8>E_@_\
MD3\YHW>95/\ '_F?<W_!)8Y_X)B? /\ [$32/_26.OH:OGO_ ()-)Y?_  3(
M^ :CG'@32?\ TECKZ$KX>6Y^BQV"BBBI&%%%% !1110 4444 %?G3_P7*R/C
M%\$&#;=N@^/&SG_J"Q_XU^BU?G9_P7'A,OQ=^"9_NZ!X[[9ZZ-'^'YUWY7_O
ME/\ Q(\_-?\ <ZO^%_D=U\/7*?\ !-27[N%\,9&,<?Z&/T^M?*W_  ;#ILN6
MSG</A1H0_P#*OK-?5'@E?+_X)HW(W,<>%CT'/_'G7RQ_P;$K^^8GD_\ "I]
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M*&VBB16=O+ /V(HK\P?!OPYU#]M'X:_M=1_#GXQ?$;6?B+\-_B7JJ^"HM/\
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MO,D!#L >X444&@ HH%%  : ,4@ZTM !GFB@44 %%%% !1110 9HHH)H !12
MY-"C% "T444 ?CK^PV-W[;NIMV/BSXB<],?\58!]>WZUM?\ !;4[OVPOV<FZ
M!=8U1@#VQIDO;%8O[#(_XSCU3T_X2SXA\<C'_%6#^N:VO^"V+AOVP_V=!N_Y
MB^JG(88_Y!<O;K_A7W5;^!3_ ,'_ ,B?G6'M_:4_^OC/O3_@E<<_\$UO@/\
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M1^)\C5@/!E^IU#,*P'S"-2RW[I%3)_A4"N'UC]@SQ%KSZDUVWP=F_MC[#]M
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M^AV7C/Q?X$::9'EU'PW):PWTD0R'@$EQ!,(U<'!>-5E7 *2(1FN@\+>&-/\
M!'AC3=%TFTAT_2M(M8K*RM8AB.VAC0)'&H_NJJ@#V%7Z,XH !Q1110 'I1BB
MB@ HHHH ***,T %%%% !1110 8Q1110 9HHHH **** "BBB@ %%%% !1FBFE
ML-B@#\=_V$''_#<.K<XQXJ^(>?4_\5;[_P">M:__  6P=H_VROV=>2NW5-7(
MSTXTJ3';_/-97["<##]N?5%8D,?$WQ"(&2>#XM)'MTK2_P""VBD_MD_L\E?^
M@EK!!/\ V"I:^\K?[O2_Z]_Y'YWA_P#D93_Z^/\ 4^_/^"68Q_P3:^!';_BA
M-(_])(Z]ZKP?_@EU_P HW_@3_P!B)H__ *1Q5[Q7PLMS]$"BBBI **** "BB
MB@ HHHH *_/'_@N-_P E'^$?'W?#?CHYR!C_ (E,-?H=7YW_ /!<?CXE?"4_
MP_\ ",^.1VX_XE<%=^5_[Y2_Q+\SSLV_W*K_ (7^1V6FG9_P3&U-AU7PDYR#
MM_Y<O\\U\S_\&Q8_<W7]W_A5?AKCG_H(:SWKZ:M@!_P3#U1L-D^$Y.@'_/E[
MU\S_ /!L7\ME>?>Q_P *L\,$>G_'_K7^>*]O/-I_XG^A\YPQ'7Y+]3]<8NII
M]-1-M.KY4^T#%%%% !1110 4444 % XHHSS0 4444 %%%%  .!1110 4444
M%%!.**  C-%%% !111F@ HHHH **** #K1110 4444 %%!.!10 48YHHH **
M** "BBB@ HHHH *** <T %%%% !1110 48HHH **** "BBB@ HHHH **** "
MBB@4 %!&:** "BBB@ HHHH **** "BBB@ HHHH **,\T4 %%%% !1110 444
M4 %%%% !10#FB@ IC<2"GTUOOK0!^0'[#N3^W/J70YU_Q[U;H/\ A*QQP/;]
M*N_\%KV"?ME_L\*,#_B8ZTV>?^@3)5']A-F_X;DO]QQ_Q/?'9&?^QK/IVJW_
M ,%LWS^VA^SP,+_Q^ZWW/7^RI/>ON\1_ I?]>U^:/SO#:YE/_KX_U/T _P""
M7@V_\$X?@3_V(FC_ /I'%7N]>%_\$PAM_P""<GP+'_4B:/\ ^D<5>Z5\++<_
M1 HHHI %%%% !1110 4444 %?G;_ ,%QTW?$KX4-U\OPOXY;[N['_$K@''YU
M^B5?G7_P7(4/\3/A6#V\)^."/ES_ ,PVWKT,I_WVE_B7YGG9O_N57_"_R.XB
M.W_@F%J@[?\ ")R#IN_Y<CVKYG_X-CCFTO/]GX5^%SR?6^UH]*^EI&S_ ,$O
M]8XW,?"4JX'.?]"/8?RKYM_X-C5_T&^]OA;X6'T_T[6NW:O:SKX9_P")_H?.
M<,_HOU/UO#<TN:C@Z5)7RJ/M H)H)HH **#S10 49HH- !1110 449HH ***
M* "BBC.: "BC/-% !UHHHH ***,T %'0444  HHHS0 449HH ,T449H ***#
M0 44=Z,T %%&:* #-&:*,T &>:* <T4 %%%% !11F@\T &<4444 %%&>:* "
MB@44 %%&:* "C/-%% !1WHS10 44 YIO/Z4 .HHHSF@ )P*!110 4444 %%%
M% !GFBBC- !1110 44#@49H **.]% !03110 449HH **** "BC-% !0#FD'
M6@4 +37^^M.S36.9%H _(']AI1_PW#=;=P;^VO'1)*D9SXL;VJU_P6Q_Y//_
M &>^Q6\UP\9Y_P")3+5?]A4^5^VU=!<AFUCQP3QC=GQ6_P#G-/\ ^"V9#_MH
M?L_C'WI]>..>G]DR?C7W6(_@4_\ KVOS1^=X3_D93_QO]3]!_P#@F+_RCG^!
M?_8BZ/\ ^D<5>Z5X=_P3*7;_ ,$Z_@;C_H1-&Z?]>45>XU\-+<_1 HHHI %%
M%% !1110 4444 %?G/\ \%S)-OQ.^%8./^12\<=2?^@=;U^C%?G1_P %S'Q\
M3/AB-Q7_ (H[QP< XS_H%K7H93_OM+_$OS//S;_<JO\ A?Y'<W8S_P $N]8W
M9"_\(C+G&?\ GR]N?\:^:?\ @V0O8(+>_MWFA6ZE^%WA1DA+JKL!>:T257.2
M!D9]*^L_ W@9O'_[ :^'\3I_;&A"R)A3=(HDMPFY1ZC=WK\M]7_8#^,W[+?A
M[0[./0_!_P 7O#_@F VVDF:"7P[XLTFW#%MEGJ5L0ZL"S$!R5R<;<5]-CL#5
MQ/M8T=;2_P NFY\;DV94,*H^V=KI6_'KL?T!V\O'Z5(K[J_&W]B3_@LGX\\&
M>*I?"]Q>:]X\^P@&[\!>/?*TWQ]8J/O'3KWY+;54 R1'($F("X<\Y_4;]E_]
MK7P3^U[X!;Q!X(U8WD-I)]FU/3[J%K74M$N<9:VN[9\202KSE6'.,@D<U\?B
M,-4HOEFC[RC7A57-3=T>G9HHZTG2L386BD)R*4<"@ )Q10!BDSS[4 +12-S2
MYH ** <T4 %%(>M+0 44'D49H **,T&@ H-!Z49H **,T9YH ***3- "T4AZ
MTM !11G%':@ HZTW/-.H *#0*.E !10.M&: "BC-% !11WH!S0 =**,T4 %%
M(:6@ HHI* %HH[4#I0 8YHHSFB@ HHHH **3K2]: "BC.*,T %%&:* #I0*,
MTG2@!:** V30 44 T YH **!10 44=*3- "T4=Z* "BBCK0 44AYI>E !10#
M03B@ HH% /- !11FC- !11FB@ HH!S1F@ I-U+UJ-^%R.3VQ0 23>6>1UIHE
M\R4<-P:^:?VQ_P#@IQX._9?UV7PGI=I-X]^)$=M]JDT#3KF*"'1H2.+G5+R0
M^386_<M(2Y!^5'K\KOC/_P %+/B9^VMXLOM$TW4/$GQ/99"AT/P+=3>&O .G
M\_<N=4XO=0(QEBC1QL00 %;%=6%P.(Q$DJ<=SEQ&,HT(N56221[?^P8RR?MK
M3,-K+_:OC8DJ>#_Q5<G.?\*/^"VRL/VS_P!G_''[W7_H?^)3)^-3_P#!,+]F
M#XK>"/C7I_B7QK:^"])T6STMM)TKP[X4TV2"RT>.2Y6XD)DD)>1V8?,S%B<Y
MS47_  6S8G]M/X _-U;Q!U/0?V1)_GWK[+&TY4X0IS5FH:K335=CX#+ZT*N.
ME5IN\7/1ZZZ/N?H=_P $TAC_ ()X? W_ +$31NV/^7**O;J\2_X)J?\ */'X
M&_\ 8B:-_P"D4->VU\)+<_20HHHI %%%% !1110 4444 %?G;_P7'C^R_$[X
M1W5Y:^(4T6ZT/Q9H]SJ6FZ)=ZHFG275I;)$94MHW95)#8)QG:>:_1*FNV#]:
MVP]=T:L:L=T[F.(H1K4I4I[25C\A_P!GC_@JUJW@RSTWPK9W7P[\2+I\,<"V
MD&M'1]3;:H7BSOXXV9C@<"3-?4'@;_@H#\/_ (F:XOAOQ7IEQX9UV9_+6RUF
MV-L\S9Y$3GY)>G\#-GZ5]2?%?X ^!_CGHC:;XT\&^%_%FG,2?(U;2H+Q%)')
M'F*=K=.1SP*^.?C_ /\ !%^UT/0[R\^"^JV]K"1N;P!XQDDU3PM=@?PVTC9N
M=.E./EEA<HIY,9ZCZ2GGF&JSOB*?*W]J+=_F?'XCA6K"/^RU+^4K-$_[7G_!
M,#X9_MI>"?WEK#+=6Y\^QO;9O)U#39<@B2&92&0CCCIQTKX(N-?^+'_!/O\
M:3T6U\:>)$T;QDP72_!_Q5GA:/3?$\0/[O0_$L"G:X?'R7CL9(L94X)KW+X'
M_M$>*OV=?%&J:;-;>)[&3PBL9\3>#M?D^T:[X0B;(6[AE4XU#2W/W9UW,BXW
M9PP7ZV^*_P +/ G_  4:_9NU#1];L+/6+/5[79-&H4[U*G$B-S@C(*L.^*]3
M$T85Z2J2E[2#TYNJ\GW7F>/@\96P-?V,H\KW<>C7=>?D>K?L3?MHZ7^V%X"O
MIFTZ;POXV\+7"Z=XL\+74PDNM O"NX+NP!+!(OSQ3J-LB'(P0RCVM&W5^#O[
M/_Q'^(G["?[3W_"-W O-<^)OPHTYIM(ED)67XK^"U8M<Z?-R/-O[!-SV[$Y#
M*5^Z3G]O_@_\4M"^-_PTT#QCX9U"/5/#WB:PAU'3KJ,_+-!*@=#CL<'!4\@@
M@\YKXO&825"IRL_1,)BH5Z:J09TM*1117*=0A-!YH!R:7% !0.* <TA.* #/
M%+FDW4H- #>@I>@I3UHS0 4TC)I2W%&:  ]*6C-)C- "]#2 XI>U&* $/ I,
M\TXG%)F@!.HH-.Z4FZ@!/XJ4=?QH)P?PS2YYH #2=:"<4 T  &*.<4M% "=!
M2GFC/-'04 %-Q_*E!YHW4 (.E.!XHHH !2&EHSQ0 G>EI <FE%  .E(*7I10
M "FTX=:,T )VHYQ1GBE!H *09I2<49H !UHSSTHZ4A- !0.E -+TH 0CF@<&
MEHH *;UIV>*0F@!!TI3UI<X%)G)H 6DH+8- '%  >M+TI,TN: $SC^E*: :3
MJ: $Z?04M+U%'6@! *,\4HIN<4 +UHI0<T4 )UI0:":,8H *3J*4G%-)X[T
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M3W-K?AW ZA+D<  5Z_\  OQ?9?M(?LM0SIMG\ZR6>('YMRLN['/MQ^=?EQ\
M_$>N_L6?M#>(M!TK7-%\)ZM\)_'-YKWA*;Q#I]Y-I.KZ)J]HR7>F,ULI<*DW
MES*JD ,@X%>MF6!G5I\D%>47;UZI_<>#P_FD*3_>RM&2YEV71K[]?O/WZ\WC
MI3M_R_TK\K_^'SOQ>W87Q'^S0WI_Q+_$?/?^[Z"G?\/G?B]M_P"1C_9G['_C
MQ\1\@X_V>]>#_8>._P"?;/JO[:P/_/Q'ZG>9\U&[GK7Y9'_@LW\7 _\ R,?[
M,H^MGXB_^)I/^'T7Q<WA1XB_9D.3_P ^WB(?3^"I_L7'?\^V']M8'_GZC]3M
MZBG9K\KU_P""S_Q<D*_\3_\ 9D.]<C]UXA[]/X/PIP_X+0?%I@!_;W[,IXS_
M *OQ"/I_RS[T?V+CO^?;#^VL#:_M4?J;D&D+8/\ 6ORS'_!9WXM$?\AW]F,^
MGR^(!G_R'3?^'TWQ6"K_ ,3S]F/YNF3KXZ_]LZK^P\=_S[8O[;P/_/U'ZG>9
M2>9QTK\M/^'TOQ6VY&M?LR$'_;U\?^TO44?\/I/BL>FM?LQ]N/-UXD?^0J7]
MAX[_ )]L:SK O_EZC]3-_3_"@'C-?EI_P^C^+"_\QG]F%3W_ 'VO<?\ D*E'
M_!:;XKL6']L_LQ>_^D:]_P#&:?\ 8>._Y],?]M8+_GXC]2^2*6ORS'_!:CXK
M#_F,?LQD#K_I6NC'0?\ /'UH7_@M3\6"/^0I^S'V_P"7S7?_ (S1_8>._P"?
M;#^VL#_S]7WGZEXI3TK\M?\ A]/\6%56;5?V8!N/0:AKG [_ /+&A?\ @M-\
M6"O_ "%/V8\XS_Q_ZWZ_]<:/[#Q__/IC_MG _P#/U?>?J0>!2XK\MO\ A]/\
M6 %SJG[+YSUQJ6N=?3_4?K2?\/J?BP2=NI?LOM@X_P"0IK8[_P#7"E_8>._Y
M],7]M8'_ )^K[S]2B-U*.:_+-?\ @M7\6F0%=0_9=;=W_M?6QW]/(H;_ (+5
M_%O8Q6^_9=8]O^)QK7_R/Z4?V'C_ /GTP_MK _\ /U?>?J9VIO\ %7Y;K_P6
MK^+0;YKW]E\]>FM:R,8_[=^]-;_@M;\6B?EO/V7>1D9US6?_ )'I/),<O^7;
M'_;.!_Y^K[S]3!Q2=17Y:'_@M3\7BIVWG[+>5ZYUS6?_ )'II_X+4_%_!_TO
M]EOKC_D.ZQR?^_%"R7'/_ETQ?VS@?^?J^\_4[-%?EB/^"U7Q?)^6Z_9;88R/
M^)]K'X?\L*!_P6L^+[?\O?[+/_@^UC\/^6%']B8[_GTQ_P!L8'_GZOO/U-!R
M:.E?EHO_  6J^+Y9?]*_9:;D#CQ#J_/';_1_6E3_ (+4_%YE+-<?LN87@_\
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M]?G+'_P6S\<EP&^'_P %UYQG_A<-KP/7_CU]\_2G?\/L_''_ $3OX-D#D_\
M%X;3CN/^77TH_LO%_P#/MA_:6$_Y^1^\_1C/-!Z5^="_\%LO'&?F^'/P=^@^
M,EGZ9_Y]OQ^E2-_P6O\ ' 7CX:_"!L] /C+9<_\ DM1_9>+_ .?;*_M'"_\
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MX&=<\?"W_P"[:?\ ;$?^?DAKAFWV5]R/HG_AI7]ET*P_X6/\/.HP!KMKW/\
MO_Y]J5_VCOV76^5?B1\/OF'&==M..W]_UKYU/_!LLO\ T&/@7_X:[_[MH_XA
MEEWM_P 3KX&G/K\+S_\ )M']LK_GY(3X8_NK[D?1A_:-_9?4G_BXWP]W<<_V
MY:G_ -G]J&_:(_9BE+?\7$^'Y5N!_P 3VUY'3^_7SC_Q#**<_P#$V^!&,?\
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MC1^S+]T^// .W R3K5I@_4[Z%^,W[,S=/'G@)O\ N-6G_P 77S"?^#92X/\
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M?:A9Y_T\D+_5>+^PON1]9CQ5^S>0?^*R\"J -O\ R%K3ICTWTX^(OV;V+?\
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MT_2C_A2/P!:3)U#P7C&>);7_ !KXQ7_@V)U]1C[+\#^HZ2Z^/_;BD_XABO$
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M  RY\!P<?\4@S<\8M3G_ #FOB9?^#9OQ8&_Y!OPF_#Q)XA'_ +-0W_!L]XL
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M%%% !1110 4444 %&*** "BBB@ [T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex3-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%?.<G_!4[X2O^TYXH^#5J_CK4OB9X-M3?ZKH5EX*U:>:"TW1J
M+E76W\N2%C-%M>-F#!P1GG !]&45\V^/?^"LOP7^%W[+,WQH\1:EXPT7X=V>
MLSZ!?:C=^#-7BFTR\@N6M)8[BV-MY\.VY5H"SQA?-&S.[BND_9Y_X*)_"?\
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MG2+YU904#J)'$0(P=S1D'-:/+:T?XON_XE*-_1R25O.]CCAQ1@)NT)-^BO\
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MW['GPY_:GO/#=[XV\.G4-7\&W;7V@ZO9:A=:5JVBS, ':VO;22*XA#@ .J2
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M(EN$D+>:KQJB[9 ^\$9W9)- 'G-Y^S_9? []D[X'_L\Z08YK+=HWAJ[6)?\
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M,_1.'L\AF-%2^U:^UKKO;H^Z].C1Z!11FBO*/H@HHHH **** "BBB@ HHHH
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MPM]DCU:7,YDEFO\ 5XRS[O-G-K/LD"[I*_2*B@ HHHH **** "BBB@ HHHH
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M/ZHE&"]V#Y(13T5OBDMW_=75=-&SQ^$<B5:#F]YJ[DUKK\*?3S??2^Q](?\
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ML_\ @'[9_P#!,7Q!=>)_V"OAC>7LGF7#:3Y9;).1'+(B]23PJ@5[R.E>-?\
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M\EW+J6CO9-H=["UMIMK#;WSJ/[2M;W3[=;DQP,T%M-"Q),EPOE_9- !1110
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M)X?LQ^(_BG\0M0%KHNA0XM[6-E^U:Q=L#Y-E;*2-\TK @#HH#.Q5$9A^:O[
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MZAU"UTRVL[:..>_NYH6,,?G73QKL#&1I+H$)L#LOV%0 4444 %%%% !1110
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MRK(P)!96 (XR".U=';W$=W!'-$Z21R*'1T;<K@\@@]P?6OBSQ;\3?AQ\0_\
M@J)XR\2^,-;\#VOA/]G?X?+X=NKS69[9((-4URX6[O(W>4X4PV6FV7&00+^5
M<<G/SA\%?VA?BM\+_!EU\*_!<LOPQTGQ$/%7Q(\)76JQ6&FR>&?#UWKDL&AV
MGD7Z2-%;JOF74D$5E<30QW%E;!("X90#]9>]%?G+XW_:F^-4W[17Q"T7PM\5
M4U2YT?Q]X0\!>&/#46B:<PUC4([:QOO$L\@$#7$.FI8W;R.3*TD4EN^V=1MB
M?K/@Q^W/XV^(GQT\/:#-XLMFTGQ'\3_&MXDPL[6/[)X1\.K)IDEJV4R7DU?R
MI%<9F$+\MC!(!]W48K\W?V8/CG\3O G@_P" 'C;5/B;X@\4>'?VD&\0:A-I%
MWIVF3:A!>WUC-JNBP07$<$0$L-I;"$Q.A3>7)V1HL:?5_P"T7:Z3;_L7K\/?
MBYX^&E7WQ*T1/AY?^);5HM/ENM3U"S>U>>WR!'%*[F21%VX4X 7C% 'K_A;Q
MSHOCFR:YT76-+UBW61XC+8W<=P@=" ZY0D;E) (Z@GFM2OS!^%_[4&K?".RT
M_0]+\+^%X/BIK'CD?!35/''A&#3K/3=?T[0=*N=6BO[2*Y>.TAN&CN)+4V[R
M2K;3_:=JW M1 _JG@CXY?%;XD:_8?">\^-GA_P *^(](\ 6_C&Z\:6NG6%_<
MZ_=:IJ-_;:7;V\$T$4%Q:VRVJK<2PP1-=O+!Y7V/<58 ^ZJ*_/,?M=?&?X=_
ML_?&S]H*^\9'Q#\._ /BOQ79^&?#%UI6G(WB"VMKA-+M3+?1K#]FLX+^WNI1
M(X+F&0M+,R(KF/XD^-OBYXT^%^G^$];^,&I6-]\5OB?HO@^PETQ-%6_T2SCL
M9-2UB*26*WEM4$]G:W1BM]]T\),(>[G\UH5 /T0H Q7P!\-_V\_%7QJ^/7PQ
MU&U^(L6@>%O%VH^+-:OO#B6=@\=EX5T$36"S3W$D1F%[<WTMC<.BL@BC=H1'
MF&6:3GO#/QE_:4\/?\$P='_:&\1?%Q;=FT+2O%4FAWWA;3/.&EOJANYVNKF-
M(T$DFDSQPGRX8A$8 ^#(7- 'Z0&N<T7XO^$_$?Q#U7PCI_BCP]?^*M"B2XU+
M1K?489=0T^-\;'F@5C)&K;EP64 Y'J*\[\0_$C4_A=^S/\6?'WBOQ-JEOH>F
MVVK^(M,NTL[6&]T+28+0NA0&)XW9?*EGC,\<C;9(UD5BK+7QA\*_%FM_LB?!
M[P+X.\2^-+SP'K6A_"FX^*'C_P :SZ;IM_XKUC5]5O3+-I6GB6V,4Q;46F,@
M\B:61FL8AB2824 ?IMBCO7PK\ _B5^T=^T=^TD-!NO&D7@&W\'> ? ]_X\L1
MH-E?VMGXFN96O=6TNUW()4:2R2*,R23RK MV&6)G9'7[JH .]%%% !1110 4
M444 %%%% !1110 4444 %%%?(G_!47_@HKK?['_C;X(_"_P)I.EZA\4/VAO%
M'_".:#=ZO'))I>@V\3P"\U">*-D>X\I;F'; LD1?<3O&PJP!]=T5\+_%3]O+
MXC_L=_\ !07X4_ WXD:SX9\2>'_V@--O+7PMXMT[1'TZ\T#6K9!NAN;8SRQW
M$$K20"-E,;*TFU]RC?7SO^PE_P %:_C1^V'X6\1>'S\5/A/:?'"W\=Z]X5\-
M>$(/"P8:Y;:38_;&N;B-M0$UK'.8Y(1/N*1R21_+)AA0!^N%->/<*_+KQ'_P
M59^('@__ (*B?'GX%^+/BS\/O!>@^!!H2>#KF3PNMQJFM7FL&U\BT,#7B?:3
M$UVBL80A*J7;8,XZ;PW^W7^T!X%_X*R>"?@)\0_%GP_MO#Y^$T?Q+\575GX8
M=)HIX9I;>ZM(9/M;JL!:!I1(4=U5MF"1OH ^G?VF_P#@E[\%_P!K&=K_ ,2^
M$;73_$GG_:8_$6@N=*UA9<CYVGAQYQXZ3"1<\XS@CYV\5_\ !!V\T:_F_P"$
M#^.GBK3]+O#YEUIGBS1+3Q%#/)W?/[@ D=V5FS_%C@=3_P $]_VSOC)_P5/^
M$VO?&/P;J'@WX9_#6\U:]TSP-I6J>'YM9U#5H+60PF_U"9;J 1K+*L@^S0JK
M1A#^^DX:O$_VG?\ @JI\9OV4?VQO@#X'^*7C3X9_#'PW\1?AM/XK\<7-QH1D
M;PSJEGI\TMS;6DLEV%ECDN8@D:.K2?-M!=F7'1'%5%'D;NET:4E]S31P8C*\
M+6ES5(*_=:/[U9FV?^"#_C9_F;XC?#\R>H\(W"IG_<6["?AC!K>T#_@@WK6N
M%+/Q?\<]4C\-AMSZ3X0\,6>B>80.-TCF97^;'WXV.!U!.1]C_LF:C\0M4^'%
MU/\ $34M'UN[GOOM&C:EIVF?V8M]IDL$$T)EMO/G\N9&DEB?]YAC#N "L!7R
MS^QQ^W?\6O\ @J?X@^->O_"77/!'P^^'/PU\377@GPU<ZMX?FUNZ\2ZA;(DD
MM[<8N;?R;0K+!LA1?,Q(29 1LJOKD][1_P# 8_AII\CFCD.!7V/Q?XZZ_,]<
M^ 7_  2+^"'P!UJ;65\,-XV\37$J2MKGC&?^V[Z-D^YY?FCRH=OK%&K' R3@
M8^EXHMOWCN/K7XZ?$+_@X1^(?Q _8&^#7QF\)+X/^'NJ:U\6[?X/_$/1=;L?
M[0LM&NGBEGEOK>Z,\.U%A2.0+(&5?.92Y\K>_P"A'["7QE\4?'N?Q9XF_P"$
M^\+_ !*^%UQ*+'PMK6E:0MA(]Y9WVH66IJSI<2QW,.^WMVBF0(K*[8W8W'&I
M5G4=YMM^9Z=&A3I1Y:45%>2L?0U%?G;^T;^UG^T1^SU_P4/_ &:/@?=>/O >
MI0_';^WI-4U*W\&/"VC_ &&W^T1);(UXV\'(1FD))VE@%SM%#]MS]O#XT_L/
M_MH?LN_#;Q5\5/A38^&?C =7A\4^(K_PQ_9MOIHTY8Y1-$TM_LB^T)-'&5D9
MQ&_*F3<$&9J?I#17Y7_#7_@J)\9/C;\=OVTM%\*?$SX7ZUX1_9Q\-1:_X6U?
M3/#BZA%K[3V,UXJ331WQC9(C T#>5M+$ELH5*'K_ /@DY_P46^*O_!1#X:?#
M;Q):_$3X<ZUX@%M!K'Q&\):?H 5='L;F\OK6!8KD7C-!<C[)YQBE1RR G";T
MR ?I#1110 4444 %%%% !1110 4444 %>8_M8?&#Q5\#OAI'X@\*^'=)\574
M-Y;P/I=SJ,EI=:CYLT<2V]IMBD5KA]YV>853(&YE4LZ>G5Y[XZ^ UQXW^,?A
M[Q=_PG'C#2X?#R[4T*S33CIMTV26=S+:/<J[J=C-#/&=@*C =PP!A^/_ (\^
M+O W[0EOX:@\&V_B3P_=>'=0UH2:1J!;5K:2U$7EQR02(D(%R\CQ19F!+Q$\
MKYC1>177_!2C4A\$O#6L:=I'AS4_$6O:=XA\07D=W/>Z/8>'-+T)Q%JCWOVB
M#[1%/#=/%:-$8@1+(22%C8UZW8?LHZAIUUXONH_BU\3A?>*[N.[BN@-'6;12
MEP)A';E=/ DCVJ(=ET)P(MRKM+NS4?B/_P $_P#P!\3-*T;3[L:W::7I]GJ&
MEZA:6M[A/$=AJ%S#=W]I?,ZM)+%=7$$<DVUD>7]XCLT<LL;@$/CO]J'Q)-JG
MP+L_"&@:1-=?%N8W5]::W=S6USHFFQV!O)[C;'&^]XV,,!5MJ^9=198#-:?Q
M-_;I^'OPD^(<GAO5KO6&N;6:6SN[JSTFXN[.RNX],GU5K226-2!<#3[:6Y,8
MRPC\LD RQ!Z/QG_8JD^+OQLM_'=K\5OB?X+U2RT"X\-V=MH)T@6MC:7,D,ES
MY(N;">1)97MK<M('W#R$"E0,'(UW_@G'X;OO&<WB#2_&OQ)\-ZPNK7FMV%SI
MVJ6[MI=W=_8O/DC$\$HD+?8@O^D"7]W<W,7^ID\L '6>,?VG?*_8Y\4_%;0]
M'N[7^P]!U'6K:Q\1PR:>9A:)*^9-H=EBD$6Y9%#!D=74,",^1Z9_P4HO?!NE
M+XC^(&A:/H_@^U\/B2>?29[G4-0O];A3S]1@LX/) DL+*'$<MV[)_I(: )OP
M&]KMOV3_  G#^RE<_!F1=2N/!=]H4_AR[1[LK<W%I/&\<Z^8@7RRZR.!Y018
MPV(P@50N-\5OV&_ _P 3_%/P_P!:%O<:+??#*RN=,T)-/6%(H+.X%OYENN^-
MV@YM+<K/;-#<QB,B.9 [A@#G]-_X*=_"G5/&>H:7'?:ZFGZ7INJ:M/KDNDS1
M:6+?3;H6=ZPD8!F:.[/V<*$W22AA&' )K6\&_M\^#O'OB?2M%TW1O'DFKZIJ
MEUI;6<GAVXBFL&M6L5N)IU8#9#$^HVJNXR%+OGB.0KY#^S[^P7XNN[#Q=8^/
M(='\,P^+M1LO%.JWNA365QJ=QXCMM4CU.*ZAN5L82]G'/'E(K];IRK*F51"K
M^I?#G_@GUX;^&?Q8TOQ1:>+/']];Z+K.I^([/0[[489M-AU._EU-[B[_ -2+
MC>4U:YBVF;RRB0%T=X4< ''?\%!O^"@/B+]CWQQH6E^'_#6A^)AJ6AWFI2I>
M3W]OB\6YM;73[%[B&VEMK/[?<7)ACN+V2&%7B;+-R!J>"?V\6TKXG>.=/\:1
M1QZ)%K>IZ?X1ETK1KAVO%TG2K:[U*":7S9$EN4G:^CC"+%Y@L9@%)0DZ?Q5_
MX)S^'/C=\7_$'B?Q5XS^(&L:3XJ.E1ZGX5>XL8M%N[?3)I+BSM6\NU6Z-NMQ
M--*\1N-LIE99-Z80=9HO[&?@S2H?#"RKJVH-X3\4ZMXQLGN;PY?4-2:^-R9
MH57C_P")A< 1D;?N$ABN2 <GX5_;.?XT?M;>%?!O@-X+SPC_ &3K6I^(-1O=
M#NE6Z^QS6MI&MA=^8L1874\B.#%(K"WF"NI3YL?QI^VSXQT/XA_$GPC9>%?#
M?]L:1-IQ\#7M]JLL.G>*XIKVWL+[S'6)FA:PN;F&.<H),&>+C)(';?LW?L/>
M%?V7=52\\/ZKXIO;B#PMI_@VV.IWJ7"VFG6,UU):H@$:C<@NF0L<EQ&C/ND,
MDCM@_86\'ZIX<\+6?BF_\1>-M0\)S:U+!JVJW$4%[=C5A.+R.?['%!$T;"?A
M1&N&AA?EXP] &1I'_!23X:ZEX?%^+G6IH"^A>3-%I,XCU&WUF]:PTZ^M0P#3
M6D]TCHLB@DJ!)CRV5VX3XK?\%-_)E2W\,:#K?A^;1_'VD>%]3/BKPY-G4X)=
M-;6-0BM(8YTFCN(M-4NKRHP64JK1%277T+P'_P $\O _@N30[BZOO$WB74]!
MU#3+Z._UB\CFFN(]+M[B#3+1U2-(A;6IN9)HXXT3_2"9F+RO([Q^+O\ @G/X
M!\<Z-K%GJ-UXDF_M<^*9/.^V1^=9S^(%,=W<0MY?RRQ0M)# [;C%%*Z?,,8
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M8>-&F\'ZV^K:7HFN:-=VXTS5-6@O(GFL$ELDU"Z^T0M>D0++/;J@9TB01(R
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M[]G?X?\ P.L=0M?!7@7P=X/MM6"B]AT31;;3X[P*&"^8(44/@.X&[.-S>IH
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MB5]&MS::>VJZ%:WAL83C,41D1O+0[5^5<#Y1Z5'K'[+/PQ\1>!=&\+ZA\.?
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M#$ECIA%FBL2S&0J L=O&TOU=110 4444 %%%% !1110 4444 %%%% !1110
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MOB%>:#J7@>S^'EU9S7]KMFTFS^V_94W+;*ZR1_;3ET*F7[/#YOF_O?,^G**
M.#^(GP0M_B / <EU=S7MYX!UV#7+:>[VLUU,EM/:N\@157<8KJ5AM55#[2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYU/4-1U.ZU74-1>.)(8O.NKJ22>01Q(J(K.0H& !DY[>B@#R_P"#/['7@3X
M?%?QMXV\,VWB.#Q'\1KE+SQ#/?>*-4U*'4)D5423R+FXDAC9(T2-3$B;8T5!
MA5"C)T']@'X5Z';Q13:%JNNI;>+XO'MK_;_B'4M:-CKD9<I>P&[GE,# NYVQ
M[4^8_+7LU% 'F'P$_8]\"_LS^+_&FO>$;?Q';ZE\0M1_M?7WU'Q/J>K1WUYL
M6/SQ'=W$L<3^6D<>8E3Y(HT^ZB@>GT44 %%%% !1110 4444 %%%% !1110
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MR%]Q=B0#Q[X#_$5OV$?V=?'&I:IXVN/^$/\ &'CR:S^$Z_$;Q+),NGV$EM$
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M;4[V6_U+5IDB2&,S3REG81Q1I&BY"HJX &3D [BBBB@ HHHH **** "BBB@
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MG>?I'F2RVT,<E_:"Y"&=8%$DL*,ZN<K0!^I5&<5^6O@KXK_M"_$O_@I%X_\
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M-[K\&OVDFEV<GR#9)<K(8D;]Y'PS _.OJ*_.OXW^%]+^']Q^V7'XTT7PC?\
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M_:X\7?$?0=%TGQ/H.L?"WQ ?#>LVNN6\$$CW/DK,#%Y4T@9#&RMSM89P5!!
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M22^$"BYDA5BRQF3&XH&9B%)P"2>]7J** "BBB@ HHHH **** "BBB@ HHHH
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M!'2CQY\(/"7Q3\/VND^)_"_AWQ)I=C()K:SU338;RWMY C1ATCD5E5@CNH(
M.UV'0D51_9_^-NC_ +2?P-\(_$+PZE]'H/C72+;6]/6]A\FY6"XB66,2("=K
M[6&5R<'BN&\$?MY>"?'7PS^(WBJ&S\6V=C\+_$5QX6U:TN=$G&HW%_$ENRQ6
MUJH::9IC=0+$JKOD:10%Y&0#TG6_A+X5\2MH;:EX9\/Z@WAB19M'-SIT,O\
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M'7BZ]^)>IOHFBOH/]F^2U\MO+<_9Y&N[RWV,T$$SAB-F(R-P8JI /9J*^5=
M_P""P?PIU_QS\.-&6S\86</Q(\0WO@R#4;O3X8+;0?$5I(T4^BZBC3>?;W8E
M"1K^Z:*1IHMDC!LCT3]H;]N+PM^SK\>/A7\,[S2?$OB+QI\8+VZM=#T_1H('
M\F.UB\ZXN;F2::)(H8X]S?>+OL<(CLI% 'LU%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOQUH'B2\L_B-JS:%>Z/IOC+2%L[J/$P*K;ZJ7N#:R031>9)&8]Q*@%&^S**
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MRW=M%)$D4E_<S7(5FS$NH'?E(S*WZ:44 %%%% !1110 4444 %%%% !1110
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M>'PNOZC?01:MX92,/!>+]@A;[)<%IP)8V,B>7&WE$L50 ^_K3_@HG\&[S3_
M]POC)8_^%B>*9_!.B03:7>PW,FMP-*LVGSPM");2>-H)%9;E8MI4 X++GVNO
MGWX=? _QM\ M"\)V?PP\!_!3P-8:]XJ;6?B+IT5W>R PS0A;B>RGCMX_M5\\
MB1GS;B*)61<$9 :OH*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* / /&/[6'B+QK^UKK'P8^&.EZ'=:UX-T.TU[Q;K^MS.=/T-;QY5LK..WB(E
MN+J98)I2"T4<<:JQ=V<)7GFJ?MF?'#PS^VG\)/A?X@\%?#_0;'XB:CKEO<W2
M7UW?.MII5K:W7VJU?;$'^TI<[ DB)]GDC<$S@9;K-;_9=\>?!S]N/Q=\9/AC
M%X/UZS^*6B:;I7B_P_X@U.YTITNM.\U;34+2ZBM[D',$[PR6[PJ#LC<2@AD?
MC?VI_P!B+Q[^U5^U_P# 7Q;XL\'_  ;\6> ?AVVM-K^D:U?S7!/]HPPP(+:W
MDT^2*X:W6$2;Y7B,C2$ 1  D X?]H'_@IG\9/@A\/OVM/$B^'_AG?6O[,]]:
M0V]LPOHY/$,,]G:W^7;>1 ZP7<:C D#2(W*J0:]/T7]O7Q3\'_VX;3X._&#3
M_"]GIOBRSLE\*^,=%6>#3KG5[@73+HUU',SF&YECM)Y(&WE)A"Z B0K&? /B
MI_P2L^,&J_ ;]K_X=^"/!_P'\'^'_P!H.^M7\,V]CXCO+*TT*&.RM;*0SV\.
MD!%=UM3/MBW O,5+?+YC?2FM?LK>)OVF?%WQ1TOXP>$/!5GX"^(/AK2-.C_L
M/Q7=7VIV=]923S"9-]A;B%XIK@203QR&1)+6-]JD@( =?\$?V@?$Y^#GCKQ9
M\25\-1Q>%=<U;3K>/P[!/NN+>QN9;=25F<EIYFCRL:\ NJ!G/S5J?L1_M/']
MKS]G'1_&-UHK^%O$/GW>C^)/#\ERMQ)X>UBQN9+2_L6D7 ?RKB&15? #IL<#
M#"O$?!_[&OQCMOA/\/\ X;>,M9\.^-/#D?B_4M>\=^)+3Q'?^&=;U>);ZXNM
M+EMX[*W!2X,QL[F?RKFW42V[1J7BD93O?LC_ +(GCW]D7]L#XKOH<>AW'P)^
M(T]IKT*ZCXPU+5O$EEKB6B6]W<L+JW<R17*Q6ZD/>NR&VW+Q(8T .4_:I_;_
M /BK\ OC]\9=#TC0/AWK7A_X1_#*'XIE+VXN[&[U6S\V]2:Q,PWQPS!;"=EF
M*.A+QJRJ-SC;_9._;H\>?M9_M!>*M#TO3_">E>#X/AYX>\>Z!=W5I=?VDR:]
M%=/9P7<7FA%:#[))YNQ_GW+MV'=BIX__ ."?NJ?'C_@I7XC^('Q&\!_"SQ=\
M(]7\$Z=X4@M-1U6>]U 36=[=7JW$EA)8BV9'DN538;AMOD*_S%MBU;__ ()^
MZM\0?^"@7Q4^)GC[X4_ OQQX-U[PII6A>%;?6+PZA?V<VFO?2*SQ3Z8T=LER
M;U5?RI9#&+9#B7(" '6_L*?MR>)?V@/V (_C1XZT?0=-OKNXU.*VT706EDWO
M:7\^GQVZ/,099IYX,( J<S1I@D;C6\0?M_>(-8_X)4^(OC]X?\/:5I?B[P?X
M;U'5==\+ZS)+)'INI:5YR:KI3R1[6\R*XMKF!9=N"45MNTXKRO\ 9!_X)[_&
M3X6?LL_"'X(>-M,^'MKX#\(Z]J>L>([OPAX_U?3[Z=7OKN_T^&T\G3[:1$AG
MN(F8+/"2;2, E&>,U/%G_!.3XS>!/!/[6/PT^&]G\/YOA=\?=.N9= ?Q)X^U
M>XU;1=9O=.6RU"[N'EL+F22*9@D^PW#LLD3X($^(@#T/X9_M]_$/Q-\>=:^%
M.HZ3X%F\5'X51?$W2]8TY[DV&GEY4A&GZC:EC+"[-)OC=)3YL<<K!%*8/0?L
M??\ !2!OV@/V&M3^)GB+PS_8OC;PG=3Z)X@\*V<YE:/5U:/[+:P2.!N%Y'<6
M4D+'@K>Q9/7'G?P)_8/^+'['4TEQ\*_"WP;TW0_B)X<2#Q[X(&OW6F:7IWB"
MWMHK6+5]+N8=,?<+F",+<PO;0@M%%*I+F7S-+X,_\$\O'WPQ^*_A_P ?,W@]
M9Y/!.EV_BOP;!JUQ)I6N^*-%B:UTF_%XUH&$7V:9_,9K;>LECIS*CF'< #O?
MV,OVW?$GQT_X)M^&_CGXLT70[?6?%VE#5--T'199-DLDSB*RL%EF/SW$TQCC
M#85=\RJ <;F]._8U_:2MOVN_V8?!WQ$M]/FT:?Q%9'^T=+E8M+H^H0R/;WMD
MY(&7M[J*>%C@9,1X%?+G[)O[ ?Q?\"?LK_L^_!+XA6G@N+P9\+[4_P#"0ZGX
M1^(.L6.IZC<VZ2K8FW,5C;2"$-()9%\^)O,2,!G1767TO]AG]E#X@?L?_M _
M&/2X;?PV_P #?&FN?\)3X:$OBS4M8\1Z=J,T$*:A]I^UVYWQW5PDEQDW;M&[
MR??$N(P"+X6_M5?%OXD?%/\ :6\,_8?AW;GX*W<.G:).(;UO[7GGT^#4HVN%
MW_NU6&X2)A&6)?+#"@(W)_LR_P#!2WQI^TOX2^"OA_2M!\)?\+3^+O@,?$Z_
M3S+A=&\&Z"[PQPO+G][=W$DLPB2)#&&,4[EXUC428UG_ ,$W/$7BGX^?M,>.
M/'?P?_9Z\;77Q.NK:]\%RZOJ#ZA=6)M]-M]/6"YDGTAC;QOY!N"83-M:0IM;
M'F%G[)?_  3I^*O[+&E_ OQE:1_#V\^)/PU^&<?PD\3Z2VO7IT?Q'I,$D4UK
M>6][]B$MO<QSQN_EM:NK)<R(7!5)* )OVKO^"I_CK]FOX(?';S?"?A/_ (6E
M\ ;?2M:OK">YN&T?Q5HNHN8X+VTE $L#^8DZ/%(LGER6S)N=)$FKZ2_:7^*/
MC3X!_L8^-/&UNOA?5/&7@GPS=Z]-%+!/#IE]):V[SR1* [2QJXC958LY4L"0
MV-I^5?VR_P#@F=\6OVHO@U^T%J*S?#L?%+XZ:9H_A2TL[G6;N'1/".B:;/)<
M1HMTMD\]U<233SR.3!$N9(T&!$6D]P_:*\(?'S]H3X#?$OP6/"7PHT&+Q7X+
MU/0K!F\:7UV9;^\06Z/*W]E)Y,$43S.=JRO(Q1<1@%B </'_ ,% /B=\*_A+
M\&_B+\0/#/@R\^'?Q<.C6=YJV@S7,5SX(N]7CC%B]S;S%A=6AN9H8))4EB=#
M(K>6P)V\KI?_  46^/1_99\1_$R+P)X#\67G@_XEWW@2[\*:(UY'J.M0V6KG
M2II;*65MGVF21'DCAD7:5VJ7W'%;5U^Q-\9OC1^SQ\&/A'XXA^'/AKP'\-_[
M O/$7]B^(+O5KSQ?-HOV>:ULE\ZPMUM;:2[MH9)9?WLFQ-BJI8N*_P $OV2_
MC]\+_P!GW5/#UYX<^$=UKVI?&6Y^(V(O&^H?9$L;G77UF2'S#I <W",1 !Y8
M1P?,+ICRR >D:C^W_8^)/^%<_$#PIXD\#W7P%\4>$-7\9:OK]W%=?;;&STY(
MI)2BJ0JD+*PD210\+6\BE68[4/AW^TW\;?C%\!M#^+'ASX<^%O\ A&_%5O:Z
MMI/A._U2:'Q"VE7!1X[J:94:".Z^SN)C9!& (\K[3N^88/C#_@EQ9:Y^T3XX
MN+74X[?X-_%SPOXAT_Q;X30F&2TU?54MH+J_L'5?W8NX$E-PA('GQI,H+S3D
M^7_'C_@FE\7OVA_^"?'A_P#9K\86/P:\5Z3X3N]$M=,\<7U[=K>M8:9=V[+.
M^F-92*E[+90R6TGEWFQ_M$IW*CF*@#U[X2_MW>+_ (W?&7Q=H?AS1? ]TW@?
MQN?"GB#PI<:K/;>*]!L%NQ NM2Q-&4>">/%S#&H"-;RHXN&=7A'U97QG\7_V
M%/'7QQ\??#.^U+P[\*-!U;X6^-+;5M"\?:)J-U::[I6@6^HF8:1%:QV:(4GL
M?]!FC>Y-NPEDE\IB%CKZ6^#GC?Q9XRU#QC%XH\+V/AV'1?$%QI^BSVM_-=+K
M6GJD;17;"6W@:*0LSHT:B2,&/*32J0U ';4444 %%%% !1110 4444 %%%%
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M)O%6K6]QXB\3S>"[2QF\+:O'J":U%#]H.GSVC6HGM[AH<21I,B&560Q[PRY
M/H&BO([?]N?X:7.MZ/I_]K:W'=:U'I;QB;PSJD*6;ZD\:6,%X[6X6RN)FEC
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M&:?5WU2"^MI)D@AN5=I'2\*B.0R!)(TFP5KUK_@E'\#_ !Q^S1^P#\.?A_\
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M7_@HE\'/B-\0_#OPR\6_"FST#6O&?PA\<0>,8-"UB\:RM_$=M_9^H:==62W
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M<+W4M%\16T&LP,+J"?1KS38]1MW. UOYLL<C(<3B)B1$SCRS^AU% 'YBV/\
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M\7?#OP(^'&J>+/%6I1Z5H.CQJ]S<-&\C$LZQQQI&@+R2R2.D:1HK.[NJJ"S
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MFB> VTWX!_#J]\$^)[BW\3W$DL\T]O8VJSVD9LE$J!=.CD*R/&?])*C/E;I
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M^&?_  4?^'GQ5\#3>*-/L_'5KX;A^U0C4=0\+7UI')>6^JMI+:<JO&)#?->
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M&WP[X(-V+73[J/7K*74]!M;R&9?])?\ >)J=Q(GD"-]GV?YMWFQGZ"_X)L?
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MU\:/#EOXK\$V-YKEND5]IO\ 9]K>7ES=RQJYM4MWO+:WQY<C227,&U0AD:(
M^J:*^3?"/[:>D?%']I#X)_VQ\*?BQX0\1>,?!/B#7-.&MROI\FD_99K6._T^
MYTQ)MTUR#]G:.22%EV2 PR'?(!QOB3_@H98_M5_#OXO_  ROO#?BCX>^*X?A
M--X\MH(=?-OK&E6DT<JI!?"V>.XTS4XG6,R6VYMHD $C8=0 ?<E%>%?\$_A-
M\3_^"9_P1_MR_P!6O+GQ!\,M!-_>KJ,\-].\VEVYDE^TQNLRRL6+>8KAPQW!
M@>:_.#]C']HOQMXMT;X!^'OA[X^^-7BCX[77Q*U:3QG;>(-4U74-%O\ P-8^
M)+ZQO+F5M1)L2L-LMI"LMC^_^T%5.7,@ !^RE%?)/[8/_!8#X>_LB>/?$F@W
MG]GZY>> UL)?$UA#KUI;ZU%'>;60:?I\C>=?RQ0NL\J+Y>(G7RVFD)B'72_M
M^-J_Q(6U\+_#KQ=XS\%VGCM?ASJGB'18_M3Z;JGW9KEK55+?V;;3?N+BZ9U,
M4H?]V\:-* #Z(HKY1L/^"K&AW\'@/Q-'X.UJY^%OQ5\1W'A#P?XIM+VWD.J:
MFC7$=J);=F3R+:^EMI([6?S'#L\/FK;K(K51^&7_  5BA\<?LS6'Q9U+X7^)
MM!\,^(+E-#T"U?5;"XU36M>DUN?1H])2%9=JR/-%&XE,GE;)6)91&Q(!]>45
M^6.J?M(WWP>^//[9%]\2_!_Q"U;0]/UKX=0W7A_3/'=S+#HTEZTF+NSNGG@D
MCLVN&MM\4"(20R&$QAC7T=\7_P#@K7;?!S6/CE_:7PQ\41Z+^SWJ6DP^*;^3
M4;(-/87ZHZWMG$DCF79'(LQBD,3&,/RL@6)@#[ J&_L(-5L9K6ZAAN;6YC:*
M:&5 \<J,,,K*>"""00>"*^7?C/\ \%/K7X3>+_%T=G\.?$WBGPSX#\9Z/\/=
M:U#3[^QM[P:WJD=D]JD%O=2Q(]L&U*RCDGEGBVO/\J2(CR+U?@;]O"Q^)'[5
MNO?"_1?#TU]<>%-731-?D34H/[0T&1]+;48[RYL?]8FGR#9;1709A)<.5";
M)6 /;?#7A'2?!>GM::/I>GZ3:LYE:&RMDMXRY !8J@ R0 ,^PK0KXW_X+'QZ
ME8>#O@A>:/XJ\<>%[C5/C#X3\+W[>'O$M]H_V_3=2U.&VN[>46TJ!@\9P'/[
MR,\HRY;.1\>O%WBC_@G?^VA\!(= \7>,/$_PN^-7B"?P1K'A;Q'JTVN3:9?M
M9R7%E?V-Y=,]VF7@DCFCEGDB*R*55&7=0!]OT5\/?LR_\%%X9/$WPI\-Z/\
M"7Q-X=\+_%SQGXLT"75=?\6?;9-!UW3KW4I+RSF)-P&:8VEP]O'%.8L*\:;$
MB7=U>M_MC0^,?&WP&D\6?#;7[/\ X3?XAZOH?AG4]*\4[M/MY;2TU%8;RY1&
MA>XAN[>WNI(HFAEB"^5(Y23RP #ZVHKXL^(7_!370?B=^S#\8M?C^'GB3Q7X
M'\)Z#XC;5_\ A'_$D%KJ-M'ILR6MW9WA$L$VEW[1237,<>_S?(@9E(FQ".X\
M0?M^0>&K'4-(\"^ ]:\=7G@#P1IOC/Q-86VJ1K=:9I]W',UM:PF4L;O4)([6
M=UB=HU98\M,K21AP#Z;HKY'_ .'L%CXX\9V^D_#WX>Z]XRM=8^%2_%O0M6EU
M*TT^QUG3=\(,*@L\\4_[W8%EB7]Z K;4W2K[;X=^(^@_M9_L?:?XPT>36K?P
MS\2/"$6M6+QW4NFZA':7MF)H\2V\BR02A)!\T4@96^ZV0#0!Z717YY_\$_OV
ME+,?"+]@W0_%VB^./$7BSQU\.;G4=/\ %;:](;1)X=*BENTNX!/OO)GCVE6F
MB=4+;D8/NQI?'/\ X*Y^)O$'["FI?%;X4^$=(N+6ZO/#T6FZK=Z[%<6MO'JF
MKV^G-:W"Q12&WU:V,\?VBSD4K!YH/FS-&\1 /OJBOC_]HC_@L'X-_9D\;:CH
M'B*UT2ZU;P=>Z7IWB_3M/\2V\NJZ?-?QV\JG3["14NM1BABNH9976.(B-\QK
M*Z2QQ^;_ /!1K]K#4?B]X,T>?P3HGC"#PSX)^./A;PC<^++#Q%+I<<NH1^(;
M*UU")K2)U-W8+OGLG:4D?:<A865//4 _0BBN"_:3_:%T?]F/X7/XFUBWOM0:
M?4+'1M-TVQ"&[U?4;ZZBM+.TAWLJ;Y9YHTR[*J@EF*JI(\"^)/\ P57;X+ZI
MXH\.^*/A;XCC\;^#=:\,V.I:5IFJ6=Q;SZ?K]^-/L=4M)YF@:X@^U$P.OE+(
MDRX91&1*0#ZZHKR?]G+]J$?'+Q]\3/".H:#-X;\4_"W6H-*U2T-VMY!/'<V4
M%[:W$4JJN5>&<!E*@I)'(OS*%=OD?_@H)^TE\3O%EC^W-X!:WT_1/!_PK^"M
MMXFT+5M&\2WEAK5K>S6.NW"70,,,;9:?3XD:'S]BQVZDF47$D2 'Z(45\9^%
M?^"HOAW]G[P,FC_$[2M3\.OX=^&NA>,[6_GU&WF.M6MW/'IJQR/(Z1V]T;UH
M4(DE,6+F-S,/W@C]._8M_;]\/_MC^+O'WAS3[?34UCX=S6:WEWHVLPZYH>IP
MW<;R036=_$%67'ER1RQLB/%(A!!5D=P#WZBOF/XM_P#!2O3_ (+?M)>'_ ^N
M>#-8T_2_$7C.S\!V.JWMW%:76IW]U:I<1W5E928DN]-1I([>2ZC;Y)O,41LL
M;N/G^Z_X*6_'V]^$.M:];>$_AS#=1?M'V7PGA!\0W!2WL1K]OIDR '3SN\P@
MKYS?,HNI)0@,4<+ 'Z.45\N^/?\ @IA;_"?]HKPKX#\4>!]2T6'Q5XNMO MI
M?SZA'%-?ZE-8K=_:;*TE5);O2T9A;->KM(G5U\K:K.-#P9^VBG[2FM:+IND_
M#[QMJ7PM^(E_K7ABQ\:Z->NGV>:P^T1S7-Q]G99K&SF>WGCMKM9=[2K'\D0E
MB=@#Z2HK\XO^"8__  4C@^#O[!'[.-M\5XM:AL?%GPPU/Q,/&&HZE]NEN&T>
M!;J_-TA+2*#;NTL<F]RXBD#+&=@?T?P[_P %P_AG-+XO;5K,M:^'/"D'C"SE
M\-ZQ9^(UU"">[ALH=,=K9_+M]7:ZN;6+[(SLC-<H4GD4.R 'VM17Q7^RAXS\
M8:Y_P5U^,]GXHTC7?"ID^&OA?4SHDWBB76M,6:2]U6-KFT5B(X-T<,44B1Q1
MJ9;>1AY@;S9/4?B/^W!K'A;]L9_@OH?POU_Q#KG_  BL?C"'46U:QL[&[LO[
M1MK*X\LM(9 \(N&DVR(F_P EE4G(:@#Z#HKX<L?^"Z/@'Q#?%O#NA-XVLM8\
M*:GXL\.CPSXAT[4+V\AL(A/)!?P>:HTR:6W+3Q+._P Z1R(WESK]G/:^!_\
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M"[M]3BLFA>XCGGMKJ6.ZFLENCF52ACC^FO%W[ 6J?%?]J;P'\4/$GB;05O?
M.O3:[I<MAX;%OXBMK>6TG@;1GU5)QYVG;KAG>-K?,FU1E< CZ<HH ^?OV_\
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M_:E_Z.&_\FM0_P#BZ^\J* /@W_A@3]J7_HX;_P FM0_^+H_X8$_:E_Z.&_\
M)K4/_BZ^\J* /@W_ (8$_:E_Z.&_\FM0_P#BZ/\ A@3]J7_HX;_R:U#_ .+K
M[RHH ^#?^&!/VI?^CAO_ ":U#_XNC_A@3]J7_HX;_P FM0_^+K[RHH ^#?\
MA@3]J7_HX;_R:U#_ .+H_P"&!/VI?^CAO_)K4/\ XNOO*B@#X-_X8$_:E_Z.
M&_\ )K4/_BZ/^&!/VI?^CAO_ ":U#_XNOO*B@#X-_P"&!/VI?^CAO_)K4/\
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MWT7QCXP\ ^(;6YM6TG7O#FL7>GW&FW$GCGQ- )72"6-;J("4DV\^Z)^ZYP0
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MC6/$7F>&9#I.L'2772+J=I()%M;:66&\M;B*.XL;J*::6)K>= ^V)).%E50
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M@C.U@W0YJQX3_9?_ &:_'?Q%OO".C>/O'6I^)M--PMQIMM\;?%,EPAMW6.X
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M\-=%\9:A\3/%ECX5\1WJ:;I>K7'QU\316FHW;NT:VT3MJH#S%T=?+7+AD<$
MJ0 #ROX?Z!^R7\,M0\!W>D_MJ:3'=?#>[U^_T26;XC>%IC%<:V\DM_)*&MR)
MBTLTDBB0,$+84!0%">#O O[$O@GX?^&_#=K^U/X3DL=!\)2> +F1_BIHZS:[
MX<>4R_V5=,C*/+5F(6> 172J67S\,P;Z7_X=D?"S_GZ^+W_AWO%O_P LJ/\
MAV1\+/\ GZ^+W_AWO%O_ ,LJ /$M%UW]B_P=\<-;\=>&?VF/ ?A.YUP&YET/
M2?BOI\7AN#4OLZVRZJFEM,UI]K6)(P"\;1%HTD:)I 'KN/V4/VIOV5_V0?@#
MX=^'&A?M.?"W6M"\*V_V/3IM9^(&B37<5N"2D1>)HPX0' 9E+D?>9CS7:_\
M#LCX6?\ /U\7O_#O>+?_ )94?\.R/A9_S]?%[_P[WBW_ .65 &A_P\Z_9K_Z
M.%^!W_A=Z7_\?H_X>=?LU_\ 1POP._\ "[TO_P"/UG_\.R/A9_S]?%[_ ,.]
MXM_^65'_  [(^%G_ #]?%[_P[WBW_P"65 &A_P /.OV:_P#HX7X'?^%WI?\
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M\:7H-[XQ\1?%S1K7Q-KUCX8TUS\5?&<_VG4;V40VT&(M08KYDA"[FP@SRP%
M'G'Q@N_V-?BKXAU;4K/]J+P!X);7)O#ES>6_A[XB:#%;/-H%S]JTN18YQ,L9
MAE6([4VJXMXPRD!@VQH/C;]C+PO\1[SQ#I_[1WPNMH;KQ%<^-(=&_P"%BZ.^
MEV/B*YA>&?6(HF<L+AUED8Q,S6PED>80"9C(?8?^'9'PL_Y^OB]_X=[Q;_\
M+*N.\$?LC_L^_$;XJ^,O!.B^(OBY>>*/A_\ 8_[?L?\ A:OC.,Z?]KC>2WR[
M:@$?>D;G]VS8QS@XH \K_9Y_X9'_ &;?%7P[U31_VPO#.I+\,;#6=,TBTU3X
MB^&YH9+?5KF*[OHYV2)))-\\$#@[P4,*A2%+*WTK_P /.OV:_P#HX7X'?^%W
MI?\ \?K/_P"'9'PL_P"?KXO?^'>\6_\ RRH_X=D?"S_GZ^+W_AWO%O\ \LJ
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MHDO_ !$UTEE]G^*/C2X@+6R[IA)-'J#10E>0!*R;F!5<L"* .N_X>=?LU_\
M1POP._\ "[TO_P"/T?\ #SK]FO\ Z.%^!W_A=Z7_ /'ZX'XP_L?? 'X!Z7H=
MYXLU[XP:5;>)->T_PQISCXJ>-+C[1J-_<);6D.(M08KYDSHN]L(N[+,HYKKO
M^'9'PL_Y^OB]_P"'>\6__+*@#0_X>=?LU_\ 1POP._\ "[TO_P"/T?\ #SK]
MFO\ Z.%^!W_A=Z7_ /'ZS_\ AV1\+/\ GZ^+W_AWO%O_ ,LJ/^'9'PL_Y^OB
M]_X=[Q;_ /+*@#0_X>=?LU_]'"_ [_PN]+_^/T?\/.OV:_\ HX7X'?\ A=Z7
M_P#'ZS_^'9'PL_Y^OB]_X=[Q;_\ +*C_ (=D?"S_ )^OB]_X=[Q;_P#+*@#0
M_P"'G7[-?_1POP._\+O2_P#X_1_P\Z_9K_Z.%^!W_A=Z7_\ 'ZS_ /AV1\+/
M^?KXO?\ AWO%O_RRH_X=D?"S_GZ^+W_AWO%O_P LJ -#_AYU^S7_ -'"_ [_
M ,+O2_\ X_1_P\Z_9K_Z.%^!W_A=Z7_\?K/_ .'9'PL_Y^OB]_X=[Q;_ /+*
MC_AV1\+/^?KXO?\ AWO%O_RRH T/^'G7[-?_ $<+\#O_  N]+_\ C]'_  \Z
M_9K_ .CA?@=_X7>E_P#Q^L__ (=D?"S_ )^OB]_X=[Q;_P#+*C_AV1\+/^?K
MXO?^'>\6_P#RRH T/^'G7[-?_1POP._\+O2__C]'_#SK]FO_ *.%^!W_ (7>
ME_\ Q^L__AV1\+/^?KXO?^'>\6__ "RH_P"'9'PL_P"?KXO?^'>\6_\ RRH
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MVM1V_C/Q3,GV::[66*6(2+$S&-3G:JEMK,K?>_\ P[(^%G_/U\7O_#O>+?\
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M/&4/C+Q#9:7K&B^'89/,LX##=.LPNTM D$"!?W$I>8_,A63T[]MOQ9XHU?\
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MX_[]7W_R#1_P^LU#_HAOCC_OU??_ "#0!]X45\'_ /#ZS4/^B&^./^_5]_\
M(-'_  ^LU#_HAOCC_OU??_(- 'WA17P?_P /K-0_Z(;XX_[]7W_R#1_P^LU#
M_HAOCC_OU??_ "#0!]X45\'_ /#ZS4/^B&^./^_5]_\ (-'_  ^LU#_HAOCC
M_OU??_(- 'WA17P?_P /K-0_Z(;XX_[]7W_R#1_P^LU#_HAOCC_OU??_ "#0
M!]X45\'_ /#ZS4/^B&^./^_5]_\ (-'_  ^LU#_HAOCC_OU??_(- 'WA17P?
M_P /K-0_Z(;XX_[]7W_R#1_P^LU#_HAOCC_OU??_ "#0!]X5^,/QYAUC4KO]
MI_2[#4KK0]!\0:]HNC>,]6MRX;2?#%S\0O$<.KW+%&5EA6T>3S6#+LA:9BRA
M2R_5W_#ZS4/^B&^./^_5]_\ (-?/W[,_[9NM?L]_M#_$'QS<_"_Q-K5K\1+6
M4FQBLM2CDTQSX@UZ^$4A>PVR;K?4+=MR$@$LIY4T ?:W_!/+XP>(/%WB[XN>
M!99/#>O?#_X5ZS8:+X+\3:#8Q65EJ5E)IMO.]CY<'^CE[%W\@M;A8]OEJ421
M)!7TW7P/I7_!9:;0K".UL?@+XPL[6$8CA@MKV.-!G/"BP '))XJQ_P /K-0_
MZ(;XX_[]7W_R#0!]X45\'_\ #ZS4/^B&^./^_5]_\@T?\/K-0_Z(;XX_[]7W
M_P @T ?>%%?!_P#P^LU#_HAOCC_OU??_ "#1_P /K-0_Z(;XX_[]7W_R#0!]
MX45\'_\ #ZS4/^B&^./^_5]_\@T?\/K-0_Z(;XX_[]7W_P @T ?>%%?!_P#P
M^LU#_HAOCC_OU??_ "#1_P /K-0_Z(;XX_[]7W_R#0!]X45\'_\ #ZS4/^B&
M^./^_5]_\@T?\/K-0_Z(;XX_[]7W_P @T ?>%?!G_!*W_D]C]HS_ 'YO_4\\
M>T__ (?6:A_T0WQQ_P!^K[_Y!K+_ .".FHZEXJ_:/^-GB*^T'6=%CUZRM[X)
M=Z;>6\43W7BOQAJ(MUEG@B661+;4+1G\O<%,RC.: /T$HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN ,L$)R=H;9)L^O* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6P5+$U\-E.?2CB)^Y?1I:_<>MF>5>UIJ*=CS73=4M--8O<74<14;BH.YN/\
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M/Q"FT+P%INM^%+CQ9=P0Z+J<%Q=,-2NH;:T$<#;)?L4$9:/>A2['RAESV?\
MP<N_\H/OCQ_UXZ9_Z=[&F_\ !3:=_P!G[_@HI^QO\:HI([739O%&H_"OQ$=R
M1"ZMM;M";/S)&!VI#>6J2  @LS;<_-6I_P '&?A:Z\8?\$4?C]:6AB66'1;:
M^;S&VKY=OJ%K<2=CSLB; [G XZT ?6GPF^&NB_"7P/#HWA^S;3]+-S=:@+?S
MY)ECEN[F6ZFVF1F*H9II"L:D)&I5$5$55'XK?\$</VI?&/@7_@O!^T(NN:A#
MJGP[_:*^)WC+PGHMQ)-(TT>J^&VCNH%" ;$C_LV]6,%@"^Q1N!CVO^XVF?\
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MCS\I)O:.$?+Y8- 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 !K\(/^#A+X93> _^"C,GB)ES'XT\.V-W W\.;8M;L#^0..X(]:_=\C-?
MF?\ \'*G[/LGB[X!^#/B59Q,TG@75&T[4BHQBRO@B+(YZD).D2@?]-R>F:]'
M*ZG+7Y?YDU]^WXV.7&0YJ7IJ?F7XR/B+5?#UU!>7OA6QTFZM%N42**WLVN 0
MLP6%  Y.X =.2#G(KSOPUXVU+1/#>@ZA?>)]+O(?#.JRV6G^'[AC]H2.<;W?
MC!,><+USG-5YM6N-4B@6XD,GV6,0IE0-JCH/H*IZ&&MO$%SI]KH.BZU>^*(5
MTBUDOW\L:=-(X$<J/D*AP2,MP.I(K[?B; ^VPU+%QUYURORO9K\4T>'E==0J
MSI+Y?UZ6/L[QKI-IX*UG2Y])U*ZU*\U"TBU*6PLX%DVR%4(E4$$!E4KU/W5R
M20,'K/\ AHG5/&&O?8]4\2MY)F:))([>"/8S!3(K?(,.%'!SD'US7!?L07MO
M#X?U+1+R:SE\6Z#<RZ;JRSO)-+"B90-#+AD$94$ *2< #TKUSQA\"=0\3VC3
MV=KH\5]):.^Y=.)GUD1IM5-Y.=S#Y=P4'/'&<U^2XA4IS:;LU^!]92DW&_<]
M,^%7[2]OX(?0_#.N>/(+KP1J5X\%_ITEO;2YT\+A)-VW,<I8Y+@@X4D<UD2?
ML[ZG<7NJ+IM_I%QI=KXK76-(U^.=I+34=/>(YBA"Y9F)<[U VAB02!@UX+<^
M&HET^#31X/O+&>:7$S%&7Y0XW=\]1N&<#@CFNJTGQG<_#K38X]/?Q1_9>FV3
M2*EW;-;>2S'<5R1C@G.5#;BQSCO-.,7&T):]V7.U]4>MI^SK:6=Y)<W6O26=
MG;ZU)JT;6^FA"(&WDVQ=YBH0%^I5@-H^7BO*OV@O#3_%#6]%T/P3HNH:AX8\
M'>9)+':DRQW#,NV3$IR))64X)]<XP !75>"?B)<?%#6;W0YM0EU[0S:QW4<<
MME,CEA<@#?OC4@E.2-S<<8'0=@OC'5/!6M>/)K>\M6T6WT_.@:?;6Y6;3Y4B
MP<C:,[G((R3U[5A'FO9NYTTXIJZ1S/PG\:>+O"K7=OXJ\*ZMI^@Z)-<SQW7V
M/:OV.-U6& 1JHWMMR0V>1D53^,7QET+XI74<D:ZC_9\*>7;QR:<\$D0],L<#
M_P"M5K2_'GQ UC1-/U2^U2&^\)R^'+F/43<(D$US>K*^UE0KNVJ-H.TXR*\1
M\8>/['1+6>\EU@F-6D:Z@,:H41>G/')R.,GUHG6:TB2\/&;O(\?^/6JPV?Q-
M\+Z3INO1^"'LII-8M]0U!T9(Y8P?+*A&."6XP>F[/(Z<#\ UN/$VM:A>7VK:
M>^KZE(\K_P!I69N(+]7+/)Y@4';@A2#CTZ8JK\4O$>I:W8W&J7^@Z#?:=\1$
MV:3<R7 GO-(A@E(.T*V8V89'S ;@W4XQ6+IO_$O6%H_E:$AAWZ?SK]-X)RIU
M*BD[>XG)^LE9?<KL^3SO$**:CLVDO3J:WQ5TZZ\1^)H])B72KK[:D-G:Q:0O
M^C@3L H4#DD[R3GG/K7]0GPU\*KX$\ Z)H2,&71-.M[ ,!PPBB5 ?_':_GW_
M ."3WP4NOVK/^"D7@>.^C^U67AVX;Q;JL@4;%BL]IB4C[NU[AX$V]<,QQP:_
MH>MOXO>O,XAQ$:M=-;.[^_1?@CHRN+5._I^!-1117@'J!1110 4444 %%%%
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M.-$"HB@8 4#@  8 '3%6HTV$U^6XBM*K5=26[_K0^MIPY(J(ZBBBLS0****
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MIUJTUFZ\66'PY%U-XB$=I+:W%I+B^BN/L]TD\HF$MS/(V5;S!*JR@ I_!_\
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MM=ZG,PO(Y4CTU)+J...&-4F?;(YG4%4'H7PO_8P\4_LZ>.?%W_"M?B%I^A>
M?&VNW7B6[\.:MX;.J3:-?WCF6\?3KI;J$01S3,\WE3Q7"))(^P*A\L%E^Q5X
MB^$7Q?\ &7C#X3^/;'PO-\2/LMSXGL/$/A]]>M+S4+>W2U74H!'=6K07,D$<
M22Y:2*0PHWEJ^]G #]@_]I_7/VT/V<_%(UXP^%O'_@SQ+KGP^\17>@QK]F@U
M33KA[9[VQ6Y$P$;KY<Z1SB4(7V/YH4L_FOP#^*WQ4\4?LL_%GP3X@^)U_)\>
MO!?C:Y\(+K@T+38EM'GFAET>YBLEB\M[:;3[BSGE#AGR]V%D3RU*?1'[*G[,
M6A?LD?"&/PIH=Q?ZG)<7]YK6KZMJ!0WNNZG>3O<7E[.8U5/,EFD=MJ*J*-JH
MJJJJ,]OV3-(B_;(;XQ6]_=6^H7GAZ+1-2TL1J;;4)K>28V5\3]Y9H(;W48./
MOI>8;_5)0!Z1X5TFZT#PQIUC>ZI>:Y>6=K'!/J-U'%'<7\BJ TTBPHD2NY!8
MB-%0$G:JC 'SO^VA^V9X@_9M^+OP_;3K'3+CX>6&N6%E\2]0N<K)HMIJSR6&
MF31.2$ 6^\IYR<F.##$ .&'O7A[2/$-EXR\0W6I:W87^AWKVYT;3X=,-O-I:
MK$%F$L_FL+CS),NI$<>P';\_WJ^7/B+_ ,$H--_:!^#GQ>L/BBWPE\<_$CXG
M?;HK3QI/\.1'<:!;S6RVUM%&CWTDW^BQ*HC:&X@.Y1(?WK22. =C\6OC[XP^
M(W[=%K\!/!.J1^#[?2_!B>-_%7B9;.&\OXH+B\EL[*RL(YMT,<SR6US))-/#
M,B1QHJQEI1)%X+^T_P#M=^-/#'PG\76/@?\ :*\+ZYXH\%?$?PQX;,NAV6E7
M>K6>G:KJ5AI<T6L6SQ21QWD<LUW)&\,=NC;(LQX#J?7/#O\ P3T\<:#XB^'/
MQ$/Q=L9OCMX)\+?\(3K'BP^$S_97CC1Q)YJ0ZAIAO"PE28>>)K:ZA82R38 B
MD,(;KW_!,)OB9\-?C18^,?'DESXM^,GB+2?%<NM:%HXTVWT#4M)M]/BTZ:UM
M9IKDL(WTRVD=)97$AWCY5;  -K]KJ'XAZ/\ $#P%IOA?XN>*O"MI>:)JXU#[
M/I&CW<FH7%G:":&X8SV;A&9S^\6,*C+PBQ'YJ^?OAU^T!\9O''P:_83UZ?XQ
M>(K>\_:&-N?%WDZ%HFTB?P_>:UBV#61\K9);+ ,[\Q,2<R?/7TWKO[,_Q,\<
MV]YJ7B+XE>$+SQ99Z)>:1X?GLO!4UKI.FR7>Q9[NXM&U&2:YEV1A%"W,**&?
M*L2"/(O#G_!,3XI>#_AC^S#X=T[XR> ]W[,J 6%Q<_#BZD776CTJXTF RHNL
MJ8]MK<N6"L=\H##8O[N@#ZR^,GQ!;X7?#;4]:AM?M]]"([?3[3<5^VWL\BP6
ML&[!V^9/)$F[H-^3P*^4IOVQO'GQ(_X)*_%;QLNLP^#?C=\&=(U_3_$W]EVL
M%S;6OB+1(I6E40W,<BFTNO+BG12 YMKR,JZL0]=UXQ_8Q^)'QR\:^&W^*?Q"
M^&?CKP/I>KR:GJGA"3X;2QZ=JJBU\FVC FU2=5,4CRS[I5G#2M$P1##&1YSX
MR_X)*>)M-O\ ]H'1_AC\0OA[\,_AI\?/#O\ 8ESX1M/AQ)+;Z'<&Q-C+J,!B
MU."+[1)"VU@L*(WDP$J61VD *_\ P3F_;+\<?'O]I*'P]8^-6^,'PV7X?6FM
M>(?$LNDVUNWA7Q/*ULXT=;JTB@MIP]M.\IA\IIH!&ADD/FJ*^Z*^4?A'_P $
M\_&7P-^)7@?QIX9^)7AS3?$UOH-EX9^(RIX.E_LSXB6=B%CL9_L_]H;[*_@@
M\R);D2S!A)AXV1(XT^KJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL
M'XE_$_P[\&O!%]XD\5ZUIOA_0=-"&YOKZ=888R[K'&N3U9Y'1%499W=54%F
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^,_CK^UIXZ_8G_;9U/4O&7B
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M"?\ 8X?X*6GB7Q==Z!_9]YIL6JRW$$6KVT5P\K[HY88419(_-.Q_+R"JDY-
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MZKX8\$?$R\TF#6CH)O)=$6W1KA-6FTNY.QY1(J6\D+32EE!6$A@&8,B^2?\
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MIM6A@O8(8;FP\DV'V'[*XMH'V?9=PDB$@8.2QK?$/_@E)\&_B7^R;JGPCO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YK^U+^UCX/\ V-_ATGBSQU)KUKX>
M^TQVDU[IVAWFJ1V;2$*C3_9HY##&6*KYDFU S*"P)%:-I^T+H-]\>9OAQ%:^
M)F\1V^D1:Y/)_8-Y_9MO;2O(D>^]\O[,LK-%*!$9/,/EL=N!FMSXH>%],\;_
M  T\1:+K6@IXHT?6-,N;*_T9XXY%U>WDB9)+4K(RQL)59DP[*IW<D#)KX<^"
M/[./QLT?_@D/_P (G)X4\5:3\8+?6;&76;#6?$MFVJ^*]+L]5M6DM!J-O=31
M[I]$MQ8J\LRG((D9 3+0!^@&:*_/70?V(_%WASXR^%_%UO\ "S4F\ V_Q&U1
MK+P,^H:<]SX6\,:EX3%A=VWEM=FT6QEU=#<-903.J+*KI'G?&FEK/[.OQ:D_
MX(?_  Y^'LG@7QHWQ7\,V7ARUNM!TSQ59V^H*]A?VQG8WJWT5O(C002.%-P=
MV] 1N' !]\45^=?A']FGXF^#OVF[+7='^#_C#1]&T_X]R:WIMQ%K6CI#I7A"
MZ\."SO%BB74"8K275FENY+2-=SDK,8C(JJOCNL_LK>+OAW\-_&7BSXG>'=+^
M&.J+H7AGQ5X1'B#6]/N-.'CS2=1U2Y:PWB]N;R_FOX6M8);N4R3WD;D[8VBA
M@B /UVHKR3]G[]G/2?#W[/M]HGB;PQH*7_Q$EO->\:Z:MO'+9WFI:DQEO8F^
M4":-2_DJS@LT<2;BQR3\<?$W_@GM\1O"7[,O@?2=!\$MX@U+X;:U'X-O;;1[
MK0XM8\9^!X#?B'$FIQ2V<LDDEQI]U<6MYM266PE(9&=68 _2(\5Y#J/[8%E9
M:SX-T:/P3X]N_$WBK3+;6KO0H;2U_M#PO8S310&>_5K@(HCEEV.D#32?NY65
M76-F'RO^S/\ L/\ B#P9\95?QAX%^-&O>%]$^%NDVFDWNO>.[*^U./5[:;5"
M]JLEK>P+%>"SO8+;SHHXX"R2CSW'[Z3QSP?_ ,$^E\1^$O#<7[1GPMC\"Z7#
M^SKIG@3Q+\2]>U+PZTGAWQ#;%HFNOM@O7G\P#RS'. RME%<@%E !^M->:VG[
M5?A?4_VB]'^&EDNJ7VK:WHFJZY;ZE;P"32MNF7\%A>VQGW?\?,5Q<(K1 $K@
M[BIP#P/_  3?\"ZI+\$H_B5XRT7PSIOQ&^*-K8WNO2Z' $LYH+6U2ULA$=JO
MY+0()U20;HS=R)P  /B>?_@G9XT\&Z-JGAG2_P!G.]^PV_ASXKV<=UH=YX?L
M;'4=2UG7+>ZT*=4%_%)E+6SA"/+&IMV2VQL,0:, _4C2O%LFI^-=8T=M%UBU
MBTF"VF34IXXULM0,WF92!@Y=GB\L;PR*!YJ8+9.-BOS'U_\ 9@^/7C[Q7XRU
M:X\#?$;3;K6M-\"WR_VOJVB^(--U'5-.TO4EU"*ZTZ750DMOYT]HC)%-:G[3
M&MU#(6A#R?3O[1'P_P#BYXD_X)G:3H_AOP]:-\4K/2O#L^J^%[;Q)+;Q:D+:
MXLIM5T>+4Y7+@7%O%=6JSRN=WF@NX#,X /INJ.L>)].\/W>FV]]>VUI<:Q=?
M8K"*60*]Y/Y<DICC'5F$<4KD#)"QNW121^:/Q(_8?^)7C7XB^#UT3X6_%[P)
M\-;J*.YTC0] \<^&DOOACK*:U/<RW4GVM;I;6TFAE@VIHT\AA@MI(/)99O+7
M7\$?\$^-:U?QUX(\7>*?@KJFM:IX5^.^O:W,/$FJZ;K5XWAF\@UD6,\33WLR
M>7#<WMG,8V99XVC9D0LH# 'V?\1_VK[3X::%9R77@WQM>:YK.NWN@:)X?MH+
M0:GKTMK%<W#S6XDN$A\EK>TFF1I98RRA%VB1TC/<?#/QS)\1_!MOK$N@Z]X;
M:XEGB_L_68$AO(Q%,\0=D1W 60()$^;.R1"P5LJ/SO\ AM^Q]XYNOCW\(M1\
M8? +Q)KEGX-^,7C373K6NZEH6KW&D:+?&Z;2YQ--J$ETRK)=6TFQ-TL;6;ML
MW)%OR?A5^RG\9]+/A[2?&OP1\>^,/!+W'B"'2+:3XBV5KK7P^O9?%E]J5CJS
M70U!I&\S3KRRB-Q;S37EO_9T\:QLL[>: ?ISK^O6/A70KW5-3O+;3]-TV![J
M[NKB010VT2*6>1V; 554$DG@ $U/:W4=[:QS1-OCF4.C#^($9!K\R?C)^PW\
M8/C!\1?C8TGPUN;?3_B-X+^)'A4K<:KI]SI^J7-Q<VDOAN]N)9KR6ZG9DBE\
MH/'''IX<01PPQJTLO3?"/]C;XC6'[=?A_7+KP%\0/!O@C1+W2M5\*3:!K?A?
M3]&\,Z<NBQ6U[H5];1QR7XC:\2YG-M92R6<TES#*6BDC+  _12B@44 %%%%
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MD;+>6L9DD(V A"=YW%2W&<#HJ^?E&S:/>C+FBI!1114E!1110 4444 %%%%
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MO 7P:.@ZQHOP8N-2UCPK%X-UR4SZQJ'VS38HVA%NDTCQ-%$ZLSM'%'$@>1B
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M6/$&,C+GNKW3V6MMK]S&60X1QY+.VJWVOO;L?"/P&_8#^/F@^'M5T_XC>/=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex3-3_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_002.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M+2FA\626WD"TM)XXK5%AM+?R-\<-L(D\Z1Y6#O@@ ^)_BK^V#J7[87_!=O\
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MHVOWD,WB2\;POXMB\$ZG:6OAV^FO+;4Y6B6)?)6(NT+&:/$Z@P\G+C:^WO\
MXK?%KPY\#_ MYXE\5ZM;Z-HMBT<<EQ*&8O)+(L4,,:*"\LTLKI''%&K/([JB
MJS, 0#\W?A+^V#\>/B/H_P /_%WBCQ5KW@/2/B5=V^C^+85T+[3%\/'GCN;M
MU4-:;;*XB:TCTY!<27#%[_S[A(6%O"_H/[1?Q;^-7A:^\2> _"GBSQ]<^)M*
M\.6-Q\-F708H[[QKK&I7MX4DU%Y;=HTT_3(8[-)QB&0(T\D_S/;BOL?X=?M'
M^&/B5)J45NVM:/<Z3]G-W!KVCW>CR1^>9!#@74<>[?Y;X"Y(P <$@5U5SXST
M>R@N))M6TV&.T+"=WND582NW.XD_+C>F<]-R^HH ^'?$GQ@^,&G:1XA\3Q^)
MO&6CZ/XJ^-MWX1\/,^F17D/AW0A&-/N+Z>/[,TCH;JRO9+'/R">]LC*9H"8C
MY+HWQ#\8>";:/QQM^*%S)XFU/XA>.-=L[_0T?4M2LO#MA#H^C6#;;;;'=LR6
M%Y"Z!3YJ7"[G8MG]/[KQ3I=C_KM1L8<V[78WW"+F!<%I>3]P9&6Z#/6K%MJE
MM>Q220W$$T<1P[)(&"<!N2.GRD'Z$&@#\WM6^-G[0GP=^$'BN'Q5X\U?^W/"
M6C_#OPUK=PVGV<,EQJL[M/XAN=*FE@%L96LKFV19K@_9HY;>>1Q"B,4Z'0?B
MC\5X_!?P]MYOC!KGB+4/&'BY_*A\-0V&K?9M&OKNYL;#R-1CL?LU[+IOEI<W
MZ.2-BSMYA6.)9O<]>^,/P%_;37PF^I:UK5C-'+'JGA+4_MFK^$;C4ENH9D2;
M3KR-K:2YBF@69ML,C*T:[V79M:O9/A9X5\'?!OP1:Z+X;DL[+29+R26,R:@U
MU)=W=W(US)(\TKO)---)*TI=V9W,A8DYS0!\Z_\ !3WXN>%Y?%GP=^%'B+4H
M+#2/%WC&R\0^)IYX':WLM)T<OJD?FR8*)]HU&RL+8*Q#2++,%#;6QXO\4V\6
M?$#]MJZ^(G@G3?%'A/P#\6->\$> #/-H+1Q^+DL)]5U/5M1NK26$R"UDT_&F
M1SSQJ78HRMY2PN_Z">*OBEX:\#[/[8U_1]+:2\MM.1;J\CB9KFY<1V\ !.3)
M*Y"HO5B> :WJ /SW_:'\5_'G0O@_\<-&A\:^/EU+PG\18='\-^((M"M"U[8:
MU;:3#91M&EH5N8;"ZU::61X4!VZ<$D+[I 6_MA_'OX@^&M7^+^F?#[Q)X\M;
M;2_"!LO#$6D>'UCM?"^JK<C1H8+N%[0NRO=W,&H0S1,5FMK6Y7RUBC1YOT*H
MH ^%_'OQ8^*C?M#7W@GP?J/B32+KP?XN\+:#X7\/6FA116&H^'O+TZ[UK7-3
MF:'RQ;FWEO[6)87B"S6BQH//DVHW]@_XJ?&3X@_'3P*_BSQ!XN7PWXFTGQ=X
MT&FZCI4:)%I-SK$">'+2>7R0ZW*6)FD<%E90(U92S,Q^ZJ* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS
MG]KKXG^*_@K^S#X[\6^!_"LWC;Q=X=T6XO\ 2M#B#,^HSQH6"!%(:0\$^6A#
MOMVJ0S"O1JX7XW?#CQ3X^7P[<>$_&?\ PA^I>'=1;4?WNF#4+/5<VT\ M[J'
MS(G> >?YF(Y8W\R*(AP%(8 \A^!W[:=UK7@'1_%VJ>*/!OQ,\'_$*&P3X>:C
MX'TBXM;OQ3>RI>27-K]DGN9C$T*6P9FEDC2)5F,S1^4^W:M/^"D7P[USP/X3
MUS18/%GB/_A+-!M_%4=AI6BRW5]IVD3/Y:7US&/N1EPZHJEI+@QR^0DWEOM\
MKN_^".FCW%_X;UB7Q'H>K>(+/Q/XE\3Z_'K7A2/4-"UJ;7WB>^$>GF=1;E&M
MX?)9I9L 2^:+AI78^P^!/V1M8^&?[3WB7X@:3XZ>2R\;:7HUCKUE?Z+#-?7$
MNEI+'#)!=1M''!'*LS>;#]G8;F=HC 7- &5X'_X*;?#/QG/XJ$W_  DVAVO@
MB778=>U#4-)?^SM+?1[M+.[CDNHC)!YIF<B.%7,L@C8A,8SG^,?^"ENBZ;X>
MB;1/!/CC5_$$GC_3?AV^BRVUM9W=M>WMM;WRRL)IT4HEC.+AD#>8FTI(L+*^
MREK'_!,;2M4_X)Y#X%CQ-(M]-J-MXCU#Q'+IHE_M;6X]7CUF:[N+7S!OBGO8
MR7A\T$1.4612%<='I_[#CV6L_".X7Q)IMCI_PMUG4->CT;2?#D&GZ7)<W=E/
M9@VT*/\ Z.(UNKMP9&N'9KJ0LY;:R@&E;?M\^"]9^,NG^"-'LO$VN:EK%]JV
MEZ==V=@O]GZA=Z5'(VHPQSR.J_Z/(J6[R-MB\^58@[,DPBXWX??\%=/A/\2/
M"'@S7K&S^(<>B^.[KP_9:9J,GA&^:P$^MW$EO8QR7<:-;KF5$21O,*QM/$C,
M'8J.8\ ?\$K==\ >!]#TFW^+4GVCPG\*-5^%^@7,7AQ8AIC7K0DZOL^T'=>$
M6UN9CN EDC++Y*L4KMOB]^S%;ZE\!_"/[/W@72=<\)Z#X5B\.7^D>)8[:WGT
M_1H]&U.TN8H</)O>Y(LDP#&5/F!F) 8  ]<LOV@/#)^%WB/QGJ5U-X=\-^$K
MC5(=6O-8A:R2S33IYH;F=B__ "Q_<.ZR#Y6CVL.#7BWQ?_X*@^&_AY\"/B/X
MJTWP?XSU37O .@V7B*+PU>VD>E7^K66H/-%IMV@N'79#<3V\T>QP+F-HG#6X
M?8C^D_M%_LGZ-^T!^RSKGPL^V7&BZ;JUO&D=TB"Y>.:*=+E))5<_OPTT8,JN
M<RAI 6!<M7S]XH_8V\3?$+XX:GI/B*#5]>U#Q7XD\,>)_&'C66VAM-&N]*T6
M>2\L]#TZT$TLD$<=]#&S1RM([?;KN1I3F-* /1/%WC7XW?LV?L1>//'&J>7\
M4_B)9:2NN6&@6NBI:G3I?LL)N;1(K>5VNHX9A<RQQJ[3N@6'SI7Q*W-^%OV\
M_$^G^%OA]K4:^&_C1X=^-&M:3I'@/6O UHNF1W@F@NKJ_FNH+R^=HQ;6EG<2
M[58MF%D8*^0OO7QO^&_BOQZ_AVZ\)>-%\'ZAX=OWU#;/I8U&RU4M;30""ZB$
ML3M"/.,FV.6-O,CB.\!2K>+_  M_X)GQ?#3QGX.UQ?&]Y<76AZ]XL\6ZND6F
MK!%J&M:^V9;NU7S&%FMNLES%$A\XF.Z?>[2$RL =EH/_  4"\#>+_B=#X7T.
MU\2:U-?6NLW>FZA;6*C3=5CTAXHM1:&X=U4I#<3P0>8VV-Y)0$=E5V7F_"/_
M  4T\,7W[*?A?XI:]X;\4Z&GC30[_P 7Z3H!BM[C4WT&V G.I2F.8V\$(M)+
M:9VEF0*UQ%%DRR1QOQ/@S_@D_K'A7X3_ /"-M\6)FFL/@?)\%]%NK/P\+6/0
ME9&C.J01?:&_>R+'9-+&7^>2S1EDC4B->J\=?\$S]-\4_&KP-XQM-:T2V;PE
MX0A\&O97WA>WU*&W@M[A;BUNM.65_+L[F*0<-+'<H56+*;HPY /I3POXCM?&
M/AG3M7L?.^QZI:Q7EOYT#P2>7(@==T;@.C8(RK ,#P0#Q5ZD5=J@9)P,9/>E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &RG"'KTSQ7YE_\%O?VEX_
M''CW0_@?::E/#X=T>W3Q5\0RF(XVMPP-A9O)@DAI%,S(BLYV0%0<[3^FDJ[T
MV^M?S\_%3]H/4/BQX\\?_&"2ZM/[0\5>))-:BEDM4OK:PTNRECLM-B$7RJ[$
M"T5GQPK;B&,C!O6R;!SQ&(4*?Q-J*\G+K\H\TEYI;['S/%68+"X-IOXKW]%J
M_6[LGY,YOQ#J6GW^KQZ_JE[<:+XH\/3I'?:/?QOI]_I<(C8&%H9O,-U#,9(H
M56,QF(/(TL821I!X[X;L]:_:>UW2[*\OIO%%GK=A?VGA97\3LO\ PBL]G-'*
M=5U""=G?['$EQ=,L;!5(N6^82-(7[7]J;XI:3XMTCP3X'O/$EAX9T'5ECMKO
M6]$\Z\TO[(KM&UZZ20QW^8UC:-H9Y)24ED,9$:B-O;_^"5G@ZV^(?QROO&6N
M:?X=U)+[2B[QVNBP:=I]Q:1K%9P#[-&FW]Y%ND9G!<EWSV ]?C+/H8&$:*C:
M%)J,8Z?$EK*]K>ZG97O:5[W;N?.<)Y+[=.LI+GJ)MORV2M?K:[VNK6LM#Z>_
MX)__  4^'^DZ'KGCC19?^$N\;ZAKNHZ=K_C'4(%>]U:]M;F6&>2)\#RX6DWE
M0N,@G/)('T[8P-(,=^A_S^M>70_LF:9^Q,RZ'X(TF\LO .O3S^([?1X+J>=X
M9Y;=4N(TD8_:65)C;R(AVCYL'<I81VO!^LQV7Q-L)[C39?$6G^1-!?K?WUS'
M, S&)VACW8$0W6Y0"(2LP>157<%7DHYE3CAX\D=6KOU]=V_4TJ<.XBIB).M4
M6_\ PWR_(]LT/06O' 5<DX'2KT>E:?-K4FE1ZAISZJH):R6Y0SC')&S.<@9)
M'4 9KSG2_BP-0\6ZE96GB^T\.^';>.X2UNQ8/J&JR.VY(Q(JDK%LP6^8B60*
MF!ER1E:!X(7Q-XCT_2X_$GA_3=+U;+6.L-J*VLMTJ@LQMK>8K.TRX5@=OE@,
M'$KD$'\SXTXDXAP.(P\<GP3Q$9RM)J2CR+3>_J]=E;7<^OR'AK 5:,WCJO))
M+16O?_A^G4J?MB?L,^ /VO?"#:5XUT6&>\MD/]G:S BIJ6E28.UX9BI( )Y4
MY4@D8YS7Y$?M5_ 'QI\#OCEXO&O)J/B3QQ;R2^+M9U)I=.T_0M:\/HT4,,MI
M;,(\W<,LNPQJ&&TE!&5=PW[+^./B)XJ_X275$CACMV\Q8UL-6,1N=/\ D4Y9
M[8%&<[MQ3D#*@,,$GXG_ ."O<.D^/='T&^_L?_A(I-!UB#5M%T[5H%4R"&.)
M[FRDFA*B59'*HP5F&RX7!1_F'WD<4J%-5JKY>]M.VJ>EI+=-:Z'@PP-6525"
M*YH[*_SZ=NC3[GRSH'CNU\16.A^+;S4++PIX?TNU^SV%G;D7=YK,_GW%R3;6
MZ%%AA1K]\+.ZPHA\HM-(K*/O?_@BK^U)-X!^.6K_  =N]2;4?"?CBVF\4^#)
M$F,EOIMVN9=2L4WA759?,^U(@4*-L[GF3C\PO@7XAT7P#\3IK>^_X1#5=!U&
MV@U^>+PW:VVL16T$\;2G3$6[63[.\5Q(+?S"&='G4MYL>T5[AX<\=^(OA5!X
M4^*4FDCPHW@CQ;;>(='2WLFLUL],>[V7-F(_+C5XI4$JLZ @[\\,S ?:YI%8
M_+X8F2]]/V<GIJWK!KK=MQ;W2C.6RV^3R^I+*\T<(OW'[R7ELT^EDKI:)WBM
M];_T)Q,61?7OFGU#8W,-[:136\D<T$RAXWC8,KJ>001P01@Y%35^<'[ %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7G?[4_P5U'X_?!G4O#NE^)M8\+
MWLQ$\<M@UJ$OF3++:7(N;:YC:TE;:LR>4Q=-RD%2RMZ)7S3\%?VGOB/^T)\+
MM'^,&DP^ ?#/PEUN2/4;&UUP7 U2?P]YH8ZQ+=B58+8O:AYTMC#( CQEYU;?
M&H!YUX4_X):^)/#5UHN@3^*[#6O"E_HWA.P\6:M>$IK.H?V#J5[JAMHH8H4M
MS'>W=X3-*Q5O+\Y2DCS":/VW]G;X4^/O GB;XS>+O%6F>#9/%?CGQ +S1(-/
MURYN+==-MM/MK6RM)YY+.-X?WL5Q*ZI'*J/=RLNXL5KD]*_X*B>'-<\<:9X?
ML_AU\5)K[7;RUM-*W6.GP_VC]ITW4=3@=4DO%DCW6VFNQCF2.6+[3;>9'&'8
MIKZ%_P %$-%U_3KAH_ 7Q$BU*;Q'+X3T72GBTTWWB/48!<M<Q0(MX1 (8[2:
M1VO6ME$>QP2)$+ &!X3_ &._&OA_Q5X=\?";PG#XTA\,3'Q!HHO;B;1]5\21
MM<R6%T+GR$E^SQMJ>JB0M"9'$MH<%K=<]]^V#\ _$'QE;X;ZYX5DT"?7OA?X
MNB\5VNDZ\TD>EZX18WEDT$TL:2/"R+>M/%,(I?+GMX3Y;#IQ?P8_X*G^ OCQ
MX]T/0=!T#QLP\17VEZ?9W\EM:&U,FH:%/K<6_9<M*FRUMY%<-&"'*, T+K,>
MD\1?'_Q?\3?VF/$GPQ^&P\,Z:W@'3["^\4>(=>LY]0AMY[WS7M]/M[2&:!I)
M3#$99)6G18EFMPJS%W$0!YI^V1^Q9\3?VR+06NN?\*U.EZAX9N=$GTNYN+JY
M@T66\O+9+RXMV:WQ-=-I@N8(;PI"]N\C;8RD\H&7\:/^"<7B3Q?X:\:RZ5H?
MPGU;Q=\0/'%QXAGU;6T=1X<MH8[.'2S;(+247&Q-+TTW-I)Y<=QB9/.52K5M
MZS_P4IUSX>Z!)_;'PS\1>)/$EEXJD\'7VC^&YM-VI=6FB?VQ?W=K<7%^BW-J
ML(9$+K;RB5#%)&CD"OHGX0?&?3OC7I=U?Z39ZI#I\/V5K>YNHT2._CN+*WO$
MDBVNQVA+E48.%8.C\%=K, ?'W[0/_!*OQA\9M4\=VMGJ'@71['5)M3ET'5TC
MD.J0V]UH,FAVVEF/R3%:Z?8P75U,L$32+<3>6Q6#=.9?=/V?_P!E?7OV;OAU
M\3[7PLWA73?$'B[7I-0T9C'+-8V=O%96FG6/G( CLZVME"T@!.Z4R'?\V1R'
MQ@_; ^(7@?XU?$+P7IJ^#_M%_IJ#X:WMUI-S)%/J\;V,-S87X6Z7S09=3LF2
M2)H"(_M1*,+<N^5\#_VG/C?\8/BKXD\'6>I_#'4KKPOXXDTW4=4M_"E[!9V6
MB6D2+<F1#J<C"^N;MWAMUW;$2TN)'5\!* .8T+_@F_\ $+1=3O+S3U^'.A:7
MINH>(O$O@SPK]NNM4TOP1K%WI-M8V1M9);5"+4SMJEU+!'%%'$]X@B1MI8Z.
MF?\ !)FS\&_'#X>_V1#X;O/A?X&\.:!IMOIUX$AN(=1TJ='_ +0DCCMBUU//
M%:Z=&9!=6X0:?&'CNHR(EZ;]I;_@H)KGP-_:5U+0K#2],UKPCX9\*7/B&^CM
M[6::_P!8FM;:_N+VQM+E9! E];1P:>_V)DDFFCU$2+Y:1.U1_"_]LGQW\2?@
M9\0-6;7?AC'J?@RXT_\ XGFBZ7=:[HUP]U8V]XVF6T*7D3WUVK7$,"21SQB=
M[B(B)&)@H XK]G#_ ()9^)O 'BKX>:YXXE\%>*M>\/\ B!-7\3ZS<2&[O/$<
ML%IJBP7>/LD,:.UYJ37/E.'EA=$)O+GRXPOW37Q_\-OVX_B1>_&/P9X8\1Z?
MX-:.3Q3!\//$!T^SN(I=1U[_ (1^?6KZ6PW7#K'9V:QQPGS/-:5Q<8:+RD$O
MLW[%GQB\2?'WX*2>+/$7]BLFI:[J\>BR:99RVL=UI,&H3V]C<,DDTI+301)-
MN5]K+*I 7.  >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ^Z'_!.KQY>?$O\ 8A^&NL7Y9KJ;1XX7+$%B(F:%>@ ^[&.WY]:]J'2O"_\
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M+85C_P $X_A99^#X-&6U\62O;ZDVJMJDGB[57UF>=].CTQS)?_:/M+JUC##
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1_P1._9%N/'WQD'Q.U"&\M_"_P )4G\/^$Y!'MBUO4I8Y8-3N26&2D+;HEV
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M\6_&+>!]*UY]0M;R6TO@S*)9[92K_9BT<P\R(R,/L\F4SL#^P'_@JKJ6H_\
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M4_)Y;996 QZ-XY_X*TZ0/^#42W^(VGZW:#QA>>"[?X8>4+A4NO[:V)IMP54
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MM=9O=[_CU;>K?5^222C@4445YI[P4444 %%%% !1110 4444 %%%% !1110
M4444 <WJ/QC\(Z/XXNO#-WXJ\-VOB2QTEM?N=)FU.%+ZWTY7\MKUX2V];</\
MIE("!N,YJS\.OB7X<^,'@K3_ !+X1\0:+XI\.:M&9;'5=(OHKZQO$#%2T<T3
M,C@,K#*D\@CM7S=^T7\'OB-\8OBA>>-?">@ZMX7\6>!=5MM!\/W5]>6:QZSH
M]W%+;:G=0M%/(R1QB\%VL4RQO)/HUJ"NU@1XWXV_93_:!\4Q:UHGA]?'G@FT
M\S4?#,=U8>.#9Z;::--JMI9Z2^DVEM>)Y']GZ3&U[+/(L5W+<1& ":.XDC4
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M0HB>6Q%^RCJFK>%=#\-Z[XQCU#PG9(CZIHUKHD-K#JL\=X+N.02%GE0;E59
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M8@$C!/S/*Y)>5V(!Z51110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXWA.&QUKX'ZU\89M'L+*22X\ PQK;/H\%Q<&0I>272S7$3 )$'ELIFB&Q&%
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M#XH\<_#7X2SZT_BZ]CBLGLRFHV]O' (XY;A))O+>(M( GR@#;O/RCZ.\/_\
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M'&JZKXZ\$_\ "%ZQ?:ZPL=2\0Z']FN)=0:VS&(9KF')D,7*A68[.1@=*[2@
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MS:W93#0+:"WT6ZEN'N2FG0;6%C;QS.[111M\A8L6:1GD;W:B@ HHHH ****
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M\$_$'P]UG1=;G\,^+I#)KZP>)]5M;_7\Q^2RWM]%<K=W2-%^[9)I75D 4@@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!:M\0/V#_@C\4/!>O_"OX8>(?B5KNF+J%O\ $B#5HM*%G-&TL]G9W,<"">\
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M2650#ZJHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOJF@W=K:)!)':11,ETZ""4NT<I"QNQVQ[B K(6_4VB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:\0:9\./%ZZWJOA<0OJ>GW.F7FEWMO%,NZ&<07<44CP2#E)D5HV[,:[/P?\
MM!>#?B!\8_&GP_T77K74/&'P[AT^?Q'IT2.6TE;^.62T$C[=F^2.%WV!BRKL
M9@H="WS=XVTS4I/V@O&/[2GAGP[)K&M1^"XOAQX!M(T#S:_%)?\ VNYU-XP5
MDDLDE\ET6/,C06ES+$'%Q$#YU_P3 >Q\'_\ !33]I;0+/2?&4<EQX7\%7=[J
M&M:2UI<7]X5UB2YNKGH%EN)IGD  "GYP@54"@ _0BBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!FGV.@>,-/31]6MK>6:-KC3T1TBL%D#^9%9Q))(D5M&RPQ+(ZHBAF!]7HH
M\(_9F_X)D_ ?]CCQ]-XH^&?PVT3PGX@GT]]*:]MI)Y)!:N\;M"OF2,%4M#$3
MM ^X.U>I^'O@_P"&?"?Q,\2>,M-T>TM/%'C""RM=9U% ?.U"*S$HME?G&(Q/
M*!@#[YZUTE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5SGQ=^&-C\:/AGK?A74KS7
M-.LM=M7M9+O1]3FTW4+7/22"XA99(I%(!#*>HYR,@]'10!^!/[/U]\5/B?\
M\$Z_VFOV;];\??%V;]K+X$>.GB\.:U8^-M5M]5\0_:,M;L':Y_>6[V]E=DQL
M3&D+1R "0AS]D?\ !(WXUV/_  4D_9#_ &5;Y-4\6-J7PXT^ZU#QI-'XKU(3
M3ZA9@V$<%^RSAKC[9<,;X1SF10MH5(VMAOI[PS_P30\%^&/^"G_B?]J*%O\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445E^,_#/\
MPF?A6_TO^T-4TK[="8OMFG7'V>ZM\_QQO@[6'8X- &I17X9?\$>?VZ_&G[?G
M[)GASPOXN_:,^)MC^T;\2/$^NZ=X:NK"XBC@T^UT[2Q>K//;FU>VD@$JK$ZX
M$K"X^5AMW+W_ /P44_X*%^/?"?[+/[>'BCP'\;?B%9^,O@OXI\+P:=HESX9L
M]+3P.+B_CL9;>*X5IAJ$-S&\DNYPI7;$P&6)(!^QU%?!OP2_;?NG_P""@OQ(
MT'5OB!X\UW_A"?A#8^);CX=CPG:);L52WF?4[/45F#7$L_G>6('6,!F8$C8
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MT_91U/Q7/KL]MXFU$MK5MK=UYFZV1M, 5X(V;*2,HD90-R EA^N5% 'X/?\
M!/C7]%^$.M_L_P#BCQ9^SO\ &J/X5:%X\U*#X97VF:YIFK^$/#MSX@U)K:VN
M;9%CCU*[AVM'L>XDD*^9)(B']TJ_K_\ MB^#_B1XXT3PA:_#W0_!>L-I_B73
M]9U0^(?$-SI B@M+F*<+!Y-E=>9(^PK\_EJO!RV<#HO"?[)OPK\!>.7\3Z%\
M,_A_HOB621YGU:P\.VEM?,[Y+L9DC#EFR<G.3DYZUZ!0!\E?'C_@E9X;^)W_
M  4W^"?[4FBK8Z)XY^'S7NG^)5!8)XATZ;2[RUASA?FN8)9T"N=NZ$LK$^7$
MJ_%W[8?_  0=_:$^*5]^U1H/@77O@S)X0_:&\<Z1XXMKW7M4U*UU+3VLY3-)
M:/##9RQJ&DD.V82/\L(!C!EW0_L-10!^6_[1G_!)/X_?&3]IS]J+QY8)\(;6
MS^/7PA@^'.FVD_BK4?-TNZ\JTBEN)F72R&B7;<%=N6?9$"$\QC'J?LK_ /!*
M+XY?!_\ ;4_96^(>OM\*F\/_  )^$,7PPUJ*P\27]Q>WLL<4\7VRV1].C0H=
MT1\MW0C<XR=H+?II10!^2W[-_P#P0:^+'AO]EGX)_ _Q]K?PW_X0SX9_%5/B
MAJNLZ+J=[<WVI^7YDJ:;%;2VD2(&FE9&G,V1& PCW$J/2?V(_P#@C3XK_9;_
M &B/%D/B/2O@OX^^&-Q\2KKXE>%-?U1;N?Q9X;GE=9%MDM6A^R[T=!MNEF#H
M3*P0^8JQ?I!10!\7?\$B?V&_BG^Q-??M!2?$!? .WXM?$?4?B!I3>']:N]1-
MG]MQNM)Q-9VW^J\M,2(6W[V^5-HW>^_L;Z9\9M(^"<,/QXU+P!JWQ %]=-+<
M>#8;F+3#:F4FW4"X ?S!&0&X X RQ!9O5** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KY=^/OA+]H[Q'^T$VM>&_ OP-\1^%O
M#"B3P@OB'Q[JFGS6MZ\+QRW]S;0Z-.C2@2-%&JS_ "1F0AMTIV?45% 'PW\8
M?^"9GCKQ?X?^/7@/1=8\)6O@/]IF]L=5\4Z@TUQ;ZCX>N7MK:SUC[';>5)'<
M"Z@M%:(R3Q>3+/(6$JJJ'N/C!X _:+?XW+?^#_ /P)UKPCX/MUB\#Q:]X^U6
MPDTZX-N\+WMQ:PZ-.K2[)#$@6<[(C( P,S$?5E% 'QG^UU_P2:T_XS:!X/7P
MGJOB+3]2M?B9H_C?Q']H^(/B.TL;B*+4Q>ZC):6T=U)'!<R$R&'RUC\MF7;)
M%M##N_VN/V;/&G[9_P ,_%_P?\2^'_!.G_"_7YM/BBUU/$EW?:T]K!/;W+LU
MD]DB1W(DA*QR"[DVMLE.64QM](T4 ?%?[9/_  3P\9_M#^)/CUIJVW@/Q?X2
M^/'AG3-%AE\2ZA<6]WX#N;&*ZCAGM88[:9;E(YKC[;&HEMG2X\T;\2!X\/\
M:3_X)@^.OC3I_P 9O"<]UX.\5Z#\7UT.:R\6:YJ-U;>(O UWIUC#:)<6T45N
MZ3M#+"]["5GML3W=PK?*[.WWA10!\8_'?]@+XAZOXR_:2L_!-YX+NO"/[4GA
M^'3=;EUZ[GAN_"]__9ATB>[A@BMY$O8GLQ _D/+;XE@(W[92T>]^T7^Q[XZF
MUK]E_3_AKI_A'4/"_P !==M]2NW\1>([FQOKFVATFZTM(HEBL9UDD\NZ\TN[
MH"8MN/GWK]844 ?$?[8W_!.+QI^T7K'QZT81> _$OACXZ:=I<-EJVO7]U;ZK
M\/+JRMG@ADLX8[>1;A()F:^@ GMF%Q<7"L=LA>O2/VR/V?/B5\5_CU^SYKW@
MZQ\&ZEHOPG\4R^(M8FUWQ!<:?>W:R:;>:<8X8X;&='8+>&;<SQ@F+9@!MZ_2
ME% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !67XUM-:O_"E_#X<U#2]*UR2(K97>I:?)
MJ%I;R=FD@CF@>1?]E94)_O"M2LSQEXJ@\#^%K[5[JWU.[M]/B,SPZ=8S7UU*
M!_#'!"K22,>RJI- 'Y;?\$W/^"L/[3'_  41_8;C^)%CK7[/7AOQ_KOB34_#
M7A;PE<^#M5>+Q!=6.G_;VC%U_;(:+?"DWSF)E0JN<YQ75?MT?\%>_BS^SQ^S
M=^U7\1O!>J?LV^)K3X&Z]H%GX?L=/U:3Q#?/;WETEC=PZQ;VUY$UC=)<.2F2
M,_9YXS&VT3'S'_@V;_X)H+\$?@1HE]\6OA#K7@'XV?#7QCJ>LZ;JNI:";6XO
M=.OM,^Q>1]L"E9H?WDS&$ON1XT;: 06\9_;0_90^+WQ.\$_\%+=#T/X0_$Z\
MO/CKXH\(W/@8KX>G$.O1:9J2-=R*^-L:JD9=3*4WJRE<G( !^FUM^WIJUI^V
M%X?\,ZIXJ^ ND_#N#X8/XP\6+?>+([3Q7HU\H2<R?8GERFG+:GS&ED7 &]C*
MFQ5E]>^&O[<7P5^,OBO2=!\'_&#X6^+-<UZVDO=,T[1_%=A?7>HP1M(LDL,4
M4K/)&C0RAF4$ Q."05./SG\??#;QY?\ _!7/X?\ Q2A^%_Q.F\$Z;^S1)X0O
M+Y/#-R6MM79+V[%DT>W?YFUTCX!42N$SG./GG]@/]AOXI?!*7_@F[]N^"_CO
M0]6^$?B+QP_Q'N8_#DD3:?\ VI=)'833RJO[Y3 4!=2_EQQD' 7% '[,7'[>
MGP-M/B,/!TGQE^%4?BYK]]+&B-XLL!J37:$![<6_F^89E) *;=PR,@5<_:6G
M^+!LO"-G\)9/!=G?ZEXAC@U_4?$VG7&HVNEZ4+6ZDDFCMX+JV>28SQVT2CS=
MH\XDC R/P[_X)K_%#]GK2/C=^S=\,_$7QN'AN3X"?$;Q/-X;T[5_"^L67B;Q
M'J&I7;P6]GJ<_P!G^P63(X)<K=3>>'CC9;=@ZU_0/K&J1Z%I%U?3)<20V<+S
MR+;V[W$S*H+$)'&&>1B!PJ LQP "2!0!^:W[#W_!1_\ :>_;#\2?M 0V]U\"
M88/V?_B8?"-W;-X4U*T;7M+M[QH[RY6X?5W2UG%M'+(BLDJ;U56."6'VKH7_
M  4!^ _BCP<WB+2_C7\)=2\/QZG#HK:G:>+M/GLUOYE+0VAF64IY\BJ2L6=[
M < U\3_\$!?A9XW^#?[0'[6\WC7X?^//!EO\4OB7?^,_#4^M:'/:PW^G37$Y
M4F3!2.4"6,F*0J^&. =K;=?]D;]@SQ3^S[_P6#^-VDZ-/9)^SEXK&E_%^WTF
M-05M?$L[7-KY2+NVK&TUO<7;808:WL%4@1,& /KKPY_P47_9\\8^*;'0])^.
MWP;U36]4O3IMEI]IXTTV:[N[H%0;>.)9B[R@LHV %LL..179>./VB?A_\,O'
M&C^&/$GCGP?X?\2>(F1=*TG4M9M[2^U(O)Y2"&&1P\FZ0A!M!RQ"CGBOP;D_
M99U_]LO]F[]O;X9_#[X=W7B+XG>,OVJ]131==CM(H[;15M=3CFEGN+TG-O'#
M";@ -@M]L(B$C&0+],?M9?\ !/?XI>/O^"D?Q[TCQCX9^,GC3X/_ +16@>%[
M73M:\"WNB6Z6-UI$46+?4);^*2:QA%TC70DM67D\).S%8P#]6_#/QB\(^-/'
MGB+PKH_BKPYJWBCP?]G&O:/9:E#<7^B>>AD@^U0(QD@\Q 63S%7>H)&171U\
MV_LNZ*VF?MO_ !ZDD_9_C^'K.FB*/B3]LMYI/B;BU?<SHB*\9MC\F2S[]V6$
M9PI^DJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *^?_\ @I%\6_B+\._V<M0TGX,QV4_QD\617-IX3CNH?/ABF@M9KN:5
MTP?E$4#1H2"OGSVZM]\ _0%?-U_^SWXH^/'[96O:_P#$7PS#I_@?PWHBZ1X(
MOM&\9WD-\[2W FOY;B&W2!HO/,5D GFRJHL03AGP "30?^"H'PSE_8=^'?Q[
MU:XUBQ\&?$*'2Q$]II5SJ3:;=7TD=NMO<FW1Q"4N7\AG<A/,&T$L5!?XL_X*
MA?#'P.GQ)74[?QU;W7PA@CU#Q;:'PM>F?1]-DA:=-290GS6K1QRL&3<_[F4;
M,QN%^1]=_P""=_[0G@[]FOXP?!7P7X,\"R?#G6/B;I_C;X?I?^.9UET.R@UN
MRU:ZL90;)RJ2W%I-)'M:0H;UPQ;9EO1OCK^R!\;_ (G>/OVPKRQ\'^$(['X^
M?#:P\%>'7F\6,LEM<06M];/+=(+0A$/]HNXV,YQ:@<&7Y #Z8^.W[=_P\_9\
MT&^U35KO6-5T_1]#3Q3K%QH6ESZJFB:.^_;J-SY"MY=NPBF93RSK;SLJLL4A
M7B-4_P""NWP3L+#X@7UOJGBC5=)^%L-C?>)]2L/#&H3V>FV%Y$9H-0$HBVSV
MC0CS1-!YBM%^\3<@9AX#K/\ P38^)"_%GPSX\NOA+^SS\49?$/PZT3P9XH\-
M^/;EKA/"U_IGGK%?:?>&PG\^WD2ZE$L!@A=_*A(<9(7+\=_\$Y?C:W@/]KSP
MCHGA7X=G2_C7X)T7P9X3N+?61I-O;"PTLZ6TTMG%:M':1%'::."$N%5%BRN0
MP /:?^"M'[8NE^ /V2/CUX9\*Z]XWM?B%X0^'NH>()+_ ,(V=Q-+X5E-G<2V
M$EU<0HPMA+)#G&0XB5I&V1 RCM)O^"@'@?\ 9_\ @;H-]XSU#Q%??V%X7TG5
M?%>J6.EW.IQ>'H;F)0EU?R1*QC5B'=C\S*BM*X6/YZ\3^*O[$_QR\1^'_P!J
M;3=+T7P'/8_M5^!EADCNO$$L$_@K7O\ A'4T66W9UM7%[9LL,,B3+Y3JP=3%
MA@Z\SI__  2[^(FA?&#4/$VK?"7]F?XIQ_$KPYHEAKT'C)VOF\#:GI]A%IS3
MV4LFFN^H64D$,4AM6%J3*K 2('9Z /4_^"M7[:>B>$?V-?CMH?@_Q+XX@\<>
M%/ %YKYU7P5;3SMX:F>TFET][F[A1E@$SQJV =ZPDRMY<1$M?1Z_&#1?A#^R
M_%X[\::RFF:#X=\,IK6M:I=%I/(@BMA+-*V 68X#' !9CP 20*^2_C'^P/\
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M*.5(_,<)P >_4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9OC&
MYUBS\+WTOA^RTW4=:CB)L[;4+U[*UGD[+),D4K1J?[RQN1_=- &E17YS_L(_
M\%JOBE_P4-_8]UCXM^!_@5X#M6L-:O- L/#6J?$ZXAU+7;RVLUNVAMW71FC,
MLD98(K$ E#N9%RP]6^,__!2GXA?!_P"#7[1GCFX^"$*Z#\#]/M-6T2ZO?&<,
M4?C>V:%IKW:(;::2SDM]A0)+&WF.0I,9#[ #["I&4.I5AE6&"/6OEK]FG_@H
M9XI_:*\0?"6Z7X3C2? 'Q&^&5MX^U3Q6?%EK+!X8O)HUE&E26[)'-*1&Z/\
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M6Q^(B_$2U\!_&/P!X3/PJ\9Z3\/M0\37NBS6T=K<36]A/"Z'1[V340\KO<(
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M=:=X=@DU>>TDO(+=6O)K>)HH&<+\[(C,S*N<D LQ XR>M?FC\._@YJ/[:O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'+';2;=T*NBJK*A 95 .0!70444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTR^2D\TGRPKN4DRDG:"0-P%<+_P46_X+&^%_V<_V5OAGX\^%NM^%?&T/Q?\
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M;3_VLO"/AC3?"=Y'>6L4'ARXLPEO<VVH">9'@$8S<!HTD1E! /F_(>H^%_\
MP3S\::5_P6%\!WGQ!^'FH?$3X8>'?V=K/X2ZMXJU.WL[S3-6U15#7,CPS3&9
MH9H6FB9VB.7F9""I9Z_4RB@#\0OVP_\ @GC\8OB!\0?^"BA\._ [Q)=VOQJT
MOPKHOP\GB73(XKN/2Y;:&X1,W(-O#^Z25 P4-' IP&5$/H_[/G[(GQ:\+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%,=1\+_"?QFK06^J>&?$5YI.IQH7FT'4XI-+%O>QJ&7<4WN&0D!TDD0D;L@
M^EM<_:2^'_AKXRZ7\.]0\9^&['QYKD!N=/\ #T^H1IJ5]$ Q,D4!.]U 1B6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA_\ !)[X5?&#0O'EAXPN_B)XJ7XD:;;:+K<VI^,M1FE>Q@G%PMK ?- MH6D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "ODW]K+]E7XK_%K_@HI^SY\6/"]G\/'\*_!--=2YM]5U^\M=0U
M<:O:16LFQ([&6.+[.(A(N7?SBVT^3C>?K*B@#XW\9_L.?$#XI?\ !3;Q9\3/
M%&B_#74_A'XR^%S_  FU'26UZ];5+BP:\N+M[IH_L0B)D%P\+6XE "G>)B1L
M.M\%/V8/CU^S%^S18?!3P7XP\"7WA_P[8G1/"_CO6H[AM;\/Z8OR6L4VEI']
MGOKBVAVQ+-]JMT?RXV:$89&^LJ* /@3Q!_P2V\8_ OQS^RC8_!'2? ,GP_\
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M-\=>%M-US1KZVU/1]8M(KZQO+=Q)#=P2H'CE1APRLK!@1U!%:!;:,GBOR_\
MV6_VW-8_X)[?\$S?CQX+U72[_P#X2_\ 9+OCHVAV7B4J9CH&H2J_AV\O3!(5
M,$=O.(I/*DR$T^49#@FNQ_X*9:3\9O '[,7BZQU;XT+>:'>>(_ EQH=]H]K:
M:?XB?[5XDLK'5;6XC^SM;MIV+BV>W*#S23)%<//'N$H!]YR_$+3X?B1#X5:/
M5O[6N--DU9'&DW1L! DJ1,#>>7]F6;=(N(#()67<X0JK,-ROC_QI\1?BT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&&K6<,^GW>J^'M=TCQ-J$>HWNG7:GR;B*2&ZB@:*>%\D6RAEQ(XH ]+\"_\
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M=8\%:CX+^$,?Q_\ $&G9O_'\-HT-P^N-<"XEUQ;Q+=;M9FN-UT(00H8^3O\
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M5ZFRYLUN(4E$4J_PR)OVL.S B@#IZ*** "BBB@ HHHH **** "BBB@ HHHH
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M)KM[ T$'AS48=8-_;RWY/_'K;W<+$)+-L"R*B2%'=5/WS10!^9O[=OP9NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/,%S8M;2,Y8DR^<#RIK[ H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%XH^('@?7=-\1>&=+\/7&D:7X*N=+EC>PEO9DG2XDU.X #R:A<[HS$?E$(#
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M&!UQ0!L45R_P9^-/A3]H?X::7XR\#Z]I_B;PKK2R/8:I8R>9;W:I(T3,C?Q
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MGV/_  33_:AUJ&SACU;4/A)K]E<W:K^]F@ATR^:*-FZ[4:XG('0&5_4UX/\
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MH7_"P?BY]CTWX@R?%*!QJ]IYR^(7F-PUV6^R\KY[R2^3_J2\KDH00!V?P_\
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M[X!PW7Q8\)Z?X%^(UG=75C?V5K/!<6L@20_9[I$ANKCREF@,,I@>=GC+E2[
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M,(S.X+>? 'PGMGQ6_P""3'PQ^--EX^AU[4_'TR_%32-.TSQ>8=?> Z_-I_\
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M\)O#WA?QGJFEII%QK&KI9ZA8WMS?Z7]IBU!;9[F%K79'=QJT3;2?)8."NO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'QO^WW\1_B)X,_;N_9G\)^&?BMXG\$^$OBQJ&N:3K]G8
M:;HTVP66D7%]#/#+>6,[QN9(U5PQ9"@PJHV6+O\ @G#^W=JOQ5^&?QPU'XA>
M)M'U[PC\'_'6H^'-*^(,-LEG:^)]/MTB?S76,")YHI)&@>2W58I70>6@.167
M_P %+_V9/$W[37[77[/%PWP;;XG?#/X?W^L7?BZ*\N=(:UO8-0TR:P2&.VN[
MA3,\;R"5]ZH JJ8V=_E7SGQ3^P?\=+?]E/QY^RII^E:+K7PZTF?3M2^$?CC5
M-1CEM;&UT^^MM2M- UVTWBZ:**2S6T%S;+,9+>2,LB,K$@'U_P"&/V]OA3XI
MT#QQJ*^)KC25^&KP1^);37-&O]%U#23<*&MM]I>0Q7#"?($)2-A,V5C+L"M5
MM(_X*&?"/6O#FO:A'XFO;>;PSK-OX=U'2;S0=1L]<@U&Y1)+:U&F2VZWKRS1
MNLD:I"WF)EEW*K$?+_B/]ACXE?&/]G77M:T'X*_!WX!_%2RUWPUXETC3+;5%
MU3_A(;O0]4BU".+4K^WMXB+5VB\N)%#E-Q=BI.Q>M^*/P/\ CM\=;SX9?&*;
MX?>"?!/CKX;>-HO$C>!H->2_FUVQ.F7FF7:SZB(8H?MQANV-N"#$@A17E7S6
M\D ]AO?^"G?P0TWP-IOB*Z\97%KINJ>+D\!!9M U*.[LM==T1=/N[9K<3V<Q
M,L1Q<I&-LB-G:P)S_CC^WE\.O^%,7"P^+O'/A75/$6A:CJ-E)9>#-3.O:-;6
MLC6\U_/8S6$LEG!',-OG7ENL1Z@D8-?,_P"T#^Q+\5M<\7^*_B9HGP[U#4->
M^)?QC\#>.+GPU;:WIL<NAZ-X:^Q-_I#RSI ^H7!MYALAEDB&8%,V$+GW3QM\
M%?B9\./V[O''Q(\.>%H/&GA7XN^ ],\,W4']JP6=_P"%=0TZ2_>!G$I"/8RK
MJ#^8T+22H\65AE!X .;_ ."??[9GAOX@_#WX/MXL^)?C+5/BH_P T+QGXB\.
MMIMQ+8WEO/;VDDVL92UQ-=--(8]D4S$AV BR,CU[X._\%*_@K\>;[P5#X9\8
M3W4?Q&TFZUSPS=WFA:CIUEK5K:@-<F&YN8(X6EB7+/#O\U55F*!58CY6_8/_
M &:_CI^SO\?O@[K7B_X2S?V5\-?V<K7X87<^C>)=-O/MFJVLUM.@C6:6!@DD
M=J$+, $GDVY:)3<'SKX>_LS?%/\ 9[_9S_8_C^(WPL^P^&/V:_#WB6+XCZA?
M>(]+.F6MC/HUU8_: 4N&EDMU23SIML>](5<(DL@"$ ^]_A/_ ,%%/@_\;O'^
MC^%_#GBB\N=;\26/]JZ+!=:#J-BNN6/.+VRDN+=([JT. ?M$+/$0\?S_ +Q-
MWF7_  5!\??$7X:_$3]G:/P/\3O$O@>Q^(WQ-LO VMVFGZ9I%W'-:3V&HW;3
MHUY9SNEP&LXU!#;-K-F,G!'@?_!-?X:?$KX'_%7X$GXK?!OQ]IL>D^$'^'WA
M/5Y_&NC:MIGA2*2T2\DMX[.UMX;SR7338H5EN7NIHU@A#M\TLI^@/^"FWPW^
M(?Q3^(?[/DW@GX=:WXPL?AG\2;+QYK5U:ZGIEHOV6"QU"T:VA6ZN8F>X)O$<
M A8MJ',@; H H^)/VC/B-^Q9^W;\)_AOXW\3R?$OX;?'5M0TO1=<O]-M;'6O
M#&L6=K]I6"X-FD4%S!=1K(L92WC>-T^9F4@UT'PI_P""C/P6\/>#O"<]O\0O
MB!XPLOBAXWU3P[X?U"^\(ZO=%M6%Y-YFE;X;!5MU@9)4B%P$/DVSMOD6*209
M.N_LU_$+]K[]M[X8?%;Q[H,?@'X?_ ]=0U#PQX6DU""^USQ!K%Y;?9C=7_D%
M[6WAMXB_DQPW$K.\A=W0 1GSGX4_L5?$SX@_\$\_BQX/U[PC-\/_ (ER?$;7
M?B5X#FO=3LKQ+?4I-:EUS29'DMI90FR=HX)UR,KYH4LK!J />OCA^V9\,8?$
M%CX;U;QQX[\$ZEI_Q%T/PF)K3PWJ5M'J6L3RPS6VEFXELGAEMKI7B222-M@C
MG'[Z,NK5VEK^V?\ #F_^(-QX7M]8U&?5+>\N].WQZ%J#V5Q=6D4LMU;0W8@^
MSS30K!,'BBD9U:-D(#C;7B/[</P&^(WB+]G?X4Z/X5\%R>,?$NE_$[P]X\\3
M1Z?JMI;0P"RUB+5KT1/=R1&3>Z-%"N!P4W%%%8?@/]E;XD?#3]MC_A8'A7PK
MJ?@?2+[Q#KNM>-])TOQ/!>>&O'5G+!=I8S0:?<-FT\023"P>>:/[-;E1<;[B
M<R;  >G? +]MSX2VO[+O@?Q3I'Q(\7?$70/&E[J4'A[4+K1+[4/$'B"2"YNC
M<1QV-O9K=2+;F*5,K; +%"A8D$.VU!_P4G^"][9?#VXM?&$M]'\59[RS\+BT
MT34+AM1NK1)7N;5E2 M!<Q^1,K03!)0\;1[-XVU\@_L3?L5?'7]F_P #?L]^
M-+[P(K>)?A-/XVT7Q1X/&LV$EQJ>F>(-674H[O3+D3?9S- \=LKQW#P;PLX#
M+MC:3>\%?L/?$_X&?&OX8^*+'P/<:\-6^.7BCXO>+H-,UFQCM_#,.K:5>Z5#
M:Q^?+$UQ*D=U#<3F-=I=;K8SEH]P!]P? ;]H+PE^TQX";Q+X,U*;4M+CO[O2
MIQ<6%QI]U97EK.]O<VT]M<QQSP31RQNK1RHK CI@@FG\;/AEXP^)>J^'X_#?
MQ&USX=Z78O/+JKZ-8:=<WNI90+#$&OK:XCCC5BSL5CWDJH! S7SK_P $ZO!?
MQ=_9\\.^/;+Q!\);[3_^$\^-6O\ B<-<>(M-)T[0]6N+B\2[<02R[YH6$<,E
MNIY,H9'=5;'USXMUJZ\.>&;Z^LM'U#7[NTA:6+3K%X([F]8#B.-IY(H@QZ R
M2(OJ10!^=W['_CKX\?M'_P#!+.T^->I?M ^,X]<NM$\4RZE:)H/A^.&,V<VH
MP6DMJ8].5XYD>UMRWF-(C*TOR@E"OT%_P3T_;J\,_&+]G?X1Z/X@\47UU\1-
M3^%NE>,-4N-3TNZLX-4C%I:"]O(KN2%+6X$<\Z"7R)&\LRIN"AAGS']@W]GW
MXL? K_@C)K'PE\3?#74;3XC:7I7B#3K33(=9TV>#5Y-0NKR>%H;A;C8L:B[1
M7,WEL#')M5QM+>?VW[%?Q?\ BW\,?@7\.M>^'.M^$=-T3]GKQ)\'O%&O#6]*
MN5T>^U.STNS2ZACCN3)/$G]DM)D -MNX?E#+(J 'VU\'OVU?AM\>/B3<^$?#
M>NWDWB.WTB/7XK*_T6_TMM0TV23RUOK1KJ&-;NV+E5\ZW,D8+IEAO7/B_P"V
ME^TQ=7/[:/PQ^ UKJWQ$\*Z=XXT'7-3U+6O#'AW49;V&X@;3[>Q$%TEK+ (D
MDOWFFDR8XC! LY2.4I+1_P""=O[,WC;P%XITO4OB'\!_@M\-O$G@[1#H$WBG
MPSJ"ZI=^*GQ&KRVF;>.2RL9#&93%*[2EBBE0$+OT/QU\%?$._P#^"HWP;\<:
M/\.-9UOP+X/\,ZYX=U;6H=5TV'R9-6N-+=)D@EN$F>* 6#&7"A\2#RUE(VD
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M_P#L'_'&TET'Q]<?!/PSXDU+P?\ $+Q_J<_@7Q1XALHCX@T7Q1J<.H13VEY
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M7XBTNW\36%KK5[9:S=SWVE.EW;3,8K>&2=X[V&&9)7Q'L^TQ>9#( ?5FF_\
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ME9:/<RII5[<:?IE[>[/LEM=WL<+6MI+,)(BB7$L;,)HB!^\3.+K7_!2GX/\
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MMUICZO\ V7N@DF2)I!+Y,O*EU.W9R,\U[=7XQ_\ !33Q_P"'?'G[.?[<5O\
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MN$"$ZFK6XS%"89 $3R $Z_\ :J^)/PMT7QK_ ,%"])TOQ_HD,?A7X3Z7XO\
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M_ +0_%/@BT\=>.KU-<O-*UF]&Z71M/D2YE0P+(LD@N9DAM_+QAX7NVPPA<4
M>L?LF_M->&_VROV;_!_Q.\)M<_V#XRTY+Z&&Y0)<63\I-;3*"0LT,JR1. 2
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M;3?#OBK3O$VC^#/BOXOT72EM-474$TW2TUBY;3X$<.V(!:M$81G;Y13;\N*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM47RBHV6\:$,HP?9+[QUH>F6<EQ<ZQI5O;Q#<\LMW&B(/4DG K.\#_&CP?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]HAU3P'\)O#GA>Q6*0"">VO[B2^F>52I8RB2VB5"K*H7?E6)!7[_ * /#_\
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M &O:ONRO@#]FSX8>+M'_ .#BG]I+Q1<:#KUKX.U;X<>'8+;5)+:2/3[VX78
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !11576](A\0:->6%PUPMO?0O;R-;W$EO,%=2I*21LKQM@\,
MC!E.""" : +5%?FC_P $H_#5]\=_@SX/M_%>G_M(WTS:QXK1O'EU\5-3DTR_
MBL]:OK.&T,::K).Q^SD1 W%O%@VQ='\Q8W/F7_!(CXL?$#XN_$O]F73[3Q)\
M6+/6+7PCK'BKX@7WC7QQ<:QI_P 0-(>>XLK8V%K-=W6Z>&]$#/+MMI((PJN&
M6YC4@'Z]YHS7PE_P4N_;MO/V>?C)X?\ $&D>)]1T_P .? _5]-U#Q[I%O97,
M\'B#3M2W6UVLCQH51M-LYDU+:S$2;H^A4;M?]MO2OB;X!_:_\'_$KX+ZMXF\
M0WVE^%M0UGQ#X ;7+FXT?Q[IL5QI\+P6MM),;:TOXXYWFMYX8U,DB"*0LDK%
M0#[6HK\P];_:0M_B]^TEX$LOA?\ $'QR/ _[37Q"AM[C7X_$VI2K8:/:^&AJ
ML^GV,-Q*5TN>YNE>&0PI#/#BX0>7(JF+W7]OW]FAO@U^QY\</&'A?XA?%C28
M](^%^N36]@/'.L3-:ZC;Q?;+74+>Y>Z-Q#+&T)1E5]DB.%9<;Q( ?8] -?F[
MX^T+QM\*/A]X3\8:M<?&3QQ\&O\ A6>F6M]>^#_'NIMXH^'^I-'-<7FLW-LU
MR)=721+F!R6>>: 6F$MWC=J]"^'GQ+E_;&_;6T?X>P_$+Q!>?"OP?\(M!\:V
M5QHFKW6CW?CZXU:6XBAU&6YMY$N#;106FX1*ZJTEX3)OV1A0#[@HKX8\7^$_
M$'A#_@H7X#^ J_$3XB+\._&MAK_Q'NOM'B&\.I3BSCTFP@T*#4?-^UI:I+-/
M>N$D$C%E0MY>\2=C\ _'6N?!W_@J/XX^!MOK'B#Q%X!N?AUIOC_3AK6J3ZK=
M>&KQ]0N+">U6ZN&>X>&X6%9E2:1_+:.4)M1@B@'UM17R%KRK^QU_P4R7Q!K7
MB3QM<?#WXT>%;V&SM]2\2ZKJ6E^'M?TTS:A<QV]G)-)!#]LT_P V55BC7R_[
M'E5 !,RGW/\ 92^#<GP7^$\=K>7GBJZU36KJ;6=0CU[Q)>Z]-837#;_LD<UU
M/,4A@4K$J1MLQ'NY9F9@#TJBOG7_ (*3?$N[TGX+)X"T'QIJ'P]\7?$Q;K3=
M-\26%K-=7/AZ.*!I9;U8XE+X#"& ,,;'O(VR<8/ST/\ @HGK7[9/PX_8]T+3
M[S5? ;_M :SJ.G>/+S3)GM+W1KK1K"XEU'1(9<>9;RS7UNT(F5DE$,4K1LK.
MDB 'Z'T5^=_[8?B#2_A7\2_BM\+_  YJ?[1.FZQ%\%M=\41/_P )C>7&DQK!
MY4MOJ]O?/J37MO<1747V4Q(H:3S\E/)WR/W&D>"V\9?\$J_V>;BZ\4?$:34M
M3E\!7EWJMOXXUB#5-1?4+[38[WS[R.Y6>9)8[JX!1W9 'RH4HA4 ^V**_)7]
MJS2-6\*_!3]M34]-^('QDT_4/!/Q:\,:1H$\'Q+\0(VCV=W#X<EN((,7F(XW
M;4KW*@8 F &!'&$_56PM=-^&W@F&%[R2VTC0;((UUJ5_).T4$*8,DUQ.[.Y"
MKEI)7+'!9F)R: -7-%?"_P"PU^V[JGQ$_;>\5>$?$?B#4M0T7XQ>&HO'_@RU
MOK.XT]_#Y@9;.]T:-9E1MT=JVEW3!0#YT]Z^!SM^7_@MX]\=7W[3%CX!\+^)
MOC)I_BZ;]HWQ%8Z1XF\1?$&]O_#-QX:T>=9+_1&MKB\G-Q/]B9EAADMD8D/-
M',!;R. #]B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JNM:>^KZ/=VL=U=6
M$EU"\2W-L5\ZW+*0'3<K+N7.1N4C(&01Q5JB@#Q[]FG]B[0?V3?@!>?#CP?X
MB\:1Z'<3WEU;7%]J27=]ILMW*\\[PS/&3EIY99?G#X>1L8& .!\+_P#!);X9
M>"_@=\/? NEZKX^L8?A+K$NL^#-<AUYH]<\./*CI-;Q7:J'>VE664203>8D@
M?:P94C"?3]% 'C6B?L2^'M,^!'Q"^'MYXA\9ZYI'Q.EU"36[K5;^.ZOI/MT?
ME7*)*8OE0IE%4@B-<*FQ515H_ K]@O0?V??$W@O4-(\9?$C4(? /AV7PKI-A
MJNLK=VHTYV1O*D!B#2,IB@VR,QD @1=VW<&]SHH \+\5?\$W_@_XNTCQA9S>
M%19#QIXNB\?W4^G7<MC<Z?XABABB35;.6%E>UNL0JS21%2[O*6W>;)OO>/\
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M1XZ_8O\ !?Q#TWP^VH#6U\2>$]1?6=(\40:E)'KMA>R0&WEG6YSDB2$^4\+
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M:/NOB<VN>*)M6N-&&@KILUZKZ5:VXD60F* I^[D:10SNK!GPH8E40+Y-:_\
M!*#X4R6GC:VU/_A*M<MO''BY?'TJ76KO&^B>(5<NNJZ;+ (Y;&Z&0-\#KD+@
MYW-N\:_:Q_;X^(WBGX.>.?!^E>%='\'_ !(\!_$SP7X1\46T?C"Y6UETW6=6
MTL0RV-_'I_FM'=V]R]O(QAAEMLSNGF/%&LOJW[0GPA^)GP1_8ZT'1?A;)XQ\
M376E^(8-0\1:3_PEK7?B*_T62>2:]TW3-5OMKF2,2*L+S-'(T$)C66&1DE0
M]&^'G[%'A/P3\5[[QUJ5_P")?&WBZ^\/MX4;4?$=_P#:_+TIIA,]HL*JD)1Y
M%5F9HR[;0"Q&0:OPB_8-\&_!B+PS8:;J7C&^\,^!65O"_AW4];EN]+\/[$,<
M*PHWSR+#&2D2SO*L("^6%**5^:/#?[<7BBQT3P%'\*?$$WCRW\;?%Y/".IZ1
M\1I;G1/$7@.)=#>[;1;E3923>:);.:3SYTD=HYT >82"X2A^T_\ \%D?&O@;
MPU\9-#\/^ ?#6B^,O!O@77_%^CO?>*!?2VD>EZE;6,BZC;0VQ2UN7CO+>[A@
M6:;<DBB4PY&0#VCQS_P20\!_$;0OB)I>K>,OBI<:=\5=>M/$WB6!=?2,7U]:
M^1]GD5EA#1",6MJH2,JI6VB!! .>L\?_ /!/_2OBQX9\2:;XF^(OQ6UD>)M+
M&B3W#ZU#;26UD9A+-!"L$$<:+.R1K,VPM(D:H6V94\+XA_X*8:]X<_:!M? *
M?"N^U^YT7Q)H_A/QE<:%=:AJ!T*]U&UM;GS[?&G+#<V=O%?6CS32S6LB(TK"
M%O+ ?ZVH \>_:!_8MT#]H[Q9\-]?UCQ%XTTO7?A5?2:GH5_H^H)9S"ZDA\B2
M27$9$@>(R1M&1Y3+-(&0@C'!6G_!)GX8CX1>-?!E]J7CS5M/\;>+5\>RWEQK
MKQZEHWB 7 N/[3T^ZB5);2<RJC?NF"@*5"A7D5_IZB@#-\(>'W\*>%M/TR34
M=1U=]/MTMS>ZA(LEU=[0!YDK*JJSG&20HR>U:5%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ[H?@3X@6_A:'Q!HNH:E,7\/ZK/J-G-%=7T]XA$DUM;N&7[04*^61^[R&^;
M]^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"MJ^C6?B"P>UO[2VOK63&^&XB62-\<C*L"#4UM;QV=O'##
M&D4,2A$1%VJBC@  = /2GT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/PZ\/ZEX?D\.I+;Z59ZWH5W/KBK=QQAY%LK]+9!/YA6$OME+[P  ?K#1110
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M^#O@L?;+BVM]0M 3_P 3"_<6[&WED6.S4PPI,J&"1A(_FA(@#Z/^)/[3UAX
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex3-3_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_003.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MR9;ZX@%1G_@ST_9':X9OM'Q:VL20G_"2Q[5]A_H^?S-?JE10!^5X_P"#/?\
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MX_9%4M\_Q6.>F?$R?+]/W'\Z_4^B@#\KV_X,]_V164#S/BMC))'_  DR<_\
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M(^'O_3_IU>U/^S#82_M4S?%>3Q%XEFU"?0(O#K:))]C;2!!%<&YCD"_9_/\
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M'>O<*D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y)_X+F_\ *,+X
M@?\ 81\/?^G_ $ZM7]IK_@JOX5_9<;Q VJ?#/XZ:Y:^'=3MM'EOM+\&2K87E
MU<SP6T"6UU=/!!/ON+B*$&-R"Y(SA6(RO^"YO_*,+X@?]A'P]_Z?].IW_!;K
MXD>"O ?_  3:^)EOXMU*PL=3UK1KJ+PE#-:/>7%UKT$$EW8?9X8T>1I8Y[=)
M@RK^[$1D8JJE@ =*_P"T/^T9XTO'7PU^SGH_ANUZI-X^^(MI8R_C%I4&I+GZ
M25!^S[^UA\1/'_A?XZZ=X\\,^$_"OCSX2WC6T&GZ)J%SJ5G>0/I4%[;7BS3P
M6[21R22RQ#$2_-;2#GK7;?"3]LO2/CK\-]*\3^%?!_Q)U"QUJRBO[-+GPW/I
M3SQ2('4J;WR$P01@[L$8()!!/A_QP^*5]\&OVI-0\9ZAX5U30+3XL?#;5/#S
M:?J]S:JUUJF@Q76J6*&2UEN$19K.]UC+<L!9#*GY,@'%_$+_ (*5?$+]EK_@
MG7^R3\2-8;1O'VH?$F\T-O'NIRZ>;5XM!DT2\U34]4BBBD5(Y[>WMA,P :,B
M.4+&H9=GZ!1N)(U96#*PR"#D$5^1/@:#]H+QA^SC^PCX+U#X5?"GPUIL=M#H
M%A<^(?%UQK U96\#:M!(;FPMK2,1QO:B=L+=LV\K&0 3(.Z_9YTCXW?#+]F'
MXH>'_B9^TQXF\.6O[+EM<:/K5GX'\%:8VJWFCVNG)>6-VEW?K=F5Y]/>)MP1
M'259$9]\;2$ _3ZBOS^_8I_X*U0W/B?Q)X-\>-X9C\(?#;X;MXQ?QK8>,W\7
M-<PV MQJ$-W=PV45O<7MO#<V<UP;5I$5[Q$0R'<P]P^,'_!7/]G;X*:!X%U;
M5/BIX1O=+^(E]%:Z7=:7J,-\D4,B.QOYQ&Y:&QC*!9;E@(H6D3S&4'( .O\
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M2ZTWP_8:-/-J6I^&-9B0W5O8:E=*YAG:YLHKR0R01K##+9>5YDOFQNP!Q/\
MP4Y\-3?M%?\ !,+XP_"?PC?^&[OQQXON]2TNVLKS7;/3UM6;5Y)#),TTB[55
M%)P 6.5PO)(^?_VJ/V;_ !I^TYX'T:STW5K&W.C>%O&W@2-_'/C_ $NZU6Z'
MBBR*-J<\MH\L7V>RE$<0C4F9X5)5 55&^MOVU?&?BCX8?L%>*_$?@G7-:\.>
M)--\5D07.D6FFW%Y<)-XC^SR0(NH0RVVZ2.9E5I H5MI+J 37G_CC]HWX@>
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MU)OA^GB"\U.:TU&R,(L]&MM+O+AUW.K^<]KJD3I$4 WH49UR&H ^8/ 7[/\
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M4?8(/^>,/_? H YO_A>W@?\ Z'+PK_X-K?\ ^+H_X7MX'_Z'+PK_ .#:W_\
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M^%=Z#]X8/_(/@KW-7##BH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A':O_ /(U'_"_=#_Y\?&O_A':O_\ (U ':T5Q7_"_=#_Y\?&O_A':O_\
M(U'_  OW0_\ GQ\:_P#A':O_ /(U ':T5Q7_  OW0_\ GQ\:_P#A':O_ /(U
M'_"_=#_Y\?&O_A':O_\ (U ':T5Q7_"_=#_Y\?&O_A':O_\ (U'_  OW0_\
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MVX=,<U "T444 %%%% !1110 4444 %%%% !10S;1S7SC_P %$_\ @I[\+_\
M@FO\*AX@\=:M))JNH*RZ)X>T_9-JFN2@A2L4;, $4D;Y'*HH[YP")7 ^C/,4
MGJ/SKYK_ &FO^"O_ .S=^R!=36OCWXN>%=-U2WE2&32K*5M5U)&;H#;6BRRC
MU)*@ $9(S7\]O[='_!;;]H#_ (*317NFW7B*#X6_#6:]BADTG29I+2"*)Y%0
M/>72_O[D(LJM*$P@!W",<5\XZ9^S/H.@>.]5T7Q/->:?:QZ?+:KJKO#%:V>J
M_( S%-XD@26: 28(=5EW-C:5.B@!^^WB7_@[:_95T;49H=/B^*&O1QL%$UKX
M;$*-UZ"XEC;MW4=:;X3_ .#MO]E77=06+4(_B=H$+XQ/=>'!.BC/)(MY9&P!
MSPI/RG&3@'^?'Q[X,\-Z#H5O)9ZGX=CN]/TR*VU"SM[LS2W=XMQ=QR31'E&!
MCCB8D, 1(-HZ@=A8>&?A+K6J6-O)<:6;2;4-(F1XR\02SAL&?4TG9RN'DN5=
M$ .=V.54J37L_(#^HS]F+_@KQ^SC^V'J,%CX!^+GA35-4N)&A32KR1]+U*1U
MZA;>Z6.5OJJD'L:^D1,OR_,/F&>M?Q1:'\(M-^+OQ)TW0](MYK..\46D/V:$
MS@R#S")BK,/+3:NYL-\B@^A-?87[ W_!;S]H+_@FYJ5OI[>((?BW\*[:Z,(L
M]4FGN;:11MEE6QO9 LT,OEL<)(&569<H1C$<B _J>HKYU_X)Y_\ !3WX5_\
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M+/5-.VW-KYZ>9')8ZFRE8WC*S0K(&\MF@H ^UU8.H92&5AD$=Z6L[P?X7L_
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M-X=\1:+HUY\.M.^(=Q:SHLE_%#?F86EI'$O^NFF^S3[-I ;$>!\_ !XS>_\
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M'XZ?M7^&?V>OB3\,?#?B!+Y)?BEX@/AK3[V-%^R6%V;2XN(1<.S#9Y[6Y@B
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MS!45/F/WCM&.@&5X6^(WB7X6>(M4\!:+=6DNH:]>QZ<DT&L>7IAG)\OF1G2
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M_A79MJ6DZ+\&K+QYJ%]\2UCU36/$CC4IM+-K-?I=64,:!K9B;\1RM*TUNQB
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M;[Q'=ZA::A=>$-5_M)[FVCO9?.4LL.GR-91O$)C]U,LJEQ^K2GBC3H 4444
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M1_T9G<_^'7T7_P")H_X;)_:H_P"C,[G_ ,.OHO\ \30!]<T5\C?\-D_M4?\
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MD2KJVDZC/K LXM#:T26:YQ%(1&\LB1H #ABR[5!) K?2]@/OS_@GO^V1??\
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MZ7&VC0WT\FI2RW8LXHUD\[%P9UC=7@"EC(N9/@__ ,&[WPO^#/PJ\4>&M/\
M&_Q :X\2:5HFGQZK$--L;K2)]%O6O-+OK?[/:1J+J&3;ND<.9L,9-Q<FM#QK
M_P $#O!'Q%T*Z77_ (F?$KQ!K^I>/(OB%J&LZLFE7[WU\--33I(WM9;-K,Q&
M%24!A)@8CRRH4+3O$#UCQU_P40L?$_\ P2I\1?M+?"_3X=6LU\$7GBS1++Q
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M.XOKUBN7G,ES<3!EV@/,W&, 8?B;_@DAX4\2_MEQ_%=O&'C*#1Y/%%KX\O?
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 #-M%?RD_\
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MSU/X9ZIJ CUK2TB\9Z3JJ))IVIR+-(?+"QD-M15B=) RR1NI=&!QC[^\(?\
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MKHI?VA? =O'=-)XR\+QK8Z['X7N-VJ0KY&K2% E@WS<7+>9'B(_.=ZX'(HU
M[&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1>P'RQ_P4<_X--?&7PL.J>*OV<=9F\8:.S&0>$]8N8XM6M4V#*V]RVV*YY!
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M0O$EU\%IO@SXI/BVUGL[#3(Y+R>Z&H6"6]NPF*B?RGC=(C/]F@<LIW 8J?\
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MC]G$MC_A7?Q__#PU9\?^3E'*!^L%%?E&/^#P7]FK8K-X#^/Z[L8_XI>TY_\
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M +;T<K[ ?;5%?$\/_!Q=^Q7./E^/GAD?[UA?KC\X*LC_ (.'/V+F./\ A?\
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M0_#K_#GQF_@G4?$>G://<VNK2F*WD@G6&TBD(=_M)5O*39\H?"A\#ZF^"?\
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MM<\"WP\2K%;B.^\2V]]J/DFUN+H+YJVPQ;&3&0B0%@"0,_!W[3?C2SO?A/\
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M/V=0"/\ A0?P5^8Y/_%#:7ZY_P">'J<U[;10!X:W_!,7]FUY&9OV>_@>S/\
M>8^ ]*RWU_<4W_AU[^S2&)'[/'P+&>O_ !06E?\ QBO=**+ >#G_ ()9_LQE
MBW_#.?P'RW4_\(!I//I_RPJ-O^"5'[+[,S']G'X"DN,,3\/])Y'_ 'X_SBO?
M**+ ?/\ _P .G/V6B!_QC7\ >.Y^'ND__(]0_P##HW]E7<K?\,U_ ;*G(_XH
M+2\=NWD>W3_Z]?0U% 'SRW_!(_\ 97=-O_#-GP%^]NR/ .E Y_[\=/;I5>;_
M ((]_LHW$N]OV;?@<#C&%\$Z<H_(18KZ.HH ^:V_X(W?LG/U_9O^"?"[>/!U
MB./^_?7WZU7E_P""+7[),S,S?LX_!P;V+';X6M%&3Z )P/8<5].44 ?*]U_P
M1 _9#O"-_P"SK\)UQD#9H,,?7_= ]/PIEQ_P0W_9!N75F_9U^%8*G(V:)&@_
M$#&?QKZKHH ^3W_X(6?L?R2LQ_9W^%^7ZXTE0/P&<#\*JR?\$%?V.9#S^SS\
M.?N[>+)AQQZ-UXZ]>OJ:^NJ* /D%O^"!7[&[ON_X9[^'_?I;2 <^V_WJK<?\
M&^?[&-TI5OV?? XW+M^3[0AQ^$HY]^M?9%% 'Q4__!NK^Q7(^X_ 'PKG '%Y
M? ?D)ZBD_P"#<K]BF0G_ (L'X9&YMQQ?WX]./]?TXK[:HH ^'9/^#;C]B=]_
M_%B-#7?W75=1^7Z?Z15>3_@VI_8GE9C_ ,*.TM=R[<#6=2 ^O_'QUK[JHH ^
M#Y/^#9[]B>22-O\ A2=@OEDG:-;U(!LYZ_Z1VST^E53_ ,&Q?[%!N5D_X4[&
M,$DH-?U':>0?^>_;&/Q-??5% 'Y^O_P:]?L3.Z-_PJ*3*L6X\1:E\V>Q'G]/
M:JLG_!K/^Q/(6S\*[[YO3Q-J7'_D:OT,HH _.N3_ (-5OV)W_P":9ZNOT\4:
MCQ]/WU?/?C+_ ()7_!7_ ()D?\%P?V$4^#?AN]\,GQI=^-_[7>;5KF\:Y%KH
ML?D@&5VV@"YF!"XW;^<X%?LQ7YZ_\%)1G_@N7_P3H_Z^/B(>?^P':T ?H511
M10 4444 %%%%  PRM?RM?\'$.F>;_P %C_C.WFQC=/I1P8B<?\2>Q]J_JE)P
M*_EK_P"#AG6S;?\ !8CXR1[8_EFTH<OC_F#V-7 #^A3_ ()0X_X=B?L][1M7
M_A7>A< =/] AKZ KP'_@E,GE_P#!,C]GQ<;<?#O0N/\ MPAKWZH **** "BB
MB@ HHHH ^&/^#E1_+_X(A_'H_P#4/TX?GJUD*^E?V&UV?L4?!]?3P1HHQ_VX
M0U\S_P#!RXVW_@B!\>/^O'3!_P"5>QKZ<_8E7R_V,OA&O]WP7HP_\D8: /3J
M*** "BBB@ HHHH **** "BBB@ HHHH "<4F\9KY:_P""R'_!1-?^"7W["'B?
MXHV^FVVM>((YX-(\/:?<[OL]WJ%P2(_-VD,8T19)652"PB*@@G(^)=4_9S_X
M*<^&?V:=/^-FC_M$Z7XO^)EY!;ZO<_"I?#%BNE/:R%7^QQ3LJ SHK -C9G:Z
MK,<!F /V HKY?^*G_!2_PU^Q-^R+X%\=_M+&U^&/B_Q+:P6UUX8L)/[6NI=4
M*#SK:S2#>TZJQSN&0H90S9(S=_9,_P""L7P5_;3^'_C/7O _B*^ED^'<#7/B
M;1]2TR>PUC146-Y,RVLBAR"L;@,NY2R$ YH ^DZ"V!7YUZU_P=#?LDW/A@W&
M@^--=US4YM$N]9@L;7PS?RR1"$RJ([@+&3"S&/=\V (V5R5# UXI^QS_ ,%V
M+[]N[_@DW\<O%'B3X@#X5_%KP+:3ZK?ZKH/A66\M/"=E-=>79-!%(6%T=J,&
M!=F&XDXX%.S _7WS%]:4,#7XE?\ !5S_ (+8^)/V;OV._P!EKP1X#^-VIZ?\
M0/B5HN@>)O$WC^7P@#/<:!<PR1OJ*V\D;Q+)),C2-;IF4! H(#9/N_[*'[5/
MB#4O^"A'[.G@NY_:V\1_$;3O&'PQE\3'P]??#N+2_P#A-5E_M&:'49)T0"T9
M(Q&OD\'_ $-<Y,C$E@/T_HKXM_:$_P"#@O\ 9-_9A^-NI?#_ ,6?%2"'Q'H=
MX=/U=;#2KS4+;1[A6*O%/-#$R*Z,"K*"2K J0&! ]/\ VJ_^"IGP'_8O^$WA
M7QIX]^(>DV>A^.E5_#3:>KZG-XA0JC^9:QVZNTL>V2,EU&P>8@)RZ@JP'T'1
M7Q>?^"\'[._C']C#XI?&3P;XTAU_3?A3:1MK&G36-W9WUG=7$GD6<$T#Q>:B
MSW!6(2!&13O)(V-CC_\ @CE_P6X\*_MV?L-Z]\0/B-XG\,>&_%OP^,][X]C2
MWET[2?#5O->7?V%1+,2K@VL*<B1F+#!P2!18#] **^5_V2/^"T_[-7[<?Q8?
MP/\ #;XF6.L>*VCDGM-.NK&ZT^75(HP6>2U^T1H)P%#$A,L CG&%)'U)=7<=
MC;23321PPPJ7=W8*J*!DDD\  #.: )*,U\4Z7_P<1?L;ZS\8U\#P?'#PV=6>
MZ%DEV]O=)I4DQ<IM%Z8A;[<C_6;_ "R""&(.:^7_ /@OI_P6TU?]ES]H_P"&
M?P5^%_Q<T7X5ZO>:@+CX@^)KOPXVLMX8T^6.![5UB>)TE#I)(Y$09SL093)R
M[,#]=LT9KSO]DC5=1\0_LP?#_4M6\:1_$:^U3P_97TGBB/3!I:Z_YL*R+=BU
M7B$2*P81_P .<=:_*7_@OG_P6,_: ^ G[7%S\/?V9[Y53X+^$#XV^)3KI5M?
MHL$US;K'%+YRLRI'%)$[>5M;;=D[ODRJ _7SXL'Q5_PK;6O^$'_X1\^+_LCG
M2!KOG?V:;G'R?:/)_>"//4IEAV!Z5\NZ!H/[:WA.WEBTO0_V/M/CFD,SQVKZ
M];I([?>9@L6"QXR2,U[)X%_;@\ ^,/V(]-_: FU9--^'=UX67Q;=7C*UPVGV
M8@\Z8.L:LS/%AU954MN1AC/%>/Z%_P %\?V0/$WQ \/^&+'X[>#IM6\4)"]@
M&\^.WS,%,:2SM&(H)#O'R2LC*>&"GBGJ!G^/?!/[9GQ1\/S:+XF\)_L8^)M'
MF97>SU1M<NK:1E)*DQR6[*2."/0_G6F9_P!N:"P6WCT/]D?R541B(:KX@\L+
MTQC[-]T#C%=7^RW_ ,%=OV<OVU/BYJ/@/X7_ !4\/^+/%>F123O8P)/"US%&
M0)'@>6-$G5=P),1;CYON_-5'XY_\%G?V7?V:OC>WPY\<?&GP?H/C"&0175C)
M+)*NGR''R7,T:-%;M\P)65U(')P.:-0/-_AY\%OVK/@Y?W^I>$?A/^P]X9U/
M5B7OIM'EU>PFO&)R3))%8@R$D=6]JU+?P?\ M@6/Q#NO%T7PQ_8W'BJ\MA83
MZU%J^L1ZC/:@AA"]Q]@\QH\JI"%MH*CC@5[Q\>OV[/A'^S#J'@>V\?>/-!\+
MGXD7#VWAR:\D;[-J3JJ.Q$ZJ8D0+)&=\C*F&'S5S?[*7_!4G]G_]N#Q[K'A?
MX4_%/PUXT\0:#"US>6%FTD<P@5U1IHQ(B^;$K.@,D>Y077)^896H'EFD^'?V
MO_#*:LNG_"?]C^T3Q!,USJ@M=?U: :E(X(=IP-/_ 'KMDY9\Y!/6L_X1?"W]
MJ/\ 9WTF\T_X?_ W]C#P3I]_/]JN+;P]J^I:7#<2X WR)#IJAWQQN(S@5U?[
M2_\ P6D_9R^!OCSQ/\-+KXS>"]+^*6FV=U%!ITTCR16M^L3-'!-/M^SQR[P
M8I) V[Y2 2 ?*?\ @D__ ,%<H?&O_!*7X:_&;]I;Q]X=T/5O'7B:[\-0:G-:
MK8VUU=_:;E;: )$NQ&,5NYW$!<(22*>H'?\ B^]_;-^(/AJ[TCQ!\'_V5-<T
M?4$,5WIU_P"+M4N+>Y3/*O&^G%'4]<$'&.:P/@W\(OVD_P!FRTN8/AW^S?\
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MCV?_  3E_9(ATO4+Z/4KBS3Q];XEN(PPCDYT$@% [A,$!-[;0-QS^F6:3<*
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M=U !11GBC- !103BC- !106Q06Q0 44$XHS0 44%L44 %%%% !1110 4444
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M  0S^.V/^>&C#_RN:?7U;^QJ,?LA?"G&?^1.TCKU_P"/*&@#TFBBB@ HHHH
M***,XH **,T4 %%%% !10#F@G% 'P3_P<C?L->+_ -O'_@F-K>A^ ;.;5O&'
M@W5[3Q9IVEPC,NJ_9A(DT$8R,R>3-(Z*,EVC5 ,L*^8?%'_!UOX3F_8WTW2?
MA[X'\:ZI^U%<6L&BP^!+SP]=3)9ZF J2R2.@4RQ JY5$Q*Q"@I'RR_LGN!JA
M'X4TN'7)-433;!=2D 5[L6Z"=P!@ OC<>"1UZ&G<#\1O^"Z=K\8-+^*'[#?Q
M\^)%W)\(X_#<5S%XNU[0M!'B:Q^&>K77V:19VM9@ZRXQMR0WS6K%=S",-7_X
M)XKH?[0_[6?[57QFT7XX?$'XZ7]G\*=2\.ZWXKE^&=GX5\-ZR#;QM L<L,X:
M2X00D -;*2L;,7QMW_N3J>D6NMZ?-:7EM;W=K<+LDAFC$D<B^A4Y!'L:KZ)X
M2TOPSI"Z?INFZ?I]@N<6UM;I#",]?D4 <]^.:?,!^5O_  ;._"33[G_@@1'=
M:;H]F^O>)F\3$SK;(;BXF,DUL@W ;C\L:)R>@ Z8%?&?["_[2W@G7_\ @U5^
M/WPBLM4_XN1X!TK4;WQ#I$MC/%)8PW6J+Y+F1D$;%@"-JN64KA@.*_HDTG1;
M/0=/2TL;2VLK6,DI#!$L<:$DDX50 ,DD_4UF6'PQ\-Z2VJ&S\/:%:G7'\S4C
M%81)_:#<_--A?WAY/+9ZU('XC?MIVL,G[%'_  2!MVC3$GB;P4A#KG*_9-/!
M4\=\]*]I^.ENS?\ !WM\'TBVP^7\(;L(V.$_=:H!^6:_5G4?!.BZNFGK=Z3I
METNDR+-8B:U2063K]UXLCY&&."N"*L/X>T^?6%U)K&S;4$C,*W1A4S*AZJ'Q
MNVGTSB@#^>__ ()N?MT? 7_@F1^QI^U5\%_VIO#L6H?%I?'.KW>I^%-4T:6X
MF\>1206\5O''<>4\>UIHY65F;8JRB920Y->Q?M[?MU_\*U\9?L8^%=%^'7PV
M_9)T'Q9X;GU?2/'WCGP5;:Y=_# '>J65E$P2.WEV+ T@<@#[7#O\O8S']F/$
MGPB\*>,=>L]4U?PSX>U34]/(-M=WFFPSW%O@Y&QV4LN/8BI_''PU\._$W3(;
M/Q)H&B^(+.WF%Q%!J=C%=Q1RC.'59%(##)P1SS3 _!?_ (),:C;_ !&_:Q_X
M*.2Z7X\U;XP7WB/X=O<6.O7&BKI]QXQ+VMQNNXK.-%38TK*L7EIADDC*Y#9/
ME>A^.;']J+_@T<7X;_"_4EUGQO\ !W54USXC:'96SB[@TR36M1GBD;Y0)%"F
M&8E2VU(&)QBOZ/=)^'/A_0?$,FK66A:-9ZM-;)927MO91QW#P1XV1&10&,:X
M&%)P,# JOX)^$/A3X:/J#>&_"_AWP^=6E\^^.FZ;#:&\DY^>3RU&]N3RV3R:
M0'X._!OQ-X4_;8_;H_8YM=/_ &M]/^*GB/P+=PZUX?T7P=\"4TO_ (1VRA%N
MTUCJ%Q%?*;:)HXBG*2+&(V9E 90_[#?\%4_A[XP^+'_!-SXX>&? *W4OC#7/
M!>IV>F06R[KB\D>W<-;QC_GI*FZ-<<AI!7JO@/X'>"_A;?WMUX9\'^%_#MUJ
M1S=S:7I4%G)==#^\:-06Y ZYZ5U)&10!_.7KO[;G[,?B/_@VVTO]GG2=*M+K
MX_7%G;:!#X(B\/S'7E\2C4%\RYR(?OL=\FX-N97\K[Q*5[]^U%\)=8^%W[7O
M_!(OPAXWM86\6Z#I,6E:\LX2:0W5M8:=')&[\^9LD5EW$G)R>]?L9!\#?!-I
MX^F\61>#_"T7BB<AI=9328%U"0@$9,^SS#P2.6Z$UH:Y\._#_B;7M)U;4-#T
M;4-4T%WDTV\NK*.:XTYV&&:&1@6C)'!*D9% &;\9?BKH/[.?P0\4>-->F33_
M  WX(T:YUB_=%P(;:VA:5]JC_80@ =3@"OP!_P""=/[,O[;7[;'@;XX_M ?#
MS3_@;!X=_:VO=2M=77QT;F:];3UFN8/(M_+0^7;KYKQ+R2WV:,D85<_T/ZWH
M-CXGT>XT_4K.TU"PO$,4]M<PK-#.IZJR,"&!]"*9X<\,:;X.T*VTO2-/L=+T
MRS3R[>TLX%@@@7^ZB* JCV %&H'X$?L$_&[Q%\(O^"*W[=7[(_Q&D6W\??L]
MZ#K\=K;-.75]-NH90_DD@;XDNO,</P&6\BP!61^WA\#?!EM_P;*_L7QPZ%I=
MO<:MXKT%YKF.!$FD>^AO&O&+@ DR'&[.<[%_NBOWRU?X'>"_$&I:W>7_ (0\
M+7MWXEM38ZO//I,$DFJVY55,-PS*3+&51!M?(PJC' J/6O@!X%\2>!]+\,ZC
MX+\)7_AO0Y(9M-TFXT>WEL=/>'_5-#"R%(V3^$J 5[8HN!^6?[5/A71_AS_P
M=B_LEV7A_3[#0;5_AA>VC6]A EM"88X=<6*,(@"A5"@  <!0.@ 'YS_LR^(9
MO@O^RW^UA\+?B[\:/@K\+_$5]XFU2U\<Z'XR\!SZUXJUJ:1#&EU8SK.C3$2&
M22((K>4Y\W(63<?Z<-5^$7A/7?B)IWB^^\+^';SQ9H\#6MAK<^FPR:C8PMNW
M1Q7!4R(AWOE58 [F]37/>/?V1OA3\5?','BCQ1\,OA[XD\26I0PZMJOAVSO+
MZ'9C9MFDC9QMP,8/&.*=P/Q/_;$^ FECX7_\$COAUX@UC_A8GANZ\3I9"\O]
M&FT]=7TQYM,,$<EG<Y=4^S/%'L<$%5Z;2!7O/Q0\(:7\//\ @[U^$,?AVRLM
M#77/A3=O?QV4*0QW3+;ZDJEU7 ;"P0CGM$G917ZJ^,_@SX/^(VO>']5\0^%/
M#>O:IX3N3>Z'>:CID-U<:-.=N9;9Y%+0R?*OS1D'Y1SP*BO?@=X-U+XKV7CR
MX\)^&;CQMIMFVGVGB"33(6U2UMFW;H4N2OF+&=S?*&Q\S<<G* _ C_@FM\?/
M@#^QQ^Q%^V=\)_VC(M#LOC?=>*-=M=2TG5[$W.K>)D>V6*TBMCL8RG[5YSH4
M)VF82Y"D/7F'CKP_:^,/^#67]DS2;[,UGJG[0"6=RH;[T<AUU'&?H37]'^I_
ML\^ =;^)L?C6]\#^#[SQE#%Y$>O3:-;R:I''MV[!<LAE"[>,!L8XK*U/]D'X
M3ZO\.]%\(W7PQ^'MQX2\-Z@FKZ3HDGAVT;3M+O4+E;F"W\ORXI@99,.JAAYC
M<_,:+@?EC^W-^R;\-+C_ (.<_P!CGPO'X'\*VGAV7P9J%Y/IEMID$-K</I]M
MJ<UF9(E4*WE/!%MR.!&H'"@5XKI/@/Q%:?M-?\%>O"OPILVT[4+CPU#)9Z;I
M4.PR%DG>Y6&-.?,DC>X "\EI..<5^ZFN? WP9XF^*>C^.M0\)^&;[QMX=MY;
M32O$%QI<,FJ:9#*&62*"Y93+&CJ[AE5@"&;/4U'X/^ ?@CX??$/Q%XNT'P?X
M6T7Q5XP,1UW6;#2H+>_UDQY$9N9D4/,5!(&\G&: /YE?"NCZ'\9_^":?[._A
M!?C?^R;X%E_X2"TD\/C1O"FKW/Q'TW65DE^2[^QB:<,\QPTIB6)SY!0XV&OT
M<O\ X'^'/C5_P=B75GXZT/0_%8\._!BVU**'4;..ZMOMJND0G$3@KN FDVDC
MY=V1@X(_1_PY^P)\#_!WQA;X@Z1\'OACI?CAI3.=?M/#-G#J(E/+2"98PXD/
M=P=Q[FNMM_V?? MI\:I_B1%X/\,Q_$"ZTX:1-XC738AJLMF&#"W:XV^88\JI
MVDX^4>@H _$/]C[X4>'M&T/_ (+*^$;'0-*'AG1%U233-'%G&]I920VVO/ 8
M8=NU#&Z(4V@%2B8Y4$?;'_!L#KWPRU7_ ()0_#VW\%R^#V\7V=DP\9QZ6(%U
M)+LW5UY)OPG[PN8U.PR\E!\ORU]O>!OV;/A]\+_$WC#6O#?@GPGH.L?$"X%U
MXFO;#2H;>;7Y1O\ GNF509F_>RG+YR9'/5CG/_9\_9#^%G[)]MJ\/PR^'7@O
MX?QZ].MQJ*^']'@T\7KIN"&3RE&[9O<*#PN]L 9- 'S3^VE^U+X\T;7_ (K6
MOA7Q!X@T2W\%ZWX#\)6UMH5E976J3SZOJUJU_/ +N-XFF>SNH;>$2#RU=92<
MD_)!\)OC'\:/ GQZ^'ND^,-8\;6O@?QQX^N-'T@>-K/18]>U&T3PQJ%W)'/_
M &?&L4<?]H6RM#@),PC<-E"H/TYJW[+OA?7?C!JGC&^M_MUQK-KI45W87$44
MEE+<Z7>27=A?;2NX74,DAVR!NB1<?NU(U_C=^S_X+_:2\#'PWX\\,:-XKT3[
M1%>+:ZC;+,L,\1S'-&3S'*A)*R(0RY.",T7 ^&?BG^UQ\7M5_:1NM T37/BC
MJ'ARW\1>-$6T^'FD>'+G57M-)@T!8D!U2,QR)%<7=^C+&3.\LBI\VP*,^T_:
M7^/GQ,^ /PMUC2_&VM:Y-J'A75_$VLK\/O\ A&KCQ3';/J##1[VYLKY!;W,<
M=HABNH+$Q-]K5T7*E57[N^'?[-W@7X26GAVW\,^$_#^@P^$;*ZT_15LK)(?[
M-@NI(I;E(\#(\Z2&)Y#U=D!8DY-<GXZ_X)]?!7XF65G;:]\,?!NJ0:?=7]Y;
M++IR?N9+^?[1?8QCY+F8F26/[DC$EE8FG<#P+2/VZ_$WBC]F/]I'QEI7C33]
M37P?\,]-\8^#]4CT9+"$+=>&3?1WRV\V]Q'+<J[K%.TFS:8R3M-9C_\ !2;Q
M)H/[>GA'PGJE]>1^"K/^Q_ GB:U_X1JX9'\3:K:+=I=F_6(PPBWE.G67V?>N
MY]7D+ -!&#]+?$?]@OX._%WQ1HNL^(_AQX3U34?#UG!IUC(]BJ*EI!)YD%JZ
M+A);>)\LD4BLB$L549.>FO/V;/ VH?#_ %SPK-X7TB3P_P")-2FUC4[(P_N[
MV]EN?M4ER_.3*9P)-V<AE7&,#!<#XI^&/[=WQ8U7Q1\-O /BW7K32]>^(WQ"
MU&+0]>M+&V0Z[X<$.M;X8XY(VC6\T^>VLTD(4[HWM)&W>=*M>T?\$^+SXD>)
M_B1\8)O&GQ;\2>.M,\$^,;WPAING7VC:191"*.VT^X2Y=[2TBD:8&:9/O",J
M_P!S(#5[@?V=?!)D\+/_ ,(OHN_P1J$^JZ WV8;M(NITFCFEA/5&=;B8-C@B
M0^V-GP3\-=#^'4^N3:+I=IILWB34Y-9U1H$V_;;QXXXWG?GERD48)]$%(#X\
M^(?Q:^*W[/OQ1_:(UB?XH>)/&VA_!OP':^,],\-WFC:/;P:A-<P:RQMYYX+1
M)_)C:RMV!1U<!7R9,XKO/"'BKXD? []H/X3Z#XB^*</Q8T?XK6^HPW*OHUCI
MS:9/;67VU;ZR-JH)L3L,)28S.&NK8^<>0_T);_"[P_!XMUS7ETFR.J>);.WT
M_5+AH]S7]O;^=Y,4@/!5/M$^!C_EJV<UQ?P3_8D^%/[.7BFXUOP3X'T7P[JE
MQ9?V8D]LC'['9[E?[);*S%;:WW(C>3"$CRBG;\HP ?*OQU_X*)?$7X)^,?CU
M8:E/I-KH=CXHMO#_ ,/=:-LNVUOUL-(N+C2[D$;7DF2\GGMW8DMY5PAP4B5L
M/3/VV_B[=?M$6.GQ^(/%_P#Q/?C)J/@G2['4/"NFV_@ZXTVSU.:.>+^T_EN5
MNAI]M</'EF:6YC$:QN,X^U_%O[*WP_\ 'WA[Q!I.M>%='U33?%.M6_B+5;>Y
MB+I>:E!]F\FZ//$B?9+;!7&/*'OEVL_LM^ _$/@*\\,7GAVSFT._U_\ X2F6
MV#R)_P 33[>-1^V*ZL'247@$P96&&Z8'%%P/F/\ 9^_:;^*EQ^UKH6G^.?$M
MU#X:\;:UK%EHR+H5C>>$M>M46[N+#^R-7LI'F2[%O;AY8M0"^8([GRPI1 W9
M?&;QK\4O"7[;^CV.D_%"QB\ 6>F77C#Q9I=[X=MQ;:!HUO%Y,<1O ?.\VZNA
M(Z.00L5I=G!*(#ZAX _87^%?PN^*:^,M"\)V^GZY%<7=Y;!;VY>QT^XNBQN9
M[6S:4VUM-+OD#R0QH["20$X=@>Y_X57H/_"7ZWKK:;;R:GXDL+;2M3EES(MY
M:VYN&AA9&)3:INKC@ 9\ULYXP ?+?_!+']K7XE_M!W^M:;\3(KRWOCX6\/\
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MDT .K\[?^"T__!1/XK_!_P".GP9_9K_9[ET?2_C)\=;F4Q^(=3A6XA\+V$3
M-<"%T=)&8+.<LK!$MW^1F92OZ)5^2/\ P7O\)>*/V0?^"B'[-?[:VF^&]8\6
M>!_A.+C0?&MOID8DN-+LYO-1;D+GE6CO+E<G:JO'&&8>8" #:TO]G7_@HC^P
M1\?/A[K&C_&(?M;> _%&K):^,M!U?3+/0YM'B;YI+F":20E$5%;:4D"[RJF%
M@P(^K/VV_P#@LG\!?V _B%I_@[Q[XHU";QC?6WVXZ'H.DW&KW]K:Y_X^)XX%
M;R4QEAO(+*"5! KY$\6_\')\?[6G[3'PG^%O[&WA4_%'6/$VJI)XLU#Q!HU[
M:6&@:8?ED8X:-U://F-*P:,+&$42/( OS)^T_P"-]1_86_X.'OCUXJ\?_'+6
M/V=-.^*&@65YX9\;?\(5;>([/6[*&ULU>R ECD,9C:W\O*+DM  W#IN=NC _
M6+Q3_P %?/@%X:_8;C_:,C\;+K'PG:>&T;4],L9[J>&XDE6(0R6X7S8Y%=E#
M(Z@KD$C!!/R+_P % O\ @Z(^#_PS_9=^(&I_ G6&\;?$+0KR#2-)FO/#NH_V
M!-<2N09?M018G58X[AT!D7S&@(&5Y/P3\6OAGX;\&_\ !L-\;O%W@W4OB)?>
M'/B;\4[+6K=O%7AZUT+[1)]IM4DNK.WMI9(OLTA0*K#9S"RA0$&?OK_@N;\"
MK'X=?\&TNL>&_#.DV,=GX;\.^%EQ:VJQA88+NR#2X4>[,2?[['/)R 2>,O\
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M-9:3XHU'1O ">'/"^H76Z(P7,$L=U(DLP6&9#^Z&_=+(&(;+(#Z"_P""]/\
MP6$/_!)[X!^')O#]OH^I?$3QSJ?V/2;75(;A[:VM(QFZO3Y8"N8MT*B)I$+&
M8,-P1EKV/Q%_P5I_9Y\"?LB>&_CAKGQ.T?2?AKXM#C1=4O()X9M6='>-T@M3
M']H=PT;Y58R0%R>.:^.?^#ORWBC_ ."8WA._FM?.M]-^)FCS7,HA\SR(?L]Z
M&)XX4DJO8$D#O@^*_P#!4/X__"?7O^"E7[#/[1GB"\TSQ;^QW]DU72[74H+%
MKC1-.U</<Q&:2 IA-LZVC'* D6$A ;RC2 _43]BC_@I]\"?^"B%IJ3?"'XA:
M3XLNM'59+_3Q%-9W]FC' =[>=$EV9XWA2N3C.>*]ZD;:F:_%OX >.O /[8__
M  =$:!\0_P!FE-/U#X?>"_AY/:_$7Q%H5H+;2M4O9A>+&K,JJLTC-)8@/R7-
ML< B'=7VS_P7U_;C_P"&"O\ @F#\0O$EC>&U\5^*+?\ X1+PSY;,LW]H7RO&
M)(BO.^&$3SCW@'T(!\!?#'_@X(^,'B3_ (*Y6>J:AJ,"?L:^)OB3??"S2)QI
MMFL!O8;:..*Z%WL%Q\\TD%P0S[1%.RXRF!^R'[0W[2W@/]DSX7WOC3XE>+-%
M\&>%]/*I-J.IW BC+MG;&@^])(V#M1 6;!P#7\]7QA_X)%?MP:+_ ,$=K+X8
MZEX+^",/PS\"A_B*$L;B;_A,$N!%+<3%G)\M[@1S21LH'(C5%8X&?1/V_OVU
M+?\ ;G_8,_X)X_'SQW%_;7PR\.?$6TM?B["]J;JTBO+>:VBG>ZA (9988+QU
M0J=R7 7^/!>X'[%_L<?\%2O@%^W[J^J:;\(_B5HGB[5-%B%Q=Z>D<UK>1PD[
M1*(9T1WCR0-Z@J-RY(W#/'_$;_@N7^R9\)OC//\ #_Q!\<O!>G^*+2[^P746
M^:6ULKC.#'-=(AMXF5LAM\@V$$-@@X^>?"O[5W[+/[5?_!2'5=+_ &>_"$/C
M'XY1_#*Z-K\3/"T$8T+P_$T$ZP6]U(DL8\W<\" B)R#+%'N7RV$?P;_P3%_:
MN_8R_9Y_X(?^,O W[1?A[0]5\<:/XJNT\7>"KBS6/Q5K5X+M1 T6\QR[HD&T
ML)%\ORI58J207;H!^YG[5'[>7P>_8G^'MCXH^*GQ"\.^#=%U9BNGRWDY>34B
M%#'[/%&&DFPK*28U8 ,I. 147[*?[?GP;_;?\$ZAX@^%'Q"\.^-=-T@@:A]B
MF*W&GY!8>= X66,$!L%U ;:V,X./R$_;'UWX:_"/_@MK^QWX\^,OA.X\&_LV
MW/PKM['P?I_BZQ#:?X7O$AG\JWNXF:5$E@,UGNW$F)C"S$"/<.X_8CU[P7\>
M/^#BKXX>/_V<DTE_@_HOPQ.F^,=4T.%8=$U;6)"A0Q! J.S&/.\!@QMYV!.[
M)5NH'W-=_P#!?#]CRRTC0+Z7X_>!TMO$Q<6&7G\PA9&B+2IY>Z!-Z, TH13@
MD$CFNT\-?\%:_P!FSQE^T?#\(])^,W@?4OB%<7'V.'2K:]\T3W&,^0DX'DM-
MQCRU<ON^7&[BOP__ &7_ -GWP7#_ ,&>_P 7_%\_AW1)O$VI:[+?'59+*)KV
M.2'4[*WA"S;=X"JA  .!YC_WCGV+]M;X%^#_ (,?LB?\$H+[PSX>T/1=:D\4
M>$/-U*SL8H+JY-Q;64]RSNH!8RSGS&W$Y8DT ?K%\:O^"KW[.?[.7C3Q=X<\
M=?%WPAX5U_P+':R:UIVH3O'<VOVF,2P*B;<S.\;!PD0=MO) &:[KX1_ME_"O
MX\? :;XH>$?'_A?6OA[:Q3376OQ7R)96*PC=-Y[N1Y)1>6$FTJ""0 17X_V?
MQ<^!/PC_ .#LK]H74/CI<>#]-L9_"6G6OAW4O%*0MIUEJ!TS2&8!YE*13/;B
M95D)7Y1*@.9 #Y9^R-\>?!?P%_9Z_P""HWQ6\&_#O3?B-^SB_B32K7PQX:N+
M>2+P]JTLU]<02M%&,!+>(75K,ZHJMY(@ *;5V@'[#? C_@LE^R_^TS\4[3P3
MX&^-?@K7_%6H2M!9Z='</#+?2*NXI#YBJLK8!("$DX.,X-;/QD_X*I?L[_L]
M^*O&&A^-OB]X-\,:UX">TCUVPO[LQW-D]U%YMN@CQNE9XSO"QAB%R2 *_![X
MJ>,H;C]KC_@GSK.H?$+]FF:2\\::%J%CX0^%7AZ*SA\%Z<]Y9&-;J],CSRDM
ME#%-M*O%(>22:^V/V0?@CX-^-_\ P=-?MD7/B[PSX?\ %"Z%X8TD6,6JV$5]
M';/+8Z7#(Z+*K!6,89"0,[79<X8Y;BD!^AES_P %2?V>[3]FVP^,#_%KPC_P
MK/4K\:5#X@6Y9K5;LJS?9Y,*6BEVJ24D"L.,CD9[GXX?M9_#?]FW2/#E]XZ\
M::%X;M?%^H1:5HDEW/\ \A6ZE&8XH0N2[,.1CCD>HK\9?^"4?[".E_MH?\$Q
M_P!OCX(Z?96UO#??%36+;PU#A(X["]M$ADL=O18U$D,*$C V%ATKE?\ @DW\
M:]:_X++_ +8?[(?AGQ):W@T;]C;P5/K?B=+N-D^U:]#="SL"=V=TBI;V,V2
M5=+E>PR@/W:^/OBZ^\ ? GQIKVFM$NI:'H-]J%H94WH)HK=Y$W+D9&Y1D=Q7
MY*_\$_\ ]KC_ (*7?\%#_P!DW2OC%X&\0?LQKHNK3W<%MI>LZ5?6UY*UO*T3
M F,,BAF0[3O],XK]5?VMIULOV4?B=*Y;;#X2U5F(ZX%G*37\\'[&7_!'GXA?
MM-_\$#;7XK?"#XM?%VR\<1S:K<S>!+?Q#+%X=URVMKF6.2W@MH]A6Y=(RP+,
MRR/\I W!@(#]>O\ @B'_ ,%9-2_X*/\ [''B?QM\1=+T'P;XB^'.MW.A>([F
MUN/+TB00PQS?:D>1B(T".0X+LH*%@V& 'T)^S]_P4-^!G[5OB[4/#_PU^+7@
M#QQKNF(\MQIVCZS!=72QJ0&D6-6W/&"0-Z@KDCGD5^)/QO\ V@?AY\4_^#3C
M6E_9W\*KX!L='\1:9IWQ,T&UNI9KFRF>YB^T333.3+-'<2?9"KL3^Z81G'EL
MJ['PX^%-GJ?[=G[%.JZ'\1OV,? OB#2;JTN?#UG\)]-UP:MXOT9O*$]K>M'!
M+&C-!YPS=-&<S7&YL*^'R]0/V0^-'_!3/]GO]G+XA_\ ")>//C5\,_"?B8%1
M)IFI^(+:"ZMMPROG(6S$".09-N0:\?\ ^"JO_!9KP/\ \$V_AC\.]4AF\/\
MBS5_B;K%E9Z5;C6HX;>'39N9=89UW&2TB3'S(,,TD8W '(_)WX]?"C3?!G[1
M/[6?CKX'^//V9?CMX3FUW4=1^(G@3XL:$]AXBTR8&=KJVM+FZC@F=4?SUCEM
MKA &5,9< GH_^"D/Q'^%_P"TC_P1D_87^*L/PK\-_#?1?^%FZ;H3V%Q MQ%I
MFE1&_6\MDGD!D>PE>V\W8Y(("[@2N:+ ?MG\0_V^_@C\(?A1X?\ ''B?XM?#
M[0_!_BN/S-#UB]UVWCM=93&[-LY?]\ N#\F>#7._%3_@II\&? ?['/C+XW:1
MX_\ !OC+P7X0M)G>YT;7K6XBO+Q%S'8)*'*"XE<HB(QW%I%X.:_.W_@HQX^^
M%OQ*_P""C7P)^"?P<^"O[-_BKQ-9^!I=7\,>)_'<[-X$T+2&:X*QV>GVI%M=
M$""5U*J=K!-N-A9/FG_@FG\/-%\9?L=_\%5O#]Y;_#KQ;IND^;J5G'X;TV-?
M#*7,,.L21W6F6[;EAA22%6A*'Y!$FUOE!HL!^P'_  3&_P""HGA#_@H'^Q59
M_%B\U/P?X7OK6*YNO$^CPZ_%=#P?&MQ<"%;V5MGE,UO"LA:14!R6 "XKU[X%
M_MD_"7]IZ[U"W^&_Q.^'_CZXTD;KV+P]K]KJ4EHN=H:1878JI/ 8C![&OYZ_
MCF/#7AW_ (-3O@Y+\/4\,6E_K_CC3;?XLSZ&8H;JZMO-U<P+K#VX\YE\P6@7
MSLL!Y>T'BOICX%? 9_!O_!9']E_6/#^I?L:_"K6HM*O@?#GPGO\ 4I)?'&B3
M6KG,J+9B!Y$C$DJ/-(K.!NRWE*0@/UJ^*'[=GP<^$OQ*C\!Z_P#%/X>:)X^O
M8MUGX>U#Q!:V^H3NPS&ODLX?<_&U2 6SQFO"?^"#/_!0SQI_P4Z_80B^*'CW
M3?#^E:])K]]I/D:+#+#:^5 (MK;9'=@Q+MGYL<#I7YM_\$O]#_9D\7^%OVZM
M2_:VA^']U\4K?X@ZZFOR^*5MFU:STY5(3^SC/F5)!<BX"_9SN#I;@<B.OI__
M (-(?%.E^%O^"0.AC5-2L=.EUCQWJMG:"[N$A:\N6\HK#'N(WR$(Q"KDG:>.
M*.@'W#_P4O\ VT=/_P"">_[#WQ#^+=_';7$OA73&;3;2=B$O]0E98;2 X(8J
MTTD8;;R$W'C&:^;_ /@@W_P5^\5?\%,O#/Q$\/\ Q2\,Z3X)^*GP\O[9[K2+
M*VGM4ETVZA5X)_*G=I V]90W.-K1'^*OF'_@YG^+7B[]J7]JGX&_LG_#7P9>
M?$[5([@?$7Q3X7M;]+-=7MK<NL%I+,S*D2-''=LQ8Y^>$@;BN?&?#7[5?QL_
M92_X+^_#KXZ?&CX&W?P"T'X_1P?#K7+;^UH+^SU.3$,$=T98SA6B=;$MN PD
M3$$@D4: ?M]X[_;0^#_PNO\ 7+7Q-\5_AKX>NO#,]M:ZQ#J7B:RM9-)FN03;
M1W"R2@PM*%8H' +A21D U\^_!;_@M?\ "WX]_P#!2CQ-^S_H.K>%YK3P[HD%
MY;>*1XEM)+7Q'J4SPXT^PC0D3LD<K%RLA</&R^7\I8_#?P4_8:^&/[<W_!RU
M^V%8_%/PGI?C3P]X;T/2Y[?2[]I#;B[EM+*(3E%(#,D?FJI)RIE)7GD6/V&/
MV7?@IX$_X.B?VA?#Z>"_ NBVOA#PYI6K>#],%I###IFHO'ISR3V<7 28M*QS
M& 1YC8')HT _0C_@FO\ M6_$/]IO3/BA<?$1OA"/^$1\77.BZ2_@3Q'!K$?V
M., @WIBN)O(N1GYHW\MAW05[%\._VJ_A?\8/%=WX?\)_$CP%XIUZQ1GN=-TC
MQ!:7UY;JO!+Q12,Z@9&21QFOY[_A7\1?%GP__P""#O\ P4,USPA<WVFZC??&
M1[*\NK&5HYH+*XO+**Y"E>=KQ2M&W/W)7SQ7V=X*_8^_8!_9]\,_L6^/[;Q)
M<?#GQI?'33X,U3P?-+]O\;WTL,.^/4C;PS/(K2ML??Y8#3-$6"DI18#Z>_8&
M_P""F?C;]JG_ (*=?M/_  5US1/#-CX8^"-U;6^CWEC%,M]=B1V4^>S2,C'Y
M<_(J_C7UKH'[0/@/Q7X^O/">E^-?"6I^*M/W"ZT:TUBWFU"VV_>WP*YD7'?*
MC%?A1H_Q"\6?#C]IW_@L%XD\"SWECXDTC1':VNK*0Q7%DH:X6:XC=2&1XH1+
M('4@J4!!! ->%^%?V5?$"?\ !-W]G?X@^!?"7[/WPC\8-KEKJFA?&*\^*7V/
M7->U,^<TUI=1M OSL00T)E;R_+*C[S!G8#^D[XE_'?P3\%H[9_&/C'PKX36^
M)%LVM:M;V N,$ [/-==V,CIZBNAT77+3Q)I-O?:?=6U]9748E@N+>5989D/(
M974D,#Z@XK\1O^"F/[''C#XX_P#!8#XC^./AGH7[/_[5]];>%K/3M=^$WB_6
M!_;7@Z!(H4=[6)I8D@9R0Z2A]RM=-\F2KGZ__P"#;+XU_#GXI_\ !/V\T?X<
M^!_%'PXL_ OB>]T75?#NM:]-K7]GWV(Y91;W$F"(6\P'RPJ;'\S@DEW70#[V
M\2>*=-\&Z-<:CK&H66EZ=:KOGN[R=8((5]6=B%4?4U!X2\>:)X^T--4T/6-+
MUK3),E+NPNX[F!L#/#H2O0YZU^0O_!:[3=-_:B_X+K_LJ_ +XNZQ?6GP!UW1
M'UN72A>R6=EXAUKS;Y([>9E8!B3!9QKT8"Y=5*F7-9/[/_PM\+_L#?\ !QQX
MF^#?P :XTKX8>*/A9/J_CKPI:WTEQI^@WR0NT,H1V8I(?]%(R2RB]8#"N  #
M]?M.^-W@S5[S3+>T\6^&;JXUII$TZ*'5()'OVC^^(0'S(5[A<X[UU#' XZ]J
M_#'_ (-,O^";/PM^*W[,NE_'[Q5HLVN?$3PCXWU"W\,74U[/]FT*WBMHT"1V
MX?R23)<W$N2IP[(PPR!J_2+_ (+7?MKK^P'_ ,$U_B7X^M[Q;/Q%)IS:)X<;
M=ASJ=X## R^IBW-,1_=@:CK8#YF_9N_X.0]+^/\ _P %;KS]GT>"[&Q\ WVN
MZIX7\.^-UU-F35]0L8RQ4*4$925D94V.S'SK?C]X*_3C4?$=AI%Q:PW5Y:VL
MM\_EVT<TRHUPW'RH"<L>>@R>17\K'Q:M?B=\&/\ @EE\'-(TG]E?XS?#_P 8
M? [Q/)\1G^*6H6,BV<T\\@>::0>2"L;;+ !F?A;2,'-?>W_!:WXK:/\ \%)-
M&_X)I>)-#U/4-&TOXQ>.K5&N]*NVM[W23=R:=#<I%,OS1S0NTJ;ARKQY[4 ?
MM19^.-'U"*]DM]6TRXCTTXO'CND9;0X)_>$'Y.!_%BKFDZU::]I\5U97-O>6
MLPS'-!()(Y!ZAER"/I7X1Q?\$F?A#I/_  <<W/P#T+2]8T/X(Z]\,H/%GB3P
M?9:]?067B":%VBBBN2LOF2QB?RKC:SX\Q">Y!X/X&_&#Q=^P'_P3K_X*?>%_
MA/K.N:'I?PC^)O\ 8?A)X;R1[CPW;7&J/I\TL,A.Y)!;QH!(I#!U#YR,T ?T
M*6/B.QU*_N+6WO+2>ZM3B>&*97DA/HR@Y7\:<WB"RCDF1KRU62W7?*K2J&B'
MJPS\O;KZU_.G\%/V.OB#\%]"_93^*OPA^"NI?"OQ[>:MI&J:EXZUGXUZ1)!\
M3[.YBBENX'M)+I'<SJV5A4!U1I$96;!'O6E?L9^#_P!OO_@YV_:A\%_$4Z]J
M'@;3_!VFZE?:'8ZS=:?:ZS,D&EQPK=>0Z-)''YKR*A8#>JMSBBP'[;V6HP:C
M:K-;S1W$,B[DDB8.KCU!'!_"OE/_ (*X?\%2+/\ X)??LE?\+0M/"]O\1&C\
M0VF@2Z7#K2V!A:=96WM*(IL%?*^X4R<]1BOQ^_9M^,?CS]D/_@CO_P %%/!W
M@?Q/XACTWX4^/!X?\-3F^=KG0[.YO?L=P89,[HR8E!RF,.S.,,Q-8O\ P6'_
M .":/P5_8R_X(O\ P+\=?#W5M:L_&'Q(NM!GUF1M>N)H/')GT^2[>ZEMF<Q,
MT3MOC=5'EK*1SNIV _I)N;N.SA9Y'2-%ZL[;5'XFGA\KFOPX_P""C>J>(OVX
M/^"^_BKX+^+OAW\3/C1\,_A=X$MM8TOX?>%O%=OX>AN+J7[&TFIW#37,"RA?
MMCQ81_,SY0 V+)G@O$7Q+_:4_8._X(7_ +6&CWT/BWPIH&B^,K/2O %Y?^+[
M'6=;\,Z/>Z@(+JRDN+*YE:-X0J0D94A[IRH&"%5@/U@_X*O_ /!3>Q_X)@?L
MV:3\1F\)OX^AU/Q39^%S8VVJK9- ]PDS^89/+DSM\G&S:"=PY&*^IMW7VK^<
MG_@L3_P2_P#A'^PO_P $V?V=?%7P[\3>*(]9\<^)] 36K>X\0W5Y8^-#)92W
M+:@ULS&,21/C8Z*H5+AEQEEK^BKQ!K=IX9T.\U&_NHK&QL89+BYN)&"I;QHI
M9W8G@!5!))]*0%H2 GWZXH\SGH?RK^7G]M;3M'\4?LC_ !._:&^"^G?M7>-I
M-)\4"?\ X7WXG\:1Z+:0EM3BMUCM-/CD$UQ"7D6)71(VC=PQ"*AB'W)_P4$T
MSQ?^U5_P4Y_8$\'R?$/QMX+/Q&^'MY/XDU#PSJKZ;>SH]D)KD1LGRH\H5X]X
M7*B0D8(%,#]H]WUKA/VH/CM:?LP_LU_$#XE7]A<ZI8_#_P .:AXCN+.!U26[
MCM+:2=HT9N S",@$\9-?DS_P3UM]6_X)T?\ !9_]KCX)^#_$WC3Q)\,_!_PW
M3QII6B>(-9EU+R+_ .S65SE6D/#%KF5"PP638'+% U?//P%_8_N/VH_^"#'Q
MF_:Z\;?&;XI7'QF\1:3XBN[C4/\ A*IUT][*(RV[Z/+:Y,3P7*!X_+(POG1J
MFP* 4!^Z?[$'[4MC^VU^R?X&^+&FZ3>:#I_CK35U."PNI5EFM59F4*S+\I/R
MYX]:]5KY%_X(**5_X(Z?L\[O^A1M_P#T)Z^NJ "BBB@ K\[_ -O,J?\ @X._
M8)7/S+I7CXD8['1Q_P#7K]$*_.S]N4^=_P '#W["Z=?)T#QS(0.V=+(S0!^B
M=%%% !1110 4444 %?RH_P#!Q-?VT?\ P64^-"M;S,PGTH$@-@G^Q['VK^JZ
MOY4_^#B18/\ A\E\:-T$;-Y^E9)N ,_\2>Q[8JX ?T7?\$IV1O\ @F1^SX8Q
MA/\ A7>A8YS_ ,N$->_#BO ?^"4P _X)C_L][>G_  KK0O\ T@AKWZH ****
M "BBB@ HHHH ^ /^#H[_ )04?'/_ +@'_J0:97V%^RLNS]F#X;@-O \+:8 W
M][_1(N:^/?\ @Z._Y04?'+_N ?\ J0:97V/^S-_R;?\ #[_L6M.Z?]>L= '<
M4444 %%%% !367=_GK3J* ,SPWX.TGP=;S0Z3IFGZ7%<2F>5+.V2!99#U9@@
M +'N3S47B[P!HGC^PCM==T?2=:M895GCAO[2.YCCD7HX5P0&'8CD5L44K= *
M=QH-G=:<MI);6\EJBJJP-$IC 7&!MQC P,>E37=C%J%C);W$<<T$R&.2.10R
MR*1@JP/!!'!!ZU-118#'\,> =#\$Z%;Z7HNCZ7I&F6C%X+2RM([>"%B2Q*H@
M"J223D#J<U9_X1C3_P"VVU+[%:+J3Q?9VNQ"OGM'G.POC=MSSC.,U?HIVL!6
MM=*M[&:>2&&&%[IM\K(@5I6QC<Q Y..,FN?\/? _P7X1\:7GB32?"/A?3/$6
MHAA=ZK::5!!>W6XY/F3*H=LD G).<5U-%%@.9U?X+^$/$'CZQ\5W_A;P[?>*
M-,3RK/6+C389+^T3.=L<[*709[ BI#\(O"K>$]0T$^&] .AZL[R7VG'3H?LE
MXSXWM+%MV.6P,E@<X%=%14\J Y-O@1X)?X9IX+;PCX9?P;''Y*:$VEP-IJIG
M=M%OM\O&23C;U)/6KWPY^%OAKX/>&(=$\)^']%\,Z+;LSQV&E6,5G;(S<L1'
M&JJ">YQDUO450&1XZ\ Z'\3_  K>:%XDT?2]>T74%V75AJ-K'=6URN<X>-P5
M89 /(Z@5D1_ 'P-#\*(_ :>#?"J^"88O(3P__94']EK'NW[/L^WR\;B6QMZG
M/7FNNHI6 YGX5?!7P?\  KPU_8W@KPKX=\(Z3O\ ,-EH^G0V,!? &XI&J@M@
M 9//%7/&?PX\/_$6WM8?$&AZ/KD-E.+JW34+**Z6"5?NR()%(5QV88(K:HI@
M1O"LD6QL,I&#GG-<K;? 7P/9_#W4/",7@[PK#X5U7=]MT:/2;=-/N]P ;S(
M@C;.U<Y!S@>@KXE_X.*_^"BOQ2_X)P?LU?#GQ%\);C0;?Q#XM\;P>'ICJUA]
MLA:&2TN9,!=PVGS(X_F!SC-?//[<O[;7_!1+_@D[\);7XN?%+5?V;?B#X"T_
M6+73=2TK1[6[L[VY69B 8F<(0WRXRH<KNW&-E5L%@/U3^!G[,'PY_9CTJ^L?
MASX%\)^!;/4Y1/>0Z%I4-@ETX! :01J-Q ) STR<=:QO$7[#OP<\6_&>U^(V
MJ?"WP%J7CRS8/#K]SH=M)J$;@@J_FE-V\$##$[AC@BLSXE?M^_"KX"_L\^&_
MB;\2?%^D?#SPSXHLK6[LWUR?R)G:>!9UA6/!=Y55N5121@UTGP;_ &K_ (:_
MM"_"!_B!X)\=>&/$W@F%)7GUFRU"-[.T$2[Y?.<D>447YF#[2HY( HL!L?%[
MX%^#?V@O!DGAWQUX5\/^,-!FD$KZ?K.GQ7UL7&</LD4C<,G!'(R:3X3? CP5
M\!?!7_"-^!_"?AOPCX?WM(=-T?38;*U+LH5G,<:A2Q55!)!)"@=J\A^"/_!6
MO]FS]I'XKQ^!O OQH\!^)?%EPSI;Z;::@/-NV3EA"6 64@9.$+$@$CH:\+O_
M /@O+X!A_P""O;_LTMJ'A+3M!TG3Y(=0\3WFL+_I>O&:*&/1X$ "K,KLZN&9
MF+J5"KMRQR@?8EG^S#\.-.^$=Q\/[?P'X.M_ MYN\_P['H]NNE3;G#MNM@GE
MMEP&.5Z@'K5KQ)^SYX%\8Z?X9M-6\&^%]2M?!,T-SX>AN=+AECT.6)0L3VH9
M2(610 I3!4 8Z5Y3\=_^"L'[-_[,7Q.?P5X^^,W@/POXLA*"?3+O4E\^T+@,
MHF"@B'*D'YRO!!Z$&O(?^"L?_!:[P?\ \$W/#OPQCL)/#GBG7OBEJUE%9K)J
MZ):Z?I$SCS=8<IN,EN%R%*D*S$'=@$$L!C^!O^"1EWXE_P""K_[3'Q6^)^C_
M  ^\9?"'XU:!H^EZ?HEXK7MSYMG;VD;FX@DA$:X>W<JRR,>5/!R!]C^%OV</
M /@?X,_\*YT?P9X8TOP"UI+8MX=MM-ACTQX)<^;&T 78RON;<"#N+$G.:Y;X
ME?MY_!CX-_!?1/B-XH^*'@O0_ OB9$?1];NM5B6SU8.A=3;MG][E 6^3/'-=
MA\)OCYX*^._PRM?&G@SQ5H'BCPE?(\D.KZ;?1W%FZIG?^\4[1M((8'!4@YQ1
MY@>?>#/^":G[/GP\\)P:%HOP6^&.G:/:ZNNOPVD7AVU\N+4%4HETN4.)55BJ
ML.5!P,"N^\+_ +/G@?P3\4_$'CG1_"/AS2_&GBQ(XM9UVVT^*/4-52-56-9Y
M@N^0*J( &)P%'H*^!O\ @J?_ ,%__ OP/_8C\:>,_P!G7XE?"CXA?$#PAJNG
MV=QIDMU_:$:0SW BDD\J.6-Y%&<;T8J#C)[5^CWAZ\EU#P_8W$VT33V\<D@4
M84,5!./;)H \*^.'P;\4_LT? +Q=<?LJ_#WX36/Q$U[5UUJXT_5[9M.TS6;B
M1U%S/,UL48W#1C(=C@E>3S7C7_!#O_@EIXB_X)U_##Q_K_Q)U?1/$'QB^,7B
M&3Q'XKO-'W?8(,O(T5M"61"0K332,0BC=,5 *HK'RW_@X!_X+5?$+_@FQXJ\
M ^!O@UX=\.^*_B!XATS4?%&L6VK6-Q>1Z=HUI$Y\X)#+&1EHKARY8A4M7XY!
M'V]^R5^UWX9_:L_8Y\&_&6PN[/3_  YXGT"/6[B6:<+#IN$/VF.1VP!Y$B2H
MS' 'EF@#U#6M&M?$>CW6GW]O#>6-]"]O<V\R!XYXW!5T93P59200>H-8?PA^
M"_A']G_P':^%_ _AK0_"/ANQ9WMM,TFSCL[2!G8NY6- %&YB2<#DDUY/X]_X
M*B_L]^ /#K:A=?&?X93^9I%SK=E;V_B>R:;4[:#>&, \P!R6C=%P>64@=#CY
MM^#?_!:R^_;)_P""5?CSXV?#./X7^%_B%H-Q)]B\.>,/%,$=KI=L-06VAFU*
M4R0^1YT0D9-Q1"Y559NI=F!]A>!_V+?A'\-'\:MX>^&O@G11\2 1XJ6ST>"%
M/$0/FY%VH7$P/GS<."/WK_WCGD?V:/\ @EO^SW^QOX]OO%/PQ^$O@_P;XBU!
M)(I=1L;4_:$CD(+QQLY8Q1MM&4CVKQTK>^&O[3&G^&OV/O!/Q&^+/BCP!X5?
M5O#^GW^L:G%K,,>@K=SVZ2.+:Y>0I)"7+>6P=MZX()SFJ?C']LWPEXJ_9'^(
MGQ*^%GB[P?X\B\'^'M1U."XTW48]0LQ<V]I).D<QA?(R57*Y5L'MUI <[^T)
M_P $COV:OVK/B8_C+XA?!KP3XF\4S;?/U.XM#'<7>T!5\XQLOFX4 ?O-W  Z
M"NZ^-W[%'PH_:.^ %K\*_&O@/P]KOP]T^*WALM"DM_)M;!+=/+@$ C*F'RT^
M53&5*KD#@UX__P $DOV_]4_;1_X)<>!/CU\4)O"GA6^U^/59M6EM7-CI-C':
MZK>6B-NGE?8/+@0L6<C<6(P" /H;X1?'?P5\?_##ZUX%\7>&O&6CQRFW:]T3
M4X;^W648RA>)F 89!P><$>M 'C/Q+_X) _LS_&+P#X'\+^)O@WX/U?0?AO;F
MS\-VLL,BC2X"VYH597#/&6^8I(64L22"237=?";]A+X-_ C4?%EUX,^&O@_P
MPWCRUAL?$,6G:;'!;ZM;Q1M%'%+$H\LH$=UV[<$.V<Y-:"_MA?"=OBQ_P@8^
M)WP_/C?S_LO_  CX\0VG]I^=Q^Z^S^9YF_D?+C=STKT@'(H ^??@I_P2J_9Y
M_9V^%?C;P/X/^$_A;2_"/Q(</XETF2)[NVU? (19%G9\(FYBB+A4))4 \U%^
MR1_P2>_9W_83\7ZAX@^$_P *_#W@_7M3A:VGU&)I[JZ$3'<T:23R2-&C'&50
MJ#M7(.!CZ'W4 YH \'^)W_!,3X ?&?\ :+T_XM^*OA3X1UWXC:6\,L&MW5J6
MF+P@"%Y%SY<K1@+M:16*[5P1M&-+P-_P3M^!?PV\%^%_#NB_"GP39:+X(U[_
M (2CP_:?V9'(FC:IN#"]@W@F.8, 0ZD$;5QC Q[*'![T%LCK["@#S?0OV0/A
MIX8_:4UOXQ6'@_2;?XG>([!-+U'Q&%9KVYM4$:K%N)(50(8A\H&1&H.:B_:I
M_8S^&'[;G@?3_#?Q5\&Z7XTT72M035;.UO2ZBWNE1XUE5HV5@0LCCK@AN1TK
MTR(, =VT\G&/2G9H \Q^'7['/PU^$OQ[\8_%'PYX5L]*\?>/[>VM?$&L1SS/
M+J4=NH2%65G*+M55&452=HR3@5P_Q(_X)5? /XM_M?:#\>M?^'MC>?%;PY+;
MSV>N)?74#>;;\02R0QR+#*\8 "M(C' 4'(5<?0I<"EW#% 'C_P (OV!/@[\"
M?AUXV\(^%? .B:5X9^(][<ZAXFTPA[BVUF:Y3RYS*LK,,.GRE1A<= *\D_9?
M_P""$?[*G['/QOC^(WP_^$NFZ1XNLV9K"\N-2O=072RR[6:WCN)I$C;&<.%W
M#<0" 2*^NPV:,T >/_"_]@;X0_!KXM_$KQUX=\%V-CXH^,+!O&-W)<W%RFM_
M?X>&61HD4^8^5C10=QR#7AOPH_X-[/V1O@G\?]/^)/ASX26=GXAT>^&IZ;%+
MJU[<:=IUT#N$T5I),T*LK %1M*H0I4*57'VEFC- 'R;^VS_P1*_9R_X*!?$B
MW\9?$;P-+<>,(H%M9-:TK5;G2[R\@4;1'.T#J)0$^0%P6"_*"!Q7MG[*G[)7
MP\_8D^"^G?#[X7^&;+PGX3TMWEBL[=WD:25SEY9))&:221CU9V)P .@ 'HV:
M* /#OVZ_^"<WP?\ ^"D/PXL_#'Q<\(P>)+/2YVN=-N4N);2]TR5@ S0SQ,KK
MN &Y<E6VKE3M&,#]A;_@DU\"_P#@G/H/B&U^%O@]M+O/%B"+6M3O=0GOM0U%
M!NPC32L2J@L3M3:I)R03S7TA1F@#R/\ 8K_8=^&O_!/CX+)\/OA5H<_A_P *
MI>S:C]FFOY[UVGFV[W,DSN_.Q1C.!CIUJO\ MB?L#_"W]O;1_"NF_%3P[+XF
MTWP;K<7B'3;0ZC<VMN+R,%5:5(G59EVLR[9 PPS#N<^R9HH Q?B)\/-'^*_P
M^UOPKX@L8]2T'Q%83Z7J-G(2J75M-&T<L9*D$!D8C(((SQBOF+PK_P $1_V?
M_!'A'X,Z#I?A[7K?2O@)XFD\6^#H&\07<PL;^2>.X=G+NQDC,L2/Y9^7.[C#
M,#];T4 >.0_L*?#N+]MQOVA/[-OC\3&\-#PG]L-])]G%CYGF;1!G9OW?Q=<5
MSOPH_P""7WP=^$3?'!;'P[-J%G^T5JMSJ_CFSU2\>[MM3DN/.,J*C<1QDW$I
MVK@C=P1A<?0M% 'P/^SS_P &X/[-_P"SG\:O"_C2QM_'GB,> ;QM1\):%XA\
M2S:AHWA>X,@E\VUMV PPE <;V8;P&.6 8?0GPQ_X)X_#GX2?MN>/OV@M'M]8
M3XA_$C3(=)UF26_:2S:&+R OEPXPC'[/%DY/0],FO=** /F_X'?\$I?@W\!M
M"^-&DZ=H=]JVB_'[4;C4_&.GZO>M=V]\\XE$J(, QH?.DX!R"001@8^<])_X
M-9?V4;+PE<:+>:7X^UJU6[2YTQM0\5W$C^'XU<NUO9XPL<4C8WY#.VU?FXS7
MZ.44 ?)G[>7_  1U^&?[>_Q8\._$74M8\??#WXG>%[(Z98^+O!6N-I>J+:%I
M&^SLVUT9,S2X.T,!(PW8.*U?V=O^"0'P+_9M_8V\3? O2_"CZQX)\;F>3Q,V
MLW)NK_Q#-* &GN)_E/F+M384"^645EPV6/T]10!^;WAK_@UK_9ET;PU9Z;J%
MQ\4O$?\ 8U_#>:%<:KXJDFD\/0QR>9]CM$V"*.!WP7^0NVT?,.<_HKKNA6GB
M;1+S3=0MX[JQU"%[>Y@D&4FC=2KJP]"I(/UJY10!^9Z?\&N7P7G^%^O?#V[^
M)7QUNOA=J%Y/J.C^#?\ A*%CTCPS=2R!S/!&(OWKJ 57S_,&'8D,YWU](_\
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MIY?P;\)+_=T:S'_D!* .FHHHH **** "BFH6\QMP^7^$YZTZ@ HHHH ****
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M.>>5IIW!20VI<(H!4. 6)%>52?MM_&SX4CXQ:EXTTGX8^(--^$FK6'AQ-/\
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M\,O^"\7['NA?#KP]I]Q^T!X AN+/3+:"2,W$OR,L2J5/R=B"*]8_X*(_&O\
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M&.G_ "]^PIR?\$-?VZHXT*_\%"O&F[ W PWQ4=>A^T\]J/= _7ZC.*_($_\
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M*[1,RQ_M;?!]PO1FTNWY_P#*,?I3E_8O_P""OB;@O[5OP7^1OE+:7;?O./\
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M]$$EQ!N*>8H/\.Y6&?45Y^O_  6Y_9%;_FXCX4+M[MKT2Y_,T6Z@?-O[2?\
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M,^-7_!,3PGKO@Y;O7_@O?:]X7UGQ=;^'K:7S-1\#B\@EOTBAA E\O[+M+Q(
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MF =13=W^R:-_^RU%P'44W>?[II-[?W:.8!]%-RQ]*-S8[4[@.H'%-!.:=NH
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M\$@?V0?AC\.]>\2_\,_>']<CT>SGO#I^BVLUW?7QB5G:&WA$HWRG:0$!'/'
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MP7IG@U->U2^GU?3;.;3+5=<=8HIA%<ZP;4W"2R1%I#<Q)L99,-7,ZG\)=/\
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M3*T?[:WQ("KU5_A_X58M^/V$5"/V'?VF=O\ R>YXXR/7X:>%N?\ R4KZ^HH
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MG<[_ (:+U<1JS?"GXG*S=5^S:>S+PIYQ=X_B(X)Y5O8GU+8/0?E1L'H/RI6
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MOC3I[7RK_P"RU]=U\A_\$?5QX3_:&;^]\?O&YSZXU(C^E?7E !1110 4444
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M&H<9P^.N-R]=OS.'A3XJ*W'C;P%MXX/@V[R?NYY_M/OA\<<;EZ[3N]$7[M%
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MG=\>?B"<#M_Q4%V/Z5];5\F_\$@N?A1\9V^;]Y\=?B"PS_V,5Y7UE0 4444
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M?DG:/B]/N_\ 35CGUS4Q_:)_;.62/_C&/X0LK=0OQCERASCD_P!D?CQG\^*
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MTYPQOVTOVO45C_PQ1:-UVA?C+I&3]<VXQGKWX]^* /LG;BDV*.W7K[U\<_\
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M.XO^"DGQG=6)_8J^.JXR?^0SX>S_ .EU1I_P4T^+:2*K_L5_M!J6;;E+W0&
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M5_ Q_2\.?PJ0/K31?!6C^&]0O+O3M)TW3[K4/+^U36UJD4ESY:[4WLH!;:O
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M^)W]I30Z;;I:77A/6/&7AD6GB?3-2O=;L]-MOM4D=S:V\SRZ;<26_P"]2.Y
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M?:ZJ LS>7:K/DS++LGA0%FB KQ?P9_P0;A\)^&IM-/Q"T/=_P@?B/P']OLO
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MQ#^"-W!JGA#QNFG?/9W:2N95DMQ*/,M;F"66WF@,FUTDR?F52&!W-I_P4E\
MWWQE7PK%I_B[^RYO$[^"8O%[:5M\.2Z\A96TU;@OO,HD1H=_E^29E,0D,GRU
MYOX__P""QOAF;]F+XJ_$#P+X'^(6N0^!O">L^)M"O;[0);71O%4>G/Y,K07(
M)VQI,5+K*(YO+$CI&X0XR_"?_!&31?!G[49\:64_PX;0V\=W'Q#+W'P_M+GQ
M8+V>9[J2R75Y7;;9_;)&F4B#[0B[8EE55#5D67_!%S4->\2_%&X\0>./#5M'
M\2? ^O\ @O4[_P ,>%/[$U#Q.VJJJ#4]:6.X-I=WENH?:\5O 7>61B5!" T
M]>^(7_!3_P '_"&+3F\4>#?BII=K]GTN;7]2_P"$5FDT_P (OJ#(L$=],I*A
MP9$WB'SO*#*9-N1G'\!_\%1]-U/6OBE9>(/!7C&QO/!GQ+N/ASX;T[3M*DO;
M_P 83Q64=V6MHUX)\M;F=F)6-+=$D9QDX\G_ &G?^"-GCK]K&^\1WWBKXC?#
M^\U;Q)9:-)%J%WX,N+ZX\*7MA# KQZ.)KXQ6=K<30&9OW;S!KB8>8V4*=/\
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MU37M2OIU3D1P22ZR!'&&)58<'L:I_$O_ ()KZ'^TU^U1XT\>_%*YU+5M(O-
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M$\R1X]S>5>&/^":_[0_Q#T.ZM?%]C:6-UJ'P'\4_"JXFOO%-I-966HW]O8K
MUAI]C:06UGIH>U*HJ*90FT2(-BEIY4!]TW?[8GP&TR;P0NH>//AMIM[\2K."
M[\-076H6D<VM03LJQ-""<NKR.J CAG.!D\5G_M&?MM_"?]G?Q7IOA6XU3PCJ
MWCR]UK1-+3PI!J%I'JZ+J6H6UDESY#'?LC%SYIXR40XZ@U\C?M*_\$^OC/\
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M@#Q<_P#!.']GHQLO_"B/@SM=@S+_ ,(3IN&(Z'_4]:KR?\$R?V;Y7D9OV?\
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MIGBW1=%T/Q5X)L_"FJ6MUI<MQ=QR66K_ -I6\\$BRJH5O,ECD1U)X0J1SDT
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M<#PVVOZ]X:\:ZI$GE6+0_;;._P!+DM&M-:!1)DMKA_LTB+*B-M$*NZT ^W_
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MM+\*2^*TOY=1.G:/-''>"T,1O'B8(=P9M^TJ0% W;N/6?'W[=_PI\!?$W5?
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MK2?AM8RV$O@G3O!EKJ,FG^+VGU,)IEK*SQI%8.A:2Z9YG1''F.B1UT_[5'[
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M-XU+8'&?^$DU&OK6@ HHHH **** $<94U_'9_P ')T:G_@MS\>MN,?VCI_\
M&.O]E66?UK^Q0]*_CE_X.2AC_@MQ\>N__$SL/_379T ?U=_\$^.?V"/@?P1_
MQ0&@\'J/^)=;UZ_7D?[ '_)B'P4XV_\ %!:%QZ?\2Z"O7* "BBB@ HHHH **
M** /SL_X.6/#3^-?V1/A#HD>AZ;XHDUKXU^%;%=%U&[:TL]8,LLZ?99IE5FC
MCESL9PK%58G!QBOC7X+_ !=U?_@FNW[;7Q,\*_#WP[\$_&GPO\-Z5HT/P3M-
M6N=6TMGFNH1!XK:=A&D\!6X(Q B#;$XD,;/N/[;_ !0^%7A/XK:?I<?B[0-#
M\06N@:G;ZY8+JEI'<1V%];MN@NH]X(26,DE7&"N3@UC^)_V<?AUXX^)UWXKU
MGP;X4U7Q9J'A^3PQ=ZC>:;#-=W6CRN7DL9&8$O:LY8F-LH23QR:+@?F'HO\
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MITKQ'HFJ:]K+:4AUG58M2CNK:]GCN;J:5)(5%R953[5DLODE56CW4!Z;JO\
MP4?T_P '?\$JM+_:>U[PY<P6=]X+L/%LFAV-PUTZO=PQ/';),(@2-\RKYIC
M ^8@#-=MK'_!0#X.^&/BOI/@74O'VBV'BS6C9I;Z=<B6&2.6\ :T@G+(%M[B
M=64QP3%)7W#:IR*\QUW]AOQA=?\ !&6T_9]M]0\.)X\L_AK:>%5NE,JZ0VHP
M6<<?#;!(+9I8R VP,$.=H/%>>_$/]A3XU^,[#XH>"[>P^&D'@WX[>+=*\9>(
M=9NM:NIM5\+NL.F1W]G;Q+:!;UT.GC[)<-)!Y89-R#RUW&@'V!\=?VB?!7[-
M'@N/Q!XZ\0V/AW29KE+."2XW-)=3ODK##$@:260A6;8BLVU&.,*2,.P_;/\
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MKZ9KK5+6#5Q?.L4%B(U,>I0R7OD"Y,K1BUB88+.(P:= />?VC/V[?AQ^S/\
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M%WX'U1=:T3SY9?+LKU1A)_+5@DCIPR&16V, RX8 CLV4/U^M+12 ;Y8SGO\
M6C&#]:=0>: /DO\ X(JR>?\ L57TG_/3XA>-&_/Q)J-?6E?)_P#P16&?V%8Y
M!TF\<>,7SGDY\2:EUKZPH **** "BD9=W<BEH :[A!S7\<O_  <BMN_X+;?'
MO[O_ "%+'I_V#+.O[&I%W+C /UK^.7_@Y&_Y3;?'OI_R%+'I_P!@RSH _K!_
M8#4)^PG\%0!C'@/0AC_N'P5ZW7D_[!B"+]ASX,JO*KX%T0#G/_,/@KUB@ HH
MHH **** "BBB@#P']NB^EU7Q#\$?!]TZP^&?'7Q%MK#7G8 K/#:Z=?ZI;VS9
M'W9KS3[6-N1N5F0Y#E3\)6<?P[\$_MR6/B&SO?AKXW\1:U\:"K6\E]/H/Q>\
M.7MQJ;V[V[QJ\G]H:1 C,WE.L,1T[YQN\M7;]/\ XR_![2/CCX.CT761=+#;
M:C9:M;3VLODW%G=6ES'<P2QO@[662)>W*EE.0Q%:W_"$Z1)XE76FTK3?[:6,
MPB_^RQ_:@A_@$F-VWVSB@#\;/B[_ ,% _C-^T3^S)\7K3Q7<6-MI?B3P1XLN
M-7\.G4=&%UX+DL9EBMXX8+8G4%*L5@G^W?>>5'3RA^[/OY_X*-_&Q?VW/$FE
MQZ?;W6E:3XVUKPI;>!I+O1X9]0LK/3I[BWN;>/S#JK7=P8H[@,8S;M!.%"#
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MWN^35GQW\,?#?Q1TN&Q\3>']$\16=M,MS%!J=A%>112KRLBK(I 8'HP&14W
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MEU<71L#(I@0S6J+'#(TF^.1R"[B+;\<_\%Z_#6C^#_#6K:+X3TZ[:^\ Z?\
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M3S !JEV/F^7G_6_[*\>WN::/V<O":R;EM=25L;?EUF]7 QCM-[#FNXW\=_\
M&C?Q]UORHN!PQ_9O\*F1F\G6MS$L<:]?C!.<X_?\=3TZ?@*>?V=_#)D#;-=5
ME;<,>(-0'.<]I^GMT[=*[;?[-^5&_CHWY47 X4_LW^&"N,^)5Y#97Q/J:G(Q
MW%Q[#]?4U)_PSWX=\L+YWB?:H &/$^IC&  .?M'^R/U]3GMBWU_*C=_O?E1=
M@<2W[/?A]D5?M/BP!1M&WQ7JJ_RN>OOUH?\ 9^T%EQ]L\8+R3QXMU8==V>ES
M_M''IQCH,=P3BDW<]Z .+A^ >AV\WF+?>,MV=W/B_5F7KGH;DCOTQ_2F7/[/
MVB77WM2\<+\P;Y/&&K)T^ES^E=QGB@'- '$_\*#T?*?\33QL/+QC_BK=4YZ=
M?](YZ=_4^M(?@)I9_P"8QXW'.0/^$IU'C_R-_.NVW4;O8T >:ZEX!C^'OBOP
MQ/9:UXKF^W:J+::*\UJXO(94-M<MM*2NP^\%;(P<HO/8^E8#=O:N2^)DA77O
M!@X&[70.0?\ GSNCQCZ=^*ZZ@!OEKZ4NT8Z4M% #?+7TI=H!I:* $*AJQ=/^
M&_A_2O&^H>)K;1-(M_$6K6T-G?:I'9QI>WD$)8Q123 ;W1"[E58D+N..IK;/
M2FPL63GUH =1110 4&B@T ?)_P#P14CV_L"::W>3QAXO<GU/_"2ZG7UA7RC_
M ,$4&W_\$]- =3N63Q1XL8?0^)=4Q7U=0 4444 %%%% !7\<G_!R.RM_P6W^
M/>T +_:ECT]?[,L\_KFO[&R<"OXW_P#@X\.?^"V7Q\QS_P 3>S]/^@=:>E '
M]9'[")V?L1_!Q3MX\#Z(,J<J?^)?!T/I7K%>4?L,V[#]B/X.1MPT?@C1 <=,
MC3X*]7!S0 4444 %%%% !1110!Q/QS^,]O\ !K1M#;['+JNK>)M<L] TG389
M DE]<3OEL$@X6&W2XN9#@D16TI ) %>#_#S_ (*J>'?BA^T3X3^&>D^'KEO$
MWB;7/%.GRPW&J6T']GV.@ZB^G37Y5CND\^=#Y<,8+[5E)($9-=Q^V3X4U*+Q
M]\$?'=C8W^K6OP[\=+<:G9V4#3SFTU#3KW1S.J+DD02:A%,Y )$,<Q[5P_[)
MO["GB7X!_'*Q\6:MJVAWEK:S?$%V@M/-,C?\)#XEL=6ML%E _=PVC)(/[[+M
MR,F@#VCQ3^UU\+_ _P 8+#X?ZQ\0O!NE^.-4>&*UT*ZU>"+4)GFSY*"(MN#2
MX;RU(!DVG:&P:YG5O^"D?[/N@SZI'??''X1VLFAJS:A')XNL UD%D,3>8/-R
MI60%&!Y4\''%?#?[9WBJRU?]MCQ0VI>/)+/1])\?^$_$:6\>A>*8EL$T:;3Y
M[FTEM;'33::C+*]F[QWDUS+Y:RI&L8$2N*?P8\<?!;X<ZI\+[K4O&%O?+X$L
MO']M=_\ %O?$.+N7Q'J4=U"R;M/QA(4DCESUWD#<,T: ?I!??M1?#?2_B'HO
MA&X\?>"[?Q5XC@CN=*T>36[9;[4HI 3&\,)??(KA6*E0=P5B,A3BIX1_;!^$
M_C_QCJGAW0OB;\/=:U[0[::\U'3;#Q'9W-W800OY<TLL:2%D2-_E=F "$@-@
MD5^2WP]T?X=_#7Q;X>6\^(\>M:-]K\!ZIJ\\UOXTT]-,G\.6.EVLD<.G062P
MWA=]+66"666$Q27#EXY538^OXWM?@[X_^ OA?P7#\5O#FD7^FP_$--4O4\(:
MX%N/^$CENI(.#9(9%!EA\]&9=PC.TMA33Y0/T5\ _P#!3'X7?%[XI:QX:\&:
M]I'BVWT.XTBVN=<TK7--GTEFU&*^E01S"X_>/$EA(9(D!D D1E5EW%?0/!W[
M77PJ^(6G>(+S0/B9\/=<M/"5LE[KDVG^([.ZCT:!U9TEN620B%&5'8-)M!"L
M0< U^8]_\=?!/Q*^/VJ?$3Q#X\^$O@6ZUK5_#EX=*TB/6;S;'I>F:U9R&263
M38-\K2:G;A/W8Q%#M)RHW<3\1];^#O@[]G7X9Z=I7Q,^'MQ-X#^%_AKP9J&G
M6.AZG/#X@U73_$&B:B_FQ1VF^2PE-C=)-(5:1([J9_*?YU(T!^Q7PL^-?@_X
MY:#-JG@KQ7X:\8:9;R_9Y;O0]4@U"".78LFPO"S*&V.C8)SM=3T(K$T#]K?X
M5^+/[>_LOXF?#_4O^$6ECAUK[)XBLYO['DDD,4:7.V0^2S2 HH?!+#:,GBOA
M;]A/_@I1\*_">N_M):OXJ\7?#SP#K?C3XBO?Z7#9K>W&FW")X?T>U^U*\EM;
MO<*;J&=7D\M!(\<FTD8<_*GAZ?P3XNT6QL_&_P 8/@=';)X8TCPSJ-G-K@DT
M^Z2T\2Z1J=Q]EL[;2[:WMK%[>RNUC@P[AI$5VY+% ?LK%^UC\+KCX8+XVC^)
M'@!_!DEU]A37U\0VATMKC<4,(N?,\KS-P*[=V<C&,U?_ &?OCGHO[27PGTWQ
MGX=%X-&U9[A+8W,:I(PAN)(&;"LPVEHF*D$Y4J>,XK\Q?%?Q[^"?AK]I'4?B
M!X?^)'P \5:=!\1[SQ58^$]1UT:=;RVMWX6T_2)+A7:W>.*\CN+69L%&5XKB
M8[P[8K[4_P""/UMHNA?\$]_ .A:+K_@OQ%'X;BN-/N;CPE=-<Z-!/]HDE:"V
M=E1C'&)5494$  4P/IFBBBD 4444 %?(W_!*Z1IOB1^U\YYW?'O4P/\ @.A:
M$O\ [+7US7R'_P $H$/_  F/[6TF<^9\?=;(_#2](7_V6@#Z\HHHH **** "
MBBB@ HHHH R?'G@C2_B9X*U;P[K=M]LT?7+26QO;?S'C\Z&12CKN0AERI(RI
M!'8BOR^T']A?X5_"[X8_MU>+M'T76+'6OA/?:_I/A6['B+4YCH=J? NEW#I$
MDEPR$^=>W;AG!(:8X(PN/U7)Q7%S_L_>";[PYXZTF3P[ITFF_$Z6>?Q3;E3L
MUQYK.*RE:;GG=:P0Q'&/EC% 'PSXA_X*&?&3]C;X<:QH_C#2_!GC;6K?P+X0
MUGPQ_86EWZ&UN]7U=-$^R74?G3S7JQ320RAXO*DFQ(@16=,?0'_!/3]JCQ]\
M?=9^(7AWQ[H-]:7?@NZLCI^N2^%+WPLNMVUU"SX.G7DDLT,L4D<BLPD>-U:-
ME(.]5]7\9_LJ_#CXA)J2Z]X-T'5X]6T"+PO=K=P>:L^FQ2-+%;$'C:DC,ZD?
M,K8(((!$?[.W[./P^_9YT[7H_ >EPV?]OZ@UWJ]XU_-J-YJ%TBB#,]S/))-(
MT:QB,*SD1A-H"@8H ^6=2_X*(_%/P[\(/%GQXOK?X6_\*?T.?QE;0>%I9+FT
M\47 T!=45&BNF=H)[BXFTJ<M:B!##"Y?S&,+@\)J?_!6KXV>!_A+XZO-0^'M
MKJ7B'3O#6DZYH<^H>"M=\):6M]=:M:Z?+I4IOR7N=INXVCNH" P5R\284-]B
MVO[ 7P?M?BYJ'C8>!=*FU[4S?/.+B2:XL!)?1^5>S)9.YM8YKF,LDTJ1*\JN
MX=F#MG&\._\ !-GX&_#_ ,/ZU;Q^"[5K/5;:QM;I]2U2\O6M[.QN$NK2UADN
M)G:VM(9HUD6")DB!4?+Q3 ^5/BK\9OC9X)^-7QDL?B=KG@GQ1H?AS3_AK&FD
M>';?5=%@@NM1\4RP":&07K2(?+60R@L1-LME.(TD23A_!7QD\1_LI_&+Q-\6
MOB!]E\<ZIJ?C3X@SS2:;JNL6IMK'PYI6ILEM';37LEIM(A,:)Y.U-V\EY,.O
MZ%_$?]C+X;_%KXF7'C#Q#X;CU#7[W3K'2[J8WMQ'%=066H)J-H)84D$4C0W4
M:R([(74%U#;'=3:?]D;X;W-[:W%QX3TNZDLM0U?4XA<!I8_M&JB1=0=D9BK"
M=9I RL"N'(  IWT ^<_$_P"V7\</@=\*+C6/B-)^SW9ZIKUEHUSX?CL=3U+=
M;7%[<^5-:-9HDUSJ31(5:%K58S=.&C$<6-]><^$_VZ/C9\?_ !1\([*.;P]X
M7N]'^.]QX)\5+_PC^JZ3_P )#IL?AR?5486-VRW5KF%B?*FW9EB@<$QDJWTA
M:_\ !*CX'V?A>;2U\+ZM)E]/:SU";Q/JDVJ:*NGN\EC'87KW!N+**W>25HX[
M>2-%,CX'S'.KI/\ P3B^#_AS35M[/P[J-LR>+[;Q_P#;/^$AU%KZ37+>!;=;
MY[EIS,\CPKY<H9RLRNXD#[VR70'A'[$W_!5[Q=^U!\8_ =O?> =2M_!?Q8&H
MS:'<6OA/7K5_#T%O%-<6TM]?W5LEA<K<PPL-UK)A)7C1?.5O,'I_QP_:I^+$
MO[07C/P?\*?#?P]U"U^%FAZ=KOB.7Q7J]QI[ZJ;UKEDL[-XXVC@VP6DK-<SY
MC#NB;,"21.S^%'[!7PK^$'Q.M?&7AO0[R&^L6O9M'MY-:O+O2M!-Z_F7;:=9
M22M;67G$G=]GC3*LRC"L0;GQO_8;^&_[1GC(Z]XHTG4I[ZYL8M+U2.RUJ\T^
MU\0644K2QV>H002I%>VZN\G[JX5UVS3)C;(ZLM /&1_P4#^(*Z_+XTD\'>$T
M^",/Q,/PO>;^U9F\3?:?[:_L$:B(1']G,']J$)Y(;S/L_P"^W9_<UQO@G_@H
MS\?OB7X#^&&I:3\._A1;WWQJ\6W^@>%[>[\07^RQL[*TU.>:\O66VR&<Z>I2
M*(-\LP#,""1]%0?\$]_AA;_&MO'2Z3JPOVUO_A)SI7]N7G]@_P!L;-G]I?V;
MYOV7[7C#>;Y>X2 2?ZSYZW/"/['O@#P#IOP[L]+T:2TM?A7>75_X:3[9,_V&
M:Y@N8)F)9B9-T=U.,/D OD8P,&@'RY\)_P#@L7JGQ+_: T_3T\$R3?#_ %?Q
M9JG@^.XLM*UJ75-,:Q>[A_M*XE-D-/-K+/92+L2YWQ)+$S%F\R./&^/'[>7[
M1'B;_@G?XF^*_AWPCX!\':;XO\!0^,/!.I1^(Y+K4M(2>6S,4%[;O;;6N'M;
MLR!H=\44L9C<D%)&^G?#?_!/?X:^%/C%;^,K"V\1QS6>L7GB*UT5O$5])X?M
M-4NQ*+F^BTUI3;),YGG;<J8#SRN '=F/+Z=_P29^#&GZ'K^DR:9XDO=(UCPY
M=>$;.PN_$E[<6WAG2KF19);32T:0BQC+QPE?*P4%O"BE4C10_= \V^%G[8OB
MKX3_ +8GQ-T?QP8KKPWJ_P 4=*\(37G]IRO8^#KB;P+H^H1) LB "UGO1<)D
M^7^]N8R5W2''K6E_MK:]KO\ P3UN/CIIGP_U36KC4-&G\1^'_#>GM)<7NIZ=
M)*S:?(RI$TBR2VC03R1QQR/'N=%$C*-W&?M7_P#!-2'XP?!OQ'\/O#*V;Z1\
M6_$6C7WQ!UCQ!J]Y<ZFEMIUMI]LMQ9G:Q>]:#3+>/>[H [&8ER"C?0_Q3^!7
MACXQ?!;4/ .L64L/AG4+-+(0:=<R:?):)&5,1@EA97A>)D1D9""I12.E2!\;
MW'_!:>/3?@+I^N/:?#75/$GB#QG_ ,(?I+Z7XFN[C1HV&GF_EN;[_0OM]BT4
M<<L9MI+3S6?RB/W4GFK5\&_\%-_B1\=/CG\'+CPKX7M/^$;NK#QS'XLT2WNI
M'FURZT860A?2Y)K2-IHI#<(T)?R-YN&60(T6#[Y+_P $S?AW<:#>>?J/CNX\
M47FOVWB?_A,'\1W'_"10:A;VK6<$L=T"-J):O+#Y.WRF2:4,C>8^YT?_  3/
M^&[:=X/CGN/&5[<>$;C6;EKZY\17,MYKHU="NHQ7\I;=/%.?+8I\H0PP[-@1
M0'H!B_\ !.3_ (*!WW[;BZ[#JVC^#]!U31+2SO)]/TKQ#+=ZAI;7'FAK+4+&
MZM;6\L[F$Q@%FA,,F[]W(Q1U7PWX<_M7?%[PO^VA\8EO=/M_%FN>*OB0OPW^
M'7AA_&LMMX?TRVLM#CU6[N[A/L1-N1;XE:5%N)9)KEH JI&DC_5G[-W[#OA7
M]FKQM?>);'6/&7BCQ%?:+9^'!JGB?67U2[MM,M9)I8+2.1@#L$D\C%FW.Y(+
M,Q JEX\_X)\^!_&K:I>6]UXG\-^(-0\9-X\M]=T;4S;ZEI6K-I\>G22V[LKJ
ML<EI'Y3PNKQNKON4YX6@'E'A7_@I9X\^(WQ3\(_#[P[\'[&X\>7NH^(-,\66
ME_XM%KI_AE]&FTU)Y4N%M))+F&>+4[>6 ^3&["6,.J98IXU^S/\ MU_M*?$[
MQE\(YY?#?A?Q1K7B3PY\1KN_T5?$@TS2G73/$NFVEG<2SBP+B2&)I;6-4C;S
M/-$KLNY_+^Q?@=^P9X'^ 'C#1?$6C/X@O?$&CVVM0RZCJ>HM=7&K3:O=6EU?
M75TQ \R=Y+&W (VJB+L554*%J_ ?_@GYX+_9X\9V^N:+>>)KRZL(O$%MI\.H
M7ZRP:;;:UJ%OJ-Y;Q*J+B,7-LC1[BS(&<;B", ' _M._MR^))O\ @C3XD_:$
M^&>GQZ;XCO/AN/&.D6NJ2(W]EO):I.=YV.DKP*SD+MV2M&%RJMN'GT__  4%
M^*GP1^/_ ,;9O$W@-?$/@#P;XH\*:;J4]KXCA5?"@U+3-)26WL8VMD>^\NYN
MVN)&E,)*2C9EOD7Z7;]B;P1+^Q!_PS]+'JDWP_;PE_PAC*UWB]:Q^S?9\^<
M/WNSG<%QNYQCBL-O^">OA'4?A_XYT'5M:\8:X_Q&U#1M6U_4[R^A^W7MUI=O
MI\$$N8XE1"ZZ;;M(%0!F:0@*" !6 \IT'_@LOX/UO]K"'X=K;^&_[,O/&]U\
M.[>>+Q7;3>(EU6V>>&2:;1D4RQ6!N;>2!;@R%LF-VC6-P]=A^U7^V3XH_9I_
M:S\/VMYI.EO\(;#X9>*?''BK4C?!;ZU&E2Z=NDB@\IC(8TN-H02*)#=$DKY
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M7Q%8>'(/#2Z?IW]I737VFW&I6MTO^F^0MN]M:SEC)*DD1C82I'AB.#?_ (+
M:7IWQKU.;4]-OM'\ Z=X'M]0ETF\L4B\2P^(Y/$EQH9TMQY_V</Y\(B W^7D
M^9YWE?/78?M ?\$[]0\5_&'0_%W@7QAX@\)ZU>^+=,UG6=5MYK9KC3+?3] U
M7383:QS021R,[WD2RQRJRNCR8V\51UC_ ((Y_#WQ%87_ /:7B3Q=J6N:EI,%
MK/JUT;2:XDU&'79M?756C: P-.=0F9C$T9M_+ B\KR_EIZ 5;O\ X*YZ%K7C
MGX>VNC^&]6AT74_$.MZ)XYN=0N;#?X'_ +-T8ZH6G>&[>&17A:*8/ \Z&(2
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M /#=KXTNI;JY?4X[;#K/=)Y=S.J9\M)ID)6255#R D,QR<WM0_9"^&NK>&?
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M;2?]!@[=J]0KS']BMV?]CGX3M(VYV\&Z.6;U/V&&O3J "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[+6?^3E/V?\ _P .'I'_ ,D4 ?0-%>"1?\%4_P!F&<X7]H[X"N?]GX@:2?\
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MX@\2Z5J&MOI-C'"2@M=-LL2W4LLQ1#AQL7)"N3QTW_!.K]H[7OVNOV'?A?\
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MW5U%<6<<.G.Q1+^/SHU,UFS @7$.^(D</7G*?\%BOAQXZ\8^+-#\#7-EKO\
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M5WXZT75H5B@^+EYXY@TO2_$]QH5Y<Z?=>$[#1C(ETMM((KZ*>UE(C*F-X9Y
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M@_'W_@J%^TO\(]:\%R:5X&^$D>A+HNIK);EM]U:-<%K@B9G=KI9%EB5$Q%'
M5EV2-M.U\:?^"2G@'XU>#_CUHEUKOC#3;/\ :"TK1-'UH6MQ;G^RH=*@$-O]
MDWPL064?/YIDR>5VUVWPE_88TGX,?MI_$KXSZ/XJ\4+=?%C3],MM>\.S&V?2
MY;G3[=+6VNT/D^>DBVZ!-HE$9+NQ4DKL8'YZ_M*?M\_%[5O^"F?QO^%]C^U#
MXD^"^C>%-5T72O"^FZ3\$$\;Q3->:?#*[3720$PD3/P)G&0V0=JG'JW[5?\
MP4+^)/PM^.D&B>&?&E[-;R?M4>"OA??6M[X=L8H['1=1TBUN;NR@E4N\PD>0
MR^?(L<L9E9%PJJ3]F_ O]D+1?@1^T)\8OB)IVJ:Q>ZI\9M2T_4M4M;IHC;V#
M6=FMI&L&U VUD7<V\L<],"O(OB__ ,$DO"_Q=^)J^)YO%GB2RNO^%TZ#\:Y(
M4C@>-[[2=/BL8K$94$6[I"K,22X/0T >9_"K_@KK+X+_ +-\/ZAH_P 1_C1X
MR^('Q/\ ''A+PQ9Z5H>E:3<0#19W;[(0UTL1ACA&!<R.K,L;/(J'BNM\(_\
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MWIUKIEU]CU&6ZM0NZ$6]T/)8$[GD^6,2&N1_99_X)12?LZ^-/#6M-XG\-?\
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MTH Q110 8H(W444 -\M?[M'EKZ4ZB@ *Y&.U-**3TIU% "% 3THV#/3K2T4
M-$:@_=HDB65-I'!&/PIU% &?X9\*Z;X,T"STG2=/L=+TO384MK.SLX%M[>TB
M086..-0%15  "J  !5[RU]*=10 TQ*?X11Y*_P!T4ZB@!HC4#I0(E4_=%.HH
M R?'?@31_B;X/U+P_P"(--L]7T76+=[6\L[J(20W$3##*P/8_F#R.:U(T\M
MOH,9/>G44 -\M<=*/+7&,4ZB@!OEJ!THV 4ZB@!HB51PHI=@QBEHH :(U!SC
MGIFE"@4M% ";!G.*-@Q2T4 )MXQ1L%+10 @7%)Y2AMVT;NF?\_4TZB@!GV=
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MI6T6X&JW6FRV,UR(XGV26\L;;I-D:8R<\ =>>.\(?\$I/V;O#GP&\1?"?2?
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MSUK\Z/B9\'/&&J?\$\O^"A>DP^%_$<FL>-/%7BN70K-;"1KC68Y=%L((9+5
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M\@OB;\7=/\5_LD?&"/Q)\4OBWJ?QXOO!?Q#3QQX$;4[B[T70HX[2^$<=Q82
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MK?7-U##<P3364@AN$20,T#E5<*X!RK%65L'G# ]"*S#\2O#X\16&D_VYH_\
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M+\1E=9O-0CO+2&*WO&TYKMH;$-:174D;;I0)-P*;GRL#].-WS8I-V6Q7YL?
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M[]KI9-/53D^68W(*;QOK)_X)\?M5?$+1OA=^SG\&+5K%;SQAX'\!>(_#U_\
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MSS^UAX=^/_PF\&^*VAN/![?$"!KO1-'UZ]L4U.[B!)5E2WN)D8LFU]J.S(&
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MPP\-+^6E6PKW:O$?^"9_'_!.#]G[C;_Q;;P[P>W_ !*[:O;J "BBB@ HHHH
M9.P"<\;N*_BT_P""Z,_VC_@L!^T2V[=CQM?+G.>C 8_#&*_M,E^X?I7\6?\
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MBM?A_J_CKPSI_C.^,:0Z1->JMPSRH[Q1D=%DD6-VCC8AY C%0P% %*V_8?\
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MH]<U35=%^(VMRZ\VEW2QA-)FGA2.Z2&5%$C1RLGF8<DHS,%., ?/_A__ ()
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MR=\+XSU3PEI2GCTLXJ]$KA?V7H%M?V9_AW&NXK'X8TU1GK@6L0KNJ "BBB@
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M'=$?7-6_:.TGXC+?&>#[5)HUM+8*\[2<$2"&"<>4#NVL0!\Y!^Z@G-.VCTI
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MQHS:+'XNL].^(>CWGB2-[>.2W>P2"Z2YEEC?@Q$NH*X/WP,8S7T>$ [4;0:
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M$\9^+_%NM76M>*X[OQ=/K=W,8+F)/L-QJB:.&F@/E95X)-$LY8220'+[@X(
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M]'F^R16T-N\=W'#?73"27[2N?M):/>J&O1?VQ/V\O$?[/?B[Q+HG@OX=6_Q
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MQE;4+V;Q-XX_MN2#2_$<,WB.VN8!;CSBMU&;1,QQ[8S9PQRQX5GV/]:_#_\
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M=:1IUK:7+:0]W';)&UW!JDJP1NS6[:A')L1O,:/Z+^*'[*?CWXD_\$J_@_\
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MKEQHNBVUY9^'M!DL-.MK?1X;J0/(CSV]M'<W8C"^7#]HE?RXR0=[?..O\?\
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M^G_#/P#:?#?3);"^GNU\86L>JZ'=2W5Q$UJ@LXO(T=@MKFX_>7D@,@5=TBT
M^C/CI_P5 ^$?P0^&?A;QA'KW_";>&/%OBF#PA:ZAX14:Y;17TK[=DKVY8+M
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MVW=X;*Y^L\(H ^O**** "BBB@ H!R*"-PIL:[$Q_(4 -N9=B\<YZ?6OXE?\
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MEUC4M171_ WB*#Q(FDPILL]4O+9)/LGVD%"S1V\Y2Y15*CSK>%CG8!7B]O\
M\$U/BI:C$?[9_P"T5G;@&2U\.2=O?3*/^'='QHAA/E?MJ?'03?WGT+PS(O\
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MUUT!H _MRA.5IU-C&%^M.H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJYNM?\075]9Z&9-&OH+'Q#)8B4WOV&\DA%O=+;^3(LCPR,JLN,Y(SH?M)?\
M!0+X3_LDZVVF^._$EQIM];Z8=<NX;/2+W4WTS31(T1O[L6L,GV:U\Q77SIMB
M$HP!.TX>H'BOQ"_8/\<>)/C]JWB*VDT@:7J'Q>\.>,T87C)<0Z;8^&HM,G8?
M+Q.+A6*+DY7!R.E?/GPR_P""+?Q'G^&%G\.=?NFT^Q\)^ /$/@W3O%-QX\U+
M6(;B74-/;3XIK/2BL<=G$\;>;/%(T@#!4CR0)5_1GXU?M*>!_P!G7X;0^,/&
MGB*QT/PU<7%O:Q7[AYHI9;A@D")Y:L6,C,H7:#DL .HKS_X;?\%-_@?\6_'>
MB>&=!\=6]UKWB"^FTJVLY=.O+5X+^%97>PN3+"HM;W9!,XMIS',RQEE0C!)J
M!Q'[+'PE^+.L?MJWWQ1^(GP]\#_#VS;X;6'@Z&UT37?[4FFNH+^XN),D01!;
M8"4>2O)4%MV"^U?"/C'_ ,$MOB'XI_::\>1Q1^(-<\%_$[XCZ5XZFU1/'SZ7
MI^DPVS:<\D-SIR1>=-<PM8_Z,\4NULQ;S$(B'^Q/A[_P4$^#OQ3^(>H>%M#\
M>:1>:QIT%Y=/O66WM+F&S<)=RVUU(BP720,P$K02.(R?FQ7BVO?\%D/!/B;X
M@ZQI/P\O/#7B33='\&KXKGU75+^YTFVB,FJ6EC"K;[9G\B9+AI8IT5DE\L!<
MJ=P%<"+X=_L/>,?#$GPKNI='T6WO/#O[0?C#XD:U)#<1[O[,U-/$R6\H8#+R
MLNHV"LG+ 9!XCX\'\-_\$R?C->_LEW'@F_\ #6@Z;JVA_ .X^&5D@U>&:VU3
M5+?4_-@D5@,QQ744,<@9US$9-K9*DGZ-^#'_  5!D^.O[7OB3X?Z1H?AFS\-
M>&O'<_P_?4-1UJZMM8O[ZWTBXU&=X+)K(1.BF Q@?:=Y6*:0JJ"/S?6OAK_P
M4&^"OQ?M?%%QX=^)GA+4;/P;8/JVL77VX0VUI8(7#7HEDVI):@QR W$9:(%&
M&_(Q2U ^./C;^P9\8_B3\75^+%OHOB30[RW^(G_"6GPUX>\1Z7!K/V>[\'Z3
MI;O!<7*R67VFSN[>YBPY021/,R2+N4/@^(_^"<GQ/\$_L^>!ET'P%XHF\;6M
MAXN'F:5XQT6\N]%?6=0%Y_9E_#J%M'IE]IL^V)KA88=T4L;"%71V8_:'[+O_
M  4#\$_M@_''QQX7\!7UGX@T?P7H6B:O+K-M,VV2;49=27[*T+(KQ/''8QRY
M;[R7<9  P6WX/VZ_@W<_&2'X>Q_$SP6_C:;4)M)711JD7VS[;$"7M2F?EGPK
M$1G#L%8J" 2*U3N!Y5^TY^SMX^\9_LE?!FS3P[X9\7>*OA=K7AWQ%KOA333%
MINE>(VLH3'<6MH)BL,2QS.+FW27$>ZTA4E,[U\T\ ?L5>./&'QI\,^-=>^'.
MF^&=%U3X]77Q*O/"\][8W;>';%?!D^C17$XB=H'NIK]([@K;M+L:Y5RQ99''
MT_X<_;N^#?C'XA:WX3TKXE^"]0\0^'8+NYU&R@U2-WMH[1MMV20=K>0V!*%)
M,1(#A2:YY/\ @J-^SB]O=3+\</A8T5G-%!,Z^)+4A#+G8V=_,9PW[P?(-C98
M;6PE?H!\>)_P3HU32M%UK3_B38Z#\/OA;_PA?Q2TBXUN;4[*&T\-R:QXW&J:
M1.H$N(]MLD%RA  B:-4;8X"5(="\3?$S_@CWXS\:^*K6SC^,7[7MSIL=A#$X
M=H);[[+8:.D#, VRWM(TOBI"[&-RY"?,1]U_$W]HSX0Z=X^L?A?XP\8> D\2
M>+(TCM?#.K:A;&XU1921&@MY#E_,*L$4CYRI"@X.+7Q;^)VD_#GQSX#T_4K'
M1?L^K7UX(K^\U"UM3HOV?3KF=YHDE(>0^4DB,(?F2-W9L(&HNP,[]I;X,>/_
M (N#0?\ A!?B]KGPG;3;IY=1.FZ%IVJ?VQ$0N(F^V12"+:02&CP3O.<X&/4X
MH]D:AOF*CKZUP7PA_:K^&7[0&L:AI_@7XA>"?&E_I,44]];Z'K=MJ$MI'*,Q
MR.L3L55N<,>"01U!KS_X=_\ !1#PCX\_;Z^(7[.\UGJ6C^,? ]E9ZC:7-WM%
MGXBBFM8;B9;5@<F6W6XA\R,_-MD5QE=Q5 ?0%%>%_"G_ (*&?#/QI^SM\._B
M-XG\3>'OAMI_Q.LTNM%LO%&M6EC<3LW_ "R4O(%D<97A"<;AZBO5+WXK^&=-
MTK6+ZX\1:%;V?A^Y6RU2:6_B2/3IV$;+%,Q;$;E9HB%;!(E0@?,,@'045Q>C
M_M%^ -?^*MWX%L?'7@^^\;:?&TMUX>M]:MI-5MD7[S/;*YE4#(R2O&17*V7[
M;WP[US]H?2OAOHWB#2_$&L:AI.M:M=7&EZC:W5KHHTJ;3XKB"[*R%H9BVHQ%
M5*](I=Q7 R >O45Q/A;]H[X?>-O#5_K6B^._!NL:/I-RMG?7]EK=M<6ME.S*
MJQ2R(Y5'+,JA6()+ 8Y%=LK;A0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !01N%%% #=E.Q110 5\B_\ !=X_\:H_BTIZ20:=&>,\-JMFI_G7
MUU7R)_P7<8C_ ()7?$Y0<&231HQD=VUJP7^M 'UW1110 4444 %%%%  W2OX
MB?\ @I\\C_\ !2W]HAI(RLA^)WB4NK$94_VK<Y''%?VZMV^M?Q$?\%+R)?\
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MX!ZPFAZ/IFD_#[X)WG@/5S:/&K17[W.A2PPJJ\R1C['>L&&5!8]Y.>7^(/\
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M*G^(Q^4-M#Z1NS@G'_']VP!Z98>^&!Z517FY^.FN*F3\+?B)GG(']EG'WO\
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M* /3**\W'[3FBJY0Z'\15;)'_(D:L0<;NXM\?PG'KE?44?\ #47A]6;=I7Q
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M<91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'SK_P %>Y/+_P""4W[21]?AEXB'YZ;<"O9O@W&+?X0^%(QT71[11^$*
M5XA_P6.D\O\ X)1?M&97?N^'>M)CZV<H_K7NWPSBV?#CPZ/[FF6X_P#(2T ;
MM%%% !1110 4A<#N*XK]I?XI7?P._9R\?^-;#3?[9OO!_AS4-;M[#<5^VR6U
MM),L61R-Y0+QSS7S%^S]^S]XHTSP+\(_B]JW[3'C23Q)XG.CWWB'^W;V*;PM
MXG2_$>=.M=-+10V;2/,D=J\!\U7\O<)R65@#[3#9HK\^_P!A3]OOXH:?\/\
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M L$%W&UU$=D;W$>-_P"\^7GV;QK_ ,%E_!^@_L_V'Q(TW2K6Z\,^-?%3^%/
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M8?&J:; 9Y5B1+IIK8F/;*JWD<#O%N902"*+,#Z//@+QVEUN7X@1-'G.R3P_
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M> UQZ_\ %8Z-7U%7RW_P6$^?]CO38]NXR?$KP$H&/^INTB@#ZDHHHH ****
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ME<@JQ:&5%C;*%)%>%&5U(.>+_;V_X*(Z/^Q%K'@;09[7P_>>)/'QOY=/&O\
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MU2/7-:M;.*&_U&.T%HE_<*@$DPA!81AV!;8&(7.,G&:^:?$'_!8/X5Z5X/\
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M@W4HM)T^*_UZ"SUZTNY/#0>'S62],<A$#( V[S-H&QO0T > _##_ ((T:/\
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M9&57F8#]3 JA<<8H**PHYK@?E;XU^#/CO]JWX,^+-%OO@=XZTZ'0_P!E_5/
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M#<><J!#$71C$4D^VOA'^T'X+^.\5X_A'Q%INO+I\-I/=?97):W2[MTN;8N"
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M(^%;.5'Z;J% QQ5:_P!7L]-O+.UN+JVM[C49&BM8Y)522X=49V6,$Y9@BLQ
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M=/\ $E[%J6K6VFZ#:VL.I7,3K)%-,J( [I(JNI;.U@",'FBX'P[^T?\ M?\
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MVJ -\DTLDC'JS.Q.236M2 **** "BBB@ HHHH **** "BBB@ HHHH *^2?\
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M%-[,1F@#^Z5&WC-.H!R** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!VR2^'?LL?\ !3CXE_L]?L-_#?Q+\9/#FDZ_I5W\ 9?B3INH:7K=Q>:YJO\
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MX@Z'H5@EUX;\!OIEFOB&.\$D&K7MW9K?201(%QLAMKBQ?S [!FN2N 8SGAO
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M8GD@MYS$HW-=JUO<L]LORA("1,694.C:?\%E_"&H_M%:QX'M]!>ZL[#6-?\
M#<%W!K%O)J$FHZ-!=2W8FL /-@M6:RN(H[AF;<ZIE$61&8U ^O$UBX_BT^[&
M?]N+CK_M_A^-(VM7&?\ D&WS#)'#0\]?^FGL/S'OCX:\2?\ !73QQKOPOT:^
M\/\ P<O-&\2>)4\%:_HFGZOK]HXU+0M=UNVTYG=H\K;W(\Y4V,6"&XCD);9(
M@^B?VGOVN-2^ ?CGP+X3T7X>ZYX\\3>/+74[JUM;"_MK2&S2PBAEF:>:=E"J
M1,%4J&)?:, '<"S ]=379MG.F:A]"T/'_D2D'B"X^7_B4ZB-Q_OP<=/^FGN?
MR/MGY(^'/_!830_'5IX>N;[X>>+O#]KXVM/"&K^&VNKFSF?4=-\1ZM%I=K<R
M+%(WD/'-*KO$Q+>6002V56Q\?_\ @KSX=^!GB'5-)_X0O7M2O=)\6:AX4::Y
MU73M'TZ2:ST^POGQ>7DT<"RS)J$:00,P>9XIL85&8.S ^LO[;DV9_L^]SC.-
MT6>W^W[_ *'VRBZ[*3SIM^OU,7'&>S_A^->1_LS_ +1GB;XT?'GXT^'=6\,I
MHV@_#W6M.T[1KT744DFH)<:39WS^:BNQ5U:Y!Z!=KJ!DJQKP/X!?\%?FT?X
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M@CRW6-)++_@E+:^%?@!\4/!/A_Q=#ITGC[0M TFRNAH%O#;:3-I%G%!#,;6
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M0\(^ ]!OWL/$T>G6?AB?0(HEF15DLI;F6W66,W%N;>6)S+*X<1@^8?2O%_\
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M.:UN-4U#3+ZPL;<7&C7^HK="[OK<2(R+<2->W3,S*P=IY-P8,P/>YI-WS8H
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M..2YD=DMX3<3E44@9E8G).:PM&_X)X?"_P .> O$WANQT>]ATOQ;X7O/!^I
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M%N,DL<6S=Y:[6RV,9!'4&OD?]A3]HCQ)J?\ P47F\,:AX\U[XD+JESXHCO\
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MQW:Q1%I++QK)<2QWNEHY/RBQ6SD+J1N8:A;-Q@BO(/BQ_P %'?B1X1_:K1M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5I?%.J-)]]KV=F^ID;-/H!_>C&VX?C3LT=*:(\2[L]L8I .HH!R** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***:8P9-W\6,4 .HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"OJQQI\W('[I^O3H:_@Q\43%?%&J?,K?Z9-R.<_O&
MYK^\[5?^0=<9Z>4^3GIP:_@O\0+CQ#J&WE?M4N">2?G:GT _O8!S3=_S[>?K
M1&NP4+'B3=D^E(!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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6>#XT;;H]UC_GVE_] :OX-#Q5= /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex3-3_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_004.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M<?\ QFOU*HI6 _+0_P#!G]^R#G[GQ1QZ?\),/_C-+_Q!_P#[(.#^[^*//?\
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MK_P:<_L6[,'P/XJ/N?%M_P#_ !ROTEHH _-M/^#3S]BL'YO 7BAA[^+M0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR^((U^&M\S:%8_#R^);6D'G+XMDC1!Q"<&U\SGKYN.-G6OJ+]N?]K6Q_8?\
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MMMP#5CQ!_P $IOBUJOQ&TGQ0O[05[-XSTWX-W?P\D\9W.A0OJD^K3:K%J U
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M,NO OCKPU9_V_I_PZL_#B:U93RBV;PI*CYNS%C>)O+7_ %>",GIP:[3XU?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(GXG>%X_@Q\4/["N/^$=7_A'KIM&6TM]/<2ZK8<2P:E.K?NVD=)%SA@X:(9
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M!^TO\:/CYI/C[P-_PI[0_A/=Z+%I]OXANX8]4:"_MI)EFOBLKP0L^(RL:ME
M^UBS=(OVC?\ @J,O@3]M_P"#/PA\!:/9>,+7QGK=O9>+_$".9;'PW#=V-U=6
M$"21MM:[N4M99E4EML,>\KB6-J[>7_@G!X$\6_%3X\:MXVMX/'6@?'XZ(^L^
M'-5LT>PMAI5NL4(4]7+.J2Y;!5D7'3->5>._^#?7]FW7?BOX'\7>&_!Q\$:A
MX.\267B&:'2+^[CM=5%I;-!#;-#YWEPHN(6#1*K?N0O*LP+T X+XJ?\ !87X
MN?LF_%;X@V7Q:^&/@6/2M&\!:]\0=+TCPYXB>[US0[33[A8+--9;8UO&-0+C
MRI(20K*ZE7*MCI-)_P""I_Q;\&_"CX]:7XL^#MEXH^,WP.EL%N-*\%Z@S:+>
M0ZAI)U.WN9)KSRI((8%62*<X=MT68U8R!!!\.?\ @AYJFBZY\;H_&GQ\\6^.
M_"_[0D.I+XPTRY\.Z=;75W+=0^3"Z7^U[B..T4_Z/;JP@CQ@( 2#[#^S]_P3
M<7X2_#'XQ6/B+XA>(/'WC;XX6XM?$?BS4+&UM)WBBTU=,M4CM[=5B40VZ YP
M2[L[,?FP%H!ZG^Q=\;;[]I;]COX3_$?5+.ST_4_B!X-T?Q)=VMIN^SVTUY90
MW#QQ[B6V*TA W$G &237I=<)^R_\#X?V9/V:/AW\-K34)M5M?A[X9TWPU#>R
MQB.2\2RM8K9964$A6<1[B 2 3C)KNZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,T5#)%N<F
M@#E_V?Y5F^!7@ME8,K:%8D$="#;1^E==7$_LUR"7]G?P$R^9M;PYIQ'F$EO^
M/6+J3SFNVH **** "FRRK"FYO7'U-.HH  <BBBB@ HHHH *9.FY/<<C-/HH
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MCPDVJ:DMO90B22Q\,V)>.=9F++=(\I#Y>2^FQP(U3[>_:\_;*^#G[./[2WQ
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MXP?#5O\ _)5&H'ZL45^5:_\ !X3^R>3SI?QB3G&3X9A_^2:%_P"#PK]DUO\
MF&_&!?4'PS#Q_P"3-39@?JI17Y6G_@\%_9)*'=9_%Q<=CX9CR?\ R8J7_B+^
M_9%"JWE_%<#N3X97C_R/0!^IM%?EFW_!X#^R"&^:3XH+@]_#(Y_\C4)_P> _
ML@NO,GQ07USX9''Y34 ?J917Y:'_ (._/V/A_P O'Q./_<L]/_(M/'_!WO\
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M4[6U^OA'5?\ XQ0!^C=%?G./^#JW]B&4_P#)4]87MSX0U;_Y'IR_\'5'[#[
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M\;#_ (.#OV,2,_\ #07@G\KG_P"-5*O_  <!?L9M_P W!^ ^?62?_P"-T<K
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M-]AL]P.0?(7(.0?3U /X"FMX7TULYT^Q.[@_Z.G/Z5?HI<J SQX3TM5VC3;
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MG1;;S!:V@9X]D4SO&7!8/(K29!>CE0'L/P-_X*2^ _V\/^"5GQ@^)7A?P_\
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M)-?LLM_S;7\ 1SGCX>Z1_P#(]1O_ ,$DOV5Y&RW[-?P$ZYX\ :4O\H*^AJ*
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MCEX@\)?!WQSH=W-;7&H_"K0-'O9O$&FVUPZ@(BQ*TAE7>%8+-.T>0Q60+(%
M/V#SFBO%?%_[>?P^^!G[,?AGXG_%_5K;X-Z=X@L+>YDT[Q9.MI?V-S+$)&LC
M%]^2X3Y@4C5F^0G&*O\ P@_;P^#OQ_\ @9K7Q+\%_$3POXF\"^'()KG5M6L+
MP2Q:6D,7G2^>H^>)EC^<JZAMI!QS0!ZW1FOC?XM?\%[/V5?AQ\-]2UJU^-/@
M+6M2A\/SZ_INE0:F$N-5"*_EP+E?DEE=0JHPWX8-M*\U\_?"O_@M[JG[:/\
MP1G^('Q9\*^/OA+\(OC'X5FA?4TUG[5>:1X(@N-<:VLEO0L,\KO<6D3!66(A
MI7#;(UX5V8'ZDT9K\B?^"KG_  7#\8?LK?#/]F_P+\/_ (H?">W^*7Q,MM*O
M/&'BB_M)9]*T.QN;> C4Q$R*4M9I))) S1EA%$1L5B,>W?LB?M:?%CQA^WYX
M$\#>)/C_ /!'QYX=U/X6VWB2[T/0M-N;;6-9N9E$L>J6^;;RELWCDC('V@,0
M<^6,TK,#]"**^>OB;_P5C_9J^#/Q=?P'XJ^.'PTT'Q=#/]EN=-NM<A62QFR
M8[AL[('!/W964BNU_:8_;3^%/[&W@ZRU_P"*7C_PMX%TO4G:*REU6_2)KYP
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MB5$551 %50,  4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX6N)[6T^*2O?^&/#FO2@R3V]_P"64'F1[[$;CL42(A;Y4;%/]C'PG'>?$O\
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MA;"YT^\O8YF19)(&^215:5RJ2*5R%.W*@C[N\$_\$6_V5_AQ\=H?B5H?P-\
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M9_:<^&W[1UM>3?#SX@^"/'D.GL$NI/#FNVNJ):DYP)# [A"<'&[&<&J/BO\
M;$^$?@3XE6_@S7/BE\.=%\87;K'!H5]XELK;4YF;A56W>02L3V 7)KX3\-?
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MX/M_$/AW7-'U[P_>(9;?4].O8[JSG0$@LDL9*, 002#@8-?BLGP(^#?[2/\
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M["YFL[R-O-,_R-+Y>T%OF"MNPKL#]J_^".'_  55M_\ @JI^SMKWB:^\(R^
M?%G@K79O#GB+1'NS=);7$:*X=)"B'8P8C:R@JR.,L &/TKX$^.'@OXI:C?6?
MACQ=X8\27FEL4O8-*U2"\DM&!P1(L;,4.>/FQ7X/^-_B?\,?A+_P:>>+-<_9
M@D\4:6OB[7;&P\?WFH7PGUZPOI[FWCO4NIXU12CH(84*JBO#<J=H9V%.^%O[
M(OB']GS]K;]C'QG\.?AS\%_V=;ZXFL('N;3XQ0WMY\5=$F^R+.GV9X8OM,TB
M3%@4+EVG0<[$92UP/W9\:_'SP+\-M;M-,\1^-/"?A_4K_!MK34M7M[2>XSG&
MQ)'#-G!Z ]*\4_X*:?\ !4+P3_P3)^#_ (>\2^(K677M0\7:Y:Z!HVEVMY#;
MM/)-N)N)'<_N[:-$8O*%< E!CYP1^.?[5G[%'BB__:X_:G^(GAWX>? W]N#X
M<ZSK-S>^)9E\4"+QI\.XU2;?9QN)E-K)"%D11''.2+2,A4(:,+_P4U?X&_M6
M_P#!$_\ 8U^)'@OPGK6AZ-9>/[+P-:Q^(M7FOM0TC32;Q;VP-R[D2P"6V79(
M<8CCC"B, H#0#]_=:^,OA'PQX-A\1ZIXJ\-Z=X?N"!#JEUJ4,-E-G.-LS,$.
M<'H>Q]*Q?BO^T_X)^$/[/OB;XG:AKNGWGA'PKIEQJEU>6%U#.LR0H7,<3;PC
MRL0$1-PW.RCO7Y7_ /!4[X3?!%OVSOV>_P!E[P/\ =2^,7C;PAX;N[_PWX(N
M_&DFA^"]#L)/._TB\$GF-/(OE22$(5<K&BDOE8S\V_\ !.3]GS3]6_9B_P""
MJGPN\9>&?#MKH?@R&+5K?PMH6K7%YHN@:G:PZQ<)]DE9A(RQ3VEORW+?9U5@
M0"*+ ?M3_P $Z/V^?#G_  45_9/T'XK:'9C0;;7/M4CZ3<W\5Q>:9'%=SP1F
MXV<1M(D'F[3P ^ 6QN/K_A3XC>'_ !Y]J_L/7='UK[#(8;C[!>QW/V=QD%7V
M,=K @C!YK^<'QSX3M_V7O^#4#X<^+OAQ8W7AO7OCYXLM=%^)&M:?>RPSZK81
M76M*BS29*QQGRH8#@!664JX8,0?HW]GC]CKQ3^RQ_P %6?V:=>^'OP@^&_[,
MMA>6MSI?B+0X?C19ZY/\0](>-5$Z6C+%)<21;GDW()-[^4P"F/) /VLUKXJ>
M&O#WBJST&^\0:'9Z]J2&2STRXOXH[R[4<9CB+;W&>,J#7S!_P1*_X*6:Q_P5
M:_8SF^*6M^%=-\'W<?B&\T5;&QO'NHV2".%A)N=5(),I&,8^4>M?G#_P2_\
MV2_@M_P4 ^)G[<7Q'_:85=2^(?A7X@:I97.H7^JS07G@/3+;SFCN;5U8&W,+
M1R*DFWY!9JH &5/T1_P9X-N_X)&W#;F;=X\U8Y(QG]U:U('W]^W%^U;HO[#W
M[)'C[XLZ^J3:;X'TB74!;M+Y7VV?B.WMPV#M:6=XHP<'F0<'I7S+_P $/?\
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MXR_;&^,7B+PKK]U,OQ,M-:&@^"?!:1S(S6-L!*'N(X@^,0HGR/$R!1\S^_\
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M:!D9P#1R@?+W[3__  ;[?LL_M;_&[5/B%XJ\ WUOXF\1'.N2Z+KMYI<.N$@
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M/'J^$/ OQ C^(^D02:[YLMMJ21>4(][QD_9CRQC&"7).[+'/W!10!X7\0?\
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M,P4;_*+$L8LXZ*"J )7Z,T4 >,_\$_OV*_#_ /P3N_9*\)_!WPKJFM:UX?\
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M(V>*/]KQ)H@_\G$K]'O#YSH5E\I7]Q'P>WRB@"Y1110 4444 %%%% !1110
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MK6P\'_"6[_9G^"OB7P5=3>,O!^M_$[3?$ @G@BN#;ZY';M<-.H,D$49D"LH
MFRP0D#]#(?\ @C3\ C^P%IO[-.H>$;C7/A9HMU-?:?:ZAJ$SWME<RW$UP9XK
ME661)%>XE"LI'RL5(968&/\ 8F_X(R_ W]@[Q]JOB[PII.O>(/&6L:?_ &1/
MK_BK6)M:OTL?E M8VE.R.+"J"%4$JH4DJ *=P/P/O?V6]0_9I^&NI>//CI\%
M]8^,FAV/B<ZG<_M(_!WXIM?:M#(MR@,GFEYH,JWR9FB@8,57>KX:OZ:OV=_B
M7I/QG_9^\"^,/#]WJ6H:#XL\/V&LZ;=:@H6\N;:YMHYHI)@.!(R.I8#^(FOC
M*X_X-I?V5WUG4(K?1/'5AX.U745U:\\$VGC'4(/#-Q<CG>UHLGU  ?"@[5VK
M@#[Q\-^&K'P;X;T_1])L[73=+TJVCL[.TMHA%!:PQJ$CC1!PJJH"@#@  4F!
M\+?$3_@I[XT&H_#Z:RUSX6_#GP[\1M-\4>(=+U+Q9HM_J7FV&G:AI]II\8CM
M[N$F>ZANY+HD9 4)&$+ N>Z^ O[?GCKXF_#'XCZQXB\(:7X7U;P/\.=*\7)I
ML@N59KNY@U.1TE$H218&^Q0NBLD<JI,PD <87TO]FW]C.Q^!^O:/J%U=-J%[
MX(MM=\/^&)8Y)%6VT/4[^UOOLLT9^5I86M+>%7!_U<(/!=@(?VD?^"?GA+]I
MCQ=J6K:EXA\?>'&\2:,GASQ+:^'=<?3[?Q3IB-,R6MV K-M7[3<J)(6BEVW#
MKO(V[4!\I^-O^"Q'CKP_K>LQVLWPX_M:PN]!LM%\%'P]K%UJ_C&XO]#TS4C;
MVMY#(;>&:22^EAB66(A1;[Y"$8NOLD_[>'CS2?VX+SX>ZY:>"?">C?\ "2P:
M+I&F:_:ZCI^H>);"2")O[2T_5'']G74OFO(!81@S;87!=7&P^M^*?V$_ /BW
MX6?$KP?<6NHP:/\ %"^@U+4A:W;0S:?<P6%A8VTUDZC-O)!'IMG)$RY*2Q!P
M<\#";_@G+X3E^)W]O3>*/B%<:._B.#QA-X3EUD-H$VLPS)<1WQA\OS$?[5&M
MR8HY$@,V7,630!F_#/\ ;5\0^-?A#^SUX@NM%TB.\^,'B:70M4C@DD\NPC33
MM6N_,AR<D[]/C&&R-LC]\&O%=*_X+&ZQXS^!7QN\2>&]%\%ZQKGA.VC\0^ -
M/AUCS(_$FB3:A)IUM-=,K9AF>:WDD8+\J0W=F3RS >V6'_!,+P9INL2R1>*O
MB0NC6IU>;0-"36UCT[PC=:G%<P75UIX6(2I*(KRZ2(2R2I L[B-$&,7O'W_!
M,+X/^-=,T.UL_#<7A./0=(D\/Q?\(\L>GM=:<[6DGV68JA,B+)8VDBY^8- ,
M'!8,P.'C_;Y\6_&S0_$5Q\-;7PSHUUX9\&Q^)-1MO%=C<S7&EW\5UJ-K?Z3<
MQ02Q^7-!+9!-P8C(9AO1D->H?LW>-?BM\6_V1=.\5:O=_#VW\;>+=+M]8T86
M>FW@TJQBN+:&6.*X1K@RRLK-(&9'0$;<*""3I6?[%?@73/C!\3O'%G8W-EKW
MQ>T6TT/Q,UO<&.*[CMDN(XYE4#Y9S'<%&<'E8HN,J2>^^&?@"Q^%/PW\/^%M
M+-PVF>&]-MM+M#.^^4PP1+$FYL#+;4&3@9/:D!\C?"_]MCXV>)?AGH,VH:?\
M+;OQC\1O&NJ>"/"EG9PWUM86+Z5=:JFH7U](\KO)$+;2Y)8XHE5FD=(BZAC*
MGM/[+WQ_\5^.?B1X^^'?Q L-!M_&WP]:PNI+[03*-+UK3K])6M+F..4M)!+O
MM[F.2!FDVF)661U<;7:_^PIX3U;X0V'A.SU+Q-H4FA>);[QAH>NZ=?*FK:'J
MEW>7=W-/#(R-&REKZYB,4L;QO#*T;JZDYWOV>?V8=+_9['B"^CUG7_%GBKQA
M>1WWB#Q)KTT4FHZM)'$(H@PACBABBBC 5(88HXURQ"[G=F- /D/P'_P6BU[Q
M=^ROX-\77G@.PT7QQ>:/JFH^)O#ES>LPT[R/#-WKUA/!(N?,M;R*&(JYSM#R
MH?WL,BK<^$?_  5@\=?$:T\7+X:\/^"?C=>>'_ %SXL4?#PZCML-200&VTF\
M\Z)P)+I997A$3/,RVDW[D_*3[)XV_P""47PJ\>:)X!M;R/7HKCX<^!KSX=Z;
M?VU\(KJZTBYTU].:.Y;9MF=(I)'C8J/+DDD90 [JW4?%7]@'P1\7-06\O+CQ
M)I-\_A-_!EU=:/J;6%Q?V(>*6V:65!O\^UFC\VWE4JT3RS8RLKJ7H!C_ + _
M[76K?M3:9XL75-4^&NM2^')K=%O/"6H7&8S,CL;:^T^[1+NPN8BG*3 B1)$9
M=IWQIYKXJ_X*$_%3X3Z/\;M2\4>#_AS=:1\'X=-M9=2T;7;Y[>35+R6(M;2B
M2T#[;6TN+:YF\E99"+B.*))9=RCW;]GO]DJW^!WC;Q)XLU+QEXL^(7C3Q19V
MFEW>N^(19)<+8VC3O:VJ1V=O;PJB-<SL6\LR.TK%F("A8[_]BWPS=?!KQ%X,
MAU#7K.'Q%XFG\8OJD4\9U"TU5]5&JPW,;-&4/V>Y2'RTD1T\N".-E=000#'_
M &6/VTK'XR?LIZE\3O%$VCZ'I>@WNJVE]?6LDK64D5A=2P-=(DB+/&L@BW"&
M1!(I.WYOE9O.="_X*'>/OB)X+T)=!^&-GI?C?Q!?>+)8]#\1ZLUJMCINA77V
M<O.\,<I6YG,MFOEJ&2)IWR[^5A_2?#/[ WAFQ\,ZEH?B+5]8\=:+XJEO+[Q;
M8>((+.>W\6ZA</9LM[<I' BQR0+91I$D BC52<HS ,.:3_@ECX#\(^"%TGP#
MJGB#X9W4>M:OJRZIX?-M]J$>JL/MUIMGADB\ET6%4.S?&;:!E8%3DT Q_"O_
M  4/U_QI\;/@QI\/A?0]+\#_ !TL(KKPW/>ZI)_;K1OH;ZL;N2V6+R%A1E6U
M,33K,SEG5=@&?=/V8/C--\?O@?HOB>ZT_P#LG4[AKBQU2P#^8MAJ%I<2VEY
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M.\ENJ\(C[I-LLC>6Q4_N_?C\@OV]K#XM:O\ \$#?V4?#_P 3]>M[_P ::?\
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M\V$S3!;F1@87!*+*&#B(*O-_L4?'OX]>%O\ @IMXK_83_:F\8>%?C]X=\>^
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M_P"./^"KWQ(T'X7_  X\2WW@KP+\,K?Q9X8.O3WGC[4=1L-$O[P7$D2Z=#J
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MOJ&I7%ZNU5EEFN+<-A0D865T$87:%_8:3PU>>2\8T3PNR,.5)(#')(R/*/\
ML_F?09)?"=Q+.TK:%X7DE9]S.^=Q[$Y\KKC^5 'XEZI_P6E_8=F\#IX;T/X[
M?M1>$M'DT"7PC=V]EIEM<K>:-YUS);V;B[M9PHMH[R6"*:/;/Y*HLDDA16JU
MXW_X+.?L#>+8]4TW3/BM\?/!W@?Q19:;I_B7P=I&A1#3/$%O8V\-K'%,\UO+
M=1[[2"&VF,$\?FPQ!2<_,?VD'@NX^WQ7#>&_"/G1'*RC_6)G:#M/D_W2_?G"
M^IQ'X8\/Z9J6I:AI=[X9T*UDT]89&$%LDD,GF!CP2B\C:0>/2BX'XWG_ (+1
M?\$WAJLVNIJ'CZ/Q]-XS_P"$X/CE/!T/_"3+=_VC]L^SB\\G=]D\K_0?)Q_Q
MYDQ9S\]6O!W_  6U_P""=O@KQ)\"=<L?%?Q676?@!I)T/0[IM D$FJ6@L)K)
M([\+&%G\M)Y7C90AC>67:5665'_9]/AOX?0<:'HXX"\6,7 &<#[O;)_.HA\*
MO#*HZ_\ ".Z#MDQO']GP_/CIGY><4[@?ES\$/^#FC]AOX&:?XDM]*\;?$.>/
MQ-XBU'Q/=&]\,SN4N+V<S2)'L1<1ACA006 ZL>M8?B/_ (.#/^"?_C>Y^+(U
MSQIX^U/3_C-:6^GZ[8R>';R...&&T^RCR'C19(V*'=OW%E8 J5(%?JY)\&?"
M,I^?POX;;A1SID'\/W?X>W;TJ&7X$>"9Y)&?P?X69ICF1CI-N3)TZ_)ST Y]
M!2T _)?X+?\ !?[]BWX=?%J'QQXH_:!^,WQ.\1:5I$F@:)+XE\*JD>AV<TD4
MD_E1V5E KSS&& 23R!W98%4%06#XOQ,_X+(?\$ZOB[H6I6FK?$GXB1W5W\0$
M^(MKJ5KX=NH+S3+]?($D$+B _P"BSQ0&"6-PV^.>09!V,GZ_-^S[X#DQN\%^
M$6VKL&=&MN%]/N=/:FS?L\> ;@_O/!/A!^=WS:+;'GU^Y2N!^3=Q_P %P_\
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M&J_\,Y_!AU4X 7P]IXP,DCK;CT7\_;ELO_!.7X(*ZR+^SA\&'D0L%_XI^P7
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M[%\APO[0'@W/O%=CU_Z8^W\O6IH_^#@G]C.3=_QD%X&^4$\FX7I_VRK5N?\
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MCV'A;X;>#[WPSJ&CZ%8PA(+*YO=*+W<N\CS'>4Q19+NV!&H& ,5]KT %%%%
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M^-7C;PW="Q\1>#_ >N:YI=R84F%O=6VGSS0OL<,K;9$4[6!!Q@@CBO6JX_\
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M ?\ X9B_9C\#^ 3J6I:O)X5T>WL);N^U";4)II%7+GSIOWC('+! P&U B@*
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M<#VY!_$U]<5\C_L8KG_@J%^V<W_3_P"#EQ]-!0_UH ^N**** "BBB@ HHHH
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M/'Q \,_"?1_'VHV$OQ(O[73(=555\-Z'J-CI<UY]B%I'#)<WVIN)F@#N;2*
M29RLAK<#]#!IFK+)M.N1%MI.W[&N>X!^]V)'Y>]16\&HZE'-]F\06LICDDC8
MI:H_EL"X*G#=5)4$=?DYZ\?"7_!.+QYXN^(_[<=AXJ^)'B#7;?Q3XL^"&FRV
M&F7MM'I\.MVT&OZLG]H"U,8:*X-L=.GEC1@(FU(J4"F,)YC\+_COXN^$GQQ\
M;6GPN\<:QXJ^($WQA\=G4_A)-8VR6CZ8EOJ5U'?8$2W2A[N*R*79F\J1[@VP
M&XC:^4#]1/[+U4!LZNG5C_QZ+P"3@=>PP,]\>]5=(-YJ\4DEKXBL[V.&5X':
M&W1PLD;[9$)#$!E974CJISGIBOB+_@C[^U5\2/C[X^UJU\4?$30/B%HS>$-*
MUF]%MJ*ZE=Z#K$TDJS6\CP:78PV89%R;"8RW$)BR2%?)^>_BG^UAXG^!/PH\
M6:%X1\;>(/ >M3>-?BSXBLC%<Z;I5GK5S;^*;U(81/>6EW+=W"N<I8VD'F2^
M:&>1%VY+:V _6>+2]6"A6UJ-F7 8BS49^[G^+C.&_P"^O:G+I.L",!M8A+;<
M9%D "<=<;O7G%?E7??M6_$#P':>.==T[Q]>Z9KWQ'\9^#+WQ2;[4;'2;/PCH
ME[X*MIO[5@GGL[A+*&XU.U-B9IXYH@5**(Y<RU[%^Q+\=?C!^TI\<_A/I.N?
M%2X_X1FT\,^(?$EU<>'X;*ZA\:1V?B);#3_M%W+81!D:U9O,DLXH$N&"RPLD
M;@4@/NR>TU2VA;S->M(V8[59K-5 +,P7@OR<L@]RO^UQ*NE:RA^;6+<C)_Y<
M<=R1_'V&!^&:_.S_ (*!Z5>:G^W7X^T&R^(^M:3KVO:+\(KC1=+*V5S%IV/'
MMS#+J%O;/"7D^SR+ 269D#WI$@=6A6.C^T)^V=XW^#5[JGPWU+XQ^,+'4-%\
M8ZYINF>(YF\.Z+<:M;6FE:-?1PW=_>6KVWFH^JR!(+6Q>>Y2$'Y1#*9 #](O
M[*UCC_B;V_;/^A=?N_[?LW_?0].:VD::OA"^U#4-3U2U9M2:!&=T%N@=5" <
ML02QZ#Z#FOS>TO\ ;(^.7Q0_9^@^*$?Q*OO#MWX2^&'PX\7W.A6>A6#Z;K6I
M:NTW]J1W7FPO.(F1 J)!+"T3DG+8VUZM_P %=K'PG9_%/X4ZUX\7X0^(?"]K
M8>(+'_A%_B?J<FE^'KJZFCLRFI)<&VN(&O+6..=$@=1*\-Y=-#EHV! /N275
MK6"[AMY+B!+BXW>5$S@/+M&6VCJ<#KCI4Y< =:_&[P;I=JGP@\-P_$Y;.Y_:
M,M?!WPOC^%R:LG_$\C82Q-(-.,@^T;OM/V@7[1'?Y"C[0=@!K[6_X*0?M"ZI
M\+OBCX+\-W7Q9C^!?@S6?#?B#5I?%1@L7;4-6L_L8L]+#WL4L(#Q3W=PT2J)
MIA:;8V4*^6!]=13+,@9&5E89!!R#3B<"OQQ\ _\ !1;Q5\$?AW\!M"\.^/-0
ML8?#/A_X6:1>>'+J+1=/T^\@U6/3%O'\NX\S5-08VUT[":U^SP6SQ$,TK13*
M/?/%G[</QDTS2?C%X67Q1X?\-^)/V?\ 3=;;Q#XD\0:;Y>EW<E[=J?#4\IBA
M<1Q_V:TD\[QH426.,NICWJ2P'Z)4UYTB0LS*JJ,DDX %?('[#G[9UW\0/V/_
M (I>*M8\5:YXCN_A??:C;7.IW]IIFK.OV?3H+S$<VBNMIJ:J)<A[=+>0Y\EX
MXY8W)^+?%O[5WBK]LWX)>//AUK'Q8U+7="UK2OA[K;33+X8NKQQJGB9+&^MW
MAT]9[6.RDB:W<6D[SS*&"R2R1R,KH#]D8ITG0-&RLK $$'((/0TXG%?DKH'[
M3/CC]F'17\ :'\4+JUTF3XC_ ! MM3UV]N?#>GW7AXZ9<6_]F:.C7L<5A!'+
M:S?:_):(2-!$1!Y,(!C^F/V&?C[\7OVLOCII.L:YXUT?1?">A_#[POX@U/PS
MHND136NNZAJ]G>O+(MW,#/%;(T4,L2)ACRK,R]0#ZPOO#%]'XNN=4L=2L;=K
MZT@M&CGLVESY3SN""LB'_EL>/]GWJR=/UPEL:II??'_$OD]\?\M_]W\CZC'Y
MF?'ZY\6>)?\ @H5KWAO3OBIJ6F:Q-^T'X7ATJTN(K:X/AVQ?P)>SO-!;E066
M4K<HAE#P^; 7*.RRACXO_P#!2[XT?#OP[I^CR>)M+M;[P[IGC>[F\4R6VBV%
MIXDN]!\1W>EPQW,=]=0QI MO;PS7B61\\FZ4Q&$#!=@/TT&GZX7);4M+V]L:
M=(/7_IO]/R/KQ')I_B#S%VZKHX7/S!M,E)(RO0_:!CC=V/)![$'P']K#]HOQ
M5X1^%GP4-KXBT7X;R?%3Q!8Z+KOB:XBCNK?PS'+IEW>?N?/Q#YTUQ;PV<3SJ
MR!KI24=BJ'Y'^(W_  5+^+7AK7KNST7QKX5\2V7@CP_8ZI9Z_#9Z5I.C?$.2
M;5K^SDEF^WWL=Q]G"6D, ;2XY";J1I$\R-X('5K@?INUGKP@7_B::1N ^9CI
MLFTGC.!Y_ Z]^,CKCE)+?7C\J:IHJLQ;!;3Y#GAL<>?VRA/J W3(Q^?/BGXR
M_%[XI?$#POXHUCXN6OAOP79?M(7'@:TT73-'AMH_L-C<ZE;HEY=.Y,LD\D4<
M07"IN,6%,F#7C7A"^N/%7Q-\&_$/5F\,WRV/A'X<6^CZ-=:2'L]!?5_'EQ9W
M-Q:N9/,B=HX"2=Q+DJ'+)&J4TNX'ZUO8^(3)(8]2T;:?N9T^7C[W7]_SU3IC
M[K?WAM3['XB#+G4M'Z]/L,@SS_UV],CZX/M7Y_77_!2/QQX>^#>L?$36OC%\
M,]'NO$"ZO8V7@?\ X1634-2\)7EOK4&EV\?[N[C>:6-YXX;G[4T,7VB:$J\$
M88-@_"7]L_XJ?&OXH^!=+\0>-KC1Y/A[\?&\)7Z&PTR"[\2V<G@V[U)+*\2R
MOKBT\_[0985$4I4L;=C&LT)%'*]P/T?-EXDRO^G:+PW(^Q2C</E_Z:\?Q^O5
M?0[EAMO$>%W7FBGN<6LOIV_>>OZ?K\1?\$PO^"A?Q2_:I^+GAFU\:0Z)'H_Q
M \!S^-(+:-M+MYM&FCNK2$6ULEMJ5U<W%N%N6222[A@D2:WZ#S#%%YU\6/VX
M_B?\(]1^(O\ P@=UX0T73])^(/C2ZUMTL8]6U9K;3+72W6Y6QNM2MC-:HURY
MNS:,9D7[.(HAN=BK:V _2*6'Q"N0EQI#<'&8I!S\V/XC_L_D?48;Y?B(,W[W
M1]O.T%)<_P 6,\_[F?\ @7M7RK_P4+@N?VB?#7[,,.E^(K>W\(>-_B5I$^JV
MKV=QY/B"R_LV]OXX77S87$;- K;) ?F\LLO[LHWRO\%OVV?'W@W5-.G\'Z?#
M_P )%\6['P%H,,=M&+^UT'S-)\07TA@AOK^!&FE^QB)!-=C<\JG,K*L+OE3
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MQIN@7>K6\.IZA'EAOAMV<22+E6Y52#M;T-%@/FO_ (?3^"E;;_PIG]J[V/\
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M]KN\OPWH$8D #!=.A&['3/R]J<?A7X9)&?#NA$J-H_XE\/ ]/NT: ?*>I_\
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M@>"_$MUXQ\-QO;7,FE7^D>*],T:]OENMH,EO:0R7T_RE?-A7/EA]H'J_C_\
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MXLU7Q7IFG)H6G0S32ZC:ZA;3)?7JQ?:KYD749O+EEDW *N_S&&ZC0#(\(_\
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MV9M6\)7?_"<76N-X2T_QE80*-%MM/20>(M6L=3D(C@Q'&()+,JB(@4K-T0(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M73M0T&Y&KFTF&J<I-";>;3HDM%8FW:WPR1[5,GJ'_!7WX8WWQA^/?P]T>_\
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M--M$U#4K6VL+O43HML^2D]\UM%(MG$P!8/<&-2JL02 2.._90^%LWP%_;?\
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MWQ;UF.VO=.OM5EL(+CP_IVR\U5)[L13M&D\2161<HQ)U <Y.:^:O"'Q<\9?
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M:*"X34,;_,"6YF(98J\!^&/[2UM\+OV,O@W\/_#OQ6\0Z%>:/X$UW5+V2_\
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M@#ZTHHHH **** #;30F/6G44 &WC&.*:8E(^Z/RKP'_@H]\5O&WPJ^#/A?\
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MOASX'\7>(O#H"Z9J6L:';7MU8*&WA8Y)$+!0YWA<X#@, & -? OCW]IOXG?
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MH 0J".@_*C8,]!^5+10 A7/_ .KI2;!WY_"G44 (5!'U]J38#UP?PIU%  %
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MRHHHH **** #.*,UYKXSUOQ=KOQF;PYX=US1]$M;'18M2F:[T9[]YGDN)(P
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M)X.OM6U*;QGH%QIOB:T\(76BZKX2U*UUR'4[R+SK.'[ 8?M#?:$(\IE0K(2
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MU0W;+):17UP\RJ+592%CC:4JK;_0OA-^Q3;_  Z_8(_X43>>(KC5K.3P[?\
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M>^&\^H?9;3Q?X;;Q!HNH6U]#''<12VZSP.L@:"WDCF20%#$059785C_LT_\
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M?H]A)>VUM'&;%[:^-[93VLL$K1RPW&9([AT<;PLR^]_$O]A3Q-\1/^":NE_
MV7XG7UQXLT[2M'M'\<:OIK:G/<W=A=6MR;J2W>8-)O>V/RO,S88;WD();W;X
ML_%#1_@E\*O$WC3Q%/):>'_".DW6M:G.D32O#:VT+S3,$4%F(1&.T DXP*U=
M URW\3:%9:E:LSVNH01W,#%"I9'4,I(/(.".#R* /B/X_P#_  2C\6_M6R:A
MXN\?^+O ^J_$!-?T+5],LH?#US%X;CMM(@U."*SGC-T;F0SKK&H.TPE4Q-+"
M%1Q!^]Y;6?\ @B;<7_@#PE?JWPND\8>%?$VL:_\ V$NC7MIX8O+?4K6VM)+-
MI(I_MGFQI9VLBWCM([/&ZF(1NJQ_H>TH!V_Q>E(),G_ZQH ^2/V:O^";&H?
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MP^UK%,9V(@U%(I=2BM P1TY1?ECPM?X@?">%I?C+??LZ^"/BMX5\!WGA_P
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MZ_XPL]*TSQ&VK_:9!>^'A;K>!K6$17-O#>.#Y;R1DW3@,VS)^TLYKY<^'/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI&^Z?I2T-R* /D'_ ())1[-5_:H8_>D^/WB0GC_IWT\#] *^OJ^0?^"2)W:A
M^U(W8_'[Q-C\(; ?S!KZ^H **** "BBB@ K'U2_,%_(OE7#8QRJ@CH/>MBL/
M6+UH=1D7YN,=(R>PJH@<3^PY$L'[%?PA1/,V+X)T55$GWP!80=<=Z]2KSK]D
M&(0_LG_#%0BQ[?"6DC8%VA/]"AXP>GTKT6I **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KY,_X)?MN^*?[7W7_ )+O??\
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M110 4444 %%%% !1110 4444 %%%% !12$\TM !1110 4444 %%%% !1110
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M(C\;O6/\*K?M3$?\*OL<C</^$H\.=L_\QRPH ]#GN8K2V::1HXHHE+N[':J
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M:3J&L2:WXG-Q<:>_^BW\J^(=1\V>W!9F,+,=R\MA67D]26 ^I****0!1110
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M\1>.)/%&H?#;P#?>)I8H8'U:X\/6<M\\<.TPH9VC,A6/8FT9PNQ<8P*]!HH
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M^";;QWJGF?:_$$>C6ZZE.9(Q%(S3;-^YXP$9LY90%)(&*]'HH \A\3?\$_\
MX'^-=+\+6.L?"3X=ZM:>";2/3]!BO- MIETFUC8,EO%N0[80RJWE_<W*#C(!
MK:\=_LC?"_XH:CXHO/$?@#PCKEWXVLK73M?FO=+AFDU>"U<O;).Q7+^2[;HR
M>4(4J05&/1** /(]0_8*^"^J?"'3? ,WPQ\&MX-T?4&U:QTE=,C2WM;QBY>Y
M0  B5_-DWOG<XD<,2&(.YX(_95^&_P ,]3\-WGAWP3X<T&;P=:WUCH?V"R2W
M32;>]F6>ZB@5 %1)945F4#&5'2O0** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *#THH/2@#Y&_X)!_-X-^/S9^5_CWXYQ^&JNO\ ,&OK
MFOD;_@C\_F?#_P".[=&/Q[\? ^^-:G'\@*^N: "BBB@ HHHH *\]\<^)([#Q
M3=0M;K(5V?-YF,Y13ZUZ%7DOQ-LIIO'%\RV\$BGR\,Q?)_=KZ*151W WOV68
ME@_9F^':JNQ5\,:8%7.=H%I%Q7>5PW[,P;_AG/X?[E,9_P"$;T[*GM_HL7%=
MS4@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 V7_5M7R+_P2/4B3]I]BN-WQ^\4GIC/RV8_I7UU+S&U?(G_  2*D:6V_:89
ML\_'[Q:!GT#VZ_TH ^O:*** "BBB@#@_%'POUZ[^)-]X@T77-%L1J&G65C+;
MW^BO?8:UFNI4D5EN(L9-T>-I(* @\X%/Q/\ "+Q)XPFL?M_B#PYY,-]87=TU
MOX>DCN+A+2[CNEB$ANFVJ7C[JP&YC@DUZ110!YQ^T]^R[X9_:R^&D?AKQ,VJ
M6OV&_@U?2M5TF[:RU30M0MVWP7MI.N3%,ASS@JRLZ,K(S*> ^%O_  3PT/PM
MK7B;7O&GC+QQ\6/&'BO0;CPI=:[XGN8%FL]'G;=)8VL-I%!;VZ.5C9W2,22/
M%&78[$"]/^V?^T%XT_9G^%%UXM\)_#=?B-::+:W6H:S"/$,.D26%K;P-,TB&
M5&$K$(0$&#G'->/^#/\ @JVNB>$OAAXB^+W@>P^#?ASXLW#?V-JFJ^,+*XM8
M[7^RI-1CFG<!%C:38(EB)W%V^@)J!UW@[_@F;X3\*_"3QQX1G\4^-=<A\??#
MRQ^&>HZAJ-Q;&\72[*+48;=D:.%$\]8]2E4NRG=Y498%MS,M_P#\$W=&;XJW
M6N:3\0/B/X:\/ZQJUAX@UWPOI-];VVGZYJ5DEM'%<RS"'[7$'CM+99HH)XHI
MO)&]#NDW]]KW[;WP;\+?!S1?B)J?Q3^'^G^ _$;B+2O$-SKUM%INI.=WR0SL
MX21OD?(4DC8V<;3COD\;:-)X.'B)=6TUO#YL_P"T1J8N4^QFUV>9Y_G9V>5L
M^;?G;MYSBC4#SOP9^RE:_#7X;V/AGPWXL\5:':VOC2_\:3SVTL'G7\E]J]UJ
MMU92[HBOV5YKN2,JH#^6%&_(+'UBO(_"?[?7P.\>?#[7/%FC?&#X9ZGX7\,S
M0P:QJUOXDM)++2GF(6$3RB39%YA(";R-Y/&:X?P)_P %3_A7\:?B3J_AGX>^
M(/#OC:XT'5]"TR[O+'Q'IPLY8]50O%<6S^<?M"H,*40;W<[$#$&@#Z4HKY]_
M:*_X*4_"_P"!_P ./B?J6D^*?"OCCQ5\*-)FU;6O"6D:]:OJT"1.J.LD09FB
MP[JK%U^4D \D"O1Y?VG_ (<VGQBMOAU<>._!]O\ $*[MUN8O#$FL6ZZO)&4,
M@9;;?YK#8K-POW5)Z#- '=T5P_@K]IGX<_$GXF:UX+\.^/O!FO>,/#BLVJZ'
MI^M6UUJ.FA65&,T".9(PK,JDLHP6 ."17%W?[?OPY\-_M1>(/A/XE\0:+X1\
M1:/%I+6)UK5K6S'B&341<&.&S1Y!)+(AM\, O61 ,YH ]LHKA]0_:9^'.D?%
MZU^'UWX^\&6OCR^C\VW\-S:U;1ZM.N-P*VI?S2"O(PO(!/05N:=\2_#FKV6B
MW-KK^BW5OXE)&D2PWL;QZJ1$\I^SL#B7$<;O\F<*C-T!- &Y17*_"SXZ^"?C
MGIM[>>"?&'A?QA:Z;<-:7<VB:I!J$=M,O6-VB9@KC^Z<&N/^&W[:W@'XC_&7
MQ;\/QKFFZ/XP\*Z])H"Z1J.H6T-]K#QV-K>O/:6XD,LD(CNU!8J"&C?C !(!
MZU17,Z9\:?!^M_$._P#"-EXJ\.7GBS2HEN+W1(-2ADU*SC;!#RVZL9$4[ARR
M@<CUINA_&[P;XGO-?M]-\7>&-1N/";,FN16NJ03/HS*"2+E58F$C:V1)MQM/
MH: .HHK!\&_%+PS\1KG4H?#_ (BT+7IM%N#::A'IU_%=-83#.8I0C'RW&#\K
M8/!XJO<_&;PC8_$*W\(W'BKPW!XLNXO/@T634X5U&:/!.];<MYC+@$Y"XXH
MZ:BN1N_C]X$L+O5+>X\:^$H;C0[47VHQR:Q;J^GVY;8)I@7S'&6^7<V!GC.:
MT-6^*7AG0+/2[B^\1:'8V^N2)#ILMQ?111ZB[KN1869@)"RD$!,Y'(H WJ*Q
M=4^)/AW0]<M=+O=>T6SU*^N/LEM:3WL<=Q<3; _EHA8,S[2&V@$X(.,&N2^,
M'[5/@[X*Z_X=TG5-02YU;Q)KEAH-OI]G)%+=P2WLAC@EEB+AEAW Y?!XZ T
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M%_LXV_V/]GSP+#DMY/A[3TR1UQ;1BNTJ0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ;+_JVKY#_P""07S:1^TDV%&[X_\
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M:]E"C V5^A0\/*$V_:[X]>?-Y[^W;/Z"GC1%VD&XNVSZR?7_ !_047 ^-O\
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MB<3ZE+$T+8+*TDDS#];WT(LJ@7MXNTCD%,_^@T/H#-G_ $^^&1C@I[_[/O\
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M2N!^;OQ=\-W=]\1M4U7QIX=^*&H?LZW7Q2_M#5;"QTG67D?3F\%Z3'I<DEE
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M32R!4\H%>S_X7)XV\7?\$U_BUXA/BW0?'<G@KXH:!_PK._TGQ%=>*1:W0O\
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MO#&0H)W/++&@XZMZ9-'@?XL>&_B0-<_L?5;6^'AK59M$U(J65;2\BV^9"Q8
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M!3&^']DP;]YJ"[@1Q?S\9.?[_P#+IVI>0%;XEVD</PHUZUMXXXXUTJ>*..(
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MZI^W-&Z[O#_[*<J_Q8UO7DQ_Y+'Z9_'V+9?$'[<\>[;X1_96FXXQXGUU,_\
MDD>O3\?;!5P/K:BODBX\1_MS1RGR_!?[*\BXX)\6ZZO_ +8&DD\9_MS1D[?A
MS^R[)R,'_A.=;7CO_P PS_./?A@?7%%?)I\<?MO1?+_PK']F.4X WCXA:T@!
MYR<?V2?8=:(/B%^V\AVR?"C]F>1?5?B1K*?^X<T ?65%?)\?Q+_;82/+_!W]
MG!V]%^)VK+GZ9T8]*E'Q0_;1CZ_!C]G9S@<K\4]4 )_'1*0'U717RNOQ:_;,
M(_Y(?^S^"#U_X6QJ6#_Y0Z<?B[^V0I.?@7\ W&?X?BWJ(X_'0Z8'U-17RS)\
M8_VQH=N/@+\"9,YR%^+M_P ?GH5-'QO_ &Q ^YOV>O@FRDXVCXPW@9>O)/\
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M5/BUX^MII-6UF]FT>VT.6P\0G2?-LVD-NE@;R/2I8R(\[W0@X?%>I7?_  5
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M\,ZN,?\ DK_D4V3_ (+F?LJP[?,^+-G#YG"F31-30'IW-L/44 ?65%?);_\
M!=/]D^/S-WQBTA/+.'W:9J"[3Z']Q_G!I8_^"Z/[)LC[?^%T>'E;&<-9WJ\?
MC#_G\* /K.BOE%/^"Y'[);CGXY>#8^ <2&>,X/3AHP:EA_X+??LES(S#X]>
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MLBTQ_P!^$KIJQ_A['Y/@314SNV6$"Y'?$2UL5(!1110 4444 %%%% 'YA_\
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M%1O',?Q0U'P%XXO+.+3-0UWP#\0Y/#M]K5I&=\=O=FVE"W"IO^4NI=0P 8#
MHU S/^"5>@VOPA^-'[3_ ,*O"'R_"7X;^/K6#PG;1W0GMM$DO='LK_4=,MP"
M1'!!>7$C+$,",SN@ VD5]F5XC^SC;? G]DCX36/@WP'KW@G0/#MH9KU8QKT<
M\MU)*YDFN9II96DFE=B6:61F8]S@"N]'[0_@$[_^*X\(?NR0_P#Q.+?Y2-V<
M_/VVM_WR?2@#L:*Y7_A>W@??*O\ PF7A7="=L@_M:#,9R1@_/QR".>X/I3?^
M%\^!LK_Q6?A/YL;?^)O;\YZ8^?W'YT =917(P_'_ ,!W**T?C;PC(KXVE=8M
MR&SM Q\_^VG_ 'VOJ*%_: \!NQ5?&WA%F4 D#6+?@$ @_?[@@_0T ==17(CX
M_P#@-HF<>-O")1>K?VQ;X'7OO]C^1IY^.W@@;O\ BLO"ORY!_P")M;\8SG^/
MV/Y'TH ZNBN73XW>"Y#\OB[PNW;C58/I_>J0?&/PB6C7_A*O#>Z3[@_M.'Y^
MG3YN?O#\QZT =)17/#XM>%6"X\2^'SOP5QJ,/S9QC'S>X_,>M3K\2O#KIN77
M]%9?47T6/_0J -JBL<?$/0"P7^V](W-P!]MCY_\ 'JD3QSHKL575]+8@;B!=
MQ\#IGK0!J4503Q3IDB,RZC8LJYW$7"8&.N>:?'XCT^525OK-@O!(G4X_6@#D
M=>G"_M+>$XOFW/X9UMQZ8%UI /\ ,?K7=5P.K7\%W^TKX4\F>WD_XIK6^%<,
MW_'UI'H>G//U%=]0!\E_\$5Y/,_8JNV_O?$#QH>O_4R:C7UI7R9_P15D2?\
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M-T2^M=.T?7)XK<^9J>E0R0B]LU <>7]JMXY("V6V+.V 3BO)OB-_P2-\+_\
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M-OWIH#]/K<YC'T'\JDJ.S&+9>_ Y/>I*0!1110 4444 %%%% !1110 4444
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M"HHHH **** "BBB@ HHHH **** "BC-&: "BC<!WI"X'<4 +12;AZBC>/44
M+12!U/<?G1N![B@!:*-PHW4 %%&ZDWCU% "T49I"WN.M "T4;J-PH **-U&[
MF@ HHS1F@ KB?B%/Y?Q5^'\9(_>7EY@$]2+*7_Z]=M7&^.D#_%+P.3MRMQ>$
M''/_ ![./Z_I0!V0.11110 444;J "BC-&<4 %%&ZC.: "BC-&Z@ HHS1NH
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M5ASC_/ZUW5 'R/\ \$+B'_X)A^ V'\6J^)&_/Q#J1KZXKY'_ ."%PQ_P2_\
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MEWX:U:SEEU?QT=25)#]FN5G1;7>9!:VW[F?S+F&4-QA57+J V+_@BII:*O\
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M1GYO[>BYX..-G?"C\?;GN=@]!^5+M'I0!PK_ !!\91D_\4!(WILUNV]#ZX]
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MEI,-C!#/</$(XG>5G#NB*=OS,C,<!A0!] 45^>?A[_@J!\0/#G[)ESXP\+^
M]'\2:;\./ &F>,/$<GB?QE+%J.H"^-YLAMI1:,LAC2VWM-+L$C-Y2J&5F6Y\
M//VX_C1X-7Q%8ZGHOAO7-'\3?$?X@^$O".MWNN2"_M+G33K-[9+<6J6NP6:I
MILEO\LK2 (C88-M!8#] **^8_ O[6GC3P9_P3D^$/CSQ%I.F>*/B1XZT_P ,
MZ>+5+_[%8WVIZJ]K LLLXM\01[I_-?9"=N&2-7)0-YAXF_X*1?$+1_%&N07W
MPW#>+/AW<>*;&Y\/:%XK6ZL/$SZ9HFE:HA1WL/-WS+?%8H\(4=?GW[B% /NN
MBOB3XH?\%B(;3Q=8Z7\/_!:^-;7Q%J-Q:^'];2?49M.U*VM-.L[R^NRNGZ?>
M3B..74+2T79$X,WVC>T?DX:#6_\ @K5XPF\(0^*-#^"^?#.A^ ]"\?\ BT:_
MXBFT?5](M]1O=0M9+6WLVL7-Q/!_9TT@,KP+*I7!4L,NS ^XJ*^9OVZOVLO$
MW[+_ ,;?@U]CCTMO FJ/XBU#QI)-*5NEL=.T:>]'D+Y3[F!C9\!HRS1HA8*[
M$:_[,7[8OBCXO_$;3?#/C;X>VW@6^\3^%$\;>'C9Z^-92YT_S(8Y8;H^1"+>
M[B:YMMT:>=$PE.R9]C4@/H*AC@44V4XB;Z&@#Y0_X(9H4_X)2?!TG.9-.NI#
MGONO[EL_CFOK&ODW_@A@_F?\$F/@BP &[1)#Q_U]3U]94/< HHHH ,\T444
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M>'](M[E[TZ=$VJ6.GW3W$46+@IO6.1[:Y4*&P?*?BO@W]F3_ ()Z:A\0]>\
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MS$# :578@L2:^"?#>@_M(I^TUXZ73;SXA6?Q'EN_&\B23^']9D\-SV1@O_\
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M%Q\0/!_B+PWXCN--L/[/,D^N:G/?WEQ;!I)#"B&<QQQL7(6)"S,V2?/?#_\
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MJ2?\$R?[+T?5;#3O$EI;65Y\4_"?Q!MH_P"SMOV:VT.RT6T%CA7 S(ND$JX
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M2_V"_ .C_LDGX+P1:K'X1WM=+-'=^5J$5ZU]_: ODF0*([A;W_2$**$1PNU
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ME_P4L^),<IL/,7^R\^8ZAO\ D%69YH5^@'[T"BBB@ HHHH **** "BB@C(H
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M#X,?\%D"=O\ PM_X&_<+9-C8\D'H/^)?U/Y8J/\ X5!_P62$VW_A;'P,V?\
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M]P/UX+X-('S7Y"_\-(?\%BH7S_PH/]G^5<9XO;?'_IX!J9?VF?\ @L,B;O\
MAGO]GEN,X-]#_36OY?SHN!^NN[V-&[ZU^1$G[4O_  6*MYE4?LW_ +/LW&,K
M?P;3GO\ \AP&FG]KK_@L-&C'_AF'X L%X(6_A_3_ (GO-%T!^O5%?D"/VU_^
M"P-NFY_V3?@A)A<G9J,&3CV_M[WZ4X_MQ_\ !7F%=S?LC?!EQQD+J=OW]/\
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M1]-OO$&A6^C6]W#8V_B.;3AIOG>=,[BYE@B^TK$5C<CAKWQ6_P""M?Q=\:_
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M-/"?[&$GB^+58TNXKRYC_M#2Q;6DQ-PZ/&BRHUQ.4\UVAD=2@)CK]$/V1O\
M@EI\%_V0_AM;Z1I'P_\  ]QKU]X4M/"?B/6UT&"";Q/;Q6R0S>>GS )<%3)+
M&"5D9LOO/S5V'PI_8,^#/P0TVRL?"OPW\)Z1:Z?H-WX7@ACLQ(JZ5=7'VFYL
MB'W;H)9OG9&R"?;BJN!^?_Q3_P""I_[0W[(?AGXIZ-XQ\3?!/XE^(M,^"LGQ
M>T#6_"^GS066F2K?VUI]AGA^T/\ :+>3[2'@N \;.(GRIZCJ/$/_  4Z^.'[
M.VJ?';0?BEX@^#EKJWAOX:^'_'_AK5X="U-=*T>XU2\DL/[.N889)[F\Q<B-
M(FB"O(2,JHDVQ_77@#_@F!^SS\*OAKXR\'^'/A#X%T;PW\0(A;^([&UTY435
MHADK%*WWC&A)*H"%0D[0,FKGC3]EOX%?M&>+?'VCZ[X/\)>*M7O-!L/"OBJW
MN(/.<Z<K-=V=I+V7:S><@&'4F-\CY#4W _*?XY_MY_%;]IGP)HO@GXGQ&P\1
M_"W]IKX=:7'?Q:')X;N]2M+Z-KH"ZL?M-QY+CYCM\S.QH]R(X8#] O\ @H5X
MSA\/?M[_ +&.FR:/I^HOK7C+6XTN9[F[BET\QZ'<OYD2PS)$Y.,$3I*H!X4-
M\U=9X)_X)S_LPZ-K%YX0T+X;^$;'4/#NKZ+XRN["V$L4ZWUKYXTW492&#2L"
M+D"1RP=ED#%BIQT'Q<^)OP!\3_$[P'K7B[6O"-YXJ\)>,+CPUX4EGN2UU::_
M-;&&>TA13EIO(EPP((56#'&,BN;6Z ^*OV/?^"I_[3'Q[U/]G'4M<L_@[:>'
M_P!H_P#X2W1]+AMM,OOM.BWNDV]Y+;7D[&YQ)'(]L5>% I"#B3<WR^"?\$A/
MV@_C9X!_9@^ OASP7>?#NX^*W[76M^+?$U[XR\7OJE\L=IHTQ2036YN0)[R1
MG94%N88T@C4LCL&D/ZX> OV)/A+\,;#X>VN@>"=%TNW^$]Q?77A*.$OC0I;U
M94NFBRQYE6>4-NS]\XQQ7,>*?^"7/[/OC3]G?PU\*=2^&'AVX\ >#9Y+G0=+
M5IHO['DD>221K>9'$T9=I9"VUQN#$'(XHY@/CCP1_P %<?VBOVFO%GP$\#_#
MGPY\&]%\9?$:'Q=:>*+[6A?ZCHVGW7AZ^CM9KJQ:"5'FMIR'\M6R09%R^$)?
M)O?^"O7[46N>-;"Z\.^%_@2WA'Q-\<]6^!NAI?IJD=_'<PFX-MJ5PR3,AB1;
M=_,B0!I"AVM&'!3]"O ?[%WPH^%^O^!M2\-^!]!T.\^&FD7.@^&#8QF!-'LK
MDH9XHT4A/WC1JS,P+$Y.<L2:&G?L$?![2;?28;;P1ID,>@^-IOB-8JL\V+?Q
M!,)1)J'W^9&\Z7Y6R@W<*,#$@?$VI_\ !6GXZW7[.7A-+.P^$UO\8I?'/BSP
M=J^GV^A:[KHUDZ#<20O-I6F66Z=HF?R1--/<1QVXD#'=N 7S[X+_ /!0/XX?
MM=_MD_#/Q-]N\+Z1\/?%G[+NI>.]:\*B2^CA65KR."XE@:.53]J^TI;K%(Y/
ME6S3J/WC[S][_$'_ ()8_ #XHV>GPZY\/;&Z73=<U?Q';R)J5Y!,M[JTGF:F
MQDCF5VCN6(\R%B8F 4%,  .TS_@EQ\ ]"O\ X?W%C\/[&QE^%NFWVC>&C;ZC
M>1C3[&\\S[1:D"7]]"WFR8CEWJN[Y0O%.X'PW^S+_P %,/C5XE^!OPM\ ?!G
MPO\ #.+5?"WP,T[XI>)[SQYJVISPW=O-O6*QLY/-:8R'RG+W5Q)(JE@""1SO
M?$[_ (+2_'+QOX<UCQ)\(_A_\-;?PWH/P'TCXVWR^+[B]^V1I=?:WET^,0%%
MD9H[<^7(=B_+N.X2*%^H?CM_P2I_9?\ $_PK\-1^-/ .CVGAGX5>'FT>QN?[
M7O-/%AHL0#O:7,\<R//9A5+-'<,\>"Y(^9B?1M9_8+^$?B!_%CR>"]/A7QUX
M.M_ &L0VTTMO;SZ% LZPV4<4;B.%$6XE4&)5;!49PJX- /"O^"E?[4$FI_\
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M8--::9#,2MO')M0,?F<JBJ&"Y4\]\+_^"&O[//P>D^&?]A^%;RWC^$_C*_\
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M%\*D3]D/]LZ,_P#)YW@^0<<-\#;7GUZ:F* /LRBOCN/]E']LM/\ F\#P&_\
MO? Z'^FK5-#^RW^V1$%W?M<?#Z3'][X'IS^6KB@#Z^HKY)C_ &:OVQ8=W_&5
M7PSEW$8W_!(C;^6L_P Z<?V=/VQH$RO[4'PJF8D9#_!:1<<\XQK/;]: /K2B
MODU/@/\ ME1W*C_AH[X-21+SN;X.W(9O8@:UC\C43_!?]M1,[?C]\"7[ M\)
MKX?RUBE= ?6]%?(<WPB_;>#+Y?QP_9\9<_Q?"[45R.W_ #%CU[^E1O\ "S]N
MA)OD^,G[-\D?."_PVU16[8X&J?7OV'7/#N@/L"BOCZ/X9?MUC&[XO?LT]?\
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MG9P?IGCI0W[8_P"VHM^L/_#%/A-HV7)G'QTLO+4YZ$?V;NSWX7%/F ^>;O\
M90^-'P\'C+0_A[X7^(/AUVUGXK:E?2Z9J!LTU@:GKFDWNF/:3M+L%Q-I9N8+
M>4[?)N%ESL8,QZ;1/V9/%7Q(^,7AZS\+^%?C)X5_9\U3XE:---H&L:GJ%A=)
M!!X<\0#4IWB>;[3!IL]W)H\1BD95EGBE;RRLF^3U:?\ ;5_;8AD7;^PUX=EW
MC)*_'73L)['-@#^6:;)^VW^VO')M_P"&%]'?CED^.FE[>O;-D#^8%&H'S#^T
MO\%_CTWP.L/!NG^$_B=<7N@Z/XZL_"&JJFKZQ>)<+XCOET2%3!J%M%9S1Z=%
MI\D6H7[3!HF"JI;S$D^IOV6O"?C3X:_ 3]K;7O$NG:QX=U7Q)XDO/$5A<W<!
MM9+H?\(=HD3728P0!=6]PN5QAXG'!%1Q_MM?MI*5$G[#.D[B<9C^..E,J_7-
MF#[\"C5?VQOVP=9M+JPOOV%-+OK&Z1X)XI/C1H\D5Q&RX961K;#*P)!##!'7
MB@#YG^$%M\0M5_97_P"$F^'?A'X^7'AO6OA=X;A\4Q>)-6UN2\US6Y]0LGFU
M&T6.9KVX6&P-[)<_V>R?:HY888F#K^[V/@;H/CKPY<:3I/Q0M_C5J?P[C\3>
M))](T/1)=8T#5)@=/T"73KN*TFU"34UTR*2354'G7)2VN+J$S)" H@^@-$_:
M_P#VM?"^CVNFZ?\ L(V=CINGQ);6EK9_&'0XX;>)%"HB((55451@*, !0 ,5
MR_QF^)WQX_:.TZSLOB%_P3DT'QM9Z7.T]E%K7Q,\-:@EO(R[69!*AV[E)5L?
M>4D$$'%&H'S1\.;+]H;Q_P###X2^(CK?Q?O+S5/AUX&O_ NHZ;H^KZVQO7C#
MZBUU-#?VVG1S/(P:=]65HY;=@%8@-'7KWQ2\)^(/$7P1\3PVMSX^MO$6G_'O
MQ7<^)QH6BZKK%M=JWVK^RX]5@T:ZM]5$!TR323!);%_+>.T,BF+)'M.G?MG_
M +5^DZ?%;P_L*WEO;VJ+%#!;_%SP^%C4<!57Y5 48&!P.U5-)_:S_:8T37]4
MU:U_8'U:UU37#$VHW,'Q3\-+)>F)-D;2-Y@W%4^4$\@*!T H E_9=U+Q1J?[
M7?P CUK2M:T7Q-9_ *^?QO9:IJ3:G>V<TFH:,NGQWEPRJ\LYDAU0H\H#-LNL
M@-OKB_!'P*\>?$/_ (*5>"?%7B[2_B5<:;X/\?>/Y=+OY[G4;>PT_3Y+32EL
M1\KK$;>5A.L8;*2;9% 8 @=EIO[7/[2FC^(]2UJ']@;7H=8UA(8KZ\M_BAX7
M,]U'"&$*.[3J65/,DVJ>%+N1RQS<'_!0#]IR"3;-^PK\0E;//E?$?PQ(,?47
M5(#D_P!J#P5\6+_X[?&KQ9H-Y\7I)O".M^ F\#Z?IE]J4>D/')=6ZZNR6D3"
M"\C,#RB<2)*D:ACA&W-7D_AN_P#VG4^/?C)=*U;XB/\ $<S>.U;3[G1]8;P_
M);B'43X=Q/=R#1H80XTLPR62-.Y,JS*2;AD^@Y/^"@_[1MO*5?\ 87^*&Z/&
M=GCOPTXR?0B[P>_3IWZTV/\ X*0?'YF*I^PW\8OE!)W>*_#JCC.<$WF#TXQU
M[4]0/GSQYXA\96'PB\-_\*[U+]J*/PG#K>ACXDW_ (S/B$O;'^S=2^TQV[1@
M:U%_IRZ>;UK(K:H'C$15/M0'.^-/''QPT7X8_"74+SQ!\=_$>O+H^H-INDQZ
M7XAT"3Q)MUN?['MN[82@:E]BCMU$>N6IAFMV664V[&Y9/J3_ (>6_'&(,9?V
M'_CDKQKN;R]?\/R#;UX/VWD\]!S0W_!3GXRVR[I?V(_C^JD%OW6J:#(>!D\"
M^Z^W?M0!X?XR^+7Q<^'7[3'QS;38_CIXVC?1_%<UO::?_:NG77ALJBO8)'!/
M#=Z1)'M3%E=:?BY<.?-MKB02^7D_ 8?&;XV>)E\(OXL^,ND> =>^(.@2#5=*
MN?$2M'IDFA:S)?Q6VJ:M&M\UJ]U:6B/-B-4DD!B6%G1C]$)_P4Z^,CL?^,(_
MV@.%#C_B9Z#W_P"W[KUXZ]/6I+7_ (*;_%ZY'F?\,3_M"*%)3YK_ $!6STZ&
M_''OT[T 9?P2U+QWKG[8'CCX/^,-9UC4_AQ\'AJNOZIJFJS>:OBG3==C+Z58
M7,CDF:.S1M9BD5@,"ST]B6+-7LG_  2NO-8U#_@F_P#!&;7&E>\D\&Z:T339
M\YK7R$^RF7//FFW\DOGG>6S7SQI?[0^L>'O#/CK0X/V!?CO#IOQ)NKN]\4QI
M?Z#)_;<ES&(YS*_]IEF#1@1[00JI\J@ 8KO;'_@I9\2--ABM8?V+?VBK:"W1
M8T2+^P!'$H& J@:AC   P.!2 ^R**^/%_P""GWQ& ;S/V-_VE$VG#;8]#?TZ
M8U#GKVI?^'I'CQ4+/^QY^TZNW[V+#1F(X&, :AS^'I2U ^PJ*^.C_P %5?&"
M<M^Q_P#M3[<?PZ-I;'CKP+_V_&GQ?\%7?$98AOV2/VL%V_>_XIK3CCZ?Z=S^
M% 'V%17Q^?\ @K#K$7,O[)O[7"]#\GA&QDX_"^_2D?\ X*YW4:%F_94_; X&
M2!X"MV_E>4 ?8-%?'O\ P]VN.?\ C%;]L+Y>O_% 0<?^3G/X9I?^'O#*NYOV
M7?VP%!.!_P 6[1L_E=']: /L&BOCM?\ @L+;[FW?LS?M?QA1DD_#1R!^4YZ^
MU#?\%CM-B0-)^SC^UY&&.!GX6W+9/T60T: ?8E%?'4G_  69\/PP^8_P!_:W
M5??X2ZB3^@I&_P""T?A.- S? _\ :R52,Y_X4]JYX_".G8#[&HKXZ3_@M-X+
MQ^\^#7[5D..I?X.:V=OUQ":?'_P6E^'X91)\+?VH(6) *O\ !O7\KGUQ;G]*
M0'V%17R/'_P6=^&I'[SX?_M(V\G\4<GP:\2;E^N+0BG?\/H/A.Q4?\(I^T$N
MX9'_ !9SQ-R/7_CRZ4 ?6U%?)<7_  6=^#\B*S:'\=XMWW=WP<\4\_3%@:<O
M_!:'X)\[K7XU1[25.[X/>*^".H_Y!U 'UE17R2?^"V_P!CC9Y+KXLQQH,LS?
M"/Q8%7OR?[.] 3^!JO<?\%T?V<;9-TVN_$J%>?O_  H\5KC'7_F&T ?7U%?&
M\7_!?/\ 9<ECW?\ ":>,E5>"6^&?BE0,?73J5?\ @OE^RO(S#_A8'B3*\,/^
M%?>) 5/N/L'% 'V/17QO'_P7W_9/D;;_ ,+.OE;H5?P;KRL/P-EFAO\ @X _
M9'C56?XNPQ!NGF>&]8CSV[V@HU ^R**^.1_P7^_9#;_FLVF+@X^?1M37'US;
M<=OSIJ?\' /['K_\UR\.KSC#6-^O\X/\X-*X'V117QXO_!?K]CM_^:]>#U/3
M:R72L/P,.:E3_@O=^QV__-P'@1?]^:9,=N\=,#Z^KD_CS/\ 9O@=XRDX'EZ%
M?-D].+=SS7SHO_!=[]CYFQ_PT)\.UXS\U\R_S6N:^.'_  6__9,\2_ _QE9Z
M;\?OAO=7]UH-_';0)J?SS2&VD"J!MZDD >YIV8'K/_!)4;?^"5_[-7_9+/#/
M_IJMJ^@Z\#_X)36[6G_!+S]F^)L[H_A=X94Y[8TJVKWRD 4444 %%%% !7\]
M_P#P7#2Z/_!47XH>6JE/^)5C,F/^839>U?T(5_.]_P %TKV2'_@JA\4E6-F
M_LGG<?\ H$655$#^B&BBBI **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ()8Q>3_ ,$QOV<U(QM^&/AH8!S_ ,PJVKWB@ HHHH **** "OYT_P#@NWH
MO?\ @JM\5)/WGS?V3TQC_D#V0]*_HLK^>'_@N>TP_P""IWQ2VS;5_P")3@>:
M%Q_Q*++M0M0/Z'J*16W"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\X_;#./V2_BAG_H4=6Z?]>4U>CUY?^VV2/V-
M?BUMX;_A"]9P?3_09J .<_X)@)Y7_!-/]GE?F.WX9^&QD]?^07;5[G7B?_!-
M)%C_ ."<G[/ZK]U?AOX= _\ !9;5[90 4444 %%%% !7\['_  77E=?^"J?Q
M2PW'_$I_A_ZA%E7]$]?SM_\ !=2^:'_@JC\4EV*<?V3R;97_ .819=R,U40/
MZ(8VV_*!3Z:@*'UR?RIU2 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y;^W#)Y7[%OQ>;^[X*UD_^2$]>I5Y/^WI/]G_
M &'/C,_3;X%UQLDXQC3YZ ,__@F_#]F_X)X? 6/H8_AUX>7 &.FF6XKVBO'_
M /@GI MK^P)\#HU^['\/]!4?0:=;BO8* "BBB@ HHHH *_G)_P""\:9_X*N_
M%7_CZ_YA'W-NW_D#V/K7]&U?S@_\%ZFG'_!6'XK;(8W7_B48);&?^)/8T(#^
MCZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ2R<5_-;_P %^Y67_@K=\6<*Q'_$GZ*3_P P:Q]Z /Z4$;<M.IL8 !V^M.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\7_ ."D#>7_ ,$\OCPW/R_#KQ">/^P9<5[17B/_  4M;9_P3H^/A.?^2<>(
MCQU_Y!=S0!O?L0+M_8M^$(_ZDK1O_2&&O4*\S_8J5D_8W^$JL-K+X,T<$>A^
MPPUZ90 4444 %%%%  WW:_FG_P""_P#/$/\ @KC\6MW7_B3Y^9A_S!K'T%?T
ML5_-#_P<!/M_X*Y_%O\ <,W.C\B%CG_B36/<+0!_2]11G-(K;EZ8H 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#O\
M@ITYC_X)L_M",/X?AIXD/_E+N:]QKPS_ (*?-L_X)J?M#,1P/AGXD)_\%5S0
M!UG['2"/]D;X6*OW5\(:2!G_ *\H:]'KSO\ 9"B:']DWX7HZE77PCI2L#V(L
MXJ]$H **** "BBB@ K^9+_@X*A5_^"O7Q>/F3+\VD<#_ + UC[5_3;7\R/\
MP<&W.S_@KW\7AY4C<Z/R&7G_ (DUA[4 ?TV*_.,4ZF1H V[[S=,T^@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %> _\%66V_P#!,+]HC_LFOB$?^4VXKWZOGS_@K+_RB]_:(P,_\6XU_@_]
M@^>@#T[]FU=G[._@)2<D>'-.&?7_ $6.NUKD?V?T\OX$>"5 QMT"P&/3_1XZ
MZZ@ HHHH ****  \U_,/_P '"-O&W_!8#XOEF?.[2.D2G_F#6%?T\-RM?RV_
M\'#L<S?\%BOC(1C'F:3CY6_Z UCZ4 ?U(JVX4M(K;ES2T %%%% !1110 444
M$X% !11FC-%P"BC=1NH **3?Q2>8/?\ *@!U%-$H-'FCWI70#J*;Y@H\P4[@
M.HIOF#W_ "H\T>] #J*;Y@]Z/,% #J*;YHI=U "T4FZC=1<!:*-U&Z@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MFONXVX]\TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG?\
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MP3#\;].(7Z[K%3^0[T]?VT?VQ AW?L3Z=N SA?C3I1SST&;4?7GM[\5]H44
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M&6#>U44 ?*>B_P#!+6#X=>#O#$/@CXM?$;PMXM\)WOB*:U\4E-.O[ZZM]=U
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MT-;O3V75H/(MQ%<37MX9F6\EGD DW+##L^8'?G<.ZHH **** "BBB@ HHHH
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MGB+2V>XT*.V^%.H1SSZ)I%]!!IVF7,<D=Q']JMTX@</%&Q(\MG50CET^6A6
MQOV)?^"BUQ^V3XX\3:6? >I^$=/T^SDU+1]1O)YF^W6Z7UQ9D3QRV\ BF#P;
MBL#W$8!93,'1EJE^SA^U-XBL/A9\6O'GB3Q6OQ0\ ^!]-;4K'7-*T:*Q.L7-
MI!<R:I'IT4;GSK!7BBCMI'9G=Q./-F54E;W>QT'X=_"BY\3:U#9>"_#4VK7"
MMXBOT@MK%KR=AN4W<F%+NPE)'F$DB3/\7-/X>>!_A7\#-)FD\*Z+\/\ P;8Z
MU]E:9M)L[33X;_S,QVQ8QA1)OR5CSG=R%S0!X-X _;,^)GQH_:>\$^"E\.>'
M?"-K8W-W>>+_ +%XB365N;8:59W=I%;3_9%5]S7Z><N(G3RD9'>.16?J?A+\
M7/B!XC_;A\5^'!XFTGQ9X&T>UNO[8CM-(%K!X1O/,MSIUA'=;V>[O)+=IYKI
M2"L7[C B#JLOK'P\^'7PV^"\<FC>$]!\$^%%T:-[R2QTFQMK'[ DV-\K1QJO
MEK((%RQ #>4.3M&*G@OX0_"CPC\0&\8>'O#/P^TWQ1XP,LO]M:?IUI#?ZV9
M)I6\]%#S[PH=B&;.T$YQFF!Z+1112 **** "BBB@!&^Z?I7\G_\ P<9(Q_X+
M._&S][$O^D:5QGI_Q)[&OZP&^Z?I7\HW_!Q<!_P^:^-7[N%O](TKDDY_Y ]C
M0!_5U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 (_*FOY+/^#CN\$?\ P6E^-R_O.+K2^F?^@/8U_6F_W37\
MF7_!QO+(/^"T7QNP8?\ CZTOJTF?^0/8^G% ']9P.:*:AX^]NIU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex3-3_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_005.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M[ZHH ^!Q_P &P7[#(!_XL:O/_4X:_P#_ "=3?^(8#]AC.?\ A1J_^%AK^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &L&SG/;I7\Z'_!=S6-
M6M?^"K'Q4CM[/5)85.D[7BFA53_Q*++H&0G\S7]&)Z5^!/\ P6LT*]OO^"FG
MQ*EBNK>*-O[+PK Y'_$JLQZ4T#/WU5=HI:**0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %(S;!S2T4 %1R6^^97W,-HQM_A/3K^7ZFI** "BBB@ H
MHHH **** "BBB@ HHHH **** "OPE_X++:O>6O\ P4D^(\<6NW]G&O\ 9F(8
MXW94_P")79]"!CGK^-?NU7X7?\%C?C5X)\)?\%'OB-I^KZ:9]0M_[,\U_/A7
M=NTNT9>&Y^Z1UH0'[HCI138VW(/H*=0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?A7_P6
M0^'UGKG_  4@^(UU+=:'')+_ &9E;A+0R#&EV@Y\R56[=P.,=L&OW4K\6?\
M@K1\8]"\*_\ !03X@:?>?VA]IM_[.W^7;HZ\Z;:L,$G/0BJB!^TD/^K'.>*=
M4=F<VR>N!FI*D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:6%Q'(_^A74EM-"\<X! PY0KE'Q-6_9S^,7P]_X*9_!/XL6'PIUGQ1X8\#?
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M!GA\^=LN(XW?RU&"[$G'A7[>/[&_QZ^+?Q(\%_M+> ?"WVCXQ?"OX@&X\/\
M@^;[#9ZC=^&R?L%S9/J1OOLPAN;82W>U@&1KR5.3Q4@?9%A_P4%^&=W^VEJ7
M[/\ -J]UIOQ2L=+&LV^EWUJUO'J]MM5RUI,W[N=U5MQC5MX5'8KM1B,'7O\
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MX+:>,/@+\1?VCK)O 7A'6=,_9W\0^'=(DLH]=FAUKQ='JZQNBV,'DLINHUD
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $XK\PO\
M@H=)&/VP_&&Z&X8_Z%RC@*?]"MZ_3UONFORM_P""CTUPG[9WC)8Y%5/]!P/L
M1DQ_H-O_ !>8,_E51 _3;X9SI=?#S09(Y/-233K9U?&-X,28./>MRN3^!]R+
MSX/>$957:)-%LW  ^Z#;QG%=94@%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%(S;:3?]?RH =13=_P#O?E1O]F_*@!U%-#Y-.#9H **;O^OY4N_/K^5
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M^S#X \#?'#Q)\2M)\*Z38^/O&%O#::WKT<9^VZI%$J)$DKY^8(L<:J#T" #
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZL98QKX(T0(6^\5^P08SCC->JU(!11FB@ HHHH **** "BBB@ HHHH ****
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M3^"-0CNTG\=Z%X>\36NJ^&]3BO8=.U.&XE@FM(&2.21YA"/*=$E5_G4*7&
M?6U%>%_$K]LGPYJ7[$%]\7_!?B_1-.T&:V66PUS6]"U"ZL[5S<K;,+FRB\J[
M!67=$Z'8\;@[P-K"NZ\'_M)>$/'WQ0U3P?H]]?7FL:/]H6X==+NEL3);O$EQ
M%'=M&+>26)YHU>-)&968@@%7"@'=45\K_LK_ /!230?B/XI\6>%?'FL:+H/B
MS2/&'B_2-/2'3KRUT^XTW1+^2(N]W+NM_M*6HBFEC$P8*^\1JG3I->_X*F_
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M0_B=<>#=&\36E]XBMX;FX6U$4J+>1VTPM[EK>5D$=R()F6.4PL_E.P5]I.*
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MG]@^"2T_8?\ @W%*K+-'X&T1'#=0PT^ '->K5(!1110 4444 %%%% !1110
M4444 %%%% 'B<'[ ?P[M]:N]06UUIKB^\>Q_$R<OK%PROKL<*P)<8W8$8B1%
M\@8BPB_)Q6'J/_!+OX3:DWAU_L/B:SN/#-YK%S#<6'B:_L9KV/5KYK_4;.Z>
M&5&N;2>Z8RM!*60'@ *2I^B** .=\ ?#+3_AQ/KDFGS:I)_;^I/JMPMYJ$UV
ML$KQQ1E(!(S""$+$N(8]J*2Q"@L:Z*BB@ HHHH **** "BBB@ HHHH ****
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M,[6']GP<C/./K7K%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%&I:3>7_ /;UDC7#/!)>&T:Q3=,#%<) L)=DR![E\6_V8M>G_P""-WBKX?\
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MK59?,AM0Z>;;6N+I[;SO**><\U(#]-)]4@M[^&U>:);BX#-'$6 >0+C<0.I
MW#..F14^ZORD\+>!_B_>V_A76]/\-_%:?XK>'/"'QB\+^%=7U72M4MK>SNSK
M5M-X?\T7,DD<44FGJ1;273NCM%&ADE>-2/HC]DB/QOJ/[)'QFU;X=W7QD3Q%
MKEE/=^$-,^*NA2Z1-HNL_P!FA%@CAO,W#0_:%A>1W9H&E:4QLP,A+ ^OO'7C
MC2?AKX,U;Q#KM_;Z7HNAVDM_?WEPVV*TMXD+R2,>RJH)/TKS5?V[_AC#HNE:
MAJ.N:AX=M=9\1_\ "(VS:]H5_I/_ !-MRJEI(+F&/RFD+J(S)M67<-C-7PC^
MT=X'\8?%/]D+XU0^%]!^.VH^#_$7PBM([WP_X@L-=DUN7Q>+AABUAD4SRN8P
M1="WW6S,D+#<#(:^Q/VS/A#X1^,/P-\#> ?$7A;7/&7@/Q'KUCIFJ:;<Z?J&
MIN;-H)L/=MM:>(*WEDS3,IC<*Q=6 -(#VJ7XH:+%\3$\'FYG'B&33FU9;?[)
M-L:V601%Q+L\KAV4%=V[YAQS709K\W_'7A;]HWX ^"O'GADV_C/QTWPU\.V-
MOX:\;Z5 UYKOBWP[-K-H]]:F)"A;6[;3[>ZBS'(CW):WE1DE=MNEIEC\7O ?
M@SX<_$SX<ZK\7OB!9MXKU/0[CPWXJTJ_T<IINL*L5E=/I]U)]J%OINI>4WFW
M7[U;*6[()C2$@ _0W=S7*Q_&OPS+\:IOAVNI_P#%8V^C)XADT[[/*"+!YVMU
MG\S;Y9!E1EVABV1TQS7P)\3M9^*GPG_;-\+Z'X1F^.>O+X-\3:1X=GN-5M-7
MU+2_$.G3>%+S;<R30I]A2S;55MOM$\QEN1<^:6>W@CC#><^!_'OBR"^\4>.O
M^$=_:4?Q<WP'TFP\37$FBZU#J%OKZZP_]IPVDUS;R1Q;"\DC+8(Z^2CO;(S(
MM.P'ZN>*O$]EX+\,:EK&I2M;Z?I%K+>W4JQ/*T<4:%W8(@+-A5)PH)/0 FF>
M#?%^G^/_  CI.O:3-)<:7KEG#?V<KPO"TL,J"2-BCA74E6!VL PS@@'BOC3]
ME/QQ\0K[]@W]HFSU:;XCCQ%X5UCQ79^&)[_2=6M=4-CY#3:<;(WBF[N !(HB
M;=))G:N0P"#F_@?\1_B/#^U%\#_[3U#QUXGL]2\*Z%;ZWI,SZII=WX=N)-$N
MI)[Z[@DB-GJ%I+,0)GD>.YMKN*%,N&$=(#[;O_C+X7TKXH:7X)NM>TNW\7:Y
M9SZC8:0\X%Y=6T!59IDCZE$:1 6Z L!WJIX/_:"\%>/OB'J_A/1O$VDZEXDT
M$.;ZP@F#2P^6XCE]F\N1E23:3Y;LJOM8@'QWX[6UQ-_P4\_9XNDL]0DL[/PI
MXRBN;N*SEDM;628Z,84EF53'&T@@FV!V!?RFQG!KYQ_8#^$7BS1?C/\  3PW
M>:;K5GKWP9A^(Z>/+ZXL9H;>634M8B>V43,H23[<Q2_C5&(,<(8XPN0#[*\3
M?MS?"'P7\0-5\+:Q\1/"^D^(-!GM;;4[.\O! VG276/LRS,V%B,V1Y>\C?D;
M<YKU82AAGZBORC_;M\/:EXT^*'[='AZSUSQGILWC#PYX?L-+T32_!]QK*^-I
M(]*F$UA$8X&D;S2?LSM;R*T/F,Y*E<CUJ^^*WQ0U;XCW%C=2>+_ _P 4M)\7
M^#T\+>#K::>XT.^\,7%OI7]KK(%C,-RD4CZRLUTX,MNUI!M:,/&LK ^T_'OQ
M]\(?#'Q1:Z+KVO6>F:I>Z3J&NP6LH8R2V-AY7VR<8!RL7GP[N_[Q< YK?\'>
M+]-\?^$-)U[1[J.^TC7+.&_L;E 56X@E021N 0" RL#R >:_+'3_ (J^,_&W
MQ@T/QAJ3?$RS^*F@?#;XK6?B.&;2KUK7PEJRW&DO8P6>Z$V\:&&!3 T>1<)'
M$[&223<_=^"?V@OB=XM_:&^%?A_7OB!XN\(W5]X<\&ZQX;@M_!U_JT'CF&2V
M)UI+F:.1+6*9I=Z3?:DW6L20SQE"[EBP'W#\2OVLOAK\'/&$?A_Q5XX\-^']
M;FLFU)+&^O5AN&M%;8UP$)SY2MP7^ZI(!(S79>$O%^E^/O#5CK6AZEI^L:/J
MD*W-E?6-PEQ;7D3#*R1R(2KJ000RD@U\D_&_XQ^&_A!_P5U\&:IXDU*/1M)M
M_A!K=H][+&_DB>76-*>*WW*"/-=8)&2,?.X1B <5X-\#_!GQ"M?C+H>@Z3KO
MQ&^"_P /?CI\6O&WB32=.L+2*SU"/2/[)MI(9)(;RUD:P-QJ$%W>+"ZHX6\P
MZ*[%40'Z0_#?XI^'OB]H-QJGAG5K/6M/M=0N]*EGMFW)'=6L[V]Q"3_>CFBD
M1AV9#70;N*_/71OC]\8_#?P:\#_%.UOO&7CZ/1/BMXK\(>)/#,-K'YFK:==Z
MU?V&C3[1&A M9AIF&38AMII9&+;5-&F?%KXI>%_V^])^%_B3XJ:YI=[X8FT&
M32K-_"EQ>Q?$;2SIJ_VO<>='M@!-ZT^]WPUJ+6$J LC)* ?H+>7L.GVTDUQ)
M'##$I=Y';:J*!DDD\  #.37#?##]J7X;_&K6FTWPAX[\)^)M06 W8MM-U2&Y
MF>W#;3.JJQ+1;B%\P IGC.>*^=O^"B7C6U_;/_X)BMXF^%TUUX^\$:]J6C:G
MJ]MH]I+-=>(/#L&K6[:M:16^T2O(UM%<1O;[0[[9(BI+;3H_M:?M:_#?6?V:
M]<^(W@'QA:ZGK/A;1]EIXD\*V\&K7'ARTO+RSBG#N0\5HK[$,AG4^4EK),8G
M^S,M 'UIOI2V*_,[]FO]HSXJ?M"_'KP'X"N/C%X@T6SC\4>/K/49M)M=/NI]
M2L]+O]-ETJ$W-U8_.K6=PX$RQHT\#^8,DK*&_"_]NCQSJ.L6NE>*/B)</X5O
M/%NGV7B#XB:%=:=>>'M-TZ\MM8DLS;2FU5],GEO+:RL[JVO4=K0O"%D+7*RU
M5@/TS+@50\4>*M-\$^'KS5]9U"QTG2=-A:XN[V]G6WM[6)02TDDCD*B@ DLQ
M %?ES\=/VO\ X[Z-\-?%$UK\5=5T&;PK\*?'_BO1M0L]'TJ8^*#H_B"*WT+4
MI!):NK"]L=K,( D4ZRL\2H&4CZ6_X*.ZK;GQO^S-XN\3-#-\&]!\=KJOBVYV
M^986$S:9=#2+^[?[BV<-^\+&60^7'*UM(2-@=9 ^A-,_:A^&^M:);ZG9>/O!
MM]IMWJ-OH\-U;:S;S127MP_EP6P97(\V1SM5/O,> *[O=T]Z^2_VI/C)X5\-
M7GAGQI\-]7T"35_%GQ&\&>&/$>L6,5O?6^K6;:@R"V:5E>(RI%<2MNC(FC5X
MSN4;*\$^"?[1?Q,^!_P+\,>-K/Q=XL^*>GZ?\6/%O@GQSX<N+>SN-0MKN\UB
M]M=&+-%;K- 4NO[.1HL@+%J0<*(XXTH _3"BN#^"_CW3Y#-X!N_&NG^+_B#X
M$TS3AXJ*&&.\26XB8Q7,T$0581<&*9T4*HPIP,"N\H **** "BBB@ HHHH *
M*** "BBB@ K\[/VZ_"E[J?[5/BF:%O"XCD^R8%V9?.XLX!\VU2.W&#TQ7Z)U
M^87_  4/\4+IW[8?C"'[+:R;/L7S.WS'-E;GTJH[@?=/[#$*VW[%/P?C19%2
M/P1HJJL@^< 6$ ^;KS^->J5Y3^PE_P F1?!S 91_P@^B<,<L/^)?!U->K5(!
M1110 4444 %%%% !112,N[N: %HH'%% !390S+\K;3GK3J1C@4 ?*7PE_P""
MDMUX[@^+GAG7/"-GX5^+'PMMM4U.WT&?5I9=.\5:99RR0#4;*]-LC/;FXB:"
M7$)>WDP'4AXS)V'@7]LO4KC]K+6/ACXR\-Z/X5AA\#VWCC1-8CUJ2ZCURV,A
MAOT\MK:,0FSD,(<F1BZ74+[5RP7C_CS_ ,$]+[]H[X"76DZAK5MX/^(VA>(=
M>UWP7XLT,M--HG]HW-S(891(B^=;S0W!@N;<@I*@R"'6-DZ+]LC]A"#]J>Y^
M%5]#JW]@ZG\/=59+N=8O,_M;0;NV-KJVDMD']U=PB,$D<-#&PPRJ0 ;^J?M4
M:UX-_8*U/XS:[X)N#JFE^$KKQ8_A;2+UKZ>=([=[B*WCE:&,F1XPF?W7R,S#
M#;<GR;X<_P#!4F^^*&F>&;+1O"?AW5?$/CCQK+X0\-7MEXDDF\*Z\D6BG5Y[
M^#4?LGF/#%&LMLRBWRUS"\8) 9E^AOVI_A5KWQK_ &;/'7@_PKXFN/!?B+Q)
MH=WIVF:Y;@F32KB6)D28;2&^4D9*%6 SM*M@CYS^%O\ P3DU/P#\%?'&@KH'
MPQMQXC\91^+/"OAS-U=^'?AM.+6"-[BP'E12L[727%V8HQ;)NNY(PZ@LSB K
M_$+_ (*=?$N']F7_ (6?X#^!.G^*M'T>QU%?$UOJGCV+1YM,UBPOIK"YTFU"
MV<YNY!<V\B+(1"DF^';DNRIVL/\ P4<CC^-D/A^\\,10>%U\>0?"Z[UV+53*
M\/B*72UO_+2#R 'M%=EM#.9%<SL!Y.S,E:'@K]@:R^$GP&^"_P *?#=XDG@?
MX?ZW;:SXA>]8K>^(I;437<<S;%V&675C;WDOW5_=LH&"%KD=:_X)R:KK_P =
MKSS=4T>/X9WGQ2C^+;P1F4:H=172EM#9;=GEB$W:"\\X2;QS$(\?O  >E?LC
M?MIZ?^V;K'B#4O"<.C2^!])GDM+#4?[:CEU/5BDKQ?:C8HA-O9R/%.(9)9!)
M,(]XB5&5FZ/]J;XQ^+_@AX!O->\*^#-,\70Z1I]]JNJ&_P!?_LB*TM[:W:7:
MC+;W#R32$!538J !BSKA0WSC^S?_ ,$\?B+^S/<:!JFBWGP]DU[X2_"ZX^&/
M@IW-W';^(X?M44]M=:P$B5HBBVT(,</G9DGNI _SA1]5_M%>"]5^)7P \;>'
M-#_L_P#MCQ!H5[IED;^5XK999X'B4R,B.X0%@3M4G Z4 ?.ND?\ !2KQ%I/@
M?X,^+?''@/PSX)\&_&"?3V@U9_&7VJ/3;>ZT2_U4F4/:0XEB^QQ1,A(5OM*E
M'<JRCWE?VK_AK]A\*70\<>&39^.HK>X\/W"ZA&T.K17!58)(G!VE)6=%1L@.
MSJJY8@5X_H_['/B^Q^%7[)N@W$WA>>X^ ]Y87.OL;J<PW@MM O-+!M,PY9O-
MN4E'F!,!#SGFO"/AM_P27^(G@?5_A_#JFG_ [QIH7_")V'A;Q9::]%?3G27T
M_6M1U.UOM-"PJER3_:+!H+@0JLEO ZR?*0ST ^W_ (Q?M.?#O]GGR?\ A._&
M_A;P?]JM;B]@75]3BLVG@@\OSY$#L"RQ^;'N(X7>N>M$_P"TW\/;;XB:;X1?
MQMX77Q-K$"7-CIO]HQ?:+J-XI)D9%SSOBBED7NR1.PRJDCS']K;]E;Q)\=/C
MEX+\2:3_ ,(TUAX9\)>+=$E34Y9EF^U:K;6D5O)&$B==B^1(LC$A@LORAN0?
MGSPC_P $TOC-X8\4_"!IKWX8WFD_"^Z\&7B^3J6H63RG2]%?3=01HH[79<R,
M[F2"YG9F$82'9"%+LE8#ZGB_X*(? >XT]KR/XQ_#.2U5;-S,OB.T,>V\8K:G
M._&V4JVT]#M/H:[F]^.?@_3?BC9^";CQ/H</B_4(VEMM&>]C6]G58VD.V/.X
MGRT=\==J,V,*2/A#2O\ @DM\1K#]E0>!3-\-EUA/V=-8^#ZW27=T(5U2^F5A
M<@_9-WV4!!(QQYGF<;#C?7J/A7]@;Q9HW[<NJ^-]4T7X7>(O!NM:[8^,H-4U
M&ZU!_$?AC5(-)@TZ2"V@$8M9X2ENOE3L\4D*SS+Y<GRT] /ISQ[\>O!?PN\2
M:/H_B/Q5H&AZKX@E2#3;6^OHX)KQW<1H$5B"=TC*@_O.RJ,L0*\J^$_[;DWQ
M[_:J\:>!?!NE>']7\._#;5CH'B?5?[?$>H6-W]@BNU>.R\DB6WWR_9F?SE=9
M4<["JY/%_M7_ +#_ (W^,_CCXQV>D77A:\\'_'?P+8^#]7FU>]N(M0\*26QO
MD6[LHD@D2<>7?/*L;20E+B$,'(D)3T[]ECX(^*/A'\5?CAK&OKH;:?\ $+QE
M%XAT8V%]-<7 MDTG3]/VW*R0QK'*6L2^(VD7$F-V1DJR \[U#_@K?\+Y/''@
MTZ7K_AN[^'OB"^\2Z9J_B^[UA;&S\/W6BJGFQNLB8=9&8A7,B @*RAU=37O]
M]\>/!>F>*M#T*X\6>&X-9\31K-I-D^HPB;4HW#,C0KNRX94<KMSN".1G:<?(
MGA;_ ()X_$K2_''ARXOA\/;K2?"WBCXE:O;O_:5VT]U;>(Y;B:R)C:S*I*C7
M,D<RAV54&Y6DW%!SWP#_ ."6?C_X5_$?X=MKNF_"SQCX=TW0?!::K-J&KZJ+
MKPUJWAZVBMQ-IT"PK!>1OY*2PM/Y#02O*Y$@.PF@'VWXN^/O@;P+XXTOPOK?
MC+POH_B37#&-/TJ\U6""]OO,D\J/RHF8.^Z3Y%V@Y;('->=_"35OV</A)9>)
M/%7@0_!OPS"M['8:[JN@)IUEYEU,R&*&XEA"EI)&>/8K$ERZ[0217,?'[]B/
M5/CS^UIJ'BRZFT6Q\-7OPHU/P)#J$;L^MZ7J%W>PSI=6\;0^6%C2(,'$P<2*
MN$P-U?'GQ9_9@\7_ +*'[/G@'5O&&@_!?P)\0=/\8>&%B\2Z1XGULZ7-_8MC
MJ'EW-[?7.GW*V,+Q2RV\<$EO-&BW,@\[>\;0TD@/T+'[4.BZ_P#$'P78^&=8
M\"^(?#_B:#4IKG4H?%=LL]L+2**3_1[=5<W2_O1YK*Z" ;&;=O JHW[=OP?F
M\8^"-%L_B'X3U34OB)J-UI.@+8ZE%=)?7%M"9IHPZ,54JNQ<$@EYHE&2ZY^0
M_@A^R5X@^.'P[^'^J:+X.\$_V#X5M?B#8ZK;ZIXEN;G3_&=WX@BCG%Y:W,.G
MPM)97%U-<I*X@M_* ;R$E18RW5>!_P#@G]\8[*^^'DNK>)M/U"U\*>)-;\L:
MEK\MYK&BZ#J.@QZ>B#45LD;4+NVN%D:-IT1FA:%'G9HB[+0#ZNC_ &KOAC-8
M:E=+\0_ _P!GT:^BTN_E.NVJI9W<N?+@D)?"R/@[5/+8.,X-7_"O[0_@+QSK
MNFZ7HOC3PIK&J:UIT>KZ?:6>K03S7UE)&LJ7,2JQ+Q-&Z.'7(*NK9P03\,_#
M;_@ES\2--^ /A_PSX@\*_!U/$FA:[X%BOM6LO$6K7J>)M'\.ZJE[NE2ZMF%N
MQB61([- \8>>4F8+M6NIO/\ @F+XMN_C;\1;?R/!,/@OQ'?:QK?A;Q7%K&I1
MZ_X,NM0T-M+,5OI:(++="&8)<B56$&V+R]P$BF@'T/\ !S]M#P_\<OVI/&_P
M\\-S:+K5CX-T#2]:DUK3-;AOHI9+R>^@:U>.,'RI(S9%CN<[A*IP.I[S2_CQ
MX)USQ7KNA6/B[PO>:WX8C,VL:?!JL$EUI2#J]Q&&W1*.Y< "OG?]A;]FOXJ?
M"WXT7GBGX@^'_AIX=MY/AMX<\$1VGA/6+F^5KC2I]0+3!9;*W$4#QW:;$R[(
M%"G.,U\Y_M-?L2?$[0])^*OB[QMI7@&3P9=>%?B5X?GBTK6=13S+/Q!J%O=6
M,ZV-K8%;=@8]U[*&DD9VGN'DD 5%+ ?H1:?M,?#O4/!=_P")+?QYX-F\/Z5M
M^VZDFMVS6EIN.%\R7?M3<>!N(SVS3[C]I#X?6>I:=8R^.O!D=YJ_V,6-N^MV
MJRWAO YM!$N_+^>(Y#%MSYGEMMSM./SO^&WPP\<_M5:1J7B[P/8>"_%'C32?
MB)I/Q U;6K/XBRS>'_'>S1+K0FL8M5TVPM'M+JWMEAG"I;R*LAC,G$NQ>V\9
M_P#!*;Q.VA>,+;PWX3^&.BIJ7A;X?Z-H%E;:E<M;Z-+H?B2]U>_B2>6W:81&
M.YB$4F-TLEN"R0C:$0'VI\#OVE_ O[2,7B)_!/B;2_$B^$]9N- U5K*82"SO
M8#MEB/T;(W="5."0,UC_ !1_;1^&?PI^#WQ"\<7GC#P_?Z-\+;&>]\1KIVI0
M74^GF*-W\AT5\K.^PHD;89WPHYKA_P!F/]FCQE\//AY\:?"NO7>GZ/#XU\:>
M)=;T#6-%O7FNX[759I+A)7C>)!#/"TVW:&D!:+=NP0*\&U__ ()V_$[QO^S;
MJ>AW&C^"_#WBS2?@#K'P6LUTS5W-AXGGO(;>."\F/V=6@M;?[.[Q(RO(K:A=
M+@!0\IH!]"^$?V\=%T/]GS_A9/Q2/AGX;^&=0U:VTW1M0'B:WU:PUJ.Z\A;6
M:*>-4P6EF>)HV4&-K>5LF("4[/[-O[9>@_M >+O&7A]OL.A^(/"OBC5/#T&E
MS:I#+>:M!8M"KW\40P_DL9E' .W(!.3BN<_:S^ 7C#XP?L7^'/#/A_3-%E\7
M:#K'A763IM_J+6]G.=+U6PO)X1<K$Y7=';2!'\HY)7*C/'@FH_\ !,OQSKGQ
M(O-46U\.^'[K5_B7XU\0W&O:?>"34;33-8\/W6F6DJ$Q*7FCFFB=HB0JK$"&
M8@"C0#[H\&?$KP[\28;Z3P[KVBZ_'I=RUC>'3;Z*Z%K<+C=#(8V.R09&5;!&
M>E>(>&OV_)OB/X5D\9>#?AMXP\7?#5=4.F0>([&>T#:@J79M)[VWM&D$\EG%
M(LA,A"NZ1%XXY$*LV#_P3%_9<\4?L]^'-6NO&W@;POX1\5SZ/HWAN[O-'\9:
MIXD77H],CGCBG7[:!]DM_P!^_DVZ@N@=@['"@6/V$/@]\2OV,_@CX;^"LWAO
M2]:\/^!7.F:)XMCU9$@N=&6=S!]IMB@G2^2$HC1HKPR,N_SD#%5 /;O%'C'P
M'\0].\6^$=6UGPOJL-C8/!XFTJ74(7:TM)HV#"ZCW9CC>/</G !7/;-5?"GQ
M.^&O@#PCI>CZ3XF\':;HNEI%I5A;Q:M;K#;K&R6T=NGS_P +;(@O4,57K@5\
M/>(O^"9GQ,\;?L^V?@O4--T-/$'P_P#"_COP_;>(UU)2/B#_ &]:W,4'GC9O
MC6266&ZO/.4;;JVC,7GKEQQ_[0'[$VB^)OV@])^$6B_"?X?7_B+7OV;=3T>>
MRE2T@M-'OY]0L+8:A*0F]ECD\QS-$K3$QC8I+$J<J _35_B!H,'C)/#;ZUI"
M^(9+<W::6;R,7C0C@RB'._8#_%C'O5&]^-'@_3+-KFY\5^&[>W6YCLFEEU2!
M4$\@S'$26QYC $A>IP< U\?^&/V!_'6F^-O[%U2WM]872?BGIOQ'TSXDS7<1
MU6XLK>W@BET^>/ E^U/%%)8<9@:RFW&177R3X[XC_P""2WCJR_8(\!_#?PW\
M,?AII_BB[\&^*="\6ZA!<6MI>1W][9F&SE-R;>42V\BADF*+YZ_Z.J,L7G4:
M; ?>WBO]JSP^FL^(M#\)W&F>,?%O@_5=*TS7=$M=7M;2XTL7TT*AY'F=4!2&
M7SO+!+N%"*"[JI[R#QYHLVO7VDKK&ER:MI<*W-[9"[C^T6D3<K))'G<BMV+
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M[:UO+@R,QDAM_-,,8!.%53-,<*!DR,3DFMBBB@ HHHH **** "BBB@ HHHH
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ML_86^"Z_-QX$T,<G)_Y!\'4UZU4@%%%% !1110 4444 %%%% !1110 4444
M%%-+@"E+@4 +132X'<5S7Q;^+VA_!#P'=>)O$4]U;Z/8RP0S26UE->RAIIXX
M(P(H$>1LR2H#M4X!). "070'3UF^+O".E^.=$.FZUI]KJFGM-#<-;W,8DC:2
M&5)HF*G@E9(T89[J*T%?(]/;-0ZG?1:?I\]Q,Q6&W1I)" 6*J!DG Y/'8<T
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MV&UFU!66^GMK?S/*M9I]\A>6%4=FFF;.Z60MYS\0/^";^A^,OC+\-UA#Z?\
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MK*H !'( P*.8#X%_;H^.\?[3O_!O/8?$#7[GPY/>>.O#/A75+ULJ-.:]FO\
M3GE0#<<*)2X*;B5"D9R#7#^&_P!H;4/V,K+]KKQ)?1Z!X,^,W_"3^'KK5- M
MX&A\-V'AN2YMM.A\362JDCSP_8I;B>ZN3$Q2:R:-XMD*A_TYD\*Z7+HT6G-I
MUBVGPJ%CM3 IA0#H F-H [8'%+-X8TVYE\R6PLY9!"UN&>%681'K'DC[I[KT
M/I0!\&+^VO\ %+X4>$OA[XUO/&O@_P"+G@KQ1K^L^!1/X.5-2@GU&Y_>>'9W
MNX[:-)&\Z-M/G>%4A,UU;ML4K)AWQ#_:'^)'PI^.?QB\.V&L>%=:\5^'](^'
MJRSV\>EZ-K.L&Z_M7[?#:S7*BWDNW2SEEM8;L^4IDD12F[=7WAI_A?3=)TJV
ML;33[.UL;,*+>WAA6.&#:<KL0#"X/(P.*J:]\-O#OBJ"[BU30=&U*._\O[4E
MW91S+<^7GR]X8'=MR=N<XR<8IW ^"_AO_P %&?&GQC^.GP]T/1/'?@/P_I]Q
MH_A#6A8>,BND:Y\0-/U*%_MMU:Z<L$C&;S T4:07"I#/;R"3S(G0U5_83_:.
M7]JK]O+X/?$'4/&&BZSKGC#X)>([^ZT&TBMHI/!\QUK0Q+IS;/WY\IE,3+<%
MG66WN#E0_EI^@$_P_P!!NM<T[5)-%TF34]'C:&PO&M(S<6,;##)$^-T:D<$*
M0"*;H_PW\.^'M8N-0T_0='L-0NVD>>ZMK*.*:9I"K2%G4!F+%5+$GDJ,YP*5
MP/SZ_:KT^'X+_MA^-/B,(_ 7Q@\"ZGXM\*6/B_PQ<D0^-/ >KQFPBTZ?291G
MSK=O.M[AK1]C$O,T;MYLB'F/$?[>7CCX,_!WXA1Q?&"'4/&T'CKXC"SM]4M]
M.:XA@T4S_8X"9/+AAM$1(&E3:UQ(C*( N7D7]*+[X6^&=4\6VOB"Y\.Z'<:]
M99^SZE+81/>6^1M.R4KO7Y>.#TXJ'4/@[X1U>Y::[\*^'+J9[UM1:2;389&:
MZ:+R6G)*Y\TQ?(7^\5^7..*$P/SW\-?M]>-+7QWX^\;/\0K)M+N-3^$Y@T*Y
M^R-I>C:9KLUC!J$L;8$BQEKR;;,SD!E4$MM #;C]O[QQXF^*_A_Q/9^,$UK2
M_#T_Q;BL?#FCBV^S^,9= O(HM+@) 9Y)W@D88C8;OOJH)S7Z$W?P9\(7^GW%
MG/X5\-S6EW90Z;/!)IL+1SVL))AMW4KAHHRS%$/RJ2< 9JU'\-/#D-U8S)H&
MBI-IEU+?6<BV48:TN)0ZRS1G;E)'#N&=<,P=@2<FG<#X,T3]NGXP^(?V>]0\
M6:%XQ^%?Q&TNZN=+U"VE\ ZG;:MXA@L)=.O+B^CAMKF.TM9IHYK>*5+9G,_V
M07:LQFCB=_MCX"?&K0?C=\.M%U;1O$&FZ])>:3I^I3O;#R9%2[M8[B&22W8F
M2W\V-Q(J288*PZ]:DE_9U^'T_AZ32'\"^#GTF;4&U:2R;1;8VSWK9W7)CV;3
M,<G,A&XY/-=#I'A'2M U&\O+'3;"RN]1,;7<T%ND<ET8T$<9D90"^U%5%W9P
MH & ,4@-&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;AM_M3J* "OS=_;X&E_\
M-9^+/M'B31M/F_T/=!.$\R/_ $.#&<Q,>1SU/!_"OT@E+?+M[G!K\Y_V\/&F
ML:1^U;XJM[7PR=0MX_LFVX_<?O,V<!/WD)X)(Y/:JCN!]B_L*A5_8E^#HCD\
MY!X(T3;(3GS!]@@P?QZUZK7E'[!TSW'[#_P;DD?S))/ VB,S8QN)T^#)QVS7
MJ]2 4444 %%%% !1110 4444 % &T444 %%%% !1110 4444 %%%% !1110
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M':4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZA9/ID$=S?F2!%+!(8)K>0N,JPN8-I8RH#?M_P#@HE\*[[Q-X5TRWUK4I/\
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M-"A(:2Y3?F%%((+2;0,')K.7]KCX5O=0P+\2OA^TUQ>KIT48\1V>Z6Z:4PK
MH\S)E,JM&$'S%U*XR,4 >B45SDGQ=\+Q^-)O#;>)/#Z^(K6W-Y-I1U"$7T,
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MOXM_M/>%? NGZ7H&C^'+KQ'X\\.ZZ_VB9KR[BT6.W2WF@=0/*9_M1=AU#1J
M^.3YY^PW_P %(O&'@/\ 9C^$O@_QAX=M=2\1ZE\-OAM=:!J\NO37+:U<>(/-
MT]'U*62(-%*)K*2=RGFEEE"AF<\EF!]9>)/V/ROQ1\3>,?!_C77_  %KGCRW
MM8/%,FFV]I<1ZQ);0FW@O EQ$XANTAVQB5/E9(HE='$<>V[\%_V//#?P$NM%
MM?#<UU:^&-#\++X6BT.81SP7$?GM.UU-(RF66XD9Y"[,Q#F1V8%F)KQ'5O\
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M)^+WP!TV2#6)O^$N\=3:3')8ZU)81PNNA:M=AKB)5(NX2MJP\ERJB0Q2<F,
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M-T72]<TG_B3>$M(NH;ZSU*YMGDL]6L'UF(1O*(&>5ENKB"?S29520'/TD/\
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M&T70X?B0M[!HNH?#Z\CD?P_L:5/"EO;0JA N" ;K[,C%A_JLD /P:]!^(_\
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MA8D!'R(PC9SMP<4@/J']G_\ 9J\$_LO?#./P?X'T*'1/#T<C3?9OM$UTTKL
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M/UJ+6]0\6ZBFI1WMK ;&T)U![@7&!!*]N(S+M=)Y%(;S&W5]*_X)8_ W19/
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M#M;'1_#VIW_AB7PA:ZM%H]M=R6>E2-&TEAY<JE'LY/*19(> RC *,%=?7**
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M::%8275]=6]G:P_ZR:>01QQ\XY9B .2!SZT2:Y9QS+$UU;B9RH5#(-S%@Q4
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MB0W93>KGRY-2MH7B8&7]TY52H4GB_AQ^P)\8M!^ _P .?!^A^$[?X=ZWX7\
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M+X*_X1V]\0>&]'M[]?BC;7NHV/GS7-O%XLEG>VEC0QH))+=95$BLZ@F,;6/
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M0UV7AW]JSX=^)++P?)%XR\-0S>/K6&\T"UN-4@CN=4252R"*,OEV.&&%SRC
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M\ ^'=6\ V_B-/&'A/Q+'XJN[&3PB1HD.D?V7%HL:"!MD<<JI*&6/R;G!7?$
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M*:CI?C.W\96\8\#:CIND16=U9W-N'\ZZ7[2+FX40F2&Y^VR1S;5!+<E\.O\
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M;PKJNCV]_P"%'N_$+76B:A&]XSBWA6QVI%<6[BXL@F% #E0 ?H1XX_:C\)>
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MWB3S&U34KFX\[2O[>U"XTSR8WE>.*'[/<JRA%4CS"",C%?2] !1110 4444
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MM5M?+GTK7-7&F1W2SQ.4\Z*99(I(21LD:-MSQ,'/=7/_  3+^&NKPQ6NJ_\
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M5+K5_%=WXPUU]0EL<:_=W-@EF\<ZPVT:K"OEQS*D0CVR1KSL&RO:Z0!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 -V#/ZTX+MHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** #&:*** "N=\2?!_PEXQ\6Z9K^L>%_#NJZ
M]HISIVI7FFPSWE@>O[F5E+Q_\!(KHJ* &M C@!E5MO3(Z4Y5"*% P!P!110
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MYD=P+1E\]=RS%0PB(SPY5@=O7!!QS5Z@ HHHS0 45''=Q2W$D2R1M+#CS$#
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M.>M>H5YQ^QW+'-^R5\+FA62.%O".DLBR*%=5-E#@, 2 <=@2/<UZ/4@%%%%
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M=^!_C_\ LFZ?1B+F^C7Q#IPTFYDA$8C^VW&GVT5R;;:K/(KKY8Y4<G%\??\
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MA_#'X;67Q'N+/7-.NI;W6\WU]#/I\,T=S&L3RQVF(Y#%)ME= 4</\O%^/O\
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M$\>J0Y\MY+F"6VN+2ZE&QHFDC01N&:?[_P!@QT'Y4;0>U*[ ^&OC,_Q+U?\
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M\;^(+A]4\!>,K;2(FBCM;#Q=!:>)8X;/4&@6()Y\VF+:73M%L'S1LH5&*']
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MW\,:\VHW@D(@8QEX6Q'AWWO][:#FONHC-&*0'YK?$#_@F;\;/B)=?$X7-O\
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M]_P5B\(R:E^W_P"/IEM;&17_ +.PT@EW'&FVHYVG':OVAK\8?^"L(U$_M_\
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M#Q6F@QV.F3:L&DGATF3R99%%XEOLA>6,"VEN(GC1DE/V=>X_94_:^\*_MD>
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M-:SJ'C_Q*VG7FN?"#P-XDB\#F.*&#3;J]74'O9[="//V^8B;BQ) GC1S^[C
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M]U:P^"?@^-OBEXMU#P;H,4_Q%E55N;*+6Y)IK@KI9,<.-'X*!W(N0=H*%6/
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M-8N]%MIKY3:R&6VQ.R&3]U*2Z8;Y&.5P>:[2B@#PK]DS]@3P1^R]\')/"O\
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M0BO!/@)X9UZQ_P""FO[0VNWWAWQ!8^'-:\-^$;#2M5N+0I9:G+:+JC7*PO\
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MPW=^'-<\/:'?:KH^MS133G68-1NO-^S6S3L</]L4JMN8?((D0"O8+JY;0/\
M@HW\7-2\56^K76DCX0Z1)X;BL+>>>[EMH;[5CK4=I'"#+).6?2MRQ R$M; <
ME* /5/AI^VU\*?C)+K0\*^//#^OQ^&]8C\/ZI-9S^9#8ZA)(8H[=Y,; [R#8
MO.&8J 264'U+=V[XK\Z_%OP\A^'G_!,7]IO1]'UGXCZG\%I? $I\ 0>+(KY-
M=TBX?3IT-C:F\5;U[=)!8?9O.S()9)HU)5$KT?\ ;[\6?$[PA\.?A5<V<_BK
M4/$UK8RW'B'P[X;34+-_$-P(;9)!:W]E&\4-['*[FWM[L?9+G?()-H021@'U
M3\-/C#X;^,%IK$WAS5(=4C\/ZQ=Z!J#(CI]FOK63R[B [E&61^"1D'L372E@
M*_,[P'>?$;X/?&J_UK0[/XQ+8ZY\6?B0NL:/8Z+,UO<6"Z3=7=E/!%-#Y!>2
M\@M!;W$A*2R3&)696V#D_!?Q2^-?CJPT[08_$?Q\\.Z+K/C_ ,!?9]0ET?4C
MJ":;J&ERIJL;75Y9@F,7$9DE81QQ02D%5BCV@NP'ZN>:*4."*_-Y/'WQ>TSX
M]?$[2-:^)OQ8\)WW@&+78+*$_#R\UC3]4T+^QL:9JPO%/V&:6*X1;AE@A^U2
M7)FMRK1E0G=?#/XQ?%Z#_@F)\1M6TK3?%%Q\0_#>H7%I;WD-Y<>(AJMLK6SS
MZAHKW,*W%U$+>6X:"*:-W%Q"\.90H+ 'VAXW\>:/\./#%SK.N:C;:7IEGL$M
MQ.VU0SNL:*.Y9W9450"69E !) K(\+?'GPAXW^$G_">:3X@TV\\'K:S7CZLD
MF+>**$N)V<G!0QF.175@"A1@P!! _/[]HC6-8^)WPZ\16EOXL\:>(OA+'\7O
MAO=^#=:66[_M!%_MC3[C5XQ<;-\]I:K']H6>3=Y,AG0N/LZJOKG_  4.@N-%
M_:J^$MTUYXN.B2> O'5L8++[3-I]YJ M+!K9;A8U9/,:$WS*TF,A'P>"*7*@
M/L'P;XQTSX@>$M+U[1;VWU+1];LXK^PO(&W17=O*@DCE0]U96!!]"*NWM_#I
MUG)<7$T<-O"ADDE=@J1J!DL2>  !DD\"ORO^'_[0GQ4_9@_9DTW2K/Q%XMU#
MP_I/P_\ A9J-_<W7A[[9/X/LKM[BTUQX(;:&.5UAM[:U:1!OF@$CR#YNOL'[
M2NE>,OC!_P $EM!N;K5]=^+>GIXITC6/$KVWAN6QU#Q9X5@\017%Q#'98,LH
M_L]%R-H>[BA?Y<S[2 ?7WPP_:3^'_P :=2FL_"/C?PKXFO((/M4EOIFJ0W,R
MP[MHFV(Q;RRQ #@;2>A-=QFODO\ :K_:<\*>(/A5<?$#X5:G9^(/$&BI8Z7J
M'BOPY;+JT_A70+W5M.759?E21!-%;(USY,BLR?9B[)M1@?)K[XW?%#Q9\>O!
M_@?0/C!KUEX"\3?$[4]!T7Q=9V6F7EUKFC#P@=0RD\UK)!*MOJQ-O'<(F&*"
M-S(X));L!^AN: <FORYTW]LWX[6]UXNUSP7XZUCXN>)O#/BCXGZ'>?#[^PK
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MUTVQ^*=WX @N+OQ$T$FJ6MOHBZE)<6L;0@R7B2/Y;VIV[$AG<R?N\'T[P/\
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MO$T.B7OB+0;/6+B:*WAL)]0ACNII95=HHUB+!BSK'(54#+"-R,[37RS^R-X
M\/\ C_\ ;C^+/B_P/KEEK'PMM=6_M9;*.PDACL/&TD+Z=JSQ.P56V6MM"6*
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M\/6M_P#"O0?&FE7OB--3&[XBKK-C=VUM%)&$W 23317EW]I&U+B!/*$X)D0
M^X_'7[17@7X:?"77?'6L^*]"L_"/AF![C4M5%XDEM:J@#$%D)R_S* @RQ+J
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MUE=-UR^DUW3-.G9HS]J.GS.L/W6(DCPRORK _0OX)_%WPK\3V\5Z;X562%?
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M_P#@YX.^%=YH=YI=Y'X;ABTH/)J'B"]D.GVND7@OM/@CGEF+06UM<*'6-65
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M!5A_PA?]L>"/$7AGXK> _#NOVDSV-\+BPUC4+$R6Y=#,BE[>YDBD"%9(I(V
M; #-Z_JW_!.7PGJGQ1\=>(_^$I^)%I8?$BSDB\0>&K/7?LVB7MX]DMBVIB%$
M#I>&W1!N60)OCCE\OS45QS7@C_@DOX&\#Z9#:Q^+OB1J"QZMX3UDM=W]F=TW
MAOR_[/7:EJJ+&1#")415#B,8V$L2: 87[.?[=6H>%_%LGAWQ]-K6L1>+/BWX
MR\(Z/X@FCM;>PT6/33/<6ME.5V'+V]O.L3!&+&!M[;B"WMOB']J>+PU^SMX>
M^($_A7Q$8_$B6CQ:=F!);!;D!DDNYFD$-O$B$-)([[4Z<L0I\>^-?_!/QO&&
M@V_PQL=$M?$/PW\<>.KGXA^+=;US6=FH:%>#4[;41;6%O#;KYB7#">+<TJ&*
M-GW&4-L;W/\ :+_9QTO]I'PUX?T^^UC7]"D\+^(;'Q-I]WI$D*2Q7=HY>(,L
M\4L3QY)RKQG!PR[756" ^?;C_@M/\/9/A[I_BO3_  ?\1-6T.X\&VOCV\N+>
MUM!_96ERW\EA*\H:X&Z2"6%RT<6\LN#'Y@W;;W[0'[;>L:E^TC\*_"_@-=;M
M]"C^+*^"/%6L_9;.33[Z1=%OKR?3U\UC<*49;<F:)%7>CQ[\A@6V/_!&SX>Z
M?\+M;\*+XR^)S:;KG@V7P/+++J-E)<0V#ZK/J>Y7:T.9EDN9(@[ALQ8#!G'F
M'JF_X)H>&/\ A?UOXZM_&GQ%L;>W\9I\0%\,P7ED-%.M?87L9KK:UJ9P)XI'
M:2-9A&9&9U568Y>@#_VCO^"EGA#]EOQ!\0K'Q1HGB2%?AQIVBZW?7""U$=YI
MVIWCV:7=ONF!:.WGBD6;>%9 N0K @G-^+_[<EOX.^*^E?9U\8+#8Z'XTU*+1
MH+33S8^+1H8LEE8W3N9;<I+,R1 ;1(3*9/E2,GT?XV?L5^ _V@/B38^*?%&F
MS:EJ%EX8U?P@\)FVVM[IVI^0+B.>/&)<"'";N$\V0X)8$<G/_P $V_ S:7\,
M["/4O%D.G_"_P9K'@>RMQ>0O_:MEJEO:P74MY(T1DDN3]DCD$J,F9'D9@^[
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MQHO@>XU_P9I,WA[XZ6O@?6+RPT*9H];TR?P@?$4<2I)=%H9$9Q SAR9-B/A
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MEW=OXIU:33BJ2NK23) T9:.[6-$N$;>L*+MW^D?"G]MCXL^.?V@F\'W'P_\
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M%=A(-1N!(FIZA#)#?W4:F7[\D4TBG P@D8J%)S62?^">/P9C\$_\(_\ \(7
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MK.Y:ZMX)<?,D<K)&TB@Y 8HA/7:.E?+_ ,4?^"DFO?#C]H#Q;X;/PP^W^"_
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M+';V\G$D*+MPL;_Q*.&[@UKZ5IEIH.G6]C8V]O9V=J@BA@@C$<<*#@*JC 4
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M-X5\5V'A#3I94URZU+4=(?6+640-<.8F54CDAAC!NIEFN1+)(@/EG?[EH_\
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M6D_#]&T7Q);:!XET70[K4M4U">VM5UZX6ZU(2[)EE(EG17#ABT+ %,8VF_\
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MU0 4444 % .:* ,&@ HHHH **** "BBB@ KPO_@I]!9W/_!-OX_)J"VS6O\
MPKO7RXN%5HP1ITY4D-QPV"/<"O=*RO'.MZ-X:\&ZIJ/B*ZTVQT&QM9+C4;G4
M9$CM+>W12TCRL_R*@4$DMP #F@#\ZKO_ ()HW7Q"U#2]:T?X/^'_  ]X)\1>
M,? FJZGX0-SI\EN\>F)>_P!HZQ(L;M;R&>.[@@*JS2SQVH+K\^T=]X7_ &#_
M !)I'Q4L='7P7INFQ^%?B@/%VB^.[5[547PP83&-#$887"E+4C3/L_EBV%JD
M<@<LHCKZ2E_;<^#/A[P;;ZM<?$CP-I>CR2W5G"]SJL-KB6SB\RYA\MRK+)#'
MAFCP&52N0,C/,_MA_P#!0#PC^S#\%;;Q-8:EX7\2:KK/]F2Z'I9UQ+<ZS;7M
M[;VRW$+JLF],7&],+B4J$#+G<#4#YQ\3_P#!,GQIH'[$_P"T+\-[/2='UZVM
M_"7B;P5\&M.CDC22VTO55-XL4SRL$B\NY>WM4RPQ%I<;\EP!8^*_[(OQ*\7?
MM=+K4WPRAUY!\7/#7CO3/&;:AIZ2:-H<&EPV=SIK)))YZ2V\L<[B.%6BE6Y:
M3>)&9#]F_%OXIS?#OQ+X#TZ%O#._Q;XA.DRIJNLKI\YA%E=W+M9QE&-U<+]G
M4^0-O[KS9-P$1!SO"W[87PG\<PZI-HOQ*\!ZQ'H>G1:QJ#V6NVUPME9RY\NX
MD*.0L3;3ACP<>XHU ^ / _\ P3]^+F@_ 'Q9;W7PTO)OB/H=GI.C:U=W/C2"
M73?C#8V6N0:A=K%&H!1KZW2[#/?!'5[UH"3$\KCW_P#8TC\1?LE^+-:T&^^$
M.J^%])^,WQ5U74]+M;.\TQU\/V3Z5;2I/<0V\[@*\MM,KB+>(V8$DJP)]RTC
M]M[X4^(_BWHW@G3?''AV_P!>U[0+SQ-:1V]XDD4MA:7"V\TGF [<K*9!MSD>
M1.2!Y;8U)OVL?A7'X';Q1)\1/ J^'8[QM.;4WUNV6T6Y5/,:$R;]H<1@R%2<
MA!N/RC-&O4#Y'_X*2_L3^+?VB_B_\3?$&C^ 7\1WC?#30M.\'ZC]JM8I+37+
M77;J\9H#)*K0S11R02+,0,!74-DE6U=/_9%\:>)?V@[$ZQX/,.LZ3\4=8\3:
MAX\::VFMO$?A.\@O$BT=R7-P^(;FTM&M9(A"OV 2ACLB+>[_ +5/[;_AG]FS
M3_"R1WGA_7-<\5Z_H6CV>CC6XK>\FM]4U*&Q%[%'AWF2/SC)A5PZQ/AE"DCU
M;XA>/]$^$W@36/$_B34[/1?#_A^SEU#4;^[D\N&SMXD+R2.W954$FC4#\^_A
M1_P3,^*G@3QQX M[J30[KPCH,FI?"_4;=YUDDO\ P%'>'4M-NIVV[GO/]&AL
M&CY79<R2<%VVV/AS_P $ZM<^-'Q%^,OAWXK>$_'%G>>)D\5:2WCJ+7K$Z/K6
ME:K?FZT]K>WA(O&N[11;A4N5V6IM2(I&5PM?2'PF_P""C/@/XJ?&R]\,QZMX
M=T_1;CPWX9\0>'-:NM;AB7Q*VMR:I'%:0PL ?.C.F/\ (KNS&3&U2IS[18?$
M_P ,ZKX[O/#%KX@T.Y\3:? +F[TF*^B>^MHB5 DDA#;U7+J-Q 'S+ZBG[P'P
M)\2/V=/CAXK_ &=_A_XR^(7@J^\6^,M2U^.7XH>#O"-]I\EQJ%C#ID^FVAM/
MMP2UG5)2M\T$I0*]W+M8F&,UJ_#_ /9\7]DWXM>)_BSXD^&_C;5M)^$OPF\,
M+X8%SKUO>W_VVQBURWO8O.:XCAFO!8W5I%)-)A'((1WV[F^F/$?[74^J?'/Q
M/\/? '@^\\>:[X#@M9O%$JZA!IUGHTEU$9K:T\R7F6ZDA E\M%VHDD1=T\Q
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M-'INL>!OB_J5SI>G63E]/O[?Q4)=*GLX)8#'#=M!<WTL1=&:>/YMLH1%'7?
M'QYXN\>?M _"FU\13>+-8T_P?\?M4DTBZU&PU-X[31+KX>W[V["ZO8UFFA^V
M7CQK-*<EI4'RAHU'Z0/XDT]/$*:2UY;#4Y+=KM;0RCSFA5E1I G7:&95+8QE
M@*\Q^,W[;'@7X#?$O_A$=?;Q1)KAT&?Q08-+\-:AJH738)4BGN2UM#(,1O(@
M9?O_ #KA3D4_0#Y)LO">O:W_ ,&[GBS2;'1]>DUV?PQKJQ64.G2MJ!)U&[8%
M+<H9&?9\ZKL.[C@@UA?$'XZ_$CX0:-KU_!\1/'FO? .\^(EM;1^.[G2;C5]0
ML-/GT.62;:U@(+AM/35S;QBXBP8V9XLF-"*_1?X?^/=$^*G@71_$WAW4K/6O
M#_B*QAU+3=0M)/,@O;:5!)%*C#[RLC!@?0UL#;NW?Q8I78'R7\<OB!X\^&W_
M  30\&:M;>+O$6K^-(]3\(6EWKYT/^R]0UJ"76].@O+B6R8.;?SK1YWD0A6C
M5G)$94A?(?B%^T+\1+/XF_&/1;;XB6<*0W$DFE>(WU2>WT'1XH]=M(#I&K1"
MU:;1KMH9'MH;Z'S8YH#)=E0T8)_1)0J].,\T!E'\A1<#\M?C+^W)\2_!GP;\
M07UKK'Q.\.:AK7PBTO5/"=C>V4>J7\VLVVNWT%_-#+#;%+I3:FR;S=BK);/%
M.43>Y'3>,_VOOC%!\5_CM_8OB76C\0OAO:^+9=+^&B>#KJY75M/BM7?1+Z&;
M_5,K&.&0.A+32W$ML0"4\O\ 1^^OK?2[*>YN)HK>WMT:6:65PB1HHR68G@
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M$3WPM('E9&$4=PY^4@.OC'Q!_:W^)&@^&O%5GI'Q*UR^\6>&_ ^DZ[\+5O\
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M,<CEE*@@GD$#&* /SR_8A^->O_#[]I/1/#NG>*M,F\'_ !+^,'Q7TRYT 6<
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M$=)TS2=-L;73-/MK+1U1;"WBMD2*Q"(401*!B/:A*C:!@$@<47 ^&=9_;O\
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M#[RY\X\0?\%:/@S8_"_Q=XHTW5/$.MV_A'PSJ_BR2WM_#>H0RZC9Z5<&UO\
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M"/[(/C#X>R>-M+\ ^$?%UO\ &_6(-6=+-H=?U"W\5:FD.DQM.C1X,%Q-.T:
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MO2;\W5ZCM'(EO]KNKB,.X:5I&,:JWEL$]F_:=_:%TG]E+X&>(/B%X@L=9O\
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M2M2FT;5-#U_QR8-5ET6>ST>32M UBYMGQ<D&-YH;189)-IY^<@ JRJ]6!O\
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M1=+\(>--*LM8\.V<5G>VNI6(F1VEM[K[0-DX13 4N8-L<A>0! $5WY?X\_\
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MRHVUT)4G#*P(*GD$8-7* "BBB@ HHHH **** "BBB@ HHHH ;(N]?UK^>/\
MX+F1WG_#TOXH>6L!CQI."753_P @BR[$YK^AQQC+ 9)&*_G7_P""ZG@33=5_
MX*I?%*XN)/$JS2?V26%K*_DC_B460^7C_)IJ_0#^B+2RIL(=K;AL'.,9X%6*
MIZ$ZG2K7R]OEM$A7'3&T8Q5RD 4444 %%%% !1110 4444 %%%% !7,_&+PG
MX<\=_"W7]'\7B!O"^H6,L6J^==-:QK;%3YC-,K*T8"@G>&4KC.1C-=-7CO\
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M%#]DKQ;)XVCTWX4^.K6+6--:_MKN"\@TC8)1:ZD52:58SY)AN&A>5C&25+,
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MS:KIWB'QAJ%]H=Q<>/WO[6"Q2VFN8?%D\DUQ&DH<F-K<R,$< [N"0"*R9O\
M@KY8^'/AWX:^(.O>$?L_PW^(WAC5O%'@[4;+4Q/?7<=A$MPD%Y"\:);27-NW
MF1LLLB(4=)&0@,V'^VK^VMXH_9F^(_P2\3_$ZUD^'NE:;X_U32=2MM'\1M?:
M3XGL9?"^HS6LDA*0[8EOA$A:[CC2&2V>4LL?ST:@?3'[*'P/\6? SP1<:=XU
M^(]U\3M<D=%.JRZ)::/B)%VH##;C:TA^9GD))=FX"*%4</\ M"?L#?\ "_\
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M9FFM1'\L2W4$S0.)7W*K,R1ED%=/^U[^V-:_LJ_';Q5K%UIOCC7E\$_"2_\
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M$_A;+^ST?'^DVV@7^FG6&AEOSY>HV_G*8X+Y;4@F.4R1J&C"[WWJ'=V ^_\
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MW1O"\NAVOPU\%6NBW&FV>CRV4>EQ+!+9V<[7%I;LH&#'#.[RHI^Z[LPY))^
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M@?\ !*V3X?6/@6/PC\:OBAX9OOA[;7GA_3-1C^PWMW+X;N)8I1HL[7,$BRI
M8(E@N&7[1$JD;VR2?5+C]B3P;=?M5W7Q:F6_FUK4/"<?A*\L)9B]A>0QR3&.
MYE0_?NEBN)X!*26\J9US@UX&/VL/%'QZ_;7_ &>]2T1I='^&NI>+?''AL"#7
M;A9M=DTFVO;.1KRR6,0F/[79320DR2,BI&V%:1E3U#_@HC^WK<?L*>#&UV/P
MO;>)K2Q\/ZMXFOHCJ3PW+VVG+ \L4$$4,TKNR3,WFNJ6T7ECS94,B9-0.8\#
M?\$NKSPI\'/"?@.^^,GCSQ1X>^'_ (GT#6_#$6KV5@SZ59:-=QW-KI[/#%&U
MP&,44;3S%I=D8"E269I_C3_P2IT']HGXF>-_$GBCQ1J$=WXLT>ZT6WN=&T^#
M2]1LXI)[2YM6GN8_^/Q[&XLXY+1IDS"6<98-7<? ?]L__A<O[4/COX:W.DV/
MA_4/!?GL;*\OIHM:G@CN!#%>?99($22SN%(EBN+::= &5)#'*3&,?X__ +>]
MQ\"OVF?#O@>3P>NI:-K&J:'H]QJD&JAKJUFU:>XMX)#;1Q.(X4DA4%KF6 R^
M8_DB4Q,I-0/3OV?OA)XF^%GPP;2O%_Q U;XC>([IWEN]<O-.M=-,A**@6.WM
M42*)0$!P,DLSL3S@>'^-/^"8#?&6*\D\>_$"^\2:NGPXUOX:Z?K,.BP6.I?8
M]5ABBN;B\D5BMU,H@C:,!(HU9I3L)?*^C?MD?M2Z[^S./A_:^'?! \>:U\2/
M$[>%--L3K*:4L5S_ &9?WZ222O&ZB(BP=&.-R[P55R-A\RM_^"G>L:F/$NI:
M7\&?'.O^%M!MO$,::II<<USYFHZ+<-:W%JZ^0%*S3Q720O;O<.PMF+1(S*A+
M 7[+_@FS=2ZAJEGJ7Q FU+PIXTU#0O$'C/2'T**-M:UC2DLHUNK>99/]$BG3
M3;!)8=LORV_R.C.[G!O_ /@EGKM]^SQ\3/A')\8=4N/AOXKANK+PUHUSX>MY
M1X6MKJ\6[FAED\P-?!&WQ0[_ "Q%%)M(D(#5:@_X*M65QX DUZU\.Z)K]O\
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M'XG7NIZ=JFM7-ZL-W8)9Z7-="2.-4"-([)N)P% 1E"?."GSS^Q5_P5<FT_\
M9$\!GXF:#XSU#QA)\-O"?B5-25+:YF\:3ZQ<IIT7DQ0.2DLEZR?(R*=DRM@8
M95-0/K[]F>W\?VOP@T^/XG7FF7_C);B]%S<6%BMC#+!]LF^R$PK-,L<GV7R-
MZK*Z[]^&(KOJ\^_9L^.<W[0/P^FUJZ\*>)_!MU9ZC=:9/I^N6,EK*[02M'Y\
M/F*IDMI0 \<FU=RMRJL&4>@T@"BBB@ HHHH **** "BBB@ HHHH #TK^;O\
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MB#+O7#QS1L"&)0>NV_BO3+I[X1ZA8R'325O-MPK?9"!DB3GY"!S\V.*_/O\
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M%U\0_B#J]Q>RZE#9R7^DZII5W%IT4UQ _GBWFNVMF>-#OB*^9M#*&KG?@?\
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M6M>6QEN-2U[5)M4U/49B #+/<2DN[$*J@<*JJJJJJJJ.PHHH **** "BBB@
MHHHH **** "BBB@ ;I7\TO\ P7\UJ"V_X*W_ !:C;2[>9E.D9=G0%O\ B36/
MK7]++?=.:_F,_P"#@S4-*C_X*^?%Y9;J19%?2 P$8X/]C6/^P?YT ?TU:&<Z
M5;_?_P!6A^?[WW1U]ZM5#81^3:HHZ* .!CI[#C\JFH **** "BBB@ HHHH *
M*** "BBB@ H(S110 8HQ110 8S1BBB@ Q0!BBC.* "C%&ZC- !BC% ;-&:
MC-(W"FES1F@ Q1M'I1F@'- !BC%!.*,T &T#M1B@G%&<T &WVHHHH ***,T
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MX#\#W$7P7\&3^!M'@N?BE-(EQ831V*,;G;X<4R2A=.ML,AC'#94[C7G.C?\
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M?? W6M1U:PDUWP\^H^&=<COC=)/!=6;2B0'R;D%95DW))'N PQ%(#U#]J?\
MX*1>#_@_\'=#\1>$-:\-^,+[Q-=>'GTR"&Z>6VN]/U;5(+&*\\Z%75599)GB
MWE1*UM(JD[6QU_[=/[7%G^Q5\%+;Q=J$%G]EO-<TW06O]2N3::3HIO;E(!>W
M]P%8P6L98;GVD;F124#%U^?_ !]_P2X\=.FM:3X0\9?#W1/#'C%?"5YK%D?"
M<EO#IE_H.H6]R!IL%O<*D%G/%"%$#EC$T>0\AF=E^K?C[X/\1^./!T-GX=;P
MQ/NN/^)GI?B&S:YT[7[!HY$FL92N3$)0XQ+LE"%1F*5<H30#A]%_;1L?"^M?
M#OP[X^L;?1?%7Q2U>]TOPY'HMP^KZ=J<5O ]PMZMRL:".&6%4*AQN#2@?,JM
M(.H\-_MB_"WQ?::[<:;X\\,7-KX:LEU/4I_MR)#;V3%PMX';"O;,T<BB="T9
M:-U#$J0/F7X<?\$HM4^&7A_P1I^A:OH/AW1='\:>(-?O/#=D;J73_#^EZQID
M]E+IND2EE=#"T@D1F2./?+,RQ1+LB$>L?\$P_'_C?X8^$['4O&'A72/%WPC\
M'6OA/P7K>EV4\D.HRV>JZ1J=K?:C;,5"H9=#L5>TC:10)+DB4AU57H!Z[K/_
M  40\(_\+Q\&:/I.K^&=2\#Z]H/BC5]8\1C4O+'AZ;1)-.2>"="N(V'VX^8)
M&1XS%@K\W'L_CCXO^%_AG\-KKQCXCU_2= \*V%LMY=:MJ5RMK9VL)QB221R%
M1?F'+8'(KXY_:$_X)O\ Q:_:;UGP#XRUCQEX)\*_$3P)::YJ-C/X;M+JWTRT
MUJYGTFXLF:)\F^M5?2R+@7/S2BZ8HL9BBV_7'B#X<+\9_@3J'A/X@:?I=W'X
MJT2;2?$5E9N\EG<+<0-%<QQF158QL'<#<H.",T@([W]H?P6NKZOI-OXK\,R:
MYHM[:Z7=V#ZE&LMK>W<8DL[>51EHWG5E:,%<N&!4-Q7BGP<_X*9>%_C9^Q$O
MQ)T_7/ACI/C*W\$V/BO5O#VK^,8K6R\.R7<&^&.^NPC/;P&0-'YS0]4;Y<@J
M.9_9M_X)F:_\#/C3X2\>:UX^F\9>(+/PFNE^*YKB!K<>)M7LHGM-(U#&YA#Y
M%A=ZA;R!1^],L4C!I%W5YO+_ ,$F/B$/V6Y/ <>J> QJ4G[.\?P<-P+BZ6!M
M165LWA_T?/D%6+]-^\D8P=]/0#[-\<?M*^$?".MZAX;C\2^%YO'5K87%Y;^'
M9M7BAO;IHK<W&SR_FD&8P')",0AW[2*P/V*?VS/"O[:7P,\+^*=#U70'UK5/
M#NDZYK6A6&K0W]SX;EO[-+E+>XV?,I&YU!95W>6V!P0/--&_96^*GA[XS_$7
M9-\.-5\ ^+M6N_%FF76HK<2>(M(U&YTI;"6S23RS&L&Y3MNA^\2WD:#RB,.L
M_P"P=^Q7XJ_9<\7>'[C6KKPY<6.C_!?P9\-W_L^>5I&OM$;4C/,%:)1Y#B^0
M(<[OW9RHR,(#?_:-_P""B_@OX(#QQI^FW.G>(O%'PYN/#J>(=(-^MJVG0ZQJ
M$5I%*SE6YC643,I &UD!9=X(]*N?VHOAK9> 8?%<WQ"\$Q^%[FYELXM8;7+;
M[!+/$[1R1+/O\LNCHZLH.5*,#C!KYS_:5_84\>?%?XF_&"ZTIO"%QX?^)A\$
M747]H7<T,T$FAZJMQ=6\D2PNK1RVZG8^[[S;2F/FKA?BO_P3.^).M>/KOQ)I
MMG\.?$]G>>*_&$U]X5UO6-0TVQU?1]?73EWO<VL9:.YA-@=T)BECECGE3>K,
M&# ^Q_VB_P!HGPY^S!\$=:\?>)I;HZ+HL*-Y=E$)[J_FED2*WMK=,@/-/-)'
M%&I(!>1<D#)'/>#OCOXTB\665GXX^'+^#])U#2[K5O[9BUV'4+/2$@\HM;Z@
M^R,07#+(6'EF:'$,O[[(4-B?M4?L=M\??V,%^&6DZEIWAW5M&32KO0+]+%VL
M=/O]+N+>ZLV:W\PL;?S;:-6C+EO+)&XMAJQ/CW\*_B]^U;^S9K7A?5-)\%>!
M=<D%E?6Z1ZU/K-EJ%Y:7]O>+;3-]F@9;&;[.89<HSM'<,-@VX= >JO\ M3_#
M.+P8OB1_B)X%C\/-/-:C5&UZU6S,T,;R31^<7V;XXXW=USE51B0 ":N^%_V@
M_ ?CCQ*FBZ)XU\(ZSK$EN]VMA8ZQ;W%TT*/L>41HY;8K_*6Q@'@D&OE'Q-^P
M!XP^*/[0NA_$;7O#_@R.#4OB9IOBWQ!X6EU$WUC;6EIX:U+1S.K-;A)[R2:\
MA<CRT4QVD W;ES7A_P ./V#+S]M+P[\0K+P[:^&/ 5OH_P 3?B:EMXVTYA)J
MSO?Q:EI,=L(4C1EA7[6DSDS$,EC %P7#1/0#](='^/G@;Q%H=UJ>G^,O"E]I
MME>#3[B[M]7MY((+DXQ [JY59#N7"$Y.X<<U$O[17@!Q\OCCP>W_ !+&UO(U
MJV_X\%3S#=_?_P!0(_G,OW O.<<U\=_%G]@/X@?'6SO-<U3P9X#T74]2A\ :
M-J/AN#5?M.FWL&@>(5U.YNV<VZAA]G,D%O&R!BC,'*@A%?\ $#]@3XB7_P"U
MM9:SH'A/X?Z5X#T7QD;W3A8ZF--B72+CPA-HLIDL8K0B6ZBG:,9>7:T$4$<?
ME#S"#0#ZC^&7[46B_&B^\)WWA.2QUWP5XN\+OXHM/$<&IVZQB+? (D-L6\_Y
MUE=C)MV1F(HY#$"NLTWXQ^$M8\/1:O:>*/#MUI,\DD45]#J4+VTCQJS2*L@8
MJ654<D Y 4DXP:^"W_X)O?%[Q+\$OAOH)L_"/AO6?"/P*_X5W>.NJM=6MWJ,
M&H:1/';2%849K*ZATV6.5@"46[8!7P2W4^,?V /%?Q:^.&@>/+[P7X?T?2]4
M^*.@^+=;\(7%]!=6]C#8:'J-C+J!*H8I;N6:ZMD**.8K*%B^[**@/N?2-8M=
M?TNWOK&ZM[RSO(UF@N()!)%/&PRKJRY#*0001P0:L5X?_P $Y?@AKW[.'['_
M (5\%>)-/L=)U319=1!L[*X6>WMH)-1NIK=(V4!0H@DB 4 !/NCA<U[A0 44
M44 %%%% !1110 4444 %%%% #9!P3WQ7\S7_  <"Z>TO_!7;XN-]C@?<VD?,
M9L9_XDUCV\L_S-?TS/\ =/TK^7S_ (.%-5N8O^"P?QA58U95DTD F0#_ )@U
MC[4 ?U" Y%%"GBB@ HHHH **** "BBB@ HHHH **** "O.?VLOB!XL^%WP#U
MK7/ ^DV>O>*+26TCLM.N)(D^V>9=PQ2)$)9H(Y+@QN_DQ/-$)9O+C+KOR/1J
MP_B/\-_#WQ=\'7?A[Q5HND^(M"OS&;C3]2M4NK:<QR++&6C<%25D1'4XRK(I
M&" : /S$U_\ ;<\7>'_C/XN^.'A&[\%ZS<:;\(?"4_B"+4/#=_IIU%1XLUVQ
MN[6.V>Y$MC=)LE0F9YQ'+ %*R+\P]F^(/[='BCQS\;/%GPWO[?P;K7@+Q'H'
MQ LK6[LK29'BN-"-I;O;M-+/_I+YN9DN MK'%%*GEI+-L9V^L;S]F#X:ZC83
MVEQX!\&36MUIT&D3POHMLR2V4$IF@MF&S!ACE)D5#\JL2P /-5+W]D[X4GQ3
M?^);CX>^!?[:O9+JZO=4DT6V^U3O<6_V>Y>24IN)E@_=N2?F3(.1FBZ ^4?^
M"9$<<7[37A;KYS?LN?#EG^;.XFZUH;CZGY0,^P]!6=XR^-/C#]GG_@I#\;/$
M'AR/PW/H6K>+/A;X8UZSO[>X>ZN(M5F;3/-MI$E2.*2(W44FYTE$BQ%-J':]
M?5O[.-_\'/'6K:AKWPS@\(W%]X=L[;PA=7>DV:0S6=G @N+6RR%5A;+'<"6$
M#]V4F#H2K9/2Z[^SOX!\3^(-2U34/!_AR]U+5[VPU*^NIM/C>:ZNK AK*=W(
MRTEN0#$Q.8R,KB@#XO/_  4K^-WB[Q#\1-+\#^'OASXPO['P/K/C;P<+&UO'
M@U@:9K9LFL49KE9+MIH,*LXBMHQ< [%FB(>NN\8?\%,?$GCV+P1<_":T\,^(
M=%^,VIW=IX U:[B'D7L-GI?VF9I%EO+82227GF0I&KQLL=K/(%EVJ#]*>!OV
M3?A?\,/'C>*/#?P_\&Z#XE=KQFU2PT>""\8WDJS77[Q5#?O9$5GYY(^M-^(G
M[)7PM^+?P?L/A_XG^'_A#7O VE- ]EH%]I,,VGV;0Y\HQ0E=J% 2!M P&(Z$
MBBZ Y/XA?M+>(/ 7["MI\1]2A\&Z'XLN-*TR2>VN=1EO]'M=0NY+>!H(IK56
MDNQYTQ2%8@#<.8D!3S-P\+^'G_!3'X@>(==T?1]5T'POI]ZU[\0M)U.>6*6%
M8Y_#K1_9IA&MS*L:2K)^]C\V0J0=LE?7_CCX/>$_B7\+KOP3X@\.Z+JWA&^M
MELIM'N;-)+&2!-NR/RL;0J[5V@ ;2HQC KB#^P3\%9]&AT\_"SP'_9]OK4OB
M&.V_L6#R1J$L!MY+K:%P9'A)C8G[R\'-&@'P'\9OVO?B?^U1\#/'5[JEUX=M
M=)?P1\&/&.DZ+8PSVK6>I:SK?FW"F[\QG\MG@\L_NSF+RAC*R&7Z7^'7[<GQ
M*^)'Q3E^%,=GX!TSXB0ZQXJMEU>X@O&T6ZM='.FF,1V_FB8W$JZM;;E\W""W
MN7&X;%/MM]^Q%\(-1MK>.;X<^#VCM-)L-!A TR-?*L+&=;BRM5P.(H)E62-1
MPC*",&K7B/\ 8\^%_BN.==0\%Z+,USKLOB:218C%,=3EA\B6[$B$.))(?W;$
M$!D^4@CBBZL!\K^ O^"A?Q*_:S\,ZY-I7@?P3I?@ZS^%&F>-]=L]:O[W^T6_
MM&VUR)[*$P@*RBXTQ,394M"[,!N92N'X$_:Y^-'AKP=XDN/A[X=\'ZMH/@/X
M#>!?'.B>"_*NY+AC>?VG]JM8KDRM)+,(-.=8@^=[) I(+22'[4C_ &;/ -O?
MZW=0^$]$AE\1Z%!X8U+RK81K>:7 LJ0V;*N%\F-9I0J  *)&QUKS?QW^SKX8
MO->DTOX.Z]X'^&_Q>\)>'=*\/QZG'I%OK-_H7AU9Y&M[4V;2H4A<)=+ \GRJ
MWF$!P'4EP.Z_9L^/,7[2W@[4_%^@W&EZCX'U*] \):K:.SKK%DL,0>Y;)^Z;
MG[0BX W)$K<[@3\M?LO?MY_&/XQ^"-$\.PV_@#4OB9JVE>*?%SSWD-U8Z2]C
MI^N/IUM8Q!79P[.55IF+"&-8RRRL^:^SOA/\,]'^"GPQ\/\ A#P_;?8]#\,Z
M=;Z780 #]U##&L:#@ 9PHR<#)S7E'Q"_9 ^ 7@GPQ;W'B'P[X2\-Z3%KEW>0
MW,]Z=,C&H:S,L5Q&)1(F?MLTD<;0;MDSF-=A.T4:7 Y']IC]J/3OB3_P2+U+
MXP1^%[R\T?Q5X(LO$HT&]U"?3;C[/=Q0S>0\]L1+'(JRXW1D?,O4 YK-\>?M
M_>-/!_QA^*/@^T\"_:M<\(:/=ZKX;\.M;W:ZIXMMX&LU-[82@&VOHA]HE\VW
MA<7,+QQ1E&:=2OT=\2/@QX5^+OPMOO _B30['4_">I6Z6ESI3ILMI85VE8]J
M$84;5P!C& .E<GK7[$GPN\0WVM75]X5@N;CQ 9WNY&N[G<KSS03SO#^\_P!'
M>2:VMY':#8S/"C$D@&CF2W ^8_%?_!7G5M"^%WBWQ#I&E>$O%4'AGX3>(_B,
MMU:RWME'-<Z1J;6C6$UO<1+/;2% /-CD'F03))&0X 8^N^!/VU?&/Q/_ &H]
M4\.:#\/_ +=\.?#?BNZ\%ZWX@DU*""XT^\AL8K@3^4\@9XVFE6 1!-Y#),"R
MML'3^.?^";WP3^)>@66F:_\ #_2M8L[&RU+3U6ZGN)&N(-1E$]ZD[F3=<>=,
MJS,9BY\U1("' :IM2_9:^"GP@^/MQ\;+[0O#7AWQSJ$=GHL_B*\O3;"Y=A'9
M6J,))!"URRM';1R%3,RLL08@[2 <Y^T]\8=4^&G[3.@)HO@N^\9>(+/X;>+/
M$&CVEGK,]M)?3VD^DK]A^S_\>\C3M/$$EDR\91@H'F-GKOV+OVEX_P!JGX+R
M>)X[S1;IH-4N=-E_L^*[M7@>%@&BN+6[CCN+2Y0G:\$J[E(!!965CM?&;X#?
M#_XDO<^(/&FFV<WV#0;_ $:>^N;V6U6TTVZ,4EVA=70(K?9X69^&7R5(8;:T
M?@E\-?"?PV\!K'X-_>:3KDQU@WW]I2ZI+JLDRJWVI[J:222X+H$ =G;Y%0 [
M0  #YS_95TWXB> /^"AOQ"TSXIR:]>7WB_3;WQ!X1OM.\87]]X7ETB&^AA:U
M_LJ<)'87]ND]B&>,2+,)I&#J=ZGS+X@_M#>/+/\ :.\2>*H=>\0VUQX7_:,\
M.?"BQT!+V0:7<Z#>Z3I;W7F6@8123,VJ3WGGD&5!;0@,(T9&^G+O_@G_ /#>
MU^ _C+X?Z1I-Y8Z3XWTR72KU[C5[^^G2V<R$1132W!FBB1I9&2**1$0L=J@<
M5T&E_L=_#[3OB+HOC%]%DNO%&APP+!J%U?7$K2S0VK6D=W-&7\F6\6WDDA%R
MZ&81R.@<*2*8'YL:A^V_\6OAK^R/X3^(VG^+-7U#Q9\9/@OXH\::XE[=O=6?
MAC4H=6T:&TN;6"0E+1+2'6+F(QHH5Q:1&0.Z,S?;W[$7B76-#_:9_:%^&,^K
M:]X@\,?#W5=$DT2]UK4I]2OK?[=I$$]Q:-<S,TDBK*OG*&)*_:RHP@15])\,
M?L8?#'PA)XJ:Q\(Z>L?C2UN;#5X)Y);FWFM;F6::XMHXI':.""6:XGD>*%41
MWD9BI;FL:X_8/\!V%GX2AT>UU325\)^+XO&JSQZQ?2WM_?QVK6N^XN'G,EP&
M@*0LLYE4PH(PHPA1 ?GC-^W;\6O O[(?A/XC6/BG6M0\4?&;X(>(O&^L17-T
MUQ;^&-4CU?1;>VN;."3,=K':0ZS<1F-5".+.)I [H[/['+\5?&6D_MD3?L[V
M_BKQE+X&G^*NEZ,^MS:S<2:U%8/X+O->GT[^T2_VA?,N[",[U<2+%=2(K*OE
M[?J#P%^SA\![&;6[?0]+\)WR_$S3=2L[FU_M+[=#J>GO<R/J$%M"\KI':FXN
MI&FCMU6/S)\N-Q%0:!^SQ\"]:T6^^'>EW&FWUU'KO]NW<-OXLN9O$$&JVZPH
M;IKP7)OTN(HQ#%N\T,D12/B,A2P(/^"7?Q;\0_&K]BWP[K7BK4I=9UBUU36]
M";4I0/,U.'3M8O=/@N7*\&22&VC=V  9F9@ "*XO]H7_ (*1^)/@=\=/'.AV
M_P -[36O!_PRE\+2>(]97Q"T5\MGKEQ-;"6VL_LS"5[>2/>Z-*FZ/E&9SL'K
M_@;]DKPW\,?B[X9\2>&XYM#T_P )^$9/!MAHUI<3I8+:-<0S(S0F4PL\9APK
M^7YO[V3=(P(4>>:W^Q)H,_[7_P 1OBUX^OK*X\-Z]!X6&F63ZS=V=K;7.D2W
M4D<MY )$M;C%S<0O$)5DVO$I #;<(#S;QW_P6#U'X;7GQ.BU#X;1WK^!_"^I
M^+-/6QUXR1ZE#8:N-,EM'N/(^SBY)>.3$$DRHS-#(T;ID_0GQ#^-?Q ^&G[(
M7B;Q]>_#JSO/''AO3[[5#X0L->-P+V.W>1EBBNQ;_--+;H'5?)QYCB/./GKC
M;G_@DG\!+VPU:UD\':K]EUO2K_0[J%/%FLI&+"^O4O[FUB5;L"&%KI%D5(@J
MQDL$"!V!^CTA58@OW@!CYCG/U]: /EGQ9_P4?>Z^'5GXM\$>&]'\6>&=<NK&
MTT;59-;>"'4GGT>356,<,5O-<3 )]GA1;:*>1I)I-R1I!(]>7>'?^"A.H1_'
M?_A8UM9^(-0\'^/_  #\++JQ\,W6KE(M&F\2Z_>Z<;A$"O'YJ+-;E]H7S!;@
M;AP:^CI/^"=_PA3X;>!_"-EX6FT7P_\ #G4KC5?#MMI&KWNG-IT]PES'<8E@
MF21XY4N[A7B=F1EE(*\#&/8?\$NO@OI?P[D\+V_A_7(M-?P_H_AE&'BC53<V
M]EI%T]WIGE2FYWQ2VUR[2I-&5D!P-Q4 !Z <#XJ_X*GWEGJFL:'X?^%^N>)O
M&6G:YXJTVTTFSN)YUU*WT![-)IED@M96CDG>_M8XT>,1AY&WS*JAF]4_:VU/
MXE>.OV.-0U3X4V=]I7CB\LK+4HM+O98[#46MO-AEO+!)6$D5M>O;":%)6#I%
M,RDG W#FO$G_  2R^!=[IFFV\VB^(-+NK/Q+?^);/5+/QIK%GJRZCJ*HE]MO
MDNUN=ETJ*)81)Y<A 8KO&ZO6?'GP8\,_&#X9P>&6DOK/2]+E@-E+H>IS:=<:
M;-:L/*,,T#JR&-DP5R5(!1U92RD ^"?V7_VG=<_:$\/_  $^'OAOXH?$2.Q\
M::3XAU7Q->ZNHA\4>';S2--TB/\ LB6:5"Y/VO4OMN^0,TL0C&]X7^?UJ\_;
M4\=>*O\ @D#\'_B=#+!I/C[XL6G@S3KS48K91#IL^M7EA:7-[$C;E4*MS+)$
M&#*&,60P!!]3T_\ X)P?"?PE\(-(\-M!KMO#H-U)J']NMX@NH-8GN9K+[!<S
M2WJR+(3-:XA905146,1K'Y46SK?$'[%_P_\ %'@R[\-W&EWL?AFX\/:=X8AT
M>WU*X@T_3K33Y7FLVM84<);SQ.ZE9XPLO[F#YCY28.H'R3X;_:6^(_C#]J"/
M]GP>,-:T_3],\>>)M,D\7Q^2=6O=.L-"TS5+6U\YD:,RI/K*(S^6&>+3\,2Q
MD9^I^!/[6WCWXX>$_P!AGQ=?:Q<Z6_Q96\3Q?IEM;PI8ZR\?AR_NA.-R&6-3
M=6R31JD@4(^&W\&O=-7_ &"_AO+\/[/27AUC3YM-UB]\1_V_!J\T&L-?WD4T
M-]<O>!@Y:>&>:)AD*B%!&(_)A\O>_P"&0_!,%W\*I-/L;K2;7X*JT?A&QL;I
MX;33XS8/IXC:/D2(MJ[1J'SM!R,-S2 ]-NI)%MI#"JR3!"41FV*S=@3@X!/?
M!QZ&OC_PI_P5ST7Q,WAFRN/!^I:9KOBC0=>O(]*FU*)KBTUG2;\V$VAS87:M
MU),DWEMG:RVUP?NQEC]$? /X/W?P;\.:SI]UX@UKQ NJ:W?ZO"VIWDMXVGQW
M,QD6TCDE9I#%'D[0S87<0H1 J+S=Q^P5\*;GQ@NO'PG9KJP\<)\1C.LLFY]=
M2S-FMT?F[1,W[L83>S/MW,Q(!X5^S+^VSXDT7]HWQ9X'\5:7XBU[2?$_Q=U_
MPEX>UZ6\MG@TZ:VTE=2BTY8@5E\D0VUX!*P^5PJG(;<NC^R?^WJ_C3X$^ 8?
M"/ACXD_$R];POHGB+6Y-5U'3VU^QL=4O)[:VFGV^5#<SC[+=RR+$$58K9B"S
MF-']<TW]A#P+H_CBR\0V[Z^FI:?XWO\ XA6Y;4&>./5[VPDL)I-K CR_L\TJ
MK%]Q2Y(&0,<EX9_X)5?"_P %GP#_ &/<^.M+C\ Z#%X76.S\2W-NGB'2H96F
M@LM35& NX8I'D90V#B61&+)(Z,] . _8@_;NUS6?C!??#OQEI?BK5)?$GQ#^
M(&E>'O$UQ)9FS,>CZQ<(ECY:.)E6.U5561HP"8F!).&;O?VP/^"E&F_LA^/-
M>T6\\ ^,_%$/A;PE!XVU>^TF2Q6&UTU[YK20JLT\;R2Q[&D\L+\PP%).=O3^
M _V"/!'P_P#'V@>)+&Z\22:CX9\1>(_$]L)KY7B>\UV1Y;_>H093?([(HQLW
M8'&!3OVA?V#O!?[2_B'Q=J'B*Z\11R>-?!Z>"-1CLKU88_[/6Z>Z^0%"5E,C
ML"^3\IQC@$(#D[S_ (*0P:7HGBUK[X=^*M)UCP;XP'@_4;'4=0TV"&T:338]
M3@O);L7#0I!+!+%&H#-(;B5(MGS!JJ> O^"J?A+XB6>E3:?X5\9+_P )1\/]
M*^(GAB*XCM8Y?$]KJ$\-M':6X\XA;J.YN;6&59"B(UW =Y1]U=3XG_X)Z>$/
M$_Q'NO%C:WXUL?$%UXQB\;_;++4T@>&]71_[%=(\1X6&73RT3 ?."Q='CDPX
MXOX0_L!?\*_^*7PET&70=)D^&O[-^EFV\ ZU>:[-?>(KV2:T6V>"YB\B.**W
MACS@;Y2[16S 1F(Y .F_X* ?&KQ9\%9?@G=>%?[8NYM?^(]IHVHZ3IHM?.UN
MUDT_4)6MMUP51,R0Q-O\R/&PY;&0>-B_X+$^"KSP]IDUKX)^)-[KK0O/KOAV
MVTR.XU;PT(M6GTB>.:*.5A++'=VMT-D#2%H[:1UW?(']Z_:$_9XTO]HC1_#T
M%]J.M:'J'A+6X/$6BZII4D2W6G7L22Q+(%FCDAD4Q33(R2QNI$A. P5AYEJ?
M_!,7P'_PEOAG7=%USX@^%=6T6VN;'5+G1?$$EK)XNM;F]EO[B#46P3()+R>X
MG\R+RI$:XF".BN5I@=?^U7\5X?AEK/PHMYM4\6:7_P )5XZL-$0Z)!9RI>-)
M!=2"WO/M )2T<1$LT \X,B $ M7F.F_\%:O ^H?"0>-5T36(=#N]<M_#FGSW
M&IZ3;Q7%],EP_P!FN)7NQ'87$?V<QR07C0R)+-!'M+R**]O^-W[/VD_'2^\#
MW&J7FK6;> _$=OXHL%L9(T6>YABFB5)=R-F(K/)D*5;."&&*\LG_ .";6AW%
MOXFFF\:^,+K6O&D5G9^(=3N;729V\06-K#=PQ6E[;M9&UNEVWDNZ66%IW*0[
MI"L2*$!<N/\ @HMX9L/$]WH]YX;\96.H:=XQ\/\ @B[AFMK<-;7NLV-M>6S,
M!/\ ZN,721RXRZNK[5=0'//Z%_P5M^&_B9]6DL]+\97.F6]K%<:3J4%C%+:^
M(VFU2/2K>"V=92$FFNYX!&ESY)>.99.$60I)8_\ !*'P!X?\4Z/>Z3X@\?:3
MI.BZCX;U>'0X-3B>QEOM!MHK2QN96EA>>1C:P0PR*9=CB-7VB4"01VG_  2I
M\(67PN\4^!U\;?$QO!FKWT>I^'-'.KQ"W\ W45_%J4,FF$1;_P!U>00RQK<M
M.L:Q^4JB)Y(W>@'1?L$_'#Q5\<+[XWMXHCU2S;PK\2+S0-*T[48;6.XTNRCT
MW3IE@8VS-'(/,GE=7WNS)(N6SP.&\-_\%*M#\$:SH?AV;3_BE\0O$OC_ ,9>
M-=%T.UM]'TZ&:.70KBX-Q9Y$\42Q(D12"61MTH0&0JQQ7MO[,O[,UK^S58^+
MO*\2>)/%>H>.->?Q+JU_K7V432WCVMM;.56VAAC1"EK&=H3 ).,# 'G_ (;_
M .":_A?PK\5O!OB^'Q+XJFU+P1XE\6>*+"*3[+Y#W/B(R->)(%A!,<;32&(
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MQ%]WO^-.HHH **** "BBB@ HHHH **** "BBB@ KYS_X*Q?$K7OA!^P?XO\
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M_=H>7\F;'^K-"DP/S[\6?M;^,?#'P.\(^*/#OQBOOBAX9U;6M5O],M=-L9M
MU_Q!IJC31%#I<UW%*FI3VDL]P/L\YB-TLS(K;K4L?T*^%WQM\*_&F'7W\+ZO
M!K"^%M;N_#FJB*-U:RU"U(6>W8,H.Y<J<C*L&!!((-=1C+?Q;OK5#P]X5T[P
MN+S^S[6.U;4+I[V[(R6N)WQND<G))P%'/154#    /R^\/?M,^,/BG)\-U\1
M?$#Q+=Z?H_Q:\.#5O%7AK5TN/#'B"VO;'56A6,+ LUJ3=Q6:S:?<JQMI9;=5
M=MZ-7&_'W]M_Q]\3_!GQ>TFR^)'BB/P_)X8NM8:6WB%AJNB2Z?XRCLKU61(
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MW\.^)U\&ZEJ%]H-_!I5AK#B QV<M\T7V:-Y!<V^PM(%<SQA26=093>P'GO\
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M'QDOAR+^W-5O1JEWF\N#97-Z+46GVQK/S/LQN?LX$7G^7YA0!=V* /F71_\
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M\?>.9/#6B>-O"^J>(HXI+C^S+;4HI+MXHY'ADE2,'<\:2QR1LZ@J'C920RD
MNP/+/VP?!.O>)/VJ_P!EW4M)T#5=6TGPEXVU/5-;O+:$21:5;R>'=4L8Y)#G
M.&N+R%?E!(!9C@*37BOQ+_9X\:-^VGKWCS1_#OC:*Z;XU>%[JVO+.[FBLY]!
M_P"$>M++4)S$LHC>+S$FCD+H6/EQD9"H1]Q^,O&>D?#[PW=:SKVI6&CZ38J'
MN+R]G6"" $A06=B ,L0!ZD@#DUY_XB_;?^#7A'P38^)M8^*GP]TGP_JANEM-
M0O?$%K;V]RUKQ<JK.X!:$\2+U0\, :7H!\Y?\$K/A?\ $;PIXIU34_B9I_Q@
ML?'5MHR:+XKEUZ]L'\-:WJ,=RTBW^GB#]Y<-(CL1,^#'"8X&W-&%3PCXU?LP
M?$CQSI?[1&GZ#X5^)4WC#Q3\<K/QCX/T:]LMOA#7[>SAT017.I/(%B^QB6PF
M=D,J3'R(RB,=BM]O>./V_P#P#9W'Q#T;PSXL\$:CXL\!^%+/Q9+'JVNIIND-
M:WJRM9R27VV14A?R@S2*KA5FA/.\5Z2/CSX-M_B+9^#;KQ7X9A\9WD>Z+1/[
M3B^W2D1>:0D1(=L1@R8VY*#=C&33UO<#Y&N_ 'Q6O_CW)>1Z?XZA^(.C?%&[
MU%]72XF30=7\$R03&&T5V86HQ"T$ @($R7L7V@ILWRGP/X9_"[XT:EI:Z/?>
M'_C]HFB^(KGX8:C<QB]U**XL)8]3O4\1))="Z>:6;[.(!<S@1+<;!,L:JT1;
M]&O"W[8_PB\=6NK7&B_$_P"'NL6^AZ;_ &SJ4MEXBM)TL+'<Z_:I660A(=R.
M/,;"Y4C/%<]XG_;/T-/BO\']$\+-HOC#1/BMK>JZ&=9T[5TDCTN>QTVZO6&U
M%82$FU>)EWHT;$9!Y >H'R1\7/@=XR3]HSP_X9N/!?Q4UF/P/\7O"&H>$-82
M[OM2T>'P=:V-I%(T]P\S(TT5XMZTRW&ZY=GBF_>(%9/6?V[_  OX]\3?%KQM
M8PVOQ$GL=1^':K\,+KPI+>Q1:7XLCFO#*UXULRI&[[]*,4EYBV"6]TK,H:0/
M]0_$CXT>#?@]#9R>+O%/AWPO'J#^7;/JVHPV:W##:"$,C#=C<H..FX>HJ-/C
MEX)N?B9_PA:>+O"\GC$!R="758#J0\N.*5\V^[S/ECFA<_+PLJ$\,"9 ^>_V
M%O@UK'@K]KS]HOQ%XCTW7H-6\17N@D:C,M['IFKLFB6:74MJ)3Y+(MVDRC8,
MH%"C"%17D^@IXBTOX%?M=>!E^%?CGQ-XF^*GCGQ*GAW2+OPW=6VEZY;WUA;6
MD,\U[-&MI':%E<NSR;O+1MJ.Q16^X=>^-'@_PMX[T[PKJ7BKPYI_B?65#:?I
M%SJ4,5]? [L&*%F#OG8^-H.?+?\ NG'B=[_P5"^&<OB+P%+I.O\ AW5/!?B_
M6/$.AWWBA]9AM;'0+C1X9Y)_-+_*49K>0!BRC:4<;E8&C4#YBNO@-\8OA5X3
MO?AS)KGQ@U2S\*W?PCT&/6]#N=3A6_M[4Q6^NW-J\9.R-XD=[C9@<@OE\&NH
M\+> ?BIX4_;.UWPI%JGQLM9O"-V)/ 5XZW.I>%M:T)="CMXX=2U">9XW=+XR
MO,DR_;))DBD1V1F(^XKGXT>#K35]!L)?%7AN*_\ %,8FT:V;4H1-JZ%2ZM;K
MNS,"H+ IG(!(XH\ _&+P?\4VO$\+^*O#GB)M.\O[4-*U.&\-KYF[9YGELVW=
ML;;G&=IQT-',P/SIU#PCJ_QG_9#TW5=6\)_M+0^(-%\4?#VZ\=:1K$^K.8]1
ML=;B.KSZ;"CF:X'ER/)++:;K9DBM6A >)RG=::OQ<UO7;>YD_P"%HZ;\2-*\
M2^+H?'4&_41H=UX::UU9M*?3^3:-()#H8@-H?M(;SPXR+@C[/G_:)\ 6LVJQ
MOXZ\'I)H5TEEJ2MK5LITZX=G5(9AO_=NS1R *V"3&X )4X5OV@_ (\!Z7XH/
MCCPC_P (QK;B/3M7_MFW^P7['< (9]_ER'*MPK'[I]#57 ^"_#OA'XH?"WX;
M?LTZC::E\:/&'B34-*T74/%_A?7M0U];B]OYO[)BNIEU!6,-I+:&VE>2QOD^
MSSQW%SM,;&1S]!?MQS>-H_VCOA['X;U;X@Z+H%QX+\:)JMYX=L;B_BL[K['9
M_8)WMTS%+<QMY[01N,NX95Y.*^@-5^+/AC3/%LWA]_$6@KXDBLWOCI,FI0QW
MAA49,AB+;P@!&7(V@$$U@_#O]H30_%'A3P/)KVJ>&?#OBCQOI5KJ5MH0\06M
MY)(TT0D,=O(C!;M%.X"6(%'"EEXJ0/G/X 3^-O$/_!.GXT:?KVBZ_<:Y;V6M
M6.F7#3:M=Q^*$.E1>7<V-OJ6;^".21FC-M*TA6=)_+>1&0U\^VC?&#]GOX4W
MVD^'_P#A<ESX.TOPK\,=0UQ39:GJ>H6431W\.N+IT.Z.7<B0:6UQ:VC(\<;3
M%$5V*U^A7[,OQ^A_:1^&=]XFCTJXT..Q\0:WX?>WGF65M^F:I=:<\NY>-LC6
MK.!V# 'D&I+S]H+1[[Q=X6TSPY?>'_$ZZYJC:??2VGB"T#Z6GV*XNEE$1??.
M6\E5$<8+[9#)C9&Q!J!\4^"/ 'Q>\2_$*P@\/^//CEK$>@?"6\U_PI+K\=[H
M5IK>N+K-\VGQZE%+R2+=[:,P73B:2WV-.A=24X<>'_%WQE^ 7AGQ!JFM?'Z^
MT^W^(?@S4/$>GZWX8U/2[[P=-;M<1ZF]JTS2W,OS/ 9I;4M;1D!X&7]Z4^\/
MVD_VR/"WP#^!/C'QM:S67C#_ (0E%>_TO2M2MWNE)GCA96^8A"AD!8-SQC&2
M >@U[]J?X<>'-5\+V=WXX\+I<^,]6FT+1%74X6_M*^ACDDEMXR&P718F##/#
M;5/S,H-78'Q7X:\/_';X9:+\-;@>)OB%KNG_ !"U'Q+\+;:+5=3D74M*TJYO
M+J[T#Q-<)*49KRUT^T=92P%RZ7$6\"2-P/I+_@H#8>./ ?P*TGQM\.V\4ZMK
M7PMUFR\077A[2[EVN/&.E0GR[_3W4L!-*]J\LL0;),\$79F![CP]\,_ACXX_
M: O/B1ID'AW6OB!I&G#PM=:K;7@NKC3K=)9)?LK*'*POODDR=JN02I)  KLQ
MX^T*7Q)=:*-:TG^V+& 7=Q8B\C^U6\/'[UX\[E3D?,0!R*D#X._:"UGXP>$?
MCGX.\*ZMXR^)/A.W\4:';ZUH^J^'_#-]XDM_^$GDU>>ZO])F:VE$4-O';-9V
M\'V\&V\CSCO5T9CPOQS\1^./&^B?$_2]8N_B;X@\/Z'XY\*^(?\ A(]"GUJT
M6#2T\9Q_:[-].,0EANK.Q$N?L1EAN(((9]BOL+_IEX?\3Z7XKMY)M+U&QU*&
M-@KO:7"S(K%%< E21DHZ-@_PNIZ$54@^(GAVYN[JWCUW1I)]/F%M<QK?1E[6
M4L%$;C=E6+%5VG!R0.II@?GAXI^-GQX?X@?&R7PYK7Q%_P"%G^";?Q3)HO@<
M^"[Z32=9THI(="NX;^>1M/:41K;NJ1J+F2X::&564,R^L?\ !,_4-(\7?M1?
MM">(?#E]X\UKPMKT7A5M,U7Q/9:C;W%V%TZ42*CWL4<K;78EE'^K>0KA>%'U
MUJ7CS0=&L'NKS6=*M+6.Y^QO+/>1QQI/G'E$D@"3/&WK[5YGJO[7UO!\3/B5
MX3TWP?XFUC6/AF-">Y6.>Q@CU--59PKV[S7"#$"QR-()?+)V$()#@%;@?)%U
MJ_[3O@KQ3I?AV-O'6I:=X6\4Z[\--0UN:59I-<M-;(NM#\2+@A2-)B>U@G;'
MSO/<#@PX%KXZZMXJU+XY7%KK6L?$QO"G@O\ :)\.6]L]M]N"KI+^%;?&XVZ;
MI[5]5D968[U68G)7&5^DOB5^W?:^&?C#K'@OPGX%\5?$K5/"UQ8VGB/^P;W3
M(?[!>\4O"TJWEU 614 :0IDIYD0 <LVSW5=8LWU5[!;JW:^CB$S6RRCSDC)P
M'*9R%)!&<8R* /SY_P""<=QXT^'_ ,9_AYIYU;QDOA7QM<_%NZU/1;ZR*Z=:
MSP>-/.TV9?W2M#)+#=7CJ78F9'XRL:!=#XM?M*_$"W_X*$)X7T/6/&T>EW'B
MV\\+7ME+87'D1VLOA">]LWMU2W^SQP_VE%$4O'F,TDKSQ$)%#S]L:K\:?"&C
MW7A^&Z\2:+')XNO6TW1E^VHW]J7*QR2-%#@G>RI%(Q S@(<U)X*\?KXIT%KS
M4-+U+PS(=4NM+BM=5D@2:X,-Q+"DJ>5*ZE)UC$L8W;S'(NY4;<H /R_\4_M1
M^,OVA/@+ITNI>+/B1'HVE^"_A%KOB2[M=-O=+DMM0;Q,T7B&;>L",VRVCS/'
M'N5?*.5!5A7H/A/QIXX^%?[5GBC5_!^I>))E\5?'?6](D\.3VZ1:9KD0\ 1S
MVSRN\0D7.HV-F@G\Q5!WI_$^?T;:^A2=8S-'YDAPJ%_F) R<#Z<_3FG6EU;W
MQD$,T<ODL8W".&V,.JGT/J#0!^8WCG]KCXL6'[.MUXG\(^/_ !1>?;/AOIVI
M>++F\TJ-KOP9XL;5]-MWMD@>']RTL,VIK+:%2(191L!'YF]]_P#;?U3QMX,M
MOC5X)N/B9\0K[0O"?AGX>ZPNM%8(-0BCG\5:B-5F::UMHPR+8I#YBA2JQHI*
M@,V[[F^,'QYTCX,>+_AYH^J6FJW%Q\2O$9\,:7+:QH\5O=BPO+_=.6=66,PV
M,XW*'.XH,8.1L?#CQK-X^\)V^J76@:[X7FFFGB_L[6$BCO(A%,\0=EBDD3;(
M%$B8<DI(F0K$J#FN@/F_X9>,_B3:?MM:_P##"\U[Q'K7A6ZDL_B5HGB":"$1
MPZ%);&SDT&1A&K>:-1A%P"REFM[AE,@:/%>;_MH_&7QA\"?VY/B/JV@:]XFF
MO+'X.Z5J&E:.L1O+.VB.N74.KZA;VOEL)9[6S6&XV9)=EB4JX94KZCT[X9:#
M^RY;^+_%F@Z#XS\6:UXNUJ*[U&*&_DU;47-Q=A?+@^USA8+*W:YEF^SQLD<2
M&9D0L=K>@Z%XSTCQ=+J2:9J-EJ#:/>MIU[Y$PD%K=($9H7QP) '3*]02 >>*
M /$/V)?B?K'COXB?$ZPM_%TGQ&^&^DW&FS>%?%,K02M<O<6QDO+(3P*D=PD#
MB%Q(%)7[48F8F(@?*'[(/C9O ?@;X$WUMXYFUIO%7QU\?Z1J]_JL.GW5Q%IY
MD\2W;;+CR!);K)+:6,[.K+N,PY\MT0?H'\0OC-I_@?3=>-C9:GXMUKP[!;7%
MYH.A+'=:J([F1DB80LZ !MDC#<RY6)R,XQ76KT_^R- 'Q_\ \$[?VD?&'Q,^
M+?BSPCX_\77FN7NC:9!K'@^Z-C:VL/CCPU>7$SV>OD1(-MQM"VLD*B,((5E,
M:_:D">/_ !>_;]^(G@#7?CI%#XNDO)/!MU'JUAJND/I^HZ#I6D0>)K:TNX;N
M$VZW6GWUO9O-%-'<&6.9(9;F&1"C+'^D.,_>W>M*L49+?+C=C=QU^M%P/SGU
M3_@I#J5YXH\26OB#XM#P'\-;KXC>(O#FE_$"+3+22'3#;Z7IMQIEAOEA:%HY
MY+B_D25T8S"T2)9"9%+8_A_XV^*/A9^UYXSU[3_'T*MKWQ7^'OAK7M/DT6"T
MA\0)J/ARQAFDEBD5[BVDR?,CC213&T+*_F#('Z72*LJ_,NY00>>>0<@_@:!$
MLA^91USR._K0!\%?\%I/VBYO#7@#XI?#75O%4?@/0=>^!_BK5],N)4M?^*PU
M-+=X6TQ'N$<9BA8.T,6V:472E&41/G.\ _MT>+-1_:*USPG#\1_ /@^W\ I.
MB^%M95YKC4M&'AM+NSU98TMA+Y(NLS/<K<F'RHY(/+$VUJ_02:WCNF5I(E8Q
MG<FY<E3@C(]#@D?0FFSV\"M)-)'#N\O8\C#G8.<%O[HY.#Q1<#X%_9__ &OO
M%'Q-\4?!&Q\3:M;ZAK[_ !5O?#.M?VA#H^I0[E\&W6HK)I5_91K%- S-$R3Q
MI',J74EO*H96!\]\)?\ !3KXF^._V3OBQ\1-+^)GP\FN?!7PKF\0/8Q2:7>S
MVGB)9+KS!##!,9ETY(EM"HNT$I:=0S;A)''^D$-MX?U[X<+-ID4%SH=[8/<6
MCZ1]V6&9"V^W>'!RZL65HSDE@0><UX[^S'^QKX.\.Z9X0\:23>-O$-U9Z.!H
M,7C6TMX=2\-VMS;QB2V>..WAD\WRECCD^U>;*NPJ6!+9+@>$^._VTO''PW\4
M^.O!.K_%/1UU#3_B;8^&M'UA=,T^QDGM[SPH=8%GYDQ:UMMLZ2NL\T<SO%&8
M5229TD'C/AW]N[Q9\:_@I\6/'>K>.O#.K?VK^S[X(\5VGA2]L[*\\/K>W-QJ
ML6J2);2 M(JSPK&^YVVM*B2;O+B5?TOU?QGX<MM>T6SCTZ76)-:UE]-\_3=.
M-]!I]W;P2S;[N2-2MN$$!022E0)&CC!#.H/0CP7HRHJ?V5IH58%M0OV5,>2K
M;ECQC[@;D+T!YHN!\A:;^VAXZU_XU6RV5_8--:_%^Z^&VJ> 7MHENX=+6.5H
MM564_OO-,"Q:ADDPM;2&,(''FUY!^SM_P4,^-WCOX2>'=3NO%'@/Q!X@\>?!
MW3/'NGVKVMOHL-O?R:M#926T$TDK1^9<1SB.+[0?+6Z$>[$;,H_1Y/">DKKK
M:HNFV*ZHUL+1KL6Z?:&@!W"(OC=LSSMSC/:N6^*=A\/?A=\*]9UGQ3IGAK3_
M  GHNER#4'N;")K>*R7]XT93:=R%@"(P#N;& 6(H X[]B[]J+2/CO\)]#6Z\
M0-/XQNH=1FNM*U2WM]/UJ!+349K&;S;6&1T;R9XC T\#-!*Z%XSM=0/"?%?[
M8GQ6TK]J3Q!86/B#P;?^'?#GQKT?X<_\(M_9)35+_3=1T33+V2Y6X\\D2VIN
M[BXXBVM#:3ANQ3Z1^"]KX)^+%UIOCK1?#M]H]]X?M;SPO:0ZEHTVDW&EQ).H
MG@6"1$PA>"/#J"C*H*-M8[G_  K_ &4/"_PJ^+?Q \;0QC4_$/Q#UL:W=7=[
M:VS3:>W]GV5@;>WD6-9%@,5A"2KLQ+%SG!P #X?\-_\ !1KXS7/P"^#>N:MX
MV^$^FWWQVT[5;O2]:O[+^Q='T*[L(@8K%YI99UF>Z+-+AO+(2TN%0EBK+#\>
M_C%JGA3XU_%7XH>*QX'\8W7@/X3?#WQ/I^FS6?VK1_"NHW.JZNLNJ03,//2&
MW96N6E"))) B!L",&OT0UCX/>$?$/A"W\/W_ (7\.7V@6TRSPZ9<:;#+9Q2*
M^]76%E*!E<E@0,@\]:MM\/= DUO4-2;1=(;4M6MQ9W]T;./S[V  @12OC<Z
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M\^!/[1GPW\-WUO\ #OX?^(O#.E17=MHBWGAF#R;&.25DN4ABFB!C1Y(VW *
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M"?3.0:[*L_PKX5TWP-X9T_1=&T^STK2=*MTM+*RM(5AM[6%%"I&B* %55
M& !6A0 4444 %%%% !1110 4444 %%%% #9%WI7\M?\ P<.7=LO_  6*^,@;
M7%MV$ND@Q_82VS_B3V/&>_UK^I1U_B]!T]:_E._X.*M1"?\ !9;XTKYUV-L^
ME#"S  ?\2>QZ<4 ?U9!MRY7FD3.WYJ(D\M<4Z@ HHHH **** "BBB@ HHHH
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M-2,+7$D:I'*+,_:C;NRRK%F0H%!(%<#XQ^,G[!_QL^)GAKX@P_\ "N?"\?\
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M:$G4)X+4BXGDD>#S-WR;W+*H!K:=_P $L[[3_#7]DM\1EDLK/2O'VB:<#X?
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MQ9V/V^"-4A=G&]MCJV7"C<,$*#\H\2U7_@E]\1S\-M*T[3?$_@VSUKP[\,_
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M+?C+6M&T,ZM=-H<]U;2WKZ7<1:?<36MR]I=10W+((I'AN(Y(G56R&4G!7!*
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M=I?6%C<2LZ26]O>PB&ZB!1AE)4"@J<C**PPRJ1ROB3_@GQ\&?%W@C7/#>I>
M='OM#\1:!I?A?4+.629HY].TQG;3X/OY7[,SNT3IAT9MP8'FOGGXW_\ !0'7
MO '_  4=\/\ @.S\;:'_ ,(_/X[TOP=JNB7,%I:-9PWOA^[OU<&0FZGG-REL
M5G3R[4+(( LTWF&/QGX9?\%3/B]X8_9^TGQMXD\6>&O%!\4?")?&KM'H*6]M
MX9F37K;39K\I"Y>6VBMKQKB9&;_ER;:8PS  'Z'> /@[\-])^#NI?"WP_INA
M2^$=-M9="U+0XIA<I&DT698+G+,Y>6.7<YE)=_-W$G=D\O)_P3T^#MYX>NM)
MF\&PS6-YHNF>'9XY-1O',UAIUP;JRA9C,6/E3LT@;.XLS%B<FO+?^"7VL6.M
M_%S]J9K/QEIGCTM\2;.3^VK/[*/MD;>&=$V%OLP$18892Z!0Q0\ @UY3\$?V
MJ_'<OQI\2> =0^*C0S>+/B[XKT,:]?6EI,WAB+3[97T_3(HBHBCDN8T>1#,I
M#I97&U2\N\ 'V%!^QC\-K7Q?'K\?AI$UB+Q;)XZ6Y%_=9&M261L7O-OF;=QM
M28=I&S:<;:3]G;]BWX7_ +)M]KES\._"&G^%I/$=PUS>K;2RO&I9VD*0QR.R
M6\1D=W\J$)'N8MMR2:\_^'G[3/C7Q9_P3#U7XH:E%I-CXWTWPMK&H1W$,!DT
MZ^GLA<K!?11%\FVN1!'<(F\_NYU&\_>/S);?\% /CEHEKI=G)XV^'OB#_A*C
M\,;^UURV\.;+716\2ZJ;"\TQXUNB)F6)%N8G+J^V0@K@HU%@/M35_P!B'X9:
MY'XD^T>')&E\6>(;?Q9J-PFJ7D=Q_:\"1QPWL$JRA[:9$BC0- T9VJ%Z<5<T
M']F;X<_"/Q5I?C*TTN/2=2\*:1J&F0:E-J=QB"SO+E+V^,QDE*R-+<0I-)--
MN=G3<7SDU\T:?^UW\5=(\374=YXD\/ZOJ'@7XF:%\+]<\,IHJV=[K\-[%8)+
MK40,K/"Y^V/?I&"\(M;:5#N8-(G+>//VP?B=KG[(/[16G^*K?P?J/B+X!^%/
M&%KXUBU3P[YFC>(;E86N=%'D.Y0VUQIA6>>(,^/M$:,5Y4E@/J/]I']BWX/_
M +3&L0ZW\0M#M]3GO-+/AP3_ -L75@E]:37$<\=NX@FC68B=$DBW;FC<EH]I
M8DWM)_8:^%VE:W8ZE#X8W76G^(=3\50_:-3O+B/^TM2MY+6]G>-Y6202PS2H
M8W#1J)&VJI)-?&'[7_[1,WQ?^(%CX-GUWPGX?TOX4?&;X4V-MX=-E']LUA;R
M]T>_6^AD:0&*,-<201K$A&VPNE).[]U[%_P3\_;>\=_M7_%^[N-4U#X<Q>%[
MNWU9)/#=KJ&[Q-X9O[+4S;""X@"Y55B^68R[<3;#'E) H.4#USX$_L;_  ?_
M &,_%EO>^$=/_P"$=U/5M,MO"]F+[Q'>WADLK:26:WL;>.ZN) J1&679'&!L
M4[0 HQ6CIW[#GPSTKXH?\)E:Z%=P^(/^$HE\9I+'K-\L,6KRV$FG2W2P";RE
M:2UFE1E";6\QF(+8(^1/V^_'<OPX_;F^(GBK7(] \5:)\.?A7X<\0Z1H^M:8
M+FTT"\E\1W40U8MOW1K:RVT-W*Z!6:.T"[TV!JZKXB?M>?'#1_VGM+^#.@Z_
MX"EU#5_%D.CVOC"\\.RW%K]FNO"^LZND3VL=W&#=6\VEQEMLFV2"]MSA"2Q+
M >UV'_!+KX(Z5JG@>\M?"-U:W7P^L6TG29(M?U%6EL3<&Z^QW9$_^FVPN&,@
MAN?-0,3@8)!E_:S_ &2]3_:/^/?P7UZ/4O[-T'X=ZCJ][JK6NJW>FZFXN]+F
MLHOLLEO@[@\VYMSJ-HXW'@7/VT?CCKGP/\#^"[?1]:T73?$'C'Q-:^'K=[FP
M-S)>N]M<W$D=I$TL<(FV6SN#<3)$L<<I+,X1'^,W_P""M?QD\4_ +3_'VCM\
M-;*'3/@]H?Q*UBQFTV>Z-]=3ZK/9W5I#*MTJPQM';OM<B0QNP^^*.4#[B\-_
ML9_#/X?:A?/I.CR:3_;7A"R^'[P0:G<1PG1[/[2UM:QQ^9M1H_M=T1(@$A\U
MB6-8=S^P%\(_#=KI<C:7=:;I>BZ'IGAZXMCK5S%8ZMI^FG-A!?H9-MTL#,0I
MFW$AV1BR,5/SCXY_: U/]I/]L?X)7UQ?>&[+1?!'[0FO>"XM"^R'^UH)K'PM
MKR?:99S+TFR)A$(@#%/:MNR"7]6_X*'^'M0^(?[0_P"S+X1FOM'D\)^*/&NI
MP:YHNJ:4-0M-9CB\/:G.J2HTBJRCRV*A@P60QR=8@I /3+']BCX<S^$[72+>
MTU&33=/\=R_$6%%UFY?9KCWTM[)-N\PG8;N660P?ZH,Q&P#BO-_C+_P3FMO'
M6EQ_#G2;+PQ'\$_%GB27QCXVT[5Y[[4-0EOQJ5OJ2P::C.8+:WGN$F:8#&TS
M.8U#.2/!_"W[8&M?L7_L;^$M4\)^'?AIX;\ V?B[QCX/U.ST[3+F.V\-):Z[
M?6%IXA=1,[FPAEBB:^!);_2Q(LB[=K?2/_!4CXM>-_@#_P $VOB=XP\'>(K'
M2?&?AOP]]I@U8Z<)HA)E%DDCA:3",0S%"S.$)4D/C! /9?C/\'?#'[0_POUG
MP3XLL(]4T'6H%@O+59GA=<,LD;I)&RO%(CHKHZ$,CHK*00#7 7'[ _@/5-#T
M^UU"3Q-J5]8^*['QM)JMSK4S:AJ&JV4:16LUQ*"/,2..*-!"1Y6$&4)R3\I>
M&_C%XY_9Y_;I^*U]I][X1U/1_$'Q,\ >%_$D<UA.MUJ+:CH5G;-<VK+/LMMD
MKQ2[668N ZEEP';V'_@GQ^VU\0OVO?&5OK.J:/X-L?A]XDT*[U+3$MM3B;6=
M)O+:^2WDL9X5FD:39'(OFR,D)BF0H4(==H!WO[6_[+VN_M"_'#X*:SI^J#2-
M$^'NLZIJFK3VNI366ID7&DW5C$+5HXV!8/<EF#LHVK_$2 ,OQ#_P2K^#>MWF
MGR1:3XBT:'3;+0K&&VTGQ+J%C 5T6Z:ZTZ5UCF'F312/)^]?+L)&W$MAAXW\
M7/V\?B%\#OVD_CE9W&K:#J&@Z;XH\%^#O#%I=6:V\.@R:M;+)+<W,[7"+("T
MC*H8QAY# FY1P=?PQ^UU^T)XI^*?@_P)):_!W1_$4_A'6?$VO2-]IU.+_B6Z
MU;66V'[/<A(WFMKC>T9=_(F!0O(!FBP'I'PD_8MOO&_@?XP7GQDT_P '0^,?
MCU8KHGBY?!DUU':OID5I)8P0I<3!)GD\F69C)M0H9MJY$:N=W4_^">/P_P!8
MO-6FFD\2%]:G\,W-UMU>1=TGAZ59M,8>FR5$=\?ZPJ-V1Q7R/;?\%5/CE;?"
M:W\6W6G_  MEMU^&'@[XK36L.GWJ.UMJUY+:76F*S7'$G[HR1W17:A^0PN#O
M'U!\+_VLO%&L_MT>(/ACXJL;+P[IWV>]NO"\3:;/)_PDEK;-:*]U;ZBDC6SM
M&\TR3VDB13PGR2!(A+EZ@%Y_P2T^%]WIOQ,TU9/&EOH'Q3-VVIZ)'XEN_P"R
MM.>\D$M[)8VQ8QVKW,F6D9!G+R!=@D<-O^(OV"/ GB;QY>^);BX\3QZ_?>,+
M+QTUY;:Q);RQZE:::NE*4,>W;$]B/(DC'#*S'ACNKSK]IO\ ;P\7?"OQ)\9+
MCPQIGA^[TGX V6CZKK^EW\,K:CXEM[Q'GE6RD215@9($*Q%HYO.G5X\)MW&K
M^RO\-[CXI?\ !0+]H#Q=XRDTO6M2^&_C6TTOPE<16T]O=:+:S^&=.D>V#^>R
MM RWKLT)389RTV%;8$0'MGQK_9$\)_'CX@:;XGU>77+75]-\/:MX6$NG:D]L
MEQI^I+"+F&5!E9!N@AD0D?*\:GVK@O$O_!+/X7^*?#&H:9<MXJC^V:)X;T2"
M]M]9DM[[2AX?>:32KJUG0!X;J&2XF<R _.7(<,ORUQGCS_@HSX@\$^"OBM\2
MHK#PAJ'PY^$U]XHT;5=$>ZFMO$3W>C6CSJT;_-&_VAH7/DF)2EO)%/O<9CJC
M\8OVZOBM\$/%5]X/NM)\ ^(?$#7O@:;3M5M(KNVTF>T\1:X^CO%(OFR.LUO)
M&TJ2!BLT9_U:,K @'M7A3]A7P7X:\7?VS<7'B+Q%=S>#Y?!-^-<U-M075K&:
MX>YG:Y,@+2322.^YMP 5MJJJ@ <;X&_X);>"_AUX.\-Z;I?B[XHMJ7@?4XM0
M\+:[?^)&U+4_#,<<$ULEG;-<I)']D^SSS1-%)&XD5P7+,D;+YOI?_!4#Q1\.
M=#\'>(?B1I/AVU\(W7C3Q;\.O$>JZ1#.&AU?2;F]BT][>.21BL=_]AEC$;%R
MMQ)!&'?S01IK^W?\8[KXKZOX9L_AWX9O)/AW<:/I/CV7^U[>"'3[J_TB*_:X
M@:2Z$[0PRW,$2QBWD-SMFV2(Z;*+ >T^$/V'_!_@3XA?#_Q+IESKUO??#NUU
MJVLD-XLD>H/K$\5SJ-Q=[D+2S37$2RE@R@/N( #$')_:'_X)Z>$?VDOB?=^*
MM6U[QOH^H7]CI%C=1:/JPMK>X&E:HVIZ?*RE&/F0W+RD8(5A(=RL50KXCIO_
M  4D^)VB?LZ?!OXE>-/#O@GPUX3^*>F6&N76N6D6I:IIGAB"[MM,D@M=0:-5
MEM6GDNKX+>%'MHC;0I*1YOF"]\!_VJM<U;XL^*?AOX%\.^%_#_BWQ!XS\=:@
M+W6+Z^OM/N8]&N].MI'*[_,$]S)J%L?*C98X4CF95;:J. >H2?\ !,3X<:E;
M6MGJDWB36M,BNO%MU<6-Y?J8;\>)GE?5(IMD:N49II?+VLI3>1D@#'1?LQ?L
M3:3^S#XPU37K;Q=X\\7ZMJV@Z7X;EN?$NH0W<BV6G/=-:(#'#'EE^V2AG;+/
M]YBS%F/S);?\%@O&GBWPNOBO1? /AVU\-V.A?#_Q!J=M?ZI.=16/Q'K5[I-Q
M;P[(Q&[026ADCE)"R*!\O[P&/ZQ_:=^/=Y\&+GX?Z+I5O8SZ_P#$SQ/'X5TJ
M:_9UL[*8V-[?O-,$^9PL%A,%C!4R2-&F] Q8 '$'_@F[X5TWQ_<>*M%\3>-=
M \2+XMO_ !AIM[:W5M+_ &-<W\ BU""&.:!T:VN?OO',),.%9"FQ-O1>*?V%
M?!/BC]D>/X-QMK.F>';=H;JUO[*]\O5+2_AO%OX]12<@_P"E"]07!9E*M)NW
M*58J?FCXF_'[QG^UQXE^!O@K4+/2M"L=4^*7B7P-\0-+AN[P6NL'2M+U1P]K
M<1-%(8'\A+A5.&CF6)6+>4Y;W#]K7]J&\_89T7X?V$%B&\(3J=/U#Q5X@GOK
MNRTDPFUBMX+ZZC662%[E9)2+VY/DJ]OB5]TRF@#)U+_@E7H%X5U2W^)7Q6TS
MQQ'XJN/%R>+[&_LK?5$N;JSM[.\@V+:_9C;3PVL.Z%H2JLB,FTJN+WQ,_P""
M7O@WXE:EXMNW\4?$#2;OQ5'H,T=Q8ZI']IT;4M&P++5+:>2)Y1=!%1'\QWBD
M4-NC)D<MPOB;_@JW<> 6:_USPE;KH.F^*?'F@ZE+:7CO<I;^&[*[O%N8HRF&
M:=;1E,9.%+C#-C!R_P!HSXT_%3Q1XB^!<DVF>&]*O-0^).C7.C'1O%\XLM;L
MKS0M7F>"\58PWEQ20<,4=)_*5T6-@50 ]T\/_L/Z=HGCW_A*+SQIXWU_79?!
M%QX'NKS5+JVFDO()[HW3W;[85 N/,8A0@6%4PHB 48X>[_X)/>";[X6W7A)O
M%'C3^S;SP%X>^';2">T\U=.T2XDN+1U/D8\YFED$C8VLK<*" 1Z=^QM\?;C]
MKS]E;P[XRU324T&^UR*YM-0L;6\>6.WN+>ZFLY_)FPCE#)"[(V%8*5S@U^??
M[%WQS^.'PX_8T\"?M *OCKQ-X.\,_![Q%XE\=?\ "8>,1?6_C34(-D^G?80T
M]S/:2JL5V))##$A1XU*NP!C /N3Q%_P3]\.^)/$6O:E)XB\3POXB^)6D_%"Y
MBC>V\M=1TZVLK:&!<PD_9V33[8NI)?*L0ZYKEH/^"7^E^'-1\/ZGX9^)OQ)\
M'Z]H>I>(;F75=*EL!/J=EKFJ2:I>Z=,LEJ\?DBZD+12*@FA_AD!))PM2_P""
MA7Q.L/B)#X1A^"RZUXFL-+TKQ-K=AH_B(7"6>D:EJ5W:6\B3S0P1F>.&RGN)
M5;"?N_+5V+;U\ULOVA_%GAC]J7Q]XBURSU#7?$D?Q9E^&W@;2M,\4Z@NEB ^
M&;;4)([RT$8A=$2&6X5A&\OVB9U!"*'HU8'V5^TA^S=H/[4'P!USX<^(9-1@
MT?7((HC<V5TT-]920RI-!<0S<LD\4T4<B2<E716ZBO+_ !S_ ,$P?A_XI\%_
M&31=-DU;PNGQM73H]9ETUX\626-O!;PK;1R(T<>4@&XE26+$]0"/-]3_ ."H
M/Q,TC0?'^H7_ ,!K?11\*? 4'C;Q7:ZGXUCCNK%Y+'4YQ91)#:RK(WGZ=Y>_
M</W<ZN5#!HAN:G_P44^)&F>*+/PVGP.N-6\70:?I_B+5M(T?Q ;YK72;^^GM
MK:2.?[*D)N/+MKF:1)6CC7R-BRL7#  Z+XA_\$V+7Q9\1=6\::+\2_'7@[QQ
M=^+V\7V&MZ9'822:4\NE6NE7-FL,]O)#-;36MI#N6=)"LD:2*0RBK'BC_@F]
MI/B3X@:QKI\=>,HQKFI>$]:N[>0VEQY]]X>N(IK:X:5X3(3-]GA25=P4A6*A
M6;(\_P#"_P"U3XC_ &@/V\O@GJ&DQR:7\-M6A\>6-J;?796_MYM-N;.S$]U9
MB-8E'FQ3/"3)(RHYR(V9EH_X*6^,/B%\+?B38^*%_P"%@7WP8L/"]Y;Z_-X!
MU$PZ[X(OWF#1:]+9HPDU&UCBC=?*42;/+E8Q2@G::W Z[4/^"97V#Q)I_B#P
MI\5_'W@OQ18^(O$>L'5M.AT^5[BSUV]CO+_37BFMWB:(30PM%(4,L31@ACE@
M?7?@3^SG;_ KQE\1]6MM:U/5?^%C^((?$-Q!>+&?L,T>FV6G;4< .X:*QA8F
M0LQ8L<\U\Y^%/^"E&M?\+G\5:'!I_AOQ7X;EO/".@^ ;^UU62"3Q'=:QI[7O
MVBY9K<K#";=7F++O8+"%5'>0"NG\/?\ !1SQ#XZUW6O!?ASX8KJWQ9\+SZ_%
MJ_AJ3Q$MK:L-)^P$FUO7@VS&Z75=/:'?'$H$["5H3&03E8$/Q>_X)3Z)\;O'
M/Q'\2:QXNOX?$'CS19M$AU*PTJTM;JSB-];7UHUPR+MOVLIK2%+<SKE(3+&2
MWF,U%Y_P2YN[+Q)/XMT'XP>--#^)$GB^Z\6IXE73M/GV"\TZRTZ]L#:-#Y#V
MTL5C ZAE+QRQQL&(4JV/^S9^V#>:A_P4+^-_PH2ZNM<UK_A*K'5H-,U757C3
MPUH/_"+Z%+.]J=DB3G[==G-O VU6N6=G160O[U\<OVB;SX<?$GPEX&\.Z#;^
M)/&OC2TU+4=/M+O4O[-LTM=/2 W$LLXBE8?O+NUC55C8EILG:JLP'<#S7Q;_
M ,$V;3Q;XSUS6IO'&OR3ZWK_ (+U^0W5O#<2B3PU<QW,"M)A2_VB2,&5L#&3
ML"UUW[3'[']U\<OB[\.?B#X?\;:IX%\:?#==2L[.Z@LH;^UOK#45MUO+6>"7
MAMQM;=T<,#&\2DAU+(>#_9^_X*57_P"T_P#%_P +>'?!_P ,M5GTC5O#&G>*
M=:U6^UFWM6\.PW5SJEE) \&&::>&[TR2(B)BC*Y=7PH#;7[:_P#P4%C_ &,M
M9'VSPFVM:3::=!JM]<KJT<%PT,E\EHRVMLJ223/%O\V1I/)A52@\TLVT&H%7
M]GK_ ()IZ-\#!X;M+SQ#=>+=#T'X36?PEFT[4;"%%U.RMY68SRLA'+QN8V3&
M,<YR3EW@S_@FYI_@+X&_!GP/9^,-:O8_A'XGM?$KZIJ<*75_XC:"WN+817$F
M5V_N9UC5QDJD$2@;1BLOP]_P4JU+Q3\9)?"MG\+]4:WN/%OB/P+I6HOKEJJZ
MGJ^DV<MXJ>7@M'#/'!,!*Y_=N@#*0P:O0OV2/VS+']K[PSH6L:+H=Y8V&I>&
M[;6M0-Q,/,T:]EFF@?2Y4V@_:(9+:X67'W#& 1\ZD@'A-C_P1BCNO!=KX5US
MXK>(M4\+^&O U[\/?"<$&DVUK>^'].:_T^]T^0W +>?<V3:9:HCLBK(L2ETW
M;BWIUC^P[XMUG6/AKK?B[XI#Q-XE\ S:S/<7D?ABWT^WU-[_ $\V*[((I,0+
M$I\S&Z0N[-RH*A:OQ4_X*<^&/A!\5_B7X<UC2Y8X_A;I#ZQJ:_;8TU:\A^S0
MS1S6E@X62YM99)A;+/$S 7$;HX0 ,<G4?^"EWB"TBT?3X/@=\0+SQ7X@\4W_
M (5TK2VEBTN+5);?2)-56Y@GU 6VZW>.)X2S(I2:.12"%5F>H'%Q_P#!&W4-
M$^%^F^$= ^+<^F:/)X7\'^'=?2;PW'='59?#,T+V5Y#FX'V9Y8X1%,G[Q6 5
ME\M@2WL_P*_8A?X._M5^.OBDVO:?]H\;6\EM=Z;HVDMI5MJ+&Z\Z*[OXQ.\5
MS?0Q!;=;E(X7>/=YF\E=GF&E_P#!1[3?AF?%]C;Z#\2/&'BZX\9^)K2ST&Z=
M+R;R])2U:Z6U>VB81VP-Q;I"C@MYEP [J"S)Z=\)_P!OK1_C'^T:_P .=/T'
M4]-U*WTBTUF[@UB>+3]5MH+FSBNHYCI\I$[VX,PMWE0,([A'C8#;N*L[ >;_
M !X_X)17'QR\:?%36QXXTOPS??$W1KC1;J?2?#K0M?1O<6LMM+J48NA%?7%G
M';/!!,$AD$<[!F?&#H?%7_@F?KGQ$\0^-KBW^)%K:Z3\0/'4WB[5]'NO#@O+
M&Y@E\.6NA_998S< 3/%]DBNHI'_=K+]Z&3:A7-_X*,_ME^-OA7=?%;P3X7T^
M31?^$?\ @GKWQ M_%D%W$US9WUN3';1I ZD;0R-N)#;O,7 4(=VU8?\ !3_2
M_"^D:EI/B+P?XLTOQEH_B6Q\(PZ5.8;B75KBYT@ZM%<B2V:5$C-K%<.X.60P
M,-IW+DC?= <Y_P .F]7N/@7K'@ZY^(]C)-J_PM\,_#0WJ^'2HA71KBYE6[\O
M[3\WFK<LGE[AM**VYLE:]Y_:S_9UU/\ :%\/>#6T?6[/0]>\"^*K#Q9I\MW9
MM=6ES-;"5#!*BNCA'29QN5@5.#A@"I\EN/\ @K1H=C!'=WGPS^)NF:78>!H/
MB#XBN=0M+6SD\+Z9(U]&WVBWEG6=YEEL)(Q%#&[/O1D#*2PWO"'_  4ALO&V
MH+H-G\/_ !M'XWO-8ETK3-"NX8[1=52*SCO9KJ*ZE*PM#%%*J2$,628B/:=R
ML34#S[5O^"2M[IWC[0_%6A>+_"+Z[>#58_&1\1>"8-:M-7_M'5)]4DN+*&28
M?8YX9[F=(MS2QF.11*DI0$^P_M7_ +,WC3XF^-?A[XT^&OC;2O!OC;X?O>VD
M;ZSI#ZKIFIZ=?1Q)=0301S0OO#6]O-&Z2+AX0I!5V%>-P_ME>)OVS?VE?A=X
M8^'MUXM\$^#O$/@_5_%5[JD,5@+^UU'3-8LK":PNX)_,S'#*;NWF2,'>\JLD
MA5-U>J?M8_M4Z?\ LU?&+2[K5KOQBVFZ3\//%?C*YTG3+:RDLM5M]+.FM.SO
M*PF6XA6X7RE5EC<3R[B2J@ '"_$S_@FUXN\;_&ZZ\06?Q&TNWT?5M;\%>)=4
M@O?#WGWMY?\ AVYCD^62.>...*XCBCRHC)209!VDK5&Q_P""7FOV&CZ/;MXV
MT>:;3-%^)>F2,=)D59G\6ZHFHHX'G':MJR>6PR3*#D>6>*N>+/\ @JT8[>QM
M=&^&'C :_)XW\+^&+K3-6N+&UFBLM;030:@I6=T8&,2QB)G619%^=549/I7P
MZ_;]\+_$;XF^%-#@TGQ!:Z3\0KG4['PCXBEBA;3?$5SIPE:ZACV2-+$?+@N)
M(S-&BRQV\C*?NAC4#QK7O^"7?C6>2QL])\?>&;#1[C1? %GK"7&@S7$\]UX6
MU$72F!A<((X;A."'#NC(,,0QVT/CC_P2L\<_%'X<^-/"UCX_\-V>D^.M4\=7
M=]:W6E7$L*IX@C M93Y<T;236;!UV.?)D$YD*>9#%CU_XK?'7Q5X^_;MTWX%
M^$]7;PC;Z9X+'COQ'K\5G#=WS0S7SV5G96J3JT*,[P74DDKQR[5A10H,F]6:
MK^U'K7[+=AJOA[QT=5^*7BC1[*_\532>%M+@@N;;PY#(H6ZN+=Y44S+N>,10
M%Y+AH)&BBZHKU X'6?\ @G)X[UC3O'5G)XL\(_9_&VO^ O$\I73;E'M[SP_)
MI+74:_O&'DS+I*>7G+(;AMQ.P;NG\9?\$SM/\:?$KX[W<OB2ZL?"OQJ\.7-@
MFCVUNF-"U6_L/[.U+5(B>#+-:P6( X"LEP>LSEI[[_@K'\.8_%D>GZ=HWCKQ
M!I\NK:-HT>MZ7I4<^G33ZQ8I>Z7L;S1(ZW"2Q(&5"(WD7S?*0[Z2]_X*N>!;
M/P!H^N#PK\2+B76-'\2ZP=+@TF&2]L$\/7B6>K13_O\ RUDAF8@8D99 OR,Y
M9 QJ!T?[!7[,_B;]G7P1J2^-+7X5KXGU!;>UN;WP1X??28M4BMD9(KBYWLS-
M,P=CL&(XLE4R"2? ?$__  2G\<^+_P!F2'X8WWB+PC]E\ _#WQ3X \$ZM']H
M%U?Q:M9"Q@FU)-F(_)MP/,2)I//E59<Q[=A]T\,?\%,?AYXK35EM[3Q;#>6;
M:'_9MA=:2;>Z\21ZUYO]ERV:,PRDY@N!^^,1B^SRM*(D4M69XG_X*K?#OPS9
MP1MH?CZ^\022:[;7.@6.B?:=2TZZT6.&6_MIPK^4CK%/%(CB0Q3)(AC=PZ;E
M9] /HGPEIDFD>%M-M9DMXYK6TB@D6 DQ*RH%(3(!V@CC(''85I5B_#CQ]I7Q
M6^'N@^*-!NOMVA^)-.M]5TZY"-']HMIXUEB?:P#+N1E." 1GD5M4 %%%% !1
M110 4444 %%%% !114>]O/*X^7 .: 'O]P_2OY3/^#BK4&C_ ."R_P :5^V:
MDFVXTH;4F<*/^)/8] &'\J_JS;[IK^4O_@XK\.17'_!9?XU2%[C+W&E$XG91
M_P @>Q[;30!_5K1110 4444 %%%% !03BBB@ HHHH **** "N/\ C=\5/#/P
M7\"R>(/%DWE:;!<VMK$JVKW<US=7$Z06T$,**SR323R1HBJ"2SCZUV%>+_M^
M?#'PY\8_V;;[PYXM\+>*/%7A_4M1T_[5'X;DGCUC2F2[BDBU&U:#$PEM95CG
M_=?/MB; <_(P!O\ @/XE?#_XQZ&S6UK;*+;76T^2PUC26L+F#58XQ.8_(N$5
MC.(R) R@Y7YU8KS7?KI%FNJ->K;6ZWLD2P-<>6/->,$L$+8R5!9B!G +$]Z_
M.7PW\&_B;XA\4?!#5/':^,OB59_#GXS7MOX>\6W7AZ?2]8O]%F\,W,-K?ZM9
M0^60(M39;9[EXXQ)%!'*RJDK%L^P\+_'I?@[I^K>"=-^)EM\3+'X=:Q9_%2P
MU&YN[?\ X2+Q#'/I_E-ITLY^S^?,$U4VT]D?+CBGB5BH$"JP/O#Q]\1/!'A#
MXV^#O#.M6=L?%GQ :X71Y#IAE^T'3X6N'#3A2(S&DCL@=@26?;_%776_@/0[
M556/1]*C"6[VBA+2-=L+G+Q#C[C$DE>A)Y%?FG\=_!_CGQC!\,_&7P/\#_&*
MUM[?6O$NNC2O&L>H07T=J^A013V%L\S&?2OM7ESPVSRYVW<LDJH492?JC]HW
MQ#KVO?L(^%]5^'N@^/;+3I+WP_<:QHS0W=KXH@\/B_MCJ=N(W/VK[4MF)U95
M8S.%<1LSLA*L!ZWX_P#'G@O]E?P/!=36=MH]G>75OI=AI^DZ>&N-1NG41P6U
MO!$N9)"J8"@?*D9)PJDC(U+QK\,?&7P-N/&6J:5IMSX7UW2CXLNH-2T%A=7D
M,$"2&>6REC\YIHHUC&UHS(I5%P#@5\;>.O@;K/B_4? /VK3_ (F:UX T_P#:
M"M=3\'K<C5VO]%T'^Q"MQ),<BXBM%U/[0(FN<%(Y%VD1,JUZ/_P4-^%UUJG[
M7G@GQ-'H'C#5HG^$?Q T""YTB"^NK:'4IETJ:UAGCM\HOFPQ7X4R+MD=47)<
M1 &B ^EM7TGP_P#M8_LNW5CI>H75KX5^)7A=H;6^LXA%,EE?6F$EC212%812
M@@.A . 1QBH_AW^SKX'^"GP8T;PM'HV@MH?AF&WE::[L+:,2S6T*1B]F"HL8
MGVQ!C(%&,<8 &/SFT+PM\8/V>_@5<Z?H%G\:9/"MKX+^%6H>(+)(-3U+4+=1
M]OAU^+38G<.)4ABTSS[2U="L8<(BLQ!^E?B!^SUXQ^-__!&KX@?#?PSX@\<:
MYXF\6>%M8T_0KSQA;MINK:C'.9FAM9TF(E@1XV%NIN#YJQ,AE^<-0!ZSX%_:
M;^"?Q3^+GAV\T>?3;SQ1XHAFM/#NN2^'[B :_!%$\\JV&H20+'=1+$CR?N97
M4K\PR#D^NZIX,T?7=,U*QOM+TV\L]9!_M"WGMDDBOP46,^:K B3*(B_-GY54
M= *^<?'WQYU#XN?LB:XGPD\'^(M/^*FB>&+Z;PYIFL^%YM/;PSJT>GRQ11;K
MF-8%E#.8$\MG1_,X+0EFKYY^(#^-]?N?,^'.M?'2S^%NM^(?AVI^TOK*ZYI^
MH2:Q<1^($W3J;E+<:;]C-P#^X27>5P_F@ 'W_K'P1\%^(=<L-4U#PEX8OM2T
MJ&.VLKNXTJ"6>SBCD62..-V0LBK(JNJJ0 R@CD"KOA_X:^'/"?B75M:TO0=%
MTW6/$#I)J=]:6,4-SJ;(,(9Y%4-*5!(!<G -?G+;:-XST[]L7QQX8\">/_C)
MJGBCX9?%3PII.AZ9J6MZEJ&A/X>?P]H<^L#4'DW02[X9;R;?*YE6<P^5M:7$
MG.^/?&?QLF_8_P!:USPSJ7QDA^) ^"VN+\2+.6#5&FL/&\7V/[$=,C*[$E:[
M;451+']P]L(SC8(22P'Z=7GPQ\,ZCXBO-8N/#^ASZMJ%F=.N[Z2PB:XN;4]8
M'D*[FBY/R$E>>E<6OAKX4?"O6_!'ANV\+^%]+GOM5NE\-6UAH*>3:7T5K++.
M\;11%+:000R NQ0G&P$DA3\8_M5:SXU^"'[2/A/1/"&M?':\L?#^O>#=3DU"
M]?5]:M=5TW4?$TRZQ$@@C\K;':W&V4W9E:*);5((H=OF5@_!ZR^*'PC^&GPJ
MT'X;P_$8>*(?B!\4H-2T[77U*2QO)UM]=FTS[;)<Y1K9KC^S6CE+>6[R95F=
MGR60'Z1>.?AOX=^*&DP6/B30]&\06-O<Q7L-MJ5E'=Q13Q'='*JR @.C<JP&
M0>E<Y!^RM\,8-'N-.7X=^!$L+RT^P7%LN@VJPSVWGFX\AEV8:/SV:78>-[%L
M;B37P!\0_'7Q1O/@[)J_P\\2?&A=)U3PQX7/B-K^'4/[:T?Q*?$.GQW0@CF1
MFC9[%]0^U01)]GC6"%@BAR6^C/V=?%7B[P=^S_\ M%0WE]\1]:D\#>*_$=OX
M8EGC>_UR6R2RAN84LVNE/VLB:658"^]"0J995Q18#WRX_9M^'=Y\3D\;3>!/
M!LOC*-HI$UU]&MVU)6BC:*,BXV>9E(W9%.[A6('%5?CZ/AWX-\,_\+$^(=EX
M?73_ (:Q3ZY'K6I62W#>'T2/,US&VUGB(0'<R<[0>U?G-\#OC-\3/B)XL\,^
M&O\ A+?B]9^&];^(GA2ZBN5BU<S-I%]X7NI+V!K^ZA5Y(6OH 7D B6.5B8U@
MR@'(?&+XS?$'X@_L&>(O!_Q&U'XM3VNK_!SQE9>%;BVT_4?M?BK6[;4=3LTM
M]0\F(R22'3XM/*K. DZ75S)ABH="R0'Z9>)/AS\'?A=\-K[6M0\+^!]'\,W6
MGSV=W(VD0+#<VU_.KRVY0)F075PZ$Q $S2NHVLY%,^!/Q/\ A)^UM\$M7TOP
M2VA>)O >GM-X2U'3#IC0V4/EPHDVGR6TT:@*D<BQO$5PO*$ JRCQK_@J!X<M
M_%?[%'@&&XD\40%/'7@><)I+WEO<^6FN:>\[2+!APL4 EE)<?NVB5_E9%(\W
M^)GC#XP:_#\3M+^&_B_Q%'\2/#?QHV_#_3=5CF_L?7M/M]$TZZN],O9&"C^S
MW+7P\_=O6<($=G^1CE ^RK+]F3X:Z3%_H_@+P;;JEQ8W@\O1[=0)K&,1V4O"
M??MXU58FZQJH"D 5C_!SP[\(?#_QQ^(Z>!='\%Z9X_DGL[SQO)I.G16^H7$M
MS&TEM)>2(H:1G0,REB2<D]3S\^?$WQ=<_M&_\$-OB#K7A?4/B-=:YKGP^U>[
M'VQKJT\16^I"&:2:U95"R*T=P'A$<>4**%4NA!;Q&75M8\+?M-^(/&_@#Q5X
M\MM&;Q%\(=,A*P2O;>(=+NI/LUZUT9H3),HL[B1F9F'E$"0[6 -'*!^A/C;]
MF3X<_$J]\1W'B#P+X/UVX\8:9%HVNR:AI$%P^L643,\=M<%E)EB1G9E1LA2<
MC!IOA[]E_P"&_A'^R_[)\"^$-,_L71)/#5A]ETJ"'[%I<A#264>U1MMV903&
M,*2 2,U\J_\ !-?XR^//B]^T9XJ_X3+X@^))/$FC1ZMIWBWP!=>#KZTLM!ND
MU,BPN(K^:4VY3[("L0M44744BS."Z,U=!J6H_%_PS^VSXU^'%G<>*=:\.ZU]
MG^)OA_5I96CM+*VBADMKGPV;@_*@;4(K.8+@DV]_. <0@J<NH'OD_P"Q[\)6
M\.MI<GPY\#_V7_8]MH#6S:/;^2=-M9?.M[,KMQY$4GSI']U6Y !J/X9^#OA/
M%\=O&U]X6TOPK#\0M)GCB\3SV5LBW]O+=PPW $S 9#31K Y/5PB$YVC'YP?'
MKXJ^/_BK^Q=J%S:^./B)JT.K_"V/6?BG;-]HMKWP?XBAU?1_,MU2-%>S62VE
MUI);-1L\FRC?;@EY?6?BA^T!X]U7X\>(O#/AWXA>,=+T%_B[X&T+3[JWMHFN
M(]&O=!BFN8PTT#$K),79I) 663(+#!2CE ^XO%W[//@/Q[\1--\7:UX3\/:I
MXFTA(XK35+FR22ZA2*;SXE#D9(CF_>(#D(YW+AN:O>"OA!X5^&_B/Q%K&@Z!
MI&CZIXNO%U'6[JTMEAFU:Y"",33L.9'"!5W-DX4#H!7Y>^,?VY?B)X2_9]\"
MV>I?&:?P[K&IZ+X_TS1=<UF2VT^0ZUIWB)+'0M1U&62'R;BV2S#&:$(3*L@D
M\IR4=/KO]O\ ^,^K?#C]G'X3ZOX=^)UQH-CXB\;^&-)U'Q79FQD6]TV\F6.>
M?S)(7MU61&$@D5 HX/"94E@/:;7]E#X96GQJUKXC)X#\(CQYXCL!I>J:_P#V
M9#_:&H6H4)Y,LNW<Z%552#U5%!R  *?AW]C+X4>$O"<&AZ?\/_"MKI%KJ%EJ
MD-HE@ACANK)P]G(H.=IMV53$!Q%@; N*^$?#'[4?Q0B\)7OAWQI\6/$7AS2[
M7PYXHU#X<>.OL5HMUX\N[+6[NWT\SKY BN918I92);1HHODN7D5'V@KTGQN^
M/W[2?PKN];N+BR\23:E)X9\._%U=,T^&-[/2[73A&/%7AE)#$YEDFQ']G4GS
M6:_8JX6WVD2 ^Y+/]GCP/IWA^YTF'PKX?CTN\U\^*I[4V:-%+JQNUO3?%2/]
M>;I1-OZ^8-W6L?QO^QQ\*_B5\9K?XB:YX!\*ZKXZL]/?2H=<N+!&ODM75E,7
MF8R0%DD )R5$CX(W'/QM\7_VG?B=X<^._@/PEJ?Q4G^%MQXS\/:?XK\,G5/#
M,FJ+KVI7>LW4EYH 2)5$TEI8FQM5BWI(RW)GY:,NGJW[#7[1TCP7NO?$CXS7
M&L7'C?XA>(O GA?0M0MK&UMX9M/UG55MHH6@@1Y)Y+*&,DNV&2-"HR<L >J:
MQ^SY\#KCQ/X(^'MWH?A'^U/".@2CPUX<\T)):Z/%);1R*EL&'F6B2):*5=6C
M#+%P"!67X'^#/[._[2.G:S%X7M? WBB/1O%5SK>HRZ)?B2;3]:NX0;B9I8)-
M\<L\,V7PP$L<O(96Y\V_;I^*NMZ9^T+XL\'P^+)M#T&Z^ ?BK762WCM4N+2\
M@N[*..Y2=XFD4^7)*NW<4^7<%W+N%/PQX\M_V:O^",7@OQ7IOBR[T>XC\&>&
MED\2PZ;97=Q")196XWY6.W58TD\GSY@4MT7S9!((F5BP'T)XD_8P^%OBVRU.
MVOO!&@36NL6>E:?>0K$8X9[?2IC/IL)12%"6TK%XE  0L2.IKJ?BU\&O"_QV
M\)KH?BS2+76M/CN[>_A24LDEM<P2"6&>*1"'BEC=0RR(RLI'!K\V_"O[</Q8
M^)XT'PS;_&;^P9K4?%6UU+4],M-,U"XN!HEQ9OI$GG3V:QL8[:X!,BP(L\3%
MBNYA(OKWP>_:4^,GCSQW\)[.[UZ]FT7]H;X?>'?$^B:C8Z9:-;^%+^T6&X\0
M0-^Y/R7-K<0F!IR^V4RJN,**8'U3_P ,H?#]+CP5,OAFQAD^'=]<ZGX<:*26
M-M-NKA9%N)P58;Y)1--O:3<7\Z3=G>V6_'[X%?#WXH6D>M>/[.UFL="M+B*6
M:ZU&:SM/LDAB>>*Y"2)'-;L8(BT<P:,[!E:Y[XU?M40W'[%'Q$^)WPEGTSX@
M7GAG1-8N=)CT^3[7#>W]@LZ/!B/YG9)X65HU^9BA4<D5\4?M=?&[7OB)\%_$
M^B0_&63Q=\/6U;X5ZYI'C2TATN*3[5J/BB**[TYBD'D21I#;VU\J%/,19]LI
M>$A60'V5\-/V5_@+\1?%D?Q<\):#X/\ $5[KE[>:S;^(-/N_M]I<7%S;FRNY
MH2LC0CSHU:.4( '()<%LFJOP,_8@^ /@/3H-+\ ^&?#<,/@/Q.-22+3]2EN&
MT35XK9HEC8^:S1-%;W+*ENV$BCG(5%#\\;_P4E^+WB+]DWX%^'[KP'JUCH<-
MO>7U_K<-E)I=GK6HV:6MQ/<SZ?%>1?8[FZ6=UNI+<B-YU2;8ZDG/A?P(^-GB
M'P)^V'JVI:'XPC@\)?$3]H2?P_J^@2Z5!'_:"R^ ;6]6=G=3<13I<6D $:%1
M_K$8,2-HH@??'PK^"/AGX(_#&'P=X5TT:)X<M?/,%I;W,W[HSRO-*5D9S("T
MDKMD-D%L@BN=T#]CKX;^&/V7IO@O8^'5M_AE<:9-HK:$+ZY,8LI@PDMQ(9/-
M",'88#C 8@8'%?GEX-_X*B_$+QMI]O8Z+\8O#^I2^)4^&>I:7JL^F:8UQ'#K
MOB*XTO4\V,0'V>,1) _V:66:>V,@62?>Q5?6O"7[7_Q.M?VP->^'>K?%SX?:
M???#*^CTS4M%\011VVI>+K ^'X[D:S'9P6N]0UXTLS2P7/V>*&"6)XE9=]5R
M@?4?C_\ 8-^%/Q2^(W@_Q=KOA."^\2> [--.TF_^VW,<OV1&#I:W&V0"[@61
M5D$5P)%#C=C<231\?_\ !/+X0?$KPGXJTC7?"LE]9^,O$D?C'4G;6+Y;A-8B
M2..._MYA,)+29$BC0-;M'A5V],BO.?V%?VIO''C_ /9M^)6I>)H]4\7_ !$\
M!SGSM)B&GR6UW,=%L[R*#3[VP'D7EM<-(98I61)T6Z6.6,-&&?YS^//[5_CS
MXF?L(?$Z;_A8EEXGT3QS^S3KGC^;5=+LK:S?P;JD=JB"Q4H"1#=?:)TC6;=<
M1MIUQB4L?W<[ ?7'A[]FO]GS5_A[XV_LIO#]SX7\?:+%X(\1S6OBB:2TO[2U
M2>);1I%N"J2JMQ<;V0K*S2NSLS$FMSQ=^Q#\(_C7XJ\'>+=1T./5M3\(::FE
M:5J-OK%VGVK3TD206ERT4H%];>9&CF*Y\U"X)(.YL_.?_!3#X7Z)X"_X)&K;
MVMOX?NYM6\4> ;N]NI+.VLH=9N3XCT.+SYQ#'L),$:1E@C'RXP,$#%5?%'PK
M^*G['_CO3[3PKXT\%_#^_P#VF?C!):KI5AHYU;1_"%LOA6^<&UCE:W\VXEN-
M*BN)FV1HTEPPV'!9P#Z=\$?L&?"[X;_&J/X@:+H-Y9^)(+_4]3MBNM7S65G<
M:GM.H20V;3&VB^T.BR2!(P&D^<_-S3_&7P&^&G[56M:AKBZM=ZE<K:R>%]4N
M/#OBJZM4GMU=GDL+@6LRJ<-*^0P$B[R 5!.?C_Q)^VO\0OC5\._V@;?_ (6%
MX%\/CPAH'CW2+S0[.\7_ (270;C2I)(;&^%N8 UNDMO&TTC2RR(PN[9H67'S
M5?@#\>]?^$?Q2\!_#7PGKGPF\'7#>&O!/B#4$UQH--O_ (DP7L9M+F:!(K<M
M<RQ06T%K"87W++$@D#HZ@58#[ \2_P#!/CX3^)M4UJ\D\-M8W&N6^D0R?V=J
M-U8QV;Z2V[3;BVCBD5+>XM\*$FB"N%14)*@J:?C_ /X)O?"GXF:9X?AU/2=;
M6\\-ZC>:I;:I8^(;^QU2>:]V_;1-=PS)--'<A$$L;L481QC "(%^7_ '[5'[
M0WQ.B^%TEK\4OAWIJ?%_XA>+/!-B&\#FX_L:'1O^$E"7&1?*+B27^S;,E/W8
M4JPRP8U7NO\ @J9\1]'\-?%#QO)JWPM;0_!4WB#1+WPW+?E]:\,75EK<>G6U
M]=6L:"1;:.W9[JZ$DFTHT1C=%895F!]6Q_L-_"37/BS_ ,);9:?)%XLT7Q7#
MXI-UI^L7$,MAJ*:7!IH3;'(!'"^GPV\+VV!%(D<99&(!KJ?C/^S[X3_:!UW0
M[[4KB_L_$G@FYDFTO5=&U)[+4M):XB\N:,21G/ES18#1N"K;4;&Y$9?$_P#@
MFTK1?M$?M9";Q%I_BJZ;XBZ7(^I6<,4*72MX2T$JQ2(E0W52PX8J3@9('S#X
M&N]8_9,N%CLXO"?C)O%_AOQEKOPN^,^@1(VKR2&UGU.2UU^S<?OY5PVVY+LC
M20JCQQ2/M9 ?H1\+?V3? _P9^(0\2>&=-FTN^7PU8^$4ACO)6M8]-LIIYK>,
M1,Q7<LES.QD.78RMN)KE_P!I#_@G_P##?]ICQ7JVO^+/^$DAFUK0$\.ZNFF^
M(;O3;?4[*&>2XMQ.D,BAFMY99GC;@J9GSD' ^7_A_P#MY?$[1?V>=0U&QU[0
MM?OO@[X"\)^(;ZSU"R,E_P#$0:A;^9,8IED_=,^UK6%D23==QOOW ^6-;XR?
MM5^(OCU\&?BY&WC#X9P^&9-/^(7A'5?!5[ Z^(K&;2X;V"WDC99"',L=L]S*
M)8U417,'EDX#2@'T!<?L0>&_!FEKXB\"V\EUXNT77M8\=>'AJ^N73:=<:[J%
ME-;/)<NHD<V[K,X(56V"1F52V*Z7]CW]G^3]G_X;ZFNJ6?AVU\7>,M<O?%?B
M@Z&LBZ?)J5Y*7E\DR .R(H2,.RJS[-Y52Y \L_X).?M"W/Q\_9ZAAO)X=*NO
M!5KIOAZ;PM/:^7JF@^58P&.6ZD$C+,MW&R74+Q 1^3,@#.RN1XYXZ_X*B?$[
MPY^S98_%;3['PGJ6E^.? WC'Q)INBO93+<>#;S0[.>[CAO)!-_I$9:!K6X.V
M)HKEHPO#% 6 ^HOBK^P)\/\ X[^)]6OO'$&J^+['5+74+1-(U2^:6PTY+^T%
MG>?9E $D7FP J5#[ S,ZJKG=47@/]@CPGX#/@.?^WO'_ (@U+X=ZQ<:YINI:
M]XDN-4OKBXFLI; BXEF+-)&MM,Z*G &=W+$L<WQU\<O&WP,_86\0?$#Q?X@\
M -XF@MOM]G>#2KRVTBU2YE1;6%X$EFGFD7S4C^1E,[[<"+?\OSWH_P#P42^-
M/C'7[?PCI\?@/1/$,&N^.-"O;_5=(DNMG]B6EM<VLIMK:^V!V^T".5%G8<;U
M9<&.GJ![UXQ_X)B_#OQ?,U]'J7CC0?$"^+=1\96FO:)X@EL-4TZ[U!42]AAF
MC (M9HT56A8,N%4C#*K+V5A^QGX7M?C5X?\ &]Q?>(=2NO"!ED\/:?>WHGL]
M"DEL4L97MRR>>-]NK!D:5HR\KR%/,(8?/_PV_P""A/Q!\<Z_\-[&[T[PSILW
M[0'@+P[XL^'<<=I+,J7<JQ2Z_:7$AF E^QVLT5W&0(C)&9%^9XQN]1_X*(?M
M/>+OV6? &DZ]X>L;?^Q89[FX\2ZU)I,VM#PW80V[/]LEL8)HKB2U64QB>:'S
M&@0[O*8-N1 =#^T?^PGX/_:?\2ZGJFO7WB2PN=:\':CX%U!=+U#[/'?:9>D&
M1)%*L"Z'<8V&-ID8G=A=O-_$_P#X)I>!/BGJ&NZA<:YXYTGQ%K6LZ5XAMM;T
MK6!::AHFHZ=8G3X+FT<1[49K5Y(I%=7219G!7#8KRG5O^"C7Q*UE_B-XE\+^
M'O ]UX'\#R>+-(D%_J*1WUM>Z19S3VLNQ;CS9UNFMW<P>3"R6\\,JR.%;?@^
M/?VS?%?P?N?"_P 5/B-X0^'^KZU9_!CQ=\0+%]$-W#-I]K ="E%AYLTA0A_M
M/[V4Q\"W5E"!G0UR@?2%W_P3_P# NLW'BG^V)O$7B&W\:>!H_A_K=OJFIM<+
M?Z:LEU*SO(0)?M#O>W+-+OSF3@#:N,?PW_P3IT7PSX=\(I)\1?BKK7BKP+J+
M7^A^+M8UF&_UNR1K=K5[7=) 8)+=X&*NCPL7;$C$RJL@\F^*W[?'QD^"GPOO
M]<\2>&_"=GHNFZJ9+GQ79VC:U:V&CMIT=S%?7FFV%Y-/;VWVEI(9+I)IA'#&
MEPT060B/V/\ :H^*GC'0/CI^S9IG@_6M#L_#OQ \97>F:^MQI[7IU&R3P]JN
MH(D3B5 @+68YP26,;9VHT<AJ!K?";]AGPG\&/BGX;\5Z!?>(+>X\+^&[_P ,
MP64MQ'):W4=]?QZA=W4V8_,:ZENHQ(T@<*2S?+R:G_:6_8F\,_M3:ZU_X@U7
MQ'92-X-U[P,8].GAC3[!K*VJWC?O(G/G8LX=C9PN#\IS7PM^Q5_P4'\8_LJ_
ML/?#C2M8T/P_K&E-\*=*U[P[,-0E2ZBFFUFUTC%_/<.(VCW7UO<-)NC"*LR,
MQ"B4_1$'[87Q\/QA^'_PZN/ 7@'2O$WBFX\1/?7&IZLRQQZ?I<VF-%<K!:27
M7ERW%MJ!_P!'>=C&ZHQ=D;!FS [CQ-_P32\'^)=;U+5/^$C\966J7VI>&=6B
MNK>XM=UA<: -MF\2M;LI\Q2PE#A@VX[0G&-?X1?L$>%?@SXQT6^L]6\0ZAI'
MA'5-2UCPKH%[) ]AX7N=0\[[4UL5B69E*W-RB+-)((DN)$0!=H7PSX>_\%1O
MB%XU\$^#_%4OP]T?3_"/QB_L>V\#ZM/JMN5L[W4+\6WV>]ABN)991#$\<K2;
M;;=,?LI2-RLAS?C]\:_'W[0^O^ ?AQK,/AO3(['XU3?#_P ;6R173Z?XIME\
M.W&KVSQ;95>.&2%H'D@9W*3HJF1E0^8>H'U!\7_V3-/^)OQB\._$;2?$.O>"
M?'OAVPGT>/5](6VD-_IL\B2R6-S%<12QRP^;&DBG:KQN"5<!G#8?Q!_89MO'
M'B^S\20^/?&VC^)CH=YX8U?5;9[1Y]=TRYD$K02J\#1Q-%("T+PI&8O,D !#
MFO8/ ?A.Q^'_ (*TCP_I?VO^SM!LH=.M?M5W+>3^5"@C3S)I6:25]JC+R,SL
M<EB22:UJ /FFQ_X)=^"="U6232=8\1:/IJ^*/#'BBTTNU^RBUL&T"T@M+.SC
MW0E_L[16T0?<Q?*_*Z9(J*T_X)A>'[*R6%?&GB]E32?&VD*76S.(_%-^E_>O
M_J/O0S1KY/8+D.'S7TW10!\MZA_P2U\.W4QO+?QCXJM-=L=,\)6>BZHD=H9=
M&N/#ANS9W2+Y6V1IEO;F.>.0%'CE95$><U<O_P#@FAH=[XZ7Q1_PEFO1^(+J
M'Q(VJW:V]M_Q-;O6K2SM);AE\O"&"&QM8XE7@)$ Y<Y8_3%% '*? CX46_P&
M^!_@WP/9WESJ%GX,T.RT*WNK@*)KF.U@2!)'"@+O94!.T 9)P .*ZNBB@ HH
MHH **** "BBB@ HHHH **** $8_*?I7\I7_!Q9KMC;_\%F/C4DEG'(ZSZ4&;
M[(S9/]CV/?>,_E7]6K?=-?R=?\'&GQ&T_3_^"S_QL@:.V9H;G2D8G?G(T>Q!
MZ&@3/ZQ5;>,BEI%;<.F*6@84444 %%%% !1110 4444 %%%% !0R[J** &F)
M2,;1_C2[!Z4M% "% :0IE:=10 U4QUYI=HI:* $V"E"X%%% #2@Q_GBD\KGW
MQBGT4 <MX'^#/AWX<^+_ !=KVCV+6NJ^/-0BU779S<RR?;KF*UAM(Y-KL50B
MWMX(\(%&V)>,C-=/Y?UIU% #?+]^*/+7%.HH :8\_7UH$>*=10 UDR/_ *]
MC.>M.HH 3:!2>7S[>E.HH ,4TI3J* &JF*4J#2T4 &VD*9%+10!Y;\7_ -DG
MP[\9/B#8^*+K6?'6@ZQ:6@TZ67P]XHOM(74+02-(L$Z02*KA7=R' $B[V <
MXJYX_P#V6O"7Q"\%^"?#TMK<Z7H_P]U;3-8T2UTV<VT=K+IY'V5, ',2X V'
M@@ 5Z-10 WRE)Y&:4I2T4 -\I21\H^4Y'L>E9?B3P/I?BZZTN;4K..[;1;Q;
M^S$A)2*=595DVYVEEW,06!VDY&" 1K44 ,>!)#EE4GIG':D>TC>%HS&AC8%2
MI7Y2#U&/>I** (OL41.6CC+9)SM'?@_G7">#OV<])\'?'#Q)X^_M;Q1JNL>(
M88[6&UU+5I;G3M!@"0K)#86Q^2V29H(I)=HR[HI)X 'H%% &+X%^'^D_#C1)
M-/T>T6TMIKNXOY0&+--<3RO--*S,269Y'9B2>^.@ %J'PEI=OIYM8]-L([5I
M3.85MT$9D+;B^W&-Q8DD]<\UH44 4M8\.:?XA@ABU"PL[Z*WE6:)+B!95CD7
ME74,#AAV(Y%+_P (_8^=YGV.U\SS?/W^2N[S,8WYQ]['?K5RB@#+B\#Z-"@5
M=)TQ54@@"TC &':0=O[[,W^\Q/4FI;CPOIUWK']H2V-E)??9VM/M+0*TWDL=
MQBWD;MA/)7.":OT4 9?A3P3H_@325T_0])TW1K!6+K;6-JEO"K'J0B #)QUQ
M56+X7^&X+'4[6/P_HB6NM2F;485L(A'?N>KS+MQ(Q]6R:WJ* ,C6/ .A^(="
MATO4-'TJ^TVU*-#:7%G'+!$4^[M1@5&WM@<=JFU3PCI>M3Z?->:;I]Y-I,OG
MV3SVZ2-9R8QOC)'R-@D97!P:T:* ,"Z^%OAN\U;5[^7P_H<E]X@@2UU2X>PB
M:;4H4!"1SMMS*B@D!7) SQ2M\+/#,FI:->MX>T,WGAQ&CTF?[!%YFEJR[&6W
M;;F(%>"$(R..E;U% '.V?PD\+:<NFK;>&] MUT>YEO+ 1Z="OV&>4L9)8L+^
M[D?>^YEP6W').:2#X0^%;;Q%K6L1^&O#\>K>)(%M=7ODTZ%;G58E4JL=Q)MW
M2J%) 5R0 <8KHZ* .<^'/P?\)_![39+/PEX8\/>%[.;89(-(TV&QBD**$4E8
ME4':H"C/0  <5!X;^!G@OP9KEYJ>C^$?#&DZEJ43P7=W9Z5!!/=1NVYD=U0,
MRLW)!)!/)YKJJ* .'L/V9_AWI=YX?N+7P%X+M[CPE"+?0Y(M$MD;1H@V\1VQ
M"?N5#?,%3 !YZ\U)/^SIX!N?%7B+77\$>#VUSQA9_P!GZ]J)T:V^UZW;;=GD
M74NS?-'L^79(67'&,5VE% ',^$O@UX2\!:]-JFA^%_#NC:G=65OIL]W8Z;#;
MSS6MNNVW@9T4,8HE^5$)VH.% %9O_#-'P[$_B63_ (07P?YGC.*:#7S_ &/;
M_P#$ZCF_UR7/R?OED_C#Y#_Q9KN** .?\4_"OPUXW^'5UX/UCP_HNJ^%+ZS_
M +.N-&N[*.:PGMMNWR&A92ACV@#;C& *YG1_V0_A7X=U)KS3_AKX!L+QS<%I
M[;0+6*1OM$"V\^66,']Y"B1O_>1%4Y Q7HU% 'D/P_\ V4H_ _QFC\0?VZTG
MA3PWID>D^"?!]MI%G8Z7X+A\B*&;R#%&))"ZPJ%#MMB1G15PW'8?%'X#>#?C
M;]A_X2_POH/B5=+:1K0:E9)<?9_,79(%W _*Z_*R]&'!!%==10!YK??L=?"K
M5/B'XD\77'PY\$3^*O&.F-HNNZN^BVYO-8LFC\IK>>79NDC,8"%6)!554Y
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M';/6OZXI3A.F?6OY&?\ @Y#L3)_P6L^.3?:-N;S3./3_ (E%C[T ?UT4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%&>: $<_(?I7\CG_!R#JEHO_!:OXXJUU;JRWFF @GD
M$:18U_7&_*-]*_D!_P"#DO0[E_\ @MI\=FCM8V5K[36!\L\YTFR- ']?RYQS
M2TBONI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ H)XHHH 1<XYI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **0OA@/6EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *,<T44 -DR5X_&OY'?\ @Y!T
MRZE_X+5_'%EDF56O-,( MD88_LBQ[YK^N&<CRSGO7\B7_!R%JT+_ /!:WXZ;
M;RVPM[IJ'YNA&DV0(//4$$?A0!_78L>XGM4@.14%M*Q?:?UJ>@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA1<2+MO]-&/*''_$ILO>@#^P*WB*,?3.14U-B&U?QIU "*NT8I:** "BBB@
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M4 6\T574\GZU._W#]* %S1FJL39G_&K"_?;\* '45%&?WM2T %%%% !1110
M9HJ!/]<WU%3T %&:*9/_ *O\: 'T4Q3^^;Z4L1ROXF@!U%%% !1110 4444
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2O_!;?X]X_P"@I8_^FRSH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex3-3_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_006.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MD6Q7UTD>/E8Y-28H ^1?^'#'['@=&_X9X^&_[M]X_P!!;D^XW<CV/'M2P_\
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M$/@CIDJR6_P;^%-O(CB16B\):>A5AT8$1=1ZUZQ11:X'E;_L,?!21(5;X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D(.X4M% !1110 4444 !Z51F.9#^\D7V'2KU5W)W?=)_"@"Q13
M4;<*=0 44V49%"/O&<4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J(Q29X=<>ZYJ6H3*!U5OPH
MF Q1110 $9%'2BB@ HHHSS0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%-2/8S'^\<T .HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ W<TSR?>GT4 %%-W_
M #XQ3J "BBB@ QBD*Y;-+10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6.Y81W4:3,TJ"?:!'M; !XW4: >B?\% ?VE?$G[(?P(@^(6CZ1I.L:#H.M6
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M.9[O2/BE*+R(P7$5PFPS:!(@^>) <H>,CC@T75P*GQS^/OC3]C;]I7P[X/\
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M[S6)M:U235X]-?\ L>Y^QZF=)N?LFIF*X"&+;;7.V%R[*"\D87=O4GRG5_\
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M_".FZIJGB:W>VU*2X:1X[I9+,V#L8M_EK(UFQMS(JAS$2A8J<5R_AS]D_P"
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MMO[4\4:O8^(+^]M;NYM+K^T;*%8+:\AEAE5[>=(5$?F0E&9!M8LN11H!X?\
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M5H8\)G^Q?&6FZEHVHZ?_ &M?_98K'4G\R_MK6/S]ME%</\TB6HB#D D' P:
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M4\O/EB%D?DAJXSP]_P %*_%>M_M#+X1E^'^AVN@WWCSQ)\.['5!X@EFNGO\
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M6G:E]B^,46I0:IHT_B>_-B?MK&;4&L+5I_+LWFD9I9'ME1MQSD#BEH!1UO\
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M6/B232]>T;6-!U33M,GC62&"2.9;:YFN55&<P76=S@+&JR?37B[]E#P-\2?
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MI4A.!41N<?PG\ : %A.X8;^=25&LBICOGH0*DH **** "BBB@ HHHH ****
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M)_.7P;\>_$VB?!KP3XZT7XU7R_$GPC^SC\0O$-[K6H?V=J&HOJ5GK&E3O8W
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M.^M_!/AFWO=/OK[4[6>+3HDDMKJ^C,=[.A RLD\;,LC#EP2#G-/0#Y'^%?\
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M 4444 %%%(": !EW+BF!& _B_.I*C,W^<4 &\$ _PX]*D5=HQ4<";1^G%24
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M-U'0]6\.ZC=ZE?:7XG^WO=:B-3FO9R]HLT9LU7[2AMHXTO(@B;F1OTJHI\S
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M6\N3H\C6]W8QZD3&P28.+5%+*69E\UUKX.>-]!_9OU_P7INE1ZQ/X\^%6O\
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M /3Z,UYOX4_:U^'OC?Q#I.DZ7XFLKK4M<U+5]'L+;9*DEQ>:5(T6HP ,@Q)
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M>,?!MCK&OZ5J'@_X9_$/7/B%X=NX5F76;E]3CU-?L%V&S&5B;6+PF=7+2B*
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M?PI:1EW4 +10!B@]* "F";(_^O3P<K5=@V>AH L 8HI,9;-+0 4444 %%%%
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M5\1:M-HOCKQ?X,U7PO#JUG9P^)WL-',\4S33$+&@<HR@G(8G((Y'-^//^"B
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M444 %%%% !1110 4444 %?.G[;_PD_95NK_2_%O[1>C_  /CFN$_L/3M7^(
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MXT?0+_PM;?;;^YFC_LR_BCBO+:2-I-DJSI%$',@9F\I"3E01S'A'_@F[\%?
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M''8Z7I^I+?:E!#':W377G[K6-DD<F>W\D><I 5?/BVL^3M^>?VA_V;+C5_\
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M;Q!H?PP\>:/]A^ ?CG2O"\ +Z?=6FNG4-..C)MAD41S2&R-Q$C$B,)&6V/\
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M*K J ?IC?>.]%TSQC8>'KG5M-M]=U6WFN[+3I+E%NKN&$H)I(XB=S)&98PS
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MU(!1110 4444 %%%% !1110 4444 (0=P].]0@@?Q?K4S9*\=:KR0L7/7\J
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MC]GXW'_"3^%TU*TNWF1-/AU*.6UNU<0RQR6=Q%)SM=3N0IN ![SXN_M>Z?\
M#WQ+X(\)Z3H\GB3Q_P#$*V>^TG0TO([5+>TC$0FO+NX?(AMTDG@BRJO))),B
MQQN=VWR;4OV6OB]\1/V$OCE\.=;T/X:Z#XM^)6C:G865U9^)[[5(]2O;^U>&
M:_U"[>P@93EHU2&&W98XX$1"$")'S7[<7_!-/Q3^TIK.KZII>F^ M3O/''PA
MF^%FJQ:]=2A?#,IG-Q!J=E(MN[2F.664M'B!G:&U8.A3@\@/N"V/FP*64*>X
M!R ?K_6F7^EVVJ1+'=6\-Q&KK(%EC#J&5@RM@]PP!![$ U!X9TF30/#MC8R7
M=UJ$EC;QP-=7+;IKDHH4R.>[-C)/J35Z@! H%#*&ZTM% #1&H.<<BE* TM%
M";!NSWHV#=G')XI:* &M$&'I7,^!O@WX=^''B3Q5K&C:?]CU+QMJ*:MK<WGR
MR?;[I+>*V69E=BJL(((8_D &V)!_",=110 SRL?= Q2[,]=N/I3J* &>5@\8
MI#%GLOY5)10!'Y7.?EJ"'0;&WUBXU".SM8]0NXHX)[E8E$TT<9<HC/C<RJ9'
M(!. 7;'4U;HH ;Y*_ET]J#&IIU% #3&,=*:(L#^&I** *NLZ'9>(](N=/U"T
MMK^PO(F@N+:XB$L,\;##(Z-D,I!(((((-36UK'9V\<,,:111*$1$7:J #
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M74FO(]+TV.\9Q(9TMD64L(Q$#NQG(C 3/]T =.*TZ** "BBB@ HHHH ****
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M1\%8_ \?B*\\2:?8ZG?WEA-=6L5O):07-S)<+;GRP ^QI6&]OF;.3C@#U*@
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MBW'CCP_XY\-ZB_A.^^(6M^%=)_X19YKI[CQ-=KJ*QSNU_%'*8+OS%&#"KQ,
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MO^$:^S&_$+LS(MS*T-L\:XS,DTJ/'&\0=9'1E4E@17AVK?\ !.7Q1K_Q7O\
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MHI-X_+K[4;LT +112%@HYH 6BFB3/TQG-.W?IUH **** "BB@G% !BBC/-%
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M,L7W1\!-5\3ZU\$/"-[XT.DMXPO-(M9]:&E_\>,=X\2M,L!WONC5RRJV]MP
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M:U_P4(@T'P_:ZMI=K>&%;RY\4SV,VEG_ (0[3KLI:Q"&39B:>2?<CQ_O)B0
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MP69BQ).I^S-^R9X%_9"\#R>'? 6DW6F:9(X9OM>I76I7!"J$BC\^YDDE\J)
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MTN\\8KX@AU#6M1AMY=?N)-.MY-7:"34%2V)V!)IK:*8KCB4%AZ5[Q0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*2#&'GC /\63C.UL '745FZ=XRTG5].-Y:ZIIMS:K,;<S17*21B0':4W XW
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M3XE?MK>%OA3\4O$G@_5]/\1)K'AWPB?&B".U1H]9LQ.;=HK,F0&:Y$QBC,6
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M^UU&SD2R2S:"U"PPNDT<*L6D!D>2=I2Z>L:NGC?PQ^T9JOQ,\,^"_&5Q<?\
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MCERR1A7;S-R]=\*/V]/B-\4OCAX+\"M\$W\-ZCJWAB+Q1XE&M>)5MYO#T/\
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M<03KL M+PV]W;2K'NE1A(X\P-&RUR7QB_;@UWXOZ5HUA;Z/XD^&GB'PG\8O
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MG@7QGIWC.WF?3/M\=U-9,[) Z>;&1&Q?YBK!L# (/->:G_@F,W_"=ZM\1O\
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M/B3^TO\ #7Q]INN:9I]IX"TO7;":PN+&2:2^?48;>-'6195$8C:W4D%6W!B
M5.#7G\W_  54\,OXQ70].^&OQ<UG4+K6O$/AO3A9:98LFJZEHDKI>6L+/>*
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M=<F^+?@SP9<ZE;Z)8S2QP7_ARWGN%/F)^]<W!<Q/+N90JIRH*DMT ]N\%_\
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M:Y^QO\-_$M]XJN;_ ,,PW4WC;6-/\0:VSW=Q_I]_8& V=R1YF%DA^RVX0KC
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MB5\5O%L.DV_A'P1X?U;P?;^'?^%A:-JWB FXTVXU,,;A;.XA#PR);;?D9O\
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M/5]/UAY [6^^2,F95(%S Z1IF6)2"R _3!/#NGQWEY<+8V:W&HA5NI1 N^Y
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M@A\'=%^ 7P7\+^!=!AC@T/PGI5OI%H@C5,Q0QK&&*J NYL9; Y+'UKS'3O\
M@F/\#](^'TGA6W\%O'H,GA/_ (08VAUK4& T3[0UP+$,9RPC$C'!!W*OR A
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MZAKU_*B;MD9N;Z>:;RU+,0F_:"[$#+$GMJ* &^7SW_.CRQGO^=.HH ;LY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%!;:*A+-GCD?6@!UJZO"I6I*CMQB,<8J2@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **,T4 %%&:,T %%%% !111F@ HHS1F@
MHHHS0 449HS0 449Q10 449Q1G- !111F@ HHS1F@ HHS1G- !7S7\0?VYI/
M!O\ P4!\%_#%[?2&\&>(EO/#MUJ@NA]LM_$_V2/4[2R,>X;8FTZ.Y<O@[I)8
M5!!5@?I-QE#7S1\3/^":F@_$_P"#=CH=SKLMGXUT_P 6V_C:'QU;Z19_VTNJ
M0:C]NCE^:,I@<0;2-OD?N\!>* /"?CW_ ,%,?B5\+_VJOBSX!\-ZAX'\2>)/
M"OBSPYH?@KP')H\QUGQC#?6%K?7X%S'<*L300RW$@N#%Y44=OF57SN/LW[17
MQB^,7PX_:T^%?@W2/$O@.UT'XM:WJUC;"X\,7%Y<:5;6>D27B,T@O8EDE>:%
M@WRJH1P -REFF^)G_!+OP[\7=2^+E]K7B?75U+XI:SH_B:SOK%(K:[\%ZOI5
MG#:V5]ITN"R2*((V8/N#YD0CRY&0]UXY_9/O_B-\5O@OXRU7QG>3:Q\'YKRY
MW)IL"1Z_-=63V<S2@?ZK,<C,!%@!CW  I@>%>//^"C/C']F+Q=^T5_PL*'P[
MK^F? OP#X5\006VA6$ME-K&JZM_:$$D'F2S2!8&N;*,1_)NC6X.]I2@+>H_$
M#Q!\?/A!\)]2\5ZIK?PQU3^R_#6IZIJMG!H5W"NEWD-E)/;K;N;LFY@$R".0
M2+&[JQ=6B^X'>-O^"=7AOXK?$WXWZQXNU*[UW0_CMX9TOPMK.B&%8$L;;3Q>
M""2"=3Y@EW7LS[SR'$97;L%;'_#+WC?Q#\&]<\&^*OBQ?>(8=2T2ZT*WU :#
M;VMXT<\#0?:+LJQ2XN%1B<HL,1<[C%P $!S7C']JWQEX5_X)$ZI\=5C\.S>.
M-.^%,WC\0&RF&E/>)I+7XA\GSO-\C< F/.W[>=V>:UOV1?C]XB^.'B%A<>./
MAOXPT^W\.VE_J<&@Z%>:;=:7>76&@7?)=W$<L;I'<[E^1XS'&?F$GR\MJW_!
M.CQ)XH_99NO@_K'Q<U*Z\&R?#R\^'L$-OH4%J_E7%DE@+V=ED_?316XE")\L
M6^8NR,43;ZI\(O@AXR\">)])N-;^(9U[1=%T?^R[?2;70X=/BF<&,)<3N'=Y
M&1$9412B#SI"58[-H!YS>?MB^)?A+^U[\6? GCX:"GAS1_ D?Q!\$W.F:9.M
MU?6$+R0:G!</)<&.:XMYS:86)8@4O(LG).)OAO\ '_XJ6W[8GP]^%_C)O C'
M5OA?=>+O$3:5I-W#)'JD%Y9VS16TDETZK;YNFX='<^4#N&["]M^TO^QEX8_:
M@^(?PL\3:U-?6NH_"OQ'_;]F]I(8S?H871[*8@C=;/*+:=TZ,]G$"",@S:E^
MS++J'[:VC_&'_A(FC_LCPC=^$1HWV)2DL5Q=0733F;?N#A[>, !<;2PZD$ '
MK5%&:"<4 %%&:,T %%&<T4 %%!.*,T %%%&: "BC-&Z@ HHW49H **,T9H *
M*** "BBB@ I&7<1UXI<T4 %%%&<4 %%&:* "BBC- !11FB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *:T08TI;#8I/,'O^5 !",1BG4V.,1(%7H/>
MG4 %%%% !1110 4444 %%%% !1110 4444 %%)O7U'YT;QCJ* %HI-ZGN*7<
M* "LOQMXPT_X?>#=6U[5KA;/2]#LYM0O9VZ0P1(9)'/T52:TO,7/WE].M<;X
MGN? OQNO_$?P[UC_ (1WQ--I]M:S:[X?NC'=&&"X:1K9KB!L_)(UO(4W#!,3
M8Z4 ?)7[$OQB\>^#_P!N'QYX1\>6OB[0YOCEH$7Q&\+VWB=+<QZ9J-J(['5-
M*MQ#,Q:&VMVT9@/E=BUPYV[ACC?A!_P4F_:+^*'P,;6K/0_A9K'BW5/@AH?Q
MBTC2M/T;4%61IIIA>Z9AKUC+)+#$/L[ QA)7V.)%'F'[Q\8?!#P;\0?%6@Z]
MKGA?0]7USPJLZ:-J%W9I+=:4)X_*G$$C#=&)(_E?:1N7@Y%<#\0_V/;&'P7:
MV?PEU#2_@KXDTZRL]$LM?T/PUI]W<6&CP7 F;388KB-HD@;+A5V[8V?>JDY!
M+]0-#]FK]HV/]HCX8:I\1M/OM&N?AWK$YNO"-\B/;M=:8EO&'N;AF9@-]RMR
M5(5<0B(LNXM7RC\%/^"K'C_QOK%GX=UY/AY9ZAXPN_",/ASQ'!I]W#HB1Z[9
M:G<K(T,MSY]Q&6TMXK9W-F]P]Y;[H8,C=]GZ/_PA?[//@_P;X)^V:1H6GR+#
MX;\.:?=W:1O?-%;,4MH0Y!FD$$,CE1EBJ.W8UYLW[&O[-/AUYOAG_P *W^$E
MK+XRT(VS^'3I5FLNL:597"R$>1MW2007%TC9 *QO*G0[< 'S9\?OVH_BL]U\
M5M)\57WPI\2:#X9_9YU_Q+K&@:58W=UI&LZE#<WUI+&;HSQRK$PM C18W1[Y
MXP[,!-7?)^WKXN\/:#JVJZ#H/AM?!OPO\8>%? &LZ"]K<'6;T:K!I'^EV<OG
M!(DB;6;?RXI(I#,MK+^\5G7;]&ZS^Q]\*_$.F6-G>_#OP?/:Z;X>N/"=I$VE
M0[;72+A%CGT] %^6VD10K1#Y2N01@G-+QO\ !_X.?"2^A^)'B/1_ _AIO"EG
M;6H\0:D8;.+3X(-T5L'FD(0>7YSI&SG*>:P4C<<@'A7[&_[>7Q,^-?QU\'Z'
MXOTWP+#X?\:V?CK[)_8T-TEY:7'ASQ'%I0=WEE9&CGAG#;54,CQD[B'VIG_M
M,?\ !1'XE? ?XL_'":'1? 5Q\.O@G8Z/<W;7$EPFK7S:I;.(27+K;PQ0W0C:
M5W./(\P_(5W'Z>\$?LQ?#WX=:MHNH:%X-T'2+[PZE_'I<UM:K&]@M_,)[U8R
M/NB>8"20#[[@,<D9JU=_L]>!]0U?QC?7/A30[JZ^(5K%8^)GGM%E_MZWBB:&
M.*Y# B5%C=T"L" K$=Z- /EU?VY_C)8^*9/A_K6A?#_PUX^-IXB\0V=_?-Y]
MC?Z1I=OIDB*UI:WLK6]Y-)JB#RS=2!(;:2?#!TCKF?"/_!5[QQK_ (!DUJ?P
M[X3B9- ^$>N^4OGXQXQU(V-Y#DOUMRI>%N^0K _>KZ \5?\ !-+X*ZI\!;+X
M?Z1\,_A_H^C^'VNKOPY%_8,4MOH5]/%)&UW'$-N6^?+#<I<  D8!'/Z5^P1\
M%_A#^S_X'D^+.E?#_P 277PK\(:/X<N?&&O6$-C#]FTORGMYY#-(ZPJDT8E7
M=(VQG;#88Y>@'C?A;]JWXC>'?B)>^$?AGX1^&UEKGCKXR^,/#DMQK5]J+6A>
MQTQKR.]<*SMOE^SA9(X]J*2-BC!)O2?\%5?'<?@KQ9\0F^'^D#X6V<^L:)I5
M_=:E;VMQ;ZO::XNC6\5R!<22-!-(9)IG%O"UJD6")MP:OJFP_9:^&>@^)+7Q
M+!X1T&SU33-:O?%$%^(MKV^HWD7E7=X&SQ)+%E7;NN<US7@[]COX ^/+CQAX
MXT'P-\/-<7XSZ:]OXAUBQMH+J#Q79S*!())%RDL<H"EBO$A52Q) (6FX'G?[
M!5UXBT#XZ?M6MXNNK.\U#3O'%B[_ -DI<?9/+_X1O2IOW$$KR/&6WLQC5F!=
MSC.:X/Q%_P %2O'?A;]G>'XC2>%?"FH:?XR^">M_&7PK;VD\Y.GKIEM973Z9
M?/DB5I(M0@"W$0C4/'(IC(*,WTY\)_@G\)_V/A'HOA/2?"W@6;QM>QQ1V\<R
MV]QKMW#:A5"[VWSRK;6^< LVR)B> 36+I7[)_P "]!;Q)\/K7PWX1AD\::1=
M'5/#GVC,ESI<T[?:42V+YBLWFF.](E6(O)@C)% ',_'+]IOXF?LY_P#!._QW
M\6/$F@^!KCQIX5TF\UVVTG3KZZDTR6W1B\$;S/&DOF>25#D)MWYQ\M>8Z]_P
M4:^*?@_XLZM\)]4\#^%9_B;+XOAT/1;G2;M[C1[BRN-%N]6BD87$EL[W2+9R
M0O")$+!EE3*Y2OH#]LG]EK_AI_\ 8R\;?"'2=4M?"\/BS0)- @O9K-KV.PB9
M0F3%YD9DP@(QYB_6F^,_V"?@_P#$WX47G@KQ-\/?#FO>'=0U5->NK6]A:?S=
M15%C6[\QV,@F6-5C5PVY8U" A1BC0#YM\8_\%*/C9H6C_%;4&^&_P_T=O@S\
M,K#Q[XDTV_\ $$US=I=7&G:O*^GPO;QO#(8[O350R;P#'*3C>-M: _X*/?%3
MP]\7;[0]<\(_#]M+T/Q_X4\*:A-8ZC=M<2VWB&&V^SO"KQA?-MIK@&0L=LJ
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M[0VJ:EXLUCPSH7BB7QIX9C\/7>H>:TT.K:27:XA3*-L=5>5Y(Y1\Z&0E&&:
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M_$^L>%T@^%^J^*=;\%PZU::@USJ,6H:5%J#SRR6?E*!:R/I=[&C+*9,B!FC
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M6O\ Q(\2>(/$'A6?0;34-/ACT[4='L(M0D5KF>6-'AN+:>&6&0 920;UC?\
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M+0?%VL6%X]GIE[JNG-/]NM='759()!%+)Y=N4\V!+KE'FMIL+Y821^/^&O\
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M5:#?1Z]XHTVQT.*6PN-0OK/0KY[.[NU'VE8V(D$:^4KF1I) L2R@;S/\<?\
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M<:%?W:>%[QK:2U"QZC);N+><^:\<D,$Q8.;>4A2(W%>QL%*[6^;Y<'(ZCWH
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MVE6]K>P(KNZP7B6RSA49@!,=C%2I//M^VB_P&_:?^,GB+PW\2OA[XR7QO?\
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MS_VPM<_9T_:"^#_@^QOO .BZ5\37U>*ZU?Q/+)##ICV-HMRFTK+&K^9DIM+
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@C(H P*
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M1:;!/<6=E=_V7%>WT<;6T+W#1F.V:X,L?DQ7$B2.)8@ S.N;'PO_ &Z_A/\
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M[LK:1':6-)I%OG#C>"\>GS%"CN"OT3^U5^T=X]^'O[/WP;UCP[J7@O3?$?Q
M\6^&O#VI74UG-JFEHFI,(YFM@98';#NK1,Y!8  KEN#4#NG_ &)? C_%^_\
M& M]72;5M8MO$M]I*ZA*-'N]8MXDBAU)[7.S[0B10\C",\,4C*TL:R";Q/\
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M!A%OB0/D(#OO@;^R[<_!;]H7XI^,X]>@O-+^(\FDM;:.FF^0=$%A8I9A?/\
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M4 %%%%  1D57, 8YJQ5<LXZ;<>] #;.^61%W!E+=F7&35JJMH5,"GYO;-6J
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M?_$;5+G1O#R6>IPW"ZC=6\#3S1JR,1E4"@Y_BEB7K(H/QO)_P21^(?B?X/\
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MQSTCP')";7Q9XRTZ]UZV6.P<1WT-D]M%/(\ZKLWH;N ;6;<0_ P#7YQ?LN?
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M2Q^))K6"QT9/$<4MYI5Y:QZMICR+"EY8F2(?;86E>.,&W\PEIH, B>$R>/\
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MS>.?!OB/Q/H-KK.K> +U]1T&6X=REA<L%'F^6&V.R[492ZML=%==K $=Q10
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M4 YHH **** #O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M1F#)^\U29YIOF?[+?E0 0L&3BG4Q6^?OTIX.10 4444 %%%% !1110 4444
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MCM6E<',X16(*R$ANK F@#QO]FD>+OVZO!/Q%\<7WQ"\5>#;I?%_B'PMX2L-
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M,FBBB@!"N6S2T'I10 'FD1=B[1T%##<O7'O2B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "ODS_@M]J%OI_\ P37\<>?>6-BT^HZ%%#+=X:%7
M_MNP;++N7<JA2S $?*C'( )'UG39(ED/S*&QZT ?GK^VM\4_#_CS]E_XG>9X
M]^&_Q#\1CQ;X#EN+_P )V MX-.TP^)-,6VM;F07%P&D%PFH3*&FR$E/RHO)Q
MO$7_  4#^+-KX[^.5WIOC#1YM>^%\?BN*X^&/]CFYU6RM+60?V9J\42VJ3F,
MVJ)<;WN)H;HW0AC$<FP+^CZ6,*# CC7/4!< T+8PK<-,L2+-( K2 89@,X!/
M7C<V/3)]:+@?GNGQ_F\<?M(?LTZIX?\ VDM8\??#GQ)\0M8M(-5@L--L;+4E
M;PY+);Z=/<16ZP7DBW*3*AB2)@;AHF5IX1(O%_#K]N/XCZA\$&M[GXA6?P_N
MM/\ !'B#Q3X:U6#P]IPM?&^L6WB#5K9M/,+0E'6&&VL"\%J([B;^T=PDW D_
MIS'HUI#%%&EM"L<!W1*J +$>>5'8\GIZGUILV@V-RD"R6=K(MK*)X0T2D0R#
M(#KQ\K#)Y'/)]:8'Y[6?[:GQA?\ :?\ -U;Q5'H.CV?Q@\+>!+GP4^G6,T=O
M!JOA*RU"Z@DNO+$[20WMQ(8W1UYC96\Q2%3U?]NC]ISQ5\/_ (RZ[X3L?'EO
M\*;72_AO=>,/#^K7&GVMU'XGU6*XD26Q87*,&CMXTMF>& I/(+]2LB>7S]:-
MHUF\OF-:VYDWB3<8AG>.C=.H['J*;J.@6.L2V\EY9VMT]G*)X&FB60P2#HZ$
MCY6'J,&D!\6?LGF]^-?_  4:^)>J^.)GAU3_ (5O\/M:G\%ZA#9W,?AN_9M7
MG*(6B\Y)+6?+*X8$/<%CG]V$\[M]2^ K^(_VXK;XLKX2O=.OO'T:-8?NI-:O
M)%\-Z2L:V,<9^T-=F8LL/D_O?.^YAZ_1B/0[.'4)+M+2W2ZE&UYUC D<>A;J
M15>+P?I5MJGVZ'3-.COLD_:%MD$N3U._&>>_- 'Y@-^U%\;?V</@[]F\2:QH
MND_%?P[\%?A?+JVH:MI-M=ZA;:EJ/B&[TZ^6[FR'F"QC.POM25Y74_.<^LV?
M[7?Q2\,_MOR?"'4OB?X!_MCP3J&D1MI>N)'INJ_$K3+NS,T]W8V4=NSR21S.
MT*M;SK%";&1ID*OD?=%[X4TO4I9)+G3;&XDE"J[2P*[.%.5!)'(!Y'H:DF\.
M:?<:O!J$EC:2:A:QM%#=-"IFA1L;E5\;E4X&0#@XI@?F1XB_;E\4?'?]D'2?
M&NE_M&:+I5UJ&K>![KQ7I&GZ=96]W\-KF[\06]MJ6G7L[Y%O B3B+RKM1.6L
MIV:5HG>-?7]+_;7^(.M_$[2;FS\2:6TUU\3M;^'VL>!);.W^T:#IMK#?/;:P
M9!^^,C0VMK?L6/D/;WZJJJ0DC?9Q\!:&UG?VYT?2VM]5E\^^C-JA2]DX^>48
MQ(W Y;)X'I2KX%T1/$-QJXT?2QJUY +:XO?LJ?:9XATC>3&YE']TDBBX'YY>
M&/VY_C%X1_97^ 7Q/\7^/M+US1OB5X>TOQ3XC_X1[0K"/4M CNH=)1%2PEF,
ME_9^?/=+</:E;B)[F HC(#&?HK]LOXP>/?#O[2OPF\ ^#O&&E^#[7QUH_B>Z
MU&[GTB+4+B)K"VMG@DA$CJHV/,2VX,I P0.M>]7?PK\,WTFCO-X=T&9O#[%]
M+,EA$QTTG&3!E?W1X'W,=!6A?>&=-U2_M[JZT^SN+JU1XX9I85>2%7&'56(R
MH8#! X(ZTK@?G3\(_P#@IU\2OC=XH^#VFIXO^%/@W5_$'@KP/XKET_7;S[)_
MPG7]JR2+JRZ?#Y4DLS0K$R11V\@:*=D$V^-UK.\,?\%8_B'JG@[Q3XRNO&'P
MDL]+MU.FZMX>:[:YUSX8W;>)+72VN]1M1'$T5K:6EQ++.+B3+R01LC+"[%/T
M97X9>&TO-)N%\/Z(MQH ==+E%C%OTT.-KB [<Q;EX.S&1UI(OAAX;MYM:DC\
M/Z'')XE&-7=;&(-JHV;,7!VYF^0[?GSQQTHN!\O?\$O-6CN$_:::W\4:3XDF
MB^+=^6UJTBMTCN6_L72,2,D)\O<,8<K@.R.V%R0/GWX8?\%4?BWHWPF\*^(/
M%'B7P/K1\??"OPUXV^TQ:/\ 9+?PD]_KUKI=U>RJL[--;0P7OVA]S(JM9O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>"==\6WGP<FDTV\5;ZP@ADOTN8;=H)%-Q]HM_FG613-$GG1(SQ;U*D]O=?\
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M;^*(U"(ZC#HFJ7WAJTEL[5YB2D6)E25_)4[I/W"/)(QD$8#UJ!>^.'PA\7>
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MCPSXD7Q)XCUM]4L8[&222TU^2*74=,,<MN\1@:2WMG1F1I$>WC;<W(/*Z?\
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M:UI4UV)88[Z."&X0Q7"J/,@EAN;>1)#&K;9,-&K*RCXETO\ X*C?$K3A\/\
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M(WP&22-V1U965B#1J!\RZO\ L&^--7^--WKES_PA-]HMW\=(/B<UO<7,[/\
MV:GAB/1C"4-L4-R)HQ,HW;,8^<$9KS_5_P#@E%XT\5ZO\9]!U$_#6/0O%B>*
M[CP=XT_T^Z\2Z1)K\<WFVTMHY%LD<4D[(TL4F9K>*.(QJ2SCZ:O/VF+CQ!^V
MC??"C1;-FA\%>%;?Q;XIO@OFL%O)KF"QL84!SYLAM+F9V(^5(XU4$S%H_/\
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MMQIFJW5SH%]::>EW!<26\UO%=2Q+!-(DD1++&[$*R,>'!/J%2 4444 %%%%
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M/_\ "06_A74IO#]_X[$E_P"&KJSNGMXI(_":P0>.+6Y'^CK\I?3)(6++D1L
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M_:-V<"OBK_@E[X US3?BS\#K-='U729_A-\$+CP9\07N;9XE/B!M0L?W#.P
MED,MGJ%R&7=B.Y1\[;A"W2>$?C#\3O$_[0NDVJZ[XIMO&UO\4=6T/Q5X0N82
MNCVW@X1WIL]0M_W8VCR%T^9+P.?,N9986."(HW8#W#P+\.?V;OB&_B[X3Z!X
M1^%6H06-O:1^(/#,'AZS^R2PV\LD5N)(O*\N98)H98QC<(9(V7Y'&*[GP5IW
MPQO/C#J=OX?L?"/_  G7@32;/1+UK.R@74-%TZ8&>VLRZJ'CMVV&18@0GRYQ
M7Q5\)/ ^J#_@@;\5[7P]JGCN7Q)-I'CBXLITGN%UA;C^T-1EB\H[5E#2X1\
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ML2^FNK?Q7J'C4+/J]Y/"^J7]C)874CQ/*4:-[6:6/R6!B42,50$YKQ?]M?\
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M:@ HHHH **** "BBB@ HHHH **** "BBF>=B@!R @?-S2T44 %%%% !1110
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MM')I:= />9_VH/ ,'[/2_%8^*M*?X<MI@UH^((Y#)9K9$;OM!902$ .22/E
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M+'U$9/ZBK[G"^M9D]M-)*S*RJIZ DT :4/*?7FG5&BE6]JDH **** "BBB@
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MPRI\SH;2W<.H4L4P_F(S(>BU;_@G%X'UCQ1JVJ2:SXU$FM>-=$^(%S!_:JO
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M9WPBN+B&1)HY7-R\8G7Y4"HQBDPP:UX%_P""I_A>\T:3XC:M<>-H?#&K> O
M/B:W\,1^'XKF32SXFNKFWM98[B-_-N6EF\N"1-NV(VVY=WF$#JY_^"::ZE#\
M4M*NOBEXZC\(_&37[G7?%&CV,-C9M=_:+:"VEM$NUA^T10/#;HA\MUEP6VR*
M3FK?Q0_X)G>&?B!K.N36.N:IX:TW5=,\':/:Z9IUK;BUTFU\,ZK-J=A% K(<
M*TTS(X.1L"A=I&:>@#8/^"J?PQ7X@Z/X5U9?$7AG6-2E@L[^#5[2&VE\-WDU
MB=0CM;^+S6EA<VNV0R!&A7S(U:56=5-?X@_\%-]-\)^$=)U+3_AM\3=2_MO7
M_#>DV GTJ.SBO;76[DPVU]%+)*$90J29AR)T<PK+'"LH<=!J?[!-M>_M'^,?
M&D'CSQI8^%?B0(I_%_@:,VK:-K]Y'8QZ>MPTC1&ZAW6L$$<D<$J)+Y"%@?F#
M<GI/_!,J^L?@'IO@6\^-'Q*UQ?"NL:'J/A34M1ATV2?PY!H]S'-:6ZHMNL=R
MQ5/+DGN!)+(-I9B5Y- .RNO^"B?@&SUHPRQ^(ETFZ.KP:3K8TTOIOB"YTJ.:
M2^M;216+/,B6UTRAE191;2F-G"$UB_#W_@J#X"^)\_A*#1M!^(4M]XVM4U/2
M;*X\/26MY=::_P!C_P")BD,K+)+:C[;%N>)7*B.9BH6-C5.P_P""9>D:?H9\
M._\ "6:Q)X+T;4-<UKPIH\EK 6\,7^K6]]!/*EQC?.D2:GJ ACER$%SAB_EQ
M;*WQ+_X)AV'Q3^'/PO\ "&J>*FGT'X9:/IFF6DDFB6QU:">P> QZA87RE9M/
MNI%@5)'BRK+@!1BEH!]$_%/XGZ'\&/AWK/BKQ+?1Z;H6@VKWEY<LK/L11T55
M!9V)PJHH+,Q"@$D"OG7]H+_@HS:^&?A-X@;POH7B:'QSHOB7PWX:U#1;[2PN
MH:*FMW]O:V]^T!DVRQ&.:5HBK%'F@:)L,DBKV6L_LL:_\?OV=/B5\/OBUXJN
M]<L_&NK:BVDWEC!;V=[H.GO,LM@B-$@C>:U=%=)&1B=D8D\PAF;GO%G_  3X
MO/B!I.L:AKGCR:Z\?>(M4\*7^I>((-%BABFA\.ZBNHV5LEIYA5%:X,[.Q<L?
MM#@$*$530#Q/PG^V1\8+GQ+XNB\0>.;;PQI7PI^)6C^ =4N[KX>&Y7Q1#?\
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M\$TO@'X<LO)TWX7>%=+W1V\+2V4+6T[I!;O;1*TL;!V @D>(@L0R$*<@  T
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MCXBVGP[^(T>H_9/"ZC3VLO"\FHSO<7LEK(;;[1(&DDF*1SRR11"9MB A&1Z
M>S?L[_M.:+^T;)XNMM.TOQ%H.K>!=9_L/6=,UNR6UN[2=K6"[B;:K.I26VNH
M)5(;.) &"L"H](KSGX-_L\6_P>^*/Q0\4PZO?:C=?%/7+77KZ">.-8[*:#3+
M/356+: =IAL86.XD[BW.#@>C4@"BBB@ HHHH **** "BBB@ H8\<444 ,"$Y
M#'[WO43HSMG^M3[<OGTJ)[)9&W%I/P:@":BFDD2#TIU !1110 4444 %%%%
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M;:19=S;Y9]RMY9@-K%-N_> E,S_@BM\8O&#_  S^&_PUUS4_#^J>'=-_9_\
MA[XLT,66FO9W.GK>6UW:/;RNTT@G 6PB<2 1_,\GR@;0OV2?@IX-;55OSX2\
M,_;ETHZ$+C^RX/.&G'K9AMN?L_\ TRSL]JG\+?"3PIX&U..]T3PSX>T>\BL(
M]*2>QTZ&WE2SC):.V#(H(A0DE8_N@DD 9I7 _/O6_P#@I9\=/!?PTO/&=S??
M"_6]-O[3XF6UGIMKX?NH;C1I_##ZDUI?W#?;G\ZWD^QQ031@18>Z@*R M@[_
M ,0?V^_C9X(\3:?X)D\2?!&#QS>^![?Q_87&L1/H6E:S'<7$JFP3SKQW*6D<
M!,\Z$NWVJ!Q%&%97^FOV;?V$? W[.W@'7]%_LO2/$T_BB_U>\U?4M2T>T%WJ
ML6HW]Q>RVMPR1CSH5>X=%5\C8J@YQFMOP?X2^$'[4/P^\$^)]+T'P'XT\.Z
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M4G.!0F!\_P"B?MQ?$J3XV2?"76IO ,?BN_\ BA=^"K+Q!%HMT-+2RB\,0>(
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M4 N&5D_T7# _-L/WBP9V^J/%_P"QY\)_B'XGL=<U[X;^"=;UC3;2TL;2]O\
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MQ*U".UT/XG>$;^YDTV^U?RUOE5DMK*3R[QW#8V&W8XE1L/'G+*!S1J!\'O\
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M]!\&_$6*U7X3_"]?&^D1ZE<++J=SINH2)K^GVS2SA4NA8;$,<3*LL*"%"?E
M_0OXH_M>^ _A5XT^'GAJ^UW3AK_Q8FN+;PK TP6+4VBM7N2?,Y 1@$12 Q9Y
MHPJMDXXC]EK_ (*2?#/X_?LRZ/X^UCQ?X#\*7Q\/:;KOB32I?$EM(?"PO?EA
M2Y=BA0-*#&C2*F]A@#/%*[ \B\4?LX^-O%__  3L_:\\&^%]'\0)H_Q L]>@
M^%WAO4<VMW:6ESH,$(MHX[A@UK#+J0O7B@E\ORDF4;8UPJ^2_$;]G[XC>#5U
MC6_!^@_&R^^ ^K^+=)O]4\)0SM?>)IXSHVH07]Y#9:H[2-;?VC-ICO:R#>[V
M=Q.B,IC9OOC1OVP/A+XB;P[_ &=\2_ -_P#\)=)Y6AFVUZUE&KOYLD 6W*N1
M*QFAFC 7)+Q2*,E6 Y_QS_P4&^"?@#P'XB\277Q*\&W6E^$[JTLM6:QU2"Z>
MPGNKHVMNDBHQ*F2=9$!. 3%+S\C8-0/EKP7\)?'_ (4^-?@KPWXH\'?'?Q=#
M8Z-X7G\ >*+GQ!'GPX]B9?M]OX@N+:=(S,_R/<E4E6]BD$"M*T2UYKXM^"GQ
MGU_]E75&T?0OB]H?Q)A^$GB#1/B3&;R^$WB7Q8TED--N+&99 EQ(94OY8[BS
M)CBMIA!(4'EQ)^C&K?M2_#'P_KVH:7?_ !"\$V>I:3IKZQ?6\^MVT<EG9)&D
MKW,@9QLB6.1'9S@*CJQ(# E-)_:F^%_B#PUKFM6'Q$\"W^C^&9X[75[ZVUVU
MFM]+FD5&CBG=7*QNZR1E58@L'7 .15:@?#M]^SWXX\%?M0ZAK/ARS^,G]DZ7
M\:O#-UI!FU76;JT_L2YT:V36I#'-*RO;O<>?YOF*0L@R IP3S?P?^&?Q>E^%
M_C:7QQ>?M(>'/B):V*:-XGOETL:QX=U"[_MJ&>*]M+2VE6YU*U> 2)(+5TDC
ML9)8"5D$07[#_;._X*&^!?V4?V3=6^*%IK7@_P 4>7HLFM^']-_X2*"T_P"$
MIB382+.7#^:2'7:45@69%R-V1[OJFIV>A:9<7M]-;V=G9QO-/<3.(XH(U!9G
M9CPJ@ DDG  J=>H'Q;XH/Q F_P""<GPUM=2\%>---UJ?Q98VVMV>A7VK7KV>
MG_VG*/MTL!9=4FT^6,12&Q9EN(XKA(IBJQ38X'Q!XD^(G@G_ ((H^%7\=WOQ
M4\/>-O#_ (PT32M2N7NKVU\136P\76]L0'@E>>826;A!M>0RJPP9,AF^UF_:
MZ^$R^%X=:;XF_#U=&N+B>TAOCXALQ;RS0PFXGB63S-I>.%6E=0<J@+$!>:\S
M_P""AW[17PE\ ?L5Z[XW\8-X-\:>'=-T=_&>A:5=:Y#;0^*9=/1;^W^QRY82
MR%HXGB*!QO,1[@TP/C']H+X9_%[1_@[XJT+P=9?M"7&B:E=^-[SX;W,M[K=U
MJ&EA-+T]K""YC\Y+Q))-174GL9K^41P1H0T<C3P!=#X_?LZ>,OVA?V=_VC/$
MWB+3?CUJ6L0:_P"';WP[H,^I:[:V\VE?8/#5QJ+6NFQR+'-(MQ;ZEF)$=T='
M"(K.-_Z6:G\4_#?AJ]TFRUC7-$TG5M:M9KRSLKN]CBN+N.",23O$C$-(L2L&
M=E!" @G ->8_M _MS>%?@QX;\#ZMI=UX?\66/C+Q#HFE"6TUN!4M;'4[K[-'
MJ@8;A);JV3D$*^UL/D478'D7@7X8>.M-_;CUGP5I^O>,)/A3XD32/B?]IU#Q
M#>W&I>'Y+<?97T$>;.TT-O=W%O!=;6S&RQZE 4.\&/"_;?MOBMJWQ?\ BAI^
MBR?$>S\42:%HMQ\%KS0'U!=$&J(\_P!JCU#R#]E_U_E&<7W[MK1U"9VR[?H+
MX6R? +]G[0=2\9^$]0^&/A?2OBIJTFMWFN66H6D%MXHOG)#S_: ^V=R=WW6(
M!+="3G%^+_\ P49\!_#KQ3'HNEZAI/B;4-/\<Z7X&\2PV^IQPGPQ/?1F59I]
MV?E1-I9>.25R"K &K P?^"?OPYUZ+XC_ !F\6>*M4^)TVH2^/M=TO2;+Q#J^
MHMI<.D"XBDMFL[2=O($?WMDT:'Y69 VT!1\V^'M9^,-CHOP:N)&^+GB'4K7Q
M1JD5_P"%]1.O6%S?64OBV46UZNII^ZWVEBL+M:ZDK13V3$1M'\Y/Z"GX]>!1
MH.@ZM_PF7A7^RO%,B1:+>_VM!]GUAG("+;2;]LQ8D !"<D@=ZOZ%\4/"_B?Q
M)=:-I?B'0=0UBQ5GN;"UOXIKJW"/Y;%XU8LH5_E.0,-QUXI ?GK_ ,%0?@GK
MOB+X[_M"7.E^'_B!J4WC#X,>&[#2)M.M=1OK.>Z@\0:A]LBB5 ]ND\<4MC($
M(#8=I$4_OFJWJ?PX\?\ B'X^0_#UO$WQ]T_X?R_&W4K3^T;/7-92Z309_!AF
MYO\ +2?9/[:9EC<OLB<A49 JX^[V_:"\ +H%]JS>-O!XTK3;O[!>7IUFW^SV
MES@'R9)-^U),$?(Q#>U4=,^-D-Y\1_%&ES0Z1:>'?#.BZ?JYUUM;MGCE%R;H
MNLD"MYD$<<=NCB:3"2B8["?+?#N!^?D/C'XN:1)\=+_7-6_:,F\:^#[#Q7:7
M?AS0M%OH=.OM/DN\Z/?:;J,YN+5I$M%B\K[%";S+7)EAD=<G-^%8\>>)_P!I
M/X8WFMK\7-9L/!/Q6\26^@7MYI?B6ULHK6_\,PRZ:9A<%IGM/M3W$?FW+NL:
MLR.T4<GEG[W_ &8/VL]%_:<\,^.-8L;6/3=)\#^*]1\,F\>]AN+>_6SV%KR.
M2,E!"X?(R<J =V#D#MM,^,/A#6-)2_L_%'ARZL9K6:]2YAU*&2%[>)]DLP<,
M08T?*LV<*>"0>*6H'YE_#+Q1\7/%_P !M*U*^\:?M$6/C:\\2>!M%\;:/-X>
MU738]!U%=82/69+6XF,JSPRV[W/F-9?Z"L44+A8V(#6/&WC;XL:)X4T7PKJ_
MBWX[>'/ ?_"2>/\ P[9>*=-T#6_$6NV=XFL1#PZTWV=A=SQ&S:Y,,TXFMG*1
MB8."I'WOXZ_:\\,?"/Q'KO\ PFMUH_A/PMI9TBVL=?OM9M/)U>[U&22*.VCA
M60S1LK+& TBJKB4LN51V'H?B'QYH?A&UM9]6UC2]+AOITM;:6[NT@2XE?)2-
M&8@,[ '"C).*=V!^>G]O>,O&_P"W[\,8/'-A\4Y/%O@KXP73!?[+U'_A'(_#
MLWA+4H+*]4PH^G!I+B0B1Q(98YY9D8B,(!>_:(NO&GPH_;Q^-6L:3;_$XZ7K
MD7@&35+O31JES';>&DN[N+5Y+'9NB66,LA:.W'VE(Y;F2)0S,]?H"/&.C_VX
MNE?VGIW]J,&VV?VA/M!VA6;$>=W =">. RD\$5#!X_\ #]QJ<EE'K6DR7L,+
MW,ENMY&98XT;8\A7.0JM\I8C /!P: /CGQ5X?\<>//\ @F?^UIH-O)XH\8:)
M?:5XGL/AM)J,<]SK6JZ;-HPVQ'S1Y\X6_DO((&D!DEBBA.7#([>/^(_B5\3?
MA!X<OM2T'QI\6-=^ =YX@\/C5]?O='U'5]8T99-*U+^TUMH;7R-0-@MXNB;C
M;X\E[BZ2,!(I(T_263XC^'8K2&X;7M&6"XN4LXI3>Q!)9V 98E;=@R%2"%')
M!!Q5N3Q/ID7B"+2VOK-=5FA:XCLVF47$D0."ZQYW%0>"P& >*+@?'?Q6U?X@
M>'?V(?@-;6?CSXBZUXAU/QUX4TG4/$<6A2Z3J^L:9-J2QW$UW:%':U5[,LTA
MF"LF-S^6^5'C/P[^+?Q6^&NLZ;=R>,/C3X@M63XMZ*T#V!U2X^QZ-?R-H,L,
M4D(CDO3;(K0RS$M=>9AFD4*$_20>-M%;3;Z]&K::UGIKR17MP+I#%:,GWUD;
M.$*]PQ&.]</^U%^U1X;_ &5O@1J7C_6([S5M-TU(94M=+>!KJ]1Y8X]\(EEC
M1U02B1B'^XK$!CA2M0/@7X-_M;^./[4_LWQ%XH^(Q^%=YX_T1;_7+:UU:YNM
M.TB]\+&:!%OI+6.X:WGUJ-$EN(U01,[1XACD 7A?@O\ %/QY\/OV>?A'X'F^
M('Q!^$.GZMX6>3PAK,?@'5=:GU+Q ->U)KN&Z@MS%^^^SI8E8+N/RI5N9F4
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M8M=_MNPN8;5[[P]<Z3J*:9+9W*1SLOGS7DB10K&SA\[MP0%@]0*>C_\ !/\
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M>.9-'L?!'Q%U1)H_%;Z==:=IUO>-J;>&[K['J<<=NDYN?-^TE(H8S$&E,B8
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M%?W%S+K,"ZQ#J:_9H"@$+^7<6,9$K!0\3DA<D8])_;2_:FU#]D>[^'OB"_\
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M&NGZ]IOQ=T;6=1^',:>(&AN-5N;"![J&SOP;8K:/=VT<KHR&81/&8W!X<C3
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M4;WXD^*M%L=/70]-^'/QN\#>%=/;1=9Q>^)K>^^P7-S;W(DC2-8Y8KY5*[\
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MRBRA\[#C!X";]@;QWJOQ=NO%%Y<^$X/[2^.-G\3YUMK^X\V&PC\)1:%) CF
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M(\J;U8VWB,H1 ???ACX/^%/!OC*^\0Z/X=T?3-;U*PM=+NKVUM4BFGM;;?\
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MIGD\1:0]Z!O8HJ+_ *0'4D[460-P&KA_VO/&>A^#OVA?C)XP^ TWA==#\._
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M_C[X>\ ^%/A7XLOKF]\/VWB#7[R?4;&VB\*QMJ>H:5=0SJ\H:66VO=.N(R(
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M2;0-+3$,[L;621+N*]B<0G<GE*"%0Q"C0#ZBAT*QLWN)(;.UC>Z 6=DA53,
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MM\+3Z/<V%UH=@+'6;I+-':&&.[M-0AV+;SVMX9 [6KR12$&0)U__  5_=D^
MOP\5?%U]X1^T?%[P) 9[9K53-N\1V''^D12*=F#, !C,(+AHPZ,NH'I'P:_9
M>^!-_P" -%U+P%X3^'M]X7N-'U#3=+N=(@@NM/GT[4)%DO(8F3=&\$[QH749
M5O+4=% &OX>_8K^%?A70-)TNQ\#Z!#9:'JUGKUBC0>8UO?6B".UN [$L7AC
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MA =S/\+_  Z_X*F_%?QE9:9:PZC\.;N\\0WWPZGT_4!I$PMI[+Q+>WMK.\4
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MQG('^% $\<;&-5/WL_I5@=*CCC,0&6J2@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI&8+UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1 0.
M:6B@ HHHH **** "LF]MH)+EF:#>QZG9G/Z5K5S6LI:_VE)YB_/QG_1P_8=Z
M .B@8LGS=?3TI](J[*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1D#CYAFEH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#U+PW]OO7F
M^U31[L?*NW X [UN5AZE);+>OYDTRMQD*C$=!Z4 :<%RS'U]B>]3K)N7(K#C
M.Z1CW$;<_@:FFF;[-$=S9(Y.>M7*-BFC6C.2>M ?+8K&,K+XEVAFV[0=N>.N
M*TU/[Q?I_A4$EBBBF,?WRT /HHI$^Z/I0 M%1D_O_P !4E !1393B-OI36/S
MK]* )**CD^Y)4,K$7:_C_6@"U14%HQ)_X"*G/2@ HJ& _O?S_G4U !1110 4
M444 %%%% !14<GWOS_E34/SCZT 345',<,M1(?WS#MCI^= %FBF0]#]?Z4^@
M HJ$-^Z7ZU-0 44V4XC;Z5&Q^[]?Z4 3457/2IHSE%^E #J*** "BBB@ HHJ
M-_\ 6K0!)1144Y^;\* ):*;.<1FF3G'^?I0!+113)/OK]: 'T9HI&&5- "T4
M+]VB@ HJ&?F9:FH *:S[?Z4ZF1??D^M #Z*AC.;AOQJ:@ HHHH **** "BBB
M@ HILO\ JS3$/[X?0T 2T444 %%59V/VOJ>H_E3W. ?J* )Z*CB/S_A4E !1
M36_UB_C3J "BBB@ HHHH **** "BBB@ HHHH **** "BFQ');ZTZ@ )HIDYQ
M'3Z "BBFS'$34 .HI$^Z/I2T %%-F/[IJ2#[E #Z**:G^L?Z_P!* '4BMNS[
K'%,/$I_SVH@^[0!)5&6/=)T'ZU>/2N%\67<L?B"X59)%4;> Q_NB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex3-3_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex3-3_007.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M7I-O7=XPU7Y^<\XG_#C'Y\U(?^#5;]B4N&_X5?K.,YQ_PF&KX/\ Y,5^BE%
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MQZC[9ST[U]X44P/A=?\ @VN_8C%PTG_"A=$W,"#_ ,3S5MO/^S]JQ_A5B/\
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M[(%LH5?V=OA:<?W]&1_YYKZNHH ^56_X(<_LA$G_ (QU^%/S=?\ B1QTX?\
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MA,97]G_X,@Q'<G_%'6'!_P"_5>^45/*F!X-#_P $M_V:[8$1_ 'X-C<V\_\
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M/'WP[6/=E5_X0:[R!QP3_:O/'?CK^% '20?%:SN;E(5TOQ.))',8WZ)=(H(
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MB>W,6ZVNF#;H9G$NY%*_,$<Y'&[K<YH * <T44 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 457L8)X&G,T_G"24M&-@7RDP %XZ\@G)]:L4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_'+_ ,')/'_!;CX]
M_*$_XF=CP/\ L%V?/X]?QK^QEVVJ37\=?_!R@C?\/NOCU\H_Y".G_=7_ *A5
ME3 _L3"[6]O2G4V.3>*=2 **** "BBB@#F/',RQ^)_"H+,&;49 N#U/V.Y//
MY5T]<G\0E_XK'P6>_P#:DV.?^G"[KK* "J=_I"7]_9W#27"M9LSJJ3.B/D8.
M]00']0&!P<$<U<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5G_B;@TZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@=** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSX<^*?$TG@;4]:%[JC06TMQKEMK]O:MIS(DP'F):W(WP "1#Y9PHX-/]M?\
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M%_%KQ:FE7'C>ZMK6\L8=.DT;4[M)8S<LL22&:TA12^0'8*R-RA^9;+_@H/\
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M!_X)M_!OPQ8-:V/A$VMO]KL;N"./5[]5T\6-Z;^SM[7$_P#HUK#='SDM8=D
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MT[3_  $EC:ZQ''!J8M]9U&-]8@2#[/\ 9[QQ<;KJ!H,1/#,7CD145U8*H%:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +<_Q5\3?!SXJ>'=>OO ]UX9\10_$[PI!_PC%O?:9KWAH^']/OYX-2FG^V2
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M+_$CPII%K>Z_IEO%?W5QKTFCW]W/:W3171>UGWVL963[/)!((+P-)#*JH#E
M_1;--W_6OC/XA_M^>.-,_:3U[P[H\/AG['X8^)7A[X?3^&[FU=M:U*SU6RMI
MSKD4JS86")KF5E0PLKIIEUF16;]UY1^SWJ^L?#7_ ((\_'#]H#0_%%KJ?Q7F
M\-^-[[_A*8UDECO7TO4=:DM7>!YWAD>,JR))C*QB*/YDB5:0'Z1AP6V]Z4MB
MOR^_9Q_:U\6^ ?VP->U#1?&7@_XB>"O'7CS2/#^J0V,+W5[JMZ?A^=2:;3YT
MO&@AW75@%, C=6::8[U->L?\$Q_V]?B5^VM\ O%WB6[UOX1^+-2N?#%AX@T*
MV\'W,TLVD7UW;3.=-OU<M&C1S1JJAY%FP'\R-1M=JY0/NH-D49XK\L/AM\<_
M WPS_P"">WPZ^/5KXHOO$/[1>A^&=3\2:[I\^N7<EYKNNQZ5<IK5GJMDC[_L
MEA<2S2>3Y:BV%G#'#LW*K^AZK^W'\;->^+>D?#/PCXZ^#MU?ZG\2?^$0LO&<
MOAV:^TW5;0^%'UU]EI%J*$7,$B+"Y69HV2YA;"N'4E@/T+W>]9L.H7ZZL87M
M-UMO;_2#(H  6,KA1DG)9QSC'ED]US^:6E?\%5?C#9^"O">H:EXA^%.KKX_D
MFTR]NM-T&XMU^&_E^+;/0EU&^0WTIDAEANY9-DC0>7-9L-[IYGE])X9_X*(_
M&;6OC'IOAF3Q5\);'3_#L/CG4-;U:7P[=W47B>P\.ZA80+/:1Q7GF0-)'<W$
M<FP7&R6UE*HX 0'*!^CF: V17Y0_LV?\%8O%G[2'QA^%NFZQ\6OAYI>F+\1K
M?1M5^Q):?9]7M]2\&'4;:TG>*[DC#C4GN;:$1RDNT"!@TL+Y=\!/^"C?C#X>
M_LO>!8/!K?#_ $NS\'^!?!VMV7AF&RN)O^$V&K:[=Z7>6]G))</-']G\B(1X
M,K">X3S2595)R@?JX6Q1FOAG]A3]N;XD?&G]JG3_  SXN\1^ =<T/Q+I'C>]
ML;;1='>QNM-?P_XJAT>(M(UU-YPN()S(PV)L,(QN!8UY=J?[5?C?X5?&?QQX
M4^'_ (G^%?@B7Q1\7?&<.HZAJ&E3:D673_"MGJ?VAHVOXPLJR)LF(98PI4A$
MQ\T@?IONHW5^8VM?\%9_'7C_ $'QQJ6B^-_AGX,\2^'?"\NK:9X"O=%GU+5=
M:MV\)1:W;ZO;.DZE[8W<C0'<@A\J&0&438!UM,_X*;^,OV@/VAXO OPI^+_P
M3:'7O'EMX?L-2?2QKJVUG+X/;66*K#?P"=EO()H0P;!W[,AXFS7*!^D>Z@MB
MOR5\0?\ !5GX]Z!^S5\,/$UY\1/V?=-F^+CZ_<Z3XDUNPFT7P[I#Z;((8=-G
ME-Q<">6YW/,"IB;;;R(FXY>NL^'W[8\G[3?_  5&_9\_M3Q9X<T[7-'\0>.M
M&N?A_!"]OJWAU+;3S%!+=^<RSR_:8D2Y0O!$-MR@ S&Q8Y0/T\,RA]O<T22"
M-"QZ"OSI^*'[4WBWP%^W/\3O"?@3Q)\+_"^O>)OBCX8\*W.H:GH\VH3F&Z\*
MS7*F2+[?$'GC:V7;L\M63Y2I;+GTRW_X*'ZO<_\ !*CP+\:KS5O"EK?>)FTC
M3]8\206S3:%H0N=2CL+K5'B$A(MX<O(4:7:F,/(%5FI6 ^S,TWS%+[<_-C./
M\_2OQE^&7_!2;Q=\&+W4_"OPW\??!>XA\4>/O&.O?\)=XGO98]&\6W,6MV<?
M]G6$=L+AI)3:7'F""W8R.98&CR-T;/B_:=US]G#QOXH\;:!XN^$L7CSXA?$W
MX@>&)?B'XRG:UT_3(=*O?,L-#N9HQ-O$RHC11N4=8;22.#:9 P?*!^S.::TR
MIMW';O.%!/4XS_0_E7Y<-_P5X^*WA+4M9\0:AXB^%?B339;'Q_!I_AG2M$N8
M;RQN?#PCECGD=[HW$_[MG\V'R(7")G:C9 YCX0?M%Z#J'[5DU]9_$KX8_%=]
M7^/5HMOXG"Q1VMN[?#BYDBNK9(;@1(ZS1/ V682;G7Y9#N!RL#]< V:,U^3/
MP^_X+!_%#1OV7H?%GCSQ]\-XYM>\,?#KQ9/J.G: 89/"EIX@O;RTO8_LS74B
MW3P_9HG5F,>#._RMM2-OI[Q'^W!XJ\%?\$I?#_Q>\0>+_AW#XDUB31H+O7M+
M6*;0;,7^L6UD[*QNG@5HXIV!>2Y,*3*2[; 03E ^R,TF\;L9&>N*^ ? '_!4
M'Q1XF_X)8?#WXO:GK?@W3=2\1^+HO"7B7Q5%$MUHGA6'^V)]/DU*5%E";-L4
M.6,@B1[D2,3$I!X:T_:F\?QZY\4?''@_7/AOXN\=>%_AAX7\5ZGJ^BZ--%_P
MF6DV>M>((KU+>&6Y?Y)+2!Y;9T&TRS*=TD<J87*!^G&:,U^2G_!0#XT2?%;X
M7>/-8\8-X3#>-OV:?B1XH\,N]M)8ZUINF-?::^DQ,?/*[Y;:2%Y%\H/YL;+G
M"L#]I_M@?M/:M\(O^%0Z1H7B3PUX-T?XBW5W;7'C35XDO-,TKR-*FO+>(YDC
MC)N&BX=G *1R*OSNC*@/I@'-%?$?_!.[]L;XP?M@?&IV\0:Q\/=$\.Z%X(\+
MZ[K7A:VT*X_MA+W6-+-S_P ?+W?[J)98V=4>W+&.0(2&0L?MR@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ;*=JGZ<U_)U_P<9:9'+_ ,%GOC8S00LS
M7.EDDGD_\2BQ_P!JOZQF7>N#7\HG_!Q7X7N+C_@LQ\:I%B7:]SI;#_1-W!TB
MQ[[>:J(']4G@:7[5X-TDMSYEE"Q]\QJ:V*P?AQ96^C_#[0[6W4+#:Z=;Q1J/
MX46)0./H!6\#D5(!1110 4444 <#\4K5I_BM\-9 JD0:I>,2>HSIUR./S_6N
M^KS[XL&3_A;7PQVYVG5;W?CT_LVZ_KBO0: "BBB@ HHHH **** "BBB@ HHH
MH ,\US_Q4^)%A\(/AKKWBK5(=3NM-\.6$VI746G6,M]=R11(78101*TDCX!P
MJ@DFO)_^"CG@;QQX_P#V8[JV\ Z9+XCU2QUG2=3U#PY%>1V,GBK2[:_@FOM,
M6>0A(VN+=)$&XJKY\MB$=C7Q?XV_X)Q^,/&_AWXJ76F?"CXC>';X?!V^T_X?
M6$GQ+2X&F>(;BXU\+;N5OU3SEM]1L@K.#;6Z(8HY7$,;D _3^ROQ=Z=#<!9
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MBGXQ^)_%UOJ_@7Q/X5U;1M3^&6EZ#IUWJUYJ4%^FMWDVEQ37*[X68+-!+E)
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M#Q'#K?BSX;>!?%.L6Y0PWVKZ#:WUS'L!";9)49@%R<8.!DXZU\-?\%0?V?\
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M/P]BUNSN=+MC8Z)K%E?ZK'& (72Y>[TZ#R3\\T6GJTP&[RU]9L?V6_BMI_\
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M?EQ5DF!]N:5H/@?0O$TVN65GX5LM:\7,()M0@BMX[K6VC5L(TH :<JJMP2V
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M,AB!V@'Z%:)_PAUK<QW6FGPU'-#;+,DUMY"M'!*W#!EY$;MG!'#'U-5;S3O
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MCC:16".X&V0*Q7)/1ZHWAW2K.VT.];1[>WU</:6^GSF)([P$'?$D1X?*DY4
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M(JU[1K]UX7UW0[ZSU270;S3;.-;B\ANFBD@@1&)5Y%;*JJM&2"W *>HKX_\
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M% !1110 4444 %%%% !1110 4 ;:** "BBB@!&^Z<=<5_*'_ ,'%?Q FT_\
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M:^^(G]F_V9#IFHZ1<^*KR;3=>^SV[6MM<7L1?]_/!;%88V)"A(8,JQAC*JZ
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M(ZE>>'X_#=YX4%G>^)]7NU73KJ^2_EC!DNF(D%U''*D^?.C:--CJ% '-:O\
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M(,[%W\K>WS.PKUZI :SA2 3RW3WIU0W%A'<W4$S9\RWW;#D\9&#QG!_'-34
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M$CQ'/:W7_"*FV-_HMMIVD7EK 9;VQ/E6[7#7B1NV"T;N@+':1[Q\'_CQ\$_
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M9>ST;-L5G5(Y8+='$\1A40LR-M\JO;_$?[=OCSXB?%^WT"+1?%?PZ\0>$_\
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MQ'D:1H8DC7 D:1XXF+ROH!F_'?\ 9=^(WC*#X#ZCH]YX*UCQ)\-3<Q:[)?\
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M+\2/VN?V9?CYX)\::'HO@NYUZX\0>#O"UW \\T5[I<MI]GM[^9)%1PQEDE!
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MI6C:MIOCCQB-#UBXO+J2-[*R33+_ %"26!4C?S'V6+ 9]0 #NW(:@?/NL_\
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M!/C7PYXIL-'T3Q'KME-XDT#Q%>6EJEM-<Q6UU#&NE)Y=XL*N\I622=F0B>$
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M+[.HGB1_+WR#>\;HN71E'F?@G_@EQXD^&VD^ [K2_C+JU]XH^$;I9>![W5-
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M^#]8%C'HL;FR/AR_^W01K*9<L)Y"1(2O"XV!3DL; ;MA_P %+/@IJ,%S,GC
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M\-O$'A*6;Q-X<\8:Y:6FHWJZ3J0;3["X;4(%ECB6W+RW+76GR0K;8$I^9@I
M&?9/VM_V:[']K#X$:MX+O-0OM#GO);>_TW6K#:+[0M0M;B.YM+ZW8_=FAGBC
M=3ZK@\$UXWX._P""5N@_".XLX_ _B&Z\/Z38_$>W\?P:;-:?:K>RCCMY$;2[
M9?-40P//<7ER2 2)+N0@5/N]0-3P[_P4K\"^(?&=QJ4/B3P[<?#:;P-I/BK3
M;N&WU!M8OI;_ %"YLXHEM3;A7\QXHH8X8V:Y-P9(VB4A<X7@G_@KG\-?$?[1
M+>&+K5K6S\-ZU8Z)_P (SJ/V&_\ M5WJ-[JFIZ5<6=["UN/L#07MC%;GSRG[
MZX6,X<A:X^S_ .",5U9^$(]/C^+6K6FI:;X=TW3-'U6TT&".XTO4=-\0SZ[8
MZB%>5XY DTYB>!UVR(OWE)S74:G_ ,$Q_%6N7NN7VH_&";5=3\2'PI/?W-WX
M7@&ZXT'Q!<:Y$8XXIHTCBEFN9(3&!E8PAWM(&=G>('OOQD_:?\$_ /Q1H>C>
M*-0O+'4O$EKJ%WID4.E7=Y]L2QMFNKI5,,;CS$A1G$9.]PIV*Q!%>?\ B;_@
MI]\$/"OAO3=:NO%TS:7JNEVVN074&B:A/&-.GMA=B]<I ?+MX[<K)+(^%@62
M/S"F]-W7?M9_LG:-^UQX.T#2]6U+6-'F\-Z]:Z[97VEW'D741020W,(<<A+F
MSN+NU<CD1W+$<@5\T?&#_@AYH7C;]GV/X;^%_B!K'@_P^USX@-U!-I5OJT,M
MIJ<(MK>UBAF(2$:?;1V\%JZ@M%'#\NUVW!:=0/J/X0?M8>!/CK\0_$WAGPMJ
MT^J:EX3GFM=1<:=<QVAEAG>WF2&Y>-89S%-&\4@B=MCKAL<5Z57S3^R+^P#J
M7[-?Q[\4>/M4\<0Z_J/BG3A87T.F:"FA6^KRBX,J7]_!#,UO<7Z1X@6YCBA8
MQ A]Y(*_2U&G0 HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1@#UK^6+_
M (.(/"&EW?\ P6-^,TLEOJ#223:4S%(\J2='L<X_>C^0K^IUAE:_E:_X.)/"
M-U=?\%D?C/(D,++)-I3 EFR?^)/8U40/ZB/A<TA^'/A_S5=9?[,MBX8Y(/E)
MG)R>:WJPOAC*)OASH+B3S=VFVS;]V[?F)><]\^M;M2 4444 %%%% 'GOQ017
M^-?PSRV,7FH8'K_H,E>A5YY\479?C9\,L9^:[U =_P#GQD/^<UZ'0 4444 %
M%%% !1110 4444 %%%% 'B_[>7QY\4?LY? JU\0^$8_"LVM7GB?0= C3Q \R
M6974=5M; L3$0VY?M.\=OE/!Z5\FW?\ P54^+WPX\*:G=>-+?X*1W#>'?%DN
MERV#ZB(&U/0/$UGH+O*A9W:&X-ZLD=O'\X:+8TW[S='^@GC+P'H?Q$TI;'Q!
MH^EZY8QSQ72VVH6D=U"LT3B2*0)("N]' 96QE2 0017,R?LM?#.>"2.3X=^!
M7CECNX75M M"KQW;![M2/+Y6=@&D'20C+9-" _/S4/\ @K=X_P! $WC"]UKX
M=ZE;^$_!WC%;[PW9K'%_:^JZ7KZ:?'=-*M],EJBVHBNY4\R80PFY)D9666/K
M?"_[=/QR^-NK7?A&Z7X!R6,/@_7/$.N7&FZQ<W-Q>6%O,;>+R#8W<J6LLJ3P
MNP%S(82C8=C(C1_;UG^SE\/]-\G[/X'\'V_V<W)B\K1K9/*-S&([G;A./.C5
M4DQ]]5"MD#%1>'/V8_AOX.A6/1_ '@G28TTR;1%6RT*UMU%A-)YLUGA(Q_H\
MDGSM%]QFY()YJN;R _/CP!_P5!U*_P!9^'/PLN)_A_:^#?%/@O3-&N8X=6N?
M[6TNXO/!EQK,3M=W%R)=Q:&.!(U2=F2XBE>Z65Q$WLS?&CQCX%_8H_8SU+P_
MXRT/P[:^*+GPQI_B&_URU-]%?V<VA3RM&TGGQ;6DECCP^\EG*=02&^E[G]D?
MX57MY;W$WPS^'\UQ9V46FV\C^'+-G@M8HWCB@0F/*Q)'(Z*@^55=@  2#NS?
M!;P?<> M.\*R>%?#;>%]',!L=(.F0?8+(P,KP&*#;Y:&)D5DVJ-A4$8(%*_D
M!\S?L*?M[^,?VD_'_A&S\06'A1]&^)W@6X\>:.NC)-'>>%1;WT%I+I>I%Y)%
MEG#7"@3*(/WMK=QF$>7FOEGQU^V5\9_#VL:SXTTGQM\-_$WCKX<W7Q=QINHK
M=6UA#I6C:A;B""XL[>Z+23&.T<1.Q0QI,23(5;S/U \%_!KPC\-]>UC5?#OA
M?P[H.J>(I?/U:\T[3(+6XU23<[[YWC4-*VZ21LN2<R,>K'.)JG[*'PNUO7-3
MU.\^&_@&[U+6C<G4+N;P]9R3WWVF)8;GS7,9:3SHT1)-Q.]556R !2OV ^9?
M@K_P4D\;_&G_ (*#ZGX L=,^'\'P]TO59M"N8[G5X8?$B/\ V1;ZC;7T,/VA
MI+B&;S)5"BUC01*)EG<!EKF_BI_P5,\8>$=6^(NK6>O?!&QT7PKK.J^$QX;U
MFYNH_$FCWMIJ=I96U[+'&Q^TP727#SB+9;A5DL0+@B=I$^U/#_P*\$^$_&<?
MB32_!_A?3?$,>FQZ*FJ6NDP0WJ6,>-EH)E0.(%VKMBSL&T8 Q5/7_P!FKX=^
M*]7\2:AJO@/P9J=_XQL4TS7[F[T2UFFURT082WNG9"9XE[)(64=A1\@/@/2?
M^"W7B*/X;ZSJ>HZI\';>^T31[^0I->)%]LU"P\5R:1-&%6_D0>?9>1,D:2R>
M5)*I\R='0&;XJ?\ !8#XH?#_ .,GBKP(^E^ ;'6=6\40:+X0O+^$Q:3;V4DN
MM*E[)?F]%K>+.--M;=4\VUEBO)KB)XCY<8E^Z&_9"^$[V]C"WPQ^'K1:8UP]
MFA\-V6VT-QM\\QCR_D,NU=Y7&_:,YP*2Y_9!^$][HGB#39OAC\/9M-\72B?7
M;1_#EFT&M2"1I0]RACVS,)'=P9 Q#.S=233NNJ \D\4?M<^-Y/@A^SZUG_P@
MNA^-?C=J%MI%QJS.=<\-:/<G2KO4)6A>&>+[6LK6;0V^V90YF1LMC:WA7P/\
M;^)/^"B7[6_P<U;QY/H^FZ#I/@G4/%$?AS2;O4+=H]9T_7HK'^TK:YBNHQ/;
M2O 'B,L+*UM.T;"03,Q^\?%WP<\)^/O \?AG7/#/A_6O#<0B":5?:=#<V*"(
M@Q8@=3&-A52OR_*0,8Q5;2O@+X'T+QKI_B2R\'>%K3Q%I6G+H]EJD.DV\=[9
MV2\+:QS!-Z0#M&I"#TI ?#_Q\_X+"Z]^SO\ &;XI6=Z_PXU?PWX2L]8M]+LX
M;F2&]MKW3FT<%KJ8REY%$>I3SSK%:*L$5FQ664B0+QGQ_P#VQ_BMJ4_Q-T#Q
M%\0?@7XF\-Z5\(?']ZUIX;^WPVOB62R2R:%GFBO5FLY_(NU62.":1X1YK++N
MEC:#]"9?V:?AU-XWU#Q,W@/P6WB35MYOM5.AVOVZ\WP^0_F3>7O?=#^Z.XG*
M?*?EXJDO[(_PKC\(:7X?7X:^ %\/Z):7=AIVECP[9_8M/M[L%;J&&'R]D<<R
MDB1% 60$A@:=P/E.T_X*,>.+/QY'8Z#9^#+CPYI_BZQ^&_\ 84UM=OKL<]SH
M,6HV^M&9KC#6(+EF0Q%C:Q2SB<LIC'4_\$^O^"@?BKXS"X3XP7GPMT635O"G
M@[Q=H4^@W4MO;%/$*7,<-A(UU(3)<_:+1MA3;Y@N(T"EERWT?_PS)\-SXC76
M/^%?^"?[672O["6^_L.U^TKIX0QBS$GE[OL_ELR>5G9M)&,'%4]!_9%^%/A:
MYCFTOX9_#[39H5LDC>U\.6<+1K92"2S"E8P0+>15>(#_ %; %<$ T: >AJH'
M\.*7&:**0!1C-%% !1110 8Q1110 4444 '2BBB@ Z4444 %%%% !1C-%% !
M1C-%% !1110 4444 %%%% !C-%%% !BC'-%% !1C-%% !1BBB@ QBBBB@ QF
MBBB@ HQ110 4444 %%%% !1110 48S110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M99+"0,RC<BG*!^M]%?F'\8_^"D?QD\/^'O'D&@_$7X:6?_"!V/C;5M)UZZT
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M%B\3^*O&-OX7LDT^WU;Q+<Q76J7,48VIY\L442R,J@+NV!B%&23DG\^?!/\
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MM&;A'V#!VJ^4#]4&E57"D\GI[TZORNTC]O7PMJ__  4^\%^,/B+\2_!^E_\
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MGQ7>ZK8KHU^MRTZ$1R+.73RG@*.9DC4LP"%\-CY@F_X)H_$+QMI7B'Q<]]X
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M(_B+I^N:[I7P4U"U.HW<UU8#6;VZ$5M>^&+#2+J-&;3XTVB;3(2L2Q(ABN)
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M_P#"J_!?BCQEJ/B^76O$GA]IY-0@MM7T%+*W5&-K$]QMO0TTB22(,*'5FD)
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MC[XG^ ^I:+9^(KCQ#X0N[WQ#<6TML]K<6J7$5E<:=<O%+]H6;$L6Z-T53&V
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M>&;JUO;$CQ1J[*L]M=W-Y!-*K71$\D<][=LK3!R!<2)G8Q6NK^(?_!/#X/\
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M0:9##XJFT>:[CU(QLLCO (Q;1^7YL8\U[N-1M59)$Z;X+?\ !2>/XZ?M1_\
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MP/\ $7A71]>UCPE>:UI%SI]EK=A,ZZAI$TL3+'=QN3N,T;L),L3N9?FSDY^
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M=>?N158??WQ(^/?P-\#1>#_C+K6K>%9GUO1IK?PWXFMK=M0N+O2YHUOIS;O
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MO="TM=<L;BPDNI[74/[.9\.G[N)[AHD220JI:9$)$F4!J!Y?^Q+\1/BAK_\
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MZ'X!L-+MK#4+[4M0L)-/EMI;V>X\F:%(+BY**4BR9,.7V(#VGP-_8;F^'/\
MP3DNO@W9ZYJ_AG6-=\/7>G3ZNMP-3O-&FNH&C54EDP)UM(VCMXV(7=';1X"<
M8ROB[^U5\4+O6?V;]+\"V_PZL=0^,UM/=ZJ=;2[OK>R6'34OV6U>)X6?(\Q
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MO]EWX:^)-(OM/U'X>^!]0L=4N;>\O;:YT&TDANY[=0L$LBM&0[QJ $9@2H
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M]N6O@WPI;ZU]JNK[^T(M'MUNOM%TJ)<S>:$W^9,L:+(V<N$4,2 *9X5_9T\
M>!8]"30_ _@_18_"\ES+HR6.BVUNND/<Y%PUN$0>2TN3YA3!?)W9KLZ:[[!0
M!R'@K]GKP'\-AI@\.^"_">@_V*UR^G#3='M[46#7)4W)B\M!Y9F**7*XW[1G
M.!78TBYV\]:6@ HHHH **** "BC-&: "BC-&<4 %%&: <T %%&:* "BB@#!^
MM !1110 4444 %%%% !1110 9S1350*Q;NW6G4 %%%% !1110 4444 %%%'>
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXN\(:KKWAS6O#MYH=E;#3]&L?#4U_:>+MN/,19;J*"1V=S:$7PME19(PYK?
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MP:G:OH<UBEY';.JS*Y&!OCD\S/EE6'.0:ZRP_:C^%MXOAM;7XB> &7Q89!H
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M--)'(GZMZ9^V+\)=>326L/BA\.[X>(+U],TTV_B.SE&HW:&(/;PE9#YDJF>
M%%RP,\0QEUS@_%']MWP/X-^&.K>)/#.H:/\ $1?#VNZ;H6J6?AW5K6ZFTV>]
MOX+1?-VN0A1YU<J?F(5L D8H0'YL>%?^"F'Q,AE\=>)I/BU_9=OXPUGP.;R^
MU6UC31OA[HNH>$X;V74H<VDHMX9M7\ZR$LZRQ*5<./,5I5_2#X/?%GQQJ'[
MMAXRG6Q\=_$"'PE-J,9T[3KC3[/Q+?10.8F@@E ECBN71&0$ E900%! '>:=
M^T)\/=3TY;NV\;>#KBUG2]D2:+6+9XY4LB%O&#!\%;<D"4](LC?MKS']I?\
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M5(^[JABLHH;F298XUDD^^RK@O]3W_&IJ0!1110 4444 %%%% !1110 4444
M%%%% !1110 UVP/Y5_(W_P '(7AS3;C_ (+5_'*229?,>\TPMP3@_P!D6/\
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MB>VFN88-3OKJV.HZK::M:K(]S.SW2?:8IH[DRN#+ 5499V*_I?M [4%<T<S
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MO%[?#G3#X]7PVGB[8W]HC0'F?3=^]MODF8"3&S83N&0V>V#734=** "BBB@
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M"O2M)O\ Q1XR\*^&['7FV:;<ZKJUO90Z@Q3>%B>1U60E/FPI)V@GH*(OV@?
MMQ\,+KQM'XS\*S>#;,L)]=BU6"338=DGEONN QC7:_RMEN",'%?('[=7Q3\3
M_M*GX6R>#/ GQBT2T\"_%72M3NM;E\#S-<1VXTW4A-<P6=PGF-'&TMO&9'CP
M6G(56,;$>Q_LT>.[KP1^R=XHUS7/!_CS6+FPU+4KB\23P;'I>M^,W:0NUTFE
MQG(,N_RE$FQG$.\A585-O,#U#_AJ'X;_ -FZ7>?\+ \%?8];TV?6=.G_ +<M
M?+O[& 9GNXFWXD@C&"\JY10020#4_@C]HSP%\2O$L.C>'O&GA;7-6N=/&K0V
M5AJD%Q<2V1VA;I41BS0DLH$@&PEA@FOSX^#GP&\;?LQZ!\5/"FH_#'Q1K&E?
M$/X>ZI<_#R72+">_C^'%G<I<2'P;(6QY864Q21O&H#D^4^U+:US[!^POX5\0
M:+^UEX5N=0\$^,=#TW3_ ( >&O#DE[J.C26UM#J%M<W$D]F9&&!*BS1Y4<'#
M<G JM /MRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  C(H'%%% !1110 4
M444 %%%% "/]P_2OY#O^#D:?'_!;#XZ?\32.'%[I@V>8_P O_$HLN.M?UY5_
M)'_P<>Z1K4W_  6G^.#0S*L37>EE 8D.!_9%CCO51 _K!^'Q8>!]%!9I?] @
M!=N&8^4O)'K6TJX^OK61X%B^S>$-)C#.VRQA +=3B-1D^];%2 4444 %%%%
M'CVN/O\ V_O"Z_-F/X?:P0>QW:CI>?\ T$?_ %N_L->/ZB&D_;\T<_PP_#^^
M_ OJ-G_/9^E>P4 %%%% !1110 4444 %%%% !1110 4444 %%)N^;;W^E+0
M5P7[0_B7QUX4\%PWG@'2_#.IZA#<-)?G7;Z:TMK:T2":1G7R8W=Y#(D487
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M)KFE+XPTUM%\=7J-XUTC1_#2Z3IGB"RCT7^REMXH!/(UG-(%AGFN8GWRO$
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MI>@:*-"\%:G'J%U8:QX>B;1$TJ>:YN+:>/\ M&:;]],YG78WGO&4*$@P7O\
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M4E !1110 444U PSN.>>* '4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!I6\TK3+.&(#A7*9 -=];_ +',C?&#X3^-=4^)WC;7-:^%>CZAHL1O8M,
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MNJ>"=&UN30H-"?2=:TZ>XDO%DN[B$W,XC@F,&V.,%@K0RXED4JQ0'TI1110
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MV:KO$F! H^8.9 W3KO);/]XYZ\U<HI60%&3PMIDSWC/IUBS:@R/=%K=";DH
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MGM5S3_#]AI,_F6MC9VLGDQV^^*%4;RH]WEQY ^ZNYMJ]!N.,9-7**8!1110
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MNE_$30;[Q3XD-NNG:=$TADN#<6 U"W!)0*AELSYR!B"ZAMN2K <3X,_X*G>
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MX)M^*O$?C./4+SQ=X7BM?^$_TKQ?.EGH<\%Q);6WA8^'[BV63[0=DC ^=%(
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M MAXRUBVL++X=:A8ZOJ-K:^&4L&2\LIKNUC<0W,T6J&:Y+%&#H8H^!&&./\
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M\)^'=0N)]6L]=DEN-/B=Y-0M @M;MF*Y,T(C0(Y^90B@$ 8KK5&U<=?K2T4
M%%%% !1110 4444 %%%% !1110 445Y[^T]^TOX=_9.^$]QXN\2+J=U#]KMM
M,T_3=+M3=ZEK=_<RK!:V5K""#)/-*ZHJY &2695#, #T*BO&_P!ES]L2S_:1
M\6^-O"]YX5\1>!/&WP^>Q_MSP]K3VDUQ9Q7T!GM)/-M)IH&\Q%?*"0NA0[@
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M44 %%%% 'E'AA%_X;C\<,!\W_""^'E)SV^WZWC^9KU>O*?"A'_#;GCSD[O\
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M!T1_X;N^(<FUMO\ P@OAE2V>"1?Z^?Z_K7KM'4 HHHH **** "BBB@ HHHH
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MD/&?QJ\,_M9^!?!_AWQQX=TO1?B;)K:V0D\-+=-HRV6FQ30;W:4&4O<>:7X
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M^"KWPO\ B!^TIX?^%%DOB&/Q?KZ0J();6';I]U)I:ZJ+2Y5)FEBD%HP)?RS
M),Q^;O!6F[@?3E%?'_C_ /:K^+'Q%UGX_:M\-;CP?H_A_P#9YNY=)-AK.F2W
M<_C/4X-)@U2XA:=9X_L-OLN[>%)%CE??OD(95$3>*?&K_@JK\6/%4.I>*OAM
MX=U#3?"^A^$_ NO1VEQI-CJ#:U_PE3R0IEY+ZWDBDMG,.S";7>*=9%V/'(I8
M#]*Z*^,?@K^WMJGPH\&>-]+\?:CXP^+_ (Z\,^-=2T"/3/#W@2'2=3\JST>S
MU.5%MQ>RQ7"QP7"N;@21^=)<)%%$6,8DUO%7_!9SX/\ A76O$%G]F\=:H/#L
M,KS2:=X?DN6DFAEM(9[4P*WVB">.2]B4I<Q0[F28(7,3@+4#ZXHKG/A'\0U^
M+/PWT?Q(FC^(/#ZZQ;B<:;KNGM8:E9<D%)X&),;@@\9/8@D&NCH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &N"1Q_^NOXY?^#D9Y'_ ."VWQ[,BQJW
M]J6(&SIM&F68'XXQGWS7]C;DA3CK[U_'!_P<=7K7_P#P6Q^/DC(\976+2/##
MDA=.M%!^A R/8CKUH _L:LUQ"I[D#/Y5-4-@NRU1=V[:H&X]3Q4U !1110 4
M444 >3^!6D;]M7XDAE_=+X0\,[&SU/VK7,_T_.O6*\F\#%8_VT?B0S#;N\)>
M&1N+##?Z5K=>LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !138T\M=O)^M.H **** "BBB@!-OS[O;%+110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 1W;RQVLC0QI),J$QH[[%=
ML< M@X!/?!QZ&G(6*_-][OBG44 %>9?$GX%>$OB'^T%\/_%.JZKJMOXK\$I?
MW6AV,&K-!%/'*D<%U(]L#B= LL:$D$(9$Z%A7IM?GM^U!\4/$7PPU3]L+Q9:
M>+-4\'^+O#FM^#-*T/5X[.&\FT;P[/%IF9((9895>-[RYUG(V-O>)@,,@( /
M>_&O_!.#X:W'C&X\976L>-]%NH]>U;Q7?W-IXGGLH9I+^R@M+N.8J1FT\JUM
MG\DD(K6ZGIN#4_@S_P $Z/A/H_B#P/XX\%^(/&C:1I7A?2M)L;?3O%EPVB>(
M[:R@":;?W<<;;+ZXAA9!%/(6X2(_,8XROS;X4UWX\>./BI=Z%??%#XL3?#G1
MM#\6ZMI6JMX)L))/&UI;RV"V$5\[Z68]S>=?I&L21M<PV\3JKARSY?P@^,'Q
MVT;4?A7+%K'Q&T_2]/T_X8:9<^$4\"QV>DS'4;&YCUA9?^)>)8$B*1,Y21$M
M&0!P@(2GR@?97QI_9C\#:S^S5X/^%OB[QMXLM])M=5T:#3M4O_$Q76M8U"RN
M([JS$EW-E[B=IK9)".6<Q], UV7BO]F+PWXX^.-IX\U635+Z_M?#-YX2;39;
M@/I=U87<L4MPLMN5VNSM!$"2?NIC&"<_!OPU^-WQ$^*?AGX4ZUX@OOBSJ^MW
M7CSP7%XGT+Q3\-([:U\':L7OX]5BLYY+-7,.YXL31[EMXXHB+G_2&5N%^"O[
M9'QQU[]F[2/&R_%#XD^.K?6-&EA\2M:^$+9H?#-_'XMLK.#[/<6>FLRK+ISW
MXF(BNGBC@6X6(DJ&:0'UCHO_  2Q^#^F^%9OA3_PGGQ.U2U;3'AO="U/Q[<:
ME+/H<JFVCL9(;AG*V,8#+"556C?>R2!\M6KX_P#^"07PT\?:!<6;>(?BAI%S
M<:KXAU%M0TCQ1-8WK0ZZXDU+3C)&!NLI)5241,#MDC1@VX9KQW_@F)\2_%OQ
M?_:0\)Z]X_M?$S>-X_A'<:3K-YK'AJ[T>:XEMO$<\:;Q-;P LT05^%4G+,%7
M)KB;S]H7X]^(_''QHL=6^)7Q&\ ZWH]]K^CZ3I6F_#;[9;V4AUB.+PU=07EU
M:_8WBN+=HHV'F.9EN)G9H#;M)&>5P/IS4_\ @D)\+=3D\8)_:WQ-M]/\=:.V
MEZKID/B^\&FRS/9)83:B+8L8A?2VB+$\VT[AN; =F8]8G_!.OP(OQ=M?'!U#
MQD?$5GXO;QK%.-;D4?;7TJ/2I(R% W6\EK#"'A.58Q+GC*GXJ\9?MD_'OQ7_
M ,(39R^*/&GP_O=0EURPUVZTWP!+XC32?&-GJ5H$T!8K>V82Z>;(W7V:=WQ<
MKF1YD= %UYOVP?C'HEOJOBB^\3?%BRUKPWXNL+/Q_P"$)OAXLFC>%]/7Q7;6
M\LMI=BU+S02://)(# UR[Q1BX\R$H=X_4#Z*_:=_X)B_"SXG_%#7?BQXH\8?
M$+P=>;;74=3O-,\7R:1IMM]ALKNT%U(O^K7%I=SQR,WR["W W/NL:S_P2;^&
MOB2PCFMO$'Q&T[6+>V\/PZ9K^G>(F@U/2#HUK<VEK-;3!,*\EM>74<Q(995N
M'R.A'Q-\7?B_\2/BA\-?B!XHUK4OBYJ$VL?![XD:9HNE:MX (T^]DL]>N/L2
M75C/IWE++)8"S7$ZKYNT+AG+J?IWX@?$#]H3PG\<?B-X=\'2:MXGT<:#+\2/
M!-W-I=I'8S0#29[:/PN9%@7+G5A;7(8D3?9Y-A?@EBWF![M9_L"?#\?L;6OP
M+U"+7M<\%6=HEO%-J&JRR:HDD<WVB*Z6[4K(ES%.%ECE0JR.BE<8%<UJW[!_
MA+P[X<T?5O''Q,^)GB+_ (0?7;'Q8-<\3^)HPL']G&22&.4+%';+;C>3(PC5
MY-B,\C%%(\@_8^_:$^,?BC]B3XP>*],\1^(_BUXXLM .J>%K'7_ DGAF>SU?
M^S&,FDLK)%]I*7D8+!(\1F81"5\83QCXE?$;QO\ &GX<VVG_ /"R_B=XD\!Q
M_$#X5ZKHOB>Z\-VEAJT5Y-J@FU:RG6.R2#R[*.&VNWWP@VTK%)&94,8+7 ]O
MT'_@G_\ LSZY80^!8_BA?:Y/K_AN32=-TX>-K5M0-O<ZJVOP7UIY(6;[1'=J
M+B"=,X6%2-P!->Y?"C]@S2?A7\6/"/C5?'WQ0\1:YX4T74-$:77=9CO1K27T
MT,UQ-=YA#-*6M;0+Y9C2-;6)415W!OA'X ?"RS^"_P 8_"-YX3LU\32V/[0W
MB[2K,:GX2T]5T^WF\/:@8VM[B*QB>TAFO8+)3<0LJ-A5#%"5-.?]N7XV/\(_
M >M:;\2/BU::+XFGM+?QSK6O?"?R;CX;ZN=+O?,TXK#8L[P-?I;[LVLOD;(D
M:Z(NE(?+Y@?;GQ&_X)[>'O$?Q6\=>)IOB;\4-#D^+4UE;Z[IECJEC!9ZE%;0
MF*.SCW6IFC1H1(K"*19"'=MP;#"EXO\ ^"2_PT\>Z]XBU;5=4\<76J>,],N]
M+\0WBZJD,^N++>+>6DT[QQ*QGTZ1$%C*I5K5%")\N0?F3Q/XJ^*'Q0_9A_:J
MUSQU\4=5U^'X8^$O^)'HTW@VUT-8-;7PWIFJ6VIP$Q?:X[F'5?M"QQ&5MC_N
MSEXQ7Z.?"K4M8UGX8^'+SQ!;_9->N]+M9M2@V;/)N6A0RIM[8<L,=L5+TT \
M!E_X)5>"[SQ)X;UVZ\:_%RZ\2:/9R:;K.L2>*G6]\;6+RI*;/5'5 )8 T:[4
MA$.U2ZJ0LCJV1)_P1V^'CS^*I%\7?%1?^$DM+RQMD_X2%6C\-PW&L)K(&GH8
MBD1AO8T:,N)#L 1]Z@ ?6M%+4#Y]E_X)J_#G7?A/XB\&^)'\2>,-(\4^+K3Q
MM?MK>I>?<OJ%LUH4Q*JJWELMG$C*<ED>12<.16KHG["WAOPM^U!JGQ.TGQ%X
MZTN37KJ/4]5\,6NLF+PWJ6I);K:C4);0+EKCR$C0C>(F,,3F,R(KCVVB@#Y_
M^,/_  3P\+_%CQIXPU2#Q-XZ\)V/Q,MXK7QSH^@W\-O8^+HXX1;CS]\+RP2-
M;A8'FM)()7B1%9SL0KD_$#_@E[X+\=W_ (VDA\2>./#=GXWM_#=G+I^C7%C;
MVFDP:#/Y^G0V:&U;R8TD+%ERP8,1P  /I:B@#Y?\=?\ !*_PKXS\4:MXCMO'
M/Q.\-^+M4\8R^-%\0:+J=K:ZA87$^FVVEW-K"WV9E%I/:6ENKQNKD-$DBLKJ
M&%#4O^"0_@2XTSQ9I6G^,_BQHGAGQ5?P:LGA^S\0I)IFBWR3VT\MU:QSPR,)
M9Y+8-(9FE&Z:=D$;2LQ^KZ* &QIY:!<EO4GO1EM_^S3J* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!'&5(K^-C_@XHOI-1_P""U'Q^DD,Q9==@B'F+
MM;"6-L@_#"C![C!K^RBOXU_^#BBVEM?^"U'Q^69F9CKL#@G^ZUC;,H_!2!0!
M_9#8,3;KN^]M!..G05/4-BGEVR+_ '5 _2IJ "BBB@ HHHH \C\#Q17/[:/Q
M)5F\QE\*>&24(X0_:=;((]_\*]<KR'X=R%_VUOB@N[A/#'AI0,]/WVL'\N?T
M->MP(T<>'?S&R>2* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH "<"OXR_^#@J/RO^"S?[00%NUO\ \5+G823G
M-O"=W_ OO?\  J_LR=L<>O2OXT?^#A81+_P6@_:!\G[G_"1(3\I7YOLL&[K_
M +6>>AZCB@#^RJP5DM(U9_,95 +XQO..OXU-4=I\L"@]0!4E !1110 4444
M>/\ POL8M3_:;^,D+&94FAT6&0QRF)P3:2Y*LI#*=K## @@CC& :]<L[1+&U
MCACW>7&H5<L6. ,#D\GZFO)O@RCG]J/XR2-&P3S=%C5ST8BQR1^&X>W->NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%!.!110 UAOVM^/-?QL_\'$\:Q?\%J/C^%"J/[=A;Y4VC)LK8GC)YR>3W//&
M<5_9,27)[=OK7\9?_!P3++-_P6:_:":8.&_X28J-QR=HMX0OX;0,>V* /[,X
MDPO/6GTU/N]=U.H **** "@T44 >._ M2W[3OQN;'R_VCHZ'YLY8:7"3].&6
MO8J\C^ PW?M"_'!L_,NOZ:GT T6Q/_LQKUR@ HHHH * V:*:J[6;CJ<]>M #
MJ*** "BBB@ HHHH ***101U.>: %HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $X% .1110
M 444B9Q\U "T444 -=L#ZU_%[_P7GN$NO^"Q7[0S1K(BCQ?<H0_7*JBD_0D$
MCV(K^T*4*1S7\6?_  7.D\W_ (*__M$GR/L__%;7XV9)SA\;N?[WWO3YN,#B
M@#^T[.:*C@.5/UJ2@ HHHH *,XHHH \=_96+'XA?'(G^+X@MCC'31=(%>Q5X
MW^R@A'C?XWL?X_B%*1@YZ:3I8_I7LE.6X!1112 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBDW?-B@!:*** "BBB@ HHHH **** &R;]R[=N,_-D]J=110 4444 %
M%%% !1110 4444 %%%,@E,L09E*'N#VH ?1110 444V0,4^4X;B@!U% Z44
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** (X+R.YEE16RT+;7'H<9_D14E%% !1110
M4444 %%%% !1110 4WRQYA;GD8QVIU% !BBBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+!<G&3SC)QZFIJ &M(J=3CG%.J.:V6=D9E!:-MRDC[IP1Q^!(_&I!0 4444
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MP*OJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%1R']X/P_G1<'#+^- $F><456M6)NI.3P!BIH3E*; ?1112 ***;*?D_$4
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)0G)JMD#V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>30
<FILENAME>cphi-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:37 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.chinapharmaholdings.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cphi="http://www.chinapharmaholdings.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cphi-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet" id="cphi_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals" id="cphi_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" id="cphi_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals" id="cphi_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" id="cphi_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" id="cphi_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies" id="cphi_r_OrganizationandSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/Inventory" id="cphi_r_Inventory">
        <link:definition>995308 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment" id="cphi_r_PropertyPlantandEquipment">
        <link:definition>995309 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets" id="cphi_r_IntangibleAssets">
        <link:definition>995310 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OtherPayables" id="cphi_r_OtherPayables">
        <link:definition>995311 - Disclosure - Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions" id="cphi_r_RelatedPartyTransactions">
        <link:definition>995312 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility" id="cphi_r_LinesofCreditandConstructionLoanFacility">
        <link:definition>995313 - Disclosure - Lines of Credit and Construction Loan Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable" id="cphi_r_ConvertibleNotePayable">
        <link:definition>995314 - Disclosure - Convertible Note Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/Leases" id="cphi_r_Leases">
        <link:definition>995315 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes" id="cphi_r_IncomeTaxes">
        <link:definition>995316 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements" id="cphi_r_FairValueMeasurements">
        <link:definition>995317 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity" id="cphi_r_StockholdersEquity">
        <link:definition>995318 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties" id="cphi_r_RisksUncertainties">
        <link:definition>995319 - Disclosure - Risks &amp; Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents" id="cphi_r_SubsequentEvents">
        <link:definition>995320 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy" id="cphi_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/InventoryTables" id="cphi_r_InventoryTables">
        <link:definition>996001 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables" id="cphi_r_PropertyPlantandEquipmentTables">
        <link:definition>996002 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables" id="cphi_r_IntangibleAssetsTables">
        <link:definition>996003 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables" id="cphi_r_OtherPayablesTables">
        <link:definition>996004 - Disclosure - Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables" id="cphi_r_LinesofCreditandConstructionLoanFacilityTables">
        <link:definition>996005 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LeasesTables" id="cphi_r_LeasesTables">
        <link:definition>996006 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables" id="cphi_r_IncomeTaxesTables">
        <link:definition>996007 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables" id="cphi_r_FairValueMeasurementsTables">
        <link:definition>996008 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" id="cphi_r_OrganizationandSignificantAccountingPoliciesDetails">
        <link:definition>996009 - Disclosure - Organization and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable" id="cphi_r_ScheduleofInventoryTable">
        <link:definition>996010 - Disclosure - Inventory (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails" id="cphi_r_PropertyPlantandEquipmentDetails">
        <link:definition>996011 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable" id="cphi_r_ScheduleofPropertyPlantandEquipmentTable">
        <link:definition>996012 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable" id="cphi_r_ScheduleofEstimatedUsefulLivesofTheAssetsTable">
        <link:definition>996013 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" id="cphi_r_IntangibleAssetsDetails">
        <link:definition>996014 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KH52LXZPg3KWPe7cxF0jLm7M=] CSR-->
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable" id="cphi_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996015 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable" id="cphi_r_ScheduleofAggregateAnnualAmortizationExpenseTable">
        <link:definition>996016 - Disclosure - Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable" id="cphi_r_ScheduleofOtherPayablesTable">
        <link:definition>996017 - Disclosure - Other Payables (Details) - Schedule of Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" id="cphi_r_RelatedPartyTransactionsDetails">
        <link:definition>996018 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails" id="cphi_r_LinesofCreditandConstructionLoanFacilityDetails">
        <link:definition>996019 - Disclosure - Lines of Credit and Construction Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable" id="cphi_r_ScheduleofPrincipalPaymentsTable">
        <link:definition>996020 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" id="cphi_r_ConvertibleNotePayableDetails">
        <link:definition>996021 - Disclosure - Convertible Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails" id="cphi_r_LeasesDetails">
        <link:definition>996022 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable" id="cphi_r_ScheduleofOperatingLeaseLiabilitiesTable">
        <link:definition>996023 - Disclosure - Leases (Details) - Schedule of Operating Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" id="cphi_r_IncomeTaxesDetails">
        <link:definition>996024 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable" id="cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable">
        <link:definition>996025 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals" id="cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals">
        <link:definition>996026 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable" id="cphi_r_ScheduleofDeferredIncomeTaxAssetsandLiabilityTable">
        <link:definition>996027 - Disclosure - Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable" id="cphi_r_ScheduleofAssetsandLiabilitiesRecordedatFairValueTable">
        <link:definition>996028 - Disclosure - Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" id="cphi_r_StockholdersEquityDetails">
        <link:definition>996029 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails" id="cphi_r_RisksUncertaintiesDetails">
        <link:definition>996030 - Disclosure - Risks &amp; Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails" id="cphi_r_SubsequentEventsDetails">
        <link:definition>996031 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
  <xs:element name="ScheduleOfPrincipalPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfPrincipalPaymentsAbstract"/>
  <xs:element name="ScheduleOfOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
  <xs:element name="ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
  <xs:element name="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UnlabeledAbstract10"/>
  <xs:element name="DeferredIncomeTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DeferredIncomeTaxAssetsAbstract"/>
  <xs:element name="DeferredIncomeTaxLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DeferredIncomeTaxLiabilityAbstract"/>
  <xs:element name="BankersAcceptances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankersAcceptances"/>
  <xs:element name="AdvanceToSupplies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdvanceToSupplies"/>
  <xs:element name="OtherReceivablesLessAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
  <xs:element name="StockIssuedDuringPeriodValueStockSplits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_StockIssuedDuringPeriodValueStockSplits"/>
  <xs:element name="AccountsReceivableCollectedWithBankersAcceptances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
  <xs:element name="InventoryPurchasedWithBankersAcceptanceNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
  <xs:element name="ConversionOfRelatedPartyNoteAndInterestToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ReverseStockSplitsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ReverseStockSplitsPolicyTextBlock"/>
  <xs:element name="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
  <xs:element name="InterestRateRiskPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestRateRiskPolicyTextBlock"/>
  <xs:element name="UsefulLiveOfAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_UsefulLiveOfAssetsTableTextBlock"/>
  <xs:element name="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
  <xs:element name="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems"/>
  <xs:element name="IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable"/>
  <xs:element name="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems"/>
  <xs:element name="OtherPayablesDetailsScheduleofOtherPayablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable"/>
  <xs:element name="OtherPayablesDetailsScheduleofOtherPayablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_WorkingCapital"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_IntangibleAssetsDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_IntangibleAssetsDetailsLineItems"/>
  <xs:element name="PercentageOfNetProfit" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PercentageOfNetProfit"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="AggregateAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AggregateAmounts"/>
  <xs:element name="RestrictedCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_RestrictedCommonStock"/>
  <xs:element name="LoanAndReceivedProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_LoanAndReceivedProceeds"/>
  <xs:element name="RepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_RepaidAmount"/>
  <xs:element name="ConvertibleNotePayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_ConvertibleNotePayableDetailsTable"/>
  <xs:element name="PercentageOfBalanceNoteAndAccruedInterest" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_PercentageOfBalanceNoteAndAccruedInterest"/>
  <xs:element name="InterestAccruesOnNoteDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterestAccruesOnNoteDescription"/>
  <xs:element name="RedeemOfOutstandingNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_RedeemOfOutstandingNote"/>
  <xs:element name="NoteRedeemableIntoShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NoteRedeemableIntoShares"/>
  <xs:element name="WeightedAveragePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_WeightedAveragePrice"/>
  <xs:element name="DeferredTaxAssetValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_DeferredTaxAssetValuationAllowance"/>
  <xs:element name="AftertaxNetIncomePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_AftertaxNetIncomePercentage"/>
  <xs:element name="ReserveAccountBalancesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ReserveAccountBalancesPercentage"/>
  <xs:element name="TotalOptionOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TotalOptionOutstanding"/>
  <xs:element name="AdditionalSharesAvailableForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_AdditionalSharesAvailableForIssuance"/>
  <xs:element name="IssuanceOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cphi_IssuanceOfCommonStock"/>
  <xs:element name="ClosingMarketPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ClosingMarketPrice"/>
  <xs:element name="PurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PurchaseOfCommonStock"/>
  <xs:element name="RisksUncertaintiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_RisksUncertaintiesDetailsTable"/>
  <xs:element name="RisksUncertaintiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RisksUncertaintiesDetailsLineItems"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cphi_SubsequentEventsDetailsTable"/>
  <xs:element name="AggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cphi_AggregateAmount"/>
  <xs:element name="RedemptionPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RedemptionPercentage"/>
  <xs:element name="RedemptionAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cphi_RedemptionAmount"/>
  <xs:element name="RedemptionOfWeightedAveragePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_RedemptionOfWeightedAveragePercentage"/>
  <xs:element name="BankOfChinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankOfChinaMember"/>
  <xs:element name="BankOfCommunicationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankOfCommunicationsMember"/>
  <xs:element name="BankersAcceptanceNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_BankersAcceptanceNotesMember"/>
  <xs:element name="CITICBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CITICBankMember"/>
  <xs:element name="ChairpersonCEOAndInterimCFOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ChairpersonCEOAndInterimCFOMember"/>
  <xs:element name="ChinaCITICBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ChinaCITICBankMember"/>
  <xs:element name="ChinaPharmaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ChinaPharmaMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerMember"/>
  <xs:element name="CustomerOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerOneMember"/>
  <xs:element name="CustomerThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerThreeMember"/>
  <xs:element name="CustomerTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_CustomerTwoMember"/>
  <xs:element name="EffectiveMarchSixTwoZeroTwoFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_EffectiveMarchSixTwoZeroTwoFourMember"/>
  <xs:element name="EffectiveMarchSixTwoZeroTwoThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_EffectiveMarchSixTwoZeroTwoThreeMember"/>
  <xs:element name="HainanHelpsonMedicalBiotechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
  <xs:element name="HelpsonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_HelpsonMember"/>
  <xs:element name="InterimChiefFinancialOfficerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InterimChiefFinancialOfficerMember"/>
  <xs:element name="InventionPatentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_InventionPatentMember"/>
  <xs:element name="NMPAApprovedMedicalFormulasMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_NMPAApprovedMedicalFormulasMember"/>
  <xs:element name="OnnyInvestmentLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_OnnyInvestmentLimitedMember"/>
  <xs:element name="PostalSavingsBankOfChinaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_PostalSavingsBankOfChinaMember"/>
  <xs:element name="ProductOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ProductOneMember"/>
  <xs:element name="ProductThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ProductThreeMember"/>
  <xs:element name="ProductTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_ProductTwoMember"/>
  <xs:element name="SalesBenchmarkMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SalesBenchmarkMember"/>
  <xs:element name="SuppliersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SuppliersOneMember"/>
  <xs:element name="SuppliersTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_SuppliersTwoMember"/>
  <xs:element name="TechnologyFromBonierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TechnologyFromBonierMember"/>
  <xs:element name="TwoThousandTenIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_TwoThousandTenIncentivePlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cphi_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>31
<FILENAME>cphi-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:38 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofInventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofAggregateAnnualAmortizationExpenseTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOtherPayablesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPrincipalPaymentsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOperatingLeaseLiabilitiesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofDeferredIncomeTaxAssetsandLiabilityTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptances"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cphi_BankersAcceptances" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20231231.xsd#cphi_AdvanceToSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cphi_AdvanceToSupplies" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLineOfCredit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KH7RNc8p5ttvY9yKyojarV6Q=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionPlanExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>32
<FILENAME>cphi-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:38 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ShareholdersEquityType2or3" roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OrganizationandSignificantAccountingPolicies" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_Inventory" roleURI="http://www.chinapharmaholdings.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipment" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssets" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OtherPayables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RelatedPartyTransactions" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacility" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConvertibleNotePayable" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_Leases" roleURI="http://www.chinapharmaholdings.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxes" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_FairValueMeasurements" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_StockholdersEquity" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RisksUncertainties" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_SubsequentEvents" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_AccountingPoliciesByPolicy" roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_InventoryTables" roleURI="http://www.chinapharmaholdings.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipmentTables" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssetsTables" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OtherPayablesTables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityTables" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LeasesTables" roleURI="http://www.chinapharmaholdings.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxesTables" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_FairValueMeasurementsTables" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofInventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofEstimatedUsefulLivesofTheAssetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofAggregateAnnualAmortizationExpenseTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOtherPayablesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPrincipalPaymentsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOperatingLeaseLiabilitiesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofDeferredIncomeTaxAssetsandLiabilityTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofAssetsandLiabilitiesRecordedatFairValueTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipmentDetails" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssetsDetails" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RelatedPartyTransactionsDetails" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityDetails" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConvertibleNotePayableDetails" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LeasesDetails" roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxesDetails" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_StockholdersEquityDetails" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RisksUncertaintiesDetails" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_SubsequentEventsDetails" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="cphi_BankersAcceptances" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20231231.xsd#cphi_AdvanceToSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="cphi_AdvanceToSupplies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermLineOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20231231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_StockIssuedDuringPeriodValueStockSplits" xlink:href="cphi-20231231.xsd#cphi_StockIssuedDuringPeriodValueStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="cphi_StockIssuedDuringPeriodValueStockSplits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20231231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:href="cphi-20231231.xsd#cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertainties">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ReverseStockSplitsPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_ReverseStockSplitsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_ReverseStockSplitsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRateRiskPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cphi_InterestRateRiskPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20231231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcess" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable">
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NMPAApprovedMedicalFormulasMember" xlink:href="cphi-20231231.xsd#cphi_NMPAApprovedMedicalFormulasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cphi_NMPAApprovedMedicalFormulasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TechnologyFromBonierMember" xlink:href="cphi-20231231.xsd#cphi_TechnologyFromBonierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cphi_TechnologyFromBonierMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InventionPatentMember" xlink:href="cphi-20231231.xsd#cphi_InventionPatentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cphi_InventionPatentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_TaxesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KHziS/pNsHo75rqrFh+HDRdg=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable">
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptanceNotesMember" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptanceNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cphi_BankersAcceptanceNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_OwnershipAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_OnnyInvestmentLimitedMember" xlink:href="cphi-20231231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cphi_OnnyInvestmentLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20231231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WorkingCapital" xlink:href="cphi-20231231.xsd#cphi_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="cphi_WorkingCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityIndexedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityIndexedShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="cphi_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_IntangibleAssetsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_IntangibleAssetsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaPharmaMember" xlink:href="cphi-20231231.xsd#cphi_ChinaPharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_ChinaPharmaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_HelpsonMember" xlink:href="cphi-20231231.xsd#cphi_HelpsonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cphi_HelpsonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_DividendsStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfNetProfit" xlink:href="cphi-20231231.xsd#cphi_PercentageOfNetProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="cphi_PercentageOfNetProfit" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChairpersonCEOAndInterimCFOMember" xlink:href="cphi-20231231.xsd#cphi_ChairpersonCEOAndInterimCFOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cphi_ChairpersonCEOAndInterimCFOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterimChiefFinancialOfficerMember" xlink:href="cphi-20231231.xsd#cphi_InterimChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cphi_InterimChiefFinancialOfficerMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesToAffiliate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdvancesToAffiliate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsForLoans" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AggregateAmounts" xlink:href="cphi-20231231.xsd#cphi_AggregateAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_AggregateAmounts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RestrictedCommonStock" xlink:href="cphi-20231231.xsd#cphi_RestrictedCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_RestrictedCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansHeldForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansHeldForSaleTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_LoansHeldForSaleTerm" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfCommunicationsMember" xlink:href="cphi-20231231.xsd#cphi_BankOfCommunicationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_BankOfCommunicationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaCITICBankMember" xlink:href="cphi-20231231.xsd#cphi_ChinaCITICBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_ChinaCITICBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CITICBankMember" xlink:href="cphi-20231231.xsd#cphi_CITICBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_CITICBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_BankOfChinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_BankOfChinaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PostalSavingsBankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_PostalSavingsBankOfChinaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cphi_PostalSavingsBankOfChinaMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRateFloor" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRateFloor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InvestmentInterestRateFloor" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsForMortgageDeposits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_LoanAndReceivedProceeds" xlink:href="cphi-20231231.xsd#cphi_LoanAndReceivedProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="cphi_LoanAndReceivedProceeds" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AggregateAmounts" xlink:href="cphi-20231231.xsd#cphi_AggregateAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="cphi_AggregateAmounts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RepaidAmount" xlink:href="cphi-20231231.xsd#cphi_RepaidAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="cphi_RepaidAmount" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNotePayableDetailsTable" xlink:href="cphi-20231231.xsd#cphi_ConvertibleNotePayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_ConvertibleNotePayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_ConvertibleNotePayableDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaPharmaMember" xlink:href="cphi-20231231.xsd#cphi_ChinaPharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cphi_ChinaPharmaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfBalanceNoteAndAccruedInterest" xlink:href="cphi-20231231.xsd#cphi_PercentageOfBalanceNoteAndAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_PercentageOfBalanceNoteAndAccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAccruesOnNoteDescription" xlink:href="cphi-20231231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_InterestAccruesOnNoteDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RedeemOfOutstandingNote" xlink:href="cphi-20231231.xsd#cphi_RedeemOfOutstandingNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_RedeemOfOutstandingNote" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_NoteRedeemableIntoShares" xlink:href="cphi-20231231.xsd#cphi_NoteRedeemableIntoShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_NoteRedeemableIntoShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrice" xlink:href="cphi-20231231.xsd#cphi_WeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="cphi_WeightedAveragePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_SharesIssued" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2023Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredTaxAssetValuationAllowance" xlink:href="cphi-20231231.xsd#cphi_DeferredTaxAssetValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="cphi_DeferredTaxAssetValuationAllowance" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoFourMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoFourMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoThreeMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoThreeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenIncentivePlanMember" xlink:href="cphi-20231231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cphi_TwoThousandTenIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AftertaxNetIncomePercentage" xlink:href="cphi-20231231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_AftertaxNetIncomePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ReserveAccountBalancesPercentage" xlink:href="cphi-20231231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_ReserveAccountBalancesPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_TotalOptionOutstanding" xlink:href="cphi-20231231.xsd#cphi_TotalOptionOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_TotalOptionOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AdditionalSharesAvailableForIssuance" xlink:href="cphi-20231231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_AdditionalSharesAvailableForIssuance" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_IssuanceOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_IssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_IssuanceOfCommonStock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ClosingMarketPrice" xlink:href="cphi-20231231.xsd#cphi_ClosingMarketPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_ClosingMarketPrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonUnitIssued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_PurchaseOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="cphi_PurchaseOfCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_SharePrice" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_Cash" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails">
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_RisksUncertaintiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersOneMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="cphi_SuppliersOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersTwoMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="cphi_SuppliersTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerMember" xlink:href="cphi-20231231.xsd#cphi_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerOneMember" xlink:href="cphi-20231231.xsd#cphi_CustomerOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerTwoMember" xlink:href="cphi-20231231.xsd#cphi_CustomerTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerThreeMember" xlink:href="cphi-20231231.xsd#cphi_CustomerThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="cphi_CustomerThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductOneMember" xlink:href="cphi-20231231.xsd#cphi_ProductOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cphi_ProductOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductTwoMember" xlink:href="cphi-20231231.xsd#cphi_ProductTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cphi_ProductTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductThreeMember" xlink:href="cphi-20231231.xsd#cphi_ProductThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cphi_ProductThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesBenchmarkMember" xlink:href="cphi-20231231.xsd#cphi_SalesBenchmarkMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="cphi_SalesBenchmarkMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsTotalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cphi_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_AggregateAmount" xlink:href="cphi-20231231.xsd#cphi_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cphi_AggregateAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionPercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cphi_RedemptionPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionAmount" xlink:href="cphi-20231231.xsd#cphi_RedemptionAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cphi_RedemptionAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionOfWeightedAveragePercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionOfWeightedAveragePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cphi_RedemptionOfWeightedAveragePercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>cphi-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:37 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross (loss) profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Net other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash (Used In) Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase in Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Organization and Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="cphi_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of The Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:to="cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfIntangibleAssetsAbstract" xlink:to="cphi_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Aggregate Annual Amortization Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Net carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Lines of Credit and Construction Loan Facility [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfPrincipalPaymentsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfPrincipalPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfPrincipalPaymentsAbstract_lbl" xml:lang="en-US">Schedule of Principal Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfPrincipalPaymentsAbstract" xlink:to="cphi_ScheduleOfPrincipalPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">Convertible Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract_lbl" xml:lang="en-US">Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Deferred Income Tax Assets and Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred income tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks &amp; Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankersAcceptances_lbl" xml:lang="en-US">Banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts of $13,786,074 and $16,739,527, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables, less allowance for doubtful accounts of $27,017 and $27,149, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20231231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Other receivables, allowance for doubtful accounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvanceToSupplies" xlink:href="cphi-20231231.xsd#cphi_AdvanceToSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdvanceToSupplies_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract" xlink:to="cphi_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract0" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract0" xlink:to="cphi_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Advances from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: Operating lease liabilities, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Current portion of lines of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl0" xml:lang="en-US">Repaid under this line of credit (in Yuan Renminbi)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible, redeemable note payable, net of issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US">Lines of credit, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 10,625,788 shares and 1,498,180 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract1" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract1" xlink:to="cphi_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Bad debt (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract2" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract2" xlink:to="cphi_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract3" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract3" xlink:to="cphi_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract4" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract4" xlink:to="cphi_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss) - foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Issuance of common stock for intangible assets (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock option compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversions of note payable to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversions of note payable to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of related party note and interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of related party note and interest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_StockIssuedDuringPeriodValueStockSplits" xlink:href="cphi-20231231.xsd#cphi_StockIssuedDuringPeriodValueStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_StockIssuedDuringPeriodValueStockSplits_lbl" xml:lang="en-US">Share rounding due to reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockIssuedDuringPeriodValueStockSplits" xlink:to="cphi_StockIssuedDuringPeriodValueStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Share rounding due to reverse split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock and stock option compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Advances from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract5" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract5" xlink:to="cphi_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract6" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract6" xlink:to="cphi_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from lines of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings and interest from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract7" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract7" xlink:to="cphi_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate Changes on Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract8" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract8" xlink:to="cphi_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract9" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract9" xlink:to="cphi_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UnlabeledAbstract10" xlink:href="cphi-20231231.xsd#cphi_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract10" xlink:to="cphi_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Noncash Investing and Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl" xml:lang="en-US">Accounts receivable collected with banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20231231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl" xml:lang="en-US">Inventory purchased with banker&#8217;s acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Common stock issued for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:href="cphi-20231231.xsd#cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl" xml:lang="en-US">Conversion of related party note and interest to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:to="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property, plant &amp; equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Trade accounts and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Payments of line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other	Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20231231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of The Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Aggregate Annual Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Compensation payable to officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation and interest to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Business taxes and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Schedule of principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTE PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes Calculated at the Federal Statutory Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">(Benefit) tax at statutory rate of 25%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">(Benefit) tax at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior year refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Other, primarily the difference in U.S. tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Income Tax Assets and Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred income tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xml:lang="en-US">Allowance for doubtful other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory obsolescence reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Expenses not deductible in current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl" xml:lang="en-US">Advances for intangible assets impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Lease liability, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">PRC net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">U.S. net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract_lbl" xml:lang="en-US">Deferred income tax liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Recorded at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">RISKS &amp; UNCERTAINTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Permit of land use [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xml:lang="en-US">Plant, machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Motor vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Motor vehicle [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Plant, machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NMPAApprovedMedicalFormulasMember" xlink:href="cphi-20231231.xsd#cphi_NMPAApprovedMedicalFormulasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NMPAApprovedMedicalFormulasMember_lbl" xml:lang="en-US">NMPA approved medical formulas [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NMPAApprovedMedicalFormulasMember" xlink:to="cphi_NMPAApprovedMedicalFormulasMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TechnologyFromBonierMember" xlink:href="cphi-20231231.xsd#cphi_TechnologyFromBonierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TechnologyFromBonierMember_lbl" xml:lang="en-US">Technology from Bonier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TechnologyFromBonierMember" xlink:to="cphi_TechnologyFromBonierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InventionPatentMember" xlink:href="cphi-20231231.xsd#cphi_InventionPatentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InventionPatentMember_lbl" xml:lang="en-US">Invention Patent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventionPatentMember" xlink:to="cphi_InventionPatentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US">Lines of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankersAcceptanceNotesMember" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptanceNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankersAcceptanceNotesMember_lbl" xml:lang="en-US">Banker&apos;s Acceptance Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptanceNotesMember" xlink:to="cphi_BankersAcceptanceNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US">Stock Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WorkingCapital" xlink:href="cphi-20231231.xsd#cphi_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WorkingCapital" xlink:to="cphi_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Bad debt expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Uncollectible trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityIndexedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityIndexedShares_lbl" xml:lang="en-US">Purchase of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:to="us-gaap_OptionIndexedToIssuersEquityIndexedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares issuable upon conversion of the convertible note payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Issuance of shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expanse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xml:lang="en-US">Amortization intangible by useful life, descriptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense relating to intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsStock_lbl" xml:lang="en-US">Common stock value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Closing price of common stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset useful life,term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfNetProfit" xlink:href="cphi-20231231.xsd#cphi_PercentageOfNetProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PercentageOfNetProfit_lbl" xml:lang="en-US">Percentage of net profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfNetProfit" xlink:to="cphi_PercentageOfNetProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesToAffiliate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvancesToAffiliate_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLoans_lbl" xml:lang="en-US">Loan payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AggregateAmounts" xlink:href="cphi-20231231.xsd#cphi_AggregateAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AggregateAmounts_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmounts" xlink:to="cphi_AggregateAmounts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_AggregateAmounts_lbl0" xml:lang="en-US">Aggregate amount (in Yuan Renminbi)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmounts" xlink:to="cphi_AggregateAmounts_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_RestrictedCommonStock" xlink:href="cphi-20231231.xsd#cphi_RestrictedCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RestrictedCommonStock_lbl" xml:lang="en-US">Restricted common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RestrictedCommonStock" xlink:to="cphi_RestrictedCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Total advance received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Proceeds from loan agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansHeldForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansHeldForSaleTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansHeldForSaleTerm_lbl" xml:lang="en-US">Term of loan agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansHeldForSaleTerm" xlink:to="us-gaap_LoansHeldForSaleTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRateFloor" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRateFloor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRateFloor_lbl" xml:lang="en-US">interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRateFloor" xlink:to="us-gaap_InvestmentInterestRateFloor_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit, amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Total interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForMortgageDeposits_lbl" xml:lang="en-US">Advance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMortgageDeposits" xlink:to="us-gaap_PaymentsForMortgageDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Percentage of loan bears interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LoanAndReceivedProceeds" xlink:href="cphi-20231231.xsd#cphi_LoanAndReceivedProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LoanAndReceivedProceeds_lbl" xml:lang="en-US">Loan and received proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAndReceivedProceeds" xlink:to="cphi_LoanAndReceivedProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RepaidAmount" xlink:href="cphi-20231231.xsd#cphi_RepaidAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RepaidAmount_lbl" xml:lang="en-US">Repaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RepaidAmount" xlink:to="cphi_RepaidAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt extension fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PercentageOfBalanceNoteAndAccruedInterest" xlink:href="cphi-20231231.xsd#cphi_PercentageOfBalanceNoteAndAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl" xml:lang="en-US">Note and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfBalanceNoteAndAccruedInterest" xlink:to="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Debt redemptions weighted average price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US">Note converted into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestAccruesOnNoteDescription" xlink:href="cphi-20231231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl" xml:lang="en-US">Interest accrues on note, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RedeemOfOutstandingNote" xlink:href="cphi-20231231.xsd#cphi_RedeemOfOutstandingNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RedeemOfOutstandingNote_lbl" xml:lang="en-US">Redeem of outstanding note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Debt instrument redemption price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_NoteRedeemableIntoShares" xlink:href="cphi-20231231.xsd#cphi_NoteRedeemableIntoShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_NoteRedeemableIntoShares_lbl" xml:lang="en-US">Note redeemable into shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_WeightedAveragePrice" xlink:href="cphi-20231231.xsd#cphi_WeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_WeightedAveragePrice_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xml:lang="en-US">Debt redemption amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued during period shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Share issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Operating use liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease weighted average lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Enterprise income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Operating loss carryforwards available for future taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards limitations, descriptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">U.S. federal corporate income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_DeferredTaxAssetValuationAllowance" xlink:href="cphi-20231231.xsd#cphi_DeferredTaxAssetValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_DeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Valuation allowance on deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredTaxAssetValuationAllowance" xlink:to="cphi_DeferredTaxAssetValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AftertaxNetIncomePercentage" xlink:href="cphi-20231231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AftertaxNetIncomePercentage_lbl" xml:lang="en-US">After tax income, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ReserveAccountBalancesPercentage" xlink:href="cphi-20231231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl" xml:lang="en-US">Reserve account balances, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_lbl" xml:lang="en-US">General and statutory capital reserves amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock and stock option granted and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TotalOptionOutstanding" xlink:href="cphi-20231231.xsd#cphi_TotalOptionOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TotalOptionOutstanding_lbl" xml:lang="en-US">Total option outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdditionalSharesAvailableForIssuance" xlink:href="cphi-20231231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl" xml:lang="en-US">Additional shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IssuanceOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_IssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_IssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IssuanceOfCommonStock" xlink:to="cphi_IssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl" xml:lang="en-US">Compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ClosingMarketPrice" xlink:href="cphi-20231231.xsd#cphi_ClosingMarketPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ClosingMarketPrice_lbl" xml:lang="en-US">Closing market price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Additional shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PurchaseOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_PurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStock" xlink:to="cphi_PurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl" xml:lang="en-US">Options granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Percentage of volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Percentage of risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected life, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Issued an aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Unpaid cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AggregateAmount" xlink:href="cphi-20231231.xsd#cphi_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AggregateAmount_lbl" xml:lang="en-US">Aggregate transfer price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmount" xlink:to="cphi_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock per share based</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionPercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RedemptionPercentage_lbl" xml:lang="en-US">Redemption percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionPercentage" xlink:to="cphi_RedemptionPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionAmount" xlink:href="cphi-20231231.xsd#cphi_RedemptionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RedemptionAmount_lbl" xml:lang="en-US">Redemption amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionAmount" xlink:to="cphi_RedemptionAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RedemptionOfWeightedAveragePercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionOfWeightedAveragePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_RedemptionOfWeightedAveragePercentage_lbl" xml:lang="en-US">Redemption of weighted average percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionOfWeightedAveragePercentage" xlink:to="cphi_RedemptionOfWeightedAveragePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ReverseStockSplitsPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_ReverseStockSplitsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ReverseStockSplitsPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReverseStockSplitsPolicyTextBlock" xlink:to="cphi_ReverseStockSplitsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl" xml:lang="en-US">Advances to Suppliers and Advances from Customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KH3L+ccuuAhPMMiGYfcr4y3I=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_InterestRateRiskPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl" xml:lang="en-US">Interest Rate Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OnnyInvestmentLimitedMember" xlink:href="cphi-20231231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_OnnyInvestmentLimitedMember_lbl" xml:lang="en-US">Onny Investment Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OnnyInvestmentLimitedMember" xlink:to="cphi_OnnyInvestmentLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20231231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaPharmaMember" xlink:href="cphi-20231231.xsd#cphi_ChinaPharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ChinaPharmaMember_lbl" xml:lang="en-US">China Pharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaPharmaMember" xlink:to="cphi_ChinaPharmaMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_ChinaPharmaMember_lbl0" xml:lang="en-US">China Pharma&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaPharmaMember" xlink:to="cphi_ChinaPharmaMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_HelpsonMember" xlink:href="cphi-20231231.xsd#cphi_HelpsonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_HelpsonMember_lbl" xml:lang="en-US">Helpson [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HelpsonMember" xlink:to="cphi_HelpsonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ChairpersonCEOAndInterimCFOMember" xlink:href="cphi-20231231.xsd#cphi_ChairpersonCEOAndInterimCFOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ChairpersonCEOAndInterimCFOMember_lbl" xml:lang="en-US">Chairperson, CEO and Interim CFO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChairpersonCEOAndInterimCFOMember" xlink:to="cphi_ChairpersonCEOAndInterimCFOMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cphi_ChairpersonCEOAndInterimCFOMember_lbl0" xml:lang="en-US">Chairperson Li [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChairpersonCEOAndInterimCFOMember" xlink:to="cphi_ChairpersonCEOAndInterimCFOMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_InterimChiefFinancialOfficerMember" xlink:href="cphi-20231231.xsd#cphi_InterimChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_InterimChiefFinancialOfficerMember_lbl" xml:lang="en-US">Interim Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterimChiefFinancialOfficerMember" xlink:to="cphi_InterimChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableMember_lbl" xml:lang="en-US">Loans Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfCommunicationsMember" xlink:href="cphi-20231231.xsd#cphi_BankOfCommunicationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankOfCommunicationsMember_lbl" xml:lang="en-US">Bank of Communications [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfCommunicationsMember" xlink:to="cphi_BankOfCommunicationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ChinaCITICBankMember" xlink:href="cphi-20231231.xsd#cphi_ChinaCITICBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ChinaCITICBankMember_lbl" xml:lang="en-US">China CITIC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaCITICBankMember" xlink:to="cphi_ChinaCITICBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CITICBankMember" xlink:href="cphi-20231231.xsd#cphi_CITICBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CITICBankMember_lbl" xml:lang="en-US">CITIC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CITICBankMember" xlink:to="cphi_CITICBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_BankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_BankOfChinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_BankOfChinaMember_lbl" xml:lang="en-US">Bank of China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfChinaMember" xlink:to="cphi_BankOfChinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PostalSavingsBankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_PostalSavingsBankOfChinaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_PostalSavingsBankOfChinaMember_lbl" xml:lang="en-US">Postal Savings Bank of China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PostalSavingsBankOfChinaMember" xlink:to="cphi_PostalSavingsBankOfChinaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxYear2023Member_lbl" xml:lang="en-US">Tax Year 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2023Member" xlink:to="us-gaap_TaxYear2023Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">United States Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoFourMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoFourMember_lbl" xml:lang="en-US">Effective March 6, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_EffectiveMarchSixTwoZeroTwoFourMember" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoThreeMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoThreeMember_lbl" xml:lang="en-US">Effective March 6, 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_EffectiveMarchSixTwoZeroTwoThreeMember" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_TwoThousandTenIncentivePlanMember" xlink:href="cphi-20231231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl" xml:lang="en-US">2010 Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerMember" xlink:href="cphi-20231231.xsd#cphi_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerMember" xlink:to="cphi_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SalesBenchmarkMember" xlink:href="cphi-20231231.xsd#cphi_SalesBenchmarkMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SalesBenchmarkMember_lbl" xml:lang="en-US">Sales Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesBenchmarkMember" xlink:to="cphi_SalesBenchmarkMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Revenue One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerOneMember" xlink:href="cphi-20231231.xsd#cphi_CustomerOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerTwoMember" xlink:href="cphi-20231231.xsd#cphi_CustomerTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersOneMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SuppliersOneMember_lbl" xml:lang="en-US">Suppliers One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductOneMember" xlink:href="cphi-20231231.xsd#cphi_ProductOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ProductOneMember_lbl" xml:lang="en-US">Product One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductOneMember" xlink:to="cphi_ProductOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductTwoMember" xlink:href="cphi-20231231.xsd#cphi_ProductTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ProductTwoMember_lbl" xml:lang="en-US">Product Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductTwoMember" xlink:to="cphi_ProductTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ProductThreeMember" xlink:href="cphi-20231231.xsd#cphi_ProductThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_ProductThreeMember_lbl" xml:lang="en-US">Product Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductThreeMember" xlink:to="cphi_ProductThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_CustomerThreeMember" xlink:href="cphi-20231231.xsd#cphi_CustomerThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_CustomerThreeMember_lbl" xml:lang="en-US">Customer Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerThreeMember" xlink:to="cphi_CustomerThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SuppliersTwoMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cphi_SuppliersTwoMember_lbl" xml:lang="en-US">Suppliers Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US">Inventory, Current [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US">Schedule of Inventory [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable_lbl" xml:lang="en-US">Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:to="cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Assets (Details) - Schedule of Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:to="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems_lbl" xml:lang="en-US">Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable_lbl" xml:lang="en-US">Other Payables (Details) - Schedule of Other Payables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:to="cphi_OtherPayablesDetailsScheduleofOtherPayablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems_lbl" xml:lang="en-US">Schedule of Other Payables [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">Organization and Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsDetailsTable" xlink:to="cphi_IntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_IntangibleAssetsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IntangibleAssetsDetailsLineItems_lbl" xml:lang="en-US">Intangible Assets (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IntangibleAssetsDetailsLineItems" xlink:to="cphi_IntangibleAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RelatedPartyTransactionsDetailsTable" xlink:to="cphi_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RelatedPartyTransactionsDetailsLineItems" xlink:to="cphi_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_ConvertibleNotePayableDetailsTable" xlink:href="cphi-20231231.xsd#cphi_ConvertibleNotePayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConvertibleNotePayableDetailsTable_lbl" xml:lang="en-US">Convertible Note Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConvertibleNotePayableDetailsTable" xlink:to="cphi_ConvertibleNotePayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Convertible Note Payable [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationTable_lbl" xml:lang="en-US">Income Tax Examination [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxExaminationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RisksUncertaintiesDetailsTable_lbl" xml:lang="en-US">Risks &amp; Uncertainties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RisksUncertaintiesDetailsTable" xlink:to="cphi_RisksUncertaintiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RisksUncertaintiesDetailsLineItems_lbl" xml:lang="en-US">Risks &amp; Uncertainties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RisksUncertaintiesDetailsLineItems" xlink:to="cphi_RisksUncertaintiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cphi_SubsequentEventsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SubsequentEventsDetailsTable" xlink:to="cphi_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl0" xml:lang="en-US">Accounts receivable collected with banker&apos;s acceptances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl0" xml:lang="en-US">Number of additional shares available for issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvanceToSupplies_lbl0" xml:lang="en-US">Advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for advances to suppliers and advances from customers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AftertaxNetIncomePercentage_lbl0" xml:lang="en-US">After tax net income percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AggregateAmount_lbl0" xml:lang="en-US">Aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmount" xlink:to="cphi_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_AggregateAmounts_lbl1" xml:lang="en-US">Aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmounts" xlink:to="cphi_AggregateAmounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_BankersAcceptances_lbl0" xml:lang="en-US">A banker&apos;s acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ClosingMarketPrice_lbl0" xml:lang="en-US">Closing market price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl0" xml:lang="en-US">Conversion of related party note and interest to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:to="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_DeferredTaxAssetValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets Valuation Allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredTaxAssetValuationAllowance" xlink:to="cphi_DeferredTaxAssetValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl0" xml:lang="en-US">Description of interest accrues on Note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for interest rate risk.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl0" xml:lang="en-US">The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_IssuanceOfCommonStock_lbl0" xml:lang="en-US">Number of common stock issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IssuanceOfCommonStock" xlink:to="cphi_IssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and Going Concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_LoanAndReceivedProceeds_lbl0" xml:lang="en-US">Loan and received proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAndReceivedProceeds" xlink:to="cphi_LoanAndReceivedProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_NoteRedeemableIntoShares_lbl0" xml:lang="en-US">Number of shares redeemable by Notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Other receivables, less allowance for doubtful accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl0" xml:lang="en-US">Percentage of balance note and accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfBalanceNoteAndAccruedInterest" xlink:to="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PercentageOfNetProfit_lbl0" xml:lang="en-US">Percentage of net profit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfNetProfit" xlink:to="cphi_PercentageOfNetProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_PurchaseOfCommonStock_lbl0" xml:lang="en-US">Number of purchase common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStock" xlink:to="cphi_PurchaseOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RedeemOfOutstandingNote_lbl0" xml:lang="en-US">Amount of redeem of outstanding note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RedemptionAmount_lbl0" xml:lang="en-US">Redemption amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionAmount" xlink:to="cphi_RedemptionAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RedemptionOfWeightedAveragePercentage_lbl0" xml:lang="en-US">Redemption of weighted average percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionOfWeightedAveragePercentage" xlink:to="cphi_RedemptionOfWeightedAveragePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RedemptionPercentage_lbl0" xml:lang="en-US">Redemption percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionPercentage" xlink:to="cphi_RedemptionPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RepaidAmount_lbl0" xml:lang="en-US">Amount of repaid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RepaidAmount" xlink:to="cphi_RepaidAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl0" xml:lang="en-US">Reserve account balances percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_RestrictedCommonStock_lbl0" xml:lang="en-US">Restricted common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RestrictedCommonStock" xlink:to="cphi_RestrictedCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_ReverseStockSplitsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReverseStockSplitsPolicyTextBlock" xlink:to="cphi_ReverseStockSplitsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_StockIssuedDuringPeriodValueStockSplits_lbl0" xml:lang="en-US">Amount of share rounding due to reverse split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockIssuedDuringPeriodValueStockSplits" xlink:to="cphi_StockIssuedDuringPeriodValueStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TotalOptionOutstanding_lbl0" xml:lang="en-US">Total option outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl0" xml:lang="en-US">Useful live of Assets table text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WeightedAveragePrice_lbl0" xml:lang="en-US">The weighted average price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_WorkingCapital_lbl0" xml:lang="en-US">Working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WorkingCapital" xlink:to="cphi_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerOneMember_lbl0" xml:lang="en-US">Customer one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_CustomerTwoMember_lbl0" xml:lang="en-US">Customer two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand ten incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl1" xml:lang="en-US">Other Receivables Less Allowance For Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:to="cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl0" xml:lang="en-US">Proceeds from Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerOneMember_lbl1" xml:lang="en-US">Customer One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerOneMember" xlink:to="cphi_CustomerOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WorkingCapital" xlink:to="cphi_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="cphi_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_OnnyInvestmentLimitedMember_lbl0" xml:lang="en-US">Onny Investment Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_OnnyInvestmentLimitedMember" xlink:to="cphi_OnnyInvestmentLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl1" xml:lang="en-US">Conversion Of Related Party Note And Interest To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:to="cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl0" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl0" xml:lang="en-US">Operating Lease, Payments, Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl0" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PostalSavingsBankOfChinaMember_lbl0" xml:lang="en-US">Postal Savings Bank Of China Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PostalSavingsBankOfChinaMember" xlink:to="cphi_PostalSavingsBankOfChinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl1" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl0" xml:lang="en-US">Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_HelpsonMember_lbl0" xml:lang="en-US">Helpson Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HelpsonMember" xlink:to="cphi_HelpsonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForMortgageDeposits_lbl0" xml:lang="en-US">Payments for Mortgage Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMortgageDeposits" xlink:to="us-gaap_PaymentsForMortgageDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl0" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AftertaxNetIncomePercentage_lbl1" xml:lang="en-US">Aftertax Net Income Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AftertaxNetIncomePercentage" xlink:to="cphi_AftertaxNetIncomePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl1" xml:lang="en-US">Inventory Purchased With Bankers Acceptance Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventoryPurchasedWithBankersAcceptanceNote" xlink:to="cphi_InventoryPurchasedWithBankersAcceptanceNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersTwoMember_lbl0" xml:lang="en-US">Suppliers Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersTwoMember" xlink:to="cphi_SuppliersTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptances_lbl1" xml:lang="en-US">Bankers Acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptances" xlink:to="cphi_BankersAcceptances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_IssuanceOfCommonStock_lbl1" xml:lang="en-US">Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_IssuanceOfCommonStock" xlink:to="cphi_IssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract10" xlink:to="cphi_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesToAffiliate_lbl0" xml:lang="en-US">Advances to Affiliate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RedemptionOfWeightedAveragePercentage_lbl1" xml:lang="en-US">Redemption Of Weighted Average Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionOfWeightedAveragePercentage" xlink:to="cphi_RedemptionOfWeightedAveragePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityIndexedShares_lbl0" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Indexed Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:to="us-gaap_OptionIndexedToIssuersEquityIndexedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TechnologyFromBonierMember_lbl0" xml:lang="en-US">Technology From Bonier Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TechnologyFromBonierMember" xlink:to="cphi_TechnologyFromBonierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract2" xlink:to="cphi_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract1" xlink:to="cphi_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract4" xlink:to="cphi_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract3" xlink:to="cphi_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract0" xlink:to="cphi_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl1" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract9" xlink:to="cphi_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract6" xlink:to="cphi_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract5" xlink:to="cphi_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract8" xlink:to="cphi_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract7" xlink:to="cphi_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DeferredIncomeTaxLiabilityAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxLiabilityAbstract" xlink:to="cphi_DeferredIncomeTaxLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl0" xml:lang="en-US">Deferred Tax Assets, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UnlabeledAbstract" xlink:to="cphi_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl1" xml:lang="en-US">Line of Credit, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfInventoryAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule Of Inventory Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfInventoryAbstract" xlink:to="cphi_ScheduleOfInventoryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers And Advances From Customers Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:to="cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RepaidAmount_lbl1" xml:lang="en-US">Repaid Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RepaidAmount" xlink:to="cphi_RepaidAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdvanceToSupplies_lbl1" xml:lang="en-US">Advance To Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdvanceToSupplies" xlink:to="cphi_AdvanceToSupplies_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SalesBenchmarkMember_lbl0" xml:lang="en-US">Sales Benchmark Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SalesBenchmarkMember" xlink:to="cphi_SalesBenchmarkMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_WeightedAveragePrice_lbl1" xml:lang="en-US">Weighted Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_WeightedAveragePrice" xlink:to="cphi_WeightedAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ReserveAccountBalancesPercentage_lbl1" xml:lang="en-US">Reserve Account Balances Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReserveAccountBalancesPercentage" xlink:to="cphi_ReserveAccountBalancesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">Hainan Helpson Medical Biotechnology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:to="cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChairpersonCEOAndInterimCFOMember_lbl1" xml:lang="en-US">Chairperson CEOAnd Interim CFOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChairpersonCEOAndInterimCFOMember" xlink:to="cphi_ChairpersonCEOAndInterimCFOMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_SuppliersOneMember_lbl0" xml:lang="en-US">Suppliers One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_SuppliersOneMember" xlink:to="cphi_SuppliersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_lbl0" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Assets And Liabilities Recorded At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:to="cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl0" xml:lang="en-US">Line of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterimChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Interim Chief Financial Officer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterimChiefFinancialOfficerMember" xlink:to="cphi_InterimChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RedeemOfOutstandingNote_lbl1" xml:lang="en-US">Redeem Of Outstanding Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedeemOfOutstandingNote" xlink:to="cphi_RedeemOfOutstandingNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChinaCITICBankMember_lbl0" xml:lang="en-US">China CITICBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaCITICBankMember" xlink:to="cphi_ChinaCITICBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ProductOneMember_lbl0" xml:lang="en-US">Product One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductOneMember" xlink:to="cphi_ProductOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RestrictedCommonStock_lbl1" xml:lang="en-US">Restricted Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RestrictedCommonStock" xlink:to="cphi_RestrictedCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RedemptionAmount_lbl1" xml:lang="en-US">Redemption Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionAmount" xlink:to="cphi_RedemptionAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankersAcceptanceNotesMember_lbl0" xml:lang="en-US">Bankers Acceptance Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankersAcceptanceNotesMember" xlink:to="cphi_BankersAcceptanceNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl1" xml:lang="en-US">Percentage Of Balance Note And Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfBalanceNoteAndAccruedInterest" xlink:to="cphi_PercentageOfBalanceNoteAndAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsStock_lbl0" xml:lang="en-US">Dividends, Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsStock" xlink:to="us-gaap_DividendsStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestRateRiskPolicyTextBlock_lbl1" xml:lang="en-US">Interest Rate Risk Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestRateRiskPolicyTextBlock" xlink:to="cphi_InterestRateRiskPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankOfCommunicationsMember_lbl0" xml:lang="en-US">Bank Of Communications Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfCommunicationsMember" xlink:to="cphi_BankOfCommunicationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_LoanAndReceivedProceeds_lbl1" xml:lang="en-US">Loan And Received Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_LoanAndReceivedProceeds" xlink:to="cphi_LoanAndReceivedProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ProductThreeMember_lbl0" xml:lang="en-US">Product Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductThreeMember" xlink:to="cphi_ProductThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CITICBankMember_lbl0" xml:lang="en-US">CITICBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CITICBankMember" xlink:to="cphi_CITICBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerTwoMember_lbl1" xml:lang="en-US">Customer Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerTwoMember" xlink:to="cphi_CustomerTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AggregateAmount_lbl1" xml:lang="en-US">Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmount" xlink:to="cphi_AggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableMember_lbl0" xml:lang="en-US">Loans Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2023Member_lbl0" xml:lang="en-US">Tax Year 2023 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2023Member" xlink:to="us-gaap_TaxYear2023Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoThreeMember_lbl0" xml:lang="en-US">Effective March Six Two Zero Two Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_EffectiveMarchSixTwoZeroTwoThreeMember" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AdditionalSharesAvailableForIssuance_lbl1" xml:lang="en-US">Additional Shares Available For Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AdditionalSharesAvailableForIssuance" xlink:to="cphi_AdditionalSharesAvailableForIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl1" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ProductTwoMember_lbl0" xml:lang="en-US">Product Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ProductTwoMember" xlink:to="cphi_ProductTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ChinaPharmaMember_lbl1" xml:lang="en-US">China Pharma Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ChinaPharmaMember" xlink:to="cphi_ChinaPharmaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DeferredIncomeTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredIncomeTaxAssetsAbstract" xlink:to="cphi_DeferredIncomeTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansHeldForSaleTerm_lbl0" xml:lang="en-US">Loan, Held-for-Sale, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansHeldForSaleTerm" xlink:to="us-gaap_LoansHeldForSaleTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_EffectiveMarchSixTwoZeroTwoFourMember_lbl0" xml:lang="en-US">Effective March Six Two Zero Two Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_EffectiveMarchSixTwoZeroTwoFourMember" xlink:to="cphi_EffectiveMarchSixTwoZeroTwoFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InventionPatentMember_lbl0" xml:lang="en-US">Invention Patent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InventionPatentMember" xlink:to="cphi_InventionPatentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AggregateAmounts_lbl2" xml:lang="en-US">Aggregate Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AggregateAmounts" xlink:to="cphi_AggregateAmounts_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_RedemptionPercentage_lbl1" xml:lang="en-US">Redemption Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_RedemptionPercentage" xlink:to="cphi_RedemptionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NMPAApprovedMedicalFormulasMember_lbl0" xml:lang="en-US">NMPAApproved Medical Formulas Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NMPAApprovedMedicalFormulasMember" xlink:to="cphi_NMPAApprovedMedicalFormulasMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Other Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRateFloor_lbl0" xml:lang="en-US">Investment, Interest Rate, Floor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRateFloor" xlink:to="us-gaap_InvestmentInterestRateFloor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerThreeMember_lbl0" xml:lang="en-US">Customer Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerThreeMember" xlink:to="cphi_CustomerThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_InterestAccruesOnNoteDescription_lbl1" xml:lang="en-US">Interest Accrues On Note Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_InterestAccruesOnNoteDescription" xlink:to="cphi_InterestAccruesOnNoteDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLoans_lbl0" xml:lang="en-US">Payments for Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLoans" xlink:to="us-gaap_PaymentsForLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ReverseStockSplitsPolicyTextBlock_lbl1" xml:lang="en-US">Reverse Stock Splits Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ReverseStockSplitsPolicyTextBlock" xlink:to="cphi_ReverseStockSplitsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_ClosingMarketPrice_lbl1" xml:lang="en-US">Closing Market Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_ClosingMarketPrice" xlink:to="cphi_ClosingMarketPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_UsefulLiveOfAssetsTableTextBlock_lbl1" xml:lang="en-US">Useful Live Of Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_UsefulLiveOfAssetsTableTextBlock" xlink:to="cphi_UsefulLiveOfAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TwoThousandTenIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Ten Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TwoThousandTenIncentivePlanMember" xlink:to="cphi_TwoThousandTenIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_TotalOptionOutstanding_lbl1" xml:lang="en-US">Total Option Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_TotalOptionOutstanding" xlink:to="cphi_TotalOptionOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_CustomerMember" xlink:to="cphi_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PercentageOfNetProfit_lbl1" xml:lang="en-US">Percentage Of Net Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PercentageOfNetProfit" xlink:to="cphi_PercentageOfNetProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_DeferredTaxAssetValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Asset Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_DeferredTaxAssetValuationAllowance" xlink:to="cphi_DeferredTaxAssetValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl0" xml:lang="en-US">Debt Instrument, Repurchase Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_BankOfChinaMember_lbl0" xml:lang="en-US">Bank Of China Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_BankOfChinaMember" xlink:to="cphi_BankOfChinaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_PurchaseOfCommonStock_lbl1" xml:lang="en-US">Purchase Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_PurchaseOfCommonStock" xlink:to="cphi_PurchaseOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl1" xml:lang="en-US">Accounts Receivable Collected With Bankers Acceptances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_AccountsReceivableCollectedWithBankersAcceptances" xlink:to="cphi_AccountsReceivableCollectedWithBankersAcceptances_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_NoteRedeemableIntoShares_lbl1" xml:lang="en-US">Note Redeemable Into Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_NoteRedeemableIntoShares" xlink:to="cphi_NoteRedeemableIntoShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cphi_StockIssuedDuringPeriodValueStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period Value Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cphi_StockIssuedDuringPeriodValueStockSplits" xlink:to="cphi_StockIssuedDuringPeriodValueStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl1" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAppropriated_lbl0" xml:lang="en-US">Retained Earnings, Appropriated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAppropriated" xlink:to="us-gaap_RetainedEarningsAppropriated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>34
<FILENAME>cphi-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 01 15:37:38 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedBalanceSheet" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedIncomeStatement" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ShareholdersEquityType2or3" roleURI="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConsolidatedCashFlow" roleURI="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OrganizationandSignificantAccountingPolicies" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_Inventory" roleURI="http://www.chinapharmaholdings.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipment" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssets" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OtherPayables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RelatedPartyTransactions" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacility" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConvertibleNotePayable" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_Leases" roleURI="http://www.chinapharmaholdings.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxes" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_FairValueMeasurements" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_StockholdersEquity" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RisksUncertainties" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertainties"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_SubsequentEvents" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_AccountingPoliciesByPolicy" roleURI="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_InventoryTables" roleURI="http://www.chinapharmaholdings.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipmentTables" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssetsTables" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OtherPayablesTables" roleURI="http://www.chinapharmaholdings.com/role/OtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityTables" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LeasesTables" roleURI="http://www.chinapharmaholdings.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxesTables" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_FairValueMeasurementsTables" roleURI="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofInventoryTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofEstimatedUsefulLivesofTheAssetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofAggregateAnnualAmortizationExpenseTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOtherPayablesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofPrincipalPaymentsTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofOperatingLeaseLiabilitiesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofDeferredIncomeTaxAssetsandLiabilityTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ScheduleofAssetsandLiabilitiesRecordedatFairValueTable" roleURI="http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_PropertyPlantandEquipmentDetails" roleURI="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IntangibleAssetsDetails" roleURI="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RelatedPartyTransactionsDetails" roleURI="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LinesofCreditandConstructionLoanFacilityDetails" roleURI="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_ConvertibleNotePayableDetails" roleURI="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_LeasesDetails" roleURI="http://www.chinapharmaholdings.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_IncomeTaxesDetails" roleURI="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_StockholdersEquityDetails" roleURI="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_RisksUncertaintiesDetails" roleURI="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cphi-20231231.xsd#cphi_r_SubsequentEventsDetails" roleURI="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="BankersAcceptances" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceToSupplies" xlink:href="cphi-20231231.xsd#cphi_AdvanceToSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="AdvanceToSupplies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermLineOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesLessAllowanceForDoubtfulAccounts" xlink:href="cphi-20231231.xsd#cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="OtherReceivablesLessAllowanceForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStockSplits" xlink:href="cphi-20231231.xsd#cphi_StockIssuedDuringPeriodValueStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="StockIssuedDuringPeriodValueStockSplits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionPlanExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableCollectedWithBankersAcceptances" xlink:href="cphi-20231231.xsd#cphi_AccountsReceivableCollectedWithBankersAcceptances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="AccountsReceivableCollectedWithBankersAcceptances" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventoryPurchasedWithBankersAcceptanceNote" xlink:href="cphi-20231231.xsd#cphi_InventoryPurchasedWithBankersAcceptanceNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InventoryPurchasedWithBankersAcceptanceNote" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRelatedPartyNoteAndInterestToCommonStock" xlink:href="cphi-20231231.xsd#cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfRelatedPartyNoteAndInterestToCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertainties">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitsPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_ReverseStockSplitsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReverseStockSplitsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRateRiskPolicyTextBlock" xlink:href="cphi-20231231.xsd#cphi_InterestRateRiskPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InterestRateRiskPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UsefulLiveOfAssetsTableTextBlock" xlink:href="cphi-20231231.xsd#cphi_UsefulLiveOfAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="UsefulLiveOfAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract" xlink:to="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable" xlink:to="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NMPAApprovedMedicalFormulasMember" xlink:href="cphi-20231231.xsd#cphi_NMPAApprovedMedicalFormulasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="NMPAApprovedMedicalFormulasMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TechnologyFromBonierMember" xlink:href="cphi-20231231.xsd#cphi_TechnologyFromBonierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="TechnologyFromBonierMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InventionPatentMember" xlink:href="cphi-20231231.xsd#cphi_InventionPatentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="InventionPatentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofIntangibleAssetsTable" xlink:to="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra7VfVHXJUWJttX8O8GMnrqIgsDYXxN0MYVhFnjwv5K3a3SHZsrzk4MXCdcMWYeAT905r3tB2WL9EKaspgBTTGKYpO6hggWAAEFYenJdohpaU4ba9UoRvso61Ym24QwH+cbsYmOqQuS74temkHQfLvpXe8BK3pfvUFl03ytA98Zyoczw53N5AYCz/3v93mMpJH9NuKc1i1KH4Ytf1hSZcAVKl9waIb0ZfE=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAggregateAnnualAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:href="cphi-20231231.xsd#cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="OtherPayablesDetailsScheduleofOtherPayablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherPayablesDetailsScheduleofOtherPayablesTable" xlink:to="OtherPayablesDetailsScheduleofOtherPayablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherPayablesDetailsScheduleofOtherPayablesLineItems" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfPrincipalPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_LineOfCreditMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxAssetsAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="DeferredIncomeTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxLiabilityAbstract" xlink:href="cphi-20231231.xsd#cphi_DeferredIncomeTaxLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract" xlink:to="DeferredIncomeTaxLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxLiabilityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:href="cphi-20231231.xsd#cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankersAcceptanceNotesMember" xlink:href="cphi-20231231.xsd#cphi_BankersAcceptanceNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="BankersAcceptanceNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OnnyInvestmentLimitedMember" xlink:href="cphi-20231231.xsd#cphi_OnnyInvestmentLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="OnnyInvestmentLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HainanHelpsonMedicalBiotechnologyCoLtdMember" xlink:href="cphi-20231231.xsd#cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="HainanHelpsonMedicalBiotechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAppropriated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAppropriated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RetainedEarningsAppropriated" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="cphi-20231231.xsd#cphi_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="WorkingCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityIndexedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityIndexedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityIndexedShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_IntangibleAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairedIntangibleAssetsLineItems" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChinaPharmaMember" xlink:href="cphi-20231231.xsd#cphi_ChinaPharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChinaPharmaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HelpsonMember" xlink:href="cphi-20231231.xsd#cphi_HelpsonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="HelpsonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="IntangibleAssetsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_DividendsStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfNetProfit" xlink:href="cphi-20231231.xsd#cphi_PercentageOfNetProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsLineItems" xlink:to="PercentageOfNetProfit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ChairpersonCEOAndInterimCFOMember" xlink:href="cphi-20231231.xsd#cphi_ChairpersonCEOAndInterimCFOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ChairpersonCEOAndInterimCFOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterimChiefFinancialOfficerMember" xlink:href="cphi-20231231.xsd#cphi_InterimChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="InterimChiefFinancialOfficerMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ManagementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvancesToAffiliate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvancesToAffiliate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AdvancesToAffiliate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsForLoans" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmounts" xlink:href="cphi-20231231.xsd#cphi_AggregateAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="AggregateAmounts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCommonStock" xlink:href="cphi-20231231.xsd#cphi_RestrictedCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="RestrictedCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansHeldForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansHeldForSaleTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_LoansHeldForSaleTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankOfCommunicationsMember" xlink:href="cphi-20231231.xsd#cphi_BankOfCommunicationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BankOfCommunicationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChinaCITICBankMember" xlink:href="cphi-20231231.xsd#cphi_ChinaCITICBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChinaCITICBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CITICBankMember" xlink:href="cphi-20231231.xsd#cphi_CITICBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CITICBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_BankOfChinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BankOfChinaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PostalSavingsBankOfChinaMember" xlink:href="cphi-20231231.xsd#cphi_PostalSavingsBankOfChinaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PostalSavingsBankOfChinaMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LoansPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRateFloor" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRateFloor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InvestmentInterestRateFloor" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMortgageDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMortgageDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsForMortgageDeposits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAndReceivedProceeds" xlink:href="cphi-20231231.xsd#cphi_LoanAndReceivedProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="LoanAndReceivedProceeds" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmounts" xlink:href="cphi-20231231.xsd#cphi_AggregateAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="AggregateAmounts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaidAmount" xlink:href="cphi-20231231.xsd#cphi_RepaidAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="RepaidAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePayableDetailsTable" xlink:href="cphi-20231231.xsd#cphi_ConvertibleNotePayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="ConvertibleNotePayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChinaPharmaMember" xlink:href="cphi-20231231.xsd#cphi_ChinaPharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ChinaPharmaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBalanceNoteAndAccruedInterest" xlink:href="cphi-20231231.xsd#cphi_PercentageOfBalanceNoteAndAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="PercentageOfBalanceNoteAndAccruedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestAccruesOnNoteDescription" xlink:href="cphi-20231231.xsd#cphi_InterestAccruesOnNoteDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="InterestAccruesOnNoteDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedeemOfOutstandingNote" xlink:href="cphi-20231231.xsd#cphi_RedeemOfOutstandingNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="RedeemOfOutstandingNote" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoteRedeemableIntoShares" xlink:href="cphi-20231231.xsd#cphi_NoteRedeemableIntoShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="NoteRedeemableIntoShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAveragePrice" xlink:href="cphi-20231231.xsd#cphi_WeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="WeightedAveragePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_SharesIssued" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_TaxPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxYear2023Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxExaminationLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetValuationAllowance" xlink:href="cphi-20231231.xsd#cphi_DeferredTaxAssetValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="DeferredTaxAssetValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenIncentivePlanMember" xlink:href="cphi-20231231.xsd#cphi_TwoThousandTenIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EffectiveMarchSixTwoZeroTwoFourMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="EffectiveMarchSixTwoZeroTwoFourMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveMarchSixTwoZeroTwoThreeMember" xlink:href="cphi-20231231.xsd#cphi_EffectiveMarchSixTwoZeroTwoThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="EffectiveMarchSixTwoZeroTwoThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AftertaxNetIncomePercentage" xlink:href="cphi-20231231.xsd#cphi_AftertaxNetIncomePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="AftertaxNetIncomePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveAccountBalancesPercentage" xlink:href="cphi-20231231.xsd#cphi_ReserveAccountBalancesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="ReserveAccountBalancesPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOptionOutstanding" xlink:href="cphi-20231231.xsd#cphi_TotalOptionOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="TotalOptionOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalSharesAvailableForIssuance" xlink:href="cphi-20231231.xsd#cphi_AdditionalSharesAvailableForIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="AdditionalSharesAvailableForIssuance" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_IssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="IssuanceOfCommonStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClosingMarketPrice" xlink:href="cphi-20231231.xsd#cphi_ClosingMarketPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="ClosingMarketPrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_CommonUnitIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStock" xlink:href="cphi-20231231.xsd#cphi_PurchaseOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="PurchaseOfCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_SharePrice" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_Cash" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RisksUncertaintiesDetailsTable" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RisksUncertaintiesDetailsLineItems" xlink:href="cphi-20231231.xsd#cphi_RisksUncertaintiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="RisksUncertaintiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SuppliersOneMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuppliersTwoMember" xlink:href="cphi-20231231.xsd#cphi_SuppliersTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SuppliersTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SalesBenchmarkMember" xlink:href="cphi-20231231.xsd#cphi_SalesBenchmarkMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="SalesBenchmarkMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_CostOfGoodsTotalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="cphi-20231231.xsd#cphi_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerOneMember" xlink:href="cphi-20231231.xsd#cphi_CustomerOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerTwoMember" xlink:href="cphi-20231231.xsd#cphi_CustomerTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerThreeMember" xlink:href="cphi-20231231.xsd#cphi_CustomerThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ProductOneMember" xlink:href="cphi-20231231.xsd#cphi_ProductOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ProductOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductTwoMember" xlink:href="cphi-20231231.xsd#cphi_ProductTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ProductTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductThreeMember" xlink:href="cphi-20231231.xsd#cphi_ProductThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ProductThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsTable" xlink:to="RisksUncertaintiesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksUncertaintiesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="cphi-20231231.xsd#cphi_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="cphi-20231231.xsd#cphi_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="AggregateAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionPercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="RedemptionPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionAmount" xlink:href="cphi-20231231.xsd#cphi_RedemptionAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="RedemptionAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionOfWeightedAveragePercentage" xlink:href="cphi-20231231.xsd#cphi_RedemptionOfWeightedAveragePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="RedemptionOfWeightedAveragePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/dei/role/document/Cover"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772021104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 24, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">China Pharma Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">73-1564807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,896,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Second Floor, No. 17, Jinpan Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Haikou<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hainan Province<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">570216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">86 898-6681-1730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPHI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,816,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768227856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BF Borgers CPA PC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Lakewood, CO<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772126240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,423,838<span></span>
</td>
<td class="nump">$ 2,029,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_BankersAcceptances', window );">Banker&#8217;s acceptances</a></td>
<td class="nump">65,915<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts of $13,786,074 and $16,739,527, respectively</a></td>
<td class="nump">504,448<span></span>
</td>
<td class="nump">421,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $27,017 and $27,149, respectively</a></td>
<td class="nump">157,944<span></span>
</td>
<td class="nump">29,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdvanceToSupplies', window );">Advances to suppliers</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">444,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,732,517<span></span>
</td>
<td class="nump">2,947,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">110,258<span></span>
</td>
<td class="nump">77,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,996,933<span></span>
</td>
<td class="nump">5,964,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,100,425<span></span>
</td>
<td class="nump">9,973,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">116,610<span></span>
</td>
<td class="nump">39,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,255,232<span></span>
</td>
<td class="nump">1,807,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">16,469,200<span></span>
</td>
<td class="nump">17,784,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">966,420<span></span>
</td>
<td class="nump">667,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">298,829<span></span>
</td>
<td class="nump">404,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">2,282,692<span></span>
</td>
<td class="nump">2,390,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">90,507<span></span>
</td>
<td class="nump">520,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">77,727<span></span>
</td>
<td class="nump">40,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Current portion of lines of credit</a></td>
<td class="nump">1,030,680<span></span>
</td>
<td class="nump">2,440,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible, redeemable note payable, net of issue discount</a></td>
<td class="nump">940,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,820,664<span></span>
</td>
<td class="nump">12,739,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">39,910<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Lines of credit, net of current portion</a></td>
<td class="nump">1,411,891<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">742,114<span></span>
</td>
<td class="nump">754,698<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">9,014,579<span></span>
</td>
<td class="nump">13,494,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 10,625,788 shares and 1,498,180 shares issued and outstanding, respectively</a></td>
<td class="nump">10,625<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">35,282,256<span></span>
</td>
<td class="nump">28,926,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(39,290,314)<span></span>
</td>
<td class="num">(36,211,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">11,452,054<span></span>
</td>
<td class="nump">11,573,065<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">7,454,621<span></span>
</td>
<td class="nump">4,289,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">16,469,200<span></span>
</td>
<td class="nump">17,784,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Borrowings from related parties</a></td>
<td class="nump">$ 1,133,809<span></span>
</td>
<td class="nump">$ 2,475,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvanceToSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvanceToSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_BankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_BankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772161520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 13,786,074<span></span>
</td>
<td class="nump">$ 16,739,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts', window );">Other receivables, allowance for doubtful accounts (in Dollars)</a></td>
<td class="nump">$ 27,017<span></span>
</td>
<td class="nump">$ 27,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">10,625,788<span></span>
</td>
<td class="nump">1,498,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">10,625,788<span></span>
</td>
<td class="nump">1,498,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other receivables, less allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519861089952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 7,011,299<span></span>
</td>
<td class="nump">$ 8,104,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">7,292,384<span></span>
</td>
<td class="nump">8,598,008<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross (loss) profit</a></td>
<td class="num">(281,085)<span></span>
</td>
<td class="num">(493,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">780,328<span></span>
</td>
<td class="nump">1,069,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,466,084<span></span>
</td>
<td class="nump">1,893,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">240,080<span></span>
</td>
<td class="nump">185,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt benefit</a></td>
<td class="num">(15,757)<span></span>
</td>
<td class="num">(93,851)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,470,735<span></span>
</td>
<td class="nump">3,055,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,751,820)<span></span>
</td>
<td class="num">(3,548,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,602<span></span>
</td>
<td class="nump">10,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(333,600)<span></span>
</td>
<td class="num">(434,619)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net other expense</a></td>
<td class="num">(326,998)<span></span>
</td>
<td class="num">(423,864)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,078,818)<span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,078,818)<span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss) - foreign currency translation adjustment</a></td>
<td class="num">(121,011)<span></span>
</td>
<td class="num">(990,764)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,199,829)<span></span>
</td>
<td class="num">$ (4,963,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (in Shares)</a></td>
<td class="nump">3,383,573<span></span>
</td>
<td class="nump">1,051,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772080864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (3.78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772010896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Accumulated Other	Comprehensive Income</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 25,691,760<span></span>
</td>
<td class="num">$ (32,238,655)<span></span>
</td>
<td class="nump">$ 12,563,829<span></span>
</td>
<td class="nump">$ 6,017,881<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">946,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for intangible assets</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">1,707,142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,707,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for intangible assets (in Shares)</a></td>
<td class="nump">310,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">36,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">41,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">1,449,765<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock (in Shares)</a></td>
<td class="nump">234,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,972,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(990,764)<span></span>
</td>
<td class="num">(990,764)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="nump">28,926,931<span></span>
</td>
<td class="num">(36,211,496)<span></span>
</td>
<td class="nump">11,573,065<span></span>
</td>
<td class="nump">$ 4,289,998<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">1,498,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for intangible assets</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">1,647,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for intangible assets (in Shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of related party note and interest</a></td>
<td class="nump">$ 2,751<span></span>
</td>
<td class="nump">1,851,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of related party note and interest (in Shares)</a></td>
<td class="nump">2,751,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_StockIssuedDuringPeriodValueStockSplits', window );">Share rounding due to reverse split</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Share rounding due to reverse split (in Shares)</a></td>
<td class="nump">14,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock</a></td>
<td class="nump">$ 3,362<span></span>
</td>
<td class="nump">2,856,638<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,860,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of note payable to common stock (in Shares)</a></td>
<td class="nump">3,362,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,078,818)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,078,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(121,011)<span></span>
</td>
<td class="num">(121,011)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 10,625<span></span>
</td>
<td class="nump">$ 35,282,256<span></span>
</td>
<td class="num">$ (39,290,314)<span></span>
</td>
<td class="nump">$ 11,452,054<span></span>
</td>
<td class="nump">$ 7,454,621<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">10,625,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,625,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_StockIssuedDuringPeriodValueStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of share rounding due to reverse split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_StockIssuedDuringPeriodValueStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772494304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,078,818)<span></span>
</td>
<td class="num">$ (3,972,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,753,653<span></span>
</td>
<td class="nump">2,700,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt (benefit) expense</a></td>
<td class="num">(15,757)<span></span>
</td>
<td class="num">(93,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock and stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property, plant &amp; equipment</a></td>
<td class="nump">45,385<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(938,021)<span></span>
</td>
<td class="num">(170,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Advances to suppliers</a></td>
<td class="nump">437,431<span></span>
</td>
<td class="num">(459,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(25,032)<span></span>
</td>
<td class="nump">689,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">312,045<span></span>
</td>
<td class="num">(187,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">257,778<span></span>
</td>
<td class="nump">692,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Advances from customers</a></td>
<td class="num">(423,261)<span></span>
</td>
<td class="nump">339,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses</a></td>
<td class="num">(25,089)<span></span>
</td>
<td class="num">(24,722)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(699,686)<span></span>
</td>
<td class="num">(409,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(11,517)<span></span>
</td>
<td class="num">(401,964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(11,517)<span></span>
</td>
<td class="num">(401,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments of line of credit</a></td>
<td class="num">(1,490,049)<span></span>
</td>
<td class="num">(2,140,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">1,532,622<span></span>
</td>
<td class="nump">564,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings and interest from related party</a></td>
<td class="nump">30,572<span></span>
</td>
<td class="nump">28,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(223,013)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash (Used In) Provided By Financing Activities</a></td>
<td class="nump">73,145<span></span>
</td>
<td class="num">(1,770,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="nump">31,925<span></span>
</td>
<td class="num">(247,573)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(606,133)<span></span>
</td>
<td class="num">(2,829,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">2,029,971<span></span>
</td>
<td class="nump">4,859,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">1,423,838<span></span>
</td>
<td class="nump">2,029,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">92,439<span></span>
</td>
<td class="nump">141,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AccountsReceivableCollectedWithBankersAcceptances', window );">Accounts receivable collected with banker&#8217;s acceptances</a></td>
<td class="nump">865,733<span></span>
</td>
<td class="nump">503,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InventoryPurchasedWithBankersAcceptanceNote', window );">Inventory purchased with banker&#8217;s acceptances</a></td>
<td class="nump">813,105<span></span>
</td>
<td class="nump">575,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">156,273<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for intangible assets</a></td>
<td class="nump">1,650,000<span></span>
</td>
<td class="nump">1,707,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock', window );">Conversion of related party note and interest to common stock</a></td>
<td class="nump">$ 1,854,542<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AccountsReceivableCollectedWithBankersAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AccountsReceivableCollectedWithBankersAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of related party note and interest to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InventoryPurchasedWithBankersAcceptanceNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InventoryPurchasedWithBankersAcceptanceNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519861003456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization and Nature of Operations &#8211;&#160;</i></b>China
Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns 100% of Onny Investment Limited (&#8220;Onny&#8221;), a
British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a
company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;). China Pharma Holdings, Inc. and its
subsidiaries are referred to herein as the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Onny acquired 100% of the ownership in Helpson
on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former shareholders. The transaction was approved
by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises
with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise
(&#8220;WFOE&#8221;) status on June 21, 2005.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located.
Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin
oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one
or more therapeutic indications by the National Medical Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug
Administration, or CFDA) based upon demonstrated safety and efficacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity and Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had cash
and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company&#8217;s Chairperson, Chief Executive Officer
and Interim Chief Financial Officer (&#8220;Chairperson Li&#8221;) has advanced an aggregate of $1,133,809 as of December 31, 2023 to
provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company
anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its
existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its
ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Accounting Standards
Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i> management
must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially
does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of
the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating
effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating
effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern
within one year after the date that the financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 205-40, the strategic alternatives being
pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s current plans have been finalized
at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively
implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial doubt is deemed to exist about
the Company&#8217;s ability to continue as a going concern within one year after the date these financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reverse Stock Split&#160;</i></b>&#8211;
Effective March 6, 2024, the Company implemented a 1-for-5 reverse stock split as more fully discussed in Note 14. All share and per
share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Consolidation and Basis of Presentation&#160;</i></b>&#8211;
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States dollars. The accompanying consolidated financial
statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson&#8217;s functional currency is the Chinese
Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average exchange rate for the period.
Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#8217;s
financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Gains
and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction
are included in the results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Accounting Estimates&#160;</i>-&#160;</b>The methodology used
to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. &#160;Significant
estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance,
valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used
to calculate derivative liabilities. Therefore, actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents&#160;</i></b>&#8211;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#8217;s
acceptances notes purchased with maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Accounts Receivable and Allowance
for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for
doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts
and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company reviews a customer&#8217;s
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in
an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable
to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense totaled ($15,757) and ($93,851) for
the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable that have been fully
allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company
charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December
31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current
balances when calculating the allowance for doubtful accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advances to Suppliers and Advances from
Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from
customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances
received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&#8217;s
credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate,
resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the
period they are considered unlikely to be collected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory&#160;&#8211; </i></b>Inventory
consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated
portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable
value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable
value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs
to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value.
Net realizable value for raw materials is based on replacement cost. Provisions for inventory write-downs are included in the cost of
revenues in the consolidated statements of operations. Inventories are carried at this lower cost basis until sold or scrapped.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Leases</i></b></span><b><i>
&#8211; </i></b><span>At lease commencement, the Company records a lease liability based on the present
value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain
to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases
do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would
have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date,
the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received
and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial
term of 12 months or less (&#8220;Short-Term Leases&#8221;). For any Short-Term Leases, the Company records the rent expense on a straight-line
basis and does not record the leases on the balance sheet. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>After lease
commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments
using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability,
adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent
expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line
basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Long-Lived Assets</i></b>&#160;&#8211;
The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate
that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated
from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying
value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash
flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the Company will use the projected discounted
cash flows to be generated by the asset. For the years ended December 31, 2023 and 2022, the Company evaluated its long-lived assets and
determined that no impairment adjustments were necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property, Plant and Equipment</i></b>&#160;&#8211;
Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are
capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;&#8211;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration
that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company does not disaggregate its
revenue streams as the economic factors underlying the contracts are similar and provide no significant distinction. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following
five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether
the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement
of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
(or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed price and reflect standalone pricing for each
item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s performance obligations are transferred
to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer picks up the goods at the Company&#8217;s
warehouse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For all reporting periods, the Company has not disclosed the value
of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is
an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year.
These advances total $90,507 and $520,295 and are recorded as a liability on the accompanying balance sheet as &#8220;Advances from customers&#8221;
as of December 31, 2023 and 2022, respectively. The subsequently recognized revenue was $81,456as of March 29, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues</i></b>&#160;&#8211; Cost
of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery
of products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;&#8211;
Research and development expenditures are recorded as expenses in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b>&#160;&#8211; The carrying
amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure to credit risk in relation to its
financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations
of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate
have not exceeded management&#8217;s estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has its cash in bank deposits primarily
at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#8217;
interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation
of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow
the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest Rate Risk</i></b>&#160;&#8211;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and
viability of securing future debt instruments within the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic
loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31, 2023,
the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares
issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods
presented because the effect is anti-dilutive due to net losses of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;<i>Financial Instruments &#8211; Credit
Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance
introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies
the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial
assets with credit deterioration since their origination.&#160;The pronouncement will was effective for public business entities that
are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including interim periods within those
fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December 15,
2019, including interim periods within those fiscal years. The adoption of the standard had no material impact on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the FASB or other standards
setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise
discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to
have a material impact on its consolidated financial statements upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519860992160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 &#8211; INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,849,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,839,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">413,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,469,707</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">551,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Inventory</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,732,517</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,947,787</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768945568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; PROPERTY, PLANT AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property, plant and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Permit of land use</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">397,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">404,427</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,234,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,391,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,170,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,780,585</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">303,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">388,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,847</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,495,080</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,323,430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,394,655</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,350,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,100,425</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,973,065</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation is computed on a straight-line basis over the estimated
useful lives of the assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: left"><b>Asset</b></td><td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><b>Life - years</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permit of land use</td><td>&#160;</td>
    <td style="text-align: center">40 - 70</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: center">20 - 49</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5 - 10</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: center">5 - 10</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation relating to office equipment was
included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was
$2,529,858 and $2,663,975 for the years ended December 31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768891776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 - INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets represent the cost of medical
formulas approved for production by the NMPA, the intellectual property acquired from Chengdu Bonier Medical Technology Development Co.,
Ltd. (&#8220;Bonier Agreement&#8221;) and the Technology Transfer Agreement (the &#8220;<b>Agreement</b>&#8221;) with Tao Liu discussed
below. The Company did not obtain NMPA production approval for any new medical formulas during the years ended December 31, 2023 and 2022
and no costs were reclassified from advances to intangible assets during the years ended December 31, 2023 and 2022, respectively. On
August 9, 2023, the Company obtained the &#8220;Drug Supplementary Application Approval Notice&#8221; from the NMPA for the indicating
that the Company&#8217;s existing formular Candesartan tablets have passed the quality and efficacy consistency evaluation of generic
drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approved medical formulas are amortized from the
date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&#160;&#160;It
is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to
changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets
was $223,796 and $36,558 for the years ended December 31, 2023 and 2022, respectively which was included in the general and administrative
expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2023, the Company entered into
a Technology Transfer Agreement (the &#8220;Agreement&#8221;) with Tao Liu (the &#8220;Transferor&#8221;). The Transferor owns an invention
patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the &#8220;Invention Patent&#8221;). Pursuant
to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third
party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing
of registration materials, registration application and other technical services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective December 15, 2023 China Pharma issued
3,000,000 shares of its common stock valued at $1,650,000 based on the closing market price of its common stock of $0.55 per share at
that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2023. The value of the
intangible asset will be amortized over its remaining useful life of approximately 14.8 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the ten years after the product launches
to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual
basis to the Transferor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2022, the Company entered into
a Technology Transfer Contract (the &#8220;Bonier Agreement&#8221;) with Chengdu Bonier Medical Technology Development Co., Ltd (&#8220;Bonier&#8221;).
Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which
has obtained a utility model patent (the &#8220;Utility Model Patent&#8221;) and applied for an invention patent (the &#8220;Invention
Patent&#8221;) at the same time. Pursuant to the Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical
invention and the Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant
technical services in Haikou, which include but are not limited to product research and development, writing of registration materials,
registration application and other technical services, with a term of ten years. Effective November 28, 2022 the Company issued 310,446
share of its common stock valued at $1,707,452 based on the closing market price of its common stock of $5.50 per share at that date.
The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2022. The value of the intangible
asset will be amortized over its remaining useful life of approximately 9.7 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will pay a service fee of 15% of the
net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent
on the successful authorization of the above mentioned Invention Patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates each approved medical formula
for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement.
The Company&#8217;s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data
for the related drug and the Company&#8217;s estimated market share. If the carrying value of the medical formula exceeds the estimated
future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula,
which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the years ended December
31, 2023 and 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">NMPA approved medical formulas</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,766,353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,847,176</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Technology from Bonier</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,726,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707,452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Invention Patent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,653,028</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,890,646</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,747,142</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,255,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,807,486</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The estimated aggregate annual amortization expense for each of the
next five years and thereafter is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">327,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,730,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,255,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519770400992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; OTHER PAYABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Payables consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation payable to officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,243,506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">951,506</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation and interest to related parties</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">372,578</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Business taxes and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,027,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,282,692</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,390,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772026272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A member of the Company&#8217;s board of directors
(&#8220;Board&#8221;) had previously advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2022 which is recorded
as &#8220;Other payables &#8211; related parties&#8221; on the accompanying condensed consolidated balance sheets. The advances bore interest
at a rate of 1.0% per year.&#160;&#160;Total interest expense years ended December 31, 2023 and 2022 was $6,773 and $13,546, respectively.
Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance
sheet totaling $12,000 and $372,578 as of December 31, 2023 and 2022, respectively. On August 23, 2023, the director entered into a certain
debt transfer agreement with Chairperson Li, pursuant to which the rights to collect a total amount of $1,854,452 were assigned to Chairperson
Li. On September 28, 2023, Chairperson Li entered into a certain loan settlement agreement, pursuant to which both parties agreed to convert
the aggregate amount of $1,854,452&#160;owed by the Company into&#160;2,751,412&#160;shares of restricted common stock of the Company.
Such issuance was completed on September 29, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received advances totaling $2,928
and $0 and repaid $0 and $223,013 of the advances during the years ended December 31, 2023 and 2022, respectively from its Chairperson,
Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,121,273 and $1,425,123 and are recorded as Other
payables &#8211; related parties on the accompanying condensed consolidated balance sheets as of December 31, 2021 and 2020, respectively.
On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief
Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the
loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2023. Total interest
expense related to the loan for the years ended December 31, 2023 and 2022 was $27,644 and $28,962, respectively. Compensation payable
to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying consolidated
balance sheet totaling $1,243,506 and $951,506 as of December 31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768928672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Lines of Credit and Construction Loan Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; LINES OF CREDIT AND CONSTRUCTION
LOAN FACILITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lines of Credit</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021 the Company entered into a loan
with Bank of Communications bearing an interest rate of 4.17%. <span>The Company paid all principal and
interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing interest at&#160;4.17% and
due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line of credit for an aggregate
amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The Company received an advance
on the line of credit in the amount of RMB 3,800,000 (approximately $0.56 million) on December 30, 2022. On February 24, 2023 the Company
received an advance on the line in the amount of RMB&#160;3,500,000&#160;(approximately $0.51&#160;million). The Company has no further
availability on this line of credit.&#160;The line of credit was payable on December 20, 2023. The line of credit was paid in full on
December 15, 2023.&#160;On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest
rate of 3.9% and is due December 15, 2024. </span>In addition, the Company&#8217;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for
the years ended December 31, 2023 and 2022 was $31,750 and $53,283, respectively. On February 2, 2024 the Company repaid RMB 3,500,000
under this line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company obtained a line of credit of RMB 3,200,000
(approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million),
and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of
4.50% per annum. In September, 2021 the Company repaid the line of credit in full. Also in September, 2021 the Company entered into a
new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million). The loan bears interest at the rate of 4.50% per annum.
The line of credit was due on September 2, 2022. <span>The line of credit was paid in full on September
6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears interest at a rate of&#160;4.5%
and is due on September 7, 2023</span> and was repaid in full as of that date. In addition, the Company&#8217;s Chief Executive Officer
and Chair of the Board had personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total
interest expense under this facility for the years ended December 31, 2023 and 2022 was $19,579 and $20,548, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 18, 2021 the Company obtained a
line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per
annum. <span>The line of credit was paid in full on the due date of September 18, 2022. On September
30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at the rate of 3.45% and was due
September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a
three-year revolving loan and received proceeds of RMB&#160;10,000,000&#160;(approximately $1.4&#160;million). The interest rate for
the loan is&#160;3.35% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate
less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month
anniversary of the loan.&#160;The loan is due on September 24, 2026. </span>The loan is collateralized by the Company&#8217;s new
production facility and the included production line equipment and machinery. In addition, the Company&#8217;s Chief Executive
Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was $48,624 and
$54,923 for the years ended December 31, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal payments required for the remaining
terms of the lines of credit as of December 31, 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lines of<br/>
 Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,442,571</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,442,571</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2020, the Company obtained a line of
credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000
(approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The
loan bore interest at a rate of 4.25% per annum. Advances on the line of credit were due two years from the date of the advance. A third
party company had guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next
to the creditor of the construction loan facility as discussed above. In addition, the Company&#8217;s Chief Executive Officer and Chair
of the Board personally guaranteed the line of credit. Total interest expense under this facility for the years ended December 31, 2022
was $12,063. The Company repaid the remaining RMB 5,900,000 (approximately $0.85) during the year ended December 31, 2022 as per the repayment
schedule in full satisfaction of the line of credit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Lines of Credit</i></b> &#8211;
Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts
of the construction loan facility outstanding as of December 31, 2023 and December 31, 2022 approximated its fair value because the underlying
instrument bears an interest rate that approximated current market rates.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519776498496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">CONVERTIBLE NOTE PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; CONVERTIBLE NOTE PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 17, 2021,
China Pharma entered into a Securities Purchase Agreement (the &#8220;Agreement&#8221;) pursuant to which the Company issued an unsecured
convertible promissory note (the &#8220;Note&#8221;) to an institutional accredited investor Streeterville Capital, LLC (the &#8220;Investor&#8221;).
The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13,
2023 China Pharma entered into an Amendment (the &#8220;Amendment&#8221;) with the Investor which extended the maturity date of the Convertible
Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of $65,639, representing&#160;2.0%
of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance
by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition,
China Pharma decreased the price at which the Investor can convert the balance from&#160;85% to&#160;82% of the lowest daily volume weighted
average price during the ten trading days immediately preceding the applicable redemption conversion,&#160;and assumed an additional obligation
to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Note was originally
convertible into&#160;70,000&#160;shares of China Pharma&#8217;s common stock at a price of $75.00&#160;per share through April 19, 2022.
Thereafter, the Note was convertible into&#160;35,000&#160;shares at a price of $150.00&#160;per share. As of December 31, 2023 the Note
is convertible into&#160;6,267&#160;shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Interest accrues on the
outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest
accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor
may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%,
depending on the nature of the Event of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Pursuant to the terms
of the Agreement and the Note, the Company must obtain Investor&#8217;s consent for certain fundamental transactions such as consolidation,
merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization
or recapitalization. Any occurrence of a fundamental transaction without Investor&#8217;s prior written consent will be deemed an Event
of Default.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Investor may redeem all
or any part the outstanding balance of the Note, subject to $500,000&#160;per calendar month, at any time after one hundred twenty-one
(121) days from the Purchase Price Date, as defined in the Note, upon three trading days&#8217; notice, in cash or converting into shares
of China Pharma&#8217;s common stock, at a price equal to&#160;82% multiplied by the lowest daily volume weighted average price during
the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations
specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note.
The Company may prepay the outstanding balance of the Note with the Investor&#8217;s consent. At inception, the Note was redeemable into&#160;176,229&#160;shares
based on the lowest volume weighted average price of $29.79085&#160;on the inception date of November 19, 2021. As of December 31, 2023,
the Note was redeemable into&#160;2,159,964&#160;shares of common stock based on&#160;82% of the lowest volume weighted average price
of $0.436&#160;on that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Total interest expense
for the years ended December 31, 2023 and 2022 was $206,744 and $250,314, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>2023
Redemptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
5, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $3.815, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;39,319&#160;shares of common stock to the Investor on
January 6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
18, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion price
of $3.815, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;65,531&#160;shares of common stock to the Investor on
January 19, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
2, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion price
of $2.875, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;86,957&#160;shares of common stock to the Investor on
March 8, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On April
7, 2023&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion price
of $1.404, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;142,450&#160;shares of common stock to the Investor
on April 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 1,
2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of
$1.322, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;113,465&#160;shares of common stock to the Investor
on May 3, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On May 24,
2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of
$1.2435, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;120,628&#160;shares of common stock to the Investor
on May 25, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
6, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.328, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;112,952&#160;shares of common stock to the Investor
on June 13, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
23, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.4225, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;105,448&#160;shares of common stock to the
Investor on June 27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
9, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.0715, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;139,991&#160;shares of common stock to the Investor
on August 11, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
21, 2023&#160;the Investor delivered its notice of redemption for $245,000&#160;of the Note and related interest at the conversion price
of $1.0715, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;228,652&#160;shares of common stock to the Investor
on August 22, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September
1, 2023,&#160;the Investor delivered its notice of redemption for $140,000&#160;of the Note and related interest at the conversion price
of $0.666, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;210,211&#160;shares of common stock to the Investor on September
6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On September
12, 2023,&#160;the Investor delivered its notice of redemption for $75,000&#160;of the Note and related interest at the conversion price
of $0.579, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;129,534&#160;shares of common stock to the Investor on September
13, 2023.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2023&#160;the Investor delivered
its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price of $0.546, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;183,150&#160;shares of common stock to the Investor on October 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2023&#160;the Investor delivered
its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.513, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;224,172&#160;shares of common stock to the Investor on October 13, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 17, 2023&#160;the Investor delivered
its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.513, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;224,172&#160;shares of common stock to the Investor on October 17, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 6, 2023&#160;the Investor delivered
its notice of redemption for $80,000&#160;of the Note and related interest at the conversion price of $0.3765, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;212,444&#160;shares of common stock to the Investor on November 7, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 29, 2023&#160;the
Investor delivered its notice of redemption for $125,000&#160;of the Note and related interest at the conversion price of $0.368, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;339,674&#160;shares of common stock to the Investor on November 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On November 30, 2023&#160;the
Investor delivered its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.368, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;312,500&#160;shares of common stock to the Investor on December 1, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On December 13, 2023&#160;the
Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of $0.4045, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;370,828&#160;shares of common stock to the Investor on December 18, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Subsequent
to December 31, 2023 the Investor delivered additional notices of redemption as discussed in Note 14.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>2022
Redemptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On March 21, 2022 the
Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of $15.565 during the
ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 6,425 shares of
common stock to the Investor on March 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
30, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $15.645, which
was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;12,874 shares of common stock to the Investor on March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June
13, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $9.90, which
was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;20,202 shares of common stock to the Investor on June 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On August
3, 2022&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion price
of $8.775, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;22,792 shares of common stock to the Investor on August 4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On October
17, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price
of $5.60, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;17,857 shares of common stock to the Investor on October 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
1, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;24,126 shares of common stock to the Investor on December 2, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
5, 2022&#160;the Investor delivered its notice of redemption for $310,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;74,789 shares of common stock to the Investor on December 6, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
13, 2022&#160;the Investor delivered its notice of redemption for $90,000&#160;of the Note and related interest at the conversion price
of $4.55, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;19,781&#160;shares of common stock to the Investor on December
14, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On December
14, 2022&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;36,181 shares of common stock to the Investor on December 15, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771583664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has leases for certain office and
production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options
to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the
lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount
rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company&#8217;s incremental borrowing
rate at the initial measurement date. For the years ended December 31, 2023 and 2022, operating lease cost was $77,265 and $78,092, respectively
and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $80,647
and $82,015, respectively. As of December 31, 2023 and 2022, the Company reported operating lease right of use assets of $116,610 and
$39,046, respectively and operating use liabilities of $117,637 and $40,445, respectively. As of December 31, 2023, its operating leases
had a weighted average remaining lease term of 1.50 years and a weighted average discount rate of 4.75%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Minimum lease payments for the Company&#8217;s
operating lease liabilities were as follows for the twelve month periods ended December 31:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,910</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has leases with terms less than one year for certain provincial
sales offices that are not material.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772131984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered
or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that
includes the enactment date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liabilities are established for uncertain tax
positions expected to be taken in income tax returns when such positions are judged to meet the &#8220;more-likely-than-not&#8221; threshold
based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a
component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2020 through December 31, 2023 and the Chinese income tax return for the year
ended December 31, 2023 are open for possible examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the current tax law in the PRC, the Company is and will be subject
to the enterprise income tax rate of 25%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no provision for income taxes for the
years ended December 31, 2023 and 2022, respectively due to continued net losses of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following is a reconciliation of income taxes calculated at the federal
statutory rates to the provision for income taxes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(Benefit) tax at statutory rate of 25%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(769,704</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(973,717</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prior year refund received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other, primarily the difference in U.S. tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">766,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">965,301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The temporary differences which give rise to the deferred income tax
assets and liability are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Allowance for doubtful trade receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,446,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,184,882</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Allowance for doubtful other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,787</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory obsolescence reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,921</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible in current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,069,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,087,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Advances for intangible assets impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,619,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,782,172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">257</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">PRC net operating loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,275,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,036,114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,078,262</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,849,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,531,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,985,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,531,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,985,554</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net deferred income tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred income tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742,114</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">754,698</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had net operating
loss carryforwards for PRC tax purposes of approximately $21.1 million which are available to offset any future taxable income through
2028. Approximately $3.4 million of these carryforwards expired in December 2023. The Company also has net operating losses for United
States federal income tax purposes of approximately $9.9 million of which $5.1 million is available to offset future taxable income, if
any, through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each
tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. federal tax legislation, commonly referred
to as the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;), was signed into law on December&#160;22, 2017. The U.S. Tax Reform
significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax
rate from 35% to 21% for taxable years beginning after December&#160;31, 2017; limiting and/or eliminating many business deductions; migrating
the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory deemed repatriation of previously deferred
foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends
from foreign subsidiaries; and providing for new taxes on certain foreign earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realizability of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&#160;&#160;The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those
differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management considers projected future taxable income
and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment of the level of historical taxable income and
projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management
believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2023 and 2022.&#160;&#160;Therefore,
the Company provided for a valuation allowance against its deferred tax assets of $21,531,017 and $21,467,355 as of December 31, 2023
and 2022, respectively.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also incurred various other taxes,
comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts
are reflected on the balance sheets as accrued taxes payable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519769076880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 11 &#8211; FAIR VALUE MEASUREMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Fair value is defined
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,
a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#8211; Quoted
prices in active markets for identical assets or liabilities; Level 2 &#8211; Observable inputs other than Level 1 including quoted prices
for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable
market data; and Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial instruments whose value is
determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination
of fair value requires significant management judgment or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company uses fair
value to measure the value of the banker&#8217;s acceptance notes it holds as of December 31, 2023 and 2022.&#160;The banker&#8217;s acceptance
notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at
fair value:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Reporting Date Using</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">65,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">65,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,915</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,915</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reporting Date Using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519867085312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue 500,000,000
shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued
in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#8217;s
Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to relevant PRC laws, companies registered
in the PRC, including the Company&#8217;s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as
determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account
balances reach 50% of the company&#8217;s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves
and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash
dividends. The amount designated for general and statutory capital reserves is $8,145,000 at December 31, 2023 and 2022.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2024, the Company implemented
a 1-for -5 reverse stock split as more fully discussed in Note 14. All share and per share disclosures have been retroactively restated
to reflect the impact of the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2023&#160;China Pharma&#160;implemented
a&#160;1-for-10&#160;reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s Board of Directors
through unanimous written consent and&#160;China Pharma&#8217;s stockholders at its Annual Meeting for the fiscal year ended on December
31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of&#160;China Pharma&#8217;s
issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional
shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up
to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s percentage
interest in&#160;China Pharma&#8217;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying consolidated financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2010 Incentive Plan</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2010, the Company&#8217;s Board
adopted the Company&#8217;s 2010 Incentive Plan (the &#8220;Plan&#8221;), which was then approved by stockholders on December 22, 2010.
On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &#8220;Amendment&#8221;), pursuant
to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December
19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to
the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000
shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated
Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares
from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive
Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted
stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees,
directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares
of common stock. Through December 31, 2023, there were 84,700 shares of stock and stock options granted and outstanding under the Plan.&#160;
A total of 13,300 options were outstanding as of December 31, 2023 under the Plan. As such, there are 482,000 additional units available
for issuance under the Plan.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">There were no issuances of securities from the Plan for the year ended
December 31, 2023 and as such, no compensation expense was recognized for the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On October 3, 2022 the
Company issued 6,000 shares of common stock pursuant to a contract with a consultant to the Company for services. The Company recorded
compensation expense totaling $42,000 based on the closing market price of its common stock of $7.00 per share on the issuance date. The
contract also calls for the issuance of up to 18,000 additional shares of common stock contingent upon the achievement of certain milestones
as described in the contract. At December 31, 2023 these milestones had not been met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On October 4, 2022 the
Company issued an option to purchase <span>12,000 shares of common stock at an exercise price at $28.00
per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires on October 3, 2027.
</span>The fair value of the options granted of $36,270 was calculated using the Black-Scholes option valuation model using the closing
market price of $7.50 per share, volatility of 115.5%, risk free interest rate of 3.84% and an expected life of 2.5 years. The value was
charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On September 9, 2021
the Company issued an aggregate of 35,200 fully vested shares of common stock at the price of $33.50 per share, representing the closing
market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan, as amended,
to partially offset certain unpaid cash compensation totaling $1,179,200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Also on September 9,
2021 the Company issued an option to purchase <span>1,300 shares of common stock at an exercise price
at $73.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. </span>The fair value of the options
granted of $15,243 was calculated using the Black-Scholes option valuation model using the closing market price of $33.50 per share, volatility
of 118.4%, risk free interest rate of 0.75% and an expected life of 1.5 years. The value was charged to general and administrative expenses
on the accompanying Statement of Operations for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2020 the Board approved the issuance
of 40,000 shares of common stock from the Company&#8217;s 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid
compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, there was no remaining
unrecognized compensation expense related to stock options or restricted stock grants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772131984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks &amp; Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">RISKS &amp; UNCERTAINTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; RISKS &amp; UNCERTAINTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current vulnerability due to certain concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2023, no customer
accounted for more than 10% of sales and two customers accounted for 62.59% and 13.5% of accounts receivable. One suppliers accounted
for 13.8% of raw material purchases, and three different products accounted for 29.2%, 27.3% and 12.5% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, no customer
accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and 10.4% of accounts receivable. Two suppliers accounted
for 21.7% and 11.1% of raw material purchases, and three different products accounted for 25.0%, 22.8% and 13.9% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nature of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Impact
from the New Coronavirus Global Pandemic (&#8220;COVID-19&#8221;)&#160;</b>- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Economic
environment -&#160;</b>Substantially all of the Company&#8217;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#8217;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In addition,
all of the Company&#8217;s revenue is denominated in the PRC&#8217;s currency of Renminbi (RMB), which must be converted into other currencies
before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require
approval of the PRC government.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771771696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>NOTE
14 &#8211; SUBSEQUENT EVENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On February 2, 2024,
the Company entered into a Technology Transfer Agreement with Lihua Li (the &#8220;Transferor&#8221;). The Transferor owns an invention
patent of a pharmaceutical composition for treatment of psoriasis (the &#8220;Invention Patent&#8221;). Pursuant to the Agreement, the
Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide
relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration
materials, registration application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The aggregate transfer
price as contemplated by the Agreement is $1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000
shares of common stock of the Company at $0.455 per share based on the closing market price of the Company&#8217;s common stock as of
that date. During ten years since the product launches to the market, if and only if the product generates profit, Helpson shall pay 10%
of the net profit of the sales in cash on an annual basis to the Transferor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 6, 2024 the Company implemented
a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company&#8217;s Board of Directors through unanimous
written consent and the Company&#8217;s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held
on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company&#8217;s issued and outstanding
common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a
result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number.
The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#8217;s percentage interest in the Company&#8217;s
outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts
have been retroactively restated for the years ended December 31, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On January
11, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3945, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;380,228 shares of common stock to the Investor on January
16, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February
1, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3725, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;402,685 shares of common stock to the Investor on February
5, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On February
16, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3675, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;408,164 shares of common stock to the Investor on February
21, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771309024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,078,818)<span></span>
</td>
<td class="num">$ (3,972,841)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772580064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519860977968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Organization and Nature of Operations &#8211;&#160;</i></b>China
Pharma Holdings, Inc., a Nevada corporation (the &#8220;Company&#8221;), owns 100% of Onny Investment Limited (&#8220;Onny&#8221;), a
British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (&#8220;Helpson&#8221;), a
company organized under the laws of the People&#8217;s Republic of China (the &#8220;PRC&#8221;). China Pharma Holdings, Inc. and its
subsidiaries are referred to herein as the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Onny acquired 100% of the ownership in Helpson
on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#8217;s three former shareholders. The transaction was approved
by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises
with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise
(&#8220;WFOE&#8221;) status on June 21, 2005.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located.
Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin
oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one
or more therapeutic indications by the National Medical Products Administration (the &#8220;NMPA&#8221;, formerly China Food and Drug
Administration, or CFDA) based upon demonstrated safety and efficacy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity and Going Concern</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had cash
and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company&#8217;s Chairperson, Chief Executive Officer
and Interim Chief Financial Officer (&#8220;Chairperson Li&#8221;) has advanced an aggregate of $1,133,809 as of December 31, 2023 to
provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company
anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its
existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its
ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions
that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#8217;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Accounting Standards
Codification (ASC) 205-40, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i> management
must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially
does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of
the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating
effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating
effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern
within one year after the date that the financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 205-40, the strategic alternatives being
pursued by the Company cannot be considered probable at this time because none of the Company&#8217;s current plans have been finalized
at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively
implemented as none of the plans are entirely within the Company&#8217;s control. Accordingly, substantial doubt is deemed to exist about
the Company&#8217;s ability to continue as a going concern within one year after the date these financial statements are issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ReverseStockSplitsPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reverse Stock Split&#160;</i></b>&#8211;
Effective March 6, 2024, the Company implemented a 1-for-5 reverse stock split as more fully discussed in Note 14. All share and per
share disclosures have been retroactively restated to reflect the impact of the reverse stock split.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Consolidation and Basis of Presentation&#160;</i></b>&#8211;
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) and are expressed in United States dollars. The accompanying consolidated financial
statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in the consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Helpson&#8217;s functional currency is the Chinese
Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average exchange rate for the period.
Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#8217;s
financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Gains
and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction
are included in the results of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Accounting Estimates&#160;</i>-&#160;</b>The methodology used
to prepare the Company&#8217;s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. &#160;Significant
estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance,
valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used
to calculate derivative liabilities. Therefore, actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents&#160;</i></b>&#8211;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#8217;s
acceptances notes purchased with maturities of three months or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Accounts Receivable and Allowance
for Doubtful Accounts &#8211;&#160;</i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for
doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts
and an estimation of the overall economic conditions affecting the Company&#8217;s customer base. The Company reviews a customer&#8217;s
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in
an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable
to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense totaled ($15,757) and ($93,851) for
the years ended December 31, 2023 and 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable that have been fully
allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company
charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December
31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current
balances when calculating the allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advances to Suppliers and Advances from
Customers</i></b>&#160;&#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from
customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances
received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&#8217;s
credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate,
resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the
period they are considered unlikely to be collected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory&#160;&#8211; </i></b>Inventory
consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated
portion of the Company&#8217;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable
value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable
value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs
to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value.
Net realizable value for raw materials is based on replacement cost. Provisions for inventory write-downs are included in the cost of
revenues in the consolidated statements of operations. Inventories are carried at this lower cost basis until sold or scrapped.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Leases</i></b></span><b><i>
&#8211; </i></b><span>At lease commencement, the Company records a lease liability based on the present
value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain
to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#8217;s leases
do not provide an implicit interest rate. The Company&#8217;s incremental borrowing rate for a lease is the rate of interest it would
have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date,
the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received
and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial
term of 12 months or less (&#8220;Short-Term Leases&#8221;). For any Short-Term Leases, the Company records the rent expense on a straight-line
basis and does not record the leases on the balance sheet. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>After lease
commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments
using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability,
adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent
expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line
basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Valuation of Long-Lived Assets</i></b>&#160;&#8211;
The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate
that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated
from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying
value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash
flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the Company will use the projected discounted
cash flows to be generated by the asset. For the years ended December 31, 2023 and 2022, the Company evaluated its long-lived assets and
determined that no impairment adjustments were necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Property, Plant and Equipment</i></b>&#160;&#8211;
Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are
capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b>&#160;&#8211;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration
that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company does not disaggregate its
revenue streams as the economic factors underlying the contracts are similar and provide no significant distinction. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following
five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether
the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement
of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
(or as) the performance obligation is satisfied. The Company&#8217;s contracts are fixed price and reflect standalone pricing for each
item. Due to the nature of the products sold, there are no returns. Generally, the Company&#8217;s performance obligations are transferred
to customers at a point in time, typically upon buyer&#8217;s designated carrier or the buyer picks up the goods at the Company&#8217;s
warehouse.</p>For all reporting periods, the Company has not disclosed the value
of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is
an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year.
These advances total $90,507 and $520,295 and are recorded as a liability on the accompanying balance sheet as &#8220;Advances from customers&#8221;
as of December 31, 2023 and 2022, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues</i></b>&#160;&#8211; Cost
of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery
of products.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b>&#160;&#8211;
Research and development expenditures are recorded as expenses in the period in which they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b>&#160;&#8211; The carrying
amount of accounts receivable included in the balance sheet represents the Company&#8217;s exposure to credit risk in relation to its
financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations
of each customer&#8217;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate
have not exceeded management&#8217;s estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has its cash in bank deposits primarily
at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#8217;
interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation
of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow
the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest Rate Risk</i></b>&#160;&#8211;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and
viability of securing future debt instruments within the PRC.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Common Share&#160;</i>-&#160;</b>Basic
loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31, 2023,
the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares
issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods
presented because the effect is anti-dilutive due to net losses of the Company.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13,&#160;<i>Financial Instruments &#8211; Credit
Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance
introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies
the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial
assets with credit deterioration since their origination.&#160;The pronouncement will was effective for public business entities that
are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including interim periods within those
fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December 15,
2019, including interim periods within those fiscal years. The adoption of the standard had no material impact on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the FASB or other standards
setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise
discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to
have a material impact on its consolidated financial statements upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to suppliers and advances from customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest rate risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ReverseStockSplitsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ReverseStockSplitsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772027488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,849,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,839,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">413,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,469,707</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">551,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Inventory</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,732,517</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,947,787</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519769013296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">Property, plant and equipment consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Permit of land use</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">397,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">404,427</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,234,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,391,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,170,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,780,585</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">303,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">388,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">308,847</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,495,080</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,323,430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,394,655</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,350,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,100,425</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,973,065</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_UsefulLiveOfAssetsTableTextBlock', window );">Schedule of Estimated Useful Lives of The Assets</a></td>
<td class="text">Depreciation is computed on a straight-line basis over the estimated
useful lives of the assets as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: left"><b>Asset</b></td><td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><b>Life - years</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permit of land use</td><td>&#160;</td>
    <td style="text-align: center">40 - 70</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Building</td><td>&#160;</td>
    <td style="text-align: center">20 - 49</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Plant, machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5 - 10</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Motor vehicle</td><td>&#160;</td>
    <td style="text-align: center">5 - 10</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: center">3-5</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_UsefulLiveOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful live of Assets table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_UsefulLiveOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768794016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible assets consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">NMPA approved medical formulas</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,766,353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,847,176</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Technology from Bonier</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,726,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707,452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Invention Patent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,653,028</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,890,646</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,747,142</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,255,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,807,486</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Aggregate Annual Amortization Expense</a></td>
<td class="text">The estimated aggregate annual amortization expense for each of the
next five years and thereafter is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">327,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,730,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,255,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519769089920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Payables</a></td>
<td class="text">Other Payables consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation payable to officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,243,506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">951,506</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation and interest to related parties</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">372,578</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Business taxes and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,027,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065,979</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other Payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,282,692</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,390,063</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519769080736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Lines of Credit and Construction Loan Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of principal payments</a></td>
<td class="text">Principal payments required for the remaining
terms of the lines of credit as of December 31, 2023 are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Lines of<br/>
 Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">2024</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">2,442,571</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,442,571</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772131984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text">Minimum lease payments for the Company&#8217;s
operating lease liabilities were as follows for the twelve month periods ended December 31:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,637</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Operating lease liabilities, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,910</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768950416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Taxes Calculated at the Federal Statutory Rates</a></td>
<td class="text">Following is a reconciliation of income taxes calculated at the federal
statutory rates to the provision for income taxes:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(Benefit) tax at statutory rate of 25%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(769,704</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(973,717</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prior year refund received</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other, primarily the difference in U.S. tax rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,416</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">766,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">965,301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Assets and Liability</a></td>
<td class="text">The temporary differences which give rise to the deferred income tax
assets and liability are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred income tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Allowance for doubtful trade receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,446,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,184,882</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Allowance for doubtful other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,787</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory obsolescence reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,921</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,201</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible in current year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,069,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,087,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Advances for intangible assets impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,619,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,782,172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liability, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">257</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">PRC net operating loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,275,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,036,114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. net operating loss carry forward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,078,262</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,849,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,531,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,985,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,531,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,985,554</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net deferred income tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred income tax liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">742,114</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">754,698</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519867185280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Recorded at Fair Value</a></td>
<td class="text">The Company uses fair
value to measure the value of the banker&#8217;s acceptance notes it holds as of December 31, 2023 and 2022.&#160;The banker&#8217;s acceptance
notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at
fair value:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Reporting Date Using</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">65,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">65,915</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,915</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">65,915</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reporting Date Using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Banker&#8217;s acceptance notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">13,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771422416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 25, 2005</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Organization and Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAppropriated', window );">Accumulated deficit</a></td>
<td class="num">(39,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Bad debt expense</a></td>
<td class="nump">15,757<span></span>
</td>
<td class="nump">$ 93,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Uncollectible trade accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Advances from customers</a></td>
<td class="nump">$ 90,507<span></span>
</td>
<td class="nump">$ 520,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityIndexedShares', window );">Purchase of common stock (in Shares)</a></td>
<td class="nump">13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issuable upon conversion of the convertible note payable (in Shares)</a></td>
<td class="nump">6,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cphi_OnnyInvestmentLimitedMember', window );">Onny Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Organization and Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember', window );">Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Organization and Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Organization and Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 1,133,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the option contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAppropriated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(30)(a)(3)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAppropriated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cphi_OnnyInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cphi_OnnyInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519860065936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of Inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,849,213<span></span>
</td>
<td class="nump">$ 1,839,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">413,597<span></span>
</td>
<td class="nump">557,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,469,707<span></span>
</td>
<td class="nump">551,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 3,732,517<span></span>
</td>
<td class="nump">$ 2,947,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519861003984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expanse</a></td>
<td class="nump">$ 2,529,858<span></span>
</td>
<td class="nump">$ 2,663,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771396944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 37,495,080<span></span>
</td>
<td class="nump">$ 38,323,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(30,394,655)<span></span>
</td>
<td class="num">(28,350,365)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,100,425<span></span>
</td>
<td class="nump">9,973,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Permit of land use [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">397,684<span></span>
</td>
<td class="nump">404,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">9,234,836<span></span>
</td>
<td class="nump">9,391,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Plant, machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">27,170,123<span></span>
</td>
<td class="nump">27,780,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">303,697<span></span>
</td>
<td class="nump">438,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 388,740<span></span>
</td>
<td class="nump">$ 308,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519776016688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Permit of land use [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Permit of land use [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">49 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Plant, machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Plant, machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicle [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems', window );"><strong>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772510912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod', window );">Amortization intangible by useful life, descriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Approved medical formulas are amortized from the
date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense relating to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,796<span></span>
</td>
<td class="nump">$ 36,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock issued (in Shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">310,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsStock', window );">Common stock value</a></td>
<td class="nump">$ 1,650,000<span></span>
</td>
<td class="nump">$ 1,707,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing price of common stock (in Dollars per share)</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life,term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PercentageOfNetProfit', window );">Percentage of net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cphi_HelpsonMember', window );">Helpson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PercentageOfNetProfit', window );">Percentage of net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaPharmaMember', window );">China Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsLineItems', window );"><strong>Intangible Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life,term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntangibleAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntangibleAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PercentageOfNetProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PercentageOfNetProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482710/350-30-35-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cphi_HelpsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cphi_HelpsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772171392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (4,890,646)<span></span>
</td>
<td class="num">$ (4,747,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">3,255,232<span></span>
</td>
<td class="nump">1,807,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_NMPAApprovedMedicalFormulasMember', window );">NMPA approved medical formulas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">4,766,353<span></span>
</td>
<td class="nump">4,847,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_TechnologyFromBonierMember', window );">Technology from Bonier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">1,726,497<span></span>
</td>
<td class="nump">1,707,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_InventionPatentMember', window );">Invention Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 1,653,028<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_NMPAApprovedMedicalFormulasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_NMPAApprovedMedicalFormulasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_TechnologyFromBonierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_TechnologyFromBonierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_InventionPatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_InventionPatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519776451680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract', window );"><strong>Schedule of Aggregate Annual Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 327,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">321,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">292,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">292,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">292,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,730,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,255,232<span></span>
</td>
<td class="nump">$ 1,807,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768865392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Payables (Details) - Schedule of Other Payables - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems', window );"><strong>Schedule of Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Compensation payable to officer</a></td>
<td class="nump">$ 1,243,506<span></span>
</td>
<td class="nump">$ 951,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Compensation and interest to related parties</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">372,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Business taxes and other</a></td>
<td class="nump">1,027,186<span></span>
</td>
<td class="nump">1,065,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total Other Payables</a></td>
<td class="nump">$ 2,282,692<span></span>
</td>
<td class="nump">$ 2,390,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519763924720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 28, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Loan payment</a></td>
<td class="nump">$ 1,854,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AggregateAmounts', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,854,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RestrictedCommonStock', window );">Restricted common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,751,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansHeldForSaleTerm', window );">Term of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">372,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cphi_ChairpersonCEOAndInterimCFOMember', window );">Chairperson Li [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121,273<span></span>
</td>
<td class="nump">$ 1,425,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,773<span></span>
</td>
<td class="nump">13,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,506<span></span>
</td>
<td class="nump">951,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,379<span></span>
</td>
<td class="nump">&#165; 4,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Total advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cphi_InterimChiefFinancialOfficerMember', window );">Interim Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Total advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,644<span></span>
</td>
<td class="nump">$ 28,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AggregateAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AggregateAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansHeldForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of loan held for sale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansHeldForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cphi_ChairpersonCEOAndInterimCFOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cphi_ChairpersonCEOAndInterimCFOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cphi_InterimChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cphi_InterimChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519752191680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 02, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 20, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 24, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 21, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 06, 2022</div></th>
<th class="th"><div>Jun. 22, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>Jun. 25, 2021</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRateFloor', window );">interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="nump">&#165; 3,800,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">&#165; 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540,000<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,750<span></span>
</td>
<td class="nump">$ 53,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Repaid under this line of credit (in Yuan Renminbi)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,680<span></span>
</td>
<td class="nump">2,440,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMortgageDeposits', window );">Advance amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">&#165; 856,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">&#165; 3,000,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AggregateAmounts', window );">Aggregate amount (in Yuan Renminbi)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,854,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RepaidAmount', window );">Repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRateFloor', window );">interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Repaid under this line of credit (in Yuan Renminbi) | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember', window );">Bank of Communications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510,000<span></span>
</td>
<td class="nump">&#165; 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember', window );">China CITIC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRateFloor', window );">interest rate, percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,579<span></span>
</td>
<td class="nump">20,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMortgageDeposits', window );">Advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">&#165; 2,343,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Percentage of loan bears interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_CITICBankMember', window );">CITIC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">&#165; 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember', window );">Bank of China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRateFloor', window );">interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,624<span></span>
</td>
<td class="nump">54,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_LoanAndReceivedProceeds', window );">Loan and received proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AggregateAmounts', window );">Aggregate amount (in Yuan Renminbi) | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_PostalSavingsBankOfChinaMember', window );">Postal Savings Bank of China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AggregateAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AggregateAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_LoanAndReceivedProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan and received proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_LoanAndReceivedProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMortgageDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for advance payment to show intention to complete mortgage financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMortgageDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfCommunicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_ChinaCITICBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_CITICBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_CITICBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_BankOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_PostalSavingsBankOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cphi_PostalSavingsBankOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519768824064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments - Lines of Credit [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,442,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,442,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519749692896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 17, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 13, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 12, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 09, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 13, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 12, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 06, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 11, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 13, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 25, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 03, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 13, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 08, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 19, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 06, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 05, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 02, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 18, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 04, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt extension fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PercentageOfBalanceNoteAndAccruedInterest', window );">Note and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt redemptions weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_InterestAccruesOnNoteDescription', window );">Interest accrues on note, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest accrues on the
outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest
accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor
may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%,
depending on the nature of the Event of Default.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RedeemOfOutstandingNote', window );">Redeem of outstanding note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_NoteRedeemableIntoShares', window );">Note redeemable into shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,159,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_WeightedAveragePrice', window );">Weighted average price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,757<span></span>
</td>
<td class="nump">$ 93,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt redemption amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares (in Shares) | shares</a></td>
<td class="nump">370,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="nump">339,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,172<span></span>
</td>
<td class="nump">224,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,181<span></span>
</td>
<td class="nump">19,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt redemptions weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt redemptions weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Note converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,229<span></span>
</td>
<td class="nump">6,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.368<span></span>
</td>
<td class="nump">$ 0.368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3765<span></span>
</td>
<td class="nump">$ 0.513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.145<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.775<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.79085<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,744<span></span>
</td>
<td class="nump">$ 250,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cphi_ChinaPharmaMember', window );">China Pharma&#8217;s [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cphi_ChinaPharmaMember', window );">China Pharma&#8217;s [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Convertible Note Payable [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Note converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_InterestAccruesOnNoteDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of interest accrues on Note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_InterestAccruesOnNoteDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_NoteRedeemableIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares redeemable by Notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_NoteRedeemableIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PercentageOfBalanceNoteAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of balance note and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PercentageOfBalanceNoteAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RedeemOfOutstandingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of redeem of outstanding note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RedeemOfOutstandingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_WeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_WeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cphi_ChinaPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cphi_ChinaPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519776438592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 77,265<span></span>
</td>
<td class="nump">$ 78,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">80,647<span></span>
</td>
<td class="nump">82,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">116,610<span></span>
</td>
<td class="nump">39,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating use liabilities</a></td>
<td class="nump">$ 117,637<span></span>
</td>
<td class="nump">$ 40,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average lease term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted average discount rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519867277648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Operating Lease Liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract', window );"><strong>Schedule of Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 80,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">40,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">120,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(3,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">117,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Operating lease liabilities, current portion</a></td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">$ (40,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 39,910<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771941760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Enterprise income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating loss carryforwards available for future taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards limitations, descriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each
tax year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. federal corporate income tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredTaxAssetValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,531,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. federal corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredTaxAssetValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,467,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member', window );">Tax Year 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519956752688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract', window );"><strong>Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate of 25%</a></td>
<td class="num">$ (769,704)<span></span>
</td>
<td class="num">$ (973,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Other, primarily the difference in U.S. tax rates</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">8,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">766,322<span></span>
</td>
<td class="nump">965,301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771874416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract', window );"><strong>Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">(Benefit) tax at statutory rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772371424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful trade receivables</a></td>
<td class="nump">$ 3,446,519<span></span>
</td>
<td class="nump">$ 4,184,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses', window );">Allowance for doubtful other receivables</a></td>
<td class="nump">6,754<span></span>
</td>
<td class="nump">6,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory obsolescence reserve</a></td>
<td class="nump">32,355<span></span>
</td>
<td class="nump">34,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Expenses not deductible in current year</a></td>
<td class="nump">1,069,198<span></span>
</td>
<td class="nump">1,087,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Advances for intangible assets impairment</a></td>
<td class="nump">9,619,060<span></span>
</td>
<td class="nump">9,782,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Lease liability, net</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">PRC net operating loss carry forward</a></td>
<td class="nump">5,275,411<span></span>
</td>
<td class="nump">5,036,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">U.S. net operating loss carry forward</a></td>
<td class="nump">2,078,262<span></span>
</td>
<td class="nump">1,849,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">21,531,017<span></span>
</td>
<td class="nump">21,985,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,531,017)<span></span>
</td>
<td class="num">(21,985,554)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_DeferredIncomeTaxLiabilityAbstract', window );"><strong>Deferred income tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 742,114<span></span>
</td>
<td class="nump">$ 754,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_DeferredIncomeTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_DeferredIncomeTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519772128080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 65,915<span></span>
</td>
<td class="nump">$ 13,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cphi_BankersAcceptanceNotesMember', window );">Banker's Acceptance Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">65,915<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Banker's Acceptance Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">65,915<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Banker's Acceptance Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">65,915<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Banker's Acceptance Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cphi_BankersAcceptanceNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cphi_BankersAcceptanceNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519767674368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2022</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Sep. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 27, 2022</div></th>
<th class="th"><div>Dec. 27, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AftertaxNetIncomePercentage', window );">After tax income, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ReserveAccountBalancesPercentage', window );">Reserve account balances, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">General and statutory capital reserves amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_TotalOptionOutstanding', window );">Total option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AdditionalSharesAvailableForIssuance', window );">Additional shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_ClosingMarketPrice', window );">Closing market price (in Dollars per share)</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_PurchaseOfCommonStock', window );">Purchase of common stock</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price of per share (in Dollars per share)</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited', window );">Options granted (in Dollars)</a></td>
<td class="nump">$ 36,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Percentage of volatility</a></td>
<td class="nump">115.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Percentage of risk free interest rate</a></td>
<td class="nump">3.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected life, term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issued an aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price of per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Unpaid cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,179,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoFourMember', window );">Effective March 6, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for -5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoThreeMember', window );">Effective March 6, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember', window );">2010 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock and stock option granted and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_IssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AdditionalSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AdditionalSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AftertaxNetIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After tax net income percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AftertaxNetIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ClosingMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing market price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ClosingMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_IssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_IssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_PurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_PurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_ReserveAccountBalancesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve account balances percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_ReserveAccountBalancesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_TotalOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total option outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_TotalOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cphi_EffectiveMarchSixTwoZeroTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519771623616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks &amp; Uncertainties (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesBenchmarkMember', window );">Sales Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">62.59%<span></span>
</td>
<td class="nump">52.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">27.30%<span></span>
</td>
<td class="nump">22.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Product Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember', window );">Suppliers One [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember', window );">Suppliers Two [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RisksUncertaintiesDetailsLineItems', window );"><strong>Risks &amp; Uncertainties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RisksUncertaintiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RisksUncertaintiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_SalesBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cphi_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cphi_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cphi_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cphi_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cphi_ProductTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cphi_ProductTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cphi_ProductThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cphi_ProductThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140519764615664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 21, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 16, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_AggregateAmount', window );">Aggregate transfer price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RedemptionPercentage', window );">Redemption percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,625,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RedemptionAmount', window );">Redemption amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cphi_RedemptionOfWeightedAveragePercentage', window );">Redemption of weighted average percentage</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,685<span></span>
</td>
<td class="nump">380,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">$ 0.3675<span></span>
</td>
<td class="nump">$ 0.3725<span></span>
</td>
<td class="nump">$ 0.3945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RedemptionOfWeightedAveragePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of weighted average percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RedemptionOfWeightedAveragePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cphi_RedemptionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cphi_RedemptionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cphi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "[@(%8N5DS)\L'  #@-   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;:V_;-A2&_PKA#4,+Q+%NOJ1+ B1RO*:7U(C3%EVQ#XS$V$(DTJ.H7/[]
MCBX1HXVBI8'^DEBRSBOQ,0]Y7DHZ?F3\/MT0(M!3$M/T9+ 18OMN-$J##4EP
M>LBVA,(W=XPG6, F7X_2+2<X+(*2>.18UF24X(@.3H^+?4M^>LPR$4>4+#E*
MLR3!_/F<Q.SQ9& /7G9<1^N-R'>,3H^W>$U61'S=+CELC6J5,$H(32-&$2=W
M)X,S^]W<<_* XHAO$7E,7WU&>5-N&;O/-R[#DX&57Q&)22!R"0S_'HA/XCA7
M@NOXNQ(=U.?, U]_?E%?%(V'QMSBE/@L_AZ%8G,RF U02.YP%HMK]OB>5 T:
MYWH!B]/B+WHLCQV[ Q1DJ6!)%0Q7D$2T_(^?*A"O ERO)<"I IQ_!=AM 6X5
MX'8-\*H KR!3-J7@,,<"GQYS]HAX?C2HY1\*F$4T-#^B^>^^$AR^C2!.G/KL
M@7 T1%]7<_3FU[?'(P&B^5>CH!(X+P6<%@';09\9%9L47="0A$V!$5Q-?4G.
MRR6=.UK%.0D.D6L?(,=R7,4%^?KPSY@?(L<KPCU%^%P?_B&C<'9+=?9&:]P:
ML%OHN6VM84$&>2+0)2VS-._M/S_!4>A2D"3]2X6\E/34DOE0\"[=XH"<#"#7
M4\(?R.#TMU_LB?6["I=)L;DAL09*KT;IZ=0ERIOG+5%ATX?;UO"CBH\VJB\?
M0V(-/N.:S[@;GS-*,QRC:[)E7*A Z74$SU1X?6U47U"&Q!J@)C6H2<>.Q#',
M8$5*ML/2:]WA.%72TH;UI65(K$%K6M.:=J.UB"BF000]:R4PC%WYO@O.&4<^
MX[R:R'\N8KQ6#FKZL[1RU(;UY6A(K,%Q5G.<:5MX044DGF$>$(27Y0[*IVSD
M9P"/*KN>7O '257 M$%]@1D2:P [JH$=:=MWZ2^NT5D61@*ZV)D0)!7E])EW
M,14NO5QK#].&]05F2*P!S+9D-6=IVW@&21F6R=K":(= *R1]7%]*IM2:F%X5
MO7:W(6U)>,3"O'3-<U%95.R2>JE66\M5O4!O<H;4FN0<2<[I.AFD <P$/PCF
M: $[54/1^0ZQ5F+:L-[$#*DUB<GZW];6Q/\A5G6Y=F9ZN<4/)3&C1;XIM28Q
M6>;;GM8RU1-E=\-DFRSB?:-J<U-J39K2%-CZ:KZB>4W642J@WA7H"B?JD4XO
MY&^@_D/+#88?!;UG<1C1=7H /U-PJ(1HU"Z84FM"E(;!UE?Y%40?\IA##E_2
MD#RAC^19B5$O95F6;5N3B:=:G/#UP;VI[<,WV-(XV/J:OJ*VB&*"KK+DEG E
M+[T(X!JZGC>UE;B,N@-3:DU<TA_8G0S"#7Y"ER'TM.@N"LKA3P-/+SEUA_9X
MXLVLJ9*>4:M@2JU)3YH%6U_>U[-&P#A8^0+<0>E446%1,\A=2&$6J@<_O?K5
M-R5 H];!E%ISU55Z!T=?^E<^M%'9Z0KC'7+#H>T,7676ZB/[8C.EUL0FO82C
M-P!5O_M.XGAX3]DC12N"4T9)B"[3-%.G[0[-*Z;$9M1(F%)K8I-&PM'7_A6V
M;RR&O,2\G"6XLB+>H=0"RZB',*76A"4]A*,O^E_*CRI#R[5**+^*X4UM(W8H
MMJP=Z:-Z4]N'CW"DCW#T"_X5M=4&4A/&_62+J;)@VR'3NB2BC^L-:Q\VP9$V
MP>ED$XHL1#X,^6O&U;3T.E>,#G$0$) !D; 45-(SZ@],J37I27_@=/('JP1#
M5SO/4O@Z5:>E7J?MUHL^K#>L?=@"1]H"IY,MN$@(7^>#V!^@(#;:#/V?]P[T
M<;VQ[<,>.-(>.)WLP3*[C:, +6*&E?<,]"I]ET*,JLTKM7&AEC^2\G#JSHXF
M1QZ4B0\J.++Z=XZZK!GY#(J)H%C7A1*,DGCGRI%CLH3WC:K-3:DU'UR0AL#5
M5_ 5T[,P!/7TX.4#*HA^H4I3L$-R10(&E@(Z+^,'Z(H=(GMZ@#Y$%#(?73,<
MJJ#J-7L_P; /N^!*N^!VL@MJJ#>/JEKV?(?D>QS=LTQ)SJAC,*76)"<=@]O)
M,=3D_'P+G/T->"XE-;T<4*/0Z9:</40T4$X?>H7>^/;A(=Q7SR%U\A 27[D@
MHB2G5_*OE+#,/F>T#^O@2NO@=K(.-:PE2P6.T9_1MG4!:8?B>&HY]D0)SJB-
M,*76!"=MA#ON,@\O-PR&LP5^JI8NT]V/O)FT [Y1M;DIM293:2Y<O2DH!KHS
M3G![W],+O+%L6_5HIZ^/ZXUI'[;"E;;"U;N 3ZRXO5KTO/8%\QTBLPF:'<V&
MD\G,'MI3UU)2,^HJ3*DUJ4E7X<ZZ).RG*,T7E#KDJ5%[851M;DJMB5)Z$%=_
MC^ F$C%![ [9SIO;MPAJW8P#6R5%O1)8X811M!(LN%=B,VHS3*DU'^J5-L/3
M>X(;CL-B+?,YN66QBM8. 7_Y_E)%21_6^\G>??@&3_H&3U_DO_0F=/$4;#!=
MD];;^#N$KGZL+I2TC'H%4VI-6M(K>)V\PNL\.D"K#89SH2^9@&*.YGU.B<]D
MT>]7:I-7*QZV-[,GL\FX7O*HB!FU!Z-7KX3DZVS%JS4I"O*BOWP[I-Y;O[YS
M5KRT,I*'E^_^?,;Y,EV*8G('H=;A%*HA7KY.4VX(MBU>,+EE0K"D^+@A."0\
M/P"^OV-,O&SD)ZA?:CK]!U!+ P04    " "[@(%8/TQT&BX"  "E!0  &
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M/R%&QHABRAS#+UX_G!X.GP#!'4NZ8TE;?VR(Y:JN9:716=, L<\N/AL'W.W
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M!B3J0;/MJ.!1% ]@$SMLPHOMMI;+),^0_ F%1N/>Q\*>7X)IT%_,MED4A6(
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M;+K89J!%63>"&Z&QK:PO,^S\09H ?+X50M\/3&_9_9:(OP-02P,$%     @
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MU4_".ZM6PK[AA^:.?Q(++Q:9VOH+1CR(9%*LMO]6T1*K:*DMM"&]O00 S1I
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M4_Q"5/\I"[TYFZ4S5/ UVU7Z6MS_RO<!1<9?+BIE_Z+[UC:A,Y3OE!;;_6!
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MJ76>]2)[#VHUDI_;5<,]V78]K=3A=D0PA;A#F'97\=R$W1\F&T]"G\H5G2X
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MIQXO_3\)PU^G=\9J^E3^?BOW#7+V-K*[/D.SXA6.0[H?!O4]AI/W[^)^]/$
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M29&'H#?3;[.Q:N4GSIVR-+_\<DE_&% [ WH_5\H^;5R W5^0R3]02P,$%
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ML0,%K!4>'L)CA%^H''.Y8*FVCNDY*T4F4UY$1 55P2WCRZ71*Y$QO&%XS*H
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M\<VW3="CW: ?;0%M=C1T=FRD;->VNT23[N/=@;W6':(_LSNP;W>'Z+_J#G%
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MT3_HNF;JK:(H#]D@F<2]48\&(PSZL'%$@S%+SI.X/QK38-(>G&T&CULUB.<
MG79R'CUJ!]/;'A^[(CUMW5^7PBS\+;V_8%(N7&5OWF[^$# -]]_;Z>&O"'?<
M++!#98688VFO.QEUPNZJ&3B]]+?A,^VPP?6/N>#@(IJ [W.M73,@!9L_CUS]
M!U!+ P04    " "[@(%8S[\-&ZT"  #2!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6R-5-]/VS 0?N]?<0J(IX@D3G_31FJ!B4EC5, V3=,>W.32
M1"1Q9KL4_ON=G38KJ%1[B>_L^SY_Y\O=9"/DD\H0-;R41:6F3J9U/?8\%6=8
M<G4N:JSH)!6RY)I<N?)4+9$G%E06'O/]OE?RO'*BB=U;R&@BUKK(*UQ(4.NR
MY/)UCH783)W V6W<YZM,FPTOFM1\A0^HO]4+29[7LB1YB97*1042TZDS"\;S
MKHFW =]SW*@]&TPF2R&>C/,YF3J^$80%QMHP<%J>\1*+PA"1C#];3J>]T@#W
M[1W[)YL[Y;+D"B]%\2-/=#9UA@XDF/)UH>_%Y@:W^?0,7RP*9;^P:6)9WX%X
MK;0HMV!24.95L_*7[3OL 8;^!P"V!3"KN[G(JKSBFD<3*38@332Q&<.F:M$D
M+J],41ZTI-.<<#JZTQE*6/!7OBQ033Q-G.;$B[?X>8-G'^ #!K>BTIF"ZRK!
MY"V!1V):16RG:,Z.,EYA? YAX +S67B$+VPS#"U?^%\9PJ_94FE)/\/O0\DV
M5-W#5*9!QJKF,4X=Z@"%\AF=Z.PDZ/L71X1V6Z'=8^S1W>/-]3TL9C]G\R_7
M#X?4'<4?5O?U[O$:>G!V,F1!< %O[X!W;Q,+:C:E,0&1 AU!*@KJVKQ:C3M4
M%BR7%&U*L^]T3)U,L5CG4I0T+!2W_58WK* %L:5Y3-&!R[JAV_/[,.H%9GV+
MX%4">:61Q&L#DUAP(Z;F4N<D[Q0"YOJ^3T8X8&YO,.S,UXI>02G0_(4B#(.P
M.06NSP9N,.P;J]]S1X-1YU%H7KS/^128RX;,[8^8M<.13X 0#A74V^NS$N7*
M3A/S;.M*-RW7[K8#:];TZ;_P9MK=<KG**P4%I@3USP<]!V0S01I'B]IV[5)H
MF@'6S&CHHC0!=)X*H7>.N: =X]%?4$L#!!0    ( +N @5@8NSC$J 4  $T.
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)U7VV[;.!!]UU<,W+1H
M <'6Q;<TB0$G3;%=M$W@9'>Q6.P#+=$644E422J._WYG2$FVTR3;YB&Q2 V'
MY\R<&8JG&ZF^Z8QS _=%7NJS7F9,]7XPT$G&"Z;[LN(EOEE)53"#0[4>Z$IQ
MEMI%13Z(@F \*)@H>[-3.W>M9J>R-KDH^;4"71<%4]MSGLO-62_LM1,+L<X,
M30QFIQ5;\QMN_JBN%8X&G9=4%+S40I:@^.JL-P_?GP_)WAK\*?A&[ST#,5E*
M^8T&G]*S7D" >,X30QX8_MSQ"Y[GY AA?&]\]KHM:>'^<^O]H^6.7)9,\PN9
M_R52DYWUICU(^8K5N5G(S6^\X3,B?XG,M?T/&V<;HW%2:R.+9C$B*$3I?ME]
M$X>]!=/@B051LR"RN-U&%N4'9MCL5,D-*+)&;_1@J=K5"$Z4E)0;H_"MP'5F
MMN Y,SR%:Z;,%FX5*S6S\=*G X/^R6J0-+[.G:_H"5]A!%]D:3(-EV7*TT,'
M P36H8M:=.?1LQX_\*0/<>A#%$3Q,_[BCFUL_<6_S!;^F2^U43CZ]S'BSNWP
M<;=4..]UQ1)^UL/*T%S=\=[LS:MP')P\ WK8@1X^YWVVN/P\O[W\ -?SQ>W?
M<+N8?[V97]Q^NOIZ\QC2YWU]O;J]A#&\>36-PO $GG8-<RAXL>0*Y I,QN%"
M%A4KMW;EY$3#4C*5TLM4**PPJ;3WEEY&P<DYO;+/X<D[R%@*&)4[(6N=;X&E
M=ZQ,, =&[OL%AA6Z7BN^Q@0!*V1=&O)^%/KQ:.B/QA-@FB90$@Y7(XL(-IE(
M,A :>T0B%0K/0\L&RA5NH:!B6[;,N>YXJT8'%>I <-U@!>P2!(DEB0,ERC4D
M$K5<:C3&)RUSD=J52Y83#;"5I_MP2^L<-8J-XB!*PU$,QF,&&"BBA?##?O :
M*L2TY4SA,FE8WID"OZ]H+_M2 Z<J^H%PC*%*&^9(]&CL3R9N[BB,_=%P[",]
M77';[O)MWZ,(HU?FNB#:==LU<6E3X5+:I!WC*<HDKPF"*.%!(,4O1\IS9XPA
MPF1]%$9^$ 0.>#R)_-%D^D2*=XP?4(.K$N;U&KLD1+$S]2VN5I,80J)J*4O,
M0L*5P8/*2_D2H5#YKW ;AK+C>- 8[+TF@XN,"84ITABNS\*'JE:Z9B5A;[1&
M6RAJ]YKFL 73&8/N+;E#\4Y1O,,1I@IA(#TMUJ73_MXNWF=AJ=SPRCCBT;1E
M<PCF"3Z02RP?S8W)'8^.T6/HEQ))-LIWEJFC4=ZA.\_F]?%*;,G(#>5U>U"_
M%E'D3T:A/\2#0&<,4T7K2&E*),;JHBB0!QYJR;<'?:7OW=2VB@DLUA5)F[25
M<UHH#X)S[(+CBJ[='Q/.417IK@IW4HO\XVCJ6:4YP2E>,=&-CB*,=!#&+:3.
M0UHK6D]S/U>1A_J$E9(%"%3)7A9][R(3? 67]SRIR0ZN5BN1D S1R2?*KRC
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MTJ _&?7<:=8.C*SLA0$/"KQ^V,<,[WM<D0&^7TEIV@%MT-T@9_\!4$L#!!0
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MNE>2R@*;BS+?QD2YZ.>+#9 )5B "RK!26F4TCZ$J(9998DJHI3!N'$0+(<R
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M$]![3<,T1WMIK,ZY.^$YA005KLQU)? B>9VC@&Y;7N2F[U$(O1OZW<%TU#R
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MM7\>\I(7I\<TL(HGXME\MHSGHXEX3C?+^3B>)W/Q//J$G&29*-0.U< +%BK
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M2"^A5")3I?*/\"-9XH/R$?(G4#IXHIW.52U*!JB,\R#DO=">1H=I7$(CY9;
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MS)0$+6D!WF^,\>T7.J#[J?3B?U!+ P04    " "[@(%8!:"H0OT#   H"0
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MR@K0]UQ*L]U8 [O'T>0O4$L#!!0    ( +N @5@_\QGLT08  !82   9
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M%L#SI45^NQM6L/T4=/%?4$L#!!0    ( +N @5CK5!_<0 (  )D%   9
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M.T&8 KV_X5P= G- /XWSWU!+ P04    " "[@(%89#JB:T,"  "*!@  &0
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M.RSUSP*$"=#/<\[5<6(V&'X_R1M02P,$%     @ NX"!6"/DY[?B$@  I#<
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M9\4$1H!4J0+.9)Z<LC7;4\TJ6_)JH W^Q%M7RU6NW9:%P=NW)'IEM5,N8=D
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M0*IUK;QZ,K*$>@OH8F6UUD6Q4_D-(UC4SC7 >O'9$  B./MIA]PF3&6<Y7K
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M&W:V+Z-?$Z/8H5FE6]*&QQ+OWZW^14__9)I02C+B3]]IC%-QV5C74/D5$"+
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MHNL=+\9[N>]C"7Y%-G#,U/\FD3YO75-O,=[4HP.SU'NVSANRK@_&,:KSE6<
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M\2[\/J:S1TF.HSA_S$W#<EAZ:  #^AF\[-.':!)^/<$Q&3@FI]"S>_1;L15
M5$D&OL=(GH0Y3O)-?Z[03\9"X9:Q%9!2"30FEYOY"'<=ZC7H;N</DY$[!G<6
M='3'6KQ^%C1GPI#(GR8SGT:QB^*9/TFBT2.ZD'!)&JUR,(8D4>R/9RD9CU,_
M2B:C*RXYWM>";)0J'$0RF?EIZ HB/PS#T8.R3+QM ?E(8C^-J3^.4HRI/TM2
M/YVFY-B>!P=.J$%O.K\;5+V5MC?%,#H\*>>]D][*^_?HAND-EX8(*+$U/$O'
M'M&]Q_O$JJ;SU5I9=&D75O@L@G8%.%\J9?>)6V!X:+._4$L#!!0    ( +N
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M$I0-P.^5E.;5L06FQW?S'U!+ P04    " "[@(%8T+S&@I\"  #)!0  &0
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M)9CNWO6O.J&NBFMT@8JQ5-Z@UJ7U5?U9<4%]4#YS3^?EA?M.IKS_O\)\1:A
M*2R5I',R4,1X>:5>ODB6%Y?,"R;5,;EX3 #'P'4%]7W)U&Y?O6@']3\VIO\#
M4$L#!!0    ( +N @5AAP0S]AP(  .,&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;*U574_;,!3]*U8V32 -\IU0UD8:K="0-@G1,1ZF/9CDMK5P
M[,QV&_CWNTY"*&VH>-A+XH]SSCTGB6_&M50/>@5@R&/)A9XX*V.J<]?5^0I*
MJD]E!0)W%E*5U.!4+5U=*:!%0RJY&WA>XI:4"2<;-VO7*AO+M>%,P+4B>EV6
M5#U= )?UQ/&=YX4;MEP9N^!FXXHN80[FMKI6.'-[E8*5(#23@BA83)RO_ODT
ML?@&\(M!K;?&Q":YE_+!3JZ*B>-90\ A-U:!XFT#4^#<"J&-OYVFTY>TQ.WQ
ML_IEDQVSW%,-4\GO6&%6$^?,(04LZ)J;&UE_@RY/;/5RR75S)76+C2.'Y&MM
M9-F1T4')1'NGC]USV"+X;Q&"CA"\EQ!VA+ )VCIK8LVHH=E8R9HHBT8U.VB>
M3</&-$S8MS@W"G<9\DQV)38@C%1/Y&@&AC*NC\D)F>/'4JPY$+D@+X@3<CN?
MD:./QV/78&DKX.9=F8NV3/!&F1GDIR3T/Y/ "\(!^O3]]. UW<7 ?>J@3QTT
M>N$;>L/Y?G]'&+DR4.H_0Q%;S6A8TQZW<UW1'"8.GB<-:@-.]NF#GWA?A@+_
M)[%7\<,^?GA(/;NA-7Y#!A2C7 \E;>EQ0[=]8)/Y9]$H\/'5;;9##.'"41+Y
M/>Z5OZCW%QWT=X<GGS!!*B5ST(,.6X%DJW+DA_$HW3&X#XOCU(^287]Q[R\^
MZ.^2"89'KB!+*8M!>_%>72PZ2KU=?_NX./8]SQOVE_3^DH/^?DI#^<N'/60P
MV7MS81H&L;]K<!\7C*(T/4MW'+I;+<BV_Q]4+9G0A,,"F=YIBA*J;:GMQ,BJ
MZ4KWTF"/:X8K_ N!L@#<7TAIGB>VT?7_M>P?4$L#!!0    ( +N @5A!$F.\
M50(  *\%   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U4VV[;, S]
M%<$;AA;H:L=.TLL< TW28GLH$+3H]C#L0;&96*@LN1)SZ=^/DATO+=)B&/9B
MB1+/X2$M,MUH\VA+ &3;2BH["DK$^C(,;5Y"Q>VIKD'1S4*;BB.99AG:V@ O
M/*B281Q%P[#B0@59ZL]F)DOU"J50,#/,KJJ*F^<Q2+T9!;U@=W GEB6Z@S!+
M:[Z$>\"'>F;("CN60E2@K-"*&5B,@JO>Y:3O_+W#=P$;N[=G+I.YUH_.^%:,
M@L@) @DY.@9.RQHF(*4C(AE/+6?0A73 _?V._<;G3KG,N86)EC]$@>4H. ]8
M 0N^DGBG-U^AS6?@^'(MK?^R3>,[B *6KRSJJ@63@DJH9N7;M@Y[@-[P#4#<
M N+7@/X;@*0%)#[11IE/:\J19ZG1&V:<-[&YC:^-1U,V0KF_>(^&;@7A,)L9
M>A &GT_83'*%C*N"73^M1$U_"MG1%) +:8_99_9P/V5''X_3$"FL X=Y&V+<
MA(C?"-&+V:U66%IVK0HH7A*$I+<3'>]$C^-W&:>0G[*D=\+B*$X.")K\/3Q^
M1T[2U3#Q?,D_U?#GU=RBH>?ZZU#I&N;^86;7PI>VYCF, NI1"V8-0?;I0V\8
M?3F4]G\B>U&$?E>$_GOL5%0BS07WS0G;FBL+AQ)N6 :>Q8V8=18/XHOSP7D:
MKO=S.> W'"879X/.KY$9[KW]"LS2CP3+<KU2V+RH[K2;.E>^V5Z=CVD:-</C
M#TTSRFZY60IEF80%44:G9Z3*-..A,5#7OL/F&JE?_;:DB0K&.=#]0FO<&2Y
M-Z.SWU!+ P04    " "[@(%8_\8*W.\#  "M$P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6RU6%UOHS@4_2L6.UK-2&VQ,9_=)-*VW=6.--5&TYG=
MA]$^N'#3H &<,2:9_ONU"860$*NIR$N"X=[#N=<'<_!DP\7W<@D@T<\\*\JI
MM91R=6W;9;R$G)57? 6%NK+@(F=2#<637:X$L*1.RC/;P=BW<Y86UFQ2GYN+
MV817,DL+F M45GG.Q/,-9'PSM8CU<N)S^K24^H0]FZS8$SR _+J:"S6R6Y0D
MS:$H4UX@ 8NI]3NYOG6P3J@C_DEA4^X<(UW*(^??]>!C,K6P9@09Q%)#,/6W
MAEO(,HVD>/QH0*WVGCIQ]_@%_<^Z>%7,(ROAEF?_IHE<3JW00@DL6)7)SWSS
M%S0%>1HOYEE9_Z)-$XLM%%>EY'F3K!CD:;']9S^;1NPD$/=(@M,D.*]-H$T"
MK0O=,JO+NF.2S2:";Y#0T0I-']2]J;-5-6FAI_%!"G4U57ER-A=*$4(^7Z!Y
MQ@J)6)&@/WY4Z4I-E43O[T"R-"L_H$OTH!245!D@OD#FK$OT]>$.O7_W86)+
M15'?R(X;.C=;.LX1.G<07R%*+I"#'3J0?OOZ=*>?;JO&M-UQVNXX-1Y]4W>^
M?5+AZ*.$O/QOJ-0MMCN,K9_/ZW+%8IA:Z@$L0:S!FOWZ"_'Q;T.%CP36:P-M
MVT!-Z+,O7+)LJ,)MFE>GZ05C/:.!&WDXQ!-[O<M^(#"D#G5I%]ACYK;,7".S
M3U"6UVHMB*N\RIB$1#W"J@%QRO0B,41YB^?O,+FDF$:N[WE[G <BG9!ZF/K>
M,&FO)>T927>J6K6J@A=57: "Y!!Q[X!.0#!VG7W:AW%1%%!\C+3?DO;-I$'D
MJ=0/?Z;Y5B6@;_>0/X(8U+X1[%3MCP36JSMHZP[.N 0$8[9A)+!>&\*V#>';
MEH#P0&XT"OS0W5/E89B+7=<)AD49M:PB(ZN;*LV2M'@R2M$(<>H<C 36JY;@
M[F6-SRC&!GRD3HR%UF_%CF\A;Q-DD]=; -6;)J3^GB2' FE$7$J'14DZUT",
M;^-9/3D7RJ;%2W5%//=7>*-8S<@GS]$Y7 /I; .AYY2KT92<W(J1T/JMZ'P*
M,1N5XW(]M!E.0 ),'+JOUZ'((,1>>.353CI#0LR.Y)Y++M :EFF<06D6J!'I
MY%D9":U?=^=IB'].@8YJ<L9"Z[>BLSG$:!\, @T.W_#* T?!OCP/XUP:$AH>
M$6?G/(C9>OR]6*0QO';]-&*=/"<CH?4K[]P-B<XISU&-SUAH_>_PSODX1CMQ
M7)Y-7O_3,@S<_2_0H3@<ANZ^ [5W]E+T1M8]$T]I4:(,%BH17P4*06SWAK8#
MR5?U]LHCEY+G]>$26 )"!ZCK"\[ERT#OV+0[=+/_ 5!+ P04    " "[@(%8
MM1(F*\(#   <&@  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6S-65UO
MVS84_2N$!@P;D$4BY8\DLPTT38<5:#"C6;>'8@^,=&41I427I.($V(\?*3NB
M!R24I56#7FQ1U#T\]_*(1Y06.R&_J!Q H\>"EVH9Y%IOK\)0)3D45)V++92F
M)Q.RH-HTY2946PDTK8,*'I(HFH4%966P6M3GUG*U$)7FK(2U1*HJ"BJ?KH&+
MW3+ P?.)CVR3:WLB7"VV= -WH#]MU]*TP@8E9064BHD22<B6P1M\=1W7 ?45
M?S#8J:-C9%.Y%^*+;;Q/ET%D&0&'1%L(:OX>X"UP;I$,CZ\'T* 9TP8>'S^C
M_U(G;Y*YIPK>"OXG2W6^#"X"E$)&*ZX_BMVO<$AH:O$2P57]BW:':Z, )972
MHC@$&P8%*_?_]/%0B*, /'DE@!P"2,U[/U#-\H9JNEI(L4/27FW0[$&=:AUM
MR+'2SLJ=EJ:7F3B]6DLSP5(_G:$UIZ5&M$S1NZ\5VYK*:_3##6C*N/H1_83N
MC"#2B@,2&7JG-#,5@11]4I!5''TPI56VY_<<T!NE0*M%J T_.TJ8'+A<[[F0
M5[C<0'*.8GR&2$3B?X>')JTF-]+D1FJ\R6NY@2R8MJRX3:M2@#[?0G$/\B_T
M-[IE)2NJHCGU$E\OOKUAKM26)K ,S!VA0#Y L/K^.SR+?O:PCQOV<8T>_^\S
M@SY_,&.A]QH*]6+:\0!I3YJT)]Y)<PE4^P2X3> EEGZ<282>@$KEH31M*$W_
MBX[H8ZN.O/@]"SIKV,_&JJ/9 &G/F[3GWTA'?IQYNXXN&DH77JCKBO&4E9NN
MJY 7M6<9+QO.EV-5S^4 :>/(^6+TC?33 D3:!82/W!IWE] )"Y ?MF\QG1%C
M,E85X2$\'#L3QUZS["(C/]#DLEU&SF.QWQSK63@SSY%);GKD4STAT$Q(Q_7)
M/UC?$CMWQM/1BFL(8\?.V;'70;N(RP\T;=>6\UWL-\P.VCIEX?(.UK?"SK'Q
MQ6BU-83M8^?[V.NO7;3E!\+M_D><*Q._F=X*+21Z@)PEO/MNSHO=LZ+$>3?!
M8]42&<+^R=$^W+\1/UU++4#MZQ1QSDS\AOJZE$Y8EOS8?0OJ_)M,1BNE(<R>
M.+,G_KUX!RGY@4Y9EIP1$[]__I9E+('^3U!^^+Y%=99-YJ.5TQ#^3IR_$_^6
MO(.<_$!QNYJ<]1*_8WK5=,KB-,3..78>'4=C55,\A,/'SN%C_^[\=#6U 'E\
M+CQZUV^_F]Q2N6&E0APR Q6=S\VR)_>?(O8-+;;UZ_][H;4HZL,<: K27F#Z
M,R'T<\-^46@^"*W^ 5!+ P04    " "[@(%8O"#LA^<$  !H&@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6RU6=MNXS80?>]7$&Y19(&M=;'E2VH;
M2"P7&Z!9&!ML^[#H RV-+2*4J)*TG?3K2TJ*;'EE)EXP>8A):N9P>&8TY(B3
M/>./(@&0Z"FEF9AV$BGS:\<140(I%EV60Z:>K!E/L51=OG%$S@''A5)*'=]U
M!TZ*2=:938JQ)9]-V%92DL&2([%-4\R?;X&R_;3C=5X&OI!-(O6 ,YOD> ,/
M(+_F2ZYZ3HT2DQ0R05B&.*RGG1OO>N$-M$(A\1>!O3AJ([V4%6./NG,73SNN
MM@@H1%)#8/6S@SE0JI&4'?]6H)UZ3JUXW'Y!_Z-8O%K,"@N8,_HWB64R[8PZ
M*(8UWE+YA>T_0;6@0.-%C(KB/]J7LD&O@Z*MD"RME)4%*<G*7_Q4$7&DX/7/
M*/B5@O]6A5ZET#M1&+EG%/J50O^M,P250K%TIUQ[05R()9Y-.-LCKJ45FFX4
M[!?:BB^2Z4!YD%P])4I/SNXRB;,-65% -T* %.@J!(D)%1_0;^CK0XBN?ODP
M<:2:2BLX404;EK#^&5C/1_<LDXE BRR&N G@*!MK0_T70V]](V((41=YP4?D
MNWZOQ:"Y6?TSVW61/SJK'KYA]IYW5GWQ=G7?0$:O]EJOP.O]@->^_:F$T9V$
M5/S38NEMB=QO1]9YZ5KD.()I1R4> 7P'G=FO/WL#]_<VTFV"A3;!%I; &N[I
MU^[IF]!G-RGCDOR'BU1(#KY:/:.M@/66(DK6\%$E-!%QDFLQT>8JXRR7NLHF
M6/C*^O.<LQW$*(681)@BO:%M*18(<T"X9$<]7G.6(IG 3S&6@#[?+V\0+E25
M"A&(K51(9TI.87$M1[AB,R8[$F\QI<^(Q)!)LB98DPM"$K5Q*/$&Q_N$1 GB
MR@50S0<9DDS!$2Y!M9\!<]%M"R%+C#5"**A#*'A[",&3.A<(4!LS50/91MM_
M%%:X2 %M 62<X]( L@D6EF!! :8/,[N9[_>&X\'$V1V[X'NQWB (1K54@]M!
MS>W R.V#9-&C"C"Q5<%R13+TD*BX%&W;W&V)-#@VP"W^FH;.6^0\M]\_64]H
M-.S2%&<)K,'AL.9P:.1PSM)41:8HJ%3OZQ;:V!M^YSYO$+2PUR(W=(?]P#^A
MSVC3I?19 FO0-ZKI&YGIHTSH%SGG) +$UB@ZYE/'9,@H58D)Y2KU"1V?K>%9
MSC(Z(L[M!L$)NZ60YQY)!=T3H=!H[Z746@)K4#NNJ1T;J;T[28R-[4 "3]MX
M-$)>FBAM@H7FQ8[+[0N-4%H>M]7!.\;/;9O!PI)9#:=X[J'.<(V6+H%':K=6
MQ:<.]TSY16WT:R+;O&&&NM0=5M'""FW<>.6\D[=I86O.)ME'19UG)/L3T%RH
M=/+M'M(5\-8ZP QQ,<DVT4*K: M;:$UG^ =G^.]6K%70MIQD$RVTBK:PA=9T
MTJ&@]HP%X67IR6H);14MK-!>2T_O41U[A_+8,]>'\X1D&"W5J2;%YAQEM0*V
MBA9:15O80FMZY%!M>L'[Y2BK5:95M- JVL(66M-)A[+5,]>M/W2R-6->[!V;
M:.$KZ_7ZU>EV7)]N1V=/M[8L*WWC''U13X%OBJL,H:JT;2;+;];U:'U=<E-<
M$IR,A_H:I?A2?X I[V#N,=^03" *:P7I=H<JN'AYK5%V),N+[_8K)B5+BV8"
M. :N!=3S-6/RI:,GJ"^79O\#4$L#!!0    ( +N @5@]!%T^3P,  '@.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,57;6_:,!#^*U8V39VT-N\)
M=!")4FU#6B=4UNW#M \F'& UL3/;0+M?/SNA*8$042E3OX =WSU^[LG9N>MM
M&+\72P")'M*$BKZQE#*[-$T1+R'%XH)E0-7*G/$42S7E"U-D'/ L=TH3T[&L
MP$PQH4;4RY^->=1C*YD0"F..Q"I-,7^\@H1M^H9M/#VX)8NEU _,J)?A!4Q
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MX5*UAL"U@5J?,R:?)KKY*)O-Z!]02P,$%     @ NX"!6)$ZP/V] @  H D
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULK99;;],P&(;_BA40VB18
M$N?8D4;J6A"[0)I6!A>("S?]<M"<N-AN._CUV$D6NBY+2\5-:\=^7S_OEX,=
M;1F_%SF 1 \EK<38R*5<79JF2'(HB;A@*ZC42,IX2:3J\LP4*PYD68M*:F++
M\LV2%)411_6U&QY';"UI4<$-1V)=EH3_N@+*MF/#-AXOW!99+O4%,XY6)(,Y
MR+O5#5<]LW-9%B54HF 5XI".C8E].1WI^?6$KP5LQ4X;Z20+QNYUYWHY-BP-
M!!02J1V(^MO %"C51@KC9^MI=$MJX6[[T?UCG5UE61 !4T:_%4N9CXW00$M(
MR9K*6[;]!&T>3_LEC(KZ%VW;N9:!DK60K&S%BJ LJN:?/+1UV!'8[@L"W KP
ML0*G%3AUT(:LCC4CDL019UO$]6SEIAMU;6JU2E-4^B[.)5>CA=+)^+J2I,J*
M!04T$0*D0&<SD*2@XAR]0W/UT"S7:HRE:))E'#(BU<2J6A.*)B7CLOA-ZMOQ
MX4$]5P*4YFX^0V>OSR-3*CR]B)FT*%<-"GX!90;)!7+LMPA;V.F13X^7XZ=R
M4Q6EJPSN*H-K/^<%OW_/_GVR$)*K!_-'7_AF-;=_-?VR7HH526!LJ+=1 -^
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MT,%,GYQ$:,\)JGE0S8=J 50+H5J$TO1P=PTL]A6^CL6@K2VHYD(U#ZKY4"V
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M1+4ZJC50S4*U)JJU4*V-:AU4ZZ):#]5L5.NCFH-J+JIYJ.:CV@#5AJ@V0K4
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M8GTO5OABC2]6^6*=+U;Z8JTO5OMBO2]6_&+-+U;]8MTO5OYB[2]6_V+]+S8
MB$T 8B. V P@-@2(30&&30&&30&&30&&30'FG +>/ATBG;1?;YBX;+:D7ILM
M*=]FR^?58K%:6KWMZNY/Z]\-9_'%6?_'L\'BRXG<8"%I>9160&E%E%9":664
M5D%I59160VEUE-9 :4V4UD)I;93606E=E-9#:7V4-D!I0Y0V0FECE#9!:5.4
MI@#-1V^PH#A6]V)]+U;X8HTO5OEBG2]6^F*M+U;[8KTO5OQBS2]6_6+=+U;^
M8NTO5O]B_2\V (A- &(C@-@,(#8$B$T!ADT!ADT!ADT!ADT!!DL!EXV8]&LC
M)GW@)ZXV8I;?G/5VOO\ DL,'DK1G/PZ?1O+O_9969>LL-MZ-F33:F"%I>916
M0&E%E%9":6645D%I59160VEUE-9 :4V4UD)I;93606E=E-9#:7V4-D!I0Y0V
M0FECE#9!:5.4)K$XUO9B=2_6]V*%+];X8I4OUOEBI2_6^F*U+];[8L4OUOQB
MU2_6_6+E+];^8O4OUO]B X#8!" V HC- &)#@-@48-@48-@48-@48-@48+ 4
M<-F8R;PV9C*^5\@<+XTYW8YT_[R>+[_N/X]DOKJ/_!FQF7>7\"0RL:R=O;S;
M[+/_@"+W8#RJ'A[,<%FUX+5=(I?.)-W/>2!'5_*H:L?M9-)5M8Q6K7A5M9/Q
MC.U^'$2X[6KHZ.H>5>/91#SEFK$&6K7I5=7.I1*NF6BA5=N>\Q^SXZX'P'30
MJEW/><VF4ZYY[:%5^UY'.)'+Y5S[.D"K#KVJQE+)I&O5&:%5QUY5][].KB,\
M0:M./7^'8VGW"JN -3_Z6;G7WB:2[N=9BUW:Y;6VQY/[9Y&XZA;8ND6/NMET
MSOUT)Y78LF6/LNE4*N%Z_ZC"EO6R0"*7B.=<95D+R$L#B70\Z][;AM<O02[S
M;KLF.[R61]E,,I-U'Y4V6[;CM70GX[;K$>[JLF5[7@<YDWWW&]]GRPX\197)
MN591#=FR(Z^RL=U_WST& BT[\5R^L^X$JBE:UK R,(;%L<HP>1:'B>7RY"S[
M>G*6]3TY:\R7\\7SPO_.!5]$Y#^0D[0\2BN@M")**Z&T,DJKH+0J2JNAM#I*
M:Z"T)DIKH;0V2NN@M"Y*ZZ&T/DH;H+0A2ANAM#%*FZ"T*4I3@.&CGXJC.%;W
M8GTO5OABC2]6^6*=+U;Z8JTO5OMBO2]6_&+-+U;]8MTO5OYB[2]6_V+]+S8
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M^<6J7ZS[Q<I?K/W%ZE^L_\4& +$)0&P$$)L!Q(8 L2G L"G L"G L"G L"G
M8"G@LBN3>NW*I Y\_@ZE%-J8(6EYE%9 :4645D)I991606E5E%9#:764UD!I
M39360FEME-9!:5V4UD-I?90V0&E#E#9":6.4-D%I4Y0FL3C6]F)U+];W8H4O
MUOABE2_6^6*E+];Z8K4OUOMBQ2_6_&+5+];]8N4OUOYB]2_6_V(#@-@$(#8"
MB,T 8D. V!1@V!1@V!1@V!1@V!1@L!1PV9A)OS9FTKZ7RQR:,7?'[HQS;\V7
MV]7NV\5BM;0VV]7=GYX]&5]DY)X,2<NCM )**Z*T$DHKH[0*2JNBM!I*JZ.T
M!DIKHK062FNCM Y*ZZ*T'DKKH[0!2ANBM!%*&Z.T"4J;HC0%&#]Z3P;%L;H7
MZWNQPA=K?+'*%^M\L=(7:WVQVA?K?;'B%VM^L>H7ZWZQ\A=K?['Z%^M_L0%
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M"C!L"C!L"C!L"C!L"C!8"KALS"1?&S-)W\MI#LV8NV-WQKFWYLOM:O?MX1'
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M:JEAMY3*">>\(@DL//G2<V!WX"U__A&/@U^[,+D4BQV)&0B'#<*A37WYKA3
M*I9Q0%E-4Y![Q(B +H96K;X,:[&9%E,Y]6X9#,+1W+\[9>.H18/-J&$SLK+Y
MHP()(BNW**><HX0P]B"GAP-A*>^B8U7K2\>E6%R+C4Y0AQ@'ZJ_!;1 :-X3&
MWTP(D3N9 ,DZ!R2KT&8O]DP_7;JJ?MBZ*%I;[$MQ_-7 1T_&70-RU*@!<=)
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M(::^W. Y$X0VP.<KSM7K0)]DNI/K_#]02P,$%     @ NX"!6/GU5W+3 P
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M796H([M>#_!.ED8X0C//.%H[%@;'.N5PZL]<H9DTM?XLM!J;_7JUQ_4P'@Z
MS-IVSKGLINIGS1_\(K>OT[OC_\?)5MC:L3 ZUL9P:N)<H9DTM28NM!^W[=\8
M![BF[HWQZT!5;?[.F;G^8'%#^ ,M!,I@H9"#D[$R2KSZ!E -)%N5Q^AS)B7+
MR\LED!2XGJ">+YC:$O5 G\PW7V+B[U!+ P04    " "[@(%8&-("A?$*  !8
M@P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RUG5ESV\@5A?]*%Y-*
M/%6VB(V+'(E5MK U*JI1V7'R,)6'%M@D4<;" 4!)GE\? (0(-MEJ I-C/UA<
M<+_;),]M7O016C?/6?Z]V'!>DI<D3HO;T:8LMQ_'XR+<\(055]F6I]4SJRQ/
M6%G=S=?C8IMSMFR"DGAL:-ITG+ H'2UNFL<>\L5-MBOC*.4/.2EV2<+R'Y]Y
MG#W?CO31ZP-?HO6FK!\8+VZV;,V_\O+;]B&O[HT/E&64\+2(LI3D?'4[^J1_
M#"RK#FB.^'?$GXNCVZ1^*8]9]KV^0Y>W(ZT>$8]Y6-8(5OUXXG<\CFM2-8[?
M6^CHD+,./+[]2G>;%U^]F$=6\+LL_D^T+#>WH_F(+/F*[>+R2_;L\_8%36I>
MF,5%\S]YWA\[N1Z1<%>46=(&5R-(HG3_D[VT;\11@#Y[(\!H XS3 .N- +,-
M,$\#IF\$6&V U3=@T@9,^@YIV@9,^P;,VH!9WX!Y&S#O&W#=!ESW#="UUT].
M:Q2T_\@;O=BL9(N;/'LF>7U\Q:MO-*)KXBN91&E='U_+O'HVJN+*Q=<R"[]O
MLGC)\^+OQ/E]%Y4_R#N;ERR*BU_(!_+MJTW>_?67FW%99:MCQF%+=O9DXPVR
M;I#[+"TW!7'2)5^*@'$US,-8C=>Q?C:4Q%_#\HIHUGMB:(8A&=!=GW#SS7!;
M'?Z5;ZOPZR9<E[T=ZG";AU?$U)MP4Q+N]@C79V^&>_VSRUZ[WR/<F+T93ON'
MR]ZZH$_X_H/3%#HR#YHW&YXY1/.__;,ZBM"2)\5_)4/\O$=:<F3]+?:QV+*0
MWXZJKZF"YT]\M/C;7_2I]@^94)$P&PESD# 7"?.0,!\)HTA8 (()A6$="L-2
MT1=W69)4/4M1U\=[4FQ8E8*P7;G)\NB/TRE\7Q9*X-"R0,)L),S9PZ8-K&XY
MGQ83K?UW,WXZUCPRK=<[K8],2Y&P  03!#TY"'HR0-!;EI,G%N\X>1>EQ,[B
MF.4%V?)\+W59C_-9R1^J;R3,1L*</6QV)#3M2M/T$VTC4WJ]4OK(E!0)"T P
M0=?3@ZZG2ET_5">1/,_Y<M!<K60.U3(29B-ASO2M2?-$S<BD7L^D/C(I1<("
M$$S0\^R@Y]DP/?^9J5J98JB\D3 ;"7-FO:9J9$JO5TH?F9(B80$()DA[?I#V
M7"GM3ZNR4FW)7DB4AEG"W]<J#GE:LC67J5A)&ZIB),Q&PIP][%J0U*F&D0D]
M),Q'PB@2%H!@@M2O#U*_5DK]RYY(6!AFN[0DCRQF:<B+2Y)74H=*'@FSD3#G
M6B+YR8GDD0D]),Q'PB@2%H!@@N1UK5L_UY2B]WC*<Q83EM;-"RMW99;_("';
M1F7U:)NQZLR3IB2.NAEI#Z-.-K06H#0;2G-:VN2H'.:Z-3EOTZ%IO;YI?6A:
M"J4%*)HH^2/+2.^]JO*J\&5["BH5M1(W6-1(F@VE.5":"Z5Y4)K?THY/>'7)
M^2[M>5R &ITH::.3M*&4]+^R>K;.MHUGG^W*:B9/EU&ZELI9B1HL9R3-AM*<
MEB9\>*9Y/D,CDWI0F@^E42@M0-%$S7<NJ*[TDA:?ELNHUGLE_-?EPR<6Q>PQ
MYF25Y20JBEW=OTMK &J'0FDVE.:TM.,:L.:&I$V!FIU0F@^E42@M0-'$(N@<
M3_VBY;GE:<&:B9^_U+?YY2X=ZGJVM..6U#H7F U-ZD!I+I3F06D^E$:AM !%
M$\7?N:/Z!7LTSHJJR2$)R[_SDFSS*!RRX-[2Z[.1@W)GITL:=^U1Q_*>G4I;
M C+-4Y*C?C6#-0MU,Z$T'TJC4%J HHF:[9Q/76U]GG<MV8J$1V>D4J5"K4_]
MW.S3YY()&^IJ0FDNE.9!:3Z41J&T $43Q=_9I/H%GW27AQM6=2A]-#\[5^EY
M6W&GSCBX]Y8D/3MA=* Y72C-@])\*(U":0&*)FJY\T5UM3'JO/ \C"HM[]N.
M2M&';F-(#S(_ZRZ,^:G$H39H2Q.['O-J=JIQ9%(72O.@-!]*HU!:@**)&N\,
M45WMB/[:+"@69)VSM.3+RR>6UV=J-J?&[&S.AIJ<DJ3ZQ+#,4T$CD[I0F@>E
M^5 :A=("%$V\ *=S.PVUV_EP,/+K"?LIBUD9Q5'Y0R;F%J4;Q\*ZTB>G)XCJ
ME$/5_$;6N74B9VA6%TKSH#0?2J-06H"BB7+NG$Q#[62*<LZCXCM9Y9R3J)JM
MJWPER5DI7?]NN8+*M"O-/)79G7H @\4M3ZO-3I=*H&E=*,V#TGPHC4)I 8HF
MJKLS-0VUJ>F\;'E8MQUQM.+O227I1*IE-<4@/WC=AT])TES.*5L142,&JUP]
M(+T9D&H\#G0\+I3F06D^E$:AM !%$^7?^9N&VM^D1;&KQ,]2PM;KG*_?FLJA
M5B:49AOGYJ,Y,<[64Z!)72C-@])\*(U":0&*)LJ]<S(-M9/Y\/\LHZC9@XL
M2;-;VB5W")K4A=(\*,V'TBB4%J!H8A%TCJ:A=C2_I5L6+4G(BLW%Q18U:K#F
MH1=W&N>FJ:[/KB53/]03A=(\*,V'TBB4%D@^KOG4LN;=IR7JN7,[#;7;Z:Q6
MO-E!B-RS/-R0:;,)AD5^N^?)(\^E.U6HD8-U#;W0$TISH#072O.@-!]*HU!:
M@**))=)YHL;>IX+NYF) +Q:%TFPHS8'27"C-@])\*(U":0&*)M9(Y[4::J_U
M"W^JJH.WEVP4VS@JWY,E+\(\:APJ:8E KT2%TFPHS;GPYND?ZM^&_C"1U@/4
MEX72?"B-0FD!BB;60^?+&FI?5MY6F>JV"GJ9*I1F0VD.E.9":1Z4YD-I%$H+
M4#1QB[S.Z34U?%ME0B]?A=)L*,V!TEPHS8/2?"B-0FD!BB;62&<?FVK[^,^T
M56KDX!*!VLM0FG/AS6O:J@^Z)JT'J.$,I?E0&H72 A1-K(?.<#8O6,6:KA&:
MUK]24?=6#S%+E2V5&C>X%J F-)3F0&DNE.9!:3Z41J&T $43R^-HV^&?L>\P
M=N-A[,[#V*V'L7L/8S<?QNX^C-U^&+O_\,]PL<W.Q3;5+K:PMTC4_ :'M"J@
M?C649D-I3DL3=I:<2W:SA&;UH#0?2J-06H"BB7KO#&M3;5@WWPGMYE'UK78+
MDM<+!NHG+FQ'HDXPN!2@-C:4YK2TXU*86[/S2H":V%":#Z51*"U T<1*Z*QN
M4VUUWT=IE.P2]0D#U-J&TFPHS8'27"C-@])\*(U":0&*)I9$9VV;/\':-J'6
M-I1F0VD.E.9":1Z4YD-I%$H+4#2Q1CIKVU2[LT,W(U3C!I<'U-:&TAPHS6UI
MQ\V7(3D/\:!9?4E679*52HZ3'!:@!B=JM;.=3;7M?,]>+K<X4)L92K.A- =*
M<Z$T#TKSH30*I04HFO@'ISJ;V?H)-K,%M9FA-!M*<Z T%TKSH#0?2J-06H"B
MB372V<P6=K]E-6YP>4 M9BC-@=)<ZWRO8ME2JP?-ZDNRRAHK*CE.U@H%J-&)
M8NT\8$OM ;=BW:]KJAH=-6>P2J'F+Y3F0&DNE.9!:3Z41J&T $43ZZ(S?ZV?
M8/Y:4/,72K.A- =*<Z$T#TKSH30*I04HFE@C1W]^5FW^TG;'\3[;&ZI1@TOC
MW&6=GN_H"<WI0&DNE.9!:3Z41J&T0/+)6T)7M=?RN-AP7MJL9(N;A.=K?L?C
MN"#-'[JZ'=6M_.'1JD5?U5O#??QDC,959'?XXF;+UOR>Y>LH+4C,5U6H=C6;
MC$@>K3>'.V6VK9'D,2O++&EN;CBKOCCJ ZKG5UE6OMZI$SQG^?=F>(O_ 5!+
M P04    " "[@(%8]\_)5(D$   K'P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-2YX;6R]6=MNXS80_15"!18M4$0BY6O6-I XO2S08(.DVSXL^J!(XUB(
M)*HD;6^!?OR2LBR:JL3463HOL43/' T/SRC'Y&Q'V3-? PCT)<\*/O?60I27
MOL_C->01OZ E%/*;%65Y).0M>_)YR2!*JJ0\\TD0C/P\2@MO,:O&[MAB1C<B
M2PNX8XAO\CQB_UQ#1G=S#WN'@?OT:2W4@+^8E=$3/(#X5-XQ>><W*$F:0\%3
M6B &J[EWA2^79*H2JH@_4MCQHVNDIO)(Z;.Z^9#,O4!5!!G$0D%$\F,+2\@R
MA23K^+L&]9IGJL3CZP/ZS]7DY60>(PY+FOV9)F(]]R8>2F 5;3)Q3W>_0CVA
MH<*+:<:KOVA7QP8>BC=<T+Q.EA7D:;'_C+[41!PEX%%/ JD32#MAT),0U@EA
M-=%]9=6T;B(1+6:,[A!3T1)-753<5-ER-FFAEO%!,/EM*O/$XC[ESQR]B_+R
M/?I4Q,"$7'J1 D??WX"\SO@/,U_(!ZEP/ZY!K_>@I <4$W1+"['FZ*<B@<0$
M\&6%39GD4.8UL2+>0'R!0OPC(@$).PI:_O]T8BDG;%@+*[Q!#]Y#E$F&KJ&(
MUU+\S^CS+>2/P/Y"_Z)EM6; T))*.@O!HDJNBN?.L,-8%\O6(E2#7_(RBF'N
MR0[FP+;@+=Y]AT?!^RZ&'($9? T:O@85>OAZE:'/O\DD]$% SCO)&+@DPQ&8
M0<:P(6-H%8\I#*:$40)30_*]V37S/=RT@E.OY>TBN, S?WL\(7N,4>>HJ7-D
MK?,JCNFF$!S=0PSI-GK,X%N$_K$ J]BMQ9RZOH[ #-[&#6_CLXM][)(,1V &
M&9.&C(E;L>_A,#&4/"+#:4OPG7%#,NW6_+0I=_J6FO]]1ZV:MQ9SZC([ C-X
MPX'V$<'955\_PA$?KM!,0HZ,%7:K_!JO)6D<#EO*[XG#@V[I8Z(K)F\J_C4#
M^RO?7L_)Z^T(S61/6T(<GK\!G#H^5V@F(=KS8:N+>D4#.+5X-5J[38*^-M'V
M#=O]VSULH=C -]G_.T:332Q>-$7V4DZFQ!&:29SVDWAT_@YQ:A-=H9F$:*.(
MK=;K%1TR[M(TF9+VOXAQQ\\!,NQ1OO9RV&[F7"K_)6MD+^7DA7:$9A*G726>
MGE_Y3LVB*S1S-T>[16(U7Z<KO\9K*W\<MI3?$T<FW=HGVLX1NYUSJOT7G9&]
MF%,7VQ6:29WVE82<7?W$J55TA682HJTBL6\?GJ[^L-/+D/9/@YZXL.=7,=%>
MCMB]W,.F++,4&#<<BU(^Y0+1%?J%TH2CJ$C0@Z0KC7L:Y8!C:Y1. IQ:0U=H
M)IG:0)+A^?O!J3%TA682HHTAL>\TGMX/HVZ=3]K]T!E'\+BG'[1S(W;GIOOA
MV,>\83\XW2!TA6:2J6TEF9R_'YS:15=H)B':+A+[+N3I_>#4&]9H_]E@:I\G
M^$?'CM+\/%6GL1Q5FTC[H[UFM#GQO:K..5OCU_ARN3^WU3#[8^3;B#VE!4<9
MK"1D<#&6+RJV/YG=WPA:5H>;CU1(!U9=KB%*@*D ^?V*4G&X40]HSL<77P%0
M2P,$%     @ NX"!6)GE'P%-!@  @4$  !D   !X;"]W;W)K<VAE971S+W-H
M965T-38N>&ULM9SMCYLV ,;_%2N;IE;:+N 00KI<I/9X\[1.IYZZ?:CV@22^
M!#5 "LZEE?;'S[P<A!QQ07MV'W) _/QLDD>V\0-9G)+T<[;C7)"OT3[.;D<[
M(0YOQN-LO>-1D-TD!Q[+=QZ3- J$W$VWX^R0\F!3B*+]F&J:.8Z",!XM%\6Q
M^W2Y2(YB'\;\/B79,8J"]-L[OD].MR-]]'S@0[C=B?S >+DX!%O^P,7'PWTJ
M]\8U91-&/,[")"8I?[P=O=7?,&KD@J+$GR$_96?;)#^559)\SG?8YG:DY2WB
M>[X6.2*0_Y[X'=_O<Y)LQY<*.JKKS(7GV\]TMSAY>3*K(.-WR?ZO<"-VMR-K
M1#;\,3CNQ8?DY//JA*8Y;YWLL^*5G,JR,VU$UL=,)%$EEBV(PKC\'WRM/H@S
M@6Y<$=!*0/L*)I5@TE=@5 +C4F!>$4PKP;1O#68E,/L*9I5@UE=@50*KKV!>
M">:%'<KOK_CR[4 $RT6:G$B:EY:T?*-P4*&6WWD8YV9_$*E\-Y0ZL7PXKC+^
MY<AC09PG^9J15S870;C/7I-?R,<'F[SZ\?5B+&15N6"\KK!.B:57L#HE[Y-8
M[#+BQ!N^:0/&LHUU0^ES0]]1)='EJQNBFS\3JE&CHT%W/>2:?E5NJ^6_!;&L
M_;K<4<MMOKXADU(^Z9"[/1I/K]?N]3GWZ56YW^?<KW_RK/^Y4X41)K5C)P5O
MTMNQGWZ710@3/,K^[FC?NY)G=//RT>1-=@C6_'8DAXN,IT]\M/SI!]W4?NVR
M&1)F(V$.$N8B81X2YB-A# 1K&=FHC6RHZ,NWVVW*MX'@1*1!G#WRE!S2<,V[
M+*PD#;4P$F8C84X)FQ6P?)KVM-1O)N9T,7XZ]R:R2@\)\Y$P!H*UO#FMO3E5
M>I-EV3&(UYPDCR3;!;*"?&N=1)&<H,I)R?ISETN5S*$N1<)L),PI8>:92TUJ
MSBY,BJS10\)\)(R!8"V3FK5)3:5)[\[L2 ZR^RR<6ES[;+KLJ:0-M2<29B-A
MCOFB$]5NC.EE)XJLTD/"?"2,@6 M?\YJ?\Z4_OS -SPZ%-?TTIUK.5<-MIVC
MNQ(SU)A(F(V$.25LWC*F?F%+9(4>$N8C80P$:]G2JFUI*6WY4/22H1SAN[M)
MI7JH&Y$P&PESK!>CN*Z9=#JSK M+(FOUD# ?"6,=GX<QMW1+JS^.EMOFM=OF
M?0;IAV*0_O2>1RN>=EZE*S%#;8>$V4B8@X2Y2)B'A/E(& /!6O[5M6:%5 ,O
M.%5 D)>A-!M*<Z T%TKSH#0?2F,H6MO29XO^^O]P>:^&#K8UDF9#:4Y%.Q\,
M)UKQ=S$W@%;K06D^E,90M+9C:>-8JIZT7G3"RJF$FC78J$B:#:4Y4)H+I7E0
MF@^E,12M[>8FPM+1&98.#;&@-!M*<Z T%TKSH#0?2F,H6MO239BEJ].LL\6N
M($J.L>AT<<F8GE]D3E\.JW<]R]D]RSGJM@_V%#2 @M)\*(VA:&U/-2&4KDZA
MSCPEIZ>GXL8EOB'!$T^#+?_.HFK%;B\W6O32:7U*V;U*.>JS&>PR:(($I?E0
M&D/1VBYK4B1='2-=G5J2?TCOU2MU'8/'9VBZ!*4Y4)H+I7E0F@^E,12M[?(F
MB])GZ"DG-):"TFPHS8'27"C-@])\*(VA:&U+-SF6_M^"++5\L(&A41:4YD!I
M+I3FZ2^#)4.CIG5Q0X+?46YB:91>Q'$,U;JVZ9HX2_]>GA7+Z:<(5WM._D@$
MS\A]\"W(]\ZF#<-6JZ#)%Y1F0VD.E.9":1Z4YD-I#$5KWWC?!& 4'8!1:  &
MI=E0F@.EN5":!Z7Y4!I#T=J6;@(PJ@[ REZ\>&+KZCW7%4(W6E?]$W-V,7+=
M72DXHQ<%[2L%Y\9%04?=^L&N@H944)H/I3$4K>VJ)J2BZI"*25-E(DE[306&
MK"ZHZQW<GT(#+2C-@=)<*,V#TGPHC:%H;><W@19%!UH4&FA!:3:4YD!I+I3F
M06D^E,90M+:EFT"+J@.M[ZTNJ.6##8RDV5": Z6Y%:V]'F#IIM&> WG06GTH
MC:%HI37'9X]O1SS=%L_^9V2=IZCED]SUT?KW!=X63]6/F^+ECQ.\#])M&&=D
MSQ^E5+N934<D+9_W+W=$<B@>!E\E0B11L;GCP8:G>0'Y_F.2B.>=O(+Z5Q>6
M_P)02P,$%     @ NX"!6$'(#N%L P  \A8   T   !X;"]S='EL97,N>&UL
MW5CM;MHP%'V5*%VG5IH:0M9 5D#:D"I-VJ9*[8_]JPQQP)+C9([IH.^S%]F3
MS=<.X:.^C/;'"@.5V/?XGGOL>YTX[55JP>GME%+ES7,NJKX_5:K\$ 35>$IS
M4ET4)14:R0J9$Z6[<A)4I:0DK< IYT&[U8J#G##A#WIBEE_GJO+&Q4RHOI\T
M)L]>/J=]/XS?^YZE&Q8I[?OW9V]_S IU]<:SUY-W)R>M^_.K;?N9 <[]P$EZ
MN0?I1:N%$P.(D<?[D>_BQJ@[F]1F^*DFLHZGF%MW+T4[!&'$B9OX]R\D.PVP
M,SV=EF.:>E56,X4.YASNF=O=R46UM?>E_PN_#1#4FV#0RPJQV@N1;PU: <FI
M]T!XWQ\2SD:2@5=&<L87UMP&P[C@A?24WH1:4@B6ZM'"H>W!_JQY<B8*:6+;
M"/9W5 _? I8]$,@X;P2V?6L8]$JB%)7B6G?,8&-\ GEU^VY1:H43219A^])?
M.9B+#C(J9$IE$R;TEZ9!C],,Y$@VF<)5%64 H%)%KALI(Y-"$*-AZ5$W-.V8
M<GX+-Z_OV0;W/%O+K:DZT32UH+II:6P'^-?9+/<Z;?PB7J]D#X7Z--/3$:8/
M]4)O),W8W/3G62, 8P]Q=E*6?/&1LXG(J9W\W@$'/;+T\Z:%9(\Z&I3*6!NH
M]+T'*A4;KUM^2E+>T;E:EM,\PS6WCU#SOUWG"154$KXN6M?^(:_RBQ773_O7
MT&QN*]N*G2*CSN%KK$\XARXR/@:11Y'N[C&(3(Y 9.?5[IK/N ,=Q4*&QR"R
M?9 B@_I,N79PW3BV-E8/7@_Z_C=X(>&KH-YHQKABHNY-69I2\>3TJND5&>D7
M^@U^/3ZE&9EQ==> ?7_5_DI3-LN39M0-+$0]:M7^ M/31^'ENXF.Q41*YS0=
MUETY&9FFIQLZ:OT!AVWDVGS<".9C,3<"&!8'4X#Y6"\LSO\TGRXZ'XMAVKI.
MI(OZ=%$?Z^5"AN:+Q7'[)/KCGFF21%$<8RLZ'#H5#+%UBV/X<[-AVL #BP.1
MGK?6>+;Q"ME=!UA.=U4(-E.\$K&9XFL-B'O=P"-)W-G&XH 'E@6L=B"^.P[4
ME-LGBB"KF#9L!^-(DF (U**[1N,869T8ON[\8+LDBI+$C0#F5A!%& *[$4<P
M!: !0Z+(/ >WGD?!\CD5K/[+/?@#4$L#!!0    ( +N @5B7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ NX"!6&5K
MH5R2!   ]20   \   !X;"]W;W)K8F]O:RYX;6S%FEMOVS84@/\*H8<M!;K9
MNJ5M5A?(DK8SD#5&G.6UH"7:)B*1+DDY=7[]#J6YI1SE8"\G?K)%W3X=4><[
MI/3^09O[A=;W['M=*3N)ULYMSD8C6ZQ%S>WO>B,4K%EJ4W,'BV8ULALC>&G7
M0KBZ&B7C\>FHYE)%'][OCS4SHW!!.U$XJ14T^H8[*1[LS_5^D6VEE0M92;>;
M1.W_2D2LEDK6\E&4DV@<,;O6#W]I(Q^U<KR:%T97U22*NQ5WPCA9/&F>>\A;
MOK!MB^.+&PX@D^AT# =<2F-=NT5[? Z,6P$;=TN-TY]DY82YY$Y\-KK92+7R
MAX&K& 67T<9A_]L%\<S\GS#JY5(6XE(732V4Z^)H1.4!E5W+C8V8XK681!=Z
M*XR_'CC!M.RNS0%4$"ES)F&%F98M'AW*>5-*QZ:JVQG6!E@)@I708EW LJYD
M"6<OV9^\XJH0K+VS-@!,$<#T:(#L9,8#R R!S%X0<NXA_ Z6Z26[WO1Z8(Y
MYD>$_)H$D*<(Y.G1(.=.%P'D&P3RS=$@+[A=!Y!O$<BWM)#79L65?&Q7,*X
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M6?>YQ.034$L! A0#%     @ NX"!6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "[@(%8L@7 *.\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ NX"!6"^*O/#J!P
MUR$  !@              ("!<Q(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( +N @5AXV&<-:0,  %<,   8              " @9,:
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "[@(%8 %A[
MV5,%   '%0  &               @($R'@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ NX"!6)$GL%EG @  N@4  !@
M ("!NR,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +N
M@5@%1"=%W@8  'XL   8              " @5@F  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " "[@(%82JJHG=8'  "2(0  &
M        @(%L+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( +N @5C/OPT;K0(  -(%   9              "
M@?-8  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ NX"!
M6!B[.,2H!0  30X  !D              ("!UUL  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " "[@(%8O5>+()$'  "*%0  &0
M        @(&V80  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( +N @5@Y])ISR0L  %Y    9              " @7YI  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ NX"!6#3Q0;?=!   /0L
M !D              ("!?G4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " "[@(%8*3&_US *  "M&   &0              @(&2>@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +N @5A[V9?A
M# 4  #@,   9              " @?F$  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ NX"!6'DRP,;="@  -AT  !D
M ("!/(H  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "[
M@(%8!:"H0OT#   H"0  &0              @(%0E0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +N @5@_\QGLT08  !82   9
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M970R-BYX;6Q02P$"% ,4    " "[@(%8D9T7G8D#   B"   &0
M    @(%6NP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M +N @5A$R%Q^6@,  (@'   9              " @1:_  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ NX"!6-"\QH*? @  R04  !D
M             ("!I\(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " "[@(%8?SKM G0"  "0!0  &0              @(%]Q0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +N @5AP @52S (
M !H&   9              " @2C(  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ NX"!6+-_MI"3!   4 H  !D              ("!
M*\L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "[@(%8
M5Q*HUO\"  "(!P  &0              @('USP  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( +N @5AZ^+D)U 0  .08   9
M      " @2O3  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ NX"!6&'!#/V' @  XP8  !D              ("!-M@  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "[@(%801)CO%4"  "O!0
M&0              @('TV@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( +N @5C_Q@K<[P,  *T3   9              " @8#=  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ NX"!6+42)BO"
M P  '!H  !D              ("!IN$  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " "[@(%8O"#LA^<$  !H&@  &0
M@(&?Y0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +N
M@5@]!%T^3P,  '@.   9              " @;WJ  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ NX"!6)$ZP/V] @  H D  !D
M         ("!0^X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " "[@(%87!*TM: "   O!P  &0              @($W\0  >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( +N @5A$U[:$J0<  (!2
M   9              " @0[T  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ NX"!6(HVJOYG%   BX(! !D              ("![OL
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "[@(%8):;"
M["\"  #,!   &0              @(&,$ $ >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( +N @5@^K?SG5!\   (_ @ 9
M  " @?(2 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MNX"!6*D8;+/T @  8@D  !D              ("!?3(! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " "[@(%8;9>>[O("  #W"0  &0
M            @(&H-0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( +N @5@CO0/AO00  #$<   9              " @=$X 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ NX"!6-/,=5DG P
M6 D  !D              ("!Q3T! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " "[@(%8Y/'0HF\"   4!@  &0              @($C
M00$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +N @5@E
MM %E&00  ,4.   9              " @<E# 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ NX"!6/GU5W+3 P  E1D  !D
M     ("!&4@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M  #R%@  #0              @ &/8@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( +N @5B7BKL<P    !,"   +              "  29F 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( +N @5AE:Z%<D@0  /4D   /              "
M 0]G 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "[@(%8##^0_.4!  !_
M(0  &@              @ '.:P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "[@(%8C^&W:=,!   V(0  $P              @ 'K
L;0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0 !  '<1  #O;P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>303</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OtherPayables</Role>
      <ShortName>Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Lines of Credit and Construction Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility</Role>
      <ShortName>Lines of Credit and Construction Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Convertible Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConvertibleNotePayable</Role>
      <ShortName>Convertible Note Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Risks &amp; Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RisksUncertainties</Role>
      <ShortName>Risks &amp; Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OtherPayablesTables</Role>
      <ShortName>Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OtherPayables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Organization and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Inventory (Details) - Schedule of Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/InventoryTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable</Role>
      <ShortName>Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable</Role>
      <ShortName>Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Other Payables (Details) - Schedule of Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable</Role>
      <ShortName>Other Payables (Details) - Schedule of Other Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/OtherPayablesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/RelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Lines of Credit and Construction Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable</Role>
      <ShortName>Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Convertible Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails</Role>
      <ShortName>Convertible Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/ConvertibleNotePayable</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Leases (Details) - Schedule of Operating Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of Operating Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/LeasesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/StockholdersEquity</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Risks &amp; Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails</Role>
      <ShortName>Risks &amp; Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/RisksUncertainties</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0202772-10k_china.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy in us-gaap/2023 used in 1 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202772-10k_china.htm 8207</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202772-10k_china.htm 9760, 9776</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202772-10k_china.htm 9760, 9776</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202772-10k_china.htm 9760, 9776</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted -  ea0202772-10k_china.htm 9990, 9991</Log>
  </Logs>
  <InputFiles>
    <File>cphi-20231231.xsd</File>
    <File>cphi-20231231_cal.xml</File>
    <File>cphi-20231231_def.xml</File>
    <File>cphi-20231231_lab.xml</File>
    <File>cphi-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0202772-10k_china.htm">ea0202772-10k_china.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="704">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0202772-10k_china.htm": {
   "nsprefix": "cphi",
   "nsuri": "http://www.chinapharmaholdings.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cphi-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cphi-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cphi-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cphi-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cphi-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0202772-10k_china.htm"
     ]
    }
   },
   "keyStandard": 286,
   "keyCustom": 35,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 28,
   "hidden": {
    "total": 64,
    "http://fasb.org/us-gaap/2023": 60,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://www.chinapharmaholdings.com/20231231": 1
   },
   "contextCount": 303,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 711,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 704,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "995304 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.chinapharmaholdings.com/role/Inventory",
     "longName": "995308 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment",
     "longName": "995309 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssets",
     "longName": "995310 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.chinapharmaholdings.com/role/OtherPayables",
     "longName": "995311 - Disclosure - Other Payables",
     "shortName": "Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions",
     "longName": "995312 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility",
     "longName": "995313 - Disclosure - Lines of Credit and Construction Loan Facility",
     "shortName": "Lines of Credit and Construction Loan Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable",
     "longName": "995314 - Disclosure - Convertible Note Payable",
     "shortName": "Convertible Note Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.chinapharmaholdings.com/role/Leases",
     "longName": "995315 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxes",
     "longName": "995316 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.chinapharmaholdings.com/role/FairValueMeasurements",
     "longName": "995317 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.chinapharmaholdings.com/role/StockholdersEquity",
     "longName": "995318 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.chinapharmaholdings.com/role/RisksUncertainties",
     "longName": "995319 - Disclosure - Risks & Uncertainties",
     "shortName": "Risks & Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.chinapharmaholdings.com/role/SubsequentEvents",
     "longName": "995320 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c29",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c29",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.chinapharmaholdings.com/role/InventoryTables",
     "longName": "996001 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables",
     "longName": "996002 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables",
     "longName": "996003 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.chinapharmaholdings.com/role/OtherPayablesTables",
     "longName": "996004 - Disclosure - Other Payables (Tables)",
     "shortName": "Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables",
     "longName": "996005 - Disclosure - Lines of Credit and Construction Loan Facility (Tables)",
     "shortName": "Lines of Credit and Construction Loan Facility (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.chinapharmaholdings.com/role/LeasesTables",
     "longName": "996006 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxesTables",
     "longName": "996007 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables",
     "longName": "996008 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
     "longName": "996009 - Disclosure - Organization and Significant Accounting Policies (Details)",
     "shortName": "Organization and Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OtherCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable",
     "longName": "996010 - Disclosure - Inventory (Details) - Schedule of Inventory",
     "shortName": "Inventory (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails",
     "longName": "996011 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable",
     "longName": "996012 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
     "longName": "996013 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets",
     "shortName": "Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails",
     "longName": "996014 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996015 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets",
     "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable",
     "longName": "996016 - Disclosure - Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense",
     "shortName": "Intangible Assets (Details) - Schedule of Aggregate Annual Amortization Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable",
     "longName": "996017 - Disclosure - Other Payables (Details) - Schedule of Other Payables",
     "shortName": "Other Payables (Details) - Schedule of Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails",
     "longName": "996018 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c70",
      "name": "us-gaap:PaymentsForLoans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c70",
      "name": "us-gaap:PaymentsForLoans",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
     "longName": "996019 - Disclosure - Lines of Credit and Construction Loan Facility (Details)",
     "shortName": "Lines of Credit and Construction Loan Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InvestmentInterestRateFloor",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InvestmentInterestRateFloor",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable",
     "longName": "996020 - Disclosure - Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments",
     "shortName": "Lines of Credit and Construction Loan Facility (Details) - Schedule of Principal Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c115",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c115",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
     "longName": "996021 - Disclosure - Convertible Note Payable (Details)",
     "shortName": "Convertible Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c116",
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c116",
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.chinapharmaholdings.com/role/LeasesDetails",
     "longName": "996022 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable",
     "longName": "996023 - Disclosure - Leases (Details) - Schedule of Operating Lease Liabilities",
     "shortName": "Leases (Details) - Schedule of Operating Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
     "longName": "996024 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable",
     "longName": "996025 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals",
     "longName": "996026 - Disclosure - Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)",
     "shortName": "Income Taxes (Details) - Schedule of Income Taxes Calculated at the Federal Statutory Rates (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable",
     "longName": "996027 - Disclosure - Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability",
     "shortName": "Income Taxes (Details) - Schedule of Deferred Income Tax Assets and Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable",
     "longName": "996028 - Disclosure - Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value",
     "shortName": "Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails",
     "longName": "996029 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cphi:AftertaxNetIncomePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails",
     "longName": "996030 - Disclosure - Risks & Uncertainties (Details)",
     "shortName": "Risks & Uncertainties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c277",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c277",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails",
     "longName": "996031 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "cphi:AggregateAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "cphi:AggregateAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202772-10k_china.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER PAYABLES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Payables",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Accounts Payable, Other",
        "documentation": "Amount of obligations incurred and payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "cphi_AccountsReceivableCollectedWithBankersAcceptances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AccountsReceivableCollectedWithBankersAcceptances",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable collected with banker\u2019s acceptances",
        "documentation": "Accounts receivable collected with banker's acceptances.",
        "label": "Accounts Receivable Collected With Bankers Acceptances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts of $13,786,074 and $16,739,527, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation payable to officer",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r720"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r178",
      "r587"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r108",
      "r184",
      "r582",
      "r609",
      "r613"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other\tComprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r35",
      "r444",
      "r447",
      "r509",
      "r604",
      "r605",
      "r883",
      "r884",
      "r885",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r741",
      "r962"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r626",
      "r890",
      "r891",
      "r892",
      "r940",
      "r964"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "cphi_AdditionalSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AdditionalSharesAvailableForIssuance",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares available for issuance",
        "documentation": "Number of additional shares available for issuance.",
        "label": "Additional Shares Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_AdvanceToSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AdvanceToSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to suppliers",
        "documentation": "Advances to suppliers.",
        "label": "Advance To Supplies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvancesToAffiliate",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings from related parties",
        "label": "Advances to Affiliate",
        "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "cphi_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to Suppliers and Advances from Customers",
        "documentation": "Disclosure of accounting policy for advances to suppliers and advances from customers.",
        "label": "Advances To Suppliers And Advances From Customers Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_AftertaxNetIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AftertaxNetIncomePercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After tax income, percentage",
        "documentation": "After tax net income percentage.",
        "label": "Aftertax Net Income Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_AggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate transfer price",
        "documentation": "Aggregate amount.",
        "label": "Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_AggregateAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "AggregateAmounts",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "verboseLabel": "Aggregate amount (in Yuan Renminbi)",
        "documentation": "Aggregate amount.",
        "label": "Aggregate Amounts"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r786",
      "r802",
      "r830"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r789",
      "r805",
      "r833"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r790",
      "r806",
      "r825",
      "r834",
      "r838",
      "r846"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts (in Dollars)",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r261",
      "r305"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense relating to intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r63"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r180",
      "r208",
      "r241",
      "r250",
      "r254",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r435",
      "r437",
      "r468",
      "r576",
      "r662",
      "r741",
      "r753",
      "r904",
      "r905",
      "r949"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r189",
      "r208",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r435",
      "r437",
      "r468",
      "r741",
      "r904",
      "r905",
      "r949"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "cphi_BankOfChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "BankOfChinaMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank of China [Member]",
        "label": "Bank Of China Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_BankOfCommunicationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "BankOfCommunicationsMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank of Communications [Member]",
        "label": "Bank Of Communications Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_BankersAcceptanceNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "BankersAcceptanceNotesMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Banker's Acceptance Notes [Member]",
        "label": "Bankers Acceptance Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_BankersAcceptances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "BankersAcceptances",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Banker\u2019s acceptances",
        "documentation": "A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank.",
        "label": "Bankers Acceptances"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "verboseLabel": "Board of Directors Chairman [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building [Member]",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r782"
     ]
    },
    "cphi_CITICBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "CITICBankMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CITIC Bank [Member]",
        "label": "CITICBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid cash (in Dollars)",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r579",
      "r637",
      "r657",
      "r741",
      "r753",
      "r879"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r176",
      "r717"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r117",
      "r206"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase in Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r117"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Noncash Investing and Financing Activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ChairpersonCEOAndInterimCFOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ChairpersonCEOAndInterimCFOMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chairperson, CEO and Interim CFO [Member]",
        "verboseLabel": "Chairperson Li [Member]",
        "label": "Chairperson CEOAnd Interim CFOMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Financial Officer [Member]",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "cphi_ChinaCITICBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ChinaCITICBankMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China CITIC Bank [Member]",
        "label": "China CITICBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ChinaPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ChinaPharmaMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Pharma [Member]",
        "verboseLabel": "China Pharma\u2019s [Member]",
        "label": "China Pharma Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r181",
      "r182",
      "r183",
      "r208",
      "r231",
      "r232",
      "r234",
      "r236",
      "r239",
      "r240",
      "r294",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r350",
      "r351",
      "r354",
      "r357",
      "r364",
      "r468",
      "r617",
      "r618",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r649",
      "r671",
      "r693",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r864",
      "r887",
      "r894"
     ]
    },
    "cphi_ClosingMarketPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ClosingMarketPrice",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing market price (in Dollars per share)",
        "documentation": "Closing market price.",
        "label": "Closing Market Price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r91",
      "r578",
      "r648"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Common Stock, Convertible, Conversion Price, Decrease",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r890",
      "r891",
      "r940",
      "r961",
      "r964"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r649"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Share issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r98",
      "r649",
      "r668",
      "r964",
      "r965"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 500,000,000 shares authorized; 10,625,788 shares and 1,498,180 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r581",
      "r741"
     ]
    },
    "us-gaap_CommonUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitIssued",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares of common stock",
        "label": "Common Unit, Issued",
        "documentation": "Number of common units issued of limited liability company (LLC)."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r191",
      "r193",
      "r199",
      "r572",
      "r592"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r87",
      "r88",
      "r258",
      "r614",
      "r712"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r87",
      "r88",
      "r258",
      "r712",
      "r869"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r158"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RISKS &amp; UNCERTAINTIES",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r51",
      "r87",
      "r88",
      "r258"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation and Basis of Presentation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r721"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances from customers",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ]
    },
    "cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ConversionOfRelatedPartyNoteAndInterestToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of related party note and interest to common stock",
        "documentation": "Conversion of related party note and interest to common stock.",
        "label": "Conversion Of Related Party Note And Interest To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued (in Shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "cphi_ConvertibleNotePayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ConvertibleNotePayableDetailsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, redeemable note payable, net of issue discount",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r142"
     ]
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsTotalMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service Benchmark [Member]",
        "label": "Cost of Goods and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r208",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r468",
      "r904"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenues",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "verboseLabel": "Revenue One [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r258"
     ]
    },
    "cphi_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "CustomerMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Member]",
        "label": "Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One [Member]",
        "documentation": "Customer one.",
        "label": "Customer One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Three [Member]",
        "label": "Customer Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two [Member]",
        "documentation": "Customer two.",
        "label": "Customer Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lines of Credit and Construction Loan Facility [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note converted into common stock",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r74",
      "r132",
      "r133",
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extension fee (in Dollars)",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r339"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument redemption price percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemptions weighted average price",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption amount (in Dollars)",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_DeferredIncomeTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "DeferredIncomeTaxAssetsAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Deferred Income Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r577"
     ]
    },
    "cphi_DeferredIncomeTaxLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "DeferredIncomeTaxLiabilityAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liability:",
        "label": "Deferred Income Tax Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_DeferredTaxAssetValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "DeferredTaxAssetValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance on deferred tax assets",
        "documentation": "Deferred Tax Assets Valuation Allowance.",
        "label": "Deferred Tax Asset Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory obsolescence reserve",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. net operating loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability, net",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRC net operating loss carry forward",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses not deductible in current year",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful trade receivables",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances for intangible assets impairment",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful other receivables",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Financing Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on financing receivable."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofDeferredIncomeTaxAssetsandLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r938"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r809"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expanse",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r246"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r809"
     ]
    },
    "us-gaap_DividendsStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsStock",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock value",
        "label": "Dividends, Stock",
        "documentation": "Amount of paid and unpaid stock dividends declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r134"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782",
      "r826"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782",
      "r826"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States Federal [Member]",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r461",
      "r462",
      "r573",
      "r593",
      "r724"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r461",
      "r462",
      "r573",
      "r593",
      "r724"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Exchange Rate Changes on Cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Benefit) tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r416",
      "r428"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal corporate income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r939"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r939"
     ]
    },
    "cphi_EffectiveMarchSixTwoZeroTwoFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "EffectiveMarchSixTwoZeroTwoFourMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective March 6, 2024 [Member]",
        "label": "Effective March Six Two Zero Two Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_EffectiveMarchSixTwoZeroTwoThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "EffectiveMarchSixTwoZeroTwoThreeMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective March 6, 2023 [Member]",
        "label": "Effective March Six Two Zero Two Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense (in Dollars)",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "documentation": "The amount of plan compensation cost recognized during the period."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r169",
      "r194",
      "r195",
      "r196",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r228",
      "r238",
      "r298",
      "r304",
      "r366",
      "r406",
      "r407",
      "r408",
      "r424",
      "r425",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r460",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r509",
      "r604",
      "r605",
      "r606",
      "r626",
      "r693"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r786",
      "r802",
      "r830"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r799",
      "r827"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued an aggregate",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r465",
      "r524",
      "r525",
      "r526",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r371",
      "r376",
      "r465",
      "r524",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r371",
      "r376",
      "r465",
      "r525",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r465",
      "r526",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r524",
      "r525",
      "r526",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsNonrecurringValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r346",
      "r362",
      "r450",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r591",
      "r728",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset useful life,term",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r323"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization intangible by useful life, descriptions",
        "label": "Finite-Lived Intangible Assets, Amortization Method",
        "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r555",
      "r559"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r559"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAggregateAnnualAmortizationExpenseTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Net carrying amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r555"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479",
      "r690"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r834"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r793"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property, plant &amp; equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r673"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross (loss) profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r208",
      "r241",
      "r249",
      "r253",
      "r255",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r468",
      "r726",
      "r904"
     ]
    },
    "cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "HainanHelpsonMedicalBiotechnologyCoLtdMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hainan Helpson Medical &amp; Biotechnology Co., Ltd [Member]",
        "label": "Hainan Helpson Medical Biotechnology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_HelpsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "HelpsonMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Helpson [Member]",
        "label": "Helpson Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r769",
      "r782"
     ]
    },
    "us-gaap_ImpairedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairedIntangibleAssetsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r127"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r109",
      "r145",
      "r241",
      "r249",
      "r253",
      "r255",
      "r574",
      "r589",
      "r726"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r411",
      "r417",
      "r418",
      "r421",
      "r426",
      "r429",
      "r430",
      "r431",
      "r622"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination [Table]",
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement",
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r164",
      "r227",
      "r228",
      "r247",
      "r415",
      "r427",
      "r594"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, primarily the difference in U.S. tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r416"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Benefit) tax at statutory rate of 25%",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIncomeTaxesCalculatedattheFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior year refund received",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade accounts and other receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncollectible trade accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables and accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances from customers",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r886"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances to suppliers",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r790",
      "r806",
      "r825",
      "r834",
      "r838",
      "r846"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r850"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r850"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r850"
     ]
    },
    "cphi_IntangibleAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "IntangibleAssetsDetailsLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) - Schedule of Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "IntangibleAssetsDetailsScheduleofIntangibleAssetsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) - Schedule of Intangible Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r61"
     ]
    },
    "cphi_InterestAccruesOnNoteDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "InterestAccruesOnNoteDescription",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrues on note, description",
        "documentation": "Description of interest accrues on Note.",
        "label": "Interest Accrues On Note Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r148",
      "r197",
      "r245",
      "r489",
      "r677",
      "r752",
      "r963"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense",
        "verboseLabel": "Interest expense (in Dollars)",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r345",
      "r348",
      "r731",
      "r732"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r204",
      "r205"
     ]
    },
    "cphi_InterestRateRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "InterestRateRiskPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Risk",
        "documentation": "Disclosure of accounting policy for interest rate risk.",
        "label": "Interest Rate Risk Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_InterimChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "InterimChiefFinancialOfficerMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interim Chief Financial Officer [Member]",
        "label": "Interim Chief Financial Officer Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_InventionPatentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "InventionPatentMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invention Patent [Member]",
        "label": "Invention Patent Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inventory",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r718",
      "r741"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r175",
      "r186",
      "r315",
      "r316",
      "r317",
      "r553",
      "r722"
     ]
    },
    "cphi_InventoryPurchasedWithBankersAcceptanceNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "InventoryPurchasedWithBankersAcceptanceNote",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory purchased with banker\u2019s acceptances",
        "documentation": "The amount of inventory purchased with banker&amp;amp;#8217;s acceptances.",
        "label": "Inventory Purchased With Bankers Acceptance Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r244"
     ]
    },
    "us-gaap_InvestmentInterestRateFloor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInterestRateFloor",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "interest rate, percentage",
        "label": "Investment, Interest Rate, Floor",
        "documentation": "Minimum rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r968",
      "r969"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946"
     ]
    },
    "cphi_IssuanceOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "IssuanceOfCommonStock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "documentation": "Number of common stock issued.",
        "label": "Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permit of land use [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted cash flows",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r208",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r436",
      "r437",
      "r438",
      "r468",
      "r647",
      "r725",
      "r753",
      "r904",
      "r949",
      "r950"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r144",
      "r585",
      "r741",
      "r889",
      "r900",
      "r942"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r208",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r436",
      "r437",
      "r438",
      "r468",
      "r741",
      "r904",
      "r949",
      "r950"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, amount",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r143",
      "r958"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r888"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lines of Credit [Member]",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lines of credit",
        "verboseLabel": "Repaid under this line of credit (in Yuan Renminbi)",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r142"
     ]
    },
    "cphi_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Liquidity and Going Concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_LoanAndReceivedProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "LoanAndReceivedProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and received proceeds",
        "documentation": "Loan and received proceeds.",
        "label": "Loan And Received Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansHeldForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansHeldForSaleTerm",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of loan agreement",
        "label": "Loan, Held-for-Sale, Term",
        "documentation": "Period between issuance and maturity of loan held for sale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable [Member]",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r143",
      "r341",
      "r347",
      "r729",
      "r730",
      "r958"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r212",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of loan bears interest",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacility"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lines of credit, net of current portion",
        "label": "Long-Term Line of Credit, Noncurrent",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r66",
      "r67"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r68"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r735",
      "r907",
      "r959",
      "r960"
     ]
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management [Member]",
        "label": "Management [Member]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r947"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r378",
      "r551",
      "r601",
      "r639",
      "r640",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r713",
      "r714",
      "r727",
      "r733",
      "r739",
      "r743",
      "r906",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r378",
      "r551",
      "r601",
      "r639",
      "r640",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r713",
      "r714",
      "r727",
      "r733",
      "r739",
      "r743",
      "r906",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "cphi_NMPAApprovedMedicalFormulasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "NMPAApprovedMedicalFormulasMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NMPA approved medical formulas [Member]",
        "label": "NMPAApproved Medical Formulas Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r735",
      "r907",
      "r959",
      "r960"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash (Used In) Provided By Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for the year",
        "netLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r119",
      "r146",
      "r172",
      "r190",
      "r192",
      "r196",
      "r208",
      "r217",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r233",
      "r241",
      "r249",
      "r253",
      "r255",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r462",
      "r468",
      "r590",
      "r670",
      "r691",
      "r692",
      "r726",
      "r752",
      "r904"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r229",
      "r237",
      "r262",
      "r263",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r325",
      "r406",
      "r407",
      "r408",
      "r422",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r467",
      "r472",
      "r473",
      "r474",
      "r475",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r556",
      "r557",
      "r558",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r229",
      "r237",
      "r262",
      "r263",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r325",
      "r406",
      "r407",
      "r408",
      "r422",
      "r423",
      "r424",
      "r425",
      "r432",
      "r433",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r467",
      "r472",
      "r473",
      "r474",
      "r475",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r556",
      "r557",
      "r558",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r790",
      "r806",
      "r825",
      "r834"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_NoteRedeemableIntoShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "NoteRedeemableIntoShares",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note redeemable into shares (in Shares)",
        "documentation": "Number of shares redeemable by Notes.",
        "label": "Note Redeemable Into Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_OnnyInvestmentLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "OnnyInvestmentLimitedMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Onny Investment Limited [Member]",
        "label": "Onny Investment Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r249",
      "r253",
      "r255",
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r740"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "negatedLabel": "Less: Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r500"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating use liabilities",
        "label": "Operating Lease, Payments, Use",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r500"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use asset",
        "verboseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r740"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease weighted average lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r740"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards limitations, descriptions",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards available for future taxable income",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityIndexedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityIndexedShares",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock (in Shares)",
        "label": "Option Indexed to Issuer's Equity, Indexed Shares",
        "documentation": "The number of issuer's shares to which the option contract is indexed."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r120",
      "r121",
      "r139"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Other Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) - foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and interest to related parties",
        "label": "Other Employee-related Liabilities, Current",
        "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings from related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r741"
     ]
    },
    "cphi_OtherPayablesDetailsScheduleofOtherPayablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "OtherPayablesDetailsScheduleofOtherPayablesLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Payables [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_OtherPayablesDetailsScheduleofOtherPayablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "OtherPayablesDetailsScheduleofOtherPayablesTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Payables (Details) - Schedule of Other Payables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "OtherReceivablesLessAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables, allowance for doubtful accounts (in Dollars)",
        "documentation": "Other receivables, less allowance for doubtful accounts.",
        "label": "Other Receivables Less Allowance For Doubtful Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables, less allowance for doubtful accounts of $27,017 and $27,149, respectively",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r788",
      "r804",
      "r832"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r791",
      "r807",
      "r835"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r791",
      "r807",
      "r835"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLoans",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payment",
        "label": "Payments for Loans",
        "documentation": "Cash payments for and related to principal collection on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForMortgageDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForMortgageDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance amount",
        "label": "Payments for Mortgage Deposits",
        "documentation": "Amount of cash outflow for advance payment to show intention to complete mortgage financing."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_PaymentsForProceedsFromProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments for (Proceeds from) Productive Assets",
        "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "cphi_PercentageOfBalanceNoteAndAccruedInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PercentageOfBalanceNoteAndAccruedInterest",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note and accrued interest",
        "documentation": "Percentage of balance note and accrued interest.",
        "label": "Percentage Of Balance Note And Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_PercentageOfNetProfit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PercentageOfNetProfit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net profit",
        "documentation": "Percentage of net profit.",
        "label": "Percentage Of Net Profit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "cphi_PostalSavingsBankOfChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PostalSavingsBankOfChinaMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postal Savings Bank of China [Member]",
        "label": "Postal Savings Bank Of China Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "verboseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r350"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r649"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r350"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r649",
      "r668",
      "r964",
      "r965"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r580",
      "r741"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r318",
      "r319",
      "r719"
     ]
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaymentFeesOnAdvancesNet",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total advance received",
        "label": "Prepayment Fees on Advances, Net",
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from lines of credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r888"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from loan agreement",
        "label": "Proceeds from Loans",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings and interest from related party",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "cphi_ProductOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ProductOneMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product One [Member]",
        "label": "Product One Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r554",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r716",
      "r734",
      "r742",
      "r870",
      "r902",
      "r903",
      "r907",
      "r959"
     ]
    },
    "cphi_ProductThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ProductThreeMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Three [Member]",
        "label": "Product Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ProductTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ProductTwoMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Two [Member]",
        "label": "Product Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r554",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r716",
      "r734",
      "r742",
      "r870",
      "r902",
      "r903",
      "r907",
      "r959"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r177",
      "r588"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant, machinery and equipment [Member]",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r575",
      "r588",
      "r741"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Other, Net",
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant, machinery and equipment [Member]",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r159",
      "r162",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesofTheAssetsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of The Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow",
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt benefit",
        "verboseLabel": "Bad debt (benefit) expense",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r308"
     ]
    },
    "cphi_PurchaseOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "PurchaseOfCommonStock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock",
        "documentation": "Number of purchase common stock.",
        "label": "Purchase Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r370",
      "r378",
      "r402",
      "r403",
      "r404",
      "r527",
      "r551",
      "r601",
      "r639",
      "r640",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r713",
      "r714",
      "r727",
      "r733",
      "r739",
      "r743",
      "r746",
      "r901",
      "r906",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r370",
      "r378",
      "r402",
      "r403",
      "r404",
      "r527",
      "r551",
      "r601",
      "r639",
      "r640",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r713",
      "r714",
      "r727",
      "r733",
      "r739",
      "r743",
      "r746",
      "r901",
      "r906",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable and Allowance for Doubtful Accounts",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r783",
      "r799",
      "r827"
     ]
    },
    "cphi_RedeemOfOutstandingNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RedeemOfOutstandingNote",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeem of outstanding note (in Dollars)",
        "documentation": "Amount of redeem of outstanding note.",
        "label": "Redeem Of Outstanding Note"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RedemptionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption amount",
        "documentation": "Redemption amount.",
        "label": "Redemption Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RedemptionOfWeightedAveragePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RedemptionOfWeightedAveragePercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of weighted average percentage",
        "documentation": "Redemption of weighted average percentage.",
        "label": "Redemption Of Weighted Average Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RedemptionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RedemptionPercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption percentage",
        "documentation": "Redemption percentage.",
        "label": "Redemption Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails",
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r513",
      "r514",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r667",
      "r669",
      "r700"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r513",
      "r514",
      "r515",
      "r516",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r667",
      "r669",
      "r700"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r948"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails",
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r513",
      "r514",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r667",
      "r669",
      "r700",
      "r948"
     ]
    },
    "cphi_RelatedPartyTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r514",
      "r517",
      "r623",
      "r624",
      "r625",
      "r674",
      "r675",
      "r676",
      "r697",
      "r699"
     ]
    },
    "cphi_RepaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RepaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repaid amount",
        "documentation": "Amount of repaid.",
        "label": "Repaid Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of line of credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r888"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments to related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r410",
      "r957"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "cphi_ReserveAccountBalancesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ReserveAccountBalancesPercentage",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve account balances, percentage",
        "documentation": "Reserve account balances percentage.",
        "label": "Reserve Account Balances Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r784",
      "r800",
      "r828"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r785",
      "r801",
      "r829"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r792",
      "r808",
      "r836"
     ]
    },
    "cphi_RestrictedCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RestrictedCommonStock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted common stock (in Shares)",
        "documentation": "Restricted common stock.",
        "label": "Restricted Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r134",
      "r584",
      "r608",
      "r613",
      "r621",
      "r650",
      "r741"
     ]
    },
    "us-gaap_RetainedEarningsAppropriated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAppropriated",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings, Appropriated",
        "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r107",
      "r207",
      "r583"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r228",
      "r298",
      "r304",
      "r406",
      "r407",
      "r408",
      "r424",
      "r425",
      "r442",
      "r445",
      "r446",
      "r449",
      "r460",
      "r604",
      "r606",
      "r626",
      "r964"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r715",
      "r723"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r208",
      "r242",
      "r243",
      "r248",
      "r251",
      "r252",
      "r256",
      "r257",
      "r258",
      "r294",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r468",
      "r574",
      "r904"
     ]
    },
    "cphi_ReverseStockSplitsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ReverseStockSplitsPolicyTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "documentation": "Disclosure of accounting policy reverse stock split.",
        "label": "Reverse Stock Splits Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r740"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks &amp; Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RisksUncertaintiesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RisksUncertaintiesDetailsLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks &amp; Uncertainties (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_RisksUncertaintiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "RisksUncertaintiesDetailsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks &amp; Uncertainties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion of the convertible note payable (in Shares)",
        "verboseLabel": "Issuance of shares of common stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing price of common stock (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_SalesBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "SalesBenchmarkMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Benchmark [Member]",
        "label": "Sales Benchmark Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r868"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "auth_ref": [
      "r229",
      "r379",
      "r865",
      "r893"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Payables",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfAggregateAnnualAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfAggregateAnnualAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Aggregate Annual Amortization Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets And Liabilities Recorded At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfDeferredIncomeTaxAssetsAndLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Income Tax Assets and Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Income Tax Assets and Liability",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Taxes Calculated at the Federal Statutory Rates",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "cphi_ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives of The Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Recorded at Fair Value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465"
     ]
    },
    "cphi_ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfIncomeTaxesCalculatedAtTheFederalStatutoryRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes Calculated at the Federal Statutory Rates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "cphi_ScheduleOfInventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfInventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Inventory Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of principal payments",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "cphi_ScheduleOfOperatingLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfOperatingLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfPrincipalPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfPrincipalPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Principal Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r131",
      "r133",
      "r134",
      "r181",
      "r182",
      "r183",
      "r239",
      "r350",
      "r351",
      "r352",
      "r354",
      "r357",
      "r362",
      "r364",
      "r617",
      "r618",
      "r619",
      "r620",
      "r733",
      "r864",
      "r887"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Annual Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling expenses",
        "label": "Selling Expense",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life, term",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term",
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of volatility",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of risk free interest rate",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock per share based",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable [line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE NOTE PAYABLE",
        "label": "Short-Term Debt [Text Block]",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r181",
      "r182",
      "r183",
      "r208",
      "r231",
      "r232",
      "r234",
      "r236",
      "r239",
      "r240",
      "r294",
      "r330",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r350",
      "r351",
      "r354",
      "r357",
      "r364",
      "r468",
      "r617",
      "r618",
      "r619",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r649",
      "r671",
      "r693",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r864",
      "r887",
      "r894"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r169",
      "r194",
      "r195",
      "r196",
      "r213",
      "r214",
      "r215",
      "r218",
      "r226",
      "r228",
      "r238",
      "r298",
      "r304",
      "r366",
      "r406",
      "r407",
      "r408",
      "r424",
      "r425",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r460",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r509",
      "r604",
      "r605",
      "r606",
      "r626",
      "r693"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r238",
      "r554",
      "r616",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r672",
      "r673",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r693",
      "r747"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofInventoryTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "auth_ref": [
      "r229",
      "r379",
      "r865",
      "r866",
      "r893"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r238",
      "r554",
      "r616",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r672",
      "r673",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r693",
      "r747"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and statutory capital reserves amount (in Dollars)",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r787",
      "r803",
      "r831"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in Dollars)",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for intangible assets",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversions of note payable to common stock (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r74",
      "r134",
      "r343"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of related party note and interest (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r97",
      "r98",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services (in Shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r97",
      "r98",
      "r134",
      "r617",
      "r693",
      "r707"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for intangible assets (in Shares)",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock and stock option granted and outstanding",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share rounding due to reverse split (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for intangible assets",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversions of note payable to common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of related party note and interest",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "cphi_StockIssuedDuringPeriodValueStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "StockIssuedDuringPeriodValueStockSplits",
     "crdr": "debit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share rounding due to reverse split",
        "documentation": "Amount of share rounding due to reverse split.",
        "label": "Stock Issued During Period Value Stock Splits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of per share (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock and stock option compensation",
        "label": "Stock or Unit Option Plan Expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet",
      "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r102",
      "r122",
      "r651",
      "r668",
      "r694",
      "r695",
      "r741",
      "r753",
      "r889",
      "r900",
      "r942",
      "r964"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r207",
      "r349",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r366",
      "r451",
      "r696",
      "r698",
      "r711"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split, description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/LinesofCreditandConstructionLoanFacilityDetails",
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r519"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk [Member]",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "cphi_SuppliersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "SuppliersOneMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers One [Member]",
        "label": "Suppliers One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_SuppliersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "SuppliersTwoMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/RisksUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers Two [Member]",
        "label": "Suppliers Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2023Member",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2023 [Member]",
        "label": "Tax Year 2023 [Member]",
        "documentation": "Identified as tax year 2023."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business taxes and other",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "cphi_TechnologyFromBonierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "TechnologyFromBonierMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology from Bonier [Member]",
        "label": "Technology From Bonier Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r947"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_TotalOptionOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "TotalOptionOutstanding",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total option outstanding",
        "documentation": "Total option outstanding.",
        "label": "Total Option Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r346",
      "r362",
      "r450",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r591",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "cphi_TwoThousandTenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "TwoThousandTenIncentivePlanMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Incentive Plan [Member]",
        "documentation": "Two thousand ten incentive plan.",
        "label": "Two Thousand Ten Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r156",
      "r157",
      "r160",
      "r161"
     ]
    },
    "cphi_UsefulLiveOfAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "UsefulLiveOfAssetsTableTextBlock",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of The Assets",
        "documentation": "Useful live of Assets table text block.",
        "label": "Useful Live Of Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesofTheAssetsTable",
      "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicles [Member]",
        "verboseLabel": "Motor vehicle [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r236"
     ]
    },
    "cphi_WeightedAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "WeightedAveragePrice",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in Dollars per share)",
        "documentation": "The weighted average price per share.",
        "label": "Weighted Average Price"
       }
      }
     },
     "auth_ref": []
    },
    "cphi_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.chinapharmaholdings.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "documentation": "Working capital.",
        "label": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "c(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "35",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482710/350-30-35-6"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-14"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001213900-24-028731-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-028731-xbrl.zip
M4$L#!!0    ( ," @5BNV4>!PA$  &3%   1    8W!H:2TR,#(S,3(S,2YX
M<V3M76U3VSH6_GY_A9:=V>W.+LT;E,(6=D(@+24T7!+:TIV=.\96$E\<VY7D
M /WU*\EVXMB2+ ?HU>QZIC,-]M'1<_3HY>CHQ>_^]3#WP (B[ ;^X5;K=7,+
M0-\.'->?'FY=C[:[H][9V=:_C@#XY=V?MK?!>^A#9!'H@-M'T OFX<AVP1A9
M/IX$: Y>D?G?P#:8$1(>-!KW]_>O;2J#;1=!'$3(AI@] -O;5&&JLH<@4W@
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M3=L=C[W6-@V:>X6_'Q \7L*>@U=&#A-JMW1ZL]&80F,X<MB??JC+S95GG<<
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MA3Q@\LP*MG1&*WR'+D>(XE">&_\%: 1?@SD7TV475E#K9R]126,@+F1=&%B
MAIO6J#D$\.:S8_L#0.0AOM"'%RS6I;_NYRVG5/@*XEQ>J4N..8U[-R!4U1-?
MF.KD*S>QN=YZ#  4&QYB-YHNW^S.54XPL<+44NP "XT <9QDG>E7Z$7;PR&!
M0]J_-D(N,*.="5:2RZ;$+)XX\-*8L)ESXDU(P8-UB;#BQIG1< IFUY2>NRDT
M)_"*SH%&HGUM2644&V*^ 1&UPK+@"UW/6TV91PC(W10K'0"A#LK7*60S/P=;
M[#&P DI0GD6?PBBJA>K,JQ+2?;P%'B5;78<N=D5O92NHA-J=0E7P[6,M^&Q5
M 37H=]53SI3X!U#N8<U[CK,2RML#!Y):\![7Y.]-_@+J_*-;BF=2WC0R."IH
M1R9-!4L!T9.';)99W<ODN267>8_(;[0/3$!DO[*^*$3Q]*< MRE/KR>0$WWM
MS^G8,O$,PF!'4#4/2"\7JGP.4Y*^O-B*O)/.NUE-ZE.Z:1+41J62-*5"EK7#
M0^E"B($TPV*OEOG;^-Z"3Z&'DH(W/"7LHHPU7;@ $VWE"C@N\<B,[F*<(W*.
M)%?BRNFB]OG0%)[3WG(M"'/FVHC*-"WUK6#C+64K-"0AS5XAYQGBT"Q/A+_H
MDEML\=I77A&R[:RH&FI-;,5A$3._PL"+?!0EKQ9RRMRK2E?]?EL%="\O<:O>
M23>_R[<3B(,Z<&C6VX4Z>R^&O8SF^CNM'%@R5:G1I;T%%>]!#=,8:OK+RAQ)
M;6<1N[??4Q!E=5>(;LIW/66.D-0;CL5P(G ^SM&,IE_8*XQ%;*Z:L9 J6?G,
MO#S7Z8B*G(IS!'>\[=CGZ!0!ML>Z4L/FR%:];%B>31ZH_!V-$A@]@0-(B"?=
MKW"S]]U])$T33P'2*J8YCT(U>!="!/&YL,]>1%28287:SSOI]P&@>0EK5F;*
MF@!'QJ90CI#"I9]$>_2/\+-@N+"G[\C$>UO8J_@!TYZS+?\:7PD**LZ@LL=)
M_(9F\>0(?N6CF(K1^XLO,?!NJ1.>:@E53:D#ESUB>'2(W?25T&U^0$(V\6^"
MUI7&"%1BDZT< X8]@T'_"X+=V4'V8/=IO(7'P(9Z] OLD>GJ[7AU%=6NI0DU
MZ +\\%(T22-(QJ5TN<6JGG8)Y3I^!UURTU9U(?Q\; &#L")JC8)W0JF_%?FY
M6.#NYA(R-"JQY(C=KB5S<2,5=5%VV@#QKX'J $)F TRF@ @_>IM7ZCK'TU04
MDY=B"PR1;ZM25,U*Z<N0K+S<7,;D,@!-7GU=XA6J!;F1W0[BC]XMDU:OR4PZ
M%)FL23GT6WU].&<!N%ZV58"NC&)O^F7(:;7>CTTFZ(G.2Y@S_3]02P,$%
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MJ&I'!-N19,1&)*0^V/I]W8-=$U"K9]2[CV3C^0[,272%8W]?7@8.K8/W:O=
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MV\LD=_ONW5F%\WK[_J\,IU%K&""?E8C*H,*X#RC.K$>L;(=U.Z][Q-*\M:J
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M(BJC,6&$,"EDP9KI8Y2"F?S-L4<C@Q8D*HFN XK'"1)EZ.D;A8NX"%'VZPT
M)W&0_RO*5_HD^%=6&%) *4M 3+K3L]P9WZE4!R 6&+\QAU&@F2"C-!*'BA0L
MU?0:;1%5:8Y5Z!?025Y(9AQN%C%*E6#L5EYMTSOVDM '%DE!PYWNZYN),GF4
M^ #5&OB,6%,+%$P>J F[0%<9>XG9O!,S!"$E/=I.SX\Z M2$5*DXU&'%8G&R
M"_]4H5GMV7 21EEJ/7I41&4T!KT0)L4X+@>3/N>SD?Y[1T=]C\F'5Z:9\:(<
M9-O9LCL" V;V=K0[E@((Q6HQ.)1YY.UZ(YD57VI"T)VL.$[I+#N-\E_]]"I!
MBU61+6SQ>+'EHIB%S(#&<5ZHJ]9XWK9<N+2@Q+2D3Q(_NT>OZ:?L9(#C'K$U
MYB179'RP8 Z +5K-9O2VM@ N#2@[MA+#ZZ#Q+@)IR"9F8Q?@XP32%X5+Z[>W
M^Y(*T*:\DPN:>UF40@J&@045O%7+2;AL6!CVTSC*\5VZ1Z3Z09"J4<$"TS2(
M7ZD+1!1R6@X=(\I2Z4%+88W8*&\&(AP!D5$L%A% ($V"%(IKP:P>9;H.75K*
M"TD=1+!V07_&^F1FA6;WLON_Y',J%&;NS=Z4E2<W7R5%4N])1BBI:T1"7*3/
M3WPZ/8JT4_O'3T6RAU&2H']!*4$(DT;$)U_,H>N,^$LO0;,Y2*MB/=KCE:4(
M3+C"FH+Y5/0\8@?#V?P3Q6^?Z[)+V[% #>:]ZKKEX QT&2=]#4?B%A%W7#0<
M0-A"F&U;1'FU/=F,*S;^==01LJ ZH>I8K@M5FPA-#ZP]FT8%^RQ+GB1BJ<$N
M30YUY^6KP58G#VJP4^,NF"RYPP)_4!6B@0)VKJ6'VCP,+>=OMLY-O1M4F'WH
M%I&'T$?%Z]P@'R\*P5AWO>V'ZS&<H_8F0:C^K#+%EWM3]FCS%?3&('8%U* 2
MTJ3:J_C\#)-R(NUUG^@2/X BC>8', Z6_8TK(8]@M1:TM\BGOP3H\S:,EY'*
M6Q5IF 0:Y<."0_FK,G,0M2'-E[SZ'+#=M.[/DJVC)J2])>J(LSX^TC=AU(M\
M._LY%SJ4QR R+225$C(.("IYZB7+LP@_OK(0[T@U2CD:5%$T*:DAA2M0RL;+
MZ\=06(\WGQ(6L+VMGC&A8GXHVML 5;+09^ PO/\2F;?4G3; ( $\?Y9=R'Q&
M]^]2=B5R@M8$^6'N,:!_1ZC,2)RL,+5-_O  W#M*))UF>5J0G1JN<.UG7JJ7
MV9*D4EDSNU%;-=?==>3%0#4U^41<GK#L"$R$'IB7O3) 9_&M%Z'9G/)/.4XW
MC'H>R[Q>V>_%IDCT.:Q 57Q!XA?H#DR0EZ 35/RWQGWI?H?+^E,E//XUJX,R
M6 &]+A.5GJ<;=[NW'+BT9;1=5Z+27!%R24M!!BSJUN;CFJ"U%P:WV7H=V7=\
M]M-SGA5K5:H=-('R#;J4687 F#ZP#QG6:;DMEF%5> T(H2)2Q)K@VMNPY7]'
MO,!^M44EHL]K+?)Q5;"'K8F5CAC4VE3O0ZAMDD[K\]D69P?//=F^K&(@8_1S
MF"ZG69+B%2(5'[8S4G2I.ZXD957$/3CWF\!63:*JB#A$O(XBT>>ED/FX*D3T
MP%ZO.+M6.8Q[?>NW*6!&KX"%HC:VPQLS&0//X<9,"C"(*YB:;'GPYQDFE!D?
MH2"OW$O_#C+& P+)A%*EZK)XO/$2:#CW5>&%J<"B_A+.UN]S4,U</(&./P(6
MRM:G[E2SC('GH)JE (.<CFZH#5=HC]G\(HRI&3>?$A18+TTNIN.V583Q1&]6
MPQ""")2B6-?SD&(3TWD&8I. "&3RUBG>H+P8Q[5'TLT)NH>47(?405ZH#I!>
M%TL0.[:^SH'%)R7U',0GQQ*D+(,ZX\ZLF4.\!=<4K [*"NW\#*M"SN?(I\;8
MZ9._].(%NJ'S:Q8SOMC_6+C%@Q>QR7=#;6H2^F48\R0.FA_4?GD>^U'&PJ!/
MPF2-$R_Z2'"V9OT\P\0O>M"@8->"QO(4.H 7&I6!?0!X]3NXC>HW#7F%(HVG
MZ\HM7ZP.5@&@Y5F\9^9'-6/W+=A>1_W>9^<A3;9#R-+<Q\0!2]=E(3/Y6WA1
M]1;G\1R35=$@""BY1Y&JTPHL>M)5!K(_[]8\%J)JH\<J-E#[SO[M:9N XV0^
MO<G+[6!7 PN\IRN46)JCN]U-AXBDA9)2JQ>CK8]QQ1I+TC]W[OHXX)Q]F,U(
MJ69@[; &LS,B'3D<>I7^DOK%Q:J0M5TP\!1'$6+;,(N).?;BKX@D]%=HG5(N
MVWX'09DQ_5$=BM+6JMC6(#/ U+(//F>C"B[=5+6T^-2O<(J4A*HSGMO-T;I$
MM:"$T=TWK%78;/XI*:[*9_=%=?/SN#HXG6&R#8VY8$<KJ'C!(9P\DV5N12AP
M*8U%691WMD\N]:%=.H$A)-G$326%45L?UXO2U*\3F-:@K%<VX!VNU?164LQ&
M S\7 0Z 5B5:P4'ADAE9>'&9NN[%P6VXB,-YZ'MQ6AH6K-@1CD*?W4\89X5T
MQP*R\B6$#'5<':!=E9<B[_^:RIF=P-)\+I2SR8NVYGI]-O5@>T?%>!QU%N%@
M0/;.OLNEWC_-&HV]]RY9E6(?#G3 UN T7^#;(:X07,-4#HDAB6KE<#M)0JU!
M*2G7.1!BN35]1C*T#G1>-TH*T,UM5U7 W,78&'-2&Q-HUO?3&^ O%0X.OR:T
M2#L\R"G+NQ6*I8&KJCO<R<Y U\V"5;,L0^8-4PY7:R\D[*C:'.X"J/EP/[UA
MEPR-0?>Q?_13=%L\0E6^K6N(?AP/=&?)<_O*Q.OB6&28!I0/P"J(L>Q?+X(Z
M%LDH&0?OMA+0NPG,5>V/VD<[(1<U/U.H-6.9.;=6FL)$:;4VM"H8M?L"!\NP
M[GVIU8X=X*@0C0BT+GO)#>C8RA\9?K?2H>QV6:D*NQFFK8'KP2X<MC$GN,SN
MH"<CYOZ@/.6O<H&]^,SSBWL#<S.)Q:V#7^H+B!BOF@L<+^X06;%QH=8'GX:[
M\#JYH.IS7X#.@=IHM5+\S#-?;H:O3./WEIBD[.6/,2'XD9&"BMF34#)OX5<-
M"CFS!42<YAKWBZUQ,2> 22E1W(4>9[>\IJ?RXF&@6=P:W#00X0+1LR%JWFJ#
MW97T$'-ZQ.8+JZ&=>Z ZU#E<BQ U=2]5(X#;&S)*0VJKM0>%\R1)2+F^B>@5
M(C>N>%R&]YD7DKQQU"5=GI3G_"[1<-ISQ[K",6&-AUB3HO:70(O"G _C)<,C
M>1ZOLWUX8_5H.]TT!L^01J\>/<P/^%8CC\AA'R.2L*N9\IQK' '7&"J/ H)J
MU2,E-K [9&=@^*6D3M=Q6^]>"7>B^]305%DDCERK8?(U^13[] 1-$4K# =<<
M^5"3.&B,!N50E=(R3F7!=#A6NY,!S4C +PTEDNY6A9),&RDI2A >K-UVF]TG
MZ/>,OL'IPP"3K3T,6-JG@(QY]FIS0+ -04C'<;*=7&S-_%0A5(=Z N_&+!YO
M\K\VAM-\Q.&^5UY*5=)L#E:XA$/ [<%;+VB6AX_=,IIYC/U%2 VG@)I.=(_Y
MB%E%9K9_D+B8E@+U(\A84!W+8929F@STD%%I0Z<OF!O$<A]0;N/>KJ,P34Q$
MTC_*&-:$*B!0O38:0>M2,=@P1\6DQB K-<SZ4[%,Y/0IH0KS-$G#E9=:KZ76
M&OS@E9@(%(729Z95"*BF;)<'@ETL2C3'DRBCB"%(>:]:W["\PTT5NM9->Y]$
M$7YDB=&<EIZE-6O9UV"3-7='>;VY8%<>"LTQ3,I,! ]YI8,[7#8J(WGD9/DI
MJX]:=5\Q,EX&##^&G7(PA/T%M 9F;,%J;R&9T6RM8J 4:F*91VD4$0>PPI%1
M&L^&*L6KM_2.>09.7D*(5.4Z9W,6T'<1/J"@R,  7E<F+(Q'IF8(5X=TRRU(
MA EHL")6)NO4FZLG5W4H*UG:\[CLC"ZJT#-$;2N\**""E6,_O3$8,AKH5:*3
MN6C,/#1).INS!N?01TXQH;&<+&185?*Q6__^!B6(O@X[VY[0.1+A?%V7_?N
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M>?.CI!G,XIN*EV,O"?>U0FWPYM+];[4XE661'6JEAIV'KAD#8*%Q$]C%09?
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MQJ!TE2%1:[_A('HA#P=G'R.2% G#C8+[0^I^15Z2S.9W!'E)1C8YH0Z(=FN
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MOAW& .-*VK*2R=KK:DJ'H+KTTB-?4:K>$8SSV*CL.^&[5R!;ZP39/#=\HJ"
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M8TL,3'\O)4,!,*=&Y<FPIHC$8SM41+(9UP*?!PI B7(A-2O*J$<(SI31(#G
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M3CNO7T'<=^@4I++^^(8-?^\EB+W[_P=02P,$%     @ P("!6$A"']R[E
M7#<' !4   !C<&AI+3(P,C,Q,C,Q7VQA8BYX;6SLO6MSY#:R(/KY[J_ SNQU
MV+%J6^JVW=WVS-DHO=H:JU4:J=J>/HZ)"8I$J3C-(LLD2P__^HL$'T46D2 (
MD@![]D:<.59+ #*1F4PD$OGXR_]Y6@?D@<:)'X5__=/1UX=_(C1T(\\/[__Z
MIP^W+V:W)Q<7?_H__T7(__C+_WSQ@KRC(8V=E'KD[IF<1.O-K>N31>R$R3**
MU^3+=/T5>4%6:;KYX9MO'A\?OW;9F,3U8YI$V]BE"?R"O'C!%BR6/(DI+/@#
M>1^%9+:)R>$1.?KNAU>OV?^1#XL3\O+PY;?9E/_QE\ //]TY"24,[S#YZY\J
MD)[NXN#K*+[_YN7AX:MOBH%_RD;^\ 2_J(U_?,5''[U]^_8;_M=R:.*+!K)E
MC[[YQ_O+6W=%U\X+/TQ2)W0!0.+_D/!?7D:NDW)*MN)%T!'PKQ?%L!?PJQ='
M+U^\.OKZ*?'^E-&-D+_$44!OZ))PS'](GS?TKW]*_/4F (3X[U8Q78H1">+X
M&YC_34CO@?0 Y"T .?H>@/PY__6E<T>#/Q$8^>'F MW3V]I:V:1OAL8S;>*8
M=L4OW>$&F 7PKTN&00TW^I32T*->@1W,E;"3+\V%I]@QK!RYM34#$(LH+I;D
M@/_ZIVWRXMYQ-O^:)0E-DY-M'-,P;1(E87 YS*63W'' ^42&P,M7W] @38K?
MO(#?<.J(U\ZX4B )6-30++[1+EM/H]0)<D:T[^Y?P5W OS(V"A0,#5]\N/W3
M?RU@$9*/(=F,OWS#%_JO.KZSN$Y9)W8+N.S'%H3S$=^X$?ML-^F+H(KV,H[6
M+3Q)(]FVOOFO7OP?A?& E 5N8VR>+V:79'9[>[:XG0)[<;[N&*K%T1L:@"J\
M=N+TF9^-C@NG0G+\7/W+[,D?FNL= '_S7P-K@D B%NIX(:*3#R-\W %9,"S)
M;S#^GW8%J3NGJ\+6D2R[C[F3-%[ZSIT?^*E/1SID! !LG#1--)2.F\HTN[*$
M\ZDJ,\@NM4^?RGKCB87Q<Z@"6RH$4V1^"]=[GDVW:>1^6D6!Q^Y\9[]O_?1Y
M8+8+ -C0!DTTI()0'?[%G]^\/'K](\FF5>3"BF3@#*L*"++=P4_Y#8W]R+M-
MV<'4G?J' O(?.P'<HG=4_LQ(?%C_%@<D\EGH=2?QD0J)/S]!/NJA\2JZ<Q9Z
MH^N_5G"#?Y-=3D,A2M+[VN7%[/CB\F)Q<79+9E>GY'8Q/_GYI_GEZ=G-;:DI
M__[A8O'1MH"I,AHY6''2:!K>[^(H2:[C:.D/;7%75S9M6E5@(W+#1Y O _;_
MOR(;/M*V: A8496"_3WI*YOY!MSC?GA_]K2A83*X4=U<W[PZ:> @M:RB8C2A
M^?!2&"P( LJ?JCB(-ZBI!<K%+D(W6M-+)FECR40%PC?_94LH=D@@8@%_(L"5
M0C2BL'KYLBH531X)Y6)OC_7[32?IN(K"J+YJ+G,#RP@.9WCSM5564&00B;FB
M*8G2%8T+%6+UMM#*LJK(R+=:^4H[2<U._LX9:B=1R);?,@CS\H,ZILLHIMFX
MA?-$D[.G-':BV/-#)WZ^2.DZ8:BQW:9LVP%'+J6,V4-;*F-B:MKR&7$O,E5Y
MQQ<E/E^5I+"L;7/*@/Q5/Z*Q":]O[C'---JQ7E_;A@^MAH%$-X.E;].H$W*A
MIH4;&QG<:GZ@\5V4T$[D%/G#"GH2)M"$G7GDF3JQW?.N,W4']8GMAV\HTE;D
M"&O(JB7UV9VB??Q?$*45TQ4S.OR'7$6R]>=+IB<'UE@R2.:OJ1)L$%U6FS$)
M25'@755NVK:L>85ERZZCD#O';E<.8]9\FT+P&T0)#B]".*@1SD#%]PP96H@P
MY5YW\J4?DFS.5W:?&%6XN"=,\CV/]+C4\N[1AI;DD4G,B_\ 5HSQ",7L8[DY
MTX:4Z 3.YI $)AV0A$\CT6Z>32MR:*;T.;.90F)W%AJFV2L$Z/4H9/],1@@:
MD\,:VI$H"Q.38H*HV6PHV8V=1%R8$O_JSYYM6^_C9*3IB9.LKN/HP?>H=_S\
M(:'>15BZ,V=NZC^,$0+4 ;!Y^U =.<G5%U8@,)&PHZ6<2G9S+7NVN[-^[Q[2
MA42:YB4"Y2)\H(D-\10!GHQX"I!3%<]RZN3%4\)Z!?'$2#2L>)[[(;,I+8BG
M"/!DQ%. 7)MX?LGE\R+\BA2+D>-G4BXD%M;IR*I$#A1D%:.7[DV=@8#_@17Q
MX 1@0-RP;R'VW91Z\(=9Z-5_41EYS:]?%Z$;4R>AIS3[+_MWL/7X8[B[8@RD
M-\Q2.5LNJ3OT6Y%AY"T\?)K=H>3#*U:!8P' '&2?8@4:81<9LL.%_]VR_\**
M;-=N?.;9I_M"W O5*7W70[_RJCK\^N",N9?A$X//JOFMI>28WOMA".==M"29
MK%AW/@\A0X-]/\V76H,^Q[Z(BYR2ZGH7Y(-A^/]+AHS /?PC,]>-MA!4<'\=
M!;X+L<!W#)8SN(4C 32PFI.YV7 L$,4UC^^=T/^#AUIP^;SU[T-_Z;L.I&N7
MJY%B.?);L> _;4MJ.VMKV;]RRNC[<^%*&K(_/S/C:R39$H(87E_*!$N$ B)2
MY= )R8J,2?5P)&2;^N%\NP5'E H+7H(J>&F4>#G0ZKN<B!$8Y_>NZ6;>W/81
M$-D5GR<I#[6_GNL8(FS3YVM&A939"6 9;. I921%VPYOA#@%F=IM10CY\HIY
M!X3/Y"=[.5>LERT(DC)[J]*E1I+.2?/N9N7_"^H_>=N SI<=)0]F<W$Z>IE5
M<_ISY_4,2597O! !*U;@%Y?.PF90UG3Y"B*G1:O!==WQ,]1$&2$Z0 6B62M3
M 2,TG#Z\?W'I/[!K]8+]WK]CHLD+_C1B!J:DYYJL5=)T>]087.+FD) SO,':
M#L]&)'PK5JU'[*;4>K28>T!"FDY3YO:9JR1Q-5KT/5O/DM1?0PVD#PE=;@/X
M:I/Y<K&B684NS1-6=54344]ZJ"D<M>5*)%N*\+7@+VRUO+S>!*[=_1@N.'J[
M4+"[*R>)TW_=P N-ZB'+)E04'OO73MG5US+@^JL!Q$0H=5*?D=!EU_'WU$FV
M,<UML[UX.J-2(B0[,+^Y)6WWRWKC^#&\QJ>Y59 )S*4?4IXZ-K1/IA6>X0MD
M*T*H$R^MF5%"K6+#]Z#*T)I#0HD(?8^U_=4USS%T&0L'%X:+PDDU-0'JR"S!
M&20EAO[[P;D?^BGE5Y=]",?/[YU_1_%)X"1C1(=W@6Q8;75 #9'%;(7\2M@4
MQKMGPI<A?!W+!V$/4:BJN:Y$ZZOP9O?W,:\,/@O#K1/,UE&<YD^)>24$3178
M86$CM6ZUT5/0D^5B)%N-5)<C^7J(26]/?79GO4"A=J1CCR@ R9<QO)NC!9B%
MV$0Y1K+'NPEK1,2%H;#7P0LHM3WMM>.$E0MPG3A^AO@+9PW1"_^)[#C4+W!\
M[3P[;#DH[S=SW9CID+&B>V20C)9;ER""1?CPZDK%/-O/,1U85W-,MFQ;,Z8^
M#PI*\N6+U:DW>F'U+I"M]/90QT\:_%&7/LNM(;IS6Q!!IDP2;;6&]0X82;>U
M@IM$/XD6+5?K(D&J$^W;SEWYJM)'8@CM=TKOTE,_<8,(',(C21<"Q*A,B7'
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M+NI FAX52[,RNPOGB290%>6*CA!:M _ 4L3&'AHR5QMTDL\+5?&BS2G,LUZ
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M>UMXZ:.C=.13A6I!J2FBA@E>_@"05*\:W)";Q VC([=KZ38=Z-)#$=XP <\
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MPQC82R\5%1$"F*# V%:M8B?C5L:KFJ2@^]6/$UHX3]<T]B-O! &IKVU8C]2
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M==F(Y&0%S^Z.D*5:1V@+ ',:M!T9S.T!D^ 5J)PFTJF&CU UOA6GJ,*^AW]
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M=*/!-#@>:.Q#^ FNG?4I0DDP;6.TLZ2T+5JVK=]"8'N7T-^W$/;WT,FVZ%)
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MBM+T71QM-^SK&<,050)I4">KX-,JB@?D[IGDTPF?3XH%IF"I=F&S4!#;:#.
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MK]2-GWPZIJ&[6COQ2-ZD-G"F+XY2;/#;XVX:@7FDG&A;J+KR=>\BV4X.S4M
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MQKO%JK#@LV\K7Y!LBA7K_MOUYD?XWY_?O#QZC3ER;?!3F0X"WG:DH7GCIO!
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M6:%V%6TAF9O[LB3D&2+SY:_4OU^EU)L]T)@IP/:H@0K5F; _YM.)D\V?3/R
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MY=\-31T_I%XA4FV/;-EH4GY# K/=SEN;:!OB]S9\PR;/LH;%RGXH?I<[NGC
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MB"UJ!#%]NI0:$&VPD ^LG!FV"E2)\<:4^_[.IE&UJ&.AHLE4MI5L"7FCE5/
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M!J!@UP^0>?VI<JSR'9\\N&)UBZZ"TOG%A\S'P$O0<?)[9/S=%_N:5!.8WG)
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M0MV#';*!B8'#,L("6TO#RJ(>N7_;<U3]1?V?'\I$@1;_!U!+ P04    " #
M@(%8&H; WW ^  !B" 0 %0   &-P:&DM,C R,S$R,S%?<')E+GAM;.U]:W?C
M-I+H]_T5WKY?[CU[>OJ53-(YD]DCRW;'$]OR^)%.SYX].30%29RF"(4/V<JO
MOP I2GP )  65*3C#[OCN,VJ0E6A4"C4XV___;3TC]8DC#P:_/CJW5_>OCHB
M@4NG7C#_\=7][>O1[?C\_-5___WHZ#_^]I^O7Q]](@$)G9A,CQXV1V.Z7-VZ
MWM%=Z 31C(;+H_\;+__?T>NC11RO?GCSYO'Q\2\N^YO(]4(2T21T2<1_<?3Z
M-0.8@QR'A /\X>B2!D>C57CT]MW1NV]_^/#=#Q^^/[J_&Q^]?_O^F^R3__B;
M[P5?'YR('#&Z@^C'5P5,3P^A_Q<:SM^\?_OVPYO\#U]E?_G#$_]%Z>\?/Z1_
M_>[CQX]OTG_=_6GDB?Z0@7WWYM?+BUMW09;.:R^(8B=P.8+(^R%*?WE!72=.
M.=E*UY'T+_A_O<[_[#7_U>MW[U]_>/>7IVCZ*N/;T='?0NJ3&S([2BG_(=ZL
MR(^O(F^Y\CE!Z>\6(9G]^,I=+3P&Y/V'=^\S$/^'_^:W\+<Q#2+J>U/.^V/'
MYTNY71 2OSKBH.]OSDN+<!=>X*P63KAT%M3GZI%*\@W_VS=24&_^;I?6WZZ=
MD 3Q@L2>Z_@1(.E5R#96<LXVVI+<QNSG)</5D?HJM#=_MZ H%22P_&\!#K:@
M6T8+X:0PLW?Z>^+%FSL&Y#T-/Q@LH '8FW2SP@MA[$2+,Y\^=F3W#DQ*)PB5
MDW#N!-X?J0UT@NFM-P^\&9->$(]<ER9!S*BY9OA=CY@HBQ9XJ!U['JR9%M)P
M8T#P_ELH:JY#NB)AO+EFIHH=/U.N<BM#ZR&'!:<1YQSRW'OPR2B*2&PB]1H(
MR'TU8?8EO'8V#@-OI)*E[]_ '<\WQ.>;E-E 9E&X?^6X7.U-:)2"@E+*"R]@
M[MV,.7)3CRL2MS)QF*18+J@3G#FNYS/+:$"[,F@XE64HF$,<<X6[HC'9"M?,
MV(H @9UC%X0YB"8*L?T0<A]E9_>=\V1$4/%K2*K.'"_\Q?$3<LE6G(2I6V%"
MGQ@.)*6W,76_EMP($U^D#@32(GG1U^B>.<AA['CLK#62M  (((FWR4-$?D^8
M=$[7AJ*N@8"4<MU-.=ZD/YE(NP$8[,[>^C!WIF=D%0*<J99Z,,:TMD&$Y6S9
ML>G 8"$@L(.FY.084RF"<F@/Q)AX3020:I*=UN:4%S\'4XG"B=U!;:LPP,@3
M'MC&A#9!@XM*N LR37Q"9V5[:7*&R4!!;;<]@F9[V8GV%M!PI\@>Y6D4>TM^
M5[J/R"SQ+[PUW_1WBZ)=[;0F)02@?F5!%02'1$?E$D&T0_UH/@_)G'%N% 2)
MXX^6E%VLLDC0Z=.*!!'IOAY5'/"[J'XT=EJ( !RDDUW8H5[@>BO'9[CV-K'C
MIA>"M&!E)RO^D,7H2 _("\]YX >X!\+_9M V+%?A+!T[OIND$1\G9HIP1MAU
MT/%Y6#WA)\$-^Q>0S6^ T,IAJ4]']V<+6/P6V')"9B0,\S<51EYFHMDQFJLC
M@'>AC,2&QM=PL?UU0UP:3CG_=RX;P+&@@PCJ;-!YZC@AL>,9J;$)%LCS7>KB
MF2^I%23@%:CL_IC3+(-T@.<$<Z+;(()>@15OW^:KT<4 ^;HN>"0P7T@S/+!X
M2QI4Z,#NTO> >EXXCKOLQQH02/^Y%J4WIU0."^[(K8?L.Q@-*2Q %Z$2P>_
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M%3#4_G;/5$=VNY92<>=0U EA.%TOY2+[V2?;-@>C)657G#\<"_%L)93(S2,
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M\!G_"A-XB?]].S4#3*)BE&2OPS5ZXN5T[BDPLH^)2HF-G=2I:A]'(P6>Y<]
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M*;_(R=?$XMB]PTF@OCOO(BG'1-9$4(.HUF$V8,A$L>#,,![?ZB,62LIFNF_
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M(M#@7>Q'_3R%;H@6Z\1F[Z+(UI_;;6;O72<+8D#7)]8N4BET)'X+3"32IJ-
M:]9S1MT*6T[7A-BB5IOM\KXF]:0&AP4$"QS/ ZNT?SO[R9A%[T]MN">([.^'
M"$.&7*O#_A]D<+"CN998R3G2+TC;-,^[3#G&375?7&V-)ELMO""F?7+XOMOJ
M;:Z%_21-V949PWG6Z^S\Y"K;2IAO]-(DCTD<TUP1(WJC2_'T+.%),)/4'F<:
M/\3XVSMSHW>W.]VYX8/YX1^5#/CG."&-!X;;+%39;[DM'+2RW9"Q/46T)>"B
MQ5$2ZR2&UGPZX0JZ<)10:C7(&K1<3@+?'.(@-K5'UV2&0X5T"W:6=,*%:X?;
MAM\1E7L1G:+R-)/(&:_Y5'L$1;EB6AKQ>[<V6?TID$6$_*3-SL9/YCZJ+#9W
MI!/\TQBVHR**82G'"JJ9299T;XA&7!$LNS,1O0P8\3J""6.<UF2*AN4]98UQ
M%O? [A [A6GWR)8?H'96_$NBVTHIK=YG:%E3,N(&LW#@X.P+!?&FHZV/W2+_
MG'$ZV)B)F+,0.71)_R"^ .;*B:U+"!*![C>A+G 7C[L,,E07]&^,(O_2PTPC
M^'W4)*DGI(+_JNF>[H%?MM=:H)T AZW/V>:MZ>,V1:G1B,CP7/@RW]1)/THC
M7<FW?.I++A$X*7' M\D[*V=8^J0ILH #O=(/S3N^D)-Y8%]#$Z3+TF._+Y=D
ML6BS5]1%>>T&%;KB4%>09V9L,03T0@*W$'M/.^N;AL^;U[J@J3<N?<VJ+AV#
M@&*4DJ@2528!-<K"G<V?ENP.;8N=CYF):37*^1#6-=S=>%O6TW?5^.U+_"_)
MV'/5QF5KX[&Y[6 7H\Y %!1C6ZW'975[I'8-DM0)=%K"J9I6XK_L[7#:9;<5
M2!DN#:+-)02ED31=F]IWE'=.D0'9V^YL_V1>4N75\M_(+JX9TPW\VL:YN7!4
M^(V4W"$E">IAT-MF=DF_W(1/E7XT45%6NN+ <\A8/^]XXB7$+YL&:!^GT,\+
M(GZ]82/&=;;PL64^0(*HNU0J<.A9RZ] %(,I2-Y[3%<+Q"XQ>K&%=3"<!!1F
M4R3P)\7$[!4J (63BM-80X]@/-'[V!> .ZLE0SH+AO1?U'Z+V!Q&YWG1 K@
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MKW.0IZF$^@(.:T"^#97!26=QS\%[4D])&I>27R@57X7J%^XS4RU#RD8$*Q/
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M&3-/I*=-?B3#&@]J)V8GX&FF7$DO;]63P<2DTL&;6IA&%[;*/HRDZD!\)1H
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M[F1:@K\VSDGI#?(+AE\C2S^)DPA0PN[<0E)ZQ0V;QRKUM9D(YI:!(3&?.R^
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M(UM\H&#SN86?-"VQHHW',1(E*(2G^S6Y_D^^-IK B5*+C^*>.CB[)=]RVBV
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MT>?00@K<SX>)U 8>9FFCW(.P5B5$&YJSRW?TLGA:,[I O )=$'S9?#'&O'H
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M%8([DH8PDBEF2YH:]]8$1MBS;1Z,8H([5.NK$?1C<I,S,\XAMTTN#.@<C/%
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M#$29'#?21? ==IQ!(>Q,A29 P5MO^GUJ)<G8#:Y]:]9T4E9.[I9*<*@DG,%
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M3XOA6'6CQ ?E;#/V &3/\M=*5DW?MV^DD0F(@JC#Z-*DYV%"H)/4T@_1;4Y
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MTTMP::42Q(FSK9W97H0E"!)7/.//BS>QEO7I(E8)9@=?Y:-X\4Q(VU-!W8P
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MCE&2#SH(Y0[\1/E#N@C_VINXI&7R(MTY;-!$]&7Y;([-(#9J##-E.IA(H"5
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ME+Q#Q<ZA6*/:9T=_SGMLT?M)%0L_HE&Y#^S>1&C4,#N+-Y/'Y@KFVZB&?0.
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MZY9;&X&91R(_ZRQBL"DUID<G<>.7U7[#L(#@]%"4GR? KY6K7TP#*VT3A'Z
MTL *FUC#..K(IG)T4?.J_(F,>?0[M:M2G"".5HDV),&BF)=]U<_&]0<29)T\
M4&V7;60_GOG;Z$@K "11M%M?3@?HL@&..I112=?@9BORFTVZ,\EXPT$:;H+!
M&Y@6:1I^E?O,\7TVF6'\9RZPCW&3//[V8U=TGQ[!*:S#UV>LPQCK\-49Z_#Y
M6' QMOW5HYG!/$_&MI]5'2.+*10&<C"UY%\E/B4P?1# \Z<8+Z9OC,+?ST1C
MO_744T>90+1'P$2OC7 ?B061!D($<D)_T[;O% Q;0N\R40E/ZG+TN^!6[NF"
M6J*0AM3N#;G%W$1/D[;ER*H)?W5]-N+)XB51[Q@'V7[L;E!RNN=_$U0,CRDX
M6G7L"0*FK;JLK#G<;TY; O;23@B.+#]\X&:E(@7N50T<I7)WO>?UR"ZECHGA
M5CJTL;>.7AP.$99^9NIA*5._QP9&%Z[SVQ+(9+F*_>[&>^IPV"0XI[&;V7#
MMAERN&D19+8Z-LDI$Z*=E 7X_TQ=5"I"&@EB+H JED^E+#6:K49XOK8T;I42
MPSQZ_/5E\6;?]?L2=3ENXE>FXMC85#%P!M00 60-V-7LSM+/-88T J7:8A28
M3<$L6%TDH0D6#IM0HZ/PM1J&XG/M_)HKT159PI6Y&<!U)"\<NIDLWPTF=:Q
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M"J6^BL*N=:%GZZ?39>$>Z C=*O7Q!B[B9;'UJIR7;M,Q(%Q5^V*PZ+N<3XT
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ME</K!:&?OO0WWIF_$FLMQ<)3RXNEX6(UN4SK+DS,94EI\-1^,7@&/'ODJ?N
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M3HQ>.D-E+&):X61(..4H*L(2\JIL6$)#7!Q:DTB5<4"I4,(=EU/ZO8J6?W7
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MHX%+9*)#KNUNP-%43<Z&3XE^'<912>#4;6F),OEZW4:U7]-A:E1KLA_FB5U
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M4Y(XMYR691U #Y7KH93B:)@RBKX*@.7F"SOQ"]NOZ#"-(#(C[YNKY,BO]05
M(F+/*E5@9*T+=3Z5W^JRT ALVU+JKA( 1?$[&E.M>2]DT2,!T+AAAMHE&Y7Q
M0Z51 "\V%A5^!L84TKJ+D48R-Q3.TII;"A(Q\M*^JALMU(0C-;;_:D%?=,L
M!6K-VU6$74K4Q!$II3PU;1@7@=6W[4?CU.FL>[V>'>G1KG&+E'"I76&R=HLN
MV2:A@PBCSFH@>8D@2RX<? 'A+4\$NA@TXGFQU0)2ZQ =DG<''?^9(FK_REG&
MS#+7-!4<M6PDT>G!38LF% $R%1&4D$QG^I2C8$4%6G+Z5KPOB_RKY%BPE8V-
MPL;WB0$)O64F/L$*O8.I1S93;L5'OJ+>H$%>L? C<"Q:]_/>[*^W/@]+LT/
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MJ]M50%ZN''&M&F]T.EPHQL8V"5<U47E+5O#<4>H9#\R"!8+_TC7WE7C8QC3
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M< #1PQ5#IE'>;'1&HX%I%5[[4)QIIR.AE8K9NIE-Z%B;G\XF-*H1/I^\[";
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M(/[EX?'8,<OL0XZ9+(=3)77 )9T53BI67JEF(@6WK,7W3/G S[P8DS4R"9[
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MX8]NPENXGKK[53,(+IFC<"BS9H%SV 4YM@FG=EAO>E:,?Z5'A4H2T-Q77LH
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M!^[_TMN9>LV^\WI(_IXJ)3%5<_+^L@A/TX=K17AL"W=V3<M:D3][5]]Q?=
M7OJ^(]B8-(*-W2\<'/"0[&]^[Z9NV[=&X8>N%R6#;7[1@'MH0Z67O>2>J<RU
MWGJC,M/=AS+35IGI_O9#F>D=.7$ZMM3?BQ^/*&7H=OP]+:",7]=U]EYZS)HZ
M29:1JI?&/&K)Y6ZHCW2/&FSO];?;]OIZ><Q03$F5CM\^[?N ;R_!LP_Z@ZYG
M1V>-#>"BR44S903" .BO83<&%BCB8I+\EGZ^C BT\-Y$!P#9!XP;'1!34NB
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M+OA79F2O1SK.'%]9+3>/^J&@ZW-5'=VT<FO#$Y05^"=V[/Z-50!!JX]OQD=
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M4PPTP*_"B#M88I8/;2M1'(47"Q "!)/N@E?"^T#;VE!)V,O9UI']U-+[J6_
M?F[ KK8<,(;1PV/&T,;BB6%AV864)%1+2VAB#5%/PZ;?<PXSL(8OS:P5CK>'
M0.4J6VA8W4<;CE8DR/V(NI4Q#/D#>+P/'G7!@#USHI[*#7.LR.T^:H0[_QPW
MNY%MF'S+#D2F?P\GFL'[P$/.;TZ2DW!-E0@/'G7/\6 =OHN&39*)[/NC9?M@
MQ<&&:.0JPBKZ>N=%=",J>[E"OP,TU:,5.P<]U=T$./_9\W_0X-+#G$[)0)'2
MEHV6XKFRU=.8> 7]GP(8X54/A/B1WCN*5:.O!$87%BNE!Z: #I7 MB=@%SE[
M\1GSU1W:%:07-Y8A,:3!N'$.?8-M=6AU6*Z!.CSTM(CJ 3Y1DCLU;](CZ7IA
MPU=*HP?&(L'W!4T.6Y=0KSKW0?4] A_.Z7%*//4_ 09'UZ,'>@8,N: V6%A%
M0$CUR?XI9H*/M3AQW[O_-Q\?@T):Y.[>YEGJBY.0+Z%7S,"Q=\ U#V+(R7\$
MAP\\V]<M2O[<&0.Q6 Y\;9\#/YX#7][GP&\J<U-P]RJ^BFFA!K'Q&+EK@=Y9
M;Q'H[!9)3RVYH[)BPJ@X8+VHI>Z:IH4#Q[JW5LR/NJH:(4BE6F@,-R,:.#$,
M03TK\[OO:'([JL54 VPW;D<K.V 7DPH BEUD[W<F'?)_)MZ?' +RV'/#)FL>
M^DY\OU'7\N]@2ZD[C5VG:[XV/:=SWUZ;?LG6N4S6C*Y4NYI2NW9,P7&U6YQP
ML8827=S?V"9L>!:[\C\W&[;1H/<=C\[0&-"D>$CJ8)AA,0U9K*[/8=E_R[!A
M-WZ;8N;<-Z%5,@OU-UXT=K.\._PZDSD"2^]S+ 3/U([ T[=^?=/6'>LY,%(]
MC7V![9$Q;*Y)(L)3Z6 *.@_XP_RXN"_4 9[KQR5LN,XUY0%V]'056(-^:!9_
M/9)A?]OGQKW'H?5"*@Q#;@-!]PX]@<=CBBMQ)#>%]D$WE[*%J<(4>)!]B^,B
M0EJ";$<<D=F%4_O0B0+5?#=QA7!(1Y6JI[_28J@47\((],/79"G59"D)-57W
MV82H<>QFZ-L<VE?-7P=V&%(@(6YHBZ$G.2(L(!.&D'#LN$:-QPA2C821"CP$
M!BH\S&*X%RQ!J,D5A((^!")X@?R!NLZ@?')LTIUN5SMR*1'C+/@#NMCSX">P
M4QRQHOL-$MSXQN/M>[%)M:&2J^*0&[FL?(]$7A0LYY?#DE%J-(UBL7C$*0*'
M9K-(?QI:MK8TU2H<TYI\F]O9>FX\S6R/0GC6H\"1E;UZ,49:4;XU2T+@(08.
M0!XY  W$D<WC:<()2RK.4-NHVJ9'@0QLX>[ /L8;Q"*&\CBR/58P0G^#9E%E
MV)G1"8\SIXJGX8_NO?!1_Z5AF)4JDG6A^MXXA*9)\E',3,Y''V#OWX"H![..
M?8YQF4763@06H8D$L+JMV"*] S#\Y$+@\< >ESB[L=XB'2*99@;=D2I%#I^%
M\X2Q3C=\G%B2_%.9H+M4$_('E"QWP(7N@8<=JDD/R?;T"/6B)??\@;P'OOEV
MBEF)'K)&N@;&EAJ,13NM1U,/2&5*=U&9C:>T;!GU5:I0,@\P!*AI6+!-+>==
M#VR0Q7=1.)E1C1S/"UB2BMA95*VNY"/K!RA2QT*\+CMDI $_OD&Y%M[0$;%0
MGF+Z@YJO%E\68U8$7EV&CYYO_Z^\<XXX[R00J2FD21-*8 0Y*>[6^I_(DW=9
MT]ZNE/<0'3[+P2N4_F@14GR)/<-X>KP:::E1IE+7?H'R(+AS*_@9 SM0/&"I
M5VG6<.C8+*-LB$+O0="PB&(6WQC X<>SNW)C!=VT\)T@=[9/=%*RF)A2DAUU
MZO .PHVH!,2I1#?)S%J:F7ECR"?%ZQ1E:-ADR!N'1 4;\E)H/-$ =8Y4\Z38
M,J8O3^5+5M+8%.MOF.)UGIO2Y</K>^M5OW\LRX_TVT<!I&N!-^,R!MU/EXTU
M,1+UC$@@[%7PE1G>WP+II)^K!40Z*T6ZG;%7.4S31K%%^(A6<JZX]D##V#]?
M M^W&+$QUN!X\1JQ%B8+J4#<9))7G%:AQ1>^\BR&J=/\6)R]QEB)!. 8#>5U
M[-0D#>63)L!H0U]PG,!F]#B_1Q*/VE_[[E(2R&U(MD[ZVYC,33>NHI<^/<I4
M16P:?HCK+15_^[W5NJ9_FK\=<:Y=;MZ(+_J(?,EF2A (IJ)/8IQ2>(3T-LE3
M<CGJMCL!R40%/T!7 8\,!!T'GRF 3S9C_XYZ#RR0^K5#87G*1\%?4C*,J8Q$
MFJI:/E7EBJ_\!SBQ_J\5K^ V]?8<D9#426$*Q?PA6:*K!"IG\1^H2-9XO[W.
M=VW2I7U]?VD_?FE?V5_:+\EQI/]8NMW[ZX'UKZ)90O:T3E8^I?.[SC>]WBKH
M?__>NKP[OVO=G?^CH[<NO^ '%^KO+^>W[8NKV^\WG5NM=7KU_4[_UKKYHW.G
MWYS?_K$:/V(CJGYN!V!?Z4B'B9.< 2>#H'&B=#HP+"\/R';8+I[?V/3$S]!!
M$C-IP5)]O-\YPG/E=?)<HZ"?G5^V+MOGK0O]%OBL\ZUS>7=+K'?[_?KZ@OYN
MW?RI?6G=M7:8QZY&_41Y4M'II!+05<$4..<D3.18X6AN<,JS&_%7L?8 V-D7
MC\(-,%$32Z(,^('7_2'#PBK4SYF26ER6@9=7G+U)MP8RGA\^>Q*M4(;2&<)Q
M*G:A,1+E2*\%DZC3@3 41$TZ8TA)3)9$_S(5[QU&]PZ6B"4>6M^F/$0460S%
MPKSA+1[/4;J*9\KW0R,4\(KBE.D5B.K,4EE9IU0V"WK[:^OR]\ZM?GY)L@BJ
MO_7[34=*YS_/[[[JK7;[ZCO()GR@75VJ/\\O?Z<?)%*=6(T=%M]+SQ4?E)0E
M9S C'U77RD?@4;2O+N]NKBY8I5_?7+4[7]"!V*6P0\[R.T]P2+ 4%/@7+NG
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M\D+DP>+TC=@_3CCBX[WC-0I%*\@<$5)<KN6SN/'&)KZQ@_I,.RA8A0EVN;C
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M_F?]O]KM3N?L+&'+)4[X?QYMQW;U"SMO(]XB^VH9I&XN,I\5;&RJ0Y6!A[:
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M/YTXNL>5^6H[],#&6L%2L5B3/0<8.%_-1'^K/S#]5H??5ODESS1TW^,<R33
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MC^Z/#LWBT:']=#065/VCH-^ELA-A+.2_^U?=POJ* $?N1[YK!X^Z!3,;TB4
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M%#?T4MR $F@EN__F=.\FJ9>>AZI,XYLS03=05@])RU\3909X=I'J(.FK#%,
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M:@7]>#-69ID.TX<!"?8&VX $]]Y:NE(*'Z;J;+^U3=79(A2N"V^3&NNK,P^
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MMS,5TYJ'<#6)?WT&8\&.)OB5UD]'>+/\%@7B^^0Z!.-!" QV8QWQ^R>R8R+
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MV=TX=_. <Q^LG/N&29>X_<M.N@-:K0'W1$O/T6M%LPS!^1L*\F_2"%C].NQ
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MLO<L8R6@(7*B#J>AGQ)0&QW:2JQ'6B5LCGUZUWKM=3?.EB=CK]XU3%YKG>3
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M-GHZ2K@!T\2YP]%OQG^&SA"'+D8CA(7H7:VKY^3NXD6X?NXE_%,5S+T+%O1
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M;XH?KM(;CN@3V#HWG#@LZ+[PA%0"PBES/W097F1ICR+K;\>32$8,XD2+P.,
MEW !6YZ\CD/]>V$_L0_,'(<A.-#);;0^S_S .9ZZ?SO3UV,4D\<@[^A/.JQB
M A;GQ)_:RJ.%"!3?XWCGT<1##45%&<1BOK1I8L@3]9P#:V1H/'# '+9O2NL7
MR'G$Y\C+7IIWC#\ V6YAU=PY2'&&/?!AR(!HXW'4#.A&3Y.\V%JT=$N@2'=M
M^ Z',<&O5TV"K@$WHM>(\"?*GR?W)WFT'Q< OK20IOG3) +13">NYX1.=HC4
M",I*9 V0S0>BT-.PD! 3 8!.ULSUZ'9OZ*$Y.@4;W6$+%)HF%R\2$&T9$T]4
M>W&G4SP9X>+QWW!2% X<)Y5C'KA+M"P28BQ15.:<!*7[[,07)\83[T#8>0BL
MHRV 7YZ!@'0E9,>& ".6%*XQO"CV<D_(1&#1%SJ'3/\*17Y0LDU.?)Z4HD"R
M% 3"7C@H6V)UB&P8T%Y")Q97G(EJ[+B;Z;>[4FNLO]ONEKD%@]9';D%>;L'@
M([=@!][_Z++[D2*P-9_DPA0*6K25&*+;6-KW(]#B%U/G9ESL_M\% %-FC)0V
M8<+J+@BV@H8F*E%DC"7OXA69NHM!1QDMF,;. >!C!Z0Y>DTB*UI$/IB6@0#2
MLZ+;J^[UQB%?*MJZ-P&!23S$*USW.*UCAL_#=Z;V2H]QGE\79H;9F/_WJ'M4
MW#V;,V2>]/J+U,#SC!I8T".:&66WJ,Z^"&A43T 4\=40ZXVLUM@O:^P6H>%'
MN-?-!3%]^N)XSMB-?F:^-"!"2MP>VHX=1A?L&K@7TTH]7-"X-?4- 9D277+W
MN HCUT3/VNR'QP6N#[66@/\G=$L1./[U.?/6<:8N2G>\-&'ZL %K8F9F^^BT
MUQUHO=9FE,9:6O[<]/TID>9PR/W!5B:]MM;32^(ZMXZ;%\'%W 8NJ*D4'0R<
M\8(EDSH@-NRZL3*2;P"3,H[=[\<3U[8=>(3]]W@,5#I&!,(Q-XRV@JL<?N;]
M'6>^;VS4#084-*SQ G:%B]$URL,5\3)T0I/K/P[('1)&5;V0/J.@WJ5WSN*.
M.8=\]=EF^+B<EL9-X=7]RM,RI.P>G?:UCI[-\6L@2NTLC@-C4CPSJ2UT*UAP
M7MX\(.U YT^@!N !R@T-_R%H.Q2D+<9)B%GK=K6VL?E8[H0B>J];6Y\\J&QK
MX4H==$VMW=H,;V]@GL,&"SY?Y'20HRZ3,"X/_&]:;F<71H275-M?/$Z=W1&(
MJ[ZQK?8T6*D]Y2QU]R/[UNF$+NWJZ'0 @&0]M3UWCF)D1-70LR7\4MD QE:?
M3\N^ 4-]YD/:&-SM"0PWE7 ?/!IA9Y%X2@XP[97 ,TE.;UVABNVB$KMNQ4=
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M0!W&#*0)/'40NR:90R;Z4 B/]7*@?#(F,Q>Q^M@-*+J91Z85L6D&>"RC>^
MZ*[WNOHN 5!'T"U]!$OS]&?P!AD\&T@M)G3U!Z,01AL(=!L\PJS"_H-?)S,=
M#LB&:#H!#*6>O")I#3E"D3Z@6Y$,4PE1T0B\R4)$M =_PJ4R3FP@5(3W!WO\
M;.*[05_ZX&NN@I^<< "NQ)]J') $W]%!@2HA,>^YV6=#GO 1R],9D4#GTYD+
M9B1ID7@JX#*9V-]HYIAXD]OF?'$,4'66P290+@NQH?P0A H(?*3TF1@2X=F+
M;DA%EY!WV'MX-Y>@)N_IYC2[G8Y@/&A=(CQ9? $EG>#*^#UU)X NI0OINL/
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M6'S"X.%\C]PX7$N<%\J3@3H*VP5B2PP(<Q:(AN<7 ::T;1E<>9&7BS]Y!%9
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MHS\;L_V(35J!V!G[ T^G\! 8*%[( ML1-:.QTUM]YZC&ZR_O,GV3<+AT1%'
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M.DVBTVS3HG(IS-A/7H!"EF4X!_QK)L*BXI5UPV)&#NM4@"*4"V>HF\X#=33
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M<$W>$I*M9WBUT8ZV@;S.6^'<=JJJO.DHN1BN8I^TL@RGEP3[D/(FG[:>X4F
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M*-X?-R/HS_)FA 4AGQ"''?PO:NK?JN%_7_L'4$L#!!0    ( ," @5AM9B0
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MW\4"L(<_67N"'^BG;O\'4$L#!!0    ( ," @5@!^.UNW@\  ,5R   <
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MCP3;W3TY[EW\XL?C>MFU*J&>?+>[0+.LFF37KF5HQSCJQH\["T_C;':-_$/
MEWCC0.E0:-?:600&#2\SHR(9YE_ZEMWW+?_]7&30_DGVLS"#O84I_#VA?F:Z
MGS75-.TAG\AHUOV<'W%\<?+HAW:STV[!U"YR0WUQTOS+34)[AXW6X=&C'PXZ
MK<,6_-MJ/-L_/,K:[OSMAG,V<9&#Z6ZW3P$'B( C:/]3*N( <>?@0#[@+;AN
MMM:L]$$!KXN0;-8[<U NSSI&QR;ZHLFOPNB+\%><O-L&J[,;@#OS<7<@P,T"
M$20DDF+3!VN:1BD4YU-8FUN[+.Z_;[/U_I0/;\=1S5@(>^R9M!!/;J,DC!A)
MM;)I2G++4+<CD$LQ@IEJD6AA8"7 ;Y\*Y!CLM[&,9%R.29Z&(4S/=-EYXW 7
MF &L]T>5LA>P^@R $ KVFXI%.>::\<0YPI4&A!^_/YGSQO<;]SNV,]6+'GNM
MZC2YFYN;\LPKA^M;I29LOP&(_1FI;KO&SE(9A3(>L6:GQOXGN1JK>%2M],4D
MB01<27E\G;(>AKYD8.%^(3_ [660R[('@*X"8"!F=BP-QO/(!Z@QOP'4=6RJ
M%<Z2,0>S'8C4DE(/U"111E)\$DRHBPY2K!$\"5#_6G(#[=48QB?5 &.:&,($
M0VOQIL<87,P^Q^ED(#3&'P&!OUVV&LV#!O#D@_;3IPC&)_5L+*?5BAGS*&(\
M^)1*+=R(93S%\",,PS57HV"F'[U[(-%J*D.,9D9B2K%,-$0T#R/T5 ;"U-D9
M1D43>$Z"@,=\BK?S8 RCQK$.512I:X0,]U'5:D7%+F3JPTDP]<*\*%;MKF%L
M=6[[[%BK=#1F0,!(DK%)(TNAWAH;< ,]Y@VG@J8S3&$6X@:MB\&INHZDQM6I
M5JZE&2,&*(H;@W@"X&0<J!UX'3"G?-81OS9TDQ:C-*(.X:GKL0S&F: &@CG(
M1S-8-)0-#&8P<Q'C3#;?SF+3S\Y!O;7L,=Q9E.<49AA$ ACQE58?1&!1>+":
M83$>OXVQ;$=#-NM-UA.P-R.#D.H#Y*X(NYNWKK1#T.S\OG[7;V<$0G1__^:!
MH-O,+"DJI?=ZPL W0G=93U$:)I0FB)01+.:3C=.G3/0\M6-0TG^X#%,(%[OL
M%9^Q)@9\FL\V/8I7F.,*(@[J; AZF ;A[$"7G1XT_]-N[G4.VX]; (AZH_ED
MT\/I"SW!'? +?!%*L!SPV0FJ()7VAJ6R9)E;C7HSV5(V99T.;&428._ -J6F
M=$']%B@_-S6WVD08'FF#:56@%<@$)\Z5RPUNM3)G&X\M]%AC202<J,8F K93
M2,;5 *U ;QBUZ?SV11H4K]"6>DY9\$ZCHFE&/&X9")AX4>04V#-RLDC8[$$@
M/591-C<44Q&IA-@9978G0EBS0%4$,2J\XQO:]SNU;:UZBY8 Z%4HOV3%JA62
MC5^&!%2"!"D!\Q$:A*48)M#MPJ(&2'KA0Q<L62PV++AE]? ,8VQWIQ[:C'3X
MFP'<XJAD81N5AR*U04MX2(Q2CI400ABWC:0%@@VL&<TY &G&8@&>A*'$2:B"
ME+83(<SRCV+Q#F#I3FB.K:-C 1#+')U<"Q7W)7XOP%70(JO,@*'^450*"W[(
MLGXIR[9NUUNW.'?X>>[7 :/A(#'<U'/!".<1 6S;#;AC!M(?6I"7=7J"/%_4
MH@+=2A3W< @^0&DDUUZ27(XFPK+QQH G291QLFK%.;&A@MZ1JH(;I &K#H*1
M&(%FQ2(BY^N:S ,%D0IC21\@YD'@.B3O<59G%W#-7P&]JLA=!<UJ//8=>%TO
M$_+GZ8MJY6SNHT:2#R)!<8<!.>GXD%_ TBS7_CP&XR!:$"38=-0ZY)J"?[XD
M(K\EO$@I#+ :\\!@@8OAUN C5H^A&AJDEI8ZDF#_D$LH;"],R1DV@FL0-ZYS
M@574V+4&),##L Z^9,SAQY>8P>2+7Q1!1JV1F5T7E[D3HWH'@;C<GC^DGN]#
MZKGUD'J^-]MG.=_=>LAWW_M\]]T#<,$;VF=Y3>E0@'>9F2_\A<Q;PF<N9>#<
MSO+X1_O@'_6+O@?.>%T>1!KV_EVO6H&MPD"=16#XZ^R_CHTW,S:>5ZZ'64D:
M<AQRC=;EIDYK>2;%L5>-O6$0!%GG.33,V15EK=A+1>D^F-I%'-2![1B3"D/Y
M). T[%II($@PO,+@YN[8&0-^_/[=OQMU&">05D9/;5RRVUH_%R8I G:8\<VE
M]>MFSA.L88/-@ @6W2=/$6&=(F!Y(LQ7R7-2#*,V?O38B(7%9X;2YFC)6C \
M$J8H?8P4<X.D,TZA)>=$(%W$>!RZ)5E#RSTBB1T([T,[(LMG>;/K!Y-#$(>Q
M-+3O*\#3P8+0H?2'4):R@.718)U"A"?W,$$K)"HVTKN97KVA6UJMX$T%CU<M
MQL *KK3;.F0 M$JT%!9#/\54<![S*8G;VBG$9SX;R<8@=K7RA5%L&% Z!/6?
M:F<1OI,X=F<E;+,&GIG,<G"2#15!Q$GOS8-BBT')0CC!"H-/ET9F^ZSG<2+8
MU&?UP'A+%>8E&3FA<%'"&+J<RXH'8RFF6>AU@L5M/LX"!J988I(:W\^:"$L6
MB:$@#=[BPAQ.YOEJ?E RIHJ+ZUB$U<K&ZBWN>$TZ7[DFZX1-=3D4_B;-NC8K
M0THDR\S@9:>!9%Q4%,7P4Q;B%)&<"KUVJ:H5W&0F'1CR(2VJ,EA8 D>=Z!-L
MR#2B"-B?H,B%X3#6# 02Y@@S!^$$9#2P<<MCK!NE<Y4T_FDAQ>=.]T"W(RP"
MRL$3*9<YH"BHPQ7.O_"KN]/E'N&!6 #-N:.PVEU1F0-'9;)SJH"Z\K"7@YR]
MG*XI?.,#Z1370@D;9H\7Q%%D,-URR.5Q\\G"HI-B(3 2>?,E<86R+K"<&-7&
MO-%0H@L"N[*HAUDXUUZYMYMI+\=;%/SF5 IL4\SSE<1'?-QZPMX%,+LLS3(7
MJDOAQ"+JYB(%'>4OLA"XF*LEU"#I_+=EG;Q$ (M'W^5276I9)-I^LJR2,BAA
MW8]SKDLRU8=\QKW(9[0?\AEWO"F6LQ3MARQ%6;(4VR.#K942HK<^5"#)RJ C
MTW/UQJDNR5FMBV%.@4,Y3:,1-&@$N% 6VI&6XE"QREW&:@5X"'AO>IE\+.0P
M$B[#A1P ,),!V&5Z",-0L%E B,6JMY)XZ@?SB--WB:*S-2CR^$(HY>&':@7P
MD84<\V?ATCJ8E+F29<'7?LHN)2_ 9+5 JSS.]U-PO@NP&=)!&@" 20<3:>=>
M9EX$!3YFL=R3,#)0&.:1>6ER=D)K'L@F'39/HGDH)B+FD3NJT-X#,MQH, %*
M;8:IU))HHJ=@SPKRG4J%A[$,.\UKD#$+J(9S"8'WN5Y$;U^=-?.\<UFDTV8%
MTY>C#QQ)=* I#U4([.#AA96S@7G] DC:AV#]>V#6XNYL'>XP*;X-U-U5_/"9
M.TDPYECYNARI9A-XHEH9"'<R=.6\9%ZD4#SHF46,*+_J B%9!66=O537N(]K
M+ 55KJF"-DM#S\^@!E('Z00#Q@'.2L7"!ZHGL%*H/(2Q*PD'P$8V!X2&'S]:
MJ/7)S%J6)EJ7MM BB69+U=1'"$<D6O@=Y>9'<BIB?Q>Q+5@&5UE:0-< DU5B
M0AD_;KOEL0_-.GO%/V XG\1.!;<QR19C9^"'!8B/2/"0:.F$[N4A/N\R!I)"
MB700-8M?EB4LU,KS)JZB&$Q?G&\M/V?XZ*2!:;%<C&%)1-"NK]!LI4<\]J<Z
MYD# ^&DFDVH%X2*\+$HBBOTZ>T,J!@Q7@*G^#P+\BI+8Z8(A.2RF0#,[3<;X
M3]*?3D?F]?XL\T"*>@&MD#]-X>P*72H$TNM+B:&O:(ZR12OME4=)%X_]-]"K
M35+DF%Q+2NSG!6&%Y0)EM,255HS^_'T*PMJ(3-LM+ #LGLS6",VG&"DKLPH9
M/?_2T;N:2Q]S(SS=Q1[(V\B.:F3O8+K J%QN:D[U0/J#%^<JU98\,SZ_6M+E
M;+(7*$,.PM'N_!+%?7SF21J';4=V.0@R\15*>$ O?WMRP&-:23RU_V7TSAFW
MV]KS003#@0RY,V;@&)I%#0!HB-U* ]8F0H^("X;NY2?NQ2LU9A*)5A,<(*I)
M+9P U&A:K4Y]O10T0I':!&#MB$BVZS%/Z;SS/'V9U<,@VF&^6-#@BVI!QH!J
M/_XY52RZ'8NS*"NP^@LN@,Q*A$"LGU(>ZM15EX@:OIP%L%(HQQB[4F1FKX&-
MJ\05^)111BTGHUQ#.HV(IRO=X4HR]=7*;37?6Y'*=AW*ATSH?<B$[C]D0O\9
M>V,Y(;K_D! M3T)TVZ&\_(VE1O#HK[^K=.N&NG]Z=OF<G3^_O'QW=7I^\?KG
MGW8:._3[U6FOYW__ZI$4+$>^-P(513PQ #/_:8?0<=Q_ZSL \DRO__.C!@CN
M> 3U>_XN^J,+NR;AN&MC=:UYLCA9_#,1^1C:3V$("0^1%2WJ^Z(5(^RN*M"%
M;\_6OH9US[_J2N2O''CLG-]4BR?=(@HS[=KOK<[I<_HCG\Y^X]M-9\_L92^0
MI?>3?6:(V0!:[1_G*(+[X,=;MXY[!*9[1#.;^XE=UUW^9T9Z]-XR_[IZEK^M
MO@1_X&15>2W\T8('1;09171_=<Y?4R^+B'K0+M^)=LEZ>O!([X-'^O<=QWOM
MD?X3=L6R+]HY8F\2=UZ&77)COQO7=$M^XMJ_NKB'?X;R!#_0GZ_\/U!+ P04
M    " # @(%8Q^>?>G\;  "T]P  '    &5A,#(P,C<W,C Q97@Q,"TQ-E]C
M:&EN82YH=&WM/5USV[:R[YK1?\#-S.DX,XIBV;'3.#Z>L>/T)KUNDDF==MHW
MB(0DG) $0Y"V=7[]W5T )$C)MIQ*MJRP#XTED< 2W._/PW?GOYT==3N'[]X>
MG\*_#/\[/']_?O;VZ/"Y^1=^?6Y_/CSY>/H7^_W\K[.W_WXR4DE^P ;;:<[.
M92PT^R NV6<5\Z1GONBQWT4F1T_@1KCUD[LO%U?Y,Q[)<7+ ,CF>Y*]9S+.Q
MA(_;3XX.?_GXX=S?XIF6_Q5F'_CUY.CMU40.90Y?] ?[A\]/ $Z\!?[YU-AH
MX55_2H8Z?7WM.HL^J/<<<.GV:^8_Z7\*G<O1=($'?".RG,N$R62DLICG4B7=
M#JS\582,:_93%'XKU.NKJZN?,OJ+3>#;H1 )$U=!5(1PV2A3,<LG@AV/,R%B
MD>1P0< ++1B<G(3+53YAB<H!XAQ YQ'C28@_X$WY-(7_37A.GS(QECK/>))W
M.WDF>*X1BC23%W K4QD+5#*2(>P!R]SX/NPY_OR/SC$2HWR!0W2O=-7@!/#<
M(EL H(^CD0P$.Q-<BVZG?"^+0'A7Q*/_[PS2?"X&VB]E@J_L@.WNI+>>YRKH
M8Q'8MOL[>S*Y#;HSH;7*#KJ==T U/&&?"PG8RGZ5?,(E>Y^$L#:A^!O5[[&S
M\],^VYJ(3,#%(WAW@. CD65 -;E"S/[$LWS*CI^NZ^.N]\LX#D-X$_;L3PH9
MA3(9]]@'U6>#ESUX*4F*KTCQL/S@O:&_52)Z#-[C5U6P-S*?]MB;";RG/OND
M=!ZH$/;9>[F]@XQ_/9]_O=_.&_B"!\#(DR(>BNR [>__O//RQ<^OUA7@]3Y.
MY#Q"5)SGG8A2K1+V:<)!< >BR&4 6'TB52Z"2:(B-9[>B0N=M%SHNZ [*;1,
MX.5T.V<@=!,-/X"^M*[0KO=9SN,9@U?;.]OK"O"C.$Y@&G]/5#)F?_,8).2Z
M0KO>9_D>#",>!"H+>0*Z]:4$HP9-%CSC# Z9G?%+ID;TW2>ATDC\E&DTF33[
M+-)B&,D ?R85@PP@L(J(%4?B NP=%O%+3=^##51$9(G!$UD%D7ZP;+K'@.O#
MO=W.D&NPHF!1\:V )X0?\;(+%17PVC-B2CW&4?M'+C]24:1@#[@;##$0 QHW
M![N*Q(!=O(0Y0ML!U[80E#^DF8BE%OI@)9;$B^W^WMYBKVV_O[=&UL0"5MEQ
M!B(Z@O<V8"?PY@)01DNCN\0<>[K+-]6^%^KKC=OSXY.SM^S-V[.S3\>GI^\_
M_.^_GVP_H<^_?SI^XSY_)\S/<I5:N.T70Y7G*K;?7<HPG^!ZV_\"*,\_NVTN
M1$9ZD'M.6.6:!\<'.'6WV>5*3O#\_/3HNI_O[B+8&E2J57WA[W@ECB.HR\1X
M4-),I0*_(_]6MP.8-&,212H@0N>YM8[JQE'-"++ZY:=,74C@='UV#IM$R%G0
MI4.;.&P=V@W0F:.&Z$B"/893%@N>@#YT^.5(C0Z??SEBZ-+1H'/V_7- 7]_Y
M9_P;$6F)3&3WQ7>B^VI\<_\,IJW?@7T?)XFX0L9A'7+O%+Z+CY<)</&)3!FZ
M\>1(XDNVCKJG_?5ZC/E'V[*015G(SA)9R#EQ#2-HC* GJB7.TNV<W&@K^D+J
M*=*]8RU&*6%:! I8Q2A2*F.SK,CH39R-,Z6UO8IG@N.E?*B*G '3>#G80=[P
MY0A4#O@1V EJ*RWO^)X7#?*@Y!(ZYWFA'?.>( ]Y4'?PX-5#J7#_]& MJ1Q3
M.&141":D423#""EC@N10GOH\>8Q7-P4H14A4EH_Y6(2KX=YWT*YW]OVS?U @
MRNW_Y]DS]HL447@ O&HL7L,>WPH!.@J \IK]P:,"_MIASY[9X.+AZ?L_ZO$Y
M(Q(&.W-DPCY^-P3S3F3E=R<1#[ZR 6(ITRJ2(0#S'6<P&\-92$3!9MX3NV=]
MS<ZG*3SG<<:',GC-/O!8F//XH%ZSCRD9C@?LG0SA#/$L[#OTEGKNUL*?\70/
MG\-)S3FT(7#FK\^& LP4V".E,_<!WY\#^,#$>&8#HW5\JFWIPX9/8E[APR'<
MXS,I=]BG(DN5,=E)I#\&"W)=?#NEYD,GI^NL&9"?D26#,56R9D!N]IW#A%WR
M#./5V@2Q)3"*"0=Y@-P\F/!D+&BUPKP9_-,I7+Y&A(H/_G:9R3P72;<#2I3&
M2'KE@"EEAKA"+Y[Q&N!W/ 4+\()';OW2H\0+6!@6E(*BZ!D0O01%K@(]AB-C
M/ @$'/NLF\=:E? .@"(Q?-SMX'::CP1\K0OX^4)J@&)-9-4CI-I=8UN3JPVD
M0EQ#$<J0N%1L*GC6^H,VRIA;IC^H@4& -)20\VL1 4?;'O38SO;.+AIOOQ:)
M8+O;],7>_1A3]V$(M%CW$"Z$+ZFU]\55*C/?A=WM5-C88W(V@%!91BA.AC9Z
MRD*038%;I^DU")4G4+U53Y@$=3H)-2(XR,Q<)H7 ORT,%"4IK:Y2..MB&,,'
M[N0MR48!PK ,A!R3V#>K9"(1ER!?=[=9R*<:MF0\O.#D&SVV/A(>3!!.GIAX
M"V7!Y9-,%>,)PJ6+**=#ZG4[<T(Z%JQ,P!F/$T\$!"ZX!," Q$TC6IEGTVH;
MXY\M4M!#,':4N&<<"GA5_W(2)5<YC^AGDW[7[90"'@XU&XM[<J_<)-5;^E\M
M_>_>)_WW&K@]X1?"ABLD*J73&I56ZF8!(B$SGD0P;)$ 0DDF[<KQ<Z$$QE=K
MI&DV39W;0?-USSWV&9G%+^*^+,7OLLQ:A7/M%$Y"&YV#$ &)<\!^<=HF&X!P
MFZML]HB>8UAH I>1C!H)LF\^_W;"!GN][?V]_O9V:>'.L3W]&W9Z>[MT/5QD
M5C4RT)=QQE8M%_*W>]G;W]ZNW;Z5\RN0ZB:?_6DK"#>=&I8:2X/#0LE'6)WR
M:4S,[3.Y2^S'2B&+>2A0?51 ' G/BPSPU4/@D<QTN4BY:/UN]!;!"GM&%34A
M.I*6 #1JH"2$ =6=YMCO=L[)*00K;6D1%"1[0Y$J+?.GGK,*-N"8(&0B?;&Z
M($@+4*DC5)Q)Q;6N,4R#@A]:0MET0EFFQOC9(Q",Z$Y4:!@^'.*!LXJ<MACS
MKZ*\&-#1PSK 7<1UBCF[H#584R[KA C 9INP+:P8XGKRU"6Q>.25^X1+T3O
M='*6=CMH^Q$5$7%6%%B6.@VV,?O/P+6#?V,2'A"(I>:6,#:<,%XLD3","\'A
M<28"(2\,H^UV"#F!#6.(N4H&-?@HM2X$>AQD<J&PW,N:^H'*,J%3-)S0(Q$3
MT509GH\5.=?.@-HW]75.EK*M4RM4'[S,;F>_/UCH65K3:KU,JS_G*G<@AUR2
M>;<#'U#\B;#I8 &YYCD.'5(V')JH/4Z4\:DV,[Z'I.*AI_%"JJB6E5PJDR1&
M=2H"3#8$&\LP%X#I\,L1&5?;O6TRKBA.N@7/<JFR4!^0Y74NT&6D"@W2%JX'
MH8Q7S65J#29&3#'UN1@KT %EOZ><5X33/O5C97$MT3V$!6?D+UC^19 CLN76
M7.JQ2'XK9(B:9K<3\IB/\5 #%:<BT98^LMKG)DV2&END/FXZ VY@B9SPN!DB
M 7M,8G3A?17G&'$9490#U^QVYB]*GG[4:R,9R[RI,)0N6)/#C>JKR"B50-2Y
M3$L_FTX_RP\%6$RR1"%X%DW]+RV+]I"LB9V9&!76_W>-"#MQFK"5C!7)-D69
MC7.-A.@Q($X>85V#3Z@ 3I-RYSD=JS(M<867"A/\FZD"\VG')]I0"9/7*9.@
MR&"Y:96=XU;T(H+N(/(B2Q8ZB'4@U/M.$5TL'W2GS0<5'Q0^^DZ;^;G)5NA+
M]I$8U%O+3C;!^%R7X.-ID8%TZ7;R6HI5KQ(&7OUL[M?4E Y#X!^)7WS[X$6S
MWY\JV2I7#U?MZ>P)+7(T)RZQCU:W8\JB2$D!I2+(,QE@;,=^K47*,[@P,E7A
MZ!Z@^V:NM_D_%1+/ZD$I03$G+\NH0H9(G)<^+T#UHIRGF(H1C-/ [&WVLJ'8
MPR]'>\Y5\#PH0'H9V*ORF%DPJUL'_5V\\_G__?FNS[;*+6S@5UV2@HB TQ-<
M2D.0:%F-)-;GC$@=XR&^",JC>KH&RE1+F(_%:U GS"$8/!@^!9@BD4Y4 I+9
MTA6<ZQ_L0HI+JB400L^W*L ^R/R(%NGX*'3PM@;9K8/:OQ'*T\_L5$02D'5J
M.V^0Y66=B>G*6C&T[OSUY1'+%-X.N0X:KH[0?&\42U=,W3#OY[6:H9S?D)30
MN=$!EO.OL) 8C4!LUO*+4W0U.L<F_5)S+9#T+O.2M=W(".XSJ2D7Y1<>V/@X
MW?_V6R%3V^PS4LF8/*>J5AY>J<$AIBJ3FDP^2.H?:@\!FU+0DT@;W*#4[!SC
M&R;.0;MIP2/#':F9*(IU!PCN^%5,'=6&6%$.ZTS@-Q3S%_?5=*(5[)LAV#^3
M$#A@Y-:L93<W#4%T=-;\GJ-:0ZAF,,#SZY440HUPL<EM L0585[_J"(SCR9=
M<P4>"PQ%3/N-M4.I7?$G7B=S$>LZ87JLI6:J DD! "("Q*@OB6[+QK+4KJ$'
M>G84H=L220W0ZD^04V#:]N8_1*7L<"-UY\)%3X@'H2Y-4:.! 92C(JO: T^Q
M500^P5BIL$H--RI_+L/R6.855U!EA>,E]#BW<K;C/,>DMW"&L1F.92HG31W(
M^U&5PE2&:KPWGLYP^>-F)*C*Y9O)J6\BW43<B'A-C_)LX*=()'HN,OAU2E*#
M#=&S68/4TXAF0L7N#6JB3X=4&6K!F5)QOR[PNIU9"!JH-8N/M'\0<1E7@DM5
MKO72\F1UP]-"C%&[Q\KW'[@H]15[CR[I! [S5, A$XZU]:>;)"]7X:&*.:85
M$[Z(&DEW.Z4"FR+3TMKR+)]7EY$R6Z5N:5[GJLX(%3 0F1@'D^'^-_)-Y))]
MXR&_!%@\SCBQO8Q*AL3UUY*YP$?8.<7DE:],QJ"[2O*D]6^-J#=6,4\@Z@T%
M<@6:+LHZ]RS8ET?X18TAW)8IJ[+#GP7PMJSDE57G@(F,A#MTJG"L_D8YP4.Z
M+ ',1DDSU@OP98 XD*16^X8%\6(7+A6UE*+9E,-(:?)I5,\#S%MA!W]\9F8S
M*6J/TNU43^GZ(7C(0A@BM1H*>R:5;_*Q,OF663V$<N^B9(2YU "K)!FG1\H8
MVVF(>N&&B>-4SKFF_DW^/\OAM$*:ELE_"NM6PHYH*I8!$0:CR1B^HZ]JN4'W
M)@+4>2_P5,%G-3)JN.8^FNT]TG0DN3 @0/.DGS_: N '!ZL)T UI";MM6H)-
M2]AMTQ+6A@;^>4/C;?8;ITX,Y+!LVG34I6B.<Z U*C9)3B_5<TX"L.'ZZ+D.
MI<?SW4-UM]I\;Y3Q'^E"YGP8">8:6E7F1)_].1&EQX.-)#47F;>#4>*OW<:H
MN2%JO#&/1D5"S4WJ?4A TXC3/)J:L'15S$9Z>,IE-DM'U^T)RLML$R\;7WRL
MDKVEO8>/;%L\-*HG_MG42GLUC=E:G;X-/NO:ZWGNV6//W4R]/\@;2:;^$, N
MK7FS>8O)FX[)R\Q,KV,R&GLD&,AM;]!X(=9*X5AT;J-!A5(#WD0BLCY[;UO@
M7%C?M&'Y2 ,8 O \-M=OT^UX^X2F=Q71$S:GH*:1&2,GV-@W/YNAI2'YRE*5
M:(GPC4CF>/I89@S4F=QS$PF6H*$;"/K=SOL%=;>:C+. NY8&?$QBKD[@M\!(
MO<!\(+L=!V5+])M.],LLI_;*+\C#H4M72*,GC'53^C%($%[H^,Q"F_'H"!(H
MMDF4\2WV3D4I#6+M=H:":,X20:V>K-3A3C9%AUN[G*_!@)U9CC>E%R#1BBAY
MD&EONPDY7^N>15\78=+8<BY5N7HI1%5%;%RV+D7 $7'/<YI6F0:>1$-;"R-3
M)%IDXD$1EO3:9S>9F[,^WE*,R7+F5HV($=!Y[M<:Y^EV*D>PKQ4O=/,-OMLU
M>_F/A2GLL-^+H6U<&(G$MJ:Q?60V@1NTRLC#EV^@C:L=FF&?S"3LE4C6H[K9
M*Z]G?*E/4/S<$'H/C1%43AA)+G8Y49%X;7ZD"/>L9=!(OC3-'81)G,R*B%Q'
M,^;XO,!P@,F4KD8D$"+454,D]UB/54UIR>,A7$V>KF[1LAQI9T8+Z+*U1XJ]
M/BB] ,N:QAE/)YXCM4)S7C4R&57MDZ^/W%+3Z9%IG6)OK+?8PP8-V(C)=""Q
MT+B^T:91@R$#2T#7=VT (H'5S8;2QG"]Q@V:R_"6[@U&?=G4]@WKIQ7LLC>&
M'<-KK[<M1V6,7].MO%47?B1^N$QUX7V5%.?4 L,02^2;-][3IHM<8[YX#O8J
MQ$1YX,C$\+Y7<_K:UYGD!0]<5I^QG;!]O%5.KIGQ!XL=?CFR2U.)IQLGB/WM
M'+@W\-':7!QO' Y^Q(PV.I+'RNI:\GH(=>,:,U\24F6"ZH^P*-CJX%8N+S2A
MHH?)F"#=L1=C=.'4&-33&_,U,76=8FF4YJKKR:)FEN9,_OY=2->/K37(%YTG
M#=?'O '?C2<SZ;NP@=OKCG3\6$ET_;21%^S\^J*/5NGXD;CB<@=(^9G>QEE:
MF18A]IH#=(L+*J^IIML _OFUF(^5S%N<>PA)_(6FO*"L=:6%U!^'Q$T@LZ"(
M-176Z5ZC$*$T]RL$)8&7"$FN?Q.W*Z_RXFRS7H&#%F77!F57@;&#_C*99*WN
M1MB:'BHA(+W1C4&7NIPDXA1(':B47 BNX"!6D2U=\HL8(W[I LY%-N0)&3U4
M%8.7)NAO73&3O4O89ZEM_^X4;UH@S?Y%FV9OT^Q?_(AI]JL.7[8,>#$&O+-D
M!FSX)W!8FW?6PV!X;GJY\B0Q0VPH,)ZH+*;:=LM0 9$#S-O[C\ D _+#<XU=
M:O/)MP)=\YBS!_;X&C'8%C$?9YII/7)*G77JW1:\H(TWX+.X5B-F-86X55K7
M!S4?@])J>"96NQO^Z'=>ZG;*7D]D(ME.)"T3_"$P;9G2^1CY%AG@LWUIP*(O
MVPB4Z(86% [""X)BY97'+<*MB]1=9I[W'5Q(=^N&-%\^4S[@_$9),Q&>5D:O
M#R*ONXR>&17AYCAE-$(4^Z7,^X6UDOO'Q;]E2FY*<')AW+3(O*9LW<[0S^C
M7 Q>P+^9_"_)][68R/YB#_UQ+;ZM$M]VEXAOI^3]UA/*F> 12%O;K(I\.F6A
M")97W=3YZ@'PL>5^ZX&-+Y:(C5^T8WU>=S8FDC$?8U@G83**Q!CCWD$N+^0]
M!+I;+%L/+-M;@8YGZU$U')DJG!>[G)Q1Y61E#*4P*'CEI?DD$[R<A.VN](:6
M^55CIH2QSXZI#WB9\29'IKQ.C49V6K J0^8M7O\H>+V_ KRNJAP4F-8HEU79
M#OG:O,)2AC>O<[F^MZ0=-F]KI"":^2XTA</F<E8)_"KS4CSGIW>N3?)B@T3V
M6VUWU13R<B5^4>JK6K:^)>NJZJZZD6[1=8'N+66&=3LF-0SS&Z^IFT(/WM@P
M%PYLYQFP'<=-K.!57HX9IEQCKCCFD5O7-_ 4XS3TW8\TM&NDLGQ"]>=E]9IF
M6X.GN/#6_E/&A\ YO<JQ8Y+LRO:G:,#K?))-QR;ZAU0"MA/\/JG-0O4' '!=
MJU8W+5_*.2%NUPI=Y\T9OVV7XYE=5I.:_+*_(-L<O/I^OKE^B>![C0X6LZF-
M;3;X>LJK]<\&]UA0*");6V(CQO4V'O4JDJ9V5W$<O]\A]ZI@W&1F)KYA9CG<
M,/B)>GY'K\N0CLQT7LTLHH[N*J=./K$JJGJP^ISD$0V@!H) !HXUZV'1)O;\
M*+2PHO+TBA8 ATLZ0,QLH/<B:.V0]]*T9?"[Z=\SWM[&U5ML?3QI:("MM2((
MHQ4@=S;Z;]5/LV%NU/LH3$04WEPWL19QGW^BT;7X^1 )&W^651/1'.V5"MO+
M; NIJY8V#%9/"].S!FUC@^)EAQ##5#TSKF?R>\LKRE[+XH++:*V0=ZE%%'>D
MFP7**/;:,@I;1K'W(Y91K)X1KY]IO0_[Y'E4EKB6' GGU14YA4F6;UHO>,[[
MR^H(.<<N><V6]PX6\8K:\P1++I,4A#4)\#4'5Z64:'HIE&/G&BO0A,Q)IHKQ
MQ$R;CW+C:D(O6J*\2N6 )Z;[L!WF..>F7K=3TYVH"CHSGD <%E!&WH1*(^&%
M*HJLG'Z8 E\37FU@&9LS>89>C6"S[&]%WK'E*O7K1ZLOS6 WI\S&/ <AL))Q
MW?=$GZU>^A >K]MFC<2F'6V*,[55=NU@COE-TG,*$N3P/FP ,Z%>+E4 \^26
MWBV!,JW&L"O,;)O&LB>MWXZZ[.XN@1&*0&@-4+6.A(TFB'MHDV0)PB$F*,JA
M< (Y$V.TT(QO(4%>[.8S5LW1K32L_]1T&U<S[>K#0+0( "K;;5GS1!JY7;:'
MM!YI#D*^ZJC<XOQ&X_PRG6?'@'$YOW+-^P5-_0"4HRJY8369R6?0MK:X3" I
M>T+J:P='UA? 1N*8<G(AHND-2F&+O!N(O,OTK)4CF.%R3)H6R3C'(6; !4%I
MN 2F:/!S1#7NY D#]HNNL;F=(VFPC<EKL'?,S"Q=8  -^=S*R1MFV$:O/H+4
M1 Y+R4##:"C;-LAD3).1_=DTMV\YTX6?^N=+2]1N'P?,;!-]AEQ@YD>?<D=(
MZ3@+1-GS*$?JA (M1Q1K\ZB_/C\9[W3Y<2<MG6\TG>^M:+2-BF,S2&IJ6V>3
M-K10)]C9 D@:=DX.<]-AVU&D%MF%#"S]7&*)I)DC'('4RF2 ^IB?640&3J7?
M&8.EWN^ZDH1SZ%FK""7A#"=)IM=1I3<\.5.A:974$M1&$]3^T@6GI8N>UX,#
M^#OA']6NFW&&<*ACT-0 T:3*ZIA?(N%6RF7X%'V(7Y&.=,J#U4?P?SPG_<_L
MW.M\2F79F@FJ=G@H[U^;[_9(O7_4_?3PRU&)3?CQ^9<C#8M0AQ3T-PAN@P]^
MQU,&XNS7 N05W#WHT4T[VSN[^+'R8H"<QBJ#L@65<K,>8IR>B%ZY+T>MO-ID
M9%VF9Z[>JA?^CGEH^I1G,HVD;1Y.XX*<:)LHFX]YJ0 94V<,.=W+_8P9W?#S
MZMW$;6[/NB#F4MUGI/K7JRF0]6GB?=T.,;]>+79K^"/-Q4&-*U9A927@T-LB
M36T8WL9>J^2@I"SV@G7C%F5_&)1=IM,,54B>I@+4^RM&@Q\05\4X0W>5F; V
M:J0C(./$3FJE!#?>*J-Y,OKA/L<PW1]>^GC8Q-,[/X.'<F5N6*"BB*<: ')_
M/:'DIILQ\HE+@*H0(<7I\\GX&:)3A6AVRSW<<4%4&?%81M.#VQYFYBC/A-;
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M3)9(>&S7BIG6.T>L$%:+TB5Q6 !L+Q4.RT6PAT9$!?+5?B\6F3(R?\0BCDL
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MU2,3)-7W=)N 923H3:3S6E"X=(Z."^O H-F,X(GE\%3L$T53OQ"<\:NX*#T
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M"-L?&@86NW_#P.+:(ENUL\NA[<GAAZ-_D8SU[N3WX_W_!U!+ P04    " #
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M8+C 2AVP1G,\-DO/91HC\_%,8AR9ABJ/,";PN 2,.K LC9JQ,>!$3""&*+6
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M\Y"VIV4W>G_NF-Y8]:^PTINN?P-02P,$%     @ P("!6'HG1S,,!0  D!<
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M4.@99%:!,_4T$WP+Y\P*XHM$H\VX7J6$:]"B7&50@-L-NS61+N%4M1;W$=V
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MDU&4*KWG$)D1S-RH;Z_8S4W\GU!+ P04    " # @(%8YW>=%%(6  ";?@
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M+;Z]%D%8-]=(P'[(2VN$OJ70L.D\Y(-E=/'/>"%^?KFN@W9SU/51C]8[:O2
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M/M9 ,W2<3<A[7_YMLO!5'PXOFDYF0\01AW+(@6MIMH,:O;/$36 FV$/"5%/
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M+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " # @(%8&H; WW ^  !B" 0
M%0              @ &?^@  8W!H:2TR,#(S,3(S,5]P<F4N>&UL4$L! A0#
M%     @ P("!6! X$HY =0( '+<2 !<              ( !0CD! &5A,#(P
M,C<W,BTQ,&M?8VAI;F$N:'1M4$L! A0#%     @ P("!6"=?LLLA"P  A$T
M !P              ( !MZX# &5A,#(P,C<W,C Q97@Q,"TQ,U]C:&EN82YH
M=&U02P$"% ,4    " # @(%8;68D !,0  #Q=@  '               @ $2
MN@, 96$P,C R-S<R,#%E>#$P+3$T7V-H:6YA+FAT;5!+ 0(4 Q0    ( ,"
M@5@!^.UNW@\  ,5R   <              "  5_* P!E83 R,#(W-S(P,65X
M,3 M,35?8VAI;F$N:'1M4$L! A0#%     @ P("!6,?GGWI_&P  M/<  !P
M             ( !=]H# &5A,#(P,C<W,C Q97@Q,"TQ-E]C:&EN82YH=&U0
M2P$"% ,4    " # @(%8>%.+ZSD;   ^\P  '               @ $P]@,
M96$P,C R-S<R,#%E>#$P+3$W7V-H:6YA+FAT;5!+ 0(4 Q0    ( ," @5BV
M!<<F-0(  )\&   ;              "  :,1! !E83 R,#(W-S(P,65X,C,M
M,5]C:&EN82YH=&U02P$"% ,4    " # @(%8-2",%\8!   :&   &@
M        @ $1% 0 96$P,C R-S<R,#%E>#,M,E]C:&EN82YH=&U02P$"% ,4
M    " # @(%8_*BU3\T!   H%   &@              @ $/%@0 96$P,C R
M-S<R,#%E>#,M,U]C:&EN82YH=&U02P$"% ,4    " # @(%87F$2$88'  !F
M*0  &P              @ $4& 0 96$P,C R-S<R,#%E>#,Q+3%?8VAI;F$N
M:'1M4$L! A0#%     @ P("!6)'E1-J"!P  \"H  !L              ( !
MTQ\$ &5A,#(P,C<W,C Q97@S,2TR7V-H:6YA+FAT;5!+ 0(4 Q0    ( ,"
M@5AZ)T<S# 4  ) 7   ;              "  8XG! !E83 R,#(W-S(P,65X
M,S(M,5]C:&EN82YH=&U02P$"% ,4    " # @(%8YW>=%%(6  ";?@  &P
M            @ '3+ 0 96$P,C R-S<R,#%E>#DW+3%?8VAI;F$N:'1M4$L!
M A0#%     @ P("!6",UH3"-,0  .#<   T              ( !7D,$ &EM
A86=E7S P,2YJ<&=02P4&     !, $P Z!0  %G4$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>ea0202772-10k_china_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cphi="http://www.chinapharmaholdings.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cphi-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:OnnyInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-05-25</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:HelpsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-11-28</startDate>
            <endDate>2023-11-28</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-11-28</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:NMPAApprovedMedicalFormulasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:NMPAApprovedMedicalFormulasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:TechnologyFromBonierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:TechnologyFromBonierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:InventionPatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cphi:InventionPatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-08-23</startDate>
            <endDate>2023-08-23</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-09-28</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:InterimChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:InterimChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-08</startDate>
            <endDate>2019-07-08</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-08</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cphi:ChairpersonCEOAndInterimCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-22</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-21</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-21</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfCommunicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:CITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-06</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:ChinaCITICBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-18</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-18</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:BankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cphi:PostalSavingsBankOfChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-04-13</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-13</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-13</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cphi:ChinaPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-05</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-01-05</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-01-18</startDate>
            <endDate>2023-01-18</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-19</startDate>
            <endDate>2023-01-19</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-04-07</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-07</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-04-07</startDate>
            <endDate>2023-04-07</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-13</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-05-24</startDate>
            <endDate>2023-05-24</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-13</startDate>
            <endDate>2023-06-13</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-08-21</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-06</startDate>
            <endDate>2023-09-06</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-09-12</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-12</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-09-12</startDate>
            <endDate>2023-09-12</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-13</startDate>
            <endDate>2023-09-13</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-10-06</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-06</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-10-17</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-17</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-10-17</startDate>
            <endDate>2023-10-17</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-17</startDate>
            <endDate>2023-10-17</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-11-06</startDate>
            <endDate>2023-11-06</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-11-29</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-29</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-11-29</startDate>
            <endDate>2023-11-29</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2023-12-13</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-13</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-03-21</startDate>
            <endDate>2022-03-21</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-06-13</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-13</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-06-13</startDate>
            <endDate>2022-06-13</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-13</startDate>
            <endDate>2022-06-13</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-18</startDate>
            <endDate>2022-10-18</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-15</startDate>
            <endDate>2022-12-15</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cphi:BankersAcceptanceNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cphi:EffectiveMarchSixTwoZeroTwoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cphi:EffectiveMarchSixTwoZeroTwoThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-27</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-27</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-17</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-17</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cphi:TwoThousandTenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2022-10-04</startDate>
            <endDate>2022-10-04</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2021-09-09</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cphi:SalesBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cphi:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">cphi:SuppliersTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cphi:ProductThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-11</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-21</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-11379">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-11380">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-11381">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-11382">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-11383">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-11384">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-11385">001-34471</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-62">China Pharma Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-74">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-79">73-1564807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-96">Second Floor, No. 17, Jinpan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-11386">Haikou</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-11387">Hainan Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-11388">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-11389">570216</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-11390">(011)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-11391">86 898-6681-1730</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-131">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-135">CPHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-11392">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-11393">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-11394">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-11395">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-11396">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-11397">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-11398">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-11399">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-11400">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-11401">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-11402">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-11403" unitRef="usd">3896941</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-11404"
      unitRef="shares">14816865</dei:EntityCommonStockSharesOutstanding>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c29" id="ixv-11405">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c29" id="ixv-11406">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c29" id="ixv-11407">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c29" id="ixv-11408">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorName contextRef="c0" id="ixv-11409">BF Borgers CPA PC</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-11410">5041</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-11411">Lakewood, CO</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-11412" unitRef="usd">1423838</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" id="ixv-11413" unitRef="usd">2029971</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <cphi:BankersAcceptances contextRef="c3" decimals="0" id="ixv-11414" unitRef="usd">65915</cphi:BankersAcceptances>
    <cphi:BankersAcceptances contextRef="c4" decimals="0" id="ixv-11415" unitRef="usd">13784</cphi:BankersAcceptances>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" id="ixv-11416" unitRef="usd">13786074</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c4" decimals="0" id="ixv-11417" unitRef="usd">16739527</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-11418" unitRef="usd">504448</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-11419" unitRef="usd">421531</us-gaap:AccountsReceivableNetCurrent>
    <cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" id="ixv-11420" unitRef="usd">27017</cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts>
    <cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts contextRef="c4" decimals="0" id="ixv-11421" unitRef="usd">27149</cphi:OtherReceivablesLessAllowanceForDoubtfulAccounts>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-11422" unitRef="usd">157944</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-11423" unitRef="usd">29139</us-gaap:OtherReceivablesNetCurrent>
    <cphi:AdvanceToSupplies contextRef="c3" decimals="0" id="ixv-11424" unitRef="usd">2013</cphi:AdvanceToSupplies>
    <cphi:AdvanceToSupplies contextRef="c4" decimals="0" id="ixv-11425" unitRef="usd">444637</cphi:AdvanceToSupplies>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-11426" unitRef="usd">3732517</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-11427" unitRef="usd">2947787</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-11428" unitRef="usd">110258</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" id="ixv-11429" unitRef="usd">77697</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-11430" unitRef="usd">5996933</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" id="ixv-11431" unitRef="usd">5964546</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-11432" unitRef="usd">7100425</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-11433" unitRef="usd">9973065</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-11434" unitRef="usd">116610</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-11435" unitRef="usd">39046</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" id="ixv-11436" unitRef="usd">3255232</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" id="ixv-11437" unitRef="usd">1807486</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-11438" unitRef="usd">16469200</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-11439" unitRef="usd">17784143</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="0" id="ixv-11440" unitRef="usd">966420</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="0" id="ixv-11441" unitRef="usd">667082</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-11442" unitRef="usd">298829</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-11443" unitRef="usd">404807</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-11444" unitRef="usd">2282692</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="0" id="ixv-11445" unitRef="usd">2390063</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" id="ixv-11446" unitRef="usd">90507</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c4" decimals="0" id="ixv-11447" unitRef="usd">520295</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-11448" unitRef="usd">1133809</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c6" decimals="0" id="ixv-11449" unitRef="usd">2475840</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-11450" unitRef="usd">77727</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" id="ixv-11451" unitRef="usd">40445</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c3" decimals="0" id="ixv-11452" unitRef="usd">1030680</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c4" decimals="0" id="ixv-11453" unitRef="usd">2440915</us-gaap:LinesOfCreditCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" id="ixv-11454" unitRef="usd">940000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c4" decimals="0" id="ixv-11455" unitRef="usd">3800000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-11456" unitRef="usd">6820664</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-11457" unitRef="usd">12739447</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-11458" unitRef="usd">39910</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermLineOfCredit contextRef="c3" decimals="0" id="ixv-11459" unitRef="usd">1411891</us-gaap:LongTermLineOfCredit>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c3" decimals="0" id="ixv-11460" unitRef="usd">742114</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c4" decimals="0" id="ixv-11461" unitRef="usd">754698</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-11462" unitRef="usd">9014579</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-11463" unitRef="usd">13494145</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-11464"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-11465"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-11466"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-11467"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-11468"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-11469"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-11470"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-11471"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-11472"
      unitRef="shares">10625788</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-11473"
      unitRef="shares">10625788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-11474"
      unitRef="shares">1498180</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-11475"
      unitRef="shares">1498180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-11476" unitRef="usd">10625</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" id="ixv-11477" unitRef="usd">1498</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" id="ixv-11478" unitRef="usd">35282256</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" id="ixv-11479" unitRef="usd">28926931</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-11480" unitRef="usd">-39290314</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-11481" unitRef="usd">-36211496</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-11482" unitRef="usd">11452054</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="0" id="ixv-11483" unitRef="usd">11573065</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-11484" unitRef="usd">7454621</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-11485" unitRef="usd">4289998</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-11486" unitRef="usd">16469200</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-11487" unitRef="usd">17784143</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-11488" unitRef="usd">7011299</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-11489" unitRef="usd">8104092</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" id="ixv-11490" unitRef="usd">7292384</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="0" id="ixv-11491" unitRef="usd">8598008</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-11492" unitRef="usd">-281085</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-11493" unitRef="usd">-493916</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" id="ixv-11494" unitRef="usd">780328</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c7" decimals="0" id="ixv-11495" unitRef="usd">1069785</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-11496" unitRef="usd">1466084</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-11497" unitRef="usd">1893269</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-11498" unitRef="usd">240080</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-11499" unitRef="usd">185858</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-11500" unitRef="usd">-15757</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="0" id="ixv-11501" unitRef="usd">-93851</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-11502" unitRef="usd">2470735</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="0" id="ixv-11503" unitRef="usd">3055061</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-11504" unitRef="usd">-2751820</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-11505" unitRef="usd">-3548977</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-11506" unitRef="usd">6602</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c7" decimals="0" id="ixv-11507" unitRef="usd">10755</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" id="ixv-11508" unitRef="usd">333600</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c7" decimals="0" id="ixv-11509" unitRef="usd">434619</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-11510" unitRef="usd">-326998</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-11511" unitRef="usd">-423864</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-11512" unitRef="usd">-3078818</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-11513" unitRef="usd">-3972841</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11514" unitRef="usd">-3078818</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-11515" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-11516" unitRef="usd">-121011</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="0" id="ixv-11517" unitRef="usd">-990764</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-11518" unitRef="usd">-3199829</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="0" id="ixv-11519" unitRef="usd">-4963605</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-11520"
      unitRef="usdPershares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-11521"
      unitRef="usdPershares">-3.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-11522"
      unitRef="shares">3383573</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-11523"
      unitRef="shares">1051371</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-11524"
      unitRef="shares">946791</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-11525" unitRef="usd">947</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-11526" unitRef="usd">25691760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-11527" unitRef="usd">-32238655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-11528" unitRef="usd">12563829</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-11529" unitRef="usd">6017881</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="c13"
      decimals="0"
      id="ixv-11530"
      unitRef="shares">310446</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c13" decimals="0" id="ixv-11531" unitRef="usd">310</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c14" decimals="0" id="ixv-11532" unitRef="usd">1707142</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c7" decimals="0" id="ixv-11533" unitRef="usd">1707452</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c14" decimals="0" id="ixv-11534" unitRef="usd">36270</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c7" decimals="0" id="ixv-11535" unitRef="usd">36270</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c13"
      decimals="0"
      id="ixv-11536"
      unitRef="shares">6000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c13" decimals="0" id="ixv-11537" unitRef="usd">6</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c14" decimals="0" id="ixv-11538" unitRef="usd">41994</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c7" decimals="0" id="ixv-11539" unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c13"
      decimals="0"
      id="ixv-11540"
      unitRef="shares">234943</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c13" decimals="0" id="ixv-11541" unitRef="usd">235</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c14" decimals="0" id="ixv-11542" unitRef="usd">1449765</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c7" decimals="0" id="ixv-11543" unitRef="usd">1450000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss contextRef="c15" decimals="0" id="ixv-11544" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-11545" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c16" decimals="0" id="ixv-11546" unitRef="usd">-990764</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c7" decimals="0" id="ixv-11547" unitRef="usd">-990764</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c17"
      decimals="0"
      id="ixv-11548"
      unitRef="shares">1498180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-11549" unitRef="usd">1498</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-11550" unitRef="usd">28926931</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-11551" unitRef="usd">-36211496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-11552" unitRef="usd">11573065</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-11553" unitRef="usd">4289998</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="c21"
      decimals="0"
      id="ixv-11554"
      unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c21" decimals="0" id="ixv-11555" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c22" decimals="0" id="ixv-11556" unitRef="usd">1647000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c0" decimals="0" id="ixv-11557" unitRef="usd">1650000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c21"
      decimals="0"
      id="ixv-11558"
      unitRef="shares">3362111</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c21" decimals="0" id="ixv-11559" unitRef="usd">3362</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c22" decimals="0" id="ixv-11560" unitRef="usd">2856638</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="0" id="ixv-11561" unitRef="usd">2860000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c21"
      decimals="0"
      id="ixv-11562"
      unitRef="shares">2751412</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c21" decimals="0" id="ixv-11563" unitRef="usd">2751</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c22" decimals="0" id="ixv-11564" unitRef="usd">1851701</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="0" id="ixv-11565" unitRef="usd">1854452</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="0" id="ixv-11566" unitRef="usd">-3078818</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11567" unitRef="usd">-3078818</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c24" decimals="0" id="ixv-11568" unitRef="usd">-121011</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="0" id="ixv-11569" unitRef="usd">-121011</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c21"
      decimals="0"
      id="ixv-11570"
      unitRef="shares">14085</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <cphi:StockIssuedDuringPeriodValueStockSplits contextRef="c21" decimals="0" id="ixv-11571" unitRef="usd">14</cphi:StockIssuedDuringPeriodValueStockSplits>
    <cphi:StockIssuedDuringPeriodValueStockSplits contextRef="c22" decimals="0" id="ixv-11572" unitRef="usd">-14</cphi:StockIssuedDuringPeriodValueStockSplits>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c25"
      decimals="0"
      id="ixv-11573"
      unitRef="shares">10625788</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-11574" unitRef="usd">10625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ixv-11575" unitRef="usd">35282256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" id="ixv-11576" unitRef="usd">-39290314</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" id="ixv-11577" unitRef="usd">11452054</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-11578" unitRef="usd">7454621</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-11579" unitRef="usd">-3078818</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-11580" unitRef="usd">-3972841</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-11581" unitRef="usd">2753653</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="0" id="ixv-11582" unitRef="usd">2700533</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-11583" unitRef="usd">-15757</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="0" id="ixv-11584" unitRef="usd">-93851</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:StockOptionPlanExpense contextRef="c7" decimals="0" id="ixv-11585" unitRef="usd">78270</us-gaap:StockOptionPlanExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-11586" unitRef="usd">-45385</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c0" decimals="0" id="ixv-11587" unitRef="usd">938021</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c7" decimals="0" id="ixv-11588" unitRef="usd">170194</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" id="ixv-11589" unitRef="usd">-437431</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c7" decimals="0" id="ixv-11590" unitRef="usd">459959</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-11591" unitRef="usd">25032</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="0" id="ixv-11592" unitRef="usd">-689104</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="0" id="ixv-11593" unitRef="usd">312045</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="0" id="ixv-11594" unitRef="usd">-187734</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" id="ixv-11595" unitRef="usd">257778</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c7" decimals="0" id="ixv-11596" unitRef="usd">692190</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c0" decimals="0" id="ixv-11597" unitRef="usd">-423261</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c7" decimals="0" id="ixv-11598" unitRef="usd">339659</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="0" id="ixv-11599" unitRef="usd">25089</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c7" decimals="0" id="ixv-11600" unitRef="usd">24722</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-11601" unitRef="usd">-699686</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-11602" unitRef="usd">-409545</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="c0" decimals="0" id="ixv-11603" unitRef="usd">11517</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="c7" decimals="0" id="ixv-11604" unitRef="usd">401964</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-11605" unitRef="usd">-11517</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="0" id="ixv-11606" unitRef="usd">-401964</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c0" decimals="0" id="ixv-11607" unitRef="usd">1490049</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c7" decimals="0" id="ixv-11608" unitRef="usd">2140921</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c0" decimals="0" id="ixv-11609" unitRef="usd">1532622</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c7" decimals="0" id="ixv-11610" unitRef="usd">564965</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-11611" unitRef="usd">30572</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-11612" unitRef="usd">28962</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-11613" unitRef="usd">223013</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-11614" unitRef="usd">73145</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ixv-11615" unitRef="usd">-1770007</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c0" decimals="0" id="ixv-11616" unitRef="usd">31925</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c7" decimals="0" id="ixv-11617" unitRef="usd">-247573</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-11618" unitRef="usd">-606133</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="0" id="ixv-11619" unitRef="usd">-2829089</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-11620" unitRef="usd">2029971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c12" decimals="0" id="ixv-11621" unitRef="usd">4859060</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-11622" unitRef="usd">1423838</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-11623" unitRef="usd">2029971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-11624" unitRef="usd">92439</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ixv-11625" unitRef="usd">141797</us-gaap:InterestPaidNet>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="c0" decimals="0" id="ixv-11626" unitRef="usd">865733</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:AccountsReceivableCollectedWithBankersAcceptances contextRef="c7" decimals="0" id="ixv-11627" unitRef="usd">503383</cphi:AccountsReceivableCollectedWithBankersAcceptances>
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="c0" decimals="0" id="ixv-11628" unitRef="usd">813105</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <cphi:InventoryPurchasedWithBankersAcceptanceNote contextRef="c7" decimals="0" id="ixv-11629" unitRef="usd">575713</cphi:InventoryPurchasedWithBankersAcceptanceNote>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-11630" unitRef="usd">156273</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c0" decimals="0" id="ixv-11631" unitRef="usd">1650000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c7" decimals="0" id="ixv-11632" unitRef="usd">1707452</us-gaap:StockIssued1>
    <cphi:ConversionOfRelatedPartyNoteAndInterestToCommonStock contextRef="c0" decimals="0" id="ixv-11633" unitRef="usd">1854542</cphi:ConversionOfRelatedPartyNoteAndInterestToCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-9612">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 &#x2013; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;China
Pharma Holdings, Inc., a Nevada corporation (the &#x201c;Company&#x201d;), owns 100% of Onny Investment Limited (&#x201c;Onny&#x201d;), a
British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (&#x201c;Helpson&#x201d;), a
company organized under the laws of the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;). China Pharma Holdings, Inc. and its
subsidiaries are referred to herein as the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Onny acquired 100% of the ownership in Helpson
on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#x2019;s three former shareholders. The transaction was approved
by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises
with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise
(&#x201c;WFOE&#x201d;) status on June 21, 2005.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located.
Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin
oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one
or more therapeutic indications by the National Medical Products Administration (the &#x201c;NMPA&#x201d;, formerly China Food and Drug
Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, the Company had cash
and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company&#x2019;s Chairperson, Chief Executive Officer
and Interim Chief Financial Officer (&#x201c;Chairperson Li&#x201d;) has advanced an aggregate of $1,133,809 as of December 31, 2023 to
provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company
anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its
existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its
ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions
that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#x2019;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the requirements of Accounting Standards
Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt; management
must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially
does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of
the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating
effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating
effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern
within one year after the date that the financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 205-40, the strategic alternatives being
pursued by the Company cannot be considered probable at this time because none of the Company&#x2019;s current plans have been finalized
at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively
implemented as none of the plans are entirely within the Company&#x2019;s control. Accordingly, substantial doubt is deemed to exist about
the Company&#x2019;s ability to continue as a going concern within one year after the date these financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
Effective March 6, 2024, the Company implemented a 1-for-5 reverse stock split as more fully discussed in Note 14. All share and per
share disclosures have been retroactively restated to reflect the impact of the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) and are expressed in United States dollars. The accompanying consolidated financial
statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Helpson&#x2019;s functional currency is the Chinese
Renminbi. Helpson&#x2019;s revenue and expenses are translated into United States dollars at the average exchange rate for the period.
Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#x2019;s
financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. Gains
and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction
are included in the results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates&#160;&lt;/i&gt;-&#160;&lt;/b&gt;The methodology used
to prepare the Company&#x2019;s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. &#160;Significant
estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance,
valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used
to calculate derivative liabilities. Therefore, actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#x2019;s
acceptances notes purchased with maturities of three months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for
doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts
and an estimation of the overall economic conditions affecting the Company&#x2019;s customer base. The Company reviews a customer&#x2019;s
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in
an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable
to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense totaled ($15,757) and ($93,851) for
the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable that have been fully
allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company
charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December
31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current
balances when calculating the allowance for doubtful accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from
Customers&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from
customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances
received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&#x2019;s
credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate,
resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the
period they are considered unlikely to be collected.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&#160;&#x2013; &lt;/i&gt;&lt;/b&gt;Inventory
consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated
portion of the Company&#x2019;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable
value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable
value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs
to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value.
Net realizable value for raw materials is based on replacement cost. Provisions for inventory write-downs are included in the cost of
revenues in the consolidated statements of operations. Inventories are carried at this lower cost basis until sold or scrapped.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;i&gt;
&#x2013; &lt;/i&gt;&lt;/b&gt;&lt;span&gt;At lease commencement, the Company records a lease liability based on the present
value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain
to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases
do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would
have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date,
the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received
and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial
term of 12 months or less (&#x201c;Short-Term Leases&#x201d;). For any Short-Term Leases, the Company records the rent expense on a straight-line
basis and does not record the leases on the balance sheet. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;After lease
commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments
using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability,
adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent
expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line
basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate
that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated
from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying
value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash
flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the Company will use the projected discounted
cash flows to be generated by the asset. For the years ended December 31, 2023 and 2022, the Company evaluated its long-lived assets and
determined that no impairment adjustments were necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are
capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration
that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company does not disaggregate its
revenue streams as the economic factors underlying the contracts are similar and provide no significant distinction. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following
five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether
the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement
of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
(or as) the performance obligation is satisfied. The Company&#x2019;s contracts are fixed price and reflect standalone pricing for each
item. Due to the nature of the products sold, there are no returns. Generally, the Company&#x2019;s performance obligations are transferred
to customers at a point in time, typically upon buyer&#x2019;s designated carrier or the buyer picks up the goods at the Company&#x2019;s
warehouse.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-indent: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For all reporting periods, the Company has not disclosed the value
of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is
an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year.
These advances total $90,507 and $520,295 and are recorded as a liability on the accompanying balance sheet as &#x201c;Advances from customers&#x201d;
as of December 31, 2023 and 2022, respectively. The subsequently recognized revenue was $81,456as of March 29, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Cost
of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery
of products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying
amount of accounts receivable included in the balance sheet represents the Company&#x2019;s exposure to credit risk in relation to its
financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations
of each customer&#x2019;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate
have not exceeded management&#x2019;s estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has its cash in bank deposits primarily
at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#x2019;
interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation
of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow
the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and
viability of securing future debt instruments within the PRC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share&#160;&lt;/i&gt;-&#160;&lt;/b&gt;Basic
loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;As of December 31, 2023,
the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares
issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods
presented because the effect is anti-dilutive due to net losses of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&#160;&lt;i&gt;Financial Instruments &#x2013; Credit
Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance
introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies
the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial
assets with credit deterioration since their origination.&#160;The pronouncement will was effective for public business entities that
are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including interim periods within those
fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December 15,
2019, including interim periods within those fiscal years. The adoption of the standard had no material impact on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the FASB or other standards
setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise
discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to
have a material impact on its consolidated financial statements upon adoption.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-9616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;China
Pharma Holdings, Inc., a Nevada corporation (the &#x201c;Company&#x201d;), owns 100% of Onny Investment Limited (&#x201c;Onny&#x201d;), a
British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (&#x201c;Helpson&#x201d;), a
company organized under the laws of the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;). China Pharma Holdings, Inc. and its
subsidiaries are referred to herein as the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Onny acquired 100% of the ownership in Helpson
on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&#x2019;s three former shareholders. The transaction was approved
by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises
with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise
(&#x201c;WFOE&#x201d;) status on June 21, 2005.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Helpson is principally engaged in the development,
manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases
and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located.
Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin
oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one
or more therapeutic indications by the National Medical Products Administration (the &#x201c;NMPA&#x201d;, formerly China Food and Drug
Administration, or CFDA) based upon demonstrated safety and efficacy.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c30" decimals="2" id="ixv-11634" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c31" decimals="2" id="ixv-11635" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c32" decimals="2" id="ixv-11636" unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <cphi:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-9627">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, the Company had cash
and cash equivalents of $1.4 million and an accumulated deficit of $39.3 million. The Company&#x2019;s Chairperson, Chief Executive Officer
and Interim Chief Financial Officer (&#x201c;Chairperson Li&#x201d;) has advanced an aggregate of $1,133,809 as of December 31, 2023 to
provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company
anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its
existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its
ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions
that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern, management plans to enhance the sales model
of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic
alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company&#x2019;s existing fixed
assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations
in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising
substantial doubt about its ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the requirements of Accounting Standards
Codification (ASC) 205-40, &lt;i&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt; management
must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially
does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of
the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating
effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating
effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern
within one year after the date that the financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 205-40, the strategic alternatives being
pursued by the Company cannot be considered probable at this time because none of the Company&#x2019;s current plans have been finalized
at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively
implemented as none of the plans are entirely within the Company&#x2019;s control. Accordingly, substantial doubt is deemed to exist about
the Company&#x2019;s ability to continue as a going concern within one year after the date these financial statements are issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</cphi:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:OtherCashEquivalentsAtCarryingValue contextRef="c3" decimals="-5" id="ixv-11637" unitRef="usd">1400000</us-gaap:OtherCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAppropriated contextRef="c3" decimals="-5" id="ixv-11638" unitRef="usd">-39300000</us-gaap:RetainedEarningsAppropriated>
    <cphi:WorkingCapital contextRef="c33" decimals="0" id="ixv-11639" unitRef="usd">1133809</cphi:WorkingCapital>
    <cphi:ReverseStockSplitsPolicyTextBlock contextRef="c0" id="ixv-9671">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
Effective March 6, 2024, the Company implemented a 1-for-5 reverse stock split as more fully discussed in Note 14. All share and per
share disclosures have been retroactively restated to reflect the impact of the reverse stock split.&lt;/p&gt;</cphi:ReverseStockSplitsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-9678">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) and are expressed in United States dollars. The accompanying consolidated financial
statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances
and transactions have been eliminated in the consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Helpson&#x2019;s functional currency is the Chinese
Renminbi. Helpson&#x2019;s revenue and expenses are translated into United States dollars at the average exchange rate for the period.
Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#x2019;s
financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#x2019; equity. Gains
and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction
are included in the results of operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-9686">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates&#160;&lt;/i&gt;-&#160;&lt;/b&gt;The methodology used
to prepare the Company&#x2019;s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. &#160;Significant
estimates made by management include, but are not limited to, the allowance for doubtful accounts, deferred tax asset valuation allowance,
valuation of stock-based compensation, the useful life of property and equipment, valuation of intangible assets and the assumptions used
to calculate derivative liabilities. Therefore, actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-9691">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&#160;&lt;/i&gt;&lt;/b&gt;&#x2013;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#x2019;s
acceptances notes purchased with maturities of three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="c0" id="ixv-9696">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts &#x2013;&#160;&lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for
doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts
and an estimation of the overall economic conditions affecting the Company&#x2019;s customer base. The Company reviews a customer&#x2019;s
credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in
an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable
to the extent they are considered unlikely to be collected. Charges (credits) to bad debt expense totaled ($15,757) and ($93,851) for
the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable that have been fully
allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company
charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December
31, 2023 and 2022, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current
balances when calculating the allowance for doubtful accounts.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="0" id="ixv-11640" unitRef="usd">15757</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c7" decimals="0" id="ixv-11641" unitRef="usd">93851</us-gaap:InterestExpenseDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-11642" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="0" id="ixv-11643" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef="c0" id="ixv-9704">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from
Customers&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from
customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances
received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&#x2019;s
credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate,
resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the
period they are considered unlikely to be collected.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</cphi:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-9735">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&#160;&#x2013; &lt;/i&gt;&lt;/b&gt;Inventory
consists of raw materials, work in process and finished goods and is stated at the lower of cost or net realizable value. Cost is determined
using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated
portion of the Company&#x2019;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable
value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable
value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs
to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value.
Net realizable value for raw materials is based on replacement cost. Provisions for inventory write-downs are included in the cost of
revenues in the consolidated statements of operations. Inventories are carried at this lower cost basis until sold or scrapped.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-9740">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;i&gt;
&#x2013; &lt;/i&gt;&lt;/b&gt;&lt;span&gt;At lease commencement, the Company records a lease liability based on the present
value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain
to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company&#x2019;s leases
do not provide an implicit interest rate. The Company&#x2019;s incremental borrowing rate for a lease is the rate of interest it would
have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date,
the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received
and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial
term of 12 months or less (&#x201c;Short-Term Leases&#x201d;). For any Short-Term Leases, the Company records the rent expense on a straight-line
basis and does not record the leases on the balance sheet. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;After lease
commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments
using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability,
adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent
expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line
basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-9753">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate
that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated
from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying
value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash
flows estimated to be generated by the asset. If there is uncertainty both in timing and amount, the Company will use the projected discounted
cash flows to be generated by the asset. For the years ended December 31, 2023 and 2022, the Company evaluated its long-lived assets and
determined that no impairment adjustments were necessary.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-9758">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are
capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation
relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of
revenue.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-9763">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration
that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature,
amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company does not disaggregate its
revenue streams as the economic factors underlying the contracts are similar and provide no significant distinction. The amount of revenue
that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following
five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether
the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement
of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
(or as) the performance obligation is satisfied. The Company&#x2019;s contracts are fixed price and reflect standalone pricing for each
item. Due to the nature of the products sold, there are no returns. Generally, the Company&#x2019;s performance obligations are transferred
to customers at a point in time, typically upon buyer&#x2019;s designated carrier or the buyer picks up the goods at the Company&#x2019;s
warehouse.&lt;/p&gt;For all reporting periods, the Company has not disclosed the value
of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is
an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year.
These advances total $90,507 and $520,295 and are recorded as a liability on the accompanying balance sheet as &#x201c;Advances from customers&#x201d;
as of December 31, 2023 and 2022, respectively.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c3" decimals="0" id="ixv-11645" unitRef="usd">90507</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c4" decimals="0" id="ixv-11646" unitRef="usd">520295</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-9799">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; Cost
of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery
of products.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-9804">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-9809">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013; The carrying
amount of accounts receivable included in the balance sheet represents the Company&#x2019;s exposure to credit risk in relation to its
financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations
of each customer&#x2019;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in aggregate
have not exceeded management&#x2019;s estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has its cash in bank deposits primarily
at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#x2019;
interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation
of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow
the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <cphi:InterestRateRiskPolicyTextBlock contextRef="c0" id="ixv-9817">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt;&#160;&#x2013;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and
viability of securing future debt instruments within the PRC.&lt;/p&gt;</cphi:InterestRateRiskPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-9824">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share&#160;&lt;/i&gt;-&#160;&lt;/b&gt;Basic
loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;As of December 31, 2023,
the Company has potentially dilutive common shares related to the option to purchase 13,300 shares of common stock and the 6,267 shares
issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods
presented because the effect is anti-dilutive due to net losses of the Company.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:OptionIndexedToIssuersEquityIndexedShares
      contextRef="c3"
      decimals="0"
      id="ixv-11647"
      unitRef="shares">13300</us-gaap:OptionIndexedToIssuersEquityIndexedShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c0"
      decimals="0"
      id="ixv-11648"
      unitRef="shares">6267</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-9832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13,&#160;&lt;i&gt;Financial Instruments &#x2013; Credit
Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance
introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies
the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial
assets with credit deterioration since their origination.&#160;The pronouncement will was effective for public business entities that
are SEC smaller reporting company filers in fiscal years beginning after&#160;December 15, 2022, including interim periods within those
fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after&#160;December 15,
2019, including interim periods within those fiscal years. The adoption of the standard had no material impact on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the FASB or other standards
setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise
discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to
have a material impact on its consolidated financial statements upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-9873">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &#x2013; INVENTORY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventory consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,849,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,839,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;413,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,469,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;551,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total Inventory&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,732,517&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,947,787&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-11649">Inventory consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,849,213&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,839,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;413,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,469,707&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;551,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total Inventory&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,732,517&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,947,787&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" id="ixv-11650" unitRef="usd">1849213</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="0" id="ixv-11651" unitRef="usd">1839641</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" id="ixv-11652" unitRef="usd">413597</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="0" id="ixv-11653" unitRef="usd">557146</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" id="ixv-11654" unitRef="usd">1469707</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="0" id="ixv-11655" unitRef="usd">551000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-11656" unitRef="usd">3732517</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-11657" unitRef="usd">2947787</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-9940">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &#x2013; PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property, plant and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;397,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;404,427&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Building&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,234,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,391,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,170,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,780,585&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;303,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;388,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,847&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,495,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,323,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,394,655&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,350,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,100,425&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,973,065&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Depreciation is computed on a straight-line basis over the estimated
useful lives of the assets as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: left"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;40 - 70&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Building&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20 - 49&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation relating to office equipment was
included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was
$2,529,858 and $2,663,975 for the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-11658">Property, plant and equipment consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;397,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;404,427&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Building&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,234,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,391,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,170,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,780,585&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;303,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;388,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;308,847&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,495,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,323,430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,394,655&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,350,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,100,425&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,973,065&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c34" decimals="0" id="ixv-11659" unitRef="usd">397684</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c35" decimals="0" id="ixv-11660" unitRef="usd">404427</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c36" decimals="0" id="ixv-11661" unitRef="usd">9234836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c37" decimals="0" id="ixv-11662" unitRef="usd">9391433</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c38" decimals="0" id="ixv-11663" unitRef="usd">27170123</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c39" decimals="0" id="ixv-11664" unitRef="usd">27780585</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="0" id="ixv-11665" unitRef="usd">303697</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c41" decimals="0" id="ixv-11666" unitRef="usd">438138</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c42" decimals="0" id="ixv-11667" unitRef="usd">388740</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c43" decimals="0" id="ixv-11668" unitRef="usd">308847</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-11669" unitRef="usd">37495080</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" id="ixv-11670" unitRef="usd">38323430</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-11671" unitRef="usd">30394655</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-11672" unitRef="usd">28350365</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c3" decimals="0" id="ixv-11673" unitRef="usd">7100425</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c4" decimals="0" id="ixv-11674" unitRef="usd">9973065</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <cphi:UsefulLiveOfAssetsTableTextBlock contextRef="c0" id="ixv-11675">Depreciation is computed on a straight-line basis over the estimated
useful lives of the assets as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%; text-align: left"&gt;&lt;b&gt;Asset&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"&gt;&lt;b&gt;Life - years&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permit of land use&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;40 - 70&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Building&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;20 - 49&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Plant, machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Motor vehicle&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 - 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cphi:UsefulLiveOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c44" id="ixv-11676">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c45" id="ixv-11677">P70Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c46" id="ixv-11678">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c47" id="ixv-11679">P49Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c48" id="ixv-11680">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c49" id="ixv-11681">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c50" id="ixv-11682">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c51" id="ixv-11683">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52" id="ixv-11684">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c53" id="ixv-11685">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-11686" unitRef="usd">2529858</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="0" id="ixv-11687" unitRef="usd">2663975</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-10081">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 - INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets represent the cost of medical
formulas approved for production by the NMPA, the intellectual property acquired from Chengdu Bonier Medical Technology Development Co.,
Ltd. (&#x201c;Bonier Agreement&#x201d;) and the Technology Transfer Agreement (the &#x201c;&lt;b&gt;Agreement&lt;/b&gt;&#x201d;) with Tao Liu discussed
below. The Company did not obtain NMPA production approval for any new medical formulas during the years ended December 31, 2023 and 2022
and no costs were reclassified from advances to intangible assets during the years ended December 31, 2023 and 2022, respectively. On
August 9, 2023, the Company obtained the &#x201c;Drug Supplementary Application Approval Notice&#x201d; from the NMPA for the indicating
that the Company&#x2019;s existing formular Candesartan tablets have passed the quality and efficacy consistency evaluation of generic
drugs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Approved medical formulas are amortized from the
date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&#160;&#160;It
is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to
changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets
was $223,796 and $36,558 for the years ended December 31, 2023 and 2022, respectively which was included in the general and administrative
expenses. Medical formulas typically do not have a residual value at the end of their amortization period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 15, 2023, the Company entered into
a Technology Transfer Agreement (the &#x201c;Agreement&#x201d;) with Tao Liu (the &#x201c;Transferor&#x201d;). The Transferor owns an invention
patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the &#x201c;Invention Patent&#x201d;). Pursuant
to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third
party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing
of registration materials, registration application and other technical services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective December 15, 2023 China Pharma issued
3,000,000 shares of its common stock valued at $1,650,000 based on the closing market price of its common stock of $0.55 per share at
that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2023. The value of the
intangible asset will be amortized over its remaining useful life of approximately 14.8 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the ten years after the product launches
to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual
basis to the Transferor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 28, 2022, the Company entered into
a Technology Transfer Contract (the &#x201c;Bonier Agreement&#x201d;) with Chengdu Bonier Medical Technology Development Co., Ltd (&#x201c;Bonier&#x201d;).
Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which
has obtained a utility model patent (the &#x201c;Utility Model Patent&#x201d;) and applied for an invention patent (the &#x201c;Invention
Patent&#x201d;) at the same time. Pursuant to the Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical
invention and the Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant
technical services in Haikou, which include but are not limited to product research and development, writing of registration materials,
registration application and other technical services, with a term of ten years. Effective November 28, 2022 the Company issued 310,446
share of its common stock valued at $1,707,452 based on the closing market price of its common stock of $5.50 per share at that date.
The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2022. The value of the intangible
asset will be amortized over its remaining useful life of approximately 9.7 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company will pay a service fee of 15% of the
net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent
on the successful authorization of the above mentioned Invention Patent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates each approved medical formula
for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement.
The Company&#x2019;s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data
for the related drug and the Company&#x2019;s estimated market share. If the carrying value of the medical formula exceeds the estimated
future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula,
which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the years ended December
31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;NMPA approved medical formulas&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,766,353&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,847,176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Technology from Bonier&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,726,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,707,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Invention Patent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,653,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,890,646&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,747,142&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,255,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,807,486&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The estimated aggregate annual amortization expense for each of the
next five years and thereafter is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;327,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,730,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,255,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="c0" id="ixv-11688">Approved medical formulas are amortized from the
date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-11689" unitRef="usd">223796</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c7" decimals="0" id="ixv-11690" unitRef="usd">36558</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c54"
      decimals="0"
      id="ixv-11691"
      unitRef="shares">3000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DividendsStock contextRef="c54" decimals="0" id="ixv-11692" unitRef="usd">1650000</us-gaap:DividendsStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c55"
      decimals="2"
      id="ixv-11693"
      unitRef="usdPershares">0.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c56" id="ixv-11694">P14Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cphi:PercentageOfNetProfit contextRef="c57" decimals="2" id="ixv-11695" unitRef="pure">0.15</cphi:PercentageOfNetProfit>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c58"
      decimals="0"
      id="ixv-11696"
      unitRef="shares">310446</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DividendsStock contextRef="c58" decimals="0" id="ixv-11697" unitRef="usd">1707452</us-gaap:DividendsStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c59"
      decimals="2"
      id="ixv-11698"
      unitRef="usdPershares">5.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c3" id="ixv-11699">P9Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cphi:PercentageOfNetProfit contextRef="c0" decimals="2" id="ixv-11700" unitRef="pure">0.15</cphi:PercentageOfNetProfit>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0" id="ixv-11701">Intangible assets consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;NMPA approved medical formulas&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,766,353&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,847,176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Technology from Bonier&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,726,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,707,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Invention Patent&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,653,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,890,646&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,747,142&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,255,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,807,486&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c60" decimals="0" id="ixv-11702" unitRef="usd">4766353</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c61" decimals="0" id="ixv-11703" unitRef="usd">4847176</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c62" decimals="0" id="ixv-11704" unitRef="usd">1726497</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c63" decimals="0" id="ixv-11705" unitRef="usd">1707452</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c64" decimals="0" id="ixv-11706" unitRef="usd">1653028</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-11707" unitRef="usd">4890646</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="0" id="ixv-11708" unitRef="usd">4747142</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-11709" unitRef="usd">3255232</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-11710" unitRef="usd">1807486</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-11711">The estimated aggregate annual amortization expense for each of the
next five years and thereafter is as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;327,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,730,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,255,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="0" id="ixv-11712" unitRef="usd">327050</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="0" id="ixv-11713" unitRef="usd">321235</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="0" id="ixv-11714" unitRef="usd">292156</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="0" id="ixv-11715" unitRef="usd">292156</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c3" decimals="0" id="ixv-11716" unitRef="usd">292156</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c3" decimals="0" id="ixv-11717" unitRef="usd">1730479</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-11718" unitRef="usd">3255232</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-10283">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; OTHER PAYABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other Payables consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Compensation payable to officer&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,243,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;951,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Compensation and interest to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;372,578&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Business taxes and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,027,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,065,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,282,692&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,390,063&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-11719">Other Payables consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Compensation payable to officer&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,243,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;951,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Compensation and interest to related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;372,578&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Business taxes and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,027,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,065,979&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total Other Payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,282,692&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,390,063&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c3" decimals="0" id="ixv-11720" unitRef="usd">1243506</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c4" decimals="0" id="ixv-11721" unitRef="usd">951506</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-11722" unitRef="usd">12000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-11723" unitRef="usd">372578</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ixv-11724" unitRef="usd">1027186</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c4" decimals="0" id="ixv-11725" unitRef="usd">1065979</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-11726" unitRef="usd">2282692</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-11727" unitRef="usd">2390063</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-10374">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A member of the Company&#x2019;s board of directors
(&#x201c;Board&#x201d;) had previously advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2022 which is recorded
as &#x201c;Other payables &#x2013; related parties&#x201d; on the accompanying condensed consolidated balance sheets. The advances bore interest
at a rate of 1.0% per year.&#160;&#160;Total interest expense years ended December 31, 2023 and 2022 was $6,773 and $13,546, respectively.
Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance
sheet totaling $12,000 and $372,578 as of December 31, 2023 and 2022, respectively. On August 23, 2023, the director entered into a certain
debt transfer agreement with Chairperson Li, pursuant to which the rights to collect a total amount of $1,854,452 were assigned to Chairperson
Li. On September 28, 2023, Chairperson Li entered into a certain loan settlement agreement, pursuant to which both parties agreed to convert
the aggregate amount of $1,854,452&#160;owed by the Company into&#160;2,751,412&#160;shares of restricted common stock of the Company.
Such issuance was completed on September 29, 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company received advances totaling $2,928
and $0 and repaid $0 and $223,013 of the advances during the years ended December 31, 2023 and 2022, respectively from its Chairperson,
Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,121,273 and $1,425,123 and are recorded as Other
payables &#x2013; related parties on the accompanying condensed consolidated balance sheets as of December 31, 2021 and 2020, respectively.
On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief
Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the
loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2023. Total interest
expense related to the loan for the years ended December 31, 2023 and 2022 was $27,644 and $28,962, respectively. Compensation payable
to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying consolidated
balance sheet totaling $1,243,506 and $951,506 as of December 31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AdvancesToAffiliate contextRef="c66" decimals="0" id="ixv-11728" unitRef="usd">1354567</us-gaap:AdvancesToAffiliate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c67" decimals="3" id="ixv-11729" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestIncomeExpenseNet contextRef="c68" decimals="0" id="ixv-11730" unitRef="usd">6773</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c69" decimals="0" id="ixv-11731" unitRef="usd">13546</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c67" decimals="0" id="ixv-11732" unitRef="usd">12000</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c66" decimals="0" id="ixv-11733" unitRef="usd">372578</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:PaymentsForLoans contextRef="c70" decimals="0" id="ixv-11734" unitRef="usd">1854452</us-gaap:PaymentsForLoans>
    <cphi:AggregateAmounts contextRef="c71" decimals="0" id="ixv-11735" unitRef="usd">1854452</cphi:AggregateAmounts>
    <cphi:RestrictedCommonStock
      contextRef="c72"
      decimals="0"
      id="ixv-11736"
      unitRef="shares">2751412</cphi:RestrictedCommonStock>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c73" decimals="0" id="ixv-11737" unitRef="usd">2928</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c74" decimals="0" id="ixv-11738" unitRef="usd">0</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c75" decimals="0" id="ixv-11739" unitRef="usd">0</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c76" decimals="0" id="ixv-11740" unitRef="usd">223013</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:AdvancesToAffiliate contextRef="c77" decimals="0" id="ixv-11741" unitRef="usd">1121273</us-gaap:AdvancesToAffiliate>
    <us-gaap:AdvancesToAffiliate contextRef="c78" decimals="0" id="ixv-11742" unitRef="usd">1425123</us-gaap:AdvancesToAffiliate>
    <us-gaap:ProceedsFromLoans contextRef="c79" decimals="0" id="ixv-11743" unitRef="cny">4770000</us-gaap:ProceedsFromLoans>
    <us-gaap:ProceedsFromLoans contextRef="c79" decimals="0" id="ixv-11744" unitRef="usd">738379</us-gaap:ProceedsFromLoans>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c80" decimals="4" id="ixv-11745" unitRef="pure">0.0435</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LoansHeldForSaleTerm contextRef="c3" id="ixv-11746">P1Y</us-gaap:LoansHeldForSaleTerm>
    <us-gaap:InterestIncomeExpenseNet contextRef="c81" decimals="0" id="ixv-11747" unitRef="usd">27644</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c82" decimals="0" id="ixv-11748" unitRef="usd">28962</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c83" decimals="0" id="ixv-11749" unitRef="usd">1243506</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c84" decimals="0" id="ixv-11750" unitRef="usd">951506</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-10384">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; LINES OF CREDIT AND CONSTRUCTION
LOAN FACILITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Lines of Credit&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 25, 2021 the Company entered into a loan
with Bank of Communications bearing an interest rate of 4.17%. &lt;span&gt;The Company paid all principal and
interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing interest at&#160;4.17% and
due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line of credit for an aggregate
amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The Company received an advance
on the line of credit in the amount of RMB 3,800,000 (approximately $0.56 million) on December 30, 2022. On February 24, 2023 the Company
received an advance on the line in the amount of RMB&#160;3,500,000&#160;(approximately $0.51&#160;million). The Company has no further
availability on this line of credit.&#160;The line of credit was payable on December 20, 2023. The line of credit was paid in full on
December 15, 2023.&#160;On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest
rate of 3.9% and is due December 15, 2024. &lt;/span&gt;In addition, the Company&#x2019;s Chief Executive Officer and Chair of the Board personally
guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for
the years ended December 31, 2023 and 2022 was $31,750 and $53,283, respectively. On February 2, 2024 the Company repaid RMB 3,500,000
under this line of credit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company obtained a line of credit of RMB 3,200,000
(approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million),
and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of
4.50% per annum. In September, 2021 the Company repaid the line of credit in full. Also in September, 2021 the Company entered into a
new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million). The loan bears interest at the rate of 4.50% per annum.
The line of credit was due on September 2, 2022. &lt;span&gt;The line of credit was paid in full on September
6, 2022.&#160;On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears interest at a rate of&#160;4.5%
and is due on September 7, 2023&lt;/span&gt; and was repaid in full as of that date. In addition, the Company&#x2019;s Chief Executive Officer
and Chair of the Board had personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total
interest expense under this facility for the years ended December 31, 2023 and 2022 was $19,579 and $20,548, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 18, 2021 the Company obtained a
line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per
annum. &lt;span&gt;The line of credit was paid in full on the due date of September 18, 2022. On September
30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at the rate of 3.45% and was due
September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a
three-year revolving loan and received proceeds of RMB&#160;10,000,000&#160;(approximately $1.4&#160;million). The interest rate for
the loan is&#160;3.35% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate
less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month
anniversary of the loan.&#160;The loan is due on September 24, 2026. &lt;/span&gt;The loan is collateralized by the Company&#x2019;s new
production facility and the included production line equipment and machinery. In addition, the Company&#x2019;s Chief Executive
Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was $48,624 and
$54,923 for the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Principal payments required for the remaining
terms of the lines of credit as of December 31, 2023 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lines of&lt;br/&gt;
 Credit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,442,571&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,442,571&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2020, the Company obtained a line of
credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000
(approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The
loan bore interest at a rate of 4.25% per annum. Advances on the line of credit were due two years from the date of the advance. A third
party company had guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next
to the creditor of the construction loan facility as discussed above. In addition, the Company&#x2019;s Chief Executive Officer and Chair
of the Board personally guaranteed the line of credit. Total interest expense under this facility for the years ended December 31, 2022
was $12,063. The Company repaid the remaining RMB 5,900,000 (approximately $0.85) during the year ended December 31, 2022 as per the repayment
schedule in full satisfaction of the line of credit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Lines of Credit&lt;/i&gt;&lt;/b&gt; &#x2013;
Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts
of the construction loan facility outstanding as of December 31, 2023 and December 31, 2022 approximated its fair value because the underlying
instrument bears an interest rate that approximated current market rates.&#160;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:InvestmentInterestRateFloor contextRef="c85" decimals="4" id="ixv-11751" unitRef="pure">0.0417</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InvestmentInterestRateFloor contextRef="c86" decimals="4" id="ixv-11752" unitRef="pure">0.0417</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InvestmentInterestRateFloor contextRef="c87" decimals="4" id="ixv-11753" unitRef="pure">0.0417</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:LineOfCredit contextRef="c88" decimals="0" id="ixv-11754" unitRef="cny">7300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c88" decimals="-5" id="ixv-11755" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:InvestmentInterestRateFloor contextRef="c89" decimals="3" id="ixv-11756" unitRef="pure">0.039</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:LineOfCredit contextRef="c90" decimals="0" id="ixv-11757" unitRef="cny">3800000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c90" decimals="-4" id="ixv-11758" unitRef="usd">560000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c91" decimals="0" id="ixv-11759" unitRef="cny">3500000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c91" decimals="-4" id="ixv-11760" unitRef="usd">510000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c92" decimals="0" id="ixv-11761" unitRef="cny">3800000</us-gaap:LineOfCredit>
    <us-gaap:InvestmentInterestRateFloor contextRef="c92" decimals="3" id="ixv-11762" unitRef="pure">0.039</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="0" id="ixv-11763" unitRef="usd">31750</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c7" decimals="0" id="ixv-11764" unitRef="usd">53283</us-gaap:InterestExpenseOther>
    <us-gaap:LinesOfCreditCurrent contextRef="c93" decimals="0" id="ixv-11765" unitRef="cny">3500000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LineOfCredit contextRef="c94" decimals="0" id="ixv-11766" unitRef="cny">3200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c94" decimals="-5" id="ixv-11767" unitRef="usd">500000</us-gaap:LineOfCredit>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c95" decimals="0" id="ixv-11768" unitRef="cny">2343340</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c95" decimals="-5" id="ixv-11769" unitRef="usd">300000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c96" decimals="0" id="ixv-11770" unitRef="cny">856660</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c96" decimals="-5" id="ixv-11771" unitRef="usd">100000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:InvestmentInterestRateFloor contextRef="c97" decimals="4" id="ixv-11772" unitRef="pure">0.045</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:LineOfCredit contextRef="c98" decimals="0" id="ixv-11773" unitRef="cny">3200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c98" decimals="-5" id="ixv-11774" unitRef="usd">800000</us-gaap:LineOfCredit>
    <us-gaap:InvestmentInterestRateFloor contextRef="c99" decimals="4" id="ixv-11775" unitRef="pure">0.045</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="c100"
      decimals="3"
      id="ixv-11776"
      unitRef="pure">0.045</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InterestExpenseOther contextRef="c101" decimals="0" id="ixv-11777" unitRef="usd">19579</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c102" decimals="0" id="ixv-11778" unitRef="usd">20548</us-gaap:InterestExpenseOther>
    <us-gaap:LineOfCredit contextRef="c103" decimals="0" id="ixv-11779" unitRef="cny">10000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="c103"
      decimals="-4"
      id="ixv-11780"
      unitRef="usd">1540000</us-gaap:LineOfCredit>
    <us-gaap:InvestmentInterestRateFloor
      contextRef="c104"
      decimals="4"
      id="ixv-11781"
      unitRef="pure">0.0385</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InvestmentInterestRateFloor
      contextRef="c105"
      decimals="4"
      id="ixv-11782"
      unitRef="pure">0.0345</us-gaap:InvestmentInterestRateFloor>
    <cphi:LoanAndReceivedProceeds contextRef="c106" decimals="0" id="ixv-11783" unitRef="cny">10000000</cphi:LoanAndReceivedProceeds>
    <cphi:LoanAndReceivedProceeds
      contextRef="c106"
      decimals="-5"
      id="ixv-11784"
      unitRef="usd">1400000</cphi:LoanAndReceivedProceeds>
    <us-gaap:InvestmentInterestRateFloor
      contextRef="c107"
      decimals="4"
      id="ixv-11785"
      unitRef="pure">0.0335</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InterestExpenseOther contextRef="c108" decimals="0" id="ixv-11786" unitRef="usd">48624</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c109" decimals="0" id="ixv-11787" unitRef="usd">54923</us-gaap:InterestExpenseOther>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c0" id="ixv-11788">Principal payments required for the remaining
terms of the lines of credit as of December 31, 2023 are as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Lines of&lt;br/&gt;
 Credit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;2,442,571&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,442,571&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c115" decimals="0" id="ixv-11789" unitRef="usd">2442571</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt contextRef="c115" decimals="0" id="ixv-11790" unitRef="usd">2442571</us-gaap:LongTermDebt>
    <cphi:AggregateAmounts contextRef="c110" decimals="0" id="ixv-11791" unitRef="cny">10000000</cphi:AggregateAmounts>
    <us-gaap:LineOfCredit
      contextRef="c111"
      decimals="-5"
      id="ixv-11792"
      unitRef="usd">1400000</us-gaap:LineOfCredit>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c112" decimals="0" id="ixv-11793" unitRef="cny">5000000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits
      contextRef="c112"
      decimals="-5"
      id="ixv-11794"
      unitRef="usd">700000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits contextRef="c113" decimals="0" id="ixv-11795" unitRef="cny">3000000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:PaymentsForMortgageDeposits
      contextRef="c113"
      decimals="-5"
      id="ixv-11796"
      unitRef="usd">400000</us-gaap:PaymentsForMortgageDeposits>
    <us-gaap:InvestmentInterestRateFloor contextRef="c3" decimals="4" id="ixv-11797" unitRef="pure">0.0425</us-gaap:InvestmentInterestRateFloor>
    <us-gaap:InterestExpenseOther contextRef="c114" decimals="0" id="ixv-11798" unitRef="usd">12063</us-gaap:InterestExpenseOther>
    <cphi:RepaidAmount contextRef="c4" decimals="0" id="ixv-11799" unitRef="cny">5900000</cphi:RepaidAmount>
    <cphi:RepaidAmount contextRef="c4" decimals="2" id="ixv-11800" unitRef="usd">0.85</cphi:RepaidAmount>
    <us-gaap:ShortTermDebtTextBlock contextRef="c0" id="ixv-10457">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 &#x2013; CONVERTIBLE NOTE PAYABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On November 17, 2021,
China Pharma entered into a Securities Purchase Agreement (the &#x201c;Agreement&#x201d;) pursuant to which the Company issued an unsecured
convertible promissory note (the &#x201c;Note&#x201d;) to an institutional accredited investor Streeterville Capital, LLC (the &#x201c;Investor&#x201d;).
The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13,
2023 China Pharma entered into an Amendment (the &#x201c;Amendment&#x201d;) with the Investor which extended the maturity date of the Convertible
Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of $65,639, representing&#160;2.0%
of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance
by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition,
China Pharma decreased the price at which the Investor can convert the balance from&#160;85% to&#160;82% of the lowest daily volume weighted
average price during the ten trading days immediately preceding the applicable redemption conversion,&#160;and assumed an additional obligation
to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Note was originally
convertible into&#160;70,000&#160;shares of China Pharma&#x2019;s common stock at a price of $75.00&#160;per share through April 19, 2022.
Thereafter, the Note was convertible into&#160;35,000&#160;shares at a price of $150.00&#160;per share. As of December 31, 2023 the Note
is convertible into&#160;6,267&#160;shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Interest accrues on the
outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest
accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor
may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%,
depending on the nature of the Event of Default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Pursuant to the terms
of the Agreement and the Note, the Company must obtain Investor&#x2019;s consent for certain fundamental transactions such as consolidation,
merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization
or recapitalization. Any occurrence of a fundamental transaction without Investor&#x2019;s prior written consent will be deemed an Event
of Default.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Investor may redeem all
or any part the outstanding balance of the Note, subject to $500,000&#160;per calendar month, at any time after one hundred twenty-one
(121) days from the Purchase Price Date, as defined in the Note, upon three trading days&#x2019; notice, in cash or converting into shares
of China Pharma&#x2019;s common stock, at a price equal to&#160;82% multiplied by the lowest daily volume weighted average price during
the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations
specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note.
The Company may prepay the outstanding balance of the Note with the Investor&#x2019;s consent. At inception, the Note was redeemable into&#160;176,229&#160;shares
based on the lowest volume weighted average price of $29.79085&#160;on the inception date of November 19, 2021. As of December 31, 2023,
the Note was redeemable into&#160;2,159,964&#160;shares of common stock based on&#160;82% of the lowest volume weighted average price
of $0.436&#160;on that date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Total interest expense
for the years ended December 31, 2023 and 2022 was $206,744 and $250,314, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;2023
Redemptions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On January
5, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $3.815, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;39,319&#160;shares of common stock to the Investor on
January 6, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On January
18, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion price
of $3.815, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;65,531&#160;shares of common stock to the Investor on
January 19, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On March
2, 2023&#160;the Investor delivered its notice of redemption for $250,000&#160;of the Note and related interest at the conversion price
of $2.875, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;86,957&#160;shares of common stock to the Investor on
March 8, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On April
7, 2023&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion price
of $1.404, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;142,450&#160;shares of common stock to the Investor
on April 13, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On May 1,
2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of
$1.322, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;113,465&#160;shares of common stock to the Investor
on May 3, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On May 24,
2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of
$1.2435, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;120,628&#160;shares of common stock to the Investor
on May 25, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On June
6, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.328, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;112,952&#160;shares of common stock to the Investor
on June 13, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On June
23, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.4225, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly,&#160;China Pharma&#160;issued a total of&#160;105,448&#160;shares of common stock to the
Investor on June 27, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On August
9, 2023&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $1.0715, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;139,991&#160;shares of common stock to the Investor
on August 11, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On August
21, 2023&#160;the Investor delivered its notice of redemption for $245,000&#160;of the Note and related interest at the conversion price
of $1.0715, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;228,652&#160;shares of common stock to the Investor
on August 22, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On September
1, 2023,&#160;the Investor delivered its notice of redemption for $140,000&#160;of the Note and related interest at the conversion price
of $0.666, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;210,211&#160;shares of common stock to the Investor on September
6, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On September
12, 2023,&#160;the Investor delivered its notice of redemption for $75,000&#160;of the Note and related interest at the conversion price
of $0.579, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;129,534&#160;shares of common stock to the Investor on September
13, 2023.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 6, 2023&#160;the Investor delivered
its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price of $0.546, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;183,150&#160;shares of common stock to the Investor on October 9, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 12, 2023&#160;the Investor delivered
its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.513, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;224,172&#160;shares of common stock to the Investor on October 13, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 17, 2023&#160;the Investor delivered
its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.513, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;224,172&#160;shares of common stock to the Investor on October 17, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 6, 2023&#160;the Investor delivered
its notice of redemption for $80,000&#160;of the Note and related interest at the conversion price of $0.3765, which was&#160;82% of the
lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption conversion. Accordingly,
the Company issued a total of&#160;212,444&#160;shares of common stock to the Investor on November 7, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On November 29, 2023&#160;the
Investor delivered its notice of redemption for $125,000&#160;of the Note and related interest at the conversion price of $0.368, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;339,674&#160;shares of common stock to the Investor on November 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On November 30, 2023&#160;the
Investor delivered its notice of redemption for $115,000&#160;of the Note and related interest at the conversion price of $0.368, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;312,500&#160;shares of common stock to the Investor on December 1, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On December 13, 2023&#160;the
Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price of $0.4045, which
was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;370,828&#160;shares of common stock to the Investor on December 18, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Subsequent
to December 31, 2023 the Investor delivered additional notices of redemption as discussed in Note 14.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;2022
Redemptions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On March 21, 2022 the
Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of $15.565 during the
ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 6,425 shares of
common stock to the Investor on March 23, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On March
30, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $15.645, which
was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;12,874 shares of common stock to the Investor on March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On June
13, 2022 the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the price of $9.90, which
was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable redemption
conversion. Accordingly, the Company issued a total of&#160;20,202 shares of common stock to the Investor on June 13, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On August
3, 2022&#160;the Investor delivered its notice of redemption for $200,000&#160;of the Note and related interest at the conversion price
of $8.775, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;22,792 shares of common stock to the Investor on August 4, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On October
17, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price
of $5.60, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;17,857 shares of common stock to the Investor on October 18, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On December
1, 2022&#160;the Investor delivered its notice of redemption for $100,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;24,126 shares of common stock to the Investor on December 2, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On December
5, 2022&#160;the Investor delivered its notice of redemption for $310,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;74,789 shares of common stock to the Investor on December 6, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On December
13, 2022&#160;the Investor delivered its notice of redemption for $90,000&#160;of the Note and related interest at the conversion price
of $4.55, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;19,781&#160;shares of common stock to the Investor on December
14, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On December
14, 2022&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $4.145, which was&#160;85% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the applicable
redemption conversion. Accordingly, the Company issued a total of&#160;36,181 shares of common stock to the Investor on December 15, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c116" decimals="0" id="ixv-11801" unitRef="usd">65639</us-gaap:DebtInstrumentFeeAmount>
    <cphi:PercentageOfBalanceNoteAndAccruedInterest
      contextRef="c116"
      decimals="3"
      id="ixv-11802"
      unitRef="pure">0.02</cphi:PercentageOfBalanceNoteAndAccruedInterest>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c117"
      decimals="2"
      id="ixv-11803"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c118"
      decimals="2"
      id="ixv-11804"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c119"
      decimals="0"
      id="ixv-11805"
      unitRef="pure">70000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c120"
      decimals="2"
      id="ixv-11806"
      unitRef="usdPershares">75</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c121"
      decimals="0"
      id="ixv-11807"
      unitRef="pure">35000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c122"
      decimals="2"
      id="ixv-11808"
      unitRef="usdPershares">150</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c123"
      decimals="0"
      id="ixv-11809"
      unitRef="pure">6267</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <cphi:InterestAccruesOnNoteDescription contextRef="c0" id="ixv-11810">Interest accrues on the
outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest
accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor
may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%,
depending on the nature of the Event of Default.</cphi:InterestAccruesOnNoteDescription>
    <cphi:RedeemOfOutstandingNote contextRef="c0" decimals="0" id="ixv-11811" unitRef="usd">500000</cphi:RedeemOfOutstandingNote>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c0" decimals="2" id="ixv-11812" unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c124"
      decimals="0"
      id="ixv-11813"
      unitRef="pure">176229</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c125"
      decimals="5"
      id="ixv-11814"
      unitRef="usdPershares">29.79085</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <cphi:NoteRedeemableIntoShares
      contextRef="c0"
      decimals="0"
      id="ixv-11815"
      unitRef="shares">2159964</cphi:NoteRedeemableIntoShares>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c0" decimals="2" id="ixv-11816" unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <cphi:WeightedAveragePrice
      contextRef="c0"
      decimals="3"
      id="ixv-11817"
      unitRef="usdPershares">0.436</cphi:WeightedAveragePrice>
    <us-gaap:InterestExpenseDebt contextRef="c123" decimals="0" id="ixv-11818" unitRef="usd">206744</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c126" decimals="0" id="ixv-11819" unitRef="usd">250314</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c127" decimals="0" id="ixv-11820" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c128"
      decimals="3"
      id="ixv-11821"
      unitRef="usdPershares">3.815</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c129"
      decimals="2"
      id="ixv-11822"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c130"
      decimals="0"
      id="ixv-11823"
      unitRef="shares">39319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c131" decimals="0" id="ixv-11824" unitRef="usd">250000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c132"
      decimals="3"
      id="ixv-11825"
      unitRef="usdPershares">3.815</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c133"
      decimals="2"
      id="ixv-11826"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c134"
      decimals="0"
      id="ixv-11827"
      unitRef="shares">65531</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c135" decimals="0" id="ixv-11828" unitRef="usd">250000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c136"
      decimals="3"
      id="ixv-11829"
      unitRef="usdPershares">2.875</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c137"
      decimals="2"
      id="ixv-11830"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c138"
      decimals="0"
      id="ixv-11831"
      unitRef="shares">86957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c139" decimals="0" id="ixv-11832" unitRef="usd">200000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c140"
      decimals="3"
      id="ixv-11833"
      unitRef="usdPershares">1.404</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c141"
      decimals="2"
      id="ixv-11834"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c142"
      decimals="0"
      id="ixv-11835"
      unitRef="shares">142450</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c143" decimals="0" id="ixv-11836" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c144"
      decimals="3"
      id="ixv-11837"
      unitRef="usdPershares">1.322</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c145"
      decimals="2"
      id="ixv-11838"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c146"
      decimals="0"
      id="ixv-11839"
      unitRef="shares">113465</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c147" decimals="0" id="ixv-11840" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c148"
      decimals="4"
      id="ixv-11841"
      unitRef="usdPershares">1.2435</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c149"
      decimals="2"
      id="ixv-11842"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c150"
      decimals="0"
      id="ixv-11843"
      unitRef="shares">120628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c151" decimals="0" id="ixv-11844" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c152"
      decimals="3"
      id="ixv-11845"
      unitRef="usdPershares">1.328</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c153"
      decimals="2"
      id="ixv-11846"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c154"
      decimals="0"
      id="ixv-11847"
      unitRef="shares">112952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c155" decimals="0" id="ixv-11848" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c156"
      decimals="4"
      id="ixv-11849"
      unitRef="usdPershares">1.4225</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c157"
      decimals="2"
      id="ixv-11850"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c158"
      decimals="0"
      id="ixv-11851"
      unitRef="shares">105448</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c159" decimals="0" id="ixv-11852" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c160"
      decimals="4"
      id="ixv-11853"
      unitRef="usdPershares">1.0715</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c161"
      decimals="2"
      id="ixv-11854"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c162"
      decimals="0"
      id="ixv-11855"
      unitRef="shares">139991</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c163" decimals="0" id="ixv-11856" unitRef="usd">245000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c164"
      decimals="4"
      id="ixv-11857"
      unitRef="usdPershares">1.0715</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c165"
      decimals="2"
      id="ixv-11858"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c166"
      decimals="0"
      id="ixv-11859"
      unitRef="shares">228652</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c167" decimals="0" id="ixv-11860" unitRef="usd">140000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c168"
      decimals="3"
      id="ixv-11861"
      unitRef="usdPershares">0.666</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c169"
      decimals="2"
      id="ixv-11862"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c170"
      decimals="0"
      id="ixv-11863"
      unitRef="shares">210211</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c171" decimals="0" id="ixv-11864" unitRef="usd">75000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c172"
      decimals="3"
      id="ixv-11865"
      unitRef="usdPershares">0.579</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c173"
      decimals="2"
      id="ixv-11866"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c174"
      decimals="0"
      id="ixv-11867"
      unitRef="shares">129534</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c175" decimals="0" id="ixv-11868" unitRef="usd">100000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c176"
      decimals="3"
      id="ixv-11869"
      unitRef="usdPershares">0.546</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c177"
      decimals="2"
      id="ixv-11870"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c178"
      decimals="0"
      id="ixv-11871"
      unitRef="shares">183150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c179" decimals="0" id="ixv-11872" unitRef="usd">115000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c180"
      decimals="3"
      id="ixv-11873"
      unitRef="usdPershares">0.513</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c181"
      decimals="2"
      id="ixv-11874"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c182"
      decimals="0"
      id="ixv-11875"
      unitRef="shares">224172</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c183" decimals="0" id="ixv-11876" unitRef="usd">115000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c184"
      decimals="3"
      id="ixv-11877"
      unitRef="usdPershares">0.513</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c185"
      decimals="2"
      id="ixv-11878"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c186"
      decimals="0"
      id="ixv-11879"
      unitRef="shares">224172</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c187" decimals="0" id="ixv-11880" unitRef="usd">80000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c188"
      decimals="4"
      id="ixv-11881"
      unitRef="usdPershares">0.3765</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c189"
      decimals="2"
      id="ixv-11882"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c190"
      decimals="0"
      id="ixv-11883"
      unitRef="shares">212444</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c191" decimals="0" id="ixv-11884" unitRef="usd">125000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c192"
      decimals="3"
      id="ixv-11885"
      unitRef="usdPershares">0.368</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c193"
      decimals="2"
      id="ixv-11886"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c194"
      decimals="0"
      id="ixv-11887"
      unitRef="shares">339674</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c195" decimals="0" id="ixv-11888" unitRef="usd">115000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c196"
      decimals="3"
      id="ixv-11889"
      unitRef="usdPershares">0.368</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c197"
      decimals="2"
      id="ixv-11890"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c198"
      decimals="0"
      id="ixv-11891"
      unitRef="shares">312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c199" decimals="0" id="ixv-11892" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c200"
      decimals="4"
      id="ixv-11893"
      unitRef="usdPershares">0.4045</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c201"
      decimals="2"
      id="ixv-11894"
      unitRef="pure">0.82</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c202"
      decimals="0"
      id="ixv-11895"
      unitRef="shares">370828</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c203" decimals="0" id="ixv-11896" unitRef="usd">100000</us-gaap:DebtInstrumentRepurchaseAmount>
    <cphi:WeightedAveragePrice
      contextRef="c204"
      decimals="3"
      id="ixv-11897"
      unitRef="usdPershares">15.565</cphi:WeightedAveragePrice>
    <us-gaap:SharesIssued
      contextRef="c205"
      decimals="0"
      id="ixv-11898"
      unitRef="shares">6425</us-gaap:SharesIssued>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c206" decimals="0" id="ixv-11899" unitRef="usd">200000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c207"
      decimals="3"
      id="ixv-11900"
      unitRef="usdPershares">15.645</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c208"
      decimals="2"
      id="ixv-11901"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c209"
      decimals="0"
      id="ixv-11902"
      unitRef="shares">12874</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c210" decimals="0" id="ixv-11903" unitRef="usd">200000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c211"
      decimals="2"
      id="ixv-11904"
      unitRef="usdPershares">9.9</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c212"
      decimals="2"
      id="ixv-11905"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c213"
      decimals="0"
      id="ixv-11906"
      unitRef="shares">20202</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c214" decimals="0" id="ixv-11907" unitRef="usd">200000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c215"
      decimals="3"
      id="ixv-11908"
      unitRef="usdPershares">8.775</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c216"
      decimals="2"
      id="ixv-11909"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c217"
      decimals="0"
      id="ixv-11910"
      unitRef="shares">22792</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c218" decimals="0" id="ixv-11911" unitRef="usd">100000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c219"
      decimals="2"
      id="ixv-11912"
      unitRef="usdPershares">5.6</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c220"
      decimals="2"
      id="ixv-11913"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c221"
      decimals="0"
      id="ixv-11914"
      unitRef="shares">17857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c222" decimals="0" id="ixv-11915" unitRef="usd">100000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c223"
      decimals="3"
      id="ixv-11916"
      unitRef="usdPershares">4.145</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c224"
      decimals="2"
      id="ixv-11917"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c225"
      decimals="0"
      id="ixv-11918"
      unitRef="shares">24126</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c226" decimals="0" id="ixv-11919" unitRef="usd">310000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c227"
      decimals="3"
      id="ixv-11920"
      unitRef="usdPershares">4.145</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c228"
      decimals="2"
      id="ixv-11921"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c229"
      decimals="0"
      id="ixv-11922"
      unitRef="shares">74789</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c230" decimals="0" id="ixv-11923" unitRef="usd">90000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c231"
      decimals="2"
      id="ixv-11924"
      unitRef="usdPershares">4.55</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c232"
      decimals="2"
      id="ixv-11925"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c233"
      decimals="0"
      id="ixv-11926"
      unitRef="shares">19781</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c234" decimals="0" id="ixv-11927" unitRef="usd">150000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c235"
      decimals="3"
      id="ixv-11928"
      unitRef="usdPershares">4.145</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c236"
      decimals="2"
      id="ixv-11929"
      unitRef="pure">0.85</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c237"
      decimals="0"
      id="ixv-11930"
      unitRef="shares">36181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-10677">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 - LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has leases for certain office and
production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options
to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the
lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount
rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company&#x2019;s incremental borrowing
rate at the initial measurement date. For the years ended December 31, 2023 and 2022, operating lease cost was $77,265 and $78,092, respectively
and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $80,647
and $82,015, respectively. As of December 31, 2023 and 2022, the Company reported operating lease right of use assets of $116,610 and
$39,046, respectively and operating use liabilities of $117,637 and $40,445, respectively. As of December 31, 2023, its operating leases
had a weighted average remaining lease term of 1.50 years and a weighted average discount rate of 4.75%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;Minimum lease payments for the Company&#x2019;s
operating lease liabilities were as follows for the twelve month periods ended December 31:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,334&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Operating lease liabilities, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77,727&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,910&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company has leases with terms less than one year for certain provincial
sales offices that are not material.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-11931" unitRef="usd">77265</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c7" decimals="0" id="ixv-11932" unitRef="usd">78092</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-11933" unitRef="usd">80647</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="0" id="ixv-11934" unitRef="usd">82015</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-11935" unitRef="usd">116610</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-11936" unitRef="usd">39046</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c0" decimals="0" id="ixv-11937" unitRef="usd">117637</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c7" decimals="0" id="ixv-11938" unitRef="usd">40445</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-11939">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" id="ixv-11940" unitRef="pure">0.0475</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-11941">Minimum lease payments for the Company&#x2019;s
operating lease liabilities were as follows for the twelve month periods ended December 31:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total undiscounted cash flows&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;120,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,334&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Operating lease liabilities, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77,727&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,910&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" id="ixv-11942" unitRef="usd">80647</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" id="ixv-11943" unitRef="usd">40324</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" id="ixv-11944" unitRef="usd">120971</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" id="ixv-11945" unitRef="usd">3334</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-11946" unitRef="usd">117637</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-11947" unitRef="usd">77727</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-11948" unitRef="usd">39910</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-10735">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 - INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered
or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that
includes the enactment date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Liabilities are established for uncertain tax
positions expected to be taken in income tax returns when such positions are judged to meet the &#x201c;more-likely-than-not&#x201d; threshold
based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a
component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken.
U.S. income tax returns for the years ended December 31, 2020 through December 31, 2023 and the Chinese income tax return for the year
ended December 31, 2023 are open for possible examination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the current tax law in the PRC, the Company is and will be subject
to the enterprise income tax rate of 25%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There was no provision for income taxes for the
years ended December 31, 2023 and 2022, respectively due to continued net losses of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Following is a reconciliation of income taxes calculated at the federal
statutory rates to the provision for income taxes:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;(Benefit) tax at statutory rate of 25%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(769,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(973,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prior year refund received&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other, primarily the difference in U.S. tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;766,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;965,301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The temporary differences which give rise to the deferred income tax
assets and liability are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred income tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Allowance for doubtful trade receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,446,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,184,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Allowance for doubtful other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inventory obsolescence reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses not deductible in current year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,069,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,087,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Advances for intangible assets impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,619,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,782,172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liability, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;257&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;PRC net operating loss carry forward&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,275,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,036,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;U.S. net operating loss carry forward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,078,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,849,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,531,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,985,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,531,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,985,554&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Net deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred income tax liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742,114&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;754,698&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company had net operating
loss carryforwards for PRC tax purposes of approximately $21.1 million which are available to offset any future taxable income through
2028. Approximately $3.4 million of these carryforwards expired in December 2023. The Company also has net operating losses for United
States federal income tax purposes of approximately $9.9 million of which $5.1 million is available to offset future taxable income, if
any, through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each
tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;U.S. federal tax legislation, commonly referred
to as the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d;), was signed into law on December&#160;22, 2017. The U.S. Tax Reform
significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax
rate from 35% to 21% for taxable years beginning after December&#160;31, 2017; limiting and/or eliminating many business deductions; migrating
the U.S. to a territorial tax system with a&#160;one-time&#160;transition tax on a mandatory deemed repatriation of previously deferred
foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends
from foreign subsidiaries; and providing for new taxes on certain foreign earnings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In assessing the realizability of deferred tax
assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&#160;&#160;The
ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those
differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management considers projected future taxable income
and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment of the level of historical taxable income and
projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management
believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2023 and 2022.&#160;&#160;Therefore,
the Company provided for a valuation allowance against its deferred tax assets of $21,531,017 and $21,467,355 as of December 31, 2023
and 2022, respectively.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also incurred various other taxes,
comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts
are reflected on the balance sheets as accrued taxes payable.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="2" id="ixv-11949" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-11950">Following is a reconciliation of income taxes calculated at the federal
statutory rates to the provision for income taxes:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;(Benefit) tax at statutory rate of 25%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(769,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(973,717&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prior year refund received&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other, primarily the difference in U.S. tax rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;766,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;965,301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-11951" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-11952" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-11953" unitRef="usd">-769704</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="0" id="ixv-11954" unitRef="usd">-973717</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="0" id="ixv-11955" unitRef="usd">3382</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c7" decimals="0" id="ixv-11956" unitRef="usd">8416</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-11957" unitRef="usd">766322</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="0" id="ixv-11958" unitRef="usd">965301</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-11959">The temporary differences which give rise to the deferred income tax
assets and liability are as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred income tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Allowance for doubtful trade receivables&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,446,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,184,882&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Allowance for doubtful other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,787&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inventory obsolescence reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,355&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,921&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses not deductible in current year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,069,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,087,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Advances for intangible assets impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,619,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,782,172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liability, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;257&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;PRC net operating loss carry forward&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,275,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,036,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;U.S. net operating loss carry forward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,078,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,849,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,531,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,985,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,531,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,985,554&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Net deferred income tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred income tax liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;742,114&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;754,698&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c3" decimals="0" id="ixv-11960" unitRef="usd">3446519</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c4" decimals="0" id="ixv-11961" unitRef="usd">4184882</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="c3" decimals="0" id="ixv-11962" unitRef="usd">6754</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="c4" decimals="0" id="ixv-11963" unitRef="usd">6787</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c3" decimals="0" id="ixv-11964" unitRef="usd">32355</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c4" decimals="0" id="ixv-11965" unitRef="usd">34921</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="0" id="ixv-11966" unitRef="usd">3201</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c4" decimals="0" id="ixv-11967" unitRef="usd">3201</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c3" decimals="0" id="ixv-11968" unitRef="usd">1069198</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c4" decimals="0" id="ixv-11969" unitRef="usd">1087328</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="c3" decimals="0" id="ixv-11970" unitRef="usd">9619060</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="c4" decimals="0" id="ixv-11971" unitRef="usd">9782172</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="0" id="ixv-11972" unitRef="usd">257</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="0" id="ixv-11973" unitRef="usd">349</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="0" id="ixv-11974" unitRef="usd">5275411</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c4" decimals="0" id="ixv-11975" unitRef="usd">5036114</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-11976" unitRef="usd">2078262</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-11977" unitRef="usd">1849800</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" id="ixv-11978" unitRef="usd">21531017</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" id="ixv-11979" unitRef="usd">21985554</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-11980" unitRef="usd">21531017</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-11981" unitRef="usd">21985554</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c3" decimals="0" id="ixv-11982" unitRef="usd">742114</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c4" decimals="0" id="ixv-11983" unitRef="usd">754698</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="-5" id="ixv-11984" unitRef="usd">21100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c238"
      decimals="-5"
      id="ixv-11985"
      unitRef="usd">3400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c239"
      decimals="-5"
      id="ixv-11986"
      unitRef="usd">9900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c3" decimals="-5" id="ixv-11987" unitRef="usd">5100000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="c0" id="ixv-11988">through 2039, and $4.8 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each
tax year</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c240"
      decimals="2"
      id="ixv-11989"
      unitRef="pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c241"
      decimals="2"
      id="ixv-11990"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cphi:DeferredTaxAssetValuationAllowance contextRef="c242" decimals="0" id="ixv-11991" unitRef="usd">21531017</cphi:DeferredTaxAssetValuationAllowance>
    <cphi:DeferredTaxAssetValuationAllowance contextRef="c243" decimals="0" id="ixv-11992" unitRef="usd">21467355</cphi:DeferredTaxAssetValuationAllowance>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c0" id="ixv-11046">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 11 &#x2013; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Fair value is defined
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value,
a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#x2013; Quoted
prices in active markets for identical assets or liabilities; Level 2 &#x2013; Observable inputs other than Level 1 including quoted prices
for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable
market data; and Level 3 &#x2013; Unobservable inputs supported by little or no market activity for financial instruments whose value is
determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination
of fair value requires significant management judgment or estimation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company uses fair
value to measure the value of the banker&#x2019;s acceptance notes it holds as of December 31, 2023 and 2022.&#160;The banker&#x2019;s acceptance
notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at
fair value:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker&#x2019;s acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker&#x2019;s acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-11993">The Company uses fair
value to measure the value of the banker&#x2019;s acceptance notes it holds as of December 31, 2023 and 2022.&#160;The banker&#x2019;s acceptance
notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at
fair value:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker&#x2019;s acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;65,915&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Reporting Date Using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt"&gt;Banker&#x2019;s acceptance notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueNetAssetLiability contextRef="c244" decimals="0" id="ixv-11994" unitRef="usd">65915</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c246" decimals="0" id="ixv-11995" unitRef="usd">65915</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c3" decimals="0" id="ixv-11996" unitRef="usd">65915</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c249" decimals="0" id="ixv-11997" unitRef="usd">65915</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c251" decimals="0" id="ixv-11998" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c253" decimals="0" id="ixv-11999" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c4" decimals="0" id="ixv-12000" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c256" decimals="0" id="ixv-12001" unitRef="usd">13784</us-gaap:FairValueNetAssetLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-11210">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 - STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is authorized to issue 500,000,000
shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued
in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#x2019;s
Board.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;According to relevant PRC laws, companies registered
in the PRC, including the Company&#x2019;s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as
determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account
balances reach 50% of the company&#x2019;s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves
and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash
dividends. The amount designated for general and statutory capital reserves is $8,145,000 at December 31, 2023 and 2022.&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 6, 2024, the Company implemented
a 1-for -5 reverse stock split as more fully discussed in Note 14. All share and per share disclosures have been retroactively restated
to reflect the impact of the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 6, 2023&#160;China Pharma&#160;implemented
a&#160;1-for-10&#160;reverse split of its common stock. The reverse stock split was approved by the Company&#x2019;s Board of Directors
through unanimous written consent and&#160;China Pharma&#x2019;s stockholders at its Annual Meeting for the fiscal year ended on December
31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of&#160;China Pharma&#x2019;s
issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional
shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up
to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#x2019;s percentage
interest in&#160;China Pharma&#x2019;s outstanding common stock, except for adjustments that may result from the treatment of fractional
shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying consolidated financial
statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2010 Incentive Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 12, 2010, the Company&#x2019;s Board
adopted the Company&#x2019;s 2010 Incentive Plan (the &#x201c;Plan&#x201d;), which was then approved by stockholders on December 22, 2010.
On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the &#x201c;Amendment&#x201d;), pursuant
to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December
19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to
the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000
shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated
Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares
from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive
Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted
stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees,
directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares
of common stock. Through December 31, 2023, there were 84,700 shares of stock and stock options granted and outstanding under the Plan.&#160;
A total of 13,300 options were outstanding as of December 31, 2023 under the Plan. As such, there are 482,000 additional units available
for issuance under the Plan.&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;There were no issuances of securities from the Plan for the year ended
December 31, 2023 and as such, no compensation expense was recognized for the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On October 3, 2022 the
Company issued 6,000 shares of common stock pursuant to a contract with a consultant to the Company for services. The Company recorded
compensation expense totaling $42,000 based on the closing market price of its common stock of $7.00 per share on the issuance date. The
contract also calls for the issuance of up to 18,000 additional shares of common stock contingent upon the achievement of certain milestones
as described in the contract. At December 31, 2023 these milestones had not been met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On October 4, 2022 the
Company issued an option to purchase &lt;span&gt;12,000 shares of common stock at an exercise price at $28.00
per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires on October 3, 2027.
&lt;/span&gt;The fair value of the options granted of $36,270 was calculated using the Black-Scholes option valuation model using the closing
market price of $7.50 per share, volatility of 115.5%, risk free interest rate of 3.84% and an expected life of 2.5 years. The value was
charged to general and administrative expenses on the accompanying Statement of Operations for the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On September 9, 2021
the Company issued an aggregate of 35,200 fully vested shares of common stock at the price of $33.50 per share, representing the closing
market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan, as amended,
to partially offset certain unpaid cash compensation totaling $1,179,200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Also on September 9,
2021 the Company issued an option to purchase &lt;span&gt;1,300 shares of common stock at an exercise price
at $73.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. &lt;/span&gt;The fair value of the options
granted of $15,243 was calculated using the Black-Scholes option valuation model using the closing market price of $33.50 per share, volatility
of 118.4%, risk free interest rate of 0.75% and an expected life of 1.5 years. The value was charged to general and administrative expenses
on the accompanying Statement of Operations for the year ended December 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 23, 2020 the Board approved the issuance
of 40,000 shares of common stock from the Company&#x2019;s 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid
compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, there was no remaining
unrecognized compensation expense related to stock options or restricted stock grants.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-12002"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-12003"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-12004"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-12005"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <cphi:AftertaxNetIncomePercentage contextRef="c0" decimals="2" id="ixv-12006" unitRef="pure">0.10</cphi:AftertaxNetIncomePercentage>
    <cphi:ReserveAccountBalancesPercentage contextRef="c0" decimals="2" id="ixv-12007" unitRef="pure">0.50</cphi:ReserveAccountBalancesPercentage>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c3" decimals="0" id="ixv-12008" unitRef="usd">8145000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c4" decimals="0" id="ixv-12009" unitRef="usd">8145000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c258" id="ixv-12010">1-for -5</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c259" id="ixv-12011">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c260"
      decimals="0"
      id="ixv-12012"
      unitRef="shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c261"
      decimals="0"
      id="ixv-12013"
      unitRef="shares">80000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c262"
      decimals="0"
      id="ixv-12014"
      unitRef="shares">180000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c263"
      decimals="0"
      id="ixv-12015"
      unitRef="shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c264"
      decimals="0"
      id="ixv-12016"
      unitRef="shares">180000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c265"
      decimals="0"
      id="ixv-12017"
      unitRef="shares">280000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c266"
      decimals="0"
      id="ixv-12018"
      unitRef="shares">280000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c267"
      decimals="0"
      id="ixv-12019"
      unitRef="shares">580000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="c268"
      decimals="0"
      id="ixv-12020"
      unitRef="shares">580000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c268"
      decimals="0"
      id="ixv-12021"
      unitRef="shares">84700</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <cphi:TotalOptionOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-12022"
      unitRef="shares">13300</cphi:TotalOptionOutstanding>
    <cphi:AdditionalSharesAvailableForIssuance
      contextRef="c3"
      decimals="0"
      id="ixv-12023"
      unitRef="shares">482000</cphi:AdditionalSharesAvailableForIssuance>
    <cphi:IssuanceOfCommonStock
      contextRef="c269"
      decimals="0"
      id="ixv-12024"
      unitRef="shares">6000</cphi:IssuanceOfCommonStock>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="c270" decimals="0" id="ixv-12025" unitRef="usd">42000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <cphi:ClosingMarketPrice
      contextRef="c270"
      decimals="2"
      id="ixv-12026"
      unitRef="usdPershares">7</cphi:ClosingMarketPrice>
    <us-gaap:CommonUnitIssued
      contextRef="c271"
      decimals="0"
      id="ixv-12027"
      unitRef="shares">18000</us-gaap:CommonUnitIssued>
    <cphi:PurchaseOfCommonStock
      contextRef="c272"
      decimals="0"
      id="ixv-12028"
      unitRef="shares">12000</cphi:PurchaseOfCommonStock>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c272"
      decimals="2"
      id="ixv-12029"
      unitRef="usdPershares">28</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited contextRef="c272" decimals="0" id="ixv-12030" unitRef="usd">36270</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <cphi:ClosingMarketPrice
      contextRef="c272"
      decimals="2"
      id="ixv-12031"
      unitRef="usdPershares">7.5</cphi:ClosingMarketPrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="c272"
      decimals="3"
      id="ixv-12032"
      unitRef="pure">1.155</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="c272"
      decimals="4"
      id="ixv-12033"
      unitRef="pure">0.0384</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="c272" id="ixv-12034">P2Y6M</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c273"
      decimals="0"
      id="ixv-12035"
      unitRef="shares">35200</us-gaap:ExcessStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="c273"
      decimals="2"
      id="ixv-12036"
      unitRef="usdPershares">33.5</us-gaap:SharePrice>
    <us-gaap:Cash contextRef="c273" decimals="0" id="ixv-12037" unitRef="usd">1179200</us-gaap:Cash>
    <cphi:PurchaseOfCommonStock
      contextRef="c274"
      decimals="0"
      id="ixv-12038"
      unitRef="shares">1300</cphi:PurchaseOfCommonStock>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c274"
      decimals="2"
      id="ixv-12039"
      unitRef="usdPershares">73.7</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited contextRef="c274" decimals="0" id="ixv-12040" unitRef="usd">15243</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <cphi:ClosingMarketPrice
      contextRef="c274"
      decimals="2"
      id="ixv-12041"
      unitRef="usdPershares">33.5</cphi:ClosingMarketPrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="c274"
      decimals="3"
      id="ixv-12042"
      unitRef="pure">1.184</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="c274"
      decimals="4"
      id="ixv-12043"
      unitRef="pure">0.0075</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="c274" id="ixv-12044">P1Y6M</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <cphi:IssuanceOfCommonStock
      contextRef="c275"
      decimals="0"
      id="ixv-12045"
      unitRef="shares">40000</cphi:IssuanceOfCommonStock>
    <us-gaap:Cash contextRef="c276" decimals="0" id="ixv-12046" unitRef="usd">864480</us-gaap:Cash>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-11296">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2013; RISKS &amp;amp; UNCERTAINTIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Current vulnerability due to certain concentrations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2023, no customer
accounted for more than 10% of sales and two customers accounted for 62.59% and 13.5% of accounts receivable. One suppliers accounted
for 13.8% of raw material purchases, and three different products accounted for 29.2%, 27.3% and 12.5% of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2022, no customer
accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and 10.4% of accounts receivable. Two suppliers accounted
for 21.7% and 11.1% of raw material purchases, and three different products accounted for 25.0%, 22.8% and 13.9% of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Nature of Operations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;Impact
from the New Coronavirus Global Pandemic (&#x201c;COVID-19&#x201d;)&#160;&lt;/b&gt;- Although the outbreak of COVID-19 since the first quarter
2020 has been under control, and China has returned to normal production and social life in an orderly manner, China is still encountering
frequent resurgences in many of the major cities. For now, these resurgences have not caused material impact to our daily operations.
However, we cannot guarantee subsequent resurgence will not have any material effect on the operation of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;Economic
environment -&#160;&lt;/b&gt;Substantially all of the Company&#x2019;s operations are conducted in the PRC, and therefore the Company is subject
to special considerations and significant risks not typically associated with companies operating in the United States of America. These
risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The
Company&#x2019;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by
changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance
abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely
affect the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In addition,
all of the Company&#x2019;s revenue is denominated in the PRC&#x2019;s currency of Renminbi (RMB), which must be converted into other currencies
before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require
approval of the PRC government.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c277"
      decimals="2"
      id="ixv-12047"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c278"
      decimals="4"
      id="ixv-12048"
      unitRef="pure">0.6259</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c279"
      decimals="3"
      id="ixv-12049"
      unitRef="pure">0.135</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c280"
      decimals="3"
      id="ixv-12050"
      unitRef="pure">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c281"
      decimals="3"
      id="ixv-12051"
      unitRef="pure">0.292</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c282"
      decimals="3"
      id="ixv-12052"
      unitRef="pure">0.273</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c283"
      decimals="3"
      id="ixv-12053"
      unitRef="pure">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c284"
      decimals="2"
      id="ixv-12054"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c285"
      decimals="3"
      id="ixv-12055"
      unitRef="pure">0.529</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c286"
      decimals="3"
      id="ixv-12056"
      unitRef="pure">0.114</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c287"
      decimals="3"
      id="ixv-12057"
      unitRef="pure">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c288"
      decimals="3"
      id="ixv-12058"
      unitRef="pure">0.217</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c289"
      decimals="3"
      id="ixv-12059"
      unitRef="pure">0.111</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c290"
      decimals="3"
      id="ixv-12060"
      unitRef="pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c291"
      decimals="3"
      id="ixv-12061"
      unitRef="pure">0.228</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c292"
      decimals="3"
      id="ixv-12062"
      unitRef="pure">0.139</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-11346">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;NOTE
14 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;On February 2, 2024,
the Company entered into a Technology Transfer Agreement with Lihua Li (the &#x201c;Transferor&#x201d;). The Transferor owns an invention
patent of a pharmaceutical composition for treatment of psoriasis (the &#x201c;Invention Patent&#x201d;). Pursuant to the Agreement, the
Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide
relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration
materials, registration application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The aggregate transfer
price as contemplated by the Agreement is $1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000
shares of common stock of the Company at $0.455 per share based on the closing market price of the Company&#x2019;s common stock as of
that date. During ten years since the product launches to the market, if and only if the product generates profit, Helpson shall pay 10%
of the net profit of the sales in cash on an annual basis to the Transferor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 6, 2024 the Company implemented
a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company&#x2019;s Board of Directors through unanimous
written consent and the Company&#x2019;s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held
on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company&#x2019;s issued and outstanding
common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a
result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number.
The reverse stock split affects all stockholders uniformly and does not alter any stockholder&#x2019;s percentage interest in the Company&#x2019;s
outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts
have been retroactively restated for the years ended December 31, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On January
11, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3945, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;380,228 shares of common stock to the Investor on January
16, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On February
1, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3725, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;402,685 shares of common stock to the Investor on February
5, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On February
16, 2024&#160;the Investor delivered its notice of redemption for $150,000&#160;of the Note and related interest at the conversion price
of $0.3675, which was&#160;82% of the lowest volume weighted average price&#160;during the ten trading days immediately preceding the
applicable redemption conversion. Accordingly, the Company issued a total of&#160;408,164 shares of common stock to the Investor on February
21, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <cphi:AggregateAmount contextRef="c3" decimals="3" id="ixv-12063" unitRef="usd">1.365</cphi:AggregateAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c293"
      decimals="0"
      id="ixv-12064"
      unitRef="shares">3000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-12065"
      unitRef="usdPershares">0.455</us-gaap:SharesIssuedPricePerShare>
    <cphi:RedemptionPercentage contextRef="c0" decimals="2" id="ixv-12066" unitRef="pure">0.10</cphi:RedemptionPercentage>
    <cphi:RedemptionAmount contextRef="c294" decimals="0" id="ixv-12067" unitRef="usd">150000</cphi:RedemptionAmount>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c295"
      decimals="4"
      id="ixv-12068"
      unitRef="usdPershares">0.3945</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <cphi:RedemptionOfWeightedAveragePercentage
      contextRef="c294"
      decimals="2"
      id="ixv-12069"
      unitRef="pure">0.82</cphi:RedemptionOfWeightedAveragePercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="c296"
      decimals="0"
      id="ixv-12070"
      unitRef="shares">380228</us-gaap:CommonStockSharesIssued>
    <cphi:RedemptionAmount contextRef="c297" decimals="0" id="ixv-12071" unitRef="usd">150000</cphi:RedemptionAmount>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c298"
      decimals="4"
      id="ixv-12072"
      unitRef="usdPershares">0.3725</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <cphi:RedemptionOfWeightedAveragePercentage
      contextRef="c297"
      decimals="2"
      id="ixv-12073"
      unitRef="pure">0.82</cphi:RedemptionOfWeightedAveragePercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="c299"
      decimals="0"
      id="ixv-12074"
      unitRef="shares">402685</us-gaap:CommonStockSharesIssued>
    <cphi:RedemptionAmount contextRef="c300" decimals="0" id="ixv-12075" unitRef="usd">150000</cphi:RedemptionAmount>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c301"
      decimals="4"
      id="ixv-12076"
      unitRef="usdPershares">0.3675</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <cphi:RedemptionOfWeightedAveragePercentage
      contextRef="c300"
      decimals="2"
      id="ixv-12077"
      unitRef="pure">0.82</cphi:RedemptionOfWeightedAveragePercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="c302"
      decimals="0"
      id="ixv-12078"
      unitRef="shares">408164</us-gaap:CommonStockSharesIssued>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermLineOfCredit
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-3.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c15"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c16"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c15"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c15"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c16"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c15"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c16"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c13"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c14"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c15"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c23"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c24"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c23"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c24"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c21"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c22"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c23"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockOptionPlanExpense
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c7"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c7"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c7"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <cphi:ConversionOfRelatedPartyNoteAndInterestToCommonStock
      contextRef="c7"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c65"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c0"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c7"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c245"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c247"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c248"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c250"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c252"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c254"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c255"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c257"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-12142">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-12143">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-12144">0001106644</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
